<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">32851186</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>11</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2375-2548</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>33</Issue><PubDate><Year>2020</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Science advances</Title><ISOAbbreviation>Sci Adv</ISOAbbreviation></Journal><ArticleTitle>Noncanonical function of an autophagy protein prevents spontaneous Alzheimer's disease.</ArticleTitle><Pagination><StartPage>eabb9036</StartPage><MedlinePgn>eabb9036</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">eabb9036</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/sciadv.abb9036</ELocationID><Abstract><AbstractText>Noncanonical functions of autophagy proteins have been implicated in neurodegenerative conditions, including Alzheimer's disease (AD). The WD domain of the autophagy protein Atg16L is dispensable for canonical autophagy but required for its noncanonical functions. Two-year-old mice lacking this domain presented with robust &#x3b2;-amyloid (A&#x3b2;) pathology, tau hyperphosphorylation, reactive microgliosis, pervasive neurodegeneration, and severe behavioral and memory deficiencies, consistent with human disease. Mechanistically, we found this WD domain was required for the recycling of A&#x3b2; receptors in primary microglia. Pharmacologic suppression of neuroinflammation reversed established memory impairment and markers of disease pathology in this novel AD model. Therefore, loss of the Atg16L WD domain drives spontaneous AD in mice, and inhibition of neuroinflammation is a potential therapeutic approach for treating neurodegeneration and memory loss. A decline in expression of ATG16L in the brains of human patients with AD suggests the possibility that a similar mechanism may contribute in human disease.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Heckmann</LastName><ForeName>Bradlee L</ForeName><Initials>BL</Initials><Identifier Source="ORCID">0000-0002-3271-7183</Identifier><AffiliationInfo><Affiliation>Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teubner</LastName><ForeName>Brett J W</ForeName><Initials>BJW</Initials><AffiliationInfo><Affiliation>Department of Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boada-Romero</LastName><ForeName>Emilio</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-2482-076X</Identifier><AffiliationInfo><Affiliation>Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tummers</LastName><ForeName>Bart</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guy</LastName><ForeName>Clifford</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-7486-7107</Identifier><AffiliationInfo><Affiliation>Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fitzgerald</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayer</LastName><ForeName>Ulrike</ForeName><Initials>U</Initials><Identifier Source="ORCID">0000-0003-2328-0052</Identifier><AffiliationInfo><Affiliation>School of Biological Sciences, University of East Anglia, Norwich, Norfolk, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carding</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Quadram Institute of Bioscience, Norwich, Norfolk, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zakharenko</LastName><ForeName>Stanislav S</ForeName><Initials>SS</Initials><Identifier Source="ORCID">0000-0001-8115-202X</Identifier><AffiliationInfo><Affiliation>Department of Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wileman</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-9033-2580</Identifier><AffiliationInfo><Affiliation>Quadram Institute of Bioscience, Norwich, Norfolk, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Norwich Medical School, University of East Anglia, Norwich, Norfolk, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Green</LastName><ForeName>Douglas R</ForeName><Initials>DR</Initials><Identifier Source="ORCID">0000-0002-7332-1417</Identifier><AffiliationInfo><Affiliation>Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>L40 CA231423</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>BBS/E/F/000PR10353</GrantID><Acronym>BB_</Acronym><Agency>Biotechnology and Biological Sciences Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R35 CA231620</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DC012833</GrantID><Acronym>DC</Acronym><Agency>NIDCD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 AI138492</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 MH097742</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>BBS/E/F/000PR10355</GrantID><Acronym>BB_</Acronym><Agency>Biotechnology and Biological Sciences Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 MH097742</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI040646</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>08</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Adv</MedlineTA><NlmUniqueID>101653440</NlmUniqueID><ISSNLinking>2375-2548</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>3</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>7</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>8</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32851186</ArticleId><ArticleId IdType="pmc">PMC7428329</ArticleId><ArticleId IdType="doi">10.1126/sciadv.abb9036</ArticleId><ArticleId IdType="pii">abb9036</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Long J. M., Holtzman D. M., Alzheimer disease: An update on pathobiology and treatment strategies. Cell 179, 312&#x2013;339 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6778042</ArticleId><ArticleId IdType="pubmed">31564456</ArticleId></ArticleIdList></Reference><Reference><Citation>Menzies F. M., Fleming A., Caricasole A., Bento C. F., Andrews S. P., Ashkenazi A., F&#xfc;llgrabe J., Jackson A., Sanchez M. J., Karabiyik C., Licitra F., Ramirez A. L., Pavel M., Puri C., Renna M., Ricketts T., Schlotawa L., Vicinanza M., Won H., Zhu Y., Skidmore J., Rubinsztein D. C., Autophagy and neurodegeneration: Pathogenic mechanisms and therapeutic opportunities. Neuron 93, 1015&#x2013;1034 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28279350</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipinski M. M., Zheng B., Lu T., Yan Z., Py B. F., Ng A., Xavier R. J., Li C., Yankner B. A., Scherzer C. R., Yuan J., Genome-wide analysis reveals mechanisms modulating autophagy in normal brain aging and in Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 107, 14164&#x2013;14169 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2922576</ArticleId><ArticleId IdType="pubmed">20660724</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubinsztein D. C., Mari&#xf1;o G., Kroemer G., Autophagy and aging. Cell 146, 682&#x2013;695 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21884931</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucin K. M., O&#x2019;Brien C. E., Bieri G., Czirr E., Mosher K. I., Abbey R. J., Mastroeni D. F., Rogers J., Spencer B., Masliah E., Wyss-Coray T., Microglial beclin 1 regulates retromer trafficking and phagocytosis and is impaired in Alzheimer's disease. Neuron 79, 873&#x2013;886 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3779465</ArticleId><ArticleId IdType="pubmed">24012002</ArticleId></ArticleIdList></Reference><Reference><Citation>Pickford F., Masliah E., Britschgi M., Lucin K., Narasimhan R., Jaeger P. A., Small S., Spencer B., Rockenstein E., Levine B., Wyss-Coray T., The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid &#x3b2; accumulation in mice. J. Clin. Invest. 118, 2190&#x2013;2199 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2391284</ArticleId><ArticleId IdType="pubmed">18497889</ArticleId></ArticleIdList></Reference><Reference><Citation>Heckmann B. L., Boada-Romero E., Cunha L. D., Magne J., Green D. R., LC3-associated phagocytosis and inflammation. J. Mol. Biol. 429, 3561&#x2013;3576 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5743439</ArticleId><ArticleId IdType="pubmed">28847720</ArticleId></ArticleIdList></Reference><Reference><Citation>Heckmann B. L., Green D. R., LC3-associated phagocytosis at a glance. J. Cell Sci. 132, jcs231472 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6432721</ArticleId><ArticleId IdType="pubmed">30787029</ArticleId></ArticleIdList></Reference><Reference><Citation>Fletcher K., Ulferts R., Jacquin E., Veith T., Gammoh N., Arasteh J. M., Mayer U., Carding S. R., Wileman T., Beale R., Florey O., The WD40 domain of ATG16L1 is required for its non-canonical role in lipidation of LC3 at single membranes. EMBO J. 37, e97840 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5813257</ArticleId><ArticleId IdType="pubmed">29317426</ArticleId></ArticleIdList></Reference><Reference><Citation>Rai S., Arasteh M., Jefferson M., Pearson T., Wang Y., Zhang W., Bicsak B., Divekar D., Powell P. P., Naumann R., Beraza N., Carding S. R., Florey O., Mayer U., Wileman T., The ATG5-binding and coiled coil domains of ATG16L1 maintain autophagy and tissue homeostasis in mice independently of the WD domain required for LC3-associated phagocytosis. Autophagy 15, 599&#x2013;612 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6526875</ArticleId><ArticleId IdType="pubmed">30403914</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu W. H., Cuervo A. M., Kumar A., Peterhoff C. M., Schmidt S. D., Lee J.-H., Mohan P. S., Mercken M., Farmery M. R., Tjernberg L. O., Jiang Y., Duff K., Uchiyama Y., N&#xe4;slund J., Mathews P. M., Cataldo A. M., Nixon R. A., Macroautophagy&#x2014;A novel &#x3b2;-amyloid peptide-generating pathway activated in Alzheimer's disease. J. Cell Biol. 171, 87&#x2013;98 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2171227</ArticleId><ArticleId IdType="pubmed">16203860</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulkarni A., Chen J., Maday S., Neuronal autophagy and intercellular regulation of homeostasis in the brain. Curr. Opin. Neurobiol. 51, 29&#x2013;36 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29529415</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon R. A., Autophagy, amyloidogenesis and Alzheimer disease. J. Cell Sci. 120, 4081&#x2013;4091 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">18032783</ArticleId></ArticleIdList></Reference><Reference><Citation>Heckmann B. L., Teubner B. J. W., Tummers B., Boada-Romero E., Harris L., Yang M., Guy C. S., Zakharenko S. S., Green D. R., LC3-associated endocytosis facilitates &#x3b2;-amyloid clearance and mitigates neurodegeneration in murine Alzheimer's disease. Cell 178, 536&#x2013;551.e14 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6689199</ArticleId><ArticleId IdType="pubmed">31257024</ArticleId></ArticleIdList></Reference><Reference><Citation>Doens D., Fern&#xe1;ndez P. L., Microglia receptors and their implications in the response to amyloid &#x3b2; for Alzheimer's disease pathogenesis. J. Neuroinflammation 11, 48 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3975152</ArticleId><ArticleId IdType="pubmed">24625061</ArticleId></ArticleIdList></Reference><Reference><Citation>Ries M., Sastre M., Mechanisms of A&#x3b2; clearance and degradation by glial cells. Front. Aging Neurosci. 8, 160 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4932097</ArticleId><ArticleId IdType="pubmed">27458370</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Cella M., Mallinson K., Ulrich J. D., Young K. L., Robinette M. L., Gilfillan S., Krishnan G. M., Sudhakar S., Zinselmeyer B. H., Holtzman D. M., Cirrito J. R., Colonna M., TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. Cell 160, 1061&#x2013;1071 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y., Wu X., Li X., Jiang L.-L., Gui X., Liu Y., Sun Y., Zhu B., Pi&#xf1;a-Crespo J. C., Zhang M., Zhang N., Chen X., Bu G., An Z., Huang T. Y., Xu H., TREM2 is a receptor for &#x3b2;-amyloid that mediates microglial function. Neuron 97, 1023&#x2013;1031.e1027 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5889092</ArticleId><ArticleId IdType="pubmed">29518356</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulland T. K., Song W. M., Huang S. C.-C., Ulrich J. D., Sergushichev A., Beatty W. L., Loboda A. A., Zhou Y., Cairns N. J., Kambal A., Loginicheva E., Gilfillan S., Cella M., Virgin H. W., Unanue E. R., Wang Y., Artyomov M. N., Holtzman D. M., Colonna M., TREM2 maintains microglial metabolic fitness in Alzheimer's disease. Cell 170, 649&#x2013;663.e13 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5573224</ArticleId><ArticleId IdType="pubmed">28802038</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez J., Malireddi R. K. S., Lu Q., Cunha L. D., Pelletier S., Gingras S., Orchard R., Guan J.-L., Tan H., Peng J., Kanneganti T.-D., Virgin H. W., Green D. R., Molecular characterization of LC3-associated phagocytosis reveals distinct roles for Rubicon, NOX2 and autophagy proteins. Nat. Cell Biol. 17, 893&#x2013;906 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4612372</ArticleId><ArticleId IdType="pubmed">26098576</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J.-Y., Zhao H., Martinez J., Doggett T. A., Kolesnikov A. V., Tang P. H., Ablonczy Z., Chan C.-C., Zhou Z., Green D. R., Ferguson T. A., Noncanonical autophagy promotes the visual cycle. Cell 154, 365&#x2013;376 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3744125</ArticleId><ArticleId IdType="pubmed">23870125</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S., Caccamo A., Smith I. F., Green K. N., LaFerla F. M., A dynamic relationship between intracellular and extracellular pools of A&#x3b2;. Am. J. Pathol. 168, 184&#x2013;194 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1592652</ArticleId><ArticleId IdType="pubmed">16400022</ArticleId></ArticleIdList></Reference><Reference><Citation>Lv X., Li W., Luo Y., Wang D., Zhu C., Huang Z.-X., Tan X., Exploring the differences between mouse mA&#x3b2;1-42 and human hA&#x3b2;1-42 for Alzheimer's disease related properties and neuronal cytotoxicity. Chem. Commun. (Camb.) 49, 5865&#x2013;5867 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23700581</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu H. Y., Kuo P.-C., Wang Y.-T., Lin H.-T., Roe A. D., Wang B. Y., Han C.-L., Hyman B. T., Chen Y.-J., Tai H.-C., &#x3b2;-Amyloid induces pathology-related patterns of tau hyperphosphorylation at synaptic terminals. J. Neuropathol. Exp. Neurol. 77, 814&#x2013;826 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30016458</ArticleId></ArticleIdList></Reference><Reference><Citation>Brion J. P., Neurofibrillary tangles and Alzheimer's disease. Eur. Neurol. 40, 130&#x2013;140 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9748670</ArticleId></ArticleIdList></Reference><Reference><Citation>Neddens J., Temmel M., Flunkert S., Kerschbaumer B., Hoeller C., Loeffler T., Niederkofler V., Daum G., Attems J., Hutter-Paier B., Phosphorylation of different tau sites during progression of Alzheimer's disease. Acta Neuropathol. Commun. 6, 52 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6027763</ArticleId><ArticleId IdType="pubmed">29958544</ArticleId></ArticleIdList></Reference><Reference><Citation>Alafuzoff I., Arzberger T., Al-Sarraj S., Bodi I., Bogdanovic N., Braak H., Bugiani O., Del-Tredici K., Ferrer I., Gelpi E., Giaccone G., Graeber M. B., Ince P., Kamphorst W., King A., Korkolopoulou P., Kov&#xe1;cs G. G., Larionov S., Meyronet D., Monoranu C., Parchi P., Patsouris E., Roggendorf W., Seilhean D., Tagliavini F., Stadelmann C., Streichenberger N., Thal D. R., Wharton S. B., Kretzschmar H., Staging of neurofibrillary pathology in Alzheimer's disease: A study of the BrainNet Europe Consortium. Brain Pathol. 18, 484&#x2013;496 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2659377</ArticleId><ArticleId IdType="pubmed">18371174</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y., Shi J., Chu D., Hu W., Guan Z., Gong C.-X., Iqbal K., Liu F., Relevance of phosphorylation and truncation of tau to the etiopathogenesis of Alzheimer's disease. Front. Aging Neurosci. 10, 27 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5810298</ArticleId><ArticleId IdType="pubmed">29472853</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed-Geaghan E. G., Savage J. C., Hise A. G., Landreth G. E., CD14 and toll-like receptors 2 and 4 are required for fibrillar A&#x3b2;-stimulated microglial activation. J. Neurosci. 29, 11982&#x2013;11992 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2778845</ArticleId><ArticleId IdType="pubmed">19776284</ArticleId></ArticleIdList></Reference><Reference><Citation>Song M., Jin J., Lim J.-E., Kou J., Pattanayak A., Rehman J. A., Kim H.-D., Tahara K., Lalonde R., Fukuchi K.-i., TLR4 mutation reduces microglial activation, increases A&#x3b2; deposits and exacerbates cognitive deficits in a mouse model of Alzheimer's disease. J. Neuroinflammation 8, 92 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3169468</ArticleId><ArticleId IdType="pubmed">21827663</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y., Zhou P., Cheng S., Lu Q., Nowak K., Hopp A.-K., Li L., Shi X., Zhou Z., Gao W., Li D., He H., Liu X., Ding J., Hottiger M. O., Shao F., A bacterial effector reveals the V-ATPase-ATG16L1 axis that initiates xenophagy. Cell 178, 552&#x2013;566.e20 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31327526</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Z., Hussain M. D., Yan L.-J., Microglia, neuroinflammation, and beta-amyloid protein in Alzheimer's disease. Int. J. Neurosci. 124, 307&#x2013;321 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">23930978</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y. S., Joh T. H., Microglia, major player in the brain inflammation: Their roles in the pathogenesis of Parkinson's disease. Exp. Mol. Med. 38, 333&#x2013;347 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16953112</ArticleId></ArticleIdList></Reference><Reference><Citation>Brosseron F., Krauthausen M., Kummer M., Heneka M. T., Body fluid cytokine levels in mild cognitive impairment and Alzheimer's disease: A comparative overview. Mol. Neurobiol. 50, 534&#x2013;544 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4182618</ArticleId><ArticleId IdType="pubmed">24567119</ArticleId></ArticleIdList></Reference><Reference><Citation>Parihar M. S., Brewer G. J., Amyloid-&#x3b2; as a modulator of synaptic plasticity. J. Alzheimers Dis. 22, 741&#x2013;763 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3079354</ArticleId><ArticleId IdType="pubmed">20847424</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe D. J., Hardy J., The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol. Med. 8, 595&#x2013;608 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4888851</ArticleId><ArticleId IdType="pubmed">27025652</ArticleId></ArticleIdList></Reference><Reference><Citation>Park D., Chang S., Soluble A&#x3b2;1-42 increases the heterogeneity in synaptic vesicle pool size among synapses by suppressing intersynaptic vesicle sharing. Mol. Brain 11, 10 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5819658</ArticleId><ArticleId IdType="pubmed">29463281</ArticleId></ArticleIdList></Reference><Reference><Citation>McLean C. A., Cherny R. A., Fraser F. W., Fuller S. J., Smith M. J., Beyreuther K., Bush A. I., Masters C. L., Soluble pool of A&#x3b2; amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 46, 860&#x2013;866 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10589538</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C., Selkoe D. J., Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid &#x3b2;-peptide. Nat. Rev. Mol. Cell Biol. 8, 101&#x2013;112 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17245412</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S., Jin M., Liu L., Dang Y., Ostaszewski B. L., Selkoe D. J., Decoding the synaptic dysfunction of bioactive human AD brain soluble A&#x3b2; to inspire novel therapeutic avenues for Alzheimer's disease. Acta Neuropathol. Commun. 6, 121 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6225562</ArticleId><ArticleId IdType="pubmed">30409172</ArticleId></ArticleIdList></Reference><Reference><Citation>Saco T., Parthasarathy P. T., Cho Y., Lockey R. F., Kolliputi N., Inflammasome: A new trigger of Alzheimer's disease. Front. Aging Neurosci. 6, 80 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4018519</ArticleId><ArticleId IdType="pubmed">24834051</ArticleId></ArticleIdList></Reference><Reference><Citation>Ising C., Venegas C., Zhang S., Scheiblich H., Schmidt S. V., Vieira-Saecker A., Schwartz S., Albasset S., McManus R. M., Tejera D., Griep A., Santarelli F., Brosseron F., Opitz S., Stunden J., Merten M., Kayed R., Golenbock D. T., Blum D., Latz E., Bu&#xe9;e L., Heneka M. T., NLRP3 inflammasome activation drives tau pathology. Nature 575, 669&#x2013;673 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7324015</ArticleId><ArticleId IdType="pubmed">31748742</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan M.-S., Yu J.-T., Jiang T., Zhu X.-C., Tan L., The NLRP3 inflammasome in Alzheimer's disease. Mol. Neurobiol. 48, 875&#x2013;882 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23686772</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin J., Zhao F., Chojnacki J. E., Fulp J., Klein W. L., Zhang S., Zhu X., NLRP3 inflammasome inhibitor ameliorates amyloid pathology in a mouse model of Alzheimer's disease. Mol. Neurobiol. 55, 1977&#x2013;1987 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5585057</ArticleId><ArticleId IdType="pubmed">28255908</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L., Chan C., The role of inflammasome in Alzheimer's disease. Ageing Res. Rev. 15, 6&#x2013;15 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4029867</ArticleId><ArticleId IdType="pubmed">24561250</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon R., Albornoz E. A., Christie D. C., Langley M. R., Kumar V., Mantovani S., Robertson A. A. B., Butler M. S., Rowe D. B., O&#x2019;Neill L. A., Kanthasamy A. G., Schroder K., Cooper M. A., Woodruff T. M., Inflammasome inhibition prevents &#x3b1;-synuclein pathology and dopaminergic neurodegeneration in mice. Sci. Transl. Med. 10, eaah4066 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6483075</ArticleId><ArticleId IdType="pubmed">30381407</ArticleId></ArticleIdList></Reference><Reference><Citation>Dempsey C., Araiz A. R., Bryson K. J., Finucane O., Larkin C., Mills E. L., Robertson A. A. B., Cooper M. A., O&#x2019;Neill L. A. J., Lynch M. A., Inhibiting the NLRP3 inflammasome with MCC950 promotes non-phlogistic clearance of amyloid-&#x3b2; and cognitive function in APP/PS1 mice. Brain Behav. Immun. 61, 306&#x2013;316 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28003153</ArticleId></ArticleIdList></Reference><Reference><Citation>Ismael S., Nasoohi S., Ishrat T., MCC950, the selective inhibitor of nucleotide oligomerization domain-like receptor protein-3 inflammasome, protects mice against traumatic brain injury. J. Neurotrauma 35, 1294&#x2013;1303 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5962912</ArticleId><ArticleId IdType="pubmed">29295651</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren H., Kong Y., Liu Z., Zang D., Yang X., Wood K., Li M., Liu Q., Selective NLRP3 (pyrin domain-containing protein 3) inflammasome inhibitor reduces brain injury after intracerebral hemorrhage. Stroke 49, 184&#x2013;192 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5753818</ArticleId><ArticleId IdType="pubmed">29212744</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao B.-Z., Cao Q., Liu C., Targeting NLRP3 inflammasome in the treatment of CNS diseases. Front Mol. Neurosci. 11, 320 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6131647</ArticleId><ArticleId IdType="pubmed">30233319</ArticleId></ArticleIdList></Reference><Reference><Citation>F&#xfc;llgrabe J., Ghislat G., Cho D.-H., Rubinsztein D. C., Transcriptional regulation of mammalian autophagy at a glance. J. Cell Sci. 129, 3059&#x2013;3066 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27528206</ArticleId></ArticleIdList></Reference><Reference><Citation>Lubas M., Harder L. M., Kumsta C., Tiessen I., Hansen M., Andersen J. S., Lund A. H., Frankel L. B., eIF5A is required for autophagy by mediating ATG3 translation. EMBO Rep. 19, e46072 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5989740</ArticleId><ArticleId IdType="pubmed">29712776</ArticleId></ArticleIdList></Reference><Reference><Citation>Bordi M., Berg M. J., Mohan P. S., Peterhoff C. M., Alldred M. J., Che S., Ginsberg S. D., Nixon R. A., Autophagy flux in CA1 neurons of Alzheimer hippocampus: Increased induction overburdens failing lysosomes to propel neuritic dystrophy. Autophagy 12, 2467&#x2013;2483 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5173282</ArticleId><ArticleId IdType="pubmed">27813694</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheon S. Y., Kim H., Rubinsztein D. C., Lee J. E., Autophagy, cellular aging and age-related human diseases. Exp Neurobiol 28, 643&#x2013;657 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6946111</ArticleId><ArticleId IdType="pubmed">31902153</ArticleId></ArticleIdList></Reference><Reference><Citation>Leidal A. M., Levine B., Debnath J., Autophagy and the cell biology of age-related disease. Nat. Cell Biol. 20, 1338&#x2013;1348 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30482941</ArticleId></ArticleIdList></Reference><Reference><Citation>Brouillette J., Caillierez R., Zommer N., Alves-Pires C., Benilova I., Blum D., De Strooper B., Bu&#xe9;e L., Neurotoxicity and memory deficits induced by soluble low-molecular-weight amyloid-&#x3b2;1&#x2013;42 oligomers are revealed in vivo by using a novel animal model. J. Neurosci. 32, 7852&#x2013;7861 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6620963</ArticleId><ArticleId IdType="pubmed">22674261</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller-Schiffmann A., Herring A., Abdel-Hafiz L., Chepkova A. N., Sch&#xe4;ble S., Wedel D., Horn A. H. C., Sticht H., de Souza Silva M. A., Gottmann K., Sergeeva O. A., Huston J. P., Keyvani K., Korth C., Amyloid-&#x3b2; dimers in the absence of plaque pathology impair learning and synaptic plasticity. Brain 139, 509&#x2013;525 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26657517</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin M., Shepardson N., Yang T., Chen G., Walsh D., Selkoe D. J., Soluble amyloid &#x3b2;-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc. Natl. Acad. Sci. U.S.A. 108, 5819&#x2013;5824 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3078381</ArticleId><ArticleId IdType="pubmed">21421841</ArticleId></ArticleIdList></Reference><Reference><Citation>Balducci C., Beeg M., Stravalaci M., Bastone A., Sclip A., Biasini E., Tapella L., Colombo L., Manzoni C., Borsello T., Chiesa R., Gobbi M., Salmona M., Forloni G., Synthetic amyloid-&#x3b2; oligomers impair long-term memory independently of cellular prion protein. Proc. Natl. Acad. Sci. U.S.A. 107, 2295&#x2013;2300 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2836680</ArticleId><ArticleId IdType="pubmed">20133875</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh D. M., Klyubin I., Fadeeva J. V., Cullen W. K., Anwyl R., Wolfe M. S., Rowan M. J., Selkoe D. J., Naturally secreted oligomers of amyloid &#x3b2; protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535&#x2013;539 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Parajuli B., Sonobe Y., Horiuchi H., Takeuchi H., Mizuno T., Suzumura A., Oligomeric amyloid &#x3b2; induces IL-1&#x3b2; processing via production of ROS: Implication in Alzheimer's disease. Cell Death Dis. 4, e975 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3877570</ArticleId><ArticleId IdType="pubmed">24357806</ArticleId></ArticleIdList></Reference><Reference><Citation>Gingras S., Earls L. R., Howell S., Smeyne R. J., Zakharenko S. S., Pelletier S., SCYL2 protects CA3 pyramidal neurons from excitotoxicity during functional maturation of the mouse hippocampus. J. Neurosci. 35, 10510&#x2013;10522 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4510291</ArticleId><ArticleId IdType="pubmed">26203146</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">32792660</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>02</Day></DateCompleted><DateRevised><Year>2025</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5578</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>10</Issue><PubDate><Year>2021</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Molecular psychiatry</Title><ISOAbbreviation>Mol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Presenilin 1 phosphorylation regulates amyloid-&#x3b2; degradation by microglia.</ArticleTitle><Pagination><StartPage>5620</StartPage><EndPage>5635</EndPage><MedlinePgn>5620-5635</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41380-020-0856-8</ELocationID><Abstract><AbstractText>Amyloid-&#x3b2; peptide (A&#x3b2;) accumulation in the brain is a hallmark of Alzheimer's Disease. An important mechanism of A&#x3b2; clearance in the brain is uptake and degradation by microglia. Presenilin 1 (PS1) is the catalytic subunit of &#x3b3;-secretase, an enzyme complex responsible for the maturation of multiple substrates, such as A&#x3b2;. Although PS1 has been extensively studied in neurons, the role of PS1 in microglia is incompletely understood. Here we report that microglia containing phospho-deficient mutant PS1 display a slower kinetic response to micro injury in the brain in vivo and the inability to degrade A&#x3b2; oligomers due to a phagolysosome dysfunction. An Alzheimer's mouse model containing phospho-deficient PS1 show severe A&#x3b2; accumulation in microglia as well as the postsynaptic protein PSD95. Our results demonstrate a novel mechanism by which PS1 modulates microglial function and contributes to Alzheimer's -associated phenotypes.</AbstractText><CopyrightInformation>&#xa9; 2020. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ledo</LastName><ForeName>Jose Henrique</ForeName><Initials>JH</Initials><Identifier Source="ORCID">0000-0002-6693-3255</Identifier><AffiliationInfo><Affiliation>Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, NY, 10065, USA. jledo@rockefeller.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liebmann</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, NY, 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Ran</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-7630-1251</Identifier><AffiliationInfo><Affiliation>Lewis Sigler Institute for Integrative Genomics, Princeton University, Princeton, NJ, 08544, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Jerry C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, NY, 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Azevedo</LastName><ForeName>Estefania P</ForeName><Initials>EP</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Genetics, The Rockefeller University, New York, NY, 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Eitan</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Chemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silva</LastName><ForeName>Hernandez Moura</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Skirball Institute of Biomolecular Medicine, New York University School of Medicine, New York, NY, 10016, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Troyanskaya</LastName><ForeName>Olga G</ForeName><Initials>OG</Initials><Identifier Source="ORCID">0000-0002-5676-5737</Identifier><AffiliationInfo><Affiliation>Lewis Sigler Institute for Integrative Genomics, Princeton University, Princeton, NJ, 08544, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Flatiron Institute, Simons Foundation, New York, NY, 10010, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bustos</LastName><ForeName>Victor</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, NY, 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greengard</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, NY, 10065, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 CA008748</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM071966</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>08</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Psychiatry</MedlineTA><NlmUniqueID>9607835</NlmUniqueID><ISSNLinking>1359-4184</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="Y">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare that they have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>11</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>7</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>8</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32792660</ArticleId><ArticleId IdType="mid">NIHMS1654955</ArticleId><ArticleId IdType="pmc">PMC7881060</ArticleId><ArticleId IdType="doi">10.1038/s41380-020-0856-8</ArticleId><ArticleId IdType="pii">10.1038/s41380-020-0856-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Heneka MT, Carson MJ, Khoury JE, Landreth GE, Brosseron F, Feinstein DL, et al. Neuroinflammation in Alzheimer&#x2019;s disease. Lancet Neurol. 2015;14:388&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5909703</ArticleId><ArticleId IdType="pubmed">25792098</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S, Dissing-Olesen L, Stevens B. New insights on the role of microglia in synaptic pruning in health and disease. Curr Opin Neurobiol. 2016;36:128&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5479435</ArticleId><ArticleId IdType="pubmed">26745839</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan Z, Brooks DJ, Okello A, Edison P. An early and late peak in microglial activation in Alzheimer&#x2019;s disease trajectory. Brain J Neurol. 2017;140:792&#x2013;803.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5837520</ArticleId><ArticleId IdType="pubmed">28122877</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamelin L, Lagarde J, Doroth&#xe9;e G, Leroy C, Labit M, Comley RA, et al. Early and protective microglial activation in Alzheimer&#x2019;s disease: a prospective study using 18F-DPA-714 PET imaging. Brain. 2016;139:1252&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">26984188</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoury JE, Toft M, Hickman SE, Means TK, Terada K, Geula C, et al. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med. 2007;13:432&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">17351623</ArticleId></ArticleIdList></Reference><Reference><Citation>Krabbe G, Halle A, Matyash V, Rinnenthal JL, Eom GD, Bernhardt U, et al. Functional impairment of microglia coincides with Beta-amyloid deposition in mice with Alzheimer-like pathology. PLoS ONE. 2013;8:e60921.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3620049</ArticleId><ArticleId IdType="pubmed">23577177</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, Stefansson K. TREM2 and neurodegenerative disease. N Engl J Med. 2013;369:1568&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">24131183</ArticleId></ArticleIdList></Reference><Reference><Citation>Griciuc A, Serrano-Pozo A, Parrado AR, Lesinski AN, Asselin CN, Mullin K, et al. Alzheimer&#x2019;s disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron. 2013;78:631&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3706457</ArticleId><ArticleId IdType="pubmed">23623698</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik M, Parikh I, Vasquez JB, Smith C, Tai L, Bu G, et al. Genetics ignite focus on microglial inflammation in Alzheimer&#x2019;s disease. Mol Neurodegener. 2015;10:52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4595327</ArticleId><ArticleId IdType="pubmed">26438529</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer&#x2019;s disease model. Cell. 2015;160:1061&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference><Reference><Citation>Haapasalo A, Kovacs DM. The many substrates of presenilin/&#x3b3;-secretase. J Alzheimer&#x2019;s Dis. 2011;25:3&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3281584</ArticleId><ArticleId IdType="pubmed">21335653</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, Selkoe DJ. Neurotoxicity of amyloid &#x3b2;-protein: synaptic and network dysfunction. Cold Spring. 2012;2:a006338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3385944</ArticleId><ArticleId IdType="pubmed">22762015</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O&#x2019;Keeffe S, et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci. 2014;34:11929&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4152602</ArticleId><ArticleId IdType="pubmed">25186741</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter J, Kemmerling N, Wunderlich P, Glebov K. &#x3b3;-Secretase in microglia - implications for neurodegeneration and neuroinflammation. J Neurochem. 2017;143:445&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">28940294</ArticleId></ArticleIdList></Reference><Reference><Citation>Arumugam TV, Chan SL, Jo D-G, Yilmaz G, Tang S-C, Cheng A, et al. Gamma secretase-mediated Notch signaling worsens brain damage and functional outcome in ischemic stroke. Nat Med. 2006;12:621&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">16680150</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Q, Li P, Lu J, Dheen ST, Kaur C, Ling E-A. Nuclear factor-&#x3ba;B/p65 responds to changes in the Notch signaling pathway in murine BV-2 cells and in amoeboid microglia in postnatal rats treated with the &#x3b3;-secretase complex blocker DAPT. J Neurosci Res. 2010;88:2701&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">20648656</ArticleId></ArticleIdList></Reference><Reference><Citation>Grandbarbe L, Michelucci A, Heurtaux T, Hemmer K, Morga E, Heuschling P. Notch signaling modulates the activation of microglial cells. Glia. 2007;55:1519&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">17705199</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J, Chan SL, Mattson MP. Adverse effect of a presenilin-1 mutation in microglia results in enhanced nitric oxide and inflammatory cytokine responses to immune challenge in the brain. Neuromol Med. 2002;2:29&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">12230303</ArticleId></ArticleIdList></Reference><Reference><Citation>Matz A, Halamoda-Kenzaoui B, Hamelin R, Mosser S, Alattia J-R, Dimitrov M, et al. Identification of new Presenilin-1 phosphosites: implication for &#x3b3;-secretase activity and A&#x3b2; production. J Neurochem. 2015;133:409&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">25458374</ArticleId></ArticleIdList></Reference><Reference><Citation>Bustos V, Pulina MV, Bispo A, Lam A, Flajolet M, Gorelick FS, et al. Phosphorylated Presenilin 1 decreases &#x3b2;-amyloid by facilitating autophagosome-lysosome fusion. Proc Natl Acad Sci USA. 2017;114:201705240.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5502640</ArticleId><ArticleId IdType="pubmed">28533369</ArticleId></ArticleIdList></Reference><Reference><Citation>Bustos V, Pulina MV, Kelahmetoglu Y, Sinha SC, Gorelick FS, Flajolet M, et al. Bidirectional regulation of A&#x3b2; levels by Presenilin 1. Proc Natl Acad Sci USA. 2017;114:201705235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5502639</ArticleId><ArticleId IdType="pubmed">28533411</ArticleId></ArticleIdList></Reference><Reference><Citation>Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science. 2005;308:1314&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">15831717</ArticleId></ArticleIdList></Reference><Reference><Citation>Haapasalo A, Meller J, Dudiki T, Cull RM, Murtazina R, Bal SK. Integrin-Kindlin3 requirements for microglial motility in vivo are distinct from those for macrophages. JCI Insight. 2017;2:e93002.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5453700</ArticleId><ArticleId IdType="pubmed">28570266</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldey GJ, Roumis DK, Glickfeld LL, Kerlin AM, Reid RC, Bonin V, et al. Removable cranial windows for long-term imaging in awake mice. Nat Protoc. 2014;9:2515&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4442707</ArticleId><ArticleId IdType="pubmed">25275789</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung S, Aliberti J, Graemmel P, Sunshine MJ, Kreutzberg GW, Sher A, et al. Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol Cell Biol. 2000;20:4106&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC85780</ArticleId><ArticleId IdType="pubmed">10805752</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O, Jedrychowski MP, Moore CS, Cialic R, Lanser AJ, Gabriely G, et al. Identification of a unique TGF-&#x3b2;-dependent molecular and functional signature in microglia. Nat Neurosci. 2014;17:131&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4066672</ArticleId><ArticleId IdType="pubmed">24316888</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazaheri F, Breus O, Durdu S, Haas P, Wittbrodt J, Gilmour D, et al. Distinct roles for BAI1 and TIM-4 in the engulfment of dying neurons by microglia. Nat Commun. 2014;5:4046&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">24898390</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu H, Subramanian RR, Masters SC. 14-3-3 proteins: structure, function, and regulation. Annu Rev Pharmacol Toxicol. 2000;40:617&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">10836149</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen MJ, Ramesha S, Weinstock LD, Gao T, Ping L, Xiao H, et al. Microglial ERK signaling is a critical regulator of pro-inflammatory immune responses in Alzheimer&#x2019;s disease. BioRxiv. 2019:798215.</Citation></Reference><Reference><Citation>Kinchen JM, Ravichandran KS. Phagosome maturation: going through the acid test. Nat Rev Mol Cell Biol. 2008;9:781&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2908392</ArticleId><ArticleId IdType="pubmed">18813294</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Garbett K, Veeraraghavalu K, Wilburn B, Gilmore R, Mirnics K, et al. A role for presenilins in autophagy revisited: normal acidification of lysosomes in cells lacking PSEN1 and PSEN2. J Neurosci. 2012;32:8633&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3467018</ArticleId><ArticleId IdType="pubmed">22723704</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccari T, Lu H, Kanwar R, Fortini ME, Bilder D. Endosomal entry regulates Notch receptor activation in Drosophila melanogaster. J Cell Biol. 2008;180:755&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2265571</ArticleId><ArticleId IdType="pubmed">18299346</ArticleId></ArticleIdList></Reference><Reference><Citation>Barth JMI, Hafen E, K&#xf6;hler K. The lack of autophagy triggers precocious activation of Notch signaling during Drosophila oogenesis. BMC Dev Biol. 2012;12:35&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3564699</ArticleId><ArticleId IdType="pubmed">23217079</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X, Fleming A, Ricketts T, Pavel M, Virgin H, Menzies FM, et al. Autophagy regulates Notch degradation and modulates stem cell development and neurogenesis. Nat Commun. 2016;7:10533&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4742842</ArticleId><ArticleId IdType="pubmed">26837467</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong C-M, Ke M, Tan Y, Huang Z, Zhang K, Ai N, et al. Presenilin 1 deficiency suppresses autophagy in human neural stem cells through reducing &#x3b3;-secretase-independent ERK/CREB signaling. Cell Death Dis. 2018;9:879&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6115391</ArticleId><ArticleId IdType="pubmed">30158533</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy K, Cusack CL, Nnah IC, Khayati K, Saqcena C, Huynh TB, et al. Dysregulation of nutrient sensing and CLEARance in presenilin deficiency. Cell Rep. 2016;14:2166&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4793148</ArticleId><ArticleId IdType="pubmed">26923592</ArticleId></ArticleIdList></Reference><Reference><Citation>Martini-Stoica H, Xu Y, Ballabio A, Zheng H. The autophagy-lysosomal pathway in neurodegeneration: a TFEB perspective. Trends Neurosci. 2016;39:221&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4928589</ArticleId><ArticleId IdType="pubmed">26968346</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan H-Y, Alamri AH, Valapala M. Nutrient deprivation and lysosomal stress induce activation of TFEB in retinal pigment epithelial cells. Cell Mol Biol Lett. 2019;24:33&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6537441</ArticleId><ArticleId IdType="pubmed">31160892</ArticleId></ArticleIdList></Reference><Reference><Citation>Uddin MS, Mamun AA, Labu ZK, Hidalgo-Lanussa O, Barreto GE, Ashraf GM. Autophagic dysfunction in Alzheimer&#x2019;s disease: cellular and molecular mechanistic approaches to halt Alzheimer&#x2019;s pathogenesis. J Cell Physiol. 2019;234:8094&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">30362531</ArticleId></ArticleIdList></Reference><Reference><Citation>Boland B, Smith DA, Mooney D, Jung SS, Walsh DM, Platt FM. Macroautophagy is not directly involved in the metabolism of amyloid precursor protein. J Biol Chem. 2010;285:37415&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2988347</ArticleId><ArticleId IdType="pubmed">20864542</ArticleId></ArticleIdList></Reference><Reference><Citation>Caccamo A, Majumder S, Richardson A, Strong R, Oddo S. Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments. J Biol Chem. 2010;285:13107&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2857107</ArticleId><ArticleId IdType="pubmed">20178983</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaeger PA, Pickford F, Sun C-H, Lucin KM, Masliah E, Wyss-Coray T. Regulation of amyloid precursor protein processing by the Beclin 1 complex. PLoS ONE. 2010;5:e11102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2886067</ArticleId><ArticleId IdType="pubmed">20559548</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilsson P, Loganathan K, Sekiguchi M, Matsuba Y, Hui K, Tsubuki S, et al. A&#x3b2; secretion and plaque formation depend on autophagy. Cell Rep. 2013;5:61&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">24095740</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguzzi A, Barres BA, Bennett ML. Microglia: scapegoat, saboteur, or something else? Science. 2013;339:156&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4431634</ArticleId><ArticleId IdType="pubmed">23307732</ArticleId></ArticleIdList></Reference><Reference><Citation>Prinz M, Priller J, Sisodia SS, Ransohoff RM. Heterogeneity of CNS myeloid cells and their roles in neurodegeneration. Nat Neurosci. 2011;14:1227&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">21952260</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer&#x2019;s disease mutations: potential factors in amyloid plaque formation. J Neurosci. 2006;26:10129&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Liebmann T, Renier N, Bettayeb K, Greengard P, Tessier-Lavigne M, Flajolet M. Three-dimensional study of Alzheimer&#x2019;s disease hallmarks using the iDISCO clearing method. Cell Rep. 2016;16:1138&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5040352</ArticleId><ArticleId IdType="pubmed">27425620</ArticleId></ArticleIdList></Reference><Reference><Citation>Condello C, Yuan P, Schain A, Grutzendler J. Microglia constitute a barrier that prevents neurotoxic protofibrillar A&#x3b2;42 hotspots around plaques. Nat Commun. 2015;6:6176&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4311408</ArticleId><ArticleId IdType="pubmed">25630253</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H-J, Cho M-H, Shim WH, Kim JK, Jeon E-Y, Kim D-H, et al. Deficient autophagy in microglia impairs synaptic pruning and causes social behavioral defects. Mol Psychiatry. 2017;22:1576&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5658669</ArticleId><ArticleId IdType="pubmed">27400854</ArticleId></ArticleIdList></Reference><Reference><Citation>Flajolet M, He G, Heiman M, Lin A, Nairn AC, Greengard P. Regulation of Alzheimer&#x2019;s disease amyloid-beta formation by casein kinase I. Proc Natl Acad Sci USA. 2007;104:4159&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1820725</ArticleId><ArticleId IdType="pubmed">17360493</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaked I, Tchoresh D, Gersner R, Meiri G, Mordechai S, Xiao X, et al. Protective autoimmunity: interferon-gamma enables microglia to remove glutamate without evoking inflammatory mediators. J Neurochem. 2005;92:997&#x2013;1009.</Citation><ArticleIdList><ArticleId IdType="pubmed">15715651</ArticleId></ArticleIdList></Reference><Reference><Citation>Hefendehl JK, Neher JJ, S&#xfc;hs RB, Kohsaka S, Skodras A, Jucker M. Homeostatic and injury-induced microglia behavior in the aging brain. Aging Cell. 2014;13:60&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4326865</ArticleId><ArticleId IdType="pubmed">23953759</ArticleId></ArticleIdList></Reference><Reference><Citation>Jahreiss L, Menzies FM, Rubinsztein DC. The itinerary of autophagosomes: from peripheral formation to kiss-and-run fusion with lysosomes. Traffic. 2008;9:574&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2329914</ArticleId><ArticleId IdType="pubmed">18182013</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashiguchi M, Sobue K, Paudel HK. 14-3-3zeta is an effector of tau protein phosphorylation. J Biol Chem. 2000;275:25247&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">10840038</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M. Tau protein and the neurofibrillary pathology of Alzheimer&#x2019;s disease. Trends Neurosci. 1993;16:460&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">7507619</ArticleId></ArticleIdList></Reference><Reference><Citation>Fulga TA, Elson-Schwab I, Khurana V, Steinhilb ML, Spires TL, Hyman BT, et al. Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo. Nat Cell Biol. 2007;9:139&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">17187063</ArticleId></ArticleIdList></Reference><Reference><Citation>Elie A, Prezel E, Gu&#xe9;rin C, Denarier E, Ramirez-Rios S, Serre L, et al. Tau co-organizes dynamic microtubule and actin networks. Sci Rep. 2015;5:9964&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4421749</ArticleId><ArticleId IdType="pubmed">25944224</ArticleId></ArticleIdList></Reference><Reference><Citation>Franco-Bocanegra DK, McAuley C, Nicoll JAR, Boche D. Molecular mechanisms of microglial motility: changes in ageing and Alzheimer&#x2019;s disease. Cells. 2019;8:639.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6627151</ArticleId><ArticleId IdType="pubmed">31242692</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang K, Zhang T, Lei Y, Li X, Jiang J, Lan J, et al. Identification of ANXA2 (annexin A2) as a specific bleomycin target to induce pulmonary fibrosis by impeding TFEB-mediated autophagic flux. Autophagy. 2018;14:269&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5902212</ArticleId><ArticleId IdType="pubmed">29172997</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S, Beja-Glasser VF, Nfonoyim BM, Frouin A, Li S, Ramakrishnan S, et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science. 2016;352:712&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5094372</ArticleId><ArticleId IdType="pubmed">27033548</ArticleId></ArticleIdList></Reference><Reference><Citation>Semick SA, Bharadwaj RA, Collado-Torres L, Tao R, Shin JH, Deep-Soboslay A, et al. Integrated DNA methylation and gene expression profiling across multiple brain regions implicate novel genes in Alzheimer&#x2019;s disease. Acta Neuropathol. 2019;137:557&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">30712078</ArticleId></ArticleIdList></Reference><Reference><Citation>Saura J, Tusell JM, Serratosa J. High-yield isolation of murine microglia by mild trypsinization. Glia. 2003;44:183&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">14603460</ArticleId></ArticleIdList></Reference><Reference><Citation>Ledo JH, Azevedo EP, Beckman D, Ribeiro FC, Santos LE, Razolli DS, et al. Cross talk between brain innate immunity and serotonin signaling underlies depressive-like behavior induced by Alzheimer&#x2019;s amyloid-&#x3b2; oligomers in mice. J Neurosci. 2016;36:12106&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6601978</ArticleId><ArticleId IdType="pubmed">27903721</ArticleId></ArticleIdList></Reference><Reference><Citation>Paolicelli RC, Jawaid A, Henstridge CM, Valeri A, Merlini M, Robinson JL, et al. TDP-43 depletion in microglia promotes amyloid clearance but also induces synapse loss. Neuron. 2017;95:297&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5519492</ArticleId><ArticleId IdType="pubmed">28669544</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3:1101&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">18546601</ArticleId></ArticleIdList></Reference><Reference><Citation>Chau D-M, Crump CJ, Villa JC, Scheinberg DA, Li Y-M. Familial Alzheimer disease presenilin-1 mutations alter the active site conformation of &#x3b3;-secretase. J Biol Chem. 2012;287:17288&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3366784</ArticleId><ArticleId IdType="pubmed">22461631</ArticleId></ArticleIdList></Reference><Reference><Citation>Renier N, Wu Z, Simon DJ, Yang J, Ariel P, Tessier-Lavigne M. iDISCO: a simple, rapid method to immunolabel large tissue samples for volume imaging. Cell. 2014;159:896&#x2013;910.</Citation><ArticleIdList><ArticleId IdType="pubmed">25417164</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelmann R, Anhut T, Kleppe I, Microsc KWI, 2014. Airyscanning: evoking the full potential of confocal microscopy. n.d.</Citation></Reference><Reference><Citation>Kolossov VL, Sivaguru M, Huff J, Luby K, Kanakaraju K, Gaskins HR. Airyscan super&#x2010;resolution microscopy of mitochondrial morphology and dynamics in living tumor cells. Microsc Res Technol. 2018;81:115&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">29131445</ArticleId></ArticleIdList></Reference><Reference><Citation>Schafer DP, Lehrman EK, Kautzman AG, Koyama R, Mardinly AR, Yamasaki R, et al. Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron. 2012;74:691&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3528177</ArticleId><ArticleId IdType="pubmed">22632727</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32788726</PMID><DateCompleted><Year>2020</Year><Month>10</Month><Day>05</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>585</Volume><Issue>7823</Issue><PubDate><Year>2020</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Interpericyte tunnelling nanotubes regulate neurovascular coupling.</ArticleTitle><Pagination><StartPage>91</StartPage><EndPage>95</EndPage><MedlinePgn>91-95</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41586-020-2589-x</ELocationID><Abstract><AbstractText>Signalling between cells of the neurovascular unit, or neurovascular coupling, is essential to match local blood flow with neuronal activity. Pericytes interact with endothelial cells and extend processes that wrap capillaries, covering up to 90% of their surface area<sup>1,2</sup>. Pericytes are candidates to regulate microcirculatory blood flow because they are strategically positioned along capillaries, contain contractile proteins and respond rapidly to neuronal stimulation<sup>3,4</sup>, but whether they synchronize microvascular dynamics and neurovascular coupling within a capillary network was unknown. Here we identify nanotube-like processes that connect two bona fide pericytes on separate capillary systems, forming a functional network in the mouse retina, which we named interpericyte tunnelling nanotubes (IP-TNTs). We provide evidence that these (i) have an open-ended proximal side and a closed-ended terminal (end-foot) that connects with distal pericyte processes via gap junctions, (ii) carry organelles including mitochondria, which can travel along these processes, and (iii) serve as a conduit for intercellular Ca<sup>2+</sup> waves, thus mediating communication between pericytes. Using two-photon microscope live imaging, we demonstrate that retinal pericytes rely on IP-TNTs to control local neurovascular coupling and coordinate light-evoked responses between adjacent capillaries. IP-TNT damage following ablation or ischaemia disrupts intercellular Ca<sup>2+</sup>&#xa0;waves, impairing blood flow regulation and neurovascular coupling. Notably, pharmacological blockade of Ca<sup>2+</sup> influx preserves IP-TNTs, rescues light-evoked capillary responses and restores blood flow after reperfusion. Our study thus defines IP-TNTs and characterizes their critical role in regulating neurovascular coupling in the living retina under both physiological and pathological conditions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Alarcon-Martinez</LastName><ForeName>Luis</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-3167-7423</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, University of Montreal, Montreal, Quebec, Canada. lalarcon@um.es.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Montreal Hospital Research Centre, Montreal, Quebec, Canada. lalarcon@um.es.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Villafranca-Baughman</LastName><ForeName>Deborah</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, University of Montreal, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Montreal Hospital Research Centre, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quintero</LastName><ForeName>Heberto</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, University of Montreal, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Montreal Hospital Research Centre, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kacerovsky</LastName><ForeName>J Benjamin</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Centre for Research in Neuroscience, Department of Neurology and Neurosurgery, The Research Institute of the McGill University Health Centre, Montreal General Hospital, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dotigny</LastName><ForeName>Florence</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, University of Montreal, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Montreal Hospital Research Centre, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murai</LastName><ForeName>Keith K</ForeName><Initials>KK</Initials><AffiliationInfo><Affiliation>Centre for Research in Neuroscience, Department of Neurology and Neurosurgery, The Research Institute of the McGill University Health Centre, Montreal General Hospital, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prat</LastName><ForeName>Alexandre</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-6188-0580</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, University of Montreal, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Montreal Hospital Research Centre, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drapeau</LastName><ForeName>Pierre</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, University of Montreal, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Montreal Hospital Research Centre, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Polo</LastName><ForeName>Adriana</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1430-0760</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, University of Montreal, Montreal, Quebec, Canada. adriana.di.polo@umontreal.ca.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Montreal Hospital Research Centre, Montreal, Quebec, Canada. adriana.di.polo@umontreal.ca.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>08</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2020 Sep;585(7823):32-33. doi: 10.1038/d41586-020-02315-3.</RefSource><PMID Version="1">32788697</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002545" MajorTopicYN="N">Brain Ischemia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020013" MajorTopicYN="N">Calcium Signaling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002196" MajorTopicYN="N">Capillaries</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002450" MajorTopicYN="N">Cell Communication</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017629" MajorTopicYN="N">Gap Junctions</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006439" MajorTopicYN="N">Hemodynamics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D043942" MajorTopicYN="Y">Nanotubes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069336" MajorTopicYN="Y">Neurovascular Coupling</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020286" MajorTopicYN="N">Pericytes</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012160" MajorTopicYN="N">Retina</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>12</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>7</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32788726</ArticleId><ArticleId IdType="doi">10.1038/s41586-020-2589-x</ArticleId><ArticleId IdType="pii">10.1038/s41586-020-2589-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Attwell, D., Mishra, A., Hall, C. N., O&#x2019;Farrell, F. M. &amp; Dalkara, T. What is a pericyte? J. Cereb. Blood Flow Metab. 36, 451&#x2013;455 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0271678X15610340</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalkara, T. &amp; Alarcon-Martinez, L. Cerebral microvascular pericytes and neurogliovascular signaling in health and disease. Brain Res. 1623, 3&#x2013;17 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2015.03.047</ArticleId></ArticleIdList></Reference><Reference><Citation>Alarcon-Martinez, L. et al. Capillary pericytes express &#x3b1;-smooth muscle actin, which requires prevention of filamentous-actin depolymerization for detection. eLife 7, e34861 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.34861</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall, C. N. et al. Capillary pericytes regulate cerebral blood flow in health and disease. Nature 508, 55&#x2013;60 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature13165</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton, N. B., Attwell, D. &amp; Hall, C. N. Pericyte-mediated regulation of capillary diameter: a component of neurovascular coupling in health and disease. Front. Neuroenergetics 2, 5 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnene.2010.00005</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu, X., Bergles, D. E. &amp; Nishiyama, A. NG2 cells generate both oligodendrocytes and gray matter astrocytes. Development 135, 145&#x2013;157 (2008).</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dev.004895</ArticleId></ArticleIdList></Reference><Reference><Citation>Henle, F. Ueber die Ausbreitung des Epithelium im menschlichen K&#xf6;rper. Arch. Anat. Physiol. Wiss. Med. 1838, 103&#x2013;128 (1838).</Citation></Reference><Reference><Citation>Cerletti, U. Die gefassvermehrung in zentralnervensystem. Histol. Histopathol. Arb. Grosshirnr. 4, 1&#x2013;168 (1910).</Citation></Reference><Reference><Citation>Cammermeyer, J. A comparative study of intervascular connective tissue strands in the central nervous system. J. Comp. Neurol. 114, 189&#x2013;208 (1960).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cne.901140206</ArticleId></ArticleIdList></Reference><Reference><Citation>Reissenweber, N. J. &amp; Pessacq, T. Intervascular strands in the central nervous system. A histochemical approach. Acta Anat. 78, 51&#x2013;57 (1971).</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000143574</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson, J. R., Tilton, R. G., Kilo, C. &amp; Yu, S. Immunofluorescent imaging of capillaries and pericytes in human skeletal muscle and retina. Microvasc. Res. 20, 233&#x2013;241 (1980).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0026-2862(80)90010-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Leibnitz, L. &amp; B&#xe4;r, B. A blood capillaries-bridging cell type in adult mammalian brains. J. Hirnforsch. 29, 367&#x2013;375 (1988).</Citation><ArticleIdList><ArticleId IdType="pubmed">2460522</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendes-Jorge, L. et al. Intercapillary bridging cells: immunocytochemical characteristics of cells that connect blood vessels in the retina. Exp. Eye Res. 98, 79&#x2013;87 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exer.2012.03.010</ArticleId></ArticleIdList></Reference><Reference><Citation>Korenkova, O., Pepe, A. &amp; Zurzolo, C. Fine intercellular connections in development: TNTs, cytonemes, or intercellular bridges? Cell Stress 4, 30&#x2013;43 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.15698/cst2020.02.212</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris, A. L. Connexin channel permeability to cytoplasmic molecules. Prog. Biophys. Mol. Biol. 94, 120&#x2013;143 (2007).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pbiomolbio.2007.03.011</ArticleId></ArticleIdList></Reference><Reference><Citation>Sartori-Rupp, A. et al. Correlative cryo-electron microscopy reveals the structure of TNTs in neuronal cells. Nat. Commun. 10, 342 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-08178-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Theofilas, P., Steinh&#xe4;user, C., Theis, M. &amp; Derouiche, A. Morphological study of a connexin 43-GFP reporter mouse highlights glial heterogeneity, amacrine cells, and olfactory ensheathing cells. J. Neurosci. Res. 95, 2182&#x2013;2194 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.24055</ArticleId></ArticleIdList></Reference><Reference><Citation>Rustom, A., Saffrich, R., Markovic, I., Walther, P. &amp; Gerdes, H.-H. Nanotubular highways for intercellular organelle transport. Science 303, 1007&#x2013;1010 (2004).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1093133</ArticleId></ArticleIdList></Reference><Reference><Citation>Pham, A. H., McCaffery, J. M. &amp; Chan, D. C. Mouse lines with photo-activatable mitochondria to study mitochondrial dynamics. Genesis 50, 833&#x2013;843 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dvg.22050</ArticleId></ArticleIdList></Reference><Reference><Citation>Osswald, M. et al. Brain tumour cells interconnect to a functional and resistant network. Nature 528, 93&#x2013;98 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature16071</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, X., Veruki, M. L., Bukoreshtliev, N. V., Hartveit, E. &amp; Gerdes, H.-H. Animal cells connected by nanotubes can be electrically coupled through interposed gap-junction channels. Proc. Natl Acad. Sci. USA 107, 17194&#x2013;17199 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1006785107</ArticleId></ArticleIdList></Reference><Reference><Citation>Longden, T. A. et al. Capillary K<sup>+</sup>-sensing initiates retrograde hyperpolarization to increase local cerebral blood flow. Nat. Neurosci. 20, 717&#x2013;726 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4533</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilsson, S. F. &amp; Alm, A. in Ocular Blood Flow (eds Kiel, J. W. &amp; Schmetterer, L.) 25&#x2013;47 (Springer-Verlag, 2012).</Citation></Reference><Reference><Citation>Alarcon-Martinez, L. et al. Retinal ischemia induces &#x3b1;-SMA-mediated capillary pericyte contraction coincident with perivascular glycogen depletion. Acta Neuropathol. Commun. 7, 134 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-019-0761-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Underly, R. G. &amp; Shih, A. Y. Photothrombotic induction of capillary ischemia in the mouse cortex during in vivo two-photon imaging. Bio Protoc. 7, e2378 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.21769/BioProtoc.2378</ArticleId></ArticleIdList></Reference><Reference><Citation>Borysova, L., Wray, S., Eisner, D. A. &amp; Burdyga, T. How calcium signals in myocytes and pericytes are integrated across in situ microvascular networks and control microvascular tone. Cell Calcium 54, 163&#x2013;174 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ceca.2013.06.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Franco, C. A. et al. Dynamic endothelial cell rearrangements drive developmental vessel regression. PLoS Biol. 13, e1002125 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.1002125</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu, D.-Y. et al. Retinal capillary perfusion: spatial and temporal heterogeneity. Prog. Retin. Eye Res. 70, 23&#x2013;54 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.preteyeres.2019.01.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Mouton, P. R. Principles and Practices of Unbiased Stereology: An Introduction for Bioscientists (Johns Hopkins Univ. Press, Baltimore, 2002).</Citation></Reference><Reference><Citation>Takihara, Y. et al. In vivo imaging of axonal transport of mitochondria in the diseased and aged mammalian CNS. Proc. Natl Acad. Sci. USA 112, 10515&#x2013;10520 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1509879112</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">32848093</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>558</Issue><PubDate><Year>2020</Year><Month>Aug</Month><Day>26</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>A second X chromosome contributes to resilience in a mouse model of Alzheimer's disease.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">eaaz5677</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.aaz5677</ELocationID><Abstract><AbstractText>A major sex difference in Alzheimer's disease (AD) is that men with the disease die earlier than do women. In aging and preclinical AD, men also show more cognitive deficits. Here, we show that the X chromosome affects AD-related vulnerability in mice expressing the human amyloid precursor protein (hAPP), a model of AD. XY-hAPP mice genetically modified to develop testicles or ovaries showed worse mortality and deficits than did XX-hAPP mice with either gonad, indicating a sex chromosome effect. To dissect whether the absence of a second X chromosome or the presence of a Y chromosome conferred a disadvantage on male mice, we varied sex chromosome dosage. With or without a Y chromosome, hAPP mice with one X chromosome showed worse mortality and deficits than did those with two X chromosomes. Thus, adding a second X chromosome conferred resilience to XY males and XO females. In addition, the Y chromosome, its sex-determining region Y gene (<i>Sry</i>), or testicular development modified mortality in hAPP mice with one X chromosome such that XY males with testicles survived longer than did XY or XO females with ovaries. Furthermore, a second X chromosome conferred resilience potentially through the candidate gene <i>Kdm6a</i>, which does not undergo X-linked inactivation. In humans, genetic variation in <i>KDM6A</i> was linked to higher brain expression and associated with less cognitive decline in aging and preclinical AD, suggesting its relevance to human brain health. Our study suggests a potential role for sex chromosomes in modulating disease vulnerability related to AD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Emily J</ForeName><Initials>EJ</Initials><Identifier Source="ORCID">0000-0001-9878-1252</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Sciences Graduate Program, University of California, San Francisco, San Francisco, CA 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Broestl</LastName><ForeName>Lauren</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-6566-3986</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdulai-Saiku</LastName><ForeName>Samira</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-3772-4646</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Worden</LastName><ForeName>Kurtresha</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-5621-7979</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonham</LastName><ForeName>Luke W</ForeName><Initials>LW</Initials><Identifier Source="ORCID">0000-0002-2533-1266</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory and Aging Center, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mi&#xf1;ones-Moyano</LastName><ForeName>Elena</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-9007-8589</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moreno</LastName><ForeName>Arturo J</ForeName><Initials>AJ</Initials><Identifier Source="ORCID">0000-0003-2357-5854</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Dan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology and Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-6227-6430</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Gina</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurology and Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurosciences Graduate Program, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garay</LastName><ForeName>Bayardo I</ForeName><Initials>BI</Initials><Identifier Source="ORCID">0000-0002-1458-6095</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lobach</LastName><ForeName>Iryna</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Devidze</LastName><ForeName>Nino</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anderson-Bergman</LastName><ForeName>Cliff</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-4721-7472</Identifier><AffiliationInfo><Affiliation>Gladstone Institute of Cardiovascular Disease, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Gui-Qiu</ForeName><Initials>GQ</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>White</LastName><ForeName>Charles C</ForeName><Initials>CC</Initials><Identifier Source="ORCID">0000-0001-9702-4516</Identifier><AffiliationInfo><Affiliation>Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Translational and Computational Neuroimmunology, Department of Neurology, Columbia University Medical Center, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harris</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials><Identifier Source="ORCID">0000-0003-0820-2021</Identifier><AffiliationInfo><Affiliation>Allen Institute for Brain Science, Seattle, WA 98109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials><Identifier Source="ORCID">0000-0002-2152-4220</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory and Aging Center, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials><Identifier Source="ORCID">0000-0003-3689-554X</Identifier><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL 60612, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arnold</LastName><ForeName>Arthur P</ForeName><Initials>AP</Initials><Identifier Source="ORCID">0000-0002-9908-9767</Identifier><AffiliationInfo><Affiliation>Department of Integrative Biology and Physiology, University of California, Los Angeles, Los Angeles, CA 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Jager</LastName><ForeName>Phil L</ForeName><Initials>PL</Initials><Identifier Source="ORCID">0000-0002-8057-2505</Identifier><AffiliationInfo><Affiliation>Center for Translational and Computational Neuroimmunology, Department of Neurology, Columbia University Medical Center, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palop</LastName><ForeName>Jorge J</ForeName><Initials>JJ</Initials><Identifier Source="ORCID">0000-0001-6086-1070</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Sciences Graduate Program, University of California, San Francisco, San Francisco, CA 94143, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurosciences Graduate Program, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Panning</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yokoyama</LastName><ForeName>Jennifer S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Neurology and Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory and Aging Center, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mucke</LastName><ForeName>Lennart</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-6256-9559</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Sciences Graduate Program, University of California, San Francisco, San Francisco, CA 94143, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurosciences Graduate Program, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dubal</LastName><ForeName>Dena B</ForeName><Initials>DB</Initials><Identifier Source="ORCID">0000-0001-7504-4372</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA 94158, USA. dena.dubal@ucsf.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Sciences Graduate Program, University of California, San Francisco, San Francisco, CA 94143, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurosciences Graduate Program, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS043196</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG011385</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG049152</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG062588</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG061356</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HD076125</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS065780</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG068325</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 AG034531</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM128431</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000004</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG062629</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG046152</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG011385</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG036836</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG062234</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS092918</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012727" MajorTopicYN="N">Sex Characteristics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013737" MajorTopicYN="N">Testis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014960" MajorTopicYN="N">X Chromosome</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014998" MajorTopicYN="N">Y Chromosome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>1</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32848093</ArticleId><ArticleId IdType="mid">NIHMS1704879</ArticleId><ArticleId IdType="pmc">PMC8409261</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.aaz5677</ArticleId><ArticleId IdType="pii">12/558/eaaz5677</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>McCarthy MM, Woolley CS, Arnold AP, Incorporating sex as a biological variable in neuroscience: What do we gain? Nat. Rev. Neurosci 18, 707&#x2013;708 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29097784</ArticleId></ArticleIdList></Reference><Reference><Citation>Prince M, Wimo A, Guerchet M, Ali G-C, Wu Y-T, Prina M, World Alzheimer Report 2015: The Global Impact of Dementia (Alzheimer&#x2019;s Disease International (ADI), 2015).</Citation></Reference><Reference><Citation>Elmaleh DR, Farlow MR, Conti PS, Tompkins RG, Kundakovic L, Tanzi RE, Developing effective Alzheimer's disease therapies: Clinical experience and future directions. J. Alzheimers Dis 71, 715&#x2013;732 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6839593</ArticleId><ArticleId IdType="pubmed">31476157</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubal DB, Sex Differences in Alzheimer&#x2019;s disease: An updated, balanced, and emerging perspective on differing vulnerabilities, in Sex Differences in Neurology and Psychiatry, Lanzberger R, Kranz GS, Savic-Berglund I, Eds., Handbook of Clinical Neurology, Vol. 175 (3rd series) (Elsevier, 2020); 10.1016/B978-0-444-64123-6.00018-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-444-64123-6.00018-7</ArticleId><ArticleId IdType="pubmed">33008530</ArticleId></ArticleIdList></Reference><Reference><Citation>Mielke MM, Vemuri P, Rocca WA, Clinical epidemiology of Alzheimer's disease: Assessing sex and gender differences. Clin. Epidemiol 6, 37&#x2013;48 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3891487</ArticleId><ArticleId IdType="pubmed">24470773</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebert LE, Scherr PA, McCann JJ, Beckett LA, Evans DA, Is the risk of developing Alzheimer's disease greater for women than for men? Am. J. Epidemiol 153, 132&#x2013;136 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11159157</ArticleId></ArticleIdList></Reference><Reference><Citation>Claus JJ, van Gool WA, Teunisse S, Walstra GJM, Kwa VIH, Hijdra A, Verbeeten B Jr., Koelman JHTM, Bour LJ, Ongerboer De Visser BW, Predicting survival in patients with early Alzheimer's disease. Dement. Geriatr. Cogn. Disord 9, 284&#x2013;293 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9701680</ArticleId></ArticleIdList></Reference><Reference><Citation>Heyman A, Wilkinson WE, Hurwitz BJ, Helms MJ, Haynes CS, Utley CM, Gwyther LP, Early-onset Alzheimer's disease: Clinical predictors of institutionalization and death. Neurology 37, 980&#x2013;984 (1987).</Citation><ArticleIdList><ArticleId IdType="pubmed">3587649</ArticleId></ArticleIdList></Reference><Reference><Citation>Ueki A, Shinjo H, Shimode H, Nakajima T, Morita Y, Factors associated with mortality in patients with early-onset Alzheimer's disease: A five-year longitudinal study. Int. J. Geriatr. Psychiatry 16, 810&#x2013;815 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11536348</ArticleId></ArticleIdList></Reference><Reference><Citation>Lapane KL, Gambassi G, Landi F, Sgadari A, Mor V, Bernabei R, Gender differences in predictors of mortality in nursing home residents with AD. Neurology 56, 650&#x2013;654 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11245718</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y, Tang M-X, Albert MS, Brandt J, Jacobs DM, Bell K, Marder K, Sano M, Devanand D, Albert SM, Bylsma F, Tsai W-Y, Predicting time to nursing home care and death in individuals with Alzheimer disease. JAMA 277, 806&#x2013;812 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9052710</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckley RF, Mormino EC, Amariglio RE, Properzi MJ, Rabin JS, Lim YY, Papp KV, Jacobs HIL, Burnham S, Hanseeuw BJ, Dor&#xe9; V, Dobson A, Masters CL, Waller M, Rowe CC, Maruff P, Donohue MC, Rentz DM, Kirn D, Hedden T, Chhatwal J, Schultz AP, Johnson KA, Villemagne VL, Sperling RA; Alzheimer's Disease Neuroimaging Initiative; Australian Imaging, Biomarker and Lifestyle study of ageing; Harvard Aging Brain Study, Sex, amyloid, and APOE &#x3b5;4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three well-characterized cohorts. Alzheimers Dement. 14, 1193&#x2013;1203 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6131023</ArticleId><ArticleId IdType="pubmed">29803541</ArticleId></ArticleIdList></Reference><Reference><Citation>Casaletto KB, Elahi FM, Staffaroni AM, Walters S, Contreras WR, Wolf A, Dubal D, Miller B, Yaffe K, Kramer JH, Cognitive aging is not created equally: Differentiating unique cognitive phenotypes in "normal" adults. Neurobiol. Aging 77, 13&#x2013;19 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6486874</ArticleId><ArticleId IdType="pubmed">30772736</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerhan JR, Folsom AR, Mortimer JA, Shahar E, Knopman DS, McGovern PG, Hays MA, Crum LD, Heiss G, Correlates of cognitive function in middle-aged adults. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Gerontology 44, 95&#x2013;105 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9523221</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr., Wiste HJ, Weigand SD, Knopman DS, Vemuri P, Mielke MM, Lowe V, Senjem ML, Gunter JL, Machulda MM, Gregg BE, Pankratz VS, Rocca WA, Petersen RC, Age, sex, and APOE &#x3b5;4 effects on memory, brain structure, and &#x3b2;-amyloid across the adult life span. JAMA Neurol. 72, 511&#x2013;519 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4428984</ArticleId><ArticleId IdType="pubmed">25775353</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr., Therneau TM, Wiste HJ, Weigand SD, Knopman DS, Lowe VJ, Mielke MM, Vemuri P, Roberts RO, Machulda MM, Senjem ML, Gunter JL, Rocca WA, Petersen RC, Transition rates between amyloid and neurodegeneration biomarker states and to dementia: A population-based, longitudinal cohort study. Lancet Neurol. 15, 56&#x2013;64 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4784263</ArticleId><ArticleId IdType="pubmed">26597325</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr., Wiste HJ, Weigand SD, Therneau TM, Knopman DS, Lowe V, Vemuri P, Mielke MM, Roberts RO, Machulda MM, Senjem ML, Gunter JL, Rocca WA, Petersen RC, Age-specific and sex-specific prevalence of cerebral &#x3b2;-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: A cross-sectional study. Lancet Neurol. 16, 435&#x2013;444 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5516534</ArticleId><ArticleId IdType="pubmed">28456479</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr., Therneau TM, Weigand SD, Wiste HJ, Knopman DS, Vemuri P, Lowe VJ, Mielke MM, Roberts RO, Machulda MM, Graff-Radford J, Jones DT, Schwarz CG, Gunter JL, Senjem ML, Rocca WA, Petersen RC, Prevalence of biologically vs clinically defined Alzheimer spectrum entities using the National Institute on Aging-Alzheimer's Association Research Framework. JAMA Neurol. 76, 1174&#x2013;1183 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6632154</ArticleId><ArticleId IdType="pubmed">31305929</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Roberts RO, Knopman DS, Geda YE, Cha RH, Pankratz VS, Boeve BF, Tangalos EG, Ivnik RJ, Rocca WA, Prevalence of mild cognitive impairment is higher in men. The Mayo Clinic Study of Aging. Neurology 75, 889&#x2013;897 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2938972</ArticleId><ArticleId IdType="pubmed">20820000</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts RO, Geda YE, Knopman DS, Cha RH, Pankratz VS, Boeve BF, Tangalos EG, Ivnik RJ, Rocca WA, Petersen RC, The incidence of MCI differs by subtype and is higher in men: The Mayo Clinic Study of Aging. Neurology 78, 342&#x2013;351 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3280046</ArticleId><ArticleId IdType="pubmed">22282647</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, Masliah E, Yu G-Q, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L, High-level neuronal expression of A&#x3b2;1&#x2013;42 in wild-type human amyloid protein precursor transgenic mice: Synaptotoxicity without plaque formation. J. Neurosci 20, 4050&#x2013;4058 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrini RL, Barrett-Connor E, Sex hormones and age: A cross-sectional study of testosterone and estradiol and their bioavailable fractions in community-dwelling men. Am. J. Epidemiol 147, 750&#x2013;754 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9554416</ArticleId></ArticleIdList></Reference><Reference><Citation>Morley JE, Kaiser F, Raum WJ, Perry III HM, Flood JF, Jensen J, Silver AJ, Roberts E, Potentially predictive and manipulable blood serum correlates of aging in the healthy human male: Progressive decreases in bioavailable testosterone, dehydroepiandrosterone sulfate, and the ratio of insulin-like growth factor 1 to growth hormone. Proc. Natl. Acad. Sci. U.S.A 94, 7537&#x2013;7542 (1997).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC23857</ArticleId><ArticleId IdType="pubmed">9207127</ArticleId></ArticleIdList></Reference><Reference><Citation>Veldhuis JD, Aging and hormones of the hypothalamo-pituitary axis: Gonadotropic axis in men and somatotropic axes in men and women. Ageing Res. Rev 7, 189&#x2013;208 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2583117</ArticleId><ArticleId IdType="pubmed">18343203</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson JF, Felicio LS, Osterburg HH, Finch CE, Differential contributions of ovarian and extraovarian factors to age-related reductions in plasma estradiol and progesterone during the estrous cycle of C57BL/6J mice. Endocrinology 130, 805&#x2013;810 (1992).</Citation><ArticleIdList><ArticleId IdType="pubmed">1733727</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson JF, Latham KR, Finch CE, Plasma testosterone levels in C57BL/6J male mice: Effects of age and disease. Acta Endocrinol. 80, 744&#x2013;752 (1975).</Citation><ArticleIdList><ArticleId IdType="pubmed">1103542</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin J, Palop JJ, Puoliv&#xe4;li J, Massaro C, Bien-Ly N, Gerstein H, Scearce-Levie K, Masliah E, Mucke L, Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease. J. Neurosci 25, 9694&#x2013;9703 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725734</ArticleId><ArticleId IdType="pubmed">16237174</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson ED, Halabisky B, Yoo JW, Yao J, Chin J, Yan F, Wu T, Hamto P, Devidze N, Yu G-Q, Palop JJ, Noebels JL, Mucke L, Amyloid-&#x3b2;/Fyn&#x2013;induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J. Neurosci 31, 700&#x2013;711 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3325794</ArticleId><ArticleId IdType="pubmed">21228179</ArticleId></ArticleIdList></Reference><Reference><Citation>Callahan MJ, Lipinski WJ, Bian F, Durham RA, Pack A, Walker LC, Augmented senile plaque load in aged female &#x3b2;-amyloid precursor protein-transgenic mice. Am. J. Pathol 158, 1173&#x2013;1177 (2001).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850367</ArticleId><ArticleId IdType="pubmed">11238065</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold AP, Chen X, What does the &#x201c;four core genotypes&#x201d; mouse model tell us about sex differences in the brain and other tissues? Front. Neuroendocrinol 30, 1&#x2013;9 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3282561</ArticleId><ArticleId IdType="pubmed">19028515</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahadevaiah SK, Odorisio T, Elliott DJ, Rattigan &#xc1;, Szot M, Laval SH, Washburn LL, McCarrey JR, Cattanach BM, Lovell-Badge R, Burgoyne PS, Mouse homologues of the human AZF candidate gene RBM are expressed in spermatogonia and spermatids, and map to a Y chromosome deletion interval associated with a high incidence of sperm abnormalities. Hum. Mol. Genet 7, 715&#x2013;727 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9499427</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy MM, Arnold AP, Reframing sexual differentiation of the brain. Nat. Neurosci 14, 677&#x2013;683 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3165173</ArticleId><ArticleId IdType="pubmed">21613996</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold AP, Mouse models for evaluating sex chromosome effects that cause sex differences in non-gonadal tissues. J. Neuroendocrinol 21, 377&#x2013;386 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2669494</ArticleId><ArticleId IdType="pubmed">19207816</ArticleId></ArticleIdList></Reference><Reference><Citation>Eicher EM, Hale DW, Hunt PA, Lee BK, Tucker PK, King TR, Eppig JT, Washburn LL, The mouse Y* chromosome involves a complex rearrangement, including interstitial positioning of the pseudoautosomal region. Cytogenet. Cell Genet 57, 221&#x2013;230 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1743079</ArticleId></ArticleIdList></Reference><Reference><Citation>Berletch JB, Yang F, Disteche CM, Escape from X inactivation in mice and humans. Genome Biol. 11, 213 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2911101</ArticleId><ArticleId IdType="pubmed">20573260</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrel L, Willard HF, X-inactivation profile reveals extensive variability in X-linked gene expression in females. Nature 434, 400&#x2013;404 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15772666</ArticleId></ArticleIdList></Reference><Reference><Citation>Tukiainen T, Villani A-C, Yen A, Rivas MA, Marshall JL, Satija R, Aguirre M, Gauthier L, Fleharty M, Kirby A, Cummings BB, Castel SE, Karczewski KJ, Aguet F, Byrnes A; GTEx Consortium; Laboratory, Data Analysis &amp;Coordinating Center (LDACC)&#x2014;Analysis Working Group; Statistical Methods groups&#x2014;Analysis Working Group; Enhancing GTEx (eGTEx) groups; NIH Common Fund; NIH/NCI; NIH/NHGRI; NIH/NIMH; NIH/NIDA; Biospecimen Collection Source Site&#x2014;NDRI; Biospecimen Collection Source Site&#x2014;RPCI; Biospecimen Core Resource&#x2014;VARI; Brain Bank Repository&#x2014;University of Miami Brain Endowment Bank; Leidos Biomedical&#x2014;Project Management; ELSI Study; Genome Browser Data Integration &amp;Visualization&#x2014;EBI; Genome Browser Data Integration &amp;Visualization&#x2014;UCSC Genomics Institute, University of California Santa Cruz, Lappalainen T, Regev A, Ardlie KG, Hacohen N, MacArthur DG, Landscape of X chromosome inactivation across human tissues. Nature 550, 244&#x2013;248 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5685192</ArticleId><ArticleId IdType="pubmed">29022598</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang F, Babak T, Shendure J, Disteche CM, Global survey of escape from X inactivation by RNA-sequencing in mouse. Genome Res. 20, 614&#x2013;622 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2860163</ArticleId><ArticleId IdType="pubmed">20363980</ArticleId></ArticleIdList></Reference><Reference><Citation>Berletch JB, Ma W, Yang F, Shendure J, Noble WS, Disteche CM, Deng X, Escape from X inactivation varies in mouse tissues. PLOS Genet. 11, e1005079 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4364777</ArticleId><ArticleId IdType="pubmed">25785854</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenfield A, Carrel L, Pennisi D, Philippe C, Quaderi N, Siggers P, Steiner K, Tam PPL, Monaco AP, Willard HF, Koopman P, The UTX gene escapes X inactivation in mice and humans. Hum. Mol. Genet 7, 737&#x2013;742 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9499428</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xf6;gershausen N, Gatinois V, Riehmer V, Kayserili H, Becker J, Thoenes M, Simsek-Kiper P&#xd6;, Barat-Houari M, Elcioglu NH, Wieczorek D, Tinschert S, Sarrabay G, Strom TM, Fabre A, Baynam G, Sanchez E, N&#xfc;rnberg G, Altunoglu U, Capri Y, Isidor B, Lacombe D, Corsini C, Cormier-Daire V, Sanlaville D, Giuliano F, Le Quan Sang K-H, Kayirangwa H, N&#xfc;rnberg P, Meitinger T, Boduroglu K, Zoll B, Lyonnet S, Tzschach A, Verloes A, Di Donato N, Touitou I, Netzer C, Li Y, Genevi&#xe8;ve D, Yigit G, Wollnik B, Mutation update for Kabuki syndrome genes KMT2D and KDM6A and further delineation of X-linked Kabuki syndrome subtype 2. Hum. Mutat 37, 847&#x2013;864 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27302555</ArticleId></ArticleIdList></Reference><Reference><Citation>Lederer D, Grisart B, Digilio MC, Benoit V, Crespin M, Ghariani SC, Maystadt I, Dallapiccola B, Verellen-Dumoulin C, Deletion of KDM6A, a histone demethylase interacting with MLL2, in three patients with Kabuki syndrome. Am. J. Hum. Genet 90, 119&#x2013;124 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3257878</ArticleId><ArticleId IdType="pubmed">22197486</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyake N, Koshimizu E, Okamoto N, Mizuno S, Ogata T, Nagai T, Kosho T, Ohashi H, Kato M, Sasaki G, Mabe H, Watanabe Y, Yoshino M, Matsuishi T, Takanashi J.-i., Shotelersuk V, Tekin M, Ochi N, Kubota M, Ito N, Ihara K, Hara T, Tonoki H, Ohta T, Saito K, Matsuo M, Urano M, Enokizono T, Sato A, Tanaka H, Ogawa A, Fujita T, Hiraki Y, Kitanaka S, Matsubara Y, Makita T, Taguri M, Nakashima M, Tsurusaki Y, Saitsu H, Yoshiura K.-i., Matsumoto N, Niikawa N, MLL2 and KDM6A mutations in patients with Kabuki syndrome. Am. J. Med. Genet. A 161A, 2234&#x2013;2243 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23913813</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyake N, Mizuno S, Okamoto N, Ohashi H, Shiina M, Ogata K, Tsurusaki Y, Nakashima M, Saitsu H, Niikawa N, Matsumoto N, KDM6A point mutations cause Kabuki syndrome. Hum. Mutat 34, 108&#x2013;110 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23076834</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Laarhoven PM, Neitzel LR, Quintana AM, Geiger EA, Zackai EH, Clouthier DE, Artinger KB, Ming JE, Shaikh TH, Kabuki syndrome genes KMT2D and KDM6A: Functional analyses demonstrate critical roles in craniofacial, heart and brain development. Hum. Mol. Genet 24, 4443&#x2013;4453 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4492403</ArticleId><ArticleId IdType="pubmed">25972376</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang P, Tan H, Xia Y, Yu Q, Wei X, Guo R, Peng Y, Chen C, Li H, Mei L, Huang Y, Liang D, Wu L, De novo exonic deletion of KDM6A in a Chinese girl with Kabuki syndrome: A case report and brief literature review. Am. J. Med. Genet. A 170, 1613&#x2013;1621 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27028180</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang G-B, Zeng Y-Q, Liu P-P, Mi T-W, Zhang S-F, Dai S-K, Tang Q-Y, Yang L, Xu Y-J, Yan H-L, Du H-Z, Teng Z-Q, Zhou F-Q, Liu C-M, The histone H3K27 demethylase UTX regulates synaptic plasticity and cognitive behaviors in mice. Front. Mol. Neurosci 10, 267 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5609596</ArticleId><ArticleId IdType="pubmed">28970783</ArticleId></ArticleIdList></Reference><Reference><Citation>Panning B, X inactivation in mouse ES cells: Histone modifications and FISH. Methods Enzymol. 376, 419&#x2013;428 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">14975322</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiedemuth R, Thieme S, Navratiel K, Dorschner B, Brenner S, UTX&#x2014;Moonlighting in the cytoplasm? Int. J. Biochem. Cell Biol 97, 78&#x2013;82 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29421189</ArticleId></ArticleIdList></Reference><Reference><Citation>Berletch JB, Deng X, Nguyen DK, Disteche CM, Female bias in Rhox6 and 9 regulation by the histone demethylase KDM6A. PLOS Genet. 9, e1003489 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3642083</ArticleId><ArticleId IdType="pubmed">23658530</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei X, Jiao J, UTX affects neural stem cell proliferation and differentiation through PTEN signaling. Stem Cell Rep. 10, 1193&#x2013;1207 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5998300</ArticleId><ArticleId IdType="pubmed">29551674</ArticleId></ArticleIdList></Reference><Reference><Citation>GTEx Consortium; Laboratory, Data Analysis &amp;Coordinating Center (LDACC)&#x2014;Analysis Working Group; Statistical Methods groups&#x2014;Analysis Working Group; Enhancing GTEx (eGTEx) groups; NIH Common Fund; NIH/NCI; NIH/NHGRI; NIH/NIMH; NIH/NIDA; Biospecimen Collection Source Site&#x2014;NDRI; Biospecimen Collection Source Site&#x2014;RPCI; Biospecimen Core Resource&#x2014;VARI; Brain Bank Repository&#x2014;University of Miami Brain Endowment Bank; Leidos Biomedical&#x2014;Project Management; ELSI Study; Genome Browser Data Integration &amp;Visualization&#x2014;EBI; Genome Browser Data Integration &amp;Visualization&#x2014;UCSC Genomics Institute, University of California Santa Cruz; Lead analysts; Laboratory, Data Analysis &amp;Coordinating Center (LDACC); NIH program management; Biospecimen collection; Pathology; eQTL Manuscript Working Group, Battle A, Brown CD, Engelhardt BE, Montgomery SB, Genetic effects on gene expression across human tissues. Nature 550, 204&#x2013;213 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherry ST, Ward M-H, Kholodov M, Baker J, Phan L, Smigielski EM, Sirotkin K, dbSNP: The NCBI database of genetic variation. Nucleic Acids Res. 29, 308&#x2013;311 (2001).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC29783</ArticleId><ArticleId IdType="pubmed">11125122</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng JS, Dubal DB, Kim DH, Legleiter J, Cheng IH, Yu G-Q, Tesseur I, Wyss-Coray T, Bonaldo P, Mucke L, Collagen VI protects neurons against A&#x3b2; toxicity. Nat. Neurosci 12, 119&#x2013;121 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2812922</ArticleId><ArticleId IdType="pubmed">19122666</ArticleId></ArticleIdList></Reference><Reference><Citation>Sampathkumar NK, Bravo JI, Chen Y, Danthi PS, Donahue EK, Lai RW, Lu R, Randall LT, Vinson N, Benayoun BA, Widespread sex dimorphism in aging and age-related diseases. Hum. Genet 139, 333&#x2013;356 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7031050</ArticleId><ArticleId IdType="pubmed">31677133</ArticleId></ArticleIdList></Reference><Reference><Citation>Buter TC, van den Hout A, Matthews FE, Larsen JP, Brayne C, Aarsland D, Dementia and survival in Parkinson disease: A 12-year population study. Neurology 70, 1017&#x2013;1022 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18362281</ArticleId></ArticleIdList></Reference><Reference><Citation>Forsaa EB, Larsen JP, Wentzel-Larsen T, Alves G, What predicts mortality in Parkinson disease?: A prospective population-based long-term study. Neurology 75, 1270&#x2013;1276 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20921512</ArticleId></ArticleIdList></Reference><Reference><Citation>Kihira T, Yoshida S, Okamoto K, Kazimoto Y, Ookawa M, Hama K, Miwa H, Kondo T, Survival rate of patients with amyotrophic lateral sclerosis in Wakayama Prefecture, Japan, 1966 to 2005. J. Neurol. Sci 268, 95&#x2013;101 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18164728</ArticleId></ArticleIdList></Reference><Reference><Citation>Sejvar JJ, Holman RC, Bresee JS, Kochanek KD, Schonberger LB, Amyotrophic lateral sclerosis mortality in the United States, 1979-2001. Neuroepidemiology 25, 144&#x2013;152 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15990445</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorm AF, Jolley D, The incidence of dementia: A meta-analysis. Neurology 51, 728&#x2013;733 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9748017</ArticleId></ArticleIdList></Reference><Reference><Citation>Brookmeyer R, Abdalla N, Estimation of lifetime risks of Alzheimer's disease dementia using biomarkers for preclinical disease. Alzheimers Dement. 14, 981&#x2013;988 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6097953</ArticleId><ArticleId IdType="pubmed">29802030</ArticleId></ArticleIdList></Reference><Reference><Citation>Horvath S, Gurven M, Levine ME, Trumble BC, Kaplan H, Allayee H, Ritz BR, Chen B, Lu AT, Rickabaugh TM, Jamieson BD, Sun D, Li S, Chen W, Quintana-Murci L, Fagny M, Kobor MS, Tsao PS, Reiner AP, Edlefsen KL, Absher D, Assimes TL, An epigenetic clock analysis of race/ethnicity, sex, and coronary heart disease. Genome Biol. 17, 171 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4980791</ArticleId><ArticleId IdType="pubmed">27511193</ArticleId></ArticleIdList></Reference><Reference><Citation>Goyal MS, Blazey TM, Su Y, Couture LE, Durbin TJ, Bateman RJ, Benzinger TL-S, Morris JC, Raichle ME, Vlassenko AG, Persistent metabolic youth in the aging female brain. Proc. Natl. Acad. Sci. U.S.A 116, 3251&#x2013;3255 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6386682</ArticleId><ArticleId IdType="pubmed">30718410</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr., Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB, Hampel H, Jagust WJ, Johnson KA, Knopman DS, Petersen RC, Scheltens P, Sperling RA, Dubois B, A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology 87, 539&#x2013;547 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4970664</ArticleId><ArticleId IdType="pubmed">27371494</ArticleId></ArticleIdList></Reference><Reference><Citation>Caracciolo B, Palmer K, Monastero R, Winblad B, B&#xe4;ckman L, Fratiglioni L, Occurrence of cognitive impairment and dementia in the community: A 9-year-long prospective study. Neurology 70, 1778&#x2013;1785 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18184916</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganguli M, Dodge HH, Shen C, DeKosky ST, Mild cognitive impairment, amnestic type: An epidemiologic study. Neurology 63, 115&#x2013;121 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15249620</ArticleId></ArticleIdList></Reference><Reference><Citation>Koivisto K, Reinikainen KJ, Hanninen T, Vanhanen M, Helkala E-L, Mykkanen L, Laakso M, Pyorala K, Riekkinen PJ Sr., Prevalence of age-associated memory impairment in a randomly selected population from eastern Finland. Neurology 45, 741&#x2013;747 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7723964</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Carlo A, Lamassa M, Baldereschi M, Inzitari M, Scafato E, Farchi G, Inzitari D, CIND and MCI in the Italian elderly: Frequency, vascular risk factors, progression to dementia. Neurology 68, 1909&#x2013;1916 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17536047</ArticleId></ArticleIdList></Reference><Reference><Citation>Kivipelto M, Helkala E-L, H&#xe4;nninen T, Laakso MP, Hallikainen M, Alhainen K, Soininen H, Tuomilehto J, Nissinen A, Midlife vascular risk factors and late-life mild cognitive impairment: A population-based study. Neurology 56, 1683&#x2013;1689 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11425934</ArticleId></ArticleIdList></Reference><Reference><Citation>Solfrizzi V, Panza F, Colacicco AM, D'Introno A, Capurso C, Torres F, Grigoletto F, Maggi S, Del Parigi A, Reiman EM, Caselli RJ, Scafato E, Farchi G, Capurso A; Italian Longitudinal Study on Aging Working Group, Vascular risk factors, incidence of MCI, and rates of progression to dementia. Neurology 63, 1882&#x2013;1891 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15557506</ArticleId></ArticleIdList></Reference><Reference><Citation>Hohman TJ, Dumitrescu L, Barnes LL, Thambisetty M, Beecham G, Kunkle B, Gifford KA, Bush WS, Chibnik LB, Mukherjee S, De Jager PL, Kukull W, Crane PK, Resnick SM, Keene CD, Montine TJ, Schellenberg GD, Haines JL, Zetterberg H, Blennow K, Larson EB, Johnson SC, Albert M, Bennett DA, Schneider JA, Jefferson AL; Alzheimer&#x2019;s Disease Genetics Consortium and the Alzheimer&#x2019;s Disease Neuroimaging Initiative, Sex-specific association of apolipoprotein E with cerebrospinal fluid levels of tau. JAMA Neurol. 75, 989&#x2013;998 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6142927</ArticleId><ArticleId IdType="pubmed">29801024</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FRJ, Visser PJ; Amyloid Biomarker Study Group, Aalten P, Aarsland D, Alcolea D, Alexander M, Almdahl IS, Arnold SE, Baldeiras I, Barthel H, van Berckel BNM, Bibeau K, Blennow K, Brooks DJ, van Buchem MA, Camus V, Cavedo E, Chen K, Chetelat G, Cohen AD, Drzezga A, Engelborghs S, Fagan AM, Fladby T, Fleisher AS, van der Flier WM, Ford L, F&#xf6;rster S, Fortea J, Foskett N, Frederiksen KS, Freund-Levi Y, Frisoni GB, Froelich L, Gabryelewicz T, Gill KD, Gkatzima O, G&#xf3;mez-Tortosa E, Gordon MF, Grimmer T, Hampel H, Hausner L, Hellwig S, Herukka S-K, Hildebrandt H, Ishihara L, Ivanoiu A, Jagust WJ, Johannsen P, Kandimalla R, Kapaki E, Klimkowicz-Mrowiec A, Klunk WE, K&#xf6;hler S, Koglin N, Kornhuber J, Kramberger MG, Van Laere K, Landau SM, Lee DY, de Leon M, Lisetti V, Lle&#xf3; A, Madsen K, Maier W, Marcusson J, Mattsson N, de Mendon&#xe7;a A, Meulenbroek O, Meyer PT, Mintun MA, Mok V, Molinuevo JL, M&#xf8;llerg&#xe5;rd HM, Morris JC, Mroczko B, Van der Mussele S, Na DL, Newberg A, Nordberg A, Nordlund A, Novak GP, Paraskevas GP, Parnetti L, Perera G, Peters O, Popp J, Prabhakar S, Rabinovici GD, Ramakers IHGB, Rami L, Resende de Oliveira C, Rinne JO, Rodrigue KM, Rodr&#xed;guez-Rodr&#xed;guez E, Roe CM, Rot U, Rowe CC, R&#xfc;ther E, Sabri O, Sanchez-Juan P, Santana I, Sarazin M, Schr&#xf6;der J, Sch&#xfc;tte C, Seo SW, Soetewey F, Soininen H, Spiru L, Struyfs H, Teunissen CE, Tsolaki M, Vandenberghe R, Verbeek MM, Villemagne VL, Vos SJB, van Waalwijk van Doorn LJC, Waldemar G, Wallin A, Wallin AK, Wiltfang J, Wolk DA, Zboch M, Zetterberg H, Prevalence of cerebral amyloid pathology in persons without dementia: A meta-analysis. JAMA 313, 1924&#x2013;1938 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4486209</ArticleId><ArticleId IdType="pubmed">25988462</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckley RF, Mormino EC, Rabin JS, Hohman TJ, Landau S, Hanseeuw BJ, Jacobs HIL, Papp KV, Amariglio RE, Properzi MJ, Schultz AP, Kirn D, Scott MR, Hedden T, Farrell M, Price J, Chhatwal J, Rentz DM, Villemagne VL, Johnson KA, Sperling RA, Sex differences in the association of global amyloid and regional tau deposition measured by positron emission tomography in clinically normal older adults. JAMA Neurol. 76, 542&#x2013;551 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6515599</ArticleId><ArticleId IdType="pubmed">30715078</ArticleId></ArticleIdList></Reference><Reference><Citation>Kodama L, Guzman E, Etchegaray JI, Li Y, Sayed FA, Zhou L, Zhou Y, Zhan L, Le D, Udeochu JC, Clelland CD, Cheng Z, Yu G, Li Q, Kosik KS, Gan L, Microglial microRNAs mediate sex-specific responses to tau pathology. Nat. Neurosci 23, 167&#x2013;171 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7394069</ArticleId><ArticleId IdType="pubmed">31873194</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Lyoo CH, Jester-Broms J, Sudre CH, Cho H, Ryu YH, Choi JY, Smith R, Strandberg O, Palmqvist S, Kramer J, Boxer AL, Gorno-Tempini ML, Miller BL, La Joie R, Rabinovici GD, Hansson O, Assessment of demographic, genetic, and imaging variables associated with brain resilience and cognitive resilience to pathological tau in patients with Alzheimer disease. JAMA Neurol. 77, 632&#x2013;642 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7042808</ArticleId><ArticleId IdType="pubmed">32091549</ArticleId></ArticleIdList></Reference><Reference><Citation>Digma LA, Madsen JR, Rissman RA, Jacobs DM, Brewer JB, Banks SJ; Alzheimer&#x2019;s Disease Neuroimaging Initiative, Women can bear a bigger burden: Ante- and postmortem evidence for reserve in the face of tau. Brain Commun. 2, fcaa025 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7166251</ArticleId><ArticleId IdType="pubmed">32337508</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll JC, Rosario ER, Kreimer S, Villamagna A, Gentzschein E, Stanczyk FZ, Pike CJ, Sex differences in &#x3b2;-amyloid accumulation in 3xTg-AD mice: Role of neonatal sex steroid hormone exposure. Brain Res. 1366, 233&#x2013;245 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2993873</ArticleId><ArticleId IdType="pubmed">20934413</ArticleId></ArticleIdList></Reference><Reference><Citation>Halford RW, Russell DW, Reduction of cholesterol synthesis in the mouse brain does not affect amyloid formation in Alzheimer's disease, but does extend lifespan. Proc. Natl. Acad. Sci. U.S.A. 106, 3502&#x2013;3506 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2651246</ArticleId><ArticleId IdType="pubmed">19204288</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirata-Fukae C, Li H-F, Hoe H-S, Gray AJ, Minami SS, Hamada K, Niikura T, Hua F, Tsukagoshi-Nagai H, Horikoshi-Sakuraba Y, Mughal M, Rebeck GW, LaFerla FM, Mattson MP, Iwata N, Saido TC, Klein WL, Duff KE, Aisen PS, Matsuoka Y, Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model. Brain Res. 1216, 92&#x2013;103 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18486110</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Tanila H, Puolivali J, Kadish I, van Groen T, Gender differences in the amount and deposition of amyloid&#x3b2; in APPswe and PS1 double transgenic mice. Neurobiol. Dis 14, 318&#x2013;327 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">14678749</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubal DB, Broestl L, Worden K, Sex and gonadal hormones in mouse models of Alzheimer's disease: What is relevant to the human condition? Biol. Sex Differ 3, 24 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3524653</ArticleId><ArticleId IdType="pubmed">23126652</ArticleId></ArticleIdList></Reference><Reference><Citation>Broestl L, Worden K, Moreno AJ, Davis EJ, Wang D, Garay B, Singh T, Verret L, Palop JJ, Dubal DB, Ovarian cycle stages modulate Alzheimer-related cognitive and brain network alterations in female mice. eNeuro 5, ENEURO.0132-17.2018 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6325547</ArticleId><ArticleId IdType="pubmed">30627643</ArticleId></ArticleIdList></Reference><Reference><Citation>Pike CJ, Sex and the development of Alzheimer's disease. J. Neurosci. Res 95, 671&#x2013;680 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5120614</ArticleId><ArticleId IdType="pubmed">27870425</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis EJ, Lobach I, Dubal DB, Female XX sex chromosomes increase survival and extend lifespan in aging mice. Aging Cell 18, e12871 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6351820</ArticleId><ArticleId IdType="pubmed">30560587</ArticleId></ArticleIdList></Reference><Reference><Citation>Skuse DH, X-linked genes and mental functioning. Hum. Mol. Genet 14Spec No 1, R27&#x2013;R32 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15809269</ArticleId></ArticleIdList></Reference><Reference><Citation>Vawter MP, Evans S, Choudary P, Tomita H, Meador-Woodruff J, Molnar M, Li J, Lopez JF, Myers R, Cox D, Watson SJ, Akil H, Jones EG, Bunney WE, Gender-specific gene expression in post-mortem human brain: Localization to sex chromosomes. Neuropsychopharmacology 29, 373&#x2013;384 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3130534</ArticleId><ArticleId IdType="pubmed">14583743</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, Deng X, Watkins R, Disteche CM, Sex-specific differences in expression of histone demethylases Utx and Uty in mouse brain and neurons. J. Neurosci 28, 4521&#x2013;4527 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2643472</ArticleId><ArticleId IdType="pubmed">18434530</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenfield A, Scott D, Pennisi D, Ehrmann I, Ellis P, Cooper L, Simpson E, Koopman P, An H-YDb epitope is encoded by a novel mouse Y chromosome gene. Nat. Genet 14, 474&#x2013;478 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8944031</ArticleId></ArticleIdList></Reference><Reference><Citation>Ga&#x17e;ov&#xe1; I, Lengeling A, Summers KM, Lysine demethylases KDM6A and UTY: The X and Y of histone demethylation. Mol. Genet. Metab 127, 31&#x2013;44 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31097364</ArticleId></ArticleIdList></Reference><Reference><Citation>Shpargel KB, Sengoku T, Yokoyama S, Magnuson T, UTX and UTY demonstrate histone demethylase-independent function in mouse embryonic development. PLOS Genet. 8, e1002964 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3459986</ArticleId><ArticleId IdType="pubmed">23028370</ArticleId></ArticleIdList></Reference><Reference><Citation>Walport LJ, Hopkinson RJ, Vollmar M, Madden SK, Gileadi C, Oppermann U, Schofield CJ, Johansson C, Human UTY(KDM6C) is a male-specific N&#x404;-methyl lysyl demethylase. J. Biol. Chem 289, 18302&#x2013;18313 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4140284</ArticleId><ArticleId IdType="pubmed">24798337</ArticleId></ArticleIdList></Reference><Reference><Citation>Itoh Y, Golden LC, Itoh N, Matsukawa MA, Ren E, Tse V, Arnold AP, Voskuhl RR, The X-linked histone demethylase Kdm6a in CD4+ T lymphocytes modulates autoimmunity. J. Clin. Invest 129, 3852&#x2013;3863 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6715385</ArticleId><ArticleId IdType="pubmed">31403472</ArticleId></ArticleIdList></Reference><Reference><Citation>R. C. Team, R: A Language and Environment for Statistical Computing version 3.6.1, R Foundation for Statistical Computing, Vienna, Austria: (2019).</Citation></Reference><Reference><Citation>Bates D, M&#xe4;chler M, Bolker B, Walker S, lme4: Linear mixed-effects models using Eigen and S4, Journal of Statistical Software, 67 (2014).</Citation></Reference><Reference><Citation>Ag&#xfc;ero-Torres H, Fratiglioni L, Guo Z, Viitanen M, Winblad B, Prognostic factors in very old demented adults: A seven-year follow-up from a population-based survey in Stockholm. J. Am. Geriatr. Soc 46, 444&#x2013;452 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9560066</ArticleId></ArticleIdList></Reference><Reference><Citation>Aneshensel CS, Pearlin LI, Levy-Storms L, Schuler RH, The transition from home to nursing home mortality among people with dementia. J. Gerontol. B Psychol. Sci. Soc. Sci 55, S152&#x2013;S162 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">11833983</ArticleId></ArticleIdList></Reference><Reference><Citation>Beard CM, Kokmen E, O&#x2019;Brien PC, Kurland LT, Are patients with Alzheimer's disease surviving longer in recent years? Neurology 44, 1869&#x2013;1871 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">7936239</ArticleId></ArticleIdList></Reference><Reference><Citation>Bracco L, Gallato R, Grigoletto F, Lippi A, Lepore V, Bino G, Lazzaro MP, Carella F, Piccolo T, Pozzilli C, Giometto B, Amaducci L, Factors affecting course and survival in Alzheimer's disease. A 9-year longitudinal study. Arch. Neurol 51, 1213&#x2013;1219 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">7986176</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns A, Lewis G, Jacoby R, Levy R, Factors affecting survival in Alzheimer's disease. Psychol. Med 21, 363&#x2013;370 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1876641</ArticleId></ArticleIdList></Reference><Reference><Citation>Claus JJ, Walstra GJM, Bossuyt PM, Teunisse S, Van Gool WA, A simple test of copying ability and sex define survival in patients with early Alzheimer's disease. Psychol. Med 29, 485&#x2013;489 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10218940</ArticleId></ArticleIdList></Reference><Reference><Citation>Go SM, Lee KS, Seo SW, Chin J, Kang SJ, Moon SY, Na DL, Cheong H-K, Survival of Alzheimer's disease patients in Korea. Dement. Geriatr. Cogn. Disord 35, 219&#x2013;228 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23467314</ArticleId></ArticleIdList></Reference><Reference><Citation>Roehr S, Luck T, Bickel H, Brettschneider C, Ernst A, Fuchs A, Heser K, K&#xf6;nig H-H, Jessen F, Lange C, M&#xf6;sch E, Pentzek M, Steinmann S, Weyerer S, Werle J, Wiese B, Scherer M, Maier W, Riedel-Heller SG; AgeCoDe Study Group, Mortality in incident dementia&#x2014;Results from the German Study on Aging, Cognition, and Dementia in Primary Care Patients. Acta Psychiatr. Scand 132, 257&#x2013;269 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26052745</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y, Tang MX, Denaro J, Mayeux R, Increased risk of mortality in Alzheimer's disease patients with more advanced educational and occupational attainment. Ann. Neurol 37, 590&#x2013;595 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7755353</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas BM, McGonigal G, McQuade CA, Starr JM, Whalley LJ, Survival in early onset dementia: Effects of urbanization and socio-economic deprivation. Neuroepidemiology 16, 134&#x2013;140 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9159768</ArticleId></ArticleIdList></Reference><Reference><Citation>Vilalta-Franch J, L&#xf3;pez-Pousa S, Calv&#xf3;-Perxas L, Garre-Olmo J, Psychosis of Alzheimer disease: Prevalence, incidence, persistence, risk factors, and mortality. Am. J. Geriatr. Psychiatry 21, 1135&#x2013;1143 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23567368</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams MM, Xiong C, Morris JC, Galvin JE, Survival and mortality differences between dementia with Lewy bodies vs Alzheimer disease. Neurology 67, 1935&#x2013;1941 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17159097</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfson C, Wolfson DB, Asgharian M, M'Lan CE, &#xd8;stbye T, Rockwood K, Hogan DB; Clinical Progression of Dementia Study Group, A reevaluation of the duration of survival after the onset of dementia. N. Engl. J. Med 344, 1111&#x2013;1116 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11297701</ArticleId></ArticleIdList></Reference><Reference><Citation>Viechtbauer W, Conducting meta-analyses in R with the metafor package. J. Stat. Softw 36, 1&#x2013;48 (2010).</Citation></Reference><Reference><Citation>Hartung J, Knapp G, A refined method for the meta-analysis of controlled clinical trials with binary outcome. Stat. Med 20, 3875&#x2013;3889 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11782040</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartung J, Knapp G, On tests of the overall treatment effect in meta-analysis with normally distributed responses. Stat. Med 20, 1771&#x2013;1782 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11406840</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedges LV, Vevea JL, Fixed- and random-effects models in meta-analysis. Psychol. Methods 3, 486&#x2013;504 (1998).</Citation></Reference><Reference><Citation>Sidik K, Jonkman JN, A simple confidence interval for meta-analysis. Stat. Med 21, 3153&#x2013;3159 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12375296</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockenstein EM, McConlogue L, Tan H, Power M, Masliah E, Mucke L, Levels and alternative splicing of amyloid &#x3b2; protein precursor (APP) transcripts in brains of APP transgenic mice and humans with Alzheimer's disease. J. Biol. Chem 270, 28257&#x2013;28267 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7499323</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubal DB, Yokoyama JS, Zhu L, Broestl L, Worden K, Wang D, Sturm VE, Kim D, Klein E, Yu G-Q, Ho K, Eilertson KE, Yu L, Kuro-o M, De Jager PL, Coppola G, Small GW, Bennett DA, Kramer JH, Abraham CR, Miller BL, Mucke L, Life extension factor klotho enhances cognition. Cell Rep. 7, 1065&#x2013;1076 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4176932</ArticleId><ArticleId IdType="pubmed">24813892</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubal DB, Zhu L, Sanchez PE, Worden K, Broestl L, Johnson E, Ho K, Yu G-Q, Kim D, Betourne A, Kuro-o M, Masliah E, Abraham CR, Mucke L, Life extension factor klotho prevents mortality and enhances cognition in hAPP transgenic mice. J. Neurosci 35, 2358&#x2013;2371 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4323521</ArticleId><ArticleId IdType="pubmed">25673831</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciss&#xe9; M, Halabisky B, Harris J, Devidze N, Dubal DB, Sun B, Orr A, Lotz G, Kim DH, Hamto P, Ho K, Yu G-Q, Mucke L, Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. Nature 469, 47&#x2013;52 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3030448</ArticleId><ArticleId IdType="pubmed">21113149</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Jones B, Kekonius L, Chin J, Yu G-Q, Raber J, Masliah E, Mucke L, Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits. Proc. Natl. Acad. Sci. U.S.A 100, 9572&#x2013;9577 (2003).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC170959</ArticleId><ArticleId IdType="pubmed">12881482</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein WL, A&#x3b2; toxicity in Alzheimer's disease: Globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem. Int 41, 345&#x2013;352 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12176077</ArticleId></ArticleIdList></Reference><Reference><Citation>Aras MA, Hartnett KA, Aizenman E, Assessment of cell viability in primary neuronal cultures. Curr. Protoc. Neurosci Chapter 7, Unit 7.18 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18633999</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen M, Carrasquillo MM, Funk C, Heavner BD, Zou F, Younkin CS, Burgess JD, Chai H-S, Crook J, Eddy JA, Li H, Logsdon B, Peters MA, Dang KK, Wang X, Serie D, Wang C, Nguyen T, Lincoln S, Malphrus K, Bisceglio G, Li M, Golde TE, Mangravite LM, Asmann Y, Price ND, Petersen RC, Graff-Radford NR, Dickson DW, Younkin SG, Ertekin-Taner N, Human whole genome genotype and transcriptome data for Alzheimer's and other neurodegenerative diseases. Sci. Data 3, 160089 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5058336</ArticleId><ArticleId IdType="pubmed">27727239</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M, Beckmann ND, Roussos P, Wang E, Zhou X, Wang Q, Ming C, Neff R, Ma W, Fullard JF, Hauberg ME, Bendl J, Peters MA, Logsdon B, Wang P, Mahajan M, Mangravite LM, Dammer EB, Duong DM, Lah JJ, Seyfried NT, Levey AI, Buxbaum JD, Ehrlich M, Gandy S, Katsel P, Haroutunian V, Schadt E, Zhang B, The Mount Sinai cohort of large-scale genomic, transcriptomic and proteomic data in Alzheimer's disease. Sci Data 5, 180185 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6132187</ArticleId><ArticleId IdType="pubmed">30204156</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster JA, Gibbs JR, Clarke J, Ray M, Zhang W, Holmans P, Rohrer K, Zhao A, Marlowe L, Kaleem M, McCorquodale DS III, Cuello C, Leung D, Bryden L, Nath P, Zismann VL, Joshipura K, Huentelman MJ, Hu-Lince D, Coon KD, Craig DW, Pearson JV; NACC-Neuropathology Group, Heward CB, Reiman EM, Stephan D, Hardy J, Myers AJ, Genetic control of human brain transcript expression in Alzheimer disease. Am. J. Hum. Genet 84, 445&#x2013;458 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2667989</ArticleId><ArticleId IdType="pubmed">19361613</ArticleId></ArticleIdList></Reference><Reference><Citation>Carithers LJ, Ardlie K, Barcus M, Branton PA, Britton A, Buia SA, Compton CC, DeLuca DS, Peter-Demchok J, Gelfand ET, Guan P, Korzeniewski GE, Lockhart NC, Rabiner CA, Rao AK, Robinson KL, Roche NV, Sawyer SJ, Segr&#xe8; AV, Shive CE, Smith AM, Sobin LH, Undale AH, Valentino KM, Vaught J, Young TR, Moore HM; GTEx Consortium, A novel approach to high-quality postmortem tissue procurement: The GTEx Project. Biopreserv. Biobank 13, 311&#x2013;319 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4675181</ArticleId><ArticleId IdType="pubmed">26484571</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, Jack CR Jr., Jagust WJ, Shaw LM, Toga AW, Trojanowski JQ, Weiner MW, Alzheimer's Disease Neuroimaging Initiative (ADNI): Clinical characterization. Neurology 74, 201&#x2013;209 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2809036</ArticleId><ArticleId IdType="pubmed">20042704</ArticleId></ArticleIdList></Reference><Reference><Citation>Saykin AJ, Shen L, Foroud TM, Potkin SG, Swaminathan S, Kim S, Risacher SL, Nho K, Huentelman MJ, Craig DW, Thompson PM, Stein JL, Moore JH, Farrer LA, Green RC, Bertram L, Jack CR Jr., Weiner MW; Alzheimer's Disease Neuroimaging Initiative, Alzheimer's Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: Genetics core aims, progress, and plans. Alzheimers Dement. 6, 265&#x2013;273 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2868595</ArticleId><ArticleId IdType="pubmed">20451875</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR Jr., Jagust W, Liu E, Morris JC, Petersen RC, Saykin AJ, Schmidt ME, Shaw L, Siuciak JA, Soares H, Toga AW, Trojanowski JQ; Alzheimer&#x2019;s Disease Neuroimaging Initiative, The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. Alzheimers Dement. 8, S1&#x2013;S68 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3329969</ArticleId><ArticleId IdType="pubmed">22047634</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonham LW, Desikan RS, Yokoyama JS; Alzheimer&#x2019;s Disease Neuroimaging Initiative, The relationship between complement factor C3, APOE &#x3b5;4, amyloid and tau in Alzheimer's disease. Acta Neuropathol. Commun 4, 65 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4928261</ArticleId><ArticleId IdType="pubmed">27357286</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR, &#x201c;Mini-mental state&#x201d;: A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res 12, 189&#x2013;198 (1975).</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Saykin AJ, Shen L, Yao X, Kim S, Nho K, Risacher SL, Ramanan VK, Foroud TM, Faber KM, Sarwar N, Munsie LM, Hu X, Soares HD, Potkin SG, Thompson PM, Kauwe JSK, Kaddurah-Daouk R, Green RC, Toga AW, Weiner MW; Alzheimer's Disease Neuroimaging Initiative, Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plans. Alzheimers Dement. 11, 792&#x2013;814 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4510473</ArticleId><ArticleId IdType="pubmed">26194313</ArticleId></ArticleIdList></Reference><Reference><Citation>Ongen H, Buil A, Brown AA, Dermitzakis ET, Delaneau O, Fast and efficient QTL mapper for thousands of molecular phenotypes. Bioinformatics 32, 1479&#x2013;1485 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4866519</ArticleId><ArticleId IdType="pubmed">26708335</ArticleId></ArticleIdList></Reference><Reference><Citation>GTEx Consortium, Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: Multitissue gene regulation in humans. Science 348, 648&#x2013;660 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4547484</ArticleId><ArticleId IdType="pubmed">25954001</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson MD, Oshlack A, A scaling normalization method for differential expression analysis of RNA-seq data. Genome Biol. 11, R25 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2864565</ArticleId><ArticleId IdType="pubmed">20196867</ArticleId></ArticleIdList></Reference><Reference><Citation>Stegle O, Parts L, Durbin R, Winn J, A Bayesian framework to account for complex non-genetic factors in gene expression levels greatly increases power in eQTL studies. PLOS Comput. Biol 6, e1000770 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2865505</ArticleId><ArticleId IdType="pubmed">20463871</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright FA, Sullivan PF, Brooks AI, Zou F, Sun W, Xia K, Madar V, Jansen R, Chung W, Zhou Y-H, Abdellaoui A, Batista S, Butler C, Chen G, Chen T-H, D'Ambrosio D, Gallins P, Ha MJ, Hottenga JJ, Huang S, Kattenberg M, Kochar J, Middeldorp CM, Qu A, Shabalin A, Tischfield J, Todd L, Tzeng J-Y, van Grootheest G, Vink JM, Wang Q, Wang W, Wang W, Willemsen G, Smit JH, de Geus EJ, Yin Z, Penninx BWJH, Boomsma DI, Heritability and genomics of gene expression in peripheral blood. Nat. Genet 46, 430&#x2013;437 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4012342</ArticleId><ArticleId IdType="pubmed">24728292</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">32852886</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>27</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1469-3178</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>10</Issue><PubDate><Year>2020</Year><Month>Oct</Month><Day>05</Day></PubDate></JournalIssue><Title>EMBO reports</Title><ISOAbbreviation>EMBO Rep</ISOAbbreviation></Journal><ArticleTitle>Loss of TMEM106B and PGRN leads to severe lysosomal abnormalities and neurodegeneration in mice.</ArticleTitle><Pagination><StartPage>e50219</StartPage><MedlinePgn>e50219</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e50219</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.15252/embr.202050219</ELocationID><Abstract><AbstractText>Haploinsufficiency of progranulin (PGRN) is a leading cause of frontotemporal lobar degeneration (FTLD). Loss of PGRN leads to lysosome dysfunction during aging. TMEM106B, a gene encoding a lysosomal membrane protein, is the main risk factor for FTLD with PGRN haploinsufficiency. But how TMEM106B affects FTLD disease progression remains to be determined. Here, we report that TMEM106B deficiency in mice leads to accumulation of lysosome vacuoles at the distal end of the axon initial segment in motor neurons and the development of FTLD-related pathology during aging. Ablation of both PGRN and TMEM106B in mice results in severe neuronal loss and glial activation in the spinal cord, retina, and brain. Enlarged lysosomes are frequently found in both microglia and astrocytes. Loss of both PGRN and TMEM106B results in an increased accumulation of lysosomal vacuoles in the axon initial segment of motor neurons and enhances the manifestation of FTLD phenotypes with a much earlier onset. These results provide novel insights into the role of TMEM106B in the lysosome, in brain aging, and in FTLD pathogenesis.</AbstractText><CopyrightInformation>&#xa9; 2020 The Authors. Published under the terms of the CC BY 4.0 license.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Tuancheng</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Molecular Biology and Genetics, Weill Institute for Cell and Molecular Biology, Cornell University, Ithaca, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mai</LastName><ForeName>Shuyi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, City University of Hong Kong, Kowloon, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roscoe</LastName><ForeName>Jenn Marie</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Molecular Biology and Genetics, Weill Institute for Cell and Molecular Biology, Cornell University, Ithaca, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sheng</LastName><ForeName>Rory R</ForeName><Initials>RR</Initials><AffiliationInfo><Affiliation>Department of Molecular Biology and Genetics, Weill Institute for Cell and Molecular Biology, Cornell University, Ithaca, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ullah</LastName><ForeName>Mohammed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Molecular Biology and Genetics, Weill Institute for Cell and Molecular Biology, Cornell University, Ithaca, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Junke</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Computational Biology, Weill Institute for Cell and Molecular Biology, Cornell University, Ithaca, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katz</LastName><ForeName>Isabel Iscol</ForeName><Initials>II</Initials><AffiliationInfo><Affiliation>Department of Molecular Biology and Genetics, Weill Institute for Cell and Molecular Biology, Cornell University, Ithaca, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Haiyuan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Computational Biology, Weill Institute for Cell and Molecular Biology, Cornell University, Ithaca, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Wenjun</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, City University of Hong Kong, Kowloon, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Fenghua</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-6447-9992</Identifier><AffiliationInfo><Affiliation>Department of Molecular Biology and Genetics, Weill Institute for Cell and Molecular Biology, Cornell University, Ithaca, NY, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS088448</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS095954</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>The Bluefield project to Cure FTD</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>08</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>EMBO Rep</MedlineTA><NlmUniqueID>100963049</NlmUniqueID><ISSNLinking>1469-221X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C120204">Grn protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036341">Intercellular Signaling Peptides and Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077153">Progranulins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000632372">Tmem106b protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057174" MajorTopicYN="Y">Frontotemporal Lobar Degeneration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036341" MajorTopicYN="N">Intercellular Signaling Peptides and Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008247" MajorTopicYN="N">Lysosomes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077153" MajorTopicYN="N">Progranulins</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">TMEM106B</Keyword><Keyword MajorTopicYN="N">frontotemporal lobar degeneration</Keyword><Keyword MajorTopicYN="N">lysosome</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">progranulin</Keyword></KeywordList><CoiStatement>The authors declare that they have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>2</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>6</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>7</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>8</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32852886</ArticleId><ArticleId IdType="pmc">PMC7534636</ArticleId><ArticleId IdType="doi">10.15252/embr.202050219</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ahmed Z, Sheng H, Xu YF, Lin WL, Innes AE, Gass J, Yu X, Wuertzer CA, Hou H, Chiba S et&#xa0;al (2010) Accelerated lipofuscinosis and ubiquitination in granulin knockout mice suggest a role for progranulin in successful aging. Am J Pathol 177: 311&#x2013;324</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2893674</ArticleId><ArticleId IdType="pubmed">20522652</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida MR, Macario MC, Ramos L, Baldeiras I, Ribeiro MH, Santana I (2016) Portuguese family with the co&#x2010;occurrence of frontotemporal lobar degeneration and neuronal ceroid lipofuscinosis phenotypes due&#xa0;to progranulin gene mutation. Neurobiol Aging 41: 200.e201&#x2013;200.e205</Citation><ArticleIdList><ArticleId IdType="pubmed">27021778</ArticleId></ArticleIdList></Reference><Reference><Citation>Anders S, Pyl PT, Huber W (2015) HTSeq&#x2013;a Python framework to work with high&#x2010;throughput sequencing data. Bioinformatics 31: 166&#x2013;169</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4287950</ArticleId><ArticleId IdType="pubmed">25260700</ArticleId></ArticleIdList></Reference><Reference><Citation>Arrant AE, Nicholson AM, Zhou X, Rademakers R, Roberson ED (2018) Partial Tmem106b reduction does not correct abnormalities due to progranulin haploinsufficiency. Mol Neurodegener 13: 32</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6013889</ArticleId><ArticleId IdType="pubmed">29929528</ArticleId></ArticleIdList></Reference><Reference><Citation>Arrant AE, Roth JR, Boyle NR, Kashyap SN, Hoffmann MQ, Murchison CF, Ramos EM, Nana AL, Spina S, Grinberg LT et&#xa0;al (2019) Impaired beta&#x2010;glucocerebrosidase activity and processing in frontotemporal dementia due to progranulin mutations. Acta Neuropathol Commun 7: 218</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6929503</ArticleId><ArticleId IdType="pubmed">31870439</ArticleId></ArticleIdList></Reference><Reference><Citation>Baizabal&#x2010;Carvallo JF, Jankovic J (2016) Parkinsonism, movement disorders and genetics in frontotemporal dementia. Nat Rev Neurol 12: 175&#x2013;185</Citation><ArticleIdList><ArticleId IdType="pubmed">26891767</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajaj L, Lotfi P, Pal R, Ronza AD, Sharma J, Sardiello M (2019) Lysosome biogenesis in health and disease. J Neurochem 148: 573&#x2013;589</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6368902</ArticleId><ArticleId IdType="pubmed">30092616</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker M, Mackenzie IR, Pickering&#x2010;Brown SM, Gass J, Rademakers R, Lindholm C, Snowden J, Adamson J, Sadovnick AD, Rollinson S et&#xa0;al (2006) Mutations in progranulin cause tau&#x2010;negative frontotemporal dementia linked to chromosome 17. Nature 442: 916&#x2013;919</Citation><ArticleIdList><ArticleId IdType="pubmed">16862116</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman A, Bennett HP (2009) The granulin gene family: from cancer to dementia. BioEssays 31: 1245&#x2013;1254</Citation><ArticleIdList><ArticleId IdType="pubmed">19795409</ArticleId></ArticleIdList></Reference><Reference><Citation>Beel S, Moisse M, Damme M, De Muynck L, Robberecht W, Van Den Bosch L, Saftig P, Van Damme P (2017) Progranulin functions as a cathepsin D chaperone to stimulate axonal outgrowth in&#xa0;vivo . Hum Mol Genet 26: 2850&#x2013;2863</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5886064</ArticleId><ArticleId IdType="pubmed">28453791</ArticleId></ArticleIdList></Reference><Reference><Citation>Belcastro V, Siciliano V, Gregoretti F, Mithbaokar P, Dharmalingam G, Berlingieri S, Iorio F, Oliva G, Polishchuck R, Brunetti&#x2010;Pierri N et&#xa0;al (2011) Transcriptional gene network inference from a massive dataset elucidates transcriptome organization and gene function. Nucleic Acids Res 39: 8677&#x2013;8688</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3203605</ArticleId><ArticleId IdType="pubmed">21785136</ArticleId></ArticleIdList></Reference><Reference><Citation>van Blitterswijk M, Mullen B, Nicholson AM, Bieniek KF, Heckman MG, Baker MC, DeJesus&#x2010;Hernandez M, Finch NA, Brown PH, Murray ME et&#xa0;al (2014) TMEM106B protects C9ORF72 expansion carriers against frontotemporal dementia. Acta Neuropathol 127: 397&#x2013;406</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3944829</ArticleId><ArticleId IdType="pubmed">24385136</ArticleId></ArticleIdList></Reference><Reference><Citation>Brady OA, Zheng Y, Murphy K, Huang M, Hu F (2013) The frontotemporal lobar degeneration risk factor, TMEM106B, regulates lysosomal morphology and function. Hum Mol Genet 22: 685&#x2013;695</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3554197</ArticleId><ArticleId IdType="pubmed">23136129</ArticleId></ArticleIdList></Reference><Reference><Citation>Brady OA, Martina JA, Puertollano R (2018) Emerging roles for TFEB in the immune response and inflammation. Autophagy 14: 181&#x2013;189</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5902167</ArticleId><ArticleId IdType="pubmed">28738171</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler VJ, Cortopassi WA, Argouarch AR, Ivry SL, Craik CS, Jacobson MP, Kao AW (2019) Progranulin stimulates the in&#xa0;vitro maturation of Pro&#x2010;cathepsin D at acidic pH. J Mol Biol 431: 1038&#x2013;1047</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6613950</ArticleId><ArticleId IdType="pubmed">30690031</ArticleId></ArticleIdList></Reference><Reference><Citation>Cenik B, Sephton CF, Kutluk Cenik B, Herz J, Yu G (2012) Progranulin: a proteolytically processed protein at the crossroads of inflammation and neurodegeneration. J Biol Chem 287: 32298&#x2013;32306</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3463300</ArticleId><ArticleId IdType="pubmed">22859297</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang MC, Srinivasan K, Friedman BA, Suto E, Modrusan Z, Lee WP, Kaminker JS, Hansen DV, Sheng M (2017) Progranulin deficiency causes impairment of autophagy and TDP&#x2010;43 accumulation. J Exp Med 214: 2611&#x2013;2628</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5584112</ArticleId><ArticleId IdType="pubmed">28778989</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen&#x2010;Plotkin AS, Unger TL, Gallagher MD, Bill E, Kwong LK, Volpicelli&#x2010;Daley L, Busch JI, Akle S, Grossman M, Van Deerlin V et&#xa0;al (2012) TMEM106B, the risk gene for frontotemporal dementia, is regulated by the microRNA&#x2010;132/212 cluster and affects progranulin pathways. J Neurosci 32: 11213&#x2013;11227</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3446826</ArticleId><ArticleId IdType="pubmed">22895706</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark KC, Josephson A, Benusa SD, Hartley RK, Baer M, Thummala S, Joslyn M, Sword BA, Elford H, Oh U et&#xa0;al (2016) Compromised axon initial segment integrity in EAE is preceded by microglial reactivity and contact. Glia 64: 1190&#x2013;1209</Citation><ArticleIdList><ArticleId IdType="pubmed">27100937</ArticleId></ArticleIdList></Reference><Reference><Citation>Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA et&#xa0;al (2013) Multiplex genome engineering using CRISPR/Cas systems. Science 339: 819&#x2013;823</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3795411</ArticleId><ArticleId IdType="pubmed">23287718</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruchaga C, Graff C, Chiang HH, Wang J, Hinrichs AL, Spiegel N, Bertelsen S, Mayo K, Norton JB, Morris JC et&#xa0;al (2011) Association of TMEM106B gene polymorphism with age at onset in granulin mutation carriers and plasma granulin protein levels. Arch Neurol 68: 581&#x2013;586</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3090529</ArticleId><ArticleId IdType="pubmed">21220649</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruts M, Gijselinck I, van der Zee J, Engelborghs S, Wils H, Pirici D, Rademakers R, Vandenberghe R, Dermaut B, Martin JJ et&#xa0;al (2006) Null mutations in progranulin cause ubiquitin&#x2010;positive frontotemporal dementia linked to chromosome 17q21. Nature 442: 920&#x2013;924</Citation><ArticleIdList><ArticleId IdType="pubmed">16862115</ArticleId></ArticleIdList></Reference><Reference><Citation>Deczkowska A, Keren&#x2010;Shaul H, Weiner A, Colonna M, Schwartz M, Amit I (2018) Disease&#x2010;associated microglia: a universal immune sensor of neurodegeneration. Cell 173: 1073&#x2013;1081</Citation><ArticleIdList><ArticleId IdType="pubmed">29775591</ArticleId></ArticleIdList></Reference><Reference><Citation>Deming Y, Cruchaga C (2014) TMEM106B: a strong FTLD disease modifier. Acta Neuropathol 127: 419&#x2013;422</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5494845</ArticleId><ArticleId IdType="pubmed">24488309</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR (2013) STAR: ultrafast universal RNA&#x2010;seq aligner. Bioinformatics 29: 15&#x2013;21</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3530905</ArticleId><ArticleId IdType="pubmed">23104886</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng T, Sheng RR, Sole&#x2010;Domenech S, Ullah M, Zhou X, Mendoza CS, Enriquez LCM, Katz II, Paushter DH, Sullivan PM et&#xa0;al (2020) A role of the frontotemporal lobar degeneration risk factor TMEM106B in myelination. Brain 143: 2255&#x2013;2271</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7363491</ArticleId><ArticleId IdType="pubmed">32572497</ArticleId></ArticleIdList></Reference><Reference><Citation>Finch N, Carrasquillo MM, Baker M, Rutherford NJ, Coppola G, Dejesus&#x2010;Hernandez M, Crook R, Hunter T, Ghidoni R, Benussi L et&#xa0;al (2011) TMEM106B regulates progranulin levels and the penetrance of FTLD in GRN mutation carriers. Neurology 76: 467&#x2013;474</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3034409</ArticleId><ArticleId IdType="pubmed">21178100</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallagher MD, Suh E, Grossman M, Elman L, McCluskey L, Van Swieten JC, Al&#x2010;Sarraj S, Neumann M, Gelpi E, Ghetti B et&#xa0;al (2014) TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions. Acta Neuropathol 127: 407&#x2013;418</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4003885</ArticleId><ArticleId IdType="pubmed">24442578</ArticleId></ArticleIdList></Reference><Reference><Citation>Gass J, Cannon A, Mackenzie IR, Boeve B, Baker M, Adamson J, Crook R, Melquist S, Kuntz K, Petersen R et&#xa0;al (2006) Mutations in progranulin are a major cause of ubiquitin&#x2010;positive frontotemporal lobar degeneration. Hum Mol Genet 15: 2988&#x2013;3001</Citation><ArticleIdList><ArticleId IdType="pubmed">16950801</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotzl JK, Mori K, Damme M, Fellerer K, Tahirovic S, Kleinberger G, Janssens J, van der Zee J, Lang CM, Kremmer E et&#xa0;al (2014) Common pathobiochemical hallmarks of progranulin&#x2010;associated frontotemporal lobar degeneration and neuronal ceroid lipofuscinosis. Acta Neuropathol 127: 845&#x2013;860</Citation><ArticleIdList><ArticleId IdType="pubmed">24619111</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotzl JK, Colombo AV, Fellerer K, Reifschneider A, Werner G, Tahirovic S, Haass C, Capell A (2018) Early lysosomal maturation deficits in microglia triggers enhanced lysosomal activity in other brain cells of progranulin knockout mice. Mol Neurodegener 13: 48</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6123925</ArticleId><ArticleId IdType="pubmed">30180904</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotzl JK, Brendel M, Werner G, Parhizkar S, Sebastian Monasor L, Kleinberger G, Colombo AV, Deussing M, Wagner M, Winkelmann J et&#xa0;al (2019) Opposite microglial activation stages upon loss of PGRN or TREM2 result in reduced cerebral glucose metabolism. EMBO Mol Med 11: e9711</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6554672</ArticleId><ArticleId IdType="pubmed">31122931</ArticleId></ArticleIdList></Reference><Reference><Citation>Hafler BP, Klein ZA, Jimmy Zhou Z, Strittmatter SM (2014) Progressive retinal degeneration and accumulation of autofluorescent lipopigments in Progranulin deficient mice. Brain Res 1588: 168&#x2013;174</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4254024</ArticleId><ArticleId IdType="pubmed">25234724</ArticleId></ArticleIdList></Reference><Reference><Citation>Holler CJ, Taylor G, Deng Q, Kukar T (2017) Intracellular proteolysis of progranulin generates stable, lysosomal granulins that are haploinsufficient in patients with frontotemporal dementia caused by GRN mutations. eNeuro 4: ENEURO.0100&#x2010;17.2017</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5562298</ArticleId><ArticleId IdType="pubmed">28828399</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu F, Padukkavidana T, Vaegter CB, Brady OA, Zheng Y, Mackenzie IR, Feldman HH, Nykjaer A, Strittmatter SM (2010) Sortilin&#x2010;mediated endocytosis determines levels of the frontotemporal dementia protein, progranulin. Neuron 68: 654&#x2013;667</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2990962</ArticleId><ArticleId IdType="pubmed">21092856</ArticleId></ArticleIdList></Reference><Reference><Citation>da Huang W, Sherman BT, Lempicki RA (2009a) Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 37: 1&#x2013;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2615629</ArticleId><ArticleId IdType="pubmed">19033363</ArticleId></ArticleIdList></Reference><Reference><Citation>da Huang W, Sherman BT, Lempicki RA (2009b) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44&#x2013;57</Citation><ArticleIdList><ArticleId IdType="pubmed">19131956</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain N, Chen&#x2010;Plotkin AS (2018) Genetic modifiers in neurodegeneration. Curr Genet Med Rep 6: 11&#x2013;19</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6028053</ArticleId><ArticleId IdType="pubmed">29977663</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamalainen A, Viswanathan J, Natunen T, Helisalmi S, Kauppinen T, Pikkarainen M, Pursiheimo JP, Alafuzoff I, Kivipelto M, Haapasalo A et&#xa0;al (2013) GRN variant rs5848 reduces plasma and brain levels of granulin in Alzheimer's disease patients. J Alzheimers Dis 33: 23&#x2013;27</Citation><ArticleIdList><ArticleId IdType="pubmed">22890097</ArticleId></ArticleIdList></Reference><Reference><Citation>Kao AW, McKay A, Singh PP, Brunet A, Huang EJ (2017) Progranulin, lysosomal regulation and neurodegenerative disease. Nat Rev Neurosci 18: 325&#x2013;333</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6040832</ArticleId><ArticleId IdType="pubmed">28435163</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren&#x2010;Shaul H, Spinrad A, Weiner A, Matcovitch&#x2010;Natan O, Dvir&#x2010;Szternfeld R, Ulland TK, David E, Baruch K, Lara&#x2010;Astaiso D, Toth B et&#xa0;al (2017) A unique microglia type associated with restricting development of Alzheimer's disease. Cell 169: 1276&#x2013;1290.e1217</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein ZA, Takahashi H, Ma M, Stagi M, Zhou M, Lam TT, Strittmatter SM (2017) Loss of TMEM106B ameliorates lysosomal and frontotemporal dementia&#x2010;related phenotypes in progranulin&#x2010;deficient mice. Neuron 95: 281&#x2013;296.e286</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5558861</ArticleId><ArticleId IdType="pubmed">28728022</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann S, Madore C, Cialic R, Baufeld C, Calcagno N, El Fatimy R, Beckers L, O'Loughlin E, Xu Y, Fanek Z et&#xa0;al (2017) The TREM2&#x2010;APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity 47: 566&#x2013;581.e569</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5719893</ArticleId><ArticleId IdType="pubmed">28930663</ArticleId></ArticleIdList></Reference><Reference><Citation>Kundu ST, Grzeskowiak CL, Fradette JJ, Gibson LA, Rodriguez LB, Creighton CJ, Scott KL, Gibbons DL (2018) TMEM106B drives lung cancer metastasis by inducing TFEB&#x2010;dependent lysosome synthesis and secretion of cathepsins. Nat Commun 9: 2731</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6048095</ArticleId><ArticleId IdType="pubmed">30013069</ArticleId></ArticleIdList></Reference><Reference><Citation>Lalonde R, Strazielle C (2011) Brain regions and genes affecting limb&#x2010;clasping responses. Brain Res Rev 67: 252&#x2013;259</Citation><ArticleIdList><ArticleId IdType="pubmed">21356243</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang CM, Fellerer K, Schwenk BM, Kuhn PH, Kremmer E, Edbauer D, Capell A, Haass C (2012) Membrane orientation and subcellular localization of transmembrane protein 106B (TMEM106B), a major risk factor for frontotemporal lobar degeneration. J Biol Chem 287: 19355&#x2013;19365</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3365973</ArticleId><ArticleId IdType="pubmed">22511793</ArticleId></ArticleIdList></Reference><Reference><Citation>Lattante S, Le Ber I, Galimberti D, Serpente M, Rivaud&#x2010;Pechoux S, Camuzat A, Clot F, Fenoglio C, French research network on FTD and FTD&#x2010;ALS , Scarpini E et&#xa0;al (2014) Defining the association of TMEM106B variants among frontotemporal lobar degeneration patients with GRN mutations and C9orf72 repeat expansions. Neurobiol Aging 35: 2658.e2651&#x2013;2658.e2655</Citation><ArticleIdList><ArticleId IdType="pubmed">25085782</ArticleId></ArticleIdList></Reference><Reference><Citation>Law CW, Chen Y, Shi W, Smyth GK (2014) voom: precision weights unlock linear model analysis tools for RNA&#x2010;seq read counts. Genome Biol 15: R29</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4053721</ArticleId><ArticleId IdType="pubmed">24485249</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MJ, Chen TF, Cheng TW, Chiu MJ (2011) rs5848 variant of progranulin gene is a risk of Alzheimer's disease in the taiwanese population. Neurodegener Dis 8: 216&#x2013;220</Citation><ArticleIdList><ArticleId IdType="pubmed">21212639</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CW, Stankowski JN, Chew J, Cook CN, Lam YW, Almeida S, Carlomagno Y, Lau KF, Prudencio M, Gao FB et&#xa0;al (2017) The lysosomal protein cathepsin L is a progranulin protease. Mol Neurodegener 12: 55</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5526245</ArticleId><ArticleId IdType="pubmed">28743268</ArticleId></ArticleIdList></Reference><Reference><Citation>Lieu CA, Chinta SJ, Rane A, Andersen JK (2013) Age&#x2010;related behavioral phenotype of an astrocytic monoamine oxidase&#x2010;B transgenic mouse model of Parkinson's disease. PLoS ONE 8: e54200</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3542194</ArticleId><ArticleId IdType="pubmed">23326597</ArticleId></ArticleIdList></Reference><Reference><Citation>Lui H, Zhang J, Makinson SR, Cahill MK, Kelley KW, Huang HY, Shang Y, Oldham MC, Martens LH, Gao F et&#xa0;al (2016) Progranulin deficiency promotes circuit&#x2010;specific synaptic pruning by microglia via complement activation. Cell 165: 921&#x2013;935</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4860138</ArticleId><ArticleId IdType="pubmed">27114033</ArticleId></ArticleIdList></Reference><Reference><Citation>Luningschror P, Werner G, Stroobants S, Kakuta S, Dombert B, Sinske D, Wanner R, Lullmann&#x2010;Rauch R, Wefers B, Wurst W et&#xa0;al (2020) The FTLD risk factor TMEM106B regulates the transport of lysosomes at the axon initial segment of motoneurons. Cell Rep 30: 3506&#x2013;3519.e3506</Citation><ArticleIdList><ArticleId IdType="pubmed">32160553</ArticleId></ArticleIdList></Reference><Reference><Citation>Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, Norville JE, Church GM (2013) RNA&#x2010;guided human genome engineering via Cas9. Science 339: 823&#x2013;826</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3712628</ArticleId><ArticleId IdType="pubmed">23287722</ArticleId></ArticleIdList></Reference><Reference><Citation>Martens LH, Zhang J, Barmada SJ, Zhou P, Kamiya S, Sun B, Min SW, Gan L, Finkbeiner S, Huang EJ et&#xa0;al (2012) Progranulin deficiency promotes neuroinflammation and neuron loss following toxin&#x2010;induced injury. J Clin Invest 122: 3955&#x2013;3959</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3484443</ArticleId><ArticleId IdType="pubmed">23041626</ArticleId></ArticleIdList></Reference><Reference><Citation>Nabar NR, Kehrl JH (2017) The transcription factor EB links cellular stress to the immune response. Yale J Biol Med 90: 301&#x2013;315</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5482306</ArticleId><ArticleId IdType="pubmed">28656016</ArticleId></ArticleIdList></Reference><Reference><Citation>Napolitano G, Ballabio A (2016) TFEB at a glance. J Cell Sci 129: 2475&#x2013;2481</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4958300</ArticleId><ArticleId IdType="pubmed">27252382</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Dickson DW, Trojanowski JQ, Jack CR, Boyle PA, Arfanakis K, Rademakers R, Alafuzoff I, Attems J, Brayne C et&#xa0;al (2019) Limbic&#x2010;predominant age&#x2010;related TDP&#x2010;43 encephalopathy (LATE): consensus working group report. Brain 142: 1503&#x2013;1527</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6536849</ArticleId><ArticleId IdType="pubmed">31039256</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM et&#xa0;al (2006) Ubiquitinated TDP&#x2010;43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314: 130&#x2013;133</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen AD, Nguyen TA, Singh RK, Eberle D, Zhang J, Abate JP, Robles A, Koliwad S, Huang EJ, Maxfield FR et&#xa0;al (2018) Progranulin in the hematopoietic compartment protects mice from atherosclerosis. Atherosclerosis 277: 145&#x2013;154</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6432779</ArticleId><ArticleId IdType="pubmed">30212683</ArticleId></ArticleIdList></Reference><Reference><Citation>Paushter DH, Du H, Feng T, Hu F (2018) The lysosomal function of progranulin, a guardian against neurodegeneration. Acta Neuropathol 136: 1&#x2013;17</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6117207</ArticleId><ArticleId IdType="pubmed">29744576</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng W, Minakaki G, Nguyen M, Krainc D (2019) Preserving lysosomal function in the aging brain: insights from neurodegeneration. Neurotherapeutics 16: 611&#x2013;634</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6694346</ArticleId><ArticleId IdType="pubmed">31183763</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry DC, Lehmann M, Yokoyama JS, Karydas A, Lee JJ, Coppola G, Grinberg LT, Geschwind D, Seeley WW, Miller BL et&#xa0;al (2013) Progranulin mutations as risk factors for Alzheimer disease. JAMA Neurol 70: 774&#x2013;778</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3743672</ArticleId><ArticleId IdType="pubmed">23609919</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhinn H, Abeliovich A (2017) Differential aging analysis in human cerebral cortex identifies variants in TMEM106B and GRN that regulate aging phenotypes. Cell Syst 4: 404&#x2013;415.e405</Citation><ArticleIdList><ArticleId IdType="pubmed">28330615</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson MD, McCarthy DJ, Smyth GK (2010) edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26: 139&#x2013;140</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2796818</ArticleId><ArticleId IdType="pubmed">19910308</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutherford NJ, Carrasquillo MM, Li M, Bisceglio G, Menke J, Josephs KA, Parisi JE, Petersen RC, Graff&#x2010;Radford NR, Younkin SG et&#xa0;al (2012) TMEM106B risk variant is implicated in the pathologic presentation of Alzheimer disease. Neurology 79: 717&#x2013;718</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3467659</ArticleId><ArticleId IdType="pubmed">22855871</ArticleId></ArticleIdList></Reference><Reference><Citation>Sardiello M, Palmieri M, di Ronza A, Medina DL, Valenza M, Gennarino VA, Di Malta C, Donaudy F, Embrione V, Polishchuk RS et&#xa0;al (2009) A gene network regulating lysosomal biogenesis and function. Science 325: 473&#x2013;477</Citation><ArticleIdList><ArticleId IdType="pubmed">19556463</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwenk BM, Lang CM, Hogl S, Tahirovic S, Orozco D, Rentzsch K, Lichtenthaler SF, Hoogenraad CC, Capell A, Haass C et&#xa0;al (2014) The FTLD risk factor TMEM106B and MAP6 control dendritic trafficking of lysosomes. EMBO J 33: 450&#x2013;467</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3989627</ArticleId><ArticleId IdType="pubmed">24357581</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng J, Su L, Xu Z, Chen G (2014) Progranulin polymorphism rs5848 is associated with increased risk of Alzheimer's disease. Gene 542: 141&#x2013;145</Citation><ArticleIdList><ArticleId IdType="pubmed">24680777</ArticleId></ArticleIdList></Reference><Reference><Citation>Simons C, Dyment D, Bent SJ, Crawford J, D'Hooghe M, Kohlschutter A, Venkateswaran S, Helman G, Poll&#x2010;The BT, Makowski CC et&#xa0;al (2017) A recurrent de novo mutation in TMEM106B causes hypomyelinating leukodystrophy. Brain 140: 3105&#x2013;3111</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5841038</ArticleId><ArticleId IdType="pubmed">29186371</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith KR, Damiano J, Franceschetti S, Carpenter S, Canafoglia L, Morbin M, Rossi G, Pareyson D, Mole SE, Staropoli JF et&#xa0;al (2012) Strikingly different clinicopathological phenotypes determined by progranulin&#x2010;mutation dosage. Am J Hum Genet 90: 1102&#x2013;1107</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3370276</ArticleId><ArticleId IdType="pubmed">22608501</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi H, Klein ZA, Bhagat SM, Kaufman AC, Kostylev MA, Ikezu T, Strittmatter SM; Alzheimer's Disease Neuroimaging Initiative (2017) Opposing effects of progranulin deficiency on amyloid and tau pathologies via microglial TYROBP network. Acta Neuropathol 133: 785&#x2013;807</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5391267</ArticleId><ArticleId IdType="pubmed">28070672</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka Y, Chambers JK, Matsuwaki T, Yamanouchi K, Nishihara M (2014) Possible involvement of lysosomal dysfunction in pathological changes of the brain in aged progranulin&#x2010;deficient mice. Acta Neuropathol Commun 2: 78</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4149276</ArticleId><ArticleId IdType="pubmed">25022663</ArticleId></ArticleIdList></Reference><Reference><Citation>Tropea TF, Mak J, Guo MH, Xie SX, Suh E, Rick J, Siderowf A, Weintraub D, Grossman M, Irwin D et&#xa0;al (2019) TMEM106B Effect on cognition in Parkinson disease and frontotemporal dementia. Ann Neurol 85: 801&#x2013;811</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6953172</ArticleId><ArticleId IdType="pubmed">30973966</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuruma K, Yamauchi M, Sugitani S, Otsuka T, Ohno Y, Nagahara Y, Ikegame Y, Shimazawa M, Yoshimura S, Iwama T et&#xa0;al (2014) Progranulin, a major secreted protein of mouse adipose&#x2010;derived stem cells, inhibits light&#x2010;induced retinal degeneration. Stem Cells Transl Med 3: 42&#x2013;53</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3902284</ArticleId><ArticleId IdType="pubmed">24233842</ArticleId></ArticleIdList></Reference><Reference><Citation>Valdez C, Wong YC, Schwake M, Bu G, Wszolek ZK, Krainc D (2017) Progranulin&#x2010;mediated deficiency of cathepsin D results in FTD and NCL&#x2010;like phenotypes in neurons derived from FTD patients. Hum Mol Genet 26: 4861&#x2013;4872</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5886207</ArticleId><ArticleId IdType="pubmed">29036611</ArticleId></ArticleIdList></Reference><Reference><Citation>Valdez C, Ysselstein D, Young TJ, Zheng J, Krainc D (2019) Progranulin mutations result in impaired processing of prosaposin and reduced glucocerebrosidase activity. Hum Mol Genet 29: 716&#x2013;726</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7104673</ArticleId><ArticleId IdType="pubmed">31600775</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Deerlin VM, Wood EM, Moore P, Yuan W, Forman MS, Clark CM, Neumann M, Kwong LK, Trojanowski JQ, Lee VM et&#xa0;al (2007) Clinical, genetic, and pathologic characteristics of patients with frontotemporal dementia and progranulin mutations. Arch Neurol 64: 1148&#x2013;1153</Citation><ArticleIdList><ArticleId IdType="pubmed">17698705</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Deerlin VM, Sleiman PM, Martinez&#x2010;Lage M, Chen&#x2010;Plotkin A, Wang LS, Graff&#x2010;Radford NR, Dickson DW, Rademakers R, Boeve BF, Grossman M et&#xa0;al (2010) Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP&#x2010;43 inclusions. Nat Genet 42: 234&#x2013;239</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2828525</ArticleId><ArticleId IdType="pubmed">20154673</ArticleId></ArticleIdList></Reference><Reference><Citation>Vass R, Ashbridge E, Geser F, Hu WT, Grossman M, Clay&#x2010;Falcone D, Elman L, McCluskey L, Lee VM, Van Deerlin VM et&#xa0;al (2011) Risk genotypes at TMEM106B are associated with cognitive impairment in amyotrophic lateral sclerosis. Acta Neuropathol 121: 373&#x2013;380</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3095217</ArticleId><ArticleId IdType="pubmed">21104415</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward ME, Taubes A, Chen R, Miller BL, Sephton CF, Gelfand JM, Minami S, Boscardin J, Martens LH, Seeley WW et&#xa0;al (2014) Early retinal neurodegeneration and impaired Ran&#x2010;mediated nuclear import of TDP&#x2010;43 in progranulin&#x2010;deficient FTLD. J Exp Med 211: 1937&#x2013;1945</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4172214</ArticleId><ArticleId IdType="pubmed">25155018</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward ME, Chen R, Huang HY, Ludwig C, Telpoukhovskaia M, Taubes A, Boudin H, Minami SS, Reichert M, Albrecht P et&#xa0;al (2017) Individuals with progranulin haploinsufficiency exhibit features of neuronal ceroid lipofuscinosis. Sci Transl Med 9: eaah5642</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5526610</ArticleId><ArticleId IdType="pubmed">28404863</ArticleId></ArticleIdList></Reference><Reference><Citation>Werner G, Damme M, Schludi M, Gn&#xf6;rich J, Wind K, Fellerer K, Wefers B, Wurst W, Edbauer D, Brendel M et&#xa0;al (2020) Loss of TMEM106B potentiates lysosomal and FTD&#x2010;like pathology in progranulin deficient mice. EMBO Rep 10.15252/embr.202050241</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embr.202050241</ArticleId><ArticleId IdType="pmc">PMC7534633</ArticleId><ArticleId IdType="pubmed">32929860</ArticleId></ArticleIdList></Reference><Reference><Citation>Wils H, Kleinberger G, Pereson S, Janssens J, Capell A, Van Dam D, Cuijt I, Joris G, De Deyn PP, Haass C et&#xa0;al (2012) Cellular ageing, increased mortality and FTLD&#x2010;TDP&#x2010;associated neuropathology in progranulin knockout mice. J Pathol 228: 67&#x2013;76</Citation><ArticleIdList><ArticleId IdType="pubmed">22733568</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood HB (2010) TMEM106B is a susceptibility locus for Ftld. Nat Rev Neurol 6: 184</Citation><ArticleIdList><ArticleId IdType="pubmed">20383883</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu HM, Tan L, Wan Y, Tan MS, Zhang W, Zheng ZJ, Kong LL, Wang ZX, Jiang T, Tan L et&#xa0;al (2017) PGRN is associated with Late&#x2010;onset Alzheimer's disease: a case&#x2010;control replication study and meta&#x2010;analysis. Mol Neurobiol 54: 1187&#x2013;1195</Citation><ArticleIdList><ArticleId IdType="pubmed">26820675</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan H, Kubisiak T, Ji H, Xiao J, Wang J, Burmeister M (2018) The recurrent mutation in TMEM106B also causes hypomyelinating leukodystrophy in China and is a CpG hotspot. Brain 141: e36</Citation><ArticleIdList><ArticleId IdType="pubmed">29444210</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang HS, White CC, Klein HU, Yu L, Gaiteri C, Ma Y, Felsky D, Mostafavi S, Petyuk VA, Sperling RA et&#xa0;al (2020) Genetics of gene expression in the aging human brain reveal TDP&#x2010;43 proteinopathy pathophysiology. Neuron 107: 1&#x2013;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7416464</ArticleId><ArticleId IdType="pubmed">32526197</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin F, Banerjee R, Thomas B, Zhou P, Qian L, Jia T, Ma X, Ma Y, Iadecola C, Beal MF et&#xa0;al (2010a) Exaggerated inflammation, impaired host defense, and neuropathology in progranulin&#x2010;deficient mice. J Exp Med 207: 117&#x2013;128</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2812536</ArticleId><ArticleId IdType="pubmed">20026663</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin F, Dumont M, Banerjee R, Ma Y, Li H, Lin MT, Beal MF, Nathan C, Thomas B, Ding A (2010b) Behavioral deficits and progressive neuropathology in progranulin&#x2010;deficient mice: a mouse model of frontotemporal dementia. FASEB J 24: 4639&#x2013;4647</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2992364</ArticleId><ArticleId IdType="pubmed">20667979</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Zee J, Van Broeckhoven C (2011) TMEM106B a novel risk factor for frontotemporal lobar degeneration. J Mol Neurosci 45: 516&#x2013;521</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3207134</ArticleId><ArticleId IdType="pubmed">21614538</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Zee J, Van Langenhove T, Kleinberger G, Sleegers K, Engelborghs S, Vandenberghe R, Santens P, Van den Broeck M, Joris G, Brys J et&#xa0;al (2011) TMEM106B is associated with frontotemporal lobar degeneration in a clinically diagnosed patient cohort. Brain 134: 808&#x2013;815</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3044834</ArticleId><ArticleId IdType="pubmed">21354975</ArticleId></ArticleIdList></Reference><Reference><Citation>Zerbino DR, Achuthan P, Akanni W, Amode MR, Barrell D, Bhai J, Billis K, Cummins C, Gall A, Giron CG et&#xa0;al (2018) Ensembl 2018. Nucleic Acids Res 46: D754&#x2013;D761</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5753206</ArticleId><ArticleId IdType="pubmed">29155950</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, Sun L, Bastos de Oliveira F, Qi X, Brown WJ, Smolka MB, Sun Y, Hu F (2015) Prosaposin facilitates sortilin&#x2010;independent lysosomal trafficking of progranulin. J Cell Biol 210: 991&#x2013;1002</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4576858</ArticleId><ArticleId IdType="pubmed">26370502</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, Paushter DH, Feng T, Pardon CM, Mendoza CS, Hu F (2017a) Regulation of cathepsin D activity by the FTLD protein progranulin. Acta Neuropathol 134: 151&#x2013;153</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5568051</ArticleId><ArticleId IdType="pubmed">28493053</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, Paushter DH, Feng T, Sun L, Reinheckel T, Hu F (2017b) Lysosomal processing of progranulin. Mol Neurodegener 12: 62</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5569495</ArticleId><ArticleId IdType="pubmed">28835281</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, Sun L, Bracko O, Choi JW, Jia Y, Nana AL, Brady OA, Hernandez JCC, Nishimura N, Seeley WW et&#xa0;al (2017c) Impaired prosaposin lysosomal trafficking in frontotemporal lobar degeneration due to progranulin mutations. Nat Commun 8: 15277</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5477518</ArticleId><ArticleId IdType="pubmed">28541286</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, Sun L, Brady OA, Murphy KA, Hu F (2017d) Elevated TMEM106B levels exaggerate lipofuscin accumulation and lysosomal dysfunction in aged mice with progranulin deficiency. Acta Neuropathol Commun 5: 9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5270347</ArticleId><ArticleId IdType="pubmed">28126008</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, Paushter DH, Pagan MD, Kim D, Nunez Santos M, Lieberman RL, Overkleeft HS, Sun Y, Smolka MB, Hu F (2019) Progranulin deficiency&#xa0;leads to reduced glucocerebrosidase activity. PLoS ONE 14: e0212382</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6619604</ArticleId><ArticleId IdType="pubmed">31291241</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, Brooks M, Jiang P, Koga S, Zuberi AR, Baker MC, Parsons TM, Castanedes&#x2010;Casey M, Phillips V, Librero AL et&#xa0;al (2020a) Loss of Tmem106b exacerbates FTLD pathologies and causes motor deficits in progranulin deficient mice. EMBO Rep 10.15252/embr.202050197</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embr.202050197</ArticleId><ArticleId IdType="pmc">PMC7534638</ArticleId><ArticleId IdType="pubmed">32761777</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, Nicholson AM, Ren Y, Brooks M, Jiang P, Zuberi A, Phuoc HN, Perkerson RB, Matchett B, Parsons TM et&#xa0;al (2020b) Loss of TMEM106B leads to myelination deficits: implications for frontotemporal dementia treatment strategies. Brain 143: 1905&#x2013;1919</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7296855</ArticleId><ArticleId IdType="pubmed">32504082</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32866962</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>10</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>588</Volume><Issue>7838</Issue><PubDate><Year>2020</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Neurotoxic microglia promote TDP-43 proteinopathy in progranulin deficiency.</ArticleTitle><Pagination><StartPage>459</StartPage><EndPage>465</EndPage><MedlinePgn>459-465</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41586-020-2709-7</ELocationID><Abstract><AbstractText>Aberrant aggregation of the RNA-binding protein TDP-43 in neurons is a hallmark of frontotemporal lobar degeneration caused by haploinsufficiency in the gene encoding progranulin<sup>1,2</sup>. However, the mechanism leading to TDP-43 proteinopathy remains unclear. Here we use single-nucleus RNA sequencing to show that progranulin deficiency promotes microglial transition from a homeostatic to a disease-specific state that causes endolysosomal dysfunction and neurodegeneration in mice. These defects persist even when Grn<sup>-/-</sup> microglia are cultured ex vivo. In addition, single-nucleus RNA sequencing reveals selective loss of excitatory neurons at disease end-stage, which is characterized by prominent nuclear and cytoplasmic TDP-43 granules and nuclear pore defects. Remarkably, conditioned media from Grn<sup>-/-</sup> microglia are sufficient to promote TDP-43 granule formation, nuclear pore defects and cell death in excitatory neurons via the complement activation pathway. Consistent with these results, deletion of the genes encoding C1qa and C3 mitigates microglial toxicity and rescues TDP-43 proteinopathy and neurodegeneration. These results uncover previously unappreciated contributions of chronic microglial toxicity to TDP-43 proteinopathy during neurodegeneration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhang</LastName><ForeName>Jiasheng</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pathology Service 113B, San Francisco VA Health Care System, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Velmeshev</LastName><ForeName>Dmitry</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Hashimoto</LastName><ForeName>Kei</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Huang</LastName><ForeName>Yu-Hsin</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hofmann</LastName><ForeName>Jeffrey W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Xiaoyu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Developmental and Cell Biology, University of California Irvine, Irvine, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Jiapei</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Sciences Graduate Program, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leidal</LastName><ForeName>Andrew M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dishart</LastName><ForeName>Julian G</ForeName><Initials>JG</Initials><Identifier Source="ORCID">0000-0003-0014-6141</Identifier><AffiliationInfo><Affiliation>Department of Pathology, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cahill</LastName><ForeName>Michelle K</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Neuroscience Graduate Program, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kelley</LastName><ForeName>Kevin W</ForeName><Initials>KW</Initials><AffiliationInfo><Affiliation>Neuroscience Graduate Program, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liddelow</LastName><ForeName>Shane A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Neuroscience Institute, Department of Neuroscience &amp; Physiology, NYU Langone Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seeley</LastName><ForeName>William W</ForeName><Initials>WW</Initials><AffiliationInfo><Affiliation>Neuroscience Graduate Program, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walther</LastName><ForeName>Tobias C</ForeName><Initials>TC</Initials><Identifier Source="ORCID">0000-0003-1442-1327</Identifier><AffiliationInfo><Affiliation>Department of Genetics and Complex Diseases, T.H. Chan School of Public Health, Harvard University, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farese</LastName><ForeName>Robert V</ForeName><Initials>RV</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Department of Genetics and Complex Diseases, T.H. Chan School of Public Health, Harvard University, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>J Paul</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Department of Cell and Molecular Biology, St Jude Children's Hospital &amp; Howard Hughes Medical Institute, Memphis, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ullian</LastName><ForeName>Erik M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Bo</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0003-1704-4141</Identifier><AffiliationInfo><Affiliation>Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chan Zuckerberg Biohub, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Debnath</LastName><ForeName>Jayanta</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-8745-4069</Identifier><AffiliationInfo><Affiliation>Department of Pathology, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Sciences Graduate Program, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wittmann</LastName><ForeName>Torsten</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-9134-691X</Identifier><AffiliationInfo><Affiliation>Biomedical Sciences Graduate Program, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cell and Tissue Biology, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kriegstein</LastName><ForeName>Arnold R</ForeName><Initials>AR</Initials><Identifier Source="ORCID">0000-0001-5742-2990</Identifier><AffiliationInfo><Affiliation>Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Sciences Graduate Program, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Graduate Program, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Eric J</ForeName><Initials>EJ</Initials><Identifier Source="ORCID">0000-0002-5381-3801</Identifier><AffiliationInfo><Affiliation>Department of Pathology, University of California San Francisco, San Francisco, CA, USA. eric.huang2@ucsf.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pathology Service 113B, San Francisco VA Health Care System, San Francisco, CA, USA. eric.huang2@ucsf.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Sciences Graduate Program, University of California San Francisco, San Francisco, CA, USA. eric.huang2@ucsf.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Graduate Program, University of California San Francisco, San Francisco, CA, USA. eric.huang2@ucsf.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA. eric.huang2@ucsf.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS107480</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R35 NS097305</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062422</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG068290</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 CA231300</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K99 MH121534</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R00 GM126136</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 RR026758</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>I01 BX002978</GrantID><Acronym>BX</Acronym><Agency>BLRD VA</Agency><Country>United States</Country></Grant><Grant><GrantID>K99 GM126136</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 MH114825</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 MH105989</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG057462</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM124334</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AA027074</GrantID><Acronym>AA</Acronym><Agency>NIAAA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>08</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017077">Culture Media, Conditioned</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C120204">Grn protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077153">Progranulins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578077">TDP-43 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>80295-33-6</RegistryNumber><NameOfSubstance UI="D015922">Complement C1q</NameOfSubstance></Chemical><Chemical><RegistryNumber>80295-43-8</RegistryNumber><NameOfSubstance UI="D003179">Complement C3b</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002467" MajorTopicYN="N">Cell Nucleus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003167" MajorTopicYN="N">Complement Activation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015922" MajorTopicYN="N">Complement C1q</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003179" MajorTopicYN="N">Complement C3b</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017077" MajorTopicYN="N">Culture Media, Conditioned</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D022022" MajorTopicYN="N">Nuclear Pore</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077153" MajorTopicYN="N">Progranulins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000081246" MajorTopicYN="N">RNA-Seq</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059010" MajorTopicYN="N">Single-Cell Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057177" MajorTopicYN="N">TDP-43 Proteinopathies</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013788" MajorTopicYN="N">Thalamus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059467" MajorTopicYN="N">Transcriptome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>4</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>2</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32866962</ArticleId><ArticleId IdType="mid">NIHMS1622640</ArticleId><ArticleId IdType="pmc">PMC7746606</ArticleId><ArticleId IdType="doi">10.1038/s41586-020-2709-7</ArticleId><ArticleId IdType="pii">10.1038/s41586-020-2709-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hofmann JW, Seeley WW &amp; Huang EJ RNA Binding Proteins and the Pathogenesis of Frontotemporal Lobar Degeneration. Annu Rev Pathol 14, 469&#x2013;495, 10.1146/annurev-pathmechdis-012418-012955 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-pathmechdis-012418-012955</ArticleId><ArticleId IdType="pmc">PMC6731550</ArticleId><ArticleId IdType="pubmed">30355151</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR et al. A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol 122, 111&#x2013;113, 10.1007/s00401-011-0845-8 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0845-8</ArticleId><ArticleId IdType="pmc">PMC3285143</ArticleId><ArticleId IdType="pubmed">21644037</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker M et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 442, 916&#x2013;919, 10.1038/nature05016 (2006).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature05016</ArticleId><ArticleId IdType="pubmed">16862116</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruts M et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 442, 920&#x2013;924, 10.1038/nature05017 (2006).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature05017</ArticleId><ArticleId IdType="pubmed">16862115</ArticleId></ArticleIdList></Reference><Reference><Citation>Kao AW, McKay A, Singh PP, Brunet A &amp; Huang EJ Progranulin, lysosomal regulation and neurodegenerative disease. Nat Rev Neurosci 18, 325&#x2013;333, 10.1038/nrn.2017.36 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn.2017.36</ArticleId><ArticleId IdType="pmc">PMC6040832</ArticleId><ArticleId IdType="pubmed">28435163</ArticleId></ArticleIdList></Reference><Reference><Citation>Lui H et al. Progranulin Deficiency Promotes Circuit-Specific Synaptic Pruning by Microglia via Complement Activation. Cell 165, 921&#x2013;935, 10.1016/j.cell.2016.04.001 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.04.001</ArticleId><ArticleId IdType="pmc">PMC4860138</ArticleId><ArticleId IdType="pubmed">27114033</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang MC et al. Progranulin deficiency causes impairment of autophagy and TDP-43 accumulation. J Exp Med, 10.1084/jem.20160999 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20160999</ArticleId><ArticleId IdType="pmc">PMC5584112</ArticleId><ArticleId IdType="pubmed">28778989</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward ME et al. Individuals with progranulin haploinsufficiency exhibit features of neuronal ceroid lipofuscinosis. Sci Transl Med 9, 10.1126/scitranslmed.aah5642 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aah5642</ArticleId><ArticleId IdType="pmc">PMC5526610</ArticleId><ArticleId IdType="pubmed">28404863</ArticleId></ArticleIdList></Reference><Reference><Citation>Laferriere F et al. TDP-43 extracted from frontotemporal lobar degeneration subject brains displays distinct aggregate assemblies and neurotoxic effects reflecting disease progression rates. Nat Neurosci 22, 65&#x2013;77, 10.1038/s41593-018-0294-y (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0294-y</ArticleId><ArticleId IdType="pubmed">30559480</ArticleId></ArticleIdList></Reference><Reference><Citation>Habib N et al. Div-Seq: Single-nucleus RNA-Seq reveals dynamics of rare adult newborn neurons. Science 353, 925&#x2013;928, 10.1126/science.aad7038 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aad7038</ArticleId><ArticleId IdType="pmc">PMC5480621</ArticleId><ArticleId IdType="pubmed">27471252</ArticleId></ArticleIdList></Reference><Reference><Citation>Lake BB et al. Neuronal subtypes and diversity revealed by single-nucleus RNA sequencing of the human brain. Science 352, 1586&#x2013;1590, 10.1126/science.aaf1204 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaf1204</ArticleId><ArticleId IdType="pmc">PMC5038589</ArticleId><ArticleId IdType="pubmed">27339989</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond TR et al. Single-Cell RNA Sequencing of Microglia throughout the Mouse Lifespan and in the Injured Brain Reveals Complex Cell-State Changes. Immunity 50, 253&#x2013;271 e256, 10.1016/j.immuni.2018.11.004 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2018.11.004</ArticleId><ArticleId IdType="pmc">PMC6655561</ArticleId><ArticleId IdType="pubmed">30471926</ArticleId></ArticleIdList></Reference><Reference><Citation>Ximerakis M et al. Single-cell transcriptomic profiling of the aging mouse brain. Nat Neurosci 22, 1696&#x2013;1708, 10.1038/s41593-019-0491-3 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-019-0491-3</ArticleId><ArticleId IdType="pubmed">31551601</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao J et al. Comprehensive single-cell transcriptional profiling of a multicellular organism. Science 357, 661&#x2013;667, 10.1126/science.aam8940 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aam8940</ArticleId><ArticleId IdType="pmc">PMC5894354</ArticleId><ArticleId IdType="pubmed">28818938</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu X et al. Reversed graph embedding resolves complex single-cell trajectories. Nat Methods 14, 979&#x2013;982, 10.1038/nmeth.4402 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.4402</ArticleId><ArticleId IdType="pmc">PMC5764547</ArticleId><ArticleId IdType="pubmed">28825705</ArticleId></ArticleIdList></Reference><Reference><Citation>Matcovitch-Natan O et al. Microglia development follows a stepwise program to regulate brain homeostasis. Science 353, aad8670, 10.1126/science.aad8670 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aad8670</ArticleId><ArticleId IdType="pubmed">27338705</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H et al. A Unique Microglia Type Associated with Restricting Development of Alzheimer&#x2019;s Disease. Cell 169, 1276&#x2013;1290 e1217, 10.1016/j.cell.2017.05.018 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.05.018</ArticleId><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Kao PF et al. Detection of TDP-43 oligomers in frontotemporal lobar degeneration-TDP. Ann Neurol 78, 211&#x2013;221, 10.1002/ana.24431 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24431</ArticleId><ArticleId IdType="pmc">PMC4822421</ArticleId><ArticleId IdType="pubmed">25921485</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffis ER, Xu S &amp; Powers MA Nup98 localizes to both nuclear and cytoplasmic sides of the nuclear pore and binds to two distinct nucleoporin subcomplexes. Mol Biol Cell 14, 600&#x2013;610, 10.1091/mbc.e02-09-0582 (2003).</Citation><ArticleIdList><ArticleId IdType="doi">10.1091/mbc.e02-09-0582</ArticleId><ArticleId IdType="pmc">PMC149995</ArticleId><ArticleId IdType="pubmed">12589057</ArticleId></ArticleIdList></Reference><Reference><Citation>McGurk L et al. Poly(ADP-Ribose) Prevents Pathological Phase Separation of TDP-43 by Promoting Liquid Demixing and Stress Granule Localization. Mol Cell 71, 703&#x2013;717 e709, 10.1016/j.molcel.2018.07.002 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2018.07.002</ArticleId><ArticleId IdType="pmc">PMC6128762</ArticleId><ArticleId IdType="pubmed">30100264</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasset-Rosa F et al. Cytoplasmic TDP-43 De-mixing Independent of Stress Granules Drives Inhibition of Nuclear Import, Loss of Nuclear TDP-43, and Cell Death. Neuron 102, 339&#x2013;357 e337, 10.1016/j.neuron.2019.02.038 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2019.02.038</ArticleId><ArticleId IdType="pmc">PMC6548321</ArticleId><ArticleId IdType="pubmed">30853299</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann JR et al. RNA Binding Antagonizes Neurotoxic Phase Transitions of TDP-43. Neuron 102, 321&#x2013;338 e328, 10.1016/j.neuron.2019.01.048 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2019.01.048</ArticleId><ArticleId IdType="pmc">PMC6472983</ArticleId><ArticleId IdType="pubmed">30826182</ArticleId></ArticleIdList></Reference><Reference><Citation>Liszewski MK et al. Intracellular complement activation sustains T cell homeostasis and mediates effector differentiation. Immunity 39, 1143&#x2013;1157, 10.1016/j.immuni.2013.10.018 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2013.10.018</ArticleId><ArticleId IdType="pmc">PMC3865363</ArticleId><ArticleId IdType="pubmed">24315997</ArticleId></ArticleIdList></Reference><Reference><Citation>West EE, Afzali B &amp; Kemper C Unexpected Roles for Intracellular Complement in the Regulation of Th1 Responses. Adv Immunol 138, 35&#x2013;70, 10.1016/bs.ai.2018.02.001 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/bs.ai.2018.02.001</ArticleId><ArticleId IdType="pubmed">29731006</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu G et al. Endocytosis regulates TDP-43 toxicity and turnover. Nat Commun 8, 2092, 10.1038/s41467-017-02017-x (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-02017-x</ArticleId><ArticleId IdType="pmc">PMC5727062</ArticleId><ArticleId IdType="pubmed">29233983</ArticleId></ArticleIdList></Reference><Reference><Citation>Moisse K et al. Divergent patterns of cytosolic TDP-43 and neuronal progranulin expression following axotomy: implications for TDP-43 in the physiological response to neuronal injury. Brain Res 1249, 202&#x2013;211, 10.1016/j.brainres.2008.10.021 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2008.10.021</ArticleId><ArticleId IdType="pubmed">19046946</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiesner D et al. Reversible induction of TDP-43 granules in cortical neurons after traumatic injury. Exp Neurol 299, 15&#x2013;25, 10.1016/j.expneurol.2017.09.011 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2017.09.011</ArticleId><ArticleId IdType="pubmed">28941811</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogler TO et al. TDP-43 and RNA form amyloid-like myo-granules in regenerating muscle. Nature 563, 508&#x2013;513, 10.1038/s41586-018-0665-2 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-018-0665-2</ArticleId><ArticleId IdType="pmc">PMC6324568</ArticleId><ArticleId IdType="pubmed">30464263</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Additional References</Title><Reference><Citation>Martens LH et al. Progranulin deficiency promotes neuroinflammation and neuron loss following toxin-induced injury. J Clin Invest 122, 3955&#x2013;3959, 10.1172/JCI63113 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI63113</ArticleId><ArticleId IdType="pmc">PMC3484443</ArticleId><ArticleId IdType="pubmed">23041626</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen AD et al. Murine knockin model for progranulin-deficient frontotemporal dementia with nonsense-mediated mRNA decay. Proc Natl Acad Sci U S A 115, E2849&#x2013;E2858, 10.1073/pnas.1722344115 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1722344115</ArticleId><ArticleId IdType="pmc">PMC5866607</ArticleId><ArticleId IdType="pubmed">29511098</ArticleId></ArticleIdList></Reference><Reference><Citation>Botto M et al. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet 19, 56&#x2013;59, 10.1038/ng0598-56 (1998).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng0598-56</ArticleId><ArticleId IdType="pubmed">9590289</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhaduri A, Nowakowski TJ, Pollen AA &amp; Kriegstein AR Identification of cell types in a mouse brain single-cell atlas using low sampling coverage. BMC Biol 16, 113, 10.1186/s12915-018-0580-x (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12915-018-0580-x</ArticleId><ArticleId IdType="pmc">PMC6180488</ArticleId><ArticleId IdType="pubmed">30309354</ArticleId></ArticleIdList></Reference><Reference><Citation>Finak G et al. MAST: a flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data. Genome Biol 16, 278, 10.1186/s13059-015-0844-5 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-015-0844-5</ArticleId><ArticleId IdType="pmc">PMC4676162</ArticleId><ArticleId IdType="pubmed">26653891</ArticleId></ArticleIdList></Reference><Reference><Citation>Crowell HL et al. On the discovery of subpopulation-specific state transitions from multi-sample multi-condition single-cell RNA sequencing data. bioRxiv, 713412, 10.1101/713412 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/713412</ArticleId><ArticleId IdType="pmc">PMC7705760</ArticleId><ArticleId IdType="pubmed">33257685</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy DJ, Chen Y &amp; Smyth GK Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation. Nucleic Acids Res 40, 4288&#x2013;4297, 10.1093/nar/gks042 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gks042</ArticleId><ArticleId IdType="pmc">PMC3378882</ArticleId><ArticleId IdType="pubmed">22287627</ArticleId></ArticleIdList></Reference><Reference><Citation>Mi H, Muruganujan A &amp; Thomas PD PANTHER in 2013: modeling the evolution of gene function, and other gene attributes, in the context of phylogenetic trees. Nucleic Acids Res 41, D377&#x2013;386, 10.1093/nar/gks1118 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gks1118</ArticleId><ArticleId IdType="pmc">PMC3531194</ArticleId><ArticleId IdType="pubmed">23193289</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas PD et al. PANTHER: a library of protein families and subfamilies indexed by function. Genome Res 13, 2129&#x2013;2141, 10.1101/gr.772403 (2003).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.772403</ArticleId><ArticleId IdType="pmc">PMC403709</ArticleId><ArticleId IdType="pubmed">12952881</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun 10, 1523, 10.1038/s41467-019-09234-6 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-09234-6</ArticleId><ArticleId IdType="pmc">PMC6447622</ArticleId><ArticleId IdType="pubmed">30944313</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuart T et al. Comprehensive Integration of Single-Cell Data. Cell 177, 1888&#x2013;1902 e1821, 10.1016/j.cell.2019.05.031 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2019.05.031</ArticleId><ArticleId IdType="pmc">PMC6687398</ArticleId><ArticleId IdType="pubmed">31178118</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao J et al. The single-cell transcriptional landscape of mammalian organogenesis. Nature 566, 496&#x2013;502, 10.1038/s41586-019-0969-x (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-0969-x</ArticleId><ArticleId IdType="pmc">PMC6434952</ArticleId><ArticleId IdType="pubmed">30787437</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang EJ et al. Targeted deletion of numb and numblike in sensory neurons reveals their essential functions in axon arborization. Genes Dev 19, 138&#x2013;151, 10.1101/gad.1246005 (2005).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.1246005</ArticleId><ArticleId IdType="pmc">PMC540232</ArticleId><ArticleId IdType="pubmed">15598981</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohlen CJ et al. Diverse Requirements for Microglial Survival, Specification, and Function Revealed by Defined-Medium Cultures. Neuron 94, 759&#x2013;773 e758, 10.1016/j.neuron.2017.04.043 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.04.043</ArticleId><ArticleId IdType="pmc">PMC5523817</ArticleId><ArticleId IdType="pubmed">28521131</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S et al. Activation of HIPK2 Promotes ER Stress-Mediated Neurodegeneration in Amyotrophic Lateral Sclerosis. Neuron 91, 41&#x2013;55, 10.1016/j.neuron.2016.05.021 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.05.021</ArticleId><ArticleId IdType="pmc">PMC4938715</ArticleId><ArticleId IdType="pubmed">27321923</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang Y, Zhang J &amp; Huang EJ HIPK2-Mediated Transcriptional Control of NMDA Receptor Subunit Expression Regulates Neuronal Survival and Cell Death. J Neurosci 38, 4006&#x2013;4019, 10.1523/JNEUROSCI.3577-17.2018 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3577-17.2018</ArticleId><ArticleId IdType="pmc">PMC5907057</ArticleId><ArticleId IdType="pubmed">29581378</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiegel I et al. Npas4 regulates excitatory-inhibitory balance within neural circuits through cell-type-specific gene programs. Cell 157, 1216&#x2013;1229, 10.1016/j.cell.2014.03.058 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2014.03.058</ArticleId><ArticleId IdType="pmc">PMC4089405</ArticleId><ArticleId IdType="pubmed">24855953</ArticleId></ArticleIdList></Reference><Reference><Citation>Alami NH et al. Axonal transport of TDP-43 mRNA granules is impaired by ALS-causing mutations. Neuron 81, 536&#x2013;543, 10.1016/j.neuron.2013.12.018 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.12.018</ArticleId><ArticleId IdType="pmc">PMC3939050</ArticleId><ArticleId IdType="pubmed">24507191</ArticleId></ArticleIdList></Reference><Reference><Citation>Stehbens S, Pemble H, Murrow L &amp; Wittmann T Imaging intracellular protein dynamics by spinning disk confocal microscopy. Methods Enzymol 504, 293&#x2013;313, 10.1016/B978-0-12-391857-4.00015-X (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-12-391857-4.00015-X</ArticleId><ArticleId IdType="pmc">PMC3495241</ArticleId><ArticleId IdType="pubmed">22264541</ArticleId></ArticleIdList></Reference><Reference><Citation>Schermelleh L et al. Subdiffraction multicolor imaging of the nuclear periphery with 3D structured illumination microscopy. Science 320, 1332&#x2013;1336, 10.1126/science.1156947 (2008).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1156947</ArticleId><ArticleId IdType="pmc">PMC2916659</ArticleId><ArticleId IdType="pubmed">18535242</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J et al. Essential function of HIPK2 in TGFbeta-dependent survival of midbrain dopamine neurons. Nature neuroscience 10, 77&#x2013;86, 10.1038/nn1816 (2007).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1816</ArticleId><ArticleId IdType="pmc">PMC3578579</ArticleId><ArticleId IdType="pubmed">17159989</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin S et al. Deficiency of G3BP1, the stress granules assembly factor, results in abnormal synaptic plasticity and calcium homeostasis in neurons. J Neurochem 125, 175&#x2013;184, 10.1111/jnc.12189 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.12189</ArticleId><ArticleId IdType="pubmed">23373770</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahoo PK et al. Axonal G3BP1 stress granule protein limits axonal mRNA translation and nerve regeneration. Nat Commun 9, 3358, 10.1038/s41467-018-05647-x (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-05647-x</ArticleId><ArticleId IdType="pmc">PMC6105716</ArticleId><ArticleId IdType="pubmed">30135423</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32879487</PMID><DateCompleted><Year>2021</Year><Month>01</Month><Day>14</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>586</Volume><Issue>7831</Issue><PubDate><Year>2020</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>The innate immunity protein IFITM3 modulates &#x3b3;-secretase in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>735</StartPage><EndPage>740</EndPage><MedlinePgn>735-740</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41586-020-2681-2</ELocationID><Abstract><AbstractText>Innate immunity is associated with Alzheimer's disease<sup>1</sup>, but the influence of immune activation on the production of amyloid-&#x3b2; is unknown<sup>2,3</sup>. Here we identify interferon-induced transmembrane protein 3 (IFITM3) as a &#x3b3;-secretase modulatory protein, and establish a mechanism by which inflammation affects the generation of amyloid-&#x3b2;. Inflammatory cytokines induce the expression of IFITM3&#xa0;in neurons and astrocytes, which binds to &#x3b3;-secretase and upregulates its activity, thereby increasing the production of amyloid-&#x3b2;. The expression of IFITM3 is increased with ageing and in mouse models that express familial Alzheimer's disease genes. Furthermore, knockout of IFITM3 reduces &#x3b3;-secretase activity and the formation of amyloid plaques in a transgenic mouse model (5xFAD) of early amyloid deposition. IFITM3 protein is upregulated in tissue samples from a subset of patients with late-onset Alzheimer's disease that exhibit higher &#x3b3;-secretase activity. The amount of IFITM3 in the &#x3b3;-secretase complex has a strong and positive correlation with &#x3b3;-secretase activity in samples from patients with late-onset Alzheimer's disease. These findings reveal a mechanism in which &#x3b3;-secretase is modulated by neuroinflammation via IFITM3 and the risk of Alzheimer's disease is thereby increased.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Hur</LastName><ForeName>Ji-Yeun</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Chemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Frost</LastName><ForeName>Georgia R</ForeName><Initials>GR</Initials><AffiliationInfo><Affiliation>Chemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program of Neurosciences, Weill Graduate School of Medical Sciences of Cornell University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Xianzhong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Chemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crump</LastName><ForeName>Christina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Chemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program of Pharmacology, Weill Graduate School of Medical Sciences of Cornell University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Si Jia</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Chemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Eitan</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Chemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barros</LastName><ForeName>Marilia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Chemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Chemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program of Neurosciences, Weill Graduate School of Medical Sciences of Cornell University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nie</LastName><ForeName>Pengju</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Chemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program of Pharmacology, Weill Graduate School of Medical Sciences of Cornell University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhai</LastName><ForeName>Yujia</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Chemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jen Chyong</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Ronald M. Loeb Center for Alzheimer's Disease, Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tcw</LastName><ForeName>Julia</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-3054-9374</Identifier><AffiliationInfo><Affiliation>Ronald M. Loeb Center for Alzheimer's Disease, Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Mount Sinai Center for Transformative Disease Modeling, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McKenzie</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Mount Sinai Center for Transformative Disease Modeling, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ming</LastName><ForeName>Chen</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-3295-301X</Identifier><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Mount Sinai Center for Transformative Disease Modeling, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Xianxiao</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0001-9350-4467</Identifier><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Mount Sinai Center for Transformative Disease Modeling, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Minghui</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9171-4962</Identifier><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Mount Sinai Center for Transformative Disease Modeling, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sagi</LastName><ForeName>Yotam</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular and Cellular Neuroscience, Rockefeller University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Renton</LastName><ForeName>Alan E</ForeName><Initials>AE</Initials><Identifier Source="ORCID">0000-0001-6702-8268</Identifier><AffiliationInfo><Affiliation>Ronald M. Loeb Center for Alzheimer's Disease, Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Esposito</LastName><ForeName>Bianca T</ForeName><Initials>BT</Initials><AffiliationInfo><Affiliation>Ronald M. Loeb Center for Alzheimer's Disease, Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular and Cellular Neuroscience, Rockefeller University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sadleir</LastName><ForeName>Katherine R</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trinh</LastName><ForeName>Ivy</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rissman</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vassar</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Bin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Mount Sinai Center for Transformative Disease Modeling, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Douglas S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Pfizer Worldwide Research and Development, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masliah</LastName><ForeName>Eliezer</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greengard</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular and Cellular Neuroscience, Rockefeller University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-0576-2472</Identifier><AffiliationInfo><Affiliation>Ronald M. Loeb Center for Alzheimer's Disease, Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Mount Sinai Center for Transformative Disease Modeling, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yue-Ming</ForeName><Initials>YM</Initials><Identifier Source="ORCID">0000-0002-2633-3730</Identifier><AffiliationInfo><Affiliation>Chemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. liy2@mskcc.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program of Neurosciences, Weill Graduate School of Medical Sciences of Cornell University, New York, NY, USA. liy2@mskcc.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program of Pharmacology, Weill Graduate School of Medical Sciences of Cornell University, New York, NY, USA. liy2@mskcc.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG026660</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG057440</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062429</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA008748</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG061350</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG018440</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG006170</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG057593</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS096275</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG046170</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG057907</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 OD018522</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 OD026880</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG062683</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>09</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C545487">APP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C080082">IFITM3 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016601">RNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Mol Neurodegener. 2020 Nov 12;15(1):69. doi: 10.1186/s13024-020-00417-0.</RefSource><PMID Version="1">33183335</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020134" MajorTopicYN="N">Catalytic Domain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007113" MajorTopicYN="Y">Immunity, Innate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016601" MajorTopicYN="N">RNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>COI. LYM is co-inventor of intellectual property (assay for gamma secretase activity and screening method for gamma secretase inhibitors) owned by MSKCC and licensed to Jiangsu Continental Medical Development.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>5</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>1</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>3</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32879487</ArticleId><ArticleId IdType="mid">NIHMS1599391</ArticleId><ArticleId IdType="pmc">PMC7919141</ArticleId><ArticleId IdType="doi">10.1038/s41586-020-2681-2</ArticleId><ArticleId IdType="pii">10.1038/s41586-020-2681-2</ArticleId></ArticleIdList><ReferenceList><Title>References and Notes:</Title><Reference><Citation>Shi Y &amp; Holtzman DM Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight. Nature reviews. Immunology 18, 759&#x2013;772, doi:10.1038/s41577-018-0051-1 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-018-0051-1</ArticleId><ArticleId IdType="pmc">PMC6425488</ArticleId><ArticleId IdType="pubmed">30140051</ArticleId></ArticleIdList></Reference><Reference><Citation>Griciuc A et al. Alzheimer&#x2019;s disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron 78, 631&#x2013;643, doi:10.1016/j.neuron.2013.04.014 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.04.014</ArticleId><ArticleId IdType="pmc">PMC3706457</ArticleId><ArticleId IdType="pubmed">23623698</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer&#x2019;s disease model. Cell 160, 1061&#x2013;1071, doi:10.1016/j.cell.2015.01.049 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.01.049</ArticleId><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B. Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-Secretase complex. Neuron 38, 9&#x2013;12 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12691659</ArticleId></ArticleIdList></Reference><Reference><Citation>Gertsik N, Chiu D &amp; Li YM Complex regulation of gamma-secretase: from obligatory to modulatory subunits. Frontiers in aging neuroscience 6, 342, doi:10.3389/fnagi.2014.00342 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2014.00342</ArticleId><ArticleId IdType="pmc">PMC4285130</ArticleId><ArticleId IdType="pubmed">25610395</ArticleId></ArticleIdList></Reference><Reference><Citation>Villa JC et al. Nontranscriptional Role of Hif-1alpha in Activation of gamma-Secretase and Notch Signaling in Breast Cancer. Cell reports 8, 1077&#x2013;1092, doi:10.1016/j.celrep.2014.07.028 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2014.07.028</ArticleId><ArticleId IdType="pmc">PMC4346175</ArticleId><ArticleId IdType="pubmed">25131208</ArticleId></ArticleIdList></Reference><Reference><Citation>Crump CJ, Johnson DS &amp; Li Y-M Development and Mechanism of &#x3b3;-Secretase Modulators for Alzheimer&#x2019;s Disease. Biochemistry 52, 3197&#x2013;3216, doi:10.1021/bi400377p (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi400377p</ArticleId><ArticleId IdType="pmc">PMC3796170</ArticleId><ArticleId IdType="pubmed">23614767</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner SL et al. Soluble gamma-secretase modulators selectively inhibit the production of the 42-amino acid amyloid beta peptide variant and augment the production of multiple carboxy-truncated amyloid beta species. Biochemistry 53, 702&#x2013;713, doi:10.1021/bi401537v (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi401537v</ArticleId><ArticleId IdType="pmc">PMC3929337</ArticleId><ArticleId IdType="pubmed">24401146</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner SL et al. Pharmacological and Toxicological Properties of the Potent Oral gamma-Secretase Modulator BPN-15606. The Journal of pharmacology and experimental therapeutics 362, 31&#x2013;44, doi:10.1124/jpet.117.240861 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.117.240861</ArticleId><ArticleId IdType="pmc">PMC5454592</ArticleId><ArticleId IdType="pubmed">28416568</ArticleId></ArticleIdList></Reference><Reference><Citation>Kounnas MZ et al. Modulation of &#x3b3;-Secretase Reduces &#x3b2;-Amyloid Deposition in a Transgenic Mouse Model of Alzheimer&#x2019;s Disease. Neuron 67, 769&#x2013;780 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2947312</ArticleId><ArticleId IdType="pubmed">20826309</ArticleId></ArticleIdList></Reference><Reference><Citation>Pozdnyakov N et al. gamma-Secretase modulator (GSM) photoaffinity probes reveal distinct allosteric binding sites on presenilin. The Journal of biological chemistry 288, 9710&#x2013;9720, doi:10.1074/jbc.M112.398602 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.398602</ArticleId><ArticleId IdType="pmc">PMC3617273</ArticleId><ArticleId IdType="pubmed">23396974</ArticleId></ArticleIdList></Reference><Reference><Citation>Bailey CC, Zhong G, Huang IC &amp; Farzan M. IFITM-Family Proteins: The Cell&#x2019;s First Line of Antiviral Defense. Annual review of virology 1, 261&#x2013;283, doi:10.1146/annurev-virology-031413-085537 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-virology-031413-085537</ArticleId><ArticleId IdType="pmc">PMC4295558</ArticleId><ArticleId IdType="pubmed">25599080</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar DK et al. Amyloid-beta peptide protects against microbial infection in mouse and worm models of Alzheimer&#x2019;s disease. Sci Transl Med 8, 340ra372, doi:10.1126/scitranslmed.aaf1059 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aaf1059</ArticleId><ArticleId IdType="pmc">PMC5505565</ArticleId><ArticleId IdType="pubmed">27225182</ArticleId></ArticleIdList></Reference><Reference><Citation>Eimer WA et al. Alzheimer&#x2019;s Disease-Associated beta-Amyloid Is Rapidly Seeded by Herpesviridae to Protect against Brain Infection. Neuron 100, 1527&#x2013;1532, doi:10.1016/j.neuron.2018.11.043 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.11.043</ArticleId><ArticleId IdType="pubmed">30571943</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer&#x2019;s disease mutations: potential factors in amyloid plaque formation. The Journal of neuroscience : the official journal of the Society for Neuroscience 26, 10129&#x2013;10140, doi:10.1523/JNEUROSCI.1202-06.2006 (2006).</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1202-06.2006</ArticleId><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen M et al. Human whole genome genotype and transcriptome data for Alzheimer&#x2019;s and other neurodegenerative diseases. Sci Data 3, 160089, doi:10.1038/sdata.2016.89 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sdata.2016.89</ArticleId><ArticleId IdType="pmc">PMC5058336</ArticleId><ArticleId IdType="pubmed">27727239</ArticleId></ArticleIdList></Reference><Reference><Citation>Consortium GT Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science 348, 648&#x2013;660, doi:10.1126/science.1262110 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1262110</ArticleId><ArticleId IdType="pmc">PMC4547484</ArticleId><ArticleId IdType="pubmed">25954001</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M et al. The Mount Sinai cohort of large-scale genomic, transcriptomic and proteomic data in Alzheimer&#x2019;s disease. Sci Data 5, 180185, doi:10.1038/sdata.2018.185 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sdata.2018.185</ArticleId><ArticleId IdType="pmc">PMC6132187</ArticleId><ArticleId IdType="pubmed">30204156</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen EK et al. SNP-mediated disruption of CTCF binding at the IFITM3 promoter is associated with risk of severe influenza in humans. Nat Med 23, 975&#x2013;983, doi:10.1038/nm.4370 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.4370</ArticleId><ArticleId IdType="pmc">PMC5702558</ArticleId><ArticleId IdType="pubmed">28714988</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost GR &amp; Li YM The role of astrocytes in amyloid production and Alzheimer&#x2019;s disease. Open biology 7, doi:10.1098/rsob.170228 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rsob.170228</ArticleId><ArticleId IdType="pmc">PMC5746550</ArticleId><ArticleId IdType="pubmed">29237809</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B et al. Integrated Systems Approach Identifies Genetic Nodes and Networks in Late-Onset Alzheimer&#x2019;s Disease. Cell 153, 707&#x2013;720 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677161</ArticleId><ArticleId IdType="pubmed">23622250</ArticleId></ArticleIdList></Reference><Reference><Citation>Imamura Y et al. Inhibition of gamma-secretase activity by helical beta-peptide foldamers. Journal of the American Chemical Society 131, 7353&#x2013;7359, doi:10.1021/ja9001458 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ja9001458</ArticleId><ArticleId IdType="pubmed">19432477</ArticleId></ArticleIdList></Reference><Reference><Citation>Wakabayashi T et al. Analysis of the gamma-secretase interactome and validation of its association with tetraspanin-enriched microdomains. Nature cell biology 11, 1340&#x2013;1346, doi:10.1038/ncb1978 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb1978</ArticleId><ArticleId IdType="pubmed">19838174</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T et al. Variant of TREM2 associated with the risk of Alzheimer&#x2019;s disease. The New England journal of medicine 368, 107&#x2013;116, doi:10.1056/NEJMoa1211103 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1211103</ArticleId><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R et al. TREM2 variants in Alzheimer&#x2019;s disease. The New England journal of medicine 368, 117&#x2013;127, doi:10.1056/NEJMoa1211851 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1211851</ArticleId><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram L et al. Genome-wide association analysis reveals putative Alzheimer&#x2019;s disease susceptibility loci in addition to APOE. Am J Hum Genet 83, 623&#x2013;632, doi:10.1016/j.ajhg.2008.10.008 (2008).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2008.10.008</ArticleId><ArticleId IdType="pmc">PMC2668052</ArticleId><ArticleId IdType="pubmed">18976728</ArticleId></ArticleIdList></Reference><Reference><Citation>Baruch K et al. Aging. Aging-induced type I interferon response at the choroid plexus negatively affects brain function. Science 346, 89&#x2013;93, doi:10.1126/science.1252945 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1252945</ArticleId><ArticleId IdType="pmc">PMC4869326</ArticleId><ArticleId IdType="pubmed">25147279</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Methods references</Title><Reference><Citation>Li YM et al. Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1. Nature 405, 689&#x2013;694 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10864326</ArticleId></ArticleIdList></Reference><Reference><Citation>Chun J, Yin YI, Yang G, Tarassishin L &amp; Li YM Stereoselective Synthesis of Photoreactive Peptidomimetic gamma-Secretase Inhibitors. J Org Chem 69, 7344&#x2013;7347 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15471490</ArticleId></ArticleIdList></Reference><Reference><Citation>Gertsik N, Chau DM &amp; Li YM gamma-Secretase Inhibitors and Modulators Induce Distinct Conformational Changes in the Active Sites of gamma-Secretase and Signal Peptide Peptidase. ACS Chem Biol, doi:10.1021/acschembio.5b00321 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschembio.5b00321</ArticleId><ArticleId IdType="pmc">PMC5436900</ArticleId><ArticleId IdType="pubmed">26030233</ArticleId></ArticleIdList></Reference><Reference><Citation>Crump CJ et al. Development of Sulfonamide Photoaffinity Inhibitors for Probing Cellular gamma-Secretase. ACS Chem Neurosci 7, 1166&#x2013;1173, doi:10.1021/acschemneuro.6b00127 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.6b00127</ArticleId><ArticleId IdType="pmc">PMC5576034</ArticleId><ArticleId IdType="pubmed">27253220</ArticleId></ArticleIdList></Reference><Reference><Citation>Crump CJ et al. Piperidine acetic acid based gamma-secretase modulators directly bind to Presenilin-1. ACS Chem Neurosci 2, 705&#x2013;710, doi:10.1021/cn200098p (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/cn200098p</ArticleId><ArticleId IdType="pmc">PMC3249837</ArticleId><ArticleId IdType="pubmed">22229075</ArticleId></ArticleIdList></Reference><Reference><Citation>Crump CJ et al. BMS-708,163 Targets Presenilin and Lacks Notch-Sparing Activity. Biochemistry 51, 7209&#x2013;7211, doi:10.1021/bi301137h (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi301137h</ArticleId><ArticleId IdType="pmc">PMC3470910</ArticleId><ArticleId IdType="pubmed">22931393</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang G et al. Stereo-controlled synthesis of novel photoreactive gamma-secretase inhibitors. Bioorg Med Chem Lett 19, 922&#x2013;925, doi:S0960&#x2013;894X(08)01493&#x2013;5 [pii] 10.1016/j.bmcl.2008.11.117 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmcl.2008.11.117</ArticleId><ArticleId IdType="pmc">PMC3254698</ArticleId><ArticleId IdType="pubmed">19097779</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu M et al. gamma-Secretase: characterization and implication for Alzheimer disease therapy. Neurobiol Aging 23, 1023&#x2013;1030 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12470798</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettersson M et al. Discovery of indole-derived pyridopyrazine-1,6-dione gamma-secretase modulators that target presenilin. Bioorganic &amp; medicinal chemistry letters 25, 908&#x2013;913, doi:10.1016/j.bmcl.2014.12.059 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmcl.2014.12.059</ArticleId><ArticleId IdType="pubmed">25582600</ArticleId></ArticleIdList></Reference><Reference><Citation>Sung JY et al. WAVE1 controls neuronal activity-induced mitochondrial distribution in dendritic spines. Proc Natl Acad Sci U S A 105, 3112&#x2013;3116, doi:10.1073/pnas.0712180105 (2008).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0712180105</ArticleId><ArticleId IdType="pmc">PMC2268593</ArticleId><ArticleId IdType="pubmed">18287015</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho SM et al. Rapid Ngn2-induction of excitatory neurons from hiPSC-derived neural progenitor cells. Methods 101, 113&#x2013;124, doi:10.1016/j.ymeth.2015.11.019 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymeth.2015.11.019</ArticleId><ArticleId IdType="pmc">PMC4860098</ArticleId><ArticleId IdType="pubmed">26626326</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanley S et al. Profiling of Glucose-Sensing Neurons Reveals that GHRH Neurons Are Activated by Hypoglycemia. Cell Metab 18, 596&#x2013;607, doi:10.1016/j.cmet.2013.09.002 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2013.09.002</ArticleId><ArticleId IdType="pubmed">24093682</ArticleId></ArticleIdList></Reference><Reference><Citation>Heiman M, Kulicke R, Fenster RJ, Greengard P &amp; Heintz N. Cell type-specific mRNA purification by translating ribosome affinity purification (TRAP). Nat Protoc 9, 1282&#x2013;1291, doi:10.1038/nprot.2014.085 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2014.085</ArticleId><ArticleId IdType="pmc">PMC4102313</ArticleId><ArticleId IdType="pubmed">24810037</ArticleId></ArticleIdList></Reference><Reference><Citation>R. Core Team R:
A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. . URL https://www.R-project.org/. (2017).</Citation></Reference><Reference><Citation>Chau DM, Crump CJ, Villa JC, Scheinberg DA &amp; Li YM Familial Alzheimer Disease Presenilin-1 Mutations Alter the Active Site Conformation of gamma-secretase. The Journal of biological chemistry 287, 17288&#x2013;17296, doi:10.1074/jbc.M111.300483 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.300483</ArticleId><ArticleId IdType="pmc">PMC3366784</ArticleId><ArticleId IdType="pubmed">22461631</ArticleId></ArticleIdList></Reference><Reference><Citation>Shelton CC et al. Modulation of gamma-secretase specificity using small molecule allosteric inhibitors. Proc Natl Acad Sci U S A 106, 20228&#x2013;20233, doi:0910757106 [pii] 10.1073/pnas.0910757106 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0910757106</ArticleId><ArticleId IdType="pmc">PMC2787169</ArticleId><ArticleId IdType="pubmed">19906985</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong E et al. GSAP modulates gamma-secretase specificity by inducing conformational change in PS1. Proc Natl Acad Sci U S A 116, 6385&#x2013;6390, doi:10.1073/pnas.1820160116 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1820160116</ArticleId><ArticleId IdType="pmc">PMC6442608</ArticleId><ArticleId IdType="pubmed">30850537</ArticleId></ArticleIdList></Reference><Reference><Citation>Hur JY et al. Active gamma-secretase is localized to detergent-resistant membranes in human brain. The FEBS journal 275, 1174&#x2013;1187, doi:10.1111/j.1742-4658.2008.06278.x (2008).</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1742-4658.2008.06278.x</ArticleId><ArticleId IdType="pubmed">18266764</ArticleId></ArticleIdList></Reference><Reference><Citation>Placanica L, Zhu L &amp; Li YM Gender- and age-dependent gamma-secretase activity in mouse brain and its implication in sporadic Alzheimer disease. PLoS ONE 4, e5088, doi:10.1371/journal.pone.0005088 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0005088</ArticleId><ArticleId IdType="pmc">PMC2661375</ArticleId><ArticleId IdType="pubmed">19352431</ArticleId></ArticleIdList></Reference><Reference><Citation>Placanica L et al. Pen2 and Presenilin-1 Modulate the Dynamic Equilibrium of Presenilin-1 and Presenilin-2 {gamma}-Secretase Complexes. The Journal of biological chemistry 284, 2967&#x2013;2977, doi:M807269200 [pii] 10.1074/jbc.M807269200 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M807269200</ArticleId><ArticleId IdType="pmc">PMC2631949</ArticleId><ArticleId IdType="pubmed">19036728</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YM et al. Presenilin 1 is linked with gamma-secretase activity in the detergent solubilized state. Proc Natl Acad Sci U S A 97, 6138&#x2013;6143 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18571</ArticleId><ArticleId IdType="pubmed">10801983</ArticleId></ArticleIdList></Reference><Reference><Citation>Frykman S et al. Synaptic and endosomal localization of active gamma-secretase in rat brain. PLoS ONE 5, e8948, doi:10.1371/journal.pone.0008948 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0008948</ArticleId><ArticleId IdType="pmc">PMC2812513</ArticleId><ArticleId IdType="pubmed">20126630</ArticleId></ArticleIdList></Reference><Reference><Citation>Hur JY et al. Identification of novel gamma-secretase-associated proteins in detergent-resistant membranes from brain. J Biol Chem 287, 11991&#x2013;12005, doi:10.1074/jbc.M111.246074 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.246074</ArticleId><ArticleId IdType="pmc">PMC3320946</ArticleId><ArticleId IdType="pubmed">22315232</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahn K et al. Activation and intrinsic gamma-secretase activity of presenilin 1. Proc Natl Acad Sci U S A 107, 21435&#x2013;21440, doi:10.1073/pnas.1013246107 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1013246107</ArticleId><ArticleId IdType="pmc">PMC3003001</ArticleId><ArticleId IdType="pubmed">21115843</ArticleId></ArticleIdList></Reference><Reference><Citation>Shelton CC, Tian Y, Frattini MG &amp; Li YM An exo-cell assay for examining real-time gamma-secretase activity and inhibition. Mol Neurodegener 4, 22, doi:1750-1326-4-22 [pii] 10.1186/1750-1326-4-22 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-4-22</ArticleId><ArticleId IdType="pmc">PMC3224971</ArticleId><ArticleId IdType="pubmed">19490610</ArticleId></ArticleIdList></Reference><Reference><Citation>Placanica L et al. Pen2 and presenilin-1 modulate the dynamic equilibrium of presenilin-1 and presenilin-2 gamma-secretase complexes. J Biol Chem 284, 2967&#x2013;2977, doi:10.1074/jbc.M807269200 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M807269200</ArticleId><ArticleId IdType="pmc">PMC2631949</ArticleId><ArticleId IdType="pubmed">19036728</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Y, Bassit B, Chau D &amp; Li YM An APP inhibitory domain containing the Flemish mutation residue modulates gamma-secretase activity for Abeta production. Nat Struct Mol Biol 17, 151&#x2013;158, doi:10.1038/nsmb.1743 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb.1743</ArticleId><ArticleId IdType="pubmed">20062056</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Y, Crump CJ &amp; Li YM Dual role of {alpha}-Secretase Cleavage in the regulation of {gamma}-secretase activity for amyloid production. J Biol Chem, doi:M110.128439 [pii] 10.1074/jbc.M110.128439 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.128439</ArticleId><ArticleId IdType="pmc">PMC2952257</ArticleId><ArticleId IdType="pubmed">20675367</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller PY, Janovjak H, Miserez AR &amp; Dobbie Z. Processing of gene expression data generated by quantitative real-time RT-PCR. Biotechniques 32, 1372&#x2013;1374, 1376, 1378&#x2013;1379 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12074169</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang JC et al. Risk for nicotine dependence and lung cancer is conferred by mRNA expression levels and amino acid change in CHRNA5. Hum Mol Genet 18, 3125&#x2013;3135, doi:10.1093/hmg/ddp231 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddp231</ArticleId><ArticleId IdType="pmc">PMC2714722</ArticleId><ArticleId IdType="pubmed">19443489</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang JC et al. Genetic variation in the CHRNA5 gene affects mRNA levels and is associated with risk for alcohol dependence. Mol Psychiatry 14, 501&#x2013;510, doi:10.1038/mp.2008.42 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2008.42</ArticleId><ArticleId IdType="pmc">PMC4381434</ArticleId><ArticleId IdType="pubmed">18414406</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B et al. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer&#x2019;s disease. Cell 153, 707&#x2013;720, doi:10.1016/j.cell.2013.03.030 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2013.03.030</ArticleId><ArticleId IdType="pmc">PMC3677161</ArticleId><ArticleId IdType="pubmed">23622250</ArticleId></ArticleIdList></Reference><Reference><Citation>Smyth GK Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3, Article3, doi:10.2202/1544-6115.1027 (2004).</Citation><ArticleIdList><ArticleId IdType="doi">10.2202/1544-6115.1027</ArticleId><ArticleId IdType="pubmed">16646809</ArticleId></ArticleIdList></Reference><Reference><Citation>Readhead B et al. Multiscale Analysis of Independent Alzheimer&#x2019;s Cohorts Finds Disruption of Molecular, Genetic, and Clinical Networks by Human Herpesvirus. Neuron 99, 64&#x2013;82 e67, doi:10.1016/j.neuron.2018.05.023 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.05.023</ArticleId><ArticleId IdType="pmc">PMC6551233</ArticleId><ArticleId IdType="pubmed">29937276</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoue M et al. Human brain proteins showing neuron-specific interactions with gamma-secretase. FEBS J 282, 2587&#x2013;2599, doi:10.1111/febs.13303 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/febs.13303</ArticleId><ArticleId IdType="pubmed">25893612</ArticleId></ArticleIdList></Reference><Reference><Citation>Teranishi Y et al. Proton myo-inositol cotransporter is a novel gamma-secretase associated protein that regulates Abeta production without affecting Notch cleavage. FEBS J 282, 3438&#x2013;3451, doi:10.1111/febs.13353 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/febs.13353</ArticleId><ArticleId IdType="pubmed">26094765</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">32878979</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>559</Issue><PubDate><Year>2020</Year><Month>Sep</Month><Day>02</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle><i>C9orf72</i> poly(GR) aggregation induces TDP-43 proteinopathy.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">eabb3774</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.abb3774</ELocationID><Abstract><AbstractText>TAR DNA-binding protein 43 (TDP-43) inclusions are a pathological hallmark of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS), including cases caused by G<sub>4</sub>C<sub>2</sub> repeat expansions in the <i>C9orf72</i> gene (c9FTD/ALS). Providing mechanistic insight into the link between <i>C9orf72</i> mutations and TDP-43 pathology, we demonstrated that a glycine-arginine repeat protein [poly(GR)] translated from expanded G<sub>4</sub>C<sub>2</sub> repeats was sufficient to promote aggregation of endogenous TDP-43. In particular, toxic poly(GR) proteins mediated sequestration of full-length TDP-43 in an RNA-independent manner to induce cytoplasmic TDP-43 inclusion formation. Moreover, in GFP-(GR)<sub>200</sub> mice, poly(GR) caused the mislocalization of nucleocytoplasmic transport factors and nuclear pore complex proteins. These mislocalization events resulted in the aberrant accumulation of endogenous TDP-43 in the cytoplasm where it co-aggregated with poly(GR). Last, we demonstrated that treating G<sub>4</sub>C<sub>2</sub> repeat-expressing mice with repeat-targeting antisense oligonucleotides lowered poly(GR) burden, which was accompanied by reduced TDP-43 pathology and neurodegeneration, including lowering of plasma neurofilament light (NFL) concentration. These results contribute to clarification of the mechanism by which poly(GR) drives TDP-43 proteinopathy, confirm that G<sub>4</sub>C<sub>2</sub>-targeted therapeutics reduce TDP-43 pathology in vivo, and demonstrate that alterations in plasma NFL provide insight into the therapeutic efficacy of disease-modifying treatments.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cook</LastName><ForeName>Casey N</ForeName><Initials>CN</Initials><Identifier Source="ORCID">0000-0002-5963-8442</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurobiology of Disease Graduate Program, Mayo Graduate School, Mayo Clinic College of Medicine, Rochester, MN 55902, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Yanwei</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-7474-3470</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Odeh</LastName><ForeName>Hana M</ForeName><Initials>HM</Initials><Identifier Source="ORCID">0000-0002-2164-7925</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gendron</LastName><ForeName>Tania F</ForeName><Initials>TF</Initials><Identifier Source="ORCID">0000-0002-7335-2627</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurobiology of Disease Graduate Program, Mayo Graduate School, Mayo Clinic College of Medicine, Rochester, MN 55902, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jansen-West</LastName><ForeName>Karen</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-1234-7103</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Del Rosso</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yue</LastName><ForeName>Mei</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Peizhou</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gomes</LastName><ForeName>Edward</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tong</LastName><ForeName>Jimei</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daughrity</LastName><ForeName>Lillian M</ForeName><Initials>LM</Initials><Identifier Source="ORCID">0000-0003-4644-7265</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Avendano</LastName><ForeName>Nicole M</ForeName><Initials>NM</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castanedes-Casey</LastName><ForeName>Monica</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-8441-7801</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shao</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oskarsson</LastName><ForeName>Bj&#xf6;rn</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-1725-9866</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tomassy</LastName><ForeName>Giulio S</ForeName><Initials>GS</Initials><AffiliationInfo><Affiliation>Neurology Research, Biogen Idec, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCampbell</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-1984-6052</Identifier><AffiliationInfo><Affiliation>Neurology Research, Biogen Idec, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rigo</LastName><ForeName>Frank</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Ionis Pharmaceuticals, Carlsbad, CA 92010, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis W</ForeName><Initials>DW</Initials><Identifier Source="ORCID">0000-0001-7189-7917</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurobiology of Disease Graduate Program, Mayo Graduate School, Mayo Clinic College of Medicine, Rochester, MN 55902, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shorter</LastName><ForeName>James</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-5269-8533</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. petrucelli.leonard@mayo.edu zhang.yongjie@mayo.edu jshorter@pennmedicine.upenn.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yong-Jie</ForeName><Initials>YJ</Initials><Identifier Source="ORCID">0000-0002-9900-4313</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA. petrucelli.leonard@mayo.edu zhang.yongjie@mayo.edu jshorter@pennmedicine.upenn.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurobiology of Disease Graduate Program, Mayo Graduate School, Mayo Clinic College of Medicine, Rochester, MN 55902, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petrucelli</LastName><ForeName>Leonard</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-2959-129X</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA. petrucelli.leonard@mayo.edu zhang.yongjie@mayo.edu jshorter@pennmedicine.upenn.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurobiology of Disease Graduate Program, Mayo Graduate School, Mayo Clinic College of Medicine, Rochester, MN 55902, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R35 NS097273</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS088689</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS084974</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM099836</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS099114</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG065854</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578077">Tardbp protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="Y">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042622" MajorTopicYN="N">DNA Repeat Expansion</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="Y">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057177" MajorTopicYN="Y">TDP-43 Proteinopathies</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066263" MajorTopicYN="N">Protein Aggregation, Pathological</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing interests:</b> B.O. has consulted for Biogen, Medicinova, Mitsubishi, Amylyx, and Tsumura. F.R. is a paid employee of Ionis Pharmaceuticals. G.S.T. and A.M. are paid employees of Biogen Idec. L.P. is a consultant for Expansion Therapeutics. Other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>2</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>6</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>3</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32878979</ArticleId><ArticleId IdType="mid">NIHMS1674626</ArticleId><ArticleId IdType="pmc">PMC7989020</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.abb3774</ArticleId><ArticleId IdType="pii">12/559/eabb3774</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, McCluskey LF, Miller BL, Masliah E, Mackenzie IR, Feldman H, Feiden W, Kretzschmar HA, Trojanowski JQ, Lee VM-Y, Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314, 130&#x2013;133 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, Mann D, Tsuchiya K, Yoshida M, Hashizume Y, Oda T, TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem. Biophys. Res. Commun 351, 602&#x2013;611 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, Nicholson AM, Finch NA, Flynn H, Adamson J, Kouri N, Wojtas A, Sengdy P, Hsiung G-YR, Karydas A, Seeley WW, Josephs KA, Coppola G, Geschwind DH, Wszolek ZK, Feldman H, Knopman DS, Petersen RC, Miller BL, Dickson DW, Boylan KB, Graff-Radford NR, Rademakers R, Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72, 245&#x2013;256 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, Sim&#xf3;n-S&#xe1;nchez J, Rollinson S, Gibbs JR, Schymick JC, Laaksovirta H, van Swieten JC, Myllykangas L, Kalimo H, Paetau A, Abramzon Y, Remes AM, Kaganovich A, Scholz SW, Duckworth J, Ding J, Harmer DW, Hernandez DG, Johnson JO, Mok K, Ryten M, Trabzuni D, Guerreiro RJ, Orrell RW, Neal J, Murray A, Pearson J, Jansen IE, Sondervan D, Seelaar H, Blake D, Young K, Halliwell N, Callister JB, Toulson G, Richardson A, Gerhard A, Snowden J, Mann D, Neary D, Nalls MA, Peuralinna T, Jansson L, Isoviita V-M, Kaivorinne A-L, H&#xf6;ltt&#xe4;-Vuori M, Ikonen E, Sulkava R, Benatar M, Wuu J, Chi&#xf2; A, Restagno G, Borghero G, Sabatelli M; The ITALSGEN Consortium, Heckerman D, Rogaeva E, Zinman L, Rothstein JD, Sendtner M, Drepper C, Eichler EE, Alkan C, Abdullaev Z, Pack SD, Dutra A, Pak E, Hardy J, Singleton A, Williams NM, Heutink P, Pickering-Brown S, Morris HR, Tienari PJ, Traynor BJ, A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72, 257&#x2013;268 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C, Baughn M, Rigo F, Sun S, Liu P, Li H-R, Jiang J, Watt AT, Chun S, Katz M, Qiu J, Sun Y, Ling S-C, Zhu Q, Polymenidou M, Drenner K, Artates JW, McAlonis-Downes M, Markmiller S, Hutt KR, Pizzo DP, Cady J, Harms MB, Baloh RH, Vandenberg SR, Yeo GW, Fu X-D, Bennett CF, Cleveland DW, Ravits J, Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc. Natl. Acad. Sci. U.S.A 110, E4530&#x2013;E4539 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3839752</ArticleId><ArticleId IdType="pubmed">24170860</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizielinska S, Lashley T, Norona FE, Clayton EL, Ridler CE, Fratta P, Isaacs AM, C9orf72 frontotemporal lobar degeneration is characterised by frequent neuronal sense and antisense RNA foci. Acta Neuropathol. 126, 845&#x2013;857 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3830745</ArticleId><ArticleId IdType="pubmed">24170096</ArticleId></ArticleIdList></Reference><Reference><Citation>Ash PEA, Bieniek KF, Gendron TF, Caulfield T, Lin W-L, Dejesus-Hernandez M, van Blitterswijk MM, Jansen-West K, Paul JW III, Rademakers R, Boylan KB, Dickson DW, Petrucelli L, Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron 77, 639&#x2013;646 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3593233</ArticleId><ArticleId IdType="pubmed">23415312</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K, Arzberger T, Gr&#xe4;sser FA, Gijselinck I, May S, Rentzsch K, Weng S-M, Schludi MH, van der Zee J, Cruts M, Van Broeckhoven C, Kremmer E, Kretzschmar HA, Haass C, Edbauer D, Bidirectional transcripts of the expanded C9orf72 hexanucleotide repeat are translated into aggregating dipeptide repeat proteins. Acta Neuropathol. 126, 881&#x2013;893 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24132570</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K, Weng S-M, Arzberger T, May S, Rentzsch K, Kremmer E, Schmid B, Kretzschmar HA, Cruts M, Van Broeckhoven C, Haass C, Edbauer D, The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science 339, 1335&#x2013;1338 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23393093</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron TF, Bieniek KF, Zhang YJ, Jansen-West K, Ash PE, Caulfield T, Daughrity L, Dunmore JH, Castanedes-Casey M, Chew J, Cosio DM, van Blitterswijk M, Lee WC, Rademakers R, Boylan KB, Dickson DW, Petrucelli L, Antisense transcripts of the expanded C9ORF72 hexanucleotide repeat form nuclear RNA foci and undergo repeat-associated non-ATG translation in c9FTD/ALS. Acta Neuropathol. 126, 829&#x2013;844 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3830741</ArticleId><ArticleId IdType="pubmed">24129584</ArticleId></ArticleIdList></Reference><Reference><Citation>Zu T, Liu Y, Ba&#xf1;ez-Coronel M, Reid T, Pletnikova O, Lewis J, Miller TM, Harms MB, Falchook AE, Subramony SH, Ostrow LW, Rothstein JD, Troncoso JC, Ranum LPW, RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc. Natl. Acad. Sci. U.S.A 110, E4968&#x2013;E4977 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3870665</ArticleId><ArticleId IdType="pubmed">24248382</ArticleId></ArticleIdList></Reference><Reference><Citation>Koppers M, Blokhuis AM, Westeneng H-J, Terpstra ML, Zundel CAC, Vieira de S&#xe1; R, Schellevis RD, Waite AJ, Blake DJ, Veldink JH, van den Berg LH, Pasterkamp RJ, C9orf72 ablation in mice does not cause motor neuron degeneration or motor deficits. Ann. Neurol 78, 426&#x2013;438 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4744979</ArticleId><ArticleId IdType="pubmed">26044557</ArticleId></ArticleIdList></Reference><Reference><Citation>Chew J, Cook C, Gendron TF, Jansen-West K, del Rosso G, Daughrity LM, Castanedes-Casey M, Kurti A, Stankowski JN, Disney MD, Rothstein JD, Dickson DW, Fryer JD, Zhang Y-J, Petrucelli L, Aberrant deposition of stress granule-resident proteins linked to C9orf72-associated TDP-43 proteinopathy. Mol. Neurodegener 14, 9 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6377782</ArticleId><ArticleId IdType="pubmed">30767771</ArticleId></ArticleIdList></Reference><Reference><Citation>Chew J, Gendron TF, Prudencio M, Sasaguri H, Zhang Y-J, Castanedes-Casey M, Lee CW, Jansen-West K, Kurti A, Murray ME, Bieniek KF, Bauer PO, Whitelaw EC, Rousseau L, Stankowski JN, Stetler C, Daughrity LM, Perkerson EA, Desaro P, Johnston A, Overstreet K, Edbauer D, Rademakers R, Boylan KB, Dickson DW, Fryer JD, Petrucelli L, C9ORF72 repeat expansions in mice cause TDP-43 pathology, neuronal loss, and behavioral deficits. Science 348, 1151&#x2013;1154 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4692360</ArticleId><ArticleId IdType="pubmed">25977373</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang J, Zhu Q, Gendron TF, Saberi S, McAlonis-Downes M, Seelman A, Stauffer JE, Jafar-Nejad P, Drenner K, Schulte D, Chun S, Sun S, Ling S-C, Myers B, Engelhardt J, Katz M, Baughn M, Platoshyn O, Marsala M, Watt A, Heyser CJ, Ard MC, De Muynck L, Daughrity LM, Swing DA, Tessarollo L, Jung CJ, Delpoux A, Utzschneider DT, Hedrick SM, de Jong PJ, Edbauer D, Van Damme P, Petrucelli L, Shaw CE, Bennett CF, Da Cruz S, Ravits J, Rigo F, Cleveland DW, Lagier-Tourenne C, Gain of toxicity from ALS/FTD-linked repeat expansions in C9ORF72 is alleviated by antisense oligonucleotides targeting GGGGCC-containing RNAs. Neuron 90, 535&#x2013;550 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4860075</ArticleId><ArticleId IdType="pubmed">27112497</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Pattamatta A, Zu T, Reid T, Bardhi O, Borchelt DR, Yachnis AT, Ranum LPW, C9orf72 BAC mouse model with motor deficits and neurodegenerative features of ALS/FTD. Neuron 90, 521&#x2013;534 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27112499</ArticleId></ArticleIdList></Reference><Reference><Citation>Freibaum BD, Lu Y, Lopez-Gonzalez R, Kim NC, Almeida S, Lee K-H, Badders N, Valentine M, Miller BL, Wong PC, Petrucelli L, Kim HJ, Gao F-B, Taylor JP, GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport. Nature 525, 129&#x2013;133 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4631399</ArticleId><ArticleId IdType="pubmed">26308899</ArticleId></ArticleIdList></Reference><Reference><Citation>Jovi&#x10d;i&#x107; A, Mertens J, Boeynaems S, Bogaert E, Chai N, Yamada SB, Paul III JW, Sun S, Herdy JR, Bieri G, Kramer NJ, Gage FH, Van Den Bosch L, Robberecht W, Gitler AD, Modifiers of C9orf72 dipeptide repeat toxicity connect nucleocytoplasmic transport defects to FTD/ALS. Nat. Neurosci 18, 1226&#x2013;1229 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4552077</ArticleId><ArticleId IdType="pubmed">26308983</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K, Donnelly CJ, Haeusler AR, Grima JC, Machamer JB, Steinwald P, Daley EL, Miller SJ, Cunningham KM, Vidensky S, Gupta S, Thomas MA, Hong I, Chiu S-L, Huganir RL, Ostrow LW, Matunis MJ, Wang J, Sattler R, Lloyd TE, Rothstein JD, The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature 525, 56&#x2013;61 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4800742</ArticleId><ArticleId IdType="pubmed">26308891</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K, Daigle JG, Cunningham KM, Coyne AN, Ruan K, Grima JC, Bowen KE, Wadhwa H, Yang P, Rigo F, Taylor JP, Gitler AD, Rothstein JD, Lloyd TE, Stress granule assembly disrupts nucleocytoplasmic transport. Cell 173, 958&#x2013;971.e17 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6083872</ArticleId><ArticleId IdType="pubmed">29628143</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ, Gendron TF, Grima JC, Sasaguri H, Jansen-West K, Xu Y-F, Katzman RB, Gass J, Murray ME, Shinohara M, Lin W-L, Garrett A, Stankowski JN, Daughrity L, Tong J, Perkerson EA, Yue M, Chew J, Castanedes-Casey M, Kurti A, Wang ZS, Liesinger AM, Baker JD, Jiang J, Lagier-Tourenne C, Edbauer D, Cleveland DW, Rademakers R, Boylan KB, Bu G, Link CD, Dickey CA, Rothstein JD, Dickson DW, Fryer JD, Petrucelli L, C9ORF72 poly(GA) aggregates sequester and impair HR23 and nucleocytoplasmic transport proteins. Nat. Neurosci 19, 668&#x2013;677 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5138863</ArticleId><ArticleId IdType="pubmed">26998601</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y-J, Guo L, Gonzales PK, Gendron TF, Wu Y, Jansen-West K, O&#x2019;Raw AD, Pickles SR, Prudencio M, Carlomagno Y, Gachechiladze MA, Ludwig C, Tian R, Chew J, DeTure M, Lin W-L, Tong J, Daughrity LM, Yue M, Song Y, Andersen JW, Castanedes-Casey M, Kurti A, Datta A, Antognetti G, McCampbell A, Rademakers R, Oskarsson B, Dickson DW, Kampmann M, Ward ME, Fryer JD, Link CD, Shorter J, Petrucelli L, Heterochromatin anomalies and double-stranded RNA accumulation underlie C9orf72 poly(PR) toxicity. Science 363, eaav2606 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6524780</ArticleId><ArticleId IdType="pubmed">30765536</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeynaems S, Bogaert E, Kovacs D, Konijnenberg A, Timmerman E, Volkov A, Guharoy M, De Decker M, Jaspers T, Ryan VH, Janke AM, Baatsen P, Vercruysse T, Kolaitis RM, Daelemans D, Taylor JP, Kedersha N, Anderson P, Impens F, Sobott F, Schymkowitz J, Rousseau F, Fawzi NL, Robberecht W, Van Damme P, Tompa P, Van Den Bosch L, Phase separation of C9orf72 dipeptide repeats perturbs stress granule dynamics. Mol. Cell 65, 1044&#x2013;1055.e5 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5364369</ArticleId><ArticleId IdType="pubmed">28306503</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng W, Wang S, Mestre AA, Fu C, Makarem A, Xian F, Hayes LR, Lopez-Gonzalez R, Drenner K, Jiang J, Cleveland DW, Sun S, C9ORF72 GGGGCC repeat-associated non-AUG translation is upregulated by stress through eIF2&#x3b1; phosphorylation. Nat. Commun 9, 51 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5754368</ArticleId><ArticleId IdType="pubmed">29302060</ArticleId></ArticleIdList></Reference><Reference><Citation>Green KM, Glineburg MR, Kearse MG, Flores BN, Linsalata AE, Fedak SJ, Goldstrohm AC, Barmada SJ, Todd PK, RAN translation at C9orf72-associated repeat expansions is selectively enhanced by the integrated stress response. Nat. Commun 8, 2005 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5722904</ArticleId><ArticleId IdType="pubmed">29222490</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee K-H, Zhang P, Kim HJ, Mitrea DM, Sarkar M, Freibaum BD, Cika J, Coughlin M, Messing J, Molliex A, Maxwell BA, Kim NC, Temirov J, Moore J, Kolaitis R-M, Shaw TI, Bai B, Peng J, Kriwacki RW, Taylor JP, C9orf72 dipeptide repeats impair the assembly, dynamics, and function of membrane-less organelles. Cell 167, 774&#x2013;788.e17 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5079111</ArticleId><ArticleId IdType="pubmed">27768896</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayes LR, Duan L, Bowen K, Kalab P, Rothstein JD, C9orf72 arginine-rich dipeptide repeat proteins disrupt karyopherin-mediated nuclear import. eLife 9, e51685 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7051184</ArticleId><ArticleId IdType="pubmed">32119645</ArticleId></ArticleIdList></Reference><Reference><Citation>Saberi S, Stauffer JE, Jiang J, Garcia SD, Taylor AE, Schulte D, Ohkubo T, Schloffman CL, Maldonado M, Baughn M, Rodriguez MJ, Pizzo D, Cleveland D, Ravits J, Sense-encoded poly-GR dipeptide repeat proteins correlate to neurodegeneration and uniquely co-localize with TDP-43 in dendrites of repeat-expanded C9orf72 amyotrophic lateral sclerosis. Acta Neuropathol. 135, 459&#x2013;474 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5935138</ArticleId><ArticleId IdType="pubmed">29196813</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y-J, Gendron TF, Ebbert MTW, O&#x2019;Raw AD, Yue M, Jansen-West K, Zhang X, Prudencio M, Chew J, Cook CN, Daughrity LM, Tong J, Song Y, Pickles SR, Castanedes-Casey M, Kurti A, Rademakers R, Oskarsson B, Dickson DW, Hu W, Gitler AD, Fryer JD, Petrucelli L, Poly(GR) impairs protein translation and stress granule dynamics in C9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis. Nat. Med 24, 1136&#x2013;1142 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6520050</ArticleId><ArticleId IdType="pubmed">29942091</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E, Baralle FE, Characterization and functional implications of the RNA binding properties of nuclear factor TDP-43, a novel splicing regulator of CFTR exon 9. J. Biol. Chem 276, 36337&#x2013;36343 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11470789</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y-J, Xu Y-F, Cook C, Gendron TF, Roettges P, Link CD, Lin W-L, Tong J, Castanedes-Casey M, Ash P, Gass J, Rangachari V, Buratti E, Baralle F, Golde TE, Dickson DW, Petrucelli L, Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity. Proc. Natl. Acad. Sci. U.S.A 106, 7607&#x2013;7612 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2671323</ArticleId><ArticleId IdType="pubmed">19383787</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson BS, Snead D, Lee JJ, McCaffery JM, Shorter J, Gitler AD, TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. J. Biol. Chem 284, 20329&#x2013;20339 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2740458</ArticleId><ArticleId IdType="pubmed">19465477</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura AL, &#x17d;upunski V, Troakes C, Kathe C, Fratta P, Howell M, Gallo J-M, Hortob&#xe1;gyi T, Shaw CE, Rogelj B, Nuclear import impairment causes cytoplasmic trans-activation response DNA-binding protein accumulation and is associated with frontotemporal lobar degeneration. Brain 133, 1763&#x2013;1771 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20472655</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron TF, Chew J, Stankowski JN, Hayes LR, Zhang Y-J, Prudencio M, Carlomagno Y, Daughrity LM, Jansen-West K, Perkerson EA, O&#x2019;Raw A, Cook C, Pregent L, Belzil V, van Blitterswijk M, Tabassian LJ, Lee CW, Yue M, Tong J, Song Y, Castanedes-Casey M, Rousseau L, Phillips V, Dickson DW, Rademakers R, Fryer JD, Rush BK, Pedraza O, Caputo AM, Desaro P, Palmucci C, Robertson A, Heckman MG, Diehl NN, Wiggs E, Tierney M, Braun L, Farren J, Lacomis D, Ladha S, Fournier CN, McCluskey LF, Elman LB, Toledo JB, McBride JD, Tiloca C, Morelli C, Poletti B, Solca F, Prelle A, Wuu J, Jockel-Balsarotti J, Rigo F, Ambrose C, Datta A, Yang W, Raitcheva D, Antognetti G, McCampbell A, Van Swieten JC, Miller BL, Boxer AL, Brown RH, Bowser R, Miller TM, Trojanowski JQ, Grossman M, Berry JD, Hu WT, Ratti A, Traynor BJ, Disney MD, Benatar M, Silani V, Glass JD, Floeter MK, Rothstein JD, Boylan KB, Petrucelli L, Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis. Sci. Transl. Med 9, eaai7866 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5576451</ArticleId><ArticleId IdType="pubmed">28356511</ArticleId></ArticleIdList></Reference><Reference><Citation>Meeter LHH, Gendron TF, Sias AC, Jiskoot LC, Russo SP, Donker Kaat L, Papma JM, Panman JL, van der Ende EL, Dopper EG, Franzen S, Graff C, Boxer AL, Rosen HJ, Sanchez-Valle R, Galimberti D, Pijnenburg YAL, Benussi L, Ghidoni R, Borroni B, Laforce R Jr., del Campo M, Teunissen CE, van Minkelen R, Rojas JC, Coppola G, Geschwind DH, Rademakers R, Karydas AM, Oijerstedt L, Scarpini E, Binetti G, Padovani A, Cash DM, Dick KM, Bocchetta M, Miller BL, Rohrer JD, Petrucelli L, van Swieten JC, Lee SE, Poly(GP), neurofilament and grey matter deficits in C9orf72 expansion carriers. Ann. Clin. Transl. Neurol 5, 583&#x2013;597 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5945959</ArticleId><ArticleId IdType="pubmed">29761121</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H, Neurofilament light chain as a biomarker in neurological disorders. J. Neurol. Neurosurg. Psychiatry 90, 870&#x2013;881 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30967444</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahim P, Zetterberg H, Tegner Y, Blennow K, Serum neurofilament light as a biomarker for mild traumatic brain injury in contact sports. Neurology 88, 1788&#x2013;1794 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5419986</ArticleId><ArticleId IdType="pubmed">28404801</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakae N, Bieniek KF, Zhang Y-J, Ross K, Gendron TF, Murray ME, Rademakers R, Petrucelli L, Dickson DW, Poly-GR dipeptide repeat polymers correlate with neurodegeneration and clinicopathological subtypes in C9ORF72-related brain disease. Acta Neuropathol. Commun 6, 63 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6054740</ArticleId><ArticleId IdType="pubmed">30029693</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Arzberger T, Kremmer E, Troost D, Lorenzl S, Mori K, Weng S-M, Haass C, Kretzschmar HA, Edbauer D, Neumann M, Dipeptide repeat protein pathology in C9ORF72 mutation cases: Clinico-pathological correlations. Acta Neuropathol. 126, 859&#x2013;879 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24096617</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IRA, Frick P, Gr&#xe4;sser FA, Gendron TF, Petrucelli L, Cashman NR, Edbauer D, Kremmer E, Prudlo J, Troost D, Neumann M, Quantitative analysis and clinico-pathological correlations of different dipeptide repeat protein pathologies in C9ORF72 mutation carriers. Acta Neuropathol. 130, 845&#x2013;861 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26374446</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Deza J, Lee Y.-b., Troakes C, Nolan M, Al-Sarraj S, Gallo J-M, Shaw CE, Dipeptide repeat protein inclusions are rare in the spinal cord and almost absent from motor neurons in C9ORF72 mutant amyotrophic lateral sclerosis and are unlikely to cause their degeneration. Acta Neuropathol. Commun 3, 38 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4479315</ArticleId><ArticleId IdType="pubmed">26108573</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasset-Rosa F, Lu S, Yu H, Chen C, Melamed Z, Guo L, Shorter J, Da Cruz S, Cleveland DW, Cytoplasmic TDP-43 de-mixing independent of stress granules drives inhibition of nuclear import, loss of nuclear TDP-43, and cell death. Neuron 102, 339&#x2013;357.e7 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6548321</ArticleId><ArticleId IdType="pubmed">30853299</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann JR, Gleixner AM, Mauna JC, Gomes E, DeChellis-Marks MR, Needham PG, Copley KE, Hurtle B, Portz B, Pyles NJ, Guo L, Calder CB, Wills ZP, Pandey UB, Kofler JK, Brodsky JL, Thathiah A, Shorter J, Donnelly CJ, RNA binding antagonizes neurotoxic phase transitions of TDP-43. Neuron 102, 321&#x2013;338.e8 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6472983</ArticleId><ArticleId IdType="pubmed">30826182</ArticleId></ArticleIdList></Reference><Reference><Citation>Elden AC, Kim H-J, Hart MP, Chen-Plotkin AS, Johnson BS, Fang X, Armakola M, Geser F, Greene R, Lu MM, Padmanabhan A, Clay-Falcone D, McCluskey L, Elman L, Juhr D, Gruber PJ, R&#xfc;b U, Auburger G, Trojanowski JQ, Lee VM-Y, Van Deerlin VM, Bonini NM, Gitler AD, Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature 466, 1069&#x2013;1075 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2965417</ArticleId><ArticleId IdType="pubmed">20740007</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L, Kim HJ, Wang H, Monaghan J, Freyermuth F, Sung JC, O&#x2013;Donovan K, Fare CM, Diaz Z, Singh N, Zhang ZC, Coughlin M, Sweeny EA, DeSantis ME, Jackrel ME, Rodell CB, Burdick JA, King OD, Gitler AD, Lagier-Tourenne C, Pandey UB, Chook YM, Taylor JP, Shorter J, Nuclear-import receptors reverse aberrant phase transitions of RNA-binding proteins with prion-like domains. Cell 173, 677&#x2013;692.e20 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5911940</ArticleId><ArticleId IdType="pubmed">29677512</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang A, Conicella AE, Schmidt HB, Martin EW, Rhoads SN, Reeb AN, Nourse A, Ramirez Montero D, Ryan VH, Rohatgi R, Shewmaker F, Naik MT, Mittag T, Ayala YM, Fawzi NL, A single N-terminal phosphomimic disrupts TDP-43 polymerization, phase separation, and RNA splicing. EMBOJ. 37, e97452 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5830921</ArticleId><ArticleId IdType="pubmed">29438978</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y-J, Caulfield T, Xu Y-F, Gendron TF, Hubbard J, Stetler C, Sasaguri H, Whitelaw EC, Cai S, Lee WC, Petrucelli L, The dual functions of the extreme N-terminus of TDP-43 in regulating its biological activity and inclusion formation. Hum. Mol. Genet 22, 3112&#x2013;3122 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3699067</ArticleId><ArticleId IdType="pubmed">23575225</ArticleId></ArticleIdList></Reference><Reference><Citation>Prudencio M, Jansen-West KR, Lee WC, Gendron TF, Zhang Y-J, Xu Y-F, Gass J, Stuani C, Stetler C, Rademakers R, Dickson DW, Buratti E, Petrucelli L, Misregulation of human sortilin splicing leads to the generation of a nonfunctional progranulin receptor. Proc. Natl. Acad. Sci. U.S.A 109, 21510&#x2013;21515 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3535614</ArticleId><ArticleId IdType="pubmed">23236149</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron TF, van Blitterswijk M, Bieniek KF, Daughrity LM, Jiang J, Rush BK, Pedraza O, Lucas JA, Murray ME, Desaro P, Robertson A, Overstreet K, Thomas CS, Crook JE, Castanedes-Casey M, Rousseau L, Josephs KA, Parisi JE, Knopman DS, Petersen RC, Boeve BF, Graff-Radford NR, Rademakers R, Lagier-Tourenne C, Edbauer D, Cleveland DW, Dickson DW, Petrucelli L, Boylan KB, Cerebellar c9RAN proteins associate with clinical and neuropathological characteristics of C9ORF72 repeat expansion carriers. Acta Neuropathol. 130, 559&#x2013;573 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4575385</ArticleId><ArticleId IdType="pubmed">26350237</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32887774</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>04</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>95</Volume><Issue>18</Issue><PubDate><Year>2020</Year><Month>Nov</Month><Day>03</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Association of deficits in short-term learning and A&#x3b2; and hippocampal volume in cognitively normal adults.</ArticleTitle><Pagination><StartPage>e2577</StartPage><EndPage>e2585</EndPage><MedlinePgn>e2577-e2585</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000010728</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To determine the extent to which deficits in learning over 6 days are associated with &#x3b2;-amyloid-positive (A&#x3b2;+) and hippocampal volume in cognitively normal (CN) adults.</AbstractText><AbstractText Label="METHODS">Eighty CN older adults who had undergone PET neuroimaging to determine A&#x3b2; status (n = 42 A&#x3b2;- and 38 A&#x3b2;+), MRI to determine hippocampal and ventricular volume, and repeated assessment of memory were recruited from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. Participants completed the Online Repeatable Cognitive Assessment-Language Learning Test (ORCA-LLT), which required they learn associations between 50 Chinese characters and their English language equivalents over 6 days. ORCA-LLT assessments were supervised on the first day and were completed remotely online for all remaining days.</AbstractText><AbstractText Label="RESULTS">Learning curves in the A&#x3b2;+ CN participants were significantly worse than those in matched A&#x3b2;- CN participants, with the magnitude of this difference very large (<i>d</i> [95% confidence interval (CI)] 2.22 [1.64-2.75], <i>p</i> &lt; 0.001), and greater than differences between these groups for memory decline since their enrollment in AIBL (<i>d</i> [95% CI] 0.52 [0.07-0.96], <i>p</i> = 0.021), or memory impairment at their most recent visit. In A&#x3b2;+ CN adults, slower rates of learning were associated with smaller hippocampal and larger ventricular volumes.</AbstractText><AbstractText Label="CONCLUSIONS">These results suggest that in CN participants, A&#x3b2;+ is associated more strongly with a deficit in learning than any aspect of memory dysfunction. Slower rates of learning in A&#x3b2;+ CN participants were associated with hippocampal volume loss. Considered together, these data suggest that the primary cognitive consequence of A&#x3b2;+ is a failure to benefit from experience when exposed to novel stimuli, even over very short periods.</AbstractText><CopyrightInformation>&#xa9; 2020 American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Yen Ying</ForeName><Initials>YY</Initials><AffiliationInfo><Affiliation>From Florey Institute of Neuroscience and Mental Health (Y.Y.L., J.E.B., A.M., C.F., C.L.M., P.M.), Parkville; Turner Institute for Brain and Mental Health (Y.Y.L., A.M.), School of Psychological Sciences, Monash University, Clayton; School of Computing and Information Systems (L.B.), The University of Melbourne, Parkville, Victoria; CSIRO Health and Biosecurity (J.F.), Australian e-Health Research Centre, Brisbane; Centre of Excellence for Alzheimer's Disease Research and Care (S.R.R.-S.), School of Medical Sciences, Edith Cowan University; Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital) (S.R.R.-S.), Perth; National Ageing Research Institute (D.A.), Parkville, Victoria; Academic Unit for Psychiatry of Old Age, Department of Psychiatry (D.A.), The University of Melbourne, St. George's Hospital, Kew; and Cogstate Ltd. (P.M.), Melbourne, Victoria, Australia. yenying.lim@monash.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baker</LastName><ForeName>Jenalle E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>From Florey Institute of Neuroscience and Mental Health (Y.Y.L., J.E.B., A.M., C.F., C.L.M., P.M.), Parkville; Turner Institute for Brain and Mental Health (Y.Y.L., A.M.), School of Psychological Sciences, Monash University, Clayton; School of Computing and Information Systems (L.B.), The University of Melbourne, Parkville, Victoria; CSIRO Health and Biosecurity (J.F.), Australian e-Health Research Centre, Brisbane; Centre of Excellence for Alzheimer's Disease Research and Care (S.R.R.-S.), School of Medical Sciences, Edith Cowan University; Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital) (S.R.R.-S.), Perth; National Ageing Research Institute (D.A.), Parkville, Victoria; Academic Unit for Psychiatry of Old Age, Department of Psychiatry (D.A.), The University of Melbourne, St. George's Hospital, Kew; and Cogstate Ltd. (P.M.), Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bruns</LastName><ForeName>Loren</ForeName><Initials>L</Initials><Suffix>Jr</Suffix><Identifier Source="ORCID">0000-0003-2198-2173</Identifier><AffiliationInfo><Affiliation>From Florey Institute of Neuroscience and Mental Health (Y.Y.L., J.E.B., A.M., C.F., C.L.M., P.M.), Parkville; Turner Institute for Brain and Mental Health (Y.Y.L., A.M.), School of Psychological Sciences, Monash University, Clayton; School of Computing and Information Systems (L.B.), The University of Melbourne, Parkville, Victoria; CSIRO Health and Biosecurity (J.F.), Australian e-Health Research Centre, Brisbane; Centre of Excellence for Alzheimer's Disease Research and Care (S.R.R.-S.), School of Medical Sciences, Edith Cowan University; Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital) (S.R.R.-S.), Perth; National Ageing Research Institute (D.A.), Parkville, Victoria; Academic Unit for Psychiatry of Old Age, Department of Psychiatry (D.A.), The University of Melbourne, St. George's Hospital, Kew; and Cogstate Ltd. (P.M.), Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mills</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>From Florey Institute of Neuroscience and Mental Health (Y.Y.L., J.E.B., A.M., C.F., C.L.M., P.M.), Parkville; Turner Institute for Brain and Mental Health (Y.Y.L., A.M.), School of Psychological Sciences, Monash University, Clayton; School of Computing and Information Systems (L.B.), The University of Melbourne, Parkville, Victoria; CSIRO Health and Biosecurity (J.F.), Australian e-Health Research Centre, Brisbane; Centre of Excellence for Alzheimer's Disease Research and Care (S.R.R.-S.), School of Medical Sciences, Edith Cowan University; Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital) (S.R.R.-S.), Perth; National Ageing Research Institute (D.A.), Parkville, Victoria; Academic Unit for Psychiatry of Old Age, Department of Psychiatry (D.A.), The University of Melbourne, St. George's Hospital, Kew; and Cogstate Ltd. (P.M.), Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fowler</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>From Florey Institute of Neuroscience and Mental Health (Y.Y.L., J.E.B., A.M., C.F., C.L.M., P.M.), Parkville; Turner Institute for Brain and Mental Health (Y.Y.L., A.M.), School of Psychological Sciences, Monash University, Clayton; School of Computing and Information Systems (L.B.), The University of Melbourne, Parkville, Victoria; CSIRO Health and Biosecurity (J.F.), Australian e-Health Research Centre, Brisbane; Centre of Excellence for Alzheimer's Disease Research and Care (S.R.R.-S.), School of Medical Sciences, Edith Cowan University; Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital) (S.R.R.-S.), Perth; National Ageing Research Institute (D.A.), Parkville, Victoria; Academic Unit for Psychiatry of Old Age, Department of Psychiatry (D.A.), The University of Melbourne, St. George's Hospital, Kew; and Cogstate Ltd. (P.M.), Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fripp</LastName><ForeName>Jurgen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>From Florey Institute of Neuroscience and Mental Health (Y.Y.L., J.E.B., A.M., C.F., C.L.M., P.M.), Parkville; Turner Institute for Brain and Mental Health (Y.Y.L., A.M.), School of Psychological Sciences, Monash University, Clayton; School of Computing and Information Systems (L.B.), The University of Melbourne, Parkville, Victoria; CSIRO Health and Biosecurity (J.F.), Australian e-Health Research Centre, Brisbane; Centre of Excellence for Alzheimer's Disease Research and Care (S.R.R.-S.), School of Medical Sciences, Edith Cowan University; Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital) (S.R.R.-S.), Perth; National Ageing Research Institute (D.A.), Parkville, Victoria; Academic Unit for Psychiatry of Old Age, Department of Psychiatry (D.A.), The University of Melbourne, St. George's Hospital, Kew; and Cogstate Ltd. (P.M.), Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rainey-Smith</LastName><ForeName>Stephanie R</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>From Florey Institute of Neuroscience and Mental Health (Y.Y.L., J.E.B., A.M., C.F., C.L.M., P.M.), Parkville; Turner Institute for Brain and Mental Health (Y.Y.L., A.M.), School of Psychological Sciences, Monash University, Clayton; School of Computing and Information Systems (L.B.), The University of Melbourne, Parkville, Victoria; CSIRO Health and Biosecurity (J.F.), Australian e-Health Research Centre, Brisbane; Centre of Excellence for Alzheimer's Disease Research and Care (S.R.R.-S.), School of Medical Sciences, Edith Cowan University; Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital) (S.R.R.-S.), Perth; National Ageing Research Institute (D.A.), Parkville, Victoria; Academic Unit for Psychiatry of Old Age, Department of Psychiatry (D.A.), The University of Melbourne, St. George's Hospital, Kew; and Cogstate Ltd. (P.M.), Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ames</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>From Florey Institute of Neuroscience and Mental Health (Y.Y.L., J.E.B., A.M., C.F., C.L.M., P.M.), Parkville; Turner Institute for Brain and Mental Health (Y.Y.L., A.M.), School of Psychological Sciences, Monash University, Clayton; School of Computing and Information Systems (L.B.), The University of Melbourne, Parkville, Victoria; CSIRO Health and Biosecurity (J.F.), Australian e-Health Research Centre, Brisbane; Centre of Excellence for Alzheimer's Disease Research and Care (S.R.R.-S.), School of Medical Sciences, Edith Cowan University; Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital) (S.R.R.-S.), Perth; National Ageing Research Institute (D.A.), Parkville, Victoria; Academic Unit for Psychiatry of Old Age, Department of Psychiatry (D.A.), The University of Melbourne, St. George's Hospital, Kew; and Cogstate Ltd. (P.M.), Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masters</LastName><ForeName>Colin L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>From Florey Institute of Neuroscience and Mental Health (Y.Y.L., J.E.B., A.M., C.F., C.L.M., P.M.), Parkville; Turner Institute for Brain and Mental Health (Y.Y.L., A.M.), School of Psychological Sciences, Monash University, Clayton; School of Computing and Information Systems (L.B.), The University of Melbourne, Parkville, Victoria; CSIRO Health and Biosecurity (J.F.), Australian e-Health Research Centre, Brisbane; Centre of Excellence for Alzheimer's Disease Research and Care (S.R.R.-S.), School of Medical Sciences, Edith Cowan University; Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital) (S.R.R.-S.), Perth; National Ageing Research Institute (D.A.), Parkville, Victoria; Academic Unit for Psychiatry of Old Age, Department of Psychiatry (D.A.), The University of Melbourne, St. George's Hospital, Kew; and Cogstate Ltd. (P.M.), Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maruff</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>From Florey Institute of Neuroscience and Mental Health (Y.Y.L., J.E.B., A.M., C.F., C.L.M., P.M.), Parkville; Turner Institute for Brain and Mental Health (Y.Y.L., A.M.), School of Psychological Sciences, Monash University, Clayton; School of Computing and Information Systems (L.B.), The University of Melbourne, Parkville, Victoria; CSIRO Health and Biosecurity (J.F.), Australian e-Health Research Centre, Brisbane; Centre of Excellence for Alzheimer's Disease Research and Care (S.R.R.-S.), School of Medical Sciences, Edith Cowan University; Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital) (S.R.R.-S.), Perth; National Ageing Research Institute (D.A.), Parkville, Victoria; Academic Unit for Psychiatry of Old Age, Department of Psychiatry (D.A.), The University of Melbourne, St. George's Hospital, Kew; and Cogstate Ltd. (P.M.), Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>09</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002552" MajorTopicYN="N">Cerebral Ventricles</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064368" MajorTopicYN="N">Healthy Volunteers</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007859" MajorTopicYN="N">Learning Disabilities</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059906" MajorTopicYN="N">Neuroimaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>12</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>6</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>5</Day><Hour>5</Hour><Minute>16</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32887774</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000010728</ArticleId><ArticleId IdType="pii">WNL.0000000000010728</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">32908004</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>23</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>560</Issue><PubDate><Year>2020</Year><Month>Sep</Month><Day>09</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>A patient-based model of RNA mis-splicing uncovers treatment targets in Parkinson's disease.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">eaau3960</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.aau3960</ELocationID><Abstract><AbstractText>Parkinson's disease (PD) is a heterogeneous neurodegenerative disorder with monogenic forms representing prototypes of the underlying molecular pathology and reproducing to variable degrees the sporadic forms of the disease. Using a patient-based in vitro model of <i>PARK7</i>-linked PD, we identified a U1-dependent splicing defect causing a drastic reduction in DJ-1 protein and, consequently, mitochondrial dysfunction. Targeting defective exon skipping with genetically engineered U1-snRNA recovered DJ-1 protein expression in neuronal precursor cells and differentiated neurons. After prioritization of candidate drugs, we identified and validated a combinatorial treatment with the small-molecule compounds rectifier of aberrant splicing (RECTAS) and phenylbutyric acid, which restored DJ-1 protein and mitochondrial dysfunction in patient-derived fibroblasts as well as dopaminergic neuronal cell loss in mutant midbrain organoids. Our analysis of a large number of exomes revealed that U1 splice-site mutations were enriched in sporadic PD patients. Therefore, our study suggests an alternative strategy to restore cellular abnormalities in in vitro models of PD and provides a proof of concept for neuroprotection based on precision medicine strategies in PD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Boussaad</LastName><ForeName>Ibrahim</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-3512-3364</Identifier><AffiliationInfo><Affiliation>LCSB, Luxembourg Centre for Systems Biomedicine, University of Luxembourg, 4362 Esch-Sur-Alzette, Luxembourg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Obermaier</LastName><ForeName>Carolin D</ForeName><Initials>CD</Initials><Identifier Source="ORCID">0000-0001-6653-8215</Identifier><AffiliationInfo><Affiliation>LCSB, Luxembourg Centre for Systems Biomedicine, University of Luxembourg, 4362 Esch-Sur-Alzette, Luxembourg.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Diseases and Hertie-Institute for Clinical Brain Research, University of T&#xfc;bingen, 72076 T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanss</LastName><ForeName>Zo&#xe9;</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0002-3659-3624</Identifier><AffiliationInfo><Affiliation>LCSB, Luxembourg Centre for Systems Biomedicine, University of Luxembourg, 4362 Esch-Sur-Alzette, Luxembourg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bobbili</LastName><ForeName>Dheeraj R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>LCSB, Luxembourg Centre for Systems Biomedicine, University of Luxembourg, 4362 Esch-Sur-Alzette, Luxembourg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bolognin</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-1399-2999</Identifier><AffiliationInfo><Affiliation>LCSB, Luxembourg Centre for Systems Biomedicine, University of Luxembourg, 4362 Esch-Sur-Alzette, Luxembourg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glaab</LastName><ForeName>Enrico</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-3977-7469</Identifier><AffiliationInfo><Affiliation>LCSB, Luxembourg Centre for Systems Biomedicine, University of Luxembourg, 4362 Esch-Sur-Alzette, Luxembourg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wo&#x142;y&#x144;ska</LastName><ForeName>Katarzyna</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-8377-8496</Identifier><AffiliationInfo><Affiliation>Department of Medical Genetics, Poznan University of Medical Sciences, 60-806 Poznan, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weisschuh</LastName><ForeName>Nicole</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Molecular Genetics Laboratory, Institute for Ophthalmic Research, University Clinics T&#xfc;bingen, 72076 T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Conti</LastName><ForeName>Laura</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-4391-3638</Identifier><AffiliationInfo><Affiliation>ICGEB-International Centre for Genetic Engineering and Biotechnology, Padriciano 99, 34149 Trieste, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>May</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-6532-5979</Identifier><AffiliationInfo><Affiliation>Medizinisches Proteom-Center, Ruhr-University Bochum, 44801 Bochum, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giesert</LastName><ForeName>Florian</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-6825-8858</Identifier><AffiliationInfo><Affiliation>Helmholtz Zentrum M&#xfc;nchen, Ingolstaedter Landstr. 1, 85764 Neuherberg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Site Munich, Feodor-Lynen-Str. 17, 81377 Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Technische Universit&#xe4;t M&#xfc;nchen-Weihenstephan, Developmental Genetics, c/o Helmholtz Zentrum M&#xfc;nchen, Ingolst&#xe4;dter Landstr. 1, 85764 Neuherberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grossmann</LastName><ForeName>Dajana</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>LCSB, Luxembourg Centre for Systems Biomedicine, University of Luxembourg, 4362 Esch-Sur-Alzette, Luxembourg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lambert</LastName><ForeName>Annika</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-4503-4266</Identifier><AffiliationInfo><Affiliation>LCSB, Luxembourg Centre for Systems Biomedicine, University of Luxembourg, 4362 Esch-Sur-Alzette, Luxembourg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirchen</LastName><ForeName>Susanne</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-0211-1815</Identifier><AffiliationInfo><Affiliation>LCSB, Luxembourg Centre for Systems Biomedicine, University of Luxembourg, 4362 Esch-Sur-Alzette, Luxembourg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biryukov</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>LCSB, Luxembourg Centre for Systems Biomedicine, University of Luxembourg, 4362 Esch-Sur-Alzette, Luxembourg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burbulla</LastName><ForeName>Lena F</ForeName><Initials>LF</Initials><Identifier Source="ORCID">0000-0002-6548-905X</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Massart</LastName><ForeName>Francois</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-5590-3344</Identifier><AffiliationInfo><Affiliation>LCSB, Luxembourg Centre for Systems Biomedicine, University of Luxembourg, 4362 Esch-Sur-Alzette, Luxembourg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bohler</LastName><ForeName>Jill</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>LCSB, Luxembourg Centre for Systems Biomedicine, University of Luxembourg, 4362 Esch-Sur-Alzette, Luxembourg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cruciani</LastName><ForeName>G&#xe9;rald</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>LCSB, Luxembourg Centre for Systems Biomedicine, University of Luxembourg, 4362 Esch-Sur-Alzette, Luxembourg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmid</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-0028-888X</Identifier><AffiliationInfo><Affiliation>Department of Neurodegenerative Diseases and Hertie-Institute for Clinical Brain Research, University of T&#xfc;bingen, 72076 T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurz-Drexler</LastName><ForeName>Annerose</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-9108-6994</Identifier><AffiliationInfo><Affiliation>Helmholtz Zentrum M&#xfc;nchen, Ingolstaedter Landstr. 1, 85764 Neuherberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>May</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-8698-3770</Identifier><AffiliationInfo><Affiliation>LCSB, Luxembourg Centre for Systems Biomedicine, University of Luxembourg, 4362 Esch-Sur-Alzette, Luxembourg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duga</LastName><ForeName>Stefano</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-3457-1410</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Humanitas University, Via Manzoni 113, 20089 Rozzano, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Humanitas Clinical and Research center, IRCCS, Via Manzoni 56, 20089 Rozzano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klein</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Neurogenetics, University of Luebeck, 23562 Luebeck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schwamborn</LastName><ForeName>Jens C</ForeName><Initials>JC</Initials><Identifier Source="ORCID">0000-0003-4496-0559</Identifier><AffiliationInfo><Affiliation>LCSB, Luxembourg Centre for Systems Biomedicine, University of Luxembourg, 4362 Esch-Sur-Alzette, Luxembourg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marcus</LastName><ForeName>Katrin</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-3313-8845</Identifier><AffiliationInfo><Affiliation>Medizinisches Proteom-Center, Ruhr-University Bochum, 44801 Bochum, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woitalla</LastName><ForeName>Dirk</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, 44791 Bochum, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vogt Weisenhorn</LastName><ForeName>Daniela M</ForeName><Initials>DM</Initials><Identifier Source="ORCID">0000-0002-4566-6506</Identifier><AffiliationInfo><Affiliation>Helmholtz Zentrum M&#xfc;nchen, Ingolstaedter Landstr. 1, 85764 Neuherberg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Technische Universit&#xe4;t M&#xfc;nchen-Weihenstephan, Developmental Genetics, c/o Helmholtz Zentrum M&#xfc;nchen, Ingolst&#xe4;dter Landstr. 1, 85764 Neuherberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wurst</LastName><ForeName>Wolfgang</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0003-4422-7410</Identifier><AffiliationInfo><Affiliation>Helmholtz Zentrum M&#xfc;nchen, Ingolstaedter Landstr. 1, 85764 Neuherberg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Site Munich, Feodor-Lynen-Str. 17, 81377 Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Technische Universit&#xe4;t M&#xfc;nchen-Weihenstephan, Developmental Genetics, c/o Helmholtz Zentrum M&#xfc;nchen, Ingolst&#xe4;dter Landstr. 1, 85764 Neuherberg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Feodor-Lynen-Str. 17, 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baralle</LastName><ForeName>Marco</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0417-1013</Identifier><AffiliationInfo><Affiliation>ICGEB-International Centre for Genetic Engineering and Biotechnology, Padriciano 99, 34149 Trieste, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krainc</LastName><ForeName>Dimitri</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-4716-1886</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gasser</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-1069-1146</Identifier><AffiliationInfo><Affiliation>Department of Neurodegenerative Diseases and Hertie-Institute for Clinical Brain Research, University of T&#xfc;bingen, 72076 T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), 72076 T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wissinger</LastName><ForeName>Bernd</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0001-8964-5953</Identifier><AffiliationInfo><Affiliation>Molecular Genetics Laboratory, Institute for Ophthalmic Research, University Clinics T&#xfc;bingen, 72076 T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kr&#xfc;ger</LastName><ForeName>Rejko</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-4258-6241</Identifier><AffiliationInfo><Affiliation>LCSB, Luxembourg Centre for Systems Biomedicine, University of Luxembourg, 4362 Esch-Sur-Alzette, Luxembourg. rejko.krueger@uni.lu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Diseases and Hertie-Institute for Clinical Brain Research, University of T&#xfc;bingen, 72076 T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Parkinson Research Clinic, Centre Hospitalier de Luxembourg (CHL), 1210 Luxembourg, Luxembourg.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Transversal Translational Medicine, Luxembourg Institute of Health (LIH), 1445 Strassen, Luxembourg.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D059290" MajorTopicYN="N">Dopaminergic Neurons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005091" MajorTopicYN="N">Exons</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="Y">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012326" MajorTopicYN="N">RNA Splicing</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>6</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>1</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>6</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>10</Day><Hour>5</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32908004</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.aau3960</ArticleId><ArticleId IdType="pii">12/560/eaau3960</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32926214</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>21</Day></DateCompleted><DateRevised><Year>2021</Year><Month>09</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-0533</ISSN><JournalIssue CitedMedium="Internet"><Volume>140</Volume><Issue>6</Issue><PubDate><Year>2020</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Acta neuropathologica</Title><ISOAbbreviation>Acta Neuropathol</ISOAbbreviation></Journal><ArticleTitle>The coarse-grained plaque: a divergent A&#x3b2; plaque-type in early-onset Alzheimer's disease.</ArticleTitle><Pagination><StartPage>811</StartPage><EndPage>830</EndPage><MedlinePgn>811-830</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00401-020-02198-8</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is characterized by amyloid-beta (A&#x3b2;) deposits, which come in myriad morphologies with varying clinical relevance. Previously, we observed an atypical A&#x3b2; deposit, referred to as the coarse-grained plaque. In this study, we evaluate the plaque's association with clinical disease and perform in-depth immunohistochemical and morphological characterization. The coarse-grained plaque, a relatively large (&#xd8;&#x2009;&#x2248;&#x2009;80&#xa0;&#xb5;m) deposit, characterized as having multiple cores and A&#x3b2;-devoid pores, was prominent in the neocortex. The plaque was semi-quantitatively scored in the middle frontal gyrus of A&#x3b2;-positive cases (n&#x2009;=&#x2009;74), including non-demented cases (n&#x2009;=&#x2009;15), early-onset (EO)AD (n&#x2009;=&#x2009;38), and late-onset (LO)AD cases (n&#x2009;=&#x2009;21). The coarse-grained plaque was only observed in cases with clinical dementia and more frequently present in EOAD compared to LOAD. This plaque was associated with a homozygous APOE &#x3b5;4 status and cerebral amyloid angiopathy (CAA). In-depth characterization was done by studying the coarse-grained plaque's neuritic component (pTau, APP, PrP<sup>C</sup>), A&#x3b2; isoform composition (A&#x3b2;<sub>40</sub>, A&#x3b2;<sub>42</sub>, A&#x3b2;<sub>N3pE</sub>, pSer8A&#x3b2;), its neuroinflammatory component (C4b, CD68, MHC-II, GFAP), and its vascular attribution (laminin, collagen IV, norrin). The plaque was compared to the classic cored plaque, cotton wool plaque, and CAA. Similar to CAA but different from classic cored plaques, the coarse-grained plaque was predominantly composed of A&#x3b2;<sub>40</sub>. Furthermore, the coarse-grained plaque was distinctly associated with both intense neuroinflammation and vascular (capillary) pathology. Confocal laser scanning microscopy (CLSM) and 3D analysis revealed for most coarse-grained plaques a particular A&#x3b2;<sub>40</sub> shell structure and a direct relation with vessels. Based on its morphological and biochemical characteristics, we conclude that the coarse-grained plaque is a divergent A&#x3b2; plaque-type associated with EOAD. Differences in A&#x3b2; processing and aggregation, neuroinflammatory response, and vascular clearance may presumably underlie the difference between coarse-grained plaques and other A&#x3b2; deposits. Disentangling specific A&#x3b2; deposits between AD subgroups may be important in the search for disease-mechanistic-based therapies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Boon</LastName><ForeName>Baayla D C</ForeName><Initials>BDC</Initials><Identifier Source="ORCID">0000-0002-4922-3286</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Alzheimer Center Amsterdam, Amsterdam Neuroscience, Amsterdam UMC - Location VUmc, Amsterdam, The Netherlands. b.boon@amsterdamumc.nl.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Amsterdam Neuroscience, Amsterdam UMC - Location VUmc, Amsterdam, The Netherlands. b.boon@amsterdamumc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bulk</LastName><ForeName>Marjolein</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jonker</LastName><ForeName>Allert J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Neurosciences, Amsterdam Neuroscience, Amsterdam UMC - Location VUmc, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morrema</LastName><ForeName>Tjado H J</ForeName><Initials>THJ</Initials><AffiliationInfo><Affiliation>Department of Pathology, Amsterdam Neuroscience, Amsterdam UMC - Location VUmc, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van den Berg</LastName><ForeName>Emma</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Neurosciences, Amsterdam Neuroscience, Amsterdam UMC - Location VUmc, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Popovic</LastName><ForeName>Marko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Microscopy and Cytometry Core Facility, Amsterdam Neuroscience, Amsterdam UMC - Location VUmc, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walter</LastName><ForeName>Jochen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospital Bonn, University of Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Sathish</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospital Bonn, University of Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Lee</LastName><ForeName>Sven J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Alzheimer Center Amsterdam, Amsterdam Neuroscience, Amsterdam UMC - Location VUmc, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Genetics, Amsterdam Neuroscience, Amsterdam UMC - Location VUmc, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holstege</LastName><ForeName>Henne</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Alzheimer Center Amsterdam, Amsterdam Neuroscience, Amsterdam UMC - Location VUmc, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Genetics, Amsterdam Neuroscience, Amsterdam UMC - Location VUmc, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Xiaoyue</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Biomedical and Pharmaceutical Sciences, George &amp; Anne Ryan Institute for Neuroscience, University of Rhode Island, Kingston, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Nostrand</LastName><ForeName>William E</ForeName><Initials>WE</Initials><AffiliationInfo><Affiliation>Department of Biomedical and Pharmaceutical Sciences, George &amp; Anne Ryan Institute for Neuroscience, University of Rhode Island, Kingston, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Natt&#xe9;</LastName><ForeName>Remco</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Weerd</LastName><ForeName>Louise</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bouwman</LastName><ForeName>Femke H</ForeName><Initials>FH</Initials><AffiliationInfo><Affiliation>Department of Neurology, Alzheimer Center Amsterdam, Amsterdam Neuroscience, Amsterdam UMC - Location VUmc, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van de Berg</LastName><ForeName>Wilma D J</ForeName><Initials>WDJ</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Neurosciences, Amsterdam Neuroscience, Amsterdam UMC - Location VUmc, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rozemuller</LastName><ForeName>Annemieke J M</ForeName><Initials>AJM</Initials><AffiliationInfo><Affiliation>Department of Pathology, Amsterdam Neuroscience, Amsterdam UMC - Location VUmc, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoozemans</LastName><ForeName>Jeroen J M</ForeName><Initials>JJM</Initials><AffiliationInfo><Affiliation>Department of Pathology, Amsterdam Neuroscience, Amsterdam UMC - Location VUmc, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG061775</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>09</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Acta Neuropathol</MedlineTA><NlmUniqueID>0412041</NlmUniqueID><ISSNLinking>0001-6322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002196" MajorTopicYN="N">Capillaries</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016657" MajorTopicYN="N">Cerebral Amyloid Angiopathy</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016501" MajorTopicYN="N">Neurites</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyloid-beta</Keyword><Keyword MajorTopicYN="N">Cerebral amyloid angiopathy</Keyword><Keyword MajorTopicYN="N">Coarse-grained plaque</Keyword><Keyword MajorTopicYN="N">Early-onset Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Neuroinflammation</Keyword></KeywordList><CoiStatement>The authors declare that they have no potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>5</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>14</Day><Hour>15</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>9</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32926214</ArticleId><ArticleId IdType="pmc">PMC7666300</ArticleId><ArticleId IdType="doi">10.1007/s00401-020-02198-8</ArticleId><ArticleId IdType="pii">10.1007/s00401-020-02198-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alafuzoff I, Ince PG, Arzberger T, Al-Sarraj S, Bell J, Bodi I, et al. Staging/typing of Lewy body related &#x3b1;-synuclein pathology: a study of the BrainNet Europe Consortium. Acta Neuropathol. 2009;117:635&#x2013;652.</Citation><ArticleIdList><ArticleId IdType="pubmed">19330340</ArticleId></ArticleIdList></Reference><Reference><Citation>Arendt T, Morawski M, G&#xe4;rtner U, Fr&#xf6;hlich N, Schulze F, Wohmann N, et al. Inhomogeneous distribution of Alzheimer pathology along the isocortical relief. Are cortical convolutions an Achilles heel of evolution? Brain Pathol. 2016;5:603&#x2013;611.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8029161</ArticleId><ArticleId IdType="pubmed">27564538</ArticleId></ArticleIdList></Reference><Reference><Citation>Armstrong RA. Beta-amyloid deposition in the medial temporal lobe in elderly non-demented brains and in alzheimer&#x2019;s disease. Dement Geriatr Cogn Disord. 1995;6:121&#x2013;125.</Citation><ArticleIdList><ArticleId IdType="pubmed">7620523</ArticleId></ArticleIdList></Reference><Reference><Citation>Armulik A, Genov&#xe9; G, Betsholtz C. Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Dev Cell. 2011;21:193&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pubmed">21839917</ArticleId></ArticleIdList></Reference><Reference><Citation>Asami-Odaka A, Ishibashi Y, Kikuchi T, Kitada C, Suzuki N. Long amyloid beta-protein secreted from wild-type human neuroblastoma IMR-32 cells. Biochemistry. 1995;34:10272&#x2013;10278.</Citation><ArticleIdList><ArticleId IdType="pubmed">7640283</ArticleId></ArticleIdList></Reference><Reference><Citation>Attems J, Jellinger K, Thal DR, Van Nostrand W. Review: sporadic cerebral amyloid angiopathy. Neuropathol Appl Neurobiol. 2011;37:75&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">20946241</ArticleId></ArticleIdList></Reference><Reference><Citation>Boon BDC, Hoozemans JJM, Lopuha&#xe4; B, Eigenhuis KN, Scheltens P, Kamphorst W, et al. Neuroinflammation is increased in the parietal cortex of atypical Alzheimer&#x2019;s disease. J Neuroinflammation. 2018;15:170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5975447</ArticleId><ArticleId IdType="pubmed">29843759</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006;112:389&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3906709</ArticleId><ArticleId IdType="pubmed">16906426</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas. 1960;20:37&#x2013;46.</Citation></Reference><Reference><Citation>Crook R, Verkkoniemi A, Perez-Tur J, Mehta N, Baker M, Houlden H, et al. A variant of Alzheimer&#x2019;s disease with spastic paraparesis and unusual plaques due to deletion of exon 9 of presenilin 1. Nat Med. 1998;4:452&#x2013;455.</Citation><ArticleIdList><ArticleId IdType="pubmed">9546792</ArticleId></ArticleIdList></Reference><Reference><Citation>Dela&#xe8;re P, Duyckaerts C, He Y, Piette F, Hauw JJ. Subtypes and differential laminar distributions of &#x3b2;A4 deposits in Alzheimer&#x2019;s disease: relationship with the intellectual status of 26 cases. Acta Neuropathol. 1991;81:328&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pubmed">1711758</ArticleId></ArticleIdList></Reference><Reference><Citation>Dela&#xe8;re P, He Y, Fayet G, Duyckaerts C, Hauw JJ. &#x3b2;A4 deposits are constant in the brain of the oldest old: an immunocytochemical study of 20 french centenarians. Neurobiol Aging. 1993;14:191&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">8487921</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMattos RB, O&#x2019;dell MA, Parsadanian M, Taylor JW, Harmony JAK, Bales KR, et al. Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer&#x2019;s disease. Proc Natl Acad Sci USA. 2002;99:10843&#x2013;10848.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC125060</ArticleId><ArticleId IdType="pubmed">12145324</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson TC, Vickers JC. The morphological phenotype of beta-amyloid plaques and associated neuritic changes in Alzheimer&#x2019;s disease. Neuroscience. 2001;105:99&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">11483304</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorph-Petersen KA, Nyengaard JR, Gundersen HJ. Tissue shrinkage and unbiased stereological estimation of particle number and size. J Microsci. 2001;204:232&#x2013;246.</Citation><ArticleIdList><ArticleId IdType="pubmed">11903800</ArticleId></ArticleIdList></Reference><Reference><Citation>Duyckaerts C, Delatour B, Potier M-C. Classification and basic pathology of Alzheimer disease. Acta Neuropathol. 2009;118:5&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">19381658</ArticleId></ArticleIdList></Reference><Reference><Citation>Eikelenboom P, Rozemuller JM, Kraal G, Stam FC, McBride PA, Bruce ME, et al. Cerebral amyloid plaques in Alzheimer&#x2019;s disease but not in scrapie-affected mice are closely associated with a local inflammatory process. Virchows Arch B Cell Pathol Incl Mol Pathol. 1991;60:329&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pubmed">1685040</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer O. Miliare Nekrosen mit drusigen Wucherungen der Neurofibrillen, eine regelm&#xe4;ssige Ver&#xe4;nderung der Hirnrinde bei seniler Demenz. Eur Neurol. 1907;22:361&#x2013;372.</Citation></Reference><Reference><Citation>Fischer O. Die presbyophrene Demenz, deren anatomische Grundlage und klinische Abgrenzung. Zeitschrift f&#xfc;r die Gesamte Neurol und Psychiatr. 1910;3:371&#x2013;471.</Citation></Reference><Reference><Citation>Gerth J, Kumar S, Rijal Upadhaya A, Ghebremedhin E, von Arnim CAF, Thal DR, et al. Modified amyloid variants in pathological subgroups of &#x3b2;-amyloidosis. Ann Clin Transl Neurol. 2018;5:815&#x2013;831.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6043770</ArticleId><ArticleId IdType="pubmed">30009199</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer&#x2019;s amyloid &#x3b2;-peptide. Nat Rev Mol Cell Biol. 2007;8:101&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">17245412</ArticleId></ArticleIdList></Reference><Reference><Citation>Herzig MC, Winkler DT, Burgermeister P, Pfeifer M, Kohler E, Schmidt SD, et al. A&#x3b2; is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Nat Neurosci. 2004;7:954&#x2013;960.</Citation><ArticleIdList><ArticleId IdType="pubmed">15311281</ArticleId></ArticleIdList></Reference><Reference><Citation>Hondius DC, Eigenhuis KN, Morrema THJ, van der Schors RC, van Nierop P, Bugiani M, et al. Proteomics analysis identifies new markers associated with capillary cerebral amyloid angiopathy in Alzheimer&#x2019;s disease. Acta Neuropathol Commun. 2018;6:46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5985582</ArticleId><ArticleId IdType="pubmed">29860944</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoozemans JJ, Rozemuller AJ, van Haastert ES, Eikelenboom P, van Gool WA. Neuroinflammation in Alzheimer&#x2019;s disease wanes with age. J Neuroinflamm. 2011;8:171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3248382</ArticleId><ArticleId IdType="pubmed">22152162</ArticleId></ArticleIdList></Reference><Reference><Citation>Hopperton KE, Mohammad D, Tr&#xe9;panier MO, Giuliano V, Bazinet RP. Markers of microglia in post-mortem brain samples from patients with Alzheimer&#x2019;s disease: a systematic review. Mol Psychiatry. 2018;23:177&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5794890</ArticleId><ArticleId IdType="pubmed">29230021</ArticleId></ArticleIdList></Reference><Reference><Citation>Itagaki S, McGeer PL, Akiyama H, Zhu S, Selkoe D. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J Neuroimmunol. 1989;24:173&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">2808689</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer&#x2019;s pathological cascade. Lancet Neurol. 2010;9:119&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2819840</ArticleId><ArticleId IdType="pubmed">20083042</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarrett JT, Berger EP, Lansbury PT. The carboxy terminus of the &#x3b2; amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer&#x2019;s disease. Biochemistry. 1993;32:4693&#x2013;4697.</Citation><ArticleIdList><ArticleId IdType="pubmed">8490014</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson-Wood K, Lee M, Motter R, Hu K, Gordon G, Barbour R, et al. Amyloid precursor protein processing and A&#x3b2;42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci USA. 1997;94:1550&#x2013;1555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC19829</ArticleId><ArticleId IdType="pubmed">9037091</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar S, Rezaei-Ghaleh N, Terwel D, Thal DR, Richard M, Hoch M, et al. Extracellular phosphorylation of the amyloid &#x3b2; 2-peptide promotes formation of toxic aggregates during the pathogenesis of Alzheimer&#x2019;s disease. EMBO J. 2011;30:2255&#x2013;2265.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3117653</ArticleId><ArticleId IdType="pubmed">21527912</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar S, Wirths O, Theil S, Gerth J, Bayer TA, Walter J. Early intraneuronal accumulation and increased aggregation of phosphorylated Abeta in a mouse model of Alzheimer&#x2019;s disease. Acta Neuropathol. 2013;125:699&#x2013;709.</Citation><ArticleIdList><ArticleId IdType="pubmed">23525537</ArticleId></ArticleIdList></Reference><Reference><Citation>Kummer MP, Heneka MT. Truncated and modified amyloid-beta species. Alzheimer&#x2019;s Res Ther. 2014;6:28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4055046</ArticleId><ArticleId IdType="pubmed">25031638</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier M, Peng Y, Jiang L, Seabrook TJ, Carroll MC, Lemere CA. Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice. J Neurosci. 2008;28:6333&#x2013;6341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3329761</ArticleId><ArticleId IdType="pubmed">18562603</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, et al. The consortium to establish a registry for Alzheimer&#x2019;s disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer&#x2019;s disease. Neurology. 1991;41:479&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, et al. National Institute on Aging-Alzheimer&#x2019;s Association guidelines for the neuropathologic assessment of Alzheimer&#x2019;s disease: a practical approach. Acta Neuropathol. 2012;123:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3268003</ArticleId><ArticleId IdType="pubmed">22101365</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Dickson DW, Trojanowski JQ, Jack CR, Boyle PA, Arfanakis K, et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain. 2019;142:1503&#x2013;1527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6536849</ArticleId><ArticleId IdType="pubmed">31039256</ArticleId></ArticleIdList></Reference><Reference><Citation>Oshima K, Uchikado H, Dickson DW. Perivascular neuritic dystrophy associated with cerebral amyloid angiopathy in Alzheimer&#x2019;s disease&#x2014;PubMed. Int J Clin Exp Pathol. 2008;1:403&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2480573</ArticleId><ArticleId IdType="pubmed">18787622</ArticleId></ArticleIdList></Reference><Reference><Citation>Peers MC, Lenders MB, D&#xe9;fossez A, Delacourte A, Mazzuca M. Cortical angiopathy in Alzheimer&#x2019;s disease: the formation of dystrophic perivascular neurites is related to the exudation of amyloid fibrils from the pathological vessels. Virchows Arch A Pathol Anat Histopathol. 1988;414:15&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">3144799</ArticleId></ArticleIdList></Reference><Reference><Citation>Perusini G. &#xdc;ber klinisch und histologisch eigenartige psychische Erkrankungen des sp&#xe4;teren Lebensalters. Histol und Histopathol Arb &#xfc;ber die Gehirnrinde. 1909;3:297&#x2013;351.</Citation></Reference><Reference><Citation>Price JL, Davis PB, Morris JC, White DL. The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer&#x2019;s disease. Neurobiol Aging. 1991;12:295&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pubmed">1961359</ArticleId></ArticleIdList></Reference><Reference><Citation>Richard E, Carrano A, Hoozemans JJ, Van Horssen J, Van Haastert ES, Eurelings LS, et al. Characteristics of dyshoric capillary cerebral amyloid angiopathy. J Neuropathol Exp Neurol. 2010;69:1158&#x2013;1167.</Citation><ArticleIdList><ArticleId IdType="pubmed">20940625</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405&#x2013;424.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4544753</ArticleId><ArticleId IdType="pubmed">25741868</ArticleId></ArticleIdList></Reference><Reference><Citation>Rijal Upadhaya A, Kosterin I, Kumar S, von Arnim CAF, Yamaguchi H, F&#xe4;ndrich M, et al. Biochemical stages of amyloid-&#x3b2; peptide aggregation and accumulation in the human brain and their association with symptomatic and pathologically preclinical Alzheimer&#x2019;s disease. Brain. 2014;137:887&#x2013;903.</Citation><ArticleIdList><ArticleId IdType="pubmed">24519982</ArticleId></ArticleIdList></Reference><Reference><Citation>Rozemuller JM, Eikelenboom P, Stam FC, Beyreuther K, Masters CL. A4 protein in Alzheimer&#x2019;s disease: primary and secondary cellular events in extracellular amyloid deposition. J Neuropathol Exp Neurol. 1989;48:674&#x2013;691.</Citation><ArticleIdList><ArticleId IdType="pubmed">2677252</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt ML, Robinson KA, Lee VM, Trojanowski JQ. Chemical and immunological heterogeneity of fibrillar amyloid in plaques of Alzheimer&#x2019;s disease and Down&#x2019;s syndrome brains revealed by confocal microscopy. Am J Pathol. 1995;147:503&#x2013;515.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1869826</ArticleId><ArticleId IdType="pubmed">7639340</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen Y, Yang L, Li R. What does complement do in Alzheimer&#x2019;s disease? Old molecules with new insights. Transl Neurodegener. 2013;2:21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3853043</ArticleId><ArticleId IdType="pubmed">24119446</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabira T, Chui DH, Nakayama H, Kuroda S, Shibuya M. Alzheimer&#x2019;s disease with spastic paresis and cotton wool type plaques. J Neurosci Res. 2002;70:367&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pubmed">12391599</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, Capetillo-Zarate E, Del Tredici K, Braak H. The development of amyloid beta protein deposits in the aged brain. Sci Aging Knowl Environ. 2006;2006(6):re1.</Citation><ArticleIdList><ArticleId IdType="pubmed">16525193</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, Ghebremedhin E, R&#xfc;b U, Yamaguchi H, Del Tredici K, Braak H. Two types of sporadic cerebral amyloid angiopathy. J Neuropathol Exp Neurol. 2002;61:282&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pubmed">11895043</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, Griffin WST, de Vos RAI, Ghebremedhin E. Cerebral amyloid angiopathy and its relationship to Alzheimer&#x2019;s disease. Acta Neuropathol. 2008;115:599&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pubmed">18369648</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, R&#xfc;b U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58:1791&#x2013;1800.</Citation><ArticleIdList><ArticleId IdType="pubmed">12084879</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, Walter J, Saido TC, F&#xe4;ndrich M. Neuropathology and biochemistry of A&#x3b2; and its aggregates in Alzheimer&#x2019;s disease. Acta Neuropathol. 2015;129:167&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">25534025</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomsen MS, Routhe LJ, Moos T. The vascular basement membrane in the healthy and pathological brain. J Cereb Blood Flow Metab. 2017;37:3300&#x2013;3317.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5624399</ArticleId><ArticleId IdType="pubmed">28753105</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Der Flier WM, Pijnenburg YAL, Prins N, Lemstra AW, Bouwman FH, Teunissen CE, et al. Optimizing patient care and research: the Amsterdam dementia cohort. J Alzheimer&#x2019;s Dis. 2014;41:313&#x2013;327.</Citation><ArticleIdList><ArticleId IdType="pubmed">24614907</ArticleId></ArticleIdList></Reference><Reference><Citation>Veerhuis R, van der Valk P, Janssen I, Zhan SS, Eikelenboom P, Van Nostrand WE, et al. Complement activation in amyloid plaques in Alzheimer&#x2019;s disease brains does not proceed further than C3. Virchows Arch. 1995;426:603&#x2013;610.</Citation><ArticleIdList><ArticleId IdType="pubmed">7655742</ArticleId></ArticleIdList></Reference><Reference><Citation>Verbeek MM, Otte-H&#xf6;ller I, Veerhuis R, Ruiter DJ, De Waal RMW. Distribution of A&#x3b2;-associated proteins in cerebrovascular amyloid of Alzheimer&#x2019;s disease. Acta Neuropathol. 1998;96:628&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pubmed">9845293</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T, Yan F, Lin AH-T, Lambris JD, Alexander JJ, Quigg RJ, et al. Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer&#x2019;s mice. Proc Natl Acad Sci USA. 2002;99:10837&#x2013;10842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC125059</ArticleId><ArticleId IdType="pubmed">12119423</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">32929860</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>27</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1469-3178</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>10</Issue><PubDate><Year>2020</Year><Month>Oct</Month><Day>05</Day></PubDate></JournalIssue><Title>EMBO reports</Title><ISOAbbreviation>EMBO Rep</ISOAbbreviation></Journal><ArticleTitle>Loss of TMEM106B potentiates lysosomal and FTLD-like pathology in progranulin-deficient mice.</ArticleTitle><Pagination><StartPage>e50241</StartPage><MedlinePgn>e50241</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e50241</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.15252/embr.202050241</ELocationID><Abstract><AbstractText>Single nucleotide polymorphisms (SNPs) in TMEM106B encoding the lysosomal type II transmembrane protein 106B increase the risk for frontotemporal lobar degeneration (FTLD) of GRN (progranulin gene) mutation carriers. Currently, it is unclear if progranulin (PGRN) and TMEM106B are synergistically linked and if a gain or a loss of function of TMEM106B is responsible for the increased disease risk of patients with GRN haploinsufficiency. We therefore compare behavioral abnormalities, gene expression patterns, lysosomal activity, and TDP-43 pathology in single and double knockout animals. Grn<sup>-/-</sup> /Tmem106b<sup>-/-</sup> mice show a strongly reduced life span and massive motor deficits. Gene expression analysis reveals an upregulation of molecular signature characteristic for disease-associated microglia and autophagy. Dysregulation of maturation of lysosomal proteins as well as an accumulation of ubiquitinated proteins and widespread p62 deposition suggest that proteostasis is impaired. Moreover, while single Grn<sup>-/-</sup> knockouts only occasionally show TDP-43 pathology, the double knockout mice exhibit deposition of phosphorylated TDP-43. Thus, a loss of function of TMEM106B may enhance the risk for GRN-associated FTLD by reduced protein turnover in the lysosomal/autophagic system.</AbstractText><CopyrightInformation>&#xa9; 2020 The Authors. Published under the terms of the CC BY NC ND 4.0 license.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Werner</LastName><ForeName>Georg</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-5328-3049</Identifier><AffiliationInfo><Affiliation>Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Damme</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Biochemistry, Kiel University, Kiel, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schludi</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gn&#xf6;rich</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University Hospital, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wind</LastName><ForeName>Karin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University Hospital, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fellerer</LastName><ForeName>Katrin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wefers</LastName><ForeName>Benedikt</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Developmental Genetics, Helmholtz Zentrum M&#xfc;nchen, German Research Center for Environmental Health, Neuherberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wurst</LastName><ForeName>Wolfgang</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Developmental Genetics, Helmholtz Zentrum M&#xfc;nchen, German Research Center for Environmental Health, Neuherberg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Edbauer</LastName><ForeName>Dieter</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-7186-4653</Identifier><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brendel</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University Hospital, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haass</LastName><ForeName>Christian</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-4869-1627</Identifier><AffiliationInfo><Affiliation>Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Capell</LastName><ForeName>Anja</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-3118-911X</Identifier><AffiliationInfo><Affiliation>Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>GEO</DataBankName><AccessionNumberList><AccessionNumber>GSE155065</AccessionNumber><AccessionNumber>GSE155066</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>HA1737/16-1</GrantID><Agency>Deutsche Forschungsgemeinschaft (DFG)</Agency><Country/></Grant><Grant><GrantID>EXC21455SyNetgy-ID</GrantID><Agency>Deutsche Forschungsgemeinschaft (DFG)</Agency><Country/></Grant><Grant><GrantID>390857198</GrantID><Agency>Deutsche Forschungsgemeinschaft (DFG)</Agency><Country/></Grant><Grant><GrantID>ZT-0027</GrantID><Agency>Helmholtz Association</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>09</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>EMBO Rep</MedlineTA><NlmUniqueID>100963049</NlmUniqueID><ISSNLinking>1469-221X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036341">Intercellular Signaling Peptides and Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077153">Progranulins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C556915">TMEM106B protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057174" MajorTopicYN="Y">Frontotemporal Lobar Degeneration</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036341" MajorTopicYN="Y">Intercellular Signaling Peptides and Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008247" MajorTopicYN="N">Lysosomes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077153" MajorTopicYN="N">Progranulins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">FTD</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword><Keyword MajorTopicYN="N">TMEM106B</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">progranulin</Keyword></KeywordList><CoiStatement>CH collaborates with Denali Therapeutics, participated on one advisory board meeting of Biogen, and received a speaker honorarium from Novartis and Roche. CH is chief advisor of ISAR Bioscience.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>2</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>8</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>15</Day><Hour>5</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>9</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32929860</ArticleId><ArticleId IdType="pmc">PMC7534633</ArticleId><ArticleId IdType="doi">10.15252/embr.202050241</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ahmed Z, Sheng H, Xu YF, Lin WL, Innes AE, Gass J, Yu X, Wuertzer CA, Hou H, Chiba S et&#xa0;al (2010) Accelerated lipofuscinosis and ubiquitination in granulin knockout mice suggest a role for progranulin in successful aging. Am J Pathol 177: 311&#x2013;324</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2893674</ArticleId><ArticleId IdType="pubmed">20522652</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida MR, Macario MC, Ramos L, Baldeiras I, Ribeiro MH, Santana I (2016) Portuguese family with the co&#x2010;occurrence of frontotemporal lobar degeneration and neuronal ceroid lipofuscinosis phenotypes due to progranulin gene mutation. Neurobiol Aging 41: 200.e201&#x2013;200</Citation><ArticleIdList><ArticleId IdType="pubmed">27021778</ArticleId></ArticleIdList></Reference><Reference><Citation>Arrant AE, Nicholson AM, Zhou X, Rademakers R, Roberson ED (2018) Partial Tmem106b reduction does not correct abnormalities due to progranulin haploinsufficiency. Mol Neurodegener 13: 32</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6013889</ArticleId><ArticleId IdType="pubmed">29929528</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker M, Mackenzie IR, Pickering&#x2010;Brown SM, Gass J, Rademakers R, Lindholm C, Snowden J, Adamson J, Sadovnick AD, Rollinson S et&#xa0;al (2006) Mutations in progranulin cause tau&#x2010;negative frontotemporal dementia linked to chromosome 17. Nature 442: 916&#x2013;919</Citation><ArticleIdList><ArticleId IdType="pubmed">16862116</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman A, Cheung ST, Bennett HPJ (2018) A brief overview of progranulin in health and disease. Methods Mol Biol 1806: 3&#x2013;15</Citation><ArticleIdList><ArticleId IdType="pubmed">29956265</ArticleId></ArticleIdList></Reference><Reference><Citation>Beel S, Moisse M, Damme M, De Muynck L, Robberecht W, Van Den Bosch L, Saftig P, Van Damme P (2017) Progranulin functions as a cathepsin D chaperone to stimulate axonal outgrowth in&#xa0;vivo . Hum Mol Genet 26: 2850&#x2013;2863</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5886064</ArticleId><ArticleId IdType="pubmed">28453791</ArticleId></ArticleIdList></Reference><Reference><Citation>Belcastro V, Siciliano V, Gregoretti F, Mithbaokar P, Dharmalingam G, Berlingieri S, Iorio F, Oliva G, Polishchuck R, Brunetti&#x2010;Pierri N et&#xa0;al (2011) Transcriptional gene network inference from a massive dataset elucidates transcriptome organization and gene function. Nucleic Acids Res 39: 8677&#x2013;8688</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3203605</ArticleId><ArticleId IdType="pubmed">21785136</ArticleId></ArticleIdList></Reference><Reference><Citation>van Blitterswijk M, Mullen B, Nicholson AM, Bieniek KF, Heckman MG, Baker MC, DeJesus&#x2010;Hernandez M, Finch NA, Brown PH, Murray ME et&#xa0;al (2014) TMEM106B protects C9ORF72 expansion carriers against frontotemporal dementia. Acta Neuropathol 127: 397&#x2013;406</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3944829</ArticleId><ArticleId IdType="pubmed">24385136</ArticleId></ArticleIdList></Reference><Reference><Citation>Brady OA, Zheng Y, Murphy K, Huang M, Hu F (2013) The frontotemporal lobar degeneration risk factor, TMEM106B, regulates lysosomal morphology and function. Hum Mol Genet 22: 685&#x2013;695</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3554197</ArticleId><ArticleId IdType="pubmed">23136129</ArticleId></ArticleIdList></Reference><Reference><Citation>Brendel M, Probst F, Jaworska A, Overhoff F, Korzhova V, Albert NL, Beck R, Lindner S, Gildehaus FJ, Baumann K et&#xa0;al (2016) Glial activation and glucose metabolism in a transgenic amyloid mouse model: a triple&#x2010;tracer PET study. J Nucl Med 57: 954&#x2013;960</Citation><ArticleIdList><ArticleId IdType="pubmed">26912428</ArticleId></ArticleIdList></Reference><Reference><Citation>Capell A, Liebscher S, Fellerer K, Brouwers N, Willem M, Lammich S, Gijselinck I, Bittner T, Carlson AM, Sasse F et&#xa0;al (2011) Rescue of progranulin deficiency associated with frontotemporal lobar degeneration by alkalizing reagents and inhibition of vacuolar ATPase. J Neurosci 31: 1885&#x2013;1894</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6623716</ArticleId><ArticleId IdType="pubmed">21289198</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang MC, Srinivasan K, Friedman BA, Suto E, Modrusan Z, Lee WP, Kaminker JS, Hansen DV, Sheng M (2017) Progranulin deficiency causes impairment of autophagy and TDP&#x2010;43 accumulation. J Exp Med 214: 2611&#x2013;2628</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5584112</ArticleId><ArticleId IdType="pubmed">28778989</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen&#x2010;Plotkin AS, Unger TL, Gallagher MD, Bill E, Kwong LK, Volpicelli&#x2010;Daley L, Busch JI, Akle S, Grossman M, Van Deerlin V et&#xa0;al (2012) TMEM106B, the risk gene for frontotemporal dementia, is regulated by the microRNA&#x2010;132/212 cluster and affects progranulin pathways. J Neurosci 32: 11213&#x2013;11227</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3446826</ArticleId><ArticleId IdType="pubmed">22895706</ArticleId></ArticleIdList></Reference><Reference><Citation>Clayton EL, Milioto C, Muralidharan B, Norona FE, Edgar JR, Soriano A, Jafar&#x2010;Nejad P, Rigo F, Collinge J, Isaacs AM (2018) Frontotemporal dementia causative CHMP2B impairs neuronal endolysosomal traffic&#x2010;rescue by TMEM106B knockdown. Brain 141: 3428&#x2013;3442</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6262218</ArticleId><ArticleId IdType="pubmed">30496365</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruchaga C, Graff C, Chiang HH, Wang J, Hinrichs AL, Spiegel N, Bertelsen S, Mayo K, Norton JB, Morris JC et&#xa0;al (2011) Association of TMEM106B gene polymorphism with age at onset in granulin mutation carriers and plasma granulin protein levels. Arch Neurol 68: 581&#x2013;586</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3090529</ArticleId><ArticleId IdType="pubmed">21220649</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruts M, Gijselinck I, van der Zee J, Engelborghs S, Wils H, Pirici D, Rademakers R, Vandenberghe R, Dermaut B, Martin JJ et&#xa0;al (2006) Null mutations in progranulin cause ubiquitin&#x2010;positive frontotemporal dementia linked to chromosome 17q21. Nature 442: 920&#x2013;924</Citation><ArticleIdList><ArticleId IdType="pubmed">16862115</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus&#x2010;Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, Nicholson AM, Finch NA, Flynn H, Adamson J et&#xa0;al (2011) Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p&#x2010;linked FTD and ALS. Neuron 72: 245&#x2013;256</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Deussing M, Blume T, Vomacka L, Mahler C, Focke C, Todica A, Unterrainer M, Albert NL, Lindner S, von Ungern&#x2010;Sternberg B et&#xa0;al (2018) Coupling between physiological TSPO expression in brain and myocardium allows stabilization of late&#x2010;phase cerebral [(18)F]GE180 PET quantification. NeuroImage 165: 83&#x2013;91</Citation><ArticleIdList><ArticleId IdType="pubmed">28988133</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng T, Mai S, Roscoe JM, Sheng RR, Ullah M, Zhang J, Iscol Katz I, Yu H, Xiong W, Hu F (2020a) Loss of TMEM106B and PGRN leads to severe lysosomal abnormalities and neurodegeneration in mice. EMBO Rep 21: e50219</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7534636</ArticleId><ArticleId IdType="pubmed">32852886</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng T, Sheng RR, Sole&#x2010;Domenech S, Ullah M, Zhou X, Mendoza CS, Enriquez LCM, Katz II, Paushter DH, Sullivan PM et&#xa0;al (2020b) A role of the frontotemporal lobar degeneration risk factor TMEM106B in myelination. Brain 143: 2255&#x2013;2271</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7363491</ArticleId><ArticleId IdType="pubmed">32572497</ArticleId></ArticleIdList></Reference><Reference><Citation>Finch N, Carrasquillo MM, Baker M, Rutherford NJ, Coppola G, Dejesus&#x2010;Hernandez M, Crook R, Hunter T, Ghidoni R, Benussi L et&#xa0;al (2011) TMEM106B regulates progranulin levels and the penetrance of FTLD in GRN mutation carriers. Neurology 76: 467&#x2013;474</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3034409</ArticleId><ArticleId IdType="pubmed">21178100</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallagher MD, Suh E, Grossman M, Elman L, McCluskey L, Van Swieten JC, Al&#x2010;Sarraj S, Neumann M, Gelpi E, Ghetti B et&#xa0;al (2014) TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions. Acta Neuropathol 127: 407&#x2013;418</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4003885</ArticleId><ArticleId IdType="pubmed">24442578</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallagher MD, Posavi M, Huang P, Unger TL, Berlyand Y, Gruenewald AL, Chesi A, Manduchi E, Wells AD, Grant SFA et&#xa0;al (2017) A dementia&#x2010;associated risk variant near TMEM106B alters chromatin architecture and gene expression. Am J Hum Genet 101: 643&#x2013;663</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5673619</ArticleId><ArticleId IdType="pubmed">29056226</ArticleId></ArticleIdList></Reference><Reference><Citation>Gass J, Cannon A, Mackenzie IR, Boeve B, Baker M, Adamson J, Crook R, Melquist S, Kuntz K, Petersen R et&#xa0;al (2006) Mutations in progranulin are a major cause of ubiquitin&#x2010;positive frontotemporal lobar degeneration. Hum Mol Genet 15: 2988&#x2013;3001</Citation><ArticleIdList><ArticleId IdType="pubmed">16950801</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghoshal N, Dearborn JT, Wozniak DF, Cairns NJ (2012) Core features of frontotemporal dementia recapitulated in progranulin knockout mice. Neurobiol Dis 45: 395&#x2013;408</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3225509</ArticleId><ArticleId IdType="pubmed">21933710</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotzl JK, Mori K, Damme M, Fellerer K, Tahirovic S, Kleinberger G, Janssens J, van der Zee J, Lang CM, Kremmer E et&#xa0;al (2014) Common pathobiochemical hallmarks of progranulin&#x2010;associated frontotemporal lobar degeneration and neuronal ceroid lipofuscinosis. Acta Neuropathol 127: 845&#x2013;860</Citation><ArticleIdList><ArticleId IdType="pubmed">24619111</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotzl JK, Lang CM, Haass C, Capell A (2016) Impaired protein degradation in FTLD and related disorders. Ageing Res Rev 32: 122&#x2013;139</Citation><ArticleIdList><ArticleId IdType="pubmed">27166223</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotzl JK, Colombo AV, Fellerer K, Reifschneider A, Werner G, Tahirovic S, Haass C, Capell A (2018) Early lysosomal maturation deficits in microglia triggers enhanced lysosomal activity in other brain cells of progranulin knockout mice. Mol Neurodegener 13: 48</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6123925</ArticleId><ArticleId IdType="pubmed">30180904</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotzl JK, Brendel M, Werner G, Parhizkar S, Sebastian Monasor L, Kleinberger G, Colombo AV, Deussing M, Wagner M, Winkelmann J et&#xa0;al (2019) Opposite microglial activation stages upon loss of PGRN or TREM2 result in reduced cerebral glucose metabolism. EMBO Mol Med 11: e9711</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6554672</ArticleId><ArticleId IdType="pubmed">31122931</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo A, Tapia L, Bamji SX, Cynader MS, Jia W (2010) Progranulin deficiency leads to enhanced cell vulnerability and TDP&#x2010;43 translocation in primary neuronal cultures. Brain Res 1366: 1&#x2013;8</Citation><ArticleIdList><ArticleId IdType="pubmed">20888804</ArticleId></ArticleIdList></Reference><Reference><Citation>Hara T, Nakamura K, Matsui M, Yamamoto A, Nakahara Y, Suzuki&#x2010;Migishima R, Yokoyama M, Mishima K, Saito I, Okano H et&#xa0;al (2006) Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature 441: 885&#x2013;889</Citation><ArticleIdList><ArticleId IdType="pubmed">16625204</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Rogaeva E (2014) Motor neuron disease and frontotemporal dementia: sometimes related, sometimes not. Exp Neurol 262(Pt B): 75&#x2013;83</Citation><ArticleIdList><ArticleId IdType="pubmed">24246281</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa M, Arai T, Nonaka T, Kametani F, Yoshida M, Hashizume Y, Beach TG, Buratti E, Baralle F, Morita M et&#xa0;al (2008) Phosphorylated TDP&#x2010;43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann Neurol 64: 60&#x2013;70</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2674108</ArticleId><ArticleId IdType="pubmed">18546284</ArticleId></ArticleIdList></Reference><Reference><Citation>Holler CJ, Taylor G, Deng Q, Kukar T (2017) Intracellular proteolysis of progranulin generates stable, lysosomal granulins that are haploinsufficient in patients with frontotemporal dementia caused by GRN mutations. eNeuro 4: ENEURO.0100&#x2010;17.2017</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5562298</ArticleId><ArticleId IdType="pubmed">28828399</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu F, Padukkavidana T, Vaegter CB, Brady OA, Zheng Y, Mackenzie IR, Feldman HH, Nykjaer A, Strittmatter SM (2010) Sortilin&#x2010;mediated endocytosis determines levels of the frontotemporal dementia protein, progranulin. Neuron 68: 654&#x2013;667</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2990962</ArticleId><ArticleId IdType="pubmed">21092856</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikemoto S, Hamano SI, Kikuchi K, Koichihara R, Hirata Y, Matsuura R, Hiraide T, Nakashima M, Inoue K, Kurosawa K et&#xa0;al (2020) A recurrent TMEM106B mutation in hypomyelinating leukodystrophy: a rapid diagnostic assay. Brain Dev 42: 603&#x2013;606</Citation><ArticleIdList><ArticleId IdType="pubmed">32595021</ArticleId></ArticleIdList></Reference><Reference><Citation>Kao AW, McKay A, Singh PP, Brunet A, Huang EJ (2017) Progranulin, lysosomal regulation and neurodegenerative disease. Nat Rev Neurosci 18: 325&#x2013;333</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6040832</ArticleId><ArticleId IdType="pubmed">28435163</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayasuga Y, Chiba S, Suzuki M, Kikusui T, Matsuwaki T, Yamanouchi K, Kotaki H, Horai R, Iwakura Y, Nishihara M (2007) Alteration of behavioural phenotype in mice by targeted disruption of the progranulin gene. Behav Brain Res 185: 110&#x2013;118</Citation><ArticleIdList><ArticleId IdType="pubmed">17764761</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein ZA, Takahashi H, Ma M, Stagi M, Zhou M, Lam TT, Strittmatter SM (2017) Loss of TMEM106B ameliorates lysosomal and frontotemporal dementia&#x2010;related phenotypes in progranulin&#x2010;deficient mice. Neuron 95: 281&#x2013;296</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5558861</ArticleId><ArticleId IdType="pubmed">28728022</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleinberger G, Wils H, Ponsaerts P, Joris G, Timmermans JP, Van Broeckhoven C, Kumar&#x2010;Singh S (2010) Increased caspase activation and decreased TDP&#x2010;43 solubility in progranulin knockout cortical cultures. J Neurochem 115: 735&#x2013;747</Citation><ArticleIdList><ArticleId IdType="pubmed">20731760</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleinberger G, Capell A, Haass C, Van Broeckhoven C (2013) Mechanisms of granulin deficiency: lessons from cellular and animal models. Mol Neurobiol 47: 337&#x2013;360</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3538123</ArticleId><ArticleId IdType="pubmed">23239020</ArticleId></ArticleIdList></Reference><Reference><Citation>Komatsu M, Waguri S, Ueno T, Iwata J, Murata S, Tanida I, Ezaki J, Mizushima N, Ohsumi Y, Uchiyama Y et&#xa0;al (2005) Impairment of starvation&#x2010;induced and constitutive autophagy in Atg7&#x2010;deficient mice. J Cell Biol 169: 425&#x2013;434</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2171928</ArticleId><ArticleId IdType="pubmed">15866887</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang CM, Fellerer K, Schwenk BM, Kuhn PH, Kremmer E, Edbauer D, Capell A, Haass C (2012) Membrane orientation and subcellular localization of transmembrane protein 106B (TMEM106B), a major risk factor for frontotemporal lobar degeneration. J Biol Chem 287: 19355&#x2013;19365</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3365973</ArticleId><ArticleId IdType="pubmed">22511793</ArticleId></ArticleIdList></Reference><Reference><Citation>Le NT, Chang L, Kovlyagina I, Georgiou P, Safren N, Braunstein KE, Kvarta MD, Van Dyke AM, LeGates TA, Philips T et&#xa0;al (2016) Motor neuron disease, TDP&#x2010;43 pathology, and memory deficits in mice expressing ALS&#x2010;FTD&#x2010;linked UBQLN2 mutations. Proc Natl Acad Sci USA 113: E7580&#x2013;E7589</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5127348</ArticleId><ArticleId IdType="pubmed">27834214</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CW, Stankowski JN, Chew J, Cook CN, Lam YW, Almeida S, Carlomagno Y, Lau KF, Prudencio M, Gao FB et&#xa0;al (2017) The lysosomal protein cathepsin L is a progranulin protease. Mol Neurodegener 12: 55</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5526245</ArticleId><ArticleId IdType="pubmed">28743268</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, Farias FHG, Dube U, Del&#x2010;Aguila JL, Mihindukulasuriya KA, Fernandez MV, Ibanez L, Budde JP, Wang F, Lake AM et&#xa0;al (2020) The TMEM106B FTLD&#x2010;protective variant, rs1990621, is also associated with increased neuronal proportion. Acta Neuropathol 139: 45&#x2013;61</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6942643</ArticleId><ArticleId IdType="pubmed">31456032</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Pattamatta A, Zu T, Reid T, Bardhi O, Borchelt DR, Yachnis AT, Ranum LP (2016) C9orf72 BAC mouse model with motor deficits and neurodegenerative features of ALS/FTD. Neuron 90: 521&#x2013;534</Citation><ArticleIdList><ArticleId IdType="pubmed">27112499</ArticleId></ArticleIdList></Reference><Reference><Citation>Lui H, Zhang J, Makinson SR, Cahill MK, Kelley KW, Huang HY, Shang Y, Oldham MC, Martens LH, Gao F et&#xa0;al (2016) Progranulin deficiency promotes circuit&#x2010;specific synaptic pruning by microglia via complement activation. Cell 165: 921&#x2013;935</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4860138</ArticleId><ArticleId IdType="pubmed">27114033</ArticleId></ArticleIdList></Reference><Reference><Citation>Luningschror P, Werner G, Stroobants S, Kakuta S, Dombert B, Sinske D, Wanner R, Lullmann&#x2010;Rauch R, Wefers B, Wurst W et&#xa0;al (2020) The FTLD risk factor TMEM106B regulates the transport of lysosomes at the axon initial segment of motoneurons. Cell Rep 30: 3506&#x2013;3519</Citation><ArticleIdList><ArticleId IdType="pubmed">32160553</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray ME, Cannon A, Graff&#x2010;Radford NR, Liesinger AM, Rutherford NJ, Ross OA, Duara R, Carrasquillo MM, Rademakers R, Dickson DW (2014) Differential clinicopathologic and genetic features of late&#x2010;onset amnestic dementias. Acta Neuropathol 128: 411&#x2013;421</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4412022</ArticleId><ArticleId IdType="pubmed">24899141</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Wang WX, Partch AB, Monsell SE, Valladares O, Ellingson SR, Wilfred BR, Naj AC, Wang LS, Kukull WA et&#xa0;al (2015) Reassessment of risk genotypes (GRN, TMEM106B, and ABCC9 variants) associated with hippocampal sclerosis of aging pathology. J Neuropathol Exp Neurol 74: 75&#x2013;84</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4270894</ArticleId><ArticleId IdType="pubmed">25470345</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Kwong LK, Lee EB, Kremmer E, Flatley A, Xu Y, Forman MS, Troost D, Kretzschmar HA, Trojanowski JQ et&#xa0;al (2009) Phosphorylation of S409/410 of TDP&#x2010;43 is a consistent feature in all sporadic and familial forms of TDP&#x2010;43 proteinopathies. Acta Neuropathol 117: 137&#x2013;149</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2693625</ArticleId><ArticleId IdType="pubmed">19125255</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholson AM, Finch NA, Wojtas A, Baker MC, Perkerson RB 3rd, Castanedes&#x2010;Casey M, Rousseau L, Benussi L, Binetti G, Ghidoni R et&#xa0;al (2013) TMEM106B p. T185S regulates TMEM106B protein levels: implications for frontotemporal dementia. J Neurochem 126: 781&#x2013;791</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3766501</ArticleId><ArticleId IdType="pubmed">23742080</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholson AM, Zhou X, Perkerson RB, Parsons TM, Chew J, Brooks M, DeJesus&#x2010;Hernandez M, Finch NA, Matchett BJ, Kurti A et&#xa0;al (2018) Loss of Tmem106b is unable to ameliorate frontotemporal dementia&#x2010;like phenotypes in an AAV mouse model of C9ORF72&#x2010;repeat induced toxicity. Acta Neuropathol Commun 6: 42</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5984311</ArticleId><ArticleId IdType="pubmed">29855382</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA (2013) The role of autophagy in neurodegenerative disease. Nat Med 19: 983&#x2013;997</Citation><ArticleIdList><ArticleId IdType="pubmed">23921753</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmer DN, Barry LA, Tyynela J, Cooper JD (2013) NCL disease mechanisms. Biochim Biophys Acta 1832: 1882&#x2013;1893</Citation><ArticleIdList><ArticleId IdType="pubmed">23707513</ArticleId></ArticleIdList></Reference><Reference><Citation>Petkau TL, Neal SJ, Milnerwood A, Mew A, Hill AM, Orban P, Gregg J, Lu G, Feldman HH, Mackenzie IR et&#xa0;al (2012) Synaptic dysfunction in progranulin&#x2010;deficient mice. Neurobiol Dis 45: 711&#x2013;722</Citation><ArticleIdList><ArticleId IdType="pubmed">22062772</ArticleId></ArticleIdList></Reference><Reference><Citation>Petkau TL, Hill A, Leavitt BR (2016) Core neuropathological abnormalities in progranulin&#x2010;deficient mice are penetrant on multiple genetic backgrounds. Neuroscience 315: 175&#x2013;195</Citation><ArticleIdList><ArticleId IdType="pubmed">26701296</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren Y, van Blitterswijk M, Allen M, Carrasquillo MM, Reddy JS, Wang X, Beach TG, Dickson DW, Ertekin&#x2010;Taner N, Asmann YW et&#xa0;al (2018) TMEM106B haplotypes have distinct gene expression patterns in aged brain. Mol Neurodegener 13: 35</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6029036</ArticleId><ArticleId IdType="pubmed">29970152</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, Simon&#x2010;Sanchez J, Rollinson S, Gibbs JR, Schymick JC, Laaksovirta H, van Swieten JC, Myllykangas L et&#xa0;al (2011) A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21&#x2010;linked ALS&#x2010;FTD. Neuron 72: 257&#x2013;268</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhinn H, Abeliovich A (2017) Differential aging analysis in human cerebral cortex identifies variants in TMEM106B and GRN that regulate aging phenotypes. Cell Syst 4: 404&#x2013;415</Citation><ArticleIdList><ArticleId IdType="pubmed">28330615</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutherford NJ, Carrasquillo MM, Li M, Bisceglio G, Menke J, Josephs KA, Parisi JE, Petersen RC, Graff&#x2010;Radford NR, Younkin SG et&#xa0;al (2012) TMEM106B risk variant is implicated in the pathologic presentation of Alzheimer disease. Neurology 79: 717&#x2013;718</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3467659</ArticleId><ArticleId IdType="pubmed">22855871</ArticleId></ArticleIdList></Reference><Reference><Citation>Sardiello M, Palmieri M, di Ronza A, Medina DL, Valenza M, Gennarino VA, Di Malta C, Donaudy F, Embrione V, Polishchuk RS et&#xa0;al (2009) A gene network regulating lysosomal biogenesis and function. Science 325: 473&#x2013;477</Citation><ArticleIdList><ArticleId IdType="pubmed">19556463</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwenk BM, Lang CM, Hogl S, Tahirovic S, Orozco D, Rentzsch K, Lichtenthaler SF, Hoogenraad CC, Capell A, Haass C et&#xa0;al (2014) The FTLD risk factor TMEM106B and MAP6 control dendritic trafficking of lysosomes. EMBO J 33: 450&#x2013;467</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3989627</ArticleId><ArticleId IdType="pubmed">24357581</ArticleId></ArticleIdList></Reference><Reference><Citation>Settembre C, Ballabio A (2011) TFEB regulates autophagy: an integrated coordination of cellular degradation and recycling processes. Autophagy 7: 1379&#x2013;1381</Citation><ArticleIdList><ArticleId IdType="pubmed">21785263</ArticleId></ArticleIdList></Reference><Reference><Citation>Settembre C, Di Malta C, Polito VA, Garcia Arencibia M, Vetrini F, Erdin S, Erdin SU, Huynh T, Medina D, Colella P et&#xa0;al (2011) TFEB links autophagy to lysosomal biogenesis. Science 332: 1429&#x2013;1433</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3638014</ArticleId><ArticleId IdType="pubmed">21617040</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith KR, Damiano J, Franceschetti S, Carpenter S, Canafoglia L, Morbin M, Rossi G, Pareyson D, Mole SE, Staropoli JF et&#xa0;al (2012) Strikingly different clinicopathological phenotypes determined by progranulin&#x2010;mutation dosage. Am J Hum Genet 90: 1102&#x2013;1107</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3370276</ArticleId><ArticleId IdType="pubmed">22608501</ArticleId></ArticleIdList></Reference><Reference><Citation>Snowden JS, Pickering&#x2010;Brown SM, Mackenzie IR, Richardson AM, Varma A, Neary D, Mann DM (2006) Progranulin gene mutations associated with frontotemporal dementia and progressive non&#x2010;fluent aphasia. Brain 129: 3091&#x2013;3102</Citation><ArticleIdList><ArticleId IdType="pubmed">17003069</ArticleId></ArticleIdList></Reference><Reference><Citation>Stagi M, Klein ZA, Gould TJ, Bewersdorf J, Strittmatter SM (2014) Lysosome size, motility and stress response regulated by fronto&#x2010;temporal dementia modifier TMEM106B. Mol Cell Neurosci 61: 226&#x2013;240</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4145808</ArticleId><ArticleId IdType="pubmed">25066864</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka Y, Matsuwaki T, Yamanouchi K, Nishihara M (2013) Increased lysosomal biogenesis in activated microglia and exacerbated neuronal damage after traumatic brain injury in progranulin&#x2010;deficient mice. Neuroscience 250: 8&#x2013;19</Citation><ArticleIdList><ArticleId IdType="pubmed">23830905</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka Y, Chambers JK, Matsuwaki T, Yamanouchi K, Nishihara M (2014) Possible involvement of lysosomal dysfunction in pathological changes of the brain in aged progranulin&#x2010;deficient mice. Acta Neuropathol Commun 2: 78</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4149276</ArticleId><ArticleId IdType="pubmed">25022663</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka Y, Suzuki G, Matsuwaki T, Hosokawa M, Serrano G, Beach TG, Yamanouchi K, Hasegawa M, Nishihara M (2017) Progranulin regulates lysosomal function and biogenesis through acidification of lysosomes. Hum Mol Genet 26: 969&#x2013;988</Citation><ArticleIdList><ArticleId IdType="pubmed">28073925</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Deerlin VM, Sleiman PM, Martinez&#x2010;Lage M, Chen&#x2010;Plotkin A, Wang LS, Graff&#x2010;Radford NR, Dickson DW, Rademakers R, Boeve BF, Grossman M et&#xa0;al (2010) Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP&#x2010;43 inclusions. Nat Genet 42: 234&#x2013;239</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2828525</ArticleId><ArticleId IdType="pubmed">20154673</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward ME, Chen R, Huang HY, Ludwig C, Telpoukhovskaia M, Taubes A, Boudin H, Minami SS, Reichert M, Albrecht P et&#xa0;al (2017) Individuals with progranulin haploinsufficiency exhibit features of neuronal ceroid lipofuscinosis. Sci Transl Med 9: eaah5642</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5526610</ArticleId><ArticleId IdType="pubmed">28404863</ArticleId></ArticleIdList></Reference><Reference><Citation>Wils H, Kleinberger G, Janssens J, Pereson S, Joris G, Cuijt I, Smits V, Ceuterick&#x2010;de Groote C, Van Broeckhoven C, Kumar&#x2010;Singh S (2010) TDP&#x2010;43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci USA 107: 3858&#x2013;3863</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2840518</ArticleId><ArticleId IdType="pubmed">20133711</ArticleId></ArticleIdList></Reference><Reference><Citation>Wils H, Kleinberger G, Pereson S, Janssens J, Capell A, Van Dam D, Cuijt I, Joris G, De Deyn PP, Haass C et&#xa0;al (2012) Cellular ageing, increased mortality and FTLD&#x2010;TDP&#x2010;associated neuropathology in progranulin knockout mice. J Pathol 228: 67&#x2013;76</Citation><ArticleIdList><ArticleId IdType="pubmed">22733568</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang X, Werner G, Bohrmann B, Liesz A, Mazaheri F, Capell A, Feederle R, Knuesel I, Kleinberger G, Haass C (2016) TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearance. EMBO Mol Med 8: 992&#x2013;1004</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5009806</ArticleId><ArticleId IdType="pubmed">27402340</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin F, Banerjee R, Thomas B, Zhou P, Qian L, Jia T, Ma X, Ma Y, Iadecola C, Beal MF et&#xa0;al (2010a) Exaggerated inflammation, impaired host defense, and neuropathology in progranulin&#x2010;deficient mice. J Exp Med 207: 117&#x2013;128</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2812536</ArticleId><ArticleId IdType="pubmed">20026663</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin F, Dumont M, Banerjee R, Ma Y, Li H, Lin MT, Beal MF, Nathan C, Thomas B, Ding A (2010b) Behavioral deficits and progressive neuropathology in progranulin&#x2010;deficient mice: a mouse model of frontotemporal dementia. FASEB J 24: 4639&#x2013;4647</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2992364</ArticleId><ArticleId IdType="pubmed">20667979</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu L, De Jager PL, Yang J, Trojanowski JQ, Bennett DA, Schneider JA (2015) The TMEM106B locus and TDP&#x2010;43 pathology in older persons without FTLD. Neurology 84: 927&#x2013;934</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4351662</ArticleId><ArticleId IdType="pubmed">25653292</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Zee J, Van Langenhove T, Kleinberger G, Sleegers K, Engelborghs S, Vandenberghe R, Santens P, Van den Broeck M, Joris G, Brys J et&#xa0;al (2011) TMEM106B is associated with frontotemporal lobar degeneration in a clinically diagnosed patient cohort. Brain 134: 808&#x2013;815</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3044834</ArticleId><ArticleId IdType="pubmed">21354975</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, Sun L, Bastos de Oliveira F, Qi X, Brown WJ, Smolka MB, Sun Y, Hu F (2015) Prosaposin facilitates sortilin&#x2010;independent lysosomal trafficking of progranulin. J Cell Biol 210: 991&#x2013;1002</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4576858</ArticleId><ArticleId IdType="pubmed">26370502</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, Paushter DH, Feng T, Pardon CM, Mendoza CS, Hu F (2017a) Regulation of cathepsin D activity by the FTLD protein progranulin. Acta Neuropathol 134: 151&#x2013;153</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5568051</ArticleId><ArticleId IdType="pubmed">28493053</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, Paushter DH, Feng T, Sun L, Reinheckel T, Hu F (2017b) Lysosomal processing of progranulin. Mol Neurodegener 12: 62</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5569495</ArticleId><ArticleId IdType="pubmed">28835281</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, Brooks M, Jiang P, Koga S, Zuberi AR, Baker MC, Parsons TM, Castanedes&#x2010;Casey M, Phillips V, Librero AL et&#xa0;al (2020a) Loss of Tmem106b exacerbates FTLD pathologies and causes motor deficits in progranulin deficient mice. EMBO Rep 21: e50197</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7534638</ArticleId><ArticleId IdType="pubmed">32761777</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, Nicholson AM, Ren Y, Brooks M, Jiang P, Zuberi A, Phuoc HN, Perkerson RB, Matchett B, Parsons TM et&#xa0;al (2020b) Loss of TMEM106B leads to myelination deficits: implications for frontotemporal dementia treatment strategies. Brain 143: 1905&#x2013;1919</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7296855</ArticleId><ArticleId IdType="pubmed">32504082</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32949547</PMID><DateCompleted><Year>2020</Year><Month>09</Month><Day>30</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-4465</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>10</Issue><PubDate><Year>2020</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The Lancet. Neurology</Title><ISOAbbreviation>Lancet Neurol</ISOAbbreviation></Journal><ArticleTitle>Potential human transmission of amyloid &#x3b2; pathology: surveillance and risks.</ArticleTitle><Pagination><StartPage>872</StartPage><EndPage>878</EndPage><MedlinePgn>872-878</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1474-4422(20)30238-6</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1474-4422(20)30238-6</ELocationID><Abstract><AbstractText>Studies in experimental animals show transmissibility of amyloidogenic proteins associated with prion diseases, Alzheimer's disease, Parkinson's disease, and other neurodegenerative diseases. Although these data raise potential concerns for public health, convincing evidence for human iatrogenic transmission only exists for prions and amyloid &#x3b2; after systemic injections of contaminated growth hormone extracts or dura mater grafts derived from cadavers. Even though these procedures are now obsolete, some reports raise the possibility of iatrogenic transmission of amyloid &#x3b2; through putatively contaminated neurosurgical equipment. Iatrogenic transmission of amyloid &#x3b2; might lead to amyloid deposition in the brain parenchyma and blood vessel walls, potentially resulting in cerebral amyloid angiopathy after several decades. Cerebral amyloid angiopathy can cause life-threatening brain haemorrhages; yet, there is no proof that the transmission of amyloid &#x3b2; can also lead to Alzheimer's dementia. Large, long-term epidemiological studies and sensitive, cost-efficient tools to detect amyloid are needed to better understand any potential routes of amyloid &#x3b2; transmission and to clarify whether other similar proteopathic seeds, such as tau or &#x3b1;-synuclein, can also be transferred iatrogenically.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lauwers</LastName><ForeName>Elsa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>VIB-KU Leuven Center for Brain and Disease Research, KU Leuven, Leuven, Belgium; Department of Neurosciences, Leuven Brain Institute, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lalli</LastName><ForeName>Giovanna</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>UK Dementia Research Institute, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brandner</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK; Division of Neuropathology, National Hospital for Neurology and Neurosurgery, University College London National Health Service Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Collinge</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Medical Research Council Prion Unit at UCL, Institute of Prion Diseases, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Compernolle</LastName><ForeName>Veerle</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Blood Services, Belgian Red Cross-Flanders, Mechelen, Belgium; Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duyckaerts</LastName><ForeName>Charles</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institut du Cerveau et de la Moelle &#xe9;pini&#xe8;re, Sorbonne University, INSERM, CNRS UMR, Paris, France; Laboratoire de Neuropathologie Raymond Escourolle, H&#xf4;pital de la Piti&#xe9;-Salp&#xea;tri&#xe8;re, Assistance Publique- H&#xf4;pitaux de Paris, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Edgren</LastName><ForeName>Gustaf</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Department of Cardiology, S&#xf6;dersjukhuset, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ha&#xef;k</LastName><ForeName>St&#xe9;phane</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institut du Cerveau et de la Moelle &#xe9;pini&#xe8;re, Sorbonne University, INSERM, CNRS UMR, Paris, France; Laboratoire de Neuropathologie Raymond Escourolle, H&#xf4;pital de la Piti&#xe9;-Salp&#xea;tri&#xe8;re, Assistance Publique- H&#xf4;pitaux de Paris, Paris, France; Cellule Nationale de R&#xe9;f&#xe9;rence des maladies de Creutzfeldt-Jakob, H&#xf4;pital de la Piti&#xe9;-Salp&#xea;tri&#xe8;re, Assistance Publique- H&#xf4;pitaux de Paris, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hardy</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>UK Dementia Research Institute, University College London, London, UK; Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK; Reta Lila Weston Institute, UCL Queen Square Institute of Neurology, University College London, London, UK; National Institute for Health Research University College London Hospitals Biomedical Research Centre, London, UK; Institute for Advanced Study, The Hong Kong University of Science and Technology, Hong Kong Special Administrative Region, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Helmy</LastName><ForeName>Adel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Clinical Neuroscience, Division of Neurosurgery, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ivinson</LastName><ForeName>Adrian J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>UK Dementia Research Institute, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jaunmuktane</LastName><ForeName>Zane</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, London, UK; Queen Square Brain Bank for Neurological Disorders, Queen Square Institute of Neurology, University College London, London, UK; Division of Neuropathology, National Hospital for Neurology and Neurosurgery, University College London National Health Service Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jucker</LastName><ForeName>Mathias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hertie-Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany; German Center for Neurodegenerative Diseases, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knight</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK; UK Dementia Research Institute, University of Edinburgh, Edinburgh, UK; National Creutzfeldt-Jakob Disease Research and Surveillance Unit, Western General Hospital, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lemmens</LastName><ForeName>Robin</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>VIB-KU Leuven Center for Brain and Disease Research, KU Leuven, Leuven, Belgium; Department of Neurosciences, Leuven Brain Institute, KU Leuven, Leuven, Belgium; Department of Neurology, University Hospitals Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>I-Chun</ForeName><Initials>IC</Initials><AffiliationInfo><Affiliation>UK Dementia Research Institute, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Love</LastName><ForeName>Seth</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mead</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Medical Research Council Prion Unit at UCL, Institute of Prion Diseases, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perry</LastName><ForeName>V Hugh</ForeName><Initials>VH</Initials><AffiliationInfo><Affiliation>UK Dementia Research Institute, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pickett</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Alzheimer's Society, London, London, UK; Epilepsy Research UK, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poppy</LastName><ForeName>Guy</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Biological Sciences, University of Southampton, Southampton, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Radford</LastName><ForeName>Sheena E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Astbury Centre for Structural Molecular Biology, School of Molecular and Cellular Biology, University of Leeds, Leeds, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rousseau</LastName><ForeName>Frederic</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>VIB-KU Leuven Center for Brain and Disease Research, KU Leuven, Leuven, Belgium; Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Routledge</LastName><ForeName>Carol</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Alzheimer's Research UK, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schiavo</LastName><ForeName>Giampietro</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>UK Dementia Research Institute, University College London, London, UK; Department of Neuromuscular Disorders, UCL Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schymkowitz</LastName><ForeName>Joost</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>VIB-KU Leuven Center for Brain and Disease Research, KU Leuven, Leuven, Belgium; Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Selkoe</LastName><ForeName>Dennis J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA; Harvard Medical School, Harvard University, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Colin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thal</LastName><ForeName>Dietmar R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Department of Imaging and Pathology, KU Leuven, Leuven, Belgium; Department of Pathology, University Hospitals Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Theys</LastName><ForeName>Tom</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, University Hospitals Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tiberghien</LastName><ForeName>Pierre</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Etablissement Fran&#xe7;ais du Sang, La Plaine St Denis, France; Unit&#xe9; Mixte de Recherche, INSERM, Universit&#xe9; de Franche-Comt&#xe9;, Besan&#xe7;on, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van den Burg</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>European Blood Alliance, Brussels, Belgium; Department of Transfusion Medicine, Sanquin, Amsterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vandekerckhove</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium; Blood Services, Belgian Red Cross-Flanders, Mechelen, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walton</LastName><ForeName>Clare</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Alzheimer's Society, London, London, UK; Multiple Sclerosis International Federation, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zaaijer</LastName><ForeName>Hans L</ForeName><Initials>HL</Initials><AffiliationInfo><Affiliation>Department of Blood-borne Infections, Sanquin, Amsterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>UK Dementia Research Institute, University College London, London, UK; Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK; Department of Psychiatry and Neurochemistry, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Strooper</LastName><ForeName>Bart</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>VIB-KU Leuven Center for Brain and Disease Research, KU Leuven, Leuven, Belgium; Department of Neurosciences, Leuven Brain Institute, KU Leuven, Leuven, Belgium; UK Dementia Research Institute, University College London, London, UK. Electronic address: b.strooper@ukdri.ucl.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/L501542/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_U123160657</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G-0907</GrantID><Acronym>PUK_</Acronym><Agency>Parkinson's UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_U123160651</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0701075</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_UU_00024/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L016400/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_UP_1604/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_UU_00024/8</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0802251</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_UU_00024/9</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/N026004/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0901254</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0400713</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>09</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Neurol</MedlineTA><NlmUniqueID>101139309</NlmUniqueID><ISSNLinking>1474-4422</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Neurol. 2020 Oct;19(10):802-803. doi: 10.1016/S1474-4422(20)30274-X.</RefSource><PMID Version="1">32949533</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Lancet Neurol. 2020 Nov;19(11):e10. doi: 10.1016/S1474-4422(20)30372-0.</RefSource><PMID Version="1">33098805</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007562" MajorTopicYN="N">Creutzfeldt-Jakob Syndrome</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000635" MajorTopicYN="N">transmission</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011159" MajorTopicYN="Y">Population Surveillance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>3</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>5</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>5</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>19</Day><Hour>20</Hour><Minute>8</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32949547</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(20)30238-6</ArticleId><ArticleId IdType="pii">S1474-4422(20)30238-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32971232</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>25</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-953X</ISSN><JournalIssue CitedMedium="Internet"><Volume>146</Volume><PubDate><Year>2020</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Neurobiology of disease</Title><ISOAbbreviation>Neurobiol Dis</ISOAbbreviation></Journal><ArticleTitle>How specific are the conformation-specific &#x3b1;-synuclein antibodies? Characterization and validation of 16 &#x3b1;-synuclein conformation-specific antibodies using well-characterized preparations of &#x3b1;-synuclein monomers, fibrils and oligomers with distinct structures and morphology.</ArticleTitle><Pagination><StartPage>105086</StartPage><MedlinePgn>105086</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.nbd.2020.105086</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0969-9961(20)30361-2</ELocationID><Abstract><AbstractText>Increasing evidence suggests that alpha-synuclein (&#x3b1;-syn) oligomers are obligate intermediates in the pathway involved in &#x3b1;-syn fibrillization and Lewy body (LB) formation, and may also accumulate within LBs in Parkinson's disease (PD) and other synucleinopathies. Therefore, the development of tools and methods to detect and quantify &#x3b1;-syn oligomers has become increasingly crucial for mechanistic studies to understand their role in PD, and to develop new diagnostic methods and therapies for PD and other synucleinopathies. The majority of these tools and methods rely primarily on the use of aggregation state-specific or conformation-specific antibodies. Given the impact of the data and knowledge generated using these antibodies on shaping the foundation and directions of &#x3b1;-syn and PD research, it is crucial that these antibodies are thoroughly characterized, and their specificity or ability to capture diverse &#x3b1;-syn species is tested and validated. Herein, we describe an antibody characterization and validation pipeline that allows a systematic investigation of the specificity of &#x3b1;-syn antibodies using well-defined and well-characterized preparations of various &#x3b1;-syn species, including monomers, fibrils, and different oligomer preparations that are characterized by distinct morphological, chemical and secondary structure properties. This pipeline was used to characterize 18 &#x3b1;-syn antibodies, 16 of which have been reported as conformation- or oligomer-specific antibodies, using an array of techniques, including immunoblot analysis (slot blot and Western blot), a digital ELISA assay using single molecule array technology and surface plasmon resonance. Our results show that i) none of the antibodies tested are specific for one particular type of &#x3b1;-syn species, including monomers, oligomers or fibrils; ii) all antibodies that were reported to be oligomer-specific also recognized fibrillar &#x3b1;-syn; and iii) a few antibodies showed high specificity for oligomers and fibrils but did not bind to monomers. These findings suggest that the great majority of &#x3b1;-syn aggregate-specific antibodies do not differentiate between oligomers and fibrils, thus highlighting the importance of exercising caution when interpreting results obtained using these antibodies. Our results also underscore the critical importance of the characterization and validation of antibodies before their use in mechanistic studies and as diagnostic tools or therapeutic agents. This will not only improve the quality and reproducibility of research and reduce costs but will also reduce the number of therapeutic antibody failures in the clinic.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Senthil T</ForeName><Initials>ST</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular and Chemical Biology of Neurodegeneration, Brain Mind Institute, EPFL, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jagannath</LastName><ForeName>Somanath</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular and Chemical Biology of Neurodegeneration, Brain Mind Institute, EPFL, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Francois</LastName><ForeName>Cindy</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>ADx NeuroSciences, Technologiepark 94, Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vanderstichele</LastName><ForeName>Hugo</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>ADx NeuroSciences, Technologiepark 94, Ghent, Belgium; Biomarkable, Gent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stoops</LastName><ForeName>Erik</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>ADx NeuroSciences, Technologiepark 94, Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lashuel</LastName><ForeName>Hilal A</ForeName><Initials>HA</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular and Chemical Biology of Neurodegeneration, Brain Mind Institute, EPFL, Switzerland. Electronic address: hilal.lashuel@epfl.ch.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>09</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurobiol Dis</MedlineTA><NlmUniqueID>9500169</NlmUniqueID><ISSNLinking>0969-9961</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000906">Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Binding specificity</Keyword><Keyword MajorTopicYN="N">Conformational antibodies</Keyword><Keyword MajorTopicYN="N">Oligomers</Keyword><Keyword MajorTopicYN="N">Parkinson's disease</Keyword><Keyword MajorTopicYN="N">&#x3b1;-Synuclein</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>6</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>9</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>24</Day><Hour>20</Hour><Minute>10</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32971232</ArticleId><ArticleId IdType="doi">10.1016/j.nbd.2020.105086</ArticleId><ArticleId IdType="pii">S0969-9961(20)30361-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32989305</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>09</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1545-9985</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>12</Issue><PubDate><Year>2020</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Nature structural &amp; molecular biology</Title><ISOAbbreviation>Nat Struct Mol Biol</ISOAbbreviation></Journal><ArticleTitle>Kinetic fingerprints differentiate the mechanisms of action of anti-A&#x3b2; antibodies.</ArticleTitle><Pagination><StartPage>1125</StartPage><EndPage>1133</EndPage><MedlinePgn>1125-1133</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41594-020-0505-6</ELocationID><Abstract><AbstractText>The amyloid cascade hypothesis, according to which the self-assembly of amyloid-&#x3b2; peptide (A&#x3b2;) is a causative process in Alzheimer's disease, has driven many therapeutic efforts for the past 20&#x2009;years. Failures of clinical trials investigating A&#x3b2;-targeted therapies have been interpreted as evidence against this hypothesis, irrespective of the characteristics and mechanisms of action of the therapeutic agents, which are highly challenging to assess. Here, we combine kinetic analyses with quantitative binding measurements to address the mechanism of action of four clinical stage anti-A&#x3b2; antibodies, aducanumab, gantenerumab, bapineuzumab and solanezumab. We quantify the influence of these antibodies on the aggregation kinetics and on the production of oligomeric aggregates and link these effects to the affinity and stoichiometry of each antibody for monomeric and fibrillar forms of A&#x3b2;. Our results reveal that, uniquely among these four antibodies, aducanumab dramatically reduces the flux of A&#x3b2; oligomers.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Linse</LastName><ForeName>Sara</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-9629-7109</Identifier><AffiliationInfo><Affiliation>Biochemistry and Structural Biology, Lund University, Lund, Sweden. sara.linse@biochemistry.lu.se.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scheidt</LastName><ForeName>Tom</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-0185-7730</Identifier><AffiliationInfo><Affiliation>Centre for Misfolding Diseases, Department of Chemistry, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bernfur</LastName><ForeName>Katja</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Biochemistry and Structural Biology, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vendruscolo</LastName><ForeName>Michele</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-3616-1610</Identifier><AffiliationInfo><Affiliation>Centre for Misfolding Diseases, Department of Chemistry, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dobson</LastName><ForeName>Christopher M</ForeName><Initials>CM</Initials><Identifier Source="ORCID">0000-0002-5445-680X</Identifier><AffiliationInfo><Affiliation>Centre for Misfolding Diseases, Department of Chemistry, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Samuel I A</ForeName><Initials>SIA</Initials><AffiliationInfo><Affiliation>Wren Therapeutics Ltd, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sileikis</LastName><ForeName>Eimantas</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-2849-5186</Identifier><AffiliationInfo><Affiliation>Biochemistry and Structural Biology, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lundqvist</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Biochemistry and Structural Biology, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qian</LastName><ForeName>Fang</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Biogen, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Malley</LastName><ForeName>Tiernan</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-3538-0731</Identifier><AffiliationInfo><Affiliation>Biogen, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bussiere</LastName><ForeName>Thierry</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-6818-4876</Identifier><AffiliationInfo><Affiliation>Biogen, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weinreb</LastName><ForeName>Paul H</ForeName><Initials>PH</Initials><Identifier Source="ORCID">0000-0002-0802-0052</Identifier><AffiliationInfo><Affiliation>Biogen, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Catherine K</ForeName><Initials>CK</Initials><AffiliationInfo><Affiliation>Centre for Misfolding Diseases, Department of Chemistry, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meisl</LastName><ForeName>Georg</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-6562-7715</Identifier><AffiliationInfo><Affiliation>Centre for Misfolding Diseases, Department of Chemistry, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Devenish</LastName><ForeName>Sean R A</ForeName><Initials>SRA</Initials><AffiliationInfo><Affiliation>Fluidic Analytics, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knowles</LastName><ForeName>Tuomas P J</ForeName><Initials>TPJ</Initials><Identifier Source="ORCID">0000-0002-7879-0140</Identifier><AffiliationInfo><Affiliation>Centre for Misfolding Diseases, Department of Chemistry, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cavendish Laboratory, Department of Physics, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hansson</LastName><ForeName>Oskar</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0001-8467-7286</Identifier><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Clinic, Sk&#xe5;ne University Hospital, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>Dryad</DataBankName><AccessionNumberList><AccessionNumber>10.5061/dryad.79cnp5hsn</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>09</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Struct Mol Biol</MedlineTA><NlmUniqueID>101186374</NlmUniqueID><ISSNLinking>1545-9985</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D066329">Protein Aggregates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>105J35OE21</RegistryNumber><NameOfSubstance UI="C000600266">aducanumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>4DF060P933</RegistryNumber><NameOfSubstance UI="C571128">gantenerumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>5D6PWO0333</RegistryNumber><NameOfSubstance UI="C550616">solanezumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>NC11WKO35D</RegistryNumber><NameOfSubstance UI="C545458">bapineuzumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010449" MajorTopicYN="N">Peptide Mapping</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066329" MajorTopicYN="N">Protein Aggregates</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011487" MajorTopicYN="N">Protein Conformation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>3</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>8</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>29</Day><Hour>5</Hour><Minute>35</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32989305</ArticleId><ArticleId IdType="doi">10.1038/s41594-020-0505-6</ArticleId><ArticleId IdType="pii">10.1038/s41594-020-0505-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardy, J. &amp; Higgins, G. Alzheimer&#x2019;s disease: the amyloid cascade hypothesis. Science 256, 184&#x2013;185 (1992).</Citation><ArticleIdList><ArticleId IdType="pubmed">1566067</ArticleId><ArticleId IdType="doi">10.1126/science.1566067</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe, D. J. &amp; Hardy, J. The amyloid hypothesis of Alzheimer&#x2019;s disease at 25 years. EMBO Mol. Med. 8, 595&#x2013;608 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27025652</ArticleId><ArticleId IdType="pmc">4888851</ArticleId><ArticleId IdType="doi">10.15252/emmm.201606210</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe4;rd, T. &amp; Lendel, C. Inhibition of amyloid formation. J. Mol. Biol. 421, 441&#x2013;465 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22244855</ArticleId><ArticleId IdType="doi">10.1016/j.jmb.2011.12.062</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh, D. M. et al. Naturally secreted oligomers of amyloid &#x3b2; protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535&#x2013;539 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId><ArticleId IdType="doi">10.1038/416535a</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen, S. I. A. et al. A molecular chaperone breaks the catalytic cycle that generates toxic A&#x3b2; oligomers. Nat. Struct. Mol. Biol. 22, 207&#x2013;213 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25686087</ArticleId><ArticleId IdType="pmc">4595974</ArticleId><ArticleId IdType="doi">10.1038/nsmb.2971</ArticleId></ArticleIdList></Reference><Reference><Citation>Benilova, I., Karran, E. &amp; De Strooper, B. The toxic A&#x3b2; oligomer and Alzheimer&#x2019;s disease: an emperor in need of clothes. Nat. Neurosci. 15, 349&#x2013;357 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22286176</ArticleId><ArticleId IdType="doi">10.1038/nn.3028</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, S. J. et al. Towards an understanding of amyloid-&#x3b2; oligomers: characterization, toxicity mechanisms, and inhibitors. Chem. Soc. Rev. 46, 310&#x2013;323 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27878186</ArticleId><ArticleId IdType="doi">10.1039/C6CS00731G</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiss, A. B. et al. Amyloid toxicity in Alzheimer&#x2019;s disease. Rev. Neurosci. 29, 613&#x2013;627 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29447116</ArticleId><ArticleId IdType="doi">10.1515/revneuro-2017-0063</ArticleId></ArticleIdList></Reference><Reference><Citation>Arosio, P. et al. Kinetic analysis reveals the diversity of microscopic mechanisms through which molecular chaperones suppress amyloid formation. Nat. Commun. 7, 10948 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27009901</ArticleId><ArticleId IdType="pmc">4820785</ArticleId><ArticleId IdType="doi">10.1038/ncomms10948</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen, S. I. et al. Proliferation of amyloid-&#x3b2;42 aggregates occurs through a secondary nucleation mechanism. Proc. Natl Acad. Sci. USA 110, 9758&#x2013;9763 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23703910</ArticleId><ArticleId IdType="doi">10.1073/pnas.1218402110</ArticleId><ArticleId IdType="pmc">3683769</ArticleId></ArticleIdList></Reference><Reference><Citation>Aprile, F. A. et al. Selective targeting of primary and secondary nucleation pathways in A&#x3b2;42 aggregation using a rational antibody scanning method. Sci. Adv. 3, e1700488 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28691099</ArticleId><ArticleId IdType="pmc">5479649</ArticleId><ArticleId IdType="doi">10.1126/sciadv.1700488</ArticleId></ArticleIdList></Reference><Reference><Citation>Munke, A. et al. Phage display and kinetic selection of antibodies that specifically inhibit amyloid self-replication. Proc. Natl Acad. Sci. USA 114, 6444&#x2013;6449 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28584111</ArticleId><ArticleId IdType="doi">10.1073/pnas.1700407114</ArticleId><ArticleId IdType="pmc">5488933</ArticleId></ArticleIdList></Reference><Reference><Citation>Sevigny, J. et al. The antibody aducanumab reduces A&#x3b2; plaques in Alzheimer&#x2019;s disease. Nature 537, 50&#x2013;56 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27582220</ArticleId><ArticleId IdType="doi">10.1038/nature19323</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohrmann, B. et al. Gantenerumab: a novel human anti-A&#x3b2; antibody demonstrates sustained cerebral amyloid-&#x3b2; binding and elicits cell-mediated removal of human amyloid-&#x3b2;. J. Alzheimer&#x2019;s Dis. 28, 49 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2011-110977</ArticleId></ArticleIdList></Reference><Reference><Citation>Bard, F. et al. Peripherally administered antibodies against amyloid &#x3b2; peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6, 916&#x2013;919 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10932230</ArticleId><ArticleId IdType="doi">10.1038/78682</ArticleId></ArticleIdList></Reference><Reference><Citation>Hettmann, T. et al. Development of the clinical candidate PBD-C06, a humanized pGlu3-A&#x3b2;-specific antibody against Alzheimer&#x2019;s disease with reduced complement activation. Sci. Rep. 10, 3294 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32094456</ArticleId><ArticleId IdType="pmc">7040040</ArticleId><ArticleId IdType="doi">10.1038/s41598-020-60319-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Crehan, H. et al. Effector function of anti-pyroglutamate-3 A&#x3b2; antibodies affects cognitive benefit, glial activation and amyloid clearance in Alzheimer&#x2019;s-like mice. Alzheimers Res Ther. 12, 12 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31931873</ArticleId><ArticleId IdType="pmc">6958628</ArticleId><ArticleId IdType="doi">10.1186/s13195-019-0579-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Budd Haeberlein, S. et al. Topline results from Phase 3 aducanumab studies. In Clinical Trials on Alzheimer&#x2019;s Disease (CTAD) San Diego, CA (2019).</Citation></Reference><Reference><Citation>Arndt, J. W. et al. Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-&#x3b2;. Sci. Rep. 8, 6412 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29686315</ArticleId><ArticleId IdType="pmc">5913127</ArticleId><ArticleId IdType="doi">10.1038/s41598-018-24501-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Lendel, C. et al. A hexameric peptide barrel as building block of amyloid-&#x3b2; protofibrils. Angew. Chem. Int. Ed. Engl. 53, 12756&#x2013;12760 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25256598</ArticleId><ArticleId IdType="doi">10.1002/anie.201406357</ArticleId></ArticleIdList></Reference><Reference><Citation>Colvin, M. T. et al. Atomic resolution structure of monomorphic a&#x3b2;42 amyloid fibrils. J. Am. Chem. Soc. 138, 9663&#x2013;9674 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27355699</ArticleId><ArticleId IdType="pmc">5389415</ArticleId><ArticleId IdType="doi">10.1021/jacs.6b05129</ArticleId></ArticleIdList></Reference><Reference><Citation>W&#xe4;lti, M. A. et al. Atomic-resolution structure of a disease-relevant A&#x3b2;(1&#x2013;42) amyloid fibril. Proc. Natl Acad. Sci. USA 113, E4976&#x2013;E4984 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27469165</ArticleId><ArticleId IdType="doi">10.1073/pnas.1600749113</ArticleId><ArticleId IdType="pmc">5003276</ArticleId></ArticleIdList></Reference><Reference><Citation>Br&#xe4;nnstr&#xf6;m, K. et al. A generic method for design of oligomer-specific antibodies. PLoS ONE 9, e90857 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24618582</ArticleId><ArticleId IdType="pmc">3949727</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0090857</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostrowitzki, S. et al. SCarlet RoAD investigators, a phase III randomized trial of gantenerumab in prodromal Alzheimer&#x2019;s disease. Alzheimers Res. Ther. 9, 95 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29221491</ArticleId><ArticleId IdType="pmc">5723032</ArticleId><ArticleId IdType="doi">10.1186/s13195-017-0318-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Crespi, G. A., Hermans, S. J., Parker, M. W. &amp; Miles, L. A. Molecular basis for mid-region amyloid-&#x3b2; capture by leading Alzheimer&#x2019;s disease immunotherapies. Sci. Rep. 5, 9649 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25880481</ArticleId><ArticleId IdType="pmc">4549621</ArticleId><ArticleId IdType="doi">10.1038/srep09649</ArticleId></ArticleIdList></Reference><Reference><Citation>Salloway, S. et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer&#x2019;s disease. N. Engl. J. Med. 370, 322&#x2013;333 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24450891</ArticleId><ArticleId IdType="pmc">4159618</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1304839</ArticleId></ArticleIdList></Reference><Reference><Citation>Honig, L. S. et al. Trial of solanezumab for mild dementia due to Alzheimer&#x2019;s disease. New. Eng. Med. 378, 321&#x2013;330 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1705971</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman, R. J. et al. DIAN-TU pharma consortium for the dominantly inherited Alzheimer Network. The DIAN-TU next generation Alzheimer&#x2019;s prevention trial: adaptive design and disease progression model. Alzheimer&#x2019;s Dement. 13, 8&#x2013;19 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.07.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Knowles, T. P. et al. An analytical solution to the kinetics of breakable filament assembly. Science 326, 1533&#x2013;1537 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">20007899</ArticleId><ArticleId IdType="doi">10.1126/science.1178250</ArticleId></ArticleIdList></Reference><Reference><Citation>Habchi, J. et al. An anticancer drug suppresses the primary nucleation reaction that initiates the production of the toxic A&#x3b2;42 aggregates linked with Alzheimer&#x2019;s disease. Sci. Adv. 2, e1501244 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26933687</ArticleId><ArticleId IdType="pmc">4758743</ArticleId><ArticleId IdType="doi">10.1126/sciadv.1501244</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xe5;nsson, C. et al. Interaction of the molecular chaperone DNAJB6 with growing amyloid-beta 42 (A&#x3b2;42) aggregates leads to sub-stoichiometric inhibition of amyloid formation. J. Biol. Chem. 289, 31066&#x2013;31076 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25217638</ArticleId><ArticleId IdType="pmc">4223311</ArticleId><ArticleId IdType="doi">10.1074/jbc.M114.595124</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen, S. I., Vendruscolo, M., Dobson, C. M. &amp; Knowles, T. P. From macroscopic measurements to microscopic mechanisms of protein aggregation. J. Mol. Biol. 421, 160&#x2013;171 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22406275</ArticleId><ArticleId IdType="doi">10.1016/j.jmb.2012.02.031</ArticleId></ArticleIdList></Reference><Reference><Citation>Arosio, P., Knowles, T. P. &amp; Linse, S. On the lag phase in amyloid fibril formation. Phys. Chem. Chem. Phys. 17, 7606&#x2013;7618 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25719972</ArticleId><ArticleId IdType="pmc">4498454</ArticleId><ArticleId IdType="doi">10.1039/C4CP05563B</ArticleId></ArticleIdList></Reference><Reference><Citation>Meisl, G. et al. Molecular mechanisms of protein aggregation from global fitting of kinetic models. Nat. Protoc. 11, 252&#x2013;272 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26741409</ArticleId><ArticleId IdType="doi">10.1038/nprot.2016.010</ArticleId></ArticleIdList></Reference><Reference><Citation>Padayachee, E. R. et al. Cerebrospinal fluid-induced retardation of amyloid &#x3b2; aggregation correlates with Alzheimer&#x2019;s disease and the APOE &#x3b5;4 allele. Brain Res. 1651, 11&#x2013;16 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27653981</ArticleId><ArticleId IdType="pmc">5090044</ArticleId><ArticleId IdType="doi">10.1016/j.brainres.2016.09.022</ArticleId></ArticleIdList></Reference><Reference><Citation>Frankel, R. et al. Autocatalytic amplification of Alzheimer-associated A&#x3b2;42 peptide aggregation in human cerebrospinal fluid. Nat. Commun. Biol. 2, 365 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-019-0612-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Michaels, T. C. T. et al. Dynamics of oligomer populations formed during the aggregation of Alzheimer&#x2019;s A&#x3b2;42 peptide. Nat. Chem. 12, 445&#x2013;451 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32284577</ArticleId><ArticleId IdType="doi">10.1038/s41557-020-0452-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Arosio, P. et al. Microfluidic diffusion analysis of the sizes and interactions of proteins under native solution conditions. ACS Nano 10, 333&#x2013;341 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26678709</ArticleId><ArticleId IdType="doi">10.1021/acsnano.5b04713</ArticleId></ArticleIdList></Reference><Reference><Citation>Yates, E. V. et al. Latent analysis of unmodified biomolecules and their complexes in solution with attomole detection sensitivity. Nat. Chem. 7, 802&#x2013;809 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26391079</ArticleId><ArticleId IdType="doi">10.1038/nchem.2344</ArticleId></ArticleIdList></Reference><Reference><Citation>Panza, F. et al. Are antibodies directed against amyloid-&#x3b2; (A&#x3b2;) oligomers the last call for the A&#x3b2; hypothesis of Alzheimer&#x2019;s disease? Immunotherapy 11, 3&#x2013;6 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30702009</ArticleId><ArticleId IdType="doi">10.2217/imt-2018-0119</ArticleId></ArticleIdList></Reference><Reference><Citation>Panza, F., Lozupone, M., Logroscino, G. &amp; Imbimbo, B. P. A critical appraisal of amyloid-&#x3b2;-targeting therapies for Alzheimer disease. Nat. Rev. Neurol. 15, 73&#x2013;88 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30610216</ArticleId><ArticleId IdType="doi">10.1038/s41582-018-0116-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, Y. et al. Lessons from anti-amyloid-&#x3b2; immunotherapies in Alzheimer disease: aiming at a moving target. Neurodegener. Dis. 17, 242&#x2013;250 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28787714</ArticleId><ArticleId IdType="doi">10.1159/000478741</ArticleId></ArticleIdList></Reference><Reference><Citation>Portelius, E., Westman-Brinkmalm, A., Zetterberg, H. &amp; Blennow, K. Determination of &#x3b2;-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry. J. Proteome Res 5, 1010&#x2013;1016 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16602710</ArticleId><ArticleId IdType="doi">10.1021/pr050475v</ArticleId></ArticleIdList></Reference><Reference><Citation>Kummer, M. P. &amp; Heneka, T. Truncated and modified amyloid-beta species. Alzheimers Res. Ther. 6, 28 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25031638</ArticleId><ArticleId IdType="pmc">4055046</ArticleId><ArticleId IdType="doi">10.1186/alzrt258</ArticleId></ArticleIdList></Reference><Reference><Citation>Brinkmalm, G. et al. Identification of neurotoxic cross-linked amyloid-&#x3b2; dimers in the Alzheimer&#x2019;s brain. Brain 142, 1441&#x2013;1457 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31032851</ArticleId><ArticleId IdType="pmc">6487330</ArticleId><ArticleId IdType="doi">10.1093/brain/awz066</ArticleId></ArticleIdList></Reference><Reference><Citation>Koradi, R., Billeter, M. &amp; W&#xfc;thrich, K. MOLMOL: a program for display and analysis of macromolecular structures. J. Mol. Graph. 14, 29&#x2013;32 (1996).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0263-7855(96)00009-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaar, W. et al. Refolding of N<sup>pro</sup> fusion proteins. Biotechnol. Bioeng. 104, 774&#x2013;784 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19591193</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh, D. M. et al. A facile method for expression and purification of the Alzheimer&#x2019;s disease-associated amyloid &#x3b2;-peptide. FEBS J. 276, 1266&#x2013;1281 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19175671</ArticleId><ArticleId IdType="pmc">2702495</ArticleId><ArticleId IdType="doi">10.1111/j.1742-4658.2008.06862.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Panza, F. et al. Bapineuzumab: anti-&#x3b2;-amyloid monoclonal antibodies for the treatment of Alzheimer&#x2019;s disease. Immunother. 2, 767&#x2013;782 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/imt.10.80</ArticleId></ArticleIdList></Reference><Reference><Citation>Willander, H. et al. BRICHOS domains efficiently delay fibrillation of amyloid &#x3b2;-peptide. J. Biol. Chem. 287, 31608&#x2013;31617 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22801430</ArticleId><ArticleId IdType="pmc">3438992</ArticleId><ArticleId IdType="doi">10.1074/jbc.M112.393157</ArticleId></ArticleIdList></Reference><Reference><Citation>Johansson, H., Nordling, K., Weaver, T. E. &amp; Johansson, J. The Brichos domain-containing C-terminal part of pro-surfactant protein C binds to an unfolded poly-Val transmembrane segment. J. Biol. Chem. 281, 21032&#x2013;21039 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16709565</ArticleId><ArticleId IdType="doi">10.1074/jbc.M603001200</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasir, I., Linse, S. &amp; Cabaleiro-Lago, C. Fluorescent filter-trap assay for amyloid fibril formation kinetics in complex solutions. ACS Chem. Neurosci. 6, 1436&#x2013;1444 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25946560</ArticleId><ArticleId IdType="doi">10.1021/acschemneuro.5b00104</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32989152</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>117</Volume><Issue>41</Issue><PubDate><Year>2020</Year><Month>Oct</Month><Day>13</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Single-nucleus transcriptome analysis reveals dysregulation of angiogenic endothelial cells and neuroprotective glia in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>25800</StartPage><EndPage>25809</EndPage><MedlinePgn>25800-25809</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.2008762117</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is the most common form of dementia but has no effective treatment. A comprehensive investigation of cell type-specific responses and cellular heterogeneity in AD is required to provide precise molecular and cellular targets for therapeutic development. Accordingly, we perform single-nucleus transcriptome analysis of 169,496 nuclei from the prefrontal cortical samples of AD patients and normal control (NC) subjects. Differential analysis shows that the cell type-specific transcriptomic changes in AD are associated with the disruption of biological processes including angiogenesis, immune activation, synaptic signaling, and myelination. Subcluster analysis reveals that compared to NC brains, AD brains contain fewer neuroprotective astrocytes and oligodendrocytes. Importantly, our findings show that a subpopulation of angiogenic endothelial cells is induced in the brain in patients with AD. These angiogenic endothelial cells exhibit increased expression of angiogenic growth factors and their receptors (i.e., <i>EGFL7</i>, <i>FLT1</i>, and <i>VWF</i>) and antigen-presentation machinery (i.e., <i>B2M</i> and <i>HLA-E</i>). This suggests that these endothelial cells contribute to angiogenesis and immune response in AD pathogenesis. Thus, our comprehensive molecular profiling of brain samples from patients with AD reveals previously unknown molecular changes as well as cellular targets that potentially underlie the functional dysregulation of endothelial cells, astrocytes, and oligodendrocytes in AD, providing important insights for therapeutic development.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 the Author(s). Published by PNAS.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lau</LastName><ForeName>Shun-Fat</ForeName><Initials>SF</Initials><AffiliationInfo><Affiliation>Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, The Hong Kong University of Science and Technology, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Han</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, The Hong Kong University of Science and Technology, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Amy K Y</ForeName><Initials>AKY</Initials><AffiliationInfo><Affiliation>Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, The Hong Kong University of Science and Technology, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Brain Science, Disease and Drug Development, Hong Kong University of Science and Technology Shenzhen Research Institute, Shenzhen-Hong Kong Institute of Brain Science, 518057 Shenzhen, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ip</LastName><ForeName>Nancy Y</ForeName><Initials>NY</Initials><Identifier Source="ORCID">0000-0002-2763-8907</Identifier><AffiliationInfo><Affiliation>Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, The Hong Kong University of Science and Technology, Hong Kong, China; boip@ust.hk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Brain Science, Disease and Drug Development, Hong Kong University of Science and Technology Shenzhen Research Institute, Shenzhen-Hong Kong Institute of Brain Science, 518057 Shenzhen, Guangdong, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>09</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002467" MajorTopicYN="N">Cell Nucleus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042783" MajorTopicYN="N">Endothelial Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009457" MajorTopicYN="N">Neuroglia</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017397" MajorTopicYN="N">Prefrontal Cortex</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059010" MajorTopicYN="N">Single-Cell Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059467" MajorTopicYN="N">Transcriptome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">angiogenesis</Keyword><Keyword MajorTopicYN="N">myelination</Keyword><Keyword MajorTopicYN="N">neurodegenerative diseases</Keyword><Keyword MajorTopicYN="N">synapse</Keyword><Keyword MajorTopicYN="N">synaptic signaling</Keyword></KeywordList><CoiStatement>The authors declare no competing interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>29</Day><Hour>5</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>9</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32989152</ArticleId><ArticleId IdType="pmc">PMC7568283</ArticleId><ArticleId IdType="doi">10.1073/pnas.2008762117</ArticleId><ArticleId IdType="pii">2008762117</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Reitz C., Brayne C., Mayeux R., Epidemiology of Alzheimer disease. Nat. Rev. Neurol. 7, 137&#x2013;152 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3339565</ArticleId><ArticleId IdType="pubmed">21304480</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu W. Y., Wang X., Ip N. Y., Targeting neuroinflammation as a therapeutic strategy for Alzheimer&#x2019;s disease: Mechanisms, drug candidates, and new opportunities. ACS Chem. Neurosci. 10, 872&#x2013;879 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30221933</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder E. M. et al. ., Regulation of NMDA receptor trafficking by amyloid-&#x3b2;. Nat. Neurosci. 8, 1051&#x2013;1058 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16025111</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Fu A. K. Y., Ip N. Y., Synaptic dysfunction in Alzheimer&#x2019;s disease: Mechanisms and therapeutic strategies. Pharmacol. Ther. 195, 186&#x2013;198 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30439458</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheff S. W., Price D. A., Schmitt F. A., Mufson E. J., Hippocampal synaptic loss in early Alzheimer&#x2019;s disease and mild cognitive impairment. Neurobiol. Aging 27, 1372&#x2013;1384 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16289476</ArticleId></ArticleIdList></Reference><Reference><Citation>Hynd M. R., Scott H. L., Dodd P. R., Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer&#x2019;s disease. Neurochem. Int. 45, 583&#x2013;595 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15234100</ArticleId></ArticleIdList></Reference><Reference><Citation>Parkhurst C. N. et al. ., Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor. Cell 155, 1596&#x2013;1609 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4033691</ArticleId><ArticleId IdType="pubmed">24360280</ArticleId></ArticleIdList></Reference><Reference><Citation>Christopherson K. S. et al. ., Thrombospondins are astrocyte-secreted proteins that promote CNS synaptogenesis. Cell 120, 421&#x2013;433 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15707899</ArticleId></ArticleIdList></Reference><Reference><Citation>Liddelow S. A. et al. ., Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541, 481&#x2013;487 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5404890</ArticleId><ArticleId IdType="pubmed">28099414</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic B. V., Neurovascular pathways to neurodegeneration in Alzheimer&#x2019;s disease and other disorders. Nat. Rev. Neurosci. 12, 723&#x2013;738 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4036520</ArticleId><ArticleId IdType="pubmed">22048062</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Z., Nelson A. R., Betsholtz C., Zlokovic B. V., Establishment and dysfunction of the blood-brain barrier. Cell 163, 1064&#x2013;1078 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4655822</ArticleId><ArticleId IdType="pubmed">26590417</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H. et al. ., Single-cell transcriptomic analysis of Alzheimer&#x2019;s disease. Nature 570, 332&#x2013;337 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6865822</ArticleId><ArticleId IdType="pubmed">31042697</ArticleId></ArticleIdList></Reference><Reference><Citation>Grubman A. et al. ., A single-cell atlas of entorhinal cortex from individuals with Alzheimer&#x2019;s disease reveals cell-type-specific gene expression regulation. Nat. Neurosci. 22, 2087&#x2013;2097 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31768052</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X. et al. ., Deciphering cellular transcriptional alterations in Alzheimer&#x2019;s disease brains. Mol. Neurodegener. 15, 38 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7359236</ArticleId><ArticleId IdType="pubmed">32660529</ArticleId></ArticleIdList></Reference><Reference><Citation>Habib N. et al. ., Massively parallel single-nucleus RNA-seq with DroNc-seq. Nat. Methods 14, 955&#x2013;958 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5623139</ArticleId><ArticleId IdType="pubmed">28846088</ArticleId></ArticleIdList></Reference><Reference><Citation>Stogsdill J. A. et al. ., Astrocytic neuroligins control astrocyte morphogenesis and synaptogenesis. Nature 551, 192&#x2013;197 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5796651</ArticleId><ArticleId IdType="pubmed">29120426</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xfc;dhof T. C., Synaptic neurexin complexes: A molecular code for the logic of neural circuits. Cell 171, 745&#x2013;769 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5694349</ArticleId><ArticleId IdType="pubmed">29100073</ArticleId></ArticleIdList></Reference><Reference><Citation>Narayanan M. et al. ., Common dysregulation network in the human prefrontal cortex underlies two neurodegenerative diseases. Mol. Syst. Biol. 10, 743 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4299500</ArticleId><ArticleId IdType="pubmed">25080494</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster J. A. et al. .; NACC-Neuropathology Group , Genetic control of human brain transcript expression in Alzheimer disease. Am. J. Hum. Genet. 84, 445&#x2013;458 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2667989</ArticleId><ArticleId IdType="pubmed">19361613</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris H. E., Andersson U., Pisetsky D. S., HMGB1: A multifunctional alarmin driving autoimmune and inflammatory disease. Nat. Rev. Rheumatol. 8, 195&#x2013;202 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22293756</ArticleId></ArticleIdList></Reference><Reference><Citation>Marques S. et al. ., Oligodendrocyte heterogeneity in the mouse juvenile and adult central nervous system. Science 352, 1326&#x2013;1329 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5221728</ArticleId><ArticleId IdType="pubmed">27284195</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#xe4;kel S. et al. ., Altered human oligodendrocyte heterogeneity in multiple sclerosis. Nature 566, 543&#x2013;547 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6544546</ArticleId><ArticleId IdType="pubmed">30747918</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S. et al. ., Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 352, 712&#x2013;716 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5094372</ArticleId><ArticleId IdType="pubmed">27033548</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng M., Sabatini B. L., S&#xfc;dhof T. C., Synapses and Alzheimer&#x2019;s disease. Cold Spring Harb. Perspect. Biol. 4, 10 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3331702</ArticleId><ArticleId IdType="pubmed">22491782</ArticleId></ArticleIdList></Reference><Reference><Citation>Tremblay M. &#xc8;., Sierra A., Microglia in Health and Disease, (Springer, 2014).</Citation></Reference><Reference><Citation>El Gaamouch F. et al. ., VGF-derived peptide TLQP-21 modulates microglial function through C3aR1 signaling pathways and reduces neuropathology in 5xFAD mice. Mol. Neurodegener. 15, 4 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6954537</ArticleId><ArticleId IdType="pubmed">31924226</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O. et al. ., Identification of a unique TGF-&#x3b2;-dependent molecular and functional signature in microglia. Nat. Neurosci. 17, 131&#x2013;143 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4066672</ArticleId><ArticleId IdType="pubmed">24316888</ArticleId></ArticleIdList></Reference><Reference><Citation>Habib N. et al. ., Disease-associated astrocytes in Alzheimer&#x2019;s disease and aging. Nat. Neurosci. 23, 701&#x2013;706 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9262034</ArticleId><ArticleId IdType="pubmed">32341542</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H. et al. ., A unique microglia type Associated with restricting development of Alzheimer&#x2019;s disease. Cell 169, 1276&#x2013;1290.e17 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Beckmann N. D. et al. ., Multiscale causal networks identify VGF as a key regulator of Alzheimer&#x2019;s disease. Nat. Commun. 11, 3942 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7414858</ArticleId><ArticleId IdType="pubmed">32770063</ArticleId></ArticleIdList></Reference><Reference><Citation>Hillen A. E. J., Burbach J. P. H., Hol E. M., Cell adhesion and matricellular support by astrocytes of the tripartite synapse. Prog. Neurobiol. 165-167, 66&#x2013;86 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29444459</ArticleId></ArticleIdList></Reference><Reference><Citation>Perea G., Navarrete M., Araque A., Tripartite synapses: Astrocytes process and control synaptic information. Trends Neurosci. 32, 421&#x2013;431 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19615761</ArticleId></ArticleIdList></Reference><Reference><Citation>Eid T., Tu N., Lee T. S. W., Lai J. C. K., Regulation of astrocyte glutamine synthetase in epilepsy. Neurochem. Int. 63, 670&#x2013;681 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3825815</ArticleId><ArticleId IdType="pubmed">23791709</ArticleId></ArticleIdList></Reference><Reference><Citation>Petr G. T. et al. ., Conditional deletion of the glutamate transporter GLT-1 reveals that astrocytic GLT-1 protects against fatal epilepsy while neuronal GLT-1 contributes significantly to glutamate uptake into synaptosomes. J. Neurosci. 35, 5187&#x2013;5201 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4380995</ArticleId><ArticleId IdType="pubmed">25834045</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartzokis G., Age-related myelin breakdown: A developmental model of cognitive decline and Alzheimer&#x2019;s disease. Neurobiol. Aging 25, 5&#x2013;18, author reply 49&#x2013;62 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">14675724</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson J. M. et al. ., Abnormally phosphorylated tau is associated with neuronal and axonal loss in experimental autoimmune encephalomyelitis and multiple sclerosis. Brain 131, 1736&#x2013;1748 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18567922</ArticleId></ArticleIdList></Reference><Reference><Citation>Stadelmann C., Wegner C., Br&#xfc;ck W., Inflammation, demyelination, and degeneration - recent insights from MS pathology. Biochim. Biophys. Acta 1812, 275&#x2013;282 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">20637864</ArticleId></ArticleIdList></Reference><Reference><Citation>Franklin R. J. M., Ffrench-Constant C., Remyelination in the CNS: From biology to therapy. Nat. Rev. Neurosci. 9, 839&#x2013;855 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18931697</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweeney M. D., Sagare A. P., Zlokovic B. V., Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat. Rev. Neurol. 14, 133&#x2013;150 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5829048</ArticleId><ArticleId IdType="pubmed">29377008</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett R. E. et al. ., Tau induces blood vessel abnormalities and angiogenesis-related gene expression in P301L transgenic mice and human Alzheimer&#x2019;s disease. Proc. Natl. Acad. Sci. U.S.A. 115, E1289&#x2013;E1298 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5819390</ArticleId><ArticleId IdType="pubmed">29358399</ArticleId></ArticleIdList></Reference><Reference><Citation>Mhatre M. et al. ., Thrombin, a mediator of neurotoxicity and memory impairment. Neurobiol. Aging 25, 783&#x2013;793 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15165703</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z. L., Strickland S., Neuronal death in the hippocampus is promoted by plasmin-catalyzed degradation of laminin. Cell 91, 917&#x2013;925 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9428515</ArticleId></ArticleIdList></Reference><Reference><Citation>Neefjes J., Jongsma M. L. M., Paul P., Bakke O., Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat. Rev. Immunol. 11, 823&#x2013;836 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">22076556</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Liberto G. et al. ., Neurons under T Cell attack coordinate phagocyte-mediated synaptic stripping. Cell 175, 458&#x2013;471.e19 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30173917</ArticleId></ArticleIdList></Reference><Reference><Citation>Razakandrainibe R., Pelleau S., Grau G. E., Jambou R., Antigen presentation by endothelial cells: What role in the pathophysiology of malaria? Trends Parasitol. 28, 151&#x2013;160 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22365903</ArticleId></ArticleIdList></Reference><Reference><Citation>Pober J. S., Merola J., Liu R., Manes T. D., Antigen presentation by vascular cells. Front. Immunol. 8, 1907 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5744398</ArticleId><ArticleId IdType="pubmed">29312357</ArticleId></ArticleIdList></Reference><Reference><Citation>Eimer W. A. et al. ., Alzheimer&#x2019;s disease-associated &#x3b2;-Amyloid is rapidly seeded by herpesviridae to protect against brain infection. Neuron 99, 56&#x2013;63.e3 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6075814</ArticleId><ArticleId IdType="pubmed">30001512</ArticleId></ArticleIdList></Reference><Reference><Citation>Gate D. et al. ., Clonally expanded CD8 T cells patrol the cerebrospinal fluid in Alzheimer&#x2019;s disease. Nature 577, 399&#x2013;404 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7445078</ArticleId><ArticleId IdType="pubmed">31915375</ArticleId></ArticleIdList></Reference><Reference><Citation>Dulken B. W. et al. ., Single-cell analysis reveals T cell infiltration in old neurogenic niches. Nature 571, 205&#x2013;210 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7111535</ArticleId><ArticleId IdType="pubmed">31270459</ArticleId></ArticleIdList></Reference><Reference><Citation>Renthal W. et al. ., Characterization of human mosaic Rett syndrome brain tissue by single-nucleus RNA sequencing. Nat. Neurosci. 21, 1670&#x2013;1679 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6261686</ArticleId><ArticleId IdType="pubmed">30455458</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng G. X. Y. et al. ., Massively parallel digital transcriptional profiling of single cells. Nat. Commun. 8, 14049 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5241818</ArticleId><ArticleId IdType="pubmed">28091601</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler A., Hoffman P., Smibert P., Papalexi E., Satija R., Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36, 411&#x2013;420 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6700744</ArticleId><ArticleId IdType="pubmed">29608179</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y. et al. ., Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer&#x2019;s disease. Nat. Med. 26, 131&#x2013;142 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6980793</ArticleId><ArticleId IdType="pubmed">31932797</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie M. E. et al. ., Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4402510</ArticleId><ArticleId IdType="pubmed">25605792</ArticleId></ArticleIdList></Reference><Reference><Citation>Matarin M. et al. ., A genome-wide gene-expression analysis and database in transgenic mice during development of amyloid or tau pathology. Cell Rep. 10, 633&#x2013;644 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25620700</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32997994</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>15</Day></DateCompleted><DateRevised><Year>2021</Year><Month>09</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>13</Issue><PubDate><Year>2020</Year><Month>Sep</Month><Day>29</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>Single-Nucleus RNA-Seq Is Not Suitable for Detection of Microglial Activation Genes in Humans.</ArticleTitle><Pagination><StartPage>108189</StartPage><MedlinePgn>108189</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">108189</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2020.108189</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(20)31178-5</ELocationID><Abstract><AbstractText>Single-nucleus RNA sequencing (snRNA-seq) is used as an alternative to single-cell RNA-seq, as it allows transcriptomic profiling of frozen tissue. However, it is unclear whether snRNA-seq is able to detect cellular state in human tissue. Indeed, snRNA-seq analyses of human brain samples have failed to detect a consistent microglial activation signature in Alzheimer's disease. Our comparison of microglia from single cells and single nuclei of four human subjects reveals that, although most genes show similar relative abundances in cells and nuclei, a small population of genes (&#x223c;1%) is depleted in nuclei compared to whole cells. This population is enriched for genes previously implicated in microglial activation, including APOE, CST3, SPP1, and CD74, comprising 18% of previously identified microglial-disease-associated genes. Given the low sensitivity of snRNA-seq to detect many activation genes, we conclude that snRNA-seq is not suited for detecting cellular activation in microglia in human disease.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thrupp</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Centre for Brain and Disease Research, Flanders Institute for Biotechnology (VIB), Leuven, Belgium; Department of Neurosciences and Leuven Brain Institute, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sala Frigerio</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Centre for Brain and Disease Research, Flanders Institute for Biotechnology (VIB), Leuven, Belgium; Department of Neurosciences and Leuven Brain Institute, KU Leuven, Leuven, Belgium; UK Dementia Research Institute at University College London, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolfs</LastName><ForeName>Leen</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Centre for Brain and Disease Research, Flanders Institute for Biotechnology (VIB), Leuven, Belgium; Department of Neurosciences and Leuven Brain Institute, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skene</LastName><ForeName>Nathan G</ForeName><Initials>NG</Initials><AffiliationInfo><Affiliation>UK Dementia Research Institute at Imperial College London and Department of Brain Sciences, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fattorelli</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Centre for Brain and Disease Research, Flanders Institute for Biotechnology (VIB), Leuven, Belgium; Department of Neurosciences and Leuven Brain Institute, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poovathingal</LastName><ForeName>Suresh</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centre for Brain and Disease Research, Flanders Institute for Biotechnology (VIB), Leuven, Belgium; Department of Neurosciences and Leuven Brain Institute, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fourne</LastName><ForeName>Yannick</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Centre for Brain and Disease Research, Flanders Institute for Biotechnology (VIB), Leuven, Belgium; Department of Neurosciences and Leuven Brain Institute, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matthews</LastName><ForeName>Paul M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>UK Dementia Research Institute at Imperial College London and Department of Brain Sciences, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Theys</LastName><ForeName>Tom</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Research Group Experimental Neurosurgery and Neuroanatomy, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mancuso</LastName><ForeName>Renzo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Centre for Brain and Disease Research, Flanders Institute for Biotechnology (VIB), Leuven, Belgium; Department of Neurosciences and Leuven Brain Institute, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Strooper</LastName><ForeName>Bart</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Centre for Brain and Disease Research, Flanders Institute for Biotechnology (VIB), Leuven, Belgium; Department of Neurosciences and Leuven Brain Institute, KU Leuven, Leuven, Belgium; UK Dementia Research Institute at University College London, University College London, London, UK. Electronic address: bart.destrooper@kuleuven.vib.be.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fiers</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centre for Brain and Disease Research, Flanders Institute for Biotechnology (VIB), Leuven, Belgium; Department of Neurosciences and Leuven Brain Institute, KU Leuven, Leuven, Belgium; UK Dementia Research Institute at University College London, University College London, London, UK. Electronic address: mark.fiers@kuleuven.vib.be.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017423" MajorTopicYN="N">Sequence Analysis, RNA</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059010" MajorTopicYN="N">Single-Cell Analysis</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ARM</Keyword><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">activation</Keyword><Keyword MajorTopicYN="N">microglia</Keyword><Keyword MajorTopicYN="N">microglial activation</Keyword><Keyword MajorTopicYN="N">single-cell RNA-seq</Keyword><Keyword MajorTopicYN="N">single-nucleus RNA-seq</Keyword></KeywordList><CoiStatement>Declaration of Interests P.M.M. has been reimbursed for service on a Scientific Advisory Board to Ipsen Pharmaceuticals. He has received consultancy fees from Roche, Adelphi Communications, Celgene, Neurodiem, and Medscape. He has received honoraria or speakers&#x2019; fees from Novartis and Biogen and has received research or educational funds from Biogen, Novartis, and GlaxoSmithKline.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>2</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>6</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>9</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>30</Day><Hour>20</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>9</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32997994</ArticleId><ArticleId IdType="pmc">PMC7527779</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2020.108189</ArticleId><ArticleId IdType="pii">S2211-1247(20)31178-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bahar Halpern K., Caspi I., Lemze D., Levy M., Landen S., Elinav E., Ulitsky I., Itzkovitz S. Nuclear Retention of mRNA in Mammalian Tissues. Cell Rep. 2015;13:2653&#x2013;2662.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4700052</ArticleId><ArticleId IdType="pubmed">26711333</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakken T.E., Hodge R.D., Miller J.A., Yao Z., Nguyen T.N., Aevermann B., Barkan E., Bertagnolli D., Casper T., Dee N. Single-nucleus and single-cell transcriptomes compared in matched cortical cell types. PLoS One. 2018;13:e0209648.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6306246</ArticleId><ArticleId IdType="pubmed">30586455</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler A., Hoffman P., Smibert P., Papalexi E., Satija R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 2018;36:411&#x2013;420.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6700744</ArticleId><ArticleId IdType="pubmed">29608179</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen W.-T., Lu A., Craessaerts K., Pavie B., Sala Frigerio C., Corthout N., Qian X., Lal&#xe1;kov&#xe1; J., K&#xfc;hnemund M., Voytyuk I. Spatial Transcriptomics and In Situ Sequencing to Study Alzheimer&#x2019;s Disease. Cell. 2020;182:976&#x2013;991.e19.</Citation><ArticleIdList><ArticleId IdType="pubmed">32702314</ArticleId></ArticleIdList></Reference><Reference><Citation>Del-Aguila J.L., Li Z., Dube U., Mihindukulasuriya K.A., Budde J.P., Fernandez M.V., Ibanez L., Bradley J., Wang F., Bergmann K. A single-nuclei RNA sequencing study of Mendelian and sporadic AD in the human brain. Alzheimers Res. Ther. 2019;11:71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6689177</ArticleId><ArticleId IdType="pubmed">31399126</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding J., Adiconis X., Simmons S.K., Kowalczyk M.S., Hession C.C., Marjanovic N.D., Hughes T.K., Wadsworth M.H., Burks T., Nguyen L.T. Systematic comparison of single-cell and single-nucleus RNA-sequencing methods. Nat. Biotechnol. 2020;38:737&#x2013;746.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7289686</ArticleId><ArticleId IdType="pubmed">32341560</ArticleId></ArticleIdList></Reference><Reference><Citation>Drost H.-G., Paszkowski J. Biomartr: genomic data retrieval with R. Bioinformatics. 2017;33:1216&#x2013;1217.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5408848</ArticleId><ArticleId IdType="pubmed">28110292</ArticleId></ArticleIdList></Reference><Reference><Citation>Efthymiou A.G., Goate A.M. Late onset Alzheimer&#x2019;s disease genetics implicates microglial pathways in disease risk. Mol. Neurodegener. 2017;12:43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5446752</ArticleId><ArticleId IdType="pubmed">28549481</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonseca M.I., Chu S.-H., Hernandez M.X., Fang M.J., Modarresi L., Selvan P., MacGregor G.R., Tenner A.J. Cell-specific deletion of C1qa identifies microglia as the dominant source of C1q in mouse brain. J.&#xa0;Neuroinflammation. 2017;14:48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5340039</ArticleId><ArticleId IdType="pubmed">28264694</ArticleId></ArticleIdList></Reference><Reference><Citation>10x Genomics. Creating a Reference Package with cellranger mkref -Software -Single Cell Gene Expression -Official 10x Genomics Support. https://support.10xgenomics.com/single-cell-gene-expression/software/pipelines/latest/advanced/references#premrna.</Citation></Reference><Reference><Citation>Gerrits E., Heng Y., Boddeke E.W.G.M., Eggen B.J.L. Transcriptional profiling of microglia; current state of the art and future perspectives. Glia. 2019;68:740&#x2013;755.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7064956</ArticleId><ArticleId IdType="pubmed">31846124</ArticleId></ArticleIdList></Reference><Reference><Citation>Gosselin D., Skola D., Coufal N.G., Holtman I.R., Schlachetzki J.C.M., Sajti E., Jaeger B.N., O&#x2019;Connor C., Fitzpatrick C., Pasillas M.P. An environment-dependent transcriptional network specifies human microglia identity. Science. 2017;356:eaal3222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5858585</ArticleId><ArticleId IdType="pubmed">28546318</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffiths J.A., Richard A.C., Bach K., Lun A.T.L., Marioni J.C. Detection and removal of barcode swapping in single-cell RNA-seq data. Nat. Commun. 2018;9:2667.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6039488</ArticleId><ArticleId IdType="pubmed">29991676</ArticleId></ArticleIdList></Reference><Reference><Citation>Grubman A., Chew G., Ouyang J.F., Sun G., Choo X.Y., McLean C., Simmons R.K., Buckberry S., Vargas-Landin D.B., Poppe D. A single-cell atlas of entorhinal cortex from individuals with Alzheimer&#x2019;s disease reveals cell-type-specific gene expression regulation. Nat. Neurosci. 2019;22:2087&#x2013;2097.</Citation><ArticleIdList><ArticleId IdType="pubmed">31768052</ArticleId></ArticleIdList></Reference><Reference><Citation>Habib N., Li Y., Heidenreich M., Swiech L., Avraham-Davidi I., Trombetta J.J., Hession C., Zhang F., Regev A. Div-Seq: Single-nucleus RNA-Seq reveals dynamics of rare adult newborn neurons. Science. 2016;353:925&#x2013;928.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5480621</ArticleId><ArticleId IdType="pubmed">27471252</ArticleId></ArticleIdList></Reference><Reference><Citation>Habib N., Avraham-Davidi I., Basu A., Burks T., Shekhar K., Hofree M., Choudhury S.R., Aguet F., Gelfand E., Ardlie K. Massively parallel single-nucleus RNA-seq with DroNc-seq. Nat. Methods. 2017;14:955&#x2013;958.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5623139</ArticleId><ArticleId IdType="pubmed">28846088</ArticleId></ArticleIdList></Reference><Reference><Citation>Hafner A.-S., Donlin-Asp P.G., Leitch B., Herzog E., Schuman E.M. Local protein synthesis is a ubiquitous feature of neuronal pre- and postsynaptic compartments. Science. 2019;364:eaau3644.</Citation><ArticleIdList><ArticleId IdType="pubmed">31097639</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasselmann J., Coburn M.A., England W., Figueroa Velez D.X., Kiani Shabestari S., Tu C.H., McQuade A., Kolahdouzan M., Echeverria K., Claes C. Development of a Chimeric Model to Study and Manipulate Human Microglia In&#xa0;Vivo. Neuron. 2019;103:1016&#x2013;1033.e10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7138101</ArticleId><ArticleId IdType="pubmed">31375314</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodge R.D., Bakken T.E., Miller J.A., Smith K.A., Barkan E.R., Graybuck L.T., Close J.L., Long B., Johansen N., Penn O. Conserved cell types with divergent features in human versus mouse cortex. Nature. 2019;573:61&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6919571</ArticleId><ArticleId IdType="pubmed">31435019</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen I.E., Savage J.E., Watanabe K., Bryois J., Williams D.M., Steinberg S., Sealock J., Karlsson I.K., H&#xe4;gg S., Athanasiu L. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer&#x2019;s disease risk. Nat. Genet. 2019;51:404&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6836675</ArticleId><ArticleId IdType="pubmed">30617256</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H., Spinrad A., Weiner A., Matcovitch-Natan O., Dvir-Szternfeld R., Ulland T.K., David E., Baruch K., Lara-Astaiso D., Toth B. A Unique Microglia Type Associated with Restricting Development of Alzheimer&#x2019;s Disease. Cell. 2017;169:1276&#x2013;1290.e17.</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann S., Madore C., Cialic R., Baufeld C., Calcagno N., El Fatimy R., Beckers L., O&#x2019;Loughlin E., Xu Y., Fanek Z. The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. Immunity. 2017;47:566&#x2013;581.e9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5719893</ArticleId><ArticleId IdType="pubmed">28930663</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunkle B.W., Grenier-Boley B., Sims R., Bis J.C., Damotte V., Naj A.C., Boland A., Vronskaya M., van der Lee S.J., Amlie-Wolf A. Genetic meta-analysis of diagnosed Alzheimer&#x2019;s disease identifies new risk loci and implicates A&#x3b2;, tau, immunity and lipid processing. Nat. Genet. 2019;51:414&#x2013;430.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6463297</ArticleId><ArticleId IdType="pubmed">30820047</ArticleId></ArticleIdList></Reference><Reference><Citation>Lake B.B., Ai R., Kaeser G.E., Salathia N.S., Yung Y.C., Liu R., Wildberg A., Gao D., Fung H.-L., Chen S. Neuronal subtypes and diversity revealed by single-nucleus RNA sequencing of the human brain. Science. 2016;352:1586&#x2013;1590.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5038589</ArticleId><ArticleId IdType="pubmed">27339989</ArticleId></ArticleIdList></Reference><Reference><Citation>Lake B.B., Codeluppi S., Yung Y.C., Gao D., Chun J., Kharchenko P.V., Linnarsson S., Zhang K. A comparative strategy for single-nucleus and single-cell transcriptomes confirms accuracy in predicted cell-type expression from nuclear RNA. Sci. Rep. 2017;7:6031.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5519641</ArticleId><ArticleId IdType="pubmed">28729663</ArticleId></ArticleIdList></Reference><Reference><Citation>Lake B.B., Chen S., Sos B.C., Fan J., Kaeser G.E., Yung Y.C., Duong T.E., Gao D., Chun J., Kharchenko P.V., Zhang K. Integrative single-cell analysis of transcriptional and epigenetic states in the human adult brain. Nat. Biotechnol. 2018;36:70&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5951394</ArticleId><ArticleId IdType="pubmed">29227469</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert J.C., Ibrahim-Verbaas C.A., Harold D., Naj A.C., Sims R., Bellenguez C., DeStafano A.L., Bis J.C., Beecham G.W., Grenier-Boley B. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer&#x2019;s disease. Nat. Genet. 2013;45:1452&#x2013;1458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Liberzon A., Subramanian A., Pinchback R., Thorvaldsd&#xf3;ttir H., Tamayo P., Mesirov J.P. Molecular signatures database (MSigDB) 3.0. Bioinformatics. 2011;27:1739&#x2013;1740.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3106198</ArticleId><ArticleId IdType="pubmed">21546393</ArticleId></ArticleIdList></Reference><Reference><Citation>Lun A.T.L., Riesenfeld S., Andrews T., Dao T.P., Gomes T., Marioni J.C., participants in the 1st Human Cell Atlas Jamboree EmptyDrops: distinguishing cells from empty droplets in droplet-based single-cell RNA sequencing data. Genome Biol. 2019;20:63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6431044</ArticleId><ArticleId IdType="pubmed">30902100</ArticleId></ArticleIdList></Reference><Reference><Citation>Macosko E.Z., Basu A., Satija R., Nemesh J., Shekhar K., Goldman M., Tirosh I., Bialas A.R., Kamitaki N., Martersteck E.M. Highly Parallel Genome-wide Expression Profiling of Individual Cells Using Nanoliter Droplets. Cell. 2015;161:1202&#x2013;1214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4481139</ArticleId><ArticleId IdType="pubmed">26000488</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancuso R., Van Den Daele J., Fattorelli N., Wolfs L., Balusu S., Burton O., Liston A., Sierksma A., Fourne Y., Poovathingal S. Stem-cell-derived human microglia transplanted in mouse brain to study human disease. Nat. Neurosci. 2019;22:2111&#x2013;2116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7616913</ArticleId><ArticleId IdType="pubmed">31659342</ArticleId></ArticleIdList></Reference><Reference><Citation>Maniatis S., &#xc4;ij&#xf6; T., Vickovic S., Braine C., Kang K., Mollbrink A., Fagegaltier D., Saiz-Castro G., Cuevas M., Watters A. Spatiotemporal dynamics of molecular pathology in amyotrophic lateral sclerosis. Science. 2019;364:89&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">30948552</ArticleId></ArticleIdList></Reference><Reference><Citation>Marioni R.E., Harris S.E., Zhang Q., McRae A.F., Hagenaars S.P., Hill W.D., Davies G., Ritchie C.W., Gale C.R., Starr J.M. GWAS on family history of Alzheimer&#x2019;s disease. Transl. Psychiatry. 2018;8:99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5959890</ArticleId><ArticleId IdType="pubmed">29777097</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H., Davila-Velderrain J., Peng Z., Gao F., Mohammadi S., Young J.Z., Menon M., He L., Abdurrob F., Jiang X. Single-cell transcriptomic analysis of Alzheimer&#x2019;s disease. Nature. 2019;570:332&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6865822</ArticleId><ArticleId IdType="pubmed">31042697</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer P.L., Itagaki S., Tago H., McGeer E.G. Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci. Lett. 1987;79:195&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pubmed">3670729</ArticleId></ArticleIdList></Reference><Reference><Citation>McGinnis C.S., Murrow L.M., Gartner Z.J. DoubletFinder: Doublet Detection in Single-Cell RNA Sequencing Data Using Artificial Nearest Neighbors. Cell Syst. 2019;8:329&#x2013;337.e4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6853612</ArticleId><ArticleId IdType="pubmed">30954475</ArticleId></ArticleIdList></Reference><Reference><Citation>Phipson B., Zappia L., Oshlack A. Gene length and detection bias in single cell RNA sequencing protocols. F1000Res. 2017;6:595.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5428526</ArticleId><ArticleId IdType="pubmed">28529717</ArticleId></ArticleIdList></Reference><Reference><Citation>Sala Frigerio C., Wolfs L., Fattorelli N., Thrupp N., Voytyuk I., Schmidt I., Mancuso R., Chen W.-T., Woodbury M.E., Srivastava G. The Major Risk Factors for Alzheimer&#x2019;s Disease: Age, Sex, and Genes Modulate the Microglia Response to A&#x3b2; Plaques. Cell Rep. 2019;27:1293&#x2013;1306.e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7340153</ArticleId><ArticleId IdType="pubmed">31018141</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders A., Macosko E.Z., Wysoker A., Goldman M., Krienen F.M., de Rivera H., Bien E., Baum M., Bortolin L., Wang S. Molecular Diversity and Specializations among the Cells of the Adult Mouse Brain. Cell. 2018;174:1015&#x2013;1030.e16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6447408</ArticleId><ArticleId IdType="pubmed">30096299</ArticleId></ArticleIdList></Reference><Reference><Citation>Sergushichev A.A. An algorithm for fast preranked gene set enrichment analysis using cumulative statistic calculation. bioRxiv. 2016 doi: 10.1101/060012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/060012</ArticleId></ArticleIdList></Reference><Reference><Citation>Skene N.G., Grant S.G.N. Identification of Vulnerable Cell Types in Major Brain Disorders Using Single Cell Transcriptomes and Expression Weighted Cell Type Enrichment. Front. Neurosci. 2016;10:16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4730103</ArticleId><ArticleId IdType="pubmed">26858593</ArticleId></ArticleIdList></Reference><Reference><Citation>Skene N.G., Bryois J., Bakken T.E., Breen G., Crowley J.J., Gaspar H.A., Giusti-Rodriguez P., Hodge R.D., Miller J.A., Mu&#xf1;oz-Manchado A.B. Genetic identification of brain cell types underlying schizophrenia. Nat. Genet. 2018;50:825&#x2013;833.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6477180</ArticleId><ArticleId IdType="pubmed">29785013</ArticleId></ArticleIdList></Reference><Reference><Citation>St&#xe5;hl P.L., Salm&#xe9;n F., Vickovic S., Lundmark A., Navarro J.F., Magnusson J., Giacomello S., Asp M., Westholm J.O., Huss M. Visualization and analysis of gene expression in tissue sections by spatial transcriptomics. Science. 2016;353:78&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">27365449</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuart T., Butler A., Hoffman P., Hafemeister C., Papalexi E., Mauck W.M., III, Hao Y., Stoeckius M., Smibert P., Satija R. Comprehensive Integration of Single-Cell Data. Cell. 2019;177:1888&#x2013;1902.e21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6687398</ArticleId><ArticleId IdType="pubmed">31178118</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., Paulovich A., Pomeroy S.L., Golub T.R., Lander E.S., Mesirov J.P. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA. 2005;102:15545&#x2013;15550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1239896</ArticleId><ArticleId IdType="pubmed">16199517</ArticleId></ArticleIdList></Reference><Reference><Citation>Tasic B., Menon V., Nguyen T.N., Kim T.K., Jarsky T., Yao Z., Levi B., Gray L.T., Sorensen S.A., Dolbeare T. Adult mouse cortical cell taxonomy revealed by single cell transcriptomics. Nat. Neurosci. 2016;19:335&#x2013;346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4985242</ArticleId><ArticleId IdType="pubmed">26727548</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeisel A., Hochgerner H., L&#xf6;nnerberg P., Johnsson A., Memic F., van der Zwan J., H&#xe4;ring M., Braun E., Borm L.E., La Manno G. Molecular Architecture of the Mouse Nervous System. Cell. 2018;174:999&#x2013;1014.e22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6086934</ArticleId><ArticleId IdType="pubmed">30096314</ArticleId></ArticleIdList></Reference><Reference><Citation>Zerbino D.R., Achuthan P., Akanni W., Amode M.R., Barrell D., Bhai J., Billis K., Cummins C., Gall A., Gir&#xf3;n C.G. Ensembl 2018. Nucleic Acids Res. 2018;46:D754&#x2013;D761.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5753206</ArticleId><ArticleId IdType="pubmed">29155950</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y., Song W.M., Andhey P.S., Swain A., Levy T., Miller K.R., Poliani P.L., Cominelli M., Grover S., Gilfillan S. Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer&#x2019;s disease. Nat. Med. 2020;26:131&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6980793</ArticleId><ArticleId IdType="pubmed">31932797</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33004675</PMID><DateCompleted><Year>2021</Year><Month>01</Month><Day>21</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>370</Volume><Issue>6519</Issue><PubDate><Year>2020</Year><Month>Nov</Month><Day>20</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Autosomal dominant VCP hypomorph mutation impairs disaggregation of PHF-tau.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">eaay8826</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/science.aay8826</ELocationID><Abstract><AbstractText>Neurodegeneration in Alzheimer's disease (AD) is closely associated with the accumulation of pathologic tau aggregates in the form of neurofibrillary tangles. We found that a p.Asp395Gly mutation in <i>VCP</i> (valosin-containing protein) was associated with dementia characterized neuropathologically by neuronal vacuoles and neurofibrillary tangles. Moreover, VCP appeared to exhibit tau disaggregase activity in vitro, which was impaired by the p.Asp395Gly mutation. Additionally, intracerebral microinjection of pathologic tau led to increased tau aggregates in mice in which p.Asp395Gly <i>VCP</i> mice was knocked in, as compared with injected wild-type mice. These findings suggest that p.Asp395Gly <i>VCP</i> is an autosomal-dominant genetic mutation associated with neurofibrillary degeneration in part owing to reduced tau disaggregation, raising the possibility that VCP may represent a therapeutic target for the treatment of AD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Darwich</LastName><ForeName>Nabil F</ForeName><Initials>NF</Initials><Identifier Source="ORCID">0000-0002-8324-9201</Identifier><AffiliationInfo><Affiliation>Translational Neuropathology Research Laboratory, Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Phan</LastName><ForeName>Jessica M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0002-0240-9999</Identifier><AffiliationInfo><Affiliation>Translational Neuropathology Research Laboratory, Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Boram</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-2608-3778</Identifier><AffiliationInfo><Affiliation>Translational Neuropathology Research Laboratory, Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suh</LastName><ForeName>EunRan</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Papatriantafyllou</LastName><ForeName>John D</ForeName><Initials>JD</Initials><Identifier Source="ORCID">0000-0002-7835-2706</Identifier><AffiliationInfo><Affiliation>Medical Center of Athens, Memory Disorders Clinic and Day Care Center for Third Age "IASIS," Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Changolkar</LastName><ForeName>Lakshmi</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-2532-4768</Identifier><AffiliationInfo><Affiliation>Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Aivi T</ForeName><Initials>AT</Initials><Identifier Source="ORCID">0000-0003-1809-9451</Identifier><AffiliationInfo><Affiliation>Translational Neuropathology Research Laboratory, Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Rourke</LastName><ForeName>Caroline M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Translational Neuropathology Research Laboratory, Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Zhuohao</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0003-1505-8750</Identifier><AffiliationInfo><Affiliation>Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Porta</LastName><ForeName>S&#xed;lvia</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-3667-4325</Identifier><AffiliationInfo><Affiliation>Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gibbons</LastName><ForeName>Garrett S</ForeName><Initials>GS</Initials><Identifier Source="ORCID">0000-0001-6619-2672</Identifier><AffiliationInfo><Affiliation>Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luk</LastName><ForeName>Kelvin C</ForeName><Initials>KC</Initials><Identifier Source="ORCID">0000-0002-6591-6269</Identifier><AffiliationInfo><Affiliation>Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Papageorgiou</LastName><ForeName>Sokratis G</ForeName><Initials>SG</Initials><Identifier Source="ORCID">0000-0001-8863-3635</Identifier><AffiliationInfo><Affiliation>First University Department of Neurology, Eginiteio University Hospital, National and Kapodistrian University of Athens, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grossman</LastName><ForeName>Murray</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-7447-6218</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Massimo</LastName><ForeName>Lauren</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-3407-7335</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Irwin</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><Identifier Source="ORCID">0000-0002-5599-5098</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McMillan</LastName><ForeName>Corey T</ForeName><Initials>CT</Initials><AffiliationInfo><Affiliation>Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nasrallah</LastName><ForeName>Ilya M</ForeName><Initials>IM</Initials><Identifier Source="ORCID">0000-0003-2346-7562</Identifier><AffiliationInfo><Affiliation>Department of Radiology, Perelman School of Medicine at the University of Pennsylvania, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toro</LastName><ForeName>Camilo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>NIH Undiagnosed Diseases Program, National Human Genome Research Institute, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aguirre</LastName><ForeName>Geoffrey K</ForeName><Initials>GK</Initials><Identifier Source="ORCID">0000-0002-4028-3100</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Deerlin</LastName><ForeName>Vivianna M</ForeName><Initials>VM</Initials><AffiliationInfo><Affiliation>Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Edward B</ForeName><Initials>EB</Initials><Identifier Source="ORCID">0000-0002-4589-1180</Identifier><AffiliationInfo><Affiliation>Translational Neuropathology Research Laboratory, Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, PA, USA. edward.lee@pennmedicine.upenn.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>2014100</GrantID><Acronym>DDCF</Acronym><Agency>Doris Duke Charitable Foundation</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG000255</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG066597</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 MH114253</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AG063344</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG054519</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F30 AG058317</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG017586</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS095793</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS109260</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>10</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D066329">Protein Aggregates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>30KYC7MIAI</RegistryNumber><NameOfSubstance UI="D001224">Aspartic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.6</RegistryNumber><NameOfSubstance UI="C000614178">VCP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.6</RegistryNumber><NameOfSubstance UI="D000074405">Valosin Containing Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.6</RegistryNumber><NameOfSubstance UI="C000614179">Vcp protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>TE7660XO1C</RegistryNumber><NameOfSubstance UI="D005998">Glycine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001224" MajorTopicYN="N">Aspartic Acid</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055879" MajorTopicYN="N">Gene Knock-In Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005799" MajorTopicYN="N">Genes, Dominant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005998" MajorTopicYN="N">Glycine</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008817" MajorTopicYN="N">Mice, Mutant Strains</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066329" MajorTopicYN="Y">Protein Aggregates</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066263" MajorTopicYN="N">Protein Aggregation, Pathological</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000074405" MajorTopicYN="N">Valosin Containing Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>7</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>7</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>9</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>2</Day><Hour>5</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>5</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33004675</ArticleId><ArticleId IdType="mid">NIHMS1661945</ArticleId><ArticleId IdType="pmc">PMC7818661</ArticleId><ArticleId IdType="doi">10.1126/science.aay8826</ArticleId><ArticleId IdType="pii">science.aay8826</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K, Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 112, 389 (October, 2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3906709</ArticleId><ArticleId IdType="pubmed">16906426</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs GG, Tauopathies. Handb Clin Neurol 145, 355 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28987182</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, Goedert M, Tau pathology and neurodegeneration. Lancet Neurol 12, 609 (June, 2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23684085</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee VM, Goedert M, Trojanowski JQ, Neurodegenerative tauopathies. Annu Rev Neurosci 24, 1121 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11520930</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Boom J, Meyer H, VCP/p97-Mediated Unfolding as a Principle in Protein Homeostasis and Signaling. Mol Cell 69, 182 (January 18, 2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29153394</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanson PI, Whiteheart SW, AAA+ proteins: have engine, will work. Nat Rev Mol Cell Biol 6, 519 (July, 2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16072036</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer H, Bug M, Bremer S, Emerging functions of the VCP/p97 AAA-ATPase in the ubiquitin system. Nat Cell Biol 14, 117 (February 2, 2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22298039</ArticleId></ArticleIdList></Reference><Reference><Citation>Uhlen M et al., Tissue-based map of the human proteome. Science 347, 1260419 (January 23, 2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25613900</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y et al., An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci 34, 11929 (September 3, 2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4152602</ArticleId><ArticleId IdType="pubmed">25186741</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos EM et al., Frontotemporal dementia spectrum: first genetic screen in a Greek cohort. Neurobiol Aging 75, 224 e1 (March, 2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6553875</ArticleId><ArticleId IdType="pubmed">30528349</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbons GS et al., Detection of Alzheimer Disease (AD)-Specific Tau Pathology in AD and NonAD Tauopathies by Immunohistochemistry With Novel Conformation-Selective Tau Antibodies. J Neuropathol Exp Neurol 77, 216 (March 1, 2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6251598</ArticleId><ArticleId IdType="pubmed">29415231</ArticleId></ArticleIdList></Reference><Reference><Citation>Demaerel P, Heiner L, Robberecht W, Sciot R, Wilms G, Diffusion-weighted MRI in sporadic Creutzfeldt-Jakob disease. Neurology 52, 205 (January 1, 1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">9921880</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M et al., TDP-43 in the ubiquitin pathology of frontotemporal dementia with VCP gene mutations. J Neuropathol Exp Neurol 66, 152 (February, 2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17279000</ArticleId></ArticleIdList></Reference><Reference><Citation>Watts GD et al., Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet 36, 377 (April, 2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15034582</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor JP, Multisystem proteinopathy: intersecting genetics in muscle, bone, and brain degeneration. Neurology 85, 658 (August 25, 2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26208960</ArticleId></ArticleIdList></Reference><Reference><Citation>Manno A, Noguchi M, Fukushi J, Motohashi Y, Kakizuka A, Enhanced ATPase activities as a primary defect of mutant valosin-containing proteins that cause inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia. Genes Cells 15, 911 (August, 2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20604808</ArticleId></ArticleIdList></Reference><Reference><Citation>Halawani D et al., Hereditary inclusion body myopathy-linked p97/VCP mutations in the NH2 domain and the D1 ring modulate p97/VCP ATPase activity and D2 ring conformation. Mol Cell Biol 29, 4484 (August, 2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2725746</ArticleId><ArticleId IdType="pubmed">19506019</ArticleId></ArticleIdList></Reference><Reference><Citation>Blythe EE, Olson KC, Chau V, Deshaies RJ, Ubiquitin- and ATP-dependent unfoldase activity of P97/VCP*NPLOC4*UFD1L is enhanced by a mutation that causes multisystem proteinopathy. Proc Natl Acad Sci U S A 114, E4380 (May 30, 2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5465906</ArticleId><ArticleId IdType="pubmed">28512218</ArticleId></ArticleIdList></Reference><Reference><Citation>Blythe EE, Gates SN, Deshaies RJ, Martin A, Multisystem Proteinopathy Mutations in VCP/p97 Increase NPLOC4.UFD1L Binding and Substrate Processing. Structure 27, 1820 (December 3, 2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6929323</ArticleId><ArticleId IdType="pubmed">31623962</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyu PC, Liff MI, Marky LA, Kallenbach NR, Side chain contributions to the stability of alpha-helical structure in peptides. Science 250, 669 (November 2, 1990).</Citation><ArticleIdList><ArticleId IdType="pubmed">2237416</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Neil KT, DeGrado WF, A thermodynamic scale for the helix-forming tendencies of the commonly occurring amino acids. Science 250, 646 (November 2, 1990).</Citation><ArticleIdList><ArticleId IdType="pubmed">2237415</ArticleId></ArticleIdList></Reference><Reference><Citation>Song C, Wang Q, Li CC, ATPase activity of p97-valosin-containing protein (VCP). D2 mediates the major enzyme activity, and D1 contributes to the heat-induced activity. J Biol Chem 278, 3648 (February 7, 2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12446676</ArticleId></ArticleIdList></Reference><Reference><Citation>Olszewski MM, Williams C, Dong KC, Martin A, The Cdc48 unfoldase prepares well-folded protein substrates for degradation by the 26S proteasome. Commun Biol 2, 29 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6340886</ArticleId><ArticleId IdType="pubmed">30675527</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodnar NO et al., Structure of the Cdc48 ATPase with its ubiquitin-binding cofactor Ufd1-Npl4. Nat Struct Mol Biol 25, 616 (July, 2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6044470</ArticleId><ArticleId IdType="pubmed">29967539</ArticleId></ArticleIdList></Reference><Reference><Citation>Twomey EC et al., Substrate processing by the Cdc48 ATPase complex is initiated by ubiquitin unfolding. Science 365, (August 2, 2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6980381</ArticleId><ArticleId IdType="pubmed">31249135</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooney I et al., Structure of the Cdc48 segregase in the act of unfolding an authentic substrate. Science 365, 502 (August 2, 2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7362759</ArticleId><ArticleId IdType="pubmed">31249134</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo JL et al., Unique pathological tau conformers from Alzheimer's brains transmit tau pathology in nontransgenic mice. J Exp Med 213, 2635 (November 14, 2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5110027</ArticleId><ArticleId IdType="pubmed">27810929</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedhoff P, Schneider A, Mandelkow EM, Mandelkow E, Rapid assembly of Alzheimer-like paired helical filaments from microtubule-associated protein tau monitored by fluorescence in solution. Biochemistry 37, 10223 (July 14, 1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9665729</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes BB et al., Proteopathic tau seeding predicts tauopathy in vivo. Proc Natl Acad Sci U S A 111, E4376 (October 14, 2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4205609</ArticleId><ArticleId IdType="pubmed">25261551</ArticleId></ArticleIdList></Reference><Reference><Citation>Henao-Mejia J et al., Generation of Genetically Modified Mice Using the CRISPR-Cas9 Genome-Editing System. Cold Spring Harb Protoc 2016, pdb prot090704 (February 1, 2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4905559</ArticleId><ArticleId IdType="pubmed">26832688</ArticleId></ArticleIdList></Reference><Reference><Citation>Luk KD et al., Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338, 949&#x2013;53 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3552321</ArticleId><ArticleId IdType="pubmed">23161999</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbons GS et al., GFP-Mutant Human Tau Transgenic Mice Develop Tauopathy Following CNS Injections of Alzheimer's Brain-Derived Pathological Tau or Synthetic Mutant Human Tau Fibrils. J Neurosci 37, 11485&#x2013;11494 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5700428</ArticleId><ArticleId IdType="pubmed">28986461</ArticleId></ArticleIdList></Reference><Reference><Citation>He Z et al., Amyloid-beta plaques enhance Alzheimer's brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation. Nat Med 24, 29&#x2013;38 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5760353</ArticleId><ArticleId IdType="pubmed">29200205</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee E et al., Expansion of the classification of FTLD-TDP: distinct pathology associated with rapidly progressive frontotemporal degeneration. Acta Neuropathologica 134, 65&#x2013;78 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5521959</ArticleId><ArticleId IdType="pubmed">28130640</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">32998969</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>23</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>563</Issue><PubDate><Year>2020</Year><Month>Sep</Month><Day>30</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>A&#x3b2;-accelerated neurodegeneration caused by Alzheimer's-associated <i>ACE</i> variant R1279Q is rescued by angiotensin system inhibition in mice.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">eaaz2541</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.aaz2541</ELocationID><Abstract><AbstractText>Recent genome-wide association studies identified the angiotensin-converting enzyme gene (<i>ACE</i>) as an Alzheimer's disease (AD) risk locus. However, the pathogenic mechanism by which <i>ACE</i> causes AD is unknown. Using whole-genome sequencing, we identified rare <i>ACE</i> coding variants in AD families and investigated one, ACE1 R1279Q, in knockin (KI) mice. Similar to AD, ACE1 was increased in neurons, but not microglia or astrocytes, of KI brains, which became elevated further with age. Angiotensin II (angII) and angII receptor AT1R signaling were also increased in KI brains. Autosomal dominant neurodegeneration and neuroinflammation occurred with aging in KI hippocampus, which were absent in the cortex and cerebellum. Female KI mice exhibited greater hippocampal electroencephalograph disruption and memory impairment compared to males. <i>ACE</i> variant effects were more pronounced in female KI mice, suggesting a mechanism for higher AD risk in women. Hippocampal neurodegeneration was completely rescued by treatment with brain-penetrant drugs that inhibit ACE1 and AT1R. Although <i>ACE</i> variant-induced neurodegeneration did not depend on &#x3b2;-amyloid (A&#x3b2;) pathology, amyloidosis in 5XFAD mice crossed to KI mice accelerated neurodegeneration and neuroinflammation, whereas A&#x3b2; deposition was unchanged. KI mice had normal blood pressure and cerebrovascular functions. Our findings strongly suggest that increased ACE1/angII signaling causes aging-dependent, A&#x3b2;-accelerated selective hippocampal neuron vulnerability and female susceptibility, hallmarks of AD that have hitherto been enigmatic. We conclude that repurposed brain-penetrant ACE inhibitors and AT1R blockers may protect against AD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cuddy</LastName><ForeName>Leah K</ForeName><Initials>LK</Initials><Identifier Source="ORCID">0000-0002-6764-3065</Identifier><AffiliationInfo><Affiliation>Ken and Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prokopenko</LastName><ForeName>Dmitry</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-1844-5652</Identifier><AffiliationInfo><Affiliation>Genetics and Aging Unit and McCance Center for Brain Health, Department of Neurology, Massachusetts General Hospital, Boston, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cunningham</LastName><ForeName>Eric P</ForeName><Initials>EP</Initials><Identifier Source="ORCID">0000-0001-8705-3620</Identifier><AffiliationInfo><Affiliation>Ken and Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brimberry</LastName><ForeName>Ross</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Ken and Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Peter</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-3938-6716</Identifier><AffiliationInfo><Affiliation>Ken and Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirchner</LastName><ForeName>Rory</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-4814-5885</Identifier><AffiliationInfo><Affiliation>Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chapman</LastName><ForeName>Brad A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hofmann</LastName><ForeName>Oliver</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0002-7738-1513</Identifier><AffiliationInfo><Affiliation>Department of Clinical Pathology, University of Melbourne, Victoria 3000, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hide</LastName><ForeName>Winston</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0002-8621-3271</Identifier><AffiliationInfo><Affiliation>Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Procissi</LastName><ForeName>Daniele</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-5350-0170</Identifier><AffiliationInfo><Affiliation>Department of Radiology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanania</LastName><ForeName>Taleen</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-6712-8998</Identifier><AffiliationInfo><Affiliation>PsychoGenics Inc., Paramus, NJ 07652, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leiser</LastName><ForeName>Steven C</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>PsychoGenics Inc., Paramus, NJ 07652, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanzi</LastName><ForeName>Rudolph E</ForeName><Initials>RE</Initials><Identifier Source="ORCID">0000-0002-7032-1454</Identifier><AffiliationInfo><Affiliation>Genetics and Aging Unit and McCance Center for Brain Health, Department of Neurology, Massachusetts General Hospital, Boston, MA 02129, USA. r-vassar@northwestern.edu tanzi@helix.mgh.harvard.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vassar</LastName><ForeName>Robert</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-1358-504X</Identifier><AffiliationInfo><Affiliation>Ken and Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA. r-vassar@northwestern.edu tanzi@helix.mgh.harvard.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mesulam Center for Cognitive Neurology and Alzheimer's Disease, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG013854</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000806">Angiotensin-Converting Enzyme Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000806" MajorTopicYN="N">Angiotensin-Converting Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>8</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>5</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>1</Day><Hour>5</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32998969</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.aaz2541</ArticleId><ArticleId IdType="pii">12/563/eaaz2541</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33000167</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>01</Day></DateCompleted><DateRevised><Year>2022</Year><Month>09</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1554-6578</ISSN><JournalIssue CitedMedium="Internet"><Volume>79</Volume><Issue>11</Issue><PubDate><Year>2020</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of neuropathology and experimental neurology</Title><ISOAbbreviation>J Neuropathol Exp Neurol</ISOAbbreviation></Journal><ArticleTitle>Risk of Transmissibility From Neurodegenerative Disease-Associated Proteins: Experimental Knowns and Unknowns.</ArticleTitle><Pagination><StartPage>1141</StartPage><EndPage>1146</EndPage><MedlinePgn>1141-1146</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/jnen/nlaa109</ELocationID><Abstract><AbstractText>Recent studies in animal models demonstrate that certain misfolded proteins associated with neurodegenerative diseases can support templated misfolding of cognate native proteins, to propagate across neural systems, and to therefore have some of the properties of classical prion diseases like Creutzfeldt-Jakob disease. The National Institute of Aging convened a meeting to discuss the implications of these observations for research priorities. A summary of the discussion is presented here, with a focus on limitations of current knowledge, highlighting areas that appear to require further investigation in order to guide scientific practice while minimizing potential exposure or risk in the laboratory setting. The committee concluded that, based on all currently available data, although neurodegenerative disease-associated aggregates of several different non-prion proteins can be propagated from humans to experimental animals, there is currently insufficient evidence to suggest more than a negligible risk, if any, of a direct infectious etiology for the human neurodegenerative disorders defined in part by these proteins. Given the importance of this question, the potential for noninvasive human transmission of proteopathic disorders is deserving of further investigation.</AbstractText><CopyrightInformation>&#xa9; 2020 American Association of Neuropathologists, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Asher</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belay</LastName><ForeName>Ermias</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bigio</LastName><ForeName>Eileen</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brandner</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology Queen Square, London.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brubaker</LastName><ForeName>Scott A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caughey</LastName><ForeName>Byron</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, National Institute for Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clark</LastName><ForeName>Brychan</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Damon</LastName><ForeName>Inger</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diamond</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Alzheimer's and Neurodegenerative Diseases, Peter O'Donnell Jr. Brain Institute, University of Texas Southwestern Medical Center, Dallas, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Freund</LastName><ForeName>Michelle</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>National Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>Bradley T</ForeName><Initials>BT</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jucker</LastName><ForeName>Mathias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen and German Center for Neurodegenerative Diseases (DZNE), T&#xfc;bingen.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keene</LastName><ForeName>C Dirk</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of Washington, Seattle, Washington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lieberman</LastName><ForeName>Andrew P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mackiewicz</LastName><ForeName>Miroslaw</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>National Institute on Aging, National Institutes of Health, Bethesda, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montine</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Department of Pathology, Stanford University, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morgello</LastName><ForeName>Susan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Departments of Neurology, Neuroscience, and Pathology, The Icahn School of Medicine at Mount Sinai, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Phelps</LastName><ForeName>Creighton</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Safar</LastName><ForeName>Jiri</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Departments of Pathology and Neurology, Case Western Reserve University, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Neurological Sciences, Rush Alzheimer Disease Center, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schonberger</LastName><ForeName>Lawrence B</ForeName><Initials>LB</Initials><AffiliationInfo><Affiliation>Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sigurdson</LastName><ForeName>Christina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of California - San Diego, San Diego, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silverberg</LastName><ForeName>Nina</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>National Institute on Aging, National Institutes of Health, Bethesda, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Institute on Aging and Center for Neurodegenerative Disease Research, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frosch</LastName><ForeName>Matthew P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, University of Washington, Seattle, Washington.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>C.S. Kubik Laboratory for Neuropathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG062421</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG060961</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS062684</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066509</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG061797</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG062418</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 MH100931</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG013854</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG053760</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH112391</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS105498</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R61 DA048207</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS069566</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG017586</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS108801</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS076896</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS103848</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG058267</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neuropathol Exp Neurol</MedlineTA><NlmUniqueID>2985192R</NlmUniqueID><ISSNLinking>0022-3069</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="Y">Amyloid beta-Peptides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057165" MajorTopicYN="N">Proteostasis Deficiencies</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">A&#x3b2;</Keyword><Keyword MajorTopicYN="N">Neurodegenerative disease</Keyword><Keyword MajorTopicYN="N">Propagation</Keyword><Keyword MajorTopicYN="N">Tau</Keyword><Keyword MajorTopicYN="N">Transmissibility</Keyword><Keyword MajorTopicYN="N">&#x3b1;-Synuclein</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>1</Day><Hour>5</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>10</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33000167</ArticleId><ArticleId IdType="pmc">PMC7577514</ArticleId><ArticleId IdType="doi">10.1093/jnen/nlaa109</ArticleId><ArticleId IdType="pii">5912179</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Caughey B, Kraus A.. Transmissibility versus pathogenicity of self-propagating protein aggregates. Viruses 2019;11:1044</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6893620</ArticleId><ArticleId IdType="pubmed">31717531</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F, Bolmont T, Crowther RA, et al.Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol 2009;11:909&#x2013;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2726961</ArticleId><ArticleId IdType="pubmed">19503072</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen M, Appleby B, Safar JG.. Distinct prion-like strains of amyloid beta implicated in phenotypic diversity of Alzheimer's disease. Prion 2016;10:9&#x2013;17</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4981201</ArticleId><ArticleId IdType="pubmed">26809345</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen ML, Kim C, Haldiman T, et al.Rapidly progressive Alzheimer's disease features distinct structures of amyloid-beta. Brain 2015;138:1009&#x2013;22</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5014074</ArticleId><ArticleId IdType="pubmed">25688081</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisenberg DS, Sawaya MR.. Structural studies of amyloid proteins at the molecular level. Annu Rev Biochem 2017;86:69&#x2013;95</Citation><ArticleIdList><ArticleId IdType="pubmed">28125289</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Eisenberg DS, Crowther RA.. Propagation of Tau Aggregates and Neurodegeneration. Annu Rev Neurosci 2017;40:189&#x2013;210</Citation><ArticleIdList><ArticleId IdType="pubmed">28772101</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba M, Guo JL, McBride JD, et al.Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer's-like tauopathy. J Neurosci 2013;33:1024&#x2013;37</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3575082</ArticleId><ArticleId IdType="pubmed">23325240</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaunmuktane Z, Quaegebeur A, Taipa R, et al.Evidence of amyloid-beta cerebral amyloid angiopathy transmission through neurosurgery. Acta Neuropathol 2018;135:671&#x2013;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5904220</ArticleId><ArticleId IdType="pubmed">29450646</ArticleId></ArticleIdList></Reference><Reference><Citation>Jucker M, Walker LC.. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature 2013;501:45&#x2013;51</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3963807</ArticleId><ArticleId IdType="pubmed">24005412</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraus A, Saijo E, Metrick MA 2nd, et al.Seeding selectivity and ultrasensitive detection of tau aggregate conformers of Alzheimer disease. Acta Neuropathol 2019;137:585&#x2013;98</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6426988</ArticleId><ArticleId IdType="pubmed">30570675</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigurdson CJ, Bartz JC, Glatzel M.. Cellular and molecular mechanisms of prion disease. Annu Rev Pathol Mech Dis 2019;14:497&#x2013;516</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9071098</ArticleId><ArticleId IdType="pubmed">30355150</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaquer-Alicea J, Diamond MI.. Propagation of protein aggregation in neurodegenerative diseases. Annu Rev Biochem 2019;88:785&#x2013;810</Citation><ArticleIdList><ArticleId IdType="pubmed">30917002</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker LC, Diamond MI, Duff KE, et al.Mechanisms of protein seeding in neurodegenerative diseases. JAMA Neurol 2013;70:304&#x2013;10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3665718</ArticleId><ArticleId IdType="pubmed">23599928</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauwers E, Lalli G, Brandner S, et al.Potential human transmission of amyloid &#x3b2; pathology: Surveillance and risks. Lancet Neurol 2020. (in press)</Citation><ArticleIdList><ArticleId IdType="pubmed">32949547</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M, Spires-Jones TL, Prada C, et al.Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature 2008;451:720&#x2013;4</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3264491</ArticleId><ArticleId IdType="pubmed">18256671</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiang W, Yau WM, Lu JX, et al.Structural variation in amyloid-beta fibrils from Alzheimer's disease clinical subtypes. Nature 2017;541:217&#x2013;21</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5233555</ArticleId><ArticleId IdType="pubmed">28052060</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris JA, Devidze N, Verret L, et al.Transsynaptic progression of amyloid-beta-induced neuronal dysfunction within the entorhinal-hippocampal network. Neuron 2010;68:428&#x2013;41</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3050043</ArticleId><ArticleId IdType="pubmed">21040845</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto K, Tanei ZI, Hashimoto T, et al.Chronic optogenetic activation augments abeta pathology in a mouse model of Alzheimer disease. Cell Rep 2015;11:859&#x2013;65</Citation><ArticleIdList><ArticleId IdType="pubmed">25937280</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisele YS, Obermuller U, Heilbronner G, et al.Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis. Science 2010;330:980&#x2013;2</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3233904</ArticleId><ArticleId IdType="pubmed">20966215</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisele YS, Fritschi SK, Hamaguchi T, et al.Multiple factors contribute to the peripheral induction of cerebral beta-amyloidosis. J Neurosci 2014;34:10264&#x2013;73</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6608275</ArticleId><ArticleId IdType="pubmed">25080588</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisele YS, Bolmont T, Heikenwalder M, et al.Induction of cerebral beta-amyloidosis: Intracerebral versus systemic Abeta inoculation. Proc Natl Acad Sci U S A 2009;106:12926&#x2013;31</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2722323</ArticleId><ArticleId IdType="pubmed">19622727</ArticleId></ArticleIdList></Reference><Reference><Citation>Purro SA, Farrow MA, Linehan J, et al.Transmission of amyloid-beta protein pathology from cadaveric pituitary growth hormone. Nature 2018;564:415&#x2013;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6708408</ArticleId><ArticleId IdType="pubmed">30546139</ArticleId></ArticleIdList></Reference><Reference><Citation>Cali I, Cohen ML, Haik S, et al.Iatrogenic Creutzfeldt-Jakob disease with Amyloid-beta pathology: An international study. Acta Neuropathol Commun 2018;6:5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5759292</ArticleId><ArticleId IdType="pubmed">29310723</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin DJ, Abrams JY, Schonberger LB, et al.Evaluation of potential infectivity of Alzheimer and Parkinson disease proteins in recipients of cadaver-derived human growth hormone. JAMA Neurol 2013;70:462&#x2013;8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3678373</ArticleId><ArticleId IdType="pubmed">23380910</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee G, Adams ME, Jaunmuktane Z, et al.Early onset cerebral amyloid angiopathy following childhood exposure to cadaveric dura. Ann Neurol 2019;85:284&#x2013;90</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6492172</ArticleId><ArticleId IdType="pubmed">30597599</ArticleId></ArticleIdList></Reference><Reference><Citation>Herve D, Porche M, Cabrejo L, et al.Fatal Abeta cerebral amyloid angiopathy 4 decades after a dural graft at the age of 2 years. Acta Neuropathol 2018;135:801&#x2013;3</Citation><ArticleIdList><ArticleId IdType="pubmed">29508058</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwasaki Y, Imamura K, Iwai K, et al.Autopsied case of non-plaque-type dura mater graft-associated Creutzfeldt-Jakob disease presenting with extensive amyloid-beta deposition. Neuropathology 2018;38:549&#x2013;56</Citation><ArticleIdList><ArticleId IdType="pubmed">30084170</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs GG, Lutz MI, Ricken G, et al.Dura mater is a potential source of Abeta seeds. Acta Neuropathol 2016;131:911&#x2013;23</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4865536</ArticleId><ArticleId IdType="pubmed">27016065</ArticleId></ArticleIdList></Reference><Reference><Citation>Giaccone G, Maderna E, Marucci G, et al.Iatrogenic early onset cerebral amyloid angiopathy 30 years after cerebral trauma with neurosurgery: Vascular amyloid deposits are made up of both Abeta40 and Abeta42. Acta Neuropathol Commun 2019;7:70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6498603</ArticleId><ArticleId IdType="pubmed">31046829</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamaguchi T, Komatsu J, Sakai K, et al.Cerebral hemorrhagic stroke associated with cerebral amyloid angiopathy in young adults about 3 decades after neurosurgeries in their infancy. J Neurol Sci 2019;399:3&#x2013;5</Citation><ArticleIdList><ArticleId IdType="pubmed">30735884</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikonomovic MD, Uryu K, Abrahamson EE, et al.Alzheimer's pathology in human temporal cortex surgically excised after severe brain injury. Exp Neurol 2004;190:192&#x2013;203</Citation><ArticleIdList><ArticleId IdType="pubmed">15473992</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon B, Zhang W, Murzin AG, et al.Structures of filaments from Pick's disease reveal a novel tau protein fold. Nature 2018;561:137&#x2013;40</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6204212</ArticleId><ArticleId IdType="pubmed">30158706</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon B, Zhang W, Schweighauser M, et al.Tau filaments from multiple cases of sporadic and inherited Alzheimer's disease adopt a common fold. Acta Neuropathol 2018;136:699&#x2013;708</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6208733</ArticleId><ArticleId IdType="pubmed">30276465</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon B, Zivanov J, Zhang W, et al.Novel tau filament fold in chronic traumatic encephalopathy encloses hydrophobic molecules. Nature 2019;568:420&#x2013;3</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6472968</ArticleId><ArticleId IdType="pubmed">30894745</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzpatrick AWP, Falcon B, He S, et al.Cryo-EM structures of tau filaments from Alzheimer's disease. Nature 2017;547:185&#x2013;90</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5552202</ArticleId><ArticleId IdType="pubmed">28678775</ArticleId></ArticleIdList></Reference><Reference><Citation>Lippens G, Gigant B.. Elucidating Tau function and dysfunction in the era of cryo-EM. J Biol Chem 2019;294:9316&#x2013;25</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6579466</ArticleId><ArticleId IdType="pubmed">31088912</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Tarutani A, Newell KL, et al.Novel tau filament fold in corticobasal degeneration. Nature 2020;580:283&#x2013;7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7148158</ArticleId><ArticleId IdType="pubmed">32050258</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes BB, Diamond MI.. Cellular models for the study of prions. Cold Spring Harb Perspect Med 2017;7:a024026.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5287063</ArticleId><ArticleId IdType="pubmed">27815306</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes BB, Furman JL, Mahan TE, et al.Proteopathic tau seeding predicts tauopathy in vivo. Proc Natl Acad Sci U S A 2014;111:E4376&#x2013;85</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4205609</ArticleId><ArticleId IdType="pubmed">25261551</ArticleId></ArticleIdList></Reference><Reference><Citation>Narasimhan S, Guo JL, Changolkar L, et al.Pathological Tau strains from human brains recapitulate the diversity of tauopathies in nontransgenic mouse brain. J Neurosci 2017;37:11406&#x2013;23</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5700423</ArticleId><ArticleId IdType="pubmed">29054878</ArticleId></ArticleIdList></Reference><Reference><Citation>Reilly P, Winston CN, Baron KR, et al.Novel human neuronal tau model exhibiting neurofibrillary tangles and transcellular propagation. Neurobiol Dis 2017;106:222&#x2013;34</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5593133</ArticleId><ArticleId IdType="pubmed">28610892</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes BB, Diamond MI.. Prion-like properties of tau protein: The importance of extracellular tau as a therapeutic target. J Biol Chem 2014;289:19855&#x2013;61</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4106306</ArticleId><ArticleId IdType="pubmed">24860099</ArticleId></ArticleIdList></Reference><Reference><Citation>Kfoury N, Holmes BB, Jiang H, et al.Trans-cellular propagation of tau aggregation by fibrillar species. J Biol Chem 2012;287:19440&#x2013;51</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3365982</ArticleId><ArticleId IdType="pubmed">22461630</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo JL, Lee VM.. Seeding of normal tau by pathological tau conformers drives pathogenesis of Alzheimer-like tangles. J Biol Chem 2011;286:15317&#x2013;31</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3083182</ArticleId><ArticleId IdType="pubmed">21372138</ArticleId></ArticleIdList></Reference><Reference><Citation>Narasimhan S, Changolkar L, Riddle DM, et al.Human tau pathology transmits glial tau aggregates in the absence of neuronal tau. J Exp Med 2020;217:e20190783&#xa0;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7041709</ArticleId><ArticleId IdType="pubmed">31826239</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda S, Commins C, DeVos SL, et al.Seed-competent high-molecular-weight tau species accumulates in the cerebrospinal fluid of Alzheimer's disease mouse model and human patients. Ann Neurol 2016;80:355&#x2013;67</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5016222</ArticleId><ArticleId IdType="pubmed">27351289</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegmann S, Maury EA, Kirk MJ, et al.Removing endogenous tau does not prevent tau propagation yet reduces its neurotoxicity. Embo J 2015;34:3028&#x2013;41</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4687785</ArticleId><ArticleId IdType="pubmed">26538322</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller CM, de Vos RA, Maurage CA, et al.Staging of sporadic Parkinson disease-related alpha-synuclein pathology: Inter- and intra-rater reliability. J Neuropathol Exp Neurol 2005;64:623&#x2013;8</Citation><ArticleIdList><ArticleId IdType="pubmed">16042314</ArticleId></ArticleIdList></Reference><Reference><Citation>Kordower JH, Chu Y, Hauser RA, et al.Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med 2008;14:504&#x2013;6</Citation><ArticleIdList><ArticleId IdType="pubmed">18391962</ArticleId></ArticleIdList></Reference><Reference><Citation>Li JY, Englund E, Widner H, et al.Characterization of Lewy body pathology in 12- and 16-year-old intrastriatal mesencephalic grafts surviving in a patient with Parkinson's disease. Mov Disord 2010;25:1091&#x2013;6</Citation><ArticleIdList><ArticleId IdType="pubmed">20198645</ArticleId></ArticleIdList></Reference><Reference><Citation>Prusiner SB, Woerman AL, Mordes DA, et al.Evidence for alpha-synuclein prions causing multiple system atrophy in humans with parkinsonism. Proc Natl Acad Sci U S A 2015;112:E5308&#x2013;17</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4586853</ArticleId><ArticleId IdType="pubmed">26324905</ArticleId></ArticleIdList></Reference><Reference><Citation>Watts JC, Giles K, Oehler A, et al.Transmission of multiple system atrophy prions to transgenic mice. Proc Natl Acad Sci U S A 2013;110:19555&#x2013;60</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3845125</ArticleId><ArticleId IdType="pubmed">24218576</ArticleId></ArticleIdList></Reference><Reference><Citation>Woerman AL, Kazmi SA, Patel S, et al.MSA prions exhibit remarkable stability and resistance to inactivation. Acta Neuropathol 2018;135:49&#x2013;63</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5756500</ArticleId><ArticleId IdType="pubmed">28849371</ArticleId></ArticleIdList></Reference><Reference><Citation>Woerman AL, Oehler A, Kazmi SA, et al.Multiple system atrophy prions retain strain specificity after serial propagation in two different Tg(SNCA*A53T) mouse lines. Acta Neuropathol 2019;137:437&#x2013;54</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6454887</ArticleId><ArticleId IdType="pubmed">30690664</ArticleId></ArticleIdList></Reference><Reference><Citation>Woerman AL, Patel S, Kazmi SA, et al.Kinetics of alpha-synuclein prions preceding neuropathological inclusions in multiple system atrophy. PLoS Pathog 2020;16:e1008222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6999861</ArticleId><ArticleId IdType="pubmed">32017806</ArticleId></ArticleIdList></Reference><Reference><Citation>Li B, Ge P, Murray KA, et al.Cryo-EM of full-length alpha-synuclein reveals fibril polymorphs with a common structural kernel. Nat Commun 2018;9:3609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6127345</ArticleId><ArticleId IdType="pubmed">30190461</ArticleId></ArticleIdList></Reference><Reference><Citation>Polinski NK, Volpicelli-Daley LA, Sortwell CE, et al.Best practices for generating and using alpha-synuclein pre-formed fibrils to model Parkinson's disease in rodents. J Parkinsons Dis 2018;8:303&#x2013;22</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6004926</ArticleId><ArticleId IdType="pubmed">29400668</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacino AN, Brooks M, Thomas MA, et al.Intramuscular injection of alpha-synuclein induces CNS alpha-synuclein pathology and a rapid-onset motor phenotype in transgenic mice. Proc Natl Acad Sci U S A 2014;111:10732&#x2013;7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4115570</ArticleId><ArticleId IdType="pubmed">25002524</ArticleId></ArticleIdList></Reference><Reference><Citation>Volpicelli-Daley L, Brundin P.. Prion-like propagation of pathology in Parkinson disease. Handb Clin Neurol 2018;153:321&#x2013;35</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6625652</ArticleId><ArticleId IdType="pubmed">29887143</ArticleId></ArticleIdList></Reference><Reference><Citation>Volpicelli-Daley LA, Luk KC, Lee VM.. Addition of exogenous alpha-synuclein preformed fibrils to primary neuronal cultures to seed recruitment of endogenous alpha-synuclein to Lewy body and Lewy neurite-like aggregates. Nat Protoc 2014;9:2135&#x2013;46</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4372899</ArticleId><ArticleId IdType="pubmed">25122523</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu Y, Muller S, Tavares A, et al.Intrastriatal alpha-synuclein fibrils in monkeys: Spreading, imaging and neuropathological changes. Brain 2019;142:3565&#x2013;79</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7962904</ArticleId><ArticleId IdType="pubmed">31580415</ArticleId></ArticleIdList></Reference><Reference><Citation>Henderson MX, Cornblath EJ, Darwich A, et al.Spread of alpha-synuclein pathology through the brain connectome is modulated by selective vulnerability and predicted by network analysis. Nat Neurosci 2019;22:1248&#x2013;57</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6662627</ArticleId><ArticleId IdType="pubmed">31346295</ArticleId></ArticleIdList></Reference><Reference><Citation>Karpowicz RJ Jr, Trojanowski JQ, Lee VM.. Transmission of alpha-synuclein seeds in neurodegenerative disease: Recent developments. Lab Invest 2019;99:971&#x2013;81</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6609465</ArticleId><ArticleId IdType="pubmed">30760864</ArticleId></ArticleIdList></Reference><Reference><Citation>Uemura N, Uemura MT, Lo A, et al.Slow progressive accumulation of oligodendroglial alpha-synuclein (alpha-Syn) pathology in synthetic alpha-syn fibril-induced mouse models of synucleinopathy. J Neuropathol Exp Neurol 2019;78:877&#x2013;90</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6934438</ArticleId><ArticleId IdType="pubmed">31504665</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahnawaz M, Mukherjee A, Pritzkow S, et al.Discriminating alpha-synuclein strains in Parkinson's disease and multiple system atrophy. Nature 2020;578:273&#x2013;7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7066875</ArticleId><ArticleId IdType="pubmed">32025029</ArticleId></ArticleIdList></Reference><Reference><Citation>Brundin P, Melki R.. Prying into the prion hypothesis for Parkinson's disease. J Neurosci 2017;37:9808&#x2013;18</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5637113</ArticleId><ArticleId IdType="pubmed">29021298</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiner JA, Quansah E, Brundin P.. The concept of alpha-synuclein as a prion-like protein: Ten years after. Cell Tissue Res 2018;373:161&#x2013;73</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6541204</ArticleId><ArticleId IdType="pubmed">29480459</ArticleId></ArticleIdList></Reference><Reference><Citation>Surmeier DJ, Obeso JA, Halliday GM.. Parkinson's disease is not simply a prion disorder. J Neurosci 2017;37:9799&#x2013;807</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5637112</ArticleId><ArticleId IdType="pubmed">29021297</ArticleId></ArticleIdList></Reference><Reference><Citation>Fritschi SK, Cintron A, Ye L, et al.Abeta seeds resist inactivation by formaldehyde. Acta Neuropathol 2014;128:477&#x2013;84</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4169116</ArticleId><ArticleId IdType="pubmed">25193240</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufman SK, Thomas TL, Del Tredici K, et al.Characterization of tau prion seeding activity and strains from formaldehyde-fixed tissue. Acta Neuropathol Commun 2017;5:41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5461712</ArticleId><ArticleId IdType="pubmed">28587664</ArticleId></ArticleIdList></Reference><Reference><Citation>Schweighauser M, Bacioglu M, Fritschi SK, et al.Formaldehyde-fixed brain tissue from spontaneously ill alpha-synuclein transgenic mice induces fatal alpha-synucleinopathy in transgenic hosts. Acta Neuropathol 2015;129:157&#x2013;9</Citation><ArticleIdList><ArticleId IdType="pubmed">25367384</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughson AG, Race B, Kraus A, et al.Inactivation of prions and amyloid seeds with hypochlorous acid. PLoS Pathog 2016;12:e1005914.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5042475</ArticleId><ArticleId IdType="pubmed">27685252</ArticleId></ArticleIdList></Reference><Reference><Citation>Duyckaerts C, Sazdovitch V, Ando K, et al.Neuropathology of iatrogenic Creutzfeldt-Jakob disease and immunoassay of French cadaver-sourced growth hormone batches suggest possible transmission of tauopathy and long incubation periods for the transmission of Abeta pathology. Acta Neuropathol 2018;135:201&#x2013;12</Citation><ArticleIdList><ArticleId IdType="pubmed">29209767</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie DL, Adlard P, Peden AH, et al.Amyloid-beta accumulation in the CNS in human growth hormone recipients in the UK. Acta Neuropathol 2017;134:221&#x2013;40</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5508038</ArticleId><ArticleId IdType="pubmed">28349199</ArticleId></ArticleIdList></Reference><Reference><Citation>Fenyi A, Coens A, Bellande T, et al.Assessment of the efficacy of different procedures that remove and disassemble alpha-synuclein, tau and A-beta fibrils from laboratory material and surfaces. Sci Rep 2018;8:10788.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6050226</ArticleId><ArticleId IdType="pubmed">30018327</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomzig A, Wagenfuhr K, Daus ML, et al.Decontamination of medical devices from pathological amyloid-beta-, tau- and alpha-synuclein aggregates. Acta Neuropathol Commun 2014;2:151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4213499</ArticleId><ArticleId IdType="pubmed">25344093</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye L, Fritschi SK, Schelle J, et al.Persistence of Abeta seeds in APP null mouse brain. Nat Neurosci 2015;18:1559&#x2013;61</Citation><ArticleIdList><ArticleId IdType="pubmed">26352792</ArticleId></ArticleIdList></Reference><Reference><Citation>Candelise N, Schmitz M, Llorens F, et al.Seeding variability of different alpha synuclein strains in synucleinopathies. Ann Neurol 2019;85:691&#x2013;703</Citation><ArticleIdList><ArticleId IdType="pubmed">30805957</ArticleId></ArticleIdList></Reference><Reference><Citation>Caughey B, Orru CD, Groveman BR, et al.Amplified detection of prions and other amyloids by RT-QuIC in diagnostics and the evaluation of therapeutics and disinfectants. Prog Mol Biol Transl Sci 2017;150:375&#x2013;88</Citation><ArticleIdList><ArticleId IdType="pubmed">28838670</ArticleId></ArticleIdList></Reference><Reference><Citation>Connor A, Wang H, Appleby BS, et al.Clinical laboratory tests used to aid in diagnosis of human prion disease. J Clin Microbiol 2019;57:e00769&#x2013;19</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6760952</ArticleId><ArticleId IdType="pubmed">31366689</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiorini M, Iselle G, Perra D, et al.High diagnostic accuracy of RT-QuIC assay in a prospective study of patients with suspected sCJD. Int J Mol Sci 2020;21:880</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7038328</ArticleId><ArticleId IdType="pubmed">32019068</ArticleId></ArticleIdList></Reference><Reference><Citation>Groveman BR, Orru CD, Hughson AG, et al.Rapid and ultra-sensitive quantitation of disease-associated alpha-synuclein seeds in brain and cerebrospinal fluid by alphaSyn RT-QuIC. Acta Neuropathol Commun 2018;6:7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5806364</ArticleId><ArticleId IdType="pubmed">29422107</ArticleId></ArticleIdList></Reference><Reference><Citation>Metrick MA 2nd, do Carmo Ferreira N, Saijo E, et al.Million-fold sensitivity enhancement in proteopathic seed amplification assays for biospecimens by Hofmeister ion comparisons. Proc Natl Acad Sci U S A 2019;116:23029&#x2013;39</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6859373</ArticleId><ArticleId IdType="pubmed">31641070</ArticleId></ArticleIdList></Reference><Reference><Citation>Metrick MA 2nd, Ferreira NDC, Saijo E, et al.A single ultrasensitive assay for detection and discrimination of tau aggregates of Alzheimer and Pick diseases. Acta Neuropathol Commun 2020;8:22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7036215</ArticleId><ArticleId IdType="pubmed">32087764</ArticleId></ArticleIdList></Reference><Reference><Citation>Saijo E, Metrick MA 2nd, Koga S, et al.4-Repeat tau seeds and templating subtypes as brain and CSF biomarkers of frontotemporal lobar degeneration. Acta Neuropathol 2020;139:63&#x2013;77</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7192393</ArticleId><ArticleId IdType="pubmed">31616982</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito T, Mihira N, Matsuba Y, et al.Humanization of the entire murine Mapt gene provides a murine model of pathological human tau propagation. J Biol Chem 2019;294:12754&#x2013;65</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6709628</ArticleId><ArticleId IdType="pubmed">31273083</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh S, DeMarco ML.. In vitro conversion assays diagnostic for neurodegenerative proteinopathies. J Appl Lab Med 2020;5:142&#x2013;57</Citation><ArticleIdList><ArticleId IdType="pubmed">31811072</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33004602</PMID><DateCompleted><Year>2021</Year><Month>01</Month><Day>19</Day></DateCompleted><DateRevised><Year>2021</Year><Month>09</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>96</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>Jan</Month><Day>12</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>CSF Biomarkers in Patients With COVID-19 and Neurologic Symptoms: A Case Series.</ArticleTitle><Pagination><StartPage>e294</StartPage><EndPage>e300</EndPage><MedlinePgn>e294-e300</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000010977</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To explore whether hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and neurologic symptoms have evidence of CNS infection, inflammation, and injury using CSF biomarker measurements.</AbstractText><AbstractText Label="METHODS">We assessed CSF SARS-CoV-2 RNA along with CSF biomarkers of intrathecal inflammation (CSF white blood cell count, neopterin, &#x3b2;<sub>2</sub>-microglobulin, and immunoglobulin G index), blood-brain barrier integrity (albumin ratio), and axonal injury (CSF neurofilament light chain protein [NfL]) in 6 patients with moderate to severe coronavirus disease 2019 (COVID-19) and neurologic symptoms who had undergone a diagnostic lumbar puncture. Neurologic symptoms and signs included features of encephalopathies (4 of 6), suspected meningitis (1 of 6), and dysgeusia (1 of 6). SARS-CoV-2 infection was confirmed by real-time PCR analysis of nasopharyngeal swabs.</AbstractText><AbstractText Label="RESULTS">SARS-CoV-2 RNA was detected in the plasma of 2 patients (cycle threshold [Ct] value 35.0-37.0) and in CSF at low levels (Ct 37.2, 38.0, 39.0) in 3 patients in 1 but not in a second real-time PCR assay. CSF neopterin (median 43.0 nmol/L) and &#x3b2;<sub>2</sub>-microglobulin (median 3.1 mg/L) were increased in all. Median immunoglobulin G index (0.39), albumin ratio (5.35), and CSF white blood cell count (&lt;3 cells/&#xb5;L) were normal in all, while CSF NfL was elevated in 2 patients.</AbstractText><AbstractText Label="CONCLUSION">Our results in patients with COVID-19 and neurologic symptoms suggest an unusual pattern of marked CSF inflammation in which soluble markers were increased but white cell response and other immunologic features typical of CNS viral infections were absent. While our initial hypothesis centered on CNS SARS-CoV-2 invasion, we could not convincingly detect SARS-CoV-2 as the underlying driver of CNS inflammation. These features distinguish COVID-19 CSF from other viral CNS infections and raise fundamental questions about the CNS pathobiology of SARS-CoV-2 infection.</AbstractText><CopyrightInformation>&#xa9; 2020 American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ed&#xe9;n</LastName><ForeName>Arvid</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>From the Department of Infectious Diseases (A.E., N.K., L.H., L.-M.A., M.L., M.G.), Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg; Region V&#xe4;stra G&#xf6;taland (A.E., N.K., L.H., L.-M.A., M.G.), Sahlgrenska University Hospital, Department of Infectious Diseases, Gothenburg, Sweden; Institutes of Medical Biochemistry (J.G.) and Biological Chemistry (D.F.), Medical University of Innsbruck, Biocenter, Austria; Department of Neurology (R.W.P.), University of California San Francisco; Department of Psychiatry and Neurochemistry (H.Z.), Institute of Neuroscience &amp; Physiology, Sahlgrenska Academy at the University of Gothenburg; Clinical Neurochemistry Laboratory (H.Z.), Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology; and UK Dementia Research Institute at UCL (H.Z.), London.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanberg</LastName><ForeName>Nelly</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>From the Department of Infectious Diseases (A.E., N.K., L.H., L.-M.A., M.L., M.G.), Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg; Region V&#xe4;stra G&#xf6;taland (A.E., N.K., L.H., L.-M.A., M.G.), Sahlgrenska University Hospital, Department of Infectious Diseases, Gothenburg, Sweden; Institutes of Medical Biochemistry (J.G.) and Biological Chemistry (D.F.), Medical University of Innsbruck, Biocenter, Austria; Department of Neurology (R.W.P.), University of California San Francisco; Department of Psychiatry and Neurochemistry (H.Z.), Institute of Neuroscience &amp; Physiology, Sahlgrenska Academy at the University of Gothenburg; Clinical Neurochemistry Laboratory (H.Z.), Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology; and UK Dementia Research Institute at UCL (H.Z.), London.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gostner</LastName><ForeName>Johanna</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-1532-5177</Identifier><AffiliationInfo><Affiliation>From the Department of Infectious Diseases (A.E., N.K., L.H., L.-M.A., M.L., M.G.), Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg; Region V&#xe4;stra G&#xf6;taland (A.E., N.K., L.H., L.-M.A., M.G.), Sahlgrenska University Hospital, Department of Infectious Diseases, Gothenburg, Sweden; Institutes of Medical Biochemistry (J.G.) and Biological Chemistry (D.F.), Medical University of Innsbruck, Biocenter, Austria; Department of Neurology (R.W.P.), University of California San Francisco; Department of Psychiatry and Neurochemistry (H.Z.), Institute of Neuroscience &amp; Physiology, Sahlgrenska Academy at the University of Gothenburg; Clinical Neurochemistry Laboratory (H.Z.), Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology; and UK Dementia Research Institute at UCL (H.Z.), London.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fuchs</LastName><ForeName>Dietmar</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>From the Department of Infectious Diseases (A.E., N.K., L.H., L.-M.A., M.L., M.G.), Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg; Region V&#xe4;stra G&#xf6;taland (A.E., N.K., L.H., L.-M.A., M.G.), Sahlgrenska University Hospital, Department of Infectious Diseases, Gothenburg, Sweden; Institutes of Medical Biochemistry (J.G.) and Biological Chemistry (D.F.), Medical University of Innsbruck, Biocenter, Austria; Department of Neurology (R.W.P.), University of California San Francisco; Department of Psychiatry and Neurochemistry (H.Z.), Institute of Neuroscience &amp; Physiology, Sahlgrenska Academy at the University of Gothenburg; Clinical Neurochemistry Laboratory (H.Z.), Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology; and UK Dementia Research Institute at UCL (H.Z.), London.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hagberg</LastName><ForeName>Lars</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>From the Department of Infectious Diseases (A.E., N.K., L.H., L.-M.A., M.L., M.G.), Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg; Region V&#xe4;stra G&#xf6;taland (A.E., N.K., L.H., L.-M.A., M.G.), Sahlgrenska University Hospital, Department of Infectious Diseases, Gothenburg, Sweden; Institutes of Medical Biochemistry (J.G.) and Biological Chemistry (D.F.), Medical University of Innsbruck, Biocenter, Austria; Department of Neurology (R.W.P.), University of California San Francisco; Department of Psychiatry and Neurochemistry (H.Z.), Institute of Neuroscience &amp; Physiology, Sahlgrenska Academy at the University of Gothenburg; Clinical Neurochemistry Laboratory (H.Z.), Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology; and UK Dementia Research Institute at UCL (H.Z.), London.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andersson</LastName><ForeName>Lars-Magnus</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>From the Department of Infectious Diseases (A.E., N.K., L.H., L.-M.A., M.L., M.G.), Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg; Region V&#xe4;stra G&#xf6;taland (A.E., N.K., L.H., L.-M.A., M.G.), Sahlgrenska University Hospital, Department of Infectious Diseases, Gothenburg, Sweden; Institutes of Medical Biochemistry (J.G.) and Biological Chemistry (D.F.), Medical University of Innsbruck, Biocenter, Austria; Department of Neurology (R.W.P.), University of California San Francisco; Department of Psychiatry and Neurochemistry (H.Z.), Institute of Neuroscience &amp; Physiology, Sahlgrenska Academy at the University of Gothenburg; Clinical Neurochemistry Laboratory (H.Z.), Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology; and UK Dementia Research Institute at UCL (H.Z.), London.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lindh</LastName><ForeName>Magnus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Department of Infectious Diseases (A.E., N.K., L.H., L.-M.A., M.L., M.G.), Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg; Region V&#xe4;stra G&#xf6;taland (A.E., N.K., L.H., L.-M.A., M.G.), Sahlgrenska University Hospital, Department of Infectious Diseases, Gothenburg, Sweden; Institutes of Medical Biochemistry (J.G.) and Biological Chemistry (D.F.), Medical University of Innsbruck, Biocenter, Austria; Department of Neurology (R.W.P.), University of California San Francisco; Department of Psychiatry and Neurochemistry (H.Z.), Institute of Neuroscience &amp; Physiology, Sahlgrenska Academy at the University of Gothenburg; Clinical Neurochemistry Laboratory (H.Z.), Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology; and UK Dementia Research Institute at UCL (H.Z.), London.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Price</LastName><ForeName>Richard W</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>From the Department of Infectious Diseases (A.E., N.K., L.H., L.-M.A., M.L., M.G.), Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg; Region V&#xe4;stra G&#xf6;taland (A.E., N.K., L.H., L.-M.A., M.G.), Sahlgrenska University Hospital, Department of Infectious Diseases, Gothenburg, Sweden; Institutes of Medical Biochemistry (J.G.) and Biological Chemistry (D.F.), Medical University of Innsbruck, Biocenter, Austria; Department of Neurology (R.W.P.), University of California San Francisco; Department of Psychiatry and Neurochemistry (H.Z.), Institute of Neuroscience &amp; Physiology, Sahlgrenska Academy at the University of Gothenburg; Clinical Neurochemistry Laboratory (H.Z.), Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology; and UK Dementia Research Institute at UCL (H.Z.), London.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>From the Department of Infectious Diseases (A.E., N.K., L.H., L.-M.A., M.L., M.G.), Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg; Region V&#xe4;stra G&#xf6;taland (A.E., N.K., L.H., L.-M.A., M.G.), Sahlgrenska University Hospital, Department of Infectious Diseases, Gothenburg, Sweden; Institutes of Medical Biochemistry (J.G.) and Biological Chemistry (D.F.), Medical University of Innsbruck, Biocenter, Austria; Department of Neurology (R.W.P.), University of California San Francisco; Department of Psychiatry and Neurochemistry (H.Z.), Institute of Neuroscience &amp; Physiology, Sahlgrenska Academy at the University of Gothenburg; Clinical Neurochemistry Laboratory (H.Z.), Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology; and UK Dementia Research Institute at UCL (H.Z.), London.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gissl&#xe9;n</LastName><ForeName>Magnus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Department of Infectious Diseases (A.E., N.K., L.H., L.-M.A., M.L., M.G.), Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg; Region V&#xe4;stra G&#xf6;taland (A.E., N.K., L.H., L.-M.A., M.G.), Sahlgrenska University Hospital, Department of Infectious Diseases, Gothenburg, Sweden; Institutes of Medical Biochemistry (J.G.) and Biological Chemistry (D.F.), Medical University of Innsbruck, Biocenter, Austria; Department of Neurology (R.W.P.), University of California San Francisco; Department of Psychiatry and Neurochemistry (H.Z.), Institute of Neuroscience &amp; Physiology, Sahlgrenska Academy at the University of Gothenburg; Clinical Neurochemistry Laboratory (H.Z.), Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology; and UK Dementia Research Institute at UCL (H.Z.), London. magnus.gisslen@infect.gu.se.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>10</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2021 Sep 7;97(10):508-509. doi: 10.1212/WNL.0000000000012527.</RefSource><PMID Version="1">34489342</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2021 Sep 7;97(10):509. doi: 10.1212/WNL.0000000000012529.</RefSource><PMID Version="1">34489343</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2021 Sep 7;97(10):510. doi: 10.1212/WNL.0000000000012530.</RefSource><PMID Version="1">34489344</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001812" MajorTopicYN="N">Blood-Brain Barrier</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009422" MajorTopicYN="N">Nervous System Diseases</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation &amp; purification</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>9</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>1</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>2</Day><Hour>5</Hour><Minute>36</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33004602</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000010977</ArticleId><ArticleId IdType="pii">WNL.0000000000010977</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33027662</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>15</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Oct</Month><Day>06</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>PICALM Rescues Endocytic Defects Caused by the Alzheimer's Disease Risk Factor APOE4.</ArticleTitle><Pagination><StartPage>108224</StartPage><MedlinePgn>108224</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2020.108224</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(20)31213-4</ELocationID><Abstract><AbstractText>The &#x3b5;4 allele of apolipoprotein E (APOE4) is a genetic risk factor for many diseases, including late-onset Alzheimer's disease (AD). We investigate the cellular consequences of APOE4 in human iPSC-derived astrocytes, observing an endocytic defect in APOE4 astrocytes compared with their isogenic APOE3 counterparts. Given the evolutionarily conserved nature of endocytosis, we built a yeast model to identify genetic modifiers of the endocytic defect associated with APOE4. In yeast, only the expression of APOE4 results in dose-dependent defects in both endocytosis and growth. We discover that increasing expression of the early endocytic adaptor protein Yap1802p, a homolog of the human AD risk factor PICALM, rescues the APOE4-induced endocytic defect. In iPSC-derived human astrocytes, increasing expression of PICALM similarly reverses endocytic disruptions. Our work identifies a functional interaction between two AD genetic risk factors-APOE4 and PICALM-centered on the conserved biological process of endocytosis.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Narayan</LastName><ForeName>Priyanka</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA; Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Genetics and Biochemistry Branch, NIDDK, National Institutes of Health, Bethesda, MD 20814, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sienski</LastName><ForeName>Grzegorz</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonner</LastName><ForeName>Julia M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA; Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Yuan-Ta</ForeName><Initials>YT</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seo</LastName><ForeName>Jinsoo</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baru</LastName><ForeName>Valeriya</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haque</LastName><ForeName>Aftabul</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Milo</LastName><ForeName>Blerta</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akay</LastName><ForeName>Leyla A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graziosi</LastName><ForeName>Agnese</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Freyzon</LastName><ForeName>Yelena</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landgraf</LastName><ForeName>Dirk</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hesse</LastName><ForeName>William R</ForeName><Initials>WR</Initials><AffiliationInfo><Affiliation>Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valastyan</LastName><ForeName>Julie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barrasa</LastName><ForeName>M Inmaculada</ForeName><Initials>MI</Initials><AffiliationInfo><Affiliation>Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Li-Huei</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA. Electronic address: lhtsai@mit.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lindquist</LastName><ForeName>Susan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Howard Hughes Medical Institute, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>K99 AG055697</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG062377</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 HG008097</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS087557</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007287</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG058002</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004705" MajorTopicYN="N">Endocytosis</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">PICALM</Keyword><Keyword MajorTopicYN="N">apolipoprotein E</Keyword><Keyword MajorTopicYN="N">astrocytes</Keyword><Keyword MajorTopicYN="N">endocytosis</Keyword><Keyword MajorTopicYN="N">genetic risk factors</Keyword><Keyword MajorTopicYN="N">iPS cells</Keyword><Keyword MajorTopicYN="N">neurodegenerative disease</Keyword><Keyword MajorTopicYN="N">stem cells</Keyword><Keyword MajorTopicYN="N">trafficking</Keyword><Keyword MajorTopicYN="N">yeast</Keyword></KeywordList><CoiStatement>Declaration of Interests P.N. and S.L. are inventors on US patent US20160251665A. G.S. is an employee and shareholder of AstraZeneca. S.L. was a co-founder of Yumanity Therapeutics. L.-H.T. is a member of the scientific advisory board of Yumanity Therapeutics.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>2</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>8</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>7</Day><Hour>20</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>6</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33027662</ArticleId><ArticleId IdType="mid">NIHMS1706470</ArticleId><ArticleId IdType="pmc">PMC8190562</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2020.108224</ArticleId><ArticleId IdType="pii">S2211-1247(20)31213-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Antonescu CN, McGraw TE, Klip A, 2014. Reciprocal regulation of endocytosis and metabolism. Cold Spring Harbor Perspectives in Biology 6, a016964&#x2013;a016964. doi:10.1101/cshperspect.a016964</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a016964</ArticleId><ArticleId IdType="pmc">PMC4067987</ArticleId><ArticleId IdType="pubmed">24984778</ArticleId></ArticleIdList></Reference><Reference><Citation>Aranda-D&#xed;az A, Mace K, Zuleta I, Harrigan P, El-Samad H, 2016. Robust Synthetic Circuits for Two-Dimensional Control of Gene Expression in Yeast. ACS Synth. Biol 6, 545&#x2013;554. doi:10.1021/acssynbio.6b00251</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acssynbio.6b00251</ArticleId><ArticleId IdType="pmc">PMC5507677</ArticleId><ArticleId IdType="pubmed">27930885</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanchard JW, Bula M, Davila-Velderrain J, Akay LA, Zhu L, Frank A, Victor MB, Bonner JM, Mathys H, Lin Y-T, Ko T, Bennett DA, Cam HP, Kellis M, Tsai L-H, 2020. Reconstruction of the human blood&#x2013;brain barrier in vitro reveals a pathogenic mechanism of APOE4 in pericytes. Nature Medicine 26, 952&#x2013;963. doi:10.1038/s41591-020-0886-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0886-4</ArticleId><ArticleId IdType="pmc">PMC7704032</ArticleId><ArticleId IdType="pubmed">32514169</ArticleId></ArticleIdList></Reference><Reference><Citation>Boettner DR, Chi RJ, Lemmon SK, 2012. Lessons from yeast for clathrin-mediated endocytosis. Nature Cell Biology 14, 2&#x2013;10. doi:10.1038/ncb2403</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb2403</ArticleId><ArticleId IdType="pmc">PMC5590828</ArticleId><ArticleId IdType="pubmed">22193158</ArticleId></ArticleIdList></Reference><Reference><Citation>Burston HE, Maldonado-B&#xe1;ez L, Davey M, Montpetit B, Schluter C, Wendland B, Conibear E, 2009. Regulators of yeast endocytosis identified by systematic quantitative analysis. The Journal of Cell Biology 185, 1097&#x2013;1110. doi:10.1083/jcb.200811116</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200811116</ArticleId><ArticleId IdType="pmc">PMC2711619</ArticleId><ArticleId IdType="pubmed">19506040</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataldo AM, Peterhoff CM, Troncoso JC, Gomez-Isla T, Hyman BT, Nixon RA, 2010. Endocytic Pathway Abnormalities Precede Amyloid &#x3b2; Deposition in Sporadic Alzheimer&#x2019;s Disease and Down Syndrome. The American Journal of Pathology 157, 277&#x2013;286. doi:10.1016/S0002-9440(10)64538-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9440(10)64538-5</ArticleId><ArticleId IdType="pmc">PMC1850219</ArticleId><ArticleId IdType="pubmed">10880397</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Jiang P, Xue H, Peterson SE, Tran HT, McCann AE, Parast MM, Li S, Pleasure DE, Laurent LC, Loring JF, Liu Y, Deng W, 2014. Role of astroglia in Down&#x2019;s syndrome revealed by patient-derived human-induced pluripotent stem cells. Nature Communications 5. doi:10.1038/ncomms5430</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms5430</ArticleId><ArticleId IdType="pmc">PMC4109022</ArticleId><ArticleId IdType="pubmed">25034944</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small G, Roses AD, Haines JL, Pericak-Vance MA, 1993. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer&#x2019;s disease in late onset families. Science 261, 921&#x2013;923. doi:10.1126/science.8346443</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8346443</ArticleId><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalton L, Davey M, Conibear E, 2015. Large-Scale Analysis of Membrane Transport in Yeast Using Invertase Reporters, Methods in Molecular Biology 1270, 395&#x2013;409. doi:10.1007/978-1-4939-2309-0_27</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-2309-0_27</ArticleId><ArticleId IdType="pubmed">25702131</ArticleId></ArticleIdList></Reference><Reference><Citation>Darsow T, Odorizzi G, Emr SD, 2000. Invertase fusion proteins for analysis of protein trafficking in yeast. Meth. Enzymol 327, 95&#x2013;106. doi:10.1016/S0076-6879(00)27270-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0076-6879(00)27270-4</ArticleId><ArticleId IdType="pubmed">11044977</ArticleId></ArticleIdList></Reference><Reference><Citation>Devine MJ, Ryten M, Vodicka P, Thomson AJ, Burdon T, Houlden H, Cavaleri F, Nagano M, Drummond NJ, Taanman J-W, Schapira AH, Gwinn K, Hardy J, Lewis PA, Kunath T, 2011. Parkinson&#x2019;s disease induced pluripotent stem cells with triplication of the alpha-synuclein locus. Nature Communications 2, 440&#x2013;10. doi:10.1038/ncomms1453</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms1453</ArticleId><ArticleId IdType="pmc">PMC3265381</ArticleId><ArticleId IdType="pubmed">21863007</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman G, Froom P, Sazbon L, Grinblatt I, Shochina M, Tsenter J, Babaey S, Yehuda B, Groswasser Z, 1999. Apolipoprotein E-epsilon4 genotype predicts a poor outcome in survivors of traumatic brain injury. Neurology 52, 244&#x2013;248. doi:10.1212/wnl.52.2.244</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.52.2.244</ArticleId><ArticleId IdType="pubmed">9932938</ArticleId></ArticleIdList></Reference><Reference><Citation>Gietz RD, Schiestl RH, 2007. High-efficiency yeast transformation using the LiAc/SS carrier DNA/PEG method. Nat Protoc 2, 31&#x2013;34. doi:10.1038/nprot.2007.13</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2007.13</ArticleId><ArticleId IdType="pubmed">17401334</ArticleId></ArticleIdList></Reference><Reference><Citation>Goode BL, Eskin JA, Wendland B, 2015. Actin and endocytosis in budding yeast. Genetics 199, 315&#x2013;358. doi:10.1534/genetics.112.145540</Citation><ArticleIdList><ArticleId IdType="doi">10.1534/genetics.112.145540</ArticleId><ArticleId IdType="pmc">PMC4317646</ArticleId><ArticleId IdType="pubmed">25657349</ArticleId></ArticleIdList></Reference><Reference><Citation>Harding C, Heuser J, Stahl P, 1983. Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes. The Journal of Cell Biology 97, 329&#x2013;339. doi:10.1083/jcb.97.2.329</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.97.2.329</ArticleId><ArticleId IdType="pmc">PMC2112509</ArticleId><ArticleId IdType="pubmed">6309857</ArticleId></ArticleIdList></Reference><Reference><Citation>Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Sch&#xfc;rmann B, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Fr&#xf6;lich L, Hampel H, H&#xfc;ll M, Rujescu D, Goate AM, Kauwe JSK, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, De Deyn PP, Van Broeckhoven C, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, M&#xfc;hleisen TW, N&#xf6;then MM, Moebus S, J&#xf6;ckel K-H, Klopp N, Wichmann H-E, Carrasquillo MM, Pankratz VS, Younkin SG, Holmans PA, O&#x2019;Donovan M, Owen MJ, Williams J, 2009. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer&#x2019;s disease. Nature Genetics 41, 1088&#x2013;1093. doi:10.1038/ng.440</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.440</ArticleId><ArticleId IdType="pmc">PMC2845877</ArticleId><ArticleId IdType="pubmed">19734902</ArticleId></ArticleIdList></Reference><Reference><Citation>Houlden H, 2006. Apolipoprotein E4 and traumatic brain injury. J Neurol Neurosurg Psychiatry 77, 1106&#x2013;1107. doi:10.1136/jnnp.2006.095513</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2006.095513</ArticleId><ArticleId IdType="pmc">PMC2077546</ArticleId><ArticleId IdType="pubmed">16793859</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson BS, McCaffery JM, Lindquist S, Gitler AD, 2008. A yeast TDP-43 proteinopathy model: Exploring the molecular determinants of TDP-43 aggregation and cellular toxicity. Proc. Natl. Acad. Sci. U.S.A 105, 6439&#x2013;6444. doi:10.1073/pnas.0802082105</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0802082105</ArticleId><ArticleId IdType="pmc">PMC2359814</ArticleId><ArticleId IdType="pubmed">18434538</ArticleId></ArticleIdList></Reference><Reference><Citation>Kachroo AH, Laurent JM, Yellman CM, Meyer AG, Wilke CO, Marcotte EM, 2015. Evolution. Systematic humanization of yeast genes reveals conserved functions and genetic modularity. Science 348, 921&#x2013;925. doi:10.1126/science.aaa0769</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaa0769</ArticleId><ArticleId IdType="pmc">PMC4718922</ArticleId><ArticleId IdType="pubmed">25999509</ArticleId></ArticleIdList></Reference><Reference><Citation>Koo EH, Squazzo SL, 1994. Evidence that production and release of amyloid beta-protein involves the endocytic pathway. Journal of Biological Chemistry 269, 17386&#x2013;17389.</Citation><ArticleIdList><ArticleId IdType="pubmed">8021238</ArticleId></ArticleIdList></Reference><Reference><Citation>Lah JJ, Levey AI, 2000. Endogenous Presenilin-1 Targets to Endocytic Rather Than Biosynthetic Compartments. Molecular and Cellular Neuroscience 16, 111&#x2013;126. doi:10.1006/mcne.2000.0861</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/mcne.2000.0861</ArticleId><ArticleId IdType="pubmed">10924255</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert J-C, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, Combarros O, Zelenika D, Bullido MJ, Tavernier B, Letenneur L, Bettens K, Berr C, Pasquier F, Fi&#xe9;vet N, Barberger-Gateau P, Engelborghs S, De Deyn P, Mateo I, Franck A, Helisalmi S, Porcellini E, Hanon O, de Pancorbo MM, Lendon C, Dufouil C, Jaillard C, Leveillard T, Alvarez V, Bosco P, Mancuso M, Panza F, Nacmias B, Boss&#xf9; P, Piccardi P, Annoni G, Seripa D, Galimberti D, Hannequin D, Licastro F, Soininen H, Ritchie K, Blanch&#xe9; H, Dartigues J-F, Tzourio C, Gut I, Van Broeckhoven C, Alp&#xe9;rovitch A, Lathrop M, Amouyel P, 2009. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer&#x2019;s disease. Nature Genetics 41, 1094&#x2013;1099. doi:10.1038/ng.439</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.439</ArticleId><ArticleId IdType="pubmed">19734903</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, DeStafano AL, Bis JC, Beecham GW, Grenier-Boley B, Russo G, Thorton-Wells TA, Jones N, Smith AV, Chouraki V, Thomas C, Ikram MA, Zelenika D, Vardarajan BN, Kamatani Y, Lin CF, Gerrish A, Schmidt H, Kunkle B, Dunstan ML, Ruiz A, Bihoreau MT, Choi SH, Reitz C, Pasquier F, Cruchaga C, Craig D, Amin N, Berr C, Lopez OL, De Jager PL, Deramecourt V, Johnston JA, Evans D, Lovestone S, Letenneur L, Mor&#xf3;n FJ, Rubinsztein DC, Eiriksdottir G, Sleegers K, Goate AM, Fi&#xe9;vet N, Huentelman MW, Gill M, Brown K, Kamboh MI, Keller L, Barberger-Gateau P, McGuiness B, Larson EB, Green R, Myers AJ, Dufouil C, Todd S, Wallon D, Love S, Rogaeva E, Gallacher J, St George-Hyslop P, Clarimon J, Lleo A, Bayer A, Tsuang DW, Yu L, Tsolaki M, Boss&#xf9; P, Spalletta G, Proitsi P, Collinge J, Sorbi S, Sanchez-Garcia F, Fox NC, Hardy J, Deniz Naranjo MC, Bosco P, Clarke R, Brayne C, Galimberti D, Mancuso M, Matthews F, European Alzheimer&#x2019;s Disease Initiative (EADI), Genetic and Environmental Risk in Alzheimer&#x2019;s Disease, Alzheimer&#x2019;s Disease Genetic Consortium, Cohorts for Heart and Aging Research in Genomic Epidemiology, Moebus S, Mecocci P, Del Zompo M, Maier W, Hampel H, Pilotto A, Bullido M, Panza F, Caffarra P, Nacmias B, Gilbert JR, Mayhaus M, Lannefelt L, Hakonarson H, Pichler S, Carrasquillo MM, Ingelsson M, Beekly D, Alvarez V, Zou F, Valladares O, Younkin SG, Coto E, Hamilton-Nelson KL, Gu W, Razquin C, Pastor P, Mateo I, Owen MJ, Faber KM, Jonsson PV, Combarros O, O&#x2019;Donovan MC, Cantwell LB, Soininen H, Blacker D, Mead S, Mosley TH, Bennett DA, Harris TB, Fratiglioni L, Holmes C, de Bruijn RF, Passmore P, Montine TJ, Bettens K, Rotter JI, Brice A, Morgan K, Foroud TM, Kukull WA, Hannequin D, Powell JF, Nalls MA, Ritchie K, Lunetta KL, Kauwe JS, Boerwinkle E, Riemenschneider M, Boada M, Hiltuenen M, Martin ER, Schmidt R, Rujescu D, Wang LS, Dartigues JF, Mayeux R, Tzourio C, Hofman A, N&#xf6;then MM, Graff C, Psaty BM, Jones L, Haines JL, Holmans PA, Lathrop M, Pericak-Vance MA, Launer LJ, Farrer LA, van Duijn CM, Van Broeckhoven C, Moskvina V, Seshadri S, Williams J, Schellenberg GD, Amouyel P, 2013. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer&#x2019;s disease. Nature Genetics 45, 1452&#x2013;1458. doi:10.1038/ng.2802</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.2802</ArticleId><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y-T, Seo J, Gao F, Feldman HM, Wen H-L, Penney J, Cam HP, Gjoneska E, Raja WK, Cheng J, Rueda R, Kritskiy O, Abdurrob F, Peng Z, Milo B, Yu CJ, Elmsaouri S, Dey D, Ko T, Yankner BA, Tsai L-H, 2018. APOE4 Causes Widespread Molecular and Cellular Alterations Associated with Alzheimer&#x2019;s Disease Phenotypes in Human iPSC-Derived Brain Cell Types. Neuron 98, 1141&#x2013;1154.e7. doi:10.1016/j.neuron.2018.05.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.05.008</ArticleId><ArticleId IdType="pmc">PMC6023751</ArticleId><ArticleId IdType="pubmed">29861287</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C-C, Kanekiyo T, Xu H, Bu G, 2013. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 1&#x2013;13. doi:10.1038/nrneurol.2012.263</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2012.263</ArticleId><ArticleId IdType="pmc">PMC3726719</ArticleId><ArticleId IdType="pubmed">23296339</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu R, Drubin DG, Sun Y, 2016. Clathrin-mediated endocytosis in budding yeast at a glance. J Cell Sci 129, 1531&#x2013;1536. doi:10.1242/jcs.182303</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.182303</ArticleId><ArticleId IdType="pmc">PMC4852772</ArticleId><ArticleId IdType="pubmed">27084361</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahley RW, Rall SC, 2000. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet 1, 507&#x2013;537. doi:10.1146/annurev.genom.1.1.507</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.genom.1.1.507</ArticleId><ArticleId IdType="pubmed">11701639</ArticleId></ArticleIdList></Reference><Reference><Citation>McIsaac RS, Oakes BL, Wang X, Dummit KA, Botstein D, Noyes MB, 2012. Synthetic gene expression perturbation systems with rapid, tunable, single-gene specificity in yeast. Nucleic Acids Research 41, e57&#x2013;e57. doi:10.1093/nar/gks1313</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gks1313</ArticleId><ArticleId IdType="pmc">PMC3575806</ArticleId><ArticleId IdType="pubmed">23275543</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgen K, Ramirez A, Fr&#xf6;lich L, Tost H, Plichta MM, K&#xf6;lsch H, Rakebrandt F, Rienhoff O, Jessen F, Peters O, Jahn H, Luckhaus C, H&#xfc;ll M, Gertz H-J, Schr&#xf6;der J, Hampel H, Teipel SJ, Pantel J, Heuser I, Wiltfang J, R&#xfc;ther E, Kornhuber J, Maier W, Meyer-Lindenberg A, 2014. Genetic interaction of PICALM and APOE is associated with brain atrophy and cognitive impairment in Alzheimer&#x2019;s disease. Alzheimer&#x2019;s &amp; Dementia 10, S269&#x2013;S276. doi:10.1016/j.jalz.2013.11.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2013.11.001</ArticleId><ArticleId IdType="pubmed">24613704</ArticleId></ArticleIdList></Reference><Reference><Citation>Naj AC, Jun G, Beecham GW, Wang L-S, Vardarajan BN, Buros J, Gallins PJ, Buxbaum JD, Jarvik GP, Crane PK, Larson EB, Bird TD, Boeve BF, Graff-Radford NR, De Jager PL, Evans D, Schneider JA, Carrasquillo MM, Ertekin-Taner N, Younkin SG, Cruchaga C, Kauwe JSK, Nowotny P, Kramer P, Hardy J, Huentelman MJ, Myers AJ, Barmada MM, Demirci FY, Baldwin CT, Green RC, Rogaeva E, George-Hyslop PS, Arnold SE, Barber R, Beach T, Bigio EH, Bowen JD, Boxer A, Burke JR, Cairns NJ, Carlson CS, Carney RM, Carroll SL, Chui HC, Clark DG, Corneveaux J, Cotman CW, Cummings JL, DeCarli C, DeKosky ST, Diaz-Arrastia R, Dick M, Dickson DW, Ellis WG, Faber KM, Fallon KB, Farlow MR, Ferris S, Frosch MP, Galasko DR, Ganguli M, Gearing M, Geschwind DH, Ghetti B, Gilbert JR, Gilman S, Giordani B, Glass JD, Growdon JH, Hamilton RL, Harrell LE, Head E, Honig LS, Hulette CM, Hyman BT, Jicha GA, Jin L-W, Johnson N, Karlawish J, Karydas A, Kaye JA, Kim R, Koo EH, Kowall NW, Lah JJ, Levey AI, Lieberman AP, Lopez OL, Mack WJ, Marson DC, Martiniuk F, Mash DC, Masliah E, McCormick WC, McCurry SM, McDavid AN, McKee AC, Mesulam M, Miller BL, Miller CA, Miller JW, Parisi JE, Perl DP, Peskind E, Petersen RC, Poon WW, Quinn JF, Rajbhandary RA, Raskind M, Reisberg B, Ringman JM, Roberson ED, Rosenberg RN, Sano M, Schneider LS, Seeley W, Shelanski ML, Slifer MA, Smith CD, Sonnen JA, Spina S, Stern RA, Tanzi RE, Trojanowski JQ, Troncoso JC, Van Deerlin VM, Vinters HV, Vonsattel JP, Weintraub S, Welsh-Bohmer KA, Williamson J, Woltjer RL, Cantwell LB, Dombroski BA, Beekly D, Lunetta KL, Martin ER, Kamboh MI, Saykin AJ, Reiman EM, Bennett DA, Morris JC, Montine TJ, Goate AM, Blacker D, Tsuang DW, Hakonarson H, Kukull WA, Foroud TM, Haines JL, Mayeux R, Pericak-Vance MA, Farrer LA, Schellenberg GD, 2011. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer&#x2019;s disease. Nat Genet 43, 436&#x2013;441. doi:10.1038/ng.801</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.801</ArticleId><ArticleId IdType="pmc">PMC3090745</ArticleId><ArticleId IdType="pubmed">21460841</ArticleId></ArticleIdList></Reference><Reference><Citation>Neefjes J, van der Kant R, 2014. Stuck in traffic: an emerging theme in diseases of the nervous system. Trends in Neurosciences 37, 66&#x2013;76. doi:10.1016/j.tins.2013.11.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2013.11.006</ArticleId><ArticleId IdType="pubmed">24411104</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA, 2005. Endosome function and dysfunction in Alzheimer&#x2019;s disease and other neurodegenerative diseases. Neurobiology of Aging 26, 373&#x2013;382. doi:10.1016/j.neurobiolaging.2004.09.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2004.09.018</ArticleId><ArticleId IdType="pubmed">15639316</ArticleId></ArticleIdList></Reference><Reference><Citation>Nuriel T, Peng KY, Ashok A, Dillman AA, Figueroa HY, Apuzzo J, Ambat J, Levy E, Cookson MR, Mathews PM, Duff KE, 2017. The Endosomal&#x2013;Lysosomal Pathway Is Dysregulated by APOE4 Expression in Vivo. Front. Neurosci 11, 263&#x2013;12. doi:10.3389/fnins.2017.00702</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2017.00702</ArticleId><ArticleId IdType="pmc">PMC5733017</ArticleId><ArticleId IdType="pubmed">29311783</ArticleId></ArticleIdList></Reference><Reference><Citation>Parikh I, Fardo DW, Estus S, 2014. Genetics of PICALM expression and Alzheimer&#x2019;s disease. PLoS ONE 9, e91242. doi:10.1371/journal.pone.0091242</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0091242</ArticleId><ArticleId IdType="pmc">PMC3949918</ArticleId><ArticleId IdType="pubmed">24618820</ArticleId></ArticleIdList></Reference><Reference><Citation>Park I-H, Arora N, Huo H, Maherali N, Ahfeldt T, Shimamura A, Lensch MW, Cowan C, Hochedlinger K, Daley GQ, 2008. Disease-Specific Induced Pluripotent Stem Cells. Cell 134, 877&#x2013;886. doi:10.1016/j.cell.2008.07.041</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2008.07.041</ArticleId><ArticleId IdType="pmc">PMC2633781</ArticleId><ArticleId IdType="pubmed">18691744</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Yamada K, Liddelow SA, Smith ST, Zhao L, Luo W, Tsai RM, Spina S, Grinberg LT, Rojas JC, Gallardo G, Wang K, Roh J, Robinson G, Finn MB, Jiang H, Sullivan PM, Baufeld C, Wood MW, Sutphen C, McCue L, Xiong C, Del-Aguila JL, Morris JC, Cruchaga C, 2017. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature 549, 523&#x2013;527. doi:10.1038/nature24016</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature24016</ArticleId><ArticleId IdType="pmc">PMC5641217</ArticleId><ArticleId IdType="pubmed">28959956</ArticleId></ArticleIdList></Reference><Reference><Citation>Sim&#xf3;n-S&#xe1;nchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, Berg D, Paisan-Ruiz C, Lichtner P, Scholz SW, Hernandez DG, Kr&#xfc;ger R, Federoff M, Klein C, Goate A, Perlmutter J, Bonin M, Nalls MA, Illig T, Gieger C, Houlden H, Steffens M, Okun MS, Racette BA, Cookson MR, Foote KD, Fernandez HH, Traynor BJ, Schreiber S, Arepalli S, Zonozi R, Gwinn K, van der Brug M, Lopez G, Chanock SJ, Schatzkin A, Park Y, Hollenbeck A, Gao J, Huang X, Wood NW, Lorenz D, Deuschl G, Chen H, Riess O, Hardy JA, Singleton AB, Gasser T, 2009. Genome-wide association study reveals genetic risk underlying Parkinson&#x2019;s disease. Nature Genetics 41, 1308&#x2013;1312. doi:10.1038/ng.487</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.487</ArticleId><ArticleId IdType="pmc">PMC2787725</ArticleId><ArticleId IdType="pubmed">19915575</ArticleId></ArticleIdList></Reference><Reference><Citation>Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD, 1993. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proceedings of the National Academy of Sciences 90, 1977&#x2013;1981. doi:10.1073/pnas.90.5.1977</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.90.5.1977</ArticleId><ArticleId IdType="pmc">PMC46003</ArticleId><ArticleId IdType="pubmed">8446617</ArticleId></ArticleIdList></Reference><Reference><Citation>Tebar F, Bohlander SK, Sorkin A, 1999. Clathrin assembly lymphoid myeloid leukemia (CALM) protein: localization in endocytic-coated pits, interactions with clathrin, and the impact of overexpression on clathrin-mediated traffic. Mol. Biol. Cell 10, 2687&#x2013;2702.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC25500</ArticleId><ArticleId IdType="pubmed">10436022</ArticleId></ArticleIdList></Reference><Reference><Citation>The HD iPSC Consortium, 2012. Induced Pluripotent Stem Cells from Patients with Huntington&#x2019;s Disease Show CAG-Repeat-Expansion-Associated Phenotypes. Stem Cell 11, 264&#x2013;278. doi:10.1016/j.stem.2012.04.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2012.04.027</ArticleId><ArticleId IdType="pmc">PMC3804072</ArticleId><ArticleId IdType="pubmed">22748968</ArticleId></ArticleIdList></Reference><Reference><Citation>Thinakaran G, Koo EH, 2008. Amyloid Precursor Protein Trafficking, Processing, and Function. Journal of Biological Chemistry 283, 29615&#x2013;29619. doi:10.1074/jbc.R800019200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.R800019200</ArticleId><ArticleId IdType="pmc">PMC2573065</ArticleId><ArticleId IdType="pubmed">18650430</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuang D, Leverenz JB, Lopez OL, Hamilton RL, Bennett DA, Schneider JA, Buchman AS, Larson EB, Crane PK, Kaye JA, Kramer P, Woltjer R, Trojanowski JQ, Weintraub D, Chen-Plotkin AS, Irwin DJ, Rick J, Schellenberg GD, Watson GS, Kukull W, Nelson PT, Jicha GA, Neltner JH, Galasko D, Masliah E, Quinn JF, Chung KA, Yearout D, Mata IF, Wan JY, Edwards KL, Montine TJ, Zabetian CP, 2013. APOE &#x3f5;4 Increases Risk for Dementia in Pure Synucleinopathies. JAMA Neurology 70, 223&#x2013;6. doi:10.1001/jamaneurol.2013.600</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.600</ArticleId><ArticleId IdType="pmc">PMC3580799</ArticleId><ArticleId IdType="pubmed">23407718</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R, Bennett BD, Babu-Khan S, Kahn S, 1999. &#x3b2;-Secretase cleavage of Alzheimer&#x2019;s amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286, 735&#x2013;741. doi:10.1126/science.286.5440.735</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.286.5440.735</ArticleId><ArticleId IdType="pubmed">10531052</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamazaki Y, Zhao N, Caulfield TR, Liu C-C, Bu G, 2019. Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Nat Rev Neurol 1&#x2013;18. doi:10.1038/s41582-019-0228-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-019-0228-7</ArticleId><ArticleId IdType="pmc">PMC7055192</ArticleId><ArticleId IdType="pubmed">31367008</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu J-T, Tan L, Hardy J, 2014. Apolipoprotein E in Alzheimer&#x2019;s Disease: An Update. Annu. Rev. Neurosci 37, 79&#x2013;100. doi:10.1146/annurev-neuro-071013-014300</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-neuro-071013-014300</ArticleId><ArticleId IdType="pubmed">24821312</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Z, Sagare AP, Ma Q, Halliday MR, Kong P, Kisler K, Winkler EA, Ramanathan A, Kanekiyo T, Bu G, Owens NC, Rege SV, Si G, Ahuja A, Zhu D, Miller CA, Schneider JA, Maeda M, Maeda T, Sugawara T, Ichida JK, Zlokovic BV, 2015. Central role for PICALM in amyloid-&#x3b2; blood-brain barrier transcytosis and clearance. Nature Neuroscience 18, 978&#x2013;987. doi:10.1038/nn.4025</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4025</ArticleId><ArticleId IdType="pmc">PMC4482781</ArticleId><ArticleId IdType="pubmed">26005850</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic BV, 2013. Cerebrovascular Effects of Apolipoprotein E. JAMA Neurology 70, 440&#x2013;12. doi:10.1001/jamaneurol.2013.2152</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.2152</ArticleId><ArticleId IdType="pmc">PMC4414030</ArticleId><ArticleId IdType="pubmed">23400708</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">33055242</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>23</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>565</Issue><PubDate><Year>2020</Year><Month>Oct</Month><Day>14</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>LRRK2 mediates microglial neurotoxicity via NFATc2 in rodent models of synucleinopathies.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">eaay0399</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.aay0399</ELocationID><Abstract><AbstractText>Synucleinopathies are neurodegenerative disorders characterized by abnormal &#x3b1;-synuclein deposition that include Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. The pathology of these conditions also includes neuronal loss and neuroinflammation. Neuron-released &#x3b1;-synuclein has been shown to induce neurotoxic, proinflammatory microglial responses through Toll-like receptor 2, but the molecular mechanisms involved are poorly understood. Here, we show that leucine-rich repeat kinase 2 (LRRK2) plays a critical role in the activation of microglia by extracellular &#x3b1;-synuclein. Exposure to &#x3b1;-synuclein was found to enhance LRRK2 phosphorylation and activity in mouse primary microglia. Furthermore, genetic and pharmacological inhibition of LRRK2 markedly diminished &#x3b1;-synuclein-mediated microglial neurotoxicity via lowering of tumor necrosis factor-&#x3b1; and interleukin-6 expression in mouse cultures. We determined that LRRK2 promoted a neuroinflammatory cascade by selectively phosphorylating and inducing nuclear translocation of the immune transcription factor nuclear factor of activated T cells, cytoplasmic 2 (NFATc2). NFATc2 activation was seen in patients with synucleinopathies and in a mouse model of synucleinopathy, where administration of an LRRK2 pharmacological inhibitor restored motor behavioral deficits. Our results suggest that modulation of LRRK2 and its downstream signaling mediator NFATc2 might be therapeutic targets for treating synucleinopathies.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Changyoun</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-9936-8195</Identifier><AffiliationInfo><Affiliation>Molecular Neuropathology Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD 20892, USA. changyoun.kim@nih.gov eliezer.masliah@nih.gov.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beilina</LastName><ForeName>Alexandria</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cell Biology and Gene Expression Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Nathan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Cell Biology and Gene Expression Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry and Redox Biology Center, University of Nebraska, Lincoln, NE 68588, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-3820-5960</Identifier><AffiliationInfo><Affiliation>Protein/Peptide Sequencing Facility, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Minhyung</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-5628-1062</Identifier><AffiliationInfo><Affiliation>Departments of Surgery and Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumaran</LastName><ForeName>Ravindran</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Cell Biology and Gene Expression Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaganovich</LastName><ForeName>Alice</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cell Biology and Gene Expression Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mamais</LastName><ForeName>Adamantios</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cell Biology and Gene Expression Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adame</LastName><ForeName>Anthony</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, School of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iba</LastName><ForeName>Michiyo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Molecular Neuropathology Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwon</LastName><ForeName>Somin</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-3847-3036</Identifier><AffiliationInfo><Affiliation>Molecular Neuropathology Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Won-Jae</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Neuroscience Research Institute, and Department of Medicine, Seoul National University College of Medicine, Seoul 03080, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shin</LastName><ForeName>Soo-Jean</ForeName><Initials>SJ</Initials><Identifier Source="ORCID">0000-0002-1432-6824</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Neuroscience Research Institute, and Department of Medicine, Seoul National University College of Medicine, Seoul 03080, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rissman</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, School of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>You</LastName><ForeName>Sungyong</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-3513-1783</Identifier><AffiliationInfo><Affiliation>Departments of Surgery and Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Seung-Jae</ForeName><Initials>SJ</Initials><Identifier Source="ORCID">0000-0002-5155-5335</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Neuroscience Research Institute, and Department of Medicine, Seoul National University College of Medicine, Seoul 03080, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singleton</LastName><ForeName>Andrew B</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Molecular Genetics Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cookson</LastName><ForeName>Mark R</ForeName><Initials>MR</Initials><Identifier Source="ORCID">0000-0002-1058-3831</Identifier><AffiliationInfo><Affiliation>Cell Biology and Gene Expression Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masliah</LastName><ForeName>Eliezer</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-2117-5569</Identifier><AffiliationInfo><Affiliation>Molecular Neuropathology Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD 20892, USA. changyoun.kim@nih.gov eliezer.masliah@nih.gov.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG018440</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>Z99 AG999999</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050778">NFATC Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C494006">NFATC2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C494007">Nfatc2 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C495280">LRRK2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D000071158">Leucine-Rich Repeat Serine-Threonine Protein Kinase-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C495279">Lrrk2 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071158" MajorTopicYN="N">Leucine-Rich Repeat Serine-Threonine Protein Kinase-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="Y">Microglia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050778" MajorTopicYN="N">NFATC Transcription Factors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012377" MajorTopicYN="N">Rodentia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000080874" MajorTopicYN="Y">Synucleinopathies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing interests:</b> S.-J.L. is a founder and CEO of Neuramedy Co., Ltd.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>5</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>9</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>15</Day><Hour>17</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>5</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33055242</ArticleId><ArticleId IdType="mid">NIHMS1695408</ArticleId><ArticleId IdType="pmc">PMC8100991</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.aay0399</ArticleId><ArticleId IdType="pii">12/565/eaay0399</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fellner L, Jellinger KA, Wenning GK, Stefanova N, Glial dysfunction in the pathogenesis of alpha-synucleinopathies: emerging concepts. Acta Neuropathol 121, 675&#x2013;693 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4730553</ArticleId><ArticleId IdType="pubmed">21562886</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee HJ, Bae EJ, Lee SJ, Extracellular alpha--synuclein-a novel and crucial factor in Lewy body diseases. Nat Rev Neurol 10, 92&#x2013;98 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24468877</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim C, Lee SJ, Controlling the mass action of alpha-synuclein in Parkinson&#x2019;s disease. J Neurochem 107, 303&#x2013;316 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18691382</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim S, Kim HJ, Kim DK, Lee SJ, Non-cell-autonomous actions of alpha-synuclein: Implications in glial synucleinopathies. Prog Neurobiol 169, 158&#x2013;171 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30173732</ArticleId></ArticleIdList></Reference><Reference><Citation>Desplats P, Lee HJ, Bae EJ, Patrick C, Rockenstein E, Crews L, Spencer B, Masliah E, Lee SJ, Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A 106, 13010&#x2013;13015 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2722313</ArticleId><ArticleId IdType="pubmed">19651612</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee HJ, Suk JE, Patrick C, Bae EJ, Cho JH, Rho S, Hwang D, Masliah E, Lee SJ, Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. J Biol Chem 285, 9262&#x2013;9272 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2838344</ArticleId><ArticleId IdType="pubmed">20071342</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim C, Ho DH, Suk JE, You S, Michael S, Kang J, Joong Lee S, Masliah E, Hwang D, Lee HJ, Lee SJ, Neuron-released oligomeric alpha-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat Commun 4, 1562 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4089961</ArticleId><ArticleId IdType="pubmed">23463005</ArticleId></ArticleIdList></Reference><Reference><Citation>Halliday GM, Stevens CH, Glia: initiators and progressors of pathology in Parkinson&#x2019;s disease. Mov Disord 26, 6&#x2013;17 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21322014</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon S, Iba M, Masliah E, Kim C, Targeting Microglial and Neuronal Toll-like Receptor 2 in Synucleinopathies. Exp Neurobiol 28, 547&#x2013;553 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6844834</ArticleId><ArticleId IdType="pubmed">31698547</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim C, Lee HJ, Masliah E, Lee SJ, Non-cell-autonomous Neurotoxicity of alpha-synuclein Through Microglial Toll-like Receptor 2. Exp Neurobiol 25, 113&#x2013;119 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4923355</ArticleId><ArticleId IdType="pubmed">27358579</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim C, Spencer B, Rockenstein E, Yamakado H, Mante M, Adame A, Fields JA, Masliah D, Iba M, Lee HJ, Rissman RA, Lee SJ, Masliah E, Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating alpha-synuclein transmission and neuroinflammation. Mol Neurodegener 13, 43 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6085656</ArticleId><ArticleId IdType="pubmed">30092810</ArticleId></ArticleIdList></Reference><Reference><Citation>Cookson MR, LRRK2 Pathways Leading to Neurodegeneration. Curr Neurol Neurosci Rep 15, 42 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5839465</ArticleId><ArticleId IdType="pubmed">26008812</ArticleId></ArticleIdList></Reference><Reference><Citation>Cresto N, Gardier C, Gubinelli F, Gaillard MC, Liot G, West AB, Brouillet E, The unlikely partnership between LRRK2 and alpha-synuclein in Parkinson&#x2019;s disease. Eur J Neurosci 49, 339&#x2013;363 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6391223</ArticleId><ArticleId IdType="pubmed">30269383</ArticleId></ArticleIdList></Reference><Reference><Citation>Russo I, Bubacco L, Greggio E, LRRK2 and neuroinflammation: partners in crime in Parkinson&#x2019;s disease? J Neuroinflammation 11, 52 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3994422</ArticleId><ArticleId IdType="pubmed">24655756</ArticleId></ArticleIdList></Reference><Reference><Citation>Moehle MS, Webber PJ, Tse T, Sukar N, Standaert DG, DeSilva TM, Cowell RM, West AB, LRRK2 inhibition attenuates microglial inflammatory responses. J Neurosci 32, 1602&#x2013;1611 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3532034</ArticleId><ArticleId IdType="pubmed">22302802</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillardon F, Schmid R, Draheim H, Parkinson&#x2019;s disease-linked leucine-rich repeat kinase 2(R1441G) mutation increases proinflammatory cytokine release from activated primary microglial cells and resultant neurotoxicity. Neuroscience 208, 41&#x2013;48 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22342962</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim B, Yang MS, Choi D, Kim JH, Kim HS, Seol W, Choi S, Jou I, Kim EY, Joe EH, Impaired inflammatory responses in murine Lrrk2-knockdown brain microglia. PLoS One 7, e34693 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3322140</ArticleId><ArticleId IdType="pubmed">22496842</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim C, Cho ED, Kim HK, You S, Lee HJ, Hwang D, Lee SJ, beta1-integrin-dependent migration of microglia in response to neuron-released alpha-synuclein. Exp Mol Med 46, e91 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3972795</ArticleId><ArticleId IdType="pubmed">24743837</ArticleId></ArticleIdList></Reference><Reference><Citation>Doggett EA, Zhao J, Mork CN, Hu D, Nichols RJ, Phosphorylation of LRRK2 serines 955 and 973 is disrupted by Parkinson&#x2019;s disease mutations and LRRK2 pharmacological inhibition. J Neurochem 120, 37&#x2013;45 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22004453</ArticleId></ArticleIdList></Reference><Reference><Citation>Dzamko N, Deak M, Hentati F, Reith AD, Prescott AR, Alessi DR, Nichols RJ, Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization. Biochem J 430, 405&#x2013;413 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631100</ArticleId><ArticleId IdType="pubmed">20659021</ArticleId></ArticleIdList></Reference><Reference><Citation>Vancraenenbroeck R, De Raeymaecker J, Lobbestael E, Gao F, De Maeyer M, Voet A, Baekelandt V, Taymans JM, In silico, in vitro and cellular analysis with a kinome-wide inhibitor panel correlates cellular LRRK2 dephosphorylation to inhibitor activity on LRRK2. Front Mol Neurosci 7, 51 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4042160</ArticleId><ArticleId IdType="pubmed">24917786</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi HG, Zhang J, Deng X, Hatcher JM, Patricelli MP, Zhao Z, Alessi DR, Gray NS, Brain Penetrant LRRK2 Inhibitor. ACS Med Chem Lett 3, 658&#x2013;662 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3467149</ArticleId><ArticleId IdType="pubmed">23066449</ArticleId></ArticleIdList></Reference><Reference><Citation>Steger M, Tonelli F, Ito G, Davies P, Trost M, Vetter M, Wachter S, Lorentzen E, Duddy G, Wilson S, Baptista MA, Fiske BK, Fell MJ, Morrow JA, Reith AD, Alessi DR, Mann M, Phosphoproteomics reveals that Parkinson&#x2019;s disease kinase LRRK2 regulates a subset of Rab GTPases. Elife 5, (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4769169</ArticleId><ArticleId IdType="pubmed">26824392</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito G, Katsemonova K, Tonelli F, Lis P, Baptista MA, Shpiro N, Duddy G, Wilson S, Ho PW, Ho SL, Reith AD, Alessi DR, Phos-tag analysis of Rab10 phosphorylation by LRRK2: a powerful assay for assessing kinase function and inhibitors. Biochem J 473, 2671&#x2013;2685 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5003698</ArticleId><ArticleId IdType="pubmed">27474410</ArticleId></ArticleIdList></Reference><Reference><Citation>Lis P, Burel S, Steger M, Mann M, Brown F, Diez F, Tonelli F, Holton JL, Ho PW, Ho SL, Chou MY, Polinski NK, Martinez TN, Davies P, Alessi DR, Development of phospho-specific Rab protein antibodies to monitor in vivo activity of the LRRK2 Parkinson&#x2019;s disease kinase. Biochem J 475, 1&#x2013;22 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5748839</ArticleId><ArticleId IdType="pubmed">29127256</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan Y, Howden AJM, Sarhan AR, Lis P, Ito G, Martinez TN, Brockmann K, Gasser T, Alessi DR, Sammler EM, Interrogating Parkinson&#x2019;s disease LRRK2 kinase pathway activity by assessing Rab10 phosphorylation in human neutrophils. Biochem J 475, 23&#x2013;44 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5748842</ArticleId><ArticleId IdType="pubmed">29127255</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee HJ, Suk JE, Bae EJ, Lee SJ, Clearance and deposition of extracellular alpha-synuclein aggregates in microglia. Biochem Biophys Res Commun 372, 423&#x2013;428 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18492487</ArticleId></ArticleIdList></Reference><Reference><Citation>Bae EJ, Kim DK, Kim C, Mante M, Adame A, Rockenstein E, Ulusoy A, Klinkenberg M, Jeong GR, Bae JR, Lee C, Lee HJ, Lee BD, Di Monte DA, Masliah E, Lee SJ, LRRK2 kinase regulates alpha-synuclein propagation via RAB35 phosphorylation. Nat Commun 9, 3465 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6110743</ArticleId><ArticleId IdType="pubmed">30150626</ArticleId></ArticleIdList></Reference><Reference><Citation>Bieri G, Brahic M, Bousset L, Couthouis J, Kramer NJ, Ma R, Nakayama L, Monbureau M, Defensor E, Schule B, Shamloo M, Melki R, Gitler AD, LRRK2 modifies alpha-syn pathology and spread in mouse models and human neurons. Acta Neuropathol 137, 961&#x2013;980 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6531417</ArticleId><ArticleId IdType="pubmed">30927072</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermann-Kleiter N, Baier G, NFAT pulls the strings during CD4+ T helper cell effector functions. Blood 115, 2989&#x2013;2997 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20103781</ArticleId></ArticleIdList></Reference><Reference><Citation>Fric J, Zelante T, Wong AY, Mertes A, Yu HB, Ricciardi-Castagnoli P, NFAT control of innate immunity. Blood 120, 1380&#x2013;1389 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22611159</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP, Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102, 15545&#x2013;15550 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1239896</ArticleId><ArticleId IdType="pubmed">16199517</ArticleId></ArticleIdList></Reference><Reference><Citation>Giesert F, Hofmann A, Burger A, Zerle J, Kloos K, Hafen U, Ernst L, Zhang J, Vogt-Weisenhorn DM, Wurst W, Expression analysis of Lrrk1, Lrrk2 and Lrrk2 splice variants in mice. PLoS One 8, e63778 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3651128</ArticleId><ArticleId IdType="pubmed">23675505</ArticleId></ArticleIdList></Reference><Reference><Citation>Crabtree GR, Olson EN, NFAT signaling: choreographing the social lives of cells. Cell 109 Suppl, S67&#x2013;79 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11983154</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller MR, Rao A, NFAT, immunity and cancer: a transcription factor comes of age. Nat Rev Immunol 10, 645&#x2013;656 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20725108</ArticleId></ArticleIdList></Reference><Reference><Citation>Feske S, Giltnane J, Dolmetsch R, Staudt LM, Rao A, Gene regulation mediated by calcium signals in T lymphocytes. Nat Immunol 2, 316&#x2013;324 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11276202</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z, Lee J, Krummey S, Lu W, Cai H, Lenardo MJ, The kinase LRRK2 is a regulator of the transcription factor NFAT that modulates the severity of inflammatory bowel disease. Nat Immunol 12, 1063&#x2013;1070 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4140245</ArticleId><ArticleId IdType="pubmed">21983832</ArticleId></ArticleIdList></Reference><Reference><Citation>Takagawa T, Kitani A, Fuss I, Levine B, Brant SR, Peter I, Tajima M, Nakamura S, Strober W, An increase in LRRK2 suppresses autophagy and enhances Dectin-1-induced immunity in a mouse model of colitis. Sci Transl Med 10, (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6636639</ArticleId><ArticleId IdType="pubmed">29875204</ArticleId></ArticleIdList></Reference><Reference><Citation>Yue M, Hinkle KM, Davies P, Trushina E, Fiesel FC, Christenson TA, Schroeder AS, Zhang L, Bowles E, Behrouz B, Lincoln SJ, Beevers JE, Milnerwood AJ, Kurti A, McLean PJ, Fryer JD, Springer W, Dickson DW, Farrer MJ, Melrose HL, Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice. Neurobiol Dis 78, 172&#x2013;195 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4526103</ArticleId><ArticleId IdType="pubmed">25836420</ArticleId></ArticleIdList></Reference><Reference><Citation>Giffin MJ, Stroud JC, Bates DL, von Koenig KD, Hardin J, Chen L, Structure of NFAT1 bound as a dimer to the HIV-1 LTR kappa B element. Nat Struct Biol 10, 800&#x2013;806 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12949493</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroud JC, Chen L, Structure of NFAT bound to DNA as a monomer. J Mol Biol 334, 1009&#x2013;1022 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">14643663</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, I-TASSER server for protein 3D structure prediction. BMC Bioinformatics 9, 40 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2245901</ArticleId><ArticleId IdType="pubmed">18215316</ArticleId></ArticleIdList></Reference><Reference><Citation>Atashrazm F, Dzamko N, LRRK2 inhibitors and their potential in the treatment of Parkinson&#x2019;s disease: current perspectives. Clin Pharmacol 8, 177&#x2013;189 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5076802</ArticleId><ArticleId IdType="pubmed">27799832</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Sastre M, Del Tredici K, Development of alpha-synuclein immunoreactive astrocytes in the forebrain parallels stages of intraneuronal pathology in sporadic Parkinson&#x2019;s disease. Acta Neuropathol 114, 231&#x2013;241 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17576580</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim C, Rockenstein E, Spencer B, Kim HK, Adame A, Trejo M, Stafa K, Lee HJ, Lee SJ, Masliah E, Antagonizing Neuronal Toll-like Receptor 2 Prevents Synucleinopathy by Activating Autophagy. Cell Rep 13, 771&#x2013;782 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4752835</ArticleId><ArticleId IdType="pubmed">26489461</ArticleId></ArticleIdList></Reference><Reference><Citation>Chesselet MF, Richter F, Zhu C, Magen I, Watson MB, Subramaniam SR, A progressive mouse model of Parkinson&#x2019;s disease: the Thy1-aSyn (&#x201c;Line 61&#x201d;) mice. Neurotherapeutics 9, 297&#x2013;314 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3337020</ArticleId><ArticleId IdType="pubmed">22350713</ArticleId></ArticleIdList></Reference><Reference><Citation>Volta M, Melrose H, LRRK2 mouse models: dissecting the behavior, striatal neurochemistry and neurophysiology of PD pathogenesis. Biochem Soc Trans 45, 113&#x2013;122 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28202664</ArticleId></ArticleIdList></Reference><Reference><Citation>Marker DF, Puccini JM, Mockus TE, Barbieri J, Lu SM, Gelbard HA, LRRK2 kinase inhibition prevents pathological microglial phagocytosis in response to HIV-1 Tat protein. J Neuroinflammation 9, 261 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3538654</ArticleId><ArticleId IdType="pubmed">23190742</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee HJ, Khoshaghideh F, Patel S, Lee SJ, Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pathway. J Neurosci 24, 1888&#x2013;1896 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730405</ArticleId><ArticleId IdType="pubmed">14985429</ArticleId></ArticleIdList></Reference><Reference><Citation>Bae EJ, Lee HJ, Rockenstein E, Ho DH, Park EB, Yang NY, Desplats P, Masliah E, Lee SJ, Antibody-aided clearance of extracellular alpha-synuclein prevents cell-to-cell aggregate transmission. J Neurosci 32, 13454&#x2013;13469 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3752153</ArticleId><ArticleId IdType="pubmed">23015436</ArticleId></ArticleIdList></Reference><Reference><Citation>Frank-Cannon TC, Alto LT, McAlpine FE, Tansey MG, Does neuroinflammation fan the flame in neurodegenerative diseases? Mol Neurodegener 4, 47 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2784760</ArticleId><ArticleId IdType="pubmed">19917131</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi DY, Liu M, Hunter RL, Cass WA, Pandya JD, Sullivan PG, Shin EJ, Kim HC, Gash DM, Bing G, Striatal neuroinflammation promotes Parkinsonism in rats. PLoS One 4, e5482 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2674956</ArticleId><ArticleId IdType="pubmed">19424495</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao HM, Zhang F, Zhou H, Kam W, Wilson B, Hong JS, Neuroinflammation and alpha-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson&#x2019;s disease. Environ Health Perspect 119, 807&#x2013;814 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3114815</ArticleId><ArticleId IdType="pubmed">21245015</ArticleId></ArticleIdList></Reference><Reference><Citation>Ifuku M, Katafuchi T, Mawatari S, Noda M, Miake K, Sugiyama M, Fujino T, Anti-inflammatory/anti-amyloidogenic effects of plasmalogens in lipopolysaccharide-induced neuroinflammation in adult mice. J Neuroinflammation 9, 197 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3444880</ArticleId><ArticleId IdType="pubmed">22889165</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahn MS, Kranjac D, Alonzo CA, Haase JH, Cedillos RO, McLinden KA, Boehm GW, Chumley MJ, Prolonged elevation in hippocampal Abeta and cognitive deficits following repeated endotoxin exposure in the mouse. Behav Brain Res 229, 176&#x2013;184 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22249135</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Qin L, Wilson B, Wu X, Qian L, Granholm AC, Crews FT, Hong JS, Endotoxin induces a delayed loss of TH-IR neurons in substantia nigra and motor behavioral deficits. Neurotoxicology 29, 864&#x2013;870 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2762082</ArticleId><ArticleId IdType="pubmed">18471886</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim C, Ojo-Amaize E, Spencer B, Rockenstein E, Mante M, Desplats P, Wrasidlo W, Adame A, Nchekwube E, Oyemade O, Okogun J, Chan M, Cottam H, Masliah E, Hypoestoxide reduces neuroinflammation and alpha-synuclein accumulation in a mouse model of Parkinson&#x2019;s disease. J Neuroinflammation 12, 236 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4683943</ArticleId><ArticleId IdType="pubmed">26683203</ArticleId></ArticleIdList></Reference><Reference><Citation>Valera E, Masliah E, Immunotherapy for neurodegenerative diseases: focus on alpha-synucleinopathies. Pharmacol Ther 138, 311&#x2013;322 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3925783</ArticleId><ArticleId IdType="pubmed">23384597</ArticleId></ArticleIdList></Reference><Reference><Citation>Feske S, Calcium signalling in lymphocyte activation and disease. Nat Rev Immunol 7, 690&#x2013;702 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17703229</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogan PG, Chen L, Nardone J, Rao A, Transcriptional regulation by calcium, calcineurin, and NFAT. Genes Dev 17, 2205&#x2013;2232 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12975316</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang GN, Huso DL, Bouyain S, Tu J, McCorkell KA, May MJ, Zhu Y, Lutz M, Collins S, Dehoff M, Kang S, Whartenby K, Powell J, Leahy D, Worley PF, NFAT binding and regulation of T cell activation by the cytoplasmic scaffolding Homer proteins. Science 319, 476&#x2013;481 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3602998</ArticleId><ArticleId IdType="pubmed">18218901</ArticleId></ArticleIdList></Reference><Reference><Citation>Willingham AT, Orth AP, Batalov S, Peters EC, Wen BG, Aza-Blanc P, Hogenesch JB, Schultz PG, A strategy for probing the function of noncoding RNAs finds a repressor of NFAT. Science 309, 1570&#x2013;1573 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16141075</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed I, Tamouza R, Delord M, Krishnamoorthy R, Tzourio C, Mulot C, Nacfer M, Lambert JC, Beaune P, Laurent-Puig P, Loriot MA, Charron D, Elbaz A, Association between Parkinson&#x2019;s disease and the HLA-DRB1 locus. Mov Disord 27, 1104&#x2013;1110 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22807207</ArticleId></ArticleIdList></Reference><Reference><Citation>Trang T, Beggs S, Salter MW, Brain-derived neurotrophic factor from microglia: a molecular substrate for neuropathic pain. Neuron Glia Biol 7, 99&#x2013;108 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3748035</ArticleId><ArticleId IdType="pubmed">22613083</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez de Maturana R, Aguila JC, Sousa A, Vazquez N, Del Rio P, Aiastui A, Gorostidi A, Lopez de Munain A, Sanchez-Pernaute R, Leucine-rich repeat kinase 2 modulates cyclooxygenase 2 and the inflammatory response in idiopathic and genetic Parkinson&#x2019;s disease. Neurobiol Aging 35, 1116&#x2013;1124 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24360742</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaeth M, Feske S, NFAT control of immune function: New Frontiers for an Abiding Trooper. F1000Res 7, 260 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5840618</ArticleId><ArticleId IdType="pubmed">29568499</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo J, Sun L, Lin X, Liu G, Yu J, Parisiadou L, Xie C, Ding J, Cai H, A calcineurin- and NFAT-dependent pathway is involved in alpha-synuclein-induced degeneration of midbrain dopaminergic neurons. Hum Mol Genet 23, 6567&#x2013;6574 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4240205</ArticleId><ArticleId IdType="pubmed">25051958</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen T, Di Giovanni S, NFAT signaling in neural development and axon growth. Int J Dev Neurosci 26, 141&#x2013;145 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2267928</ArticleId><ArticleId IdType="pubmed">18093786</ArticleId></ArticleIdList></Reference><Reference><Citation>Graef IA, Wang F, Charron F, Chen L, Neilson J, Tessier-Lavigne M, Crabtree GR, Neurotrophins and netrins require calcineurin/NFAT signaling to stimulate outgrowth of embryonic axons. Cell 113, 657&#x2013;670 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12787506</ArticleId></ArticleIdList></Reference><Reference><Citation>Vihma H, Luhakooder M, Pruunsild P, Timmusk T, Regulation of different human NFAT isoforms by neuronal activity. J Neurochem 137, 394&#x2013;408 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26851544</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen EN, Ballard C, de Vos RA, Wilcock GK, Jellinger KA, Perry RH, Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47, 1113&#x2013;1124 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8909416</ArticleId></ArticleIdList></Reference><Reference><Citation>Atashrazm F, Dzamko N, LRRK2 inhibitors and their potential in the treatment of Parkinson&#x2019;s disease: current perspectives. Clin Pharmacol 8, 177&#x2013;189 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5076802</ArticleId><ArticleId IdType="pubmed">27799832</ArticleId></ArticleIdList></Reference><Reference><Citation>Chesselet MF, Richter F, Zhu C, Magen I, Watson MB, Subramaniam SR, A progressive mouse model of Parkinson&#x2019;s disease: the Thy1-aSyn (&#x201c;Line 61&#x201d;) mice. Neurotherapeutics 9, 297&#x2013;314 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3337020</ArticleId><ArticleId IdType="pubmed">22350713</ArticleId></ArticleIdList></Reference><Reference><Citation>Parisiadou L, Xie C, Cho HJ, Lin X, Gu XL, Long CX, Lobbestael E, Baekelandt V, Taymans JM, Sun L, Cai H, Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis. J Neurosci 29, 13971&#x2013;13980 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2807632</ArticleId><ArticleId IdType="pubmed">19890007</ArticleId></ArticleIdList></Reference><Reference><Citation>Yue M, Hinkle KM, Davies P, Trushina E, Fiesel FC, Christenson TA, Schroeder AS, Zhang L, Bowles E, Behrouz B, Lincoln SJ, Beevers JE, Milnerwood AJ, Kurti A, McLean PJ, Fryer JD, Springer W, Dickson DW, Farrer MJ, Melrose HL, Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice. Neurobiol Dis 78, 172&#x2013;195 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4526103</ArticleId><ArticleId IdType="pubmed">25836420</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee HJ, Suk JE, Patrick C, Bae EJ, Cho JH, Rho S, Hwang D, Masliah E, Lee SJ, Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. J Biol Chem 285, 9262&#x2013;9272 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2838344</ArticleId><ArticleId IdType="pubmed">20071342</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim C, Cho ED, Kim HK, You S, Lee HJ, Hwang D, Lee SJ, beta1-integrin-dependent migration of microglia in response to neuron-released alpha-synuclein. Exp Mol Med 46, e91 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3972795</ArticleId><ArticleId IdType="pubmed">24743837</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim C, Ho DH, Suk JE, You S, Michael S, Kang J, Joong Lee S, Masliah E, Hwang D, Lee HJ, Lee SJ, Neuron-released oligomeric alpha-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat Commun 4, 1562 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4089961</ArticleId><ArticleId IdType="pubmed">23463005</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim C, Lee HJ, Masliah E, Lee SJ, Non-cell-autonomous Neurotoxicity of alpha-synuclein Through Microglial Toll-like Receptor 2. Exp Neurobiol 25, 113&#x2013;119 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4923355</ArticleId><ArticleId IdType="pubmed">27358579</ArticleId></ArticleIdList></Reference><Reference><Citation>Floden AM, Combs CK, Microglia repetitively isolated from in vitro mixed glial cultures retain their initial phenotype. J Neurosci Methods 164, 218&#x2013;224 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2041803</ArticleId><ArticleId IdType="pubmed">17553568</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang da W, Sherman BT, Lempicki RA, Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4, 44&#x2013;57 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19131956</ArticleId></ArticleIdList></Reference><Reference><Citation>Stark C, Breitkreutz BJ, Reguly T, Boucher L, Breitkreutz A, Tyers M, BioGRID: a general repository for interaction datasets. Nucleic Acids Res 34, D535&#x2013;539 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1347471</ArticleId><ArticleId IdType="pubmed">16381927</ArticleId></ArticleIdList></Reference><Reference><Citation>Salwinski L, Miller CS, Smith AJ, Pettit FK, Bowie JU, Eisenberg D, The Database of Interacting Proteins: 2004 update. Nucleic Acids Res 32, D449&#x2013;451 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC308820</ArticleId><ArticleId IdType="pubmed">14681454</ArticleId></ArticleIdList></Reference><Reference><Citation>Patil A, Nakai K, Nakamura H, HitPredict: a database of quality assessed protein-protein interactions in nine species. Nucleic Acids Res 39, D744&#x2013;749 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3013773</ArticleId><ArticleId IdType="pubmed">20947562</ArticleId></ArticleIdList></Reference><Reference><Citation>Orchard S, Ammari M, Aranda B, Breuza L, Briganti L, Broackes-Carter F, Campbell NH, Chavali G, Chen C, del-Toro N, Duesbury M, Dumousseau M, Galeota E, Hinz U, Iannuccelli M, Jagannathan S, Jimenez R, Khadake J, Lagreid A, Licata L, Lovering RC, Meldal B, Melidoni AN, Milagros M, Peluso D, Perfetto L, Porras P, Raghunath A, Ricard-Blum S, Roechert B, Stutz A, Tognolli M, van Roey K, Cesareni G, Hermjakob H, The MIntAct project--IntAct as a common curation platform for 11 molecular interaction databases. Nucleic Acids Res 42, D358&#x2013;363 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3965093</ArticleId><ArticleId IdType="pubmed">24234451</ArticleId></ArticleIdList></Reference><Reference><Citation>Licata L, Briganti L, Peluso D, Perfetto L, Iannuccelli M, Galeota E, Sacco F, Palma A, Nardozza AP, Santonico E, Castagnoli L, Cesareni G, MINT, the molecular interaction database: 2012 update. Nucleic Acids Res 40, D857&#x2013;861 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3244991</ArticleId><ArticleId IdType="pubmed">22096227</ArticleId></ArticleIdList></Reference><Reference><Citation>Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, Simonovic M, Roth A, Santos A, Tsafou KP, Kuhn M, Bork P, Jensen LJ, von Mering C, STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res 43, D447&#x2013;452 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4383874</ArticleId><ArticleId IdType="pubmed">25352553</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao F, Xuan Z, Liu L, Zhang MQ, TRED: a Transcriptional Regulatory Element Database and a platform for in silico gene regulation studies. Nucleic Acids Res 33, D103&#x2013;107 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC539958</ArticleId><ArticleId IdType="pubmed">15608156</ArticleId></ArticleIdList></Reference><Reference><Citation>Severin J, Waterhouse AM, Kawaji H, Lassmann T, van Nimwegen E, Balwierz PJ, de Hoon MJ, Hume DA, Carninci P, Hayashizaki Y, Suzuki H, Daub CO, Forrest AR, FANTOM4 EdgeExpressDB: an integrated database of promoters, genes, microRNAs, expression dynamics and regulatory interactions. Genome Biol 10, R39 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2688930</ArticleId><ArticleId IdType="pubmed">19374773</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP, Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102, 15545&#x2013;15550 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1239896</ArticleId><ArticleId IdType="pubmed">16199517</ArticleId></ArticleIdList></Reference><Reference><Citation>Linhart C, Halperin Y, Shamir R, Transcription factor and microRNA motif discovery: the Amadeus platform and a compendium of metazoan target sets. Genome Res 18, 1180&#x2013;1189 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2493407</ArticleId><ArticleId IdType="pubmed">18411406</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu T, Jung J, Lee S, Nam HJ, Hong SW, Yoo JW, Lee DK, Lee D, bZIPDB: a database of regulatory information for human bZIP transcription factors. BMC Genomics 8, 136 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1891292</ArticleId><ArticleId IdType="pubmed">17535445</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffith OL, Montgomery SB, Bernier B, Chu B, Kasaian K, Aerts S, Mahony S, Sleumer MC, Bilenky M, Haeussler M, Griffith M, Gallo SM, Giardine B, Hooghe B, Van Loo P, Blanco E, Ticoll A, Lithwick S, Portales-Casamar E, Donaldson IJ, Robertson G, Wadelius C, De Bleser P, Vlieghe D, Halfon MS, Wasserman W, Hardison R, Bergman CM, Jones SJ, Open Regulatory Annotation C, ORegAnno: an open-access community-driven resource for regulatory annotation. Nucleic Acids Res 36, D107&#x2013;113 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2239002</ArticleId><ArticleId IdType="pubmed">18006570</ArticleId></ArticleIdList></Reference><Reference><Citation>Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T, Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13, 2498&#x2013;2504 (2003).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC403769</ArticleId><ArticleId IdType="pubmed">14597658</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogata H, Goto S, Sato K, Fujibuchi W, Bono H, Kanehisa M, KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res 27, 29&#x2013;34 (1999).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC148090</ArticleId><ArticleId IdType="pubmed">9847135</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, I-TASSER server for protein 3D structure prediction. BMC Bioinformatics 9, 40 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2245901</ArticleId><ArticleId IdType="pubmed">18215316</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy A, Kucukural A, Zhang Y, I-TASSER: a unified platform for automated protein structure and function prediction. Nat Protoc 5, 725&#x2013;738 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2849174</ArticleId><ArticleId IdType="pubmed">20360767</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J, Yan R, Roy A, Xu D, Poisson J, Zhang Y, The I-TASSER Suite: protein structure and function prediction. Nat Methods 12, 7&#x2013;8 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4428668</ArticleId><ArticleId IdType="pubmed">25549265</ArticleId></ArticleIdList></Reference><Reference><Citation>Giffin MJ, Stroud JC, Bates DL, von Koenig KD, Hardin J, Chen L, Structure of NFAT1 bound as a dimer to the HIV-1 LTR kappa B element. Nat Struct Biol 10, 800&#x2013;806 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12949493</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroud JC, Chen L, Structure of NFAT bound to DNA as a monomer. J Mol Biol 334, 1009&#x2013;1022 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">14643663</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilsbach BK, Ho FY, Vetter IR, van Haastert PJ, Wittinghofer A, Kortholt A, Roco kinase structures give insights into the mechanism of Parkinson disease-related leucine-rich-repeat kinase 2 mutations. Proc Natl Acad Sci U S A 109, 10322&#x2013;10327 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3387044</ArticleId><ArticleId IdType="pubmed">22689969</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33068398</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>01</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1460-2156</ISSN><JournalIssue CitedMedium="Internet"><Volume>143</Volume><Issue>11</Issue><PubDate><Year>2020</Year><Month>Dec</Month><Day>05</Day></PubDate></JournalIssue><Title>Brain : a journal of neurology</Title><ISOAbbreviation>Brain</ISOAbbreviation></Journal><ArticleTitle>Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>3234</StartPage><EndPage>3241</EndPage><MedlinePgn>3234-3241</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/brain/awaa286</ELocationID><Abstract><AbstractText>Plasma levels of tau phosphorylated at threonine-217 (p-tau217) is a candidate tool to monitor Alzheimer's disease. We studied 150 cognitively unimpaired participants and 100 patients with mild cognitive impairment in the Swedish BioFINDER study. P-tau217 was measured repeatedly for up to 6 years (median three samples per person, median time from first to last sample, 4.3 years). Preclinical (amyloid-&#x3b2;-positive cognitively unimpaired, n&#x2009;=&#x2009;62) and prodromal (amyloid-&#x3b2;-positive mild cognitive impairment, n&#x2009;=&#x2009;49) Alzheimer's disease had accelerated p-tau217 compared to amyloid-&#x3b2;-negative cognitively unimpaired (&#x3b2; &#x2009;=&#x2009; 0.56, P&#x2009;&lt;&#x2009;0.001, using linear mixed effects models) and amyloid-&#x3b2;-negative mild cognitive impairment patients (&#x3b2; &#x2009;=&#x2009; 0.67, P&#x2009;&lt;&#x2009;0.001), respectively. Mild cognitive impairment patients who later converted to Alzheimer's disease dementia (n&#x2009;=&#x2009;40) had accelerated p-tau217 compared to other mild cognitive impairment patients (&#x3b2; &#x2009;=&#x2009; 0.79, P&#x2009;&lt;&#x2009;0.001). P-tau217 did not change in amyloid-&#x3b2;-negative participants, or in patients with mild cognitive impairment who did not convert to Alzheimer's disease dementia. For 80% power, 109 participants per arm were required to observe a slope reduction in amyloid-&#x3b2;-positive cognitively unimpaired (71 participants per arm in amyloid-&#x3b2;-positive mild cognitive impairment). Longitudinal increases in p-tau217 correlated with longitudinal worsening of cognition and brain atrophy. In summary, plasma p-tau217 increases during early Alzheimer's disease and can be used to monitor disease progression.</AbstractText><CopyrightInformation>&#xa9; The Author(s) (2020). Published by Oxford University Press on behalf of the Guarantors of Brain.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mattsson-Carlgren</LastName><ForeName>Niklas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Sk&#xe5;ne University Hospital, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wallenberg Center for Molecular Medicine, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Janelidze</LastName><ForeName>Shorena</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palmqvist</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Clinic, Sk&#xe5;ne University Hospital, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cullen</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wallenberg Center for Molecular Medicine, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Svenningsson</LastName><ForeName>Anna L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Clinic, Sk&#xe5;ne University Hospital, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strandberg</LastName><ForeName>Olof</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mengel</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Laboratory for Neurodegenerative Research, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walsh</LastName><ForeName>Dominic M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Laboratory for Neurodegenerative Research, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stomrud</LastName><ForeName>Erik</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Clinic, Sk&#xe5;ne University Hospital, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dage</LastName><ForeName>Jeffrey L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hansson</LastName><ForeName>Oskar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Clinic, Sk&#xe5;ne University Hospital, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG017586</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain</MedlineTA><NlmUniqueID>0372537</NlmUniqueID><ISSNLinking>0006-8950</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>2ZD004190S</RegistryNumber><NameOfSubstance UI="D013912">Threonine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Brain. 2020 Dec 5;143(11):3170-3172. doi: 10.1093/brain/awaa329.</RefSource><PMID Version="1">33278818</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073216" MajorTopicYN="N">Mental Status and Dementia Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013912" MajorTopicYN="N">Threonine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">biomarker</Keyword><Keyword MajorTopicYN="N">p-tau</Keyword><Keyword MajorTopicYN="N">p-tau217</Keyword><Keyword MajorTopicYN="N">plasma</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>4</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>6</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>7</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>17</Day><Hour>17</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>10</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33068398</ArticleId><ArticleId IdType="pmc">PMC7719022</ArticleId><ArticleId IdType="doi">10.1093/brain/awaa286</ArticleId><ArticleId IdType="pii">5929275</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Barth&#xe9;lemy NR, Li Y, Joseph-Mathurin N, Gordon BA, Hassenstab J, Benzinger TLS, et al.A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer&#x2019;s disease. Nat Med 2020; 26: 398&#x2013;407.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7309367</ArticleId><ArticleId IdType="pubmed">32161412</ArticleId></ArticleIdList></Reference><Reference><Citation>Delis DC, Kaplan E, Kramer JH.. Delis-Kaplan executive function system TM: examine&#x155;s manual. San Antonio: The Psychological Corporation A Harcourt Assessment Company; 2001.</Citation></Reference><Reference><Citation>Donohue MC, Sperling RA, Petersen R, Sun C-K, Weiner MW, Aisen PS.. Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons. Jama 2017; 317: 2305&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5736301</ArticleId><ArticleId IdType="pubmed">28609533</ArticleId></ArticleIdList></Reference><Reference><Citation>Donohue MC, Sperling RA, Salmon DP, Rentz DM, Raman R, Thomas RG, et al.The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol 2014; 71: 961&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4439182</ArticleId><ArticleId IdType="pubmed">24886908</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon C, Tucholka A, Mont&#xe9;-Rubio GC, Cacciaglia R, Operto G, Rami L, et al.Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer&#x2019;s disease: a study of two independent datasets. Neuroimage Clin 2018; 19: 190&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6050455</ArticleId><ArticleId IdType="pubmed">30023169</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x2018; Mini-mental state&#x2019;. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach TG, Serrano GE, et al.Plasma P-tau181 in Alzheimer&#x2019;s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer&#x2019;s dementia. Nat Med 2020. a; 26: 379&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">32123385</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, Stomrud E, Smith R, Palmqvist S, Mattsson N, Airey DC, et al.Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimerr&#x2019;s disease. Nature Communications 2020. b; 11: 1683.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7125218</ArticleId><ArticleId IdType="pubmed">32246036</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, Zetterberg H, Mattsson N, Palmqvist S, Vanderstichele H, Lindberg O, et al.CSF A&#x3b2;42/A&#x3b2;40 and A&#x3b2;42/A&#x3b2;38 ratios: better diagnostic markers of Alzheimer disease. Ann Clin Transl Neurol 2016; 3: 154&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4774260</ArticleId><ArticleId IdType="pubmed">27042676</ArticleId></ArticleIdList></Reference><Reference><Citation>Koychev I, Vaci N, Bilgel M, An Y, Muniz GT, Wong DF, et al.Prediction of rapid amyloid and phospotylated-Tau accumulation in cognitively healthy individuals. Alzheimers Dement Amst Neth 2020; 12: e12019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7086102</ArticleId><ArticleId IdType="pubmed">32211504</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Andreasson U, Zetterberg H, Blennow K.. Alzheimer&#x2019;s disease neuroimaging initiative. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol 2017; 74: 557&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5822204</ArticleId><ArticleId IdType="pubmed">28346578</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Cullen NC, Andreasson U, Zetterberg H, Blennow K.. Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease. JAMA Neurol 2019; 76: 791&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6583067</ArticleId><ArticleId IdType="pubmed">31009028</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Insel PS, Palmqvist S, Stomrud E, van Westen D, Minthon L, et al.Increased amyloidogenic APP processing in APOE &#x25b;4-negative individuals with cerebral &#x3b2;-amyloidosis. Nat Commun 2016; 7: 10918.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4786682</ArticleId><ArticleId IdType="pubmed">26948379</ArticleId></ArticleIdList></Reference><Reference><Citation>Mengel D, Liu W, Glynn RJ, Selkoe DJ, Strydom A, Lai F, et al.Dynamics of plasma biomarkers in Down syndrome: the relative levels of A&#x3b2;42 decrease with age, whereas NT1 tau and NfL increase. Alzheimers Res Ther 2020; 12: 27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7081580</ArticleId><ArticleId IdType="pubmed">32192521</ArticleId></ArticleIdList></Reference><Reference><Citation>Mielke MM, Hagen CE, Xu J, Chai X, Vemuri P, Lowe VJ, et al.Plasma phospho-tau181 increases with Alzheimer&#x2019;s disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimers Dement J Alzheimers Assoc 2018; 14: 989&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6097897</ArticleId><ArticleId IdType="pubmed">29626426</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Rabinovici GD, Smith R, Cho H, Sch&#xf6;ll M, Strandberg O, et al.Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer disease vs other neurodegenerative disorders. Jama 2018; 320: 1151&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6233630</ArticleId><ArticleId IdType="pubmed">30326496</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Insel PS, Stomrud E, Janelidze S, Zetterberg H, Brix B, et al.Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer&#x2019;s disease. JAMA Neurology 2019b; 76: 1060-69 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6895602</ArticleId><ArticleId IdType="pubmed">31709776</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Janelidze S, Quiroz YT, Zetterberg H, Lopera F, Stomrud E, et al. Discriminative accuracy of plasma Phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA 2020; e2012134. doi: 10.1001/jama.2020.12134. Online ahead of print.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7388060</ArticleId><ArticleId IdType="pubmed">32722745</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Janelidze S, Stomrud E, Zetterberg H, Karl J, Zink K, et al.Performance of fully automated plasma assays as screening tests for Alzheimer disease-related &#x3b2;-amyloid status. JAMA Neurol 2019. b.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6593637</ArticleId><ArticleId IdType="pubmed">31233127</ArticleId></ArticleIdList></Reference><Reference><Citation>Papp KV, Rentz DM, Orlovsky I, Sperling RA, Mormino EC.. Optimizing the preclinical Alzheimer&#x2019;s cognitive composite with semantic processing: the PACC5. Alzheimers Dement Transl Res Clin Interv 2017; 3: 668&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5726754</ArticleId><ArticleId IdType="pubmed">29264389</ArticleId></ArticleIdList></Reference><Reference><Citation>Reuter M, Schmansky NJ, Rosas HD, Fischl B.. Within-subject template estimation for unbiased longitudinal image analysis. Neuroimage 2012; 61: 1402&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3389460</ArticleId><ArticleId IdType="pubmed">22430496</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Li Y, Gordon BA, et al.High-precision plasma &#x3b2;-amyloid 42/40 predicts current and future brain amyloidosis. Neurology 2019; 17: e1647&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6946467</ArticleId><ArticleId IdType="pubmed">31371569</ArticleId></ArticleIdList></Reference><Reference><Citation>Thijssen EH, La Joie R, Wolf A, Strom A, Wang P, Iaccarino L, et al.Diagnostic value of plasma phosphorylated tau181 in Alzheimer&#x2019;s disease and frontotemporal lobar degeneration. Nat Med 2020; 26: 387&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7101073</ArticleId><ArticleId IdType="pubmed">32123386</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33076948</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>26</Day></DateCompleted><DateRevised><Year>2021</Year><Month>08</Month><Day>26</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1750-1326</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Oct</Month><Day>19</Day></PubDate></JournalIssue><Title>Molecular neurodegeneration</Title><ISOAbbreviation>Mol Neurodegener</ISOAbbreviation></Journal><ArticleTitle>Modeling the &#x3b2;-secretase cleavage site and humanizing amyloid-beta precursor protein in rat and mouse to study Alzheimer's disease.</ArticleTitle><Pagination><StartPage>60</StartPage><MedlinePgn>60</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">60</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13024-020-00399-z</ELocationID><Abstract><AbstractText Label="BACKGROUND">Three amino acid differences between rodent and human APP affect medically important features, including &#x3b2;-secretase cleavage of APP and A&#x3b2; peptide aggregation (De Strooper et al., EMBO J 14:4932-38, 1995; Ueno et al., Biochemistry 53:7523-30, 2014; Bush, 2003,&#xa0;Trends Neurosci 26:207-14). Most rodent models for Alzheimer's disease (AD) are, therefore, based on the human APP sequence, expressed from artificial mini-genes randomly inserted in the rodent genome. While these models mimic rather well various biochemical aspects of the disease, such as A&#x3b2;-aggregation, they are also prone to overexpression artifacts and to complex phenotypical alterations, due to genes affected in or close to the insertion site(s) of the mini-genes (Sasaguri et al., EMBO J 36:2473-87, 2017; Goodwin et al., Genome Res 29:494-505, 2019). Knock-in strategies which introduce clinical mutants in a humanized endogenous rodent APP sequence (Saito et al., Nat Neurosci 17:661-3, 2014) represent useful improvements, but need to be compared with appropriate humanized wildtype (WT) mice.</AbstractText><AbstractText Label="METHODS">Computational modelling of the human &#x3b2;-CTF bound to BACE1 was used to study the differential processing of rodent and human APP. We humanized the three pivotal residues we identified G676R, F681Y and R684H (labeled according to the human APP770 isoform) in the mouse and rat genomes using a CRISPR-Cas9 approach. These new models, termed mouse and rat App<sup>hu/hu</sup>, express APP from the endogenous promotor. We also introduced the early-onset familial Alzheimer's disease (FAD) mutation M139T into the endogenous Rat Psen1 gene.</AbstractText><AbstractText Label="RESULTS">We show that introducing these three amino acid substitutions into the rodent sequence lowers the affinity of the APP substrate for BACE1 cleavage. The effect on &#x3b2;-secretase processing was confirmed as both humanized rodent models produce three times more (human) A&#x3b2; compared to the original WT strain. These models represent suitable controls, or starting points, for studying the effect of transgenes or knock-in mutations on APP processing (Saito et al., Nat Neurosci 17:661-3, 2014). We introduced the early-onset familial Alzheimer's disease (FAD) mutation M139T into the endogenous Rat Psen1 gene and provide an initial characterization of A&#x3b2; processing in this novel rat AD model.</AbstractText><AbstractText Label="CONCLUSION">The different humanized APP models (rat and mouse) expressing human A&#x3b2; and PSEN1 M139T are valuable controls to study APP processing in vivo allowing the use of a human A&#x3b2; ELISA which is more sensitive than the equivalent system for rodents. These animals will be made available to the research community.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Serneels</LastName><ForeName>Lutgarde</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Centre for Brain and Disease Research, Flanders Institute for Biotechnology (VIB), Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences and Leuven Brain Institute, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>T'Syen</LastName><ForeName>Dries</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Centre for Brain and Disease Research, Flanders Institute for Biotechnology (VIB), Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences and Leuven Brain Institute, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perez-Benito</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Computational Chemistry, Janssen Research &amp; Development, Janssen Pharmaceutica NV, Beerse, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Theys</LastName><ForeName>Tom</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Research Group Experimental Neurosurgery and Neuroanatomy, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holt</LastName><ForeName>Matthew G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Centre for Brain and Disease Research, Flanders Institute for Biotechnology (VIB), Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences and Leuven Brain Institute, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Strooper</LastName><ForeName>Bart</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0001-5455-5819</Identifier><AffiliationInfo><Affiliation>Centre for Brain and Disease Research, Flanders Institute for Biotechnology (VIB), Leuven, Belgium. bart.destrooper@kuleuven.vib.be.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences and Leuven Brain Institute, KU Leuven, Leuven, Belgium. bart.destrooper@kuleuven.vib.be.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute at UCL, University College London, London, UK. bart.destrooper@kuleuven.vib.be.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>10</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Neurodegener</MedlineTA><NlmUniqueID>101266600</NlmUniqueID><ISSNLinking>1750-1326</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C545487">APP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="Y">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003198" MajorTopicYN="Y">Computer Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Amyloid-beta precursor protein</Keyword><Keyword MajorTopicYN="N">Knock-in</Keyword><Keyword MajorTopicYN="N">Presenilin</Keyword><Keyword MajorTopicYN="N">Rodent animal models</Keyword></KeywordList><CoiStatement>The authors report no competing interests. Bart de Strooper is, or has been, a consultant for pharmaceutical companies, including Jansen Pharmaceuticals and Eisai.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>5</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>8</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>20</Day><Hour>5</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>10</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33076948</ArticleId><ArticleId IdType="pmc">PMC7574558</ArticleId><ArticleId IdType="doi">10.1186/s13024-020-00399-z</ArticleId><ArticleId IdType="pii">10.1186/s13024-020-00399-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Center for Molecular Neurology [Internet]. [cited 2020 May 22]. Available from: https://uantwerpen.vib.be/ADMutations.</Citation></Reference><Reference><Citation>Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, et al. A mutation in APP protects against Alzheimer&#x2019;s disease and age-related cognitive decline. Nature. 2012;488(7409):96&#x2013;99. doi: 10.1038/nature11283.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11283</ArticleId><ArticleId IdType="pubmed">22801501</ArticleId></ArticleIdList></Reference><Reference><Citation>Rumble B, Retallack R, Hilbich C, Simms G, Multhaup G, Martins R, et al. Amyloid A4 protein and its precursor in down&#x2019;s syndrome and Alzheimer&#x2019;s disease. N Engl J Med. 1989;320(22):1446&#x2013;1452. doi: 10.1056/NEJM198906013202203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM198906013202203</ArticleId><ArticleId IdType="pubmed">2566117</ArticleId></ArticleIdList></Reference><Reference><Citation>Ueno H, Yamaguchi T, Fukunaga S, Okada Y, Yano Y, Hoshino M, et al. Comparison between the aggregation of human and rodent amyloid &#x3b2;-proteins in GM1 Ganglioside clusters. Biochemistry. 2014;53(48):7523&#x2013;30. doi: 10.1021/bi501239q.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi501239q</ArticleId><ArticleId IdType="pubmed">25399921</ArticleId></ArticleIdList></Reference><Reference><Citation>Bush AI. The metallobiology of Alzheimer&#x2019;s disease. Trends Neurosci. 2003;26(4):207&#x2013;14. doi: 10.1016/S0166-2236(03)00067-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0166-2236(03)00067-5</ArticleId><ArticleId IdType="pubmed">12689772</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer&#x2019;s Disease Research Models | ALZFORUM [Internet]. [cited 2020 May 22]. Available from: https://www.alzforum.org/research-models/alzheimers-disease.</Citation></Reference><Reference><Citation>Rice HC, de Malmazet D, Schreurs A, Frere S, Van Molle I, Volkov AN, et al. Secreted amyloid-&#x3b2; precursor protein functions as a GABA(B)R1a ligand to modulate synaptic transmission. Science. 2019;363(6423):eaao4827. doi: 10.1126/science.aao4827.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aao4827</ArticleId><ArticleId IdType="pmc">PMC6366617</ArticleId><ArticleId IdType="pubmed">30630900</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodwin LO, Splinter E, Davis TL, Urban R, He H, Braun RE, et al. Large-scale discovery of mouse transgenic integration sites reveals frequent structural variation and insertional mutagenesis. Genome Res. 2019;29(3):494&#x2013;505. doi: 10.1101/gr.233866.117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.233866.117</ArticleId><ArticleId IdType="pmc">PMC6396414</ArticleId><ArticleId IdType="pubmed">30659012</ArticleId></ArticleIdList></Reference><Reference><Citation>Gamache J, Benzow K, Forster C, Kemper L, Hlynialuk C, Furrow E, et al. Factors other than hTau overexpression that contribute to tauopathy-like phenotype in rTg4510 mice. Nat Commun. 2019;10(1):2479. doi: 10.1038/s41467-019-10428-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-10428-1</ArticleId><ArticleId IdType="pmc">PMC6554306</ArticleId><ArticleId IdType="pubmed">31171783</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaguri H, Nilsson P, Hashimoto S, Nagata K, Saito T, De Strooper B, et al. APP mouse models for Alzheimer&#x2019;s disease preclinical studies. EMBO J. 2017;36(17):2473&#x2013;87. doi: 10.15252/embj.201797397.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201797397</ArticleId><ArticleId IdType="pmc">PMC5579350</ArticleId><ArticleId IdType="pubmed">28768718</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Yang H, Shivalila CS, Dawlaty MM, Cheng AW, Zhang F, et al. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell. 2013;153(4):910&#x2013;918. doi: 10.1016/j.cell.2013.04.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2013.04.025</ArticleId><ArticleId IdType="pmc">PMC3969854</ArticleId><ArticleId IdType="pubmed">23643243</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito T, Matsuba Y, Mihira N, Takano J, Nilsson P, Itohara S, et al. Single App knock-in mouse models of Alzheimer's disease. Nat Neurosci. 2014;17(5):661&#x2013;663. doi: 10.1038/nn.3697.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3697</ArticleId><ArticleId IdType="pubmed">24728269</ArticleId></ArticleIdList></Reference><Reference><Citation>Reaume AG, Howland DS, Trusko SP, Savage MJ, Lang DM, Greenberg BD, et al. Enhanced amyloidogenic processing of the beta-amyloid precursor protein in gene-targeted mice bearing the Swedish familial Alzheimer&#x2019;s disease mutations and a &#x201c;humanized&#x201d; Abeta sequence. J Biol Chem. 1996;271(38):23380&#x2013;23388. doi: 10.1074/jbc.271.38.23380.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.271.38.23380</ArticleId><ArticleId IdType="pubmed">8798542</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Simons M, Multhaup G, Van Leuven F, Beyreuther K, Dotti CG. Production of intracellular amyloid-containing fragments in hippocampal neurons expressing human amyloid precursor protein and protection against amyloidogenesis by subtle amino acid substitutions in the rodent sequence. EMBO J. 1995;14(20):4932&#x2013;4938. doi: 10.1002/j.1460-2075.1995.tb00176.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/j.1460-2075.1995.tb00176.x</ArticleId><ArticleId IdType="pmc">PMC394596</ArticleId><ArticleId IdType="pubmed">7588622</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanden Berghe T, Hulpiau P, Martens L, Vandenbroucke RE, Van Wonterghem E, Perry SW, et al. Passenger mutations confound interpretation of all genetically modified congenic mice. Immunity. 2015;43(1):200&#x2013;209. doi: 10.1016/j.immuni.2015.06.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2015.06.011</ArticleId><ArticleId IdType="pmc">PMC4800811</ArticleId><ArticleId IdType="pubmed">26163370</ArticleId></ArticleIdList></Reference><Reference><Citation>Paquet D, Kwart D, Chen A, Sproul A, Jacob S, Teo S, et al. Efficient introduction of specific homozygous and heterozygous mutations using CRISPR/Cas9. Nature. 2016;533(7601):125&#x2013;129. doi: 10.1038/nature17664.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature17664</ArticleId><ArticleId IdType="pubmed">27120160</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindowski K, Bretteville A, Leroy K, Begard S, Brion J-P, Hamdane M, et al. Alzheimer&#x2019;s disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. Am J Pathol. 2006;169(2):599&#x2013;616. doi: 10.2353/ajpath.2006.060002.</Citation><ArticleIdList><ArticleId IdType="doi">10.2353/ajpath.2006.060002</ArticleId><ArticleId IdType="pmc">PMC1698785</ArticleId><ArticleId IdType="pubmed">16877359</ArticleId></ArticleIdList></Reference><Reference><Citation>Gill TJ, Smith GJ, Wissler RW, Kunz HW. The rat as an experimental animal. Science. 1989;245(4915):269&#x2013;276. doi: 10.1126/science.2665079.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.2665079</ArticleId><ArticleId IdType="pubmed">2665079</ArticleId></ArticleIdList></Reference><Reference><Citation>Tambini MD, D&#x2019;Adamio L. Knock-in rats with homozygous PSEN1L435F Alzheimer mutation are viable and show selective &#x3b3;-secretase activity loss causing low A&#x3b2;40/42, high A&#x3b2;43. J Biol Chem. 2020;295(21):7442&#x2013;7451. doi: 10.1074/jbc.RA120.012542.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA120.012542</ArticleId><ArticleId IdType="pmc">PMC7247318</ArticleId><ArticleId IdType="pubmed">32265300</ArticleId></ArticleIdList></Reference><Reference><Citation>Campion D, Flaman J-M, Brice A, Hannequin D, Dubois B, Martin C, et al. Mutations of the presenilin I gene in families with early-onset Alzheimer&#x2019;s disease. Hum Mol Genet. 1995;4(12):2373&#x2013;2377. doi: 10.1093/hmg/4.12.2373.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/4.12.2373</ArticleId><ArticleId IdType="pubmed">8634712</ArticleId></ArticleIdList></Reference><Reference><Citation>Esselens G, Oorschot V, Baert V, Raemaekers T, Spittaels K, Serneels L, et al. Presenilin 1 mediates the turnover of telencephalin in hippocampal neurons via an autophagic degradative pathway. J Cell Biol. 2004;166(7):1041. doi: 10.1083/jcb.200406060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200406060</ArticleId><ArticleId IdType="pmc">PMC2172014</ArticleId><ArticleId IdType="pubmed">15452145</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruderisch N, Schlatter D, Kuglstatter A, Guba W, Huber S, Cusulin C, et al. Potent and selective BACE-1 peptide inhibitors lower brain A&#x3b2; levels mediated by brain shuttle transport. EBioMedicine. 2017;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5652008</ArticleId><ArticleId IdType="pubmed">28923680</ArticleId></ArticleIdList></Reference><Reference><Citation>PSEN1 M139T | ALZFORUM [Internet]. [cited 2020 May 22]. Available from: https://www.alzforum.org/mutations/psen1-m139t.</Citation></Reference><Reference><Citation>Szaruga M, Veugelen S, Benurwar M, Lismont S, Sepulveda-Falla D, Lleo A, et al. Qualitative changes in human &#x3b3;-secretase underlie familial Alzheimer&#x2019;s disease. J Exp Med. 2015;212(12):2003&#x2013;2013. doi: 10.1084/jem.20150892.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20150892</ArticleId><ArticleId IdType="pmc">PMC4647268</ArticleId><ArticleId IdType="pubmed">26481686</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Annaert W, Cupers P, Saftig P, Craessaerts K, Mumm JS, et al. A presenilin-1-dependent &#x3b3;-secretase-like protease mediates release of Notch intracellular domain. Nature. 1999;398(6727):518&#x2013;522. doi: 10.1038/19083.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/19083</ArticleId><ArticleId IdType="pubmed">10206645</ArticleId></ArticleIdList></Reference><Reference><Citation>Takami M, Nagashima Y, Sano Y, Ishihara S, Morishima-Kawashima M, Funamoto S, et al. &#x3b3;-Secretase: Successive tripeptide and tetrapeptide release from the transmembrane domain of &#x3b2;-carboxyl terminal fragment. J Neurosci. 2009;29(41):13042&#x2013;13052. doi: 10.1523/JNEUROSCI.2362-09.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2362-09.2009</ArticleId><ArticleId IdType="pmc">PMC6665297</ArticleId><ArticleId IdType="pubmed">19828817</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanes J, Zilka N, Bartkova M, Caletkova M, Dobrota D, Novak M. Rat tau proteome consists of six tau isoforms: implication for animal models of human tauopathies. J Neurochem. 2009;108(5):1167&#x2013;1176. doi: 10.1111/j.1471-4159.2009.05869.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2009.05869.x</ArticleId><ArticleId IdType="pubmed">19141083</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen RM, Rezai-Zadeh K, Weitz TM, Rentsendorj A, Gate D, Spivak I, et al. A transgenic Alzheimer rat with plaques, tau pathology, behavioral impairment, oligomeric A&#x3b2;, and frank neuronal loss. J Neurosci. 2013;33(15):6245&#x2013;6256. doi: 10.1523/JNEUROSCI.3672-12.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3672-12.2013</ArticleId><ArticleId IdType="pmc">PMC3720142</ArticleId><ArticleId IdType="pubmed">23575824</ArticleId></ArticleIdList></Reference><Reference><Citation>Portelius E, Fortea J, Molinuevo JL, Gustavsson MK, Andreasson U, Sanchez-Valle R. The amyloid-&#x3b2; isoform pattern in cerebrospinal fluid in familial PSEN1 M139T- and L286P-associated Alzheimer&#x2019;s disease. Mol Med Rep. 2012;5(4):1111&#x2013;1115. doi: 10.3892/mmr.2012.774.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2012.774</ArticleId><ArticleId IdType="pmc">PMC3493058</ArticleId><ArticleId IdType="pubmed">22307680</ArticleId></ArticleIdList></Reference><Reference><Citation>Szaruga M, Munteanu B, Lismont S, Veugelen S, Horr&#xe9; K, Mercken M, et al. Alzheimer&#x2019;s-causing mutations shift A&#x3b2; length by destabilizing &#x3b3;-secretase-A&#x3b2;n interactions. Cell. 2017;170(3):443&#x2013;456. doi: 10.1016/j.cell.2017.07.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.07.004</ArticleId><ArticleId IdType="pubmed">28753424</ArticleId></ArticleIdList></Reference><Reference><Citation>Tambini MD, Yao W, D&#x2019;Adamio L. Facilitation of glutamate, but not GABA, release in familial Alzheimer&#x2019;s APP mutant Knock-in rats with increased &#x3b2;-cleavage of APP. Aging Cell. 2019;18(6):e13033. doi: 10.1111/acel.13033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/acel.13033</ArticleId><ArticleId IdType="pmc">PMC6826143</ArticleId><ArticleId IdType="pubmed">31496118</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia D, Watanabe H, Wu B, Lee SH, Li Y, Tsvetkov E, et al. Presenilin-1 Knockin mice reveal loss-of-function mechanism for familial Alzheimer&#x2019;s disease. Neuron. 2015;85(5):967&#x2013;981. doi: 10.1016/j.neuron.2015.02.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2015.02.010</ArticleId><ArticleId IdType="pmc">PMC4358812</ArticleId><ArticleId IdType="pubmed">25741723</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Karran E. The cellular phase of Alzheimer&#x2019;s disease. Cell. 2016;164(4):603&#x2013;615. doi: 10.1016/j.cell.2015.12.056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.12.056</ArticleId><ArticleId IdType="pubmed">26871627</ArticleId></ArticleIdList></Reference><Reference><Citation>Arber C, Lovejoy C, Wray S. Stem cell models of Alzheimer&#x2019;s disease: progress and challenges. Alzheimers Res Ther. 2017;9(1):42. doi: 10.1186/s13195-017-0268-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-017-0268-4</ArticleId><ArticleId IdType="pmc">PMC5470327</ArticleId><ArticleId IdType="pubmed">28610595</ArticleId></ArticleIdList></Reference><Reference><Citation>Espuny-Camacho I, Arranz AM, Fiers M, Snellinx A, Ando K, Munck S, et al. Hallmarks of Alzheimer&#x2019;s disease in stem-cell-derived human neurons transplanted into mouse brain. Neuron. 2017;93(5):1066&#x2013;1081. doi: 10.1016/j.neuron.2017.02.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.02.001</ArticleId><ArticleId IdType="pubmed">28238547</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancuso R, Van Den Daele J, Fattorelli N, Wolfs L, Balusu S, Burton O, et al. Stem-cell-derived human microglia transplanted in mouse brain to study human disease. Nat Neurosci. 2019;22(12):2111&#x2013;2116. doi: 10.1038/s41593-019-0525-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-019-0525-x</ArticleId><ArticleId IdType="pmc">PMC7616913</ArticleId><ArticleId IdType="pubmed">31659342</ArticleId></ArticleIdList></Reference><Reference><Citation>Abud EM, Ramirez RN, Martinez ES, Healy LM, Nguyen CHH, Newman SA, et al. iPSC-derived human microglia-like cells to study neurological diseases. Neuron. 2017;94(2):278&#x2013;293. doi: 10.1016/j.neuron.2017.03.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.03.042</ArticleId><ArticleId IdType="pmc">PMC5482419</ArticleId><ArticleId IdType="pubmed">28426964</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33074286</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>25</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>78</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Jan</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel: A Meta-analysis.</ArticleTitle><Pagination><StartPage>102</StartPage><EndPage>113</EndPage><MedlinePgn>102-113</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2020.3536</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Compared with non-Hispanic White individuals, African American individuals from the same community are approximately twice as likely to develop Alzheimer disease. Despite this disparity, the largest Alzheimer disease genome-wide association studies to date have been conducted in non-Hispanic White individuals. In the largest association analyses of Alzheimer disease in African American individuals, ABCA7, TREM2, and an intergenic locus at 5q35 were previously implicated.</AbstractText><AbstractText Label="OBJECTIVE">To identify additional risk loci in African American individuals by increasing the sample size and using the African Genome Resource panel.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This genome-wide association meta-analysis used case-control and family-based data sets from the Alzheimer Disease Genetics Consortium. There were multiple recruitment sites throughout the United States that included individuals with Alzheimer disease and controls of African American ancestry. Analysis began October 2018 and ended September 2019.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Diagnosis of Alzheimer disease.</AbstractText><AbstractText Label="RESULTS">A total of 2784 individuals with Alzheimer disease (1944 female [69.8%]) and 5222 controls (3743 female [71.7%]) were analyzed (mean [SD] age at last evaluation, 74.2 [13.6] years). Associations with 4 novel common loci centered near the intracellular glycoprotein trafficking gene EDEM1 (3p26; P&#x2009;=&#x2009;8.9&#x2009;&#xd7;&#x2009;10-7), near the immune response gene ALCAM (3q13; P&#x2009;=&#x2009;9.3&#x2009;&#xd7;&#x2009;10-7), within GPC6 (13q31; P&#x2009;=&#x2009;4.1&#x2009;&#xd7;&#x2009;10-7), a gene critical for recruitment of glutamatergic receptors to the neuronal membrane, and within VRK3 (19q13.33; P&#x2009;=&#x2009;3.5&#x2009;&#xd7;&#x2009;10-7), a gene involved in glutamate neurotoxicity, were identified. In addition, several loci associated with rare variants, including a genome-wide significant intergenic locus near IGF1R at 15q26 (P&#x2009;=&#x2009;1.7&#x2009;&#xd7;&#x2009;10-9) and 6 additional loci with suggestive significance (P&#x2009;&#x2264;&#x2009;5&#x2009;&#xd7;&#x2009;10-7) such as API5 at 11p12 (P&#x2009;=&#x2009;8.8&#x2009;&#xd7;&#x2009;10-8) and RBFOX1 at 16p13 (P&#x2009;=&#x2009;5.4&#x2009;&#xd7;&#x2009;10-7) were identified. Gene expression data from brain tissue demonstrate association of ALCAM, ARAP1, GPC6, and RBFOX1 with brain &#x3b2;-amyloid load. Of 25 known loci associated with Alzheimer disease in non-Hispanic White individuals, only APOE, ABCA7, TREM2, BIN1, CD2AP, FERMT2, and WWOX were implicated at a nominal significance level or stronger in African American individuals. Pathway analyses strongly support the notion that immunity, lipid processing, and intracellular trafficking pathways underlying Alzheimer disease in African American individuals overlap with those observed in non-Hispanic White individuals. A new pathway emerging from these analyses is the kidney system, suggesting a novel mechanism for Alzheimer disease that needs further exploration.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">While the major pathways involved in Alzheimer disease etiology in African American individuals are similar to those in non-Hispanic White individuals, the disease-associated loci within these pathways differ.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kunkle</LastName><ForeName>Brian W</ForeName><Initials>BW</Initials><AffiliationInfo><Affiliation>The John P. Hussman Institute for Human Genomics, University of Miami, Miami, Florida.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dr. John T. MacDonald Foundation, Department of Human Genetics, University of Miami, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>The John P. Hussman Institute for Human Genomics, University of Miami, Miami, Florida.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dr. John T. MacDonald Foundation, Department of Human Genetics, University of Miami, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klein</LastName><ForeName>Hans-Ulrich</ForeName><Initials>HU</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gertrude H. Sergievsky Center, Columbia University, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Columbia University, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naj</LastName><ForeName>Adam C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Epidemiology, University of Pennsylvania Perelman School of Medicine, Philadelphia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Penn Neurodegeneration Genomics Center, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamilton-Nelson</LastName><ForeName>Kara L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>The John P. Hussman Institute for Human Genomics, University of Miami, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Larson</LastName><ForeName>Eric B</ForeName><Initials>EB</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Washington, Seattle.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Group Health Research Institute, Group Health, Seattle, Washington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Evans</LastName><ForeName>Denis A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Rush Institute for Healthy Aging, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Jager</LastName><ForeName>Phil L</ForeName><Initials>PL</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gertrude H. Sergievsky Center, Columbia University, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Columbia University, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crane</LastName><ForeName>Paul K</ForeName><Initials>PK</Initials><AffiliationInfo><Affiliation>Penn Neurodegeneration Genomics Center, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buxbaum</LastName><ForeName>Joe D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Mount Sinai School of Medicine, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics and Genomics Sciences, Mount Sinai School of Medicine, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, Mount Sinai School of Medicine, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Friedman Brain Institute, Mount Sinai School of Medicine, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ertekin-Taner</LastName><ForeName>Nilufer</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barnes</LastName><ForeName>Lisa L</ForeName><Initials>LL</Initials><AffiliationInfo><Affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Behavioral Sciences, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fallin</LastName><ForeName>M Daniele</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Johns Hopkins University School of Public Health, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manly</LastName><ForeName>Jennifer J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gertrude H. Sergievsky Center, Columbia University, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Columbia University, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Go</LastName><ForeName>Rodney C P</ForeName><Initials>RCP</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, University of Alabama at Birmingham, Birmingham.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Obisesan</LastName><ForeName>Thomas O</ForeName><Initials>TO</Initials><AffiliationInfo><Affiliation>Howard University, Howard University Hospital, Washington, DC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamboh</LastName><ForeName>M Ilyas</ForeName><Initials>MI</Initials><AffiliationInfo><Affiliation>Department of Human Genetics, University of Pittsburgh, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alzheimer's Disease Research Center, University of Pittsburgh, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hall</LastName><ForeName>Kathleen S</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Indiana University School of Medicine, Indianapolis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Genetics and Genomics Sciences, Mount Sinai School of Medicine, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, Mount Sinai School of Medicine, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Friedman Brain Institute, Mount Sinai School of Medicine, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ronald M. Loeb Center for Alzheimer's Disease, Icahn School of Medicine at Mount Sinai, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foroud</LastName><ForeName>Tatiana M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Department of Medical and Molecular Genetics, Indiana University, Indianapolis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Eden R</ForeName><Initials>ER</Initials><AffiliationInfo><Affiliation>The John P. Hussman Institute for Human Genomics, University of Miami, Miami, Florida.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dr. John T. MacDonald Foundation, Department of Human Genetics, University of Miami, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Li-Sao</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>Penn Neurodegeneration Genomics Center, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Byrd</LastName><ForeName>Goldie S</ForeName><Initials>GS</Initials><AffiliationInfo><Affiliation>Maya Angelou Center for Health Equity, Wake Forest School of Medicine, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farrer</LastName><ForeName>Lindsay A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Department of Medicine (Biomedical Genetics), Boston University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Boston University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology, Boston University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Boston University School of Public Health, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haines</LastName><ForeName>Jonathan L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Population and Quantitative Health Sciences, Institute for Computational Biology, Case Western Reserve University, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schellenberg</LastName><ForeName>Gerard D</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Penn Neurodegeneration Genomics Center, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayeux</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gertrude H. Sergievsky Center, Columbia University, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Columbia University, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Columbia University, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Epidemiology, College of Physicians and Surgeons, Columbia University, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pericak-Vance</LastName><ForeName>Margaret A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>The John P. Hussman Institute for Human Genomics, University of Miami, Miami, Florida.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dr. John T. MacDonald Foundation, Department of Human Genetics, University of Miami, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reitz</LastName><ForeName>Christiane</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gertrude H. Sergievsky Center, Columbia University, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Columbia University, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Epidemiology, College of Physicians and Surgeons, Columbia University, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Writing Group for the Alzheimer&#x2019;s Disease Genetics Consortium (ADGC)</CollectiveName></Author><Author ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>Neill R</ForeName><Initials>NR</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinez</LastName><ForeName>Izri</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Gertrude H. Sergievsky Center, Columbia University, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ayodele</LastName><ForeName>Temitope</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Gertrude H. Sergievsky Center, Columbia University, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Logue</LastName><ForeName>Mark W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>Department of Medicine (Biomedical Genetics), Boston University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Center for PTSD, VA Boston Healthcare System, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Boston University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cantwell</LastName><ForeName>Laura B</ForeName><Initials>LB</Initials><AffiliationInfo><Affiliation>Penn Neurodegeneration Genomics Center, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jean-Francois</LastName><ForeName>Melissa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>The John P. Hussman Institute for Human Genomics, University of Miami, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuzma</LastName><ForeName>Amanda B</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Penn Neurodegeneration Genomics Center, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adams</LastName><ForeName>L D</ForeName><Initials>LD</Initials><AffiliationInfo><Affiliation>The John P. Hussman Institute for Human Genomics, University of Miami, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vance</LastName><ForeName>Jeffery M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>The John P. Hussman Institute for Human Genomics, University of Miami, Miami, Florida.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dr. John T. MacDonald Foundation, Department of Human Genetics, University of Miami, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cuccaro</LastName><ForeName>Michael L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>The John P. Hussman Institute for Human Genomics, University of Miami, Miami, Florida.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dr. John T. MacDonald Foundation, Department of Human Genetics, University of Miami, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Jaeyoon</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medicine (Biomedical Genetics), Boston University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mez</LastName><ForeName>Jesse</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Boston University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lunetta</LastName><ForeName>Kathryn L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jun</LastName><ForeName>Gyungah R</ForeName><Initials>GR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Boston University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology, Boston University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>Oscar L</ForeName><Initials>OL</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Research Center, University of Pittsburgh, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hendrie</LastName><ForeName>Hugh C</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Indiana University School of Medicine, Indianapolis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Arizona Alzheimer's Center, Banner Alzheimer's Institute, Phoenix.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kowall</LastName><ForeName>Neil W</ForeName><Initials>NW</Initials><AffiliationInfo><Affiliation>Boston University, Boston VA Medical Center, Jamaica Plain, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leverenz</LastName><ForeName>James B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Small</LastName><ForeName>Scott A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Columbia University Alzheimer's Disease Research Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levey</LastName><ForeName>Allan I</ForeName><Initials>AI</Initials><AffiliationInfo><Affiliation>Department of Neurology, Emory University, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Golde</LastName><ForeName>Todd E</ForeName><Initials>TE</Initials><AffiliationInfo><Affiliation>Center for Translational Research in Neurodegenerative Disease (CTRND), University of Florida, Gainesville.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saykin</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Medical and Molecular Genetics, Indiana University, Indianapolis.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Indiana Alzheimer Disease Center, Indiana University School of Medicine, Indianapolis.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Starks</LastName><ForeName>Takiyah D</ForeName><Initials>TD</Initials><AffiliationInfo><Affiliation>Maya Angelou Center for Health Equity, Wake Forest School of Medicine, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albert</LastName><ForeName>Marilyn S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Johns Hopkins University School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>Bradley T</ForeName><Initials>BT</Initials><AffiliationInfo><Affiliation>Massachusetts Alzheimer's Disease Research Center, Department of Neurology, Massachusetts General Hospital, Charlestown.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sano</LastName><ForeName>Mary</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Mount Sinai School of Medicine, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wisniewski</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Center for Cognitive Neurology, New York University, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vassar</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Northwestern University, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaye</LastName><ForeName>Jeffrey A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Aging &amp; Alzheimer Disease Center, Oregon Health &amp; Science University, Portland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henderson</LastName><ForeName>Victor W</ForeName><Initials>VW</Initials><AffiliationInfo><Affiliation>Department of Epidemiology &amp; Population Health, Stanford University, Stanford, California.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology &amp; Neurological Sciences, Stanford University, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeCarli</LastName><ForeName>Charles</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>University of California Davis at Medical Center, Sacramento.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>LaFerla</LastName><ForeName>Frank M</ForeName><Initials>FM</Initials><AffiliationInfo><Affiliation>University of California Irvine, Irvine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brewer</LastName><ForeName>James B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Shiley-Marcos Alzheimer's Disease Center, UC San Diego, La Jolla, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>University of California San Francisco, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swerdlow</LastName><ForeName>Russell H</ForeName><Initials>RH</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Research Center, University of Kansas, Kansas City.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Eldik</LastName><ForeName>Linda J</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Sanders-Brown Center on Aging, University of Kentucky, Lexington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paulson</LastName><ForeName>Henry L</ForeName><Initials>HL</Initials><AffiliationInfo><Affiliation>Alzheimer Disease Center, University of Michigan, Ann Arbor.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chui</LastName><ForeName>Helena C</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>University of Southern California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosenberg</LastName><ForeName>Roger N</ForeName><Initials>RN</Initials><AffiliationInfo><Affiliation>University of Texas Southwestern Medical Center, Dallas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Craft</LastName><ForeName>Suzanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Wake Forest School of Medicine, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grabowski</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Department of Radiology, University of Washington, Seattle.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of Washington, Seattle.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asthana</LastName><ForeName>Sanjay</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University of Wisconsin, Madison.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strittmatter</LastName><ForeName>Stephen M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Yale University School of Medicine, New Haven, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kukull</LastName><ForeName>Walter A</ForeName><Initials>WA</Initials><AffiliationInfo><Affiliation>National Alzheimer's Coordinating Center, University of Washington, Seattle.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, University of Washington, Seattle.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG028786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066462</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027944</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG046139</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG013854</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG053760</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG052410</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066444</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062428</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HG004610</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010129</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066507</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066518</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG059307</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG030146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>KL2 RR024151</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066511</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066512</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001863</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG032984</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066515</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062421</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG066107</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002369</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG008702</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG016976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066508</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG009956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG056270</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG047266</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062429</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K25 AG055620</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG054023</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG054080</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG049638</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062422</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG012300</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG051504</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG008051</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066530</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG009029</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG061796</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG025688</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG019085</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG060882</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG028383</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066509</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG047270</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005138</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062677</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG037212</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066468</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062715</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG015473</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005142</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG008017</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG058635</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG047366</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG026395</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC2 AG036650</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG013846</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG072959</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG035982</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>JAMA Neurol. 2021 May 1;78(5):620. doi: 10.1001/jamaneurol.2021.0456.</RefSource><PMID Version="1">33749757</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D001741" MajorTopicYN="N">Black or African American</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056426" MajorTopicYN="N">Genetic Loci</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Kunkle reported grants from the National Institute of Aging (NIA) during the conduct of the study. Dr Schmidt reported grants from the National Institutes of Health (NIH) during the conduct of the study. Dr Larson reported grants from NIA during the conduct of the study. Dr Graff-Radford reported grants from NIH during the conduct of the study; grants from AbbVie, Biogen, Eli Lilly and Company, and Novartis outside the submitted work. Dr Evans reported grants from NIH during the conduct of the study. Dr Vance reported grants from NIH/NIA during the conduct of the study. Dr Cuccaro reported grants from NIH during the conduct of the study and other support from John P. Hussman Foundation outside the submitted work. Dr Manly reported grants from NIA/NIH during the conduct of the study. Dr Mez reported grants from NIH during the conduct of the study. Dr Obisesan reported grants from NIH during the conduct of the study. Dr Bennett reported grants from NIH during the conduct of the study. Dr Hall reported grants from NIA during the conduct of the study. Dr Reiman reported grants from Banner Alzheimer&#x2019;s Institute during the conduct of the study other support from Roche/Roche Diagnostics outside the submitted work. Dr Leverenz reported grants from NIA during the conduct of the study and grants from Alzheimer&#x2019;s Drug Discovery Foundation, Avid Biopharmaceuticals, Biogen, GE Healthcare, Lewy Body Dementia Association, Michael J. Fox Foundation, National Institute of Neurologic Disorders, and Stroke, Sanofi; and consulting fees from Acadia, Aptinyx, Biogen, Eisai, Genzyme, Sanofi, and Takeda. Dr Levey reported personal fees from Karuna Pharmaceuticals and GENUV and grants from vTv Therapeutics, AbbVie, Biogen, Cognito, Esai, Genentech, and Novartis outside the submitted work. Dr Golde reported personal fees from Biogen, Eli Lilly and Company, and AbbVie; nonfinancial support from Lacerta Therapeutics outside the submitted work; and served on safety advisory boards for AbbVie, Promis Therapeutics, Biogen, and Eli Lilly and company. Dr Saykin reported grants from NIH grants during the conduct of the study and other support from Springer-Nature and grants from Eli Lilly and Company; multiprincipal investigator of NIA Small Business Innovation Research to Arkley BioTek, consultant to Bayer Oncology, and served on the advisory board of Neurovision outside the submitted work. Dr Albert reported grants from NIA during the conduct of the study and personal fees from Eli Lilly and Company outside the submitted work. Dr Hyman reported grants from NIH during the conduct of the study. Dr Petersen reported grants from NIH during the conduct of the study and personal fees from Hoffman-La Roche, Merck, Genentech, Biogen, GE Healthcare, and Eisai outside the submitted work. Dr Wisniewski reported grants from NIH during the conduct of the study and outside the submitted work. Dr Kaye reported grants from NIH during the conduct of the study. Dr Henderson reported grants from NIH during the conduct of the study. Dr DeCarli reported consulting for Novartis Pharmaceutical on a safety study in heart failure. Dr Brewer reported holds stock options in CorTechs Labs and Human Longevity and has served on advisory boards for Human Longevity and Eli Lilly and Company outside the submitted work. Dr Van Eldik reported grants from NIH during the conduct of the study. Dr Chui reported grants from NIA during the conduct of the study. Dr Rosenberg reported other support from Vitruvian during the conduct of the study; grants from NIH/NIA, Zale Foundation, AWARE, Triumph over Alzheimer&#x2019;s Disease, and Its Their Time outside the submitted work; has a patent to amyloid beta gene vaccines issued; and served as a former Editor of <i>JAMA Neurology</i>, editorial board of <i>The Journal of the Neurological Sciences</i>, and former editorial board member of <i>JAMA</i>. Dr Grabowski reported grants from NIH during the conduct of the study. Dr Asthana reported grants from NIA during the conduct of the study and grants from Genentech and Lundbeck outside the submitted work. Dr Morris reported grants from NIH during the conduct of the study. Dr Strittmatter reported being a founder and equity holder in ReNetX Bio and in Allyx Therapeutics, entities seeking to develop therapeutics for Neural Repair and Neurodegeneration, respectively. Dr Goate served on the scientific advisory board for Denali Therapeutics from 2015-2018 and has served as a consultant for Biogen, AbbVie, Pfizer, GlaxoSmithKline, Eisai, and Illumina. Dr Kukull reported grants from NIH/NIA during the conduct of the study. Dr Foroud reported grants from NIH during the conduct of the study. Dr Haines reported grants from NIH during the conduct of the study. Dr Schellenberg reported grants from University of Pennsylvania during the conduct of the study. Dr Pericak-Vance reported grants from NIH/NIA during the conduct of the study. Dr Reitz reported grants from NIH during the conduct of the study. No other disclosures were reported.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Abner</LastName><ForeName>Erin</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Adams</LastName><ForeName>Perrie M</ForeName><Initials>PM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Albin</LastName><ForeName>Roger L</ForeName><Initials>RL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Apostolova</LastName><ForeName>Liana G</ForeName><Initials>LG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arnold</LastName><ForeName>Steven E</ForeName><Initials>SE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Atwood</LastName><ForeName>Craig S</ForeName><Initials>CS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baldwin</LastName><ForeName>Clinton T</ForeName><Initials>CT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barber</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barral</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beach</LastName><ForeName>Thomas G</ForeName><Initials>TG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Becker</LastName><ForeName>James T</ForeName><Initials>JT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beecham</LastName><ForeName>Gary W</ForeName><Initials>GW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bigio</LastName><ForeName>Eileen H</ForeName><Initials>EH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bird</LastName><ForeName>Thomas D</ForeName><Initials>TD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blacker</LastName><ForeName>Deborah</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boeve</LastName><ForeName>Bradley F</ForeName><Initials>BF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bowen</LastName><ForeName>James D</ForeName><Initials>JD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boxer</LastName><ForeName>Adam</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burke</LastName><ForeName>James R</ForeName><Initials>JR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burns</LastName><ForeName>Jeffrey M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cairns</LastName><ForeName>Nigel J</ForeName><Initials>NJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cao</LastName><ForeName>Chuanhai</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carlsson</LastName><ForeName>Cynthia M</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carney</LastName><ForeName>Regina M</ForeName><Initials>RM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carrasquillo</LastName><ForeName>Minerva M</ForeName><Initials>MM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cribbs</LastName><ForeName>David H</ForeName><Initials>DH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cruchaga</LastName><ForeName>Carlos</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dick</LastName><ForeName>Malcom</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis W</ForeName><Initials>DW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doody</LastName><ForeName>Rachelle S</ForeName><Initials>RS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duara</LastName><ForeName>Ranjan</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Faber</LastName><ForeName>Kelley M</ForeName><Initials>KM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fairchild</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fallon</LastName><ForeName>Kenneth B</ForeName><Initials>KB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fardo</LastName><ForeName>David W</ForeName><Initials>DW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farlow</LastName><ForeName>Martin R</ForeName><Initials>MR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferris</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frosch</LastName><ForeName>Matthew P</ForeName><Initials>MP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Galasko</LastName><ForeName>Douglas R</ForeName><Initials>DR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gearing</LastName><ForeName>Marla</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Geschwind</LastName><ForeName>Daniel H</ForeName><Initials>DH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ghetti</LastName><ForeName>Bernardino</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gilbert</LastName><ForeName>John R</ForeName><Initials>JR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Green</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Growdon</LastName><ForeName>John H</ForeName><Initials>JH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hakonarson</LastName><ForeName>Hakon</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hamilton</LastName><ForeName>Ronald L</ForeName><Initials>RL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hardy</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harrell</LastName><ForeName>Lindy E</ForeName><Initials>LE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Honig</LastName><ForeName>Lawrence S</ForeName><Initials>LS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huebinger</LastName><ForeName>Ryan M</ForeName><Initials>RM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huentelman</LastName><ForeName>Matthew J</ForeName><Initials>MJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hulette</LastName><ForeName>Christine M</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jarvik</LastName><ForeName>Gail P</ForeName><Initials>GP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jin</LastName><ForeName>Lee-Way</ForeName><Initials>LW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karydas</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Katz</LastName><ForeName>Mindy J</ForeName><Initials>MJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kauwe</LastName><ForeName>John S K</ForeName><Initials>JSK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Keene</LastName><ForeName>C Dirk</ForeName><Initials>CD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kim</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kramer</LastName><ForeName>Joel H</ForeName><Initials>JH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lah</LastName><ForeName>James J</ForeName><Initials>JJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leung</LastName><ForeName>Yuk Ye</ForeName><Initials>YY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>Ge</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lieberman</LastName><ForeName>Andrew P</ForeName><Initials>AP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lipton</LastName><ForeName>Richard B</ForeName><Initials>RB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lyketsos</LastName><ForeName>Constantine G</ForeName><Initials>CG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Malamon</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marson</LastName><ForeName>Daniel C</ForeName><Initials>DC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martiniuk</LastName><ForeName>Frank</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Masliah</LastName><ForeName>Eliezer</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>McCormick</LastName><ForeName>Wayne C</ForeName><Initials>WC</Initials></Investigator><Investigator ValidYN="Y"><LastName>McCurry</LastName><ForeName>Susan M</ForeName><Initials>SM</Initials></Investigator><Investigator ValidYN="Y"><LastName>McDavid</LastName><ForeName>Andrew N</ForeName><Initials>AN</Initials></Investigator><Investigator ValidYN="Y"><LastName>McDonough</LastName><ForeName>Stefan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>McKee</LastName><ForeName>Ann C</ForeName><Initials>AC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mesulam</LastName><ForeName>Marsel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>Carol A</ForeName><Initials>CA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Montine</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mukherjee</LastName><ForeName>Shubhabrata</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Myers</LastName><ForeName>Amanda J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>O'Bryant</LastName><ForeName>Sid E</ForeName><Initials>SE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Olichney</LastName><ForeName>John M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parisi</LastName><ForeName>Joseph E</ForeName><Initials>JE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peskind</LastName><ForeName>Elaine</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pierce</LastName><ForeName>Aimee</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Poon</LastName><ForeName>Wayne W</ForeName><Initials>WW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Potter</LastName><ForeName>Huntington</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Qu</LastName><ForeName>Liming</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quinn</LastName><ForeName>Joseph F</ForeName><Initials>JF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raj</LastName><ForeName>Ashok</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raskind</LastName><ForeName>Murray</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reisberg</LastName><ForeName>Barry</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reisch</LastName><ForeName>Joan S</ForeName><Initials>JS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ringman</LastName><ForeName>John M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roberson</LastName><ForeName>Erik D</ForeName><Initials>ED</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rogaeva</LastName><ForeName>Ekaterina</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosen</LastName><ForeName>Howard J</ForeName><Initials>HJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Royall</LastName><ForeName>Donald R</ForeName><Initials>DR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sager</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schneider</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lon S</ForeName><Initials>LS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seeley</LastName><ForeName>William W</ForeName><Initials>WW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Small</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sonnen</LastName><ForeName>Joshua A</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spina</LastName><ForeName>Salvatore</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>St George-Hyslop</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stern</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tanzi</LastName><ForeName>Rudolph E</ForeName><Initials>RE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Troncoso</LastName><ForeName>Juan C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tsuang</LastName><ForeName>Debby W</ForeName><Initials>DW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Valladares</LastName><ForeName>Otto</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Van Deerlin</LastName><ForeName>Vivianna M</ForeName><Initials>VM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vardarajan</LastName><ForeName>Badri N</ForeName><Initials>BN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vinters</LastName><ForeName>Harry V</ForeName><Initials>HV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vonsattel</LastName><ForeName>Jean Paul</ForeName><Initials>JP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weintraub</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Welsh-Bohmer</LastName><ForeName>Kathleen A</ForeName><Initials>KA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wilhelmsen</LastName><ForeName>Kirk C</ForeName><Initials>KC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williamson</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wingo</LastName><ForeName>Thomas S</ForeName><Initials>TS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Woltjer</LastName><ForeName>Randall L</ForeName><Initials>RL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wu</LastName><ForeName>Chuang-Kuo</ForeName><Initials>CK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Younkin</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yu</LastName><ForeName>Lei</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yu</LastName><ForeName>Chang-En</ForeName><Initials>CE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhao</LastName><ForeName>Yi</ForeName><Initials>Y</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>19</Day><Hour>12</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>10</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33074286</ArticleId><ArticleId IdType="pmc">PMC7573798</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2020.3536</ArticleId><ArticleId IdType="pii">2771828</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Seshadri S, Fitzpatrick AL, Ikram MA, et al. ; CHARGE Consortium; GERAD1 Consortium; EADI1 Consortium . Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA. 2010;303(18):1832-1840. doi:10.1001/jama.2010.574</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2010.574</ArticleId><ArticleId IdType="pmc">PMC2989531</ArticleId><ArticleId IdType="pubmed">20460622</ArticleId></ArticleIdList></Reference><Reference><Citation>Naj AC, Jun G, Beecham GW, et al. . Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer&#x2019;s disease. Nat Genet. 2011;43(5):436-441. doi:10.1038/ng.801</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.801</ArticleId><ArticleId IdType="pmc">PMC3090745</ArticleId><ArticleId IdType="pubmed">21460841</ArticleId></ArticleIdList></Reference><Reference><Citation>Harold D, Abraham R, Hollingworth P, et al. . Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer&#x2019;s disease. Nat Genet. 2009;41(10):1088-1093. doi:10.1038/ng.440</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.440</ArticleId><ArticleId IdType="pmc">PMC2845877</ArticleId><ArticleId IdType="pubmed">19734902</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollingworth P, Harold D, Sims R, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative; CHARGE consortium; EADI1 consortium . Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer&#x2019;s disease. Nat Genet. 2011;43(5):429-435. doi:10.1038/ng.803</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.803</ArticleId><ArticleId IdType="pmc">PMC3084173</ArticleId><ArticleId IdType="pubmed">21460840</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, Stefansson H, Steinberg S, et al. . Variant of TREM2 associated with the risk of Alzheimer&#x2019;s disease. N Engl J Med. 2013;368(2):107-116. doi:10.1056/NEJMoa1211103</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1211103</ArticleId><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Heath S, Even G, et al. ; European Alzheimer&#x2019;s Disease Initiative Investigators . Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer&#x2019;s disease. Nat Genet. 2009;41(10):1094-1099. doi:10.1038/ng.439</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.439</ArticleId><ArticleId IdType="pubmed">19734903</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunkle BW, Grenier-Boley B, Sims R, et al. . Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A&#x3b2;, tau, immunity and lipid processing. Nat Genet. 2019;51(3):414-430. doi:10.1038/s41588-019-0358-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-019-0358-2</ArticleId><ArticleId IdType="pmc">PMC6463297</ArticleId><ArticleId IdType="pubmed">30820047</ArticleId></ArticleIdList></Reference><Reference><Citation>Sims R, van der Lee SJSJ, Naj ACACAC, et al. ; ARUK Consortium; GERAD/PERADES, CHARGE, ADGC, EADI . Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer&#x2019;s disease. Nat Genet. 2017;49(9):1373-1384. doi:10.1038/ng.3916</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3916</ArticleId><ArticleId IdType="pmc">PMC5669039</ArticleId><ArticleId IdType="pubmed">28714976</ArticleId></ArticleIdList></Reference><Reference><Citation>Ridge PG, Mukherjee S, Crane PK, Kauwe JS; Alzheimer&#x2019;s Disease Genetics Consortium . Alzheimer&#x2019;s disease: analyzing the missing heritability. PLoS One. 2013;8(11):e79771. doi:10.1371/journal.pone.0079771</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0079771</ArticleId><ArticleId IdType="pmc">PMC3820606</ArticleId><ArticleId IdType="pubmed">24244562</ArticleId></ArticleIdList></Reference><Reference><Citation>So HC, Gui AH, Cherny SS, Sham PC. Evaluating the heritability explained by known susceptibility variants: a survey of ten complex diseases. Genet Epidemiol. 2011;35(5):310-317. doi:10.1002/gepi.20579</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gepi.20579</ArticleId><ArticleId IdType="pubmed">21374718</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatz M, Reynolds CA, Fratiglioni L, et al. . Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry. 2006;63(2):168-174. doi:10.1001/archpsyc.63.2.168</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archpsyc.63.2.168</ArticleId><ArticleId IdType="pubmed">16461860</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang M-X, Cross P, Andrews H, et al. . Incidence of AD in African-Americans, Caribbean Hispanics, and Caucasians in northern Manhattan. Neurology. 2001;56(1):49-56. doi:10.1212/WNL.56.1.49</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.56.1.49</ArticleId><ArticleId IdType="pubmed">11148235</ArticleId></ArticleIdList></Reference><Reference><Citation>Hohman TJ, Cooke-Bailey JN, Reitz C, et al. ; Alzheimer Disease Genetics Consortium . Global and local ancestry in African-Americans: implications for Alzheimer&#x2019;s disease risk. Alzheimers Dement. 2016;12(3):233-243. doi:10.1016/j.jalz.2015.02.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2015.02.012</ArticleId><ArticleId IdType="pmc">PMC4681680</ArticleId><ArticleId IdType="pubmed">26092349</ArticleId></ArticleIdList></Reference><Reference><Citation>Reitz C, Jun G, Naj A, et al. ; Alzheimer Disease Genetics Consortium . Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein E &#x3f5;4,and the risk of late-onset Alzheimer disease in African Americans. JAMA. 2013;309(14):1483-1492. doi:10.1001/jama.2013.2973</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2013.2973</ArticleId><ArticleId IdType="pmc">PMC3667653</ArticleId><ArticleId IdType="pubmed">23571587</ArticleId></ArticleIdList></Reference><Reference><Citation>Reitz C, Mayeux R; Alzheimer&#x2019;s Disease Genetics Consortium . TREM2 and neurodegenerative disease. N Engl J Med. 2013;369(16):1564-1565. doi:10.1056/NEJMc1306509</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc1306509</ArticleId><ArticleId IdType="pmc">PMC3980568</ArticleId><ArticleId IdType="pubmed">24131184</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajabli F, Feliciano BE, Celis K, et al. . Ancestral origin of ApoE &#x3b5;4 Alzheimer disease risk in Puerto Rican and African American populations. PLoS Genet. 2018;14(12):e1007791. doi:10.1371/journal.pgen.1007791</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1007791</ArticleId><ArticleId IdType="pmc">PMC6281216</ArticleId><ArticleId IdType="pubmed">30517106</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin SC, Carrasquillo MM, Benitez BA, et al. . TREM2 is associated with increased risk for Alzheimer&#x2019;s disease in African Americans. Mol Neurodegener. 2015;10(1):19. doi:10.1186/s13024-015-0016-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-015-0016-9</ArticleId><ArticleId IdType="pmc">PMC4426167</ArticleId><ArticleId IdType="pubmed">25886450</ArticleId></ArticleIdList></Reference><Reference><Citation>Cukier HN, Kunkle BW, Vardarajan BN, et al. ; Alzheimer&#x2019;s Disease Genetics Consortium . ABCA7 frameshift deletion associated with Alzheimer disease in African Americans. Neurol Genet. 2016;2(3):e79. doi:10.1212/NXG.0000000000000079</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXG.0000000000000079</ArticleId><ArticleId IdType="pmc">PMC4871806</ArticleId><ArticleId IdType="pubmed">27231719</ArticleId></ArticleIdList></Reference><Reference><Citation>N&#x2019;Songo A, Carrasquillo MM, Wang X, et al. . African American exome sequencing identifies potential risk variants at Alzheimer disease loci. Neurol Genet. 2017;3(2):e141. doi:10.1212/NXG.0000000000000141</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXG.0000000000000141</ArticleId><ArticleId IdType="pmc">PMC5406839</ArticleId><ArticleId IdType="pubmed">28480329</ArticleId></ArticleIdList></Reference><Reference><Citation>Logue MW, Schu M, Vardarajan BN, et al. ; Alzheimer Disease Genetics Consortium; Alzheimer Disease Genetics Consortium . Two rare AKAP9 variants are associated with Alzheimer&#x2019;s disease in African Americans. Alzheimers Dement. 2014;10(6):609-618.e11. doi:10.1016/j.jalz.2014.06.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2014.06.010</ArticleId><ArticleId IdType="pmc">PMC4253055</ArticleId><ArticleId IdType="pubmed">25172201</ArticleId></ArticleIdList></Reference><Reference><Citation>Mez J, Chung J, Jun G, et al. ; Alzheimer&#x2019;s Disease Genetics Consortium . Two novel loci, COBL and SLC10A2, for Alzheimer&#x2019;s disease in African Americans. Alzheimers Dement. 2017;13(2):119-129. doi:10.1016/j.jalz.2016.09.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.09.002</ArticleId><ArticleId IdType="pmc">PMC5318231</ArticleId><ArticleId IdType="pubmed">27770636</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos OA, Pedraza O, Lucas JA, et al. . Ethnoracial differences in Alzheimer&#x2019;s disease from the FLorida Autopsied Multi-Ethnic (FLAME) cohort. Alzheimers Dement. 2019;15(5):635-643. doi:10.1016/j.jalz.2018.12.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.12.013</ArticleId><ArticleId IdType="pmc">PMC6511501</ArticleId><ArticleId IdType="pubmed">30792090</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes LL, Leurgans S, Aggarwal NT, et al. . Mixed pathology is more likely in black than white decedents with Alzheimer dementia. Neurology. 2015;85(6):528-534. doi:10.1212/WNL.0000000000001834</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000001834</ArticleId><ArticleId IdType="pmc">PMC4540250</ArticleId><ArticleId IdType="pubmed">26180136</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Schindler SE, McCue LM, et al. . Assessment of racial disparities in biomarkers for Alzheimer disease. JAMA Neurol. 2019;76(3):264-273. doi:10.1001/jamaneurol.2018.4249</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2018.4249</ArticleId><ArticleId IdType="pmc">PMC6439726</ArticleId><ArticleId IdType="pubmed">30615028</ArticleId></ArticleIdList></Reference><Reference><Citation>Filshtein TJ, Dugger BN, Jin LW, et al. . Neuropathological diagnoses of demented Hispanic, Black, and non-Hispanic white decedents seen at an Alzheimer&#x2019;s disease center. J Alzheimers Dis. 2019;68(1):145-158. doi:10.3233/JAD-180992</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-180992</ArticleId><ArticleId IdType="pmc">PMC7286069</ArticleId><ArticleId IdType="pubmed">30775996</ArticleId></ArticleIdList></Reference><Reference><Citation>Graff-Radford NR, Besser LM, Crook JE, Kukull WA, Dickson DW. Neuropathologic differences by race from the National Alzheimer&#x2019;s Coordinating Center. Alzheimers Dement. 2016;12(6):669-677. doi:10.1016/j.jalz.2016.03.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.03.004</ArticleId><ArticleId IdType="pmc">PMC4903907</ArticleId><ArticleId IdType="pubmed">27094726</ArticleId></ArticleIdList></Reference><Reference><Citation>The African Partnership for Chronic Disease Research. Data. Accessed September 4, 2020. https://www.apcdr.org/data/</Citation></Reference><Reference><Citation>Blacker D, Bertram L, Saunders AJ, et al. ; NIMH Genetics Initiative Alzheimer&#x2019;s Disease Study Group . Results of a high-resolution genome screen of 437 Alzheimer&#x2019;s disease families. Hum Mol Genet. 2003;12(1):23-32. doi:10.1093/hmg/ddg007</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddg007</ArticleId><ArticleId IdType="pubmed">12490529</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, Wojtas A, Bras J, et al. ; Alzheimer Genetic Analysis Group . TREM2 variants in Alzheimer&#x2019;s disease. N Engl J Med. 2013;368(2):117-127. doi:10.1056/NEJMoa1211851</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1211851</ArticleId><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>NIAGADS. Explore genetics and genomics of Alzheimer&#x2019;s Disease. Accessed September 4, 2020. https://www.niagads.org/</Citation></Reference><Reference><Citation>Yu L, Chibnik LB, Srivastava GP, et al. . Association of Brain DNA methylation in SORL1, ABCA7, HLA-DRB5, SLC24A4, and BIN1 with pathological diagnosis of Alzheimer disease. JAMA Neurol. 2015;72(1):15-24. doi:10.1001/jamaneurol.2014.3049</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.3049</ArticleId><ArticleId IdType="pmc">PMC4344367</ArticleId><ArticleId IdType="pubmed">25365775</ArticleId></ArticleIdList></Reference><Reference><Citation>de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: generalized gene-set analysis of GWAS data. PLoS Comput Biol. 2015;11(4):e1004219. doi:10.1371/journal.pcbi.1004219</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1004219</ArticleId><ArticleId IdType="pmc">PMC4401657</ArticleId><ArticleId IdType="pubmed">25885710</ArticleId></ArticleIdList></Reference><Reference><Citation>International Genomics of Alzheimer's Disease Consortium (IGAP); Jones L, Lambert J-C, Wang L-S, et al. . Convergent genetic and expression data implicate immunity in Alzheimer&#x2019;s disease. Alzheimers Dement. 2015;11(6). doi:10.1016/j.jalz.2014.05.1757</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2014.05.1757</ArticleId><ArticleId IdType="pmc">PMC4672734</ArticleId><ArticleId IdType="pubmed">25533204</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert J-C, Ibrahim-Verbaas CA, Harold D, et al. ; European Alzheimer&#x2019;s Disease Initiative (EADI); Genetic and Environmental Risk in Alzheimer&#x2019;s Disease; Alzheimer&#x2019;s Disease Genetic Consortium; Cohorts for Heart and Aging Research in Genomic Epidemiology . Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer&#x2019;s disease. Nat Genet. 2013;45(12):1452-1458. doi:10.1038/ng.2802</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.2802</ArticleId><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings AC, Jiang L, Velez Edwards DR, et al. . Genome-wide association and linkage study in the Amish detects a novel candidate late-onset Alzheimer disease gene. Ann Hum Genet. 2012;76(5):342-351. doi:10.1111/j.1469-1809.2012.00721.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1469-1809.2012.00721.x</ArticleId><ArticleId IdType="pmc">PMC3419486</ArticleId><ArticleId IdType="pubmed">22881374</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamriben L, Oster ME, Tamura T, et al. . EDEM1's mannosidase-like domain binds ERAD client proteins in a redox-sensitive manner and possesses catalytic activity. J Biol Chem. 2018;293(36):13932-13945. doi:10.1074/jbc.RA118.004183</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA118.004183</ArticleId><ArticleId IdType="pmc">PMC6130956</ArticleId><ArticleId IdType="pubmed">30021839</ArticleId></ArticleIdList></Reference><Reference><Citation>Molinari M, Calanca V, Galli C, Lucca P, Paganetti P.. Role of EDEM in the release of misfolded glycoproteins from the calnexin cycle. Science. 2003;299(5611):1397-1400. doi:10.1126/science.1079474</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1079474</ArticleId><ArticleId IdType="pubmed">12610306</ArticleId></ArticleIdList></Reference><Reference><Citation>Cormier JH, Tamura T, Sunryd JC, Hebert DN. EDEM1 recognition and delivery of misfolded proteins to the SEL1L-containing ERAD complex. Mol Cell. 2009;34(5):627-633. doi:10.1016/j.molcel.2009.05.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2009.05.018</ArticleId><ArticleId IdType="pmc">PMC2740909</ArticleId><ArticleId IdType="pubmed">19524542</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaneko M, Koike H, Saito R, Kitamura Y, Okuma Y, Nomura Y. Loss of HRD1-mediated protein degradation causes amyloid precursor protein accumulation and amyloid-beta generation. J Neurosci. 2010;30(11):3924-3932. doi:10.1523/JNEUROSCI.2422-09.2010</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2422-09.2010</ArticleId><ArticleId IdType="pmc">PMC6632277</ArticleId><ArticleId IdType="pubmed">20237263</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamboh MI, Fan KH, Yan Q, et al. . Population-based genome-wide association study of cognitive decline in older adults free of dementia: identification of a novel locus for the attention domain. Neurobiol Aging. 2019;84:239.e15-239.e24. doi:10.1016/j.neurobiolaging.2019.02.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2019.02.024</ArticleId><ArticleId IdType="pmc">PMC6739197</ArticleId><ArticleId IdType="pubmed">30954325</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen NJ, Bennett ML, Foo LC, et al. . Astrocyte glypicans 4 and 6 promote formation of excitatory synapses via GluA1 AMPA receptors. Nature. 2012;486(7403):410-414. doi:10.1038/nature11059</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11059</ArticleId><ArticleId IdType="pmc">PMC3383085</ArticleId><ArticleId IdType="pubmed">22722203</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang TH, Kim KT. Negative regulation of ERK activity by VRK3-mediated activation of VHR phosphatase. Nat Cell Biol. 2006;8(8):863-869. doi:10.1038/ncb1447</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb1447</ArticleId><ArticleId IdType="pubmed">16845380</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu GY, Deisseroth K, Tsien RW. Spaced stimuli stabilize MAPK pathway activation and its effects on dendritic morphology. Nat Neurosci. 2001;4(2):151-158. doi:10.1038/83976</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/83976</ArticleId><ArticleId IdType="pubmed">11175875</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas GM, Huganir RL. MAPK cascade signalling and synaptic plasticity. Nat Rev Neurosci. 2004;5(3):173-183. doi:10.1038/nrn1346</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn1346</ArticleId><ArticleId IdType="pubmed">14976517</ArticleId></ArticleIdList></Reference><Reference><Citation>Song H, Kim W, Kim SH, Kim KT. VRK3-mediated nuclear localization of HSP70 prevents glutamate excitotoxicity-induced apoptosis and A&#x3b2; accumulation via enhancement of ERK phosphatase VHR activity. Sci Rep. 2016;6:38452. doi:10.1038/srep38452</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep38452</ArticleId><ArticleId IdType="pmc">PMC5150261</ArticleId><ArticleId IdType="pubmed">27941812</ArticleId></ArticleIdList></Reference><Reference><Citation>van Horssen J, Wesseling P, van den Heuvel LP, de Waal RM, Verbeek MM. Heparan sulphate proteoglycans in Alzheimer&#x2019;s disease and amyloid-related disorders. Lancet Neurol. 2003;2(8):482-492. doi:10.1016/S1474-4422(03)00484-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(03)00484-8</ArticleId><ArticleId IdType="pubmed">12878436</ArticleId></ArticleIdList></Reference><Reference><Citation>van Horssen J, Otte-H&#xf6;ller I, David G, et al. . Heparan sulfate proteoglycan expression in cerebrovascular amyloid beta deposits in Alzheimer&#x2019;s disease and hereditary cerebral hemorrhage with amyloidosis (Dutch) brains. Acta Neuropathol. 2001;102(6):604-614. doi:10.1007/s004010100414</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s004010100414</ArticleId><ArticleId IdType="pubmed">11761721</ArticleId></ArticleIdList></Reference><Reference><Citation>van Horssen J, Kleinnijenhuis J, Maass CN, et al. . Accumulation of heparan sulfate proteoglycans in cerebellar senile plaques. Neurobiol Aging. 2002;23(4):537-545. doi:10.1016/S0197-4580(02)00010-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-4580(02)00010-6</ArticleId><ArticleId IdType="pubmed">12009503</ArticleId></ArticleIdList></Reference><Reference><Citation>Beckman M, Holsinger RM, Small DH. Heparin activates beta-secretase (BACE1) of Alzheimer&#x2019;s disease and increases autocatalysis of the enzyme. Biochemistry. 2006;45(21):6703-6714. doi:10.1021/bi052498t</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi052498t</ArticleId><ArticleId IdType="pubmed">16716081</ArticleId></ArticleIdList></Reference><Reference><Citation>Leveugle B, Ding W, Durkin JT, et al. . Heparin promotes beta-secretase cleavage of the Alzheimer&#x2019;s amyloid precursor protein. Neurochem Int. 1997;30(6):543-548. doi:10.1016/S0197-0186(96)00103-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-0186(96)00103-9</ArticleId><ArticleId IdType="pubmed">9152995</ArticleId></ArticleIdList></Reference><Reference><Citation>Castillo GM, Ngo C, Cummings J, Wight TN, Snow AD. Perlecan binds to the beta-amyloid proteins (A beta) of Alzheimer&#x2019;s disease, accelerates A beta fibril formation, and maintains A beta fibril stability. J Neurochem. 1997;69(6):2452-2465. doi:10.1046/j.1471-4159.1997.69062452.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.1997.69062452.x</ArticleId><ArticleId IdType="pubmed">9375678</ArticleId></ArticleIdList></Reference><Reference><Citation>Karczewski KJ, Francioli LC, Tiao G, et al. . Variation across 141,456 human exomes and genomes reveals the spectrum of loss-of-function intolerance across human protein-coding genes. bioRxiv. Preprint posted online August 13, 2019. doi:10.1101/531210</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/531210</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatsuoka C, Tseng H, Jaeger J, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Modeling the heterogeneity in risk of progression to Alzheimer&#x2019;s disease across cognitive profiles in mild cognitive impairment. Alzheimers Res Ther. 2013;5(2):14. doi:10.1186/alzrt168</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/alzrt168</ArticleId><ArticleId IdType="pmc">PMC3707057</ArticleId><ArticleId IdType="pubmed">23497709</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Zhou H, Lencz T, Farrer LA, Kranzler HR, Gelernter J. Genome-wide association study of cognitive flexibility assessed by the Wisconsin Card Sorting Test. Am J Med Genet B Neuropsychiatr Genet. 2018;177(5):511-519. doi:10.1002/ajmg.b.32642</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajmg.b.32642</ArticleId><ArticleId IdType="pmc">PMC6110090</ArticleId><ArticleId IdType="pubmed">30134085</ArticleId></ArticleIdList></Reference><Reference><Citation>Holzenberger M, Dupont J, Ducos B, et al. . IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. Nature. 2003;421(6919):182-187. doi:10.1038/nature01298</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature01298</ArticleId><ArticleId IdType="pubmed">12483226</ArticleId></ArticleIdList></Reference><Reference><Citation>Talbot K, Wang H-Y, Kazi H, et al. . Demonstrated brain insulin resistance in Alzheimer&#x2019;s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest. 2012;122(4):1316-1338. doi:10.1172/JCI59903</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI59903</ArticleId><ArticleId IdType="pmc">PMC3314463</ArticleId><ArticleId IdType="pubmed">22476197</ArticleId></ArticleIdList></Reference><Reference><Citation>Freude S, Hettich MM, Schumann C, et al. . Neuronal IGF-1 resistance reduces A beta accumulation and protects against premature death in a model of Alzheimer&#x2019;s disease. FASEB J. 2009;23(10):3315-3324. doi:10.1096/fj.09-132043</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.09-132043</ArticleId><ArticleId IdType="pubmed">19487308</ArticleId></ArticleIdList></Reference><Reference><Citation>De Magalhaes Filho CD, Kappeler L, Dupont J, et al. . Deleting IGF-1 receptor from forebrain neurons confers neuroprotection during stroke and upregulates endocrine somatotropin. J Cereb Blood Flow Metab. 2017;37(2):396-412. doi:10.1177/0271678X15626718</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0271678X15626718</ArticleId><ArticleId IdType="pmc">PMC5381438</ArticleId><ArticleId IdType="pubmed">26762506</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen E, Paulsson JF, Blinder P, et al. . Reduced IGF-1 signaling delays age-associated proteotoxicity in mice. Cell. 2009;139(6):1157-1169. doi:10.1016/j.cell.2009.11.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2009.11.014</ArticleId><ArticleId IdType="pmc">PMC3017511</ArticleId><ArticleId IdType="pubmed">20005808</ArticleId></ArticleIdList></Reference><Reference><Citation>Gontier G, George C, Chaker Z, Holzenberger M, A&#xef;d S. Blocking IGF signaling in adult neurons alleviates Alzheimer&#x2019;s Disease pathology through amyloid-&#x3b2; clearance. J Neurosci. 2015;35(33):11500-11513. doi:10.1523/JNEUROSCI.0343-15.2015</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0343-15.2015</ArticleId><ArticleId IdType="pmc">PMC6605240</ArticleId><ArticleId IdType="pubmed">26290229</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Jove Navarro M, Basset C, Arcond&#xe9;guy T, et al. . Api5 contributes to E2F1 control of the G1/S cell cycle phase transition. PLoS One. 2013;8(8):e71443. doi:10.1371/journal.pone.0071443</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0071443</ArticleId><ArticleId IdType="pmc">PMC3737092</ArticleId><ArticleId IdType="pubmed">23940755</ArticleId></ArticleIdList></Reference><Reference><Citation>Auweter SD, Fasan R, Reymond L, et al. . Molecular basis of RNA recognition by the human alternative splicing factor Fox-1. EMBO J. 2006;25(1):163-173. doi:10.1038/sj.emboj.7600918</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.emboj.7600918</ArticleId><ArticleId IdType="pmc">PMC1356361</ArticleId><ArticleId IdType="pubmed">16362037</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamada N, Ito H, Iwamoto I, Morishita R, Tabata H, Nagata K. Role of the cytoplasmic isoform of RBFOX1/A2BP1 in establishing the architecture of the developing cerebral cortex. Mol Autism. 2015;6:56. doi:10.1186/s13229-015-0049-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13229-015-0049-5</ArticleId><ArticleId IdType="pmc">PMC4617638</ArticleId><ArticleId IdType="pubmed">26500751</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandal MJ, Zhang P, Hadjimichael E, et al. . Transcriptome-wide isoform-level dysregulation in ASD, schizophrenia, and bipolar disorder. Science. 2018;362(6420):eaat8127. doi:10.1126/science.aat8127</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aat8127</ArticleId><ArticleId IdType="pmc">PMC6443102</ArticleId><ArticleId IdType="pubmed">30545856</ArticleId></ArticleIdList></Reference><Reference><Citation>Alkallas R, Fish L, Goodarzi H, Najafabadi HS. Inference of RNA decay rate from transcriptional profiling highlights the regulatory programs of Alzheimer&#x2019;s disease. Nat Commun. 2017;8(1):909. doi:10.1038/s41467-017-00867-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-00867-z</ArticleId><ArticleId IdType="pmc">PMC5714957</ArticleId><ArticleId IdType="pubmed">29030541</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JA, Damianov A, Lin CH, et al. . Cytoplasmic Rbfox1 regulates the expression of synaptic and autism-related genes. Neuron. 2016;89(1):113-128. doi:10.1016/j.neuron.2015.11.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2015.11.025</ArticleId><ArticleId IdType="pmc">PMC4858412</ArticleId><ArticleId IdType="pubmed">26687839</ArticleId></ArticleIdList></Reference><Reference><Citation>Alam S, Suzuki H, Tsukahara T. Alternative splicing regulation of APP exon 7 by RBFox proteins. Neurochem Int. 2014;78:7-17. doi:10.1016/j.neuint.2014.08.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuint.2014.08.001</ArticleId><ArticleId IdType="pubmed">25125370</ArticleId></ArticleIdList></Reference><Reference><Citation>Raghavan NS, Dumitrescu L, Mormino E, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Association between common variants in RBFOX1, an RNA-binding protein, and brain amyloidosis in early and preclinical Alzheimer disease. JAMA Neurol. Published online June 22, 2020. doi:10.1001/jamaneurol.2020.1760</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.1760</ArticleId><ArticleId IdType="pmc">PMC7309575</ArticleId><ArticleId IdType="pubmed">32568366</ArticleId></ArticleIdList></Reference><Reference><Citation>Forstner AJ, Hecker J, Hofmann A, et al. . Identification of shared risk loci and pathways for bipolar disorder and schizophrenia. PLoS One. 2017;12(2):e0171595. doi:10.1371/journal.pone.0171595</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0171595</ArticleId><ArticleId IdType="pmc">PMC5293228</ArticleId><ArticleId IdType="pubmed">28166306</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen DT, Jiang X, Akula N, et al. ; BiGS . Genome-wide association study meta-analysis of European and Asian-ancestry samples identifies three novel loci associated with bipolar disorder. Mol Psychiatry. 2013;18(2):195-205. doi:10.1038/mp.2011.157</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2011.157</ArticleId><ArticleId IdType="pubmed">22182935</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruderfer DM, Fanous AH, Ripke S, et al. ; Schizophrenia Working Group of the Psychiatric Genomics Consortium; Bipolar Disorder Working Group of the Psychiatric Genomics Consortium; Cross-Disorder Working Group of the Psychiatric Genomics Consortium . Polygenic dissection of diagnosis and clinical dimensions of bipolar disorder and schizophrenia. Mol Psychiatry. 2014;19(9):1017-1024. doi:10.1038/mp.2013.138</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2013.138</ArticleId><ArticleId IdType="pmc">PMC4033708</ArticleId><ArticleId IdType="pubmed">24280982</ArticleId></ArticleIdList></Reference><Reference><Citation>Goes FS, Hamshere ML, Seifuddin F, et al. ; Bipolar Genome Study (BiGS) . Genome-wide association of mood-incongruent psychotic bipolar disorder. Transl Psychiatry. 2012;2:e180. doi:10.1038/tp.2012.106</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/tp.2012.106</ArticleId><ArticleId IdType="pmc">PMC3565814</ArticleId><ArticleId IdType="pubmed">23092984</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang X, Detera-Wadleigh SD, Akula N, et al. . Sodium valproate rescues expression of TRANK1 in iPSC-derived neural cells that carry a genetic variant associated with serious mental illness. Mol Psychiatry. 2019;24(4):613-624. doi:10.1038/s41380-018-0207-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-018-0207-1</ArticleId><ArticleId IdType="pmc">PMC6894932</ArticleId><ArticleId IdType="pubmed">30135510</ArticleId></ArticleIdList></Reference><Reference><Citation>Laster M, Shen JI, Norris KC. Kidney disease among African Americans: a population perspective. Am J Kidney Dis. 2018;72(5)(suppl 1):S3-S7. doi:10.1053/j.ajkd.2018.06.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2018.06.021</ArticleId><ArticleId IdType="pmc">PMC6200351</ArticleId><ArticleId IdType="pubmed">30343720</ArticleId></ArticleIdList></Reference><Reference><Citation>McAdams-DeMarco MA, Daubresse M, Bae S, Gross AL, Carlson MC, Segev DL. Dementia, Alzheimer&#x2019;s disease, and mortality after hemodialysis initiation. Clin J Am Soc Nephrol. 2018;13(9):1339-1347. doi:10.2215/CJN.10150917</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.10150917</ArticleId><ArticleId IdType="pmc">PMC6140560</ArticleId><ArticleId IdType="pubmed">30093374</ArticleId></ArticleIdList></Reference><Reference><Citation>Pirici D, Stanaszek L, Garz C, et al. . Common impact of chronic kidney disease and brain microhemorrhages on cerebral A&#x3b2; pathology in SHRSP. Brain Pathol. 2017;27(2):169-180. doi:10.1111/bpa.12384</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12384</ArticleId><ArticleId IdType="pmc">PMC8029023</ArticleId><ArticleId IdType="pubmed">27062392</ArticleId></ArticleIdList></Reference><Reference><Citation>Beach TG, Monsell SE, Phillips LE, Kukull W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J Neuropathol Exp Neurol. 2012;71(4):266-273. doi:10.1097/NEN.0b013e31824b211b</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e31824b211b</ArticleId><ArticleId IdType="pmc">PMC3331862</ArticleId><ArticleId IdType="pubmed">22437338</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Arvanitakis Z, Wilson RS. Overview and findings from the religious orders study. Curr Alzheimer Res. 2012;9(6):628-645. doi:10.2174/156720512801322573</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720512801322573</ArticleId><ArticleId IdType="pmc">PMC3409291</ArticleId><ArticleId IdType="pubmed">22471860</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33077959</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>14</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1696</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>3</Issue><PubDate><Year>2021</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Nature biotechnology</Title><ISOAbbreviation>Nat Biotechnol</ISOAbbreviation></Journal><ArticleTitle>RNA timestamps identify the age of single molecules in RNA sequencing.</ArticleTitle><Pagination><StartPage>320</StartPage><EndPage>325</EndPage><MedlinePgn>320-325</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41587-020-0704-z</ELocationID><Abstract><AbstractText>Current approaches to single-cell RNA sequencing (RNA-seq) provide only limited information about the dynamics of gene expression. Here we present RNA timestamps, a method for inferring the age of individual RNAs in RNA-seq data by exploiting RNA editing. To introduce timestamps, we tag RNA with a reporter motif consisting of multiple MS2 binding sites that recruit the adenosine deaminase ADAR2 fused to an MS2 capsid protein. ADAR2 binding to tagged RNA causes A-to-I edits to accumulate over time, allowing the age of the RNA to be inferred with hour-scale accuracy. By combining observations of multiple timestamped RNAs driven by the same promoter, we can determine when the promoter was active. We demonstrate that the system can infer the presence and timing of multiple past transcriptional events. Finally, we apply the method to cluster single cells according to the timing of past transcriptional activity. RNA timestamps will allow the incorporation of temporal information into RNA-seq workflows.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Rodriques</LastName><ForeName>Samuel G</ForeName><Initials>SG</Initials><Identifier Source="ORCID">0000-0002-2509-0861</Identifier><AffiliationInfo><Affiliation>Department of Physics, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Media Arts and Sciences, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Broad Institute of Harvard and MIT, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Chen</LastName><ForeName>Linlin M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Broad Institute of Harvard and MIT, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Sophia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Biophysics Program, Harvard University, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhong</LastName><ForeName>Ellen D</ForeName><Initials>ED</Initials><Identifier Source="ORCID">0000-0001-6345-1907</Identifier><AffiliationInfo><Affiliation>Computational and Systems Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scherrer</LastName><ForeName>Joseph R</ForeName><Initials>JR</Initials><Identifier Source="ORCID">0000-0003-0424-3483</Identifier><AffiliationInfo><Affiliation>Department of Physics, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boyden</LastName><ForeName>Edward S</ForeName><Initials>ES</Initials><Identifier Source="ORCID">0000-0002-0419-3351</Identifier><AffiliationInfo><Affiliation>Department of Media Arts and Sciences, Massachusetts Institute of Technology, Cambridge, MA, USA. edboyden@mit.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA. edboyden@mit.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA, USA. edboyden@mit.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>MIT McGovern Institute, Massachusetts Institute of Technology, Cambridge, MA, USA. edboyden@mit.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Koch Institute, Massachusetts Institute of Technology, Cambridge, MA, USA. edboyden@mit.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, Cambridge, MA, USA. edboyden@mit.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Fei</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-2308-3649</Identifier><AffiliationInfo><Affiliation>Broad Institute of Harvard and MIT, Cambridge, MA, USA. chenf@broadinstitute.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA. chenf@broadinstitute.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32 GM087237</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UF1 NS107697</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM008313</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DP5 OD024583</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DA029639</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH114031</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RM1 HG008525</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH103910</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DP1 NS087724</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>10</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Biotechnol</MedlineTA><NlmUniqueID>9604648</NlmUniqueID><ISSNLinking>1087-0156</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016601">RNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>63231-63-0</RegistryNumber><NameOfSubstance UI="D012313">RNA</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.5.4.4</RegistryNumber><NameOfSubstance UI="C567955">ADARB1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.5.4.4</RegistryNumber><NameOfSubstance UI="D000243">Adenosine Deaminase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Methods. 2020 Dec;17(12):1177. doi: 10.1038/s41592-020-01016-z.</RefSource><PMID Version="1">33257829</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D016475" MajorTopicYN="N">3T3 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000243" MajorTopicYN="N">Adenosine Deaminase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020134" MajorTopicYN="N">Catalytic Domain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012313" MajorTopicYN="N">RNA</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017393" MajorTopicYN="N">RNA Editing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016601" MajorTopicYN="N">RNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017423" MajorTopicYN="N">Sequence Analysis, RNA</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072760" MajorTopicYN="N">Single Molecule Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Ethics declarations. Competing interests. All authors are listed as inventors on a patent application for this technology.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>2</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>9</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>8</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>20</Day><Hour>6</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>3</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33077959</ArticleId><ArticleId IdType="mid">NIHMS1647079</ArticleId><ArticleId IdType="pmc">PMC7956158</ArticleId><ArticleId IdType="doi">10.1038/s41587-020-0704-z</ArticleId><ArticleId IdType="pii">10.1038/s41587-020-0704-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Muhar M, Ameres SL &amp; Zuber J. SLAM-seq defines direct gene-regulatory functions of the BRD4&#x2013;MYC axis. Science 2793, 1&#x2013;10 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6409205</ArticleId><ArticleId IdType="pubmed">29622725</ArticleId></ArticleIdList></Reference><Reference><Citation>Herzog VA et al. Thiol-linked alkylation of RNA to assess expression dynamics. Nat. Methods 14, 1198&#x2013;1204 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5712218</ArticleId><ArticleId IdType="pubmed">28945705</ArticleId></ArticleIdList></Reference><Reference><Citation>Schofield JA, Duffy EE, Kiefer L, Sullivan MC &amp; Simon MD TimeLapse-seq: adding a temporal dimension to RNA sequencing through nucleoside recoding. Nat. Methods 15, 221&#x2013;225 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5831505</ArticleId><ArticleId IdType="pubmed">29355846</ArticleId></ArticleIdList></Reference><Reference><Citation>Erhard F. et al. scSLAM-seq reveals core features of transcription dynamics in single cells. Nature 571, 419&#x2013;423 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31292545</ArticleId></ArticleIdList></Reference><Reference><Citation>La Manno G. et al. RNA velocity of single cells. Nature 560, 484&#x2013;498 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6130801</ArticleId><ArticleId IdType="pubmed">30089906</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukuda M. et al. Construction of a guide-RNA for site-directed RNA mutagenesis utilising intracellular A-To-I RNA editing. Sci. Rep. 7, 41478 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5288656</ArticleId><ArticleId IdType="pubmed">28148949</ArticleId></ArticleIdList></Reference><Reference><Citation>Montiel-Gonzalez MF, Vallecillo-Viejo I, Yudowski GA &amp; Rosenthal JJC Correction of mutations within the cystic fibrosis transmembrane conductance regulator by site-directed RNA editing. Proc. Natl Acad. Sci. USA 110, 18285&#x2013;18290 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3831439</ArticleId><ArticleId IdType="pubmed">24108353</ArticleId></ArticleIdList></Reference><Reference><Citation>Montiel-Gonz&#xe1;lez MF, Vallecillo-Viejo IC &amp; Rosenthal JJC An efficient system for selectively altering genetic information within mRNAs. Nucleic Acids Res. 44, e157 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5137428</ArticleId><ArticleId IdType="pubmed">27557710</ArticleId></ArticleIdList></Reference><Reference><Citation>Wettengel J, Reautschnig P, Geisler S, Kahle PJ &amp; Stafforst T. Harnessing human ADAR2 for RNA repair - recoding a PINK1 mutation rescues mitophagy. Nucleic Acids Res. 45, 2797&#x2013;2808 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5389476</ArticleId><ArticleId IdType="pubmed">27907896</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox DBT, Gootenberg JS, Abudayyeh OO, Franklin B. &amp; Kellner MJ RNA editing with CRISPR&#x2013;Cas13. Science 358, 1019&#x2013;1027 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5793859</ArticleId><ArticleId IdType="pubmed">29070703</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthews MM et al. Structures of human ADAR2 bound to dsRNA reveal base-flipping mechanism and basis for site selectivity. Nat. Struct. Mol. Biol. 23, 426&#x2013;433 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4918759</ArticleId><ArticleId IdType="pubmed">27065196</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuttan A. &amp; Bass BL Mechanistic insights into editing-site specificity of ADARs. Proc. Natl Acad. Sci. USA 109, 3295&#x2013;3304 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3511710</ArticleId><ArticleId IdType="pubmed">23129636</ArticleId></ArticleIdList></Reference><Reference><Citation>Eifler T, Pokharel S. &amp; Beal PA RNA-seq analysis identifies a novel set of editing substrates for human ADAR2 present in Saccharomyces cerevisiae. Biochemistry 52, 7857&#x2013;7869 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3856204</ArticleId><ArticleId IdType="pubmed">24124932</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertrand E. et al. Localization of ASH1 mRNA particles in living yeast. Mol. Cell 2, 437&#x2013;445 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9809065</ArticleId></ArticleIdList></Reference><Reference><Citation>Piatkevich KD et al. A robotic multidimensional directed evolution approach applied to fluorescent voltage reporters. Nat. Chem. Biol. 14, 352&#x2013;360 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5866759</ArticleId><ArticleId IdType="pubmed">29483642</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry RP &amp; Kelley DE Inhibition of RNA synthesis by actinomycin D: characteristic dose-response of different RNA species. J. Cell. Physiol. 76, 127&#x2013;139 (1970).</Citation><ArticleIdList><ArticleId IdType="pubmed">5500970</ArticleId></ArticleIdList></Reference><Reference><Citation>Raj A, van den Bogaard P, Rifkin SA, van Oudenaarden A. &amp; Tyagi S. Imaging individual mRNA molecules using multiple singly labeled probes. Nat. Methods 5, 877&#x2013;879 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3126653</ArticleId><ArticleId IdType="pubmed">18806792</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwanh&#xfc;usser B. et al. Global quantification of mammalian gene expression control. Nature 473, 337&#x2013;342 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21593866</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Chen X. &amp; Yang Y. Spatiotemporal control of gene expression by a light-switchable transgene system. Nat. Methods 9, 266&#x2013;271 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22327833</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein AM et al. Droplet barcoding for single-cell transcriptomics applied to embryonic stem cells. Cell 161, 1187&#x2013;1201 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4441768</ArticleId><ArticleId IdType="pubmed">26000487</ArticleId></ArticleIdList></Reference><Reference><Citation>Macosko EZ et al. Highly parallel genome-wide expression profiling of individual cells using nanoliter droplets. Cell 161, 1202&#x2013;1214 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4481139</ArticleId><ArticleId IdType="pubmed">26000488</ArticleId></ArticleIdList></Reference><Reference><Citation>Perli SD et al. Continuous genetic recording with self-targeting CRISPR&#x2013;Cas in human cells. Science 353, 339&#x2013;342 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27540006</ArticleId></ArticleIdList></Reference><Reference><Citation>Farzadfard F. et al. Single-Nucleotide-Resolution Computing and Memory in Living Cells. Mol. Cell 75, 769&#x2013;780.e4 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7001763</ArticleId><ArticleId IdType="pubmed">31442423</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalhor R. et al. Rapidly evolving homing CRISPR barcodes. Nat. Methods 14, 195&#x2013;200 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5322472</ArticleId><ArticleId IdType="pubmed">27918539</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheth RU, Yim SS, Wu FL &amp; Wang HH Multiplex recording of cellular events over time on CRISPR biological tape. Science 358, 1457&#x2013;1461 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7869111</ArticleId><ArticleId IdType="pubmed">29170279</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang W. &amp; Liu DR Rewritable multi-event analog recording in bacterial and mammalian cells. Science 360, eaap8992 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5898985</ArticleId><ArticleId IdType="pubmed">29449507</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H. et al. Efficient, continuous mutagenesis in human cells using a pseudo-random DNA editor. Nat. Biotechnol. 38, 165&#x2013;168 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7775643</ArticleId><ArticleId IdType="pubmed">31844291</ArticleId></ArticleIdList></Reference><Reference><Citation>Frieda KL et al. Synthetic recording and in situ readout of lineage information in single cells. Nature 541, 107&#x2013;111 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6487260</ArticleId><ArticleId IdType="pubmed">27869821</ArticleId></ArticleIdList></Reference><Reference><Citation>Shipman SL et al. Molecular recordings by directed CRISPR spacer acquisition. Science 353, aaf1175 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4994893</ArticleId><ArticleId IdType="pubmed">27284167</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamft BM et al. Measuring cation dependent DNA polymerase fidelity landscapes by deep sequencing. PLoS ONE 7, e43876 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3425509</ArticleId><ArticleId IdType="pubmed">22928047</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt F, Cherepkova MY &amp; Platt RJ Transcriptional recording by CRISPR spacer acquisition from RNA. Nature 562, 380&#x2013;385 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30283135</ArticleId></ArticleIdList></Reference><Reference><Citation>Farzadfard F. &amp; Lu TK Genomically encoded analog memory with precise in vivo dna writing in living cell populations. Science 346, 1256272 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4266475</ArticleId><ArticleId IdType="pubmed">25395541</ArticleId></ArticleIdList></Reference><Reference><Citation>Tay S. et al. Single-cell NF-kappaB dynamics reveal digital activation and analogue information processing. Nature 466, 267&#x2013;271 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3105528</ArticleId><ArticleId IdType="pubmed">20581820</ArticleId></ArticleIdList></Reference><Reference><Citation>Nandagopal N. et al. Dynamic ligand discrimination in the notch signaling pathway. Cell 172, 869&#x2013;880 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6414217</ArticleId><ArticleId IdType="pubmed">29398116</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivera VM et al. A humanized system for pharmacologic control of gene expression. Nat. Med. 2, 1028&#x2013;1032 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8782462</ArticleId></ArticleIdList></Reference><Reference><Citation>Erhart D. et al. Chemical development of intracellular protein heterodimerizers. Chem. Biol. 20, 549&#x2013;557 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23601644</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33106633</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>29</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1718</ISSN><JournalIssue CitedMedium="Internet"><Volume>52</Volume><Issue>11</Issue><PubDate><Year>2020</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Nature genetics</Title><ISOAbbreviation>Nat Genet</ISOAbbreviation></Journal><ArticleTitle>Single-cell epigenomic analyses implicate candidate causal variants at inherited risk loci for Alzheimer's and Parkinson's diseases.</ArticleTitle><Pagination><StartPage>1158</StartPage><EndPage>1168</EndPage><MedlinePgn>1158-1168</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41588-020-00721-x</ELocationID><Abstract><AbstractText>Genome-wide association studies of neurological diseases have identified thousands of variants associated with disease phenotypes. However, most of these variants do not alter coding sequences, making it difficult to assign their function. Here, we present a multi-omic epigenetic atlas of the adult human brain through profiling of single-cell chromatin accessibility landscapes and three-dimensional chromatin interactions of diverse adult brain regions across a cohort of cognitively healthy individuals. We developed a machine-learning classifier to integrate this multi-omic framework and predict dozens of functional SNPs for Alzheimer's and Parkinson's diseases, nominating target genes and cell types for previously orphaned loci from genome-wide association studies. Moreover, we dissected the complex inverted haplotype of the MAPT (encoding tau) Parkinson's disease risk locus, identifying putative ectopic regulatory interactions in neurons that may mediate this disease association. This work expands understanding of inherited variation and provides a roadmap for the epigenomic dissection of causal regulatory variation in disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Corces</LastName><ForeName>M Ryan</ForeName><Initials>MR</Initials><Identifier Source="ORCID">0000-0001-7465-7652</Identifier><AffiliationInfo><Affiliation>Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Personal Dynamic Regulomes, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shcherbina</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kundu</LastName><ForeName>Soumya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Computer Science, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gloudemans</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0002-9924-9943</Identifier><AffiliationInfo><Affiliation>Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fr&#xe9;sard</LastName><ForeName>Laure</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Granja</LastName><ForeName>Jeffrey M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Center for Personal Dynamic Regulomes, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Biophysics, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Louie</LastName><ForeName>Bryan H</ForeName><Initials>BH</Initials><AffiliationInfo><Affiliation>Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Personal Dynamic Regulomes, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eulalio</LastName><ForeName>Tiffany</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-7084-9646</Identifier><AffiliationInfo><Affiliation>Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shams</LastName><ForeName>Shadi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Personal Dynamic Regulomes, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bagdatli</LastName><ForeName>S Tansu</ForeName><Initials>ST</Initials><AffiliationInfo><Affiliation>Center for Personal Dynamic Regulomes, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mumbach</LastName><ForeName>Maxwell R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Center for Personal Dynamic Regulomes, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Boxiang</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-2595-4463</Identifier><AffiliationInfo><Affiliation>Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biology, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Baidu Research, Sunnyvale, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montine</LastName><ForeName>Kathleen S</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greenleaf</LastName><ForeName>William J</ForeName><Initials>WJ</Initials><Identifier Source="ORCID">0000-0003-1409-3095</Identifier><AffiliationInfo><Affiliation>Center for Personal Dynamic Regulomes, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Applied Physics, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chan Zuckerberg Biohub, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kundaje</LastName><ForeName>Anshul</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-3084-2287</Identifier><AffiliationInfo><Affiliation>Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Computer Science, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montgomery</LastName><ForeName>Stephen B</ForeName><Initials>SB</Initials><Identifier Source="ORCID">0000-0002-5200-3903</Identifier><AffiliationInfo><Affiliation>Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Howard Y</ForeName><Initials>HY</Initials><Identifier Source="ORCID">0000-0002-9459-4393</Identifier><AffiliationInfo><Affiliation>Center for Personal Dynamic Regulomes, Stanford University, Stanford, CA, USA. howchang@stanford.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA. howchang@stanford.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Epithelial Biology, Stanford University, Stanford, CA, USA. howchang@stanford.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, Stanford University, Stanford, CA, USA. howchang@stanford.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montine</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials><Identifier Source="ORCID">0000-0002-1346-2728</Identifier><AffiliationInfo><Affiliation>Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA. tmontine@stanford.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>RM1 HG007735</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R00 AG059918</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HG009431</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066515</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K99 AG059918</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UF1 AG057707</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 HG007735</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T15 LM007033</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 OD018220</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG053959</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 OD025212</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS062684</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066509</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG047366</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG066490</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>10</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Genet</MedlineTA><NlmUniqueID>9216904</NlmUniqueID><ISSNLinking>1061-4036</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Mov Disord. 2021 Feb;36(2):347. doi: 10.1002/mds.28481.</RefSource><PMID Version="1">33458867</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001271" MajorTopicYN="N">Atlases as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073537" MajorTopicYN="N">Biological Variation, Population</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000033" MajorTopicYN="Y">anatomy &amp; histology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042002" MajorTopicYN="N">Chromatin Assembly and Disassembly</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004742" MajorTopicYN="N">Enhancer Elements, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057890" MajorTopicYN="N">Epigenomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018740" MajorTopicYN="N">Genetic Heterogeneity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006239" MajorTopicYN="N">Haplotypes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069550" MajorTopicYN="N">Machine Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011401" MajorTopicYN="N">Promoter Regions, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>COMPETING INTERESTS STATEMENT. H.Y.C. is a co-founder of Accent Therapeutics, Boundless Bio, and an advisor to 10x Genomics, Arsenal Biosciences, Spring Discovery. S.B.M. is on the scientific advisory board of MyOme. A.K. is a consultant for Biogen Inc. A.S. is a consultant for MyoKardia. W.J.G. is a consultant for Guardant Health, 10x Genomics, and Protillion Biosciences.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>12</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>27</Day><Hour>5</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>4</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33106633</ArticleId><ArticleId IdType="mid">NIHMS1630836</ArticleId><ArticleId IdType="pmc">PMC7606627</ArticleId><ArticleId IdType="doi">10.1038/s41588-020-00721-x</ArticleId><ArticleId IdType="pii">10.1038/s41588-020-00721-x</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES (MAIN TEXT)</Title><Reference><Citation>Kunkle BW et al. Genetic meta-analysis of diagnosed Alzheimer&#x2019;s disease identifies new risk loci and implicates A&#x3b2;, tau, immunity and lipid processing. Nat. Genet. 2019 513 51, 414 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6463297</ArticleId><ArticleId IdType="pubmed">30820047</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen I et al. Genetic meta-analysis identifies 10 novel loci and functional pathways for Alzheimer&#x2019;s disease risk. Nat. Genet. 51, 404&#x2013;413 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6836675</ArticleId><ArticleId IdType="pubmed">30617256</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert J-C et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer&#x2019;s disease. Nat. Genet. 45, 1452&#x2013;1458 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Beecham GW et al. Genome-Wide Association Meta-analysis of Neuropathologic Features of Alzheimer&#x2019;s Disease and Related Dementias. PLoS Genet 10, (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4154667</ArticleId><ArticleId IdType="pubmed">25188341</ArticleId></ArticleIdList></Reference><Reference><Citation>Pankratz N et al. Meta-analysis of Parkinson&#x2019;s Disease: Identification of a novel locus, RIT2. Ann. Neurol. 71, 370&#x2013;384 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3354734</ArticleId><ArticleId IdType="pubmed">22451204</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang D et al. A meta-analysis of genome-wide association studies identifies 17 new Parkinson&#x2019;s disease risk loci. Nat. Genet. 49, 1511&#x2013;1516 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5812477</ArticleId><ArticleId IdType="pubmed">28892059</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalls MA et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson&#x2019;s disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 18, 1091&#x2013;1102 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8422160</ArticleId><ArticleId IdType="pubmed">31701892</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallagher MD &amp; Chen-Plotkin AS The Post-GWAS Era: From Association to Function. Am. J. Hum. Genet. 102, 717&#x2013;730 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5986732</ArticleId><ArticleId IdType="pubmed">29727686</ArticleId></ArticleIdList></Reference><Reference><Citation>Nott A et al. Brain cell type &#x2013; specific enhancer &#x2013; promoter interactome maps and disease-risk association. Science 1139, 1134&#x2013;1139 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7028213</ArticleId><ArticleId IdType="pubmed">31727856</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M et al. Integrative functional genomic analysis of human brain development and neuropsychiatric risks. Science 362, (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6413317</ArticleId><ArticleId IdType="pubmed">30545854</ArticleId></ArticleIdList></Reference><Reference><Citation>Amiri A et al. Transcriptome and epigenome landscape of human cortical development modeled in organoids. Science 362, (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6426303</ArticleId><ArticleId IdType="pubmed">30545853</ArticleId></ArticleIdList></Reference><Reference><Citation>Trevino AE et al. Chromatin accessibility dynamics in a model of human forebrain development. Science 367, (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7313757</ArticleId><ArticleId IdType="pubmed">31974223</ArticleId></ArticleIdList></Reference><Reference><Citation>Nowakowski TJ et al. Spatiotemporal gene expression trajectories reveal developmental hierarchies of the human cortex. Science 358, 1318&#x2013;1323 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5991609</ArticleId><ArticleId IdType="pubmed">29217575</ArticleId></ArticleIdList></Reference><Reference><Citation>Song M et al. Mapping cis-regulatory chromatin contacts in neural cells links neuropsychiatric disorder risk variants to target genes. Nat. Genet. 51, 1252&#x2013;1262 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6677164</ArticleId><ArticleId IdType="pubmed">31367015</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajarajan P et al. Neuron-specific signatures in the chromosomal connectome associated with schizophrenia risk. Science 362, (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6408958</ArticleId><ArticleId IdType="pubmed">30545851</ArticleId></ArticleIdList></Reference><Reference><Citation>Fullard JF et al. An atlas of chromatin accessibility in the adult human brain. Genome Res. 28, 1243&#x2013;1252 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6071637</ArticleId><ArticleId IdType="pubmed">29945882</ArticleId></ArticleIdList></Reference><Reference><Citation>Fullard JF et al. Open chromatin profiling of human postmortem brain infers functional roles for non-coding schizophrenia loci. Hum. Mol. Genet. 26, 1942&#x2013;1951 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6059160</ArticleId><ArticleId IdType="pubmed">28335009</ArticleId></ArticleIdList></Reference><Reference><Citation>Bryois J et al. Evaluation of chromatin accessibility in prefrontal cortex of individuals with schizophrenia. Nat. Commun 9, (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6081462</ArticleId><ArticleId IdType="pubmed">30087329</ArticleId></ArticleIdList></Reference><Reference><Citation>Corces MR et al. An improved ATAC-seq protocol reduces background and enables interrogation of frozen tissues. Nat. Methods 14, 959&#x2013;962 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5623106</ArticleId><ArticleId IdType="pubmed">28846090</ArticleId></ArticleIdList></Reference><Reference><Citation>Sey NYA et al. A computational tool (H-MAGMA) for improved prediction of brain-disorder risk genes by incorporating brain chromatin interaction profiles. Nat. Neurosci. 23, 583&#x2013;593 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7131892</ArticleId><ArticleId IdType="pubmed">32152537</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee D et al. A method to predict the impact of regulatory variants from DNA sequence. Nat. Genet. 47, 955&#x2013;961 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4520745</ArticleId><ArticleId IdType="pubmed">26075791</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrikumar A, Prakash E &amp; Kundaje A GkmExplain: Fast and accurate interpretation of nonlinear gapped k-mer SVMs. Bioinformatics 35, i173&#x2013;i182 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6612808</ArticleId><ArticleId IdType="pubmed">31510661</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumasaka N, Knights AJ &amp; Gaffney DJ High-resolution genetic mapping of putative causal interactions between regions of open chromatin. Nat. Genet. 51, 128&#x2013;137 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6330062</ArticleId><ArticleId IdType="pubmed">30478436</ArticleId></ArticleIdList></Reference><Reference><Citation>Amlie-Wolf A et al. InferNo: Inferring the molecular mechanisms of noncoding genetic variants. Nucleic Acids Res. 46, 8740&#x2013;8753 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6158604</ArticleId><ArticleId IdType="pubmed">30113658</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulirsch JC et al. Interrogation of human hematopoiesis at single-cell and single-variant resolution. Nat. Genet. 51, 683&#x2013;693 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6441389</ArticleId><ArticleId IdType="pubmed">30858613</ArticleId></ArticleIdList></Reference><Reference><Citation>Buenrostro JD, Giresi PG, Zaba LC, Chang HY &amp; Greenleaf WJ Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position. Nat. Methods 10, 1213&#x2013;1218 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3959825</ArticleId><ArticleId IdType="pubmed">24097267</ArticleId></ArticleIdList></Reference><Reference><Citation>Satpathy AT et al. Massively parallel single-cell chromatin landscapes of human immune cell development and intratumoral T cell exhaustion. Nat. Biotechnol. 37, 925&#x2013;936 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7299161</ArticleId><ArticleId IdType="pubmed">31375813</ArticleId></ArticleIdList></Reference><Reference><Citation>Mumbach MR et al. HiChIP: efficient and sensitive analysis of protein-directed genome architecture. Nat. Methods 13, 919&#x2013;922 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5501173</ArticleId><ArticleId IdType="pubmed">27643841</ArticleId></ArticleIdList></Reference><Reference><Citation>Mumbach MR et al. Enhancer connectome in primary human cells reveals target genes of disease-associated DNA elements. Nat. Genet. 49, 1602&#x2013;1612 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5805393</ArticleId><ArticleId IdType="pubmed">28945252</ArticleId></ArticleIdList></Reference><Reference><Citation>Granja JM et al. Single-cell multiomic analysis identifies regulatory programs in mixed-phenotype acute leukemia. Nat. Biotechnol. 37, 1458&#x2013;1465 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7258684</ArticleId><ArticleId IdType="pubmed">31792411</ArticleId></ArticleIdList></Reference><Reference><Citation>Pliner HA et al. Cicero Predicts cis-Regulatory DNA Interactions from Single-Cell Chromatin Accessibility Data. Mol. Cell 71, 858&#x2013;871.e8 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6582963</ArticleId><ArticleId IdType="pubmed">30078726</ArticleId></ArticleIdList></Reference><Reference><Citation>Corces MR et al. Lineage-specific and single cell chromatin accessibility charts human hematopoiesis and leukemia evolution. Nat. Genet. 48, 1193&#x2013;1203 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5042844</ArticleId><ArticleId IdType="pubmed">27526324</ArticleId></ArticleIdList></Reference><Reference><Citation>Corces MR et al. The chromatin accessibility landscape of primary human cancers. Science 362, (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6408149</ArticleId><ArticleId IdType="pubmed">30361341</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeown MR et al. Superenhancer analysis defi nes novel epigenomic subtypes of non-APL AML, including an RAR&#x3b1; dependency targetable by SY-1425, a potent and selective RAR&#x3b1; agonist. Cancer Discov. 7, 1136&#x2013;1153 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5962349</ArticleId><ArticleId IdType="pubmed">28729405</ArticleId></ArticleIdList></Reference><Reference><Citation>Stolt CC et al. The Sox9 transcription factor determines glial fate choice in the developing spinal cord. Genes Dev. 17, 1677&#x2013;1689 (2003).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC196138</ArticleId><ArticleId IdType="pubmed">12842915</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhlbrodt K, Herbarth B, Sock E, Hermans-Borgmeyer I &amp; Wegner M Sox10, a novel transcriptional modulator in glial cells. J. Neurosci. 18, 237&#x2013;250 (1998).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793382</ArticleId><ArticleId IdType="pubmed">9412504</ArticleId></ArticleIdList></Reference><Reference><Citation>Kondo T &amp; Raff M Basic helix-loop-helix proteins and the timing of oligodendrocyte differentiation. Development 127, 2989&#x2013;2998 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10862737</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakatani H et al. Ascl1/Mash1 promotes brain oligodendrogenesis during myelination and remyelination. J. Neurosci. 33, 9752&#x2013;9768 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3892435</ArticleId><ArticleId IdType="pubmed">23739972</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith AM et al. The transcription factor PU.1 is critical for viability and function of human brain microglia. Glia 61, 929&#x2013;942 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23483680</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlingensiepen KH et al. The role of Jun transcription factor expression and phosphorylation in neuronal differentiation, neuronal cell death, and plastic adaptations in vivo. Cell. Mol. Neurobiol. 14, 487&#x2013;505 (1994).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11566974</ArticleId><ArticleId IdType="pubmed">7621509</ArticleId></ArticleIdList></Reference><Reference><Citation>Finucane HK et al. Partitioning heritability by functional annotation using genome-wide association summary statistics. Nat. Genet. 47, 1228&#x2013;1235 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4626285</ArticleId><ArticleId IdType="pubmed">26414678</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemonnot AL, Hua J, Ulmann L &amp; Hirbec H Microglia in Alzheimer disease: Well-known targets and new opportunities. Front. Cell. Infect. Microbiol. 9, 1&#x2013;20 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730262</ArticleId><ArticleId IdType="pubmed">31543810</ArticleId></ArticleIdList></Reference><Reference><Citation>Efthymiou AG &amp; Goate AM Late onset Alzheimer&#x2019;s disease genetics implicates microglial pathways in disease risk. Mol. Neurodegener. 12, 1&#x2013;12 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5446752</ArticleId><ArticleId IdType="pubmed">28549481</ArticleId></ArticleIdList></Reference><Reference><Citation>Buenrostro JD et al. Single-cell chromatin accessibility reveals principles of regulatory variation. Nature 523, 486&#x2013;490 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4685948</ArticleId><ArticleId IdType="pubmed">26083756</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghandi M et al. GkmSVM: An R package for gapped-kmer SVM. Bioinformatics 32, 2205&#x2013;2207 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4937197</ArticleId><ArticleId IdType="pubmed">27153639</ArticleId></ArticleIdList></Reference><Reference><Citation>Bromberg Y &amp; Rost B Comprehensive in silico mutagenesis highlights functionally important residues in proteins. Bioinformatics 24, 207&#x2013;212 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2597370</ArticleId><ArticleId IdType="pubmed">18689826</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu W, Tan L &amp; Yu JT The Role of PICALM in Alzheimer&#x2019;s Disease. Mol. Neurobiol. 52, 399&#x2013;413 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25186232</ArticleId></ArticleIdList></Reference><Reference><Citation>Stage E et al. The effect of the top 20 Alzheimer disease risk genes on gray-matter density and FDG PET brain metabolism. Alzheimer&#x2019;s Dement. Diagnosis, Assess. Dis. Monit. 5, 53&#x2013;66 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5198883</ArticleId><ArticleId IdType="pubmed">28054028</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrew RJ et al. Reduction of the expression of the late-onset Alzheimer&#x2019;s disease (AD) risk-factor BIN1 does not affect amyloid pathology in an AD mouse model. J. Biol. Chem. 294, 4477&#x2013;4487 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6433054</ArticleId><ArticleId IdType="pubmed">30692199</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma J, Yu JT &amp; Tan L MS4A Cluster in Alzheimer&#x2019;s Disease. Mol. Neurobiol. 51, 1240&#x2013;1248 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">24981432</ArticleId></ArticleIdList></Reference><Reference><Citation>Rouka E et al. Differential recognition preferences of the three Src Homology 3 (SH3) domains from the adaptor CD2-associated Protein (CD2AP) and Direct Association with Ras and Rab Interactor 3 (RIN3). J. Biol. Chem. 290, 25275&#x2013;25292 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4646179</ArticleId><ArticleId IdType="pubmed">26296892</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsson M et al. GWAS findings for human iris patterns: Associations with variants in genes that influence normal neuronal pattern development. Am. J. Hum. Genet. 89, 334&#x2013;343 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3155193</ArticleId><ArticleId IdType="pubmed">21835309</ArticleId></ArticleIdList></Reference><Reference><Citation>Kajiho H et al. RIN3: A novel Rab5 GEF interacting with amphiphysin II involved in the early endocytic pathway. J. Cell Sci. 116, 4159&#x2013;4168 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12972505</ArticleId></ArticleIdList></Reference><Reference><Citation>Lecours C et al. Microglial implication in Parkinson&#x2019;s disease: Loss of beneficial physiological roles or gain of inflammatory functions? Front. Cell. Neurosci. 12, 1&#x2013;8 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6125334</ArticleId><ArticleId IdType="pubmed">30214398</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaushik DK, Gupta M, Das S &amp; Basu A Kr&#xfc;ppel-like factor 4, a novel transcription factor regulates microglial activation and subsequent neuroinflammation. J. Neuroinflammation 7, 1&#x2013;20 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2965135</ArticleId><ArticleId IdType="pubmed">20946687</ArticleId></ArticleIdList></Reference><Reference><Citation>Schellenberg GD &amp; Montine TJ The genetics and neuropathology of Alzheimer&#x2019;s disease. Acta Neuropathol. 124, 305&#x2013;323 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3708460</ArticleId><ArticleId IdType="pubmed">22618995</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefansson H et al. A common inversion under selection in Europeans. Nat. Genet. 37, 129&#x2013;137 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15654335</ArticleId></ArticleIdList></Reference><Reference><Citation>Zody MC et al. Evolutionary toggling of the MAPT 17q21.31 inversion region. Nat. Genet. 40, 1076&#x2013;1083 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2684794</ArticleId><ArticleId IdType="pubmed">19165922</ArticleId></ArticleIdList></Reference><Reference><Citation>Valenca GT et al. The Role of MAPT Haplotype H2 and Isoform 1N/4R in Parkinsonism of Older Adults. PLoS One (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4961370</ArticleId><ArticleId IdType="pubmed">27458716</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen M et al. Association of MAPT haplotypes with Alzheimer&#x2019;s disease risk and MAPT brain gene expression levels. Alzheimer&#x2019;s Res. Ther. 6, 1&#x2013;14 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4198935</ArticleId><ArticleId IdType="pubmed">25324900</ArticleId></ArticleIdList></Reference><Reference><Citation>Pascale E et al. Genetic architecture of MAPT gene region in parkinson disease subtypes. Front. Cell. Neurosci. 10, 1&#x2013;7 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4826864</ArticleId><ArticleId IdType="pubmed">27147968</ArticleId></ArticleIdList></Reference><Reference><Citation>Beevers JE et al. MAPT Genetic Variation and Neuronal Maturity Alter Isoform Expression Affecting Axonal Transport in iPSC-Derived Dopamine Neurons. Stem Cell Reports 9, 587&#x2013;599 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5549835</ArticleId><ArticleId IdType="pubmed">28689993</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai MC et al. Haplotype-specific MAPT exon 3 expression regulated by common intronic polymorphisms associated with Parkinsonian disorders. Mol. Neurodegener. 12, 1&#x2013;16 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5663040</ArticleId><ArticleId IdType="pubmed">29084565</ArticleId></ArticleIdList></Reference><Reference><Citation>Huin V et al. Alternative promoter usage generates novel shorter MAPT mRNA transcripts in Alzheimer&#x2019;s disease and progressive supranuclear palsy brains. Sci. Rep. 7, 1&#x2013;10 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5626709</ArticleId><ArticleId IdType="pubmed">28974731</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>METHODS-ONLY REFERENCES</Title><Reference><Citation>Pankratz N et al. Genomewide association study for susceptibility genes contributing to familial Parkinson disease. Hum. Genet. 124, 593&#x2013;605 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2627511</ArticleId><ArticleId IdType="pubmed">18985386</ArticleId></ArticleIdList></Reference><Reference><Citation>Quinlan AR &amp; Hall IM BEDTools: A flexible suite of utilities for comparing genomic features. Bioinformatics 26, 841&#x2013;842 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2832824</ArticleId><ArticleId IdType="pubmed">20110278</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinz S et al. Simple Combinations of Lineage-Determining Transcription Factors Prime cis-Regulatory Elements Required for Macrophage and B Cell Identities. Mol. Cell 38, 576&#x2013;589 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2898526</ArticleId><ArticleId IdType="pubmed">20513432</ArticleId></ArticleIdList></Reference><Reference><Citation>Finucane HK et al. Heritability enrichment of specifically expressed genes identifies disease-relevant tissues and cell types. Nat. Genet. 50, 621&#x2013;629 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5896795</ArticleId><ArticleId IdType="pubmed">29632380</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z et al. Genome-wide association analysis identifies 30 new susceptibility loci for schizophrenia. Nat. Genet. 49, 1576&#x2013;1583 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28991256</ArticleId></ArticleIdList></Reference><Reference><Citation>Duncan L et al. Significant locus and metabolic genetic correlations revealed in genome-wide association study of anorexia nervosa. Am. J. Psychiatry 174, 850&#x2013;858 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5581217</ArticleId><ArticleId IdType="pubmed">28494655</ArticleId></ArticleIdList></Reference><Reference><Citation>Demontis D et al. Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder. Nat. Genet. 51, 63&#x2013;75 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6481311</ArticleId><ArticleId IdType="pubmed">30478444</ArticleId></ArticleIdList></Reference><Reference><Citation>Otowa T et al. Meta-analysis of genome-wide association studies of anxiety disorders. Mol. Psychiatry 21, 1391&#x2013;1399 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4940340</ArticleId><ArticleId IdType="pubmed">26754954</ArticleId></ArticleIdList></Reference><Reference><Citation>Okbay A et al. Genetic variants associated with subjective well-being, depressive symptoms, and neuroticism identified through genome-wide analyses. Nat. Genet. 48, 624&#x2013;633 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4884152</ArticleId><ArticleId IdType="pubmed">27089181</ArticleId></ArticleIdList></Reference><Reference><Citation>Anney RJL et al. Genetic determinants of common epilepsies: A meta-analysis of genome-wide association studies. Lancet Neurol. 13, 893&#x2013;903 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4189926</ArticleId><ArticleId IdType="pubmed">25087078</ArticleId></ArticleIdList></Reference><Reference><Citation>Zillikens MC et al. Large meta-analysis of genome-wide association studies identifies five loci for lean body mass. Nat. Commun 8, (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5517526</ArticleId><ArticleId IdType="pubmed">28724990</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemp JP et al. Identification of 153 new loci associated with heel bone mineral density and functional involvement of GPC6 in osteoporosis. Nat. Genet. 49, 1468&#x2013;1475 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5621629</ArticleId><ArticleId IdType="pubmed">28869591</ArticleId></ArticleIdList></Reference><Reference><Citation>Howson JMM et al. Fifteen new risk loci for coronary artery disease highlight arterial-wall-specific mechanisms. Nat. Genet. 49, 1113&#x2013;1119 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5555387</ArticleId><ArticleId IdType="pubmed">28530674</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvey CT et al. QuASAR: Quantitative allele-specific analysis of reads. Bioinformatics 31, 1235&#x2013;1242 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4393517</ArticleId><ArticleId IdType="pubmed">25480375</ArticleId></ArticleIdList></Reference><Reference><Citation>Auton A et al. A global reference for human genetic variation. Nature 526, 68&#x2013;74 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4750478</ArticleId><ArticleId IdType="pubmed">26432245</ArticleId></ArticleIdList></Reference><Reference><Citation>Granja JM et al. ArchR&#x202f;: An integrative and scalable software package for single-cell chromatin accessibility analysis. biorxiv (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8012210</ArticleId><ArticleId IdType="pubmed">33633365</ArticleId></ArticleIdList></Reference><Reference><Citation>Korsunsky I et al. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat. Methods 16, 1289&#x2013;1296 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6884693</ArticleId><ArticleId IdType="pubmed">31740819</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuart T et al. Comprehensive Integration of Single-Cell Data. Cell 177, 1888&#x2013;1902.e21 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6687398</ArticleId><ArticleId IdType="pubmed">31178118</ArticleId></ArticleIdList></Reference><Reference><Citation>Cusanovich DA et al. The cis-regulatory dynamics of embryonic development at single-cell resolution. Nature 555, 538&#x2013;542 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5866720</ArticleId><ArticleId IdType="pubmed">29539636</ArticleId></ArticleIdList></Reference><Reference><Citation>Fulco CP et al. Activity-by-contact model of enhancer&#x2013;promoter regulation from thousands of CRISPR perturbations. Nat. Genet. 51, 1664&#x2013;1669 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6886585</ArticleId><ArticleId IdType="pubmed">31784727</ArticleId></ArticleIdList></Reference><Reference><Citation>van Dijk D et al. Recovering Gene Interactions from Single-Cell Data Using Data Diffusion. Cell 174, 716&#x2013;729.e27 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6771278</ArticleId><ArticleId IdType="pubmed">29961576</ArticleId></ArticleIdList></Reference><Reference><Citation>Love MI, Huber W &amp; Anders S Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 1&#x2013;21 (2014) doi:10.1186/s13059-014-0550-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-014-0550-8</ArticleId><ArticleId IdType="pmc">PMC4302049</ArticleId><ArticleId IdType="pubmed">25516281</ArticleId></ArticleIdList></Reference><Reference><Citation>Servant N et al. HiC-Pro: An optimized and flexible pipeline for Hi-C data processing. Genome Biol. 16, 1&#x2013;11 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4665391</ArticleId><ArticleId IdType="pubmed">26619908</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattacharyya S, Chandra V, Vijayanand P &amp; Ay F Identification of significant chromatin contacts from HiChIP data by FitHiChIP. Nat. Commun 10, (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6748947</ArticleId><ArticleId IdType="pubmed">31530818</ArticleId></ArticleIdList></Reference><Reference><Citation>Machiela MJ &amp; Chanock SJ LDlink: A web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants. Bioinformatics 31, 3555&#x2013;3557 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4626747</ArticleId><ArticleId IdType="pubmed">26139635</ArticleId></ArticleIdList></Reference><Reference><Citation>Krueger F &amp; Andrews SR SNPsplit: Allele-specific splitting of alignments between genomes with known SNP genotypes [version 2; referees: 3 approved]. F1000Research 5, 1&#x2013;16 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4934512</ArticleId><ArticleId IdType="pubmed">27429743</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33149306</PMID><DateCompleted><Year>2021</Year><Month>01</Month><Day>25</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>587</Volume><Issue>7834</Issue><PubDate><Year>2020</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Host variables confound gut microbiota studies of human disease.</ArticleTitle><Pagination><StartPage>448</StartPage><EndPage>454</EndPage><MedlinePgn>448-454</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41586-020-2881-9</ELocationID><Abstract><AbstractText>Low concordance between studies that examine the role of microbiota in human diseases is a pervasive challenge that limits the capacity to identify causal relationships between host-associated microorganisms and pathology. The risk of obtaining false positives is exacerbated by wide interindividual heterogeneity in microbiota composition<sup>1</sup>, probably due to population-wide differences in human lifestyle and physiological variables<sup>2</sup> that exert differential effects on the microbiota. Here we infer the greatest, generalized sources of heterogeneity in human gut microbiota profiles and also identify human lifestyle and physiological characteristics that, if not evenly matched between cases and controls, confound microbiota analyses to produce spurious microbial associations with human diseases. We identify alcohol consumption frequency and bowel movement quality as unexpectedly strong sources of gut microbiota variance that differ in distribution between healthy participants and participants with a disease and that can confound study designs. We demonstrate that for numerous prevalent, high-burden human diseases, matching cases and controls for confounding variables reduces observed differences in the microbiota and the incidence of spurious associations. On this basis, we present a list of host variables that we recommend should be captured in human microbiota studies for the purpose of matching comparison groups, which we anticipate will increase robustness and reproducibility in resolving the members of the gut microbiota that are truly associated with human disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vujkovic-Cvijin</LastName><ForeName>Ivan</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-8611-4900</Identifier><AffiliationInfo><Affiliation>Metaorganism Immunity Section, Laboratory of Immune Systems Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. ivc@nih.gov.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sklar</LastName><ForeName>Jack</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Metaorganism Immunity Section, Laboratory of Immune Systems Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute of Allergy and Infectious Diseases Microbiome Program, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Communications Technology Laboratory, National Institute of Standards and Technology, Boulder, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Lingjing</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Biostatistics, University of California San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Natarajan</LastName><ForeName>Loki</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Biostatistics, University of California San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knight</LastName><ForeName>Rob</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-0975-9019</Identifier><AffiliationInfo><Affiliation>Department of Pediatrics, University of California San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Computer Science and Engineering, University of California San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Bioengineering, University of California San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Microbiome Innovation, University of California San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belkaid</LastName><ForeName>Yasmine</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-9962-3571</Identifier><AffiliationInfo><Affiliation>Metaorganism Immunity Section, Laboratory of Immune Systems Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. ybelkaid@niaid.nih.gov.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute of Allergy and Infectious Diseases Microbiome Program, National Institutes of Health, Bethesda, MD, USA. ybelkaid@niaid.nih.gov.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>DP1 AT010885</GrantID><Acronym>AT</Acronym><Agency>NCCIH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DK110541</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>ZIA AI001115</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>ZIA AI001132</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>11</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012336">RNA, Ribosomal, 16S</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2020 Nov;587(7834):373-374. doi: 10.1038/d41586-020-03069-8.</RefSource><PMID Version="1">33149313</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Microbiol. 2021 Jan;19(1):2. doi: 10.1038/s41579-020-00480-w.</RefSource><PMID Version="1">33154571</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000428" MajorTopicYN="N">Alcohol Drinking</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019540" MajorTopicYN="N">Area Under Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015992" MajorTopicYN="N">Body Mass Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015986" MajorTopicYN="Y">Confounding Factors, Epidemiologic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000078332" MajorTopicYN="Y">Data Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004032" MajorTopicYN="Y">Diet</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004194" MajorTopicYN="Y">Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005243" MajorTopicYN="N">Feces</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069196" MajorTopicYN="N">Gastrointestinal Microbiome</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005769" MajorTopicYN="N">Gastrointestinal Motility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008019" MajorTopicYN="Y">Life Style</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069550" MajorTopicYN="Y">Machine Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012336" MajorTopicYN="N">RNA, Ribosomal, 16S</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012111" MajorTopicYN="N">Residence Characteristics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Competing Interests. R.K. is a director of the Center for Microbiome Innovation at UC San Diego, which receives industry research funding for various microbiome initiatives, but no industry funding was provided for this project. The remaining authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>11</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>9</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>1</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>11</Month><Day>5</Day><Hour>6</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>5</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33149306</ArticleId><ArticleId IdType="mid">NIHMS1633027</ArticleId><ArticleId IdType="pmc">PMC7677204</ArticleId><ArticleId IdType="doi">10.1038/s41586-020-2881-9</ArticleId><ArticleId IdType="pii">10.1038/s41586-020-2881-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Huttenhower C et al. Structure, function and diversity of the healthy human microbiome. Nature (2012) doi:10.1038/nature11234.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11234</ArticleId><ArticleId IdType="pmc">PMC3564958</ArticleId><ArticleId IdType="pubmed">22699609</ArticleId></ArticleIdList></Reference><Reference><Citation>Falony G et al. Population-level analysis of gut microbiome variation. Science (80-. ). (2016) doi:10.1126/science.aad3503.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aad3503</ArticleId><ArticleId IdType="pubmed">27126039</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao EY et al. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell (2013) doi:10.1016/j.cell.2013.11.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2013.11.024</ArticleId><ArticleId IdType="pmc">PMC3897394</ArticleId><ArticleId IdType="pubmed">24315484</ArticleId></ArticleIdList></Reference><Reference><Citation>Plovier H et al. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nat. Med (2017) doi:10.1038/nm.4236.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.4236</ArticleId><ArticleId IdType="pubmed">27892954</ArticleId></ArticleIdList></Reference><Reference><Citation>Belkaid Y &amp; Hand TW Role of the microbiota in immunity and inflammation. Cell (2014) doi:10.1016/j.cell.2014.03.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2014.03.011</ArticleId><ArticleId IdType="pmc">PMC4056765</ArticleId><ArticleId IdType="pubmed">24679531</ArticleId></ArticleIdList></Reference><Reference><Citation>Callahan BJ et al. DADA2: High-resolution sample inference from Illumina amplicon data. Nat. Methods (2016) doi:10.1038/nmeth.3869.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.3869</ArticleId><ArticleId IdType="pmc">PMC4927377</ArticleId><ArticleId IdType="pubmed">27214047</ArticleId></ArticleIdList></Reference><Reference><Citation>Mcdonald D et al. American Gut : an Open Platform for Citizen Science. 3, 1&#x2013;28 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5954204</ArticleId><ArticleId IdType="pubmed">29795809</ArticleId></ArticleIdList></Reference><Reference><Citation>Forslund K et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature 528, 262&#x2013;266 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4681099</ArticleId><ArticleId IdType="pubmed">26633628</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin J et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 490, 55&#x2013;60 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">23023125</ArticleId></ArticleIdList></Reference><Reference><Citation>Thingholm LB et al. Obese Individuals with and without Type 2 Diabetes Show Different Gut Microbial Functional Capacity and Composition. Cell Host Microbe 26, 252&#x2013;264.e10 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7720933</ArticleId><ArticleId IdType="pubmed">31399369</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandal S et al. Analysis of composition of microbiomes: a novel method for studying microbial composition. Microb. Ecol. Heal. Dis (2015) doi:10.3402/mehd.v26.27663.</Citation><ArticleIdList><ArticleId IdType="doi">10.3402/mehd.v26.27663</ArticleId><ArticleId IdType="pmc">PMC4450248</ArticleId><ArticleId IdType="pubmed">26028277</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsen N et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One 5, (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2816710</ArticleId><ArticleId IdType="pubmed">20140211</ArticleId></ArticleIdList></Reference><Reference><Citation>Egshatyan L et al. Gut microbiota and diet in patients with different glucose tolerance. Endocr. Connect 5, 1&#x2013;9 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4674628</ArticleId><ArticleId IdType="pubmed">26555712</ArticleId></ArticleIdList></Reference><Reference><Citation>Karlsson FH et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature 498, 99&#x2013;103 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23719380</ArticleId></ArticleIdList></Reference><Reference><Citation>He Y et al. Regional variation limits applications of healthy gut microbiome reference ranges and disease models. Nature Medicine (2018) doi:10.1038/s41591-018-0164-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-018-0164-x</ArticleId><ArticleId IdType="pubmed">30150716</ArticleId></ArticleIdList></Reference><Reference><Citation>Gevers D et al. The treatment-naive microbiome in new-onset Crohn&#x2019;s disease. Cell Host Microbe (2014) doi:10.1016/j.chom.2014.02.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2014.02.005</ArticleId><ArticleId IdType="pmc">PMC4059512</ArticleId><ArticleId IdType="pubmed">24629344</ArticleId></ArticleIdList></Reference><Reference><Citation>Vich Vila A et al. Gut microbiota composition and functional changes in inflammatory bowel disease and irritable bowel syndrome. Sci. Transl. Med (2018) doi:10.1126/scitranslmed.aap8914.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aap8914</ArticleId><ArticleId IdType="pubmed">30567928</ArticleId></ArticleIdList></Reference><Reference><Citation>Lloyd-Price J et al. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature (2019) doi:10.1038/s41586-019-1237-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1237-9</ArticleId><ArticleId IdType="pmc">PMC6650278</ArticleId><ArticleId IdType="pubmed">31142855</ArticleId></ArticleIdList></Reference><Reference><Citation>Vujkovic-Cvijin I et al. HIV-associated gut dysbiosis is independent of sexual practice and correlates with noncommunicable diseases. Nat. Commun 11, 2448 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7228978</ArticleId><ArticleId IdType="pubmed">32415070</ArticleId></ArticleIdList></Reference><Reference><Citation>Llopis M et al. Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease. Gut 65, 830&#x2013;839 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26642859</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciocan D et al. Bile acid homeostasis and intestinal dysbiosis in alcoholic hepatitis. Aliment. Pharmacol. Ther 48, 961&#x2013;974 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30144108</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubinkina VB et al. Links of gut microbiota composition with alcohol dependence syndrome and alcoholic liver disease. Microbiome 5, 141 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5645934</ArticleId><ArticleId IdType="pubmed">29041989</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Roy CI et al. Red Wine Consumption Associated With Increased Gut Microbiota &#x3b1;-diversity in 3 Independent Cohorts. Gastroenterology (2019) doi:10.1053/j.gastro.2019.08.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2019.08.024</ArticleId><ArticleId IdType="pubmed">31472153</ArticleId></ArticleIdList></Reference><Reference><Citation>Valles-Colomer M et al. The neuroactive potential of the human gut microbiota in quality of life and depression. Nat. Microbiol (2019) doi:10.1038/s41564-018-0337-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-018-0337-x</ArticleId><ArticleId IdType="pubmed">30718848</ArticleId></ArticleIdList></Reference><Reference><Citation>Reese AT et al. Using DNA Metabarcoding To Evaluate the Plant Component of Human Diets: a Proof of Concept. mSystems (2019) doi:10.1128/msystems.00458-19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/msystems.00458-19</ArticleId><ArticleId IdType="pmc">PMC6787566</ArticleId><ArticleId IdType="pubmed">31594830</ArticleId></ArticleIdList></Reference><Reference><Citation>Noguera-Julian M et al. Gut Microbiota Linked to Sexual Preference and HIV Infection. EBioMedicine (2016) doi:10.1016/j.ebiom.2016.01.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2016.01.032</ArticleId><ArticleId IdType="pmc">PMC4816837</ArticleId><ArticleId IdType="pubmed">27077120</ArticleId></ArticleIdList></Reference><Reference><Citation>Amir A et al. Correcting for Microbial Blooms in Fecal Samples during Room-Temperature Shipping. mSystems (2017) doi:10.1128/msystems.00199-16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/msystems.00199-16</ArticleId><ArticleId IdType="pmc">PMC5340865</ArticleId><ArticleId IdType="pubmed">28289733</ArticleId></ArticleIdList></Reference><Reference><Citation>Vujkovic-Cvijin I et al. Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism. Sci. Transl. Med (2013) doi:10.1126/scitranslmed.3006438.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3006438</ArticleId><ArticleId IdType="pmc">PMC4094294</ArticleId><ArticleId IdType="pubmed">23843452</ArticleId></ArticleIdList></Reference><Reference><Citation>Deschasaux M et al. Depicting the composition of gut microbiota in a population with varied ethnic origins but shared geography. Nat. Med (2018) doi:10.1038/s41591-018-0160-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-018-0160-1</ArticleId><ArticleId IdType="pubmed">30150717</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasuda K et al. Biogeography of the intestinal mucosal and lumenal microbiome in the rhesus macaque. Cell Host Microbe (2015) doi:10.1016/j.chom.2015.01.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2015.01.015</ArticleId><ArticleId IdType="pmc">PMC4369771</ArticleId><ArticleId IdType="pubmed">25732063</ArticleId></ArticleIdList></Reference><Reference><Citation>Cadwell K et al. Virus-Plus-Susceptibility Gene Interaction Determines Crohn&#x2019;s Disease Gene Atg16L1 Phenotypes in Intestine. Cell (2010) doi:10.1016/j.cell.2010.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2010.05.009</ArticleId><ArticleId IdType="pmc">PMC2908380</ArticleId><ArticleId IdType="pubmed">20602997</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhernakova A et al. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science (80-. ). (2016) doi:10.1126/science.aad3369.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aad3369</ArticleId><ArticleId IdType="pmc">PMC5240844</ArticleId><ArticleId IdType="pubmed">27126040</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilck N et al. Salt-responsive gut commensal modulates TH17 axis and disease. Nature (2017) doi:10.1038/nature24628.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature24628</ArticleId><ArticleId IdType="pmc">PMC6070150</ArticleId><ArticleId IdType="pubmed">29143823</ArticleId></ArticleIdList></Reference><Reference><Citation>Korem T et al. Bread Affects Clinical Parameters and Induces Gut Microbiome-Associated Personal Glycemic Responses. Cell Metab. (2017) doi:10.1016/j.cmet.2017.05.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2017.05.002</ArticleId><ArticleId IdType="pubmed">28591632</ArticleId></ArticleIdList></Reference><Reference><Citation>Ojala M &amp; Garriga GC Permutation tests for studying classifier performance. J. Mach. Learn. Res 11, 1833&#x2013;1863 (2010).</Citation></Reference><Reference><Citation>Barter RL &amp; Yu B Superheat: An R Package for Creating Beautiful and Extendable Heatmaps for Visualizing Complex Data. J. Comput. Graph. Stat (2018) doi:10.1080/10618600.2018.1473780.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10618600.2018.1473780</ArticleId><ArticleId IdType="pmc">PMC6430237</ArticleId><ArticleId IdType="pubmed">30911216</ArticleId></ArticleIdList></Reference><Reference><Citation>Seidell JC &amp; Halberstadt J The global burden of obesity and the challenges of prevention. Ann. Nutr. Metab (2015) doi:10.1159/000375143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000375143</ArticleId><ArticleId IdType="pubmed">26045323</ArticleId></ArticleIdList></Reference><Reference><Citation>Palleja A et al. Recovery of gut microbiota of healthy adults following antibiotic exposure. Nat. Microbiol 3, (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30349083</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasolli E et al. Accessible, curated metagenomic data through ExperimentHub. Nature Methods (2017) doi:10.1038/nmeth.4468.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.4468</ArticleId><ArticleId IdType="pmc">PMC5862039</ArticleId><ArticleId IdType="pubmed">29088129</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">33169916</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>20</Day></DateCompleted><DateRevised><Year>2021</Year><Month>07</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1757-4684</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>12</Issue><PubDate><Year>2020</Year><Month>Dec</Month><Day>07</Day></PubDate></JournalIssue><Title>EMBO molecular medicine</Title><ISOAbbreviation>EMBO Mol Med</ISOAbbreviation></Journal><ArticleTitle>Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer's continuum when only subtle changes in A&#x3b2; pathology are detected.</ArticleTitle><Pagination><StartPage>e12921</StartPage><MedlinePgn>e12921</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e12921</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.15252/emmm.202012921</ELocationID><Abstract><AbstractText>In Alzheimer's disease (AD), tau phosphorylation in the brain and its subsequent release into cerebrospinal fluid (CSF) and blood is a dynamic process that changes during disease evolution. The main aim of our study was to characterize the pattern of changes in phosphorylated tau (p-tau) in the preclinical stage of the Alzheimer's continuum. We measured three novel CSF p-tau biomarkers, phosphorylated at threonine-181 and threonine-217 with an N-terminal partner antibody and at threonine-231 with a mid-region partner antibody. These were compared with an automated mid-region p-tau181 assay (Elecsys) as the gold standard p-tau measure. We demonstrate that these novel p-tau biomarkers increase more prominently in preclinical Alzheimer, when only subtle changes of amyloid-&#x3b2; (A&#x3b2;) pathology are detected, and can accurately differentiate A&#x3b2;-positive from A&#x3b2;-negative cognitively unimpaired individuals. Moreover, we show that the novel plasma N-terminal p-tau181 biomarker is mildly but significantly increased in the preclinical stage. Our results support the idea that early changes in neuronal tau metabolism in preclinical Alzheimer, likely in response to A&#x3b2; exposure, can be detected with these novel p-tau assays.</AbstractText><CopyrightInformation>&#xa9; 2020 The Authors. Published under the terms of the CC BY 4.0 license.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Su&#xe1;rez-Calvet</LastName><ForeName>Marc</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-2993-569X</Identifier><AffiliationInfo><Affiliation>Barcelona&#x3b2;eta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Servei de Neurologia, Hospital del Mar, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de sFragilidad y Envejecimiento Saludable (CIBERFES), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karikari</LastName><ForeName>Thomas K</ForeName><Initials>TK</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ashton</LastName><ForeName>Nicholas J</ForeName><Initials>NJ</Initials><Identifier Source="ORCID">0000-0002-6353-9316</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Wallenberg Centre for Molecular and Translational Medicine, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Psychiatry, Psychology &amp; Neuroscience, King's College London, Maurice Wohl Clinical Neuroscience Institute, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Biomedical Research Centre for Mental Health &amp; Biomedical Research Unit for Dementia at South London &amp; Maudsley NHS Foundation, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lantero Rodr&#xed;guez</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mil&#xe0;-Alom&#xe0;</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Barcelona&#x3b2;eta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de sFragilidad y Envejecimiento Saludable (CIBERFES), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat Pompeu Fabra, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gispert</LastName><ForeName>Juan Domingo</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Barcelona&#x3b2;eta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat Pompeu Fabra, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red Bioingenier&#xed;a, Biomateriales y Nanomedicina, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salvad&#xf3;</LastName><ForeName>Gemma</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Barcelona&#x3b2;eta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minguillon</LastName><ForeName>Carolina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Barcelona&#x3b2;eta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de sFragilidad y Envejecimiento Saludable (CIBERFES), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fauria</LastName><ForeName>Karine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Barcelona&#x3b2;eta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de sFragilidad y Envejecimiento Saludable (CIBERFES), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shekari</LastName><ForeName>Mahnaz</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Barcelona&#x3b2;eta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat Pompeu Fabra, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grau-Rivera</LastName><ForeName>Oriol</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Barcelona&#x3b2;eta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Servei de Neurologia, Hospital del Mar, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de sFragilidad y Envejecimiento Saludable (CIBERFES), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arenaza-Urquijo</LastName><ForeName>Eider M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Barcelona&#x3b2;eta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de sFragilidad y Envejecimiento Saludable (CIBERFES), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sala-Vila</LastName><ForeName>Aleix</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Barcelona&#x3b2;eta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xe1;nchez-Benavides</LastName><ForeName>Gonzalo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Barcelona&#x3b2;eta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de sFragilidad y Envejecimiento Saludable (CIBERFES), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonz&#xe1;lez-de-Ech&#xe1;varri</LastName><ForeName>Jos&#xe9; Maria</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Barcelona&#x3b2;eta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kollmorgen</LastName><ForeName>Gwendlyn</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Roche Diagnostics GmbH, Penzberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stoops</LastName><ForeName>Erik</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>ADx NeuroSciences, Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vanmechelen</LastName><ForeName>Eugeen</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>ADx NeuroSciences, Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute at UCL, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-1890-4193</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molinuevo</LastName><ForeName>Jos&#xe9; Luis</ForeName><Initials>JL</Initials><Identifier Source="ORCID">0000-0003-0485-6001</Identifier><AffiliationInfo><Affiliation>Barcelona&#x3b2;eta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de sFragilidad y Envejecimiento Saludable (CIBERFES), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat Pompeu Fabra, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>ALFA Study</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>LCF/PR/GN17/50300004</GrantID><Agency>"la Caixa" Foundation ("la Caixa")</Agency><Country/></Grant><Grant><GrantID>TriBEKa-17-519007</GrantID><Agency>Alzheimer's Association (AA)</Agency><Country/></Grant><Grant><GrantID>2017-SGR-892</GrantID><Agency>Catalan Government</Agency><Country/></Grant><Grant><GrantID>752310</GrantID><Agency>EC | H2020 | H2020 Priority Excellent Science | H2020 Marie Sk&#x142;odowska-Curie Actions (MSCA)</Agency><Country/></Grant><Grant><GrantID>A2020812F</GrantID><Agency>BrightFocus Foundation (BFF)</Agency><Country/></Grant><Grant><GrantID>681712</GrantID><Agency>EC | H2020 | H2020 Priority Excellent Science | H2020 European Research Council (ERC)</Agency><Country/></Grant><Grant><GrantID>ALFGBG-720931</GrantID><Agency>Swedish State Support for Clinical Research</Agency><Country/></Grant><Grant><GrantID>ALFGBG-715986</GrantID><Agency>ALF-agreement</Agency><Country/></Grant><Grant><GrantID>JPND2019-466-236</GrantID><Agency>EU Joint Programme - Neurodegenerative Disease Research (JPND)</Agency><Country/></Grant><Grant><GrantID>PI19/00155</GrantID><Agency>MEC | Instituto de Salud Carlos III (ISCIII)</Agency><Country/></Grant><Grant><GrantID>CP II 17/00029</GrantID><Agency>MEC | Instituto de Salud Carlos III (ISCIII)</Agency><Country/></Grant><Grant><GrantID>IJC2018-037478-I</GrantID><Agency>Ministerio de Ciencia, Innovaci&#xf3;n y Universidades (MCIU)</Agency><Country/></Grant><Grant><GrantID>FJCI-2017-33437</GrantID><Agency>Ministerio de Ciencia, Innovaci&#xf3;n y Universidades (MCIU)</Agency><Country/></Grant><Grant><GrantID>RYC2018-026053-I</GrantID><Agency>Ministerio de Ciencia, Innovaci&#xf3;n y Universidades (MCIU)</Agency><Country/></Grant><Grant><GrantID>RYC-2013-13054</GrantID><Agency>Ministerio de Econom&#xed;a y Competitividad (MEC)</Agency><Country/></Grant><Grant><GrantID>IEDI-2016-00690</GrantID><Agency>Ministerio de Econom&#xed;a y Competitividad (MEC)</Agency><Country/></Grant><Grant><GrantID>2018-02532</GrantID><Agency>Svenska Forskningsr&#xe5;det Formas</Agency><Country/></Grant><Grant><GrantID>2017-00915</GrantID><Agency>Svenska Forskningsr&#xe5;det Formas</Agency><Country/></Grant><Grant><GrantID>AF-930627</GrantID><Agency>Swedish Alzheimer Foundation</Agency><Country/></Grant><Grant><GrantID>AF-742881</GrantID><Agency>Swedish Alzheimer Foundation</Agency><Country/></Grant><Grant><GrantID>201809-2016862</GrantID><Agency>Alzheimer's Drug Discovery Foundation (ADDF)</Agency><Country/></Grant><Grant><GrantID>RDAPB-201809-2016615</GrantID><Agency>Alzheimer's Drug Discovery Foundation (ADDF)</Agency><Country/></Grant><Grant><GrantID>FO2017-0243</GrantID><Agency>Hj&#xe4;rnfonden Sweden</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>11</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>EMBO Mol Med</MedlineTA><NlmUniqueID>101487380</NlmUniqueID><ISSNLinking>1757-4676</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062706" MajorTopicYN="Y">Prodromal Symptoms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">biomarker</Keyword><Keyword MajorTopicYN="N">cerebrospinal fluid</Keyword><Keyword MajorTopicYN="N">plasma</Keyword><Keyword MajorTopicYN="N">tau</Keyword></KeywordList><CoiStatement>JDG has given lectures in symposia sponsored by the following for&#x2010;profit companies: General Electric, Philips and Biogen. GK is a full&#x2010;time employee of Roche Diagnostics GmbH. ES is an employee and EVM is a co&#x2010;founder of ADx NeuroSciences. HZ has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed and CogRx, has given lectures in symposia sponsored by Fujirebio, Alzecure and Biogen, and is a co&#x2010;founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. KB has served as a consultant or at advisory boards for Abcam, Axon, Biogen, Lilly, MagQu, Novartis and Roche Diagnostics, and is a co&#x2010;founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures&#x2010;based platform company at the University of Gothenburg. JLM has served/serves as a consultant or at advisory boards for the following for&#x2010;profit companies, or has given lectures in symposia sponsored by the following for&#x2010;profit companies: Roche Diagnostics, Genentech, Novartis, Lundbeck, Oryzon, Biogen, Lilly, Janssen, Green Valley, MSD, Eisai, Alector, BioCross, GE Healthcare, ProMIS Neurosciences. The remaining authors declare that they have no conflict of interest.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Beteta</LastName><ForeName>Annabella</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cacciaglia</LastName><ForeName>Raffaele</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ca&#xf1;as</LastName><ForeName>Alba</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deulofeu</LastName><ForeName>Carme</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cumplido</LastName><ForeName>Irene</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dominguez</LastName><ForeName>Ruth</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Emilio</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Falcon</LastName><ForeName>Carles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fuentes</LastName><ForeName>Sherezade</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hernandez</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huesa</LastName><ForeName>Gema</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huguet</LastName><ForeName>Jordi</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marne</LastName><ForeName>Paula</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mench&#xf3;n</LastName><ForeName>Tania</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Operto</LastName><ForeName>Gr&#xe9;gory</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Polo</LastName><ForeName>Albina</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pradas</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Soteras</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vilanova</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vilor-Tejedor</LastName><ForeName>Natalia</ForeName><Initials>N</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>6</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>11</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>11</Month><Day>10</Day><Hour>9</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>12</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33169916</ArticleId><ArticleId IdType="pmc">PMC7721364</ArticleId><ArticleId IdType="doi">10.15252/emmm.202012921</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Amadoru S, Dor&#xe9; V, McLean CA, Hinton F, Shepherd CE, Halliday GM, Leyton CE, Yates PA, Hodges JR, Masters CL et al (2020) Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer&#x2019;s disease. Alzheimers Res Ther 12: 22</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7057642</ArticleId><ArticleId IdType="pubmed">32131891</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreasson U, Perret&#x2010;Liaudet A, van Waalwijk van Doorn LJC, Blennow K, Chiasserini D, Engelborghs S, Fladby T, Genc S, Kruse N, Kuiperij HB et al (2015) A practical guide to immunoassay method validation. Front Neurol 6: 179</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4541289</ArticleId><ArticleId IdType="pubmed">26347708</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai H, Ishiguro K, Ohno H, Moriyama M, Itoh N, Okamura N, Matsui T, Morikawa Y, Horikawa E, Kohno H et al (2000) CSF phosphorylated tau protein and mild cognitive impairment: a prospective study. Exp Neurol 166: 201&#x2013;203</Citation><ArticleIdList><ArticleId IdType="pubmed">11031097</ArticleId></ArticleIdList></Reference><Reference><Citation>Aschenbrenner AJ, Gordon BA, Benzinger TLS, Morris JC, Hassenstab JJ (2018) Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease. Neurology 91: e859&#x2013;e866</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6133625</ArticleId><ArticleId IdType="pubmed">30068637</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustinack JC, Schneider A, Mandelkow E&#x2010;M, Hyman BT (2002) Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer&#x2019;s disease. Acta Neuropathol 103: 26&#x2013;35</Citation><ArticleIdList><ArticleId IdType="pubmed">11837744</ArticleId></ArticleIdList></Reference><Reference><Citation>Babi&#x107; Leko M, Willumsen N, Nikolac Perkovi&#x107; M, Klepac N, Borove&#x10d;ki F, Hof PR, Sonicki Z, Pivac N, de Silva R, &#x160;imi&#x107; G (2018) Association of MAPT haplotype&#x2010;tagging polymorphisms with cerebrospinal fluid biomarkers of Alzheimer&#x2019;s disease: a preliminary study in a Croatian cohort. Brain Behav 8: e01128</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6236251</ArticleId><ArticleId IdType="pubmed">30329219</ArticleId></ArticleIdList></Reference><Reference><Citation>Barthelemy N, Hirtz C, Schraen S, Seveno M, Bateman R, Marin P, Becher F, Gabelle A, Lehmann S (2015) P4&#x2013;234: Mass spectrometry follow&#x2010;up of t181, s199, s202, t205, and T217 tau phosphorylation in cerebrospinal fluid from patients revealed a specific Alzheimer&#x2019;s disease pattern. Alzheimers Dement 11: P870</Citation></Reference><Reference><Citation>Barth&#xe9;lemy NR, Fenaille F, Hirtz C, Sergeant N, Schraen&#x2010;Maschke S, Vialaret J, Bu&#xe9;e L, Gabelle A, Junot C, Lehmann S et al (2016) Tau protein quantification in human cerebrospinal fluid by targeted mass spectrometry at high sequence coverage provides insights into its primary structure heterogeneity. J Proteome Res 15: 667&#x2013;676</Citation><ArticleIdList><ArticleId IdType="pubmed">26742856</ArticleId></ArticleIdList></Reference><Reference><Citation>Barth&#xe9;lemy NR, Bateman RJ, Marin P, Becher F, Sato C, Lehmann S, Gabelle A (2017) Tau hyperphosphorylation on T217 in cerebrospinal fluid is specifically associated to amyloid&#x2010;&#x3b2; pathology. bioRxiv: 226977 [PREPRINT]</Citation></Reference><Reference><Citation>Barth&#xe9;lemy NR, Mallipeddi N, Moiseyev P, Sato C, Bateman RJ (2019) Tau phosphorylation Rates measured by mass spectrometry differ in the intracellular brain vs. extracellular cerebrospinal fluid compartments and are differentially affected by Alzheimer&#x2019;s disease. Front Aging Neurosci 11: 121</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6537657</ArticleId><ArticleId IdType="pubmed">31178717</ArticleId></ArticleIdList></Reference><Reference><Citation>Barth&#xe9;lemy NR, Bateman RJ, Hirtz C, Marin P, Becher F, Sato C, Gabelle A, Lehmann S (2020a) Cerebrospinal fluid phospho&#x2010;tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer&#x2019;s disease and PET amyloid&#x2010;positive patient identification. Alzheimer&#x2019;s Res Ther 12: 26</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7079453</ArticleId><ArticleId IdType="pubmed">32183883</ArticleId></ArticleIdList></Reference><Reference><Citation>Barth&#xe9;lemy NR, Horie K, Sato C, Bateman RJ (2020b) Blood plasma phosphorylated&#x2010;tau isoforms track CNS change in Alzheimer&#x2019;s disease. J Exp Med 217: e20200861</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7596823</ArticleId><ArticleId IdType="pubmed">32725127</ArticleId></ArticleIdList></Reference><Reference><Citation>Barth&#xe9;lemy NR, Li Y, Joseph&#x2010;Mathurin N, Gordon BA, Hassenstab J, Benzinger TLS, Buckles V, Fagan AM, Perrin RJ, Goate AM et al (2020c) A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer&#x2019;s disease. Nat Med 26: 398&#x2013;407</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7309367</ArticleId><ArticleId IdType="pubmed">32161412</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM et al (2012) Clinical and biomarker changes in dominantly inherited Alzheimer&#x2019;s disease. N Engl J Med 367: 795&#x2013;804</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Wallin A, &#xc5;gren H, Spenger C, Siegfried J, Vanmechelen E (1995) Tau protein in cerebrospinal fluid. Mol Chem Neuropathol 26: 231&#x2013;245</Citation><ArticleIdList><ArticleId IdType="pubmed">8748926</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Vanmechelen E, Hampel H (2001) CSF total tau, A&#x3b2;42 and phosphorylated tau protein as biomarkers for Alzheimer&#x2019;s disease. Mol Neurobiol 24: 087&#x2013;098</Citation><ArticleIdList><ArticleId IdType="pubmed">11831556</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Hampel H, Weiner M, Zetterberg H (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6: 131&#x2013;144</Citation><ArticleIdList><ArticleId IdType="pubmed">20157306</ArticleId></ArticleIdList></Reference><Reference><Citation>Brier MR, Gordon B, Friedrichsen K, McCarthy J, Stern A, Christensen J, Owen C, Aldea P, Su Y, Hassenstab J et al (2016) Tau and A&#x3b2; imaging, CSF measures, and cognition in Alzheimer&#x2019;s disease. Sci Transl Med 8: 338ra66</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5267531</ArticleId><ArticleId IdType="pubmed">27169802</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckley RF, Mormino EC, Rabin JS, Hohman TJ, Landau S, Hanseeuw BJ, Jacobs HIL, Papp KV, Amariglio RE, Properzi MJ et al (2019) Sex differences in the association of global amyloid and regional tau deposition measured by positron emission tomography in clinically normal older adults. JAMA Neurol 76: 542&#x2013;551</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6515599</ArticleId><ArticleId IdType="pubmed">30715078</ArticleId></ArticleIdList></Reference><Reference><Citation>Buerger K, Teipel SJ, Zinkowski R, Blennow K, Arai H, Engel R, Hofmann&#x2010;Kiefer K, McCulloch C, Ptok U, Heun R et al (2002a) CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology 59: 627&#x2013;629</Citation><ArticleIdList><ArticleId IdType="pubmed">12196665</ArticleId></ArticleIdList></Reference><Reference><Citation>Buerger K, Zinkowski R, Teipel SJ, Tapiola T, Arai H, Blennow K, Andreasen N, Hofmann&#x2010;Kiefer K, DeBernardis J, Kerkman D et al (2002b) Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol 59: 1267&#x2013;1272</Citation><ArticleIdList><ArticleId IdType="pubmed">12164722</ArticleId></ArticleIdList></Reference><Reference><Citation>Buerger K, Frisoni G, Uspenskaya O, Ewers M, Zetterberg H, Geroldi C, Binetti G, Johannsen P, Rossini PM, Wahlund LO et al (2009) Validation of Alzheimer&#x2019;s disease CSF and plasma biological markers: the multicentre reliability study of the pilot European Alzheimer&#x2019;s Disease Neuroimaging Initiative (E&#x2010;ADNI). Exp Gerontol 44: 579&#x2013;585</Citation><ArticleIdList><ArticleId IdType="pubmed">19539742</ArticleId></ArticleIdList></Reference><Reference><Citation>Chai X, Dage JL, Citron M (2012) Constitutive secretion of tau protein by an unconventional mechanism. Neurobiol Dis 48: 356&#x2013;366</Citation><ArticleIdList><ArticleId IdType="pubmed">22668776</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z, Mengel D, Keshavan A, Rissman RA, Billinton A, Perkinton M, Percival&#x2010;Alwyn J, Schultz A, Properzi M, Johnson K et al (2019) Learnings about the complexity of extracellular tau aid development of a blood&#x2010;based screen for Alzheimer&#x2019;s disease. Alzheimers Dement 15: 487&#x2013;496</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6476313</ArticleId><ArticleId IdType="pubmed">30419228</ArticleId></ArticleIdList></Reference><Reference><Citation>Chhatwal JP, Schultz AP, Marshall GA, Boot B, Gomez&#x2010;Isla T, Dumurgier J, LaPoint M, Scherzer C, Roe AD, Hyman BT et al (2016) Temporal T807 binding correlates with CSF tau and phospho&#x2010;tau in normal elderly. Neurology 87: 920&#x2013;926</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5035159</ArticleId><ArticleId IdType="pubmed">27473132</ArticleId></ArticleIdList></Reference><Reference><Citation>Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su M&#x2010;Y, Shankle WR, Elizarov A, Kolb HC (2013) Early clinical PET imaging results with the novel PHF&#x2010;Tau radioligand [F&#x2010;18]&#x2010;T807. J Alzheimer&#x2019;s Dis 34: 457&#x2013;468</Citation><ArticleIdList><ArticleId IdType="pubmed">23234879</ArticleId></ArticleIdList></Reference><Reference><Citation>Cicognola C, Brinkmalm G, Wahlgren J, Portelius E, Gobom J, Cullen NC, Hansson O, Parnetti L, Constantinescu R, Wildsmith K et al (2019) Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer&#x2019;s disease. Acta Neuropathol 137: 279&#x2013;296</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6514201</ArticleId><ArticleId IdType="pubmed">30547227</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleveland WS (1979) Robust locally weighted regression and smoothing scatterplots. J Am Stat Assoc 74: 829&#x2013;836</Citation></Reference><Reference><Citation>Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, Bakardjian H, Benali H, Bertram L, Blennow K et al (2016) Preclinical Alzheimer&#x2019;s disease: definition, natural history, and diagnostic criteria. Alzheimers Dement 12: 292&#x2013;323</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6417794</ArticleId><ArticleId IdType="pubmed">27012484</ArticleId></ArticleIdList></Reference><Reference><Citation>Ercan&#x2010;Herbst E, Ehrig J, Sch&#xf6;ndorf DC, Behrendt A, Klaus B, Gomez Ramos B, Prat Oriol N, Weber C, Ehrnhoefer DE (2019) A post&#x2010;translational modification signature defines changes in soluble tau correlating with oligomerization in early stage Alzheimer&#x2019;s disease brain. Acta Neuropathol Commun 7: 192</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6892178</ArticleId><ArticleId IdType="pubmed">31796124</ArticleId></ArticleIdList></Reference><Reference><Citation>Ercan E, Eid S, Weber C, Kowalski A, Bichmann M, Behrendt A, Matthes F, Krauss S, Reinhardt P, Fulle S et al (2017) A validated antibody panel for the characterization of tau post&#x2010;translational modifications. Mol Neurodegener 12: 87</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5697095</ArticleId><ArticleId IdType="pubmed">29157277</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Xiong C, Jasielec MS, Bateman RJ, Goate AM, Benzinger TLS, Ghetti B, Martins RN, Masters CL, Mayeux R et al (2014) Longitudinal change in CSF biomarkers in autosomal&#x2010;dominant Alzheimer&#x2019;s disease. Sci Transl Med 6: 226ra30</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4038930</ArticleId><ArticleId IdType="pubmed">24598588</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira D, Rivero&#x2010;Santana A, Perestelo&#x2010;P&#xe9;rez L, Westman E, Wahlund L&#x2010;O, Sarr&#xed;a A, Serrano&#x2010;Aguilar P (2014) Improving CSF biomarkers&#x2019; performance for predicting progression from mild cognitive impairment to alzheimer&#x2019;s disease by considering different confounding factors: a meta&#x2010;analysis. Front Aging Neurosci 6: 287</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4199277</ArticleId><ArticleId IdType="pubmed">25360114</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferretti MT, Iulita MF, Cavedo E, Chiesa PA, Dimech AS, Chadha AS, Baracchi F, Girouard H, Misoch S, Giacobini E et al (2018) Sex differences in Alzheimer disease &#x2013; The gateway to precision medicine. Nat Rev Neurol 14: 457&#x2013;469</Citation><ArticleIdList><ArticleId IdType="pubmed">29985474</ArticleId></ArticleIdList></Reference><Reference><Citation>Filon JR, Intorcia AJ, Sue LI, Vazquez Arreola E, Wilson J, Davis KJ, Sabbagh MN, Belden CM, Caselli RJ, Adler CH et al (2016) Gender differences in Alzheimer disease: brain atrophy, histopathology burden, and cognition. J Neuropathol Exp Neurol 75: 748&#x2013;754</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7299435</ArticleId><ArticleId IdType="pubmed">27297671</ArticleId></ArticleIdList></Reference><Reference><Citation>Glodzik&#x2010;Sobanska L, Pirraglia E, Brys M, de Santi S, Mosconi L, Rich KE, Switalski R, Saint LL, Sadowski MJ, Martiniuk F et al (2009) The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer&#x2019;s disease. Neurobiol Aging 30: 672&#x2013;681</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2774788</ArticleId><ArticleId IdType="pubmed">17920160</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Wischik CM, Crowther RA, Walker JE, Klug A (1988) Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule&#x2010;associated protein tau. Proc Natl Acad Sci USA 85: 4051&#x2013;4055</Citation><ArticleIdList><ArticleId IdType="pmc">PMC280359</ArticleId><ArticleId IdType="pubmed">3131773</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA (1989) Multiple isoforms of human microtubule&#x2010;associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer&#x2019;s disease. Neuron 3: 519&#x2013;526</Citation><ArticleIdList><ArticleId IdType="pubmed">2484340</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Jakes R, Crowther RA, Cohen P, Vanmechelen E, Vandermeeren M, Cras P (1994) Epitope mapping of monoclonal antibodies to the paired helical filaments of Alzheimer&#x2019;s disease: Identification of phosphorylation sites in tau protein. Biochem J 301: 871&#x2013;877</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1137067</ArticleId><ArticleId IdType="pubmed">7519852</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez&#x2010;Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, Parisi JE, Hyman BT (1997) Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer&#x2019;s disease. Ann Neurol 41: 17&#x2013;24</Citation><ArticleIdList><ArticleId IdType="pubmed">9005861</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon BA, Blazey TM, Christensen J, Dincer A, Flores S, Keefe S, Chen C, Su Y, McDade EM, Wang G et al (2019) Tau PET in autosomal dominant Alzheimer&#x2019;s disease: relationship with cognition, dementia and other biomarkers. Brain 142: 1063&#x2013;1076</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6439328</ArticleId><ArticleId IdType="pubmed">30753379</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon BA, Friedrichsen K, Brier M, Blazey T, Su Y, Christensen J, Aldea P, McConathy J, Holtzman DM, Cairns NJ et al (2016) The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging. Brain 139: 2249&#x2013;2260</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4958902</ArticleId><ArticleId IdType="pubmed">27286736</ArticleId></ArticleIdList></Reference><Reference><Citation>Grundke&#x2010;Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI (1986) Abnormal phosphorylation of the microtubule&#x2010;associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA 83: 4913&#x2013;4917</Citation><ArticleIdList><ArticleId IdType="pmc">PMC323854</ArticleId><ArticleId IdType="pubmed">3088567</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampel H, Buerger K, Zinkowski R, Teipel SJ, Goernitz A, Andreasen N, Sjoegren M, DeBernardis J, Kerkman D, Ishiguro K et al (2004) Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease. Arch Gen Psychiatry 61: 95</Citation><ArticleIdList><ArticleId IdType="pubmed">14706948</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampel H, B&#xfc;rger K, Pruessner JC, Zinkowski R, DeBernardis J, Kerkman D, Leinsinger G, Evans AC, Davies P, M&#xf6;ller H&#x2010;J et al (2005) Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease. Arch Neurol 62: 770&#x2013;773</Citation><ArticleIdList><ArticleId IdType="pubmed">15883264</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L (2006) Association between CSF biomarkers and incipient Alzheimer&#x2019;s disease in patients with mild cognitive impairment: a follow&#x2010;up study. Lancet Neurol 5: 228&#x2013;234</Citation><ArticleIdList><ArticleId IdType="pubmed">16488378</ArticleId></ArticleIdList></Reference><Reference><Citation>Horowitz PM, Patterson KR, Guillozet&#x2010;Bongaarts AL, Reynolds MR, Carroll CA, Weintraub ST, Bennett DA, Cryns VL, Berry RW, Binder LI (2004) Early N&#x2010;terminal changes and caspase&#x2010;6 cleavage of tau in Alzheimer&#x2019;s disease. J Neurosci 24: 7895&#x2013;7902</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729917</ArticleId><ArticleId IdType="pubmed">15356202</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu YY, He SS, Wang X, Duan QH, Grundke&#x2010;Iqbal I, Iqbal K, Wang J (2002) Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer&#x2019;s disease patients. Am J Pathol 160: 1269&#x2013;1278</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1867203</ArticleId><ArticleId IdType="pubmed">11943712</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishiguro K, Ohno H, Arai H, Yamaguchi H, Urakami K, Park J&#x2010;M, Sato K, Kohno H, Imahori K (1999) Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer&#x2019;s disease. Neurosci Lett 270: 91&#x2013;94</Citation><ArticleIdList><ArticleId IdType="pubmed">10462105</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J et al (2018) NIA&#x2010;AA Research Framework: toward a biological definition of Alzheimer&#x2019;s disease. Alzheimers Dement 14: 535&#x2013;562</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5958625</ArticleId><ArticleId IdType="pubmed">29653606</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Wiste HJ, Botha H, Weigand SD, Therneau TM, Knopman DS, Graff&#x2010;Radford J, Jones DT, Ferman TJ, Boeve BF et al (2019) The bivariate distribution of amyloid&#x2010;&#x3b2; and tau: relationship with established neurocognitive clinical syndromes. Brain 142: 3230&#x2013;3242</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6763736</ArticleId><ArticleId IdType="pubmed">31501889</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach TG, Serrano GE, Chai X, Proctor NK, Eichenlaub U, Zetterberg H et al (2020a) Plasma P&#x2010;tau181 in Alzheimer&#x2019;s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer&#x2019;s dementia. Nat Med 26: 379&#x2013;386</Citation><ArticleIdList><ArticleId IdType="pubmed">32123385</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, Stomrud E, Smith R, Palmqvist S, Mattsson N, Airey DC, Proctor NK, Chai X, Shcherbinin S, Sims JR et al (2020b) Cerebrospinal fluid p&#x2010;tau217 performs better than p&#x2010;tau181 as a biomarker of Alzheimer&#x2019;s disease. Nat Commun 11: 1683</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7125218</ArticleId><ArticleId IdType="pubmed">32246036</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, Schultz A, Betensky RA, Becker JA, Sepulcre J, Rentz D, Mormino E, Chhatwal J, Amariglio R, Papp K et al (2016) Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol 79: 110&#x2013;119</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4738026</ArticleId><ArticleId IdType="pubmed">26505746</ArticleId></ArticleIdList></Reference><Reference><Citation>La Joie R, Ayakta N, Seeley WW, Borys E, Boxer AL, DeCarli C, Dor&#xe9; V, Grinberg LT, Huang E, Hwang J&#x2010;H et al (2019) Multisite study of the relationships between antemortem [11 C]PIB&#x2010;PET centiloid values and postmortem measures of Alzheimer&#x2019;s disease neuropathology. Alzheimers Dement 15: 205&#x2013;216</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6368897</ArticleId><ArticleId IdType="pubmed">30347188</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanmert D, Cantlon A, Muratore CR, Jin M, O&#x2019;Malley TT, Lee G, Young&#x2010;Pearse TL, Selkoe DJ, Walsh DM (2015) C&#x2010;terminally truncated forms of tau, but not full&#x2010;length tau or its C&#x2010;terminal fragments, are released from neurons independently of cell death. J Neurosci 35: 10851&#x2013;10865</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6605107</ArticleId><ArticleId IdType="pubmed">26224867</ArticleId></ArticleIdList></Reference><Reference><Citation>Karch CM, Jeng AT, Goate AM (2012) Extracellular tau levels are influenced by variability in tau that is associated with tauopathies. J Biol Chem 287: 42751&#x2013;42762</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3522274</ArticleId><ArticleId IdType="pubmed">23105105</ArticleId></ArticleIdList></Reference><Reference><Citation>Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, Chamoun M, Savard M, Kang MS, Therriault J et al (2020) Blood phosphorylated tau 181 as a biomarker for Alzheimer&#x2019;s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol 19: 422&#x2013;433</Citation><ArticleIdList><ArticleId IdType="pubmed">32333900</ArticleId></ArticleIdList></Reference><Reference><Citation>Ki&#x111;emet&#x2010;Piska&#x10d; S, Babi&#x107; Leko M, Bla&#x17e;ekovi&#x107; A, Langer Horvat L, Klepac N, Sonicki Z, Kolenc D, Hof PR, Boban M, Mimica N et al (2018) Evaluation of cerebrospinal fluid phosphorylated tau 231 as a biomarker in the differential diagnosis of Alzheimer&#x2019;s disease and vascular dementia. CNS Neurosci Ther 24: 734&#x2013;740</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6047904</ArticleId><ArticleId IdType="pubmed">29453935</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim W, Lee S, Hall GF (2010) Secretion of human tau fragments resembling CSF&#x2010;tau in Alzheimer&#x2019;s disease is modulated by the presence of the exon 2 insert. FEBS Lett 584: 3085&#x2013;3088</Citation><ArticleIdList><ArticleId IdType="pubmed">20553717</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD, Jagust WJ, Johnson KA, Mathis CA, Minhas D, Pontecorvo MJ et al (2015) The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement 11: 1&#x2013;15.e4</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4300247</ArticleId><ArticleId IdType="pubmed">25443857</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohnken R, Buerger K, Zinkowski R, Miller C, Kerkman D, DeBernardis J, Shen J, M&#xf6;ller H&#x2010;J, Davies P, Hampel H (2000) Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer&#x2019;s disease patients. Neurosci Lett 287: 187&#x2013;190</Citation><ArticleIdList><ArticleId IdType="pubmed">10863026</ArticleId></ArticleIdList></Reference><Reference><Citation>Ksiezak&#x2010;Reding H, Binder LI, Yen SH (1988) Immunochemical and biochemical characterization of tau proteins in normal and Alzheimer&#x2019;s disease brains with Alz 50 and Tau&#x2010;1. J Biol Chem 263: 7948&#x2013;7953</Citation><ArticleIdList><ArticleId IdType="pubmed">3131334</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee V, Balin B, Otvos L, Trojanowski J (1991) A68: a major subunit of paired helical filaments and derivatized forms of normal Tau. Science 251: 675&#x2013;678</Citation><ArticleIdList><ArticleId IdType="pubmed">1899488</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee VM, Goedert M, Trojanowski JQ (2001) Neurodegenerative tauopathies. Annu Rev Neurosci 24: 1121&#x2013;1159</Citation><ArticleIdList><ArticleId IdType="pubmed">11520930</ArticleId></ArticleIdList></Reference><Reference><Citation>De Leon MJ, Segal S, Tarshish CY, DeSanti S, Zinkowski R, Mehta PD, Convit A, Caraos C, Rusinek H, Tsui W et al (2002) Longitudinal cerebrospinal fluid tau load increases in mild cognitive impairment. Neurosci Lett 333: 183&#x2013;186</Citation><ArticleIdList><ArticleId IdType="pubmed">12429378</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuzy A, Chiotis K, Hasselbalch SG, Rinne JO, de Mendon&#xe7;a A, Otto M, Lle&#xf3; A, Castelo&#x2010;Branco M, Santana I, Johansson J et al (2016) Pittsburgh compound B imaging and cerebrospinal fluid amyloid&#x2010;&#x3b2; in a multicentre European memory clinic study. Brain 139: 2540&#x2013;2553</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4995359</ArticleId><ArticleId IdType="pubmed">27401520</ArticleId></ArticleIdList></Reference><Reference><Citation>Lifke V, Kollmorgen G, Manuilova E, Oelschlaegel T, Hillringhaus L, Widmann M, von Arnim CAF, Otto M, Christenson RH, Powers JL et al (2019) Elecsys&#xae; Total&#x2010;Tau and Phospho&#x2010;Tau (181P) CSF assays: analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid. Clin Biochem 72: 30&#x2013;38</Citation><ArticleIdList><ArticleId IdType="pubmed">31129184</ArticleId></ArticleIdList></Reference><Reference><Citation>Lle&#xf3; A, Alcolea D, Mart&#xed;nez&#x2010;Lage P, Scheltens P, Parnetti L, Poirier J, Simonsen AH, Verbeek MM, Rosa&#x2010;Neto P, Slot RER et al (2019) Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer&#x2019;s disease continuum in the BIOMARKAPD study. Alzheimers Dement 15: 742&#x2013;753</Citation><ArticleIdList><ArticleId IdType="pubmed">30967340</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowe VJ, Curran G, Fang P, Liesinger AM, Josephs KA, Parisi JE, Kantarci K, Boeve BF, Pandey MK, Bruinsma T et al (2016) An autoradiographic evaluation of AV&#x2010;1451 Tau PET in dementia. Acta Neuropathol Commun 4: 58</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4906968</ArticleId><ArticleId IdType="pubmed">27296779</ArticleId></ArticleIdList></Reference><Reference><Citation>Luna&#x2010;Mu&#xf1;oz J, Garc&#xed;a&#x2010;Sierra F, Falc&#xf3;n V, Men&#xe9;ndez I, Ch&#xe1;vez&#x2010;Mac&#xed;as L, Mena R (2005) Regional conformational change involving phosphorylation of tau protein at the Thr231, precedes the structural change detected by Alz&#x2010;50 antibody in Alzheimer&#x2019;s disease. J Alzheimer&#x2019;s Dis 8: 29&#x2013;41</Citation><ArticleIdList><ArticleId IdType="pubmed">16155347</ArticleId></ArticleIdList></Reference><Reference><Citation>Luna&#x2010;Mu&#xf1;oz J, Ch&#xe1;vez&#x2010;Mac&#xed;as L, Garc&#xed;a&#x2010;Sierra F, Mena R (2007) Earliest stages of tau conformational changes are related to the appearance of a sequence of specific phospho&#x2010;dependent tau epitopes in Alzheimer&#x2019;s disease. J Alzheimer&#x2019;s Dis 12: 365&#x2013;375</Citation><ArticleIdList><ArticleId IdType="pubmed">18198423</ArticleId></ArticleIdList></Reference><Reference><Citation>Maia LF, Kaeser SA, Reichwald J, Hruscha M, Martus P, Staufenbiel M, Jucker M (2013) Changes in amyloid&#x2010; and tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein. Sci Transl Med 5: 194re2&#x2010;194re2</Citation><ArticleIdList><ArticleId IdType="pubmed">23863834</ArticleId></ArticleIdList></Reference><Reference><Citation>Marqui&#xe9; M, Normandin MD, Meltzer AC, Siao Tick Chong M, Andrea NV, Ant&#xf3;n&#x2010;Fern&#xe1;ndez A, Klunk WE, Mathis CA, Ikonomovic MD, Debnath M et al (2017) Pathological correlations of [F&#x2010;18]&#x2010;AV&#x2010;1451 imaging in non&#x2010;alzheimer tauopathies. Ann Neurol 81: 117&#x2013;128</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5319193</ArticleId><ArticleId IdType="pubmed">27997036</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka S&#x2010;K, van der Flier WM, Blankenstein MA, Ewers M et al (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302: 385&#x2013;393</Citation><ArticleIdList><ArticleId IdType="pubmed">19622817</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Sch&#xf6;ll M, Strandberg O, Smith R, Palmqvist S, Insel PS, H&#xe4;gerstr&#xf6;m D, Ohlsson T, Zetterberg H, J&#xf6;gi J et al (2017) 18 F&#x2010;AV&#x2010;1451 and CSF T&#x2010;tau and P&#x2010;tau as biomarkers in Alzheimer&#x2019;s disease. EMBO Mol Med 9: 1212&#x2013;1223</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5582410</ArticleId><ArticleId IdType="pubmed">28743782</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Insel PS, Donohue M, J&#xf6;gi J, Ossenkoppele R, Olsson T, Sch&#xf6;ll M, Smith R, Hansson O (2019) Predicting diagnosis and cognition with 18 F&#x2010;AV&#x2010;1451 tau PET and structural MRI in Alzheimer&#x2019;s disease. Alzheimers Dement 15: 570&#x2013;580</Citation><ArticleIdList><ArticleId IdType="pubmed">30639421</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson&#x2010;Carlgren N, Andersson E, Janelidze S, Ossenkoppele R, Insel P, Strandberg O, Zetterberg H, Rosen HJ, Rabinovici G, Chai X et al (2020) A&#x3b2; deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer&#x2019;s disease. Sci Adv 6: eaaz2387</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159908</ArticleId><ArticleId IdType="pubmed">32426454</ArticleId></ArticleIdList></Reference><Reference><Citation>McDade E, Wang G, Gordon BA, Hassenstab J, Benzinger TLS, Buckles V, Fagan AM, Holtzman DM, Cairns NJ, Goate AM et al (2018) Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. Neurology 91: e1295&#x2013;e1306</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6177272</ArticleId><ArticleId IdType="pubmed">30217935</ArticleId></ArticleIdList></Reference><Reference><Citation>Meredith JE Jr, Sankaranarayanan S, Guss V, Lanzetti AJ, Berisha F, Neely RJ, Slemmon JR, Portelius E, Zetterberg H, Blennow K et al (2013) Characterization of novel CSF tau and ptau biomarkers for Alzheimer&#x2019;s disease. PLoS One 8: e76523</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3792042</ArticleId><ArticleId IdType="pubmed">24116116</ArticleId></ArticleIdList></Reference><Reference><Citation>Mielke MM, Hagen CE, Xu J, Chai X, Vemuri P, Lowe VJ, Airey DC, Knopman DS, Roberts RO, Machulda MM et al (2018) Plasma phospho&#x2010;tau181 increases with Alzheimer&#x2019;s disease clinical severity and is associated with tau&#x2010; and amyloid&#x2010;positron emission tomography. Alzheimers Dement 14: 989&#x2013;997</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6097897</ArticleId><ArticleId IdType="pubmed">29626426</ArticleId></ArticleIdList></Reference><Reference><Citation>Mil&#xe0;&#x2010;Alom&#xe0; M, Salvad&#xf3; G, Gispert JD, Vilor&#x2010;Tejedor N, Grau&#x2010;Rivera O, Sala&#x2010;Vila A, S&#xe1;nchez&#x2010;Benavides G, Arenaza&#x2010;Urquijo EM, Crous&#x2010;Bou M, Gonz&#xe1;lez&#x2010;de&#x2010;Ech&#xe1;varri JM et al (2020) Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer&#x2019;s continuum. Alzheimers Dement 16: 1358&#x2013;1371</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7586814</ArticleId><ArticleId IdType="pubmed">32573951</ArticleId></ArticleIdList></Reference><Reference><Citation>Molinuevo JL, Gramunt N, Gispert JD, Fauria K, Esteller M, Minguillon C, S&#xe1;nchez&#x2010;Benavides G, Huesa G, Mor&#xe1;n S, Dal&#x2010;R&#xe9; R et al (2016) The ALFA project: A research platform to identify early pathophysiological features of Alzheimer&#x2019;s disease. Alzheimers Dement Transl Res Clin Interv 2: 82&#x2013;92</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5644283</ArticleId><ArticleId IdType="pubmed">29067295</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, Castellani RJ, Crain BJ, Davies P, Del TK et al (2012) Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol 71: 362&#x2013;381</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3560290</ArticleId><ArticleId IdType="pubmed">22487856</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xd6;hrfelt A, Johansson P, Wallin A, Andreasson U, Zetterberg H, Blennow K, Svensson J (2016) Increased cerebrospinal fluid levels of ubiquitin carboxyl&#x2010;terminal Hydrolase L1 in patients with Alzheimer&#x2019;s disease. Dement Geriatr Cogn Dis Extra 6: 283&#x2013;294</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4965532</ArticleId><ArticleId IdType="pubmed">27504117</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsson B, Lautner R, Andreasson U, &#xd6;hrfelt A, Portelius E, Bjerke M, H&#xf6;ltt&#xe4; M, Ros&#xe9;n C, Olsson C, Strobel G et al (2016) CSF and blood biomarkers for the diagnosis of Alzheimer&#x2019;s disease: a systematic review and meta&#x2010;analysis. Lancet Neurol 15: 673&#x2013;684</Citation><ArticleIdList><ArticleId IdType="pubmed">27068280</ArticleId></ArticleIdList></Reference><Reference><Citation>Orfanidis SJ (1996) Introduction to signal processing Englewood Cliffs, Upper Saddle River, NJ: Prentice&#x2010;Hall;</Citation></Reference><Reference><Citation>Palmqvist S, Janelidze S, Quiroz YT, Zetterberg H, Lopera F, Stomrud E, Su Y, Chen Y, Serrano GE, Leuzy A et al (2020) Discriminative accuracy of plasma Phospho&#x2010;tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA 324: 772</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7388060</ArticleId><ArticleId IdType="pubmed">32722745</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Aisen P, Boeve BF, Geda YE, Ivnik RJ, Knopman DS, Mielke M, Pankratz VS, Roberts R, Rocca WA et al (2013) Mild cognitive impairment due to Alzheimer disease in the community. Ann Neurol 74: 199&#x2013;208</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3804562</ArticleId><ArticleId IdType="pubmed">23686697</ArticleId></ArticleIdList></Reference><Reference><Citation>Plouffe V, Mohamed N&#x2010;V, Rivest&#x2010;McGraw J, Bertrand J, Lauzon M, Leclerc N (2012) Hyperphosphorylation and cleavage at D421 enhance tau secretion. PLoS One 7: e36873</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3352936</ArticleId><ArticleId IdType="pubmed">22615831</ArticleId></ArticleIdList></Reference><Reference><Citation>Pooler AM, Phillips EC, Lau DHW, Noble W, Hanger DP (2013) Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Rep 14: 389&#x2013;394</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3615658</ArticleId><ArticleId IdType="pubmed">23412472</ArticleId></ArticleIdList></Reference><Reference><Citation>Quiroz YT, Sperling RA, Norton DJ, Baena A, Arboleda&#x2010;Velasquez JF, Cosio D, Schultz A, Lapoint M, Guzman&#x2010;Velez E, Miller JB et al (2018) Association between amyloid and tau accumulation in young adults with autosomal dominant Alzheimer disease. JAMA Neurol 75: 548</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5885174</ArticleId><ArticleId IdType="pubmed">29435558</ArticleId></ArticleIdList></Reference><Reference><Citation>Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez J, M&#xfc;ller M (2011) pROC: an open&#x2010;source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 12: 77</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3068975</ArticleId><ArticleId IdType="pubmed">21414208</ArticleId></ArticleIdList></Reference><Reference><Citation>Roe CM, Fagan AM, Grant EA, Hassenstab J, Moulder KL, Maue Dreyfus D, Sutphen CL, Benzinger TLS, Mintun MA, Holtzman DM et al (2013) Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology 80: 1784&#x2013;1791</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3719431</ArticleId><ArticleId IdType="pubmed">23576620</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe CC, Dor&#xe9; V, Jones G, Baxendale D, Mulligan RS, Bullich S, Stephens AW, De Santi S, Masters CL, Dinkelborg L et al (2017) 18F&#x2010;Florbetaben PET beta&#x2010;amyloid binding expressed in Centiloids. Eur J Nucl Med Mol Imaging 44: 2053&#x2013;2059</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5656696</ArticleId><ArticleId IdType="pubmed">28643043</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell CL, Mitra V, Hansson K, Blennow K, Gobom J, Zetterberg H, Hiltunen M, Ward M, Pike I (2016) Comprehensive quantitative profiling of tau and phosphorylated tau peptides in cerebrospinal fluid by mass spectrometry provides new biomarker candidates. J Alzheimer&#x2019;s Dis 55: 303&#x2013;313</Citation><ArticleIdList><ArticleId IdType="pubmed">27636850</ArticleId></ArticleIdList></Reference><Reference><Citation>Salvad&#xf3; G, Molinuevo JL, Brugulat&#x2010;Serrat A, Falcon C, Grau&#x2010;Rivera O, Su&#xe1;rez&#x2010;Calvet M, Pavia J, Ni&#xf1;erola&#x2010;Baiz&#xe1;n A, Perissinotti A, Lome&#xf1;a F et al (2019) Centiloid cut&#x2010;off values for optimal agreement between PET and CSF core AD biomarkers. Alzheimers Res Ther 11: 27</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6429814</ArticleId><ArticleId IdType="pubmed">30902090</ArticleId></ArticleIdList></Reference><Reference><Citation>Saman S, Kim W, Raya M, Visnick Y, Miro S, Saman S, Jackson B, McKee AC, Alvarez VE, Lee NCY et al (2012) Exosome&#x2010;associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease. J Biol Chem 287: 3842&#x2013;3849</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3281682</ArticleId><ArticleId IdType="pubmed">22057275</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos JRF, Bauer C, Schuchhardt J, Wedekind D, Waniek K, Lachmann I, Wiltfang J, Vogelgsang J (2019) Validation of a prototype tau Thr231 phosphorylation CSF ELISA as a potential biomarker for Alzheimer&#x2019;s disease. J Neural Transm 126: 339&#x2013;348</Citation><ArticleIdList><ArticleId IdType="pubmed">30767082</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato C, Barth&#xe9;lemy NR, Mawuenyega KG, Patterson BW, Gordon BA, Jockel&#x2010;Balsarotti J, Sullivan M, Crisp MJ, Kasten T, Kirmess KM et al (2018) Tau kinetics in neurons and the human central nervous system. Neuron 97: 1284&#x2013;1298</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6137722</ArticleId><ArticleId IdType="pubmed">29566794</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindler SE, Li Y, Todd KW, Herries EM, Henson RL, Gray JD, Wang G, Graham DL, Shaw LM, Trojanowski JQ et al (2019) Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer&#x2019;s disease. Alzheimers Dement 15: 655&#x2013;665</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6511459</ArticleId><ArticleId IdType="pubmed">30846386</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;ll M, Maass A, Mattsson N, Ashton NJ, Blennow K, Zetterberg H, Jagust W (2019) Biomarkers for tau pathology. Mol Cell Neurosci 97: 18&#x2013;33</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6584358</ArticleId><ArticleId IdType="pubmed">30529601</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, Vanderstichele H, Knapik&#x2010;Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P et al (2009) Cerebrospinal fluid biomarker signature in Alzheimer&#x2019;s disease neuroimaging initiative subjects. Ann Neurol 65: 403&#x2013;413</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696350</ArticleId><ArticleId IdType="pubmed">19296504</ArticleId></ArticleIdList></Reference><Reference><Citation>Sim&#xf3;n D, Garc&#xed;a&#x2010;Garc&#xed;a E, Royo F, Falc&#xf3;n&#x2010;P&#xe9;rez JM, Avila J (2012) Proteostasis of tau. Tau overexpression results in its secretion via membrane vesicles. FEBS Lett 586: 47&#x2013;54</Citation><ArticleIdList><ArticleId IdType="pubmed">22138183</ArticleId></ArticleIdList></Reference><Reference><Citation>Singer D, Soininen H, Alafuzoff I, Hoffmann R (2009) Immuno&#x2010;PCR&#x2010;based quantification of multiple phosphorylated tau&#x2010;epitopes linked to Alzheimer&#x2019;s disease. Anal Bioanal Chem 395: 2263&#x2013;2267</Citation><ArticleIdList><ArticleId IdType="pubmed">19821112</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiegel J, Pirraglia E, Osorio RS, Glodzik L, Li Y, Tsui W, Saint Louis LA, Randall C, Butler T, Xu J et al (2015) Greater specificity for cerebrospinal fluid P&#x2010;tau231 over P&#x2010;tau181 in the differentiation of healthy controls from Alzheimer&#x2019;s disease. J Alzheimer&#x2019;s Dis 49: 93&#x2013;100</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4694576</ArticleId><ArticleId IdType="pubmed">26444757</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutphen CL, McCue L, Herries EM, Xiong C, Ladenson JH, Holtzman DM, Fagan AM (2018) Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer&#x2019;s disease. Alzheimers Dement 14: 869&#x2013;879</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6110083</ArticleId><ArticleId IdType="pubmed">29580670</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatebe H, Kasai T, Ohmichi T, Kishi Y, Kakeya T, Waragai M, Kondo M, Allsop D, Tokuda T (2017) Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case&#x2010;control studies including patients with Alzheimer&#x2019;s disease and down syndrome. Mol Neurodegener 12: 63</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5582385</ArticleId><ArticleId IdType="pubmed">28866979</ArticleId></ArticleIdList></Reference><Reference><Citation>Thijssen EH, La Joie R, Wolf A, Strom A, Wang P, Iaccarino L, Bourakova V, Cobigo Y, Heuer H, Spina S et al (2020) Diagnostic value of plasma phosphorylated tau181 in Alzheimer&#x2019;s disease and frontotemporal lobar degeneration. Nat Med 26: 387&#x2013;397</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7101073</ArticleId><ArticleId IdType="pubmed">32123386</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo JB, Xie SX, Trojanowski JQ, Shaw LM (2013) Longitudinal change in CSF Tau and A&#x3b2; biomarkers for up to 48 months in ADNI. Acta Neuropathol 126: 659&#x2013;670</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3875373</ArticleId><ArticleId IdType="pubmed">23812320</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Van Der Perre B, Sj&#xf6;gren M, Andreasen N, Blennow K (2000) Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 285: 49&#x2013;52</Citation><ArticleIdList><ArticleId IdType="pubmed">10788705</ArticleId></ArticleIdList></Reference><Reference><Citation>De Vos A, Jacobs D, Van den Abbeele L, Stoops E, Mauroo K, Bjerke M, Engelborghs S, Vanderstichele H, Vanmechelen E (2016) A novel conformational, phospho&#x2010;Threonine 231 specific assay for CSF protein tau. J Prev Alzheimer&#x2019;s Dis 1: 319</Citation></Reference><Reference><Citation>Wang H, Wang T, Qian S, Ba L, Lin Z, Xiao S (2016) A pilot longitudinal study on cerebrospinal fluid (CSF) Tau protein in Alzheimer&#x2019;s disease and vascular dementia. Shanghai Arch Psychiatr 28: 271&#x2013;279</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5434283</ArticleId><ArticleId IdType="pubmed">28638201</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33169029</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>08</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>12</Issue><PubDate><Year>2020</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Tau accumulation in astrocytes of the dentate gyrus induces neuronal dysfunction and memory deficits in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>1567</StartPage><EndPage>1579</EndPage><MedlinePgn>1567-1579</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41593-020-00728-x</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is characterized by the accumulation of the tau protein in neurons, neurodegeneration and memory loss. However, the role of non-neuronal cells in this chain of events remains unclear. In the present study, we found accumulation of tau in hilar astrocytes of the dentate gyrus of individuals with AD. In mice, the overexpression of 3R tau specifically in hilar astrocytes of the dentate gyrus altered mitochondrial dynamics and function. In turn, these changes led to a reduction of adult neurogenesis, parvalbumin-expressing neurons, inhibitory synapses and hilar gamma oscillations, which were accompanied by impaired spatial memory performances. Together, these results indicate that the loss of tau homeostasis in hilar astrocytes of the dentate gyrus is sufficient to induce AD-like symptoms, through the impairment of the neuronal network. These results are important for our understanding of disease mechanisms and underline the crucial role of astrocytes in hippocampal function.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Richetin</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-7859-9517</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Center for Psychiatric Neurosciences, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland. kevin.richetin@chuv.ch.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Neurotherapies and Neuromodulation, Neuroscience Research Center (CRN), Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland. kevin.richetin@chuv.ch.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Neuroscience (DNC), Laboratory of Neurotherapies and Neuromodulation, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland. kevin.richetin@chuv.ch.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steullet</LastName><ForeName>Pascal</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Center for Psychiatric Neurosciences, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pachoud</LastName><ForeName>Mathieu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory of Neurotherapies and Neuromodulation, Neuroscience Research Center (CRN), Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Neuroscience (DNC), Laboratory of Neurotherapies and Neuromodulation, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perbet</LastName><ForeName>Romain</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-5974-4061</Identifier><AffiliationInfo><Affiliation>Univ. Lille, Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience &amp; Cognition, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parietti</LastName><ForeName>Enea</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Center for Psychiatric Neurosciences, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maheswaran</LastName><ForeName>Mathischan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory of Neurotherapies and Neuromodulation, Neuroscience Research Center (CRN), Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Neuroscience (DNC), Laboratory of Neurotherapies and Neuromodulation, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eddarkaoui</LastName><ForeName>Sabiha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Univ. Lille, Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience &amp; Cognition, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>B&#xe9;gard</LastName><ForeName>S&#xe9;verine</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Univ. Lille, Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience &amp; Cognition, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pythoud</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Laboratory of Neurotherapies and Neuromodulation, Neuroscience Research Center (CRN), Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Neuroscience (DNC), Laboratory of Neurotherapies and Neuromodulation, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rey</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory of Neurotherapies and Neuromodulation, Neuroscience Research Center (CRN), Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Neuroscience (DNC), Laboratory of Neurotherapies and Neuromodulation, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caillierez</LastName><ForeName>Rapha&#xeb;lle</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Univ. Lille, Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience &amp; Cognition, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Q Do</LastName><ForeName>Kim</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-1968-1646</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Center for Psychiatric Neurosciences, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Halliez</LastName><ForeName>Sophie</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-6173-9752</Identifier><AffiliationInfo><Affiliation>Univ. Lille, Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience &amp; Cognition, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bezzi</LastName><ForeName>Paola</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-8279-3600</Identifier><AffiliationInfo><Affiliation>Department of Fundamental Neurosciences, University of Lausanne, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bu&#xe9;e</LastName><ForeName>Luc</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-6261-4230</Identifier><AffiliationInfo><Affiliation>Univ. Lille, Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience &amp; Cognition, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leuba</LastName><ForeName>Genevi&#xe8;ve</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Center for Psychiatric Neurosciences, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colin</LastName><ForeName>Morvane</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Univ. Lille, Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience &amp; Cognition, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Toni</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-5585-268X</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Center for Psychiatric Neurosciences, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland. nicolas.toni@unil.ch.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>D&#xe9;glon</LastName><ForeName>Nicole</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0003-4475-9476</Identifier><AffiliationInfo><Affiliation>Laboratory of Neurotherapies and Neuromodulation, Neuroscience Research Center (CRN), Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Neuroscience (DNC), Laboratory of Neurotherapies and Neuromodulation, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>11</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010320">Parvalbumins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030801" MajorTopicYN="N">Animals, Genetically Modified</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018891" MajorTopicYN="N">Dentate Gyrus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009415" MajorTopicYN="N">Nerve Net</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055495" MajorTopicYN="N">Neurogenesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010320" MajorTopicYN="N">Parvalbumins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011597" MajorTopicYN="N">Psychomotor Performance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065852" MajorTopicYN="N">Spatial Memory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>9</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>11</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>11</Month><Day>10</Day><Hour>5</Hour><Minute>45</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33169029</ArticleId><ArticleId IdType="doi">10.1038/s41593-020-00728-x</ArticleId><ArticleId IdType="pii">10.1038/s41593-020-00728-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Buee, L. et al. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res. Rev. 33, 95&#x2013;130 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10967355</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams, S. J., de Ture, M. A., McBride, M., Dickson, D. W. &amp; Petrucelli, L. Three repeat isoforms of tau inhibit assembly of four repeat tau filaments. PLoS ONE 5, e10810 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20520830</ArticleId><ArticleId IdType="pmc">2876030</ArticleId></ArticleIdList></Reference><Reference><Citation>Panda, D., Samuel, J. C., Massie, M., Feinstein, S. C. &amp; Wilson, L. Differential regulation of microtubule dynamics by three- and four-repeat tau: implications for the onset of neurodegenerative disease. Proc. Natl Acad. Sci. USA 100, 9548&#x2013;9553 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12886013</ArticleId><ArticleId IdType="pmc">170955</ArticleId></ArticleIdList></Reference><Reference><Citation>Conrad, C. C. et al. Single-molecule profiling of tau gene expression in Alzheimer&#x2019;s disease. J. Neurochem. 103, 1228&#x2013;1236 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17727636</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton, L. K. et al. Aberrant lipid metabolism in the forebrain niche suppresses adult neural stem cell proliferation in an animal model of Alzheimer&#x2019;s disease. Cell Stem Cell 17, 397&#x2013;411 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26321199</ArticleId></ArticleIdList></Reference><Reference><Citation>Santello, M., Toni, N. &amp; Volterra, A. Astrocyte function from information processing to cognition and cognitive impairment. Nat. Neurosci. 22, 154&#x2013;166 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30664773</ArticleId></ArticleIdList></Reference><Reference><Citation>Bu&#xe9;e-Scherrer, V. et al. AD2, a phosphorylation-dependent monoclonal antibody directed against tau proteins found in Alzheimer&#x2019;s disease. Mol. Brain. Res. 39, 79&#x2013;88 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8804716</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs, GaborG. et al. Aging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy. Acta Neuropathol. 2, 87&#x2013;102 (2015).</Citation></Reference><Reference><Citation>Bereczki, E. et al. Synaptic proteins predict cognitive decline in Alzheimer&#x2019;s disease and Lewy body dementia. Alzheimers Dement. 12, 1149&#x2013;1158 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27224930</ArticleId></ArticleIdList></Reference><Reference><Citation>Savioz, A., Leuba, G. &amp; Vallet, P. G. A framework to understand the variations of PSD-95 expression in brain aging and in Alzheimer&#x2019;s disease. Ageing Res. Rev. 18, 86&#x2013;94 (2015).</Citation></Reference><Reference><Citation>Boutajangout, A., Boom, A., Leroy, K. &amp; Brion, J. P. Expression of tau mRNA and soluble tau isoforms in affected and non-affected brain areas in Alzheimer&#x2019;s disease. FEBS Lett. 576, 183&#x2013;189 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15474035</ArticleId></ArticleIdList></Reference><Reference><Citation>Dujardin, S. et al. Neuron-to-neuron wild-type tau protein transfer through a trans-synaptic mechanism: relevance to sporadic tauopathies. Acta Neuropathol. Commun. 2, 14 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24479894</ArticleId><ArticleId IdType="pmc">3922636</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng, Y. &amp; Bai, F. The association of tau with mitochondrial dysfunction in Alzheimer&#x2019;s disease. Front. Neurosci. 12, 2014&#x2013;2019 (2018).</Citation></Reference><Reference><Citation>Gottlieb, R. A. &amp; Stotland, A. MitoTimer: a novel protein for monitoring mitochondrial turnover in the heart. J. Mol. Med. 93, 271&#x2013;278 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25479961</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisner, V., Picard, M. &amp; Hajn&#xf3;czky, G. Mitochondrial dynamics in adaptive and maladaptive cellular stress responses. Nat. Cell Biol. 20, 755&#x2013;765 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29950571</ArticleId><ArticleId IdType="pmc">6716149</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal, A. et al. Transient opening of the mitochondrial permeability transition pore induces microdomain calcium transients in astrocyte processes. Neuron 93, 587&#x2013;605 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28132831</ArticleId><ArticleId IdType="pmc">5308886</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakano, M., Imamura, H., Nagai, T. &amp; Noji, H. Ca<sup>2+</sup> regulation of mitochondrial ATP synthesis visualized at the single cell level. ACS Chem. Biol. 6, 709&#x2013;715 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21488691</ArticleId></ArticleIdList></Reference><Reference><Citation>Sultan, S. et al. Synaptic integration of adult-born hippocampal neurons is locally controlled by astrocytes. Neuron 88, 957&#x2013;972 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26606999</ArticleId></ArticleIdList></Reference><Reference><Citation>Crosby, K. C. et al. Nanoscale subsynaptic domains underlie the organization of the inhibitory synapse. Cell Rep. 26, 3284&#x2013;3297 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30893601</ArticleId><ArticleId IdType="pmc">6529211</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardin, J. A. et al. Driving fast-spiking cells induces gamma rhythm and controls sensory responses. Nature 459, 663&#x2013;667 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19396156</ArticleId><ArticleId IdType="pmc">3655711</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xf6;schel, B., Heinemann, U. &amp; Draguhn, A. High-frequency oscillations in the dentate gyrus of rat hippocampal slices induced by tetanic stimulation. Brain Res. 959, 320&#x2013;327 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12493621</ArticleId></ArticleIdList></Reference><Reference><Citation>Towers, S. K. et al. Fast network oscillations in the rat dentate gyrus in vitro. J. Neurophysiol. 87, 1165&#x2013;1168 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11826085</ArticleId></ArticleIdList></Reference><Reference><Citation>Espinoza, C., Guzman, S. J., Zhang, X. &amp; Jonas, P. Parvalbumin<sup>+</sup> interneurons obey unique connectivity rules and establish a powerful lateral-inhibition microcircuit in dentate gyrus. Nat. Commun. 9, 4605 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30389916</ArticleId><ArticleId IdType="pmc">6214995</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillespie, A. K. et al. Apolipoprotein E4 causes age-dependent disruption of slow gamma oscillations during hippocampal sharp-wave ripples. Neuron 90, 740&#x2013;751 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27161522</ArticleId><ArticleId IdType="pmc">5097044</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu, H., Gan, J. &amp; Jonas, P. Fast-spiking, parvalbumin<sup>+</sup> GABAergic interneurons: from cellular design to microcircuit function. Science 345, 1255263 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25082707</ArticleId></ArticleIdList></Reference><Reference><Citation>Marissal, T. et al. Restoring wild-type-like CA1 network dynamics and behavior during adulthood in a mouse model of schizophrenia. Nat. Neurosci. 21, 1412&#x2013;1420 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30224804</ArticleId><ArticleId IdType="pmc">6978142</ArticleId></ArticleIdList></Reference><Reference><Citation>LoPresti, P., Szuchet, S., Papasozomenos, S. C., Zinkowski, R. P. &amp; Binder, L. I. Functional implications for the microtubule-associated protein tau: localization in oligodendrocytes. Proc. Natl Acad. Sci. USA 92, 10369&#x2013;10373 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7479786</ArticleId><ArticleId IdType="pmc">40798</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller, R., Heinrich, M., Heck, S., Blohm, D. &amp; Richter-Landsberg, C. Expression of microtubule-asssciated proteins MAP2 and tau in cultured rat brain oligodendrocytes. Cell Tissue Res. 288, 239&#x2013;249 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9082959</ArticleId></ArticleIdList></Reference><Reference><Citation>Boisvert, M. M., Erikson, G. A., Shokhirev, M. N. &amp; Allen, N. J. The aging astrocyte transcriptome from multiple regions of the mouse brain. Cell Rep. 22, 269&#x2013;285 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29298427</ArticleId><ArticleId IdType="pmc">5783200</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada, K. et al. In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. J. Neurosci. 31, 13110&#x2013;13117 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21917794</ArticleId><ArticleId IdType="pmc">4299126</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders, D. W. et al. Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron https://doi.org/10.1016/j.neuron.2014.04.047 (2014)</Citation></Reference><Reference><Citation>Perea, J. R. et al. Extracellular monomeric tau is internalized by astrocytes. Front. Neurosci. 13, 442 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31118883</ArticleId><ArticleId IdType="pmc">6504834</ArticleId></ArticleIdList></Reference><Reference><Citation>Dujardin, S. et al. Ectosomes: a new mechanism for non-exosomal secretion of tau protein. PLoS ONE 9, 28&#x2013;31 (2014).</Citation></Reference><Reference><Citation>Goetzl, E. J. et al. Cargo proteins of plasma astrocyte-derived exosomes in Alzheimer&#x2019;s disease. FASEB J. 30, 3853&#x2013;3859 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27511944</ArticleId><ArticleId IdType="pmc">5067254</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, Y. &amp; Mandelkow, E. Tau in physiology and pathology. Nat. Rev. Neurosci. 17, 5&#x2013;21 (2016).</Citation></Reference><Reference><Citation>Ferrer, I. et al. Aging-related tau astrogliopathy (ARTAG): not only tau phosphorylation in astrocytes. Brain Pathol. 28, 965&#x2013;985 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29396893</ArticleId><ArticleId IdType="pmc">8028270</ArticleId></ArticleIdList></Reference><Reference><Citation>Goode, B. L., Chau, M., Denis, P. E. &amp; Feinstein, S. C. Structural and functional differences between 3-repeat and 4-repeat tau isoforms: implications for normal tau function and the onset of neurodegenerative disease. J. Biol. Chem. 275, 38182&#x2013;38189 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10984497</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixit, R., Ross, J. L., Goldman, Y. E. &amp; Holzbaur, E. L. F. Differential regulation of dynein and Kinesin motor proteins by tau. Science 319, 1086&#x2013;1089 (2010).</Citation></Reference><Reference><Citation>Amadoro, G. et al. AD-linked, toxic NH2 human tau affects the quality control of mitochondria in neurons. Neurobiol. Dis. 62, 489&#x2013;507 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24411077</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama, Y., Zhang, B., Bruce, J., Trojanowski, J. Q. &amp; Lee, V. M.-Y. Reduction of detyrosinated microtubules and Golgi fragmentation are linked to tau-induced degeneration in astrocytes. J. Neurosci. 23, 10662&#x2013;10671 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">14627651</ArticleId><ArticleId IdType="pmc">6740917</ArticleId></ArticleIdList></Reference><Reference><Citation>van Bergeijk, P., Adrian, M., Hoogenraad, C. C. &amp; Kapitein, L. C. Optogenetic control of organelle transport and positioning. Nature 518, 111&#x2013;114 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25561173</ArticleId><ArticleId IdType="pmc">5063096</ArticleId></ArticleIdList></Reference><Reference><Citation>Forman, M. S. Transgenic mouse model of tau pathology in astrocytes leading to nervous system degeneration. J. Neurosci. 25, 3539&#x2013;3550 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15814784</ArticleId><ArticleId IdType="pmc">6725385</ArticleId></ArticleIdList></Reference><Reference><Citation>Piacentini, R. et al. Reduced gliotransmitter release from astrocytes mediates tau-induced synaptic dysfunction in cultured hippocampal neurons. Glia 65, 1302&#x2013;1316 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28519902</ArticleId><ArticleId IdType="pmc">5520670</ArticleId></ArticleIdList></Reference><Reference><Citation>Whalley, K. Neurodegenerative disease: spreading the tau. Nat. Rev. Neurosci. 10, 548&#x2013;548 (2009).</Citation></Reference><Reference><Citation>Hainmueller, T. &amp; Bartos, M. Dentate gyrus circuits for encoding, retrieval and discrimination of episodic memories. Nat. Rev. Neurosci. 21, 1&#x2013;16 (2020).</Citation></Reference><Reference><Citation>Cope, E. C. &amp; Gould, E. Adult neurogenesis, glia and the extracellular matrix. Cell Stem Cell 24, 690&#x2013;705 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31051133</ArticleId><ArticleId IdType="pmc">7961263</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-Jim&#xe9;nez, E. P. et al. Adult hippocampal neurogenesis is abundant in neurologically healthy subjects and drops sharply in patients with Alzheimer&#x2019;s disease. Nat. Med. 25, 554&#x2013;560 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30911133</ArticleId></ArticleIdList></Reference><Reference><Citation>Toda, T., Parylak, S. L., Linker, S. B. &amp; Gage, F. H. The role of adult hippocampal neurogenesis in brain health and disease. Mol. Psychiatry https://doi.org/10.1038/s41380-018-0036-2 (2018)</Citation></Reference><Reference><Citation>Sohal, V. S., Zhang, F., Yizhar, O. &amp; Deisseroth, K. Parvalbumin neurons and gamma rhythms enhance cortical circuit performance. Nature 459, 698&#x2013;702 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19396159</ArticleId><ArticleId IdType="pmc">3969859</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazargani, N. &amp; Attwell, D. Astrocyte calcium signaling: the third wave. Nat. Neurosci. 19, 182&#x2013;189 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26814587</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak, H. &amp; Braak, E. Morphology of Alzheimer disease. Fortschr. Med. 108, 624&#x2013;624 (1990).</Citation></Reference><Reference><Citation>Braak, H. &amp; Braak, E. Staging of Alzheimer&#x2019;s disease-related neurofibrillary changes. Neurobiol. Aging 16, 271&#x2013;278 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7566337</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H. &amp; Tredici, K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. https://doi.org/10.1007/s00401-006-0127-z (2006).</Citation></Reference><Reference><Citation>Flor-Garc&#xed;a, M. et al. Unraveling human adult hippocampal neurogenesis. Nat. Protoc. 15, 668&#x2013;693 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31915385</ArticleId></ArticleIdList></Reference><Reference><Citation>Richetin, K. et al. Amplifying mitochondrial function rescues adult neurogenesis in a mouse model of Alzheimer&#x2019;s disease. Neurobiol. Dis. 102, 113&#x2013;124 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28286181</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, Y., Messing, A., Su, M. &amp; Brenner, M. GFAP promoter elements required for region-specific and astrocyte-specific expression. Glia 56, 481&#x2013;493 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18240313</ArticleId></ArticleIdList></Reference><Reference><Citation>De Leeuw, B. et al. Increased glia-specific transgene expression with glial fibrillary acidic protein promoters containing multiple enhancer elements. J. Neurosci. Res. 83, 744&#x2013;753 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16496373</ArticleId></ArticleIdList></Reference><Reference><Citation>Merienne, N. et al. Gene transfer engineering for astrocyte-specific silencing in the CNS. Gene Ther. https://doi.org/10.1038/gt.2015.54 (2015)</Citation></Reference><Reference><Citation>Colin, A. et al. Engineered lentiviral vector targeting astrocytes in vivo. Glia 57, 667&#x2013;679 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">18942755</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xe9;glon, N. et al. Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson&#x2019;s disease. Hum. Gene Ther. 11, 179&#x2013;190 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10646649</ArticleId></ArticleIdList></Reference><Reference><Citation>Sirven, A. et al. The human immunodeficiency virus type-1 central DNA flap is a crucial determinant for lentiviral vector nuclear import and gene transduction of human hematopoietic stem cells. Blood 96, 4103&#x2013;4110 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">11110680</ArticleId></ArticleIdList></Reference><Reference><Citation>Zufferey, R. et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J. Virol. 72, 9873&#x2013;9880 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9811723</ArticleId><ArticleId IdType="pmc">110499</ArticleId></ArticleIdList></Reference><Reference><Citation>Lobbestael, E. et al. Immunohistochemical detection of transgene expression in the brain using small epitope tags. BMC Biotechnol. 10, 16 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20167102</ArticleId><ArticleId IdType="pmc">2831034</ArticleId></ArticleIdList></Reference><Reference><Citation>Terskikh, A. et al. &#x2018;Fluorescent timer&#x2019;: protein that changes color with time. Science 290, 1585&#x2013;1588 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">11090358</ArticleId></ArticleIdList></Reference><Reference><Citation>Hottinger, A. F., Azzouz, M., D&#xe9;glon, N., Aebischer, P. &amp; Zurn, A. D. Complete and long-term rescue of lesioned adult motoneurons by lentiviral-mediated expression of glial cell line-derived neurotrophic factor in the facial nucleus. J. Neurosci. 20, 5587&#x2013;5593 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10908595</ArticleId><ArticleId IdType="pmc">6772542</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaech, S. &amp; Banker, G. Culturing hippocampal neurons. Nat. Protoc. 1, 2406&#x2013;2415 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17406484</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi, H. et al. Nuclear magnetic resonance spectroscopy characterization of interaction of tau with DNA and its regulation by phosphorylation. Biochemistry 54, 1525&#x2013;1533 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25623359</ArticleId></ArticleIdList></Reference><Reference><Citation>Jicha, G. A., Bowser, R., Kazam, I. G. &amp; Davies, P. Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau. J. Neurosci. Res. 48, 128&#x2013;132 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9130141</ArticleId></ArticleIdList></Reference><Reference><Citation>Richetin, K., Petsophonsakul, P., Roybon, L., Guiard, B. P. B. P. &amp; Rampon, C. Differential alteration of hippocampal function and plasticity in females and males of the APPxPS1 mouse model of Alzheimer&#x2019;s disease. Neurobiol. Aging 57, 220&#x2013;231 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28666707</ArticleId></ArticleIdList></Reference><Reference><Citation>Gebara, E. et al. Heterogeneity of radial glia-like cells in the adult hippocampus. Stem Cells 34, 997&#x2013;1010 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26729510</ArticleId><ArticleId IdType="pmc">5340291</ArticleId></ArticleIdList></Reference><Reference><Citation>Stogsdill, J. A. et al. Astrocytic neuroligins control astrocyte morphogenesis and synaptogenesis. Nature 551, 192&#x2013;197 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29120426</ArticleId><ArticleId IdType="pmc">5796651</ArticleId></ArticleIdList></Reference><Reference><Citation>Holcomb, L. A. et al. Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: lack of association with amyloid deposits. Behav. Genet. 29, 177&#x2013;185 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10547924</ArticleId></ArticleIdList></Reference><Reference><Citation>Wall, P. &amp; Messier, C. Infralimbic kappa opioid and muscarinic M1 receptor interactions in the concurrent modulation of anxiety and memory. Psychopharmacol. 160, 233&#x2013;244 (2002).</Citation></Reference><Reference><Citation>Ennaceur, A., Neave, N. &amp; Aggleton, J. P. Spontaneous object recognition and object location memory in rats: the effects of lesions in the cingulate cortices, the medial prefrontal cortex, the cingulum bundle and the fornix. Exp. Brain Res. 113, 509&#x2013;519 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9108217</ArticleId></ArticleIdList></Reference><Reference><Citation>Ennaceur, A. &amp; Delacour, J. A new one-trial test for neurobiological studies of memory in rats. 1: behavioral data. Behav. Brain Res. 31, 47&#x2013;59 (1988).</Citation><ArticleIdList><ArticleId IdType="pubmed">3228475</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodart, J. C., Mathis, C. &amp; Ungerer, A. Scopolamine-induced deficits in a two-trial object recognition task in mice. Neuroreport 8, 1173&#x2013;1178 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9175108</ArticleId></ArticleIdList></Reference><Reference><Citation>Richetin, K. et al. Genetic manipulation of adult-born hippocampal neurons rescues memory in a mouse model of Alzheimer&#x2019;s disease. Brain 138, 440&#x2013;455 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25518958</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33165506</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>11</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>78</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease.</ArticleTitle><Pagination><StartPage>149</StartPage><EndPage>156</EndPage><MedlinePgn>149-156</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2020.4201</ELocationID><Abstract><AbstractText Label="IMPORTANCE">There is an urgent need for inexpensive and minimally invasive blood biomarkers for Alzheimer disease (AD) that could be used to detect early disease changes.</AbstractText><AbstractText Label="OBJECTIVE">To assess how early in the course of AD plasma levels of tau phosphorylated at threonine 217 (P-tau217) start to change compared with levels of established cerebrospinal fluid (CSF) and positron emission tomography (PET) biomarkers of AD pathology.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This cohort study included cognitively healthy control individuals (n&#x2009;=&#x2009;225) and participants with subjective cognitive decline (n&#x2009;=&#x2009;89) or mild cognitive impairment (n&#x2009;=&#x2009;176) from the BioFINDER-2 study. Participants were enrolled at 2 different hospitals in Sweden from January 2017 to October 2019. All study participants underwent plasma P-tau217 assessments and tau- and amyloid-&#x3b2; (A&#x3b2;)-PET imaging. A subcohort of 111 participants had 2 or 3 tau-PET scans.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Changes in plasma P-tau217 levels in preclinical and prodromal AD compared with changes in CSF P-tau217 and PET measures.</AbstractText><AbstractText Label="RESULTS">Of 490 participants, 251 were women (51.2%) and the mean (SD) age was 65.9 (13.1) years. Plasma P-tau217 levels were increased in cognitively unimpaired participants with abnormal A&#x3b2;-PET but normal tau-PET in the entorhinal cortex (A&#x3b2;-PET+/ tau-PET- group vs A&#x3b2;-PET-/ tau-PET- group: median, 2.2 pg/mL [interquartile range (IQR), 1.5-2.9 pg/mL] vs 0.7 pg/mL [IQR, 0.3-1.4 pg/mL]). Most cognitively unimpaired participants who were discordant for plasma P-tau217 and tau-PET were positive for plasma P-tau217 and negative for tau-PET (P-tau217+/tau-PET-: 36 [94.7%]; P-tau217-/tau-PET+: 2 [5.3%]). Event-based modeling of cross-sectional data predicted that in cognitively unimpaired participants and in those with mild cognitive impairment, both plasma and CSF P-tau217 would change before the tau-PET signal in the entorhinal cortex, followed by more widespread cortical tau-PET changes. When testing the association with global A&#x3b2; load in nonlinear spline models, both plasma and CSF P-tau217 were increased at lower A&#x3b2;-PET values compared with tau-PET measures. Among participants with normal baseline tau-PET, the rates of longitudinal increase in tau-PET in the entorhinal cortex were higher in those with abnormal plasma P-tau217 at baseline (median standardized uptake value ratio, 0.029 [IQR, -0.006 to 0.041] vs -0.001 [IQR, -0.021 to 0.020]; Mann-Whitney U, P&#x2009;=&#x2009;.02).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">In this cohort study, plasma P-tau217 levels were increased during the early preclinical stages of AD when insoluble tau aggregates were not yet detectable by tau-PET. Plasma P-tau217 may hold promise as a biomarker for early AD brain pathology.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Janelidze</LastName><ForeName>Shorena</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences Malm&#xf6;, Lund University, S&#xf6;lvegatan, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berron</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences Malm&#xf6;, Lund University, S&#xf6;lvegatan, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Ruben</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences Malm&#xf6;, Lund University, S&#xf6;lvegatan, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Sk&#xe5;ne University Hospital, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strandberg</LastName><ForeName>Olof</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences Malm&#xf6;, Lund University, S&#xf6;lvegatan, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Proctor</LastName><ForeName>Nicholas K</ForeName><Initials>NK</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, Indiana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dage</LastName><ForeName>Jeffrey L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, Indiana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stomrud</LastName><ForeName>Erik</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences Malm&#xf6;, Lund University, S&#xf6;lvegatan, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Clinic, Sk&#xe5;ne University Hospital, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palmqvist</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences Malm&#xf6;, Lund University, S&#xf6;lvegatan, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Clinic, Sk&#xe5;ne University Hospital, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mattsson-Carlgren</LastName><ForeName>Niklas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences Malm&#xf6;, Lund University, S&#xf6;lvegatan, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Sk&#xe5;ne University Hospital, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wallenberg Center for Molecular Medicine, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hansson</LastName><ForeName>Oskar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences Malm&#xf6;, Lund University, S&#xf6;lvegatan, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Clinic, Sk&#xe5;ne University Hospital, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2021 Feb 1;78(2):143-145. doi: 10.1001/jamaneurol.2020.4200.</RefSource><PMID Version="1">33165524</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042241" MajorTopicYN="N">Early Diagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013548" MajorTopicYN="N" Type="Geographic">Sweden</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Berron reported being a cofounder of neotiv GmbH outside the submitted work. Mr Proctor reported being an employee and stockholder of Eli Lilly and Company. Dr Dage reported being an employee and stockholder of Eli Lilly and Company. Dr Hansson reported receiving grants from the Swedish Research Council, the Knut and Alice Wallenberg Foundation, Roche, and Biogen; receiving financial support from GE Healthcare outside the submitted work; receiving research support from Roche, Pfizer, GE Healthcare, Biogen, Eli Lilly and Company, and AVID Radiopharmaceuticals; and receiving consultancy and speaker fees (paid to the institution) from Biogen and Roche. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>11</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>11</Month><Day>9</Day><Hour>14</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>11</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33165506</ArticleId><ArticleId IdType="pmc">PMC7653537</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2020.4201</ArticleId><ArticleId IdType="pii">2772866</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Scheltens P, Blennow K, Breteler MM, et al. . Alzheimer&#x2019;s disease. Lancet. 2016;388(10043):505-517. doi:10.1016/S0140-6736(15)01124-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(15)01124-1</ArticleId><ArticleId IdType="pubmed">26921134</ArticleId></ArticleIdList></Reference><Reference><Citation>Beach TG, Monsell SE, Phillips LE, Kukull W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J Neuropathol Exp Neurol. 2012;71(4):266-273. doi:10.1097/NEN.0b013e31824b211b</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e31824b211b</ArticleId><ArticleId IdType="pmc">PMC3331862</ArticleId><ArticleId IdType="pubmed">22437338</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Bennett DA, Blennow K, et al. ; NIA-AA research framework: toward a biological definition of Alzheimer&#x2019;s disease. Alzheimers Dement. 2018;14(4):535-562. doi:10.1016/j.jalz.2018.02.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.02.018</ArticleId><ArticleId IdType="pmc">PMC5958625</ArticleId><ArticleId IdType="pubmed">29653606</ArticleId></ArticleIdList></Reference><Reference><Citation>Mielke MM, Hagen CE, Xu J, et al. . Plasma phospho-tau181 increases with Alzheimer&#x2019;s disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimers Dement. 2018;14(8):989-997. doi:10.1016/j.jalz.2018.02.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.02.013</ArticleId><ArticleId IdType="pmc">PMC6097897</ArticleId><ArticleId IdType="pubmed">29626426</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatebe H, Kasai T, Ohmichi T, et al. . Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer&#x2019;s disease and Down syndrome. Mol Neurodegener. 2017;12(1):63. doi:10.1186/s13024-017-0206-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-017-0206-8</ArticleId><ArticleId IdType="pmc">PMC5582385</ArticleId><ArticleId IdType="pubmed">28866979</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang CC, Chiu MJ, Chen TF, Chang HL, Liu BH, Yang SY. Assay of plasma phosphorylated tau protein (threonine 181) and total tau protein in early-stage Alzheimer&#x2019;s disease. J Alzheimers Dis. 2018;61(4):1323-1332. doi:10.3233/JAD-170810</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-170810</ArticleId><ArticleId IdType="pubmed">29376870</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, Mattsson N, Palmqvist S, et al. . Plasma P-tau181 in Alzheimer&#x2019;s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer&#x2019;s dementia. Nat Med. 2020;26(3):379-386. doi:10.1038/s41591-020-0755-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0755-1</ArticleId><ArticleId IdType="pubmed">32123385</ArticleId></ArticleIdList></Reference><Reference><Citation>Thijssen EH, La Joie R, Wolf A, et al. ; Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) Investigators . Diagnostic value of plasma phosphorylated tau181 in Alzheimer&#x2019;s disease and frontotemporal lobar degeneration. Nat Med. 2020;26(3):387-397. doi:10.1038/s41591-020-0762-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0762-2</ArticleId><ArticleId IdType="pmc">PMC7101073</ArticleId><ArticleId IdType="pubmed">32123386</ArticleId></ArticleIdList></Reference><Reference><Citation>Barth&#xe9;lemy NR, Bateman RJ, Hirtz C, et al. . Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer&#x2019;s disease and PET amyloid-positive patient identification. Alzheimers Res Ther. 2020;12(1):26. doi:10.1186/s13195-020-00596-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-020-00596-4</ArticleId><ArticleId IdType="pmc">PMC7079453</ArticleId><ArticleId IdType="pubmed">32183883</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, Stomrud E, Smith R, et al. . Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer&#x2019;s disease. Nat Commun. 2020;11(1):1683. doi:10.1038/s41467-020-15436-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-15436-0</ArticleId><ArticleId IdType="pmc">PMC7125218</ArticleId><ArticleId IdType="pubmed">32246036</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Insel PS, Stomrud E, et al. . Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer&#x2019;s disease. EMBO Mol Med. 2019;11(12):e11170. doi:10.15252/emmm.201911170</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201911170</ArticleId><ArticleId IdType="pmc">PMC6895602</ArticleId><ArticleId IdType="pubmed">31709776</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Janelidze S, Quiroz YT, et al. . Discriminative accuracy of plasma phospho-tau 217 for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2020;324(8):772-781. doi:10.1001/jama.2020.12134</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12134</ArticleId><ArticleId IdType="pmc">PMC7388060</ArticleId><ArticleId IdType="pubmed">32722745</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Sch&#xf6;ll M, Strandberg O, et al. . 18F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer&#x2019;s disease. EMBO Mol Med. 2017;9(9):1212-1223. doi:10.15252/emmm.201707809</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201707809</ArticleId><ArticleId IdType="pmc">PMC5582410</ArticleId><ArticleId IdType="pubmed">28743782</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson-Carlgren N, Andersson E, Janelidze S, et al. . A&#x3b2; deposition is associated with increases in soluble and phosphorylated tau that precede a positive tau PET in Alzheimer&#x2019;s disease. Sci Adv. 2020;6(16):eaaz2387. doi:10.1126/sciadv.aaz2387</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.aaz2387</ArticleId><ArticleId IdType="pmc">PMC7159908</ArticleId><ArticleId IdType="pubmed">32426454</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer PF, Pichet Binette A, Gonneaud J, Breitner JCS, Villeneuve S. Characterization of Alzheimer disease biomarker discrepancies using cerebrospinal fluid phosphorylated tau and AV1451 positron emission tomography. JAMA Neurol. 2020;77(4):508-516. doi:10.1001/jamaneurol.2019.4749</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.4749</ArticleId><ArticleId IdType="pmc">PMC6990861</ArticleId><ArticleId IdType="pubmed">31961372</ArticleId></ArticleIdList></Reference><Reference><Citation>Bejanin A, Schonhaut DR, La Joie R, et al. . Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer&#x2019;s disease. Brain. 2017;140(12):3286-3300. doi:10.1093/brain/awx243</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awx243</ArticleId><ArticleId IdType="pmc">PMC5841139</ArticleId><ArticleId IdType="pubmed">29053874</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Smith R, Ohlsson T, et al. . Associations between tau, A&#x3b2;, and cortical thickness with cognition in Alzheimer disease. Neurology. 2019;92(6):e601-e612. doi:10.1212/WNL.0000000000006875</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000006875</ArticleId><ArticleId IdType="pmc">PMC6382060</ArticleId><ArticleId IdType="pubmed">30626656</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239-259. doi:10.1007/BF00308809</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00308809</ArticleId><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Janelidze S, Stomrud E, et al. . Performance of fully automated plasma assays as screening tests for Alzheimer disease-related &#x3b2;-amyloid status. JAMA Neurol. 2019;76(9):1060-1069. doi:10.1001/jamaneurol.2019.1632</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.1632</ArticleId><ArticleId IdType="pmc">PMC6593637</ArticleId><ArticleId IdType="pubmed">31233127</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6(3):131-144. doi:10.1038/nrneurol.2010.4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2010.4</ArticleId><ArticleId IdType="pubmed">20157306</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, Stomrud E, Brix B, Hansson O. Towards a unified protocol for handling of CSF before &#x3b2;-amyloid measurements. Alzheimers Res Ther. 2019;11(1):63. doi:10.1186/s13195-019-0517-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-019-0517-9</ArticleId><ArticleId IdType="pmc">PMC6642586</ArticleId><ArticleId IdType="pubmed">31324260</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuzy A, Smith R, Ossenkoppele R, et al. . Diagnostic performance of RO948 F 18 tau positron emission tomography in the differentiation of Alzheimer disease from other neurodegenerative disorders. JAMA Neurol. 2020;77(8):955-965. doi:10.1001/jamaneurol.2020.0989</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.0989</ArticleId><ArticleId IdType="pmc">PMC7215644</ArticleId><ArticleId IdType="pubmed">32391858</ArticleId></ArticleIdList></Reference><Reference><Citation>Young AL, Oxtoby NP, Daga P, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . A data-driven model of biomarker changes in sporadic Alzheimer&#x2019;s disease. Brain. 2014;137(Pt 9):2564-2577. doi:10.1093/brain/awu176</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awu176</ArticleId><ArticleId IdType="pmc">PMC4132648</ArticleId><ArticleId IdType="pubmed">25012224</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Xiong C, Jasielec MS, et al. ; Dominantly Inherited Alzheimer Network . Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer&#x2019;s disease. Sci Transl Med. 2014;6(226):226ra30. doi:10.1126/scitranslmed.3007901</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3007901</ArticleId><ArticleId IdType="pmc">PMC4038930</ArticleId><ArticleId IdType="pubmed">24598588</ArticleId></ArticleIdList></Reference><Reference><Citation>McDade E, Wang G, Gordon BA, et al. ; Dominantly Inherited Alzheimer Network . Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. Neurology. 2018;91(14):e1295-e1306. doi:10.1212/WNL.0000000000006277</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000006277</ArticleId><ArticleId IdType="pmc">PMC6177272</ArticleId><ArticleId IdType="pubmed">30217935</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzforum. In DIAN-TU, gantenerumab brings down tau. by a lot. open extension planned. Accessed October 3, 2020. https://www.alzforum.org/news/conference-coverage/dian-tu-gantenerumab-brings-down-tau-lot-open-extension-planned</Citation></Reference><Reference><Citation>Alzforum. Exposure, exposure, exposure? at CTAD, aducanumab scientists make a case. Accessed October 3, 2020. https://www.alzforum.org/news/conference-coverage/exposure-exposure-exposure-ctad-aducanumab-scientists-make-case</Citation></Reference><Reference><Citation>Sato C, Barthelemy NR, Mawuenyega KG, et al. Tau kinetics in neurons and the human central nervous system. Neuron. 2018;97(6):1284-1298.e7. doi:10.1016/j.neuron.2018.02.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.02.015</ArticleId><ArticleId IdType="pmc">PMC6137722</ArticleId><ArticleId IdType="pubmed">29566794</ArticleId></ArticleIdList></Reference><Reference><Citation>Stancu IC, Vasconcelos B, Terwel D, Dewachter I. Models of &#x3b2;-amyloid induced tau-pathology: the long and &#x201c;folded&#x201d; road to understand the mechanism. Mol Neurodegener. 2014;9:51. doi:10.1186/1750-1326-9-51</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-9-51</ArticleId><ArticleId IdType="pmc">PMC4255655</ArticleId><ArticleId IdType="pubmed">25407337</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33177178</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>23</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>569</Issue><PubDate><Year>2020</Year><Month>Nov</Month><Day>11</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>Amyloid-like oligomerization of AIMP2 contributes to &#x3b1;-synuclein interaction and Lewy-like inclusion.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">eaax0091</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.aax0091</ELocationID><Abstract><AbstractText>Lewy bodies are pathological protein inclusions present in the brain of patients with Parkinson's disease (PD). These inclusions consist mainly of &#x3b1;-synuclein with associated proteins, such as parkin and its substrate aminoacyl transfer RNA synthetase complex-interacting multifunctional protein-2 (AIMP2). Although AIMP2 has been suggested to be toxic to dopamine neurons, its roles in &#x3b1;-synuclein aggregation and PD pathogenesis are largely unknown. Here, we found that AIMP2 exhibits a self-aggregating property. The AIMP2 aggregate serves as a seed to increase &#x3b1;-synuclein aggregation via specific and direct binding to the &#x3b1;-synuclein monomer. The coexpression of AIMP2 and &#x3b1;-synuclein in cell cultures and in vivo resulted in the rapid formation of &#x3b1;-synuclein aggregates with a corresponding increase in toxicity. Moreover, accumulated AIMP2 in mouse brain was largely redistributed to insoluble fractions, correlating with the &#x3b1;-synuclein pathology. Last, we found that &#x3b1;-synuclein preformed fibril (PFF) seeding, adult <i>Parkin</i> deletion, or oxidative stress triggered a redistribution of both AIMP2 and &#x3b1;-synuclein into insoluble fraction in cells and in vivo. Supporting the pathogenic role of AIMP2, AIMP2 knockdown ameliorated the &#x3b1;-synuclein aggregation and dopaminergic cell death in response to PFF or 6-hydroxydopamine treatment. Together, our results suggest that AIMP2 plays a pathological role in the aggregation of &#x3b1;-synuclein in mice. Because AIMP2 insolubility and coaggregation with &#x3b1;-synuclein have been seen in the PD Lewy body, targeting pathologic AIMP2 aggregation might be useful as a therapeutic strategy for neurodegenerative &#x3b1;-synucleinopathies.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ham</LastName><ForeName>Sangwoo</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-4569-2584</Identifier><AffiliationInfo><Affiliation>Division of Pharmacology, Department of Molecular Cell Biology, Sungkyunkwan University School of Medicine, Samsung Biomedical Research Institute (SBRI), Suwon 16419, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>ToolGen Inc., Seoul 08501, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yun</LastName><ForeName>Seung Pil</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Hyojung</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-4970-3255</Identifier><AffiliationInfo><Affiliation>Division of Pharmacology, Department of Molecular Cell Biology, Sungkyunkwan University School of Medicine, Samsung Biomedical Research Institute (SBRI), Suwon 16419, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Donghoon</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seo</LastName><ForeName>Bo Am</ForeName><Initials>BA</Initials><Identifier Source="ORCID">0000-0001-9507-2362</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Heejeong</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-9801-5088</Identifier><AffiliationInfo><Affiliation>Division of Pharmacology, Department of Molecular Cell Biology, Sungkyunkwan University School of Medicine, Samsung Biomedical Research Institute (SBRI), Suwon 16419, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shin</LastName><ForeName>Jeong-Yong</ForeName><Initials>JY</Initials><Identifier Source="ORCID">0000-0002-9614-9955</Identifier><AffiliationInfo><Affiliation>Division of Pharmacology, Department of Molecular Cell Biology, Sungkyunkwan University School of Medicine, Samsung Biomedical Research Institute (SBRI), Suwon 16419, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dar</LastName><ForeName>Mohamad Aasif</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Gum Hwa</ForeName><Initials>GH</Initials><AffiliationInfo><Affiliation>College of Pharmacy, Chosun University, Gwangju 61452, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Yun Il</ForeName><Initials>YI</Initials><AffiliationInfo><Affiliation>Well Aging Research Center, DGIST, Daegu 42988, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Companion Diagnostics and Medical Technology Research Group, DGIST, Daegu 42988, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Doyeun</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Medicinal Bioconvergence Research Center, Yonsei University, Incheon 21983, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Pharmacy and School of Medicine, Yonsei University, Incheon 21983, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Sunghoon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Medicinal Bioconvergence Research Center, Yonsei University, Incheon 21983, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Pharmacy and School of Medicine, Yonsei University, Incheon 21983, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kweon</LastName><ForeName>Hee-Seok</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>Center for Research Equipment, Korea Basic Science Institute, Cheongju 28119, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shin</LastName><ForeName>Joo-Ho</ForeName><Initials>JH</Initials><Identifier Source="ORCID">0000-0002-0499-4589</Identifier><AffiliationInfo><Affiliation>Division of Pharmacology, Department of Molecular Cell Biology, Sungkyunkwan University School of Medicine, Samsung Biomedical Research Institute (SBRI), Suwon 16419, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ko</LastName><ForeName>Han Seok</ForeName><Initials>HS</Initials><Identifier Source="ORCID">0000-0002-0864-5239</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. ylee69@skku.edu hko3@jhmi.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Yunjong</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-0182-2279</Identifier><AffiliationInfo><Affiliation>Division of Pharmacology, Department of Molecular Cell Biology, Sungkyunkwan University School of Medicine, Samsung Biomedical Research Institute (SBRI), Suwon 16419, Republic of Korea. ylee69@skku.edu hko3@jhmi.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R21 NS098006</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS107404</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS038377</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 NS072026</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C575685">AIMP2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016631" MajorTopicYN="N">Lewy Bodies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009687" MajorTopicYN="N">Nuclear Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="Y">Parkinson Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="Y">alpha-Synuclein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>2</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>4</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>7</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>11</Month><Day>12</Day><Hour>5</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>11</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>5</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33177178</ArticleId><ArticleId IdType="mid">NIHMS1691915</ArticleId><ArticleId IdType="pmc">PMC8082540</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.aax0091</ArticleId><ArticleId IdType="pii">12/569/eaax0091</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Spillantini MG, Goedert M, The alpha-synucleinopathies: Parkinson&#x2019;s disease, dementia with Lewy bodies, and multiple system atrophy. Ann N Y Acad Sci 920, 16&#x2013;27 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">11193145</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang AE, Lozano AM, Parkinson&#x2019;s disease. Second of two parts. N Engl J Med 339, 1130&#x2013;1143 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9770561</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang AE, Lozano AM, Parkinson&#x2019;s disease. First of two parts. N Engl J Med 339, 1044&#x2013;1053 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9761807</ArticleId></ArticleIdList></Reference><Reference><Citation>Norris EH, Giasson BI, Lee VM, Alpha-synuclein: normal function and role in neurodegenerative diseases. Curr Top Dev Biol 60, 17&#x2013;54 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15094295</ArticleId></ArticleIdList></Reference><Reference><Citation>Brahmachari S, Ge P, Lee SH, Kim D, Karuppagounder SS, Kumar M, Mao X, Shin JH, Lee Y, Pletnikova O, Troncoso JC, Dawson VL, Dawson TM, Ko HS, Activation of tyrosine kinase c-Abl contributes to alpha-synuclein-induced neurodegeneration. J Clin Invest 126, 2970&#x2013;2988 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4966315</ArticleId><ArticleId IdType="pubmed">27348587</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto M, Takeda A, Hsu LJ, Takenouchi T, Masliah E, Role of cytochrome c as a stimulator of alpha-synuclein aggregation in Lewy body disease. J Biol Chem 274, 28849&#x2013;28852 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10506125</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahul-Mellier AL, Fauvet B, Gysbers A, Dikiy I, Oueslati A, Georgeon S, Lamontanara AJ, Bisquertt A, Eliezer D, Masliah E, Halliday G, Hantschel O, Lashuel HA, c-Abl phosphorylates alpha-synuclein and regulates its degradation: implication for alpha-synuclein clearance and contribution to the pathogenesis of Parkinson&#x2019;s disease. Hum Mol Genet 23, 2858&#x2013;2879 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4014189</ArticleId><ArticleId IdType="pubmed">24412932</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefanis L, alpha-Synuclein in Parkinson&#x2019;s disease. Cold Spring Harb Perspect Med 2, a009399 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3281589</ArticleId><ArticleId IdType="pubmed">22355802</ArticleId></ArticleIdList></Reference><Reference><Citation>Shults CW, Lewy bodies. Proc Natl Acad Sci U S A 103, 1661&#x2013;1668 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1413649</ArticleId><ArticleId IdType="pubmed">16449387</ArticleId></ArticleIdList></Reference><Reference><Citation>Ko HS, Lee Y, Shin JH, Karuppagounder SS, Gadad BS, Koleske AJ, Pletnikova O, Troncoso JC, Dawson VL, Dawson TM, Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin&#x2019;s ubiquitination and protective function. Proc Natl Acad Sci U S A 107, 16691&#x2013;16696 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2944759</ArticleId><ArticleId IdType="pubmed">20823226</ArticleId></ArticleIdList></Reference><Reference><Citation>Ko HS, von Coelln R, Sriram SR, Kim SW, Chung KK, Pletnikova O, Troncoso J, Johnson B, Saffary R, Goh EL, Song H, Park BJ, Kim MJ, Kim S, Dawson VL, Dawson TM, Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell death. J Neurosci 25, 7968&#x2013;7978 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725452</ArticleId><ArticleId IdType="pubmed">16135753</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee Y, Karuppagounder SS, Shin JH, Lee YI, Ko HS, Swing D, Jiang H, Kang SU, Lee BD, Kang HC, Kim D, Tessarollo L, Dawson VL, Dawson TM, Parthanatos mediates AIMP2-activated age-dependent dopaminergic neuronal loss. Nat Neurosci 16, 1392&#x2013;1400 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3785563</ArticleId><ArticleId IdType="pubmed">23974709</ArticleId></ArticleIdList></Reference><Reference><Citation>Corti O, Hampe C, Koutnikova H, Darios F, Jacquier S, Prigent A, Robinson JC, Pradier L, Ruberg M, Mirande M, Hirsch E, Rooney T, Fournier A, Brice A, The p38 subunit of the aminoacyl-tRNA synthetase complex is a Parkin substrate: linking protein biosynthesis and neurodegeneration. Hum Mol Genet 12, 1427&#x2013;1437 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12783850</ArticleId></ArticleIdList></Reference><Reference><Citation>Han JM, Park BJ, Park SG, Oh YS, Choi SJ, Lee SW, Hwang SK, Chang SH, Cho MH, Kim S, AIMP2/p38, the scaffold for the multi-tRNA synthetase complex, responds to genotoxic stresses via p53. Proc Natl Acad Sci U S A 105, 11206&#x2013;11211 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2516205</ArticleId><ArticleId IdType="pubmed">18695251</ArticleId></ArticleIdList></Reference><Reference><Citation>Yun SP, Kim H, Ham S, Kwon SH, Lee GH, Shin JH, Lee SH, Ko HS, Lee Y, VPS35 regulates parkin substrate AIMP2 toxicity by facilitating lysosomal clearance of AIMP2. Cell Death Dis 8, e2741 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5477581</ArticleId><ArticleId IdType="pubmed">28383562</ArticleId></ArticleIdList></Reference><Reference><Citation>David KK, Andrabi SA, Dawson TM, Dawson VL, Parthanatos, a messenger of death. Front Biosci (Landmark Ed) 14, 1116&#x2013;1128 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4450718</ArticleId><ArticleId IdType="pubmed">19273119</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong ES, Tan JM, Soong WE, Hussein K, Nukina N, Dawson VL, Dawson TM, Cuervo AM, Lim KL, Autophagy-mediated clearance of aggresomes is not a universal phenomenon. Hum Mol Genet 17, 2570&#x2013;2582 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2722889</ArticleId><ArticleId IdType="pubmed">18502787</ArticleId></ArticleIdList></Reference><Reference><Citation>Olah J, Vincze O, Virok D, Simon D, Bozso Z, Tokesi N, Horvath I, Hlavanda E, Kovacs J, Magyar A, Szucs M, Orosz F, Penke B, Ovadi J, Interactions of pathological hallmark proteins: tubulin polymerization promoting protein/p25, beta-amyloid, and alpha-synuclein. J Biol Chem 286, 34088&#x2013;34100 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3190826</ArticleId><ArticleId IdType="pubmed">21832049</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Maio R, Barrett PJ, Hoffman EK, Barrett CW, Zharikov A, Borah A, Hu X, McCoy J, Chu CT, Burton EA, Hastings TG, Greenamyre JT, alpha-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson&#x2019;s disease. Sci Transl Med 8, 342ra378 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5016095</ArticleId><ArticleId IdType="pubmed">27280685</ArticleId></ArticleIdList></Reference><Reference><Citation>Vivian JT, Callis PR, Mechanisms of tryptophan fluorescence shifts in proteins. Biophys J 80, 2093&#x2013;2109 (2001).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1301402</ArticleId><ArticleId IdType="pubmed">11325713</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez JA, Ivanova MI, Sawaya MR, Cascio D, Reyes FE, Shi D, Sangwan S, Guenther EL, Johnson LM, Zhang M, Jiang L, Arbing MA, Nannenga BL, Hattne J, Whitelegge J, Brewster AS, Messerschmidt M, Boutet S, Sauter NK, Gonen T, Eisenberg DS, Structure of the toxic core of alpha-synuclein from invisible crystals. Nature 525, 486&#x2013;490 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4791177</ArticleId><ArticleId IdType="pubmed">26352473</ArticleId></ArticleIdList></Reference><Reference><Citation>Uversky VN, Eliezer D, Biophysics of Parkinson&#x2019;s disease: structure and aggregation of alpha-synuclein. Curr Protein Pept Sci 10, 483&#x2013;499 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3786709</ArticleId><ArticleId IdType="pubmed">19538146</ArticleId></ArticleIdList></Reference><Reference><Citation>Olanow CW, Perl DP, DeMartino GN, McNaught KS, Lewy-body formation is an aggresome-related process: a hypothesis. Lancet Neurol 3, 496&#x2013;503 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15261611</ArticleId></ArticleIdList></Reference><Reference><Citation>Kakuda K, Ikenaka K, Araki K, So M, Aguirre C, Kajiyama Y, Konaka K, Noi K, Baba K, Tsuda H, Nagano S, Ohmichi T, Nagai Y, Tokuda T, El-Agnaf OMA, Ogi H, Goto Y, Mochizuki H, Ultrasonication-based rapid amplification of alpha-synuclein aggregates in cerebrospinal fluid. Sci Rep 9, 6001 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6461702</ArticleId><ArticleId IdType="pubmed">30979935</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin JH, Ko HS, Kang H, Lee Y, Lee YI, Pletinkova O, Troconso JC, Dawson VL, Dawson TM, PARIS (ZNF746) repression of PGC-1alpha contributes to neurodegeneration in Parkinson&#x2019;s disease. Cell 144, 689&#x2013;702 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3063894</ArticleId><ArticleId IdType="pubmed">21376232</ArticleId></ArticleIdList></Reference><Reference><Citation>Volpicelli-Daley LA, Luk KC, Lee VM, Addition of exogenous alpha-synuclein preformed fibrils to primary neuronal cultures to seed recruitment of endogenous alpha-synuclein to Lewy body and Lewy neurite-like aggregates. Nat Protoc 9, 2135&#x2013;2146 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4372899</ArticleId><ArticleId IdType="pubmed">25122523</ArticleId></ArticleIdList></Reference><Reference><Citation>Luk KC, Kehm V, Carroll J, Zhang B, O&#x2019;Brien P, Trojanowski JQ, Lee VM, Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338, 949&#x2013;953 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3552321</ArticleId><ArticleId IdType="pubmed">23161999</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakur P, Breger LS, Lundblad M, Wan OW, Mattsson B, Luk KC, Lee VMY, Trojanowski JQ, Bjorklund A, Modeling Parkinson&#x2019;s disease pathology by combination of fibril seeds and alpha-synuclein overexpression in the rat brain. Proc Natl Acad Sci U S A 114, E8284&#x2013;E8293 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5625925</ArticleId><ArticleId IdType="pubmed">28900002</ArticleId></ArticleIdList></Reference><Reference><Citation>Alves da Costa C, Dunys J, Brau F, Wilk S, Cappai R, Checler F, 6-Hydroxydopamine but not 1-methyl-4-phenylpyridinium abolishes alpha-synuclein anti-apoptotic phenotype by inhibiting its proteasomal degradation and by promoting its aggregation. J Biol Chem 281, 9824&#x2013;9831 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16464850</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganapathy K, Datta I, Sowmithra S, Joshi P, Bhonde R, Influence of 6-Hydroxydopamine Toxicity on alpha-Synuclein Phosphorylation, Resting Vesicle Expression, and Vesicular Dopamine Release. J Cell Biochem 117, 2719&#x2013;2736 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27064513</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarez-Fischer D, Henze C, Strenzke C, Westrich J, Ferger B, Hoglinger GU, Oertel WH, Hartmann A, Characterization of the striatal 6-OHDA model of Parkinson&#x2019;s disease in wild type and alpha-synuclein-deleted mice. Exp Neurol 210, 182&#x2013;193 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18053987</ArticleId></ArticleIdList></Reference><Reference><Citation>Coppola-Segovia V, Cavarsan C, Maia FG, Ferraz AC, Nakao LS, Lima MM, Zanata SM, ER Stress Induced by Tunicamycin Triggers alpha-Synuclein Oligomerization, Dopaminergic Neurons Death and Locomotor Impairment: a New Model of Parkinson&#x2019;s Disease. Mol Neurobiol, (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27660269</ArticleId></ArticleIdList></Reference><Reference><Citation>da Conceicao FS, Ngo-Abdalla S, Houzel JC, Rehen SK, Murine model for Parkinson&#x2019;s disease: from 6-OH dopamine lesion to behavioral test. J Vis Exp, (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2841569</ArticleId><ArticleId IdType="pubmed">20081770</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim MJ, Park BJ, Kang YS, Kim HJ, Park JH, Kang JW, Lee SW, Han JM, Lee HW, Kim S, Downregulation of FUSE-binding protein and c-myc by tRNA synthetase cofactor p38 is required for lung cell differentiation. Nat Genet 34, 330&#x2013;336 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12819782</ArticleId></ArticleIdList></Reference><Reference><Citation>Olzscha H, Schermann SM, Woerner AC, Pinkert S, Hecht MH, Tartaglia GG, Vendruscolo M, Hayer-Hartl M, Hartl FU, Vabulas RM, Amyloid-like aggregates sequester numerous metastable proteins with essential cellular functions. Cell 144, 67&#x2013;78 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21215370</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim C, Lv G, Lee JS, Jung BC, Masuda-Suzukake M, Hong CS, Valera E, Lee HJ, Paik SR, Hasegawa M, Masliah E, Eliezer D, Lee SJ, Exposure to bacterial endotoxin generates a distinct strain of alpha-synuclein fibril. Sci Rep 6, 30891 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4973277</ArticleId><ArticleId IdType="pubmed">27488222</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SW, Kim G, Kim S, Aminoacyl-tRNA synthetase-interacting multi-functional protein 1/p43: an emerging therapeutic protein working at systems level. Expert Opin Drug Discov 3, 945&#x2013;957 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">23484969</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh YS, Kim DG, Kim G, Choi EC, Kennedy BK, Suh Y, Park BJ, Kim S, Downregulation of lamin A by tumor suppressor AIMP3/p18 leads to a progeroid phenotype in mice. Aging Cell 9, 810&#x2013;822 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20726853</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawson TM, Ko HS, Dawson VL, Genetic animal models of Parkinson&#x2019;s disease. Neuron 66, 646&#x2013;661 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2917798</ArticleId><ArticleId IdType="pubmed">20547124</ArticleId></ArticleIdList></Reference><Reference><Citation>Von Coelln R, Thomas B, Savitt JM, Lim KL, Sasaki M, Hess EJ, Dawson VL, Dawson TM, Loss of locus coeruleus neurons and reduced startle in parkin null mice. Proc Natl Acad Sci U S A 101, 10744&#x2013;10749 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC490005</ArticleId><ArticleId IdType="pubmed">15249681</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez FA, Palmiter RD, Parkin-deficient mice are not a robust model of parkinsonism. Proc Natl Acad Sci U S A 102, 2174&#x2013;2179 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC548311</ArticleId><ArticleId IdType="pubmed">15684050</ArticleId></ArticleIdList></Reference><Reference><Citation>von Coelln R, Thomas B, Andrabi SA, Lim KL, Savitt JM, Saffary R, Stirling W, Bruno K, Hess EJ, Lee MK, Dawson VL, Dawson TM, Inclusion body formation and neurodegeneration are parkin independent in a mouse model of alpha-synucleinopathy. J Neurosci 26, 3685&#x2013;3696 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674122</ArticleId><ArticleId IdType="pubmed">16597723</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi H, Ohama E, Suzuki S, Horikawa Y, Ishikawa A, Morita T, Tsuji S, Ikuta F, Familial juvenile parkinsonism: clinical and pathologic study in a family. Neurology 44, 437&#x2013;441 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">8145912</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajput AH, Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q. Neurology 53, 1375 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10522917</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimura H, Hattori N, Kubo S, Yoshikawa M, Kitada T, Matsumine H, Asakawa S, Minoshima S, Yamamura Y, Shimizu N, Mizuno Y, Immunohistochemical and subcellular localization of Parkin protein: absence of protein in autosomal recessive juvenile parkinsonism patients. Ann Neurol 45, 668&#x2013;672 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10319893</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharp ME, Marder KS, Cote L, Clark LN, Nichols WC, Vonsattel JP, Alcalay RN, Parkinson&#x2019;s disease with Lewy bodies associated with a heterozygous PARKIN dosage mutation. Mov Disord 29, 566&#x2013;568 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4281030</ArticleId><ArticleId IdType="pubmed">24375549</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruffmann C, Zini M, Goldwurm S, Bramerio M, Spinello S, Rusconi D, Gambacorta M, Tagliavini F, Pezzoli G, Giaccone G, Lewy body pathology and typical Parkinson disease in a patient with a heterozygous (R275W) mutation in the Parkin gene (PARK2). Acta Neuropathol 123, 901&#x2013;903 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22555654</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyakawa S, Ogino M, Funabe S, Uchino A, Shimo Y, Hattori N, Ichinoe M, Mikami T, Saegusa M, Nishiyama K, Mori H, Mizuno Y, Murayama S, Mochizuki H, Lewy body pathology in a patient with a homozygous parkin deletion. Mov Disord 28, 388&#x2013;391 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23401296</ArticleId></ArticleIdList></Reference><Reference><Citation>Pramstaller PP, Schlossmacher MG, Jacques TS, Scaravilli F, Eskelson C, Pepivani I, Hedrich K, Adel S, Gonzales-McNeal M, Hilker R, Kramer PL, Klein C, Lewy body Parkinson&#x2019;s disease in a large pedigree with 77 Parkin mutation carriers. Ann Neurol 58, 411&#x2013;422 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16130111</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki S, Shirata A, Yamane K, Iwata M, Parkin-positive autosomal recessive juvenile Parkinsonism with alpha-synuclein-positive inclusions. Neurology 63, 678&#x2013;682 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15326242</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer M, Chan P, Chen R, Tan L, Lincoln S, Hernandez D, Forno L, Gwinn-Hardy K, Petrucelli L, Hussey J, Singleton A, Tanner C, Hardy J, Langston JW, Lewy bodies and parkinsonism in families with parkin mutations. Ann Neurol 50, 293&#x2013;300 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11558785</ArticleId></ArticleIdList></Reference><Reference><Citation>Imam SZ, Zhou Q, Yamamoto A, Valente AJ, Ali SF, Bains M, Roberts JL, Kahle PJ, Clark RA, Li S, Novel regulation of parkin function through c-Abl-mediated tyrosine phosphorylation: implications for Parkinson&#x2019;s disease. J Neurosci 31, 157&#x2013;163 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3039694</ArticleId><ArticleId IdType="pubmed">21209200</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawson TM, Dawson VL, Parkin plays a role in sporadic Parkinson&#x2019;s disease. Neurodegener Dis 13, 69&#x2013;71 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3984465</ArticleId><ArticleId IdType="pubmed">24029689</ArticleId></ArticleIdList></Reference><Reference><Citation>Brahmachari S, Lee S, Kim S, Yuan C, Karuppagounder SS, Ge P, Shi R, Kim EJ, Liu A, Kim D, Quintin S, Jiang H, Kumar M, Yun SP, Kam TI, Mao X, Lee Y, Swing DA, Tessarollo L, Ko HS, Dawson VL, Dawson TM, Parkin interacting substrate zinc finger protein 746 is a pathological mediator in Parkinson&#x2019;s disease. Brain 142, 2380&#x2013;2401 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6658849</ArticleId><ArticleId IdType="pubmed">31237944</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MK, Stirling W, Xu Y, Xu X, Qui D, Mandir AS, Dawson TM, Copeland NG, Jenkins NA, Price DL, Human alpha-synuclein-harboring familial Parkinson&#x2019;s disease-linked Ala-53 --&gt; Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc Natl Acad Sci U S A 99, 8968&#x2013;8973 (2002).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC124407</ArticleId><ArticleId IdType="pubmed">12084935</ArticleId></ArticleIdList></Reference><Reference><Citation>Faul F, Erdfelder E, Lang AG, Buchner A, G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 39, 175&#x2013;191 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17695343</ArticleId></ArticleIdList></Reference><Reference><Citation>Waxman EA, Giasson BI, Induction of intracellular tau aggregation is promoted by alpha-synuclein seeds and provides novel insights into the hyperphosphorylation of tau. J Neurosci 31, 7604&#x2013;7618 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3122484</ArticleId><ArticleId IdType="pubmed">21613474</ArticleId></ArticleIdList></Reference><Reference><Citation>Dar MA, Wahiduzzaman, Haque MA, Islam A, Hassan MI, Ahmad F, Characterisation of molten globule-like state of sheep serum albumin at physiological pH. Int J Biol Macromol 89, 605&#x2013;613 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27180298</ArticleId></ArticleIdList></Reference><Reference><Citation>Pachahara SK, Chaudhary N, Subbalakshmi C, Nagaraj R, Hexafluoroisopropanol induces self-assembly of beta-amyloid peptides into highly ordered nanostructures. J Pept Sci 18, 233&#x2013;241 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22252985</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhee YH, Kim TH, Jo AY, Chang MY, Park CH, Kim SM, Song JJ, Oh SM, Yi SH, Kim HH, You BH, Nam JW, Lee SH, LIN28A enhances the therapeutic potential of cultured neural stem cells in a Parkinson&#x2019;s disease model. Brain 139, 2722&#x2013;2739 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27538419</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33199898</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>08</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>12</Issue><PubDate><Year>2020</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Acute targeting of pre-amyloid seeds in transgenic mice reduces Alzheimer-like pathology later in life.</ArticleTitle><Pagination><StartPage>1580</StartPage><EndPage>1588</EndPage><MedlinePgn>1580-1588</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41593-020-00737-w</ELocationID><Abstract><AbstractText>Amyloid-&#x3b2; (A&#x3b2;) deposits are a relatively late consequence of A&#x3b2; aggregation in Alzheimer's disease. When pathogenic A&#x3b2; seeds begin to form, propagate and spread is not known, nor are they biochemically defined. We tested various antibodies for their ability to neutralize A&#x3b2; seeds before A&#x3b2; deposition becomes detectable in A&#x3b2; precursor protein-transgenic mice. We also characterized the different antibody recognition profiles using immunoprecipitation of size-fractionated, native, mouse and human brain-derived A&#x3b2; assemblies. At least one antibody, aducanumab, after acute administration at the pre-amyloid stage, led to a significant reduction of A&#x3b2; deposition and downstream pathologies 6 months later. This demonstrates that therapeutically targetable pathogenic A&#x3b2; seeds already exist during the lag phase of protein aggregation in the brain. Thus, the preclinical phase of Alzheimer's disease-currently defined as A&#x3b2; deposition without clinical symptoms-may be a relatively late manifestation of a much earlier pathogenic seed formation and propagation that currently escapes detection in vivo.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Uhlmann</LastName><ForeName>Ruth E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate School of Cellular and Molecular Neuroscience, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Rother</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate School of Cellular and Molecular Neuroscience, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rasmussen</LastName><ForeName>Jay</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate School of Cellular and Molecular Neuroscience, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schelle</LastName><ForeName>Juliane</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bergmann</LastName><ForeName>Carina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ullrich Gavilanes</LastName><ForeName>Emily M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate School of Cellular and Molecular Neuroscience, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fritschi</LastName><ForeName>Sarah K</ForeName><Initials>SK</Initials><Identifier Source="ORCID">0000-0003-4665-7203</Identifier><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buehler</LastName><ForeName>Anika</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baumann</LastName><ForeName>Frank</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skodras</LastName><ForeName>Angelos</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Shaana</LastName><ForeName>Rawaa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beschorner</LastName><ForeName>Natalie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Lan</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-3508-7359</Identifier><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaeser</LastName><ForeName>Stephan A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oberm&#xfc;ller</LastName><ForeName>Ulrike</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Christensen</LastName><ForeName>S&#xf8;ren</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biotherapeutic Discovery, H. Lundbeck A/S, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kartberg</LastName><ForeName>Fredrik</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Biotherapeutic Discovery, H. Lundbeck A/S, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stavenhagen</LastName><ForeName>Jeffrey B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Department of Biotherapeutic Discovery, H. Lundbeck A/S, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rahfeld</LastName><ForeName>Jens-Ulrich</ForeName><Initials>JU</Initials><AffiliationInfo><Affiliation>Department of Drug Design and Target Validation, Fraunhofer Institute for Cell Therapy and Immunology, Halle, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cynis</LastName><ForeName>Holger</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-6655-7539</Identifier><AffiliationInfo><Affiliation>Department of Drug Design and Target Validation, Fraunhofer Institute for Cell Therapy and Immunology, Halle, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qian</LastName><ForeName>Fang</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Biogen Inc., Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weinreb</LastName><ForeName>Paul H</ForeName><Initials>PH</Initials><Identifier Source="ORCID">0000-0002-0802-0052</Identifier><AffiliationInfo><Affiliation>Biogen Inc., Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bussiere</LastName><ForeName>Thierry</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-6818-4876</Identifier><AffiliationInfo><Affiliation>Biogen Inc., Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>Lary C</ForeName><Initials>LC</Initials><Identifier Source="ORCID">0000-0001-9166-3261</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Staufenbiel</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jucker</LastName><ForeName>Mathias</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9045-1072</Identifier><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen, T&#xfc;bingen, Germany. mathias.jucker@uni-tuebingen.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, T&#xfc;bingen, T&#xfc;bingen, Germany. mathias.jucker@uni-tuebingen.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG066511</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG025688</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P51 OD011132</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>11</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019138">Antibodies, Blocking</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016900">Neurofilament Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014020">Tissue Extracts</NameOfSubstance></Chemical><Chemical><RegistryNumber>105J35OE21</RegistryNumber><NameOfSubstance UI="C000600266">aducanumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019138" MajorTopicYN="N">Antibodies, Blocking</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001923" MajorTopicYN="N">Brain Chemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016900" MajorTopicYN="N">Neurofilament Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014020" MajorTopicYN="N">Tissue Extracts</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>COMPETING FINANCIAL INTERESTS: S.C., F.K., and J.B.S are current or former employees of Lundbeck; F.Q., P.H.W., and T.B. are current employees and/or shareholders of Biogen; J.-U.R and H.C. are former employees of Probiodrug AG; M.S. is a former employee of Novartis. The other authors have no competing interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>2</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>10</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>11</Month><Day>17</Day><Hour>6</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>6</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33199898</ArticleId><ArticleId IdType="mid">NIHMS1654777</ArticleId><ArticleId IdType="pmc">PMC7783656</ArticleId><ArticleId IdType="doi">10.1038/s41593-020-00737-w</ArticleId><ArticleId IdType="pii">10.1038/s41593-020-00737-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jack CR et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer&#x2019;s disease. Alzheimer&#x2019;s Dement. 14, 535&#x2013;562 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5958625</ArticleId><ArticleId IdType="pubmed">29653606</ArticleId></ArticleIdList></Reference><Reference><Citation>Long JM &amp; Holtzman DM Alzheimer Disease: An update on pathobiology and treatment strategies. Cell 179, 312&#x2013;339 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6778042</ArticleId><ArticleId IdType="pubmed">31564456</ArticleId></ArticleIdList></Reference><Reference><Citation>Panza F, Lozupone M, Seripa D &amp; Imbimbo BP Amyloid-&#x3b2; immunotherapy for Alzheimer disease: Is it now a long shot? Ann. Neurol 85, 303&#x2013;315 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30635926</ArticleId></ArticleIdList></Reference><Reference><Citation>McDade E et al. Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. Neurology 91, 1295&#x2013;1306 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6177272</ArticleId><ArticleId IdType="pubmed">30217935</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Dor&#xe9; V, Burnham SC, Masters CL &amp; Rowe CC Imaging tau and amyloid-&#x3b2; proteinopathies in Alzheimer disease and other conditions. Nat. Rev. Neurol 14, 225&#x2013;236 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29449700</ArticleId></ArticleIdList></Reference><Reference><Citation>McDade E &amp; Bateman RJ Stop Alzheimer&#x2019;s before it starts. Nature 547, 153&#x2013;155 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28703214</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Mattsson N &amp; Hansson O Cerebrospinal fluid analysis detects cerebral amyloid-&#x3b2; accumulation earlier than positron emission tomography. Brain 139, 1226&#x2013;1236 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4806222</ArticleId><ArticleId IdType="pubmed">26936941</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR et al. Estimation of amyloid distribution by [18F]flutemetamol PET predicts the neuropathological phase of amyloid &#x3b2;-protein deposition. Acta Neuropathol. 136, 557&#x2013;567 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6132944</ArticleId><ArticleId IdType="pubmed">30123935</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Horng A &amp; Jagust WJ Memory decline accompanies subthreshold amyloid accumulation. Neurology 90, 1452&#x2013;1460 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5921038</ArticleId><ArticleId IdType="pubmed">29572282</ArticleId></ArticleIdList></Reference><Reference><Citation>La Joie R et al. Multisite study of the relationships between antemortem [11C]PIB-PET centiloid values and postmortem measures of Alzheimer&#x2019;s disease neuropathology. Alzheimer&#x2019;s Dement. 15, 205&#x2013;216 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6368897</ArticleId><ArticleId IdType="pubmed">30347188</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye L et al. A&#x3b2; seeding potency peaks in the early stages of cerebral &#x3b2;&#x2010;amyloidosis. EMBO Rep. 18, 1536&#x2013;1544 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5579388</ArticleId><ArticleId IdType="pubmed">28701326</ArticleId></ArticleIdList></Reference><Reference><Citation>Aoyagi A et al. A&#x3b2; and tau prion-like activities decline with longevity in the Alzheimer&#x2019;s disease human brain. Sci. Transl. Med 11, 1&#x2013;14 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6640844</ArticleId><ArticleId IdType="pubmed">31043574</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuller JP, Stavenhagen JB &amp; Teeling JL New roles for Fc receptors in neurodegeneration-The impact on immunotherapy for Alzheimer&#x2019;s disease. Front. Neurosci 8, 1&#x2013;10 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4139653</ArticleId><ArticleId IdType="pubmed">25191216</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M et al. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science 313, 1781&#x2013;1784 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16990547</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisele YS et al. Multiple factors contribute to the peripheral induction of cerebral-amyloidosis. J. Neurosci 34, 10264&#x2013;10273 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6608275</ArticleId><ArticleId IdType="pubmed">25080588</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xfc;ntert A, D&#xf6;beli H &amp; Bohrmann B High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain. Neuroscience 143, 461&#x2013;475 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17008022</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost JL et al. Pyroglutamate-3 amyloid-&#x3b2; deposition in the brains of humans, non-human primates, canines, and Alzheimer disease-like transgenic mouse models. Am. J. Pathol 183, 369&#x2013;381 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3730768</ArticleId><ArticleId IdType="pubmed">23747948</ArticleId></ArticleIdList></Reference><Reference><Citation>Rijal Upadhaya A et al. Biochemical stages of amyloid-&#x3b2; peptide aggregation and accumulation in the human brain and their association with symptomatic and pathologically preclinical Alzheimer&#x2019;s disease. Brain 137, 887&#x2013;903 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24519982</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye L et al. Persistence of A&#x3b2; seeds in APP null mouse brain. Nat. Neurosci 18, 1559&#x2013;1561 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26352792</ArticleId></ArticleIdList></Reference><Reference><Citation>Arndt JW et al. Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-&#x3b2;. Sci. Rep 8, 1&#x2013;16 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5913127</ArticleId><ArticleId IdType="pubmed">29686315</ArticleId></ArticleIdList></Reference><Reference><Citation>Nystr&#xf6;m S et al. Evidence for age-dependent in vivo conformational rearrangement within A&#x3b2; amyloid deposits. ACS Chem. Biol 8, 1128&#x2013;1133 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23521783</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacioglu M et al. Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases. Neuron 91, 56&#x2013;66 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27292537</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarrett JT &amp; Lansbury PT Seeding &#x2018;one-dimensional crystallization&#x2019; of amyloid: A pathogenic mechanism in Alzheimer&#x2019;s disease and scrapie? Cell 73, 1055&#x2013;1058 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">8513491</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisenberg D &amp; Jucker M The amyloid state of proteins in human diseases. Cell 148, 1188&#x2013;203 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3353745</ArticleId><ArticleId IdType="pubmed">22424229</ArticleId></ArticleIdList></Reference><Reference><Citation>Langer F et al. Soluble A&#x3b2; seeds are potent inducers of cerebral &#x3b2;-amyloid deposition. J. Neurosci 31, 14488&#x2013;14495 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3229270</ArticleId><ArticleId IdType="pubmed">21994365</ArticleId></ArticleIdList></Reference><Reference><Citation>Katzmarski N et al. A&#x3b2; oligomers trigger and accelerate A&#x3b2; seeding. Brain Pathol. 30, 36&#x2013;45 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6916291</ArticleId><ArticleId IdType="pubmed">31099449</ArticleId></ArticleIdList></Reference><Reference><Citation>Michno W et al. Pyroglutamation of amyloid-&#x3b2;x-42 (A&#x3b2;x-42) followed by A&#x3b2;1&#x2013;40 deposition underlies plaque polymorphism in progressing Alzheimer&#x2019;s disease pathology. J. Biol. Chem 294, 6719&#x2013;6732 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6497931</ArticleId><ArticleId IdType="pubmed">30814252</ArticleId></ArticleIdList></Reference><Reference><Citation>Nussbaum JM et al. Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-&#x3b2;. Nature 485, 651&#x2013;655 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3367389</ArticleId><ArticleId IdType="pubmed">22660329</ArticleId></ArticleIdList></Reference><Reference><Citation>Sevigny J et al. The antibody Aducanumab reduces A&#x3b2; plaques in Alzheimer&#x2019;s disease. Nature 537, 50&#x2013;56 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27582220</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuller JP et al. Comparing the efficacy and neuroinflammatory potential of three anti-Abeta antibodies. Acta Neuropathol. 130, 699&#x2013;711 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4612324</ArticleId><ArticleId IdType="pubmed">26433971</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMattos RB et al. A plaque-specific antibody clears existing &#x3b2;-amyloid plaques in Alzheimer&#x2019;s disease mice. Neuron 76, 908&#x2013;920 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">23217740</ArticleId></ArticleIdList></Reference><Reference><Citation>Jucker M &amp; Walker LC Propagation and spread of pathogenic protein assemblies in neurodegenerative diseases. Nat. Neurosci 21, 1341&#x2013;1349 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6375686</ArticleId><ArticleId IdType="pubmed">30258241</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeifer M et al. Cerebral hemorrhage after passive anti-A&#x3b2; immunotherapy. Science 298, 1379 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12434053</ArticleId></ArticleIdList></Reference><Reference><Citation>Boche D et al. Consequence of A&#x3b2; immunization on the vasculature of human Alzheimer&#x2019;s disease brain. Brain 131, 3299&#x2013;3310 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18953056</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer&#x2019;s Association Research Roundtable Workgroup. Alzheimer&#x2019;s Dement. 7, 367&#x2013;385 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3693547</ArticleId><ArticleId IdType="pubmed">21784348</ArticleId></ArticleIdList></Reference><Reference><Citation>Kollmer M et al. Cryo-EM structure and polymorphism of A&#x3b2; amyloid fibrils purified from Alzheimer&#x2019;s brain tissue. Nat. Commun 10, 4760 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6820800</ArticleId><ArticleId IdType="pubmed">31664019</ArticleId></ArticleIdList></Reference><Reference><Citation>Karlnoski RA et al. Suppression of amyloid deposition leads to long-term reductions in Alzheimer&#x2019;s pathologies in Tg2576 mice. J. Neurosci 29, 4964&#x2013;4971 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2688812</ArticleId><ArticleId IdType="pubmed">19369565</ArticleId></ArticleIdList></Reference><Reference><Citation>Das P et al. Transient pharmacologic lowering of A&#x3b2; production prior to deposition results in sustained reduction of amyloid plaque pathology. Mol. Neurodegener 7, 39 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3477045</ArticleId><ArticleId IdType="pubmed">22892055</ArticleId></ArticleIdList></Reference><Reference><Citation>Arosio P, Knowles TPJ &amp; Linse S On the lag phase in amyloid fibril formation. Phys. Chem. Chem. Phys 17, 7606&#x2013;7618 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4498454</ArticleId><ArticleId IdType="pubmed">25719972</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Thal DR, Ghebremedhin E &amp; Del Tredici K Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J. Neuropathol. Exp. Neurol 70, 960&#x2013;969 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">22002422</ArticleId></ArticleIdList></Reference><Reference><Citation>Pletnikova O et al. Alzheimer lesions in the autopsied brains of people 30 to 50 years of age. Cogn. Behav. Neurol 28, 144&#x2013;152 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4588069</ArticleId><ArticleId IdType="pubmed">26413742</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Mormino E &amp; Johnson K The evolution of preclinical Alzheimer&#x2019;s disease: implications for prevention trials. Neuron 84, 608&#x2013;622 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4285623</ArticleId><ArticleId IdType="pubmed">25442939</ArticleId></ArticleIdList></Reference><Reference><Citation>Westermark GT, F&#xe4;ndrich M, Lundmark K &amp; Westermark P Noncerebral amyloidoses: aspects on seeding, cross-seeding, and transmission. Cold Spring Harb. Perspect. Med 8, a024323 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5749146</ArticleId><ArticleId IdType="pubmed">28108533</ArticleId></ArticleIdList></Reference><Reference><Citation>Maia LF et al. Changes in amyloid- and tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein. Sci. Transl. Med 5, 194re2 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23863834</ArticleId></ArticleIdList></Reference><Reference><Citation>Maia LF et al. Increased CSF A&#x3b2; during the very early phase of cerebral A&#x3b2; deposition in mouse models. EMBO Mol. Med 7, 895&#x2013;903 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4520655</ArticleId><ArticleId IdType="pubmed">25978969</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisele YS et al. Peripherally applied A&#x3b2;-containing inoculates induce cerebral &#x3b2;-amyloidosis. Science 330, 980&#x2013;982 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3233904</ArticleId><ArticleId IdType="pubmed">20966215</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier FC et al. Longitudinal PET-MRI reveals &#x3b2;-amyloid deposition and rCBF dynamics and connects vascular amyloidosis to quantitative loss of perfusion. Nat. Med 20, 1485&#x2013;1492 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25384087</ArticleId></ArticleIdList></Reference><Reference><Citation>St&#xfc;rchler-Pierrat C et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl. Acad. Sci 94, 13287&#x2013;13292 (1997).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24301</ArticleId><ArticleId IdType="pubmed">9371838</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohrmann B et al. Gantenerumab: A novel human anti-A&#x3b2; antibody demonstrates sustained cerebral amyloid-&#x3b2; binding and elicits cell-mediated removal of human amyloid-&#x3b2;. J. Alzheimer&#x2019;s Dis 28, 49&#x2013;69 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">21955818</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMattos RB et al. Peripheral anti-A&#x3b2; antibody alters CNS and plasma A&#x3b2; clearance and decreases brain A&#x3b2; burden in a mouse model of Alzheimer&#x2019;s disease. Proc. Natl. Acad. Sci. U. S. A 98, 8850&#x2013;8855 (2001).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC37524</ArticleId><ArticleId IdType="pubmed">11438712</ArticleId></ArticleIdList></Reference><Reference><Citation>Adolfsson O et al. An effector-reduced anti-&#x3b2;-amyloid (A&#x3b2;) antibody with unique A&#x3b2; binding properties promotes neuroprotection and glial engulfment of A&#x3b2;. J. Neurosci 32, 9677&#x2013;9689 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6622286</ArticleId><ArticleId IdType="pubmed">22787053</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganetti PA, Lis M, Klafki H-W &amp; Staufenbiel M Amyloid precursor protein truncated at any of the y-secretase sites is not cleaved to &#x3b2;-amyloid. J. Neurosci. Res 46, 283&#x2013;293 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8933367</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMattos RB et al. Plaque-associated disruption of CSF and plasma amyloid-&#x3b2; (A&#x3b2;) equilibrium in a mouse model of Alzheimer&#x2019;s disease. J. Neurochem 81, 229&#x2013;236 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12064470</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler DT et al. Spontaneous hemorrhagic stroke in a mouse model of cerebral amyloid angiopathy. J. Neurosci 21, 1619&#x2013;1627 (2001).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762950</ArticleId><ArticleId IdType="pubmed">11222652</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasmussen J et al. Amyloid polymorphisms constitute distinct clouds of conformational variants in different etiological subtypes of Alzheimer&#x2019;s disease. Proc. Natl. Acad. Sci. U. S. A 114, 13018&#x2013;13023 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5724274</ArticleId><ArticleId IdType="pubmed">29158413</ArticleId></ArticleIdList></Reference><Reference><Citation>Schelle J et al. Early A&#x3b2; reduction prevents progression of cerebral amyloid angiopathy. Ann. Neurol 00, 1&#x2013;11 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31359452</ArticleId></ArticleIdList></Reference><Reference><Citation>Bagriantsev SN, Kushnirov VV &amp; Liebman SW Analysis of amyloid aggregates using agarose gel electrophoresis. Methods Enzymol. 412, 33&#x2013;48 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17046650</ArticleId></ArticleIdList></Reference><Reference><Citation>Preische O et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer&#x2019;s disease. Nat. Med 25, 277&#x2013;283 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6367005</ArticleId><ArticleId IdType="pubmed">30664784</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan DA, Narrow WC, Federoff HJ &amp; Bowers WJ An improved method for generating consistent soluble amyloid-beta oligomer preparations for in vitro neurotoxicity studies. J. Neurosci. Methods 190, 171&#x2013;179 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2902796</ArticleId><ArticleId IdType="pubmed">20452375</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33188775</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>18</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4172</ISSN><JournalIssue CitedMedium="Internet"><Volume>183</Volume><Issue>6</Issue><PubDate><Year>2020</Year><Month>Dec</Month><Day>10</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>Tau PTM Profiles Identify Patient Heterogeneity and Stages of Alzheimer's Disease.</ArticleTitle><Pagination><StartPage>1699</StartPage><EndPage>1713.e13</EndPage><MedlinePgn>1699-1713.e13</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2020.10.029</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0092-8674(20)31393-3</ELocationID><Abstract><AbstractText>To elucidate the role of Tau isoforms and post-translational modification (PTM) stoichiometry in Alzheimer's disease (AD), we generated a high-resolution quantitative proteomics map of 95 PTMs on multiple isoforms of Tau isolated from postmortem human tissue from 49 AD and 42 control subjects. Although Tau PTM maps reveal heterogeneity across subjects, a subset of PTMs display high occupancy and frequency for AD, suggesting importance in disease. Unsupervised analyses indicate that PTMs occur in an ordered manner, leading to Tau aggregation. The processive addition and minimal set of PTMs associated with seeding activity was further defined by analysis of size-fractionated Tau. To summarize, features in the Tau protein critical for disease intervention at different stages of disease are identified, including enrichment of 0N and 4R isoforms, underrepresentation of the C terminus, an increase in negative charge in the proline-rich region (PRR), and a decrease in positive charge in the microtubule binding domain (MBD).</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wesseling</LastName><ForeName>Hendrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>F.M. Kirby Neurobiology Center, Department of Neurobiology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mair</LastName><ForeName>Waltraud</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>F.M. Kirby Neurobiology Center, Department of Neurobiology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Mukesh</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>F.M. Kirby Neurobiology Center, Department of Neurobiology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schlaffner</LastName><ForeName>Christoph N</ForeName><Initials>CN</Initials><AffiliationInfo><Affiliation>F.M. Kirby Neurobiology Center, Department of Neurobiology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Shaojun</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>F.M. Kirby Neurobiology Center, Department of Neurobiology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA; Department of Pathology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beerepoot</LastName><ForeName>Pieter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>F.M. Kirby Neurobiology Center, Department of Neurobiology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fatou</LastName><ForeName>Benoit</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pathology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guise</LastName><ForeName>Amanda J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>F.M. Kirby Neurobiology Center, Department of Neurobiology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Long</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>F.M. Kirby Neurobiology Center, Department of Neurobiology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takeda</LastName><ForeName>Shuko</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA; Department of Clinical Gene Therapy, Graduate School of Medicine, Osaka University, Yamadaoka, Suita, Osaka 565-0871, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muntel</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pathology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rotunno</LastName><ForeName>Melissa S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Pathology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dujardin</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davies</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Feinstein Institutes for Medical Research, Manhasset, NY 11030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kosik</LastName><ForeName>Kenneth S</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>Neuroscience Research Institute and Department of Molecular, Cellular, and Developmental Biology, UCSB, Santa Barbara, CA 93106, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berretta</LastName><ForeName>Sabina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Harvard Brain Tissue Resource Center (HBTRC), McLean Hospital, Belmont, MA 02478, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hedreen</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Harvard Brain Tissue Resource Center (HBTRC), McLean Hospital, Belmont, MA 02478, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grinberg</LastName><ForeName>Lea T</ForeName><Initials>LT</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA 94143, USA; Department of Pathology, University of California, San Francisco, San Francisco, CA 94143-0511, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seeley</LastName><ForeName>William W</ForeName><Initials>WW</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA 94143, USA; Department of Pathology, University of California, San Francisco, San Francisco, CA 94143-0511, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>Bradley T</ForeName><Initials>BT</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steen</LastName><ForeName>Hanno</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pathology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steen</LastName><ForeName>Judith A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>F.M. Kirby Neurobiology Center, Department of Neurobiology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA. Electronic address: judith.steen@childrens.harvard.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG062421</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG058674</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS066973</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062422</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM112007</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC4 GM096319</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AG061196</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN271201300030C</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG059789</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>11</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D025341" MajorTopicYN="N">Principal Component Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020033" MajorTopicYN="N">Protein Isoforms</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011499" MajorTopicYN="Y">Protein Processing, Post-Translational</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">FLEXITau</Keyword><Keyword MajorTopicYN="N">absolute quantification</Keyword><Keyword MajorTopicYN="N">disease progression</Keyword><Keyword MajorTopicYN="N">multiple reaction monitoring (MRM)</Keyword><Keyword MajorTopicYN="N">post-translational modifications</Keyword><Keyword MajorTopicYN="N">prion-like molecules</Keyword><Keyword MajorTopicYN="N">protein aggregation</Keyword><Keyword MajorTopicYN="N">proteomics</Keyword><Keyword MajorTopicYN="N">proteopathy</Keyword><Keyword MajorTopicYN="N">quantitative mass spectrometry</Keyword></KeywordList><CoiStatement>Declaration of Interests B.T.H. is a member of the SAB and owns shares in Dewpoint. He also serves on an advisory panel for Biogen, and his laboratory has current research funding from AbbVie. His wife is an employee and shareholder of Novartis.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>3</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>8</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>10</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>11</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>11</Month><Day>14</Day><Hour>20</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>12</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33188775</ArticleId><ArticleId IdType="mid">NIHMS1639269</ArticleId><ArticleId IdType="pmc">PMC8168922</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2020.10.029</ArticleId><ArticleId IdType="pii">S0092-8674(20)31393-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abreha MH, Dammer EB, Ping L, Zhang T, Duong DM, Gearing M, Lah JJ, Levey AI, and Seyfried NT (2018). Quantitative Analysis of the Brain Ubiquitylome in Alzheimer&#x2019;s Disease. Proteomics 18, e1800108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6283072</ArticleId><ArticleId IdType="pubmed">30230243</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams SJ, DeTure MA, McBride M, Dickson DW, and Petrucelli L. (2010). Three repeat isoforms of tau inhibit assembly of four repeat tau filaments. PLoS ONE 5, e10810.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2876030</ArticleId><ArticleId IdType="pubmed">20520830</ArticleId></ArticleIdList></Reference><Reference><Citation>Aebersold R, Agar JN, Amster IJ, Baker MS, Bertozzi CR, Boja ES, Costello CE, Cravatt BF, Fenselau C, Garcia BA, et al. (2018). How many human proteoforms are there? Nat. Chem. Biol. 14, 206&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5837046</ArticleId><ArticleId IdType="pubmed">29443976</ArticleId></ArticleIdList></Reference><Reference><Citation>Alonso A, Zaidi T, Novak M, Grundke-Iqbal I, and Iqbal K. (2001). Hyper-phosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments. Proc. Natl. Acad. Sci. USA 98, 6923&#x2013;6928.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC34454</ArticleId><ArticleId IdType="pubmed">11381127</ArticleId></ArticleIdList></Reference><Reference><Citation>Arendt T, Stieler JT, and Holzer M. (2016). Tau and tauopathies. Brain Res. Bull. 126, 238&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pubmed">27615390</ArticleId></ArticleIdList></Reference><Reference><Citation>Arriagada PV, Marzloff K, and Hyman BT (1992). Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer&#x2019;s disease. Neurology 42, 1681&#x2013;1688.</Citation><ArticleIdList><ArticleId IdType="pubmed">1307688</ArticleId></ArticleIdList></Reference><Reference><Citation>Bierer LM, Hof PR, Purohit DP, Carlin L, Schmeidler J, Davis KL, and Perl DP (1995). Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimer&#x2019;s disease. Arch. Neurol. 52, 81&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">7826280</ArticleId></ArticleIdList></Reference><Reference><Citation>Biernat J, and Mandelkow EM (1999). The development of cell processes induced by tau protein requires phosphorylation of serine 262 and 356 in the repeat domain and is inhibited by phosphorylation in the proline-rich domains. Mol. Biol. Cell 10, 727&#x2013;740.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC25198</ArticleId><ArticleId IdType="pubmed">10069814</ArticleId></ArticleIdList></Reference><Reference><Citation>Biernat J, Gustke N, Drewes G, Mandelkow EM, and Mandelkow E. (1993). Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: distinction between PHF-like immunoreactivity and microtubule binding. Neuron 11, 153&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pubmed">8393323</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, and Braak E. (1991). Neuropathological stageing of Alzheimerrelated changes. Acta Neuropathol. 82, 239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Bramblett GT, Goedert M, Jakes R, Merrick SE, Trojanowski JQ, and Lee VM (1993). Abnormal tau phosphorylation at Ser396 in Alzheimer&#x2019;s disease recapitulates development and contributes to reduced microtubule binding. Neuron 10, 1089&#x2013;1099.</Citation><ArticleIdList><ArticleId IdType="pubmed">8318230</ArticleId></ArticleIdList></Reference><Reference><Citation>Brosch JR, Farlow MR, Risacher SL, and Apostolova LG (2017). Tau Imaging in Alzheimer&#x2019;s Disease Diagnosis and Clinical Trials. Neurotherapeutics 14, 62&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5233632</ArticleId><ArticleId IdType="pubmed">27873182</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F, Lavenir I, Falcon B, Frank S, Goedert M, and Tolnay M. (2013). &#x201c;Prion-like&#x201d; templated misfolding in tauopathies. Brain Pathol. 23, 342&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8028860</ArticleId><ArticleId IdType="pubmed">23587140</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleveland DW, Hwo SY, and Kirschner MW (1977). Physical and chemical properties of purified tau factor and the role of tau in microtubule assembly. J. Mol. Biol. 116, 227&#x2013;247.</Citation><ArticleIdList><ArticleId IdType="pubmed">146092</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen TJ, Guo JL, Hurtado DE, Kwong LK, Mills IP, Trojanowski JQ, and Lee VM (2011). The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat. Commun. 2, 252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3120096</ArticleId><ArticleId IdType="pubmed">21427723</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox J, and Mann M. (2008). MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 26, 1367&#x2013;1372.</Citation><ArticleIdList><ArticleId IdType="pubmed">19029910</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox J, Neuhauser N, Michalski A, Scheltema RA, Olsen JV, and Mann M. (2011). Andromeda: a peptide search engine integrated into the MaxQuant environment. J. Proteome Res. 10, 1794&#x2013;1805.</Citation><ArticleIdList><ArticleId IdType="pubmed">21254760</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox J, Hein MY, Luber CA, Paron I, Nagaraj N, and Mann M. (2014). Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. Mol. Cell. Proteomics 13, 2513&#x2013;2526.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4159666</ArticleId><ArticleId IdType="pubmed">24942700</ArticleId></ArticleIdList></Reference><Reference><Citation>Crowther T, Goedert M, and Wischik CM (1989). The repeat region of microtubule-associated protein tau forms part of the core of the paired helical filament of Alzheimer&#x2019;s disease. Ann. Med. 21, 127&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">2504257</ArticleId></ArticleIdList></Reference><Reference><Citation>de Calignon A, Polydoro M, Su&#xe1;rez-Calvet M, William C, Adamowicz DH, Kopeikina KJ, Pitstick R, Sahara N, Ashe KH, Carlson GA, et al. (2012). Propagation of tau pathology in a model of early Alzheimer&#x2019;s disease. Neuron 73, 685&#x2013;697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3292759</ArticleId><ArticleId IdType="pubmed">22365544</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinkel PD, Holden MR, Matin N, and Margittai M. (2015). RNA Binds to Tau Fibrils and Sustains Template-Assisted Growth. Biochemistry 54, 4731&#x2013;4740.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4526887</ArticleId><ArticleId IdType="pubmed">26177386</ArticleId></ArticleIdList></Reference><Reference><Citation>Escher C, Reiter L, MacLean B, Ossola R, Herzog F, Chilton J, MacCoss MJ, and Rinner O. (2012). Using iRT, a normalized retention time for more targeted measurement of peptides. Proteomics 12, 1111&#x2013;1121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3918884</ArticleId><ArticleId IdType="pubmed">22577012</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon B, Zhang W, Schweighauser M, Murzin AG, Vidal R, Garringer HJ, Ghetti B, Scheres SHW, and Goedert M. (2018). Tau filaments from multiple cases of sporadic and inherited Alzheimer&#x2019;s disease adopt a common fold. Acta Neuropathol. 136, 699&#x2013;708.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6208733</ArticleId><ArticleId IdType="pubmed">30276465</ArticleId></ArticleIdList></Reference><Reference><Citation>Fichou Y, Lin Y, Rauch JN, Vigers M, Zeng Z, Srivastava M, Keller TJ, Freed JH, Kosik KS, and Han S. (2018). Cofactors are essential constituents of stable and seeding-active tau fibrils. Proc. Natl. Acad. Sci. USA 115, 13234&#x2013;13239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6310788</ArticleId><ArticleId IdType="pubmed">30538196</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzpatrick AWP, Falcon B, He S, Murzin AG, Murshudov G, Garringer HJ, Crowther RA, Ghetti B, Goedert M, and Scheres SHW (2017). Cryo-EM structures of tau filaments from Alzheimer&#x2019;s disease. Nature 547, 185&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5552202</ArticleId><ArticleId IdType="pubmed">28678775</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannakopoulos P, Herrmann FR, Bussi&#xe8;re T, Bouras C, K&#xf6;vari E, Perl DP, Morrison JH, Gold G, and Hof PR (2003). Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer&#x2019;s disease. Neurology 60, 1495&#x2013;1500.</Citation><ArticleIdList><ArticleId IdType="pubmed">12743238</ArticleId></ArticleIdList></Reference><Reference><Citation>Glenner GG, and Wong CW (1984). Alzheimer&#x2019;s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120, 885&#x2013;890.</Citation><ArticleIdList><ArticleId IdType="pubmed">6375662</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Jakes R, and Vanmechelen E. (1995). Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205. Neurosci. Lett. 189, 167&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pubmed">7624036</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Jakes R, Spillantini MG, Hasegawa M, Smith MJ, and Crowther RA (1996). Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans. Nature 383, 550&#x2013;553.</Citation><ArticleIdList><ArticleId IdType="pubmed">8849730</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, Parisi JE, and Hyman BT (1997). Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer&#x2019;s disease. Ann. Neurol. 41, 17&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">9005861</ArticleId></ArticleIdList></Reference><Reference><Citation>Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, and Wisniewski HM (1986). Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J. Biol. Chem. 261, 6084&#x2013;6089.</Citation><ArticleIdList><ArticleId IdType="pubmed">3084478</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo T, Noble W, and Hanger DP (2017). Roles of tau protein in health and disease. Acta Neuropathol. 133, 665&#x2013;704.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5390006</ArticleId><ArticleId IdType="pubmed">28386764</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanger DP, Byers HL, Wray S, Leung KY, Saxton MJ, Seereeram A, Reynolds CH, Ward MA, and Anderton BH (2007). Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis. J. Biol. Chem. 282, 23645&#x2013;23654.</Citation><ArticleIdList><ArticleId IdType="pubmed">17562708</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa M, Morishima-Kawashima M, Takio K, Suzuki M, Titani K, and Ihara Y. (1992). Protein sequence and mass spectrometric analyses of tau in the Alzheimer&#x2019;s disease brain. J. Biol. Chem. 267, 17047&#x2013;17054.</Citation><ArticleIdList><ArticleId IdType="pubmed">1512244</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes BB, Furman JL, Mahan TE, Yamasaki TR, Mirbaha H, Eades WC, Belaygorod L, Cairns NJ, Holtzman DM, and Diamond MI (2014). Proteopathic tau seeding predicts tauopathy in vivo. Proc. Natl. Acad. Sci. USA 111, E4376&#x2013;E4385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4205609</ArticleId><ArticleId IdType="pubmed">25261551</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson SJ, Kerridge C, Cooper J, Cavallini A, Falcon B, Cella CV, Landi A, Szekeres PG, Murray TK, Ahmed Z, et al. (2016). Short Fibrils Constitute the Major Species of Seed-Competent Tau in the Brains of Mice Transgenic for Human P301S Tau. J. Neurosci. 36, 762&#x2013;772.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4719013</ArticleId><ArticleId IdType="pubmed">26791207</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach TG, Serrano GE, Chai X, Proctor NK, Eichenlaub U, Zetterberg H, et al. (2020). Plasma P-tau181 in Alzheimer&#x2019;s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer&#x2019;s dementia. Nat. Med. 26, 379&#x2013;386.</Citation><ArticleIdList><ArticleId IdType="pubmed">32123385</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeganathan S, von Bergen M, Brutlach H, Steinhoff HJ, and Mandelkow E. (2006). Global hairpin folding of tau in solution. Biochemistry 45, 2283&#x2013;2293.</Citation><ArticleIdList><ArticleId IdType="pubmed">16475817</ArticleId></ArticleIdList></Reference><Reference><Citation>Jicha GA, O&#x2019;Donnell A, Weaver C, Angeletti R, and Davies P. (1999a). Hierarchical phosphorylation of recombinant tau by the paired-helical filament-associated protein kinase is dependent on cyclic AMP-dependent protein kinase. J. Neurochem. 72, 214&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">9886072</ArticleId></ArticleIdList></Reference><Reference><Citation>Jicha GA, Weaver C, Lane E, Vianna C, Kress Y, Rockwood J, and Davies P. (1999b). cAMP-dependent protein kinase phosphorylations on tau in Alzheimer&#x2019;s disease. J. Neurosci. 19, 7486&#x2013;7494.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782506</ArticleId><ArticleId IdType="pubmed">10460255</ArticleId></ArticleIdList></Reference><Reference><Citation>Jucker M, and Walker LC (2013). Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature 501, 45&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3963807</ArticleId><ArticleId IdType="pubmed">24005412</ArticleId></ArticleIdList></Reference><Reference><Citation>Kampers T, Friedhoff P, Biernat J, Mandelkow EM, and Mandelkow E. (1996). RNA stimulates aggregation of microtubule-associated protein tau into Alzheimer-like paired helical filaments. FEBS Lett. 399, 344&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">8985176</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessner D, Chambers M, Burke R, Agus D, and Mallick P. (2008). ProteoWizard: open source software for rapid proteomics tools development. Bioinformatics 24, 2534&#x2013;2536.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2732273</ArticleId><ArticleId IdType="pubmed">18606607</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosik KS, Joachim CL, and Selkoe DJ (1986). Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc. Natl. Acad. Sci. USA 83, 4044&#x2013;4048.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC323662</ArticleId><ArticleId IdType="pubmed">2424016</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xea; S, Josse J, and Husson F. (2008). FactoMineR: A Package for Multivariate Analysis. J. Stat. Softw. 25 (1).</Citation></Reference><Reference><Citation>Lovestone S, and Reynolds CH (1997). The phosphorylation of tau: a critical stage in neurodevelopment and neurodegenerative processes. Neuroscience 78, 309&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pubmed">9145789</ArticleId></ArticleIdList></Reference><Reference><Citation>MacLean B, Tomazela DM, Shulman N, Chambers M, Finney GL, Frewen B, Kern R, Tabb DL, Liebler DC, and MacCoss MJ (2010). Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics 26, 966&#x2013;968.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2844992</ArticleId><ArticleId IdType="pubmed">20147306</ArticleId></ArticleIdList></Reference><Reference><Citation>Mair W, Muntel J, Tepper K, Tang S, Biernat J, Seeley WW, Kosik KS, Mandelkow E, Steen H, and Steen JA (2016). FLEXITau: Quantifying Post-translational Modifications of Tau Protein in Vitro and in Human Disease. Anal. Chem. 88, 3704&#x2013;3714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5808556</ArticleId><ArticleId IdType="pubmed">26877193</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin L, Latypova X, Wilson CM, Magnaudeix A, Perrin ML, and Terro F. (2013a). Tau protein phosphatases in Alzheimer&#x2019;s disease: the leading role of PP2A. Ageing Res. Rev. 12, 39&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">22771380</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin L, Latypova X, Wilson CM, Magnaudeix A, Perrin ML, Yardin C, and Terro F. (2013b). Tau protein kinases: involvement in Alzheimer&#x2019;s disease. Ageing Res. Rev. 12, 289&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pubmed">22742992</ArticleId></ArticleIdList></Reference><Reference><Citation>Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, and Beyreuther K. (1985). Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. USA 82, 4245&#x2013;4249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC397973</ArticleId><ArticleId IdType="pubmed">3159021</ArticleId></ArticleIdList></Reference><Reference><Citation>Min SW, Cho SH, Zhou Y, Schroeder S, Haroutunian V, Seeley WW, Huang EJ, Shen Y, Masliah E, Mukherjee C, et al. (2010). Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron 67, 953&#x2013;966.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3035103</ArticleId><ArticleId IdType="pubmed">20869593</ArticleId></ArticleIdList></Reference><Reference><Citation>Min SW, Chen X, Tracy TE, Li Y, Zhou Y, Wang C, Shirakawa K, Minami SS, Defensor E, Mok SA, et al. (2015). Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits. Nat. Med. 21, 1154&#x2013;1162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4598295</ArticleId><ArticleId IdType="pubmed">26390242</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, and Berg L. (1991). The Consortium to Establish a Registry for Alzheimer&#x2019;s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer&#x2019;s disease. Neurology 41, 479&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine TJ, Monsell SE, Beach TG, Bigio EH, Bu Y, Cairns NJ, Frosch M, Henriksen J, Kofler J, Kukull WA, et al. (2016). Multisite assessment of NIA-AA guidelines for the neuropathologic evaluation of Alzheimer&#x2019;s disease. Alzheimers Dement. 12, 164&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4562409</ArticleId><ArticleId IdType="pubmed">26327235</ArticleId></ArticleIdList></Reference><Reference><Citation>Morishima-Kawashima M, Hasegawa M, Takio K, Suzuki M, Yoshida H, Titani K, and Ihara Y. (1995). Proline-directed and non-proline-directed phosphorylation of PHF-tau. J. Biol. Chem. 270, 823&#x2013;829.</Citation><ArticleIdList><ArticleId IdType="pubmed">7822317</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris M, Knudsen GM, Maeda S, Trinidad JC, Ioanoviciu A, Burlingame AL, and Mucke L. (2015). Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice. Nat. Neurosci. 18, 1183&#x2013;1189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8049446</ArticleId><ArticleId IdType="pubmed">26192747</ArticleId></ArticleIdList></Reference><Reference><Citation>Mudher A, Colin M, Dujardin S, Medina M, Dewachter I, Alavi Naini SM, Mandelkow EM, Mandelkow E, Bu&#xe9;e L, Goedert M, and Brion JP (2017). What is the evidence that tau pathology spreads through prionlike propagation? Acta Neuropathol. Commun. 5, 99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5735872</ArticleId><ArticleId IdType="pubmed">29258615</ArticleId></ArticleIdList></Reference><Reference><Citation>Poorkaj P, Bird TD, Wijsman E, Nemens E, Garruto RM, Anderson L, Andreadis A, Wiederholt WC, Raskind M, and Schellenberg GD (1998). Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann. Neurol. 43, 815&#x2013;825.</Citation><ArticleIdList><ArticleId IdType="pubmed">9629852</ArticleId></ArticleIdList></Reference><Reference><Citation>Renard BY, Kirchner M, Monigatti F, Ivanov AR, Rappsilber J, Winter D, Steen JA, Hamprecht FA, and Steen H. (2009). When less can yield more - Computational preprocessing of MS/MS spectra for peptide identification. Proteomics 9, 4978&#x2013;4984.</Citation><ArticleIdList><ArticleId IdType="pubmed">19743429</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigurdsson EM (2018). Tau Immunotherapies for Alzheimer&#x2019;s Disease and Related Tauopathies: Progress and Potential Pitfalls. J. Alzheimers Dis. 64 (s1), S555&#x2013;S565.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6171771</ArticleId><ArticleId IdType="pubmed">29865056</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh S, Springer M, Steen J, Kirschner MW, and Steen H. (2009). FLEX-IQuant: a novel tool for the absolute quantification of proteins, and the simultaneous identification and quantification of potentially modified peptides. J. Proteome Res. 8, 2201&#x2013;2210.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2868505</ArticleId><ArticleId IdType="pubmed">19344176</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh SA, Winter D, Kirchner M, Chauhan R, Ahmed S, Ozlu N, Tzur A, Steen JA, and Steen H. (2014). Co-regulation proteomics reveals substrates and mechanisms of APC/C-dependent degradation. EMBO J. 33, 385&#x2013;399.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3989644</ArticleId><ArticleId IdType="pubmed">24510915</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith LM, and Kelleher NL; Consortium for Top Down Proteomics (2013). Proteoform: a single term describing protein complexity. Nat. Methods 10, 186&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4114032</ArticleId><ArticleId IdType="pubmed">23443629</ArticleId></ArticleIdList></Reference><Reference><Citation>Soria PS, McGary KL, and Rokas A. (2014). Functional divergence for every paralog. Mol. Biol. Evol. 31, 984&#x2013;992.</Citation><ArticleIdList><ArticleId IdType="pubmed">24451325</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, Murrell JR, Goedert M, Farlow MR, Klug A, and Ghetti B. (1998). Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc. Natl. Acad. Sci. USA 95, 7737&#x2013;7741.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC22742</ArticleId><ArticleId IdType="pubmed">9636220</ArticleId></ArticleIdList></Reference><Reference><Citation>Stacklies W, Redestig H, Scholz M, Walther D, and Selbig J. (2007). Pca-Methods&#x2013;a bioconductor package providing PCA methods for incomplete data. Bioinformatics 23, 1164&#x2013;1167.</Citation><ArticleIdList><ArticleId IdType="pubmed">17344241</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda S, Wegmann S, Cho H, DeVos SL, Commins C, Roe AD, Nicholls SB, Carlson GA, Pitstick R, Nobuhara CK, et al. (2015). Neuronal uptake and propagation of a rare phosphorylated high-molecular-weight tau derived from Alzheimer&#x2019;s disease brain. Nat. Commun. 6, 8490.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4608380</ArticleId><ArticleId IdType="pubmed">26458742</ArticleId></ArticleIdList></Reference><Reference><Citation>Th&#xe9;venot EA, Roux A, Xu Y, Ezan E, and Junot C. (2015). Analysis of the Human Adult Urinary Metabolome Variations with Age, Body Mass Index, and Gender by Implementing a Comprehensive Workflow for Univariate and OPLS Statistical Analyses. J. Proteome Res. 14, 3322&#x2013;3335.</Citation><ArticleIdList><ArticleId IdType="pubmed">26088811</ArticleId></ArticleIdList></Reference><Reference><Citation>Thijssen EH, La Joie R, Wolf A, Strom A, Wang P, Iaccarino L, Bourakova V, Cobigo Y, Heuer H, Spina S, et al.; Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) investigators (2020). Diagnostic value of plasma phosphorylated tau181 in Alzheimer&#x2019;s disease and frontotemporal lobar degeneration. Nat. Med. 26, 387&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7101073</ArticleId><ArticleId IdType="pubmed">32123386</ArticleId></ArticleIdList></Reference><Reference><Citation>Tramutola A, Sharma N, Barone E, Lanzillotta C, Castellani A, Iavarone F, Vincenzoni F, Castagnola M, Butterfield DA, Gaetani S, et al. (2018). Proteomic identification of altered protein O-GlcNAcylation in a triple transgenic mouse model of Alzheimer&#x2019;s disease. Biochim. Biophys. Acta Mol. Basis Dis. 1864, 3309&#x2013;3321.</Citation><ArticleIdList><ArticleId IdType="pubmed">30031227</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker LC, Diamond MI, Duff KE, and Hyman BT (2013). Mechanisms of protein seeding in neurodegenerative diseases. JAMA Neurol. 70, 304&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3665718</ArticleId><ArticleId IdType="pubmed">23599928</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, and Mandelkow E. (2016). Tau in physiology and pathology. Nat. Rev. Neurosci. 17, 5&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">26631930</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisniewski JR, Zougman A, Nagaraj N, and Mann M. (2009). Universal sample preparation method for proteome analysis. Nat. Methods 6, 359&#x2013;362.</Citation><ArticleIdList><ArticleId IdType="pubmed">19377485</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood JG, Mirra SS, Pollock NJ, and Binder LI (1986). Neurofibrillary tangles of Alzheimer disease share antigenic determinants with the axonal microtubule-associated protein tau (tau). Proc. Natl. Acad. Sci. USA 83, 4040&#x2013;4043.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC323661</ArticleId><ArticleId IdType="pubmed">2424015</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang XJ, and Seto E. (2008). Lysine acetylation: codified crosstalk with other posttranslational modifications. Mol. Cell 31, 449&#x2013;461.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2551738</ArticleId><ArticleId IdType="pubmed">18722172</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Lin Y, Eschmann NA, Zhou H, Rauch JN, Hernandez I, Guzman E, Kosik KS, and Han S. (2017). RNA stores tau reversibly in complex coacervates. PLoS Biol. 15, e2002183.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5500003</ArticleId><ArticleId IdType="pubmed">28683104</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">33208540</PMID><DateRevised><Year>2024</Year><Month>05</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>96</Volume><Issue>8</Issue><PubDate><Year>2021</Year><Month>Feb</Month><Day>22</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>PM<sub>2.5</sub> Associated With Gray Matter Atrophy Reflecting Increased Alzheimer Risk in Older Women.</ArticleTitle><Pagination><StartPage>e1190</StartPage><EndPage>e1201</EndPage><MedlinePgn>e1190-e1201</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000011149</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To examine whether late-life exposure to PM<sub>2.5</sub> (particulate matter with aerodynamic diameters &lt;2.5 &#xb5;m) contributes to progressive brain atrophy predictive of Alzheimer disease (AD) using a community-dwelling cohort of women (age 70-89 years) with up to 2 brain MRI scans (MRI-1, 2005-2006; MRI-2, 2010-2011).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">AD pattern similarity (AD-PS) scores, developed by supervised machine learning and validated with MRI data from the Alzheimer's Disease Neuroimaging Initiative, were used to capture high-dimensional gray matter atrophy in brain areas vulnerable to AD (e.g., amygdala, hippocampus, parahippocampal gyrus, thalamus, inferior temporal lobe areas, and midbrain). Using participants' addresses and air monitoring data, we implemented a spatiotemporal model to estimate 3-year average exposure to PM<sub>2.5</sub> preceding MRI-1. General linear models were used to examine the association between PM<sub>2.5</sub> and AD-PS scores (baseline and 5-year standardized change), accounting for potential confounders and white matter lesion volumes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">For 1,365 women 77.9 &#xb1; 3.7 years of age in 2005 to 2006, there was no association between PM<sub>2.5</sub> and baseline AD-PS score in cross-sectional analyses (&#x3b2; = -0.004; 95% confidence interval [CI] -0.019 to 0.011). Longitudinally, each interquartile range increase of PM<sub>2.5</sub> (2.82 &#xb5;g/m<sup>3</sup>) was associated with increased AD-PS scores during the follow-up, equivalent to a 24% (hazard ratio 1.24, 95% CI 1.14-1.34) increase in AD risk over 5 years (n = 712, age 77.4 &#xb1; 3.5 years). This association remained after adjustment for sociodemographics, intracranial volume, lifestyle, clinical characteristics, and white matter lesions and was present with levels below US regulatory standards (&lt;12 &#xb5;g/m<sup>3</sup>).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Late-life exposure to PM<sub>2.5</sub> is associated with increased neuroanatomic risk of AD, which may not be explained by available indicators of cerebrovascular damage.</AbstractText><CopyrightInformation>&#xa9; 2020 American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Younan</LastName><ForeName>Diana</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-1933-8098</Identifier><AffiliationInfo><Affiliation>From the Departments of Preventive Medicine (D.Y., J.C.C) and Neurology (X.W., A.J.P., H.C.C., J.-C.C.) and the Center for Economic and Social Research (M.G.), University of Southern California, Los Angeles; Departments of Biostatistics and Data Science (R.C., R.B., S.A.G., S.S., D.P.B., M.A.E.), Psychiatry and Behavioral Medicine (S.R.R.), Social Sciences &amp; Health Policy (S.A.S., S.R.R.), and Neurology (B.C.S.), Wake Forest School of Medicine, Winston-Salem, NC; Laboratory of Behavioral Neuroscience (S.M.R.), National Institute on Aging, Baltimore, MD; Department of Environmental Sciences and Engineering (M.L.S., W.V.), University of North Carolina, Chapel Hill; Departments of Health Research and Policy (Epidemiology) and Neurology and Neurological Sciences (V.W.H.), Stanford University, CA; Department of Medicine (J.E.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Center for Cognitive Neurology, Department of Neurology (J.S.), New York University Grossman School of Medicine, New York. dyounan@usc.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xinhui</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>From the Departments of Preventive Medicine (D.Y., J.C.C) and Neurology (X.W., A.J.P., H.C.C., J.-C.C.) and the Center for Economic and Social Research (M.G.), University of Southern California, Los Angeles; Departments of Biostatistics and Data Science (R.C., R.B., S.A.G., S.S., D.P.B., M.A.E.), Psychiatry and Behavioral Medicine (S.R.R.), Social Sciences &amp; Health Policy (S.A.S., S.R.R.), and Neurology (B.C.S.), Wake Forest School of Medicine, Winston-Salem, NC; Laboratory of Behavioral Neuroscience (S.M.R.), National Institute on Aging, Baltimore, MD; Department of Environmental Sciences and Engineering (M.L.S., W.V.), University of North Carolina, Chapel Hill; Departments of Health Research and Policy (Epidemiology) and Neurology and Neurological Sciences (V.W.H.), Stanford University, CA; Department of Medicine (J.E.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Center for Cognitive Neurology, Department of Neurology (J.S.), New York University Grossman School of Medicine, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casanova</LastName><ForeName>Ramon</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>From the Departments of Preventive Medicine (D.Y., J.C.C) and Neurology (X.W., A.J.P., H.C.C., J.-C.C.) and the Center for Economic and Social Research (M.G.), University of Southern California, Los Angeles; Departments of Biostatistics and Data Science (R.C., R.B., S.A.G., S.S., D.P.B., M.A.E.), Psychiatry and Behavioral Medicine (S.R.R.), Social Sciences &amp; Health Policy (S.A.S., S.R.R.), and Neurology (B.C.S.), Wake Forest School of Medicine, Winston-Salem, NC; Laboratory of Behavioral Neuroscience (S.M.R.), National Institute on Aging, Baltimore, MD; Department of Environmental Sciences and Engineering (M.L.S., W.V.), University of North Carolina, Chapel Hill; Departments of Health Research and Policy (Epidemiology) and Neurology and Neurological Sciences (V.W.H.), Stanford University, CA; Department of Medicine (J.E.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Center for Cognitive Neurology, Department of Neurology (J.S.), New York University Grossman School of Medicine, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barnard</LastName><ForeName>Ryan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>From the Departments of Preventive Medicine (D.Y., J.C.C) and Neurology (X.W., A.J.P., H.C.C., J.-C.C.) and the Center for Economic and Social Research (M.G.), University of Southern California, Los Angeles; Departments of Biostatistics and Data Science (R.C., R.B., S.A.G., S.S., D.P.B., M.A.E.), Psychiatry and Behavioral Medicine (S.R.R.), Social Sciences &amp; Health Policy (S.A.S., S.R.R.), and Neurology (B.C.S.), Wake Forest School of Medicine, Winston-Salem, NC; Laboratory of Behavioral Neuroscience (S.M.R.), National Institute on Aging, Baltimore, MD; Department of Environmental Sciences and Engineering (M.L.S., W.V.), University of North Carolina, Chapel Hill; Departments of Health Research and Policy (Epidemiology) and Neurology and Neurological Sciences (V.W.H.), Stanford University, CA; Department of Medicine (J.E.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Center for Cognitive Neurology, Department of Neurology (J.S.), New York University Grossman School of Medicine, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaussoin</LastName><ForeName>Sarah A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>From the Departments of Preventive Medicine (D.Y., J.C.C) and Neurology (X.W., A.J.P., H.C.C., J.-C.C.) and the Center for Economic and Social Research (M.G.), University of Southern California, Los Angeles; Departments of Biostatistics and Data Science (R.C., R.B., S.A.G., S.S., D.P.B., M.A.E.), Psychiatry and Behavioral Medicine (S.R.R.), Social Sciences &amp; Health Policy (S.A.S., S.R.R.), and Neurology (B.C.S.), Wake Forest School of Medicine, Winston-Salem, NC; Laboratory of Behavioral Neuroscience (S.M.R.), National Institute on Aging, Baltimore, MD; Department of Environmental Sciences and Engineering (M.L.S., W.V.), University of North Carolina, Chapel Hill; Departments of Health Research and Policy (Epidemiology) and Neurology and Neurological Sciences (V.W.H.), Stanford University, CA; Department of Medicine (J.E.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Center for Cognitive Neurology, Department of Neurology (J.S.), New York University Grossman School of Medicine, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saldana</LastName><ForeName>Santiago</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From the Departments of Preventive Medicine (D.Y., J.C.C) and Neurology (X.W., A.J.P., H.C.C., J.-C.C.) and the Center for Economic and Social Research (M.G.), University of Southern California, Los Angeles; Departments of Biostatistics and Data Science (R.C., R.B., S.A.G., S.S., D.P.B., M.A.E.), Psychiatry and Behavioral Medicine (S.R.R.), Social Sciences &amp; Health Policy (S.A.S., S.R.R.), and Neurology (B.C.S.), Wake Forest School of Medicine, Winston-Salem, NC; Laboratory of Behavioral Neuroscience (S.M.R.), National Institute on Aging, Baltimore, MD; Department of Environmental Sciences and Engineering (M.L.S., W.V.), University of North Carolina, Chapel Hill; Departments of Health Research and Policy (Epidemiology) and Neurology and Neurological Sciences (V.W.H.), Stanford University, CA; Department of Medicine (J.E.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Center for Cognitive Neurology, Department of Neurology (J.S.), New York University Grossman School of Medicine, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petkus</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>From the Departments of Preventive Medicine (D.Y., J.C.C) and Neurology (X.W., A.J.P., H.C.C., J.-C.C.) and the Center for Economic and Social Research (M.G.), University of Southern California, Los Angeles; Departments of Biostatistics and Data Science (R.C., R.B., S.A.G., S.S., D.P.B., M.A.E.), Psychiatry and Behavioral Medicine (S.R.R.), Social Sciences &amp; Health Policy (S.A.S., S.R.R.), and Neurology (B.C.S.), Wake Forest School of Medicine, Winston-Salem, NC; Laboratory of Behavioral Neuroscience (S.M.R.), National Institute on Aging, Baltimore, MD; Department of Environmental Sciences and Engineering (M.L.S., W.V.), University of North Carolina, Chapel Hill; Departments of Health Research and Policy (Epidemiology) and Neurology and Neurological Sciences (V.W.H.), Stanford University, CA; Department of Medicine (J.E.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Center for Cognitive Neurology, Department of Neurology (J.S.), New York University Grossman School of Medicine, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beavers</LastName><ForeName>Daniel P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>From the Departments of Preventive Medicine (D.Y., J.C.C) and Neurology (X.W., A.J.P., H.C.C., J.-C.C.) and the Center for Economic and Social Research (M.G.), University of Southern California, Los Angeles; Departments of Biostatistics and Data Science (R.C., R.B., S.A.G., S.S., D.P.B., M.A.E.), Psychiatry and Behavioral Medicine (S.R.R.), Social Sciences &amp; Health Policy (S.A.S., S.R.R.), and Neurology (B.C.S.), Wake Forest School of Medicine, Winston-Salem, NC; Laboratory of Behavioral Neuroscience (S.M.R.), National Institute on Aging, Baltimore, MD; Department of Environmental Sciences and Engineering (M.L.S., W.V.), University of North Carolina, Chapel Hill; Departments of Health Research and Policy (Epidemiology) and Neurology and Neurological Sciences (V.W.H.), Stanford University, CA; Department of Medicine (J.E.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Center for Cognitive Neurology, Department of Neurology (J.S.), New York University Grossman School of Medicine, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Resnick</LastName><ForeName>Susan M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>From the Departments of Preventive Medicine (D.Y., J.C.C) and Neurology (X.W., A.J.P., H.C.C., J.-C.C.) and the Center for Economic and Social Research (M.G.), University of Southern California, Los Angeles; Departments of Biostatistics and Data Science (R.C., R.B., S.A.G., S.S., D.P.B., M.A.E.), Psychiatry and Behavioral Medicine (S.R.R.), Social Sciences &amp; Health Policy (S.A.S., S.R.R.), and Neurology (B.C.S.), Wake Forest School of Medicine, Winston-Salem, NC; Laboratory of Behavioral Neuroscience (S.M.R.), National Institute on Aging, Baltimore, MD; Department of Environmental Sciences and Engineering (M.L.S., W.V.), University of North Carolina, Chapel Hill; Departments of Health Research and Policy (Epidemiology) and Neurology and Neurological Sciences (V.W.H.), Stanford University, CA; Department of Medicine (J.E.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Center for Cognitive Neurology, Department of Neurology (J.S.), New York University Grossman School of Medicine, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manson</LastName><ForeName>JoAnn E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>From the Departments of Preventive Medicine (D.Y., J.C.C) and Neurology (X.W., A.J.P., H.C.C., J.-C.C.) and the Center for Economic and Social Research (M.G.), University of Southern California, Los Angeles; Departments of Biostatistics and Data Science (R.C., R.B., S.A.G., S.S., D.P.B., M.A.E.), Psychiatry and Behavioral Medicine (S.R.R.), Social Sciences &amp; Health Policy (S.A.S., S.R.R.), and Neurology (B.C.S.), Wake Forest School of Medicine, Winston-Salem, NC; Laboratory of Behavioral Neuroscience (S.M.R.), National Institute on Aging, Baltimore, MD; Department of Environmental Sciences and Engineering (M.L.S., W.V.), University of North Carolina, Chapel Hill; Departments of Health Research and Policy (Epidemiology) and Neurology and Neurological Sciences (V.W.H.), Stanford University, CA; Department of Medicine (J.E.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Center for Cognitive Neurology, Department of Neurology (J.S.), New York University Grossman School of Medicine, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serre</LastName><ForeName>Marc L</ForeName><Initials>ML</Initials><Identifier Source="ORCID">0000-0003-3145-4024</Identifier><AffiliationInfo><Affiliation>From the Departments of Preventive Medicine (D.Y., J.C.C) and Neurology (X.W., A.J.P., H.C.C., J.-C.C.) and the Center for Economic and Social Research (M.G.), University of Southern California, Los Angeles; Departments of Biostatistics and Data Science (R.C., R.B., S.A.G., S.S., D.P.B., M.A.E.), Psychiatry and Behavioral Medicine (S.R.R.), Social Sciences &amp; Health Policy (S.A.S., S.R.R.), and Neurology (B.C.S.), Wake Forest School of Medicine, Winston-Salem, NC; Laboratory of Behavioral Neuroscience (S.M.R.), National Institute on Aging, Baltimore, MD; Department of Environmental Sciences and Engineering (M.L.S., W.V.), University of North Carolina, Chapel Hill; Departments of Health Research and Policy (Epidemiology) and Neurology and Neurological Sciences (V.W.H.), Stanford University, CA; Department of Medicine (J.E.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Center for Cognitive Neurology, Department of Neurology (J.S.), New York University Grossman School of Medicine, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vizuete</LastName><ForeName>William</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0002-1399-2948</Identifier><AffiliationInfo><Affiliation>From the Departments of Preventive Medicine (D.Y., J.C.C) and Neurology (X.W., A.J.P., H.C.C., J.-C.C.) and the Center for Economic and Social Research (M.G.), University of Southern California, Los Angeles; Departments of Biostatistics and Data Science (R.C., R.B., S.A.G., S.S., D.P.B., M.A.E.), Psychiatry and Behavioral Medicine (S.R.R.), Social Sciences &amp; Health Policy (S.A.S., S.R.R.), and Neurology (B.C.S.), Wake Forest School of Medicine, Winston-Salem, NC; Laboratory of Behavioral Neuroscience (S.M.R.), National Institute on Aging, Baltimore, MD; Department of Environmental Sciences and Engineering (M.L.S., W.V.), University of North Carolina, Chapel Hill; Departments of Health Research and Policy (Epidemiology) and Neurology and Neurological Sciences (V.W.H.), Stanford University, CA; Department of Medicine (J.E.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Center for Cognitive Neurology, Department of Neurology (J.S.), New York University Grossman School of Medicine, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henderson</LastName><ForeName>Victor W</ForeName><Initials>VW</Initials><AffiliationInfo><Affiliation>From the Departments of Preventive Medicine (D.Y., J.C.C) and Neurology (X.W., A.J.P., H.C.C., J.-C.C.) and the Center for Economic and Social Research (M.G.), University of Southern California, Los Angeles; Departments of Biostatistics and Data Science (R.C., R.B., S.A.G., S.S., D.P.B., M.A.E.), Psychiatry and Behavioral Medicine (S.R.R.), Social Sciences &amp; Health Policy (S.A.S., S.R.R.), and Neurology (B.C.S.), Wake Forest School of Medicine, Winston-Salem, NC; Laboratory of Behavioral Neuroscience (S.M.R.), National Institute on Aging, Baltimore, MD; Department of Environmental Sciences and Engineering (M.L.S., W.V.), University of North Carolina, Chapel Hill; Departments of Health Research and Policy (Epidemiology) and Neurology and Neurological Sciences (V.W.H.), Stanford University, CA; Department of Medicine (J.E.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Center for Cognitive Neurology, Department of Neurology (J.S.), New York University Grossman School of Medicine, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sachs</LastName><ForeName>Bonnie C</ForeName><Initials>BC</Initials><AffiliationInfo><Affiliation>From the Departments of Preventive Medicine (D.Y., J.C.C) and Neurology (X.W., A.J.P., H.C.C., J.-C.C.) and the Center for Economic and Social Research (M.G.), University of Southern California, Los Angeles; Departments of Biostatistics and Data Science (R.C., R.B., S.A.G., S.S., D.P.B., M.A.E.), Psychiatry and Behavioral Medicine (S.R.R.), Social Sciences &amp; Health Policy (S.A.S., S.R.R.), and Neurology (B.C.S.), Wake Forest School of Medicine, Winston-Salem, NC; Laboratory of Behavioral Neuroscience (S.M.R.), National Institute on Aging, Baltimore, MD; Department of Environmental Sciences and Engineering (M.L.S., W.V.), University of North Carolina, Chapel Hill; Departments of Health Research and Policy (Epidemiology) and Neurology and Neurological Sciences (V.W.H.), Stanford University, CA; Department of Medicine (J.E.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Center for Cognitive Neurology, Department of Neurology (J.S.), New York University Grossman School of Medicine, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salinas</LastName><ForeName>Joel</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>From the Departments of Preventive Medicine (D.Y., J.C.C) and Neurology (X.W., A.J.P., H.C.C., J.-C.C.) and the Center for Economic and Social Research (M.G.), University of Southern California, Los Angeles; Departments of Biostatistics and Data Science (R.C., R.B., S.A.G., S.S., D.P.B., M.A.E.), Psychiatry and Behavioral Medicine (S.R.R.), Social Sciences &amp; Health Policy (S.A.S., S.R.R.), and Neurology (B.C.S.), Wake Forest School of Medicine, Winston-Salem, NC; Laboratory of Behavioral Neuroscience (S.M.R.), National Institute on Aging, Baltimore, MD; Department of Environmental Sciences and Engineering (M.L.S., W.V.), University of North Carolina, Chapel Hill; Departments of Health Research and Policy (Epidemiology) and Neurology and Neurological Sciences (V.W.H.), Stanford University, CA; Department of Medicine (J.E.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Center for Cognitive Neurology, Department of Neurology (J.S.), New York University Grossman School of Medicine, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gatz</LastName><ForeName>Margaret</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-1071-9970</Identifier><AffiliationInfo><Affiliation>From the Departments of Preventive Medicine (D.Y., J.C.C) and Neurology (X.W., A.J.P., H.C.C., J.-C.C.) and the Center for Economic and Social Research (M.G.), University of Southern California, Los Angeles; Departments of Biostatistics and Data Science (R.C., R.B., S.A.G., S.S., D.P.B., M.A.E.), Psychiatry and Behavioral Medicine (S.R.R.), Social Sciences &amp; Health Policy (S.A.S., S.R.R.), and Neurology (B.C.S.), Wake Forest School of Medicine, Winston-Salem, NC; Laboratory of Behavioral Neuroscience (S.M.R.), National Institute on Aging, Baltimore, MD; Department of Environmental Sciences and Engineering (M.L.S., W.V.), University of North Carolina, Chapel Hill; Departments of Health Research and Policy (Epidemiology) and Neurology and Neurological Sciences (V.W.H.), Stanford University, CA; Department of Medicine (J.E.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Center for Cognitive Neurology, Department of Neurology (J.S.), New York University Grossman School of Medicine, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Espeland</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>From the Departments of Preventive Medicine (D.Y., J.C.C) and Neurology (X.W., A.J.P., H.C.C., J.-C.C.) and the Center for Economic and Social Research (M.G.), University of Southern California, Los Angeles; Departments of Biostatistics and Data Science (R.C., R.B., S.A.G., S.S., D.P.B., M.A.E.), Psychiatry and Behavioral Medicine (S.R.R.), Social Sciences &amp; Health Policy (S.A.S., S.R.R.), and Neurology (B.C.S.), Wake Forest School of Medicine, Winston-Salem, NC; Laboratory of Behavioral Neuroscience (S.M.R.), National Institute on Aging, Baltimore, MD; Department of Environmental Sciences and Engineering (M.L.S., W.V.), University of North Carolina, Chapel Hill; Departments of Health Research and Policy (Epidemiology) and Neurology and Neurological Sciences (V.W.H.), Stanford University, CA; Department of Medicine (J.E.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Center for Cognitive Neurology, Department of Neurology (J.S.), New York University Grossman School of Medicine, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chui</LastName><ForeName>Helena C</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>From the Departments of Preventive Medicine (D.Y., J.C.C) and Neurology (X.W., A.J.P., H.C.C., J.-C.C.) and the Center for Economic and Social Research (M.G.), University of Southern California, Los Angeles; Departments of Biostatistics and Data Science (R.C., R.B., S.A.G., S.S., D.P.B., M.A.E.), Psychiatry and Behavioral Medicine (S.R.R.), Social Sciences &amp; Health Policy (S.A.S., S.R.R.), and Neurology (B.C.S.), Wake Forest School of Medicine, Winston-Salem, NC; Laboratory of Behavioral Neuroscience (S.M.R.), National Institute on Aging, Baltimore, MD; Department of Environmental Sciences and Engineering (M.L.S., W.V.), University of North Carolina, Chapel Hill; Departments of Health Research and Policy (Epidemiology) and Neurology and Neurological Sciences (V.W.H.), Stanford University, CA; Department of Medicine (J.E.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Center for Cognitive Neurology, Department of Neurology (J.S.), New York University Grossman School of Medicine, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shumaker</LastName><ForeName>Sally A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>From the Departments of Preventive Medicine (D.Y., J.C.C) and Neurology (X.W., A.J.P., H.C.C., J.-C.C.) and the Center for Economic and Social Research (M.G.), University of Southern California, Los Angeles; Departments of Biostatistics and Data Science (R.C., R.B., S.A.G., S.S., D.P.B., M.A.E.), Psychiatry and Behavioral Medicine (S.R.R.), Social Sciences &amp; Health Policy (S.A.S., S.R.R.), and Neurology (B.C.S.), Wake Forest School of Medicine, Winston-Salem, NC; Laboratory of Behavioral Neuroscience (S.M.R.), National Institute on Aging, Baltimore, MD; Department of Environmental Sciences and Engineering (M.L.S., W.V.), University of North Carolina, Chapel Hill; Departments of Health Research and Policy (Epidemiology) and Neurology and Neurological Sciences (V.W.H.), Stanford University, CA; Department of Medicine (J.E.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Center for Cognitive Neurology, Department of Neurology (J.S.), New York University Grossman School of Medicine, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rapp</LastName><ForeName>Stephen R</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>From the Departments of Preventive Medicine (D.Y., J.C.C) and Neurology (X.W., A.J.P., H.C.C., J.-C.C.) and the Center for Economic and Social Research (M.G.), University of Southern California, Los Angeles; Departments of Biostatistics and Data Science (R.C., R.B., S.A.G., S.S., D.P.B., M.A.E.), Psychiatry and Behavioral Medicine (S.R.R.), Social Sciences &amp; Health Policy (S.A.S., S.R.R.), and Neurology (B.C.S.), Wake Forest School of Medicine, Winston-Salem, NC; Laboratory of Behavioral Neuroscience (S.M.R.), National Institute on Aging, Baltimore, MD; Department of Environmental Sciences and Engineering (M.L.S., W.V.), University of North Carolina, Chapel Hill; Departments of Health Research and Policy (Epidemiology) and Neurology and Neurological Sciences (V.W.H.), Stanford University, CA; Department of Medicine (J.E.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Center for Cognitive Neurology, Department of Neurology (J.S.), New York University Grossman School of Medicine, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Jiu-Chiuan</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>From the Departments of Preventive Medicine (D.Y., J.C.C) and Neurology (X.W., A.J.P., H.C.C., J.-C.C.) and the Center for Economic and Social Research (M.G.), University of Southern California, Los Angeles; Departments of Biostatistics and Data Science (R.C., R.B., S.A.G., S.S., D.P.B., M.A.E.), Psychiatry and Behavioral Medicine (S.R.R.), Social Sciences &amp; Health Policy (S.A.S., S.R.R.), and Neurology (B.C.S.), Wake Forest School of Medicine, Winston-Salem, NC; Laboratory of Behavioral Neuroscience (S.M.R.), National Institute on Aging, Baltimore, MD; Department of Environmental Sciences and Engineering (M.L.S., W.V.), University of North Carolina, Chapel Hill; Departments of Health Research and Policy (Epidemiology) and Neurology and Neurological Sciences (V.W.H.), Stanford University, CA; Department of Medicine (J.E.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Center for Cognitive Neurology, Department of Neurology (J.S.), New York University Grossman School of Medicine, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Women's Health Initiative</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>HHSN268201100001I</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 ES007048</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005142</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201100004I</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066515</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201100046C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG057760</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066530</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN271201100004C</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201100002C</GrantID><Acronym>WH</Acronym><Agency>WHI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG047366</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201100002I</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201100001C</GrantID><Acronym>WH</Acronym><Agency>WHI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201100004C</GrantID><Acronym>WH</Acronym><Agency>WHI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201100003C</GrantID><Acronym>WH</Acronym><Agency>WHI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>L30 NS093525</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 ES025888</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG055367</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG054068</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG049638</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG033078</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201100003I</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>02</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>MMW Fortschr Med. 2021 Feb;163(2):22. doi: 10.1007/s15006-021-9576-5.</RefSource><PMID Version="1">33527273</PMID></CommentsCorrections></CommentsCorrectionsList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>10</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>11</Month><Day>19</Day><Hour>5</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>2</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33208540</ArticleId><ArticleId IdType="pmc">PMC8055348</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000011149</ArticleId><ArticleId IdType="pii">WNL.0000000000011149</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>The Lancet Neurology. Air pollution and brain health: an emerging issue. Lancet Neurol 2018;17:103.</Citation><ArticleIdList><ArticleId IdType="pubmed">29413304</ArticleId></ArticleIdList></Reference><Reference><Citation>Cipriani G, Danti S, Carlesi C, Borin G. Danger in the air: air pollution and cognitive dysfunction. Am J Alzheimers Dis Other Demen 2018;33:333&#x2013;341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10852418</ArticleId><ArticleId IdType="pubmed">29874918</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimakakou E, Johnston HJ, Streftaris G, Cherrie JW. Exposure to environmental and occupational particulate air pollution as a potential contributor to neurodegeneration and diabetes: a systematic review of epidemiological research. Int J Environ Res Public Health 2018;15:1704.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6121251</ArticleId><ArticleId IdType="pubmed">30096929</ArticleId></ArticleIdList></Reference><Reference><Citation>Kilian J, Kitazawa M. The emerging risk of exposure to air pollution on cognitive decline and Alzheimer's disease: evidence from epidemiological and animal studies. Biomed J 2018;41:141&#x2013;162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6138768</ArticleId><ArticleId IdType="pubmed">30080655</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xe9;jot Y, Reis J, Giroud M, Feigin V. A review of epidemiological research on stroke and dementia and exposure to air pollution. Int J Stroke 2018;13:687&#x2013;695.</Citation><ArticleIdList><ArticleId IdType="pubmed">29699457</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu P, Guo X, Cheung FMH, Yung KKL. The association between PM 2.5 exposure and neurological disorders: a systematic review and meta-analysis. Sci Total Environ 2019;655:1240&#x2013;1248.</Citation><ArticleIdList><ArticleId IdType="pubmed">30577116</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters R, Ee N, Peters J, Booth A, Mudway I, Anstey KJ. Air pollution and dementia: a systematic review. J Alzheimers Dis 2019;70:S145&#x2013;S163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6700631</ArticleId><ArticleId IdType="pubmed">30775976</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu YC, Lin YC, Yu HL, et al. . Association between air pollutants and dementia risk in the elderly. Alzheimers Dement (Amst) 2015;1:220&#x2013;228.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4876896</ArticleId><ArticleId IdType="pubmed">27239507</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung CR, Lin YT, Hwang BF. Ozone, particulate matter, and newly diagnosed Alzheimer's disease: a population-based cohort study in Taiwan. J Alzheimers Dis 2015;44:573&#x2013;584.</Citation><ArticleIdList><ArticleId IdType="pubmed">25310992</ArticleId></ArticleIdList></Reference><Reference><Citation>Cacciottolo M, Wang X, Driscoll I, et al. . Particulate air pollutants, APOE alleles and their contributions to cognitive impairment in older women and to amyloidogenesis in experimental models. Transl Psychiatry 2017;7:e1022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5299391</ArticleId><ArticleId IdType="pubmed">28140404</ArticleId></ArticleIdList></Reference><Reference><Citation>Kioumourtzoglou MA, Schwartz JD, Weisskopf MG, et al. . Long-term PM2.5 exposure and neurological hospital admissions in the northeastern United States. Environ Health Perspect 2016;124:23&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4710596</ArticleId><ArticleId IdType="pubmed">25978701</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H, Kwong JC, Copes R, et al. . Exposure to ambient air pollution and the incidence of dementia: a population-based cohort study. Environ Int 2017;108:271&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pubmed">28917207</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H, Kwong JC, Copes R, et al. . Living near major roads and the incidence of dementia, Parkinson's disease, and multiple sclerosis: a population-based cohort study. Lancet 2017;389:718&#x2013;726.</Citation><ArticleIdList><ArticleId IdType="pubmed">28063597</ArticleId></ArticleIdList></Reference><Reference><Citation>Oudin A, Segersson D, Adolfsson R, Forsberg B. Association between air pollution from residential wood burning and dementia incidence in a longitudinal study in Northern Sweden. PLoS One 2018;13:e0198283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5999109</ArticleId><ArticleId IdType="pubmed">29897947</ArticleId></ArticleIdList></Reference><Reference><Citation>Carey IM, Anderson HR, Atkinson RW, et al. . Are noise and air pollution related to the incidence of dementia? A cohort study in London, England. BMJ Open 2018;8:e022404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6144407</ArticleId><ArticleId IdType="pubmed">30206085</ArticleId></ArticleIdList></Reference><Reference><Citation>Raz L, Knoefel J, Bhaskar K. The neuropathology and cerebrovascular mechanisms of dementia. J Cereb Blood Flow Metab 2016;36:172&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4758551</ArticleId><ArticleId IdType="pubmed">26174330</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilker EH, Preis SR, Beiser AS, et al. . Long-term exposure to fine particulate matter, residential proximity to major roads and measures of brain structure. Stroke 2015;46:1161&#x2013;1166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4414870</ArticleId><ArticleId IdType="pubmed">25908455</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen JC, Wang X, Wellenius GA, et al. . Ambient air pollution and neurotoxicity on brain structure: evidence from Women's Health Initiative Memory Study. Ann Neurol 2015;78:466&#x2013;476.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4546504</ArticleId><ArticleId IdType="pubmed">26075655</ArticleId></ArticleIdList></Reference><Reference><Citation>Power MC, Lamichhane AP, Liao D, et al. . The association of long-term exposure to particulate matter air pollution with brain MRI findings: the ARIC study. Environ Health Perspect 2018;126:027009.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6066342</ArticleId><ArticleId IdType="pubmed">29467108</ArticleId></ArticleIdList></Reference><Reference><Citation>Gale SD, Erickson LD, Anderson JE, Brown BL, Hedges DW. Association between exposure to air pollution and prefrontal cortical volume in adults: a cross-sectional study from the UK biobank. Environ Res 2020;185:109365.</Citation><ArticleIdList><ArticleId IdType="pubmed">32222630</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedges DW, Erickson LD, Gale SD, Anderson JE, Brown BL. Association between exposure to air pollution and thalamus volume in adults: a cross-sectional study. PLoS One 2020;15:e0230829.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7105117</ArticleId><ArticleId IdType="pubmed">32226035</ArticleId></ArticleIdList></Reference><Reference><Citation>Erickson LD, Gale SD, Anderson JE, Brown BL, Hedges DW. Association between exposure to air pollution and total gray matter and total white matter volumes in adults: a cross-sectional study. Brain Sci 2020;10:164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7139378</ArticleId><ArticleId IdType="pubmed">32182984</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedges DW, Erickson LD, Kunzelman J, Brown BL, Gale SD. Association between exposure to air pollution and hippocampal volume in adults in the UK Biobank. Neurotoxicology 2019;74:108&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">31220475</ArticleId></ArticleIdList></Reference><Reference><Citation>Casanova R, Wang X, Reyes J, et al. . A voxel-based morphometry study reveals local brain structural alterations associated with ambient fine particles in older women. Front Hum Neurosci 2016;10:495.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5061768</ArticleId><ArticleId IdType="pubmed">27790103</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Del Tredici K, Lee VM, Trojanowski JQ. Spreading of pathology in neurodegenerative diseases: a focus on human studies. Nat Rev Neurosci 2015;16:109&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4312418</ArticleId><ArticleId IdType="pubmed">25588378</ArticleId></ArticleIdList></Reference><Reference><Citation>Casanova R, Barnard RT, Gaussoin SA, et al. . Using high-dimensional machine learning methods to estimate an anatomical risk factor for Alzheimer's disease across imaging databases. Neuroimage 2018;183:401&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6457113</ArticleId><ArticleId IdType="pubmed">30130645</ArticleId></ArticleIdList></Reference><Reference><Citation>Shumaker SA, Legault C, Rapp SR, et al. . Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003;289:2651&#x2013;2662.</Citation><ArticleIdList><ArticleId IdType="pubmed">12771112</ArticleId></ArticleIdList></Reference><Reference><Citation>Shumaker SA, Legault C, Kuller L, et al. . Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 2004;291:2947&#x2013;2958.</Citation><ArticleIdList><ArticleId IdType="pubmed">15213206</ArticleId></ArticleIdList></Reference><Reference><Citation>Coker LH, Hogan PE, Bryan NR, et al. . Postmenopausal hormone therapy and subclinical cerebrovascular disease: the WHIMS-MRI Study. Neurology 2009;72:125&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677498</ArticleId><ArticleId IdType="pubmed">19139363</ArticleId></ArticleIdList></Reference><Reference><Citation>Resnick SM, Espeland MA, Jaramillo SA, et al. . Postmenopausal hormone therapy and regional brain volumes: the WHIMS-MRI Study. Neurology 2009;72:135&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677493</ArticleId><ArticleId IdType="pubmed">19139364</ArticleId></ArticleIdList></Reference><Reference><Citation>Younan D, Petkus AJ, Widaman KF, et al. . Particulate matter and episodic memory decline mediated by early neuroanatomic biomarkers of Alzheimer's disease. Brain 2020;143:289&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6938036</ArticleId><ArticleId IdType="pubmed">31746986</ArticleId></ArticleIdList></Reference><Reference><Citation>Lao Z, Shen D, Liu D, et al. . Computer-assisted segmentation of white matter lesions in 3D MR images using support vector machine. Acad Radiol 2008;15:300&#x2013;313.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2528894</ArticleId><ArticleId IdType="pubmed">18280928</ArticleId></ArticleIdList></Reference><Reference><Citation>Zacharaki EI, Kanterakis S, Bryan RN, Davatzikos C. Measuring brain lesion progression with a supervised tissue classification system. Med Image Comput Assist Interv 2008;11:620&#x2013;627.</Citation><ArticleIdList><ArticleId IdType="pubmed">18979798</ArticleId></ArticleIdList></Reference><Reference><Citation>Tustison NJ, Cook PA, Klein A, et al. . Large-scale evaluation of ANTs and FreeSurfer cortical thickness measurements. Neuroimage 2014;99:166&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pubmed">24879923</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw 2010;33:1&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2929880</ArticleId><ArticleId IdType="pubmed">20808728</ArticleId></ArticleIdList></Reference><Reference><Citation>Espeland MA, Chen JC, Weitlauf J, et al. . Trajectories of relative performance with 2 measures of global cognitive function. J Am Geriatr Soc 2018;66:1575&#x2013;1580.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6167188</ArticleId><ArticleId IdType="pubmed">29972592</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitsel EA, Rose KM, Wood JL, Henley AC, Liao D, Heiss G. Accuracy and repeatability of commercial geocoding. Am J Epidemiol 2004;160:1023&#x2013;1029.</Citation><ArticleIdList><ArticleId IdType="pubmed">15522859</ArticleId></ArticleIdList></Reference><Reference><Citation>Christakos G. Modern Spatiotemporal Geostatistics.Oxford: Oxford University Press; 2000.</Citation></Reference><Reference><Citation>Christakos G, Bogaert P, Serre M. Temporal GIS: Advanced Functions for Field-Based Applications. Berlin: Springer Science &amp; Business Media, 2012.</Citation></Reference><Reference><Citation>Xu Y, Serre ML, Reyes J, Vizuete W. Bayesian Maximum Entropy integration of ozone observations and model predictions: a national application. Environ Sci Technol 2016;50:4393&#x2013;4400.</Citation><ArticleIdList><ArticleId IdType="pubmed">26998937</ArticleId></ArticleIdList></Reference><Reference><Citation>Reyes JM, Xu Y, Vizuete W, Serre ML. Regionalized PM2.5 Community Multiscale Air Quality model performance evaluation across a continuous spatiotemporal domain. Atmos Environ (1994) 2017;148:258&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5571875</ArticleId><ArticleId IdType="pubmed">28848374</ArticleId></ArticleIdList></Reference><Reference><Citation>Heckbert SR, Kooperberg C, Safford MM, et al. . Comparison of self-report, hospital discharge codes, and adjudication of cardiovascular events in the Women's Health Initiative. Am J Epidemiol 2004;160:1152&#x2013;1158.</Citation><ArticleIdList><ArticleId IdType="pubmed">15583367</ArticleId></ArticleIdList></Reference><Reference><Citation>Margolis KL, Lihong Qi, Brzyski R, et al. . Validity of diabetes self-reports in the Women's Health Initiative: comparison with medication inventories and fasting glucose measurements. Clin Trials 2008;5:240&#x2013;247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2757268</ArticleId><ArticleId IdType="pubmed">18559413</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson-Kozlow M, Rock CL, Gilpin EA, Hollenbach KA, Pierce JP. Validation of the WHI brief physical activity questionnaire among women diagnosed with breast cancer. Am J Health Behav 2007;31:193&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">17269909</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi L, Nassir R, Kosoy R, et al. . Relationship between diabetes risk and admixture in postmenopausal African-American and Hispanic-American women. Diabetologia 2012;55:1329&#x2013;1337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4430092</ArticleId><ArticleId IdType="pubmed">22322919</ArticleId></ArticleIdList></Reference><Reference><Citation>Frisoni GB, Fox NC, Jack CR, Scheltens P, Thompson PM. The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol 2010;6:67&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2938772</ArticleId><ArticleId IdType="pubmed">20139996</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulick ER, Wellenius GA, Kaufman JD, et al. . Long-term exposure to ambient air pollution and subclinical cerebrovascular disease in NOMAS (the Northern Manhattan Study). Stroke 2017;48:1966&#x2013;1968.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5487287</ArticleId><ArticleId IdType="pubmed">28455324</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilker EH, Martinez-Ramirez S, Kloog I, et al. . Fine particulate matter, residential proximity to major roads, and markers of small vessel disease in a memory study population. J Alzheimers Dis 2016;53:1315&#x2013;1323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4992433</ArticleId><ArticleId IdType="pubmed">27372639</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee M, Schwartz J, Wang Y, Dominici F, Zanobetti A. Long-term effect of fine particulate matter on hospitalization with dementia. Environ Pollut 2019;254:112926.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7995172</ArticleId><ArticleId IdType="pubmed">31404729</ArticleId></ArticleIdList></Reference><Reference><Citation>Grande G, Ljungman PLS, Eneroth K, Bellander T, Rizzuto D. Association between cardiovascular disease and long-term exposure to air pollution with the risk of dementia. JAMA Neurol 2020;77:801&#x2013;809.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7105952</ArticleId><ArticleId IdType="pubmed">32227140</ArticleId></ArticleIdList></Reference><Reference><Citation>Berti V, Pupi A, Mosconi L. PET/CT in diagnosis of dementia. Ann NY Acad Sci 2011;1228:81&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3692287</ArticleId><ArticleId IdType="pubmed">21718326</ArticleId></ArticleIdList></Reference><Reference><Citation>Casanova R, Hsu FC, Sink KM, et al. . Alzheimer's disease risk assessment using large-scale machine learning methods. PLoS One 2013;8:e77949.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3826736</ArticleId><ArticleId IdType="pubmed">24250789</ArticleId></ArticleIdList></Reference><Reference><Citation>Petkus AJ, Younan D, Widaman K, et al. . Exposure to fine particulate matter and temporal dynamics of episodic memory and depressive symptoms in older women. Environ Int 2020;135:105196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7499893</ArticleId><ArticleId IdType="pubmed">31881430</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">33208500</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>570</Issue><PubDate><Year>2020</Year><Month>Nov</Month><Day>18</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle><i>Gga3</i> deletion and a <i>GGA3</i> rare variant associated with late onset Alzheimer's disease trigger BACE1 accumulation in axonal swellings.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">eaba1871</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.aba1871</ELocationID><Abstract><AbstractText>Axonal dystrophy, indicative of perturbed axonal transport, occurs early during Alzheimer's disease (AD) pathogenesis. Little is known about the mechanisms underlying this initial sign of the pathology. This study proves that Golgi-localized &#x3b3;-ear-containing ARF binding protein 3 (GGA3) loss of function, due to <i>Gga3</i> genetic deletion or a <i>GGA3</i> rare variant that cosegregates with late-onset AD, disrupts the axonal trafficking of the &#x3b2;-site APP-cleaving enzyme 1 (BACE1) resulting in its accumulation in axonal swellings in cultured neurons and in vivo. We show that BACE pharmacological inhibition ameliorates BACE1 axonal trafficking and diminishes axonal dystrophies in <i>Gga3</i> null neurons in vitro and in vivo. These data indicate that axonal accumulation of BACE1 engendered by GGA3 loss of function results in local toxicity leading to axonopathy. <i>Gga3</i> deletion exacerbates axonal dystrophies in a mouse model of AD before &#x3b2;-amyloid (A&#x3b2;) deposition. Our study strongly supports a role for GGA3 in AD pathogenesis, where GGA3 loss of function triggers BACE1 axonal accumulation independently of extracellular A&#x3b2;, and initiates a cascade of events leading to the axonal damage distinctive of the early stage of AD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lomoio</LastName><ForeName>Selene</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-5151-295X</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Tufts University School of Medicine, Boston, MA 02111, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Willen</LastName><ForeName>Rachel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Tufts University School of Medicine, Boston, MA 02111, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>WonHee</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0001-5530-7606</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Tufts University School of Medicine, Boston, MA 02111, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>Kevin Z</ForeName><Initials>KZ</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Tufts University School of Medicine, Boston, MA 02111, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robinson</LastName><ForeName>Edward K</ForeName><Initials>EK</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Tufts University School of Medicine, Boston, MA 02111, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prokopenko</LastName><ForeName>Dmitry</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-1844-5652</Identifier><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kennedy</LastName><ForeName>Matthew E</ForeName><Initials>ME</Initials><Identifier Source="ORCID">0000-0002-4842-4529</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Merck &amp; Co. Inc., Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanzi</LastName><ForeName>Rudolph E</ForeName><Initials>RE</Initials><Identifier Source="ORCID">0000-0002-7032-1454</Identifier><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tesco</LastName><ForeName>Giuseppina</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-3336-7488</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Tufts University School of Medicine, Boston, MA 02111, USA. giuseppina.tesco@tufts.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R25 GM066567</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R25 HL007785</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG057148</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D033942">Adaptor Proteins, Vesicular Transport</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C407306">GGA adaptor proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509282">Bace1 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D033942" MajorTopicYN="N">Adaptor Proteins, Vesicular Transport</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing Interests</b>: S.L., R.W., W.K., K.Z.H., E.K.R., D.P., R.E.T. and G.T. have no conflict of interest to declare. M.E.K. is a full-time employee of MSD/Merck&amp;Co., Inc. and owns stock.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>5</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>8</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>11</Month><Day>19</Day><Hour>5</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>11</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33208500</ArticleId><ArticleId IdType="mid">NIHMS1756484</ArticleId><ArticleId IdType="pmc">PMC8612295</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.aba1871</ArticleId><ArticleId IdType="pii">12/570/eaba1871</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chevalier-Larsen E, Holzbaur ELF, Axonal transport and neurodegenerative disease. Biochim Biophys Acta 1762, 1094&#x2013;1108 (2006); published online Epub2006/12// (10.1016/j.bbadis.2006.04.002).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2006.04.002</ArticleId><ArticleId IdType="pubmed">16730956</ArticleId></ArticleIdList></Reference><Reference><Citation>Stokin GB, Goldstein LSB, Axonal transport and Alzheimer&#x2019;s disease. Annu Rev Biochem 75, 607&#x2013;627 (2006); published online Epub2006 (10.1146/annurev.biochem.75.103004.142637).</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.biochem.75.103004.142637</ArticleId><ArticleId IdType="pubmed">16756504</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanaan NM, Pigino GF, Brady ST, Lazarov O, Binder LI, Morfini GA, Axonal degeneration in Alzheimer&#x2019;s disease: when signaling abnormalities meet the axonal transport system. Exp Neurol 246, 44&#x2013;53 (2013); published online Epub2013/08// (10.1016/j.expneurol.2012.06.003).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2012.06.003</ArticleId><ArticleId IdType="pmc">PMC3465504</ArticleId><ArticleId IdType="pubmed">22721767</ArticleId></ArticleIdList></Reference><Reference><Citation>Stokin GB, Lillo C, Falzone TL, Brusch RG, Rockenstein E, Mount SL, Raman R, Davies P, Masliah E, Williams DS, Goldstein LSB, Axonopathy and transport deficits early in the pathogenesis of Alzheimer&#x2019;s disease. Science 307, 1282&#x2013;1288 (2005); published online Epub2005/02/25/ (10.1126/science.1105681).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1105681</ArticleId><ArticleId IdType="pubmed">15731448</ArticleId></ArticleIdList></Reference><Reference><Citation>Teipel SJ, Born C, Ewers M, Bokde AL, Reiser MF, Moller HJ, Hampel H, Multivariate deformation-based analysis of brain atrophy to predict Alzheimer&#x2019;s disease in mild cognitive impairment. Neuroimage 38, 13&#x2013;24 (2007); published online EpubOct 15 (10.1016/j.neuroimage.2007.07.008).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2007.07.008</ArticleId><ArticleId IdType="pubmed">17827035</ArticleId></ArticleIdList></Reference><Reference><Citation>Cross DJ, Flexman JA, Anzai Y, Maravilla KR, Minoshima S, Age-related decrease in axonal transport measured by MR imaging in vivo. Neuroimage 39, 915&#x2013;926 (2008); published online EpubFeb 1 (10.1016/j.neuroimage.2007.08.036).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2007.08.036</ArticleId><ArticleId IdType="pubmed">17980625</ArticleId></ArticleIdList></Reference><Reference><Citation>Minoshima S, Cross D, In vivo imaging of axonal transport using MRI: aging and Alzheimer&#x2019;s disease. Eur J Nucl Med Mol Imaging 35 Suppl 1, S89&#x2013;92 (2008); published online EpubMar (10.1007/s00259-007-0707-8).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-007-0707-8</ArticleId><ArticleId IdType="pubmed">18204931</ArticleId></ArticleIdList></Reference><Reference><Citation>Preische O, Schultz SA, Apel A, Kuhle J, Kaeser SA, Barro C, Graber S, Kuder-Buletta E, LaFougere C, Laske C, Voglein J, Levin J, Masters CL, Martins R, Schofield PR, Rossor MN, Graff-Radford NR, Salloway S, Ghetti B, Ringman JM, Noble JM, Chhatwal J, Goate AM, Benzinger TLS, Morris JC, Bateman RJ, Wang G, Fagan AM, McDade EM, Gordon BA, Jucker M, Dominantly Inherited Alzheimer N, Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer&#x2019;s disease. Nat Med 25, 277&#x2013;283 (2019); published online EpubFeb (10.1038/s41591-018-0304-3).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-018-0304-3</ArticleId><ArticleId IdType="pmc">PMC6367005</ArticleId><ArticleId IdType="pubmed">30664784</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Cullen NC, Andreasson U, Zetterberg H, Blennow K, Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease. JAMA Neurol 76, 791&#x2013;799 (2019); published online EpubApr 22 (10.1001/jamaneurol.2019.0765).</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.0765</ArticleId><ArticleId IdType="pmc">PMC6583067</ArticleId><ArticleId IdType="pubmed">31009028</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT, Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 1, a006189 (2011); published online EpubSep (10.1101/cshperspect.a006189).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a006189</ArticleId><ArticleId IdType="pmc">PMC3234452</ArticleId><ArticleId IdType="pubmed">22229116</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R, Kuhn P-H, Haass C, Kennedy ME, Rajendran L, Wong PC, Lichtenthaler SF, Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects. J Neurochem 130, 4&#x2013;28 (2014); published online Epub2014/07// (10.1111/jnc.12715).</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.12715</ArticleId><ArticleId IdType="pmc">PMC4086641</ArticleId><ArticleId IdType="pubmed">24646365</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J, Fu Y, Yasvoina M, Shao P, Hitt B, O&#x2019;Connor T, Logan S, Maus E, Citron M, Berry R, Binder L, Vassar R, Beta-site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: implications for Alzheimer&#x2019;s disease pathogenesis. The Journal of Neuroscience 27, 3639&#x2013;3649 (2007); published online Epub2007/04/04/ (10.1523/JNEUROSCI.4396-06.2007).</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4396-06.2007</ArticleId><ArticleId IdType="pmc">PMC6672403</ArticleId><ArticleId IdType="pubmed">17409228</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandalepas PC, Sadleir KR, Eimer WA, Zhao J, Nicholson DA, Vassar R, The Alzheimer&#x2019;s &#x3b2;-secretase BACE1 localizes to normal presynaptic terminals and to dystrophic presynaptic terminals surrounding amyloid plaques. Acta Neuropathol 126, 329&#x2013;352 (2013); published online Epub2013/09// (10.1007/s00401-013-1152-3).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1152-3</ArticleId><ArticleId IdType="pmc">PMC3753469</ArticleId><ArticleId IdType="pubmed">23820808</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X-M, Cai Y, Xiong K, Cai H, Luo X-G, Feng J-C, Clough RW, Struble RG, Patrylo PR, Yan X-X, Beta-secretase-1 elevation in transgenic mouse models of Alzheimer&#x2019;s disease is associated with synaptic/axonal pathology and amyloidogenesis: implications for neuritic plaque development. Eur J Neurosci 30, 2271&#x2013;2283 (2009); published online Epub2009/12/10/ (10.1111/j.1460-9568.2009.07017.x).</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1460-9568.2009.07017.x</ArticleId><ArticleId IdType="pmc">PMC2869535</ArticleId><ArticleId IdType="pubmed">20092570</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrew RJ, Fernandez CG, Stanley M, Jiang H, Nguyen P, Rice RC, Buggia-Prevot V, De Rossi P, Vetrivel KS, Lamb R, Argemi A, Allaert ES, Rathbun EM, Krause SV, Wagner SL, Parent AT, Holtzman DM, Thinakaran G, Lack of BACE1 S-palmitoylation reduces amyloid burden and mitigates memory deficits in transgenic mouse models of Alzheimer&#x2019;s disease. Proc Natl Acad Sci U S A 114, E9665&#x2013;E9674 (2017); published online EpubNov 7 (10.1073/pnas.1708568114).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1708568114</ArticleId><ArticleId IdType="pmc">PMC5692556</ArticleId><ArticleId IdType="pubmed">29078331</ArticleId></ArticleIdList></Reference><Reference><Citation>Gowrishankar S, Wu Y, Ferguson SM, Impaired JIP3-dependent axonal lysosome transport promotes amyloid plaque pathology. J Cell Biol 216, 3291&#x2013;3305 (2017); published online Epub2017/10/02/ (10.1083/jcb.201612148).</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.201612148</ArticleId><ArticleId IdType="pmc">PMC5626538</ArticleId><ArticleId IdType="pubmed">28784610</ArticleId></ArticleIdList></Reference><Reference><Citation>Gowrishankar S, Yuan P, Wu Y, Schrag M, Paradise S, Grutzendler J, De Camilli P, Ferguson SM, Massive accumulation of luminal protease-deficient axonal lysosomes at Alzheimer&#x2019;s disease amyloid plaques. Proc Natl Acad Sci USA 112, E3699&#x2013;3708 (2015); published online Epub2015/07/14/ (10.1073/pnas.1510329112).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1510329112</ArticleId><ArticleId IdType="pmc">PMC4507205</ArticleId><ArticleId IdType="pubmed">26124111</ArticleId></ArticleIdList></Reference><Reference><Citation>Govero J, Doray B, Bai H, Kornfeld S, Analysis of Gga null mice demonstrates a non-redundant role for mammalian GGA2 during development. PLoS ONE 7, e30184 (2012); published online Epub2012/01/26/ (10.1371/journal.pone.0030184).</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0030184</ArticleId><ArticleId IdType="pmc">PMC3266899</ArticleId><ArticleId IdType="pubmed">22291915</ArticleId></ArticleIdList></Reference><Reference><Citation>Tesco G, Koh YH, Kang EL, Cameron AN, Das S, Sena-Esteves M, Hiltunen M, Yang S-H, Zhong Z, Shen Y, Simpkins JW, Tanzi RE, Depletion of GGA3 stabilizes BACE and enhances beta-secretase activity. Neuron 54, 721&#x2013;737 (2007); published online Epub2007/06/07/ (10.1016/j.neuron.2007.05.012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2007.05.012</ArticleId><ArticleId IdType="pmc">PMC1973166</ArticleId><ArticleId IdType="pubmed">17553422</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonifacino JS, The GGA proteins: adaptors on the move. Nat Rev Mol Cell Biol 5, 23&#x2013;32 (2004); published online Epub2004 (10.1038/nrm1279).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm1279</ArticleId><ArticleId IdType="pubmed">14708007</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang EL, Cameron AN, Piazza F, Walker KR, Tesco G, Ubiquitin regulates GGA3-mediated degradation of BACE1. J Biol Chem 285, 24108&#x2013;24119 (2010); published online Epub2010/07/30/ (10.1074/jbc.M109.092742).</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109.092742</ArticleId><ArticleId IdType="pmc">PMC2911305</ArticleId><ArticleId IdType="pubmed">20484053</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker KR, Kang EL, Whalen MJ, Shen Y, Tesco G, Depletion of GGA1 and GGA3 mediates postinjury elevation of BACE1. The Journal of Neuroscience 32, 10423&#x2013;10437 (2012); published online Epub2012/07/25/ (10.1523/JNEUROSCI.5491-11.2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5491-11.2012</ArticleId><ArticleId IdType="pmc">PMC3490187</ArticleId><ArticleId IdType="pubmed">22836275</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim W, Ma L, Lomoio S, Willen R, Lombardo S, Dong J, Haydon PG, Tesco G, BACE1 elevation engendered by GGA3 deletion increases beta-amyloid pathology in association with APP elevation and decreased CHL1 processing in 5XFAD mice. Mol Neurodegener 13, 6 (2018); published online EpubFeb 2 (10.1186/s13024-018-0239-7).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-018-0239-7</ArticleId><ArticleId IdType="pmc">PMC5796504</ArticleId><ArticleId IdType="pubmed">29391027</ArticleId></ArticleIdList></Reference><Reference><Citation>Far&#xed;as GG, Cuitino L, Guo X, Ren X, Jarnik M, Mattera R, Bonifacino JS, Signal-mediated AP AP-1/clathrin-dependent sorting of transmembrane receptors to the somatodendritic domain of hippocampal neurons. Neuron 75, 810&#x2013;823 (2012); published online Epub2012/09/06/ (10.1016/j.neuron.2012.07.007).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2012.07.007</ArticleId><ArticleId IdType="pmc">PMC3439821</ArticleId><ArticleId IdType="pubmed">22958822</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohno H, Tomemori T, Nakatsu F, Okazaki Y, Aguilar RC, Foelsch H, Mellman I, Saito T, Shirasawa T, Bonifacino JS, Mu1B, a novel adaptor medium chain expressed in polarized epithelial cells. FEBS Lett 449, 215&#x2013;220 (1999); published online EpubApr 23 (10.1016/s0014-5793(99)00432-9).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0014-5793(99)00432-9</ArticleId><ArticleId IdType="pubmed">10338135</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuda S, Yuzaki M, AP-4: autophagy-four mislocalized proteins in axons. Autophagy 4, 815&#x2013;816 (2008); published online EpubAug (10.4161/auto.6493).</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/auto.6493</ArticleId><ArticleId IdType="pubmed">18654090</ArticleId></ArticleIdList></Reference><Reference><Citation>Buggia-Pr&#xe9;vot V, Fernandez CG, Riordan S, Vetrivel KS, Roseman J, Waters J, Bindokas VP, Vassar R, Thinakaran G, Axonal BACE1 dynamics and targeting in hippocampal neurons: a role for Rab11 GTPase. Mol Neurodegener 9, 1 (2014); published online Epub2014/01/04/ (10.1186/1750-1326-9-1).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-9-1</ArticleId><ArticleId IdType="pmc">PMC4031619</ArticleId><ArticleId IdType="pubmed">24386896</ArticleId></ArticleIdList></Reference><Reference><Citation>Buggia-Pr&#xe9;vot V, Fernandez CG, Udayar V, Vetrivel KS, Elie A, Roseman J, Sasse VA, Lefkow M, Meckler X, Bhattacharyya S, George M, Kar S, Bindokas VP, Parent AT, Rajendran L, Band H, Vassar R, Thinakaran G, A function for EHD family proteins in unidirectional retrograde dendritic transport of BACE1 and Alzheimer&#x2019;s disease A&#x3b2; production. Cell Reports 5, 1552&#x2013;1563 (2013); published online Epub2013/12/26/ (10.1016/j.celrep.2013.12.006).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2013.12.006</ArticleId><ArticleId IdType="pmc">PMC3932704</ArticleId><ArticleId IdType="pubmed">24373286</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou L, Barao S, Laga M, Bockstael K, Borgers M, Gijsen H, Annaert W, Moechars D, Mercken M, Gevaert K, De Strooper B, The neural cell adhesion molecules L1 and CHL1 are cleaved by BACE1 protease in vivo. J Biol Chem 287, 25927&#x2013;25940 (2012); published online EpubJul 27 (10.1074/jbc.M112.377465).</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.377465</ArticleId><ArticleId IdType="pmc">PMC3406677</ArticleId><ArticleId IdType="pubmed">22692213</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn PH, Koroniak K, Hogl S, Colombo A, Zeitschel U, Willem M, Volbracht C, Schepers U, Imhof A, Hoffmeister A, Haass C, Rossner S, Brase S, Lichtenthaler SF, Secretome protein enrichment identifies physiological BACE1 protease substrates in neurons. EMBO J 31, 3157&#x2013;3168 (2012); published online EpubJun 22 (10.1038/emboj.2012.173).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emboj.2012.173</ArticleId><ArticleId IdType="pmc">PMC3400020</ArticleId><ArticleId IdType="pubmed">22728825</ArticleId></ArticleIdList></Reference><Reference><Citation>Cameron PL, Sudhof TC, Jahn R, De Camilli P, Colocalization of synaptophysin with transferrin receptors: implications for synaptic vesicle biogenesis. J Cell Biol 115, 151&#x2013;164 (1991); published online EpubOct (10.1083/jcb.115.1.151).</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.115.1.151</ArticleId><ArticleId IdType="pmc">PMC2289933</ArticleId><ArticleId IdType="pubmed">1918133</ArticleId></ArticleIdList></Reference><Reference><Citation>Hitt B, Riordan SM, Kukreja L, Eimer WA, Rajapaksha TW, Vassar R, &#x3b2;-Site amyloid precursor protein (APP)-cleaving enzyme 1 (BACE1)-deficient mice exhibit a close homolog of L1 (CHL1) loss-of-function phenotype involving axon guidance defects. J Biol Chem 287, 38408&#x2013;38425 (2012); published online Epub2012/11/09/ (10.1074/jbc.M112.415505).</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.415505</ArticleId><ArticleId IdType="pmc">PMC3493884</ArticleId><ArticleId IdType="pubmed">22988240</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S, Sato Y, Nixon RA, Lysosomal proteolysis inhibition selectively disrupts axonal transport of degradative organelles and causes an Alzheimer&#x2019;s-like axonal dystrophy. The Journal of Neuroscience 31, 7817&#x2013;7830 (2011); published online Epub2011/05/25/ (10.1523/JNEUROSCI.6412-10.2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.6412-10.2011</ArticleId><ArticleId IdType="pmc">PMC3351137</ArticleId><ArticleId IdType="pubmed">21613495</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Q, Lu L, Tian J-H, Zhu Y-B, Qiao H, Sheng Z-H, Snapin-regulated late endosomal transport is critical for efficient autophagy-lysosomal function in neurons. Neuron 68, 73&#x2013;86 (2010); published online Epub2010/10/06/ (10.1016/j.neuron.2010.09.022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2010.09.022</ArticleId><ArticleId IdType="pmc">PMC2953270</ArticleId><ArticleId IdType="pubmed">20920792</ArticleId></ArticleIdList></Reference><Reference><Citation>Dusart I, Sotelo C, Lack of Purkinje cell loss in adult rat cerebellum following protracted axotomy: degenerative changes and regenerative attempts of the severed axons. J Comp Neurol 347, 211&#x2013;232 (1994); published online EpubSep 8 (10.1002/cne.903470206).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cne.903470206</ArticleId><ArticleId IdType="pubmed">7814665</ArticleId></ArticleIdList></Reference><Reference><Citation>Voytyuk I, Mueller SA, Herber J, Snellinx A, Moechars D, van Loo G, Lichtenthaler SF, De Strooper B, BACE2 distribution in major brain cell types and identification of novel substrates. Life Sci. Alliance 1, e201800026 (2018); published online Epub2018 (10.26508/lsa.201800026).</Citation><ArticleIdList><ArticleId IdType="doi">10.26508/lsa.201800026</ArticleId><ArticleId IdType="pmc">PMC6238391</ArticleId><ArticleId IdType="pubmed">30456346</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonini SA, Ferrari-Toninelli G, Montinaro M, Memo M, Notch signalling in adult neurons: a potential target for microtubule stabilization. Ther Adv Neurol Disord 6, 375&#x2013;385 (2013); published online EpubNov (10.1177/1756285613490051).</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1756285613490051</ArticleId><ArticleId IdType="pmc">PMC3825115</ArticleId><ArticleId IdType="pubmed">24228073</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy ME, Stamford AW, Chen X, Cox K, Cumming JN, Dockendorf MF, Egan M, Ereshefsky L, Hodgson RA, Hyde LA, Jhee S, Kleijn HJ, Kuvelkar R, Li W, Mattson BA, Mei H, Palcza J, Scott JD, Tanen M, Troyer MD, Tseng JL, Stone JA, Parker EM, Forman MS, The BACE1 inhibitor verubecestat (MK-8931) reduces CNS &#x3b2;-amyloid in animal models and in Alzheimer&#x2019;s disease patients. Sci Transl Med 8, 363ra150 (2016); published online Epub2016/11/02/ (10.1126/scitranslmed.aad9704).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aad9704</ArticleId><ArticleId IdType="pubmed">27807285</ArticleId></ArticleIdList></Reference><Reference><Citation>Villarreal S, Zhao F, Hyde LA, Holder D, Forest T, Sondey M, Chen X, Sur C, Parker EM, Kennedy ME, Chronic Verubecestat Treatment Suppresses Amyloid Accumulation in Advanced Aged Tg2576-A&#x3b2;PPswe Mice Without Inducing Microhemorrhage. J Alzheimers Dis 59, 1393&#x2013;1413 (2017); published online Epub2017 (10.3233/JAD-170056).</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-170056</ArticleId><ArticleId IdType="pmc">PMC5611839</ArticleId><ArticleId IdType="pubmed">28800329</ArticleId></ArticleIdList></Reference><Reference><Citation>Blacker D, Haines JL, Rodes L, Terwedow H, Go RC, Harrell LE, Perry RT, Bassett SS, Chase G, Meyers D, Albert MS, Tanzi R, ApoE-4 and age at onset of Alzheimer&#x2019;s disease: the NIMH genetics initiative. Neurology 48, 139&#x2013;147 (1997); published online EpubJan (10.1212/wnl.48.1.139).</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.48.1.139</ArticleId><ArticleId IdType="pubmed">9008509</ArticleId></ArticleIdList></Reference><Reference><Citation>Cingolani P, Platts A, Wang le L, Coon M, Nguyen T, Wang L, Land SJ, Lu X, Ruden DM, A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin) 6, 80&#x2013;92 (2012); published online EpubApr-Jun (10.4161/fly.19695).</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/fly.19695</ArticleId><ArticleId IdType="pmc">PMC3679285</ArticleId><ArticleId IdType="pubmed">22728672</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen IE, Savage JE, Watanabe K, Bryois J, Williams DM, Steinberg S, Sealock J, Karlsson IK, Hagg S, Athanasiu L, Voyle N, Proitsi P, Witoelar A, Stringer S, Aarsland D, Almdahl IS, Andersen F, Bergh S, Bettella F, Bjornsson S, Braekhus A, Brathen G, de Leeuw C, Desikan RS, Djurovic S, Dumitrescu L, Fladby T, Hohman TJ, Jonsson PV, Kiddle SJ, Rongve A, Saltvedt I, Sando SB, Selbaek G, Shoai M, Skene NG, Snaedal J, Stordal E, Ulstein ID, Wang Y, White LR, Hardy J, Hjerling-Leffler J, Sullivan PF, van der Flier WM, Dobson R, Davis LK, Stefansson H, Stefansson K, Pedersen NL, Ripke S, Andreassen OA, Posthuma D, Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer&#x2019;s disease risk. Nat Genet 51, 404&#x2013;413 (2019); published online EpubMar (10.1038/s41588-018-0311-9).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-018-0311-9</ArticleId><ArticleId IdType="pmc">PMC6836675</ArticleId><ArticleId IdType="pubmed">30617256</ArticleId></ArticleIdList></Reference><Reference><Citation>Genomes Project C, Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, Marchini JL, McCarthy S, McVean GA, Abecasis GR, A global reference for human genetic variation. Nature 526, 68&#x2013;74 (2015); published online EpubOct 1 (10.1038/nature15393).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature15393</ArticleId><ArticleId IdType="pmc">PMC4750478</ArticleId><ArticleId IdType="pubmed">26432245</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouras GK, Tsai J, Naslund J, Vincent B, Edgar M, Checler F, Greenfield JP, Haroutunian V, Buxbaum JD, Xu H, Greengard P, Relkin NR, Intraneuronal Abeta42 accumulation in human brain. Am J Pathol 156, 15&#x2013;20 (2000); published online EpubJan (10.1016/s0002-9440(10)64700-1).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0002-9440(10)64700-1</ArticleId><ArticleId IdType="pmc">PMC1868613</ArticleId><ArticleId IdType="pubmed">10623648</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, Berry R, Vassar R, Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer&#x2019;s disease mutations: potential factors in amyloid plaque formation. The Journal of Neuroscience 26, 10129&#x2013;10140 (2006); published online Epub2006/10/04/ (10.1523/JNEUROSCI.1202-06.2006).</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1202-06.2006</ArticleId><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao AW, He J, Wang Q, Luo Y, Sun Y, Zhou YP, Guan Y, Lucassen PJ, Dai JP, The origin and development of plaques and phosphorylated tau are associated with axonopathy in Alzheimer&#x2019;s disease. Neurosci Bull 27, 287&#x2013;299 (2011); published online EpubOct (10.1007/s12264-011-1736-7).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12264-011-1736-7</ArticleId><ArticleId IdType="pmc">PMC5560317</ArticleId><ArticleId IdType="pubmed">21934724</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Andrea MR, Nagele RG, Wang HY, Peterson PA, Lee DH, Evidence that neurones accumulating amyloid can undergo lysis to form amyloid plaques in Alzheimer&#x2019;s disease. Histopathology 38, 120&#x2013;134 (2001); published online EpubFeb (10.1046/j.1365-2559.2001.01082.x).</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2559.2001.01082.x</ArticleId><ArticleId IdType="pubmed">11207825</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi RH, Nagao T, Gouras GK, Plaque formation and the intraneuronal accumulation of beta-amyloid in Alzheimer&#x2019;s disease. Pathol Int 67, 185&#x2013;193 (2017); published online EpubApr (10.1111/pin.12520).</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/pin.12520</ArticleId><ArticleId IdType="pubmed">28261941</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirths O, Bayer TA, Intraneuronal Abeta accumulation and neurodegeneration: lessons from transgenic models. Life Sci 91, 1148&#x2013;1152 (2012); published online EpubDec 10 (10.1016/j.lfs.2012.02.001).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2012.02.001</ArticleId><ArticleId IdType="pubmed">22401905</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Y, Zhang X-M, Macklin LN, Cai H, Luo X-G, Oddo S, Laferla FM, Struble RG, Rose GM, Patrylo PR, Yan X-X, BACE1 elevation is involved in amyloid plaque development in the triple transgenic model of Alzheimer&#x2019;s disease: differential A&#x3b2; antibody labeling of early-onset axon terminal pathology. Neurotox Res 21, 160&#x2013;174 (2012); published online Epub2012/02// (10.1007/s12640-011-9256-9).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12640-011-9256-9</ArticleId><ArticleId IdType="pmc">PMC3227764</ArticleId><ArticleId IdType="pubmed">21725719</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominguez D, Tournoy J, Hartmann D, Huth T, Cryns K, Deforce S, Serneels L, Camacho IE, Marjaux E, Craessaerts K, Roebroek AJ, Schwake M, D&#x2019;Hooge R, Bach P, Kalinke U, Moechars D, Alzheimer C, Reiss K, Saftig P, De Strooper B, Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice. J Biol Chem 280, 30797&#x2013;30806 (2005); published online EpubSep 2 (10.1074/jbc.M505249200).</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M505249200</ArticleId><ArticleId IdType="pubmed">15987683</ArticleId></ArticleIdList></Reference><Reference><Citation>Farah MH, Pan BH, Hoffman PN, Ferraris D, Tsukamoto T, Nguyen T, Wong PC, Price DL, Slusher BS, Griffin JW, Reduced BACE1 activity enhances clearance of myelin debris and regeneration of axons in the injured peripheral nervous system. The Journal of Neuroscience 31, 5744&#x2013;5754 (2011); published online Epub2011/04/13/ (10.1523/JNEUROSCI.6810-10.2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.6810-10.2011</ArticleId><ArticleId IdType="pmc">PMC3302726</ArticleId><ArticleId IdType="pubmed">21490216</ArticleId></ArticleIdList></Reference><Reference><Citation>Willem M, Garratt AN, Novak B, Citron M, Kaufmann S, Rittger A, DeStrooper B, Saftig P, Birchmeier C, Haass C, Control of peripheral nerve myelination by the beta-secretase BACE1. Science 314, 664&#x2013;666 (2006); published online Epub2006/10/27/ (10.1126/science.1132341).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1132341</ArticleId><ArticleId IdType="pubmed">16990514</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemming ML, Elias JE, Gygi SP, Selkoe DJ, Identification of beta-secretase (BACE1) substrates using quantitative proteomics. PLoS ONE 4, e8477 (2009); published online Epub2009/12/29/ (10.1371/journal.pone.0008477).</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0008477</ArticleId><ArticleId IdType="pmc">PMC2793532</ArticleId><ArticleId IdType="pubmed">20041192</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram L, Tanzi RE, Alzheimer disease risk genes: 29 and counting. Nat Rev Neurol 15, 191&#x2013;192 (2019); published online EpubApr (10.1038/s41582-019-0158-4).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-019-0158-4</ArticleId><ArticleId IdType="pubmed">30833695</ArticleId></ArticleIdList></Reference><Reference><Citation>Egan MF, Kost J, Tariot PN, Aisen PS, Cummings JL, Vellas B, Sur C, Mukai Y, Voss T, Furtek C, Mahoney E, Harper Mozley L, Vandenberghe R, Mo Y, Michelson D, Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer&#x2019;s Disease. N Engl J Med 378, 1691&#x2013;1703 (2018); published online EpubMay 3 (10.1056/NEJMoa1706441).</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1706441</ArticleId><ArticleId IdType="pmc">PMC6776074</ArticleId><ArticleId IdType="pubmed">29719179</ArticleId></ArticleIdList></Reference><Reference><Citation>Egan MF, Kost J, Voss T, Mukai Y, Aisen PS, Cummings JL, Tariot PN, Vellas B, van Dyck CH, Boada M, Zhang Y, Li W, Furtek C, Mahoney E, Harper Mozley L, Mo Y, Sur C, Michelson D, Randomized Trial of Verubecestat for Prodromal Alzheimer&#x2019;s Disease. N Engl J Med 380, 1408&#x2013;1420 (2019); published online EpubApr 11 (10.1056/NEJMoa1812840).</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1812840</ArticleId><ArticleId IdType="pmc">PMC6776078</ArticleId><ArticleId IdType="pubmed">30970186</ArticleId></ArticleIdList></Reference><Reference><Citation>Novak G, Streffer JR, Timmers M, Henley D, Brashear HR, Bogert J, Russu A, Janssens L, Tesseur I, Tritsmans L, Van Nueten L, Engelborghs S, Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer&#x2019;s disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study. Alzheimers Res Ther 12, 58 (2020); published online EpubMay 14 (10.1186/s13195-020-00614-5).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-020-00614-5</ArticleId><ArticleId IdType="pmc">PMC7227237</ArticleId><ArticleId IdType="pubmed">32410694</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewczuk P, Ermann N, Andreasson U, Schultheis C, Podhorna J, Spitzer P, Maler JM, Kornhuber J, Blennow K, Zetterberg H, Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer&#x2019;s disease. Alzheimers Res Ther 10, 71 (2018); published online EpubJul 28 (10.1186/s13195-018-0404-9).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-018-0404-9</ArticleId><ArticleId IdType="pmc">PMC6064615</ArticleId><ArticleId IdType="pubmed">30055655</ArticleId></ArticleIdList></Reference><Reference><Citation>Beaudoin GM 3rd, Lee SH, Singh D, Yuan Y, Ng YG, Reichardt LF, Arikkath J, Culturing pyramidal neurons from the early postnatal mouse hippocampus and cortex. Nat Protoc 7, 1741&#x2013;1754 (2012); published online EpubSep (10.1038/nprot.2012.099).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2012.099</ArticleId><ArticleId IdType="pubmed">22936216</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolte S, Cordelieres FP, A guided tour into subcellular colocalization analysis in light microscopy. J Microsc 224, 213&#x2013;232 (2006); published online EpubDec (10.1111/j.1365-2818.2006.01706.x).</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2818.2006.01706.x</ArticleId><ArticleId IdType="pubmed">17210054</ArticleId></ArticleIdList></Reference><Reference><Citation>Das U, Wang L, Ganguly A, Saikia JM, Wagner SL, Koo EH, Roy S, Visualizing APP and BACE-1 approximation in neurons yields insight into the amyloidogenic pathway. Nat Neurosci 19, 55&#x2013;64 (2016); published online Epub2016 (10.1038/nn.4188).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4188</ArticleId><ArticleId IdType="pmc">PMC4782935</ArticleId><ArticleId IdType="pubmed">26642089</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott JD, Li SW, Brunskill AP, Chen X, Cox K, Cumming JN, Forman M, Gilbert EJ, Hodgson RA, Hyde LA, Jiang Q, Iserloh U, Kazakevich I, Kuvelkar R, Mei H, Meredith J, Misiaszek J, Orth P, Rossiter LM, Slater M, Stone J, Strickland CO, Voigt JH, Wang G, Wang H, Wu Y, Greenlee WJ, Parker EM, Kennedy ME, Stamford AW, Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)-A beta-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer&#x2019;s Disease. J Med Chem 59, 10435&#x2013;10450 (2016); published online EpubDec 8 (10.1021/acs.jmedchem.6b00307).</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.6b00307</ArticleId><ArticleId IdType="pubmed">27933948</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimshek DR, Jacobson LH, Kolly C, Zamurovic N, Balavenkatraman KK, Morawiec L, Kreutzer R, Schelle J, Jucker M, Bertschi B, Theil D, Heier A, Bigot K, Beltz K, Machauer R, Brzak I, Perrot L, Neumann U, Pharmacological BACE1 and BACE2 inhibition induces hair depigmentation by inhibiting PMEL17 processing in mice. Sci Rep 6, 21917 (2016); published online EpubFeb 25 (10.1038/srep21917).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep21917</ArticleId><ArticleId IdType="pmc">PMC4766495</ArticleId><ArticleId IdType="pubmed">26912421</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33207193</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>08</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>7</Issue><PubDate><Year>2020</Year><Month>Nov</Month><Day>17</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>Tau Pathology Drives Dementia Risk-Associated Gene Networks toward Chronic Inflammatory States and Immunosuppression.</ArticleTitle><Pagination><StartPage>108398</StartPage><MedlinePgn>108398</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2020.108398</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(20)31387-5</ELocationID><Abstract><AbstractText>To understand how neural-immune-associated genes and pathways contribute to neurodegenerative disease pathophysiology, we performed a systematic functional genomic analysis in purified microglia and bulk tissue from mouse and human AD, FTD, and PSP. We uncover a complex temporal trajectory of microglial-immune pathways involving the type 1 interferon response associated with tau pathology in the early stages, followed by later signatures of partial immune suppression and, subsequently, the type 2 interferon response. We find that genetic risk for dementias shows disease-specific patterns of pathway enrichment. We identify drivers of two gene co-expression modules conserved from mouse to human, representing competing arms of microglial-immune activation (NAct) and suppression (NSupp) in neurodegeneration. We validate our findings by using chemogenetics, experimental perturbation data, and single-cell sequencing in post-mortem brains. Our results refine the understanding of stage- and disease-specific microglial responses, implicate microglial viral defense pathways in dementia pathophysiology, and highlight therapeutic windows.</AbstractText><CopyrightInformation>Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rexach</LastName><ForeName>Jessica E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Program in Neurogenetics, Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Polioudakis</LastName><ForeName>Damon</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Program in Neurogenetics, Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Program in Neurogenetics, Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swarup</LastName><ForeName>Vivek</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Program in Neurogenetics, Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Timothy S</ForeName><Initials>TS</Initials><AffiliationInfo><Affiliation>Program in Neurogenetics, Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Tam</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Program in Neurogenetics, Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarkar</LastName><ForeName>Arjun</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Program in Neurogenetics, Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Lawrence</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Program in Neurogenetics, Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Jerry</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Program in Neurogenetics, Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Li-Chun</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seeley</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA; Department of Pathology, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials><AffiliationInfo><Affiliation>Department of Pathology &amp; Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malhotra</LastName><ForeName>Dheeraj</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Neuroscience and Rare Diseases, Roche Pharma Research and Early Development, F. Hoffman-LaRoche, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geschwind</LastName><ForeName>Daniel H</ForeName><Initials>DH</Initials><AffiliationInfo><Affiliation>Program in Neurogenetics, Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA; Institute of Precision Health, University of California, Los Angeles, Los Angeles, CA 90095, USA. Electronic address: dhg@mednet.ucla.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R25 NS065723</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG017586</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UH3 NS104095</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010123</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG062418</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UG3 NS104095</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 NS110456</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 NS105916</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053263" MajorTopicYN="N">Gene Regulatory Networks</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D023281" MajorTopicYN="N">Genomics</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007165" MajorTopicYN="N">Immunosuppression Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061251" MajorTopicYN="N">Primary Cell Culture</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">chemical genomics</Keyword><Keyword MajorTopicYN="N">frontotemporal dementia</Keyword><Keyword MajorTopicYN="N">gene network</Keyword><Keyword MajorTopicYN="N">inflammasome</Keyword><Keyword MajorTopicYN="N">interferon</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">progressive supranuclear palsy</Keyword><Keyword MajorTopicYN="N">systems biology</Keyword><Keyword MajorTopicYN="N">transcriptomics</Keyword></KeywordList><CoiStatement>Declaration of Interests D.H.G. has received research funding from Takeda Pharmaceuticals and Hoffman-LaRoche. D.M. is a full-time employee of F. Hoffmann-La Roche, Basel, Switzerland.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>6</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>10</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>11</Month><Day>18</Day><Hour>20</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>1</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33207193</ArticleId><ArticleId IdType="mid">NIHMS1647631</ArticleId><ArticleId IdType="pmc">PMC7842189</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2020.108398</ArticleId><ArticleId IdType="pii">S2211-1247(20)31387-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ahmad S, Mu X, Yang F, Greenwald E, Park JW, Jacob E, Zhang CZ, and Hur S (2018). Breaching Self-Tolerance to Alu Duplex RNA Underlies MDA5-Mediated Inflammation. Cell 172, 797&#x2013;810.e13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5807104</ArticleId><ArticleId IdType="pubmed">29395326</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed ME, Iyer S, Thangavel R, Kempuraj D, Selvakumar GP, Raikwar SP, Zaheer S, and Zaheer A (2017). Co-Localization of Glia Maturation Factor with NLRP3 Inflammasome and Autophagosome Markers in Human Alzheimer&#x2019;s Disease Brain. J. Alzheimers Dis 60, 1143&#x2013;1160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5770146</ArticleId><ArticleId IdType="pubmed">28984607</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen M, Carrasquillo MM, Funk C, Heavner BD, Zou F, Younkin CS, Burgess JD, Chai HS, Crook J, Eddy JA, et al. (2016). Human whole genome genotype and transcriptome data for Alzheimer&#x2019;s and other neurodegenerative diseases. Sci. Data 3, 160089.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5058336</ArticleId><ArticleId IdType="pubmed">27727239</ArticleId></ArticleIdList></Reference><Reference><Citation>Basters A, Knobeloch KP, and Fritz G (2018). USP18 - a multifunctional component in the interferon response. Biosci. Rep 38, BSR20180250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6240716</ArticleId><ArticleId IdType="pubmed">30126853</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamini Y, and Hochberg Y (1995). Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. B 57, 289&#x2013;300.</Citation></Reference><Reference><Citation>Bussian TJ, Aziz A, Meyer CF, Swenson BL, van Deursen JM, and Baker DJ (2018). Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline. Nature 562, 578&#x2013;582.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6206507</ArticleId><ArticleId IdType="pubmed">30232451</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler A, Hoffman P, Smibert P, Papalexi E, and Satija R (2018). Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol 36, 411&#x2013;420.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6700744</ArticleId><ArticleId IdType="pubmed">29608179</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandran V, Coppola G, Nawabi H, Omura T, Versano R, Huebner EA, Zhang A, Costigan M, Yekkirala A, Barrett L, et al. (2016). A Systems-Level Analysis of the Peripheral Nerve Intrinsic Axonal Growth Program. Neuron 89, 956&#x2013;970.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4790095</ArticleId><ArticleId IdType="pubmed">26898779</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen JA, Wang Q, Davis-Turak J, Li Y, Karydas AM, Hsu SC, Sears RL, Chatzopoulou D, Huang AY, Wojta KJ, et al. (2015). A multiancestral genome-wide exome array study of Alzheimer disease, frontotemporal dementia, and progressive supranuclear palsy. JAMA Neurol 72, 414&#x2013;422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4397175</ArticleId><ArticleId IdType="pubmed">25706306</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen-Plotkin AS, Geser F, Plotkin JB, Clark CM, Kwong LK, Yuan W, Grossman M, Van Deerlin VM, Trojanowski JQ, and Lee VM (2008). Variations in the progranulin gene affect global gene expression in frontotemporal lobar degeneration. Hum. Mol. Genet 17, 1349&#x2013;1362.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2900863</ArticleId><ArticleId IdType="pubmed">18223198</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuellar TL, Herzner AM, Zhang X, Goyal Y, Watanabe C, Friedman BA, Janakiraman V, Durinck S, Stinson J, Arnott D, et al. (2017). Silencing of retrotransposons by SETDB1 inhibits the interferon response in acute myeloid leukemia. J. Cell Biol 216, 3535&#x2013;3549.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5674883</ArticleId><ArticleId IdType="pubmed">28887438</ArticleId></ArticleIdList></Reference><Reference><Citation>de Leeuw CA, Mooij JM, Heskes T, and Posthuma D (2015). MAGMA: generalized gene-set analysis of GWAS data. PLOS Comput. Biol 11, e1004219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4401657</ArticleId><ArticleId IdType="pubmed">25885710</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, and Karran E (2016). The Cellular Phase of Alzheimer&#x2019;s Disease. Cell 164, 603&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pubmed">26871627</ArticleId></ArticleIdList></Reference><Reference><Citation>Deczkowska A, Matcovitch-Natan O, Tsitsou-Kampeli A, Ben-Hamo S, Dvir-Szternfeld R, Spinrad A, Singer O, David E, Winter DR, Smith LK, et al. (2017). Mef2C restrains microglial inflammatory response and is lost in brain ageing in an IFN-I-dependent manner. Nat. Commun 8, 717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5620041</ArticleId><ArticleId IdType="pubmed">28959042</ArticleId></ArticleIdList></Reference><Reference><Citation>Deczkowska A, Keren-Shaul H, Weiner A, Colonna M, Schwartz M, and Amit I (2018). Disease-Associated Microglia: A Universal Immune Sensor of Neurodegeneration. Cell 173, 1073&#x2013;1081.</Citation><ArticleIdList><ArticleId IdType="pubmed">29775591</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhir A, Dhir S, Borowski LS, Jimenez L, Teitell M, R&#xf6;tig A, Crow YJ, Rice GI, Duffy D, Tamby C, et al. (2018). Mitochondrial double-stranded RNA triggers antiviral signalling in humans. Nature 560, 238&#x2013;242.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6570621</ArticleId><ArticleId IdType="pubmed">30046113</ArticleId></ArticleIdList></Reference><Reference><Citation>Dias Junior AG, Sampaio NG, and Rehwinkel J (2019). A Balancing Act: MDA5 in Antiviral Immunity and Autoinflammation. Trends Microbiol 27, 75&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6319154</ArticleId><ArticleId IdType="pubmed">30201512</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, and Gingeras TR (2013). STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3530905</ArticleId><ArticleId IdType="pubmed">23104886</ArticleId></ArticleIdList></Reference><Reference><Citation>Doody GM, Care MA, Burgoyne NJ, Bradford JR, Bota M, Bonifer C, Westhead DR, and Tooze RM (2010). An extended set of PRDM1/BLIMP1 target genes links binding motif type to dynamic repression. Nucleic Acids Res 38, 5336&#x2013;5350.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2938208</ArticleId><ArticleId IdType="pubmed">20421211</ArticleId></ArticleIdList></Reference><Reference><Citation>Edwards FA (2019). A Unifying Hypothesis for Alzheimer&#x2019;s Disease: From Plaques to Neurodegeneration. Trends Neurosci 42, 310&#x2013;322.</Citation><ArticleIdList><ArticleId IdType="pubmed">31006494</ArticleId></ArticleIdList></Reference><Reference><Citation>Efthymiou AG, and Goate AM (2017). Late onset Alzheimer&#x2019;s disease genetics implicates microglial pathways in disease risk. Mol. Neurodegener 12, 43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5446752</ArticleId><ArticleId IdType="pubmed">28549481</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrari R, Hernandez DG, Nalls MA, Rohrer JD, Ramasamy A, Kwok JB, Dobson-Stone C, Brooks WS, Schofield PR, Halliday GM, et al. (2014a). Frontotemporal dementia and its subtypes: a genome-wide association study. Lancet Neurol 13, 686&#x2013;699.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4112126</ArticleId><ArticleId IdType="pubmed">24943344</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrari R, Ryten M, Simone R, Trabzuni D, Nicolaou N, Hondhamuni G, Ramasamy A, Vandrovcova J, UK Brain Expression Consortium; and Weale ME et al. (2014b). Assessment of common variability and expression quantitative trait loci for genome-wide associations for progressive supranuclear palsy. Neurobiol. Aging 35, 1514.e1&#x2013;1514.e12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4104112</ArticleId><ArticleId IdType="pubmed">24503276</ArticleId></ArticleIdList></Reference><Reference><Citation>Frith MC, Fu Y, Yu L, Chen JF, Hansen U, and Weng Z (2004). Detection of functional DNA motifs via statistical over-representation. Nucleic Acids Res 32, 1372&#x2013;1381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC390287</ArticleId><ArticleId IdType="pubmed">14988425</ArticleId></ArticleIdList></Reference><Reference><Citation>Gamache J, Benzow K, Forster C, Kemper L, Hlynialuk C, Furrow E, Ashe KH, and Koob MD (2019). Factors other than hTau overexpression that contribute to tauopathy-like phenotype in rTg4510 mice. Nat. Commun 10, 2479.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6554306</ArticleId><ArticleId IdType="pubmed">31171783</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldmann T, Zeller N, Raasch J, Kierdorf K, Frenzel K, Ketscher L, Basters A, Staszewski O, Brendecke SM, Spiess A, et al. (2015). USP18 lack in microglia causes destructive interferonopathy of the mouse brain. EMBO J 34, 1612&#x2013;1629.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4475397</ArticleId><ArticleId IdType="pubmed">25896511</ArticleId></ArticleIdList></Reference><Reference><Citation>Grubman A, Chew G, Ouyang JF, Sun G, Choo XY, McLean C, Simmons RK, Buckberry S, Vargas-Landin DB, Poppe D, et al. (2019). A single-cell atlas of entorhinal cortex from individuals with Alzheimer&#x2019;s disease reveals cell-type-specific gene expression regulation. Nat. Neurosci 22, 2087&#x2013;2097.</Citation><ArticleIdList><ArticleId IdType="pubmed">31768052</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo C, Jeong HH, Hsieh YC, Klein HU, Bennett DA, De Jager PL, Liu Z, and Shulman JM (2018). Tau Activates Transposable Elements in Alzheimer&#x2019;s Disease. Cell Rep 23, 2874&#x2013;2880.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6181645</ArticleId><ArticleId IdType="pubmed">29874575</ArticleId></ArticleIdList></Reference><Reference><Citation>Haenseler W, Sansom SN, Buchrieser J, Newey SE, Moore CS, Nicholls FJ, Chintawar S, Schnell C, Antel JP, Allen ND, et al. (2017). A Highly Efficient Human Pluripotent Stem Cell Microglia Model Displays a Neuronal-Co-culture-Specific Expression Profile and Inflammatory Response. Stem Cell Reports 8, 1727&#x2013;1742.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5470330</ArticleId><ArticleId IdType="pubmed">28591653</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond TR, Dufort C, Dissing-Olesen L, Giera S, Young A, Wysoker A, Walker AJ, Gergits F, Segel M, Nemesh J, et al. (2019). Single-Cell RNA Sequencing of Microglia throughout the Mouse Lifespan and in the Injured Brain Reveals Complex Cell-State Changes. Immunity 50, 253&#x2013;271.e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6655561</ArticleId><ArticleId IdType="pubmed">30471926</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen KD, Irizarry RA, and Wu Z (2012). Removing technical variability in RNA-seq data using conditional quantile normalization. Biostatistics 13, 204&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3297825</ArticleId><ArticleId IdType="pubmed">22285995</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, Kummer MP, Stutz A, Delekate A, Schwartz S, Vieira-Saecker A, Griep A, Axt D, Remus A, Tzeng TC, et al. (2013). NLRP3 is activated in Alzheimer&#x2019;s disease and contributes to pathology in APP/PS1 mice. Nature 493, 674&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3812809</ArticleId><ArticleId IdType="pubmed">23254930</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickman SE, Kingery ND, Ohsumi TK, Borowsky ML, Wang LC, Means TK, and El Khoury J (2013). The microglial sensome revealed by direct RNA sequencing. Nat. Neurosci 16, 1896&#x2013;1905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3840123</ArticleId><ArticleId IdType="pubmed">24162652</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xf6;glinger GU, Melhem NM, Dickson DW, Sleiman PM, Wang LS, Klei L, Rademakers R, de Silva R, Litvan I, Riley DE, et al.; PSP Genetics Study Group (2011). Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat. Genet 43, 699&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3125476</ArticleId><ArticleId IdType="pubmed">21685912</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xf6;ing S, Rudhard Y, Reinhardt P, Glatza M, Stehling M, Wu G, Peiker C, B&#xf6;cker A, Parga JA, Bunk E, et al. (2012). Discovery of inhibitors of microglial neurotoxicity acting through multiple mechanisms using a stem-cell-based phenotypic assay. Cell Stem Cell 11, 620&#x2013;632.</Citation><ArticleIdList><ArticleId IdType="pubmed">23064101</ArticleId></ArticleIdList></Reference><Reference><Citation>Honke N, Shaabani N, Zhang DE, Hardt C, and Lang KS (2016). Multiple functions of USP18. Cell Death Dis 7, e2444.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5260889</ArticleId><ArticleId IdType="pubmed">27809302</ArticleId></ArticleIdList></Reference><Reference><Citation>Horn H, Lawrence MS, Chouinard CR, Shrestha Y, Hu JX, Worstell E, Shea E, Ilic N, Kim E, Kamburov A, et al. (2018). NetSig: network-based discovery from cancer genomes. Nat. Methods 15, 61&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5985961</ArticleId><ArticleId IdType="pubmed">29200198</ArticleId></ArticleIdList></Reference><Reference><Citation>Ising C, Venegas C, Zhang S, Scheiblich H, Schmidt SV, Vieira-Saecker A, Schwartz S, Albasset S, McManus RM, Tejera D, et al. (2019). NLRP3 inflammasome activation drives tau pathology. Nature 575, 669&#x2013;673.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7324015</ArticleId><ArticleId IdType="pubmed">31748742</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang LQ, Xia T, Hu YH, Sun MS, Yan S, Lei CQ, Shu HB, Guo JH, and Liu Y (2018). IFITM3 inhibits virus-triggered induction of type I interferon by mediating autophagosome-dependent degradation of IRF3. Cell. Mol. Immunol 15, 858&#x2013;867.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6203713</ArticleId><ArticleId IdType="pubmed">28435159</ArticleId></ArticleIdList></Reference><Reference><Citation>Johansson JU, Woodling NS, Wang Q, Panchal M, Liang X, Trueba-Saiz A, Brown HD, Mhatre SD, Loui T, and Andreasson KI (2015). Prostaglandin signaling suppresses beneficial microglial function in Alzheimer&#x2019;s disease models. J. Clin. Invest. 125, 350&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4382270</ArticleId><ArticleId IdType="pubmed">25485684</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson WE, Li C, and Rabinovic A (2007). Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 8, 118&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pubmed">16632515</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelley KW, Nakao-Inoue H, Molofsky AV, and Oldham MC (2018). Variation among intact tissue samples reveals the core transcriptional features of human CNS cell classes. Nat. Neurosci 21, 1171&#x2013;1184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6192711</ArticleId><ArticleId IdType="pubmed">30154505</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK, David E, Baruch K, Lara-Astaiso D, Toth B, et al. (2017). A Unique Microglia Type Associated with Restricting Development of Alzheimer&#x2019;s Disease. Cell 169, 1276&#x2013;1290.e17.</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Kigerl KA, de Rivero Vaccari JP, Dietrich WD, Popovich PG, and Keane RW (2014). Pattern recognition receptors and central nervous system repair. Exp. Neurol 258, 5&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4974939</ArticleId><ArticleId IdType="pubmed">25017883</ArticleId></ArticleIdList></Reference><Reference><Citation>Kodama L, Guzman E, Etchegaray JI, Li Y, Sayed FA, Zhou L, Zhou Y, Zhan L, Le D, Udeochu JC, et al. (2020). Microglial microRNAs mediate sex-specific responses to tau pathology. Nat. Neurosci 23, 167&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7394069</ArticleId><ArticleId IdType="pubmed">31873194</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, et al. (2006). The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313, 1929&#x2013;1935.</Citation><ArticleIdList><ArticleId IdType="pubmed">17008526</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, DeStafano AL, Bis JC, Beecham GW, Grenier-Boley B, et al.; European Alzheimer&#x2019;s Disease Initiative (EADI); Genetic and Environmental Risk in Alzheimer&#x2019;s Disease; Alzheimer&#x2019;s Disease Genetic Consortium; Cohorts for Heart and Aging Research in Genomic Epidemiology (2013). Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer&#x2019;s disease. Nat. Genet 45, 1452&#x2013;1458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Langfelder P, and Horvath S (2008). WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics 9, 559.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2631488</ArticleId><ArticleId IdType="pubmed">19114008</ArticleId></ArticleIdList></Reference><Reference><Citation>Langfelder P, Luo R, Oldham MC, and Horvath S (2011). Is my network module preserved and reproducible? PLOS Comput. Biol 7, e1001057.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3024255</ArticleId><ArticleId IdType="pubmed">21283776</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CYD, Daggett A, Gu X, Jiang LL, Langfelder P, Li X, Wang N, Zhao Y, Park CS, Cooper Y, et al. (2018). Elevated TREM2 Gene Dosage Reprograms Microglia Responsivity and Ameliorates Pathological Phenotypes in Alzheimer&#x2019;s Disease Models. Neuron 97, 1032&#x2013;1048.e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5927822</ArticleId><ArticleId IdType="pubmed">29518357</ArticleId></ArticleIdList></Reference><Reference><Citation>Li A, and Horvath S (2007). Network neighborhood analysis with the multinode topological overlap measure. Bioinformatics 23, 222&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pubmed">17110366</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao Y, Smyth GK, and Shi W (2019). The R package Rsubread is easier, faster, cheaper and better for alignment and quantification of RNA sequencing reads. Nucleic Acids Res 47, e47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6486549</ArticleId><ArticleId IdType="pubmed">30783653</ArticleId></ArticleIdList></Reference><Reference><Citation>Litvinchuk A, Wan YW, Swartzlander DB, Chen F, Cole A, Propson NE, Wang Q, Zhang B, Liu Z, and Zheng H (2018). Complement C3aR Inactivation Attenuates Tau Pathology and Reverses an Immune Network Deregulated in Tauopathy Models and Alzheimer&#x2019;s Disease. Neuron 100, 1337&#x2013;1353.e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6309202</ArticleId><ArticleId IdType="pubmed">30415998</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu&#x10d;i&#x16b;nait&#x117; A, McManus RM, Jankunec M, R&#xe1;cz I, Dansokho C, Dalg&#x117;dien&#x117; I, Schwartz S, Brosseron F, and Heneka MT (2019). Soluble A&#x3b2; oligomers and protofibrils induce NLRP3 inflammasome activation in microglia. J. Neurochem (December 23), e14945.</Citation><ArticleIdList><ArticleId IdType="pubmed">31872431</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao R, Yang R, Chen X, Harhaj EW, Wang X, and Fan Y (2017). Regnase-1, a rapid response ribonuclease regulating inflammation and stress responses. Cell. Mol. Immunol 14, 412&#x2013;422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5423090</ArticleId><ArticleId IdType="pubmed">28194024</ArticleId></ArticleIdList></Reference><Reference><Citation>Marazzi I, Ho JS, Kim J, Manicassamy B, Dewell S, Albrecht RA, Seibert CW, Schaefer U, Jeffrey KL, Prinjha RK, et al. (2012). Suppression of the antiviral response by an influenza histone mimic. Nature 483, 428&#x2013;433.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3598589</ArticleId><ArticleId IdType="pubmed">22419161</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H, Adaikkan C, Gao F, Young JZ, Manet E, Hemberg M, De Jager PL, Ransohoff RM, Regev A, and Tsai LH (2017). Temporal Tracking of Microglia Activation in Neurodegeneration at Single-Cell Resolution. Cell Rep 21, 366&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5642107</ArticleId><ArticleId IdType="pubmed">29020624</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H, Davila-Velderrain J, Peng Z, Gao F, Mohammadi S, Young JZ, Menon M, He L, Abdurrob F, Jiang X, et al. (2019). Single-cell transcriptomic analysis of Alzheimer&#x2019;s disease. Nature 570, 332&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6865822</ArticleId><ArticleId IdType="pubmed">31042697</ArticleId></ArticleIdList></Reference><Reference><Citation>Matys V, Fricke E, Geffers R, G&#xf6;ssling E, Haubrock M, Hehl R, Hornischer K, Karas D, Kel AE, Kel-Margoulis OV, et al. (2003). TRANSFAC: transcriptional regulation, from patterns to profiles. Nucleic Acids Res 31, 374&#x2013;378.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC165555</ArticleId><ArticleId IdType="pubmed">12520026</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore Z, Mobilio F, Walker FR, Taylor JM, and Crack PJ (2020). Abrogation of type-I interferon signalling alters the microglial response to A&#x3b2;1&#x2013;42. Sci. Rep 10, 3153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7035268</ArticleId><ArticleId IdType="pubmed">32081950</ArticleId></ArticleIdList></Reference><Reference><Citation>Mud&#xf2; G, Frinchi M, Nuzzo D, Scaduto P, Plescia F, Massenti MF, Di Carlo M, Cannizzaro C, Cassata G, Cicero L, et al. (2019). Anti-inflammatory and cognitive effects of interferon-b1a (IFNb1a) in a rat model of Alzheimer&#x2019;s disease. J. Neuroinflammation 16, 44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6380058</ArticleId><ArticleId IdType="pubmed">30777084</ArticleId></ArticleIdList></Reference><Reference><Citation>Olah M, Menon V, Habib N, Taga M, Yung C, Cimpean M, Khairalla A, Dionne D, Hopp S, Frosch M, et al. (2018). A single cell-based atlas of human microglial states reveals associations with neurological disorders and histopathological features of the aging brain. bioRxiv 10.1101/343780.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/343780</ArticleId></ArticleIdList></Reference><Reference><Citation>Onishi T, Matsumoto Y, Hattori M, Obayashi Y, Nakamura K, Yano T, Horiguchi T, and Iwashita H (2014). Early-onset cognitive deficits and axonal transport dysfunction in P301S mutant tau transgenic mice. Neurosci. Res 80, 76&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">24406748</ArticleId></ArticleIdList></Reference><Reference><Citation>Pampuscenko K, Morkuniene R, Sneideris T, Smirnovas V, Budvytyte R, Valincius G, Brown GC, and Borutaite V (2020). Extracellular tau induces microglial phagocytosis of living neurons in cell cultures. J. Neurochem 154, 316&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pubmed">31834946</ArticleId></ArticleIdList></Reference><Reference><Citation>Portales-Casamar E, Thongjuea S, Kwon AT, Arenillas D, Zhao X, Valen E, Yusuf D, Lenhard B, Wasserman WW, and Sandelin A (2010). JASPAR 2010: the greatly expanded open-access database of transcription factor binding profiles. Nucleic Acids Res 38, D105&#x2013;D110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2808906</ArticleId><ArticleId IdType="pubmed">19906716</ArticleId></ArticleIdList></Reference><Reference><Citation>Renkl AC, Wussler J, Ahrens T, Thoma K, Kon S, Uede T, Martin SF, Simon JC, and Weiss JM (2005). Osteopontin functionally activates dendritic cells and induces their differentiation toward a Th1-polarizing phenotype. Blood 106, 946&#x2013;955.</Citation><ArticleIdList><ArticleId IdType="pubmed">15855273</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivals I, Personnaz L, Taing L, and Potier MC (2007). Enrichment or depletion of a GO category within a class of genes: which test? Bioinformatics 23, 401&#x2013;407.</Citation><ArticleIdList><ArticleId IdType="pubmed">17182697</ArticleId></ArticleIdList></Reference><Reference><Citation>Rock RB, Hu S, Deshpande A, Munir S, May BJ, Baker CA, Peterson PK, and Kapur V (2005). Transcriptional response of human microglial cells to interferon-gamma. Genes Immun 6, 712&#x2013;719.</Citation><ArticleIdList><ArticleId IdType="pubmed">16163375</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossin EJ, Lage K, Raychaudhuri S, Xavier RJ, Tatar D, Benita Y, Cotsapas C, and Daly MJ; International Inflammatory Bowel Disease Genetics Consortium (2011). Proteins encoded in genomic regions associated with immune-mediated disease physically interact and suggest underlying biology. PLOS Genet 7, e1001273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3020935</ArticleId><ArticleId IdType="pubmed">21249183</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy ER, Wang B, Wan YW, Chiu G, Cole A, Yin Z, Propson NE, Xu Y, Jankowsky JL, Liu Z, et al. (2020). Type I interferon response drives neuroinflammation and synapse loss in Alzheimer disease. J. Clin. Invest 130, 1912&#x2013;1930.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7108898</ArticleId><ArticleId IdType="pubmed">31917687</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito R, Smoot ME, Ono K, Ruscheinski J, Wang PL, Lotia S, Pico AR, Bader GD, and Ideker T (2012). A travel guide to Cytoscape plugins. Nat. Methods 9, 1069&#x2013;1076.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3649846</ArticleId><ArticleId IdType="pubmed">23132118</ArticleId></ArticleIdList></Reference><Reference><Citation>Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, DeTure M, Ramsden M, McGowan E, et al. (2005). Tau suppression in a neurodegenerative mouse model improves memory function. Science 309, 476&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1574647</ArticleId><ArticleId IdType="pubmed">16020737</ArticleId></ArticleIdList></Reference><Reference><Citation>Saura J, Tusell JM, and Serratosa J (2003). High-yield isolation of murine microglia by mild trypsinization. Glia 44, 183&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">14603460</ArticleId></ArticleIdList></Reference><Reference><Citation>Schafer DP, Lehrman EK, and Stevens B (2013). The &#x201c;quad-partite&#x201d; synapse: microglia-synapse interactions in the developing and mature CNS. Glia 61, 24&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4082974</ArticleId><ArticleId IdType="pubmed">22829357</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott CL, T&#x2019;Jonck W, Martens L, Todorov H, Sichien D, Soen B, Bonnardel J, De Prijck S, Vandamme N, Cannoodt R, et al. (2018). The Transcription Factor ZEB2 Is Required to Maintain the Tissue-Specific Identities of Macrophages. Immunity 49, 312&#x2013;325.e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6104815</ArticleId><ArticleId IdType="pubmed">30076102</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Manis M, Long J, Wang K, Sullivan PM, Remolina Serrano J, Hoyle R, and Holtzman DM (2019). Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model. J. Exp. Med 216, 2546&#x2013;2561.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6829593</ArticleId><ArticleId IdType="pubmed">31601677</ArticleId></ArticleIdList></Reference><Reference><Citation>Sloan SA, Andersen J, Pa&#x219;ca AM, Birey F, and Pa&#x219;ca SP (2018). Generation and assembly of human brain region-specific three-dimensional cultures. Nat. Protoc 13, 2062&#x2013;2085.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6597009</ArticleId><ArticleId IdType="pubmed">30202107</ArticleId></ArticleIdList></Reference><Reference><Citation>Snell LM, McGaha TL, and Brooks DG (2017). Type I Interferon in Chronic Virus Infection and Cancer. Trends Immunol 38, 542&#x2013;557.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8059441</ArticleId><ArticleId IdType="pubmed">28579323</ArticleId></ArticleIdList></Reference><Reference><Citation>Song WM, and Colonna M (2018). The identity and function of microglia in neurodegeneration. Nat. Immunol 19, 1048&#x2013;1058.</Citation><ArticleIdList><ArticleId IdType="pubmed">30250185</ArticleId></ArticleIdList></Reference><Reference><Citation>Srinivasan K, Friedman BA, Larson JL, Lauffer BE, Goldstein LD, Appling LL, Borneo J, Poon C, Ho T, Cai F, et al. (2016). Untangling the brain&#x2019;s neuroinflammatory and neurodegenerative transcriptional responses. Nat. Commun 7, 11295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4844685</ArticleId><ArticleId IdType="pubmed">27097852</ArticleId></ArticleIdList></Reference><Reference><Citation>Stancu IC, Cremers N, Vanrusselt H, Couturier J, Vanoosthuyse A, Kessels S, Lodder C, Br&#xf4;ne B, Huaux F, Octave JN, et al. (2019). Aggregated Tau activates NLRP3-ASC inflammasome exacerbating exogenously seeded and non-exogenously seeded Tau pathology in vivo. Acta Neuropathol 137, 599&#x2013;617.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6426830</ArticleId><ArticleId IdType="pubmed">30721409</ArticleId></ArticleIdList></Reference><Reference><Citation>Stark C, Breitkreutz BJ, Reguly T, Boucher L, Breitkreutz A, and Tyers M (2006). BioGRID: a general repository for interaction datasets. Nucleic Acids Res 34, D535&#x2013;D539.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1347471</ArticleId><ArticleId IdType="pubmed">16381927</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, Narayan R, Corsello SM, Peck DD, Natoli TE, Lu X, Gould J, Davis JF, Tubelli AA, Asiedu JK, et al. (2017). A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles. Cell 171, 1437&#x2013;1452.e17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5990023</ArticleId><ArticleId IdType="pubmed">29195078</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun W, Samimi H, Gamez M, Zare H, and Frost B (2018). Pathogenic tau-induced piRNA depletion promotes neuronal death through transposable element dysregulation in neurodegenerative tauopathies. Nat. Neurosci 21, 1038&#x2013;1048.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6095477</ArticleId><ArticleId IdType="pubmed">30038280</ArticleId></ArticleIdList></Reference><Reference><Citation>Swarup V, Hinz FI, Rexach JE, Noguchi KI, Toyoshiba H, Oda A, Hirai K, Sarkar A, Seyfried NT, Cheng C, et al.; International Frontotemporal Dementia Genomics Consortium (2019). Identification of evolutionarily conserved gene networks mediating neurodegenerative dementia. Nat. Med 25, 152&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6602064</ArticleId><ArticleId IdType="pubmed">30510257</ArticleId></ArticleIdList></Reference><Reference><Citation>Szklarczyk D, Morris JH, Cook H, Kuhn M, Wyder S, Simonovic M, Santos A, Doncheva NT, Roth A, Bork P, et al. (2017). The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res 45 (D1), D362&#x2013;D368.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5210637</ArticleId><ArticleId IdType="pubmed">27924014</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor JP, Cash MN, Santostefano KE, Nakanishi M, Terada N, and Wallet MA (2018). CRISPR/Cas9 knockout of USP18 enhances type I IFN responsiveness and restricts HIV-1 infection in macrophages. J. Leukoc. Biol 103, 1225&#x2013;1240.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6754309</ArticleId><ArticleId IdType="pubmed">29437254</ArticleId></ArticleIdList></Reference><Reference><Citation>Teijaro JR, Ng C, Lee AM, Sullivan BM, Sheehan KC, Welch M, Schreiber RD, de la Torre JC, and Oldstone MB (2013). Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science 340, 207&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3640797</ArticleId><ArticleId IdType="pubmed">23580529</ArticleId></ArticleIdList></Reference><Reference><Citation>V&#xe9;n&#xe9;reau E, Ceriotti C, and Bianchi ME (2015). DAMPs from Cell Death to New Life. Front. Immunol 6, 422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4539554</ArticleId><ArticleId IdType="pubmed">26347745</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, Gilfillan S, Krishnan GM, Sudhakar S, Zinselmeyer BH, et al. (2015). TREM2 lipid sensing sustains the microglial response in an Alzheimer&#x2019;s disease model. Cell 160, 1061&#x2013;1071.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Li Y, Ryder JW, Hole JT, Ebert PJ, Airey DC, Qian HR, Logsdon B, Fisher A, Ahmed Z, et al. (2018). Genome-wide RNAseq study of the molecular mechanisms underlying microglia activation in response to pathological tau perturbation in the rTg4510 tau transgenic animal model. Mol. Neurodegener 13, 65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6296031</ArticleId><ArticleId IdType="pubmed">30558641</ArticleId></ArticleIdList></Reference><Reference><Citation>W&#xf6;lfl M, Schwinn S, Yoo YE, Re&#xdf; ML, Braun M, Chopra M, Schreiber SC, Ayala VI, Ohlen C, Eyrich M, et al. (2013). Src-kinase inhibitors sensitize human cells of myeloid origin to Toll-like-receptor-induced interleukin 12 synthesis. Blood 122, 1203&#x2013;1213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3744989</ArticleId><ArticleId IdType="pubmed">23836556</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodling NS, Wang Q, Priyam PG, Larkin P, Shi J, Johansson JU, Zagol-Ikapitte I, Boutaud O, and Andreasson KI (2014). Suppression of Alzheimer-associated inflammation by microglial prostaglandin-E2 EP4 receptor signaling. J. Neurosci 34, 5882&#x2013;5894.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3996215</ArticleId><ArticleId IdType="pubmed">24760848</ArticleId></ArticleIdList></Reference><Reference><Citation>Wykes MN, and Lewin SR (2018). Immune checkpoint blockade in infectious diseases. Nat. Rev. Immunol 18, 91&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5991909</ArticleId><ArticleId IdType="pubmed">28990586</ArticleId></ArticleIdList></Reference><Reference><Citation>Zambon AC, Gaj S, Ho I, Hanspers K, Vranizan K, Evelo CT, Conklin BR, Pico AR, and Salomonis N (2012). GO-Elite: a flexible solution for pathway and ontology over-representation. Bioinformatics 28, 2209&#x2013;2210.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3413395</ArticleId><ArticleId IdType="pubmed">22743224</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O&#x2019;Keeffe S, Phatnani HP, Guarnieri P, Caneda C, Ruderisch N, et al. (2014). An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J. Neurosci 34, 11929&#x2013;11947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4152602</ArticleId><ArticleId IdType="pubmed">25186741</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33238112</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>16</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>8</Issue><PubDate><Year>2020</Year><Month>Nov</Month><Day>24</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>Endosomal Dysfunction Induced by Directly Overactivating Rab5 Recapitulates Prodromal and Neurodegenerative Features of Alzheimer's Disease.</ArticleTitle><Pagination><StartPage>108420</StartPage><MedlinePgn>108420</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2020.108420</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(20)31409-1</ELocationID><Abstract><AbstractText>Neuronal endosomal dysfunction, the earliest known pathobiology specific to Alzheimer's disease (AD), is mediated by the aberrant activation of Rab5 triggered by APP-&#x3b2; secretase cleaved C-terminal fragment (APP-&#x3b2;CTF). To distinguish pathophysiological consequences specific to overactivated Rab5 itself, we activate Rab5 independently from APP-&#x3b2;CTF in the PA-Rab5 mouse model. We report that Rab5 overactivation alone recapitulates diverse prodromal and degenerative features of AD. Modest neuron-specific transgenic Rab5 expression inducing hyperactivation of Rab5 comparable to that in AD brain reproduces AD-related Rab5-endosomal enlargement and mistrafficking, hippocampal synaptic plasticity deficits via accelerated AMPAR endocytosis and dendritic spine loss, and tau hyperphosphorylation via activated glycogen synthase kinase-3&#x3b2;. Importantly, Rab5-mediated endosomal dysfunction induces progressive cholinergic neurodegeneration and impairs hippocampal-dependent memory. Aberrant neuronal Rab5-endosome signaling, therefore, drives a pathogenic cascade distinct from &#x3b2;-amyloid-related neurotoxicity, which includes prodromal and neurodegenerative features of AD, and suggests Rab5 overactivation as a potential therapeutic target.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pensalfini</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA; Department of Psychiatry, New York University Langone Health, New York, NY 10016, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Seonil</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Colorado State University, Department of Biomedical Sciences, Fort Collins, CO 80523, USA; Cellular and Molecular Biology Training Program, New York University Langone Health, New York, NY 10003, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Subbanna</LastName><ForeName>Shivakumar</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Analytical Psychopharmacology, Nathan Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bleiwas</LastName><ForeName>Cynthia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurochemistry, Nathan Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goulbourne</LastName><ForeName>Chris N</ForeName><Initials>CN</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stavrides</LastName><ForeName>Philip H</ForeName><Initials>PH</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA; Department of Psychiatry, New York University Langone Health, New York, NY 10016, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Ju-Hyun</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA; Department of Psychiatry, New York University Langone Health, New York, NY 10016, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Darji</LastName><ForeName>Sandipkumar</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pawlik</LastName><ForeName>Monika</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huo</LastName><ForeName>Chunfeng</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peddy</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berg</LastName><ForeName>Martin J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smiley</LastName><ForeName>John F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Department of Neurochemistry, Nathan Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Basavarajappa</LastName><ForeName>Balapal S</ForeName><Initials>BS</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, New York University Langone Health, New York, NY 10016, USA; Department of Analytical Psychopharmacology, Nathan Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA; New York State Psychiatric Institute, New York, NY 10032, USA; Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nixon</LastName><ForeName>Ralph A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Center for Dementia Research, Nathan Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA; Department of Psychiatry, New York University Langone Health, New York, NY 10016, USA; Department of Cell Biology, New York University Langone Health, New York, NY 10003, USA; NYU Neuroscience Institute, New York, NY 10003, USA. Electronic address: ralph.nixon@nki.rfmh.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG017617</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG062376</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.6.5.2</RegistryNumber><NameOfSubstance UI="D020696">rab5 GTP-Binding Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011992" MajorTopicYN="N">Endosomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020696" MajorTopicYN="N">rab5 GTP-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Rab5 hyperactivation</Keyword><Keyword MajorTopicYN="N">aberrant endosomal signaling</Keyword><Keyword MajorTopicYN="N">amyloid precursor protein</Keyword><Keyword MajorTopicYN="N">cholinergic neurodegeneration</Keyword><Keyword MajorTopicYN="N">endosomal dysfunction</Keyword><Keyword MajorTopicYN="N">memory impairment</Keyword><Keyword MajorTopicYN="N">spine loss</Keyword><Keyword MajorTopicYN="N">synaptic deficits</Keyword><Keyword MajorTopicYN="N">tau</Keyword></KeywordList><CoiStatement>Declaration of Interests The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>12</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>6</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>11</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>11</Month><Day>25</Day><Hour>20</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>11</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>12</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33238112</ArticleId><ArticleId IdType="mid">NIHMS1649681</ArticleId><ArticleId IdType="pmc">PMC7714675</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2020.108420</ArticleId><ArticleId IdType="pii">S2211-1247(20)31409-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alam JJ (2015). Selective Brain-Targeted Antagonism of p38 MAPK&#x3b1; Reduces Hippocampal IL-1&#x3b2; Levels and Improves Morris Water Maze Performance in Aged Rats. J. Alzheimers Dis 48, 219&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4923728</ArticleId><ArticleId IdType="pubmed">26401942</ArticleId></ArticleIdList></Reference><Reference><Citation>Alam J, Jiang Y, and Nixon R (2017). Antagonism of P38 MAPK alpha (P38&#x3b1;) reverses APP-induced endosomal abnormalities and improves lysosomal function in Down syndrome fibroblasts. Alzheimers Dement. 13, P1496&#x2013;P1497.</Citation></Reference><Reference><Citation>Androuin A, Potier B, N&#xe4;gerl UV, Cattaert D, Danglot L, Thierry M, Youssef I, Triller A, Duyckaerts C, El Hachimi KH, et al. (2018). Evidence for altered dendritic spine compartmentalization in Alzheimer&#x2019;s disease and functional effects in a mouse model. Acta Neuropathol. 135, 839&#x2013;854.</Citation><ArticleIdList><ArticleId IdType="pubmed">29696365</ArticleId></ArticleIdList></Reference><Reference><Citation>Baglietto-Vargas D, Prieto GA, Limon A, Forner S, Rodriguez-Ortiz CJ, Ikemura K, Ager RR, Medeiros R, Trujillo-Estrada L, Martini AC, et al. (2018). Impaired AMPA signaling and cytoskeletal alterations induce early synaptic dysfunction in a mouse model of Alzheimer&#x2019;s disease. Aging Cell 17, e12791.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6052400</ArticleId><ArticleId IdType="pubmed">29877034</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballinger EC, Ananth M, Talmage DA, and Role LW (2016). Basal Forebrain Cholinergic Circuits and Signaling in Cognition and Cognitive Decline. Neuron 91, 1199&#x2013;1218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5036520</ArticleId><ArticleId IdType="pubmed">27657448</ArticleId></ArticleIdList></Reference><Reference><Citation>Barlow JZ, and Huntley GW (2000). Developmentally regulated expression of Thy-1 in structures of the mouse sensory-motor system. J. Comp. Neurol 421, 215&#x2013;233.</Citation><ArticleIdList><ArticleId IdType="pubmed">10813783</ArticleId></ArticleIdList></Reference><Reference><Citation>Belichenko PV, Masliah E, Kleschevnikov AM, Villar AJ, Epstein CJ, Salehi A, and Mobley WC (2004). Synaptic structural abnormalities in the Ts65Dn mouse model of Down Syndrome. J. Comp. Neurol 480, 281&#x2013;298.</Citation><ArticleIdList><ArticleId IdType="pubmed">15515178</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourgeois A, Lauritzen I, Lorivel T, Bauer C, Checler F, and Pardossi-Piquard R (2018). Intraneuronal accumulation of C99 contributes to synaptic alterations, apathy-like behavior, and spatial learning deficits in 3&#xd7;TgAD and 2&#xd7;TgAD mice. Neurobiol. Aging 71, 21&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">30071370</ArticleId></ArticleIdList></Reference><Reference><Citation>Brinkmalm G, Hong W, Wang Z, Liu W, O&#x2019;Malley TT, Sun X, Frosch MP, Selkoe DJ, Portelius E, Zetterberg H, et al. (2019). Identification of neurotoxic cross-linked amyloid-&#x3b2; dimers in the Alzheimer&#x2019;s brain. Brain 142, 1441&#x2013;1457.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6487330</ArticleId><ArticleId IdType="pubmed">31032851</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown TC, Tran IC, Backos DS, and Esteban JA (2005). NMDA receptor-dependent activation of the small GTPase Rab5 drives the removal of synaptic AMPA receptors during hippocampal LTD. Neuron 45, 81&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">15629704</ArticleId></ArticleIdList></Reference><Reference><Citation>Calafate S, Flavin W, Verstreken P, and Moechars D (2016). Loss of Bin1 Promotes the Propagation of Tau Pathology. Cell Rep. 17, 931&#x2013;940.</Citation><ArticleIdList><ArticleId IdType="pubmed">27760323</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrillo MC, Dean RA, Nicolas F, Miller DS, Berman R, Khachaturian Z, Bain LJ, Schindler R, and Knopman D; Alzheimer&#x2019;s Association Research Roundtable (2013). Revisiting the framework of the National Institute on Aging-Alzheimer&#x2019;s Association diagnostic criteria. Alzheimers Dement. 9, 594&#x2013;601.</Citation><ArticleIdList><ArticleId IdType="pubmed">24007744</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataldo AM, Barnett JL, Pieroni C, and Nixon RA (1997). Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer&#x2019;s disease: neuropathologic evidence for a mechanism of increased beta-amyloidogenesis. J. Neurosci 17, 6142&#x2013;6151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6568334</ArticleId><ArticleId IdType="pubmed">9236226</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataldo AM, Peterhoff CM, Troncoso JC, Gomez-Isla T, Hyman BT, and Nixon RA (2000). Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer&#x2019;s disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. Am. J. Pathol 157, 277&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850219</ArticleId><ArticleId IdType="pubmed">10880397</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataldo AM, Petanceska S, Terio NB, Peterhoff CM, Durham R, Mercken M, Mehta PD, Buxbaum J, Haroutunian V, and Nixon RA (2004). Abeta localization in abnormal endosomes: association with earliest Abeta elevations in AD and Down syndrome. Neurobiol. Aging 25, 1263&#x2013;1272.</Citation><ArticleIdList><ArticleId IdType="pubmed">15465622</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataldo AM, Mathews PM, Boiteau AB, Hassinger LC, Peterhoff CM, Jiang Y, Mullaney K, Neve RL, Gruenberg J, and Nixon RA (2008). Down syndrome fibroblast model of Alzheimer-related endosome pathology: accelerated endocytosis promotes late endocytic defects. Am. J. Pathol 173, 370&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2475775</ArticleId><ArticleId IdType="pubmed">18535180</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavalli V, Vilbois F, Corti M, Marcote MJ, Tamura K, Karin M, Arkinstall S, and Gruenberg J (2001). The stress-induced MAP kinase p38 regulates endocytic trafficking via the GDI:Rab5 complex. Mol. Cell 7, 421&#x2013;432.</Citation><ArticleIdList><ArticleId IdType="pubmed">11239470</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen XQ, and Mobley WC (2019). Exploring the Pathogenesis of Alzheimer Disease in Basal Forebrain Cholinergic Neurons: Converging Insights From Alternative Hypotheses. Front. Neurosci 13, 446.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6514132</ArticleId><ArticleId IdType="pubmed">31133787</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen XQ, Sawa M, and Mobley WC (2018). Dysregulation of neurotrophin signaling in the pathogenesis of Alzheimer disease and of Alzheimer disease in Down syndrome. Free Radic. Biol. Med 114, 52&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5748266</ArticleId><ArticleId IdType="pubmed">29031834</ArticleId></ArticleIdList></Reference><Reference><Citation>Chow HM, Guo D, Zhou JC, Zhang GY, Li HF, Herrup K, and Zhang J (2014). CDK5 activator protein p25 preferentially binds and activates GSK3&#x3b2;. Proc. Natl. Acad. Sci. USA 111, E4887&#x2013;E4895.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4234543</ArticleId><ArticleId IdType="pubmed">25331900</ArticleId></ArticleIdList></Reference><Reference><Citation>Christoforidis S, and Zerial M (2000). Purification and identification of novel Rab effectors using affinity chromatography. Methods 20, 403&#x2013;410.</Citation><ArticleIdList><ArticleId IdType="pubmed">10720461</ArticleId></ArticleIdList></Reference><Reference><Citation>Colacurcio DJ, Pensalfini A, Jiang Y, and Nixon RA (2018). Dysfunction of autophagy and endosomal-lysosomal pathways: roles in pathogenesis of Down syndrome and Alzheimer&#x2019;s disease. Free Radic. Biol. Med 114, 40&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5748263</ArticleId><ArticleId IdType="pubmed">28988799</ArticleId></ArticleIdList></Reference><Reference><Citation>Cormont M, Met&#xf3;n I, Mari M, Monzo P, Keslair F, Gaskin C, McGraw TE, and Le Marchand-Brustel Y (2003). CD2AP/CMS regulates endosome morphology and traffic to the degradative pathway through its interaction with Rab4 and c-Cbl. Traffic 4, 97&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">12559036</ArticleId></ArticleIdList></Reference><Reference><Citation>David C, McPherson PS, Mundigl O, and de Camilli P (1996). A role of amphiphysin in synaptic vesicle endocytosis suggested by its binding to dynamin in nerve terminals. Proc. Natl. Acad. Sci. USA 93, 331&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC40232</ArticleId><ArticleId IdType="pubmed">8552632</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, and Karran E (2016). The Cellular Phase of Alzheimer&#x2019;s Disease. Cell 164, 603&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pubmed">26871627</ArticleId></ArticleIdList></Reference><Reference><Citation>Dou Z, Pan JA, Dbouk HA, Ballou LM, DeLeon JL, Fan Y, Chen JS, Liang Z, Li G, Backer JM, et al. (2013). Class IA PI3K p110&#x3b2; subunit promotes autophagy through Rab5 small GTPase in response to growth factor limitation. Mol. Cell 50, 29&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3628298</ArticleId><ArticleId IdType="pubmed">23434372</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, DeKosky ST, Gauthier S, Selkoe D, Bateman R, et al. (2014). Advancing research diagnostic criteria for Alzheimer&#x2019;s disease: the IWG-2 criteria. Lancet Neurol. 13, 614&#x2013;629.</Citation><ArticleIdList><ArticleId IdType="pubmed">24849862</ArticleId></ArticleIdList></Reference><Reference><Citation>Eimer WA, and Vassar R (2013). Neuron loss in the 5XFAD mouse model of Alzheimer&#x2019;s disease correlates with intraneuronal A&#x3b2;42 accumulation and Caspase-3 activation. Mol. Neurodegener 8, 2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3552866</ArticleId><ArticleId IdType="pubmed">23316765</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang F, Yang W, Florio JB, Rockenstein E, Spencer B, Orain XM, Dong SX, Li H, Chen X, Sung K, et al. (2017). Synuclein impairs trafficking and signaling of BDNF in a mouse model of Parkinson&#x2019;s disease. Sci. Rep 7, 3868.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5478665</ArticleId><ArticleId IdType="pubmed">28634349</ArticleId></ArticleIdList></Reference><Reference><Citation>Farg MA, Sundaramoorthy V, Sultana JM, Yang S, Atkinson RA, Levina V, Halloran MA, Gleeson PA, Blair IP, Soo KY, et al. (2014). C9ORF72, implicated in amytrophic lateral sclerosis and frontotemporal dementia, regulates endosomal trafficking. Hum. Mol. Genet 23, 3579&#x2013;3595.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049310</ArticleId><ArticleId IdType="pubmed">24549040</ArticleId></ArticleIdList></Reference><Reference><Citation>Fjorback AW, and Andersen OM (2012). SorLA is a molecular link for retromer-dependent sorting of the Amyloid precursor protein. Commun. Integr. Biol 5, 616&#x2013;619.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3541330</ArticleId><ArticleId IdType="pubmed">23740096</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginsberg SD, Alldred MJ, Counts SE, Cataldo AM, Neve RL, Jiang Y, Wuu J, Chao MV, Mufson EJ, Nixon RA, and Che S (2010a). Microarray analysis of hippocampal CA1 neurons implicates early endosomal dysfunction during Alzheimer&#x2019;s disease progression. Biol. Psychiatry 68, 885&#x2013;893.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2965820</ArticleId><ArticleId IdType="pubmed">20655510</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginsberg SD, Mufson EJ, Counts SE, Wuu J, Alldred MJ, Nixon RA, and Che S (2010b). Regional selectivity of rab5 and rab7 protein upregulation in mild cognitive impairment and Alzheimer&#x2019;s disease. J. Alzheimers Dis 22, 631&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3031860</ArticleId><ArticleId IdType="pubmed">20847427</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginsberg SD, Mufson EJ, Alldred MJ, Counts SE, Wuu J, Nixon RA, and Che S (2011). Upregulation of select rab GTPases in cholinergic basal forebrain neurons in mild cognitive impairment and Alzheimer&#x2019;s disease. J. Chem. Neuroanat 42, 102&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3163754</ArticleId><ArticleId IdType="pubmed">21669283</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorvel JP, Chavrier P, Zerial M, and Gruenberg J (1991). rab5 controls early endosome fusion in vitro. Cell 64, 915&#x2013;925.</Citation><ArticleIdList><ArticleId IdType="pubmed">1900457</ArticleId></ArticleIdList></Reference><Reference><Citation>Goto-Silva L, McShane MP, Salinas S, Kalaidzidis Y, Schiavo G, and Zerial M (2019). Retrograde transport of Akt by a neuronal Rab5-APPL1 endosome. Sci. Rep 9, 2433.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6385319</ArticleId><ArticleId IdType="pubmed">30792402</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouras GK, Tampellini D, Takahashi RH, and Capetillo-Zarate E (2010). Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer&#x2019;s disease. Acta Neuropathol. 119, 523&#x2013;541.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3183823</ArticleId><ArticleId IdType="pubmed">20354705</ArticleId></ArticleIdList></Reference><Reference><Citation>Granholm AC, Sanders LA, and Crnic LS (2000). Loss of cholinergic phenotype in basal forebrain coincides with cognitive decline in a mouse model of Down&#x2019;s syndrome. Exp. Neurol 161, 647&#x2013;663.</Citation><ArticleIdList><ArticleId IdType="pubmed">10686084</ArticleId></ArticleIdList></Reference><Reference><Citation>Grothe M, Heinsen H, and Teipel SJ (2012). Atrophy of the cholinergic basal forebrain over the adult age range and in early stages of Alzheimer&#x2019;s disease. Biol. Psychiatry 71, 805&#x2013;813.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3701122</ArticleId><ArticleId IdType="pubmed">21816388</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruenberg J, Griffiths G, and Howell KE (1989). Characterization of the early endosome and putative endocytic carrier vesicles in vivo and with an assay of vesicle fusion in vitro. J. Cell Biol 108, 1301&#x2013;1316.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2115527</ArticleId><ArticleId IdType="pubmed">2538480</ArticleId></ArticleIdList></Reference><Reference><Citation>Haam J, and Yakel JL (2017). Cholinergic modulation of the hippocampal region and memory function. J. Neurochem 142 (Suppl 2), 111&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5645066</ArticleId><ArticleId IdType="pubmed">28791706</ArticleId></ArticleIdList></Reference><Reference><Citation>Haas MA, Bell D, Slender A, Lana-Elola E, Watson-Scales S, Fisher EM, Tybulewicz VL, and Guillemot F (2013). Alterations to dendritic spine morphology, but not dendrite patterning, of cortical projection neurons in Tc1 and Ts1Rhr mouse models of Down syndrome. PLOS ONE 8, e78561.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3813676</ArticleId><ArticleId IdType="pubmed">24205261</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadano S, Hand CK, Osuga H, Yanagisawa Y, Otomo A, Devon RS, Miyamoto N, Showguchi-Miyata J, Okada Y, Singaraja R, et al. (2001). A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2. Nat. Genet 29, 166&#x2013;173.</Citation><ArticleIdList><ArticleId IdType="pubmed">11586298</ArticleId></ArticleIdList></Reference><Reference><Citation>Harel A, Wu F, Mattson MP, Morris CM, and Yao PJ (2008). Evidence for CALM in directing VAMP2 trafficking. Traffic 9, 417&#x2013;429.</Citation><ArticleIdList><ArticleId IdType="pubmed">18182011</ArticleId></ArticleIdList></Reference><Reference><Citation>Hausser A, and Schlett K (2019). Coordination of AMPA receptor trafficking by Rab GTPases. Small GTPases 10, 419&#x2013;432.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6748377</ArticleId><ArticleId IdType="pubmed">28628388</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooper C, Killick R, and Lovestone S (2008). The GSK3 hypothesis of Alzheimer&#x2019;s disease. J. Neurochem 104, 1433&#x2013;1439.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3073119</ArticleId><ArticleId IdType="pubmed">18088381</ArticleId></ArticleIdList></Reference><Reference><Citation>Horiuchi H, Lipp&#xe9; R, McBride HM, Rubino M, Woodman P, Stenmark H, Rybin V, Wilm M, Ashman K, Mann M, and Zerial M (1997). A novel Rab5 GDP/GTP exchange factor complexed to Rabaptin-5 links nucleotide exchange to effector recruitment and function. Cell 90, 1149&#x2013;1159.</Citation><ArticleIdList><ArticleId IdType="pubmed">9323142</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh H, Boehm J, Sato C, Iwatsubo T, Tomita T, Sisodia S, and Malinow R (2006). AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron 52, 831&#x2013;843.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850952</ArticleId><ArticleId IdType="pubmed">17145504</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu F, Spannl S, Ferguson C, Hyman AA, Parton RG, and Zerial M (2018). Rab5 and Alsin regulate stress-activated cytoprotective signaling on mitochondria. eLife 7, e32282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5847334</ArticleId><ArticleId IdType="pubmed">29469808</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung H, and Livesey FJ (2018). Altered &#x3b3;-Secretase Processing of APP Disrupts Lysosome and TitAutophagosome Function in Monogenic Alzheimer&#x2019;s Disease. Cell Rep. 25, 3647&#x2013;3660.e2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6315085</ArticleId><ArticleId IdType="pubmed">30590039</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishikawa Y, Okada M, Honda A, Ito Y, Tamada A, Endo N, and Igarashi M (2019). Phosphorylation sites of microtubule-associated protein 1B (MAP 1B) are involved in axon growth and regeneration. Mol. Brain 12, 93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6849251</ArticleId><ArticleId IdType="pubmed">31711525</ArticleId></ArticleIdList></Reference><Reference><Citation>Israel MA, Yuan SH, Bardy C, Reyna SM, Mu Y, Herrera C, Hefferan MP, Van Gorp S, Nazor KL, Boscolo FS, et al. (2012). Probing sporadic and familial Alzheimer&#x2019;s disease using induced pluripotent stem cells. Nature 482, 216&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3338985</ArticleId><ArticleId IdType="pubmed">22278060</ArticleId></ArticleIdList></Reference><Reference><Citation>Iulita MF, and Cuello AC (2016). The NGF Metabolic Pathway in the CNS and its Dysregulation in Down Syndrome and Alzheimer&#x2019;s Disease. Curr. Alzheimer Res 13, 53&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">26391047</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Y, Mullaney KA, Peterhoff CM, Che S, Schmidt SD, Boyer-Boiteau A, Ginsberg SD, Cataldo AM, Mathews PM, and Nixon RA (2010). Alzheimer&#x2019;s-related endosome dysfunction in Down syndrome is Abeta-independent but requires APP and is reversed by BACE-1 inhibition. Proc. Natl. Acad. Sci. USA 107, 1630&#x2013;1635.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2824382</ArticleId><ArticleId IdType="pubmed">20080541</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Y, Rigoglioso A, Peterhoff CM, Pawlik M, Sato Y, Bleiwas C, Stavrides P, Smiley JF, Ginsberg SD, Mathews PM, et al. (2016). Partial BACE1 reduction in a Down syndrome mouse model blocks Alzheimer-related endosomal anomalies and cholinergic neurodegeneration: role of APP-CTF. Neurobiol. Aging 39, 90&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4773919</ArticleId><ArticleId IdType="pubmed">26923405</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Y, Sato Y, Im E, Berg M, Bordi M, Darji S, Kumar A, Mohan PS, Bandyopadhyay U, Diaz A, et al. (2019a). Lysosomal Dysfunction in Down Syndrome Is APP-Dependent and Mediated by APP-&#x3b2;CTF (C99). J. Neurosci 39, 5255&#x2013;5268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6607756</ArticleId><ArticleId IdType="pubmed">31043483</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Y, Stavrides P, Darji S, Yang D-S, Bleiwas C, Smiley J, Germann U, Alam J, and Nixon R (2019b). Effects of P38&#x3b1; MAP kinase inhibition on the neurodegenerative phenotype of the TS2 Down syndrome mouse model. Alzheimers Dement. 15, 1597.</Citation></Reference><Reference><Citation>Joshi V, Subbanna S, Shivakumar M, and Basavarajappa BS (2019). CB1R regulates CDK5 signaling and epigenetically controls Rac1 expression contributing to neurobehavioral abnormalities in mice postnatally exposed to ethanol. Neuropsychopharmacology 44, 514&#x2013;525.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6333777</ArticleId><ArticleId IdType="pubmed">30143782</ArticleId></ArticleIdList></Reference><Reference><Citation>Kajiho H, Saito K, Tsujita K, Kontani K, Araki Y, Kurosu H, and Katada T (2003). RIN3: a novel Rab5 GEF interacting with amphiphysin II involved in the early endocytic pathway. J. Cell Sci 116, 4159&#x2013;4168.</Citation><ArticleIdList><ArticleId IdType="pubmed">12972505</ArticleId></ArticleIdList></Reference><Reference><Citation>Karch CM, and Goate AM (2015). Alzheimer&#x2019;s disease risk genes and mechanisms of disease pathogenesis. Biol. Psychiatry 77, 43&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4234692</ArticleId><ArticleId IdType="pubmed">24951455</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S, Sato Y, Mohan PS, Peterhoff C, Pensalfini A, Rigoglioso A, Jiang Y, and Nixon RA (2016). Evidence that the rab5 effector APPL1 mediates APP-&#x3b2;CTF-induced dysfunction of endosomes in Down syndrome and Alzheimer&#x2019;s disease. Mol. Psychiatry 21, 707&#x2013;716.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4721948</ArticleId><ArticleId IdType="pubmed">26194181</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiral FR, Kohrs FE, Jin EJ, and Hiesinger PR (2018). RA&#x3b2; GTPases and Membrane Trafficking in Neurodegeneration. Curr. Biol 28, R471&#x2013;R486.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5965285</ArticleId><ArticleId IdType="pubmed">29689231</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwart D, Gregg A, Scheckel C, Murphy E, Paquet D, Duffield M, Fak J, Olsen O, Darnell R, and Tessier-Lavigne M (2019). A Large Panel of Isogenic APP and PSEN1 Mutant Human iPSC Neurons Reveals Shared Endosomal Abnormalities Mediated by APP beta-CTFs, Not Abeta. Neuron 104, 256&#x2013;270.e5.</Citation><ArticleIdList><ArticleId IdType="pubmed">31416668</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, DeStafano AL, Bis JC, Beecham GW, Grenier-Boley B, et al.; European Alzheimer&#x2019;s Disease Initiative (EADI); Genetic and Environmental Risk in Alzheimer&#x2019;s Disease; Alzheimer&#x2019;s Disease Genetic Consortium; Cohorts for Heart and Aging Research in Genomic Epidemiology (2013). Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer&#x2019;s disease. Nat. Genet 45, 1452&#x2013;1458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee HK, Barbarosie M, Kameyama K, Bear MF, and Huganir RL (2000). Regulation of distinct AMPA receptor phosphorylation sites during bidirectional synaptic plasticity. Nature 405, 955&#x2013;959.</Citation><ArticleIdList><ArticleId IdType="pubmed">10879537</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JH, Rao MV, Yang DS, Stavrides P, Im E, Pensalfini A, Huo C, Sarkar P, Yoshimori T, and Nixon RA (2019). Transgenic expression of a ratiometric autophagy probe specifically in neurons enables the interrogation of brain autophagy in vivo. Autophagy 15, 543&#x2013;557.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6351128</ArticleId><ArticleId IdType="pubmed">30269645</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis J, and Dickson DW (2016). Propagation of tau pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies. Acta Neuropathol. 131, 27&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">26576562</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YT, Seo J, Gao F, Feldman HM, Wen HL, Penney J, Cam HP, Gjoneska E, Raja WK, Cheng J, et al. (2018). APOE4 Causes Widespread Molecular and Cellular Alterations Associated with Alzheimer&#x2019;s Disease Phenotypes in Human iPSC-Derived Brain Cell Types. Neuron 98, 1141&#x2013;1154.e7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6023751</ArticleId><ArticleId IdType="pubmed">29861287</ArticleId></ArticleIdList></Reference><Reference><Citation>Liot G, Zala D, Pla P, Mottet G, Piel M, and Saudou F (2013). Mutant Huntingtin alters retrograde transport of TrkB receptors in striatal dendrites. J. Neurosci 33, 6298&#x2013;6309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6619069</ArticleId><ArticleId IdType="pubmed">23575829</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipp&#xe9; R, Miaczynska M, Rybin V, Runge A, and Zerial M (2001). Functional synergy between Rab5 effector Rabaptin-5 and exchange factor Rabex-5 when physically associated in a complex. Mol. Biol. Cell 12, 2219&#x2013;2228.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC55678</ArticleId><ArticleId IdType="pubmed">11452015</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Lamb D, Chou MM, Liu YJ, and Li G (2007). Nerve growth factor-mediated neurite outgrowth via regulation of Rab5. Mol. Biol. Cell 18, 1375&#x2013;1384.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1838971</ArticleId><ArticleId IdType="pubmed">17267689</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Liu CC, Kanekiyo T, Xu H, and Bu G (2013). Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat. Rev. Neurol 9, 106&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3726719</ArticleId><ArticleId IdType="pubmed">23296339</ArticleId></ArticleIdList></Reference><Reference><Citation>Louneva N, Cohen JW, Han LY, Talbot K, Wilson RS, Bennett DA, Trojanowski JQ, and Arnold SE (2008). Caspase-3 is enriched in postsynaptic densities and increased in Alzheimer&#x2019;s disease. Am. J. Pathol 173, 1488&#x2013;1495.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2570138</ArticleId><ArticleId IdType="pubmed">18818379</ArticleId></ArticleIdList></Reference><Reference><Citation>Mani M, Lee UH, Yoon NA, Kim HJ, Ko MS, Seol W, Joe Y, Chung HT, Lee BJ, Moon CH, et al. (2016). Developmentally regulated GTP-binding protein 2 coordinates Rab5 activity and transferrin recycling. Mol. Biol. Cell 27, 334&#x2013;348.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4713135</ArticleId><ArticleId IdType="pubmed">26582392</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin SA, Souder DC, Miller KN, Clark JP, Sagar AK, Eliceiri KW, Puglielli L, Beasley TM, and Anderson RM (2018). GSK3&#x3b2; Regulates Brain Energy Metabolism. Cell Rep. 23, 1922&#x2013;1931.e4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6082412</ArticleId><ArticleId IdType="pubmed">29768193</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathews PM, Guerra CB, Jiang Y, Grbovic OM, Kao BH, Schmidt SD, Dinakar R, Mercken M, Hille-Rehfeld A, Rohrer J, et al. (2002). Alzheimer&#x2019;s disease-related overexpression of the cation-dependent mannose 6-phosphate receptor increases Abeta secretion: role for altered lysosomal hydrolase distribution in beta-amyloidogenesis. J. Biol. Chem 277, 5299&#x2013;5307.</Citation><ArticleIdList><ArticleId IdType="pubmed">11551970</ArticleId></ArticleIdList></Reference><Reference><Citation>Miranda AM, Lasiecka ZM, Xu Y, Neufeld J, Shahriar S, Simoes S, Chan RB, Oliveira TG, Small SA, and Di Paolo G (2018). Neuronal lysosomal dysfunction releases exosomes harboring APP C-terminal fragments and unique lipid signatures. Nat. Commun 9, 291.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5773483</ArticleId><ArticleId IdType="pubmed">29348617</ArticleId></ArticleIdList></Reference><Reference><Citation>Mondrag&#xf3;n-Rodr&#xed;guez S, Perry G, Luna-Mu&#xf1;oz J, Acevedo-Aquino MC, and Williams S (2014). Phosphorylation of tau protein at sites Ser(396&#x2013;404) is one of the earliest events in Alzheimer&#x2019;s disease and Down syndrome. Neuropathol. Appl. Neurobiol 40, 121&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pubmed">24033439</ArticleId></ArticleIdList></Reference><Reference><Citation>Mufson EJ, Ikonomovic MD, Counts SE, Perez SE, Malek-Ahmadi M, Scheff SW, and Ginsberg SD (2016). Molecular and cellular pathophysiology of preclinical Alzheimer&#x2019;s disease. Behav. Brain Res 311, 54&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4931948</ArticleId><ArticleId IdType="pubmed">27185734</ArticleId></ArticleIdList></Reference><Reference><Citation>Muratore CR, Zhou C, Liao M, Fernandez MA, Taylor WM, Lagomarsino VN, Pearse RV 2nd, Rice HC, Negri JM, He A, et al. (2017). Cell-type Dependent Alzheimer&#x2019;s Disease Phenotypes: Probing the Biology of Selective Neuronal Vulnerability. Stem Cell Reports 9, 1868&#x2013;1884.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5785690</ArticleId><ArticleId IdType="pubmed">29153990</ArticleId></ArticleIdList></Reference><Reference><Citation>Muth K, Sch&#xf6;nmeyer R, Matura S, Haenschel C, Schr&#xf6;der J, and Pantel J (2010). Mild cognitive impairment in the elderly is associated with volume loss of the cholinergic basal forebrain region. Biol. Psychiatry 67, 588&#x2013;591.</Citation><ArticleIdList><ArticleId IdType="pubmed">19375072</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA (2017). Amyloid precursor protein and endosomal-lysosomal dysfunction in Alzheimer&#x2019;s disease: inseparable partners in a multifactorial disease. FASEB J. 31, 2729&#x2013;2743.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6137496</ArticleId><ArticleId IdType="pubmed">28663518</ArticleId></ArticleIdList></Reference><Reference><Citation>Nyakas C, Granic I, Halmy LG, Banerjee P, and Luiten PG (2011). The basal forebrain cholinergic system in aging and dementia. Rescuing cholinergic neurons from neurotoxic amyloid-&#x3b2;42 with memantine. Behav. Brain Res 221, 594&#x2013;603.</Citation><ArticleIdList><ArticleId IdType="pubmed">20553766</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, et al. (2006). Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer&#x2019;s disease mutations: potential factors in amyloid plaque formation. J. Neurosci 26, 10129&#x2013;10140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Pal A, Severin F, Lommer B, Shevchenko A, and Zerial M (2006). Huntingtin-HAP40 complex is a novel Rab5 effector that regulates early endosome motility and is up-regulated in Huntington&#x2019;s disease. J. Cell Biol 172, 605&#x2013;618.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2063679</ArticleId><ArticleId IdType="pubmed">16476778</ArticleId></ArticleIdList></Reference><Reference><Citation>Pera M, Alcolea D, S&#xe1;nchez-Valle R, Guardia-Laguarta C, Colom-Cadena M, Badiola N, Su&#xe1;rez-Calvet M, Llad&#xf3; A, Barrera-Ocampo AA, Sepulveda-Falla D, et al. (2013). Distinct patterns of APP processing in the CNS in autosomal-dominant and sporadic Alzheimer disease. Acta Neuropathol. 125, 201&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3623032</ArticleId><ArticleId IdType="pubmed">23224319</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips GR, Huang JK, Wang Y, Tanaka H, Shapiro L, Zhang W, Shan WS, Arndt K, Frank M, Gordon RE, et al. (2001). The presynaptic particle web: ultrastructure, composition, dissolution, and reconstitution. Neuron 32, 63&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">11604139</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao MV, Mohan PS, Peterhoff CM, Yang DS, Schmidt SD, Stavrides PH, Campbell J, Chen Y, Jiang Y, Paskevich PA, et al. (2008). Marked calpastatin (CAST) depletion in Alzheimer&#x2019;s disease accelerates cytoskeleton disruption and neurodegeneration: neuroprotection by CAST overexpression. J. Neurosci 28, 12241&#x2013;12254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2819018</ArticleId><ArticleId IdType="pubmed">19020018</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, Sim&#xf3;n-S&#xe1;nchez J, Rollinson S, Gibbs JR, Schymick JC, Laaksovirta H, van Swieten JC, Myllykangas L, et al.; ITALSGEN Consortium (2011). A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72, 257&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Salehi A, Delcroix JD, Belichenko PV, Zhan K, Wu C, Valletta JS, Takimoto-Kimura R, Kleschevnikov AM, Sambamurti K, Chung PP, et al. (2006). Increased App expression in a mouse model of Down&#x2019;s syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron 51, 29&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">16815330</ArticleId></ArticleIdList></Reference><Reference><Citation>Sathiya Priya C, Vidhya R, Kalpana K, and Anuradha CV (2019). Indirubin-3&#x2032;-monoxime prevents aberrant activation of GSK-3&#x3b2;/NF-&#x3ba;B and alleviates high fat-high fructose induced A&#x3b2;-aggregation, gliosis and apoptosis in mice brain. Int. Immunopharmacol 70, 396&#x2013;407.</Citation><ArticleIdList><ArticleId IdType="pubmed">30856390</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, et al. (2012). Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3855844</ArticleId><ArticleId IdType="pubmed">22743772</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt SD, Jiang Y, Nixon RA, and Mathews PM (2005). Tissue processing prior to protein analysis and amyloid-beta quantitation. Methods Mol. Biol 299, 267&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pubmed">15980611</ArticleId></ArticleIdList></Reference><Reference><Citation>Schm&#xf6;le AC, Brennf&#xfc;hrer A, Karapetyan G, Jaster R, Pews-Davtyan A, H&#xfc;bner R, Ortinau S, Beller M, Rolfs A, and Frech MJ (2010). Novel indolylmaleimide acts as GSK-3beta inhibitor in human neural progenitor cells. Bioorg. Med. Chem 18, 6785&#x2013;6795.</Citation><ArticleIdList><ArticleId IdType="pubmed">20708937</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, et al. (2008). Amyloid-beta protein dimers isolated directly from Alzheimer&#x2019;s brains impair synaptic plasticity and memory. Nat. Med 14, 837&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi MM, Shi CH, and Xu YM (2017). Rab GTPases: The Key Players in the Molecular Pathway of Parkinson&#x2019;s Disease. Front. Cell. Neurosci 11, 81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5369176</ArticleId><ArticleId IdType="pubmed">28400718</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi M, Chen B, Mahajan D, Boh BK, Zhou Y, Dutta B, Tie HC, Sze SK, Wu G, and Lu L (2018). Amino acids stimulate the endosome-to-Golgi trafficking through Ragulator and small GTPase Arl5. Nat. Commun 9, 4987.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6255761</ArticleId><ArticleId IdType="pubmed">30478271</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin N, Jeong H, Kwon J, Heo HY, Kwon JJ, Yun HJ, Kim CH, Han BS, Tong Y, Shen J, et al. (2008). LRRK2 regulates synaptic vesicle endocytosis. Exp. Cell Res 314, 2055&#x2013;2065.</Citation><ArticleIdList><ArticleId IdType="pubmed">18445495</ArticleId></ArticleIdList></Reference><Reference><Citation>Stargardt A, Swaab DF, and Bossers K (2015). Storm before the quiet: neuronal hyperactivity and A&#x3b2; in the presymptomatic stages of Alzheimer&#x2019;s disease. Neurobiol. Aging 36, 1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">25444609</ArticleId></ArticleIdList></Reference><Reference><Citation>Stenmark H (2009). Rab GTPases as coordinators of vesicle traffic. Nat. Rev. Mol. Cell Biol 10, 513&#x2013;525.</Citation><ArticleIdList><ArticleId IdType="pubmed">19603039</ArticleId></ArticleIdList></Reference><Reference><Citation>Stenmark H, Vitale G, Ullrich O, and Zerial M (1995). Rabaptin-5 is a direct effector of the small GTPase Rab5 in endocytic membrane fusion. Cell 83, 423&#x2013;432.</Citation><ArticleIdList><ArticleId IdType="pubmed">8521472</ArticleId></ArticleIdList></Reference><Reference><Citation>Subbanna S, Shivakumar M, Psychoyos D, Xie S, and Basavarajappa BS (2013). Anandamide-CB1 receptor signaling contributes to postnatal ethanol-induced neonatal neurodegeneration, adult synaptic, and memory deficits. J. Neurosci 33, 6350&#x2013;6366.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3742029</ArticleId><ArticleId IdType="pubmed">23575834</ArticleId></ArticleIdList></Reference><Reference><Citation>Tackenberg C, Ghori A, and Brandt R (2009). Thin, stubby or mushroom: spine pathology in Alzheimer&#x2019;s disease. Curr. Alzheimer Res 6, 261&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pubmed">19519307</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang BL (2016). C9orf72&#x2019;s Interaction with Rab GTPases-Modulation of Membrane Traffic and Autophagy. Front. Cell. Neurosci 10, 228.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5053994</ArticleId><ArticleId IdType="pubmed">27774051</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenreiro S, Eckermann K, and Outeiro TF (2014). Protein phosphorylation in neurodegeneration: friend or foe? Front. Mol. Neurosci 7, 42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4026737</ArticleId><ArticleId IdType="pubmed">24860424</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas-Crusells J, Vieira A, Saarma M, and Rivera C (2003). A novel method for monitoring surface membrane trafficking on hippocampal acute slice preparation. J. Neurosci. Methods 125, 159&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="pubmed">12763242</ArticleId></ArticleIdList></Reference><Reference><Citation>Topp JD, Gray NW, Gerard RD, and Horazdovsky BF (2004). Alsin is a Rab5 and Rac1 guanine nucleotide exchange factor. J. Biol. Chem 279, 24612&#x2013;24623.</Citation><ArticleIdList><ArticleId IdType="pubmed">15033976</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu W, Weissmiller AM, White JA 2nd, Fang F, Wang X, Wu Y, Pearn ML, Zhao X, Sawa M, Chen S, et al. (2016). Amyloid precursor protein-mediated endocytic pathway disruption induces axonal dysfunction and neurodegeneration. J. Clin. Invest 126, 1815&#x2013;1833.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4855914</ArticleId><ArticleId IdType="pubmed">27064279</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu W, Fang F, Ding J, and Wu C (2018). Dysregulation of Rab5-mediated endocytic pathways in Alzheimer&#x2019;s disease. Traffic 19, 253&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5869093</ArticleId><ArticleId IdType="pubmed">29314494</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Hentati A, Deng HX, Dabbagh O, Sasaki T, Hirano M, Hung WY, Ouahchi K, Yan J, Azim AC, et al. (2001). The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Nat. Genet 29, 160&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pubmed">11586297</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang DS, Lee JH, and Nixon RA (2009). Monitoring autophagy in Alzheimer&#x2019;s disease and related neurodegenerative diseases. Methods Enzymol. 453, 111&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">19216904</ArticleId></ArticleIdList></Reference><Reference><Citation>Young JE, Boulanger-Weill J, Williams DA, Woodruff G, Buen F, Revilla AC, Herrera C, Israel MA, Yuan SH, Edland SD, and Goldstein LS (2015). Elucidating molecular phenotypes caused by the SORL1 Alzheimer&#x2019;s disease genetic risk factor using human induced pluripotent stem cells. Cell Stem Cell 16, 373&#x2013;385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4388804</ArticleId><ArticleId IdType="pubmed">25772071</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan A, Veeranna, Sershen H, Basavarajappa BS, Smiley JF, Hashim A, Bleiwas C, Berg M, Guifoyle DN, Subbanna S, et al. (2018). Neurofilament light interaction with GluN1 modulates neurotransmission and schizophrenia-associated behaviors. Transl. Psychiatry 8, 167.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6109052</ArticleId><ArticleId IdType="pubmed">30143609</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, Koh YH, Beckstead RB, Budnik V, Ganetzky B, and Bellen HJ (1998). Synaptic vesicle size and number are regulated by a clathrin adaptor protein required for endocytosis. Neuron 21, 1465&#x2013;1475.</Citation><ArticleIdList><ArticleId IdType="pubmed">9883738</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K, Fishel Ben Kenan R, Osakada Y, Xu W, Sinit RS, Chen L, Zhao X, Chen JY, Cui B, and Wu C (2013). Defective axonal transport of Rab7 GTPase results in dysregulated trophic signaling. J. Neurosci 33, 7451&#x2013;7462.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3722856</ArticleId><ArticleId IdType="pubmed">23616551</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, Zhang T, Wang S, Gong Z, Tang C, Chen J, and Ding J (2014). Molecular mechanism for Rabex-5 GEF activation by Rabaptin-5. eLife 3, e02687.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4102244</ArticleId><ArticleId IdType="pubmed">24957337</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu H, Zhu G, Liu J, Liang Z, Zhang XC, and Li G (2007). Rabaptin-5-independent membrane targeting and Rab5 activation by Rabex-5 in the cell. Mol. Biol. Cell 18, 4119&#x2013;4128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1995700</ArticleId><ArticleId IdType="pubmed">17699593</ArticleId></ArticleIdList></Reference><Reference><Citation>Zott B, Simon MM, Hong W, Unger F, Chen-Engerer HJ, Frosch MP, Sakmann B, Walsh DM, and Konnerth A (2019). A vicious cycle of &#x3b2; amyloid-dependent neuronal hyperactivation. Science 365, 559&#x2013;565.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6690382</ArticleId><ArticleId IdType="pubmed">31395777</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33246962</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>14</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>30</Day></DateRevised><Article PubModel="Electronic-Print"><Journal><ISSN IssnType="Electronic">2375-2548</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>48</Issue><PubDate><Year>2020</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Science advances</Title><ISOAbbreviation>Sci Adv</ISOAbbreviation></Journal><ArticleTitle>Patient-centered connectivity-based prediction of tau pathology spread in Alzheimer's disease.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">eabd1327</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/sciadv.abd1327</ELocationID><Abstract><AbstractText>In Alzheimer's disease (AD), the Braak staging scheme suggests a stereotypical tau spreading pattern that does, however, not capture interindividual variability in tau deposition. This complicates the prediction of tau spreading, which may become critical for defining individualized tau-PET readouts in clinical trials. Since tau is assumed to spread throughout connected regions, we used functional connectivity to improve tau spreading predictions over Braak staging methods. We included two samples with longitudinal tau-PET from controls and AD patients. Cross-sectionally, we found connectivity of tau epicenters (i.e., regions with earliest tau) to predict estimated tau spreading sequences. Longitudinally, we found tau accumulation rates to correlate with connectivity strength to patient-specific tau epicenters. A connectivity-based, patient-centered tau spreading model improved the assessment of tau accumulation rates compared to Braak stage-specific readouts and reduced sample sizes by ~40% in simulated tau-targeting interventions. Thus, connectivity-based tau spreading models may show utility in clinical trials.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Franzmeier</LastName><ForeName>Nicolai</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-9736-2283</Identifier><AffiliationInfo><Affiliation>Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany. nicolai.franzmeier@med.uni-muenchen.de michael.ewers@med.uni-muenchen.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dewenter</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frontzkowski</LastName><ForeName>Lukas</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-9321-956X</Identifier><AffiliationInfo><Affiliation>Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dichgans</LastName><ForeName>Martin</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0654-387X</Identifier><AffiliationInfo><Affiliation>Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rubinski</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neitzel</LastName><ForeName>Julia</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-5739-466X</Identifier><AffiliationInfo><Affiliation>Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Ruben</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-7147-0112</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Sk&#xe5;ne University Hospital, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences Malm&#xf6;, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strandberg</LastName><ForeName>Olof</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences Malm&#xf6;, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ossenkoppele</LastName><ForeName>Rik</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences Malm&#xf6;, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buerger</LastName><ForeName>Katharina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duering</LastName><ForeName>Marco</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2302-3136</Identifier><AffiliationInfo><Affiliation>Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hansson</LastName><ForeName>Oskar</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0001-8467-7286</Identifier><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences Malm&#xf6;, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Clinic, Sk&#xe5;ne University Hospital, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ewers</LastName><ForeName>Michael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-5231-1714</Identifier><AffiliationInfo><Affiliation>Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany. nicolai.franzmeier@med.uni-muenchen.de michael.ewers@med.uni-muenchen.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>11</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Adv</MedlineTA><NlmUniqueID>101653440</NlmUniqueID><ISSNLinking>2375-2548</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018802" MajorTopicYN="N">Patient-Centered Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>6</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>10</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>11</Month><Day>28</Day><Hour>5</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>11</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33246962</ArticleId><ArticleId IdType="pmc">PMC7695466</ArticleId><ArticleId IdType="doi">10.1126/sciadv.abd1327</ArticleId><ArticleId IdType="pii">6/48/eabd1327</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Benzinger T. L. S., Blazey T., Jack C. R. Jr., Koeppe R. A., Su Y., Xiong C., Raichle M. E., Snyder A. Z., Ances B. M., Bateman R. J., Cairns N. J., Fa6gan A. M., Goate A., Marcus D. S., Aisen P. S., Christensen J. J., Ercole L., Hornbeck R. C., Farrar A. M., Aldea P., Jasielec M. S., Owen C. J., Xie X., Mayeux R., Brickman A., McDade E., Klunk W., Mathis C. A., Ringman J., Thompson P. M., Ghetti B., Saykin A. J., Sperling R. A., Johnson K. A., Salloway S., Correia S., Schofield P. R., Masters C. L., Rowe C., Villemagne V. L., Martins R., Ourselin S., Rossor M. N., Fox N. C., Cash D. M., Weiner M. W., Holtzman D. M., Buckles V. D., Moulder K., Morris J. C., Regional variability of imaging biomarkers in autosomal dominant Alzheimer&#x2019;s disease. Proc. Natl. Acad. Sci. U.S.A. 110, E4502&#x2013;E4509 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3839740</ArticleId><ArticleId IdType="pubmed">24194552</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H., Braak E., Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239&#x2013;259 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;ll M., Lockhart S. N., Schonhaut D. R., O&#x2019;Neil J. P., Janabi M., Ossenkoppele R., Baker S. L., Vogel J. W., Faria J., Schwimmer H. D., Rabinovici G. D., Jagust W. J., PET imaging of tau deposition in the aging human brain. Neuron 89, 971&#x2013;982 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4779187</ArticleId><ArticleId IdType="pubmed">26938442</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufman S. K., Del Tredici K., Thomas T. L., Braak H., Diamond M. I., Tau seeding activity begins in the transentorhinal/entorhinal regions and anticipates phospho-tau pathology in Alzheimer&#x2019;s disease and PART. Acta Neuropathol. 136, 57&#x2013;67 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6015098</ArticleId><ArticleId IdType="pubmed">29752551</ArticleId></ArticleIdList></Reference><Reference><Citation>Calafate S., Buist A., Miskiewicz K., Vijayan V., Daneels G., de Strooper B., de Wit J., Verstreken P., Moechars D., Synaptic contacts enhance cell-to-cell tau pathology propagation. Cell Rep. 11, 1176&#x2013;1183 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25981034</ArticleId></ArticleIdList></Reference><Reference><Citation>de Calignon A., Polydoro M., Su&#xe1;rez-Calvet M., William C., Adamowicz D. H., Kopeikina K. J., Pitstick R., Sahara N., Ashe K. H., Carlson G. A., Spires-Jones T. L., Hyman B. T., Propagation of tau pathology in a model of early Alzheimer&#x2019;s disease. Neuron 73, 685&#x2013;697 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3292759</ArticleId><ArticleId IdType="pubmed">22365544</ArticleId></ArticleIdList></Reference><Reference><Citation>Pooler A. M., Phillips E. C., Lau D. H. W., Noble W., Hanger D. P., Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Rep. 14, 389&#x2013;394 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3615658</ArticleId><ArticleId IdType="pubmed">23412472</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R., Iaccarino L., Schonhaut D. R., Brown J. A., La Joie R., O&#x2019;Neil J. P., Janabi M., Baker S. L., Kramer J. H., Gorno-Tempini M.-L., Miller B. L., Rosen H. J., Seeley W. W., Jagust W. J., Rabinovici G. D., Tau covariance patterns in Alzheimer&#x2019;s disease patients match intrinsic connectivity networks in the healthy brain. Neuroimage Clin. 23, 101848 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6510968</ArticleId><ArticleId IdType="pubmed">31077982</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoenig M. C., Bischof G. N., Seemiller J., Hammes J., Kukolja J., Onur &#xd6;. A., Jessen F., Fliessbach K., Neumaier B., Fink G. R., van Eimeren T., Drzezga A., Networks of tau distribution in Alzheimer&#x2019;s disease. Brain 141, 568&#x2013;581 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29315361</ArticleId></ArticleIdList></Reference><Reference><Citation>Cope T. E., Rittman T., Borchert R. J., Jones P. S., Vatansever D., Allinson K., Passamonti L., Vazquez Rodriguez P., Bevan-Jones W. R., O&#x2019;Brien J. T., Rowe J. B., Tau burden and the functional connectome in Alzheimer&#x2019;s disease and progressive supranuclear palsy. Brain 141, 550&#x2013;567 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5837359</ArticleId><ArticleId IdType="pubmed">29293892</ArticleId></ArticleIdList></Reference><Reference><Citation>Franzmeier N., Rubinski A., Neitzel J., Kim Y., Damm A., Na D. L., Kim H. J., Lyoo C. H., Cho H., Finsterwalder S., Duering M., Seo S. W., Ewers M.; Alzheimer&#x2019;s Disease Neuroimaging Initiative , Functional connectivity associated with tau levels in ageing, Alzheimer&#x2019;s, and small vessel disease. Brain 142, 1093&#x2013;1107 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6439332</ArticleId><ArticleId IdType="pubmed">30770704</ArticleId></ArticleIdList></Reference><Reference><Citation>Franzmeier N., Neitzel J., Rubinski A., Smith R., Strandberg O., Ossenkoppele R., Hansson O., Ewers M.; Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI) , Functional brain architecture is associated with the rate of tau accumulation in Alzheimer&#x2019;s disease. Nat. Commun. 11, 347 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6969065</ArticleId><ArticleId IdType="pubmed">31953405</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray M. E., Graff-Radford N. R., Ross O. A., Petersen R. C., Duara R., Dickson D. W., Neuropathologically defined subtypes of Alzheimer&#x2019;s disease with distinct clinical characteristics: A retrospective study. Lancet Neurol. 10, 785&#x2013;796 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3175379</ArticleId><ArticleId IdType="pubmed">21802369</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R., Schonhaut D. R., Sch&#xf6;ll M., Lockhart S. N., Ayakta N., Baker S. L., O&#x2019;Neil J. P., Janabi M., Lazaris A., Cantwell A., Vogel J., Santos M., Miller Z. A., Bettcher B. M., Vossel K. A., Kramer J. H., Gorno-Tempini M. L., Miller B. L., Jagust W. J., Rabinovici G. D., Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer&#x2019;s disease. Brain 139 ( Pt 5), 1551&#x2013;1567 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5006248</ArticleId><ArticleId IdType="pubmed">26962052</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R., Lyoo C. H., Sudre C. H., van Westen D., Cho H., Ryu Y. H., Choi J. Y., Smith R., Strandberg O., Palmqvist S., Westman E., Tsai R., Kramer J., Boxer A. L., Gorno-Tempini M. L., La Joie R., Miller B. L., Rabinovici G. D., Hansson O., Distinct tau PET patterns in atrophy-defined subtypes of Alzheimer&#x2019;s disease. Alzheimers Dement. 16, 335&#x2013;344 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7012375</ArticleId><ArticleId IdType="pubmed">31672482</ArticleId></ArticleIdList></Reference><Reference><Citation>Day G. S., Gordon B. A., Jackson K., Christensen J. J., Rosana Ponisio M., Su Y., Ances B. M., Benzinger T. L. S., Morris J. C., Tau-PET binding distinguishes patients with early-stage posterior cortical atrophy from amnestic Alzheimer disease dementia. Alzheimer Dis. Assoc. Disord. 31, 87&#x2013;93 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5443698</ArticleId><ArticleId IdType="pubmed">28394771</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasrallah I. M., Chen Y. J., Hsieh M.-K., Phillips J. S., Ternes K., Stockbower G. E., Sheline Y., McMillan C. T., Grossman M., Wolk D. A., 18F-flortaucipir PET/MRI correlations in nonamnestic and amnestic variants of Alzheimer disease. J. Nucl. Med. 59, 299&#x2013;306 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6348438</ArticleId><ArticleId IdType="pubmed">28747523</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs K. A., Martin P. R., Botha H., Schwarz C. G., Duffy J. R., Clark H. M., Machulda M. M., Graff-Radford J., Weigand S. D., Senjem M. L., Utianski R. L., Drubach D. A., Boeve B. F., Jones D. T., Knopman D. S., Petersen R. C., Jack C. R. Jr., Lowe V. J., Whitwell J. L., [18F]AV-1451 tau-PET and primary progressive aphasia. Ann. Neurol. 83, 599&#x2013;611 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5896771</ArticleId><ArticleId IdType="pubmed">29451323</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiotis K., Saint-Aubert L., Rodriguez-Vieitez E., Leuzy A., Almkvist O., Savitcheva I., Jonasson M., Lubberink M., Wall A., Antoni G., Nordberg A., Longitudinal changes of tau PET imaging in relation to hypometabolism in prodromal and Alzheimer&#x2019;s disease dementia. Mol. Psychiatry 23, 1666&#x2013;1673 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">28507319</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack C. R. Jr., Wiste H. J., Schwarz C. G., Lowe V. J., Senjem M. L., Vemuri P., Weigand S. D., Therneau T. M., Knopman D. S., Gunter J. L., Jones D. T., Graff-Radford J., Kantarci K., Roberts R. O., Mielke M. M., Machulda M. M., Petersen R. C., Longitudinal tau PET in ageing and Alzheimer&#x2019;s disease. Brain 141, 1517&#x2013;1528 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5917767</ArticleId><ArticleId IdType="pubmed">29538647</ArticleId></ArticleIdList></Reference><Reference><Citation>Sintini I., Martin P. R., Graff-Radford J., Senjem M. L., Schwarz C. G., Machulda M. M., Spychalla A. J., Drubach D. A., Knopman D. S., Petersen R. C., Lowe V. J., Jack C. R. Jr., Josephs K. A., Whitwell J. L., Longitudinal tau-PET uptake and atrophy in atypical Alzheimer&#x2019;s disease. Neuroimage Clin. 23, 101823 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6475765</ArticleId><ArticleId IdType="pubmed">31004914</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison T. M., La Joie R., Maass A., Baker S. L., Swinnerton K., Fenton L., Mellinger T. J., Edwards L., Pham J., Miller B. L., Rabinovici G. D., Jagust W. J., Longitudinal tau accumulation and atrophy in aging and alzheimer disease. Ann. Neurol. 85, 229&#x2013;240 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6579738</ArticleId><ArticleId IdType="pubmed">30597624</ArticleId></ArticleIdList></Reference><Reference><Citation>Pontecorvo M. J., Devous M. D., Kennedy I., Navitsky M., Lu M., Galante N., Salloway S., Doraiswamy P. M., Southekal S., Arora A. K., McGeehan A., Lim N. C., Xiong H., Truocchio S. P., Joshi A. D., Shcherbinin S., Teske B., Fleisher A. S., Mintun M. A., A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer&#x2019;s disease dementia. Brain 142, 1723&#x2013;1735 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6536847</ArticleId><ArticleId IdType="pubmed">31009046</ArticleId></ArticleIdList></Reference><Reference><Citation>Congdon E. E., Sigurdsson E. M., Tau-targeting therapies for Alzheimer disease. Nat. Rev. Neurol. 14, 399&#x2013;415 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6463489</ArticleId><ArticleId IdType="pubmed">29895964</ArticleId></ArticleIdList></Reference><Reference><Citation>Digma L. A., Madsen J. R., Reas E. T., Dale A. M., Brewer J. B., Banks S. J.; Alzheimer&#x2019;s Disease Neuroimaging Initiative , Tau and atrophy: Domain-specific relationships with cognition. Alzheimers Res. Ther. 11, 65 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6661099</ArticleId><ArticleId IdType="pubmed">31351484</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R., Smith R., Ohlsson T., Strandberg O., Mattsson N., Insel P. S., Palmqvist S., Hansson O., Associations between tau, A&#x3b2;, and cortical thickness with cognition in Alzheimer disease. Neurology 92, e601&#x2013;e612 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6382060</ArticleId><ArticleId IdType="pubmed">30626656</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones D. T., Graff-Radford J., Lowe V. J., Wiste H. J., Gunter J. L., Senjem M. L., Botha H., Kantarci K., Boeve B. F., Knopman D. S., Petersen R. C., Jack C. R. Jr., Tau, amyloid, and cascading network failure across the Alzheimer&#x2019;s disease spectrum. Cortex 97, 143&#x2013;159 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5773067</ArticleId><ArticleId IdType="pubmed">29102243</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogel J. W., Iturria-Medina Y., Strandberg O. T., Smith R., Levitis E., Evans A. C., Hansson O.; Alzheimer&#x2019;s Disease Neuroimaging Initiative; Swedish BioFinder Study , Spread of pathological tau proteins through communicating neurons in human Alzheimer&#x2019;s disease. Nat. Commun. 11, 2612 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7251068</ArticleId><ArticleId IdType="pubmed">32457389</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemoine L., Leuzy A., Chiotis K., Rodriguez-Vieitez E., Nordberg A., Tau positron emission tomography imaging in tauopathies: The added hurdle of off-target binding. Alzheimers Dement. (Amst) 10, 232&#x2013;236 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5956931</ArticleId><ArticleId IdType="pubmed">29780868</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuzy A., Chiotis K., Lemoine L., Gillberg P.-G., Almkvist O., Rodriguez-Vieitez E., Nordberg A., Tau PET imaging in neurodegenerative tauopathies&#x2014;Still a challenge. Mol. Psychiatry 24, 1112&#x2013;1134 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6756230</ArticleId><ArticleId IdType="pubmed">30635637</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaefer A., Kong R., Gordon E. M., Laumann T. O., Zuo X.-N., Holmes A. J., Eickhoff S. B., Yeo B. T. T., Local-global parcellation of the human cerebral cortex from intrinsic functional connectivity MRI. Cereb. Cortex 28, 3095&#x2013;3114 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6095216</ArticleId><ArticleId IdType="pubmed">28981612</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuzy A., Smith R., Ossenkoppele R., Santillo A., Borroni E., Klein G., Ohlsson T., J&#xf6;gi J., Palmqvist S., Mattsson-Carlgren N., Strandberg O., Stomrud E., Hansson O., Diagnostic performance of RO948 F 18 tau positron emission tomography in the differentiation of Alzheimer disease from other neurodegenerative disorders. JAMA Neurol. 77, 955&#x2013;965 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7215644</ArticleId><ArticleId IdType="pubmed">32391858</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams J. N., Maass A., Harrison T. M., Baker S. L., Jagust W. J., Cortical tau deposition follows patterns of entorhinal functional connectivity in aging. eLife 8, e49132 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6764824</ArticleId><ArticleId IdType="pubmed">31475904</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed Z., Cooper J., Murray T. K., Garn K., McNaughton E., Clarke H., Parhizkar S., Ward M. A., Cavallini A., Jackson S., Bose S., Clavaguera F., Tolnay M., Lavenir I., Goedert M., Hutton M. L., O&#x2019;Neill M. J., A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: The pattern of spread is determined by connectivity, not proximity. Acta Neuropathol. 127, 667&#x2013;683 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4252866</ArticleId><ArticleId IdType="pubmed">24531916</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba M., McBride J. D., Guo J. L., Zhang B., Trojanowski J. Q., Lee V. M.-Y., Tau pathology spread in PS19 tau transgenic mice following locus coeruleus (LC) injections of synthetic tau fibrils is determined by the LC&#x2019;s afferent and efferent connections. Acta Neuropathol. 130, 349&#x2013;362 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4545685</ArticleId><ArticleId IdType="pubmed">26150341</ArticleId></ArticleIdList></Reference><Reference><Citation>Grothe M. J., Sepulcre J., Gonzalez-Escamilla G., Jelistratova I., Sch&#xf6;ll M., Hansson O., Teipel S. J.; Alzheimer&#x2019;s Disease Neuroimaging Initiative , Molecular properties underlying regional vulnerability to Alzheimer&#x2019;s disease pathology. Brain 141, 2755&#x2013;2771 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6113636</ArticleId><ArticleId IdType="pubmed">30016411</ArticleId></ArticleIdList></Reference><Reference><Citation>Sepulcre J., Grothe M. J., d&#x2019;Oleire Uquillas F., Ortiz-Ter&#xe1;n L., Diez I., Yang H.-S., Jacobs H. I. L., Hanseeuw B. J., Li Q., El-Fakhri G., Sperling R. A., Johnson K. A., Neurogenetic contributions to amyloid beta and tau spreading in the human cortex. Nat. Med. 24, 1910&#x2013;1918 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6518398</ArticleId><ArticleId IdType="pubmed">30374196</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern R. A., Adler C. H., Chen K., Navitsky M., Luo J., Dodick D. W., Alosco M. L., Tripodis Y., Goradia D. D., Martin B., Mastroeni D., Fritts N. G., Jarnagin J., Devous M. D. Sr., Mintun M. A., Pontecorvo M. J., Shenton M. E., Reiman E. M., Tau positron-emission tomography in former national football league players. N. Engl. J. Med. 380, 1716&#x2013;1725 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6636818</ArticleId><ArticleId IdType="pubmed">30969506</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai X. Y., Koepp M., Duncan J. S., Fox N., Thompson P., Baxendale S., Liu J. Y. W., Reeves C., Michalak Z., Thom M., Hyperphosphorylated tau in patients with refractory epilepsy correlates with cognitive decline: A study of temporal lobe resections. Brain 139 ( Pt 9), 2441&#x2013;2455 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5926008</ArticleId><ArticleId IdType="pubmed">27497924</ArticleId></ArticleIdList></Reference><Reference><Citation>V&#xe9;rtes P. E., Rittman T., Whitaker K. J., Romero-Garcia R., V&#xe1;&#x161;a F., Kitzbichler M. G., Wagstyl K., Fonagy P., Dolan R. J., Jones P. B., Goodyer I. M.; NSPN Consortium, Bullmore E. T., Gene transcription profiles associated with inter-modular hubs and connection distance in human functional magnetic resonance imaging networks. Philos. Trans. R. Soc. Lond. B Biol. Sci. 371, 20150362 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5003862</ArticleId><ArticleId IdType="pubmed">27574314</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolters E. E., Ossenkoppele R., Verfaillie S. C. J., Coomans E. M., Timmers T., Visser D., Tuncel H., Golla S. S. V., Windhorst A. D., Boellaard R., van der Flier W. M., Teunissen C. E., Scheltens P., van Berckel B. N. M., Correction to: Regional [18F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer&#x2019;s disease. Eur. J. Nucl. Med. Mol. Imaging 47, 2934&#x2013;2935 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7852952</ArticleId><ArticleId IdType="pubmed">32388611</ArticleId></ArticleIdList></Reference><Reference><Citation>La Joie R., Visani A. V., Baker S. L., Brown J. A., Bourakova V., Cha J., Chaudhary K., Edwards L., Iaccarino L., Janabi M., Lesman-Segev O. H., Miller Z. A., Perry D. C., O&#x2019;Neil J. P., Pham J., Rojas J. C., Rosen H. J., Seeley W. W., Tsai R. M., Miller B. L., Jagust W. J., Rabinovici G. D., Prospective longitudinal atrophy in Alzheimer&#x2019;s disease correlates with the intensity and topography of baseline tau-PET. Sci. Transl. Med. 12, eaau5732 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7035952</ArticleId><ArticleId IdType="pubmed">31894103</ArticleId></ArticleIdList></Reference><Reference><Citation>Chhatwal J. P., Schultz A. P., Johnson K. A., Hedden T., Jaimes S., Benzinger T. L. S., Jack C. Jr., Ances B. M., Ringman J. M., Marcus D. S., Ghetti B., Farlow M. R., Danek A., Levin J., Yakushev I., Laske C., Koeppe R. A., Galasko D. R., Xiong C., Masters C. L., Schofield P. R., Kinnunen K. M., Salloway S., Martins R. N., McDade E., Cairns N. J., Buckles V. D., Morris J. C., Bateman R., Sperling R. A.; Dominantly Inherited Alzheimer Network , Preferential degradation of cognitive networks differentiates Alzheimer&#x2019;s disease from ageing. Brain 141, 1486&#x2013;1500 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5917745</ArticleId><ArticleId IdType="pubmed">29522171</ArticleId></ArticleIdList></Reference><Reference><Citation>Franzmeier N., D&#xfc;zel E., Jessen F., Buerger K., Levin J., Duering M., Dichgans M., Haass C., Su&#xe1;rez-Calvet M., Fagan A. M., Paumier K., Benzinger T., Masters C. L., Morris J. C., Perneczky R., Janowitz D., Catak C., Wolfsgruber S., Wagner M., Teipel S., Kilimann I., Ramirez A., Rossor M., Jucker M., Chhatwal J., Spottke A., Boecker H., Brosseron F., Falkai P., Fliessbach K., Heneka M. T., Laske C., Nestor P., Peters O., Fuentes M., Menne F., Priller J., Spruth E. J., Franke C., Schneider A., Kofler B., Westerteicher C., Speck O., Wiltfang J., Bartels C., Caballero M. A. A., Metzger C., Bittner D., Weiner M., Lee J.-H., Salloway S., Danek A., Goate A., Schofield P. R., Bateman R. J., Ewers M., Left frontal hub connectivity delays cognitive impairment in autosomal-dominant and sporadic Alzheimer&#x2019;s disease. Brain 141, 1186&#x2013;1200 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5888938</ArticleId><ArticleId IdType="pubmed">29462334</ArticleId></ArticleIdList></Reference><Reference><Citation>Jadhav S., Avila J., Sch&#xf6;ll M., Kovacs G. G., K&#xf6;vari E., Skrabana R., Evans L. D., Kontsekova E., Malawska B., de Silva R., Buee L., Zilka N., A walk through tau therapeutic strategies. Acta Neuropathol. Commun. 7, 22 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6376692</ArticleId><ArticleId IdType="pubmed">30767766</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S., Zetterberg H., Blennow K., Vestberg S., Andreasson U., Brooks D. J., Owenius R., H&#xe4;gerstr&#xf6;m D., Wollmer P., Minthon L., Hansson O., Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid &#x3b2;-amyloid 42: A cross-validation study against amyloid positron emission tomography. JAMA Neurol. 71, 1282&#x2013;1289 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25155658</ArticleId></ArticleIdList></Reference><Reference><Citation>Young A. L., Oxtoby N. P., Daga P., Cash D. M., Fox N. C., Ourselin S., Schott J. M., Alexander D. C.; Alzheimer&#x2019;s Disease Neuroimaging Initiative , A data-driven model of biomarker changes in sporadic Alzheimer&#x2019;s disease. Brain 137 ( Pt 9), 2564&#x2013;2577 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4132648</ArticleId><ArticleId IdType="pubmed">25012224</ArticleId></ArticleIdList></Reference><Reference><Citation>Marinescu R. V., Eshaghi A., Lorenzi M., Young A. L., Oxtoby N. P., Garbarino S., Crutch S. J., Alexander D. C.; Alzheimer&#x2019;s Disease Neuroimaging Initiative , DIVE: A spatiotemporal progression model of brain pathology in neurodegenerative disorders. Neuroimage 192, 166&#x2013;177 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30844504</ArticleId></ArticleIdList></Reference><Reference><Citation>Young A. L., Marinescu R. V., Oxtoby N. P., Bocchetta M., Yong K., Firth N. C., Cash D. M., Thomas D. L., Dick K. M., Cardoso J., van Swieten J., Borroni B., Galimberti D., Masellis M., Tartaglia M. C., Rowe J. B., Graff C., Tagliavini F., Frisoni G. B., Laforce R. Jr., Finger E., de Mendon&#xe7;a A., Sorbi S., Warren J. D., Crutch S., Fox N. C., Ourselin S., Schott J. M., Rohrer J. D., Alexander D. C.; The Genetic FTD Initiative (GENFI); The Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI) , Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with subtype and stage inference. Nat. Commun. 9, 4273 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6189176</ArticleId><ArticleId IdType="pubmed">30323170</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau S. M., Mintun M. A., Joshi A. D., Koeppe R. A., Petersen R. C., Aisen P. S., Weiner M. W., Jagust W. J.; Alzheimer&#x2019;s Disease Neuroimaging Initiative , Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann. Neurol. 72, 578&#x2013;586 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3786871</ArticleId><ArticleId IdType="pubmed">23109153</ArticleId></ArticleIdList></Reference><Reference><Citation>Thurfjell L., Lilja J., Lundqvist R., Buckley C., Smith A., Vandenberghe R., Sherwin P., Automated quantification of 18F-flutemetamol PET activity for categorizing scans as negative or positive for brain amyloid: Concordance with visual image reads. J. Nucl. Med. 55, 1623&#x2013;1628 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25146124</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N., Smith R., Strandberg O., Palmqvist S., Sch&#xf6;ll M., Insel P. S., Hagerstrom D., Ohlsson T., Zetterberg H., Blennow K., J&#xf6;gi J., Hansson O., Comparing 18F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease. Neurology 90, e388&#x2013;e395 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5791788</ArticleId><ArticleId IdType="pubmed">29321235</ArticleId></ArticleIdList></Reference><Reference><Citation>Avants B. B., Tustison N. J., Song G., Cook P. A., Klein A., Gee J. C., A reproducible evaluation of ANTs similarity metric performance in brain image registration. Neuroimage 54, 2033&#x2013;2044 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3065962</ArticleId><ArticleId IdType="pubmed">20851191</ArticleId></ArticleIdList></Reference><Reference><Citation>Hahn A., Schain M., Erlandsson M., Sj&#xf6;lin P., James G. M., Strandberg O. T., H&#xe4;gerstr&#xf6;m D., Lanzenberger R., J&#xf6;gi J., Olsson T. G., Smith R., Hansson O., Modeling strategies for quantification of in vivo 18F-AV-1451 binding in patients with tau pathology. J. Nucl. Med. 58, 623&#x2013;631 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27765859</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith R., Puschmann A., Sch&#xf6;ll M., Ohlsson T., van Swieten J., Honer M., Englund E., Hansson O., 18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers. Brain 139 ( Pt 9), 2372&#x2013;2379 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4995360</ArticleId><ArticleId IdType="pubmed">27357347</ArticleId></ArticleIdList></Reference><Reference><Citation>Rousset O. G., Ma Y., Evans A. C., Correction for partial volume effects in PET: Principle and validation. J. Nucl. Med. 39, 904&#x2013;911 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9591599</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubinov M., Sporns O., Complex network measures of brain connectivity: Uses and interpretations. Neuroimage 52, 1059&#x2013;1069 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">19819337</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy K., Fox M. D., Towards a consensus regarding global signal regression for resting state functional connectivity MRI. Neuroimage 154, 169&#x2013;173 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5489207</ArticleId><ArticleId IdType="pubmed">27888059</ArticleId></ArticleIdList></Reference><Reference><Citation>Glasser M. F., Sotiropoulos S. N., Wilson J. A., Coalson T. S., Fischl B., Andersson J. L., Xu J., Jbabdi S., Webster M., Polimeni J. R., Van Essen D. C., Jenkinson M.; WU-Minn HCP Consortium , The minimal preprocessing pipelines for the human connectome project. Neuroimage 80, 105&#x2013;124 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3720813</ArticleId><ArticleId IdType="pubmed">23668970</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith R. E., Tournier J.-D., Calamante F., Connelly A., SIFT2: Enabling dense quantitative assessment of brain white matter connectivity using streamlines tractography. Neuroimage 119, 338&#x2013;351 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26163802</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">33239387</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>571</Issue><PubDate><Year>2020</Year><Month>Nov</Month><Day>25</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>Tau and other proteins found in Alzheimer's disease spinal fluid are linked to retromer-mediated endosomal traffic in mice and humans.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">eaba6334</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.aba6334</ELocationID><Abstract><AbstractText>Endosomal trafficking has emerged as a defective biological pathway in Alzheimer's disease (AD), and the pathway is a source of cerebrospinal fluid (CSF) protein accumulation. Nevertheless, the identity of the CSF proteins that accumulate in the setting of defects in AD's endosomal trafficking pathway remains unknown. Here, we performed a CSF proteomic screen in mice with a neuronal-selective knockout of the core of the retromer complex VPS35, a master conductor of endosomal traffic that has been implicated in AD. We then validated three of the most relevant proteomic findings: the amino terminus of the transmembrane proteins APLP1 and CHL1, and the mid-domain of tau, which is known to be unconventionally secreted and elevated in AD. In patients with AD dementia, the concentration of amino-terminal APLP1 and CHL1 in the CSF correlated with tau and phosphorylated tau. Similar results were observed in healthy controls, where both proteins correlated with tau and phosphorylated tau and were elevated in about 70% of patients in the prodromal stages of AD. Collectively, the mouse-to-human studies suggest that retromer-dependent endosomal trafficking can regulate tau, APLP1, and CHL1 CSF concentration, informing on how AD's trafficking pathway might contribute to disease spread and how to identify its trafficking impairments in vivo.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Simoes</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-9976-2501</Identifier><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Department of Neurology, Columbia University Irving Medical Center, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neufeld</LastName><ForeName>Jessica L</ForeName><Initials>JL</Initials><Identifier Source="ORCID">0000-0002-5666-7942</Identifier><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Department of Neurology, Columbia University Irving Medical Center, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Triana-Baltzer</LastName><ForeName>Gallen</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Neuroscience Biomarkers, Janssen Research and Development, San Diego, CA 92121, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moughadam</LastName><ForeName>Setareh</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Neuroscience Biomarkers, Janssen Research and Development, San Diego, CA 92121, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Emily I</ForeName><Initials>EI</Initials><AffiliationInfo><Affiliation>Thermo Fisher Precision Medicine Science Center, 790 Memorial Drive, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kothiya</LastName><ForeName>Milankumar</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-6233-4696</Identifier><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Department of Neurology, Columbia University Irving Medical Center, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qureshi</LastName><ForeName>Yasir H</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Department of Neurology, Columbia University Irving Medical Center, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Vivek</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-8949-139X</Identifier><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Department of Neurology, Columbia University Irving Medical Center, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Honig</LastName><ForeName>Lawrence S</ForeName><Initials>LS</Initials><Identifier Source="ORCID">0000-0002-9703-2265</Identifier><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Department of Neurology, Columbia University Irving Medical Center, New York, NY 10032, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Columbia University Irving Medical Center, New York, NY 10032, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gertrude H. Sergievsky Center, Columbia University Irving Medical Center, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kolb</LastName><ForeName>Hartmuth</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Neuroscience Biomarkers, Janssen Research and Development, San Diego, CA 92121, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Small</LastName><ForeName>Scott A</ForeName><Initials>SA</Initials><Identifier Source="ORCID">0000-0002-4777-1502</Identifier><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Department of Neurology, Columbia University Irving Medical Center, New York, NY 10032, USA. sas68@columbia.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG066462</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG008702</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG034618</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG035015</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C489697">APLP1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015815">Cell Adhesion Molecules</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C490649">Chl1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D033921">Vesicular Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C101274">Vps35 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015815" MajorTopicYN="N">Cell Adhesion Molecules</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062706" MajorTopicYN="N">Prodromal Symptoms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="N">Proteomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D033921" MajorTopicYN="N">Vesicular Transport Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing interests:</b> The authors declare competing financial interests: S.A.S. holds equity in Denali Therapeutics. S.S., Y.H.Q., and S.A.S. are coinventors on provisional patents covering retromer therapies and biomarkers. G.T.-B., S.M., and H.K. are employees of Janssen Research and Development. A patent has been applied entitled &#x201c;Methods of detecting endosomal trafficking dysfunction and neurodegenerative diseases and disorders&#x201d; (application no. 63/053,805).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>1</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>4</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>8</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>11</Month><Day>26</Day><Hour>5</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>2</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33239387</ArticleId><ArticleId IdType="mid">NIHMS1666277</ArticleId><ArticleId IdType="pmc">PMC7901670</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.aba6334</ArticleId><ArticleId IdType="pii">12/571/eaba6334</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Small SA, Gandy S, Sorting through the cell biology of Alzheimer&#x2019;s disease: Intracellular pathways to pathogenesis. Neuron 52, 15&#x2013;31 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4820242</ArticleId><ArticleId IdType="pubmed">17015224</ArticleId></ArticleIdList></Reference><Reference><Citation>Udayar V, Buggia-Pr&#xe9;vot V, Guerreiro RL, Siegel G, Rambabu N, Soohoo AL, Ponnusamy M, Siegenthaler B, Bali J; AESG M Simons, J. Ries, M. A. Puthenveedu, J. Hardy, G. Thinakaran, L. Rajendran, A paired RNAi and RabGAP overexpression screen identifies Rab11 as a regulator of &#x3b2;-amyloid production. Cell Rep 5, 1536&#x2013;1551 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4004174</ArticleId><ArticleId IdType="pubmed">24373285</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsinelos T, Zeitler M, Dimou E, Karakatsani A, M&#xfc;ller H-M, Nachman E, Steringer JP, de Almodovar CR, Nickel W, Jahn TR, Unconventional secretion mediates the trans-cellular spreading of tau. Cell Rep. 23, 2039&#x2013;2055 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29768203</ArticleId></ArticleIdList></Reference><Reference><Citation>Merezhko M, Brunello CA, Yan X, Vihinen H, Jokitalo E, Uronen R-L, Huttunen HJ, Secretion of tau via an unconventional non-vesicular mechanism. Cell reports 25, 2027&#x2013;2035.e4 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30463001</ArticleId></ArticleIdList></Reference><Reference><Citation>SStti C, Sullivan M, Crisp MJ, Kasten T, Kirmess KM, Kanaan NM, Yarasheski KE, Baker-Nigh A, Benzinger TLS, Miller TM, Karch CM, Bateman RJ, Tau kinetics in neurons and the human central nervous system. Neuron 98, 861&#x2013;864 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6192252</ArticleId><ArticleId IdType="pubmed">29772204</ArticleId></ArticleIdList></Reference><Reference><Citation>Small SA, Simoes-Spassov S, Mayeux R, Petsko GA, Endosomal traffic jams represent a pathogenic hub and therapeutic target in Alzheimer&#x2019;s disease. Trends Neurosci. 40, 592&#x2013;602 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5654621</ArticleId><ArticleId IdType="pubmed">28962801</ArticleId></ArticleIdList></Reference><Reference><Citation>Small SA, Petsko GA, Retromer in Alzheimer disease, Parkinson disease and other neurological disorders. Nat. Rev. Neurosci 16, 126&#x2013;132 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25669742</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogaeva E, Meng Y, Lee JH, Gu Y, Kawarai T, Zou F, Katayama T, Baldwin CT, Cheng R, Hasegawa H, Chen F, Shibata N, Lunetta KL, Pardossi-Piquard R, Bohm C, Wakutani Y, Cupples LA, Cuenco KT, Green RC, Pinessi L, Rainero I, Sorbi S, Bruni A, Duara R, Friedland RP, Inzelberg R, Hampe W, Bujo H, Song Y-Q, Andersen OM, Willnow TE, Graff-Radford N, Petersen RC, Dickson D, Der SD, Fraser PE, Schmitt-Ulms G, Younkin S, Mayeux R, Farrer LA, St George-Hyslop P, The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat. Genet 39, 168&#x2013;177 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2657343</ArticleId><ArticleId IdType="pubmed">17220890</ArticleId></ArticleIdList></Reference><Reference><Citation>Vardarajan BN, Zhang Y, Lee JH, Cheng R, Bohm C, Ghani M, Reitz C, Reyes-Dumeyer D, Shen Y, Rogaeva E, St George-Hyslop P, Mayeux R, Coding mutations in SORL1 and Alzheimer disease. Ann. Neurol 77, 215&#x2013;227 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4367199</ArticleId><ArticleId IdType="pubmed">25382023</ArticleId></ArticleIdList></Reference><Reference><Citation>Verheijen J, Van den Bossche T, van der Zee J, Engelborghs S, Sanchez-Valle R, Llad&#xf3; A, Graff C, Thonberg H, Pastor P, Ortega-Cubero S, Pastor MA, Benussi L, Ghidoni R, Binetti G, Clarimon J, Lle&#xf3; A, Fortea J, de Mendon&#xe7;a A, Martins M, Grau-Rivera O, Gelpi E, Bettens K, Mateiu L, Dillen L, Cras P, De Deyn PP, Van Broeckhoven C, Sleegers K, A comprehensive study of the genetic impact of rare variants in SORL1 in European early-onset Alzheimer&#x2019;s disease. Acta Neuropathol. 132, 213&#x2013;224 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4947104</ArticleId><ArticleId IdType="pubmed">27026413</ArticleId></ArticleIdList></Reference><Reference><Citation>Small SA, Kent K, Pierce A, Leung C, Kang MS, Okada H, Honig L, Vonsattel J-P, Kim T-W, Model-guided microarray implicates the retromer complex in Alzheimer&#x2019;s disease. Ann. Neurol 58, 909&#x2013;919 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16315276</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovelet-Lecrux A, Charbonnier C, Wallon D, Nicolas G, Seaman MNJ, Pottier C, Breusegem SY, Mathur PP, Jenardhanan P, Le Guennec K, Mukadam AS, Quenez O, Coutant S, Rousseau S, Richard A-C, Boland A, Deleuze J-F, Frebourg T, Hannequin D, Campion D; CNR-MAJ collaborators, De novo deleterious genetic variations target a biological network centered on A&#x3b2; peptide in early-onset Alzheimer disease. Mol. Psychiatry 20, 1046&#x2013;1056 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26194182</ArticleId></ArticleIdList></Reference><Reference><Citation>Vardarajan BN, Bruesegem SY, Harbour ME, Inzelberg R, Friedland R, St George-Hyslop P, Seaman MNJ, Farrer LA, Identification of Alzheimer disease-associated variants in genes that regulate retromer function. Neurobiol. Aging 33, 2231.e15&#x2013;2231.e30 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3391348</ArticleId><ArticleId IdType="pubmed">22673115</ArticleId></ArticleIdList></Reference><Reference><Citation>Muhammad A, Flores I, Zhang H, Yu R, Staniszewski A, Planel E, Herman M, Ho L, Kreber R, Honig LS, Ganetzky B, Duff K, Arancio O, Small SA, Retromer deficiency observed in Alzheimer&#x2019;s disease causes hippocampal dysfunction, neurodegeneration, and A&#x3b2; accumulation. Proc. Natl. Acad. Sci. U.S.A 105, 7327&#x2013;7332 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2386077</ArticleId><ArticleId IdType="pubmed">18480253</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhalla A, Vetanovetz CP, Morel E, Chamoun Z, Di Paolo G, Small SA, The location and trafficking routes of the neuronal retromer and its role in amyloid precursor protein transport. Neurobiol. Dis 47, 126&#x2013;134 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3589992</ArticleId><ArticleId IdType="pubmed">22516235</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen L, Tang F-L, Hong Y, Luo S-W, Wang C-L, He W, Shen C, Jung J-U, Xiong F, D.-h. Lee, Q.-G. Zhang, D. Brann, T.-W. Kim, R. Yan, L. Mei, W.-C. Xiong, VPS35 haploinsufficiency increases Alzheimer&#x2019;s disease neuropathology. J. Cell Biol 195, 765&#x2013;779 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3257571</ArticleId><ArticleId IdType="pubmed">22105352</ArticleId></ArticleIdList></Reference><Reference><Citation>Mecozzi VJ, Berman DE, Simoes S, Vetanovetz C, Awal MR, Patel VM, Schneider RT, Petsko GA, Ringe D, Small SA, Pharmacological chaperones stabilize retromer to limit APP processing. Nat. Chem. Biol 10, 443&#x2013;449 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4076047</ArticleId><ArticleId IdType="pubmed">24747528</ArticleId></ArticleIdList></Reference><Reference><Citation>Young JE, Fong LK, Frankowski H, Petsko GA, Small SA, Goldstein LSB, Stabilizing the retromer complex in a human stem cell model of Alzheimer&#x2019;s disease reduces TAU phosphorylation independently of amyloid precursor protein. Stem Cell Rep. 10, 1046&#x2013;1058 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5919412</ArticleId><ArticleId IdType="pubmed">29503090</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin J, Liu X, He Q, Zhou L, Yuan Z, Zhao S, Vps35-dependent recycling of Trem2 regulates microglial function. Traffic 17, 1286&#x2013;1296 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27717139</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucin KM, O&#x2019;Brien CE, Bieri G, Czirr E, Mosher KI, Abbey RJ, Mastroeni DF, Rogers J, Spencer B, Masliah E, Wyss-Coray T, Microglial beclin 1 regulates retromer trafficking and phagocytosis and is impaired in Alzheimer&#x2019;s disease. Neuron 79, 873&#x2013;886 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3779465</ArticleId><ArticleId IdType="pubmed">24012002</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataldo AM, Peterhoff CM, Troncoso JC, Gomez-Isla T, Hyman BT, Nixon RA, Endocytic pathway abnormalities precede amyloid &#x3b2; deposition in sporadic Alzheimer&#x2019;s disease and Down syndrome: Differential effects of APOE genotype and presenilin mutations. Am. J. Pathol 157, 277&#x2013;286 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850219</ArticleId><ArticleId IdType="pubmed">10880397</ArticleId></ArticleIdList></Reference><Reference><Citation>Israel MA, Yuan SH, Bardy C, Reyna SM, Mu Y, Herrera C, Hefferan MP, Van Gorp S, Nazor KL, Boscolo FS, Carson CT, Laurent LC, Marsala M, Gage FH, Remes AM, Koo EH, Goldstein LSB, Probing sporadic and familial Alzheimer&#x2019;s disease using induced pluripotent stem cells. Nature 482, 216&#x2013;220 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3338985</ArticleId><ArticleId IdType="pubmed">22278060</ArticleId></ArticleIdList></Reference><Reference><Citation>Raja WK, Mungenast AE, Lin Y-T, Ko T, Abdurrob F, Seo J, Tsai L-H, Self-organizing 3D human neural tissue derived from induced pluripotent stem cells recapitulate Alzheimer&#x2019;s disease phenotypes. PLOS ONE 11, e0161969 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5021368</ArticleId><ArticleId IdType="pubmed">27622770</ArticleId></ArticleIdList></Reference><Reference><Citation>Barth&#xe9;lemy NR, Li Y, Joseph-Mathurin N, Gordon BA, Hassenstab J, Benzinger TLS, Buckles V, Fagan AM, Perrin RJ, Goate AM, Morris JC, Karch CM, Xiong C, Allegri R, Mendez PC, Berman SB, Ikeuchi T, Mori H, Shimada H, Shoji M, Suzuki K, Noble J, Farlow M, Chhatwal J, Graff-Radford NR, Salloway S, Schofield PR, Masters CL, Martins RN, O&#x2019;Connor A, Fox NC, Levin J, Jucker M, Gabelle A, Lehmann S, Sato C, Bateman RJ, McDade E; the Dominantly Inherited Alzheimer Network, A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer&#x2019;s disease. Nat. Med 26, 398&#x2013;407 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7309367</ArticleId><ArticleId IdType="pubmed">32161412</ArticleId></ArticleIdList></Reference><Reference><Citation>Barth&#xe9;lemy NR, Bateman RJ, Hirtz C, Marin P, Becher F, Sato C, Gabelle A, Lehmann S, Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer&#x2019;s disease and PET amyloid-positive patient identification. Alzheimers Res. Ther 12, 26 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7079453</ArticleId><ArticleId IdType="pubmed">32183883</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis J-C, Collins F, Treanor J, Rogers G, Citron M, &#x3b2;-secretase cleavage of Alzheimer&#x2019;s amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286, 735&#x2013;741 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10531052</ArticleId></ArticleIdList></Reference><Reference><Citation>Dislich B, Wohlrab F, Bachhuber T, M&#xfc;ller SA, Kuhn P-H, Hogl S, Meyer-Luehmann M, Lichtenthaler SF, Label-free quantitative proteomics of mouse cerebrospinal fluid detects &#x3b2;-site APP cleaving enzyme (BACE1) protease substrates in vivo. Mol. Cell. Proteomics 14, 2550&#x2013;2563 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4597136</ArticleId><ArticleId IdType="pubmed">26139848</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C-L, Tang F-L, Peng Y, Shen C-Y, Mei L, Xiong W-C, VPS35 regulates developing mouse hippocampal neuronal morphogenesis by promoting retrograde trafficking of BACE1. Biol. Open 1, 1248&#x2013;1257 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3522886</ArticleId><ArticleId IdType="pubmed">23259059</ArticleId></ArticleIdList></Reference><Reference><Citation>Cicognola C, Brinkmalm G, Wahlgren J, Portelius E, Gobom J, Cullen NC, Hansson O, Parnetti L, Constantinescu R, Wildsmith K, Chen H-H, Beach TG, Lashley T, Zetterberg H, Blennow K, H&#xf6;glund K, Novel tau fragments in cerebrospinal fluid: Relation to tangle pathology and cognitive decline in Alzheimer&#x2019;s disease. Acta Neuropathol. 137, 279&#x2013;296 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6514201</ArticleId><ArticleId IdType="pubmed">30547227</ArticleId></ArticleIdList></Reference><Reference><Citation>Meredith JE Jr., Sankaranarayanan S, Guss V, Lanzetti A, Berisha F, Neely RJ, Slemmon JR, Portelius E, Zetterberg H, Blennow K, Soares H, Ahlijanian M, Albright CF, Characterization of novel CSF Tau and ptau biomarkers for Alzheimer&#x2019;s disease. PLOS ONE 8, e76523 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3792042</ArticleId><ArticleId IdType="pubmed">24116116</ArticleId></ArticleIdList></Reference><Reference><Citation>Barth&#xe9;lemy NR, Fenaille F, Hirtz C, Sergeant N, Schraen-Maschke S, Vialaret J, Bu&#xe9;e L, Gabelle A, Junot C, Lehmann S, Becher F, Tau protein quantification in human cerebrospinal fluid by targeted mass spectrometry at high sequence coverage provides insights into its primary structure heterogeneity. J. Proteome Res 15, 667&#x2013;676 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26742856</ArticleId></ArticleIdList></Reference><Reference><Citation>Barth&#xe9;lemy NR, Gabelle A, Hirtz C, Fenaille F, Sergeant N, Schraen-Maschke S, Vialaret J, Bu&#xe9;e L, Junot C, Becher F, Lehmann S, Differential mass spectrometry profiles of tau protein in the cerebrospinal fluid of patients with Alzheimer&#x2019;s disease, progressive supranuclear palsy, and dementia with Lewy bodies. J. Alzheimer Dis 51, 1033&#x2013;1043 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26923020</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer A, Green J, Pollard J Jr., S. Tugendreich, Causal analysis approaches in Ingenuity Pathway Analysis. Bioinformatics 30, 523&#x2013;530 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3928520</ArticleId><ArticleId IdType="pubmed">24336805</ArticleId></ArticleIdList></Reference><Reference><Citation>Chai X, Dage JL, Citron M, Constitutive secretion of tau protein by an unconventional mechanism. Neurobiol. Dis 48, 356&#x2013;366 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22668776</ArticleId></ArticleIdList></Reference><Reference><Citation>Karch CM, Jeng AT, Goate AM, Extracellular Tau levels are influenced by variability in Tau that is associated with tauopathies. J. Biol. Chem 287, 42751&#x2013;42762 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3522274</ArticleId><ArticleId IdType="pubmed">23105105</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohamed N-V, Plouffe V, R&#xe9;millard-Labrosse G, Planel E, Leclerc N, Starvation and inhibition of lysosomal function increased tau secretion by primary cortical neurons. Sci. Rep 4, 5715 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4101526</ArticleId><ArticleId IdType="pubmed">25030297</ArticleId></ArticleIdList></Reference><Reference><Citation>Barten DM, Cadelina GW, Hoque N, De Carr LB, Guss VL, Yang L, Sankaranarayanan S, Wes PD, Flynn ME, Meredith JE, Ahlijanian MK, Albright CF, Tau transgenic mice as models for cerebrospinal fluid tau biomarkers. J. Alzheimer Dis 24 (suppl 2), 127&#x2013;141 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21422517</ArticleId></ArticleIdList></Reference><Reference><Citation>Rissin DM, Kan CW, Campbell TG, Howes SC, Fournier DR, Song L, Piech T, Patel PP, Chang L, Rivnak AJ, Ferrell EP, Randall JD, Provuncher GK, Walt DR, Duffy DC, Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat. Biotechnol 28, 595&#x2013;599 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2919230</ArticleId><ArticleId IdType="pubmed">20495550</ArticleId></ArticleIdList></Reference><Reference><Citation>Schelle J, H&#xe4;sler LM, G&#xf6;pfert JC, Joos TO, Vanderstichele H, Stoops E, Mandelkow E-M, Neumann U, Shimshek DR, Staufenbiel M, Jucker M, Kaeser SA, Prevention of tau increase in cerebrospinal fluid of APP transgenic mice suggests downstream effect of BACE1 inhibition. Alzheimers Dement. 13, 701&#x2013;709 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27750032</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z, Mengel D, Keshavan A, Rissman RA, Billinton A, Perkinton M, Percival-Alwyn J, Schultz A, Properzi M, Johnson K, Selkoe DJ, Sperling RA, Patel P, Zetterberg H, Galasko D, Schott JM, Walsh DM, Learnings about the complexity of extracellular tau aid development of a blood-based screen for Alzheimer&#x2019;s disease. Alzheimers Dement. 15, 487&#x2013;496 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6476313</ArticleId><ArticleId IdType="pubmed">30419228</ArticleId></ArticleIdList></Reference><Reference><Citation>Zetterberg H, Review: Tau in biofluids - relation to pathology, imaging and clinical features. Neuropathol. Appl. Neurobiol 43, 194&#x2013;199 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28054371</ArticleId></ArticleIdList></Reference><Reference><Citation>Maia LF, Kaeser SA, Reichwald J, Hruscha M, Martus P, Staufenbiel M, Jucker M, Changes in amyloid-&#x3b2; and Tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein. Sci. Transl. Med 5, 194re2 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23863834</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayer TA, Cappai R, Masters CL, Beyreuther K, Multhaup G, It all sticks together&#x2013;&#x2013;the APP-related family of proteins and Alzheimer&#x2019;s disease. Mol. Psychiatry 4, 524&#x2013;528 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10578233</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanagida K, Okochi M, Tagami S, Nakayama T, Kodama TS, Nishitomi K, Jiang J, Mori K, Tatsumi S-I, Arai T, Ikeuchi T, Kasuga K, Tokuda T, Kondo M, Ikeda M, Deguchi K, Kazui H, Tanaka T, Morihara T, Hashimoto R, Kudo T, Steiner H, Haass C, Tsuchiya K, Akiyama H, Kuwano R, Takeda M, The 28-amino acid form of an APLP1-derived A&#x3b2;-like peptide is a surrogate marker for A&#x3b2;42 production in the central nervous system. EMBO Mol. Med 1, 223&#x2013;235 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3378133</ArticleId><ArticleId IdType="pubmed">20049724</ArticleId></ArticleIdList></Reference><Reference><Citation>Begcevic I, Brinc D, Brown M, Martinez-Morillo E, Goldhardt O, Grimmer T, Magdolen V, Batruch I, Diamandis EP, Brain-related proteins as potential CSF biomarkers of Alzheimer&#x2019;s disease: A targeted mass spectrometry approach. J. Proteomics 182, 12&#x2013;20 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29684683</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajendran L, Annaert W, Membrane trafficking pathways in Alzheimer&#x2019;s disease. Traffic 13, 759&#x2013;770 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22269004</ArticleId></ArticleIdList></Reference><Reference><Citation>T&#xfc;shaus J, M&#xfc;ller SA, Kataka ES, Zaucha J, Monasor LS, Su M, G&#xfc;ner G, Jocher G, Tahirovic S, Frishman D, Simons M, Lichtenthaler SF, Quantitative secretome analysis establishes the cell type-resolved mouse brain secretome. bioRxiv 2020.05.22.110023, (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7560198</ArticleId><ArticleId IdType="pubmed">32954517</ArticleId></ArticleIdList></Reference><Reference><Citation>Caballero B, Wang Y, Diaz A, Tasset I, Juste YR, Stiller B, Mandelkow E-M, Mandelkow E, Cuervo AM, Interplay of pathogenic forms of human tau with different autophagic pathways. Aging Cell 17, e12692 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5770880</ArticleId><ArticleId IdType="pubmed">29024336</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaz-Silva J, Gomes P, Jin Q, Zhu M, Zhuravleva V, Quintremil S, Meira T, Silva J, Dioli C, Soares-Cunha C, Daskalakis NP, Sousa N, Sotiropoulos I, Waites CL, Endolysosomal degradation of Tau and its role in glucocorticoid-driven hippocampal malfunction. EMBO J. 37, e99084 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6187216</ArticleId><ArticleId IdType="pubmed">30166454</ArticleId></ArticleIdList></Reference><Reference><Citation>Holth JK, Fritschi SK, Wang C, Pedersen NP, Cirrito JR, Mahan TE, Finn MB, Manis M, Geerling JC, Fuller PM, Lucey BP, Holtzman DM, The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans. Science 363, 880&#x2013;884 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6410369</ArticleId><ArticleId IdType="pubmed">30679382</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Drouet V, Wu JW, Witter MP, Small SA, Clelland C, Duff K, Trans-synaptic spread of tau pathology in vivo. PLOS ONE 7, e31302 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3270029</ArticleId><ArticleId IdType="pubmed">22312444</ArticleId></ArticleIdList></Reference><Reference><Citation>de Calignon A, Polydoro M, Su&#xe1;rez-Calvet M, William C, Adamowicz DH, Kopeikina KJ, Pitstick R, Sahara N, Ashe KH, Carlson GA, Spires-Jones TL, Hyman BT, Propagation of tau pathology in a model of early Alzheimer&#x2019;s disease. Neuron 73, 685&#x2013;697 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3292759</ArticleId><ArticleId IdType="pubmed">22365544</ArticleId></ArticleIdList></Reference><Reference><Citation>Morabito MV, Berman DE, Schneider RT, Zhang Y, Leibel RL, Small SA, Hyperleucinemia causes hippocampal retromer deficiency linking diabetes to Alzheimer&#x2019;s disease. Neurobiol. Dis 65, 188&#x2013;192 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4235335</ArticleId><ArticleId IdType="pubmed">24440570</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwart D, Gregg A, Scheckel C, Murphy EA, Paquet D, Duffield M, Fak J, Olsen O, Darnell RB, Tessier-Lavigne M, A large panel of isogenic APP and PSEN1 mutant human iPSC neurons reveals shared endosomal abnormalities mediated by APP &#x3b2;-CTFs, not A&#x3b2;. Neuron 104, 256&#x2013;270.e5 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31416668</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu J, Pratico D, The retromer complex system in a transgenic mouse model of AD: Influence of age. Neurobiol. Aging 52, 32&#x2013;38 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28110103</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Wen G, Morris JC, Holtzman DM, Fluctuations of CSF amyloid-&#x3b2; levels: Implications for a diagnostic and therapeutic biomarker. Neurology 68, 666&#x2013;669 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17325273</ArticleId></ArticleIdList></Reference><Reference><Citation>Triana-Baltzer G, Van Kolen K, Theunis C, Moughadam S, Slemmon R, Mercken M, Galpern W, Sun H, Kolb H, Development and validation of a high sensitivity assay for measuring p217+tau in cerebrospinal fluid. J. Alzheimers Dis 77, 1417&#x2013;1430 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7683057</ArticleId><ArticleId IdType="pubmed">32831201</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33246331</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>20</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1460-2156</ISSN><JournalIssue CitedMedium="Internet"><Volume>144</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Feb</Month><Day>12</Day></PubDate></JournalIssue><Title>Brain : a journal of neurology</Title><ISOAbbreviation>Brain</ISOAbbreviation></Journal><ArticleTitle>Alzheimer's disease brain-derived extracellular vesicles spread tau pathology in interneurons.</ArticleTitle><Pagination><StartPage>288</StartPage><EndPage>309</EndPage><MedlinePgn>288-309</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/brain/awaa376</ELocationID><Abstract><AbstractText>Extracellular vesicles are highly transmissible and play critical roles in the propagation of tau pathology, although the underlying mechanism remains elusive. Here, for the first time, we comprehensively characterized the physicochemical structure and pathogenic function of human brain-derived extracellular vesicles isolated from Alzheimer's disease, prodromal Alzheimer's disease, and non-demented control cases. Alzheimer's disease extracellular vesicles were significantly enriched in epitope-specific tau oligomers in comparison to prodromal Alzheimer's disease or control extracellular vesicles as determined by dot blot and atomic force microscopy. Alzheimer's disease extracellular vesicles were more efficiently internalized by murine cortical neurons, as well as more efficient in transferring and misfolding tau, than prodromal Alzheimer's disease and control extracellular vesicles in vitro. Strikingly, the inoculation of Alzheimer's disease or prodromal Alzheimer's disease extracellular vesicles containing only 300 pg of tau into the outer molecular layer of the dentate gyrus of 18-month-old C57BL/6 mice resulted in the accumulation of abnormally phosphorylated tau throughout the hippocampus by 4.5 months, whereas inoculation of an equal amount of tau from control extracellular vesicles, isolated tau oligomers, or fibrils from the same Alzheimer's disease donor showed little tau pathology. Furthermore, Alzheimer's disease extracellular vesicles induced misfolding of endogenous tau in both oligomeric and sarkosyl-insoluble forms in the hippocampal region. Unexpectedly, phosphorylated tau was primarily accumulated in glutamic acid decarboxylase 67 (GAD67) GABAergic interneurons and, to a lesser extent, glutamate receptor 2/3-positive excitatory mossy cells, showing preferential extracellular vesicle-mediated GABAergic interneuronal tau propagation. Whole-cell patch clamp recordings of CA1 pyramidal cells showed significant reduction in the amplitude of spontaneous inhibitory post-synaptic currents. This was accompanied by reductions in c-fos+ GAD67+ neurons and GAD67+ neuronal puncta surrounding pyramidal neurons in the CA1 region, confirming reduced GABAergic transmission in this region. Our study posits a novel mechanism for the spread of tau in hippocampal GABAergic interneurons via brain-derived extracellular vesicles and their subsequent neuronal dysfunction.</AbstractText><CopyrightInformation>&#xa9; The Author(s) (2020). Published by Oxford University Press on behalf of the Guarantors of Brain.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ruan</LastName><ForeName>Zhi</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pathak</LastName><ForeName>Dhruba</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anatomy and Neurobiology, Boston University School of Medicine, Boston, MA 02118, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Venkatesan Kalavai</LastName><ForeName>Srinidhi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoshii-Kitahara</LastName><ForeName>Asuka</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muraoka</LastName><ForeName>Satoshi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhatt</LastName><ForeName>Nemil</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Texas Medical Branch, Galveston, TX 77555, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takamatsu-Yukawa</LastName><ForeName>Kayo</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Jianqiao</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yuzhi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hersh</LastName><ForeName>Samuel</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ericsson</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gorantla</LastName><ForeName>Santhi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Experimental Neurosciences, University of Nebraska Medical Center, Omaha, NE 68198, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gendelman</LastName><ForeName>Howard E</ForeName><Initials>HE</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Experimental Neurosciences, University of Nebraska Medical Center, Omaha, NE 68198, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kayed</LastName><ForeName>Rakez</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Texas Medical Branch, Galveston, TX 77555, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikezu</LastName><ForeName>Seiko</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luebke</LastName><ForeName>Jennifer I</ForeName><Initials>JI</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Neurobiology, Boston University School of Medicine, Boston, MA 02118, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Systems Neuroscience, Boston University, Boston, MA 02118, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikezu</LastName><ForeName>Tsuneya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Systems Neuroscience, Boston University, Boston, MA 02118, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Alzheimer's Disease Center, Boston University School of Medicine, Boston, MA 02118, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>RF1 AG054199</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG066429</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG054025</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG013846</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG054672</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AG057469</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS094557</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS034239</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS104609</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain</MedlineTA><NlmUniqueID>0372537</NlmUniqueID><ISSNLinking>0006-8950</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Brain. 2021 May 7;144(4):e42. doi: 10.1093/brain/awaa452.</RefSource><PMID Version="1">33437996</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000067128" MajorTopicYN="N">Extracellular Vesicles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059330" MajorTopicYN="N">GABAergic Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007395" MajorTopicYN="N">Interneurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017966" MajorTopicYN="N">Pyramidal Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">GABAergic interneuron</Keyword><Keyword MajorTopicYN="N">extracellular vesicle</Keyword><Keyword MajorTopicYN="N">microtubule-associated protein tau</Keyword><Keyword MajorTopicYN="N">mouse model</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>4</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>7</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>8</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>11</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>11</Month><Day>27</Day><Hour>20</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>11</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33246331</ArticleId><ArticleId IdType="pmc">PMC7880668</ArticleId><ArticleId IdType="doi">10.1093/brain/awaa376</ArticleId><ArticleId IdType="pii">6007752</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Apicco DJ, Ash PEA, Maziuk B, LeBlang C, Medalla M, Al Abdullatif A, et al. &#xa0;Reducing the RNA binding protein TIA1 protects against tau-mediated neurodegeneration in vivo. Nat Neurosci &#xa0;2018; 21: 72&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5745051</ArticleId><ArticleId IdType="pubmed">29273772</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai H, Clark CM, Ewbank DC, Takase S, Higuchi S, Miura M, et al. &#xa0;Cerebrospinal fluid tau protein as a potential diagnostic marker in Alzheimer's disease. Neurobiol Aging &#xa0;1998; 19: 125&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">9558146</ArticleId></ArticleIdList></Reference><Reference><Citation>Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. &#xa0;Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology &#xa0;1992; 42: 631&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">1549228</ArticleId></ArticleIdList></Reference><Reference><Citation>Asai H, Ikezu S, Tsunoda S, Medalla M, Luebke J, Haydar T, et al. &#xa0;Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nat Neurosci &#xa0;2015; 18: 1584&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4694577</ArticleId><ArticleId IdType="pubmed">26436904</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker S, Polanco JC, Gotz J. &#xa0;Extracellular vesicles containing P301L mutant tau accelerate pathological tau phosphorylation and oligomer formation but do not seed mature neurofibrillary tangles in ALZ17 mice. J Alzheimers Dis &#xa0;2016; 54: 1207&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">27567840</ArticleId></ArticleIdList></Reference><Reference><Citation>Bareggi SR, Franceschi M, Bonini L, Zecca L, Smirne S. &#xa0;Decreased Csf concentrations of homovanillic-acid and gamma-aminobutyric acid in Alzheimers-disease&#x2014;age-related or disease-related modifications. Arch Neurol &#xa0;1982; 39: 709&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">6181768</ArticleId></ArticleIdList></Reference><Reference><Citation>Barres C, Blanc L, Bette-Bobillo P, Andre S, Mamoun R, Gabius HJ, et al. &#xa0;Galectin-5 is bound onto the surface of rat reticulocyte exosomes and modulates vesicle uptake by macrophages. Blood &#xa0;2010; 115: 696&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pubmed">19903899</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilousova T, Elias C, Miyoshi E, Alam MP, Zhu CN, Campagna J, et al. &#xa0;Suppression of tau propagation using an inhibitor that targets the DK-switch of nSMase2. Biochem Biophys Res Commun &#xa0;2018; 499: 751&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5956110</ArticleId><ArticleId IdType="pubmed">29604274</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. &#xa0;Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol &#xa0;1991; 82: 239&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunello CA, Merezhko M, Uronen RL, Huttunen HJ. &#xa0;Mechanisms of secretion and spreading of pathological tau protein. Cell Mol Life Sci &#xa0;2020; 77: 1721&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7190606</ArticleId><ArticleId IdType="pubmed">31667556</ArticleId></ArticleIdList></Reference><Reference><Citation>Budnik V, Ruiz-Canada C, Wendler F. &#xa0;Extracellular vesicles round off communication in the nervous system. Nat Rev Neurosci &#xa0;2016; 17: 160&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4989863</ArticleId><ArticleId IdType="pubmed">26891626</ArticleId></ArticleIdList></Reference><Reference><Citation>Caraiscos VB, Elliott EM, You-Ten KE, Cheng VY, Belelli D, Newell JG, et al. &#xa0;Tonic inhibition in mouse hippocampal CA1 pyramidal neurons is mediated by alpha5 subunit-containing gamma-aminobutyric acid type A receptors. Proc Natl Acad Sci USA &#xa0;2004; 101: 3662&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC373519</ArticleId><ArticleId IdType="pubmed">14993607</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan-Palay V. &#xa0;Somatostatin immunoreactive neurons in the human hippocampus and cortex shown by immunogold/silver intensification on vibratome sections: coexistence with neuropeptide Y neurons, and effects in Alzheimer-type dementia. J Comp Neurol &#xa0;1987; 260: 201&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">2886516</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng L, Doecke JD, Sharples RA, Villemagne VL, Fowler CJ, Rembach A, et al. &#xa0;Prognostic serum miRNA biomarkers associated with Alzheimer's disease shows concordance with neuropsychological and neuroimaging assessment. Mol Psychiatry &#xa0;2015; 20: 1188&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">25349172</ArticleId></ArticleIdList></Reference><Reference><Citation>Christianson HC, Svensson KJ, van Kuppevelt TH, Li JP, Belting M. &#xa0;Cancer cell exosomes depend on cell-surface heparan sulfate proteoglycans for their internalization and functional activity. Proc Natl Acad Sci USA &#xa0;2013; 110: 17380&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3808637</ArticleId><ArticleId IdType="pubmed">24101524</ArticleId></ArticleIdList></Reference><Reference><Citation>Colin M, Dujardin S, Schraen-Maschke S, Meno-Tetang G, Duyckaerts C, Courade JP, et al. &#xa0;From the prion-like propagation hypothesis to therapeutic strategies of anti-tau immunotherapy. Acta Neuropathol &#xa0;2020; 139: 3&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6942016</ArticleId><ArticleId IdType="pubmed">31686182</ArticleId></ArticleIdList></Reference><Reference><Citation>Combs B, Tiernan CT, Hamel C, Kanaan NM. &#xa0;Production of recombinant tau oligomers in vitro. Methods Cell Biol &#xa0;2017; 141: 45&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5867531</ArticleId><ArticleId IdType="pubmed">28882311</ArticleId></ArticleIdList></Reference><Reference><Citation>Cvjetkovic A, Jang SC, Konecna B, Hoog JL, Sihlbom C, Lasser C, et al. &#xa0;Detailed analysis of protein topology of extracellular vesicles-evidence of unconventional membrane protein orientation. Sci Rep &#xa0;2016; 6: 36338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5099568</ArticleId><ArticleId IdType="pubmed">27821849</ArticleId></ArticleIdList></Reference><Reference><Citation>Danzer KM, Kranich LR, Ruf WP, Cagsal-Getkin O, Winslow AR, Zhu LY, et al. &#xa0;Exosomal cell-to-cell transmission of alpha synuclein oligomers. Mol Neurodegener &#xa0;2012; 7: 42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3483256</ArticleId><ArticleId IdType="pubmed">22920859</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies P, Katzman R, Terry RD. &#xa0;Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer disease and Alzheimer senile dementa. Nature &#xa0;1980; 288: 279&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">6107862</ArticleId></ArticleIdList></Reference><Reference><Citation>Deepa SS, Carulli D, Galtrey C, Rhodes K, Fukuda J, Mikami T, et al. &#xa0;Composition of perineuronal net extracellular matrix in rat brain: a different disaccharide composition for the net-associated proteoglycans. J Biol Chem &#xa0;2006; 281: 17789&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pubmed">16644727</ArticleId></ArticleIdList></Reference><Reference><Citation>DeLeo AM, Ikezu T. &#xa0;Extracellular vesicle biology in Alzheimer's disease and related tauopathy. J Neuroimmune Pharmacol &#xa0;2018; 13: 292&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5972041</ArticleId><ArticleId IdType="pubmed">29185187</ArticleId></ArticleIdList></Reference><Reference><Citation>Delpech JC, Herron S, Botros MB, Ikezu T. &#xa0;Neuroimmune crosstalk through extracellular vesicles in health and disease. Trends Neurosci &#xa0;2019; 42: 361&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6486849</ArticleId><ArticleId IdType="pubmed">30926143</ArticleId></ArticleIdList></Reference><Reference><Citation>Dujardin S, Begard S, Caillierez R, Lachaud C, Delattre L, Carrier S, et al. &#xa0;Ectosomes: a new mechanism for non-exosomal secretion of tau protein. PLoS One &#xa0;2014; 9: e100760.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4074092</ArticleId><ArticleId IdType="pubmed">24971751</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans LD, Wassmer T, Fraser G, Smith J, Perkinton M, Billinton A, et al. &#xa0;Extracellular monomeric and aggregated tau efficiently enter human neurons through overlapping but distinct pathways. Cell Rep &#xa0;2018; 22: 3612&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5896171</ArticleId><ArticleId IdType="pubmed">29590627</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon B, Zhang WJ, Murzin AG, Murshudov G, Garringer HJ, Vidal R, et al. &#xa0;Structures of filaments from Pick's disease reveal a novel tau protein fold. Nature &#xa0;2018; 561: 137&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6204212</ArticleId><ArticleId IdType="pubmed">30158706</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon B, Zivanov J, Zhang WJ, Murzin AG, Garringer HJ, Vidal R, et al. &#xa0;Novel tau filament fold in chronic traumatic encephalopathy encloses hydrophobic molecules. Nature &#xa0;2019; 568: 420&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6472968</ArticleId><ArticleId IdType="pubmed">30894745</ArticleId></ArticleIdList></Reference><Reference><Citation>Fevrier B, Vilette D, Archer F, Loew D, Faigle W, Vidal M, et al. &#xa0;Cells release prions in association with exosomes. Proc Natl Acad Sci USA &#xa0;2004; 101: 9683&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC470735</ArticleId><ArticleId IdType="pubmed">15210972</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiandaca MS, Kapogiannis D, Mapstone M, Boxer A, Eitan E, Schwartz JB, et al. &#xa0;Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes: a case-control study. Alzheimers Dementia &#xa0;2015; 11: 600&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4329112</ArticleId><ArticleId IdType="pubmed">25130657</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzpatrick AWP, Falcon B, He S, Murzin AG, Murshudov G, Garringer HJ, et al. &#xa0;Cryo-EM structures of tau filaments from Alzheimer's disease. Nature &#xa0;2017; 547: 185&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5552202</ArticleId><ArticleId IdType="pubmed">28678775</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghag G, Bhatt N, Cantu DV, Guerrero-Munoz MJ, Ellsworth A, Sengupta U, et al. &#xa0;Soluble tau aggregates, not large fibrils, are the toxic species that display seeding and cross-seeding behavior. Protein Sci &#xa0;2018; 27: 1901&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6201727</ArticleId><ArticleId IdType="pubmed">30125425</ArticleId></ArticleIdList></Reference><Reference><Citation>Govindpani K, Guzman BCF, Vinnakota C, Waldvogel HJ, Faull RL, Kwakowsky A. &#xa0;Towards a better understanding of GABAergic remodeling in Alzheimer's disease. Int J Mol Sci &#xa0;2017; 18: 1813.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5578199</ArticleId><ArticleId IdType="pubmed">28825683</ArticleId></ArticleIdList></Reference><Reference><Citation>Grad LI, Fernando SM, Cashman NR. &#xa0;From molecule to molecule and cell to cell: prion-like mechanisms in amyotrophic lateral sclerosis. Neurobiol Dis &#xa0;2015; 77: 257&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">25701498</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo JL, Narasimhan S, Changolkar L, He Z, Stieber A, Zhang B, et al. &#xa0;Unique pathological tau conformers from Alzheimer's brains transmit tau pathology in nontransgenic mice. J Exp Med &#xa0;2016; 213: 2635&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5110027</ArticleId><ArticleId IdType="pubmed">27810929</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatch RJ, Wei Y, Xia D, Gotz J. &#xa0;Hyperphosphorylated tau causes reduced hippocampal CA1 excitability by relocating the axon initial segment. Acta Neuropathol &#xa0;2017; 133: 717&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5389999</ArticleId><ArticleId IdType="pubmed">28091722</ArticleId></ArticleIdList></Reference><Reference><Citation>He B, Liu L, Cook GA, Grgurevich S, Jennings LK, Zhang XA. &#xa0;Tetraspanin CD82 attenuates cellular morphogenesis through down-regulating integrin alpha 6-mediated cell adhesion. J Biol Chem &#xa0;2005; 280: 3346&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">15557282</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes BB, Furman JL, Mahan TE, Yamasaki TR, Mirbaha H, Eades WC, et al. &#xa0;Proteopathic tau seeding predicts tauopathy in vivo. Proc Natl Acad Sci USA &#xa0;2014; 111: E4376&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4205609</ArticleId><ArticleId IdType="pubmed">25261551</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoshino A, Costa-Silva B, Shen TL, Rodrigues G, Hashimoto A, Mark MT, et al. &#xa0;Tumour exosome integrins determine organotropic metastasis. Nature &#xa0;2015; 527: 329&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4788391</ArticleId><ArticleId IdType="pubmed">26524530</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu W, Zhang XH, Tung YC, Xie ST, Liu F, Iqbal K. &#xa0;Hyperphosphorylation determines both the spread and the morphology of tau pathology. Alzheimers Dement &#xa0;2016; 12: 1066&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">27133892</ArticleId></ArticleIdList></Reference><Reference><Citation>Im H, Shao HL, Park YI, Peterson VM, Castro CM, Weissleder R, et al. &#xa0;Label-free detection and molecular profiling of exosomes with a nano-plasmonic sensor. Nat Biotechnol &#xa0;2014; 32: 490&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4356947</ArticleId><ArticleId IdType="pubmed">24752081</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang LL, Ash PEA, Maziuk BF, Ballance HI, Boudeau S, Al Abdullatif A, et al. &#xa0;TIA1 regulates the generation and response to toxic tau oligomers. Acta Neuropathol &#xa0;2019; 137: 259&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6377165</ArticleId><ArticleId IdType="pubmed">30465259</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK, et al. &#xa0;A unique microglia type associated with restricting development of Alzheimer's disease. Cell &#xa0;2017; 169: 1276&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinney JW, Bemiller SM, Murtishaw AS, Leisgang AM, Salazar AM, Lamb BT. &#xa0;Inflammation as a central mechanism in Alzheimer's disease. Alzheimers Dement (N Y) &#xa0;2018; 4: 575&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6214864</ArticleId><ArticleId IdType="pubmed">30406177</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann S, Madore C, Cialic R, Baufeld C, Calcagno N, El Fatimy R, et al. &#xa0;The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity &#xa0;2017; 47: 566&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5719893</ArticleId><ArticleId IdType="pubmed">28930663</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, et al. &#xa0;Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet &#xa0;2009; 41: 1094&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">19734903</ArticleId></ArticleIdList></Reference><Reference><Citation>Levenga J, Krishnamurthy P, Rajamohamedsait H, Wong H, Franke TF, Cain P, et al. &#xa0;Tau pathology induces loss of GABAergic interneurons leading to altered synaptic plasticity and behavioral impairments. Acta Neuropathol Commun &#xa0;2013; 1: 34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3893396</ArticleId><ArticleId IdType="pubmed">24252661</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H, Davila-Velderrain J, Peng ZY, Gao F, Mohammadi S, Young JZ, et al. &#xa0;Single-cell transcriptomic analysis of Alzheimer's disease. Nature &#xa0;2019; 570: 332&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6865822</ArticleId><ArticleId IdType="pubmed">31042697</ArticleId></ArticleIdList></Reference><Reference><Citation>McAvoy KM, Soit HR, Marsh G, Peterson M, Reynolds TL, Gagnon J, et al. &#xa0;Cell-autonomous and non-cell autonomous effects of neuronal BIN1 loss in vivo. PLoS One &#xa0;2019; 14: e0220125.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6692034</ArticleId><ArticleId IdType="pubmed">31408457</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirbaha H, Holmes BB, Sanders DW, Bieschke J, Diamond MI. &#xa0;Tau trimers are the minimal propagation unit spontaneously internalized to seed intracellular aggregation. J Biol Chem &#xa0;2015; 290: 14893&#x2013;903.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4463437</ArticleId><ArticleId IdType="pubmed">25887395</ArticleId></ArticleIdList></Reference><Reference><Citation>Morelli AE, Larregina AT, Shufesky WJ, Sullivan MLG, Stolz DB, Papworth GD, et al. &#xa0;Endocytosis, intracellular sorting, and processing of exosomes by dendritic cells. Blood &#xa0;2004; 104: 3257&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">15284116</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulcahy LA, Pink RC, Carter DR. &#xa0;Routes and mechanisms of extracellular vesicle uptake. J Extracell Vesicles &#xa0;2014; 3: 24641.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4122821</ArticleId><ArticleId IdType="pubmed">25143819</ArticleId></ArticleIdList></Reference><Reference><Citation>Muraoka S, DeLeo AM, Sethi MK, Yukawa-Takamatsu K, Yang Z, Ko J, et al. &#xa0;Proteomic and biological profiling of extracellular vesicles from Alzheimer's disease human brain tissues. Alzheimers Dement &#xa0;2020. a; 16: 896&#x2013;907.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7293582</ArticleId><ArticleId IdType="pubmed">32301581</ArticleId></ArticleIdList></Reference><Reference><Citation>Muraoka S, Jedrychowski MP, Tatebe H, DeLeo AM, Ikezu S, Tokuda T, et al. &#xa0;Proteomic profiling of extracellular vesicles isolated from cerebrospinal fluid of former national football league players at risk for chronic traumatic encephalopathy. Front Neurosci &#xa0;2019; 13: 1059.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6794346</ArticleId><ArticleId IdType="pubmed">31649498</ArticleId></ArticleIdList></Reference><Reference><Citation>Muraoka S, Lin W, Chen M, Hersh SW, Emili A, Xia W, et al. &#xa0;Assessment of separation methods for extracellular vesicles from human and mouse brain tissues and human cerebrospinal fluids. Methods &#xa0;2020. b; 177: 35&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7667497</ArticleId><ArticleId IdType="pubmed">32035230</ArticleId></ArticleIdList></Reference><Reference><Citation>Narasimhan S, Guo JL, Changolkar L, Stieber A, McBride JD, Silva LV, et al. &#xa0;Pathological tau strains from human brains recapitulate the diversity of tauopathies in nontransgenic mouse brain. J Neurosci &#xa0;2017; 37: 11406&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5700423</ArticleId><ArticleId IdType="pubmed">29054878</ArticleId></ArticleIdList></Reference><Reference><Citation>Nazarenko I. &#xa0;Cell surface tetraspanin tspan8 contributes to molecular pathways of exosome-induced endothelial cell activation. Cancer Res &#xa0;2010; 70: 1668&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">20124479</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Mucke L. &#xa0;Epilepsy and cognitive impairments in Alzheimer disease. Arch Neurol &#xa0;2009; 66: 435&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2812914</ArticleId><ArticleId IdType="pubmed">19204149</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Gonzalez R, Gauthier SA, Kumar A, Levy E. &#xa0;The exosome secretory pathway transports amyloid precursor protein carboxyl-terminal fragments from the cell into the brain extracellular space. J Biol Chem &#xa0;2012; 287: 43108&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3522305</ArticleId><ArticleId IdType="pubmed">23129776</ArticleId></ArticleIdList></Reference><Reference><Citation>Polanco JC, Scicluna BJ, Hill AF, Gotz J. &#xa0;Extracellular vesicles isolated from the brains of rTg4510 mice seed tau protein aggregation in a threshold-dependent manner. J Biol Chem &#xa0;2016; 291: 12445&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4933440</ArticleId><ArticleId IdType="pubmed">27030011</ArticleId></ArticleIdList></Reference><Reference><Citation>Purushothaman A, Bandari SK, Liu J, Mobley JA, Brown EE, Sanderson RD. &#xa0;Fibronectin on the surface of myeloma cell-derived exosomes mediates exosome-cell interactions. J Biol Chem &#xa0;2016; 291: 1652&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4722448</ArticleId><ArticleId IdType="pubmed">26601950</ArticleId></ArticleIdList></Reference><Reference><Citation>Quast T, Eppler F, Semmling V, Schild C, Homsi Y, Levy S, et al. &#xa0;CD81 is essential for the formation of membrane protrusions and regulates Rac1-activation in adhesion-dependent immune cell migration. Blood &#xa0;2011; 118: 1818&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">21677313</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruan Z, Ikezu T. &#xa0;Tau secretion. Adv Exp Med Biol &#xa0;2019; 1184: 123&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">32096034</ArticleId></ArticleIdList></Reference><Reference><Citation>Saman S, Kim W, Raya M, Visnick Y, Miro S, Saman S, et al. &#xa0;Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease. J Biol Chem &#xa0;2012; 287: 3842&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3281682</ArticleId><ArticleId IdType="pubmed">22057275</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoenberg MR, Rum RS, Osborn KE, Werz MA. &#xa0;A randomized, double-blind, placebo-controlled crossover study of the effects of levetiracetam on cognition, mood, and balance in healthy older adults. Epilepsia &#xa0;2017; 58: 1566&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">28731266</ArticleId></ArticleIdList></Reference><Reference><Citation>Sengupta U, Carretero-Murillo M, Kayed R. &#xa0;Preparation and characterization of tau oligomer strains. Methods Mol Biol &#xa0;2018; 1779: 113&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">29886531</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigurdsson EM. &#xa0;Tau immunotherapies for Alzheimer's disease and related tauopathies: progress and potential pitfalls. J Alzheimers Dis &#xa0;2018; 66: 855&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">30400102</ArticleId></ArticleIdList></Reference><Reference><Citation>Soler H, Dorca-Arevalo J, Gonzalez M, Rubio SE, Avila J, Soriano E, et al. &#xa0;The GABAergic septohippocampal connection is impaired in a mouse model of tauopathy. Neurobiol Aging &#xa0;2017; 49: 40&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">27743524</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern RA, Tripodis Y, Baugh CM, Fritts NG, Martin BM, Chaisson C, et al. &#xa0;Preliminary study of plasma exosomal tau as a potential biomarker for chronic traumatic encephalopathy. J Alzheimers Dis &#xa0;2016; 51: 1099&#x2013;109.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4833534</ArticleId><ArticleId IdType="pubmed">26890775</ArticleId></ArticleIdList></Reference><Reference><Citation>Sung BH, Ketova T, Hoshino D, Zijlstra A, Weaver AM. &#xa0;Directional cell movement through tissues is controlled by exosome secretion. Nat Commun &#xa0;2015; 6: 7164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4435734</ArticleId><ArticleId IdType="pubmed">25968605</ArticleId></ArticleIdList></Reference><Reference><Citation>van Niel G, D'Angelo G, Raposo G. &#xa0;Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol &#xa0;2018; 19: 213&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">29339798</ArticleId></ArticleIdList></Reference><Reference><Citation>Volz F, Bock HH, Gierthmuehlen M, Zentner J, Haas CA, Freiman TM. &#xa0;Stereologic estimation of hippocampal GluR2/3-and calretinin-immunoreactive hilar neurons (presumptive mossy cells) in two mouse models of temporal lobe epilepsy. Epilepsia &#xa0;2011; 52: 1579&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">21635231</ArticleId></ArticleIdList></Reference><Reference><Citation>Vossel KA, Beagle AJ, Rabinovici GD, Shu HD, Lee SE, Naasan G, et al. &#xa0;Seizures and epileptiform activity in the early stages of Alzheimer disease. Jama Neurol &#xa0;2013; 70: 1158&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4013391</ArticleId><ArticleId IdType="pubmed">23835471</ArticleId></ArticleIdList></Reference><Reference><Citation>Winston CN, Aulston B, Rockenstein EM, Adame A, Prikhodko O, Dave KN, et al. &#xa0;Neuronal exosome-derived human tau is toxic to recipient mouse neurons in vivo. J Alzheimers Dis &#xa0;2019; 67: 541&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8373009</ArticleId><ArticleId IdType="pubmed">30584143</ArticleId></ArticleIdList></Reference><Reference><Citation>Winston CN, Goetzl EJ, Akers JC, Carter BS, Rockenstein EM, Galasko D, et al. &#xa0;Prediction of conversion from mild cognitive impairment to dementia with neuronally derived blood exosome protein profile. Alzheimers Dement (Amst) &#xa0;2016; 3: 63&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4925777</ArticleId><ArticleId IdType="pubmed">27408937</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada K, Holth JK, Liao F, Stewart FR, Mahan TE, Jiang H, et al. &#xa0;Neuronal activity regulates extracellular tau in vivo. J Exp Med &#xa0;2014; 211: 387&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3949564</ArticleId><ArticleId IdType="pubmed">24534188</ArticleId></ArticleIdList></Reference><Reference><Citation>You Y, Borgmann K, Edara VV, Stacy S, Ghorpade A, Ikezu T. &#xa0;Activated human astrocyte-derived extracellular vesicles modulate neuronal uptake, differentiation and firing. J Extracell Vesicles &#xa0;2020; 9: 1706801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6968484</ArticleId><ArticleId IdType="pubmed">32002171</ArticleId></ArticleIdList></Reference><Reference><Citation>You Y, Ikezu T. &#xa0;Emerging roles of extracellular vesicles in neurodegenerative disorders. Neurobiol Dis &#xa0;2019; 130: 104512.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6689424</ArticleId><ArticleId IdType="pubmed">31229685</ArticleId></ArticleIdList></Reference><Reference><Citation>Zetterberg H, Wilson D, Andreasson U, Minthon L, Blennow K, Randall J, et al. &#xa0;Plasma tau levels in Alzheimer's disease. Alzheimers Res Ther &#xa0;2013; 5: 9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3707015</ArticleId><ArticleId IdType="pubmed">23551972</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang WJ, Tarutani A, Newell KL, Murzin AG, Matsubara T, Falcon B, et al. &#xa0;Novel tau filament fold in corticobasal degeneration. Nature &#xa0;2020; 580: 283&#x2013;287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7148158</ArticleId><ArticleId IdType="pubmed">32050258</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmer R, Teelken AW, Trieling WB, Weber W, Weihmayr T, Lauter H. &#xa0;Gamma-aminobutyric acid and homovanillic-acid concentration in the Csf of patients with senile dementia of Alzheimers type. Arch Neurol &#xa0;1984; 41: 602&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">6721733</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33247134</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>10</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Nov</Month><Day>27</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Plasma N-terminal tau fragment levels predict future cognitive decline and neurodegeneration in healthy elderly individuals.</ArticleTitle><Pagination><StartPage>6024</StartPage><MedlinePgn>6024</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">6024</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-020-19543-w</ELocationID><Abstract><AbstractText>The availability of blood-based assays detecting Alzheimer's disease (AD) pathology should greatly accelerate AD therapeutic development and improve clinical care. This is especially true for markers that capture the risk of decline in pre-symptomatic stages of AD, as this would allow one to focus interventions on participants maximally at risk and at a stage prior to widespread synapse loss and neurodegeneration. Here we quantify plasma concentrations of an N-terminal fragment of tau (NT1) in a large, well-characterized cohort of clinically normal elderly who were followed longitudinally. Plasma NT1 levels at study entry (when all participants were unimpaired) were highly predictive of future cognitive decline, pathological tau accumulation, neurodegeneration, and transition to a diagnosis of MCI/AD. These predictive effects were particularly strong in participants with even modestly elevated brain &#x3b2;-amyloid burden at study entry, suggesting plasma NT1 levels capture very early cognitive, pathologic and neurodegenerative changes along the AD trajectory.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chhatwal</LastName><ForeName>Jasmeer P</ForeName><Initials>JP</Initials><Identifier Source="ORCID">0000-0002-7792-1698</Identifier><AffiliationInfo><Affiliation>Massachusetts General Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brigham and Women's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schultz</LastName><ForeName>Aaron P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dang</LastName><ForeName>Yifan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Brigham and Women's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ostaszewski</LastName><ForeName>Beth</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Brigham and Women's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Lei</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-4604-4629</Identifier><AffiliationInfo><Affiliation>Brigham and Women's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Hyun-Sik</ForeName><Initials>HS</Initials><Identifier Source="ORCID">0000-0002-8318-0443</Identifier><AffiliationInfo><Affiliation>Massachusetts General Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brigham and Women's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brigham and Women's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, Boston, MA, USA. reisa@bwh.harvard.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brigham and Women's Hospital, Boston, MA, USA. reisa@bwh.harvard.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, USA. reisa@bwh.harvard.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Selkoe</LastName><ForeName>Dennis J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Brigham and Women's Hospital, Boston, MA, USA. dselkoe@bwh.harvard.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, USA. dselkoe@bwh.harvard.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG036694</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>2019096</GrantID><Acronym>DDCF</Acronym><Agency>Doris Duke Charitable Foundation</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG006173</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG062750</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG049087</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG071865</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG006173</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG062667</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AG035007</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG015379</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>11</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066128" MajorTopicYN="N">Gray Matter</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061212" MajorTopicYN="N">Memory, Episodic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests with regards to the content or interpretation of the data in the present study. Dr. Chhatwal has served on a medical advisory board for Otsuka Pharmaceuticals. Dr. Schultz has served on medical advisory boards for Janssen Pharmaceuticals and Biogen. Drs Sperling and Johnson are involved in public&#x2013;private partnership clinical trials sponsored by the NIH and Eli Lilly and Co., who owns the distribution rights to Flortaucipir (AV-1451), but they do not have any personal financial relationship with Eli Lilly. Dr. Selkoe is a director and consultant for Prothena Biosciences.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>6</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>10</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>11</Month><Day>28</Day><Hour>5</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>11</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33247134</ArticleId><ArticleId IdType="pmc">PMC7695712</ArticleId><ArticleId IdType="doi">10.1038/s41467-020-19543-w</ArticleId><ArticleId IdType="pii">10.1038/s41467-020-19543-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sperling RA, et al. Toward defining the preclinical stages of Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimer&#x2019;s Dement. 2011;7:280&#x2013;292. doi: 10.1016/j.jalz.2011.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.03.003</ArticleId><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr., et al. NIA-AA Research Framework: toward a biological definition of Alzheimer&#x2019;s disease. Alzheimers Dement. 2018;14:535&#x2013;562. doi: 10.1016/j.jalz.2018.02.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.02.018</ArticleId><ArticleId IdType="pmc">PMC5958625</ArticleId><ArticleId IdType="pubmed">29653606</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura A, et al. High performance plasma amyloid-&#x3b2; biomarkers for Alzheimer&#x2019;s disease. Nature. 2018;554:249&#x2013;254. doi: 10.1038/nature25456.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature25456</ArticleId><ArticleId IdType="pubmed">29420472</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindler SE, et al. High-precision plasma beta-amyloid 42/40 predicts current and future brain amyloidosis. Neurology. 2019;93:e1647&#x2013;e1659.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6946467</ArticleId><ArticleId IdType="pubmed">31371569</ArticleId></ArticleIdList></Reference><Reference><Citation>Mielke MM, et al. Plasma phospho-tau181 increases with Alzheimer&#x2019;s disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimers Dement. 2018;14:989&#x2013;997. doi: 10.1016/j.jalz.2018.02.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.02.013</ArticleId><ArticleId IdType="pmc">PMC6097897</ArticleId><ArticleId IdType="pubmed">29626426</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino E, et al. Short-term predictors of clinical progression in the Harvard Aging Brain Study. Alzheimer&#x2019;s Dement. 2013;9:P28. doi: 10.1016/j.jalz.2013.05.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2013.05.038</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnham SC, et al. Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer&#x2019;s disease pathophysiology (SNAP) or Alzheimer&#x2019;s disease pathology: a longitudinal study. Lancet Neurol. 2016;15:1044&#x2013;1053. doi: 10.1016/S1474-4422(16)30125-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(16)30125-9</ArticleId><ArticleId IdType="pubmed">27450471</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, et al. Association of elevated amyloid levels with cognition and biomarkers in cognitively normal people from the community. JAMA Neurol. 2016;73:85&#x2013;92. doi: 10.1001/jamaneurol.2015.3098.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2015.3098</ArticleId><ArticleId IdType="pmc">PMC4710552</ArticleId><ArticleId IdType="pubmed">26595683</ArticleId></ArticleIdList></Reference><Reference><Citation>Pase MP, et al. Assessment of plasma total tau level as a predictive biomarker for dementia and related endophenotypes. JAMA Neurol. 2019;76:598&#x2013;606. doi: 10.1001/jamaneurol.2018.4666.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2018.4666</ArticleId><ArticleId IdType="pmc">PMC6515589</ArticleId><ArticleId IdType="pubmed">30830207</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, et al. Plasma P-tau181 in Alzheimer&#x2019;s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer&#x2019;s dementia. Nat. Med. 2020;26:379&#x2013;386. doi: 10.1038/s41591-020-0755-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0755-1</ArticleId><ArticleId IdType="pubmed">32123385</ArticleId></ArticleIdList></Reference><Reference><Citation>Karikari TK, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer&#x2019;s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19:422&#x2013;433. doi: 10.1016/S1474-4422(20)30071-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(20)30071-5</ArticleId><ArticleId IdType="pubmed">32333900</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, et al. Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer&#x2019;s disease. Nat. Commun. 2020;11:1683. doi: 10.1038/s41467-020-15436-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-15436-0</ArticleId><ArticleId IdType="pmc">PMC7125218</ArticleId><ArticleId IdType="pubmed">32246036</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist, S. et al. Discriminative accuracy of plasma Phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA324, 772&#x2013;781 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7388060</ArticleId><ArticleId IdType="pubmed">32722745</ArticleId></ArticleIdList></Reference><Reference><Citation>De Wolf F, et al. Plasma tau, neurofilament light chain and amyloid-&#x3b2; levels and risk of dementia; a population-based cohort study. Brain. 2020;143:1220&#x2013;1232. doi: 10.1093/brain/awaa054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa054</ArticleId><ArticleId IdType="pmc">PMC7174054</ArticleId><ArticleId IdType="pubmed">32206776</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Cullen NC, Andreasson U, Zetterberg H, Blennow K. Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 2019;76:791&#x2013;799. doi: 10.1001/jamaneurol.2019.0765.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.0765</ArticleId><ArticleId IdType="pmc">PMC6583067</ArticleId><ArticleId IdType="pubmed">31009028</ArticleId></ArticleIdList></Reference><Reference><Citation>Jakimovski, D. et al. Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: a longitudinal retrospective 5-year study. Mult. Scler.10.1177/1352458519881428 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31610732</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin M, Cao L, Dai YP. Role of neurofilament light chain as a potential biomarker for Alzheimer&#x2019;s disease: a correlative meta-analysis. Front. Aging Neurosci. 2019;11:254. doi: 10.3389/fnagi.2019.00254.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2019.00254</ArticleId><ArticleId IdType="pmc">PMC6753203</ArticleId><ArticleId IdType="pubmed">31572170</ArticleId></ArticleIdList></Reference><Reference><Citation>Molinuevo JL, et al. Current state of Alzheimer&#x2019;s fluid biomarkers. Acta Neuropathologica. 2018;136:821&#x2013;853. doi: 10.1007/s00401-018-1932-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1932-x</ArticleId><ArticleId IdType="pmc">PMC6280827</ArticleId><ArticleId IdType="pubmed">30488277</ArticleId></ArticleIdList></Reference><Reference><Citation>Forgrave LM, Ma M, Best JR, DeMarco ML. The diagnostic performance of neurofilament light chain in CSF and blood for Alzheimer&#x2019;s disease, frontotemporal dementia, and amyotrophic lateral sclerosis: a systematic review and meta-analysis. Alzheimers Dement. 2019;11:730&#x2013;743.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6939029</ArticleId><ArticleId IdType="pubmed">31909174</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z, et al. Learnings about the complexity of extracellular tau aid development of a blood-based screen for Alzheimer&#x2019;s disease. Alzheimers Dement. 2019;15:487&#x2013;496. doi: 10.1016/j.jalz.2018.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.09.010</ArticleId><ArticleId IdType="pmc">PMC6476313</ArticleId><ArticleId IdType="pubmed">30419228</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato C, et al. Tau kinetics in neurons and the human central nervous system. Neuron. 2018;98:861&#x2013;864. doi: 10.1016/j.neuron.2018.04.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.04.035</ArticleId><ArticleId IdType="pmc">PMC6192252</ArticleId><ArticleId IdType="pubmed">29772204</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanmert D, et al. C-Terminally truncated forms of tau, but not full-length tau or its c-terminal fragments, are released from neurons independently of cell death. J. Neurosci. 2015;35:10851&#x2013;10865. doi: 10.1523/JNEUROSCI.0387-15.2015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0387-15.2015</ArticleId><ArticleId IdType="pmc">PMC6605107</ArticleId><ArticleId IdType="pubmed">26224867</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacioglu M, et al. Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases. Neuron. 2016;91:56&#x2013;66. doi: 10.1016/j.neuron.2016.05.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.05.018</ArticleId><ArticleId IdType="pubmed">27292537</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhle J, et al. Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity. Mult. Scler. 2016;22:1550&#x2013;1559. doi: 10.1177/1352458515623365.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1352458515623365</ArticleId><ArticleId IdType="pubmed">26754800</ArticleId></ArticleIdList></Reference><Reference><Citation>Papp KV, Rentz DM, Orlovsky I, Sperling RA, Mormino EC. Optimizing the preclinical Alzheimer&#x2019;s cognitive composite with semantic processing: The PACC5. Alzheimers Dement. 2017;3:668&#x2013;677. doi: 10.1016/j.trci.2017.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trci.2017.10.004</ArticleId><ArticleId IdType="pmc">PMC5726754</ArticleId><ArticleId IdType="pubmed">29264389</ArticleId></ArticleIdList></Reference><Reference><Citation>Donohue MC, et al. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol. 2014;71:961&#x2013;970. doi: 10.1001/jamaneurol.2014.803.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.803</ArticleId><ArticleId IdType="pmc">PMC4439182</ArticleId><ArticleId IdType="pubmed">24886908</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabin JS, et al. Vascular risk and &#x3b2;&#x2010;amyloid are synergistically associated with cortical tau. Ann. Neurol. 2019;85:272&#x2013;279. doi: 10.1002/ana.25399.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25399</ArticleId><ArticleId IdType="pmc">PMC6351182</ArticleId><ArticleId IdType="pubmed">30565287</ArticleId></ArticleIdList></Reference><Reference><Citation>Dagley A, et al. Harvard Aging Brain Study: dataset and accessibility. NeuroImage. 2017;144:255&#x2013;258. doi: 10.1016/j.neuroimage.2015.03.069.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2015.03.069</ArticleId><ArticleId IdType="pmc">PMC4592689</ArticleId><ArticleId IdType="pubmed">25843019</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann. Neurol. 2016;79:110&#x2013;119. doi: 10.1002/ana.24546.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24546</ArticleId><ArticleId IdType="pmc">PMC4738026</ArticleId><ArticleId IdType="pubmed">26505746</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson PO, Fay LC. The Johnson-Neyman technique, its theory and application. Psychometrika. 1950;15:349&#x2013;367. doi: 10.1007/BF02288864.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF02288864</ArticleId><ArticleId IdType="pubmed">14797902</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauer DJ, Curran PJ. Probing interactions in fixed and multilevel regression: inferential and graphical techniques. Multivar. Behav. Res. 2005;40:373&#x2013;400. doi: 10.1207/s15327906mbr4003_5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1207/s15327906mbr4003_5</ArticleId><ArticleId IdType="pubmed">26794689</ArticleId></ArticleIdList></Reference><Reference><Citation>Edwards TL, et al. A general framework for formal tests of interaction after exhaustive search methods with applications to MDR and MDR-PDT. PLoS ONE. 2010;5:e9363. doi: 10.1371/journal.pone.0009363.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0009363</ArticleId><ArticleId IdType="pmc">PMC2826406</ArticleId><ArticleId IdType="pubmed">20186329</ArticleId></ArticleIdList></Reference><Reference><Citation>Barro C, et al. Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. Brain. 2018;141:2382&#x2013;2391. doi: 10.1093/brain/awy154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awy154</ArticleId><ArticleId IdType="pubmed">29860296</ArticleId></ArticleIdList></Reference><Reference><Citation>Preische O, et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer&#x2019;s disease. Nat. Med. 2019;25:277&#x2013;283. doi: 10.1038/s41591-018-0304-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-018-0304-3</ArticleId><ArticleId IdType="pmc">PMC6367005</ArticleId><ArticleId IdType="pubmed">30664784</ArticleId></ArticleIdList></Reference><Reference><Citation>Bridel C, et al. Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis. JAMA Neurol. 2019;76:1035&#x2013;1048. doi: 10.1001/jamaneurol.2019.1534.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.1534</ArticleId><ArticleId IdType="pmc">PMC6580449</ArticleId><ArticleId IdType="pubmed">31206160</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, et al. Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer&#x2019;s disease. EMBO Mol. Med. 2019;11:e11170. doi: 10.15252/emmm.201911170.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201911170</ArticleId><ArticleId IdType="pmc">PMC6895602</ArticleId><ArticleId IdType="pubmed">31709776</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Mattsson N, Hansson O, Initiative ADN. Cerebrospinal fluid analysis detects cerebral amyloid-&#x3b2; accumulation earlier than positron emission tomography. Brain. 2016;139:1226&#x2013;1236. doi: 10.1093/brain/aww015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww015</ArticleId><ArticleId IdType="pmc">PMC4806222</ArticleId><ArticleId IdType="pubmed">26936941</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, et al. Earliest accumulation of &#x3b2;-amyloid occurs within the default-mode network and concurrently affects brain connectivity. Nat. Commun. 2017;8:1214. doi: 10.1038/s41467-017-01150-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-01150-x</ArticleId><ArticleId IdType="pmc">PMC5663717</ArticleId><ArticleId IdType="pubmed">29089479</ArticleId></ArticleIdList></Reference><Reference><Citation>Thijssen EH, et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer&#x2019;s disease and frontotemporal lobar degeneration. Nat. Med. 2020;26:387&#x2013;397. doi: 10.1038/s41591-020-0762-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0762-2</ArticleId><ArticleId IdType="pmc">PMC7101073</ArticleId><ArticleId IdType="pubmed">32123386</ArticleId></ArticleIdList></Reference><Reference><Citation>Fortea J, et al. Cerebrospinal fluid beta-amyloid and phospho-tau biomarker interactions affecting brain structure in preclinical Alzheimer disease. Ann. Neurol. 2014;76:223&#x2013;230. doi: 10.1002/ana.24186.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24186</ArticleId><ArticleId IdType="pubmed">24852682</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, et al. Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. Neurology. 2015;85:1240&#x2013;1249. doi: 10.1212/WNL.0000000000001991.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000001991</ArticleId><ArticleId IdType="pmc">PMC4607601</ArticleId><ArticleId IdType="pubmed">26354982</ArticleId></ArticleIdList></Reference><Reference><Citation>Insel PS, Donohue MC, Sperling R, Hansson O, Mattsson-Carlgren N. The A4 study: beta-amyloid and cognition in 4432 cognitively unimpaired adults. Ann. Clin. Transl. Neurol. 2020;7:776&#x2013;785. doi: 10.1002/acn3.51048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51048</ArticleId><ArticleId IdType="pmc">PMC7261742</ArticleId><ArticleId IdType="pubmed">32315118</ArticleId></ArticleIdList></Reference><Reference><Citation>Papp KV, et al. Clinical meaningfulness of subtle cognitive decline on longitudinal testing in preclinical AD. Alzheimer&#x2019;s Dement. 2020;16:552&#x2013;560. doi: 10.1016/j.jalz.2019.09.074.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2019.09.074</ArticleId><ArticleId IdType="pmc">PMC7067681</ArticleId><ArticleId IdType="pubmed">31759879</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu H, et al. Neurofilament light chain plasma concentration predicts neurodegeneration and clinical progression in nondemented elderly adults. Aging. 2019;11:6904&#x2013;6914. doi: 10.18632/aging.102220.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.102220</ArticleId><ArticleId IdType="pmc">PMC6756875</ArticleId><ArticleId IdType="pubmed">31514172</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, et al. Potential value of plasma amyloid-beta, total tau, and neurofilament light for identification of early Alzheimer&#x2019;s disease. ACS Chem. Neurosci. 2019;10:3479&#x2013;3485. doi: 10.1021/acschemneuro.9b00095.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.9b00095</ArticleId><ArticleId IdType="pubmed">31145586</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, Xin Y, Meng S, He Z, Hu W. Neurofilament light chain protein in neurodegenerative dementia: a systematic review and network meta-analysis. Neurosci. Biobehav. Rev. 2019;102:123&#x2013;138. doi: 10.1016/j.neubiorev.2019.04.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neubiorev.2019.04.014</ArticleId><ArticleId IdType="pubmed">31026486</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewczuk P, et al. Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer&#x2019;s disease. Alzheimers Res. Ther. 2018;10:71. doi: 10.1186/s13195-018-0404-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-018-0404-9</ArticleId><ArticleId IdType="pmc">PMC6064615</ArticleId><ArticleId IdType="pubmed">30055655</ArticleId></ArticleIdList></Reference><Reference><Citation>Fyfe I. Alzheimer disease: neurofilament light in the blood marks Alzheimer degeneration. Nat. Rev. Neurol. 2017;13:257. doi: 10.1038/nrneurol.2017.57.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2017.57</ArticleId><ArticleId IdType="pubmed">28418024</ArticleId></ArticleIdList></Reference><Reference><Citation>de Jong D, et al. CSF neurofilament proteins in the differential diagnosis of dementia. J. Neurol. Neurosurg. Psychiatry. 2007;78:936&#x2013;938. doi: 10.1136/jnnp.2006.107326.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2006.107326</ArticleId><ArticleId IdType="pmc">PMC2117885</ArticleId><ArticleId IdType="pubmed">17314187</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 1975;12:189&#x2013;198. doi: 10.1016/0022-3956(75)90026-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-3956(75)90026-6</ArticleId><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Weschler, D. WAIS-R Manual: Wechsler Adult Intelligence Scale-revised (Psychological Corporation, 1981).</Citation></Reference><Reference><Citation>Weschler, D. WMS-R: Weschler Memory Scale-Revised manual (Psychological Corporation/HBJ, New York, 1987).</Citation></Reference><Reference><Citation>Grober E, Lipton RB, Hall C, Crystal H. Memory impairment on free and cued selective reminding predicts dementia. Neurology. 2000;54:827&#x2013;832. doi: 10.1212/WNL.54.4.827.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.54.4.827</ArticleId><ArticleId IdType="pubmed">10690971</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann. Neurol. 2007;62:229&#x2013;234. doi: 10.1002/ana.21164.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21164</ArticleId><ArticleId IdType="pubmed">17683091</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, et al. Synergistic effect of &#x3b2;-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. JAMA Neurol. 2014;71:1379&#x2013;1385. doi: 10.1001/jamaneurol.2014.2031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.2031</ArticleId><ArticleId IdType="pmc">PMC4293023</ArticleId><ArticleId IdType="pubmed">25222039</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabin JS, et al. Interactive associations of vascular risk and beta-amyloid burden with cognitive decline in clinically normal elderly individuals: findings from the Harvard Aging Brain Study. JAMA Neurol. 2018;75:1124&#x2013;1131. doi: 10.1001/jamaneurol.2018.1123.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2018.1123</ArticleId><ArticleId IdType="pmc">PMC6143121</ArticleId><ArticleId IdType="pubmed">29799986</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabin JS, et al. Associations of physical activity and beta-amyloid with longitudinal cognition and neurodegeneration in clinically normal older adults. JAMA Neurol. 2019;76:1203. doi: 10.1001/jamaneurol.2019.1879.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.1879</ArticleId><ArticleId IdType="pmc">PMC6635892</ArticleId><ArticleId IdType="pubmed">31312836</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, et al. The impact of amyloid-beta and tau on prospective cognitive decline in older individuals. Ann. Neurol. 2019;85:181&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6402593</ArticleId><ArticleId IdType="pubmed">30549303</ArticleId></ArticleIdList></Reference><Reference><Citation>Rousset OG, Ma Y, Evans AC. Correction for partial volume effects in PET: principle and validation. J. Nucl. Med. 1998;39:904&#x2013;911.</Citation><ArticleIdList><ArticleId IdType="pubmed">9591599</ArticleId></ArticleIdList></Reference><Reference><Citation>Reuter M, Schmansky NJ, Rosas HD, Fischl B. Within-subject template estimation for unbiased longitudinal image analysis. Neuroimage. 2012;61:1402&#x2013;1418. doi: 10.1016/j.neuroimage.2012.02.084.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2012.02.084</ArticleId><ArticleId IdType="pmc">PMC3389460</ArticleId><ArticleId IdType="pubmed">22430496</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YS, Lee WJ, Wang SJ, Fuh JL. Levels of plasma neurofilament light chain and cognitive function in patients with Alzheimer or Parkinson disease. Sci. Rep. 2018;8:17368. doi: 10.1038/s41598-018-35766-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-35766-w</ArticleId><ArticleId IdType="pmc">PMC6255914</ArticleId><ArticleId IdType="pubmed">30478269</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Agostino RB, Sr., et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117:743&#x2013;753. doi: 10.1161/CIRCULATIONAHA.107.699579.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.107.699579</ArticleId><ArticleId IdType="pubmed">18212285</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraus JF, Borhani NO, Franti CE. Socioeconomic status, ethnicity, and risk of coronary heart disease. Am. J. Epidemiol. 1980;111:407&#x2013;414. doi: 10.1093/oxfordjournals.aje.a112915.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/oxfordjournals.aje.a112915</ArticleId><ArticleId IdType="pubmed">7377183</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33257666</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>21</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>31</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Nov</Month><Day>30</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Single cell RNA sequencing of human microglia uncovers a subset associated with Alzheimer's disease.</ArticleTitle><Pagination><StartPage>6129</StartPage><MedlinePgn>6129</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">6129</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-020-19737-2</ELocationID><Abstract><AbstractText>The extent of microglial heterogeneity in humans remains a central yet poorly explored question in light of the development of therapies targeting this cell type. Here, we investigate the population structure of live microglia purified from human cerebral cortex samples obtained at autopsy and during neurosurgical procedures. Using single cell RNA sequencing, we find that some subsets are enriched for disease-related genes and RNA signatures. We confirm the presence of four of these microglial subpopulations histologically and illustrate the utility of our data by characterizing further microglial cluster 7, enriched for genes depleted in the cortex of individuals with Alzheimer's disease (AD). Histologically, these cluster 7 microglia are reduced in frequency in AD tissue, and we validate this observation in an independent set of single nucleus data. Thus, our live human microglia identify a range of subtypes, and we prioritize one of these as being altered in AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Olah</LastName><ForeName>Marta</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-4945-855X</Identifier><AffiliationInfo><Affiliation>Center for Translational and Computational Neuroimmunology, Columbia University Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and Aging Brain, Columbia University Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Columbia University Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cell Circuits Program, Broad Institute, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Menon</LastName><ForeName>Vilas</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-4096-8601</Identifier><AffiliationInfo><Affiliation>Center for Translational and Computational Neuroimmunology, Columbia University Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and Aging Brain, Columbia University Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Columbia University Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cell Circuits Program, Broad Institute, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Habib</LastName><ForeName>Naomi</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-6049-2487</Identifier><AffiliationInfo><Affiliation>Cell Circuits Program, Broad Institute, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Edmond &amp; Lily Safra Center for Brain Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taga</LastName><ForeName>Mariko F</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Center for Translational and Computational Neuroimmunology, Columbia University Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and Aging Brain, Columbia University Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Columbia University Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cell Circuits Program, Broad Institute, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Yiyi</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-3609-8877</Identifier><AffiliationInfo><Affiliation>Center for Translational and Computational Neuroimmunology, Columbia University Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and Aging Brain, Columbia University Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Columbia University Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cell Circuits Program, Broad Institute, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yung</LastName><ForeName>Christina J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Center for Translational and Computational Neuroimmunology, Columbia University Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cimpean</LastName><ForeName>Maria</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-3735-2643</Identifier><AffiliationInfo><Affiliation>Center for Translational and Computational Neuroimmunology, Columbia University Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khairallah</LastName><ForeName>Anthony</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Translational and Computational Neuroimmunology, Columbia University Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coronas-Samano</LastName><ForeName>Guillermo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and Aging Brain, Columbia University Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sankowski</LastName><ForeName>Roman</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-9215-8021</Identifier><AffiliationInfo><Affiliation>Institute of Neuropathology, Medical Faculty, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Berta-Ottenstein-Programme for Clinician Scientists, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gr&#xfc;n</LastName><ForeName>Dominic</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Max-Planck-Institute of Immunobiology and Epigenetics, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kroshilina</LastName><ForeName>Alexandra A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Center for Translational and Computational Neuroimmunology, Columbia University Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dionne</LastName><ForeName>Danielle</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-8338-4323</Identifier><AffiliationInfo><Affiliation>Cell Circuits Program, Broad Institute, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarkis</LastName><ForeName>Rani A</ForeName><Initials>RA</Initials><Identifier Source="ORCID">0000-0001-8291-7864</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cosgrove</LastName><ForeName>Garth R</ForeName><Initials>GR</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Helgager</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Golden</LastName><ForeName>Jeffrey A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pennell</LastName><ForeName>Page B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prinz</LastName><ForeName>Marco</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0349-1955</Identifier><AffiliationInfo><Affiliation>Institute of Neuropathology, Medical Faculty, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Signaling Research Centers BIOSS and CIBSS, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for NeuroModulation, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vonsattel</LastName><ForeName>Jean Paul G</ForeName><Initials>JPG</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and Aging Brain, Columbia University Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teich</LastName><ForeName>Andrew F</ForeName><Initials>AF</Initials><Identifier Source="ORCID">0000-0002-1916-8490</Identifier><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and Aging Brain, Columbia University Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Columbia University Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Regev</LastName><ForeName>Aviv</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-3293-3158</Identifier><AffiliationInfo><Affiliation>Cell Circuits Program, Broad Institute, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Klarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, Department of Biology, MIT, Cambridge, MA, 02140, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Genentech, 1 DNA Way, South San Francisco, CA, 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elyaman</LastName><ForeName>Wassim</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and Aging Brain, Columbia University Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Columbia University Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cell Circuits Program, Broad Institute, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bradshaw</LastName><ForeName>Elizabeth M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and Aging Brain, Columbia University Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Columbia University Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cell Circuits Program, Broad Institute, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Jager</LastName><ForeName>Philip L</ForeName><Initials>PL</Initials><Identifier Source="ORCID">0000-0002-8057-2505</Identifier><AffiliationInfo><Affiliation>Center for Translational and Computational Neuroimmunology, Columbia University Medical Center, New York, NY, USA. pld2115@cumc.columbia.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and Aging Brain, Columbia University Medical Center, New York, NY, USA. pld2115@cumc.columbia.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Columbia University Medical Center, New York, NY, USA. pld2115@cumc.columbia.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cell Circuits Program, Broad Institute, Cambridge, MA, USA. pld2115@cumc.columbia.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS113516</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG046152</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 NS089674</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG008702</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066462</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG058852</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG057473</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG048015</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS089674</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG036836</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>11</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D022423" MajorTopicYN="N">Myeloid Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017423" MajorTopicYN="N">Sequence Analysis, RNA</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>A.R. is a co-founder and equity holder of Celsius Therapeutics, an equity holder in Immunitas, and was an SAB member of ThermoFisher Scientific, Syros Pharmaceuticals, Neogene Therapeutics and Asimov. From August 1, 2020, A.R. is now an employee of Genentech. All&#xa0;other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>8</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>10</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>12</Month><Day>1</Day><Hour>5</Hour><Minute>56</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>12</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>11</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33257666</ArticleId><ArticleId IdType="pmc">PMC7704703</ArticleId><ArticleId IdType="doi">10.1038/s41467-020-19737-2</ArticleId><ArticleId IdType="pii">10.1038/s41467-020-19737-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Stevens B., &amp; Schafer D. P. Roles of microglia in nervous system development, plasticity, and disease. Dev. Neurobiol. 78, 559&#x2013;560 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29704318</ArticleId></ArticleIdList></Reference><Reference><Citation>Kierdorf K, Prinz M. Microglia in steady state. J. Clin. Invest. 2017;127:3201&#x2013;3209. doi: 10.1172/JCI90602.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI90602</ArticleId><ArticleId IdType="pmc">PMC5669563</ArticleId><ArticleId IdType="pubmed">28714861</ArticleId></ArticleIdList></Reference><Reference><Citation>Galatro TF, et al. Transcriptomic analysis of purified human cortical microglia reveals age-associated changes. Nat. Neurosci. 2017;20:1162&#x2013;1171. doi: 10.1038/nn.4597.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4597</ArticleId><ArticleId IdType="pubmed">28671693</ArticleId></ArticleIdList></Reference><Reference><Citation>Gosselin, D. et al. An environment-dependent transcriptional network specifies human microglia identity. Science356, eaal3222 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5858585</ArticleId><ArticleId IdType="pubmed">28546318</ArticleId></ArticleIdList></Reference><Reference><Citation>Olah M, et al. A transcriptomic atlas of aged human microglia. Nat. Commun. 2018;9:539. doi: 10.1038/s41467-018-02926-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-02926-5</ArticleId><ArticleId IdType="pmc">PMC5803269</ArticleId><ArticleId IdType="pubmed">29416036</ArticleId></ArticleIdList></Reference><Reference><Citation>Patrick, E. et al. A cortical immune network map identifies a subset of human microglia involved in Tau pathology. bioRxiv10.1101/234351 (2017).</Citation></Reference><Reference><Citation>Habib N, et al. Massively parallel single-nucleus RNA-seq with DroNc-seq. Nat. Methods. 2017;14:955&#x2013;958. doi: 10.1038/nmeth.4407.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.4407</ArticleId><ArticleId IdType="pmc">PMC5623139</ArticleId><ArticleId IdType="pubmed">28846088</ArticleId></ArticleIdList></Reference><Reference><Citation>Del-Aguila, J. L. et al. A single-nuclei RNA sequencing study of Mendelian and sporadic AD in the human brain. bioRxiv10.1101/593756 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6689177</ArticleId><ArticleId IdType="pubmed">31399126</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys, H. et al. Single-cell transcriptomic analysis of Alzheimer&#x2019;s disease. Nature570, 332&#x2013;337 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6865822</ArticleId><ArticleId IdType="pubmed">31042697</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen IE, et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer&#x2019;s disease risk. Nat. Genet. 2019;51:404&#x2013;413. doi: 10.1038/s41588-018-0311-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-018-0311-9</ArticleId><ArticleId IdType="pmc">PMC6836675</ArticleId><ArticleId IdType="pubmed">30617256</ArticleId></ArticleIdList></Reference><Reference><Citation>Sims R, et al. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer&#x2019;s disease. Nat. Genet. 2017;49:1373&#x2013;1384. doi: 10.1038/ng.3916.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3916</ArticleId><ArticleId IdType="pmc">PMC5669039</ArticleId><ArticleId IdType="pubmed">28714976</ArticleId></ArticleIdList></Reference><Reference><Citation>Raj T, et al. Polarization of the effects of autoimmune and neurodegenerative risk alleles in leukocytes. Science. 2014;344:519&#x2013;523. doi: 10.1126/science.1249547.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1249547</ArticleId><ArticleId IdType="pmc">PMC4910825</ArticleId><ArticleId IdType="pubmed">24786080</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, et al. Religious orders study and rush memory and aging project. J. Alzheimers Dis. 2018;64:S161&#x2013;S189. doi: 10.3233/JAD-179939.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-179939</ArticleId><ArticleId IdType="pmc">PMC6380522</ArticleId><ArticleId IdType="pubmed">29865057</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, et al. The Rush Memory and Aging Project: study design and baseline characteristics of the study cohort. Neuroepidemiology. 2005;25:163&#x2013;175. doi: 10.1159/000087446.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000087446</ArticleId><ArticleId IdType="pubmed">16103727</ArticleId></ArticleIdList></Reference><Reference><Citation>Blondel VD, et al. Local leaders in random networks. Phys. Rev. E Stat. Nonlin. Soft Matter Phys. 2008;77:036114. doi: 10.1103/PhysRevE.77.036114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1103/PhysRevE.77.036114</ArticleId><ArticleId IdType="pubmed">18517468</ArticleId></ArticleIdList></Reference><Reference><Citation>Shekhar K, et al. Comprehensive classification of retinal bipolar neurons by single-cell transcriptomics. Cell. 2016;166:1308&#x2013;1323.e1330. doi: 10.1016/j.cell.2016.07.054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.07.054</ArticleId><ArticleId IdType="pmc">PMC5003425</ArticleId><ArticleId IdType="pubmed">27565351</ArticleId></ArticleIdList></Reference><Reference><Citation>Pouyan, M. B. &amp; Kostka, D. Random forest based similarity learning for single cell RNA sequencing data. bioRxiv10.1101/258699 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6022547</ArticleId><ArticleId IdType="pubmed">29950006</ArticleId></ArticleIdList></Reference><Reference><Citation>Tasic B, et al. Adult mouse cortical cell taxonomy revealed by single cell transcriptomics. Nat. Neurosci. 2016;19:335&#x2013;346. doi: 10.1038/nn.4216.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4216</ArticleId><ArticleId IdType="pmc">PMC4985242</ArticleId><ArticleId IdType="pubmed">26727548</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Brink, S. C. S. et al. A. Single-cell sequencing reveals dissociation-induced gene expression in tissue subpopulations. Nat. Methods14, 935&#x2013;936 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28960196</ArticleId></ArticleIdList></Reference><Reference><Citation>Roider HG, et al. PASTAA: identifying transcription factors associated with sets of co-regulated genes. Bioinformatics. 2009;25:435&#x2013;442. doi: 10.1093/bioinformatics/btn627.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btn627</ArticleId><ArticleId IdType="pmc">PMC2642637</ArticleId><ArticleId IdType="pubmed">19073590</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabregat A, et al. The Reactome pathway knowledgebase. Nucleic Acids Res. 2016;44:D481&#x2013;D487. doi: 10.1093/nar/gkv1351.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkv1351</ArticleId><ArticleId IdType="pmc">PMC4702931</ArticleId><ArticleId IdType="pubmed">26656494</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H, et al. Temporal tracking of microglia activation in neurodegeneration at single-cell resolution. Cell Rep. 2017;21:366&#x2013;380. doi: 10.1016/j.celrep.2017.09.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2017.09.039</ArticleId><ArticleId IdType="pmc">PMC5642107</ArticleId><ArticleId IdType="pubmed">29020624</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman BA, et al. Diverse brain myeloid expression profiles reveal distinct microglial activation states and aspects of Alzheimer&#x2019;s disease not evident in mouse models. Cell Rep. 2018;22:832&#x2013;847. doi: 10.1016/j.celrep.2017.12.066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2017.12.066</ArticleId><ArticleId IdType="pubmed">29346778</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H, et al. A unique microglia type associated with restricting development of Alzheimer&#x2019;s disease. Cell. 2017;169:1276&#x2013;1290.e1217. doi: 10.1016/j.cell.2017.05.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.05.018</ArticleId><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Sankowski R, et al. Mapping microglia states in the human brain through the integration of high-dimensional techniques. Nat. Neurosci. 2019;22:2098&#x2013;2110. doi: 10.1038/s41593-019-0532-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-019-0532-y</ArticleId><ArticleId IdType="pubmed">31740814</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu G, et al. DOSE: an R/Bioconductor package for disease ontology semantic and enrichment analysis. Bioinformatics. 2015;31:608&#x2013;609. doi: 10.1093/bioinformatics/btu684.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btu684</ArticleId><ArticleId IdType="pubmed">25677125</ArticleId></ArticleIdList></Reference><Reference><Citation>Mostafavi S, et al. A molecular network of the aging human brain provides insights into the pathology and cognitive decline of Alzheimer&#x2019;s disease. Nat. Neurosci. 2018;21:811&#x2013;819. doi: 10.1038/s41593-018-0154-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0154-9</ArticleId><ArticleId IdType="pmc">PMC6599633</ArticleId><ArticleId IdType="pubmed">29802388</ArticleId></ArticleIdList></Reference><Reference><Citation>Plaisier SB, et al. Rank-rank hypergeometric overlap: identification of statistically significant overlap between gene-expression signatures. Nucleic Acids Res. 2010;38:e169. doi: 10.1093/nar/gkq636.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkq636</ArticleId><ArticleId IdType="pmc">PMC2943622</ArticleId><ArticleId IdType="pubmed">20660011</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu L, et al. Residual decline in cognition after adjustment for common neuropathologic conditions. Neuropsychology. 2015;29:335&#x2013;343. doi: 10.1037/neu0000159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/neu0000159</ArticleId><ArticleId IdType="pmc">PMC4420708</ArticleId><ArticleId IdType="pubmed">25495832</ArticleId></ArticleIdList></Reference><Reference><Citation>White CC, et al. Identification of genes associated with dissociation of cognitive performance and neuropathological burden: multistep analysis of genetic, epigenetic, and transcriptional data. PLoS Med. 2017;14:e1002287. doi: 10.1371/journal.pmed.1002287.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1002287</ArticleId><ArticleId IdType="pmc">PMC5404753</ArticleId><ArticleId IdType="pubmed">28441426</ArticleId></ArticleIdList></Reference><Reference><Citation>Felsky D, et al. Neuropathological correlates and genetic architecture of microglial activation in elderly human brain. Nat. Commun. 2019;10:409. doi: 10.1038/s41467-018-08279-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-08279-3</ArticleId><ArticleId IdType="pmc">PMC6345810</ArticleId><ArticleId IdType="pubmed">30679421</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano-Pozo A, et al. A phenotypic change but not proliferation underlies glial responses in Alzheimer disease. Am. J. Pathol. 2013;182:2332&#x2013;2344. doi: 10.1016/j.ajpath.2013.02.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2013.02.031</ArticleId><ArticleId IdType="pmc">PMC3668030</ArticleId><ArticleId IdType="pubmed">23602650</ArticleId></ArticleIdList></Reference><Reference><Citation>Karpagam Srinivasank, B. A. F. et al. Alzheimer&#x2019;s patient brain myeloid cells exhibit enhanced aging and unique transcriptional activation. bioRxiv10.1101/610345 (2019).</Citation></Reference><Reference><Citation>Bennett DA, et al. Overview and findings from the rush Memory and Aging Project. Curr. Alzheimer Res. 2012;9:646&#x2013;663. doi: 10.2174/156720512801322663.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720512801322663</ArticleId><ArticleId IdType="pmc">PMC3439198</ArticleId><ArticleId IdType="pubmed">22471867</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, et al. Overview and findings from the religious orders study. Curr. Alzheimer Res. 2012;9:628&#x2013;645. doi: 10.2174/156720512801322573.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720512801322573</ArticleId><ArticleId IdType="pmc">PMC3409291</ArticleId><ArticleId IdType="pubmed">22471860</ArticleId></ArticleIdList></Reference><Reference><Citation>Vonsattel JP, et al. Twenty-first century brain banking: practical prerequisites and lessons from the past: the experience of New York Brain Bank, Taub Institute, Columbia University. Cell Tissue Bank. 2008;9:247&#x2013;258. doi: 10.1007/s10561-008-9079-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10561-008-9079-y</ArticleId><ArticleId IdType="pmc">PMC2847415</ArticleId><ArticleId IdType="pubmed">18581261</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler A, et al. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 2018;36:411&#x2013;420. doi: 10.1038/nbt.4096.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.4096</ArticleId><ArticleId IdType="pmc">PMC6700744</ArticleId><ArticleId IdType="pubmed">29608179</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuart T, et al. Comprehensive integration of single-cell data. Cell. 2019;177:1888&#x2013;1902.e1821. doi: 10.1016/j.cell.2019.05.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2019.05.031</ArticleId><ArticleId IdType="pmc">PMC6687398</ArticleId><ArticleId IdType="pubmed">31178118</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson MD, et al. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26:139&#x2013;140. doi: 10.1093/bioinformatics/btp616.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btp616</ArticleId><ArticleId IdType="pmc">PMC2796818</ArticleId><ArticleId IdType="pubmed">19910308</ArticleId></ArticleIdList></Reference><Reference><Citation>Carpenter AE, et al. CellProfiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol. 2006;7:R100. doi: 10.1186/gb-2006-7-10-r100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/gb-2006-7-10-r100</ArticleId><ArticleId IdType="pmc">PMC1794559</ArticleId><ArticleId IdType="pubmed">17076895</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33252608</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>11</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>78</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Association Between Ambient Air Pollution and Amyloid Positron Emission Tomography Positivity in Older Adults With Cognitive Impairment.</ArticleTitle><Pagination><StartPage>197</StartPage><EndPage>207</EndPage><MedlinePgn>197-207</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2020.3962</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Amyloid-&#x3b2; (A&#x3b2;) deposition is a feature of Alzheimer disease (AD) and may be promoted by exogenous factors, such as ambient air quality.</AbstractText><AbstractText Label="OBJECTIVE">To examine the association between the likelihood of amyloid positron emission tomography (PET) scan positivity and ambient air quality in individuals with cognitive impairment.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This cross-sectional study used data from the Imaging Dementia-Evidence for Amyloid Scanning Study, which included more than 18 000 US participants with cognitive impairment who received an amyloid PET scan with 1 of 3 A&#x3b2; tracers (fluorine 18 [18F]-labeled florbetapir, 18F-labeled florbetaben, or 18F-labeled flutemetamol) between February 16, 2016, and January 10, 2018. A sample of older adults with mild cognitive impairment (MCI) or dementia was selected.</AbstractText><AbstractText Label="EXPOSURES">Air pollution was estimated at the patient residence using predicted fine particulate matter (PM2.5) and ground-level ozone (O3) concentrations from the Environmental Protection Agency Downscaler model. Air quality was estimated at 2002 to 2003 (early, or approximately 14 [range, 13-15] years before amyloid PET scan) and 2015 to 2016 (late, or approximately 1 [range, 0-2] years before amyloid PET scan).</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Primary outcome measure was the association between air pollution and the likelihood of amyloid PET scan positivity, which was measured as odds ratios (ORs) and marginal effects, adjusting for demographic, lifestyle, and socioeconomic factors and medical comorbidities, including respiratory, cardiovascular, cerebrovascular, psychiatric, and neurological conditions.</AbstractText><AbstractText Label="RESULTS">The data set included 18&#x202f;178 patients, of which 10&#x202f;991 (60.5%) had MCI and 7187 (39.5%) had dementia (mean [SD] age, 75.8 [6.3] years; 9333 women [51.3%]). Living in areas with higher estimated biennial PM2.5 concentrations in 2002 to 2003 was associated with a higher likelihood of amyloid PET scan positivity (adjusted OR, 1.10; 95% CI, 1.05-1.15; z score&#x2009;=&#x2009;3.93; false discovery rate [FDR]-corrected P&#x2009;&lt;&#x2009;.001; per 4-&#x3bc;g/m3 increments). Results were similar for 2015 to 2016 data (OR, 1.15; 95% CI, 1.05-1.26, z score&#x2009;=&#x2009;3.14; FDR-corrected P&#x2009;=&#x2009;.003). An average marginal effect (AME) of +0.5% (SE&#x2009;=&#x2009;0.1%; z score, 3.93; 95% CI, 0.3%-0.7%; FDR-corrected P&#x2009;&lt;&#x2009;.001) probability of amyloid PET scan positivity for each 1-&#x3bc;g/m3 increase in PM2.5 was observed for 2002 to 2003, whereas an AME of +0.8% (SE&#x2009;=&#x2009;0.2%; z score&#x2009;=&#x2009;3.15; 95% CI, 0.3%-1.2%; FDR-corrected P&#x2009;=&#x2009;.002) probability was observed for 2015 to 2016. Post hoc analyses showed no effect modification by sex (2002-2003: interaction term &#x3b2;&#x2009;=&#x2009;1.01 [95% CI, 0.99-1.04; z score&#x2009;=&#x2009;1.13; FDR-corrected P&#x2009;=&#x2009;.56]; 2015-2016: &#x3b2;&#x2009;=&#x2009;1.02 [95% CI, 0.98-1.07; z score&#x2009;=&#x2009;0.91; FDR-corrected P&#x2009;=&#x2009;.56]) or clinical stage (2002-2003: interaction term &#x3b2;&#x2009;=&#x2009;1.01 [95% CI, 0.99-1.03; z score&#x2009;=&#x2009;0.77; FDR-corrected P&#x2009;=&#x2009;.58]; 2015-2016: &#x3b2;&#x2009;=&#x2009;1.03; 95% CI, 0.99-1.08; z score&#x2009;=&#x2009;1.46; FDR-corrected P&#x2009;=&#x2009;.47]). Exposure to higher O3 concentrations was not associated with amyloid PET scan positivity in both time windows.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">This study found that higher PM2.5 concentrations appeared to be associated with brain A&#x3b2; plaques. These findings suggest the need to consider airborne toxic pollutants associated with A&#x3b2; pathology in public health policy decisions and to inform individual lifetime risk of developing AD and dementia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Iaccarino</LastName><ForeName>Leonardo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>La Joie</LastName><ForeName>Renaud</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lesman-Segev</LastName><ForeName>Orit H</ForeName><Initials>OH</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Diagnostic Imaging, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Eunice</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanna</LastName><ForeName>Lucy</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Center for Statistical Sciences, Brown University School of Public Health, Providence, Rhode Island.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allen</LastName><ForeName>Isabel E</ForeName><Initials>IE</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hillner</LastName><ForeName>Bruce E</ForeName><Initials>BE</Initials><AffiliationInfo><Affiliation>Department of Medicine, Virginia Commonwealth University, Richmond.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siegel</LastName><ForeName>Barry A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Edward Mallinckrodt Institute of Radiology, Washington University School of Medicine in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Whitmer</LastName><ForeName>Rachel A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Division of Research, Kaiser Permanente, Oakland, California.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Public Health Sciences, University of California, Davis, Davis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carrillo</LastName><ForeName>Maria C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Medical and Scientific Relations Division, Alzheimer's Association, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gatsonis</LastName><ForeName>Constantine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Center for Statistical Sciences, Brown University School of Public Health, Providence, Rhode Island.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Brown University School of Public Health, Providence, Rhode Island.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rabinovici</LastName><ForeName>Gil D</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Associate Editor, JAMA Neurology.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG062422</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D052638">Particulate Matter</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Med. 2021 Jan;27(1):21. doi: 10.1038/s41591-020-01221-5.</RefSource><PMID Version="1">33442009</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000397" MajorTopicYN="N">Air Pollution</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D052638" MajorTopicYN="N">Particulate Matter</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Ms Hanna reported receiving grants from the American College of Radiology. Dr Hillner reported receiving grants from the Alzheimer's Association. Dr Siegel reported receiving grants from the American College of Radiology during the conduct of the study and ImaginAb Inc; personal fees from Avid Radiopharmaceuticals, Curium Pharma, GE Healthcare, Siemens Healthineers, and Capella Imaging outside the submitted work; and grants and personal fees from Progenics Pharmaceuticals and Blue Earth Diagnostics. Dr Whitmer reported receiving grants from the National Institutes of Health (NIH) and the Alzheimer&#x2019;s Association. Dr Carrillo reported being a full-time employee of the Alzheimer&#x2019;s Association. Dr Gatsonis reported receiving grants from the American College of Radiology during the conduct of the study. Dr Rabinovici reported receiving grants from the American College of Radiology, Alzheimer's Association, Avid Radiopharmaceuticals, GE Healthcare, and Life Molecular Imaging during the conduct of the study; personal fees from GE Healthcare, Axon Neurosciences, Eisai, Merck, and Johnson &amp; Johnson; and grants from the NIH, Rainwater Charitable Foundation, Association for Frontotemporal Degeneration, and Michael J. Fox Foundation outside the submitted work. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>12</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>11</Month><Day>30</Day><Hour>12</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>11</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33252608</ArticleId><ArticleId IdType="pmc">PMC7879238</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2020.3962</ArticleId><ArticleId IdType="pii">2773645</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Winblad B, Amouyel P, Andrieu S, et al. . Defeating Alzheimer&#x2019;s disease and other dementias: a priority for European science and society. Lancet Neurol. 2016;15(5):455-532. doi:10.1016/S1474-4422(16)00062-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(16)00062-4</ArticleId><ArticleId IdType="pubmed">26987701</ArticleId></ArticleIdList></Reference><Reference><Citation>Masters CL, Bateman R, Blennow K, Rowe CC, Sperling RA, Cummings JL. Alzheimer&#x2019;s disease. Nat Rev Dis Primers. 2015;1(1):15056. doi:10.1038/nrdp.2015.56</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2015.56</ArticleId><ArticleId IdType="pubmed">27188934</ArticleId></ArticleIdList></Reference><Reference><Citation>Eid A, Mhatre I, Richardson JR. Gene-environment interactions in Alzheimer&#x2019;s disease: a potential path to precision medicine. Pharmacol Ther. 2019;199:173-187. doi:10.1016/j.pharmthera.2019.03.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2019.03.005</ArticleId><ArticleId IdType="pmc">PMC6827882</ArticleId><ArticleId IdType="pubmed">30877021</ArticleId></ArticleIdList></Reference><Reference><Citation>Finch CE, Kulminski AM. The Alzheimer&#x2019;s disease exposome. Alzheimers Dement. 2019;15(9):1123-1132. doi:10.1016/j.jalz.2019.06.3914</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2019.06.3914</ArticleId><ArticleId IdType="pmc">PMC6788638</ArticleId><ArticleId IdType="pubmed">31519494</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen AJ, Brauer M, Burnett R, et al. . Estimates and 25-year trends of the global burden of disease attributable to ambient air pollution: an analysis of data from the Global Burden of Diseases Study 2015. Lancet. 2017;389(10082):1907-1918. doi:10.1016/S0140-6736(17)30505-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)30505-6</ArticleId><ArticleId IdType="pmc">PMC5439030</ArticleId><ArticleId IdType="pubmed">28408086</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson JO, Thundiyil JG, Stolbach A. Clearing the air: a review of the effects of particulate matter air pollution on human health. J Med Toxicol. 2012;8(2):166-175. doi:10.1007/s13181-011-0203-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13181-011-0203-1</ArticleId><ArticleId IdType="pmc">PMC3550231</ArticleId><ArticleId IdType="pubmed">22194192</ArticleId></ArticleIdList></Reference><Reference><Citation>Nuvolone D, Petri D, Voller F. The effects of ozone on human health. Environ Sci Pollut Res Int. 2018;25(9):8074-8088. doi:10.1007/s11356-017-9239-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11356-017-9239-3</ArticleId><ArticleId IdType="pubmed">28547375</ArticleId></ArticleIdList></Reference><Reference><Citation>Landrigan PJ, Fuller R, Acosta NJR, et al. . The Lancet Commission on pollution and health. Lancet. 2018;391(10119):462-512. doi:10.1016/S0140-6736(17)32345-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)32345-0</ArticleId><ArticleId IdType="pubmed">29056410</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayaraj RL, Rodriguez EA, Wang Y, Block ML. Outdoor ambient air pollution and neurodegenerative diseases: the neuroinflammation hypothesis. Curr Environ Health Rep. 2017;4(2):166-179. doi:10.1007/s40572-017-0142-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40572-017-0142-3</ArticleId><ArticleId IdType="pubmed">28444645</ArticleId></ArticleIdList></Reference><Reference><Citation>Russ TC, Reis S, van Tongeren M. Air pollution and brain health: defining the research agenda. Curr Opin Psychiatry. 2019;32(2):97-104. doi:10.1097/YCO.0000000000000480</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/YCO.0000000000000480</ArticleId><ArticleId IdType="pubmed">30543549</ArticleId></ArticleIdList></Reference><Reference><Citation>Block ML, Elder A, Auten RL, et al. . The outdoor air pollution and brain health workshop. Neurotoxicology. 2012;33(5):972-984. doi:10.1016/j.neuro.2012.08.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuro.2012.08.014</ArticleId><ArticleId IdType="pmc">PMC3726250</ArticleId><ArticleId IdType="pubmed">22981845</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul KC, Haan M, Mayeda ER, Ritz BR. Ambient air pollution, noise, and late-life cognitive decline and dementia risk. Annu Rev Public Health. 2019;40(1):203-220. doi:10.1146/annurev-publhealth-040218-044058</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-publhealth-040218-044058</ArticleId><ArticleId IdType="pmc">PMC6544148</ArticleId><ArticleId IdType="pubmed">30935305</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters R, Ee N, Peters J, Booth A, Mudway I, Anstey KJ. Air pollution and dementia: a systematic review. J Alzheimers Dis. 2019;70(s1):S145-S163. doi:10.3233/JAD-180631</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-180631</ArticleId><ArticleId IdType="pmc">PMC6700631</ArticleId><ArticleId IdType="pubmed">30775976</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai T-L, Lin Y-T, Hwang B-F, et al. . Fine particulate matter is a potential determinant of Alzheimer&#x2019;s disease: a systemic review and meta-analysis. Environ Res. 2019;177:108638. doi:10.1016/j.envres.2019.108638</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.envres.2019.108638</ArticleId><ArticleId IdType="pubmed">31421449</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa LG, Cole TB, Dao K, Chang Y-C, Coburn J, Garrick JM. Effects of air pollution on the nervous system and its possible role in neurodevelopmental and neurodegenerative disorders. Pharmacol Ther. 2020;210:107523. doi:10.1016/j.pharmthera.2020.107523</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2020.107523</ArticleId><ArticleId IdType="pmc">PMC7245732</ArticleId><ArticleId IdType="pubmed">32165138</ArticleId></ArticleIdList></Reference><Reference><Citation>Livingston G, Huntley J, Sommerlad A, et al. . Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396(10248):413-446. doi:10.1016/S0140-6736(20)30367-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30367-6</ArticleId><ArticleId IdType="pmc">PMC7392084</ArticleId><ArticleId IdType="pubmed">32738937</ArticleId></ArticleIdList></Reference><Reference><Citation>Cacciottolo M, Wang X, Driscoll I, et al. . Particulate air pollutants, APOE alleles and their contributions to cognitive impairment in older women and to amyloidogenesis in experimental models. Transl Psychiatry. 2017;7(1):e1022. doi:10.1038/tp.2016.280</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/tp.2016.280</ArticleId><ArticleId IdType="pmc">PMC5299391</ArticleId><ArticleId IdType="pubmed">28140404</ArticleId></ArticleIdList></Reference><Reference><Citation>Levesque S, Surace MJ, McDonald J, Block ML. Air pollution and the brain: subchronic diesel exhaust exposure causes neuroinflammation and elevates early markers of neurodegenerative disease. J Neuroinflammation. 2011;8:105. doi:10.1186/1742-2094-8-105</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-8-105</ArticleId><ArticleId IdType="pmc">PMC3184279</ArticleId><ArticleId IdType="pubmed">21864400</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatt DP, Puig KL, Gorr MW, Wold LE, Combs CK. A pilot study to assess effects of long-term inhalation of airborne particulate matter on early Alzheimer-like changes in the mouse brain. PLoS One. 2015;10(5):e0127102. doi:10.1371/journal.pone.0127102</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0127102</ArticleId><ArticleId IdType="pmc">PMC4439054</ArticleId><ArticleId IdType="pubmed">25992783</ArticleId></ArticleIdList></Reference><Reference><Citation>Cacciottolo M, Morgan TE, Saffari AA, et al. . Traffic-related air pollutants (TRAP-PM) promote neuronal amyloidogenesis through oxidative damage to lipid rafts. Free Radic Biol Med. 2020;147:242-251. doi:10.1016/j.freeradbiomed.2019.12.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2019.12.023</ArticleId><ArticleId IdType="pmc">PMC7075030</ArticleId><ArticleId IdType="pubmed">31883973</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang S, Kim EW, Zhang Y, et al. . Particulate matter increases beta-amyloid and activated glial cells in hippocampal tissues of transgenic Alzheimer&#x2019;s mouse: involvement of PARP-1. Biochem Biophys Res Commun. 2018;500(2):333-338. doi:10.1016/j.bbrc.2018.04.068</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2018.04.068</ArticleId><ArticleId IdType="pubmed">29654761</ArticleId></ArticleIdList></Reference><Reference><Citation>Durga M, Devasena T, Rajasekar A. Determination of LC50 and sub-chronic neurotoxicity of diesel exhaust nanoparticles. Environ Toxicol Pharmacol. 2015;40(2):615-625. doi:10.1016/j.etap.2015.06.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.etap.2015.06.024</ArticleId><ArticleId IdType="pubmed">26363131</ArticleId></ArticleIdList></Reference><Reference><Citation>Hullmann M, Albrecht C, van Berlo D, et al. . Diesel engine exhaust accelerates plaque formation in a mouse model of Alzheimer&#x2019;s disease. Part Fibre Toxicol. 2017;14(1):35. doi:10.1186/s12989-017-0213-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12989-017-0213-5</ArticleId><ArticleId IdType="pmc">PMC5577845</ArticleId><ArticleId IdType="pubmed">28854940</ArticleId></ArticleIdList></Reference><Reference><Citation>Calder&#xf3;n-Garcidue&#xf1;as L, Avila-Ram&#xed;rez J, Calder&#xf3;n-Garcidue&#xf1;as A, et al. . Cerebrospinal fluid biomarkers in highly exposed PM2.5 urbanites: the risk of Alzheimer&#x2019;s and Parkinson&#x2019;s diseases in young Mexico City residents. J Alzheimers Dis. 2016;54(2):597-613. doi:10.3233/JAD-160472</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-160472</ArticleId><ArticleId IdType="pubmed">27567860</ArticleId></ArticleIdList></Reference><Reference><Citation>Calder&#xf3;n-Garcidue&#xf1;as L, Reed W, Maronpot RR, et al. . Brain inflammation and Alzheimer&#x2019;s-like pathology in individuals exposed to severe air pollution. Toxicol Pathol. 2004;32(6):650-658. doi:10.1080/01926230490520232</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/01926230490520232</ArticleId><ArticleId IdType="pubmed">15513908</ArticleId></ArticleIdList></Reference><Reference><Citation>Calder&#xf3;n-Garcidue&#xf1;as L, Solt AC, Henr&#xed;quez-Rold&#xe1;n C, et al. . Long-term air pollution exposure is associated with neuroinflammation, an altered innate immune response, disruption of the blood-brain barrier, ultrafine particulate deposition, and accumulation of amyloid beta-42 and alpha-synuclein in children and young adults. Toxicol Pathol. 2008;36(2):289-310. doi:10.1177/0192623307313011</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0192623307313011</ArticleId><ArticleId IdType="pubmed">18349428</ArticleId></ArticleIdList></Reference><Reference><Citation>Calder&#xf3;n-Garcidue&#xf1;as L, Mukherjee PS, Waniek K, et al. . Non-phosphorylated tau in cerebrospinal fluid is a marker of Alzheimer&#x2019;s disease continuum in young urbanites exposed to air pollution. J Alzheimers Dis. 2018;66(4):1437-1451. doi:10.3233/JAD-180853</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-180853</ArticleId><ArticleId IdType="pubmed">30412505</ArticleId></ArticleIdList></Reference><Reference><Citation>Calder&#xf3;n-Garcidue&#xf1;as L, Kavanaugh M, Block M, et al. . Neuroinflammation, hyperphosphorylated tau, diffuse amyloid plaques, and down-regulation of the cellular prion protein in air pollution exposed children and young adults. J Alzheimers Dis. 2012;28(1):93-107. doi:10.3233/JAD-2011-110722</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2011-110722</ArticleId><ArticleId IdType="pubmed">21955814</ArticleId></ArticleIdList></Reference><Reference><Citation>Calder&#xf3;n-Garcidue&#xf1;as L, Torres-Jard&#xf3;n R, Kulesza RJ, et al. . Alzheimer disease starts in childhood in polluted metropolitan Mexico City: a major health crisis in progress. Environ Res. 2020;183:109137. doi:10.1016/j.envres.2020.109137</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.envres.2020.109137</ArticleId><ArticleId IdType="pubmed">32006765</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabinovici GD, Gatsonis C, Apgar C, et al. . Association of amyloid positron emission tomography with subsequent change in clinical management among Medicare beneficiaries with mild cognitive impairment or dementia. JAMA. 2019;321(13):1286-1294. doi:10.1001/jama.2019.2000</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2019.2000</ArticleId><ArticleId IdType="pmc">PMC6450276</ArticleId><ArticleId IdType="pubmed">30938796</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark CM, Pontecorvo MJ, Beach TG, et al. ; AV-45-A16 Study Group . Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-&#x3b2; plaques: a prospective cohort study. Lancet Neurol. 2012;11(8):669-678. doi:10.1016/S1474-4422(12)70142-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70142-4</ArticleId><ArticleId IdType="pubmed">22749065</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabri O, Sabbagh MN, Seibyl J, et al. ; Florbetaben Phase 3 Study Group . Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer&#x2019;s disease: phase 3 study. Alzheimers Dement. 2015;11(8):964-974. doi:10.1016/j.jalz.2015.02.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2015.02.004</ArticleId><ArticleId IdType="pubmed">25824567</ArticleId></ArticleIdList></Reference><Reference><Citation>Curtis C, Gamez JE, Singh U, et al. . Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. JAMA Neurol. 2015;72(3):287-294. doi:10.1001/jamaneurol.2014.4144</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.4144</ArticleId><ArticleId IdType="pubmed">25622185</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikonomovic MD, Klunk WE, Abrahamson EE, et al. . Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer&#x2019;s disease. Brain. 2008;131(pt 6):1630-1645. doi:10.1093/brain/awn016</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awn016</ArticleId><ArticleId IdType="pmc">PMC2408940</ArticleId><ArticleId IdType="pubmed">18339640</ArticleId></ArticleIdList></Reference><Reference><Citation>Villeneuve S, Rabinovici GD, Cohn-Sheehy BI, et al. . Existing Pittsburgh compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. Brain. 2015;138(pt 7):2020-2033. doi:10.1093/brain/awv112</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awv112</ArticleId><ArticleId IdType="pmc">PMC4806716</ArticleId><ArticleId IdType="pubmed">25953778</ArticleId></ArticleIdList></Reference><Reference><Citation>Seo SW, Ayakta N, Grinberg LT, et al. . Regional correlations between [11C]PIB PET and post-mortem burden of amyloid-beta pathology in a diverse neuropathological cohort. Neuroimage Clin. 2016;13:130-137. doi:10.1016/j.nicl.2016.11.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2016.11.008</ArticleId><ArticleId IdType="pmc">PMC5144753</ArticleId><ArticleId IdType="pubmed">27981028</ArticleId></ArticleIdList></Reference><Reference><Citation>La Joie R, Ayakta N, Seeley WW, et al. . Multisite study of the relationships between antemortem [11C]PIB-PET centiloid values and postmortem measures of Alzheimer&#x2019;s disease neuropathology. Alzheimers Dement. 2019;15(2):205-216. doi:10.1016/j.jalz.2018.09.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.09.001</ArticleId><ArticleId IdType="pmc">PMC6368897</ArticleId><ArticleId IdType="pubmed">30347188</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, Minoshima S, Bohnen NI, et al. ; Alzheimer&#x2019;s Association; Society of Nuclear Medicine and Molecular Imaging; Amyloid Imaging Taskforce . Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer&#x2019;s Association. Alzheimers Dement. 2013;9(1):e1&#x2013;-e16.. doi:10.1016/j.jalz.2013.01.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2013.01.002</ArticleId><ArticleId IdType="pmc">PMC3733252</ArticleId><ArticleId IdType="pubmed">23360977</ArticleId></ArticleIdList></Reference><Reference><Citation>Berrocal VJ, Gelfand AE, Holland DM. A bivariate space-time Downscaler under space and time misalignment. Ann Appl Stat. 2010;4(4):1942-1975. doi:10.1214/10-AOAS351</Citation><ArticleIdList><ArticleId IdType="doi">10.1214/10-AOAS351</ArticleId><ArticleId IdType="pmc">PMC3156619</ArticleId><ArticleId IdType="pubmed">21853015</ArticleId></ArticleIdList></Reference><Reference><Citation>Berrocal VJ, Gelfand AE, Holland DM. A spatio-temporal Downscaler for output from numerical models. J Agric Biol Environ Stat. 2010;15(2):176-197. doi:10.1007/s13253-009-0004-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13253-009-0004-z</ArticleId><ArticleId IdType="pmc">PMC2990198</ArticleId><ArticleId IdType="pubmed">21113385</ArticleId></ArticleIdList></Reference><Reference><Citation>Norton EC, Dowd BE, Maciejewski ML. Odds ratios&#x2014;current best practice and use. JAMA. 2018;320(1):84-85. doi:10.1001/jama.2018.6971</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2018.6971</ArticleId><ArticleId IdType="pubmed">29971384</ArticleId></ArticleIdList></Reference><Reference><Citation>Norton EC, Dowd BE, Maciejewski ML. Marginal effects&#x2014;quantifying the effect of changes in risk factors in logistic regression models. JAMA. 2019;321(13):1304-1305. doi:10.1001/jama.2019.1954</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2019.1954</ArticleId><ArticleId IdType="pubmed">30848814</ArticleId></ArticleIdList></Reference><Reference><Citation>Calder&#xf3;n-Garcidue&#xf1;as L, Maronpot RR, Torres-Jardon R, et al. . DNA damage in nasal and brain tissues of canines exposed to air pollutants is associated with evidence of chronic brain inflammation and neurodegeneration. Toxicol Pathol. 2003;31(5):524-538. doi:10.1080/01926230390226645</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/01926230390226645</ArticleId><ArticleId IdType="pubmed">14692621</ArticleId></ArticleIdList></Reference><Reference><Citation>Kioumourtzoglou M-A, Schwartz JD, Weisskopf MG, et al. . Long-term PM2.5 exposure and neurological hospital admissions in the northeastern United States. Environ Health Perspect. 2016;124(1):23-29. doi:10.1289/ehp.1408973</Citation><ArticleIdList><ArticleId IdType="doi">10.1289/ehp.1408973</ArticleId><ArticleId IdType="pmc">PMC4710596</ArticleId><ArticleId IdType="pubmed">25978701</ArticleId></ArticleIdList></Reference><Reference><Citation>Bishop KC, Ketcham JD, Kuminoff NV Hazed and confused: the effect of air pollution on dementia. NBER Working Papers 24970. Published 2018.  Accessed April 21, 2020. https://ideas.repec.org/p/nbr/nberwo/24970.html</Citation></Reference><Reference><Citation>Chen H, Kwong JC, Copes R, et al. . Exposure to ambient air pollution and the incidence of dementia: a population-based cohort study. Environ Int. 2017;108:271-277. doi:10.1016/j.envint.2017.08.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.envint.2017.08.020</ArticleId><ArticleId IdType="pubmed">28917207</ArticleId></ArticleIdList></Reference><Reference><Citation>Carey IM, Anderson HR, Atkinson RW, et al. . Are noise and air pollution related to the incidence of dementia? a cohort study in London, England. BMJ Open. 2018;8(9):e022404. doi:10.1136/bmjopen-2018-022404</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2018-022404</ArticleId><ArticleId IdType="pmc">PMC6144407</ArticleId><ArticleId IdType="pubmed">30206085</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y-C, Lin Y-C, Yu H-L, et al. . Association between air pollutants and dementia risk in the elderly. Alzheimers Dement (Amst). 2015;1(2):220-228. doi:10.1016/j.dadm.2014.11.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dadm.2014.11.015</ArticleId><ArticleId IdType="pmc">PMC4876896</ArticleId><ArticleId IdType="pubmed">27239507</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung C-R, Lin Y-T, Hwang B-F. Ozone, particulate matter, and newly diagnosed Alzheimer&#x2019;s disease: a population-based cohort study in Taiwan. J Alzheimers Dis. 2015;44(2):573-584. doi:10.3233/JAD-140855</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-140855</ArticleId><ArticleId IdType="pubmed">25310992</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleary EG, Cifuentes M, Grinstein G, Brugge D, Shea TB. Association of low-level ozone with cognitive decline in older adults. J Alzheimers Dis. 2018;61(1):67-78. doi:10.3233/JAD-170658</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-170658</ArticleId><ArticleId IdType="pmc">PMC5755393</ArticleId><ArticleId IdType="pubmed">29103040</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerza F, Renzi M, Gariazzo C, et al. . Long-term exposure to air pollution and hospitalization for dementia in the Rome longitudinal study. Environ Health. 2019;18(1):72. doi:10.1186/s12940-019-0511-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12940-019-0511-5</ArticleId><ArticleId IdType="pmc">PMC6689157</ArticleId><ArticleId IdType="pubmed">31399053</ArticleId></ArticleIdList></Reference><Reference><Citation>Block ML, Calder&#xf3;n-Garcidue&#xf1;as L. Air pollution: mechanisms of neuroinflammation and CNS disease. Trends Neurosci. 2009;32(9):506-516. doi:10.1016/j.tins.2009.05.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2009.05.009</ArticleId><ArticleId IdType="pmc">PMC2743793</ArticleId><ArticleId IdType="pubmed">19716187</ArticleId></ArticleIdList></Reference><Reference><Citation>Genc S, Zadeoglulari Z, Fuss SH, Genc K. The adverse effects of air pollution on the nervous system. J Toxicol. 2012;2012:782462. doi:10.1155/2012/782462</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/782462</ArticleId><ArticleId IdType="pmc">PMC3317189</ArticleId><ArticleId IdType="pubmed">22523490</ArticleId></ArticleIdList></Reference><Reference><Citation>Mumaw CL, Levesque S, McGraw C, et al. . Microglial priming through the lung-brain axis: the role of air pollution-induced circulating factors. FASEB J. 2016;30(5):1880-1891. doi:10.1096/fj.201500047</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.201500047</ArticleId><ArticleId IdType="pmc">PMC4836369</ArticleId><ArticleId IdType="pubmed">26864854</ArticleId></ArticleIdList></Reference><Reference><Citation>Belloy ME, Napolioni V, Greicius MD. A quarter century of APOE and Alzheimer&#x2019;s disease: progress to date and the path forward. Neuron. 2019;101(5):820-838. doi:10.1016/j.neuron.2019.01.056</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2019.01.056</ArticleId><ArticleId IdType="pmc">PMC6407643</ArticleId><ArticleId IdType="pubmed">30844401</ArticleId></ArticleIdList></Reference><Reference><Citation>Akhter H, Ballinger C, Liu N, van Groen T, Postlethwait EM, Liu R-M. Cyclic ozone exposure induces gender-dependent neuropathology and memory decline in an animal model of Alzheimer&#x2019;s disease. Toxicol Sci. 2015;147(1):222-234. doi:10.1093/toxsci/kfv124</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/toxsci/kfv124</ArticleId><ArticleId IdType="pmc">PMC4607745</ArticleId><ArticleId IdType="pubmed">26116027</ArticleId></ArticleIdList></Reference><Reference><Citation>LaFerla FM, Green KN, Oddo S. Intracellular amyloid-&#x3b2; in Alzheimer&#x2019;s disease. Nat Rev Neurosci. 2007;8(7):499-509. doi:10.1038/nrn2168</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn2168</ArticleId><ArticleId IdType="pubmed">17551515</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Alafuzoff I, Bigio EH, et al. . Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 2012;71(5):362-381. doi:10.1097/NEN.0b013e31825018f7</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e31825018f7</ArticleId><ArticleId IdType="pmc">PMC3560290</ArticleId><ArticleId IdType="pubmed">22487856</ArticleId></ArticleIdList></Reference><Reference><Citation>Strozyk D, Blennow K, White LR, Launer LJ. CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology. 2003;60(4):652-656. doi:10.1212/01.WNL.0000046581.81650.D0</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000046581.81650.D0</ArticleId><ArticleId IdType="pubmed">12601108</ArticleId></ArticleIdList></Reference><Reference><Citation>Clouston SAP, Diminich ED, Kotov R, et al. . Incidence of mild cognitive impairment in World Trade Center responders: long-term consequences of re-experiencing the events on 9/11/2001. Alzheimers Dement (Amst). 2019;11:628-636. doi:10.1016/j.dadm.2019.07.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dadm.2019.07.006</ArticleId><ArticleId IdType="pmc">PMC6733774</ArticleId><ArticleId IdType="pubmed">31517025</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulick ER, Elkind MSV, Boehme AK, et al. . Long-term exposure to ambient air pollution, APOE-&#x3b5;4 status, and cognitive decline in a cohort of older adults in northern Manhattan. Environ Int. 2020;136:105440. doi:10.1016/j.envint.2019.105440</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.envint.2019.105440</ArticleId><ArticleId IdType="pmc">PMC7024003</ArticleId><ArticleId IdType="pubmed">31926436</ArticleId></ArticleIdList></Reference><Reference><Citation>Schikowski T, Vossoughi M, Vierk&#xf6;tter A, et al. . Association of air pollution with cognitive functions and its modification by APOE gene variants in elderly women. Environ Res. 2015;142:10-16. doi:10.1016/j.envres.2015.06.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.envres.2015.06.009</ArticleId><ArticleId IdType="pubmed">26092807</ArticleId></ArticleIdList></Reference><Reference><Citation>Younan D, Petkus AJ, Widaman KF, et al. . Particulate matter and episodic memory decline mediated by early neuroanatomic biomarkers of Alzheimer&#x2019;s disease. Brain. 2020;143(1):289-302. doi:10.1093/brain/awz348</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz348</ArticleId><ArticleId IdType="pmc">PMC6938036</ArticleId><ArticleId IdType="pubmed">31746986</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickman S, Izzy S, Sen P, Morsett L, El Khoury J. Microglia in neurodegeneration. Nat Neurosci. 2018;21(10):1359-1369. doi:10.1038/s41593-018-0242-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0242-x</ArticleId><ArticleId IdType="pmc">PMC6817969</ArticleId><ArticleId IdType="pubmed">30258234</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanisch U-K, Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci. 2007;10(11):1387-1394. doi:10.1038/nn1997</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1997</ArticleId><ArticleId IdType="pubmed">17965659</ArticleId></ArticleIdList></Reference><Reference><Citation>US Environmental Protection Agency  Particulate matter (PM2.5) trends. Accessed August 8, 2020. https://www.epa.gov/air-trends/particulate-matter-pm25-trends</Citation></Reference><Reference><Citation>Keller JP, Peng RD. Error in estimating area-level air pollution exposures for epidemiology. Environmetrics. 2019;30(8):e2573. doi:10.1002/env.2573</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/env.2573</ArticleId></ArticleIdList></Reference><Reference><Citation>Caplin A, Ghandehari M, Lim C, Glimcher P, Thurston G. Advancing environmental exposure assessment science to benefit society. Nat Commun. 2019;10(1):1236. doi:10.1038/s41467-019-09155-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-09155-4</ArticleId><ArticleId IdType="pmc">PMC6420629</ArticleId><ArticleId IdType="pubmed">30874557</ArticleId></ArticleIdList></Reference><Reference><Citation>US Census Bureau  Geographical mobility: 2016.  to 2017. Published November 2017. Accessed August 8, 2020. https://www.census.gov/data/tables/2017/demo/geographic-mobility/cps-2017.html</Citation></Reference><Reference><Citation>Wolf DA, Longino CF Jr. Our &#x201c;increasingly mobile society&#x201d;? the curious persistence of a false belief. Gerontologist. 2005;45(1):5-11. doi:10.1093/geront/45.1.5</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/geront/45.1.5</ArticleId><ArticleId IdType="pubmed">15695413</ArticleId></ArticleIdList></Reference><Reference><Citation>Forman HJ, Finch CE. A critical review of assays for hazardous components of air pollution. Free Radic Biol Med. 2018;117:202-217. doi:10.1016/j.freeradbiomed.2018.01.030</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2018.01.030</ArticleId><ArticleId IdType="pmc">PMC5845809</ArticleId><ArticleId IdType="pubmed">29407794</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly FJ, Fussell JC. Size, source and chemical composition as determinants of toxicity attributable to ambient particulate matter. Atmospheric Environment. 2012;60:504-526. doi:10.1016/j.atmosenv.2012.06.039</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atmosenv.2012.06.039</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33283854</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>19</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1460-2156</ISSN><JournalIssue CitedMedium="Internet"><Volume>144</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>Mar</Month><Day>03</Day></PubDate></JournalIssue><Title>Brain : a journal of neurology</Title><ISOAbbreviation>Brain</ISOAbbreviation></Journal><ArticleTitle>CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>515</StartPage><EndPage>527</EndPage><MedlinePgn>515-527</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/brain/awaa373</ELocationID><Abstract><AbstractText>Tau is a microtubule associated protein in the brain that aggregates in Alzheimer's disease to form pathological tangles and neurites. Insoluble tau aggregates composed of the microtubule binding region (MTBR) of tau are highly associated with the cognitive and clinical symptoms of Alzheimer's disease. In contrast, levels of soluble forms of tau, such as CSF total tau and phosphorylated tau-181 and tau-217, increase prior to tau aggregation in Alzheimer's disease, but these biomarkers do not measure the MTBR of tau. Thus, how CSF MTBR-tau is altered in Alzheimer's disease remains unclear. In this study, we used sequential immunoprecipitation and chemical extraction methods followed by mass spectrometry to analyse MTBR-tau species in Alzheimer's disease and control CSF. We quantified MTBR-tau-specific regions in the CSF and identified that species containing the region beginning at residue 243 were the most highly correlated with tau PET and cognitive measures. This finding suggests that CSF level of tau species containing the upstream region of MTBR may reflect changes in tau pathology that occur in Alzheimer's disease and could serve as biomarkers to stage Alzheimer's disease and track the development of tau-directed therapeutics.</AbstractText><CopyrightInformation>&#xa9; The Author(s) (2020). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please email: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Horie</LastName><ForeName>Kanta</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barth&#xe9;lemy</LastName><ForeName>Nicolas R</ForeName><Initials>NR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sato</LastName><ForeName>Chihiro</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bateman</LastName><ForeName>Randall J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG066444</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS065667</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS048056</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS095773</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain</MedlineTA><NlmUniqueID>0372537</NlmUniqueID><ISSNLinking>0006-8950</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Brain. 2021 Mar 3;144(2):359-362. doi: 10.1093/brain/awaa468.</RefSource><PMID Version="1">34182574</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Brain. 2021 Oct 22;144(9):e82. doi: 10.1093/brain/awab227.</RefSource><PMID Version="1">34215872</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">CSF</Keyword><Keyword MajorTopicYN="N">biomarkers</Keyword><Keyword MajorTopicYN="N">microtubule binding region</Keyword><Keyword MajorTopicYN="N">tau</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>4</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>12</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>12</Month><Day>7</Day><Hour>8</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>12</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33283854</ArticleId><ArticleId IdType="pmc">PMC7940175</ArticleId><ArticleId IdType="doi">10.1093/brain/awaa373</ArticleId><ArticleId IdType="pii">6024973</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Albert M, Mairet-Coello G, Danis C, Lieger S, Caillierez R, Carrier S, et al.Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody. Brain J Neurol 2019; 142: 1736&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6536853</ArticleId><ArticleId IdType="pubmed">31038156</ArticleId></ArticleIdList></Reference><Reference><Citation>Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT.. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer&#x2019;s disease. Neurology 1992; 42: 631&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">1549228</ArticleId></ArticleIdList></Reference><Reference><Citation>Barth&#xe9;lemy NR, Fenaille F, Hirtz C, Sergeant N, Schraen-Maschke S, Vialaret J, et al.Tau protein quantification in human cerebrospinal fluid by targeted mass spectrometry at high sequence coverage provides insights into its primary structure heterogeneity. J Proteome Res 2016. a; 15: 667&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">26742856</ArticleId></ArticleIdList></Reference><Reference><Citation>Barth&#xe9;lemy NR, Gabelle A, Hirtz C, Fenaille F, Sergeant N, Schraen-Maschke S, et al.Differential mass spectrometry profiles of tau protein in the cerebrospinal fluid of patients with Alzheimer&#x2019;s disease, progressive supranuclear palsy, and dementia with lewy bodies. J Alzheimers Dis 2016. b; 51: 1033&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">26923020</ArticleId></ArticleIdList></Reference><Reference><Citation>Barth&#xe9;lemy NR, Mallipeddi N, Moiseyev P, Sato C, Bateman RJ.. Tau phosphorylation rates measured by mass spectrometry differ in the intracellular brain vs. extracellular cerebrospinal fluid compartments and are differentially affected by Alzheimer&#x2019;s disease. Front Aging Neurosci 2019; 11:121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6537657</ArticleId><ArticleId IdType="pubmed">31178717</ArticleId></ArticleIdList></Reference><Reference><Citation>Bejanin A, Schonhaut DR, La Joie R, Kramer JH, Baker SL, Sosa N, et al.Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer&#x2019;s disease. Brain J Neurol 2017; 140: 3286&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5841139</ArticleId><ArticleId IdType="pubmed">29053874</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Chen C, Cicognola C, Wildsmith KR, Manser PT, Bohorquez SMS, et al.Cerebrospinal fluid tau fragment correlates with tau PET: a candidate biomarker for tangle pathology. Brain 2020; 143: 650&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7009597</ArticleId><ArticleId IdType="pubmed">31834365</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H-H, Liu P, Auger P, Lee S-H, Adolfsson O, Rey-Bellet L, et al.Calpain-mediated tau fragmentation is altered in Alzheimer&#x2019;s disease progression. Sci Rep 2018; 8: 16725.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6233188</ArticleId><ArticleId IdType="pubmed">30425303</ArticleId></ArticleIdList></Reference><Reference><Citation>Cicognola C, Brinkmalm G, Wahlgren J, Portelius E, Gobom J, Cullen NC, et al.Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer&#x2019;s disease. Acta Neuropathol 2019; 137: 279&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6514201</ArticleId><ArticleId IdType="pubmed">30547227</ArticleId></ArticleIdList></Reference><Reference><Citation>Colin M, Dujardin S, Schraen-Maschke S, Meno-Tetang G, Duyckaerts C, Courade J-P, et al.From the prion-like propagation hypothesis to therapeutic strategies of anti-tau immunotherapy. Acta Neuropathol 2020; 139: 3&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6942016</ArticleId><ArticleId IdType="pubmed">31686182</ArticleId></ArticleIdList></Reference><Reference><Citation>Cotman CW, Poon WW, Rissman RA, Blurton-Jones M.. The role of caspase cleavage of tau in Alzheimer disease neuropathology. J Neuropathol Exp Neurol 2005; 64: 104&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">15751224</ArticleId></ArticleIdList></Reference><Reference><Citation>Courade J-P, Angers R, Mairet-Coello G, Pacico N, Tyson K, Lightwood D, et al.Epitope determines efficacy of therapeutic anti-Tau antibodies in a functional assay with human Alzheimer Tau. Acta Neuropathol 2018; 136: 729&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6208734</ArticleId><ArticleId IdType="pubmed">30238240</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon B, Zhang W, Murzin AG, Murshudov G, Garringer HJ, Vidal R, et al.Structures of filaments from Pick&#x2019;s disease reveal a novel tau protein fold. Nature 2018; 561: 137&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6204212</ArticleId><ArticleId IdType="pubmed">30158706</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon B, Zivanov J, Zhang W, Murzin AG, Garringer HJ, Vidal R, et al.Novel tau filament fold in chronic traumatic encephalopathy encloses hydrophobic molecules. Nature 2019; 568: 420&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6472968</ArticleId><ArticleId IdType="pubmed">30894745</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzpatrick AWP, Falcon B, He S, Murzin AG, Murshudov G, Garringer HJ, et al.Cryo-EM structures of tau filaments from Alzheimer&#x2019;s disease. Nature 2017; 547: 185&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5552202</ArticleId><ArticleId IdType="pubmed">28678775</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost B, Jacks RL, Diamond MI.. Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem 2009; 284: 12845&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2676015</ArticleId><ArticleId IdType="pubmed">19282288</ArticleId></ArticleIdList></Reference><Reference><Citation>Gamblin TC, Chen F, Zambrano A, Abraha A, Lagalwar S, Guillozet AL, et al.Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer&#x2019;s disease. Proc Natl Acad Sci USA 2003; 100: 10032&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC187753</ArticleId><ArticleId IdType="pubmed">12888622</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Clavaguera F, Tolnay M.. The propagation of prion-like protein inclusions in neurodegenerative diseases. Trends Neurosci 2010; 33: 317&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">20493564</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Eisenberg DS, Crowther RA.. Propagation of tau aggregates and neurodegeneration. Annu Rev Neurosci 2017; 40: 189&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">28772101</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon BA, Blazey TM, Christensen J, Dincer A, Flores S, Keefe S, et al.Tau PET in autosomal dominant Alzheimer&#x2019;s disease: relationship with cognition, dementia and other biomarkers. Brain 2019; 142: 1063&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6439328</ArticleId><ArticleId IdType="pubmed">30753379</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo JL, Narasimhan S, Changolkar L, He Z, Stieber A, Zhang B, et al.Unique pathological tau conformers from Alzheimer&#x2019;s brains transmit tau pathology in nontransgenic mice. J Exp Med 2016; 213: 2635&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5110027</ArticleId><ArticleId IdType="pubmed">27810929</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Wiste HJ, Schwarz CG, Lowe VJ, Senjem ML, Vemuri P, et al.Longitudinal tau PET in ageing and Alzheimer&#x2019;s disease. Brain 2018; 141: 1517&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5917767</ArticleId><ArticleId IdType="pubmed">29538647</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, Schultz A, Betensky RA, Becker JA, Sepulcre J, Rentz D, et al.Tau PET imaging in aging and early Alzheimer&#x2019;s disease. Ann Neurol 2016; 79: 110&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4738026</ArticleId><ArticleId IdType="pubmed">26505746</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Guerrero-Munoz MJ, Kiritoshi T, Neugebauer V, et al.Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. Sci Rep 2012; 2: 700.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3463004</ArticleId><ArticleId IdType="pubmed">23050084</ArticleId></ArticleIdList></Reference><Reference><Citation>Malia TJ, Teplyakov A, Ernst R, Wu S-J, Lacy ER, Liu X, et al.Epitope mapping and structural basis for the recognition of phosphorylated tau by the anti-tau antibody AT8. Proteins 2016; 84: 427&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5067699</ArticleId><ArticleId IdType="pubmed">26800003</ArticleId></ArticleIdList></Reference><Reference><Citation>Meredith JE, Sankaranarayanan S, Guss V, Lanzetti AJ, Berisha F, Neely RJ, et al.Characterization of novel CSF Tau and ptau biomarkers for Alzheimer&#x2019;s disease. PLoS One 2013; 8: e76523.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3792042</ArticleId><ArticleId IdType="pubmed">24116116</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirbaha H, Chen D, Morazova OA, Ruff KM, Sharma AM, Liu X, et al.Inert and seed-competent tau monomers suggest structural origins of aggregation. eLife 2018; 7: e36584.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6039173</ArticleId><ArticleId IdType="pubmed">29988016</ArticleId></ArticleIdList></Reference><Reference><Citation>Narasimhan S, Guo JL, Changolkar L, Stieber A, McBride JD, Silva LV, et al.Pathological tau strains from human brains recapitulate the diversity of tauopathies in nontransgenic mouse brain. J Neurosci 2017; 37: 11406&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5700423</ArticleId><ArticleId IdType="pubmed">29054878</ArticleId></ArticleIdList></Reference><Reference><Citation>Neddens J, Temmel M, Flunkert S, Kerschbaumer B, Hoeller C, Loeffler T, et al.Phosphorylation of different tau sites during progression of Alzheimer&#x2019;s disease. Acta Neuropathol Commun 2018; 6: 52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6027763</ArticleId><ArticleId IdType="pubmed">29958544</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Schonhaut DR, Sch&#xf6;ll M, Lockhart SN, Ayakta N, Baker SL, et al.Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer&#x2019;s disease. Brain 2016; 139: 1551&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5006248</ArticleId><ArticleId IdType="pubmed">26962052</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson BW, Elbert DL, Mawuenyega KG, Kasten T, Ovod V, Ma S, et al.Age and amyloid effects on human central nervous system amyloid-beta kinetics. Ann Neurol 2015; 78: 439&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4546566</ArticleId><ArticleId IdType="pubmed">26040676</ArticleId></ArticleIdList></Reference><Reference><Citation>Quinn JP, Corbett NJ, Kellett KAB, Hooper NM.. Tau Proteolysis in the Pathogenesis of Tauopathies: neurotoxic Fragments and Novel Biomarkers. J Alzheimers Dis 2018; 63: 13&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5900574</ArticleId><ArticleId IdType="pubmed">29630551</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiber H.Dynamics of brain-derived proteins in cerebrospinal fluid. Clin Chim Acta 2001; 310: 173&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">11498083</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts M, Sevastou I, Imaizumi Y, Mistry K, Talma S, Dey M, et al.Pre-clinical characterisation of E2814, a high-affinity antibody targeting the microtubule-binding repeat domain of tau for passive immunotherapy in Alzheimer&#x2019;s disease. Acta Neuropathol Commun 2020; 8: 13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7001291</ArticleId><ArticleId IdType="pubmed">32019610</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders DW, Kaufman SK, DeVos SL, Sharma AM, Mirbaha H, Li A, et al.Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron 2014; 82: 1271&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4171396</ArticleId><ArticleId IdType="pubmed">24857020</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato C, Barth&#xe9;lemy NR, Mawuenyega KG, Patterson BW, Gordon BA, Jockel-Balsarotti J, et al.Tau kinetics in neurons and the human central nervous system. Neuron 2018; 97: 1284&#x2013;98.e7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6137722</ArticleId><ArticleId IdType="pubmed">29566794</ArticleId></ArticleIdList></Reference><Reference><Citation>Skachokova Z, Martinisi A, Flach M, Sprenger F, Naegelin Y, Steiner-Monard V, et al.Cerebrospinal fluid from Alzheimer&#x2019;s disease patients promotes tau aggregation in transgenic mice. Acta Neuropathol Commun 2019; 7: 72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6503541</ArticleId><ArticleId IdType="pubmed">31064413</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Blazey TM, Snyder AZ, Raichle ME, Marcus DS, Ances BM, et al.Partial volume correction in quantitative amyloid imaging. Neuroimage 2015; 107: 55&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4300252</ArticleId><ArticleId IdType="pubmed">25485714</ArticleId></ArticleIdList></Reference><Reference><Citation>Taniguchi-Watanabe S, Arai T, Kametani F, Nonaka T, Masuda-Suzukake M, Tarutani A, et al.Biochemical classification of tauopathies by immunoblot, protein sequence and mass spectrometric analyses of sarkosyl-insoluble and trypsin-resistant tau. Acta Neuropathol 2016; 131: 267&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4713716</ArticleId><ArticleId IdType="pubmed">26538150</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandermeeren M, Borgers M, Van Kolen K, Theunis C, Vasconcelos B, Bottelbergs A, et al.Anti-tau monoclonal antibodies derived from soluble and filamentous tau show diverse functional properties in vitro and in vivo. J Alzheimers Dis 2018; 65: 265&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">30040731</ArticleId></ArticleIdList></Reference><Reference><Citation>Weisov&#xe1; P, Cehl&#xe1;r O, &#x160;krabana R, &#x17d;ilkov&#xe1; M, Filip&#x10d;&#xed;k P, Kov&#xe1;&#x10d;ech B, et al.Therapeutic antibody targeting microtubule-binding domain prevents neuronal internalization of extracellular tau via masking neuron surface proteoglycans. Acta Neuropathol Commun 2019; 7: 129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6685285</ArticleId><ArticleId IdType="pubmed">31391090</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu JW, Hussaini SA, Bastille IM, Rodriguez GA, Mrejeru A, Rilett K, et al.Neuronal activity enhances tau propagation and tau pathology in vivo. Nat Neurosci 2016; 19: 1085&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4961585</ArticleId><ArticleId IdType="pubmed">27322420</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Tarutani A, Newell KL, Murzin AG, Matsubara T, Falcon B, et al.Novel tau filament fold in corticobasal degeneration. Nature 2020; 580: 283&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7148158</ArticleId><ArticleId IdType="pubmed">32050258</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, Song M, Liu X, Kang SS, Kwon I-S, Duong DM, et al.Cleavage of tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer&#x2019;s disease. Nat Med 2014; 20: 1254&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4224595</ArticleId><ArticleId IdType="pubmed">25326800</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao X, Kotilinek LA, Smith B, Hlynialuk C, Zahs K, Ramsden M, et al.Caspase-2 cleavage of tau reversibly impairs memory. Nat Med 2016; 22: 1268&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">27723722</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33298560</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>573</Issue><PubDate><Year>2020</Year><Month>Dec</Month><Day>09</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>An epoxide hydrolase inhibitor reduces neuroinflammation in a mouse model of Alzheimer's disease.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">eabb1206</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.abb1206</ELocationID><Abstract><AbstractText>Neuroinflammation has been increasingly recognized to play a critical role in Alzheimer's disease (AD). The epoxy fatty acids (EpFAs) are derivatives of the arachidonic acid metabolism pathway and have anti-inflammatory activities. However, their efficacy is limited because of their rapid hydrolysis by the soluble epoxide hydrolase (sEH). We report that sEH is predominantly expressed in astrocytes and is elevated in postmortem brain tissue from patients with AD and in the 5xFAD &#x3b2; amyloid mouse model of AD. The amount of sEH expressed in AD mouse brains correlated with a reduction in brain EpFA concentrations. Using a specific small-molecule sEH inhibitor, 1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) urea (TPPU), we report that TPPU treatment protected wild-type mice against LPS-induced inflammation in vivo. Long-term administration of TPPU to the 5xFAD mouse model via drinking water reversed microglia and astrocyte reactivity and immune pathway dysregulation. This was associated with reduced &#x3b2; amyloid pathology and improved synaptic integrity and cognitive function on two behavioral tests. TPPU treatment correlated with an increase in EpFA concentrations in the brains of 5xFAD mice, demonstrating brain penetration and target engagement of this small molecule. These findings support further investigation of TPPU as a potential therapeutic agent for the treatment of AD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ghosh</LastName><ForeName>Anamitra</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-9740-2070</Identifier><AffiliationInfo><Affiliation>Huffington Center on Aging, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Comerota</LastName><ForeName>Michele M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Huffington Center on Aging, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wan</LastName><ForeName>Debin</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Entomology and Nematology and UCDMC Comprehensive Cancer Center, University of California, Davis, CA 95616, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Fading</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Huffington Center on Aging, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Propson</LastName><ForeName>Nicholas E</ForeName><Initials>NE</Initials><AffiliationInfo><Affiliation>Huffington Center on Aging, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hwang</LastName><ForeName>Sung Hee</ForeName><Initials>SH</Initials><Identifier Source="ORCID">0000-0002-9891-928X</Identifier><AffiliationInfo><Affiliation>Department of Entomology and Nematology and UCDMC Comprehensive Cancer Center, University of California, Davis, CA 95616, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hammock</LastName><ForeName>Bruce D</ForeName><Initials>BD</Initials><AffiliationInfo><Affiliation>Department of Entomology and Nematology and UCDMC Comprehensive Cancer Center, University of California, Davis, CA 95616, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Hui</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-5427-3798</Identifier><AffiliationInfo><Affiliation>Huffington Center on Aging, Baylor College of Medicine, Houston, TX 77030, USA. huiz@bcm.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG057509</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P42 ES004699</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS093652</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG020670</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG062257</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG054111</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R35 ES030443</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004852">Epoxy Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010671">Phenylurea Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010880">Piperidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.3.2.-</RegistryNumber><NameOfSubstance UI="D004851">Epoxide Hydrolases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Sci Transl Med. 2024 Nov 20;16(774):eadu1332. doi: 10.1126/scitranslmed.adu1332.</RefSource><PMID Version="1">39565877</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004851" MajorTopicYN="Y">Epoxide Hydrolases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004852" MajorTopicYN="N">Epoxy Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010671" MajorTopicYN="N">Phenylurea Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing interests:</b> S.H.H. is a part-time employee and B.D.H. is a cofounder and CEO of EicOsis LLC. H.Z. is on the Scientific Advisory Board of the Tau Consortium managed by the Rainwater Charitable Foundation.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>1</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>12</Month><Day>10</Day><Hour>5</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>12</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>12</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33298560</ArticleId><ArticleId IdType="mid">NIHMS1655166</ArticleId><ArticleId IdType="pmc">PMC7784555</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.abb1206</ArticleId><ArticleId IdType="pii">12/573/eabb1206</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Querfurth HW, LaFerla FM, Alzheimer&#x2019;s disease. N Engl J Med 362, 329&#x2013;344 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20107219</ArticleId></ArticleIdList></Reference><Reference><Citation>Long JM, Holtzman DM, Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. Cell 179, 312&#x2013;339 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6778042</ArticleId><ArticleId IdType="pubmed">31564456</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, Selkoe DJ, Neurotoxicity of amyloid beta-protein: synaptic and network dysfunction. Cold Spring Harb Perspect Med 2, a006338 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3385944</ArticleId><ArticleId IdType="pubmed">22762015</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL, Cohen S, van Dyck CH, Brody M, Curtis C, Cho W, Ward M, Friesenhahn M, Rabe C, Brunstein F, Quartino A, Honigberg LA, Fuji RN, Clayton D, Mortensen D, Ho C, Paul R, ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease. Neurology 90, e1889&#x2013;e1897 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5962917</ArticleId><ArticleId IdType="pubmed">29695589</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL, Morstorf T, Zhong K, Alzheimer&#x2019;s disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther 6, 37 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4095696</ArticleId><ArticleId IdType="pubmed">25024750</ArticleId></ArticleIdList></Reference><Reference><Citation>Elmaleh DR, Farlow MR, Conti PS, Tompkins RG, Kundakovic L, Tanzi RE, Developing Effective Alzheimer&#x2019;s Disease Therapies: Clinical Experience and Future Directions. J Alzheimers Dis 71, 715&#x2013;732 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6839593</ArticleId><ArticleId IdType="pubmed">31476157</ArticleId></ArticleIdList></Reference><Reference><Citation>Guillot-Sestier MV, Doty KR, Town T, Innate Immunity Fights Alzheimer&#x2019;s Disease. Trends Neurosci 38, 674&#x2013;681 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4641041</ArticleId><ArticleId IdType="pubmed">26549882</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, Kummer MP, Stutz A, Delekate A, Schwartz S, Vieira-Saecker A, Griep A, Axt D, Remus A, Tzeng TC, Gelpi E, Halle A, Korte M, Latz E, Golenbock DT, NLRP3 is activated in Alzheimer&#x2019;s disease and contributes to pathology in APP/PS1 mice. Nature 493, 674&#x2013;678 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3812809</ArticleId><ArticleId IdType="pubmed">23254930</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, Kummer MP, Latz E, Innate immune activation in neurodegenerative disease. Nat Rev Immunol 14, 463&#x2013;477 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24962261</ArticleId></ArticleIdList></Reference><Reference><Citation>Prokop S, Miller KR, Heppner FL, Microglia actions in Alzheimer&#x2019;s disease. Acta Neuropathol 126, 461&#x2013;477 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24224195</ArticleId></ArticleIdList></Reference><Reference><Citation>Lian H, Zheng H, Signaling pathways regulating neuron-glia interaction and their implications in Alzheimer&#x2019;s disease. J Neurochem 136, 475&#x2013;491 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4720533</ArticleId><ArticleId IdType="pubmed">26546579</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Damotte V, Naj AC, Boland A, Vronskaya M, van der Lee SJ, Amlie-Wolf A, Bellenguez C, Frizatti A, Chouraki V, Martin ER, Sleegers K, Badarinarayan N, Jakobsdottir J, Hamilton-Nelson KL, Moreno-Grau S, Olaso R, Raybould R, Chen Y, Kuzma AB, Hiltunen M, Morgan T, Ahmad S, Vardarajan BN, Epelbaum J, Hoffmann P, Boada M, Beecham GW, Garnier JG, Harold D, Fitzpatrick AL, Valladares O, Moutet ML, Gerrish A, Smith AV, Qu L, Bacq D, Denning N, Jian X, Zhao Y, Del Zompo M, Fox NC, Choi SH, Mateo I, Hughes JT, Adams HH, Malamon J, Sanchez-Garcia F, Patel Y, Brody JA, Dombroski BA, Naranjo MCD, Daniilidou M, Eiriksdottir G, Mukherjee S, Wallon D, Uphill J, Aspelund T, Cantwell LB, Garzia F, Galimberti D, Hofer E, Butkiewicz M, Fin B, Scarpini E, Sarnowski C, Bush WS, Meslage S, Kornhuber J, White CC, Song Y, Barber RC, Engelborghs S, Sordon S, Voijnovic D, Adams PM, Vandenberghe R, Mayhaus M, Cupples LA, Albert MS, De Deyn PP, Gu W, Himali JJ, Beekly D, Squassina A, Hartmann AM, Orellana A, Blacker D, Rodriguez-Rodriguez E, Lovestone S, Garcia ME, Doody RS, Munoz-Fernadez C, Sussams R, Lin H, Fairchild TJ, Benito YA, Holmes C, Karamujic-Comic H, Frosch MP, Thonberg H, Maier W, Roshchupkin G, Ghetti B, Giedraitis V, Kawalia A, Li S, Huebinger RM, Kilander L, Moebus S, Hernandez I, Kamboh MI, Brundin R, Turton J, Yang Q, Katz MJ, Concari L, Lord J, Beiser AS, Keene CD, Helisalmi S, Kloszewska I, Kukull WA, Koivisto AM, Lynch A, Tarraga L, Larson EB, Haapasalo A, Lawlor B, Mosley TH, Lipton RB, Solfrizzi V, Gill M, Longstreth WT Jr., Montine TJ, Frisardi V, Diez-Fairen M, Rivadeneira F, Petersen RC, Deramecourt V, Alvarez I, Salani F, Ciaramella A, Boerwinkle E, Reiman EM, Fievet N, Rotter JI, Reisch JS, Hanon O, Cupidi C, Andre Uitterlinden AG, Royall DR, Dufouil C, Maletta RG, de Rojas I, Sano M, Brice A, Cecchetti R, George-Hyslop PS, Ritchie K, Tsolaki M, Tsuang DW, Dubois B, Craig D, Wu CK, Soininen H, Avramidou D, Albin RL, Fratiglioni L, Germanou A, Apostolova LG, Keller L, Koutroumani M, Arnold SE, Panza F, Gkatzima O, Asthana S, Hannequin D, Whitehead P, Atwood CS, Caffarra P, Hampel H, Quintela I, Carracedo A, Lannfelt L, Rubinsztein DC, Barnes LL, Pasquier F, Frolich L, Barral S, McGuinness B, Beach TG, Johnston JA, Becker JT, Passmore P, Bigio EH, Schott JM, Bird TD, Warren JD, Boeve BF, Lupton MK, Bowen JD, Proitsi P, Boxer A, Powell JF, Burke JR, Kauwe JSK, Burns JM, Mancuso M, Buxbaum JD, Bonuccelli U, Cairns NJ, McQuillin A, Cao C, Livingston G, Carlson CS, Bass NJ, Carlsson CM, Hardy J, Carney RM, Bras J, Carrasquillo MM, Guerreiro R, Allen M, Chui HC, Fisher E, Masullo C, Crocco EA, DeCarli C, Bisceglio G, Dick M, Ma L, Duara R, Graff-Radford NR, Evans DA, Hodges A, Faber KM, Scherer M, Fallon KB, Riemenschneider M, Fardo DW, Heun R, Farlow MR, Kolsch H, Ferris S, Leber M, Foroud TM, Heuser I, Galasko DR, Giegling I, Gearing M, Hull M, Geschwind DH, Gilbert JR, Morris J, Green RC, Mayo K, Growdon JH, Feulner T, Hamilton RL, Harrell LE, Drichel D, Honig LS, Cushion TD, Huentelman MJ, Hollingworth P, Hulette CM, Hyman BT, Marshall R, Jarvik GP, Meggy A, Abner E, Menzies GE, Jin LW, Leonenko G, Real LM, Jun GR, Baldwin CT, Grozeva D, Karydas A, Russo G, Kaye JA, Kim R, Jessen F, Kowall NW, Vellas B, Kramer JH, Vardy E, LaFerla FM, Jockel KH, Lah JJ, Dichgans M, Leverenz JB, Mann D, Levey AI, Pickering-Brown S, Lieberman AP, Klopp N, Lunetta KL, Wichmann HE, Lyketsos CG, Morgan K, Marson DC, Brown K, Martiniuk F, Medway C, Mash DC, Nothen MM, Masliah E, Hooper NM, McCormick WC, Daniele A, McCurry SM, Bayer A, McDavid AN, Gallacher J, McKee AC, van den Bussche H, Mesulam M, Brayne C, Miller BL, Riedel-Heller S, Miller CA, Miller JW, Al-Chalabi A, Morris JC, Shaw CE, Myers AJ, Wiltfang J, O&#x2019;Bryant S, Olichney JM, Alvarez V, Parisi JE, Singleton AB, Paulson HL, Collinge J, Perry WR, Mead S, Peskind E, Cribbs DH, Rossor M, Pierce A, Ryan NS, Poon WW, Nacmias B, Potter H, Sorbi S, Quinn JF, Sacchinelli E, Raj A, Spalletta G, Raskind M, Caltagirone C, Bossu P, Orfei MD, Reisberg B, Clarke R, Reitz C, Smith AD, Ringman JM, Warden D, Roberson ED, Wilcock G, Rogaeva E, Bruni AC, Rosen HJ, Gallo M, Rosenberg RN, Ben-Shlomo Y, Sager MA, Mecocci P, Saykin AJ, Pastor P, Cuccaro ML, Vance JM, Schneider JA, Schneider LS, Slifer S, Seeley WW, Smith AG, Sonnen JA, Spina S, Stern RA, Swerdlow RH, Tang M, Tanzi RE, Trojanowski JQ, Troncoso JC, Van Deerlin VM, Van Eldik LJ, Vinters HV, Vonsattel JP, Weintraub S, Welsh-Bohmer KA, Wilhelmsen KC, Williamson J, Wingo TS, Woltjer RL, Wright CB, Yu CE, Yu L, Saba Y, Pilotto A, Bullido MJ, Peters O, Crane PK, Bennett D, Bosco P, Coto E, Boccardi V, De Jager PL, Lleo A, Warner N, Lopez OL, Ingelsson M, Deloukas P, Cruchaga C, Graff C, Gwilliam R, Fornage M, Goate AM, Sanchez-Juan P, Kehoe PG, Amin N, Ertekin-Taner N, Berr C, Debette S, Love S, Launer LJ, Younkin SG, Dartigues JF, Corcoran C, Ikram MA, Dickson DW, Nicolas G, Campion D, Tschanz J, Schmidt H, Hakonarson H, Clarimon J, Munger R, Schmidt R, Farrer LA, Van Broeckhoven C, C. O. D. M, DeStefano AL, Jones L, Haines JL, Deleuze JF, Owen MJ, Gudnason V, Mayeux R, Escott-Price V, Psaty BM, Ramirez A, Wang LS, Ruiz A, van Duijn CM, Holmans PA, Seshadri S, Williams J, Amouyel P, Schellenberg GD, Lambert JC, Pericak-Vance MA, Genetic meta-analysis of diagnosed Alzheimer&#x2019;s disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing. Nat Genet 51, 414&#x2013;430 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6463297</ArticleId><ArticleId IdType="pubmed">30820047</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C, Chyr J, Zhao W, Xu Y, Ji Z, Tan H, Soto C, Zhou X, Genome-Wide Association and Mechanistic Studies Indicate That Immune Response Contributes to Alzheimer&#x2019;s Disease Development. Front Genet 9, 410 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6166008</ArticleId><ArticleId IdType="pubmed">30319691</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, Bras J, Hardy J, SnapShot: genetics of Alzheimer&#x2019;s disease. Cell 155, 968&#x2013;968.e961 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24209629</ArticleId></ArticleIdList></Reference><Reference><Citation>Felsky D, Roostaei T, Nho K, Risacher SL, Bradshaw EM, Petyuk V, Schneider JA, Saykin A, Bennett DA, De Jager PL, Neuropathological correlates and genetic architecture of microglial activation in elderly human brain. Nat Commun 10, 409 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6345810</ArticleId><ArticleId IdType="pubmed">30679421</ArticleId></ArticleIdList></Reference><Reference><Citation>Trepanier CH, Milgram NW, Neuroinflammation in Alzheimer&#x2019;s disease: are NSAIDs and selective COX-2 inhibitors the next line of therapy? J Alzheimers Dis 21, 1089&#x2013;1099 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">21504126</ArticleId></ArticleIdList></Reference><Reference><Citation>Cacciatore I, Marinelli L, Fornasari E, Cerasa LS, Eusepi P, Turkez H, Pomilio C, Reale M, D&#x2019;Angelo C, Costantini E, Di Stefano A, Novel NSAID-Derived Drugs for the Potential Treatment of Alzheimer&#x2019;s Disease. Int J Mol Sci 17, (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4964411</ArticleId><ArticleId IdType="pubmed">27376271</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen HC, Hammock BD, Discovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indications. J Med Chem 55, 1789&#x2013;1808 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3420824</ArticleId><ArticleId IdType="pubmed">22168898</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillis JW, Horrocks LA, Farooqui AA, Cyclooxygenases, lipoxygenases, and epoxygenases in CNS: their role and involvement in neurological disorders. Brain Res Rev 52, 201&#x2013;243 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16647138</ArticleId></ArticleIdList></Reference><Reference><Citation>Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, Zeldin DC, Liao JK, Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285, 1276&#x2013;1279 (1999).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2720027</ArticleId><ArticleId IdType="pubmed">10455056</ArticleId></ArticleIdList></Reference><Reference><Citation>Bystrom J, Wray JA, Sugden MC, Holness MJ, Swales KE, Warner TD, Edin ML, Zeldin DC, Gilroy DW, Bishop-Bailey D, Endogenous epoxygenases are modulators of monocyte/macrophage activity. PLoS One 6, e26591 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3197524</ArticleId><ArticleId IdType="pubmed">22028915</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmelzer KR, Kubala L, Newman JW, Kim IH, Eiserich JP, Hammock BD, Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc Natl Acad Sci U S A 102, 9772&#x2013;9777 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1168955</ArticleId><ArticleId IdType="pubmed">15994227</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang X, Soluble epoxide hydrolase: a novel target for the treatment of hypertension. Recent Pat Cardiovasc Drug Discov 1, 67&#x2013;72 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">18221075</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng VY, Huang Y, Reddy LM, Falck JR, Lin ET, Kroetz DL, Cytochrome P450 eicosanoids are activators of peroxisome proliferator-activated receptor alpha. Drug Metab Dispos 35, 1126&#x2013;1134 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17431031</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris TR, Hammock BD, Soluble epoxide hydrolase: gene structure, expression and deletion. Gene 526, 61&#x2013;74 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3733540</ArticleId><ArticleId IdType="pubmed">23701967</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren Q, Ma M, Ishima T, Morisseau C, Yang J, Wagner KM, Zhang JC, Yang C, Yao W, Dong C, Han M, Hammock BD, Hashimoto K, Gene deficiency and pharmacological inhibition of soluble epoxide hydrolase confers resilience to repeated social defeat stress. Proc Natl Acad Sci U S A 113, E1944&#x2013;1952 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4822604</ArticleId><ArticleId IdType="pubmed">26976569</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma M, Ren Q, Yang J, Zhang K, Xiong Z, Ishima T, Pu Y, Hwang SH, Toyoshima M, Iwayama Y, Hisano Y, Yoshikawa T, Hammock BD, Hashimoto K, Key role of soluble epoxide hydrolase in the neurodevelopmental disorders of offspring after maternal immune activation. Proc Natl Acad Sci U S A 116, 7083&#x2013;7088 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6452650</ArticleId><ArticleId IdType="pubmed">30890645</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren Q, Ma M, Yang J, Nonaka R, Yamaguchi A, Ishikawa KI, Kobayashi K, Murayama S, Hwang SH, Saiki S, Akamatsu W, Hattori N, Hammock BD, Hashimoto K, Soluble epoxide hydrolase plays a key role in the pathogenesis of Parkinson&#x2019;s disease. Proc Natl Acad Sci U S A 115, E5815&#x2013;e5823 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6016799</ArticleId><ArticleId IdType="pubmed">29735655</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee HT, Lee KI, Chen CH, Lee TS, Genetic deletion of soluble epoxide hydrolase delays the progression of Alzheimer&#x2019;s disease. J Neuroinflammation 16, 267 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6916033</ArticleId><ArticleId IdType="pubmed">31847859</ArticleId></ArticleIdList></Reference><Reference><Citation>Gri&#xf1;&#xe1;n-Ferr&#xe9; C, Codony S, Pujol E, Yang J, Leiva R, Escolano C, Puigoriol-Illamola D, Companys-Alemany J, Corpas R, Sanfeliu C, P&#xe9;rez B, Loza MI, Brea J, Morisseau C, Hammock BD, V&#xe1;zquez S, Pall&#xe0;s M, Galdeano C, Pharmacological Inhibition of Soluble Epoxide Hydrolase as a New Therapy for Alzheimer&#x2019;s Disease. Neurotherapeutics, (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7851240</ArticleId><ArticleId IdType="pubmed">32488482</ArticleId></ArticleIdList></Reference><Reference><Citation>Rose TE, Morisseau C, Liu JY, Inceoglu B, Jones PD, Sanborn JR, Hammock BD, 1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, and reduction of inflammatory pain. J Med Chem 53, 7067&#x2013;7075 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3285450</ArticleId><ArticleId IdType="pubmed">20812725</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapoport SI, Arachidonic acid and the brain. J Nutr 138, 2515&#x2013;2520 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3415870</ArticleId><ArticleId IdType="pubmed">19022981</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito T, Matsuba Y, Mihira N, Takano J, Nilsson P, Itohara S, Iwata N, Saido TC, Single App knock-in mouse models of Alzheimer&#x2019;s disease. Nat Neurosci 17, 661&#x2013;663 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24728269</ArticleId></ArticleIdList></Reference><Reference><Citation>Swartzlander DB, Propson NE, Roy ER, Saito T, Saido T, Wang B, Zheng H, Concurrent cell type-specific isolation and profiling of mouse brains in inflammation and Alzheimer&#x2019;s disease. JCI Insight 3, (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6124528</ArticleId><ArticleId IdType="pubmed">29997299</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang W, Tuniki VR, Anjaiah S, Falck JR, Hillard CJ, Campbell WB, Characterization of epoxyeicosatrienoic acid binding site in U937 membranes using a novel radiolabeled agonist, 20&#x2013;125i-14,15-epoxyeicosa-8(Z)-enoic acid. J Pharmacol Exp Ther 324, 1019&#x2013;1027 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18171909</ArticleId></ArticleIdList></Reference><Reference><Citation>Gauthier KM, Deeter C, Krishna UM, Reddy YK, Bondlela M, Falck JR, Campbell WB, 14,15-Epoxyeicosa-5(Z)-enoic acid: a selective epoxyeicosatrienoic acid antagonist that inhibits endothelium-dependent hyperpolarization and relaxation in coronary arteries. Circ Res 90, 1028&#x2013;1036 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12016270</ArticleId></ArticleIdList></Reference><Reference><Citation>Gauthier KM, Jagadeesh SG, Falck JR, Campbell WB, 14,15-epoxyeicosa-5(Z)-enoic-mSI: a 14,15- and 5,6-EET antagonist in bovine coronary arteries. Hypertension 42, 555&#x2013;561 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12953017</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung TH, Shyue SK, Wu CH, Chen CC, Lin CC, Chang CF, Chen SF, Deletion or inhibition of soluble epoxide hydrolase protects against brain damage and reduces microglia-mediated neuroinflammation in traumatic brain injury. Oncotarget 8, 103236&#x2013;103260 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5732724</ArticleId><ArticleId IdType="pubmed">29262558</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenberg MF, Velarde G, Ford RC, Martin C, Berridge G, Kerr ID, Callaghan R, Schmidlin A, Wooding C, Linton KJ, Higgins CF, Repacking of the transmembrane domains of P-glycoprotein during the transport ATPase cycle. Embo j 20, 5615&#x2013;5625 (2001).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC125677</ArticleId><ArticleId IdType="pubmed">11598005</ArticleId></ArticleIdList></Reference><Reference><Citation>Balimane PV, Han YH, Chong S, Current industrial practices of assessing permeability and P-glycoprotein interaction. Aaps j 8, E1&#x2013;13 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2751418</ArticleId><ArticleId IdType="pubmed">16584115</ArticleId></ArticleIdList></Reference><Reference><Citation>Elsby R, Surry DD, Smith VN, Gray AJ, Validation and application of Caco-2 assays for the in vitro evaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions. Xenobiotica 38, 1140&#x2013;1164 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18668443</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams L, Bradley L, Smith A, Foxwell B, Signal transducer and activator of transcription 3 is the dominant mediator of the anti-inflammatory effects of IL-10 in human macrophages. J Immunol 172, 567&#x2013;576 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">14688368</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann S, Madore C, Cialic R, Baufeld C, Calcagno N, El Fatimy R, Beckers L, O&#x2019;Loughlin E, Xu Y, Fanek Z, Greco DJ, Smith ST, Tweet G, Humulock Z, Zrzavy T, Conde-Sanroman P, Gacias M, Weng Z, Chen H, Tjon E, Mazaheri F, Hartmann K, Madi A, Ulrich JD, Glatzel M, Worthmann A, Heeren J, Budnik B, Lemere C, Ikezu T, Heppner FL, Litvak V, Holtzman DM, Lassmann H, Weiner HL, Ochando J, Haass C, Butovsky O, The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. Immunity 47, 566&#x2013;581.e569 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5719893</ArticleId><ArticleId IdType="pubmed">28930663</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, Berry R, Vassar R, Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer&#x2019;s disease mutations: potential factors in amyloid plaque formation. J Neurosci 26, 10129&#x2013;10140 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariani MM, Malm T, Lamb R, Jay TR, Neilson L, Casali B, Medarametla L, Landreth GE, Neuronally-directed effects of RXR activation in a mouse model of Alzheimer&#x2019;s disease. Sci Rep 7, 42270 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5311933</ArticleId><ArticleId IdType="pubmed">28205585</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S, Nam Y, Jeong YO, Park HH, Lee SK, Shin SJ, Jung H, Kim BH, Hong SB, Park YH, Kim J, Yu J, Yoo DH, Park SH, Jeon SG, Moon M, Topographical Visualization of the Reciprocal Projection between the Medial Septum and the Hippocampus in the 5XFAD Mouse Model of Alzheimer&#x2019;s Disease. Int J Mol Sci 20, (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6721212</ArticleId><ArticleId IdType="pubmed">31426329</ArticleId></ArticleIdList></Reference><Reference><Citation>Eimer WA, Vassar R, Neuron loss in the 5XFAD mouse model of Alzheimer&#x2019;s disease correlates with intraneuronal A&#x3b2;42 accumulation and Caspase-3 activation. Mol Neurodegener 8, 2 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3552866</ArticleId><ArticleId IdType="pubmed">23316765</ArticleId></ArticleIdList></Reference><Reference><Citation>Przybyla-Zawislak BD, Srivastava PK, Vazquez-Matias J, Mohrenweiser HW, Maxwell JE, Hammock BD, Bradbury JA, Enayetallah AE, Zeldin DC, Grant DF, Polymorphisms in human soluble epoxide hydrolase. Mol Pharmacol 64, 482&#x2013;490 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12869654</ArticleId></ArticleIdList></Reference><Reference><Citation>Srivastava PK, Sharma VK, Kalonia DS, Grant DF, Polymorphisms in human soluble epoxide hydrolase: effects on enzyme activity, enzyme stability, and quaternary structure. Arch Biochem Biophys 427, 164&#x2013;169 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15196990</ArticleId></ArticleIdList></Reference><Reference><Citation>Fornage M, Boerwinkle E, Doris PA, Jacobs D, Liu K, Wong ND, Polymorphism of the soluble epoxide hydrolase is associated with coronary artery calcification in African-American subjects: The Coronary Artery Risk Development in Young Adults (CARDIA) study. Circulation 109, 335&#x2013;339 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">14732757</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohtoshi K, Kaneto H, Node K, Nakamura Y, Shiraiwa T, Matsuhisa M, Yamasaki Y, Association of soluble epoxide hydrolase gene polymorphism with insulin resistance in type 2 diabetic patients. Biochem Biophys Res Commun 331, 347&#x2013;350 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15845398</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu J, Dziumbla S, Lin J, Bibli SI, Zukunft S, de Mos J, Awwad K, Fromel T, Jungmann A, Devraj K, Cheng Z, Wang L, Fauser S, Eberhart CG, Sodhi A, Hammock BD, Liebner S, Muller OJ, Glaubitz C, Hammes HP, Popp R, Fleming I, Inhibition of soluble epoxide hydrolase prevents diabetic retinopathy. Nature 552, 248&#x2013;252 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5828869</ArticleId><ArticleId IdType="pubmed">29211719</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin XH, Wu Z, Dong JH, Zeng YN, Xiong WC, Liu C, Wang MY, Zhu MZ, Chen WJ, Zhang Y, Huang QY, Zhu XH, Liver Soluble Epoxide Hydrolase Regulates Behavioral and Cellular Effects of Chronic Stress. Cell Rep 29, 3223&#x2013;3234.e3226 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31801085</ArticleId></ArticleIdList></Reference><Reference><Citation>Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, Bennett ML, Munch AE, Chung WS, Peterson TC, Wilton DK, Frouin A, Napier BA, Panicker N, Kumar M, Buckwalter MS, Rowitch DH, Dawson VL, Dawson TM, Stevens B, Barres BA, Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541, 481&#x2013;487 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5404890</ArticleId><ArticleId IdType="pubmed">28099414</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke LE, Liddelow SA, Neurobiology: Diversity reaches the stars. Nature 548, 396&#x2013;397 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28836597</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Yamada K, Liddelow SA, Smith ST, Zhao L, Luo W, Tsai RM, Spina S, Grinberg LT, Rojas JC, Gallardo G, Wang K, Roh J, Robinson G, Finn MB, Jiang H, Sullivan PM, Baufeld C, Wood MW, Sutphen C, McCue L, Xiong C, Del-Aguila JL, Morris JC, Cruchaga C, Fagan AM, Miller BL, Boxer AL, Seeley WW, Butovsky O, Barres BA, Paul SM, Holtzman DM, ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature 549, 523&#x2013;527 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5641217</ArticleId><ArticleId IdType="pubmed">28959956</ArticleId></ArticleIdList></Reference><Reference><Citation>Tejera D, Mercan D, Sanchez-Caro JM, Hanan M, Greenberg D, Soreq H, Latz E, Golenbock D, Heneka MT, Systemic inflammation impairs microglial Abeta clearance through NLRP3 inflammasome. Embo j 38, e101064 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6717897</ArticleId><ArticleId IdType="pubmed">31359456</ArticleId></ArticleIdList></Reference><Reference><Citation>Park MH, Lee M, Nam G, Kim M, Kang J, Choi BJ, Jeong MS, Park KH, Han WH, Tak E, Kim MS, Lee J, Lin Y, Lee YH, Song IS, Choi MK, Lee JY, Jin HK, Bae JS, Lim MH, N,N&#x2019;-Diacetyl-p-phenylenediamine restores microglial phagocytosis and improves cognitive defects in Alzheimer&#x2019;s disease transgenic mice. Proc Natl Acad Sci U S A 116, 23426&#x2013;23436 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6876236</ArticleId><ArticleId IdType="pubmed">31685616</ArticleId></ArticleIdList></Reference><Reference><Citation>Salter MW, Stevens B, Microglia emerge as central players in brain disease. Nat Med 23, 1018&#x2013;1027 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28886007</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarlus H, Heneka MT, Microglia in Alzheimer&#x2019;s disease. J Clin Invest 127, 3240&#x2013;3249 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5669553</ArticleId><ArticleId IdType="pubmed">28862638</ArticleId></ArticleIdList></Reference><Reference><Citation>Litvinchuk A, Wan YW, Swartzlander DB, Chen F, Cole A, Propson NE, Wang Q, Zhang B, Liu Z, Zheng H, Complement C3aR Inactivation Attenuates Tau Pathology and Reverses an Immune Network Deregulated in Tauopathy Models and Alzheimer&#x2019;s Disease. Neuron 100, 1337&#x2013;1353.e1335 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6309202</ArticleId><ArticleId IdType="pubmed">30415998</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Q, Chowdhury S, Ma R, Le KX, Hong S, Caldarone BJ, Stevens B, Lemere CA, Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice. Sci Transl Med 9, (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6936623</ArticleId><ArticleId IdType="pubmed">28566429</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarriello S, Tuazon JP, Corey S, Schimmel S, Rajani M, Gorsky A, Incontri D, Hammock BD, Borlongan CV, Humble beginnings with big goals: Small molecule soluble epoxide hydrolase inhibitors for treating CNS disorders. Prog Neurobiol 172, 23&#x2013;39 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6993804</ArticleId><ArticleId IdType="pubmed">30447256</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulu A, Appt S, Morisseau C, Hwang SH, Jones PD, Rose TE, Dong H, Lango J, Yang J, Tsai HJ, Miyabe C, Fortenbach C, Adams MR, Hammock BD, Pharmacokinetics and in vivo potency of soluble epoxide hydrolase inhibitors in cynomolgus monkeys. Br J Pharmacol 165, 1401&#x2013;1412 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3372725</ArticleId><ArticleId IdType="pubmed">21880036</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Lu X, Nguyen S, Olson JL, Webb HK, Kroetz DL, Epoxyeicosatrienoic acids prevent cisplatin-induced renal apoptosis through a p38 mitogen-activated protein kinase-regulated mitochondrial pathway. Mol Pharmacol 84, 925&#x2013;934 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3834146</ArticleId><ArticleId IdType="pubmed">24092818</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee KS, Liu JY, Wagner KM, Pakhomova S, Dong H, Morisseau C, Fu SH, Yang J, Wang P, Ulu A, Mate CA, Nguyen LV, Hwang SH, Edin ML, Mara AA, Wulff H, Newcomer ME, Zeldin DC, Hammock BD, Optimized inhibitors of soluble epoxide hydrolase improve in vitro target residence time and in vivo efficacy. J Med Chem 57, 7016&#x2013;7030 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4148150</ArticleId><ArticleId IdType="pubmed">25079952</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan D, Yang J, McReynolds CB, Barnych B, Wagner KM, Morisseau C, Hwang SH, Sun J, Blocher R, Hammock BD, In vitro and in vivo Metabolism of a Potent Inhibitor of Soluble Epoxide Hydrolase, 1-(1-Propionylpiperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea. Front Pharmacol 10, 464 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6520522</ArticleId><ArticleId IdType="pubmed">31143115</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh A, Tyson T, George S, Hildebrandt EN, Steiner JA, Madaj Z, Schulz E, Machiela E, McDonald WG, Escobar Galvis ML, Kordower JH, Van Raamsdonk JM, Colca JR, Brundin P, Mitochondrial pyruvate carrier regulates autophagy, inflammation, and neurodegeneration in experimental models of Parkinson&#x2019;s disease. Sci Transl Med 8, 368ra174 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27928028</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh A, Langley MR, Harischandra DS, Neal ML, Jin H, Anantharam V, Joseph J, Brenza T, Narasimhan B, Kanthasamy A, Kalyanaraman B, Kanthasamy AG, Mitoapocynin Treatment Protects Against Neuroinflammation and Dopaminergic Neurodegeneration in a Preclinical Animal Model of Parkinson&#x2019;s Disease. J Neuroimmune Pharmacol 11, 259&#x2013;278 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4995106</ArticleId><ArticleId IdType="pubmed">26838361</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh A, Kanthasamy A, Joseph J, Anantharam V, Srivastava P, Dranka BP, Kalyanaraman B, Kanthasamy AG, Anti-inflammatory and neuroprotective effects of an orally active apocynin derivative in pre-clinical models of Parkinson&#x2019;s disease. J Neuroinflammation 9, 241 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3488558</ArticleId><ArticleId IdType="pubmed">23092448</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo W, Allan AM, Zong R, Zhang L, Johnson EB, Schaller EG, Murthy AC, Goggin SL, Eisch AJ, Oostra BA, Nelson DL, Jin P, Zhao X, Ablation of Fmrp in adult neural stem cells disrupts hippocampus-dependent learning. Nat Med 17, 559&#x2013;565 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3140952</ArticleId><ArticleId IdType="pubmed">21516088</ArticleId></ArticleIdList></Reference><Reference><Citation>Lian H, Yang L, Cole A, Sun L, Chiang AC, Fowler SW, Shim DJ, Rodriguez-Rivera J, Taglialatela G, Jankowsky JL, Lu HC, Zheng H, NFkappaB-activated astroglial release of complement C3 compromises neuronal morphology and function associated with Alzheimer&#x2019;s disease. Neuron 85, 101&#x2013;115 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4289109</ArticleId><ArticleId IdType="pubmed">25533482</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J, Schmelzer K, Georgi K, Hammock BD, Quantitative profiling method for oxylipin metabolome by liquid chromatography electrospray ionization tandem mass spectrometry. Anal Chem 81, 8085&#x2013;8093 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3290520</ArticleId><ArticleId IdType="pubmed">19715299</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33314529</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1552-5279</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Alzheimer's &amp; dementia : the journal of the Alzheimer's Association</Title><ISOAbbreviation>Alzheimers Dement</ISOAbbreviation></Journal><ArticleTitle>Reactive or transgenic increase in microglial TYROBP reveals a TREM2-independent TYROBP-APOE link in wild-type and Alzheimer's-related mice.</ArticleTitle><Pagination><StartPage>149</StartPage><EndPage>163</EndPage><MedlinePgn>149-163</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/alz.12256</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Microglial TYROBP (DAP12) is a network hub and driver in sporadic late-onset Alzheimer's disease (AD). TYROBP is a cytoplasmic adaptor for TREM2 and other receptors, but little is known about its roles and actions in AD. Herein, we demonstrate that endogenous Tyrobp transcription is specifically increased in recruited microglia.</AbstractText><AbstractText Label="METHODS">Using a novel transgenic mouse overexpressing TYROBP in microglia, we observed a decrease of the amyloid burden and an increase of TAU phosphorylation stoichiometry when crossed with APP/PSEN1 or MAPT<sup>P301S</sup> mice, respectively. Characterization of these mice revealed Tyrobp-related modulation of apolipoprotein E (Apoe) transcription. We also showed that Tyrobp and Apoe mRNAs were increased in Trem2-null microglia recruited around either amyloid beta deposits or a cortical stab injury. Conversely, microglial Apoe transcription was dramatically diminished when Tyrobp was absent.</AbstractText><AbstractText Label="CONCLUSIONS">Our results provide evidence that TYROBP-APOE signaling does not require TREM2 and could be an initiating step in establishment of the disease-associated microglia (DAM) phenotype.</AbstractText><CopyrightInformation>&#xa9; 2020 The Authors. Alzheimer's &amp; Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Audrain</LastName><ForeName>Mickael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9941-7380</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haure-Mirande</LastName><ForeName>Jean-Vianney</ForeName><Initials>JV</Initials><Identifier Source="ORCID">0000-0002-5748-9666</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mleczko</LastName><ForeName>Justyna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Minghui</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences and Icahn Institute of Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Griffin</LastName><ForeName>Jennifer K</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>St George-Hyslop</LastName><ForeName>Peter H</ForeName><Initials>PH</Initials><AffiliationInfo><Affiliation>Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fraser</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Bin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences and Icahn Institute of Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gandy</LastName><ForeName>Sam</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-6455-4721</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute on Aging-Designated Alzheimer's Disease Research Center and Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research and Development, James J. Peters Veterans Affairs Medical Center, Bronx, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ehrlich</LastName><ForeName>Michelle E</ForeName><Initials>ME</Initials><Identifier Source="ORCID">0000-0001-9397-686X</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences and Icahn Institute of Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>RF1 AG058469</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG059319</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005138</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066514</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG062355</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG046170</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG057907</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>12</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Alzheimers Dement</MedlineTA><NlmUniqueID>101231978</NlmUniqueID><ISSNLinking>1552-5260</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498715">TREM2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498716">Trem2 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C484963">Tyrobp protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D048868" MajorTopicYN="N">Adaptor Proteins, Signal Transducing</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000686" MajorTopicYN="N">Amyloidosis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="Y">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">APP/PSEN1</Keyword><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">DAM</Keyword><Keyword MajorTopicYN="N">Dap12</Keyword><Keyword MajorTopicYN="N">PS19</Keyword><Keyword MajorTopicYN="N">RNAscope</Keyword><Keyword MajorTopicYN="N">Trem2</Keyword><Keyword MajorTopicYN="N">Tyrobp</Keyword><Keyword MajorTopicYN="N">amyloid</Keyword><Keyword MajorTopicYN="N">apolipoprotein E</Keyword><Keyword MajorTopicYN="N">microglia</Keyword><Keyword MajorTopicYN="N">tauopathy</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>10</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>11</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>12</Month><Day>14</Day><Hour>11</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>3</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33314529</ArticleId><ArticleId IdType="mid">NIHMS1647258</ArticleId><ArticleId IdType="pmc">PMC7938663</ArticleId><ArticleId IdType="doi">10.1002/alz.12256</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lambert JC, Ibrahim&#x2010;Verbaas CA, Harold D, et&#xa0;al. Meta&#x2010;analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet. 2013;45:1452&#x2010;1458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Naj AC, Jun G, Beecham GW, et&#xa0;al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late&#x2010;onset Alzheimer's disease. Nat Genet. 2011;43:436&#x2010;441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3090745</ArticleId><ArticleId IdType="pubmed">21460841</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert J&#x2010;C, Zelenika D, Hiltunen M, et&#xa0;al. Evidence of the association of BIN1 and PICALM with the AD risk in contrasting European populations. Neurobiol Aging. 2011;32:756.e11&#x2010;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">21220176</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollingworth P, Harold D, Sims R, et&#xa0;al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet. 2011;43:429&#x2010;435.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3084173</ArticleId><ArticleId IdType="pubmed">21460840</ArticleId></ArticleIdList></Reference><Reference><Citation>Jun G, Naj AC, Beecham GW, et&#xa0;al. Meta&#x2010;analysis confirms CR1, CLU, and PICALM as alzheimer disease risk loci and reveals interactions with APOE genotypes. Arch Neurol. 2010;67:1473&#x2010;1484.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3048805</ArticleId><ArticleId IdType="pubmed">20697030</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert J&#x2010;C, Heath S, Even G, et&#xa0;al. Genome&#x2010;wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet. 2009;41:1094&#x2010;1099.</Citation><ArticleIdList><ArticleId IdType="pubmed">19734903</ArticleId></ArticleIdList></Reference><Reference><Citation>Harold D, Abraham R, Hollingworth P, et&#xa0;al. Genome&#x2010;wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet. 2009;41:1088&#x2010;1093.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2845877</ArticleId><ArticleId IdType="pubmed">19734902</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen IE, Savage JE, Watanabe K, et&#xa0;al. Genome&#x2010;wide meta&#x2010;analysis identifies new loci and functional pathways influencing Alzheimer's disease risk. Nat Genet. 2019;51:404&#x2010;413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6836675</ArticleId><ArticleId IdType="pubmed">30617256</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunkle BW, Grenier&#x2010;Boley B, Sims R, et&#xa0;al. Genetic meta&#x2010;analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A&#x3b2;, tau, immunity and lipid processing. Nat Genet. 2019;51:414&#x2010;430.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6463297</ArticleId><ArticleId IdType="pubmed">30820047</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickman SE, Kingery ND, Ohsumi TK, et&#xa0;al. The microglial sensome revealed by direct RNA sequencing. Nat Neurosci. 2013;16:1896&#x2010;1905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3840123</ArticleId><ArticleId IdType="pubmed">24162652</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, Gaiteri C, Bodea L&#x2010;G, et&#xa0;al. Integrated systems approach identifies genetic nodes and networks in late&#x2010;onset Alzheimer's disease. Cell. 2013;153:707&#x2010;720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677161</ArticleId><ArticleId IdType="pubmed">23622250</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren&#x2010;Shaul H, Spinrad A, Weiner A, et&#xa0;al. A unique microglia type associated with restricting development of Alzheimer's disease. Cell. 2017;169:1276&#x2010;1290.e17.</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, Wojtas A, Bras J, et&#xa0;al. TREM2 variants in Alzheimer's disease. N Engl J Med. 2013;368:117&#x2010;127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou S&#x2010;L, Tan C&#x2010;C, Hou X&#x2010;H, Cao X&#x2010;P, Tan L, Yu J&#x2010;T. TREM2 variants and neurodegenerative diseases: a systematic review and meta&#x2010;analysis. JAD. 2019;68:1171&#x2010;1184.</Citation><ArticleIdList><ArticleId IdType="pubmed">30883352</ArticleId></ArticleIdList></Reference><Reference><Citation>Paloneva J, Kestil&#xe4; M, Wu J, et&#xa0;al. Loss&#x2010;of&#x2010;function mutations in TYROBP (DAP12) result in a presenile dementia with bone cysts. Nat Genet. 2000;25:357&#x2010;361.</Citation><ArticleIdList><ArticleId IdType="pubmed">10888890</ArticleId></ArticleIdList></Reference><Reference><Citation>Pottier C, Ravenscroft TA, Brown PH, et&#xa0;al. TYROBP genetic variants in early&#x2010;onset Alzheimer's disease. Neurobiol Aging. 2016;48:222.e9&#x2010;222.e15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5159294</ArticleId><ArticleId IdType="pubmed">27658901</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, Wu X, Li X, et&#xa0;al. TREM2 Is a Receptor for &#x3b2;&#x2010;Amyloid that mediates microglial function. Neuron. 2018;97:1023&#x2010;1031.e7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5889092</ArticleId><ArticleId IdType="pubmed">29518356</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen DV, Hanson JE, Sheng M. Microglia in Alzheimer's disease. J Cell Biol. 2018;217:459&#x2010;472.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5800817</ArticleId><ArticleId IdType="pubmed">29196460</ArticleId></ArticleIdList></Reference><Reference><Citation>Montalvo V, Quigley L, Vistica BP, et&#xa0;al. Environmental factors determine DAP12 deficiency to either enhance or suppress immunopathogenic processes. Immunology. 2013;140:475&#x2010;482.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3839651</ArticleId><ArticleId IdType="pubmed">23906311</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann S, Madore C, Cialic R, et&#xa0;al. The TREM2&#x2010;APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity. 2017;47:566&#x2010;581.e9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5719893</ArticleId><ArticleId IdType="pubmed">28930663</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahley RW. Apolipoprotein E: remarkable protein sheds light on cardiovascular and neurological diseases. Clin Chem. 2017;63:14&#x2010;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">28062606</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc Natl Acad Sci U S A. 2006;103:5644&#x2010;5651.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1414631</ArticleId><ArticleId IdType="pubmed">16567625</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanier LL. DAP10&#x2010; and DAP12&#x2010;associated receptors in innate immunity. Immunological Rev. 2009;227:150&#x2010;160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2794881</ArticleId><ArticleId IdType="pubmed">19120482</ArticleId></ArticleIdList></Reference><Reference><Citation>Dardiotis E, Siokas V, Pantazi E, et&#xa0;al. A novel mutation in TREM2 gene causing Nasu&#x2010;Hakola disease and review of the literature. Neurobiol Aging. 2017;53:194.e13&#x2010;194.e22.</Citation><ArticleIdList><ArticleId IdType="pubmed">28214109</ArticleId></ArticleIdList></Reference><Reference><Citation>Haure&#x2010;Mirande J&#x2010;V, Audrain M, Fanutza T, et&#xa0;al. Deficiency of TYROBP, an adapter protein for TREM2 and CR3 receptors, is neuroprotective in a mouse model of early Alzheimer's pathology. Acta Neuropathol. 2017;134:769&#x2010;788.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5645450</ArticleId><ArticleId IdType="pubmed">28612290</ArticleId></ArticleIdList></Reference><Reference><Citation>Haure&#x2010;Mirande J&#x2010;V, Wang M, Audrain M, et&#xa0;al. Integrative approach to sporadic Alzheimer's disease: deficiency of TYROBP in cerebral A&#x3b2; amyloidosis mouse normalizes clinical phenotype and complement subnetwork molecular pathology without reducing A&#x3b2; burden. Mol Psychiatry. 2019;24(3):431&#x2010;446.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6494440</ArticleId><ArticleId IdType="pubmed">30283032</ArticleId></ArticleIdList></Reference><Reference><Citation>Audrain M, Haure&#x2010;Mirande J&#x2010;V, Wang M, et&#xa0;al. Integrative approach to sporadic Alzheimer's disease: deficiency of TYROBP in a tauopathy mouse model reduces C1q and normalizes clinical phenotype while increasing spread and state of phosphorylation of tau. Mol Psychiatry. 2019;24(9):1383&#x2010;1397.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6447470</ArticleId><ArticleId IdType="pubmed">30283031</ArticleId></ArticleIdList></Reference><Reference><Citation>Jay TR, Miller CM, Cheng PJ, et&#xa0;al. TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer's disease mouse models. J Experiment Med. 2015;212:287&#x2010;295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4354365</ArticleId><ArticleId IdType="pubmed">25732305</ArticleId></ArticleIdList></Reference><Reference><Citation>Leyns CEG, Ulrich JD, Finn MB, et&#xa0;al. TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy. Proc Natl Acad Sci USA. 2017;114:11524&#x2010;11529.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5663386</ArticleId><ArticleId IdType="pubmed">29073081</ArticleId></ArticleIdList></Reference><Reference><Citation>Bemiller SM, McCray TJ, Allan K, et&#xa0;al. TREM2 deficiency exacerbates tau pathology through dysregulated kinase signaling in a mouse model of tauopathy. Mol Neurodegener. 2017;12:74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5644120</ArticleId><ArticleId IdType="pubmed">29037207</ArticleId></ArticleIdList></Reference><Reference><Citation>Sayed FA, Telpoukhovskaia M, Kodama L, et&#xa0;al. Differential effects of partial and complete loss of TREM2 on microglial injury response and tauopathy. Proc Natl Acad Sci USA. 2018;115:10172&#x2010;10177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6176614</ArticleId><ArticleId IdType="pubmed">30232263</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CYD, Daggett A, Gu X, et&#xa0;al. Elevated TREM2 gene dosage reprograms microglia responsivity and ameliorates pathological phenotypes in Alzheimer's disease models. Neuron. 2018;97:1032&#x2010;1048.e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5927822</ArticleId><ArticleId IdType="pubmed">29518357</ArticleId></ArticleIdList></Reference><Reference><Citation>Gratuze M, Leyns CEG, Sauerbeck AD, et&#xa0;al. Impact of TREM2R47H variant on tau pathology&#x2013;induced gliosis and neurodegeneration. J Clin Investigation. 2020;130(9):4954&#x2010;4968.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7456230</ArticleId><ArticleId IdType="pubmed">32544086</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Song WM, Andhey PS, et&#xa0;al. Human and mouse single&#x2010;nucleus transcriptomics reveal TREM2&#x2010;dependent and TREM2&#x2010;independent cellular responses in Alzheimer's disease. Nat Med. 2020;26:131&#x2010;142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6980793</ArticleId><ArticleId IdType="pubmed">31932797</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Manis M, Long J, et&#xa0;al. Microglia drive APOE&#x2010;dependent neurodegeneration in a tauopathy mouse model. J Exp Med. 2019;216(11):2546&#x2010;2561.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6829593</ArticleId><ArticleId IdType="pubmed">31601677</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich JD, Ulland TK, Mahan TE, et&#xa0;al. ApoE facilitates the microglial response to amyloid plaque pathology. J Exp Med. 2018;215:1047&#x2010;1058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5881464</ArticleId><ArticleId IdType="pubmed">29483128</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen W&#x2010;T, Lu A, Craessaerts K, et&#xa0;al. Spatial transcriptomics and in situ sequencing to study Alzheimer's disease. Cell. 2020;182(4):976&#x2010;991.e19.S0092867420308151.</Citation><ArticleIdList><ArticleId IdType="pubmed">32702314</ArticleId></ArticleIdList></Reference><Reference><Citation>Meilandt WJ, Ngu H, Gogineni A, et&#xa0;al. Trem2 deletion reduces late&#x2010;stage amyloid plaque accumulation, elevates the A&#x3b2;42:a&#x3b2;40 ratio, and exacerbates axonal dystrophy and dendritic spine loss in the PS2APP Alzheimer's mouse model. J Neurosci. 2020;40(9):1956&#x2010;1974.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7046459</ArticleId><ArticleId IdType="pubmed">31980586</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Cella M, Mallinson K, et&#xa0;al. TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. Cell. 2015;160:1061&#x2010;1071.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference><Reference><Citation>Parhizkar S, Arzberger T, Brendel M, et&#xa0;al. Loss of TREM2 function increases amyloid seeding but reduces plaque&#x2010;associated ApoE. Nat Neurosci. 2019;22(2):191&#x2010;204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6417433</ArticleId><ArticleId IdType="pubmed">30617257</ArticleId></ArticleIdList></Reference><Reference><Citation>Kloske CM, Wilcock DM. The important interface between apolipoprotein e and neuroinflammation in Alzheimer's disease. Front Immunol. 2020;11:754.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7203730</ArticleId><ArticleId IdType="pubmed">32425941</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitz NF, Wolfe CM, Playso BE, et&#xa0;al. Trem2 deficiency differentially affects phenotype and transcriptome of human APOE3 and APOE4 mice. Mol Neurodegeneration. 2020;15:41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7379780</ArticleId><ArticleId IdType="pubmed">32703241</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanier LL, Corliss BC, Wu J, Leong C, Phillips JH. Immunoreceptor DAP12 bearing a tyrosine&#x2010;based activation motif is involved in activating NK cells. Nature. 1998;391:703&#x2010;707.</Citation><ArticleIdList><ArticleId IdType="pubmed">9490415</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomasello E, Olcese L, V&#xe9;ly F, et&#xa0;al. Gene structure, expression pattern, and biological activity of mouse killer cell activating receptor&#x2010;associated protein (KARAP)/DAP&#x2010;12. J Biol Chem. 1998;273:34115&#x2010;34119.</Citation><ArticleIdList><ArticleId IdType="pubmed">9852069</ArticleId></ArticleIdList></Reference><Reference><Citation>Siddiqui SS, Matar R, Merheb M, et&#xa0;al. Siglecs in brain function and neurological disorders. Cells. 2019;8:1125.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6829431</ArticleId><ArticleId IdType="pubmed">31546700</ArticleId></ArticleIdList></Reference><Reference><Citation>Salminen A, Kaarniranta K. Siglec receptors and hiding plaques in Alzheimer's disease. J Mol Med. 2009;87:697&#x2010;701.</Citation><ArticleIdList><ArticleId IdType="pubmed">19390836</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram L, Lange C, Mullin K, et&#xa0;al. Genome&#x2010;wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE. Am J Hum Genet. 2008;83:623&#x2010;632.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2668052</ArticleId><ArticleId IdType="pubmed">18976728</ArticleId></ArticleIdList></Reference><Reference><Citation>Griciuc A, Patel S, Federico AN, et&#xa0;al. TREM2 acts downstream of CD33 in modulating microglial pathology in Alzheimer's disease. Neuron. 2019;103:820&#x2010;835.e7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6728215</ArticleId><ArticleId IdType="pubmed">31301936</ArticleId></ArticleIdList></Reference><Reference><Citation>Maphis N, Xu G, Kokiko&#x2010;Cochran ON, et&#xa0;al. Reactive microglia drive tau pathology and contribute to the spreading of pathological tau in the brain. Brain. 2015;138:1738&#x2010;1755.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4542622</ArticleId><ArticleId IdType="pubmed">25833819</ArticleId></ArticleIdList></Reference><Reference><Citation>Asai H, Ikezu S, Tsunoda S, et&#xa0;al. Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nat Neurosci. 2015;18:1584&#x2010;1593.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4694577</ArticleId><ArticleId IdType="pubmed">26436904</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W, Fan J, Kulic I, et&#xa0;al. Axl receptor tyrosine kinase is a regulator of apolipoprotein E. Mol Brain. 2020;13:66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7197143</ArticleId><ArticleId IdType="pubmed">32366277</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy O, Lavalette S, Hu SJ, et&#xa0;al. APOE isoforms control pathogenic subretinal inflammation in age&#x2010;related macular degeneration. J Neurosci. 2015;35:13568&#x2010;13576.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6605380</ArticleId><ArticleId IdType="pubmed">26446211</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy O, Calippe B, Lavalette S, et&#xa0;al. Apolipoprotein E promotes subretinal mononuclear phagocyte survival and chronic inflammation in age&#x2010;related macular degeneration. EMBO Mol Med. 2015;7:211&#x2010;226.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4328649</ArticleId><ArticleId IdType="pubmed">25604058</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, Fadale DJ, Anderson J, et&#xa0;al. Mutant presenilins specifically elevate the levels of the 42 residue beta&#x2010;amyloid peptide in vivo: evidence for augmentation of a 42&#x2010;specific gamma secretase. Hum Mol Genet. 2004;13:159&#x2010;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">14645205</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H, Cole SL, Logan S, et&#xa0;al. Intraneuronal beta&#x2010;amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci. 2006;26:10129&#x2010;10140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama Y, Higuchi M, Zhang B, et&#xa0;al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 2007;53:337&#x2010;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">17270732</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan P, Condello C, Keene CD, et&#xa0;al. TREM2 haplodeficiency in mice and humans impairs the microglia barrier function leading to decreased amyloid compaction and severe axonal dystrophy. Neuron. 2016;90:724&#x2010;739.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4898967</ArticleId><ArticleId IdType="pubmed">27196974</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoogland ICM, Houbolt C, van Westerloo DJ, van Gool WA, van de Beek D. Systemic inflammation and microglial activation: systematic review of animal experiments. J Neuroinflammation. 2015;12:114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4470063</ArticleId><ArticleId IdType="pubmed">26048578</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka KF, Matsui K, Sasaki T, et&#xa0;al. Expanding the repertoire of optogenetically targeted cells with an enhanced gene expression system. Cell Reports. 2012;2:397&#x2010;406.</Citation><ArticleIdList><ArticleId IdType="pubmed">22854021</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke D, Penrose MA, Harvey AR, Rodger J, Bates KA. Low intensity rTMS has sex&#x2010;dependent effects on the local response of glia following a penetrating cortical stab injury. Exp Neurol. 2017;295:233&#x2010;242.</Citation><ArticleIdList><ArticleId IdType="pubmed">28624361</ArticleId></ArticleIdList></Reference><Reference><Citation>Chishti MA, Yang DS, Janus C, et&#xa0;al. Early&#x2010;onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J Biol Chem. 2001;276:21562&#x2010;21570.</Citation><ArticleIdList><ArticleId IdType="pubmed">11279122</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang SS, Kurti A, Baker KE, et&#xa0;al. Behavioral and transcriptomic analysis of Trem2&#x2010;null mice: not all knockout mice are created equal. Human Molecular Genetics. 2018;27:211&#x2010;223.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5886290</ArticleId><ArticleId IdType="pubmed">29040522</ArticleId></ArticleIdList></Reference><Reference><Citation>Litvinchuk A, Wan Y&#x2010;W, Swartzlander DB, et&#xa0;al. Complement C3aR inactivation attenuates tau pathology and reverses an immune network deregulated in tauopathy models and Alzheimer's disease. Neuron. 2018;100:1337&#x2010;1353.e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6309202</ArticleId><ArticleId IdType="pubmed">30415998</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">33328329</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>23</Day></DateCompleted><DateRevised><Year>2025</Year><Month>04</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>574</Issue><PubDate><Year>2020</Year><Month>Dec</Month><Day>16</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle><i>Chi3l1</i>/YKL-40 is controlled by the astrocyte circadian clock and regulates neuroinflammation and Alzheimer's disease pathogenesis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">eaax3519</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.aax3519</ELocationID><Abstract><AbstractText>Regulation of glial activation and neuroinflammation are critical factors in the pathogenesis of Alzheimer's disease (AD). YKL-40, a primarily astrocytic protein encoded by the gene <i>Chi3l1</i>, is a widely studied cerebrospinal fluid biomarker that increases with aging and early in AD. However, the function of <i>Chi3l1</i>/YKL-40 in AD is unknown. In a cohort of patients with AD, we observed that a variant in the human <i>CHI3L1</i> gene, which results in decreased CSF YKL-40 expression, was associated with slower AD progression. At baseline, <i>Chi3l1</i> deletion in mice had no effect on astrocyte activation while modestly promoting microglial activation. In a mouse APP/PS1 model of AD, <i>Chi3l1</i> deletion decreased amyloid plaque burden and increased periplaque expression of the microglial lysosomal marker CD68, suggesting that <i>Chi3l1</i> may suppress glial phagocytic activation and promote amyloid accumulation. Accordingly, <i>Chi3l1</i> knockdown increased phagocytosis of zymosan particles and of &#x3b2;-amyloid peptide in both astrocytes and microglia in vitro. We further observed that expression of <i>Chi3l1</i> is regulated by the circadian clock, as deletion of the core clock proteins BMAL1 or CLOCK/NPAS2 strongly suppresses basal <i>Chi3l1</i> expression, whereas deletion of the negative clock regulators PER1/PER2 increased <i>Chi3l1</i> expression. Basal <i>Chi3l1</i> mRNA was nonrhythmic because of a long mRNA half-life in astrocytes. However, inflammatory induction of <i>Chi3l1</i> was gated by the clock. Our findings reveal <i>Chi3l1</i>/YKL-40 as a modulator of glial phagocytic activation and AD pathogenesis in both mice and humans and suggest that the astrocyte circadian clock regulates inflammatory <i>Chi3l1</i> induction.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lananna</LastName><ForeName>Brian V</ForeName><Initials>BV</Initials><Identifier Source="ORCID">0000-0003-1328-9619</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McKee</LastName><ForeName>Celia A</ForeName><Initials>CA</Initials><Identifier Source="ORCID">0000-0002-5271-7877</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>King</LastName><ForeName>Melvin W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Del-Aguila</LastName><ForeName>Jorge L</ForeName><Initials>JL</Initials><Identifier Source="ORCID">0000-0002-6364-8707</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dimitry</LastName><ForeName>Julie M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0002-8733-9642</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farias</LastName><ForeName>Fabiana H G</ForeName><Initials>FHG</Initials><Identifier Source="ORCID">0000-0002-5215-7304</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nadarajah</LastName><ForeName>Collin J</ForeName><Initials>CJ</Initials><Identifier Source="ORCID">0000-0001-7275-4723</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>David D</ForeName><Initials>DD</Initials><Identifier Source="ORCID">0000-0003-4990-8063</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Chun</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-2409-3999</Identifier><AffiliationInfo><Affiliation>Department of Pharmacological and Physiological Science, Saint Louis University School of Medicine, St. Louis, MO 63104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cammack</LastName><ForeName>Alexander J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elias</LastName><ForeName>Jack A</ForeName><Initials>JA</Initials><Identifier Source="ORCID">0000-0002-3124-8557</Identifier><AffiliationInfo><Affiliation>Division of Medicine and Biological Sciences, Brown University, Providence, RI 02903, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jinsong</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-8798-7316</Identifier><AffiliationInfo><Affiliation>Department of Pharmacological and Physiological Science, Saint Louis University School of Medicine, St. Louis, MO 63104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cruchaga</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-0276-2899</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center and Hope Center for Neurological Disease, Washington University School of Medicine, St. Louis, MO 63108, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Musiek</LastName><ForeName>Erik S</ForeName><Initials>ES</Initials><Identifier Source="ORCID">0000-0002-8873-0360</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA. musieke@wustl.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center and Hope Center for Neurological Disease, Washington University School of Medicine, St. Louis, MO 63108, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG064877</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG058501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG044546</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG054517</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066444</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG058922</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG044546</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG052411</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG053303</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG058501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C084533">CHI3L1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C509289">Chil1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071451">Chitinase-3-Like Protein 1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071451" MajorTopicYN="N">Chitinase-3-Like Protein 1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057906" MajorTopicYN="Y">Circadian Clocks</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing interests:</b> The authors report no financial competing interests. ESM has consulted for Eisai Pharmacauticals. No patents related to this work are pending.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>3</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>4</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>12</Month><Day>17</Day><Hour>5</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>12</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33328329</ArticleId><ArticleId IdType="mid">NIHMS1656632</ArticleId><ArticleId IdType="pmc">PMC7808313</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.aax3519</ArticleId><ArticleId IdType="pii">12/574/eaax3519</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Colonna M, Butovsky O, Microglia Function in the Central Nervous System During Health and Neurodegeneration. Annu Rev Immunol 35, 441&#x2013;468 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8167938</ArticleId><ArticleId IdType="pubmed">28226226</ArticleId></ArticleIdList></Reference><Reference><Citation>Arranz AM, De Strooper B, The role of astroglia in Alzheimer&#x2019;s disease: pathophysiology and clinical implications. Lancet Neurol, (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30795987</ArticleId></ArticleIdList></Reference><Reference><Citation>Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, Bennett ML, Munch AE, Chung WS, Peterson TC, Wilton DK, Frouin A, Napier BA, Panicker N, Kumar M, Buckwalter MS, Rowitch DH, Dawson VL, Dawson TM, Stevens B, Barres BA, Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541, 481&#x2013;487 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5404890</ArticleId><ArticleId IdType="pubmed">28099414</ArticleId></ArticleIdList></Reference><Reference><Citation>Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ, Mintun MA, Peskind ER, Li G, Galasko DR, Clark CM, Quinn JF, D&#x2019;Angelo G, Malone JP, Townsend RR, Morris JC, Fagan AM, Holtzman DM, YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer&#x2019;s disease. Biological psychiatry 68, 903&#x2013;912 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3011944</ArticleId><ArticleId IdType="pubmed">21035623</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutphen CL, Jasielec MS, Shah AR, Macy EM, Xiong C, Vlassenko AG, Benzinger TL, Stoops EE, Vanderstichele HM, Brix B, Darby HD, Vandijck ML, Ladenson JH, Morris JC, Holtzman DM, Fagan AM, Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age. JAMA Neurol 72, 1029&#x2013;1042 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4570860</ArticleId><ArticleId IdType="pubmed">26147946</ArticleId></ArticleIdList></Reference><Reference><Citation>Llorens F, Thune K, Tahir W, Kanata E, Diaz-Lucena D, Xanthopoulos K, Kovatsi E, Pleschka C, Garcia-Esparcia P, Schmitz M, Ozbay D, Correia S, Correia A, Milosevic I, Andreoletti O, Fernandez-Borges N, Vorberg IM, Glatzel M, Sklaviadis T, Torres JM, Krasemann S, Sanchez-Valle R, Ferrer I, Zerr I, YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias. Mol Neurodegener 12, 83 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5681777</ArticleId><ArticleId IdType="pubmed">29126445</ArticleId></ArticleIdList></Reference><Reference><Citation>Malmestrom C, Axelsson M, Lycke J, Zetterberg H, Blennow K, Olsson B, CSF levels of YKL-40 are increased in MS and replaces with immunosuppressive treatment. J Neuroimmunol 269, 87&#x2013;89 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24582001</ArticleId></ArticleIdList></Reference><Reference><Citation>Illan-Gala I, Alcolea D, Montal V, Dols-Icardo O, Munoz L, de Luna N, Turon-Sans J, Cortes-Vicente E, Sanchez-Saudinos MB, Subirana A, Sala I, Blesa R, Clarimon J, Fortea J, Rojas-Garcia R, Lleo A, CSF sAPPbeta YKL -40, and NfL along the ALS-FTD spectrum. Neurology 91, e1619&#x2013;e1628 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30291183</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcolea D, Vilaplana E, Suarez-Calvet M, Illan-Gala I, Blesa R, Clarimon J, Llado A, Sanchez-Valle R, Molinuevo JL, Garcia-Ribas G, Compta Y, Marti MJ, Pinol-Ripoll G, Amer-Ferrer G, Noguera A, Garcia-Martin A, Fortea J, Lleo A, CSF sAPPbeta, YKL-40, and neurofilament light in frontotemporal lobar degeneration. Neurology 89, 178&#x2013;188 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28592456</ArticleId></ArticleIdList></Reference><Reference><Citation>Querol-Vilaseca M, Colom-Cadena M, Pegueroles J, San Martin-Paniello C, Clarimon J, Belbin O, Fortea J, Lleo A, YKL-40 (Chitinase 3-like I) is expressed in a subset of astrocytes in Alzheimer&#x2019;s disease and other tauopathies. J Neuroinflammation 14, 118 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5466718</ArticleId><ArticleId IdType="pubmed">28599675</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhardwaj R, Yester JW, Singh SK, Biswas DD, Surace MJ, Waters MR, Hauser KF, Yao Z, Boyce BF, Kordula T, RelB/p50 complexes regulate cytokine-induced YKL-40 expression. J Immunol 194, 2862&#x2013;2870 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4355396</ArticleId><ArticleId IdType="pubmed">25681350</ArticleId></ArticleIdList></Reference><Reference><Citation>He CH, Lee CG, Dela Cruz CS, Lee CM, Zhou Y, Ahangari F, Ma B, Herzog EL, Rosenberg SA, Li Y, Nour AM, Parikh CR, Schmidt I, Modis Y, Cantley L, Elias JA, Chitinase 3-like 1 regulates cellular and tissue responses via IL-13 receptor alpha2. Cell Rep 4, 830&#x2013;841 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3988532</ArticleId><ArticleId IdType="pubmed">23972995</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonneh-Barkay D, Wang G, Laframboise WA, Wiley CA, Bissel SJ, Exacerbation of experimental autoimmune encephalomyelitis in the absence of breast regression protein 39/chitinase 3-like 1. Journal of neuropathology and experimental neurology 71, 948&#x2013;958 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3481009</ArticleId><ArticleId IdType="pubmed">23041842</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiley CA, Bonneh-Barkay D, Dixon CE, Lesniak A, Wang G, Bissel SJ, Kochanek PM, Role for mammalian chitinase 3-like protein 1 in traumatic brain injury. Neuropathology 35, 95&#x2013;106 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25377763</ArticleId></ArticleIdList></Reference><Reference><Citation>Musiek ES, Bhimasani M, Zangrilli MA, Morris JC, Holtzman DM, Ju YE, Circadian Rest-Activity Pattern Changes in Aging and Preclinical Alzheimer Disease. JAMA Neurol 75, 582&#x2013;590 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5885197</ArticleId><ArticleId IdType="pubmed">29379963</ArticleId></ArticleIdList></Reference><Reference><Citation>Musiek ES, Holtzman DM, Mechanisms linking circadian clocks, sleep, and neurodegeneration. Science (New York, N.Y 354, 1004&#x2013;1008 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5219881</ArticleId><ArticleId IdType="pubmed">27885006</ArticleId></ArticleIdList></Reference><Reference><Citation>Kress GJ, Liao F, Dimitry J, Cedeno MR, FitzGerald GA, Holtzman DM, Musiek ES, Regulation of amyloid-beta dynamics and pathology by the circadian clock. J Exp Med 215, 1059&#x2013;1068 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5881473</ArticleId><ArticleId IdType="pubmed">29382695</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohawk JA, Green CB, Takahashi JS, Central and Peripheral Circadian Clocks in Mammals. Annual review of neuroscience 35, 445&#x2013;462 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3710582</ArticleId><ArticleId IdType="pubmed">22483041</ArticleId></ArticleIdList></Reference><Reference><Citation>Curtis AM, Bellet MM, Sassone-Corsi P, O&#x2019;Neill LA, Circadian clock proteins and immunity. Immunity 40, 178&#x2013;186 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24560196</ArticleId></ArticleIdList></Reference><Reference><Citation>Prolo LM, Takahashi JS, Herzog ED, Circadian rhythm generation and entrainment in astrocytes. J Neurosci 25, 404&#x2013;408 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3812245</ArticleId><ArticleId IdType="pubmed">15647483</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonken LK, Frank MG, Kitt MM, Barrientos RM, Watkins LR, Maier SF, Microglia inflammatory responses are controlled by an intrinsic circadian clock. Brain Behav Immun 45, 171&#x2013;179 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4386638</ArticleId><ArticleId IdType="pubmed">25433170</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakazato R, Hotta S, Yamada D, Kou M, Nakamura S, Takahata Y, Tei H, Numano R, Hida A, Shimba S, Mieda M, Hinoi E, Yoneda Y, Takarada T, The intrinsic microglial clock system regulates interleukin-6 expression. Glia 65, 198&#x2013;208 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27726182</ArticleId></ArticleIdList></Reference><Reference><Citation>Musiek ES, Lim MM, Yang G, Bauer AQ, Qi L, Lee Y, Roh JH, Ortiz-Gonzalez X, Dearborn JT, Culver JP, Herzog ED, Hogenesch JB, Wozniak DF, Dikranian K, Giasson BI, Weaver DR, Holtzman DM, Fitzgerald GA, Circadian clock proteins regulate neuronal redox homeostasis and neurodegeneration. J Clin Invest 123, 5389&#x2013;5400 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3859381</ArticleId><ArticleId IdType="pubmed">24270424</ArticleId></ArticleIdList></Reference><Reference><Citation>Lananna BV, Nadarajah CJ, Izumo M, Cedeno MR, Xiong DD, Dimitry J, Tso CF, McKee CA, Griffin P, Sheehan PW, Haspel JA, Barres BA, Liddelow SA, Takahashi JS, Karatsoreos IN, Musiek ES, Cell-Autonomous Regulation of Astrocyte Activation by the Circadian Clock Protein BMAL1. Cell Rep 25, 1&#x2013;9 e5 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6221830</ArticleId><ArticleId IdType="pubmed">30282019</ArticleId></ArticleIdList></Reference><Reference><Citation>Del-Aguila JL, Li Z, Dube U, Mihindukulasuriya KA, Budde JP, Fernandez MV, Ibanez L, Bradley J, Wang F, Bergmann K, Davenport R, Morris JC, Holtzman DM, Perrin RJ, Benitez BA, Dougherty J, Cruchaga C, Harari O, A single-nuclei RNA sequencing study of Mendelian and sporadic AD in the human brain. Alzheimers Res Ther 11, 71 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6689177</ArticleId><ArticleId IdType="pubmed">31399126</ArticleId></ArticleIdList></Reference><Reference><Citation>Deming Y, Black K, Carrell D, Cai Y, Del-Aguila JL, Fernandez MV, Budde J, Ma S, Saef B, Howells B, Bertelsen S, Huang KL, Sutphen CL, Tarawneh R, Fagan AM, Holtzman DM, Morris JC, Goate AM, Dougherty JD, Cruchaga C, Chitinase-3-like 1 protein (CHI3L1) locus influences cerebrospinal fluid levels of YKL-40. BMC Neurol 16, 217 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5105244</ArticleId><ArticleId IdType="pubmed">27832767</ArticleId></ArticleIdList></Reference><Reference><Citation>Del-Aguila JL, Fernandez MV, Schindler S, Ibanez L, Deming Y, Ma S, Saef B, Black K, Budde J, Norton J, Chasse R, Harari O, Goate A, Xiong C, Morris JC, Cruchaga C, Assessment of the Genetic Architecture of Alzheimer&#x2019;s Disease Risk in Rate of Memory Decline. J Alzheimers Dis 62, 745&#x2013;756 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5989565</ArticleId><ArticleId IdType="pubmed">29480181</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Sloan SA, Clarke LE, Caneda C, Plaza CA, Blumenthal PD, Vogel H, Steinberg GK, Edwards MS, Li G, Duncan JA 3rd, Cheshier SH, Shuer LM, Chang EF, Grant GA, Gephart MG, Barres BA, Purification and Characterization of Progenitor and Mature Human Astrocytes Reveals Transcriptional and Functional Differences with Mouse. Neuron 89, 37&#x2013;53 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4707064</ArticleId><ArticleId IdType="pubmed">26687838</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O&#x2019;Keeffe S, Phatnani HP, Guarnieri P, Caneda C, Ruderisch N, Deng S, Liddelow SA, Zhang C, Daneman R, Maniatis T, Barres BA, Wu JQ, An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci 34, 11929&#x2013;11947 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4152602</ArticleId><ArticleId IdType="pubmed">25186741</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CG, Hartl D, Lee GR, Koller B, Matsuura H, Da Silva CA, Sohn MH, Cohn L, Homer RJ, Kozhich AA, Humbles A, Kearley J, Coyle A, Chupp G, Reed J, Flavell RA, Elias JA, Role of breast regression protein 39 (BRP-39)/chitinase 3-like-1 in Th2 and IL-13-induced tissue responses and apoptosis. J Exp Med 206, 1149&#x2013;1166 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2715037</ArticleId><ArticleId IdType="pubmed">19414556</ArticleId></ArticleIdList></Reference><Reference><Citation>Radde R, Bolmont T, Kaeser SA, Coomaraswamy J, Lindau D, Stoltze L, Calhoun ME, Jaggi F, Wolburg H, Gengler S, Haass C, Ghetti B, Czech C, Holscher C, Mathews PM, Jucker M, Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep 7, 940&#x2013;946 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1559665</ArticleId><ArticleId IdType="pubmed">16906128</ArticleId></ArticleIdList></Reference><Reference><Citation>Styren SD, Hamilton RL, Styren GC, Klunk WE, X-34, a fluorescent derivative of Congo red: a novel histochemical stain for Alzheimer&#x2019;s disease pathology. J Histochem Cytochem 48, 1223&#x2013;1232 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10950879</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraft AW, Hu X, Yoon H, Yan P, Xiao Q, Wang Y, Gil SC, Brown J, Wilhelmsson U, Restivo JL, Cirrito JR, Holtzman DM, Kim J, Pekny M, Lee JM, Attenuating astrocyte activation accelerates plaque pathogenesis in APP/PS1 mice. FASEB J 27, 187&#x2013;198 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3528309</ArticleId><ArticleId IdType="pubmed">23038755</ArticleId></ArticleIdList></Reference><Reference><Citation>Reichenbach N, Delekate A, Plescher M, Schmitt F, Krauss S, Blank N, Halle A, Petzold GC, Inhibition of Stat3-mediated astrogliosis ameliorates pathology in an Alzheimer&#x2019;s disease model. EMBO Mol Med 11, (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6365929</ArticleId><ArticleId IdType="pubmed">30617153</ArticleId></ArticleIdList></Reference><Reference><Citation>Koistinaho M, Lin S, Wu X, Esterman M, Koger D, Hanson J, Higgs R, Liu F, Malkani S, Bales KR, Paul SM, Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nature medicine 10, 719&#x2013;726 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15195085</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamanian JL, Xu L, Foo LC, Nouri N, Zhou L, Giffard RG, Barres BA, Genomic analysis of reactive astrogliosis. J Neurosci 32, 6391&#x2013;6410 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3480225</ArticleId><ArticleId IdType="pubmed">22553043</ArticleId></ArticleIdList></Reference><Reference><Citation>Koike N, Yoo SH, Huang HC, Kumar V, Lee C, Kim TK, Takahashi JS, Transcriptional architecture and chromatin landscape of the core circadian clock in mammals. Science (New York, N.Y 338, 349&#x2013;354 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3694775</ArticleId><ArticleId IdType="pubmed">22936566</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, Mattsson N, Stomrud E, Lindberg O, Palmqvist S, Zetterberg H, Blennow K, Hansson O, CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. Neurology 91, e867&#x2013;e877 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6133624</ArticleId><ArticleId IdType="pubmed">30054439</ArticleId></ArticleIdList></Reference><Reference><Citation>Dela Cruz CS, Liu W, He CH, Jacoby A, Gornitzky A, Ma B, Flavell R, Lee CG, Elias JA, Chitinase 3-like-1 promotes Streptococcus pneumoniae killing and augments host tolerance to lung antibacterial responses. Cell Host Microbe 12, 34&#x2013;46 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3613130</ArticleId><ArticleId IdType="pubmed">22817986</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi JY, Yeo IJ, Kim KC, Choi WR, Jung JK, Han SB, Hong JT, K284&#x2013;6111 prevents the amyloid beta-induced neuroinflammation and impairment of recognition memory through inhibition of NF-kappaB-mediated CHI3L1 expression. J Neuroinflammation 15, 224 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6087013</ArticleId><ArticleId IdType="pubmed">30098604</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Song WM, Andhey PS, Swain A, Levy T, Miller KR, Poliani PL, Cominelli M, Grover S, Gilfillan S, Cella M, Ulland TK, Zaitsev K, Miyashita A, Ikeuchi T, Sainouchi M, Kakita A, Bennett DA, Schneider JA, Nichols MR, Beausoleil SA, Ulrich JD, Holtzman DM, Artyomov MN, Colonna M, Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer&#x2019;s disease. Nature medicine 26, 131&#x2013;142 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6980793</ArticleId><ArticleId IdType="pubmed">31932797</ArticleId></ArticleIdList></Reference><Reference><Citation>Lananna BV, Musiek ES, The wrinkling of time: Aging, inflammation, oxidative stress, and the circadian clock in neurodegeneration. Neurobiology of disease 139, 104832 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7727873</ArticleId><ArticleId IdType="pubmed">32179175</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Weintraub S, Chui HC, Cummings J, Decarli C, Ferris S, Foster NL, Galasko D, Graff-Radford N, Peskind ER, Beekly D, Ramos EM, Kukull WA, The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord 20, 210&#x2013;216 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17132964</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33349711</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>08</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Microglia facilitate repair of demyelinated lesions via post-squalene sterol synthesis.</ArticleTitle><Pagination><StartPage>47</StartPage><EndPage>60</EndPage><MedlinePgn>47-60</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41593-020-00757-6</ELocationID><Abstract><AbstractText>The repair of inflamed, demyelinated lesions as in multiple sclerosis (MS) necessitates the clearance of cholesterol-rich myelin debris by microglia/macrophages and the switch from a pro-inflammatory to an anti-inflammatory lesion environment. Subsequently, oligodendrocytes increase cholesterol levels as a prerequisite for synthesizing new myelin membranes. We hypothesized that lesion resolution is regulated by the fate of cholesterol from damaged myelin and oligodendroglial sterol synthesis. By integrating gene expression profiling, genetics and comprehensive phenotyping, we found that, paradoxically, sterol synthesis in myelin-phagocytosing microglia/macrophages determines the repair of acutely demyelinated lesions. Rather than producing cholesterol, microglia/macrophages synthesized desmosterol, the immediate cholesterol precursor. Desmosterol activated liver X receptor (LXR) signaling to resolve inflammation, creating a permissive environment for oligodendrocyte differentiation. Moreover, LXR target gene products facilitated the efflux of lipid and cholesterol from lipid-laden microglia/macrophages to support remyelination by oligodendrocytes. Consequently, pharmacological stimulation of sterol synthesis boosted the repair of demyelinated lesions, suggesting novel therapeutic strategies for myelin repair in MS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Berghoff</LastName><ForeName>Stefan A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Neurogenetics, Max Planck Institute of Experimental Medicine, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spieth</LastName><ForeName>Lena</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-0308-0144</Identifier><AffiliationInfo><Affiliation>Department of Neurogenetics, Max Planck Institute of Experimental Medicine, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Ting</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurogenetics, Max Planck Institute of Experimental Medicine, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Medical Systems Biology, Center for Molecular Neurobiology Hamburg, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hosang</LastName><ForeName>Leon</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute for Neuroimmunology and Multiple Sclerosis Research, University Medical Center G&#xf6;ttingen, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schlaphoff</LastName><ForeName>Lennart</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-8043-4025</Identifier><AffiliationInfo><Affiliation>Department of Neurogenetics, Max Planck Institute of Experimental Medicine, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Depp</LastName><ForeName>Constanze</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-2868-6932</Identifier><AffiliationInfo><Affiliation>Department of Neurogenetics, Max Planck Institute of Experimental Medicine, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D&#xfc;king</LastName><ForeName>Tim</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurogenetics, Max Planck Institute of Experimental Medicine, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Winchenbach</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurogenetics, Max Planck Institute of Experimental Medicine, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neuber</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurogenetics, Max Planck Institute of Experimental Medicine, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ewers</LastName><ForeName>David</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-1037-1027</Identifier><AffiliationInfo><Affiliation>Department of Neurogenetics, Max Planck Institute of Experimental Medicine, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Neurophysiology, University Medical Centre G&#xf6;ttingen, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University Medical Centre, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scholz</LastName><ForeName>Patricia</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-0761-9175</Identifier><AffiliationInfo><Affiliation>Department of Plant Biochemistry, Albrecht-von-Haller-Institute for Plant Sciences and G&#xf6;ttingen Center for Molecular Biosciences (GZMB), University of G&#xf6;ttingen, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Meer</LastName><ForeName>Franziska</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Institute for Neuropathology, University Medical Centre G&#xf6;ttingen, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cantuti-Castelvetri</LastName><ForeName>Ludovico</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-0642-1610</Identifier><AffiliationInfo><Affiliation>Institute of Neuronal Cell Biology, Technical University Munich, German Center for Neurodegenerative Diseases, Munich Cluster of Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sasmita</LastName><ForeName>Andrew O</ForeName><Initials>AO</Initials><Identifier Source="ORCID">0000-0001-7379-6749</Identifier><AffiliationInfo><Affiliation>Department of Neurogenetics, Max Planck Institute of Experimental Medicine, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meschkat</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurogenetics, Max Planck Institute of Experimental Medicine, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruhwedel</LastName><ForeName>Torben</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-9535-9395</Identifier><AffiliationInfo><Affiliation>Department of Neurogenetics, Max Planck Institute of Experimental Medicine, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xf6;bius</LastName><ForeName>Wiebke</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0002-2902-7165</Identifier><AffiliationInfo><Affiliation>Department of Neurogenetics, Max Planck Institute of Experimental Medicine, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sankowski</LastName><ForeName>Roman</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-9215-8021</Identifier><AffiliationInfo><Affiliation>Institute of Neuropathology, Medical Faculty, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prinz</LastName><ForeName>Marco</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0349-1955</Identifier><AffiliationInfo><Affiliation>Institute of Neuropathology, Medical Faculty, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Signalling Research Centres BIOSS and CIBSS, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Basics in NeuroModulation (NeuroModul Basics), Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huitinga</LastName><ForeName>Inge</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-4878-8920</Identifier><AffiliationInfo><Affiliation>Neuroimmunology Research Group, Netherlands Institute for Neuroscience, an institute of the Royal Netherlands Academy of Arts and Sciences, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sereda</LastName><ForeName>Michael W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>Department of Neurogenetics, Max Planck Institute of Experimental Medicine, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Neurophysiology, University Medical Centre G&#xf6;ttingen, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University Medical Centre, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Odoardi</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Institute for Neuroimmunology and Multiple Sclerosis Research, University Medical Center G&#xf6;ttingen, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ischebeck</LastName><ForeName>Till</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Plant Biochemistry, Albrecht-von-Haller-Institute for Plant Sciences and G&#xf6;ttingen Center for Molecular Biosciences (GZMB), University of G&#xf6;ttingen, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Service Unit for Metabolomics and Lipidomics, G&#xf6;ttingen Center for Molecular Biosciences (GZMB), University of G&#xf6;ttingen, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simons</LastName><ForeName>Mikael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Neuronal Cell Biology, Technical University Munich, German Center for Neurodegenerative Diseases, Munich Cluster of Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stadelmann-Nessler</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute for Neuropathology, University Medical Centre G&#xf6;ttingen, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Edgar</LastName><ForeName>Julia M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Neurogenetics, Max Planck Institute of Experimental Medicine, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Applied Neurobiology Group, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nave</LastName><ForeName>Klaus-Armin</ForeName><Initials>KA</Initials><Identifier Source="ORCID">0000-0001-8724-9666</Identifier><AffiliationInfo><Affiliation>Department of Neurogenetics, Max Planck Institute of Experimental Medicine, G&#xf6;ttingen, Germany. nave@em.mpg.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saher</LastName><ForeName>Gesine</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-3507-9604</Identifier><AffiliationInfo><Affiliation>Department of Neurogenetics, Max Planck Institute of Experimental Medicine, G&#xf6;ttingen, Germany. saher@em.mpg.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>204034</GrantID><Acronym>ERC_</Acronym><Agency>European Research Council</Agency><Country>International</Country></Grant><Grant><GrantID>269020</GrantID><Acronym>ERC_</Acronym><Agency>European Research Council</Agency><Country>International</Country></Grant><Grant><GrantID>38.0</GrantID><Acronym>MSS_</Acronym><Agency>Multiple Sclerosis Society</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>NC/L000423/1</GrantID><Acronym>NC3RS_</Acronym><Agency>National Centre for the Replacement, Refinement and Reduction of Animals in Research</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>12</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071518">Liver X Receptors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000605214">Nr1h3 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013261">Sterols</NameOfSubstance></Chemical><Chemical><RegistryNumber>313-04-2</RegistryNumber><NameOfSubstance UI="D003897">Desmosterol</NameOfSubstance></Chemical><Chemical><RegistryNumber>7QWM220FJH</RegistryNumber><NameOfSubstance UI="D013185">Squalene</NameOfSubstance></Chemical><Chemical><RegistryNumber>97C5T2UQ7J</RegistryNumber><NameOfSubstance UI="D002784">Cholesterol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002784" MajorTopicYN="N">Cholesterol</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003711" MajorTopicYN="N">Demyelinating Diseases</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003897" MajorTopicYN="N">Desmosterol</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004681" MajorTopicYN="N">Encephalomyelitis, Autoimmune, Experimental</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050356" MajorTopicYN="N">Lipid Metabolism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071518" MajorTopicYN="N">Liver X Receptors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009103" MajorTopicYN="N">Multiple Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009836" MajorTopicYN="N">Oligodendroglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010587" MajorTopicYN="N">Phagocytosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013185" MajorTopicYN="N">Squalene</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013261" MajorTopicYN="N">Sterols</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>
<b>Competing interests</b>
. SAB and GS are listed as inventors on pending patent claims (PCT###) filed by MPG covering the application of squalene in demyelinating disorders.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>4</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>11</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>12</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>12</Month><Day>22</Day><Hour>5</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>2</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33349711</ArticleId><ArticleId IdType="mid">EMS114908</ArticleId><ArticleId IdType="pmc">PMC7116742</ArticleId><ArticleId IdType="doi">10.1038/s41593-020-00757-6</ArticleId><ArticleId IdType="pii">10.1038/s41593-020-00757-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dietschy JM. Central nervous system: cholesterol turnover, brain development and neurodegeneration. Biological chemistry. 2009;390:287&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3066069</ArticleId><ArticleId IdType="pubmed">19166320</ArticleId></ArticleIdList></Reference><Reference><Citation>Saher G, et al. High cholesterol level is essential for myelin membrane growth. Nature neuroscience. 2005;8:468&#x2013;475.</Citation><ArticleIdList><ArticleId IdType="pubmed">15793579</ArticleId></ArticleIdList></Reference><Reference><Citation>Courtney R, Landreth GE. LXR Regulation of Brain Cholesterol: From Development to Disease. Trends in endocrinology and metabolism: TEM. 2016;27:404&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4986614</ArticleId><ArticleId IdType="pubmed">27113081</ArticleId></ArticleIdList></Reference><Reference><Citation>Reich DS, Lucchinetti CF, Calabresi PA. Multiple Sclerosis. The New England journal of medicine. 2018;378:169&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6942519</ArticleId><ArticleId IdType="pubmed">29320652</ArticleId></ArticleIdList></Reference><Reference><Citation>Plemel JR, Liu WQ, Yong VW. Remyelination therapies: a new direction and challenge in multiple sclerosis. Nature reviews Drug discovery. 2017;16:617&#x2013;634.</Citation><ArticleIdList><ArticleId IdType="pubmed">28685761</ArticleId></ArticleIdList></Reference><Reference><Citation>Itoh N, et al. Cell-specific and region-specific transcriptomics in the multiple sclerosis model: Focus on astrocytes. Proceedings of the National Academy of Sciences of the United States of America. 2018;115:E302&#x2013;E309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5777065</ArticleId><ArticleId IdType="pubmed">29279367</ArticleId></ArticleIdList></Reference><Reference><Citation>Voskuhl RR, et al. Gene expression in oligodendrocytes during remyelination reveals cholesterol homeostasis as a therapeutic target in multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America. 2019;116:10130&#x2013;10139.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6525478</ArticleId><ArticleId IdType="pubmed">31040210</ArticleId></ArticleIdList></Reference><Reference><Citation>Jurevics H, et al. Alterations in metabolism and gene expression in brain regions during cuprizone-induced demyelination and remyelination. Journal of neurochemistry. 2002;82:126&#x2013;136.</Citation><ArticleIdList><ArticleId IdType="pubmed">12091473</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavrnja I, et al. Expression profiles of cholesterol metabolism-related genes are altered during development of experimental autoimmune encephalomyelitis in the rat spinal cord. Scientific reports. 2017;7:2702.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5457442</ArticleId><ArticleId IdType="pubmed">28578430</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunha MI, et al. Pro-inflammatory activation following demyelination is required for myelin clearance and oligodendrogenesis. J Exp Med. 2020;217</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7201919</ArticleId><ArticleId IdType="pubmed">32078678</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeung MSY, et al. Dynamics of oligodendrocyte generation in multiple sclerosis. Nature. 2019;566:538&#x2013;542.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6420067</ArticleId><ArticleId IdType="pubmed">30675058</ArticleId></ArticleIdList></Reference><Reference><Citation>Berghoff SA, et al. Dietary cholesterol promotes repair of demyelinated lesions in the adult brain. Nature Communications. 2017;8 14241.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5286209</ArticleId><ArticleId IdType="pubmed">28117328</ArticleId></ArticleIdList></Reference><Reference><Citation>Spann NJ, et al. Regulated accumulation of desmosterol integrates macrophage lipid metabolism and inflammatory responses. Cell. 2012;151:138&#x2013;152.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3464914</ArticleId><ArticleId IdType="pubmed">23021221</ArticleId></ArticleIdList></Reference><Reference><Citation>Meschkat M, et al. White matter integrity requires continuous myelin synthesis at the inner tongue. bioRxiv. 2020 2020.2009.2002.279612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8897471</ArticleId><ArticleId IdType="pubmed">35246535</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantuti-Castelvetri L, et al. Defective cholesterol clearance limits remyelination in the aged central nervous system. Science. 2018;359:684&#x2013;688.</Citation><ArticleIdList><ArticleId IdType="pubmed">29301957</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotter MR, Li WW, Zhao C, Franklin RJ. Myelin impairs CNS remyelination by inhibiting oligodendrocyte precursor cell differentiation. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2006;26:328&#x2013;332.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674302</ArticleId><ArticleId IdType="pubmed">16399703</ArticleId></ArticleIdList></Reference><Reference><Citation>Duewell P, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010;464:1357&#x2013;1361.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2946640</ArticleId><ArticleId IdType="pubmed">20428172</ArticleId></ArticleIdList></Reference><Reference><Citation>Boven LA, et al. Myelin-laden macrophages are anti-inflammatory, consistent with foam cells in multiple sclerosis. Brain : a journal of neurology. 2006;129:517&#x2013;526.</Citation><ArticleIdList><ArticleId IdType="pubmed">16364958</ArticleId></ArticleIdList></Reference><Reference><Citation>Widenmaier SB, et al. NRF1 Is an ER Membrane Sensor that Is Central to Cholesterol Homeostasis. Cell. 2017;171:1094&#x2013;1109 e1015.</Citation><ArticleIdList><ArticleId IdType="pubmed">29149604</ArticleId></ArticleIdList></Reference><Reference><Citation>Jakel S, et al. Altered human oligodendrocyte heterogeneity in multiple sclerosis. Nature. 2019;566:543&#x2013;547.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6544546</ArticleId><ArticleId IdType="pubmed">30747918</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda T, et al. Spatial and temporal heterogeneity of mouse and human microglia at single-cell resolution. Nature. 2019;566:388&#x2013;392.</Citation><ArticleIdList><ArticleId IdType="pubmed">30760929</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardeno A, et al. Squalene targets pro- and anti-inflammatory mediators and pathways to modulate over-activation of neutrophils, monocytes and macrophages. J Funct Foods. 2015;14:779&#x2013;790.</Citation></Reference><Reference><Citation>Saher G, et al. Therapy of Pelizaeus-Merzbacher disease in mice by feeding a cholesterol-enriched diet. Nat Med. 2012;18:1130&#x2013;1135.</Citation><ArticleIdList><ArticleId IdType="pubmed">22706386</ArticleId></ArticleIdList></Reference><Reference><Citation>Gylling H, Miettinen TA. Postabsorptive metabolism of dietary squalene. Atherosclerosis. 1994;106:169&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">8060377</ArticleId></ArticleIdList></Reference><Reference><Citation>Gudi V, Gingele S, Skripuletz T, Stangel M. Glial response during cuprizone-induced de- and remyelination in the CNS: lessons learned. Front Cell Neurosci. 2014;8:73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3952085</ArticleId><ArticleId IdType="pubmed">24659953</ArticleId></ArticleIdList></Reference><Reference><Citation>Muse ED, et al. Cell-specific discrimination of desmosterol and desmosterol mimetics confers selective regulation of LXR and SREBP in macrophages. Proceedings of the National Academy of Sciences of the United States of America. 2018;115:E4680&#x2013;E4689.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5960280</ArticleId><ArticleId IdType="pubmed">29632203</ArticleId></ArticleIdList></Reference><Reference><Citation>Hubler Z, et al. Accumulation of 8,9-unsaturated sterols drives oligodendrocyte formation and remyelination. Nature. 2018;560:372&#x2013;376.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6423962</ArticleId><ArticleId IdType="pubmed">30046109</ArticleId></ArticleIdList></Reference><Reference><Citation>Miron VE, et al. M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination. Nature neuroscience. 2013;16:1211&#x2013;1218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3977045</ArticleId><ArticleId IdType="pubmed">23872599</ArticleId></ArticleIdList></Reference><Reference><Citation>Bogie JF, et al. Myelin-derived lipids modulate macrophage activity by liver X receptor activation. PloS one. 2012;7:e44998.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3440367</ArticleId><ArticleId IdType="pubmed">22984598</ArticleId></ArticleIdList></Reference><Reference><Citation>Lloyd AF, et al. Central nervous system regeneration is driven by microglia necroptosis and repopulation. Nature neuroscience. 2019;22:1046&#x2013;1052.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6597360</ArticleId><ArticleId IdType="pubmed">31182869</ArticleId></ArticleIdList></Reference><Reference><Citation>Olah M, et al. Identification of a microglia phenotype supportive of remyelination. Glia. 2012;60:306&#x2013;321.</Citation><ArticleIdList><ArticleId IdType="pubmed">22072381</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhlmann T, et al. An updated histological classification system for multiple sclerosis lesions. Acta neuropathologica. 2017;133:13&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">27988845</ArticleId></ArticleIdList></Reference><Reference><Citation>Akula MK, et al. Protein prenylation restrains innate immunity by inhibiting Rac1 effector interactions. Nat Commun. 2019;10:3975.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6726657</ArticleId><ArticleId IdType="pubmed">31484924</ArticleId></ArticleIdList></Reference><Reference><Citation>Araldi E, et al. Lanosterol Modulates TLR4-Mediated Innate Immune Responses in Macrophages. Cell reports. 2017;19:2743&#x2013;2755.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5553565</ArticleId><ArticleId IdType="pubmed">28658622</ArticleId></ArticleIdList></Reference><Reference><Citation>Korner A, et al. Inhibition of Delta24-dehydrocholesterol reductase activates pro-resolving lipid mediator biosynthesis and inflammation resolution. Proceedings of the National Academy of Sciences of the United States of America. 2019;116:20623&#x2013;20634.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6789642</ArticleId><ArticleId IdType="pubmed">31548397</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C, et al. Sterol intermediates from cholesterol biosynthetic pathway as liver X receptor ligands. The Journal of biological chemistry. 2006;281:27816&#x2013;27826.</Citation><ArticleIdList><ArticleId IdType="pubmed">16857673</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell. 1997;89:331&#x2013;340.</Citation><ArticleIdList><ArticleId IdType="pubmed">9150132</ArticleId></ArticleIdList></Reference><Reference><Citation>Liebergall SR, et al. Inflammation Triggers Liver X Receptor-Dependent Lipogenesis. Mol Cell Biol. 2020;40</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6944475</ArticleId><ArticleId IdType="pubmed">31658997</ArticleId></ArticleIdList></Reference><Reference><Citation>Fellows Maxwell K, et al. Oxysterols and apolipoproteins in multiple sclerosis: a 5 year follow-up study. J Lipid Res. 2019;60:1190&#x2013;1198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6602132</ArticleId><ArticleId IdType="pubmed">31085627</ArticleId></ArticleIdList></Reference><Reference><Citation>Zmyslowski A, Szterk A. Oxysterols as a biomarker in diseases. Clin Chim Acta. 2019;491:103&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pubmed">30685361</ArticleId></ArticleIdList></Reference><Reference><Citation>Safaiyan S, et al. Age-related myelin degradation burdens the clearance function of microglia during aging. Nature neuroscience. 2016;19:995&#x2013;998.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116794</ArticleId><ArticleId IdType="pubmed">27294511</ArticleId></ArticleIdList></Reference><Reference><Citation>Marschallinger J, et al. Lipid-droplet-accumulating microglia represent a dysfunctional and proinflammatory state in the aging brain. Nature neuroscience. 2020;23:194&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7595134</ArticleId><ArticleId IdType="pubmed">31959936</ArticleId></ArticleIdList></Reference><Reference><Citation>Thelen KM, Falkai P, Bayer TA, Lutjohann D. Cholesterol synthesis rate in human hippocampus declines with aging. Neurosci Lett. 2006;403:15&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">16701946</ArticleId></ArticleIdList></Reference><Reference><Citation>Hendrickx DAE, et al. Gene Expression Profiling of Multiple Sclerosis Pathology Identifies Early Patterns of Demyelination Surrounding Chronic Active Lesions. Frontiers in immunology. 2017;8:1810.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5742619</ArticleId><ArticleId IdType="pubmed">29312322</ArticleId></ArticleIdList></Reference><Reference><Citation>Mailleux J, et al. Active liver X receptor signaling in phagocytes in multiple sclerosis lesions. Multiple sclerosis. 2018;24:279&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pubmed">28273782</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu S, et al. Dissociated sterol-based liver X receptor agonists as therapeutics for chronic inflammatory diseases. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2016;30:2570&#x2013;2579.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4904286</ArticleId><ArticleId IdType="pubmed">27025962</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz Sand I. The Role of Diet in Multiple Sclerosis: Mechanistic Connections and Current Evidence. Current nutrition reports. 2018;7:150&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6132382</ArticleId><ArticleId IdType="pubmed">30117071</ArticleId></ArticleIdList></Reference><Reference><Citation>Sedaghat F, Jessri M, Behrooz M, Mirghotbi M, Rashidkhani B. Mediterranean diet adherence and risk of multiple sclerosis: a case-control study. Asia Pacific journal of clinical nutrition. 2016;25:377&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pubmed">27222422</ArticleId></ArticleIdList></Reference><Reference><Citation>Beltr&#xe1;n G, Bucheli ME, Aguilera MP, Belaj A, Jimenez A. Squalene in virgin olive oil: Screening of variability in olive cultivars. European Journal of Lipid Science and Technology. 2016</Citation></Reference><Reference><Citation>Smith TJ. Squalene: potential chemopreventive agent. Expert opinion on investigational drugs. 2000;9:1841&#x2013;1848.</Citation><ArticleIdList><ArticleId IdType="pubmed">11060781</ArticleId></ArticleIdList></Reference><Reference><Citation>Quinet EM, et al. Gene-selective modulation by a synthetic oxysterol ligand of the liver X receptor. J Lipid Res. 2004;45:1929&#x2013;1942.</Citation><ArticleIdList><ArticleId IdType="pubmed">15292374</ArticleId></ArticleIdList></Reference><Reference><Citation>Bachmanov AA, Reed DR, Beauchamp GK, Tordoff MG. Food intake, water intake, and drinking spout side preference of 28 mouse strains. Behavior genetics. 2002;32:435&#x2013;443.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1397713</ArticleId><ArticleId IdType="pubmed">12467341</ArticleId></ArticleIdList></Reference><Reference><Citation>Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Canadian journal of biochemistry and physiology. 1959;37:911&#x2013;917.</Citation><ArticleIdList><ArticleId IdType="pubmed">13671378</ArticleId></ArticleIdList></Reference><Reference><Citation>Alizadeh A, Karimi-Abdolrezaee S. Microenvironmental regulation of oligodendrocyte replacement and remyelination in spinal cord injury. The Journal of physiology. 2016;594:3539&#x2013;3552.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4929323</ArticleId><ArticleId IdType="pubmed">26857216</ArticleId></ArticleIdList></Reference><Reference><Citation>Radzun HJ, et al. Detection of a monocyte/macrophage differentiation antigen in routinely processed paraffin-embedded tissues by monoclonal antibody Ki-M1P. Laboratory investigation; a journal of technical methods and pathology. 1991;65:306&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pubmed">1890811</ArticleId></ArticleIdList></Reference><Reference><Citation>Lampron A, et al. Inefficient clearance of myelin debris by microglia impairs remyelinating processes. J Exp Med. 2015;212:481&#x2013;495.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4387282</ArticleId><ArticleId IdType="pubmed">25779633</ArticleId></ArticleIdList></Reference><Reference><Citation>Bijland S, et al. An in vitro model for studying CNS white matter: functional properties and experimental approaches. F1000Research. 2019;8:117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6489523</ArticleId><ArticleId IdType="pubmed">31069065</ArticleId></ArticleIdList></Reference><Reference><Citation>Bottenstein JE, Sato GH. Growth of a rat neuroblastoma cell line in serum-free supplemented medium. Proceedings of the National Academy of Sciences of the United States of America. 1979;76:514&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC382972</ArticleId><ArticleId IdType="pubmed">284369</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Roper MG. Measurement of DCF fluorescence as a measure of reactive oxygen species in murine islets of Langerhans. Analytical methods : advancing methods and applications. 2014;6:3019&#x2013;3024.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4061712</ArticleId><ArticleId IdType="pubmed">24955137</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucchinetti CF, et al. Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain : a journal of neurology. 2008;131:1759&#x2013;1775.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2442427</ArticleId><ArticleId IdType="pubmed">18535080</ArticleId></ArticleIdList></Reference><Reference><Citation>Renier N, et al. iDISCO: a simple, rapid method to immunolabel large tissue samples for volume imaging. Cell. 2014;159:896&#x2013;910.</Citation><ArticleIdList><ArticleId IdType="pubmed">25417164</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler A, Hoffman P, Smibert P, Papalexi E, Satija R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nature biotechnology. 2018;36:411&#x2013;420.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6700744</ArticleId><ArticleId IdType="pubmed">29608179</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuart T, et al. Comprehensive Integration of Single-Cell Data. Cell. 2019;177:1888&#x2013;1902 e1821.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6687398</ArticleId><ArticleId IdType="pubmed">31178118</ArticleId></ArticleIdList></Reference><Reference><Citation>McInnes Leland, H J, Melville James. UMAP: Uniform Manifold Approximation and Projection for Dimension Reduction. arXiv.org. 2018 1802.03426.</Citation></Reference><Reference><Citation>Wickham H. ggplot2 - Elegant Graphics for Data Analysis. Springer; 2009.</Citation></Reference><Reference><Citation>Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences of the United States of America. 2005;102:15545&#x2013;15550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1239896</ArticleId><ArticleId IdType="pubmed">16199517</ArticleId></ArticleIdList></Reference><Reference><Citation>Mootha VK, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nature genetics. 2003;34:267&#x2013;273.</Citation><ArticleIdList><ArticleId IdType="pubmed">12808457</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33576571</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>10</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1552-5279</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>5</Issue><PubDate><Year>2021</Year><Month>May</Month></PubDate></JournalIssue><Title>Alzheimer's &amp; dementia : the journal of the Alzheimer's Association</Title><ISOAbbreviation>Alzheimers Dement</ISOAbbreviation></Journal><ArticleTitle>Harnessing the paradoxical phenotypes of APOE &#x25b;2 and APOE &#x25b;4 to identify genetic modifiers in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>831</StartPage><EndPage>846</EndPage><MedlinePgn>831-846</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/alz.12240</ELocationID><Abstract><AbstractText>The strongest genetic risk factor for idiopathic late-onset Alzheimer's disease (LOAD) is apolipoprotein E (APOE) &#x25b;4, while the APOE &#x25b;2 allele is protective. However, there are paradoxical APOE &#x25b;4 carriers who remain disease-free and APOE &#x25b;2 carriers with LOAD. We compared exomes of healthy APOE &#x25b;4 carriers and APOE &#x25b;2 Alzheimer's disease (AD) patients, prioritizing coding variants based on their predicted functional impact, and identified 216 genes with differential mutational load between these two populations. These candidate genes were significantly dysregulated in LOAD brains, and many modulated tau- or &#x3b2;42-induced neurodegeneration in Drosophila. Variants in these genes were associated with AD risk, even in APOE &#x25b;3 homozygotes, showing robust predictive power for risk stratification. Network analyses revealed involvement of candidate genes in brain cell type-specific pathways including synaptic biology, dendritic spine pruning and inflammation. These potential modifiers of LOAD may constitute novel biomarkers, provide potential therapeutic intervention avenues, and support applying this approach as larger whole exome sequencing cohorts become available.</AbstractText><CopyrightInformation>&#xa9; 2020 The Authors. Alzheimer's &amp; Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Young Won</ForeName><Initials>YW</Initials><AffiliationInfo><Affiliation>Program in Integrative Molecular and Biomedical Sciences, Baylor College of Medicine, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Ramahi</LastName><ForeName>Ismael</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Jan and Dan Duncan Neurological Research Institute, Houston, Texas, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koire</LastName><ForeName>Amanda</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Graduate Program in Quantitative and Computational Biosciences, Baylor College of Medicine, Houston, Texas, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Scientist Training Program, Baylor College of Medicine, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>Stephen J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Konecki</LastName><ForeName>Daniel M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Graduate Program in Quantitative and Computational Biosciences, Baylor College of Medicine, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mota</LastName><ForeName>Samantha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soleimani</LastName><ForeName>Shirin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Botas</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Jan and Dan Duncan Neurological Research Institute, Houston, Texas, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate Program in Quantitative and Computational Biosciences, Baylor College of Medicine, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lichtarge</LastName><ForeName>Olivier</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Program in Integrative Molecular and Biomedical Sciences, Baylor College of Medicine, Houston, Texas, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Jan and Dan Duncan Neurological Research Institute, Houston, Texas, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate Program in Quantitative and Computational Biosciences, Baylor College of Medicine, Houston, Texas, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Scientist Training Program, Baylor College of Medicine, Houston, Texas, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 AG046152</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG057339</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG032984</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG030146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG061105</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG032990</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS080820</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG046139</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG017216</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG018023</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM079656</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 AG052427</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM066099</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003949</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 NS072026</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG025711</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG006786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG036836</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>12</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Alzheimers Dement</MedlineTA><NlmUniqueID>101231978</NlmUniqueID><ISSNLinking>1552-5260</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053329">Apolipoprotein E2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053329" MajorTopicYN="N">Apolipoprotein E2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004330" MajorTopicYN="N">Drosophila</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="N">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006720" MajorTopicYN="N">Homozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="Y">Phenotype</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Drosophila models</Keyword><Keyword MajorTopicYN="N">apolipoprotein E</Keyword><Keyword MajorTopicYN="N">late-onset Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">paradoxical phenotypes</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>9</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>6</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>10</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>2</Month><Day>12</Day><Hour>8</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>7</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33576571</ArticleId><ArticleId IdType="pmc">PMC8247413</ArticleId><ArticleId IdType="doi">10.1002/alz.12240</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jack CR, Knopman DS, Jagust WJ, et&#xa0;al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010;9(1):119&#x2010;128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2819840</ArticleId><ArticleId IdType="pubmed">20083042</ArticleId></ArticleIdList></Reference><Reference><Citation>Attems J, Jellinger KA. The overlap between vascular disease and Alzheimer's disease&#x2013;lessons from pathology. BMC Med.. 2014;12:206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4226890</ArticleId><ArticleId IdType="pubmed">25385447</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabinovici GD, Carrillo MC, Forman M, et&#xa0;al. Multiple comorbid neuropathologies in the setting of Alzheimer's disease neuropathology and implications for drug development. Alzheimers Dement (N Y). 2017;3(1):83&#x2010;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5651346</ArticleId><ArticleId IdType="pubmed">29067320</ArticleId></ArticleIdList></Reference><Reference><Citation>Negash S, A. Bennett D, S. Wilson R, A. Schneider J, E. Arnold S. Cognition and neuropathology in aging: multidimensional perspectives from the rush religious orders study and rush memory and aging project. Curr Alzheimer Res. 2011;8(4):336&#x2010;340.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3157574</ArticleId><ArticleId IdType="pubmed">21222592</ArticleId></ArticleIdList></Reference><Reference><Citation>Negash S, Wilson R, Leurgans S, et&#xa0;al. Resilient brain aging: characterization of discordance between Alzheimer's disease pathology and cognition. Curr Alzheimer Res. 2013;10(8):844&#x2010;851.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4060425</ArticleId><ArticleId IdType="pubmed">23919768</ArticleId></ArticleIdList></Reference><Reference><Citation>Negash S, Xie S, Davatzikos C, et&#xa0;al. Cognitive and functional resilience despite molecular evidence of Alzheimer's disease pathology. Alzheimers Dement. 2013;9(3):e89&#x2010;e95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3640705</ArticleId><ArticleId IdType="pubmed">23127468</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrade&#x2010;Moraes CH, Oliveira&#x2010;Pinto AV, Castro&#x2010;Fonseca E, et&#xa0;al. Cell number changes in Alzheimer's disease relate to dementia, not to plaques and tangles. Brain. 2013;136(Pt 12):3738&#x2010;3752.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3859218</ArticleId><ArticleId IdType="pubmed">24136825</ArticleId></ArticleIdList></Reference><Reference><Citation>Arendt T. Synaptic degeneration in Alzheimer's disease. Acta Neuropathol. 2009;118(1):167&#x2010;179.</Citation><ArticleIdList><ArticleId IdType="pubmed">19390859</ArticleId></ArticleIdList></Reference><Reference><Citation>Coleman P, Federoff H, Kurlan R. A focus on the synapse for neuroprotection in Alzheimer disease and other dementias. Neurology. 2004;63(7):1155&#x2010;1162.</Citation><ArticleIdList><ArticleId IdType="pubmed">15477531</ArticleId></ArticleIdList></Reference><Reference><Citation>Dekosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann. Neurol.. 1990;27(5):457&#x2010;464.</Citation><ArticleIdList><ArticleId IdType="pubmed">2360787</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannakopoulos P, Gold G, von Gunten A, Hof PR, and Bouras C. Pathological substrates of cognitive decline in Alzheimer's disease. Front Neurol Neurosci. 2009;24:20&#x2010;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">19182459</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD, Masliah E, Salmon DP, et&#xa0;al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 1991;30(4):572&#x2010;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatz M, Pedersen NL, Berg S, et&#xa0;al. Heritability for Alzheimer's disease: the study of dementia in Swedish twins. J Gerontol Series A Biol Sci Med Sci. 1997;52A(2):M117&#x2010;M125.</Citation><ArticleIdList><ArticleId IdType="pubmed">9060980</ArticleId></ArticleIdList></Reference><Reference><Citation>Ridge PG, Hoyt KB, Boehme K, et&#xa0;al. Assessment of the genetic variance of late&#x2010;onset Alzheimer's disease. Neurobiol. Aging. 2016;41:200.e13 e13&#x2010;200 e20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4948179</ArticleId><ArticleId IdType="pubmed">27036079</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert J&#x2010;C, Ibrahim&#x2010;Verbaas CA, Harold D, et&#xa0;al. Meta&#x2010;analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet. 2013;45(12):1452&#x2010;1458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert J&#x2010;C, Heath S, Even G, et&#xa0;al. Genome&#x2010;wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet. 2009;41(10):1094&#x2010;1099.</Citation><ArticleIdList><ArticleId IdType="pubmed">19734903</ArticleId></ArticleIdList></Reference><Reference><Citation>Naj AC, Jun G, Beecham GW, et&#xa0;al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late&#x2010;onset Alzheimer's disease. Nat Genet. 2011;43(5):436&#x2010;441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3090745</ArticleId><ArticleId IdType="pubmed">21460841</ArticleId></ArticleIdList></Reference><Reference><Citation>Seshadri S. Genome&#x2010;wide analysis of genetic loci associated with Alzheimer disease. JAMA. 2010;303(18):1832&#x2010;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2989531</ArticleId><ArticleId IdType="pubmed">20460622</ArticleId></ArticleIdList></Reference><Reference><Citation>Harold D, Abraham R, Hollingworth P, et&#xa0;al. Genome&#x2010;wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet. 2009;41(10):1088&#x2010;1093.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2845877</ArticleId><ArticleId IdType="pubmed">19734902</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollingworth P, Harold D, Sims R, et&#xa0;al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet. 2011;43(5):429&#x2010;435.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3084173</ArticleId><ArticleId IdType="pubmed">21460840</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunkle BW, Grenier&#x2010;Boley B, Sims R, et&#xa0;al. Genetic meta&#x2010;analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing. Nat Genet. 2019;51(3):414&#x2010;430.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6463297</ArticleId><ArticleId IdType="pubmed">30820047</ArticleId></ArticleIdList></Reference><Reference><Citation>Ridge PG, Mukherjee S, Crane PK, Kauwe JSK. Alzheimer's Disease Genetics, &#x201c;Alzheimer's disease: analyzing the missing heritability&#x201d;. PLoS One. 2013;8(11):e79771.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3820606</ArticleId><ArticleId IdType="pubmed">24244562</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xe9;nin E. Missing heritability of complex diseases: case solved?. Hum Genet. 2020;139(1):103&#x2010;113.</Citation><ArticleIdList><ArticleId IdType="pubmed">31165258</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Na, Ren Y, Yamazaki Yu, et&#xa0;al. Alzheimer's risk factors age, APOE genotype, and sex drive distinct molecular pathways. Neuron. 2020;106(5):727&#x2010;742.e6 e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7388065</ArticleId><ArticleId IdType="pubmed">32199103</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C&#x2010;C, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat. Rev. Neurol.. 2013;9(2):106&#x2010;118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3726719</ArticleId><ArticleId IdType="pubmed">23296339</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta&#x2010;analysis. APOE and Alzheimer disease meta analysis consortium. JAMA. 1997;278(16):1349&#x2010;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Belloy ME, Napolioni V, Greicius MD. A Quarter Century of APOE and Alzheimer's disease: progress to date and the path forward. Neuron. 2019;101(5):820&#x2010;838.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6407643</ArticleId><ArticleId IdType="pubmed">30844401</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsonis P, Lichtarge O. A formal perturbation equation between genotype and phenotype determines the evolutionary action of protein&#x2010;coding variations on fitness. Genome Res. 2014;24(12):2050&#x2010;2058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4248321</ArticleId><ArticleId IdType="pubmed">25217195</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsonis P, Lichtarge O. CAGI5: Objective performance assessments of predictions based on the Evolutionary Action equation. Hum. Mutat. 2019;40(9):1436&#x2010;1454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6900054</ArticleId><ArticleId IdType="pubmed">31317604</ArticleId></ArticleIdList></Reference><Reference><Citation>Neskey DM, Osman AA, Ow TJ, et&#xa0;al. Evolutionary action score of TP53 identifies high&#x2010;risk mutations associated with decreased survival and increased distant metastases in head and neck cancer. Cancer Res. 2015;75(7):1527&#x2010;1536.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4383697</ArticleId><ArticleId IdType="pubmed">25634208</ArticleId></ArticleIdList></Reference><Reference><Citation>Osman AA, Neskey DM, Katsonis P, et&#xa0;al. Evolutionary action score of TP53 coding variants is predictive of platinum response in head and neck cancer patients. Cancer Res. 2015;75(7):1205&#x2010;1215.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4615655</ArticleId><ArticleId IdType="pubmed">25691460</ArticleId></ArticleIdList></Reference><Reference><Citation>Osman AA, Monroe MM, Ortega Alves MV, et&#xa0;al. Wee&#x2010;1 kinase inhibition overcomes cisplatin resistance associated with high&#x2010;risk TP53 mutations in head and neck cancer through mitotic arrest followed by senescence. Mol. Cancer Ther. 2015;14(2):608&#x2010;619.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4557970</ArticleId><ArticleId IdType="pubmed">25504633</ArticleId></ArticleIdList></Reference><Reference><Citation>Chun YS, Passot G, Yamashita S, et&#xa0;al. Deleterious effect of RAS and evolutionary high&#x2010;risk TP53 double mutation in colorectal liver metastases. Ann Surg. 2019;269(5):917&#x2010;923.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7462436</ArticleId><ArticleId IdType="pubmed">28767562</ArticleId></ArticleIdList></Reference><Reference><Citation>A. Bennett D, A. Schneider J, S. Buchman A, L. Barnes L, A. Boyle P, S. Wilson R. Overview and findings from the rush Memory and Aging Project. Curr Alzheimer Res. 2012;9(6):646&#x2010;663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3439198</ArticleId><ArticleId IdType="pubmed">22471867</ArticleId></ArticleIdList></Reference><Reference><Citation>A. Bennett D, A. Schneider J, Arvanitakis Z, S. Wilson R. Overview and findings from the religious orders study. Curr Alzheimer Res. 2012;9(6):628&#x2010;645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3409291</ArticleId><ArticleId IdType="pubmed">22471860</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M, Beckmann ND, Roussos P, et&#xa0;al. The Mount Sinai cohort of large&#x2010;scale genomic, transcriptomic and proteomic data in Alzheimer's disease. Sci Data. 2018;5:180185.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6132187</ArticleId><ArticleId IdType="pubmed">30204156</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen M, Carrasquillo MM, Funk C, et&#xa0;al. Human whole genome genotype and transcriptome data for Alzheimer's and other neurodegenerative diseases. Sci Data. 2016;3:160089.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5058336</ArticleId><ArticleId IdType="pubmed">27727239</ArticleId></ArticleIdList></Reference><Reference><Citation>De Jager PL, Ma Y, Mccabe C, et&#xa0;al. A multi&#x2010;omic atlas of the human frontal cortex for aging and Alzheimer's disease research. Sci Data. 2018;5:180142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6080491</ArticleId><ArticleId IdType="pubmed">30084846</ArticleId></ArticleIdList></Reference><Reference><Citation>Mostafavi S, Gaiteri C, Sullivan SE, et&#xa0;al. A molecular network of the aging human brain provides insights into the pathology and cognitive decline of Alzheimer's disease. Nat Neurosci. 2018;21(6):811&#x2010;819.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6599633</ArticleId><ArticleId IdType="pubmed">29802388</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasagna&#x2010;Reeves CA, De Haro M, Hao S, et&#xa0;al. Reduction of nuak1 decreases tau and reverses phenotypes in a tauopathy mouse model. Neuron. 2016;92(2):407&#x2010;418.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5745060</ArticleId><ArticleId IdType="pubmed">27720485</ArticleId></ArticleIdList></Reference><Reference><Citation>Chouhan AK, Guo C, Hsieh Yi&#x2010;C, et&#xa0;al. Uncoupling neuronal death and dysfunction in Drosophila models of neurodegenerative disease. Acta Neuropathol Commun. 2016;4(1):62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4918017</ArticleId><ArticleId IdType="pubmed">27338814</ArticleId></ArticleIdList></Reference><Reference><Citation>Al&#x2010;Ramahi I, Giridharan SSP, Chen Yu&#x2010;C, et&#xa0;al. Inhibition of PIP4Kgamma ameliorates the pathological effects of mutant huntingtin protein. Elife. 2017;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5743427</ArticleId><ArticleId IdType="pubmed">29256861</ArticleId></ArticleIdList></Reference><Reference><Citation>Rousseaux MWc, De Haro M, Lasagna&#x2010;Reeves CA, et&#xa0;al. TRIM28 regulates the nuclear accumulation and toxicity of both alpha&#x2010;synuclein and tau. Elife. 2016;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5104516</ArticleId><ArticleId IdType="pubmed">27779468</ArticleId></ArticleIdList></Reference><Reference><Citation>Farfel JM, Yu L, De Jager PL, Schneider JA, Bennett DA. Association of APOE with tau&#x2010;tangle pathology with and without &#x3b2;&#x2010;amyloid (in eng). Neurobiol Aging. 2016;37:19&#x2010;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4716785</ArticleId><ArticleId IdType="pubmed">26481403</ArticleId></ArticleIdList></Reference><Reference><Citation>Safieh M, Korczyn AD, Michaelson DM. ApoE4: an emerging therapeutic target for Alzheimer's disease. BMC Med.. 2019;17(1):64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6425600</ArticleId><ArticleId IdType="pubmed">30890171</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou M, Huang T, Collins N, et&#xa0;al. APOE4 Induces Site&#x2010;Specific Tau Phosphorylation Through Calpain&#x2010;CDK5 Signaling Pathway in EFAD&#x2010;Tg Mice. Curr Alzheimer Res. 2016;13(9):1048&#x2010;1055.</Citation><ArticleIdList><ArticleId IdType="pubmed">27087442</ArticleId></ArticleIdList></Reference><Reference><Citation>Wadhwani AR, Affaneh A, Van Gulden S, Kessler JA. Neuronal apolipoprotein E4 increases cell death and phosphorylated tau release in alzheimer disease. Ann Neurol. 2019;85(5): 726&#x2010;739.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8123085</ArticleId><ArticleId IdType="pubmed">30840313</ArticleId></ArticleIdList></Reference><Reference><Citation>Liraz O, Boehm&#x2010;Cagan A, Michaelson DM. ApoE4 induces A&#x3b2;42, tau, and neuronal pathology in the hippocampus of young targeted replacement apoE4 mice. Mol Neurodegener. 2013;8:16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3659080</ArticleId><ArticleId IdType="pubmed">23684315</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Najm R, Xu Q, et&#xa0;al., Gain of toxic apolipoprotein E4 effects in human iPSC&#x2010;derived neurons is ameliorated by a small&#x2010;molecule structure corrector. Nat Med. 2018;24(5):647&#x2010;657.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5948154</ArticleId><ArticleId IdType="pubmed">29632371</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y&#x2010;Ta, Seo J, Gao F, et&#xa0;al. APOE4 causes widespread molecular and cellular alterations associated with alzheimer's disease phenotypes in human iPSC&#x2010;derived brain cell types. Neuron. 2018;98(6):1141&#x2010;1154.e7 e7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6023751</ArticleId><ArticleId IdType="pubmed">29861287</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Yu&#x2010;WA, Zhou Bo, Wernig M, S&#xfc;dhof TC. ApoE2, ApoE3, and ApoE4 differentially stimulate APP transcription and A&#x3b2; secretion Cell. 2017;168(3):427&#x2010;441.e21.e21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5310835</ArticleId><ArticleId IdType="pubmed">28111074</ArticleId></ArticleIdList></Reference><Reference><Citation>Myhre O, Utkilen H, Duale N, Brunborg G, Hofer T. Metal dyshomeostasis and inflammation in Alzheimer's and Parkinson's diseases: possible impact of environmental exposures. Oxid Med Cell Longev. 2013;2013:1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3654362</ArticleId><ArticleId IdType="pubmed">23710288</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubal DB, Yokoyama JS. Longevity gene KLOTHO and Alzheimer disease&#x2010;a better fate for individuals who carry APOE &#x3b5;4. JAMA Neurol. 2020;77:798.</Citation><ArticleIdList><ArticleId IdType="pubmed">32282012</ArticleId></ArticleIdList></Reference><Reference><Citation>Arboleda&#x2010;Velasquez JF, Lopera F, O'hare M, et&#xa0;al. Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report. Nat. Med.. 2019;25(11)1680&#x2010;1683.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6898984</ArticleId><ArticleId IdType="pubmed">31686034</ArticleId></ArticleIdList></Reference><Reference><Citation>Cotto KC, Wagner AH, Feng Y&#x2010;Y, et&#xa0;al. DGIdb 3.0: a redesign and expansion of the drug&#x2010;gene interaction database. Nucleic. Acids. Res. 2018;46(D1):D1068&#x2010;D1073.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5888642</ArticleId><ArticleId IdType="pubmed">29156001</ArticleId></ArticleIdList></Reference><Reference><Citation>Kern DM, Cepeda MS, Lovestone S, Seabrook GR. Aiding the discovery of new treatments for dementia by uncovering unknown benefits of existing medications. Alzheimers Dement (N Y). 2019;5:862&#x2010;870.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6909196</ArticleId><ArticleId IdType="pubmed">31872043</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, Wang H, Ding Ke, et&#xa0;al. Inhibition of cathepsin S produces neuroprotective effects after traumatic brain injury in mice. Mediators Inflamm. 2013;2013:1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3824312</ArticleId><ArticleId IdType="pubmed">24282339</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiyota T, Machhi J, Lu Y, et&#xa0;al. URMC&#x2010;099 facilitates amyloid&#x2010;beta clearance in a murine model of Alzheimer's disease. J Neuroinflamm. 2018;15(1):137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5935963</ArticleId><ArticleId IdType="pubmed">29729668</ArticleId></ArticleIdList></Reference><Reference><Citation>Bos PH, Lowry ER, Costa J, et&#xa0;al. Development of MAP4 kinase inhibitors as motor neuron&#x2010;protecting agents. Cell Chem Biol. 2019;26(12):1703&#x2010;1715.e37 e37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7253076</ArticleId><ArticleId IdType="pubmed">31676236</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenberger AFN, Morrema THJ, Gerritsen WH, et&#xa0;al. Increased occurrence of protein kinase CK2 in astrocytes in Alzheimer's disease pathology. J Neuroinflammation. 2016;13:4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4702323</ArticleId><ArticleId IdType="pubmed">26732432</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H, Lee KS, Kim AK, et&#xa0;al. A chemical with proven clinical safety rescues Down&#x2010;syndrome&#x2010;related phenotypes in through DYRK1A inhibition. Dis Model Mech. 2016;9(8):839&#x2010;848.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5007978</ArticleId><ArticleId IdType="pubmed">27483355</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu J, Zou H, Rosset S, and Hastie T. &#x201c;Multi&#x2010;class AdaBoost,&#x201d; Statistics and Its Interface. 2009;2:349&#x2010;360.</Citation></Reference><Reference><Citation>Fan R, Chang K, Hsieh C, Wang X, and Lin C. LIBLINEAR: a library for large linear classification. J Machine Learning Res. 2008;9:1871&#x2010;1874.</Citation></Reference><Reference><Citation>Pedregosa F, Varoquaux G, Gramfort A, Michel V, Thirion B. Scikit&#x2010;learn: Machine Learning in Python. JMLR. 2011;12:2825&#x2010;2830.</Citation></Reference><Reference><Citation>Kashyap G, Bapat D, Das D, et&#xa0;al. Synapse loss and progress of Alzheimer's disease &#x2010;a network model. Sci Rep. 2019;9(1):6555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6484103</ArticleId><ArticleId IdType="pubmed">31024073</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandelkow E. Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses. Neurobiol Aging. 2003;24(8);1079&#x2010;1085.</Citation><ArticleIdList><ArticleId IdType="pubmed">14643379</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, Wojtas A, Bras J, et&#xa0;al. TREM2 variants in Alzheimer's disease. N Engl J Med. 2013;368(2):117&#x2010;127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang SS, Kurti A, Wojtas A, et&#xa0;al. Identification of plexin A4 as a novel clusterin receptor links two Alzheimer's disease risk genes. Hum Mol Genet. 2016;25(16):3467&#x2010;3475.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5179943</ArticleId><ArticleId IdType="pubmed">27378688</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Q&#x2010;L, Yang F, Calon F, et&#xa0;al. p21&#x2010;activated kinase&#x2010;aberrant activation and translocation in Alzheimer disease pathogenesis. J Biol Chem. 2008;283(20):14132&#x2010;14143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2376243</ArticleId><ArticleId IdType="pubmed">18347024</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulland TK, Colonna M. TREM2 &#x2010; a key player in microglial biology and Alzheimer disease. Nat Rev Neurol. 2018;14(11):667&#x2010;675.</Citation><ArticleIdList><ArticleId IdType="pubmed">30266932</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin SC, Benitez BA, Karch CM, et&#xa0;al. Coding variants in TREM2 increase risk for Alzheimer's disease. Hum Mol Genet. 2014;23(21):5838&#x2010;5846.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4189899</ArticleId><ArticleId IdType="pubmed">24899047</ArticleId></ArticleIdList></Reference><Reference><Citation>Sirkis DW, Bonham LW, Aparicio RE, et&#xa0;al. Rare TREM2 variants associated with Alzheimer's disease display reduced cell surface expression. Acta Neuropathol Commun. 2016;4(1):98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5010724</ArticleId><ArticleId IdType="pubmed">27589997</ArticleId></ArticleIdList></Reference><Reference><Citation>Mckenzie AT, Wang M, Hauberg ME, et&#xa0;al. Brain cell type specific gene expression and co&#x2010;expression network architectures. Sci Rep. 2018;8(1):8868.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5995803</ArticleId><ArticleId IdType="pubmed">29892006</ArticleId></ArticleIdList></Reference><Reference><Citation>Balez R, Ooi L. Getting to NO Alzheimer's disease: neuroprotection versus neurotoxicity mediated by nitric oxide. Oxid Med Cell Longev. 2016;2016:1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4677236</ArticleId><ArticleId IdType="pubmed">26697132</ArticleId></ArticleIdList></Reference><Reference><Citation>Madeddu S, Woods TA, Mukherjee P, Sturdevant D, Butchi NB, Peterson KE. Identification of glial activation markers by comparison of transcriptome changes between astrocytes and microglia following innate immune stimulation. PLoS One. 2015;10(7):e0127336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4516330</ArticleId><ArticleId IdType="pubmed">26214311</ArticleId></ArticleIdList></Reference><Reference><Citation>Sochocka M, Diniz BS, Leszek J. Inflammatory response in the CNS: friend or foe?. Mol. Neurobiol.. 2017;54(10):8071&#x2010;8089.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5684251</ArticleId><ArticleId IdType="pubmed">27889895</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng L, Mulcahy B, Cook SJ, et&#xa0;al. The cell death pathway regulates synapse elimination through cleavage of gelsolin in caenorhabditis elegans neurons. Cell Rep. 2015;11(11):1737&#x2010;1748.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4481169</ArticleId><ArticleId IdType="pubmed">26074078</ArticleId></ArticleIdList></Reference><Reference><Citation>Wetzel&#x2010;Smith MK, Hunkapiller J, Bhangale TR, et&#xa0;al. A rare mutation in UNC5C predisposes to late&#x2010;onset Alzheimer's disease and increases neuronal cell death. Nat Med. 2014;20(12):1452&#x2010;1457.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4301587</ArticleId><ArticleId IdType="pubmed">25419706</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, Stefansson H, Steinberg S, et&#xa0;al. Variant of TREM2 associated with the risk of Alzheimer's disease. N. Engl J Med. 2013;368(2):107&#x2010;116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Logue MW, Schu M, Vardarajan BN, et&#xa0;al. Two rare AKAP9 variants are associated with Alzheimer's disease in African Americans. Alzheimers Dement. 2014;10(6):609&#x2010;618.e11 e11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4253055</ArticleId><ArticleId IdType="pubmed">25172201</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruchaga C, Karch CM, Jin SC, et&#xa0;al. Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer's disease. Nature. 2014;505(7484):550&#x2010;554.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4050701</ArticleId><ArticleId IdType="pubmed">24336208</ArticleId></ArticleIdList></Reference><Reference><Citation>Ungar L, Altmann A, Greicius MD. Apolipoprotein E, gender, and Alzheimer's disease: an overlooked, but potent and promising interaction. Brain Imaging Behav. 2014;8(2):262&#x2010;273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4282773</ArticleId><ArticleId IdType="pubmed">24293121</ArticleId></ArticleIdList></Reference><Reference><Citation>Blue EE, Horimoto ARVR, Mukherjee S, Wijsman EM, Thornton TA. Local ancestry at APOE modifies Alzheimer's disease risk in Caribbean Hispanics. Alzheimers Dement. 2019;15(12):1524&#x2010;1532.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6925639</ArticleId><ArticleId IdType="pubmed">31606368</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzioras M, Davies C, Newman A, Jackson R, Spires Jones T. Invited review: APOE at the interface of inflammation, neurodegeneration and pathological protein spread in Alzheimer's disease. Neuropathol Appl Neurobiol. 2019;45(4):327&#x2010;346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6563457</ArticleId><ArticleId IdType="pubmed">30394574</ArticleId></ArticleIdList></Reference><Reference><Citation>Koire A, Katsonis P, and Lichtarge O, Repurposing germline exomes of the cancer genome atlas demands a cautious approach and sample&#x2010;specific variant filtering. Pac Symp Biocomput. 2016;21:207&#x2010;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4720392</ArticleId><ArticleId IdType="pubmed">26776187</ArticleId></ArticleIdList></Reference><Reference><Citation>Logsdon BA, et&#xa0;al. Meta&#x2010;analysis of the human brain transcriptome identifies heterogeneity across human AD coexpression modules robust to sample collection and methodological approach. bioRxiv. 2019:510420.</Citation></Reference><Reference><Citation>Szklarczyk D, Gable AL, Lyon D, et&#xa0;al. STRING v11: protein&#x2010;protein association networks with increased coverage, supporting functional discovery in genome&#x2010;wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607&#x2010;D613.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6323986</ArticleId><ArticleId IdType="pubmed">30476243</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizuno S, Iijima R, Ogishima S, et&#xa0;al. AlzPathway: a comprehensive map of signaling pathways of Alzheimer's disease. BMC Systems Biol. 2012;6:52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3411424</ArticleId><ArticleId IdType="pubmed">22647208</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizuno S, Ogishima S, Kitatani K, et&#xa0;al. Network analysis of a comprehensive knowledge repository reveals a dual role for ceramide in Alzheimer's disease. PLoS One. 2016;11(2):e0148431.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4752297</ArticleId><ArticleId IdType="pubmed">26849355</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y, Flockhart I, Vinayagam A, et&#xa0;al. An integrative approach to ortholog prediction for disease&#x2010;focused and other functional studies. BMC Bioinform. 2011;12:357.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3179972</ArticleId><ArticleId IdType="pubmed">21880147</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Mackenzie KR, Putluri N, Maleti&#x107;&#x2010;Savati&#x107; M, Bellen HJ, The glia&#x2010;neuron lactate shuttle and elevated ROS promote lipid synthesis in neurons and lipid droplet accumulation in glia via APOE/D. Cell Metab. 2017;26(5):719&#x2010;737.e6 e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5677551</ArticleId><ArticleId IdType="pubmed">28965825</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang YWA, Zhou Bo, Wernig M, S&#xfc;dhof TC, ApoE2, ApoE3, and ApoE4 differentially stimulate APP transcription and abeta secretion. Cell. 2017;168(3):427&#x2010;441 e21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5310835</ArticleId><ArticleId IdType="pubmed">28111074</ArticleId></ArticleIdList></Reference><Reference><Citation>Sim NL, Kumar P, Hu J, Henikoff S, Schneider G, Ng PC. SIFT web server: predicting effects of amino acid substitutions on proteins (in eng). Nucleic Acids Res. 2012;40(Web Server issue):W452&#x2010;W457.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3394338</ArticleId><ArticleId IdType="pubmed">22689647</ArticleId></ArticleIdList></Reference><Reference><Citation>Adzhubei IA, Schmidt S, Peshkin L, et&#xa0;al. A method and server for predicting damaging missense mutations. Nat Methods. 2010;7(4):248&#x2010;249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2855889</ArticleId><ArticleId IdType="pubmed">20354512</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33399270</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>24</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1552-5279</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>6</Issue><PubDate><Year>2021</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Alzheimer's &amp; dementia : the journal of the Alzheimer's Association</Title><ISOAbbreviation>Alzheimers Dement</ISOAbbreviation></Journal><ArticleTitle>The chronic neuropsychiatric sequelae of COVID-19: The need for a prospective study of viral impact on brain functioning.</ArticleTitle><Pagination><StartPage>1056</StartPage><EndPage>1065</EndPage><MedlinePgn>1056-1065</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/alz.12255</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">The increasing evidence of SARS-CoV-2 impact on the central nervous system (CNS) raises key questions on its impact for risk of later life cognitive decline, Alzheimer's disease (AD), and other dementia.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The Alzheimer's Association and representatives from more than 30 countries-with technical guidance from the World Health Organization-have formed an international consortium to study the short-and long-term consequences of SARS-CoV-2 on the CNS-including the underlying biology that may contribute to AD and other dementias. This consortium will link teams from around the world covering more than 22 million COVID-19 cases to enroll two groups of individuals including people with disease, to be evaluated for follow-up evaluations at 6, 9, and 18 months, and people who are already enrolled in existing international research studies to add additional measures and markers of their underlying biology.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The increasing evidence and understanding of SARS-CoV-2's impact on the CNS raises key questions on the impact for risk of later life cognitive decline, AD, and other dementia. This program of studies aims to better understand the long-term consequences that may impact the brain, cognition, and functioning-including the underlying biology that may contribute to AD and other dementias.</AbstractText><CopyrightInformation>&#xa9; 2021 the Alzheimer's Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>de Erausquin</LastName><ForeName>Gabriel A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>The Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, UTHSA, San Antonio, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Snyder</LastName><ForeName>Heather</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Alzheimer's Association, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carrillo</LastName><ForeName>Mar&#xed;a</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Alzheimer's Association, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hosseini</LastName><ForeName>Akram A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Neurology Department, Nottingham University Hospitals NHS Trust, Queen's Medical Centre, Nottingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brugha</LastName><ForeName>Traolach S</ForeName><Initials>TS</Initials><AffiliationInfo><Affiliation>Social and Epidemiological Psychiatry Research Group, Department of Health Sciences, University of Leicester, Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seshadri</LastName><ForeName>Sudha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, UTHSA, San Antonio, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>CNS SARS-CoV-2 Consortium</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>D43 MH108169</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>D43 TW011793</GrantID><Acronym>TW</Acronym><Agency>FIC NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066546</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/T005580/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P30 AG059305</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>01</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Alzheimers Dement</MedlineTA><NlmUniqueID>101231978</NlmUniqueID><ISSNLinking>1552-5260</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">cognitive decline</Keyword><Keyword MajorTopicYN="N">neuropsychiatry</Keyword></KeywordList><CoiStatement>CONFLICTS OF INTEREST. The authors declare no conflict of interest with the work discussed in this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>11</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>1</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>1</Month><Day>5</Day><Hour>8</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>8</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33399270</ArticleId><ArticleId IdType="mid">NIHMS1909754</ArticleId><ArticleId IdType="pmc">PMC10431934</ArticleId><ArticleId IdType="doi">10.1002/alz.12255</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Itzhaki RF, Golde TE, Heneka MT, Readhead B. Do infections have a role in the pathogenesis of Alzheimer disease?. Nat Rev Neurol. 2020;16(4):193&#x2013;197.</Citation><ArticleIdList><ArticleId IdType="pubmed">32152461</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson CP, Busl KM. Neurologic manifestations of severe respiratory viral contagions. Crit Care Explor. 2020;2(4):e0107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7188429</ArticleId><ArticleId IdType="pubmed">32426749</ArticleId></ArticleIdList></Reference><Reference><Citation>Foley PB. Encephalitis lethargica and the influenza virus. II. The influenza pandemic of 1918/19 and encephalitis lethargica: epidemiology and symptoms. J Neural 9. 2009;116(10):1295&#x2013;1308.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2758910</ArticleId><ArticleId IdType="pubmed">19707848</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns DM, Rouleau N, Parker RN, Walsh KG, Gehrke L, Kaplan DL. A 3D human brain-like tissue model of herpes-induced Alzheimer&#x2019;s disease. Sci Adv. 2020;6(19):eaay8828.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7202879</ArticleId><ArticleId IdType="pubmed">32494701</ArticleId></ArticleIdList></Reference><Reference><Citation>Readhead B, Haure-Mirande JV, Funk CC, et al. Multiscale analysis of independent alzheimer&#x2019;s cohorts finds disruption of molecular, genetic, and clinical networks by human herpesvirus. Neuron. 2018;99(1):64&#x2013;82. e7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6551233</ArticleId><ArticleId IdType="pubmed">29937276</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancuso R, Cabinio M, Agostini S, Baglio F, Clerici M. HSV-1-Specific IgG3 titers correlate with brain cortical thinning in individuals with mild cognitive impairment and Alzheimer&#x2019;s disease. Vaccines (Basel). 2020;8(2):255.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7349921</ArticleId><ArticleId IdType="pubmed">32485994</ArticleId></ArticleIdList></Reference><Reference><Citation>Steardo L Jr Steardo L, Zorec R, Verkhratsky A. Neuroinfection may contribute to pathophysiology and clinical manifestations of COVID-19. Acta Physiol (Oxf). 2020;229(3):e13473.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7228251</ArticleId><ArticleId IdType="pubmed">32223077</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y, Xu X, Chen Z, et al. Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain Behav Immun. 2020;87:18&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7146689</ArticleId><ArticleId IdType="pubmed">32240762</ArticleId></ArticleIdList></Reference><Reference><Citation>Baig AM, Sanders EC. Potential neuroinvasive pathways of SARS-CoV-2: deciphering the spectrum of neurological deficit seen in coronavirus disease-2019 (COVID-19) [published online ahead of print, 2020 Jun 3]. J Med Virol. 2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7300748</ArticleId><ArticleId IdType="pubmed">32492193</ArticleId></ArticleIdList></Reference><Reference><Citation>Aamodt AH, Flinstad Harbo H, Eld&#xf8;en G, Barratt-Due A, Aukrust P. How does COVID-19 affect the brain?. Hvordan p&#xe5;virkes hjernen ved covid-19?. Tidsskr Nor Laegeforen. 2020;140(10).</Citation><ArticleIdList><ArticleId IdType="pubmed">32602331</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao XY, Jin WL. The COVID-19 pandemic: consideration for brain infection. Neuroscience. 2020;437:130&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7196901</ArticleId><ArticleId IdType="pubmed">32380269</ArticleId></ArticleIdList></Reference><Reference><Citation>Baig AM. Neurological manifestations in COVID-19 caused by SARS-CoV-2. CNS Neurosci Ther. 2020;26(5):499&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7163592</ArticleId><ArticleId IdType="pubmed">32266761</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, Huang Y, Guo X. The brain, another potential target organ, needs early protection from SARS-CoV-2 neuroinvasion. Sci China Life Sci. 2020;63(5):771&#x2013;773.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7118308</ArticleId><ArticleId IdType="pubmed">32246403</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, Golenbock D, Latz E, Morgan D, Brown R. Immediate and long-term consequences of COVID-19 infections for the development of neurological disease. Alzheimers Res Ther. 2020;12(1):69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7271826</ArticleId><ArticleId IdType="pubmed">32498691</ArticleId></ArticleIdList></Reference><Reference><Citation>Beghi E, Feigin V, Caso V, Santalucia P, Logroscino G. COVID-19 infection and neurological complications: present findings and future predictions [published online ahead of print, 2020 Jul 1]. Neuroepidemiology. 2020:1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7445369</ArticleId><ArticleId IdType="pubmed">32610334</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng Kee Kwong KC, Mehta PR, Shukla G, Mehta AR. COVID-19, SARS and MERS: a neurological perspective. J Clin Neurosci. 2020;77:13&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7198407</ArticleId><ArticleId IdType="pubmed">32417124</ArticleId></ArticleIdList></Reference><Reference><Citation>De Santis G. SARS-CoV-2: a new virus but a familiar inflammation brain pattern. Brain Behav Immun. 2020;87:95&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7184990</ArticleId><ArticleId IdType="pubmed">32353523</ArticleId></ArticleIdList></Reference><Reference><Citation>Natoli S, Oliveira V, Calabresi P, Maia LF, Pisani A. Does SARS-Cov-2 invade the brain? Translational lessons from animal models [published online ahead of print, 2020 Apr 25]. Eur J Neurol. 2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7267377</ArticleId><ArticleId IdType="pubmed">32333487</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng M, Song L. Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV. Cell Mol Immunol. 2020;17(5):536&#x2013;538.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7091851</ArticleId><ArticleId IdType="pubmed">32132669</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y, Xu X, Yang L, Liu C, Yang C. Nervous system damage after COVID-19 infection: presence or absence?. Brain Behav Immun. 2020;87:55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7165112</ArticleId><ArticleId IdType="pubmed">32311495</ArticleId></ArticleIdList></Reference><Reference><Citation>Butowt R, Bilinska K. SARS-CoV-2: olfaction, brain infection, and the urgent need for clinical samples allowing earlier virus detection. ACS Chem Neurosci. 2020;11(9):1200&#x2013;1203.</Citation><ArticleIdList><ArticleId IdType="pubmed">32283006</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun SH, Chen Q, Gu HJ, et al. A mouse model of SARS-CoV-2 infection and pathogenesis. Cell Host Microbe. 2020;28(1):124&#x2013;133. e4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7250783</ArticleId><ArticleId IdType="pubmed">32485164</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang RD, Liu MQ, Chen Y, et al. Pathogenesis of SARS-CoV-2 in transgenic mice expressing human angiotensin-converting enzyme 2. Cell. 2020;182(1):50&#x2013;58. e8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7241398</ArticleId><ArticleId IdType="pubmed">32516571</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding Y, He L, Zhang Q, et al. Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways. J Pathol. 2004;203(2):622&#x2013;630.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7167761</ArticleId><ArticleId IdType="pubmed">15141376</ArticleId></ArticleIdList></Reference><Reference><Citation>Verdecchia P, Cavallini C, Spanevello A, Angeli F. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. Eur J Intern Med. 2020;76:14&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7167588</ArticleId><ArticleId IdType="pubmed">32336612</ArticleId></ArticleIdList></Reference><Reference><Citation>Hess DC, Eldahshan W, Rutkowski E. COVID-19-Related Stroke. Transl Stroke Res. 2020;11(3):322&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7202903</ArticleId><ArticleId IdType="pubmed">32378030</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin XX, Zheng XR, Peng W, Wu ML, Mao XY. Vascular endothelial growth factor (VEGF) as a vital target for brain inflammation during the COVID-19 outbreak. ACS Chem Neurosci. 2020;11(12):1704&#x2013;1705.</Citation><ArticleIdList><ArticleId IdType="pubmed">32485101</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi JY, Lee HK, Park JH, et al. Altered COVID-19 receptor ACE2 expression in a higher risk group for cerebrovascular disease and ischemic stroke. Biochem Biophys Res Commun. 2020;528(3):413&#x2013;419.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7256621</ArticleId><ArticleId IdType="pubmed">32513532</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu D, Ma M, Xu Y, et al. Single-cell transcriptome analysis indicates new potential regulation mechanism of ace2 and nps signaling among heart failure patients infected with SARS-CoV-2. medRxiv. 2020;2020. 10.1101/2020.04.30.20081257.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.04.30.20081257</ArticleId><ArticleId IdType="pmc">PMC7952310</ArticleId><ArticleId IdType="pubmed">33718452</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study [published correction appears in BMJ. 2020 Mar 31;368:m1295]. BMJ. 2020;368:m1091.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7190011</ArticleId><ArticleId IdType="pubmed">32217556</ArticleId></ArticleIdList></Reference><Reference><Citation>Bostanciklio&#x11f;lu M. SARS-CoV2 entry and spread in the lymphatic drainage system of the brain. Brain Behav Immun. 2020;87:122&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7189839</ArticleId><ArticleId IdType="pubmed">32360606</ArticleId></ArticleIdList></Reference><Reference><Citation>Buzhdygan TP, DeOre BJ, Baldwin-Leclair A, et al.
The SARS-CoV-2 spike protein alters barrier function in 2D static and 3D microfluidic in vitro models of the human blood-brain barrier. Neurobiol Dis. 2020;146(Dec):105131. 10.1016/j.nbd.2020.105131. Epub 2020 Oct 11. https://pubmed.ncbi.nlm.nih.gov/33053430/;.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2020.105131</ArticleId><ArticleId IdType="pmc">PMC7547916</ArticleId><ArticleId IdType="pubmed">33053430</ArticleId></ArticleIdList></Reference><Reference><Citation>Vavougios GD. Potentially irreversible olfactory and gustatory impairments in COVID-19: indolent vs. fulminant SARS-CoV-2 neuroinfection. Brain Behav Immun. 2020;87:107&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7185018</ArticleId><ArticleId IdType="pubmed">32353521</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng Q, Yang Y, Gao J. Infectivity of human coronavirus in the brain. EBioMedicine. 2020;56:102799.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7255711</ArticleId><ArticleId IdType="pubmed">32474399</ArticleId></ArticleIdList></Reference><Reference><Citation>Saleki K, Banazadeh M, Saghazadeh A, Rezaei N. The involvement of the central nervous system in patients with COVID-19. Rev Neurosci. 2020;31(4):453&#x2013;456.</Citation><ArticleIdList><ArticleId IdType="pubmed">32463395</ArticleId></ArticleIdList></Reference><Reference><Citation>Zubair AS, McAlpine LS, Gardin T, Farhadian S, Kuruvilla DE, Spudich S. Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019: a review. JAMA Neurol. 2020;77(8):1018&#x2013;1027. 10.1001/jamaneurol.2020.2065. https://pubmed.ncbi.nlm.nih.gov/32469387/.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.2065</ArticleId><ArticleId IdType="pmc">PMC7484225</ArticleId><ArticleId IdType="pubmed">32469387</ArticleId></ArticleIdList></Reference><Reference><Citation>Tassorelli C, Mojoli F, Baldanti F, Bruno R, Benazzo M. COVID-19: what if the brain had a role in causing the deaths? Eur J Neurol. 2020;27(9):e41&#x2013;e42. 10.1111/ene.14275. Epub 2020 May 14. https://pubmed.ncbi.nlm.nih.gov/32333819/.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14275</ArticleId><ArticleId IdType="pmc">PMC7267268</ArticleId><ArticleId IdType="pubmed">32333819</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai ST, Lu MK, San S, Tsai CH. The neurologic manifestations of coronavirus disease 2019 pandemic: a systemic review. Front Neurol. 2020;11:498.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7248254</ArticleId><ArticleId IdType="pubmed">32574246</ArticleId></ArticleIdList></Reference><Reference><Citation>Das G, Mukherjee N, Ghosh S. Neurological insights of COVID-19 pandemic. ACS Chem Neurosci. 2020;11(9):1206&#x2013;1209.</Citation><ArticleIdList><ArticleId IdType="pubmed">32320211</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson MP, Jack AS. Coronavirus disease 2019 (COVID-19) in neurology and neurosurgery: a scoping review of the early literature. Clin Neurol Neurosurg. 2020;193:105866.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7179494</ArticleId><ArticleId IdType="pubmed">32389893</ArticleId></ArticleIdList></Reference><Reference><Citation>Munhoz RP, Pedroso JL, Nascimento FA, et al. Neurological complications in patients with SARS-CoV-2 infection: a systematic review. Arq Neuropsiquiatr. 2020;78(5):290&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pubmed">32490966</ArticleId></ArticleIdList></Reference><Reference><Citation>Wadman M, Couzin-Frankel J, Kaiser J, Matacic C. A rampage through the body. Science. 2020;368(6489):356&#x2013;360.</Citation><ArticleIdList><ArticleId IdType="pubmed">32327580</ArticleId></ArticleIdList></Reference><Reference><Citation>Iroegbu JD, Ifenatuoha CW, Ijomone OM. Potential neurological impact of coronaviruses: implications for the novel SARS-CoV-2. Neurol Sci. 2020;41(6):1329&#x2013;1337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7232928</ArticleId><ArticleId IdType="pubmed">32424503</ArticleId></ArticleIdList></Reference><Reference><Citation>Helms J, Kremer S, Merdji H, et al. Neurologic features in severe SARS-CoV-2 infection. N EnglJ Med. 2020;382(23):2268&#x2013;2270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7179967</ArticleId><ArticleId IdType="pubmed">32294339</ArticleId></ArticleIdList></Reference><Reference><Citation>Conde Cardona G, Quintana P&#xe1;jaro LD, Quintero Marzola ID, Ramos Villegas Y, Moscote Salazar LR. Neurotropism of SARS-CoV 2: mechanisms and manifestations. J Neurol Sci. 2020;412:116824.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7141641</ArticleId><ArticleId IdType="pubmed">32299010</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun T, Guan J, You C. The neuroinvasive potential of severe acute respiratory syndrome coronavirus 2. Brain Behav Immun. 2020;88:59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7263246</ArticleId><ArticleId IdType="pubmed">32497777</ArticleId></ArticleIdList></Reference><Reference><Citation>Liguori C, Pierantozzi M, Spanetta M, et al. Subjective neurological symptoms frequently occur in patients with SARS-CoV2 infection. Brain Behav Immun. 2020;88:11&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7235586</ArticleId><ArticleId IdType="pubmed">32416289</ArticleId></ArticleIdList></Reference><Reference><Citation>Baig AM. Updates on what acs reported: emerging evidences of COVID-19 with nervous system involvement. ACS Chem Neurosci. 2020;11(9):1204&#x2013;1205.</Citation><ArticleIdList><ArticleId IdType="pubmed">32343122</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed MU, Hanif M, Ali MJ, et al. Neurological manifestations of COVID-19 (SARS-CoV-2): a review. Front Neurol. 2020;11:518.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7257377</ArticleId><ArticleId IdType="pubmed">32574248</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Shen Y, Li M, et al. Clinical manifestations and evidence of neurological involvement in 2019 novel coronavirus SARS-CoV-2: a systematic review and meta-analysis [published online ahead of print, 2020 Jun 11]. J Neurol. 2020:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7288253</ArticleId><ArticleId IdType="pubmed">32529575</ArticleId></ArticleIdList></Reference><Reference><Citation>Varatharaj A, Thomas N, Ellul MA, et al.
Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. Lancet Psychiatry. 2020;7(10):875&#x2013;882. 10.1016/S2215-0366(20)30287-X.. Epub 2020 Jun 25 Erratum in: Lancet Psychiatry. 2020 Jul 14; https://pubmed.ncbi.nlm.nih.gov/32593341/.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2215-0366(20)30287-X.</ArticleId><ArticleId IdType="pmc">PMC7316461</ArticleId><ArticleId IdType="pubmed">32593341</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinakaran D, Manjunatha N, Naveen Kumar C, Suresh BM. Neuropsychiatric aspects of COVID-19 pandemic: a selective review [published online ahead of print, 2020 May 30]. Asian J Psychiatr. 2020;53:102188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7261092</ArticleId><ArticleId IdType="pubmed">32512530</ArticleId></ArticleIdList></Reference><Reference><Citation>Moriguchi T, Harii N, Goto J, et al. A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. Int J Infect Dis. 2020;94:55&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7195378</ArticleId><ArticleId IdType="pubmed">32251791</ArticleId></ArticleIdList></Reference><Reference><Citation>Yashavantha Rao HC, Jayabaskaran C. The emergence of a novel coronavirus (SARS-CoV-2) disease and their neuroinvasive propensity may affect in COVID-19 patients. J Med Virol. 2020;92(7):786&#x2013;790.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7264535</ArticleId><ArticleId IdType="pubmed">32320066</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg RK, Paliwal VK, Gupta A. Encephalopathy in patients with COVID-19: a review. J Med Virol. 2020. 10.1002/jmv.26207. Epub ahead of print. https://pubmed.ncbi.nlm.nih.gov/32558956/.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26207</ArticleId><ArticleId IdType="pubmed">32558956</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosseini AA, Shetty AK, Sprigg N, Auer DP, Constantinescu CS. Delirium as a presenting feature in COVID-19: neuroinvasive infection or autoimmune encephalopathy?. Brain Behav Immun. 2020;88: 68&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7282789</ArticleId><ArticleId IdType="pubmed">32531427</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang YH, Jiang D, Huang JT. SARS-CoV-2 detected in cerebrospinal fluid by pcr in a case of COVID-19 encephalitis. Brain Behav Immun. 2020;87:149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7202824</ArticleId><ArticleId IdType="pubmed">32387508</ArticleId></ArticleIdList></Reference><Reference><Citation>Glatzel M. Neuropathology of COVID-19: where are the neuropathologists?. Brain Pathol. 2020;30(4):729.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7361599</ArticleId><ArticleId IdType="pubmed">32592310</ArticleId></ArticleIdList></Reference><Reference><Citation>von Weyhern CH, Kaufmann I, Neff F, Kremer M. Early evidence of pronounced brain involvement in fatal COVID-19 outcomes. Lancet. 2020;395(10241):e109.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7272176</ArticleId><ArticleId IdType="pubmed">32505222</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon IH, Normandin E, Bhattacharyya S, et al. Neuropathological features of Covid-19 [published online ahead of print, 2020 Jun 12]. N Engl J Med. 2020:NEJMc2019373.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7304421</ArticleId><ArticleId IdType="pubmed">32530583</ArticleId></ArticleIdList></Reference><Reference><Citation>Anoop UR, Verma K. Pulmonary edema in COVID19-A neural hypothesis. ACS Chem Neurosci. 2020;11(14):2048&#x2013;2050.</Citation><ArticleIdList><ArticleId IdType="pubmed">32614178</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, Liu T, Yang N, et al. Neurological manifestations of patients with COVID-19: potential routes of SARS-CoV-2 neuroinvasion from the periphery to the brain [published online ahead of print, 2020 May 4]. Front Med. 2020:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7197033</ArticleId><ArticleId IdType="pubmed">32367431</ArticleId></ArticleIdList></Reference><Reference><Citation>Montalvan V, Lee J, Bueso T, De Toledo J, Rivas K. Neurological manifestations of COVID-19 and other coronavirus infections: a systematic review. Clin Neurol Neurosurg. 2020;194:105921.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7227498</ArticleId><ArticleId IdType="pubmed">32422545</ArticleId></ArticleIdList></Reference><Reference><Citation>Chigr F, Merzouki M, Najimi M. Comment on &#x201c;The neuroinvasive potential of SARS-CoV-2 may play a role in the respiratory failure of COVID-19 patients&#x201d;. J Med Virol. 2020;92(7):703&#x2013;704.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7267316</ArticleId><ArticleId IdType="pubmed">32352575</ArticleId></ArticleIdList></Reference><Reference><Citation>Chigr F, Merzouki M, Najimi M. Autonomic brain centers and pathophysiology of COVID-19. ACS Chem Neurosci. 2020;11(11):1520&#x2013;1522.</Citation><ArticleIdList><ArticleId IdType="pubmed">32427468</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Li W, Wang D, et al. Clinical time course of COVID-19, its neurological manifestation and some thoughts on its management. Stroke Vasc Neurol. 2020;5(2):177&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7211099</ArticleId><ArticleId IdType="pubmed">32366614</ArticleId></ArticleIdList></Reference><Reference><Citation>Lodigiani C, Iapichino G, Carenzo L, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020;191:9&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7177070</ArticleId><ArticleId IdType="pubmed">32353746</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalleballe K, Reddy Onteddu S, Sharma R, et al. Spectrum of neuropsychiatric manifestations in COVID-19. Brain Behav Immun. 2020;88:71&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7297688</ArticleId><ArticleId IdType="pubmed">32561222</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong W, Mu J, Guo J, et al.
New onset neurologic events in people with COVID-19 infection in three regions in China. Neurology. 2020;95(11):e1479&#x2013;e1487. 10.1212/WNL.0000000000010034. Epub 2020 Jun 17. https://pubmed.ncbi.nlm.nih.gov/32554771/.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000010034</ArticleId><ArticleId IdType="pubmed">32554771</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra AK, Sahu KK, George AA, Sargent J, Lal A. Cerebrovascular events in COVID-19 patients. Monaldi Arch Chest Dis. 2020;90(2).</Citation><ArticleIdList><ArticleId IdType="pubmed">32527073</ArticleId></ArticleIdList></Reference><Reference><Citation>Merkler AE, Parikh NS, Mir S, et al. Risk of ischemic stroke in patients with coronavirus disease 2019 (COVID-19) vs patients with influenza [published online ahead of print, 2020 Jul 2]. JAMA Neurol. 2020:e202730.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7333175</ArticleId><ArticleId IdType="pubmed">32614385</ArticleId></ArticleIdList></Reference><Reference><Citation>Morassi M, Bagatto D, Cobelli M, et al. Stroke in patients with SARS-CoV-2 infection: case series. J Neurol. 2020;267(8):2185&#x2013;2192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7238403</ArticleId><ArticleId IdType="pubmed">32436105</ArticleId></ArticleIdList></Reference><Reference><Citation>Beyrouti R, Adams ME, Benjamin L, et al. Characteristics of ischaemic stroke associated with COVID-19. J Neurol Neurosurg Psychiatry. 2020;91(8):889&#x2013;891.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7231545</ArticleId><ArticleId IdType="pubmed">32354768</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Anna L, Kwan J, Brown Z, et al.
Characteristics and clinical course of Covid-19 patients admitted with acute stroke. J Neurol. 2020);267(11):3161&#x2013;3165. 10.1007/s00415-020-10012-4. Epub 2020 Jun 24. https://pubmed.ncbi.nlm.nih.gov/32583054/.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-10012-4</ArticleId><ArticleId IdType="pmc">PMC7313245</ArticleId><ArticleId IdType="pubmed">32583054</ArticleId></ArticleIdList></Reference><Reference><Citation>Paterson RW, Brown RL, Benjamin L, et al. The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings [published online ahead of print, 2020 Jul 8]. Brain. 2020:awaa240.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7454352</ArticleId><ArticleId IdType="pubmed">32637987</ArticleId></ArticleIdList></Reference><Reference><Citation>Zanin L, Saraceno G, Panciani PP, et al. SARS-CoV-2 can induce brain and spine demyelinating lesions. Acta Neurochir (Wien). 2020;162(7):1491&#x2013;1494.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7197630</ArticleId><ArticleId IdType="pubmed">32367205</ArticleId></ArticleIdList></Reference><Reference><Citation>Koralnik IJ, Tyler KL. COVID-19: a global threat to the nervous system. Ann Neurol. 2020;88(1):1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7300753</ArticleId><ArticleId IdType="pubmed">32506549</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta A, Paliwal VK, Garg RK. Is COVID-19-related Guillain-Barr&#xe9; syndrome different?. Brain Behav Immun. 2020;87:177&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7239011</ArticleId><ArticleId IdType="pubmed">32445789</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadono Y, Nakamura Y, Ogawa Y, et al. A case of COVID-19 infection presenting with a seizure following severe brain edema. Seizure. 2020;80:53&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7282752</ArticleId><ArticleId IdType="pubmed">32540636</ArticleId></ArticleIdList></Reference><Reference><Citation>Hepburn M, Mullaguri N, George P, et al.. Acute symptomatic seizures in critically ill patients with COVID-19: is there an association? [published online ahead of print, 2020 May 28]. Neurocrit Care. 2020:1&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7253233</ArticleId><ArticleId IdType="pubmed">32462412</ArticleId></ArticleIdList></Reference><Reference><Citation>Galanopoulou AS, Ferastraoaru V, Correa DJ, et al. EEG findings in acutely ill patients investigated for SARS-CoV-2/COVID-19: a small case series preliminary report. Epilepsia Open. 2020;5(2):314&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7289172</ArticleId><ArticleId IdType="pubmed">32537529</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xe9;lisse P, Rossetti AO, Genton P, Crespel A, Kaplan PW. How to carry out and interpret EEG recordings in COVID-19 patients in ICU?. Clin Neurophysiol. 2020;131(8):2023&#x2013;2031.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7217782</ArticleId><ArticleId IdType="pubmed">32405259</ArticleId></ArticleIdList></Reference><Reference><Citation>Balloy G, Leclair-Visonneau L, P&#xe9;r&#xe9;on Y, et al. Non-lesional status epilepticus in a patient with coronavirus disease 2019. Clin Neurophysiol. 2020;131(8):2059&#x2013;2061.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7217773</ArticleId><ArticleId IdType="pubmed">32405258</ArticleId></ArticleIdList></Reference><Reference><Citation>Alkeridy WA, Almaghlouth I, Alrashed R, et al. A unique presentation of delirium in a patient with otherwise asymptomatic COVID-19. J Am Geriatr Soc. 2020;68(7):1382&#x2013;1384.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7272789</ArticleId><ArticleId IdType="pubmed">32383778</ArticleId></ArticleIdList></Reference><Reference><Citation>Butt I, Sawlani V, Geberhiwot T. Prolonged confusional state as first manifestation of COVID-19. Ann Clin Transl Neurol. 2020;(8):1450&#x2013;1452.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7276856</ArticleId><ArticleId IdType="pubmed">32433817</ArticleId></ArticleIdList></Reference><Reference><Citation>Beach SR, Praschan NC, Hogan C, et al. Delirium in COVID-19: a case series and exploration of potential mechanisms for central nervous system involvement. Gen Hosp Psychiatry. 2020;65:47&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7242189</ArticleId><ArticleId IdType="pubmed">32470824</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study [published correction appears in Lancet. 2020 Mar 28;395(10229):1038] [published correction appears in Lancet. 2020 Mar 28;395(10229):1038]. Lancet. 2020;395(10229):1054&#x2013;1062.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020;369:m1966.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7243801</ArticleId><ArticleId IdType="pubmed">32444366</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area [published online ahead of print, 2020 Apr 22]. JAMA. 2020;323(20):2052&#x2013;2059.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7177629</ArticleId><ArticleId IdType="pubmed">32320003</ArticleId></ArticleIdList></Reference><Reference><Citation>Bianchetti A, Rozzini R, Guerini F, et al. Clinical Presentation of COVID19 in dementia patients. J Nutr Health Aging. 2020;24(6):560&#x2013;562.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7227170</ArticleId><ArticleId IdType="pubmed">32510106</ArticleId></ArticleIdList></Reference><Reference><Citation>Poloni TE, Carlos AF, Cairati M, et al. Prevalence and prognostic value of Delirium as the initial presentation of COVID-19 in the elderly with dementia: an Italian retrospective study [published online ahead of print, 2020 Jul 30]. EClinicalMedicine. 2020:100490.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7392565</ArticleId><ArticleId IdType="pubmed">32838241</ArticleId></ArticleIdList></Reference><Reference><Citation>Paniz-Mondolfi A, Bryce C, Grimes Z, et al. Central nervous system involvement by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). J Med Virol. 2020;92(7):699&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7264598</ArticleId><ArticleId IdType="pubmed">32314810</ArticleId></ArticleIdList></Reference><Reference><Citation>Reichard RR, Kashani KB, Boire NA, Constantopoulos E, Guo Y, Lucchinetti CF. Neuropathology of COVID-19: a spectrum of vascular and acute disseminated encephalomyelitis (ADEM)-like pathology. Acta Neuropathol. 2020;140(1):1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7245994</ArticleId><ArticleId IdType="pubmed">32449057</ArticleId></ArticleIdList></Reference><Reference><Citation>Kremer S, Lersy F, de S&#xe8;ze J, et al.
Brain MRI findings in severe COVID-19: a retrospective observational study. Radiology. 2020;297 (2):e242&#x2013;e251. 10.1148/radiol.2020202222. Epub 2020 Jun 16. https://pubmed.ncbi.nlm.nih.gov/32544034/.</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiol.2020202222</ArticleId><ArticleId IdType="pmc">PMC7301613</ArticleId><ArticleId IdType="pubmed">32544034</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilotto A, Odolini S, Masciocchi S, et al. Steroid-responsive encephalitis in coronavirus disease 2019 [published online ahead of print, 2020 May 17]. Ann Neurol. 2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7276848</ArticleId><ArticleId IdType="pubmed">32418288</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033&#x2013;1034.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7270045</ArticleId><ArticleId IdType="pubmed">32192578</ArticleId></ArticleIdList></Reference><Reference><Citation>Bostanciklio&#x11f;lu M. Temporal correlation between neurological and gastrointestinal symptoms of SARS-CoV-2. Inflamm Bowel Dis. 2020;26(8):e89&#x2013;e91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7313997</ArticleId><ArticleId IdType="pubmed">32440692</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Guennec L, Devianne J, Jalin L, et al. Orbitofrontal involvement in a neuroCOVID-19 patient [published online ahead of print, 2020 Jun 26]. Epilepsia. 2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7361605</ArticleId><ArticleId IdType="pubmed">32589794</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Long X, Zhang Q, et al. Emerging evidence for neuropsycho-consequences of COVID-19 [published online ahead of print, 2020 May 6]. Curr Neuropharmacol. 2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7903490</ArticleId><ArticleId IdType="pubmed">32379592</ArticleId></ArticleIdList></Reference><Reference><Citation>Asadi-Pooya AA, Simani L. Central nervous system manifestations of COVID-19: a systematic review. J Neurol Sci. 2020;413:116832.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7151535</ArticleId><ArticleId IdType="pubmed">32299017</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandhi S, Srivastava AK, Ray U, Tripathi PP. Is the collapse of the respiratory center in the brain responsible for respiratory breakdown in COVID-19 patients?. ACS Chem Neurosci. 2020;11(10):1379&#x2013;1381.</Citation><ArticleIdList><ArticleId IdType="pubmed">32348111</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhaskar S, Sinha A, Banach M, et al. Cytokine storm in COVID-19-immunopathological mechanisms, clinical considerations, and therapeutic approaches: the REPROGRAM consortium position paper. Front Immunol. 2020;11:1648.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7365905</ArticleId><ArticleId IdType="pubmed">32754159</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray PR, Wangzhou A, Ghneim N, et al. A pharmacological interactome between COVID-19 patient samples and human sensory neurons reveals potential drivers of neurogenic pulmonary dysfunction [published online ahead of print, 2020 Jun 1]. Brain Behav Immun. 2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7263237</ArticleId><ArticleId IdType="pubmed">32497778</ArticleId></ArticleIdList></Reference><Reference><Citation>Boziki MK, Mentis AA, Shumilina M, Makshakov G, Evdoshenko E, Grigoriadis N. COVID-19 immunopathology and the central nervous system: implication for multiple sclerosis and other autoimmune diseases with associated demyelination. Brain Sci. 2020;10(6): 345.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7349282</ArticleId><ArticleId IdType="pubmed">32512702</ArticleId></ArticleIdList></Reference><Reference><Citation>Naughton SX, Raval U, Pasinetti GM. Potential Novel Role of COVID-19 in Alzheimer&#x2019;s disease and preventative mitigation strategies. J Alzheimers Dis. 2020;76(1):21&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8057202</ArticleId><ArticleId IdType="pubmed">32538855</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogier M, And&#xe9;ol G, Sagui E, Dal Bo G. How to detect and track chronic neurologic sequelae of COVID-19? Use of auditory brainstem responses and neuroimaging for long-term patient follow-up. Brain Behav Immun Health. 2020;5:100081.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7227537</ArticleId><ArticleId IdType="pubmed">32427134</ArticleId></ArticleIdList></Reference><Reference><Citation>Brietzke E, Magee T, Freire RCR, Gomes FA, Milev R. Three insights on psychoneuroimmunology of mood disorders to be taken from the COVID-19 pandemic. Brain Behav Immun Health. 2020;5:100076.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7174985</ArticleId><ArticleId IdType="pubmed">32322822</ArticleId></ArticleIdList></Reference><Reference><Citation>Horn SR, Weston SJ, Fisher PA. Identifying causal role of COVID-19 in immunopsychiatry models. Brain Behav Immun. 2020;88:6&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7256562</ArticleId><ArticleId IdType="pubmed">32479992</ArticleId></ArticleIdList></Reference><Reference><Citation>Panariello A, Bassetti R, Radice A, et al. Anti-NMDA receptor encephalitis in a psychiatric Covid-19 patient: a case report. Brain Behav Immun. 2020;87:179&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7255176</ArticleId><ArticleId IdType="pubmed">32454137</ArticleId></ArticleIdList></Reference><Reference><Citation>Zambreanu L, Lightbody S, Bhandari M, et al.
A case of limbic encephalitis associated with asymptomatic COVID-19 infection. J Neurol Neurosurg Psychiatry. 2020;91(11):1229&#x2013;1230. 10.1136/jnnp-2020-323839. Epub 2020 Jul 13. https://pubmed.ncbi.nlm.nih.gov/32661082/.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-323839</ArticleId><ArticleId IdType="pubmed">32661082</ArticleId></ArticleIdList></Reference><Reference><Citation>Mankad K, Perry MD, Mirsky DM, Rossi A. COVID-19: a primer for neuroradiologists. Neuroradiology. 2020;62(6):647&#x2013;648.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7186113</ArticleId><ArticleId IdType="pubmed">32342126</ArticleId></ArticleIdList></Reference><Reference><Citation>Coolen T, Lolli V, Sadeghi N, et al.
Early postmortem brain MRI findings in COVID-19 non-survivors. Neurology. 2020;95(14): e2016&#x2013;e2027. 10.1212/WNL.0000000000010116. Epub 2020 Jun 16. https://pubmed.ncbi.nlm.nih.gov/32546654/.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000010116</ArticleId><ArticleId IdType="pubmed">32546654</ArticleId></ArticleIdList></Reference><Reference><Citation>Radmanesh A, Raz E, Zan E, Derman A, Kaminetzky M. Brain imaging use and findings in COVID-19: a single academic center experience in the epicenter of disease in the United States. AJNR Am J Neuroradiol. 2020;41(7):1179&#x2013;1183.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7357666</ArticleId><ArticleId IdType="pubmed">32467191</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain R, Young M, Dogra S, et al. COVID-19 related neuroimaging findings: a signal of thromboembolic complications and a strong prognostic marker of poor patient outcome. J Neurol Sci. 2020;414: 116923.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7236667</ArticleId><ArticleId IdType="pubmed">32447193</ArticleId></ArticleIdList></Reference><Reference><Citation>Katal S, Balakrishnan S, Gholamrezanezhad A. Neuroimaging and neurologic findings in COVID-19 and other coronavirus infections: a systematic review in 116 patients. J Neuroradiol. 2020;S0150&#x2013;9861(20):30204. 10.1016/j.neurad.2020.06.007. Epub ahead of print. https://pubmed.ncbi.nlm.nih.gov/32603770/.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurad.2020.06.007</ArticleId><ArticleId IdType="pmc">PMC7320684</ArticleId><ArticleId IdType="pubmed">32603770</ArticleId></ArticleIdList></Reference><Reference><Citation>Li CW, Syue LS, Tsai YS, et al. Anosmia and olfactory tract neuropathy in a case of COVID-19 [published online ahead of print, 2020 Jun 20]. J Microbiol Immunol Infect. 2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7305498</ArticleId><ArticleId IdType="pubmed">32576457</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoghi A, Ramezani M, Roozbeh M, Darazam IA, Sahraian MA. A case of possible atypical demyelinating event of the central nervous system following COVID-19 [published online ahead of print, 2020 Jun 24]. Mult Scler Relat Disord. 2020;44:102324.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7311915</ArticleId><ArticleId IdType="pubmed">32615528</ArticleId></ArticleIdList></Reference><Reference><Citation>Radmanesh A, Derman A, Lui YW, et al.
COVID-19-associated diffuse leukoencephalopathy and microhemorrhages. Radiology. 2020; 297(1):e223&#x2013;e227. 10.1148/radiol.2020202040. Epub 2020. 
May
21. https://pubmed.ncbi.nlm.nih.gov/32437314/.</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiol.2020202040</ArticleId><ArticleId IdType="pmc">PMC7507998</ArticleId><ArticleId IdType="pubmed">32437314</ArticleId></ArticleIdList></Reference><Reference><Citation>Faeez MS. Brain imaging findings in COVID-19: what do we know so far?. J Neuroradiol. 2020;47(5):329&#x2013;330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7236724</ArticleId><ArticleId IdType="pubmed">32444286</ArticleId></ArticleIdList></Reference><Reference><Citation>Anzalone N, Castellano A, Scotti R, et al. Multifocal laminar cortical brain lesions: a consistent MRI finding in neuro-COVID-19 patients [published online ahead of print, 2020 Jun 6]. J Neurol. 2020: 1&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7275660</ArticleId><ArticleId IdType="pubmed">32506390</ArticleId></ArticleIdList></Reference><Reference><Citation>Politi LS, Salsano E, Grimaldi M. Magnetic resonance imaging alteration of the brain in a patient with coronavirus disease 2019 (COVID-19) and Anosmia. JAMA Neurol. 2020;77(8):1028&#x2013;1029. 10.1001/jamaneurol.2020.2125. https://pubmed.ncbi.nlm.nih.gov/32469400/.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.2125</ArticleId><ArticleId IdType="pubmed">32469400</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandemirli SG, Dogan L, Sarikaya ZT, et al. Brain MRI findings in patients in the intensive care unit with COVID-19 infection [published online ahead of print, 2020 May 8]. Radiology. 2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7507997</ArticleId><ArticleId IdType="pubmed">32384020</ArticleId></ArticleIdList></Reference><Reference><Citation>Brun G, Hak JF, Coze S, et al. COVID-19-White matter and globus pallidum lesions: demyelination or small-vessel vasculitis?. Neurol Neuroimmunol Neuroinflamm. 2020;7(4):e777.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7286652</ArticleId><ArticleId IdType="pubmed">32444427</ArticleId></ArticleIdList></Reference><Reference><Citation>Novi G, Rossi T, Pedemonte E, et al. Acute disseminated encephalomyelitis after SARS-CoV-2 infection. Neurol Neuroimmunol Neuroinflamm. 2020;7(5):e797.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7286650</ArticleId><ArticleId IdType="pubmed">32482781</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdi S, Ghorbani A, Fatehi F. The association of SARS-CoV-2 infection and acute disseminated encephalomyelitis without prominent clinical pulmonary symptoms [published online ahead of print, 2020 Jun 18]. J Neurol Sci. 2020;416:117001.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7301801</ArticleId><ArticleId IdType="pubmed">32590204</ArticleId></ArticleIdList></Reference><Reference><Citation>Li MY, Li L, Zhang Y, Wang XS. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. Infect Dis Poverty. 2020;9(1):45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7186534</ArticleId><ArticleId IdType="pubmed">32345362</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamer M, Kivim&#xe4;ki M, Gale CR, Batty GD. Lifestyle risk factors, inflammatory mechanisms, and COVID-19 hospitalization: a community-based cohort study of 387,109 adults in UK. Brain Behav Immun. 2020;87:184&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7245300</ArticleId><ArticleId IdType="pubmed">32454138</ArticleId></ArticleIdList></Reference><Reference><Citation>Dogan L, Kaya D, Sarikaya T, et al. Plasmapheresis treatment in COVID-19-related autoimmune meningoencephalitis: case series. Brain Behav Immun. 2020;87:155&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7204750</ArticleId><ArticleId IdType="pubmed">32389697</ArticleId></ArticleIdList></Reference><Reference><Citation>Pranata R, Huang I, Lukito AA, Raharjo SB. Elevated N-terminal probrain natriuretic peptide is associated with increased mortality in patients with COVID-19: systematic review and meta-analysis. Postgrad Med J. 2020;96(1137):387&#x2013;391.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7316121</ArticleId><ArticleId IdType="pubmed">32434874</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao L, Jiang D, Wen XS, et al. Prognostic value of NT-proBNP in patients with severe COVID-19. Respir Res. 2020;21(1):83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7156898</ArticleId><ArticleId IdType="pubmed">32293449</ArticleId></ArticleIdList></Reference><Reference><Citation>Inciardi RM, Adamo M, Lupi L, et al. Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy. Eur Heart J. 2020;41(19):1821&#x2013;1829.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7239204</ArticleId><ArticleId IdType="pubmed">32383763</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinna P, Grewal P, Hall JP, et al. Neurological manifestations and COVID-19: experiences from a tertiary care center at the frontline. J Neurol Sci. 2020;415:116969.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7832569</ArticleId><ArticleId IdType="pubmed">32570113</ArticleId></ArticleIdList></Reference><Reference><Citation>Lassale C, Gaye B, Hamer M, Gale CR, Batty GD. Ethnic disparities in hospitalisation for COVID-19 in England: the role of socioeconomic factors, mental health, and inflammatory and proinflammatory factors in a community-based cohort study. Brain Behav Immun. 2020;88:44&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7263214</ArticleId><ArticleId IdType="pubmed">32497776</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki M, Saito K, Min WP, et al. Identification of viruses in patients with postviral olfactory dysfunction. Laryngoscope. 2007;117(2):272&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7165544</ArticleId><ArticleId IdType="pubmed">17277621</ArticleId></ArticleIdList></Reference><Reference><Citation>Han AY, Mukdad L, Long JL, Lopez IA. Anosmia in COVID-19: mechanisms and significance [published online ahead of print, 2020 Jun 17]. Chem Senses. 2020:bjaa040.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7449368</ArticleId><ArticleId IdType="pubmed">32556089</ArticleId></ArticleIdList></Reference><Reference><Citation>Dibattista M, Pifferi S, Menini A, Reisert J. Alzheimer&#x2019;s disease: what can we learn from the peripheral olfactory system?. Front Neurosci. 2020;14:440.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7248389</ArticleId><ArticleId IdType="pubmed">32508565</ArticleId></ArticleIdList></Reference><Reference><Citation>De Felice FG, Tovar-Moll F, Moll J, Munoz DP, Ferreira ST. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the central nervous system. Trends Neurosci. 2020;43(6):355&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7172664</ArticleId><ArticleId IdType="pubmed">32359765</ArticleId></ArticleIdList></Reference><Reference><Citation>Hustad E, Aasly JO. Clinical and imaging markers of prodromal Parkinson&#x2019;s disease. Front Neurol. 2020;11:395.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7225301</ArticleId><ArticleId IdType="pubmed">32457695</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Regemorter V, Hummel T, Rosenzweig F, Mouraux A, Rombaux P, Huart C. Mechanisms linking olfactory impairment and risk of mortality. Front Neurosci. 2020;14:140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7046549</ArticleId><ArticleId IdType="pubmed">32153360</ArticleId></ArticleIdList></Reference><Reference><Citation>Gialluisi A, de Gaetano G, Iacoviello L. New challenges from Covid-19 pandemic: an unexpected opportunity to enlighten the link between viral infections and brain disorders?. Neurol Sci. 2020;41(6):1349&#x2013;1350.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7200170</ArticleId><ArticleId IdType="pubmed">32372197</ArticleId></ArticleIdList></Reference><Reference><Citation>Pendlebury ST, Rothwell PM. Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. Lancet Neurol. 2009;8(11):1006&#x2013;1018.</Citation><ArticleIdList><ArticleId IdType="pubmed">19782001</ArticleId></ArticleIdList></Reference><Reference><Citation>Sexton E, McLoughlin A, Williams DJ, et al. Systematic review and meta-analysis of the prevalence of cognitive impairment no dementia in the first year post-stroke. Eur Stroke J. 2019;4(2):160&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6591758</ArticleId><ArticleId IdType="pubmed">31259264</ArticleId></ArticleIdList></Reference><Reference><Citation>Ku&#x17a;ma E, Lourida I, Moore SF, Levine DA, Ukoumunne OC, Llewellyn DJ. Stroke and dementia risk: a systematic review and meta-analysis. Alzheimers Dement. 2018;14(11):1416&#x2013;1426.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6231970</ArticleId><ArticleId IdType="pubmed">30177276</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbay M, Diouf M, Roussel M, Godefroy O. GRECOGVASC study group. Systematic review and meta-analysis of prevalence in post-stroke neurocognitive disorders in hospital-based studies. Dement Geriatr Cogn Disord. 2018;46(5&#x2013;6):322&#x2013;334.</Citation><ArticleIdList><ArticleId IdType="pubmed">30504699</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Z, Wang H, Edwards D, et al. Association of blood lipids, atherosclerosis and statin use with dementia and cognitive impairment after stroke: a systematic review and meta-analysis. Ageing Res Rev. 2020;57:100962.</Citation><ArticleIdList><ArticleId IdType="pubmed">31505259</ArticleId></ArticleIdList></Reference><Reference><Citation>Islam MM, Poly TN, Walther BA, et al. Association between atrial fibrillation and dementia: a meta-analysis. Front Aging Neurosci. 2019;11:305.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6857071</ArticleId><ArticleId IdType="pubmed">31780919</ArticleId></ArticleIdList></Reference><Reference><Citation>Lennon MJ, Makkar SR, Crawford JD, Sachdev PS. Midlife hypertension and Alzheimer&#x2019;s disease: a systematic review and meta-analysis. J Alzheimers Dis. 2019;71(1):307&#x2013;316.</Citation><ArticleIdList><ArticleId IdType="pubmed">31381518</ArticleId></ArticleIdList></Reference><Reference><Citation>Rochoy M, Rivas V, Chazard E, et al. Factors associated with Alzheimer&#x2019;s disease: an overview of reviews. J Prev Alzheimers Dis. 2019;6(2):121&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">30756119</ArticleId></ArticleIdList></Reference><Reference><Citation>Rensma SP, van Sloten TT, Launer LJ, Stehouwer CDA. Cerebral small vessel disease and risk of incident stroke, dementia and depression, and all-cause mortality: a systematic review and meta-analysis. Neurosci Biobehav Rev. 2018;90:164&#x2013;173.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6123527</ArticleId><ArticleId IdType="pubmed">29656031</ArticleId></ArticleIdList></Reference><Reference><Citation>Makin SD, Turpin S, Dennis MS, Wardlaw JM. Cognitive impairment after lacunar stroke: systematic review and meta-analysis of incidence, prevalence and comparison with other stroke subtypes. J Neurol Neurosurg Psychiatry. 2013;84(8):893&#x2013;900.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3717603</ArticleId><ArticleId IdType="pubmed">23457225</ArticleId></ArticleIdList></Reference><Reference><Citation>Azeem F, Durrani R, Zerna C, Smith EE. Silent brain infarctions and cognition decline: systematic review and meta-analysis. J Neurol. 2020;267(2):502&#x2013;512.</Citation><ArticleIdList><ArticleId IdType="pubmed">31691021</ArticleId></ArticleIdList></Reference><Reference><Citation>Saavedra JM. COVID-19, angiotensin receptor blockers, and the brain. Cell Mol Neurobiol. 2020;40(5):667&#x2013;674.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7207082</ArticleId><ArticleId IdType="pubmed">32385549</ArticleId></ArticleIdList></Reference><Reference><Citation>Fotuhi M, Mian A, Meysami S, Raji CA. Neurobiology of COVID-19. J Alzheimers Dis. 2020;76(1):3&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7660990</ArticleId><ArticleId IdType="pubmed">32538857</ArticleId></ArticleIdList></Reference><Reference><Citation>Troyer EA, Kohn JN, Hong S. Are we facing a crashing wave of neuropsychiatric sequelae of COVID-19? Neuropsychiatric symptoms and potential immunologic mechanisms. Brain Behav Immun. 2020;87:34&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7152874</ArticleId><ArticleId IdType="pubmed">32298803</ArticleId></ArticleIdList></Reference><Reference><Citation>Cothran TP, Kellman S, Singh S, et al. A brewing storm: the neuropsychological sequelae of hyperinflammation due to COVID-19. Brain Behav Immun. 2020;88:957.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7309913</ArticleId><ArticleId IdType="pubmed">32590055</ArticleId></ArticleIdList></Reference><Reference><Citation>Vindegaard N, Benros ME. COVID-19 pandemic and mental health consequences: systematic review of the current evidence. Brain Behav Immun. 2020;89(Oct):531&#x2013;542. 10.1016/j.bbi.2020.05.048. Epub 2020 May 30. https://pubmed.ncbi.nlm.nih.gov/32485289/.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2020.05.048</ArticleId><ArticleId IdType="pmc">PMC7260522</ArticleId><ArticleId IdType="pubmed">32485289</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers JP, Chesney E, Oliver D, et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry. 2020;7(7):611&#x2013;627.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7234781</ArticleId><ArticleId IdType="pubmed">32437679</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallamkondu J, John A, Wani WY, et al. SARS-CoV-2 pathophysiology and assessment of coronaviruses in CNS diseases with a focus on therapeutic targets. Biochim Biophys Acta Mol Basis Dis. 2020;1866(10):165889.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7320676</ArticleId><ArticleId IdType="pubmed">32603829</ArticleId></ArticleIdList></Reference><Reference><Citation>Landreau F, Galeano P, Caltana LR, et al. Effects of two commonly found strains of influenza A virus on developing dopaminergic neurons, in relation to the pathophysiology of schizophrenia. PLoS One. 2012;7(12):e51068.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3519479</ArticleId><ArticleId IdType="pubmed">23251423</ArticleId></ArticleIdList></Reference><Reference><Citation>Bostanciklioglu M. Severe acute respiratory syndrome coronavirus 2 is penetrating to dementia research. Curr Neurovasc Res. 2020. 10.2174/1567202617666200522220509. Epub ahead of print. https://pubmed.ncbi.nlm.nih.gov/32442082/.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1567202617666200522220509</ArticleId><ArticleId IdType="pubmed">32442082</ArticleId></ArticleIdList></Reference><Reference><Citation>Hascup ER, Hascup KN. Does SARS-CoV-2 infection cause chronic neurological complications?. Geroscience. 2020;42(4):1083&#x2013;1087.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7247778</ArticleId><ArticleId IdType="pubmed">32451846</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33404617</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>12</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2574-3805</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Jan</Month><Day>04</Day></PubDate></JournalIssue><Title>JAMA network open</Title><ISOAbbreviation>JAMA Netw Open</ISOAbbreviation></Journal><ArticleTitle>Progression of Behavioral Disturbances and Neuropsychiatric Symptoms in Patients With Genetic Frontotemporal Dementia.</ArticleTitle><Pagination><StartPage>e2030194</StartPage><MedlinePgn>e2030194</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e2030194</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamanetworkopen.2020.30194</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Behavioral disturbances are core features of frontotemporal dementia (FTD); however, symptom progression across the course of disease is not well characterized in genetic FTD.</AbstractText><AbstractText Label="OBJECTIVE">To investigate behavioral symptom frequency and severity and their evolution and progression in different forms of genetic FTD.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This longitudinal cohort study, the international Genetic FTD Initiative (GENFI), was conducted from January 30, 2012, to May 31, 2019, at 23 multicenter specialist tertiary FTD research clinics in the United Kingdom, the Netherlands, Belgium, France, Spain, Portugal, Italy, Germany, Sweden, Finland, and Canada. Participants included a consecutive sample of 232 symptomatic FTD gene variation carriers comprising 115 with variations in C9orf72, 78 in GRN, and 39 in MAPT. A total of 101 carriers had at least 1 follow-up evaluation (for a total of 400 assessments). Gene variations were included only if considered pathogenetic.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Behavioral and neuropsychiatric symptoms were assessed across disease duration and evaluated from symptom onset. Hierarchical generalized linear mixed models were used to model behavioral and neuropsychiatric measures as a function of disease duration and variation.</AbstractText><AbstractText Label="RESULTS">Of 232 patients with FTD, 115 (49.6%) had a C9orf72 expansion (median [interquartile range (IQR)] age at evaluation, 64.3 [57.5-69.7] years; 72 men [62.6%]; 115 White patients [100%]), 78 (33.6%) had a GRN variant (median [IQR] age, 63.4 [58.3-68.8] years; 40 women [51.3%]; 77 White patients [98.7%]), and 39 (16.8%) had a MAPT variant (median [IQR] age, 56.3 [49.9-62.4] years; 25 men [64.1%]; 37 White patients [94.9%]). All core behavioral symptoms, including disinhibition, apathy, loss of empathy, perseverative behavior, and hyperorality, were highly expressed in all gene variant carriers (&gt;50% patients), with apathy being one of the most common and severe symptoms throughout the disease course (51.7%-100% of patients). Patients with MAPT variants showed the highest frequency and severity of most behavioral symptoms, particularly disinhibition (79.3%-100% of patients) and compulsive behavior (64.3%-100% of patients), compared with C9orf72 carriers (51.7%-95.8% of patients with disinhibition and 34.5%-75.0% with compulsive behavior) and GRN carriers (38.2%-100% with disinhibition and 20.6%-100% with compulsive behavior). Alongside behavioral symptoms, neuropsychiatric symptoms were very frequently reported in patients with genetic FTD: anxiety and depression were most common in GRN carriers (23.8%-100% of patients) and MAPT carriers (26.1%-77.8% of patients); hallucinations, particularly auditory and visual, were most common in C9orf72 carriers (10.3%-54.5% of patients). Most behavioral and neuropsychiatric symptoms increased in the early-intermediate phases and plateaued in the late stages of disease, except for depression, which steadily declined in C9orf72 carriers, and depression and anxiety, which surged only in the late stages in GRN carriers.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">This cohort study suggests that behavioral and neuropsychiatric disturbances differ between the common FTD gene variants and have different trajectories throughout the course of disease. These findings have crucial implications for counseling patients and caregivers and for the design of disease-modifying treatment trials in genetic FTD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Benussi</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre for Neurodegenerative Disorders, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Premi</LastName><ForeName>Enrico</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Vascular Neurology Unit, Department of Neurological and Vision Sciences, ASST Spedali Civili, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gazzina</LastName><ForeName>Stefano</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Neurophysiology Unit, Department of Neurological and Vision Sciences, ASST Spedali Civili, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brattini</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Centre for Neurodegenerative Disorders, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonomi</LastName><ForeName>Elisa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Centre for Neurodegenerative Disorders, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alberici</LastName><ForeName>Antonella</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neurology Unit, Department of Neurological and Vision Sciences, ASST Spedali Civili, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiskoot</LastName><ForeName>Lize</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, Erasmus Medical Centre, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Swieten</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Erasmus Medical Centre, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanchez-Valle</LastName><ForeName>Raquel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Cl&#xed;nic, Institut d'Investigaci&#xf3;ns Biom&#xe8;diques August Pi I Sunyer, University of Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moreno</LastName><ForeName>Fermin</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Cognitive Disorders Unit, Department of Neurology, Donostia University Hospital, San Sebastian, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Area, Biodonostia Health Research Institute, San Sebastian, Gipuzkoa, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laforce</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Clinique Interdisciplinaire de M&#xe9;moire, D&#xe9;partement des Sciences Neurologiques du CHU de Qu&#xe9;bec, and Facult&#xe9; de M&#xe9;decine, Universit&#xe9; Laval, Qu&#xe9;bec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graff</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Center for Alzheimer Research, Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Bioclinicum, Karolinska Institutet, Solna, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unit for Hereditary Dementias, Theme Aging, Karolinska University Hospital, Solna, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Synofzik</LastName><ForeName>Matthis</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research and Center of Neurology, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Neurodegenerative Diseases, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galimberti</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Fondazione Ca' Granda, IRCCS Ospedale Policlinico, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Milan, Centro Dino Ferrari, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masellis</LastName><ForeName>Mario</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tartaglia</LastName><ForeName>Carmela</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rowe</LastName><ForeName>James B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, University of Cambridge, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Finger</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurological Sciences, University of Western Ontario, London, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vandenberghe</LastName><ForeName>Rik</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Service, University Hospitals Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leuven Brain Institute, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Mendon&#xe7;a</LastName><ForeName>Alexandre</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Lisbon, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tagliavini</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santana</LastName><ForeName>Isabel</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Neurology Service, Faculty of Medicine, University Hospital of Coimbra, University of Coimbra, Coimbra, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Neuroscience and Cell Biology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ducharme</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, McGill University Health Centre, McGill University, Montreal, Qu&#xe9;bec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Qu&#xe9;bec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Butler</LastName><ForeName>Chris R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, Medical Sciences Division, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Brain Sciences, Imperial College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gerhard</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Neuroscience and Experimental Psychology, Wolfson Molecular Imaging Centre, University of Manchester, Manchester, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departments of Geriatric Medicine and Nuclear Medicine, University of Duisburg-Essen, Duisburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levin</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ludwig-Maximilians Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster of Systems Neurology, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Danek</LastName><ForeName>Adrian</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ludwig-Maximilians Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Otto</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frisoni</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>IRCCS Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghidoni</LastName><ForeName>Roberta</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sorbi</LastName><ForeName>Sandro</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurofarba, University of Florence, Florence, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le Ber</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Institut National de la Sant&#xe9; et de la Recherche Medicale (INSERM) U1127, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre de National de la Recherche Scientifique, Unit&#xe9; Mixte de Recherche (UMR) 7225, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unit&#xe9; Mixte de Recherche en Sant&#xe9; 1127, Universit&#xe9; Pierre et Marie Curie (Paris 06), Sorbonne Universit&#xe9;s, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute du Cerveau et de la Moelle Epini&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pasquier</LastName><ForeName>Florence</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Inserm CHU Lille, Lille Neurosciences &amp; Cognition UMR-S1172 Degenerative and Vascular Cognitive Disorders, Universit&#xe9; de Lille, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CHU Lille, DistAlz Licend Memory Clinic, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology, Queen Square, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peakman</LastName><ForeName>Georgia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology, Queen Square, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Todd</LastName><ForeName>Emily</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology, Queen Square, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bocchetta</LastName><ForeName>Martina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology, Queen Square, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rohrer</LastName><ForeName>Jonathan D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology, Queen Square, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borroni</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Centre for Neurodegenerative Disorders, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Genetic FTD Initiative (GENFI)</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MOP 327387</GrantID><Agency>CIHR</Agency><Country>Canada</Country></Grant><Grant><GrantID>MR/J009482/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/K010395/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/M023664/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/T046015/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/M008525/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>01</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Netw Open</MedlineTA><NlmUniqueID>101729235</NlmUniqueID><ISSNLinking>2574-3805</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077155">Granulins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>JAMA Netw Open. 2021 Mar 1;4(3):e217664. doi: 10.1001/jamanetworkopen.2021.7664.</RefSource><PMID Version="1">33787918</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001007" MajorTopicYN="N">Anxiety</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057565" MajorTopicYN="N">Apathy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N" Type="Geographic">Canada</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003192" MajorTopicYN="N">Compulsive Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005060" MajorTopicYN="N" Type="Geographic">Europe</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077155" MajorTopicYN="N">Granulins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Graff reported receiving grants from the Swedish Research Council Joint Programme&#x2013;Neurodegenerative Disease Research GENFI-prox domain registration no. 2019-02248, the Swedish Research Council Joint Programme&#x2013;Neurodegenerative Disease Research Prefrontals domain registration no. 2015-02926, the Swedish Research Council Dnr 208-02754, the Sch&#xf6;rling Foundation Swedish FTD Initiative, the Swedish Alzheimer Foundation, the Swedish Brain Foundation, the Region Stockholm ALF-project, the Karolinska Instututet Doctoral and StratNeuro, and from the Swedish Dementia Foundation during the conduct of the study. Dr Masellis reported receiving grants from the Canadian Institutes of Health, the Cambridge Trust, the Ontario Brain Institute, the Weston Brain Institute, the Roche Clinical Trial, the Washington University Clinical Trial, and the Alector Clinical Trial; and personal fees from Arkuda Therapeutics Advisory Board, the Ionis Advisory Board, Henry Stewart Talks Royalties, Alector Advisory Board, and Wave Life Sciences Advisory Board outside the submitted work. Dr Rowe reported receiving grants from the National Institute for Health Research, Wellcome Trust, Janssen, AZ Medimmune, Lilly, and Medical Research Council; and personal fees from Biogen, Asceneuron, UCB, Althira, Astex, and SVHealth outside the submitted work. Dr Rowe also reported serving as Trustee for the Progressive Supranuclear Palsy Association, Darwin College, and Guarantor of <i>Brain</i>; and reported serving as an editor of <i>Brain</i>. Dr Le Ber reported receiving funding from the program &#x201c;Investissements d&#x2019;avenir&#x201d; and from Agence Nationale de la Recherche/Direction G&#xe9;n&#xe9;rale de l'Offre de Soins; serving as a member of the advisory board for Prevail Therapeutic; and receiving research grants from Agence Nationale de la Recherche, Direction G&#xe9;n&#xe9;rale de l'Offre de Soins, Programme Hospitalier de Recherche Clinique, Vaincre Alzheimer Association, ARSla Association, Fondation Plan Alzheimer, and PRTS PrevDemALS; personal fees from Prevail Therapeutics; and grants from Programme Hospitalier de Recherche Clinique FTLD exome, Programme Hospitalier de Recherche Clinique Predict PGRN, and ANR-10-IAIHU-06 outside the submitted work. Dr Sanchez-Valle reported receiving grants from Fundaci&#xf3; Marat&#xf3; de TV3 and personal fees from Wave Pharmaceuticals for participation in advisory board meetings and Ionis for participation in advisory board meetings outside the submitted work. Dr Moreno reported receiving grants from Tau Consortium outside the submitted work. Dr Synofzik reported receiving personal fees from Actelion Pharmaceuticals and Orphazyme outside the submitted work. Dr Santana reported receiving grants from GENFI and personal fees and travel funds from commercial sponsors outside the submitted work. Dr Levin reported receiving grants from Munich Cluster of Systems Neurology (SyNergy) and personal fees from Modag GmbH, Bayer Vital, Roche, Axon Neuroscience, Thieme medical publishers, and W. Kohlhammer GmbH medical publishers; and nonfinancial support from Abbvie outside the submitted work. Dr Otto reported receiving grants from BMBF during the conduct of the study. Dr Ghidoni reported receiving grants from the Italian Ministry of Health during the conduct of the study. Dr Rohrer reported performing medical advisory board work for Alector, Wave Life Sciences, and Prevail Therapeutics outside the submitted work. No other disclosures were reported.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Afonso</LastName><ForeName>S&#xf2;nia</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosario Almeida</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anderl-Straub</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Andersson</LastName><ForeName>Christin</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Antonell</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Archetti</LastName><ForeName>Silvana</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arighi</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Balasa</LastName><ForeName>Mircea</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barandiaran</LastName><ForeName>Myriam</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bargall&#xf2;</LastName><ForeName>Nuria</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bartha</LastName><ForeName>Robart</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bender</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Benussi</LastName><ForeName>Luisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bertoux</LastName><ForeName>Maxime</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bertrand</LastName><ForeName>Anne</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bessi</LastName><ForeName>Valentina</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Binetti</LastName><ForeName>Giuliano</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Black</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Borrego-Ecija</LastName><ForeName>Sergi</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bras</LastName><ForeName>Jose</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brice</LastName><ForeName>Alexis</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bruffaerts</LastName><ForeName>Rose</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Camuzat</LastName><ForeName>Agn&#xe8;s</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ca&#xf1;ada</LastName><ForeName>Marta</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Caroppo</LastName><ForeName>Paola</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cash</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Castelo-Branco</LastName><ForeName>Miguel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Colliot</LastName><ForeName>Olivier</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Convery</LastName><ForeName>Rhian</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cope</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cosseddu</LastName><ForeName>Maura</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deramecourt</LastName><ForeName>Vincent</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>de Arriba</LastName><ForeName>Mar&#xec;a</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Di Fede</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>D&#xec;ez</LastName><ForeName>Alina</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duro</LastName><ForeName>Diana</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fenoglio</LastName><ForeName>Chiara</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferrari</LastName><ForeName>Camilla</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>B Ferreira</LastName><ForeName>Catarina</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fox</LastName><ForeName>Nick</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Freedman</LastName><ForeName>Morris</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fumagalli</LastName><ForeName>Giorgio</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Funkiewiez</LastName><ForeName>Aur&#xe9;lie</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gabilondo</LastName><ForeName>Alazne</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gasparotti</LastName><ForeName>Roberto</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gauthier</LastName><ForeName>Serge</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gazzina</LastName><ForeName>Stefano</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Giaccone</LastName><ForeName>Giorgio</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gorostidi</LastName><ForeName>Ana</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Greaves</LastName><ForeName>Caroline</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guerreiro</LastName><ForeName>Rita</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heller</LastName><ForeName>Carolin</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hoegen</LastName><ForeName>Tobias</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Indakoetxea</LastName><ForeName>Bego&#xf1;a</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jelic</LastName><ForeName>Vesna</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karnath</LastName><ForeName>Hans-Otto</ForeName><Initials>HO</Initials></Investigator><Investigator ValidYN="Y"><LastName>Keren</LastName><ForeName>Ron</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kuchcinski</LastName><ForeName>Gregory</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Langheinrich</LastName><ForeName>Tobias</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lebouvier</LastName><ForeName>Thibaud</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jo&#xe3;o Leit&#xe3;o</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Llad&#xf2;</LastName><ForeName>Albert</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lombardi</LastName><ForeName>Gemma</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Loosli</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maruta</LastName><ForeName>Carolina</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mead</LastName><ForeName>Simon</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Meeter</LastName><ForeName>Lieke</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miltenberger</LastName><ForeName>Gabriel</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Minkelen</LastName><ForeName>Rick</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mitchell</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moore</LastName><ForeName>Katrina</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nacmias</LastName><ForeName>Benedetta</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nicholas</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>&#xd6;ijerstedt</LastName><ForeName>Linn</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Olives</LastName><ForeName>Jaume</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ourselin</LastName><ForeName>Sebastien</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Padovani</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Panman</LastName><ForeName>Jessica</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>M Papma</LastName><ForeName>Janne</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pievani</LastName><ForeName>Michela</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pijnenburg</LastName><ForeName>Yolande</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Polito</LastName><ForeName>Cristina</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Prioni</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Prix</LastName><ForeName>Catharina</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rademakers</LastName><ForeName>Rosa</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Redaelli</LastName><ForeName>Veronica</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rinaldi</LastName><ForeName>Daisy</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rittman</LastName><ForeName>Tim</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rogaeva</LastName><ForeName>Ekaterina</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rollin</LastName><ForeName>Adeline</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosa-Neto</LastName><ForeName>Pedro</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rossi</LastName><ForeName>Giacomina</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rossor</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Santiago</LastName><ForeName>Beatriz</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saracino</LastName><ForeName>Dario</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sayah</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scarpini</LastName><ForeName>Elio</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sch&#xf6;necker</LastName><ForeName>Sonja</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seelaar</LastName><ForeName>Harro</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Semler</LastName><ForeName>Elisa</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shafei</LastName><ForeName>Rachelle</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shoesmith</LastName><ForeName>Christen</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>T&#xe1;buas-Pereira</LastName><ForeName>Miguel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tainta</LastName><ForeName>Mikel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taipa</LastName><ForeName>Ricardo</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tang-Wai</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>L Thomas</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thompson</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thonberg</LastName><ForeName>Hakan</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Timberlake</LastName><ForeName>Carolyn</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tiraboschi</LastName><ForeName>Pietro</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Todd</LastName><ForeName>Emily</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Van Damme</LastName><ForeName>Philip</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vandenbulcke</LastName><ForeName>Mathieu</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Veldsman</LastName><ForeName>Michele</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Verdelho</LastName><ForeName>Ana</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Villanua</LastName><ForeName>Jorge</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Warren</LastName><ForeName>Jason</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wilke</LastName><ForeName>Carlo</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Woollacott</LastName><ForeName>Ione</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wlasich</LastName><ForeName>Elisabeth</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zulaica</LastName><ForeName>Miren</ForeName><Initials>M</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>1</Month><Day>6</Day><Hour>12</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>1</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>1</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33404617</ArticleId><ArticleId IdType="pmc">PMC7788468</ArticleId><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.30194</ArticleId><ArticleId IdType="pii">2774641</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bang J, Spina S, Miller BL. Frontotemporal dementia. Lancet. 2015;386(10004):1672-1682. doi:10.1016/S0140-6736(15)00461-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(15)00461-4</ArticleId><ArticleId IdType="pmc">PMC5970949</ArticleId><ArticleId IdType="pubmed">26595641</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrer JD, Guerreiro R, Vandrovcova J, et al. . The heritability and genetics of frontotemporal lobar degeneration. Neurology. 2009;73(18):1451-1456. doi:10.1212/WNL.0b013e3181bf997a</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181bf997a</ArticleId><ArticleId IdType="pmc">PMC2779007</ArticleId><ArticleId IdType="pubmed">19884572</ArticleId></ArticleIdList></Reference><Reference><Citation>Borroni B, Padovani A. Dementia: a new algorithm for molecular diagnostics in FTLD. Nat Rev Neurol. 2013;9(5):241-242. doi:10.1038/nrneurol.2013.72</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2013.72</ArticleId><ArticleId IdType="pubmed">23609620</ArticleId></ArticleIdList></Reference><Reference><Citation>Benussi A, Padovani A, Borroni B. Phenotypic heterogeneity of monogenic frontotemporal dementia. Front Aging Neurosci. 2015;7(SEP):171. doi:10.3389/fnagi.2015.00171</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2015.00171</ArticleId><ArticleId IdType="pmc">PMC4555036</ArticleId><ArticleId IdType="pubmed">26388768</ArticleId></ArticleIdList></Reference><Reference><Citation>Rascovsky K, Hodges JR, Knopman D, et al. . Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134(Pt 9):2456-2477. doi:10.1093/brain/awr179</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr179</ArticleId><ArticleId IdType="pmc">PMC3170532</ArticleId><ArticleId IdType="pubmed">21810890</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorno-Tempini ML, Hillis AE, Weintraub S, et al. . Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006-1014. doi:10.1212/WNL.0b013e31821103e6</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31821103e6</ArticleId><ArticleId IdType="pmc">PMC3059138</ArticleId><ArticleId IdType="pubmed">21325651</ArticleId></ArticleIdList></Reference><Reference><Citation>Lansdall CJ, Coyle-Gilchrist ITS, Jones PS, et al. . Apathy and impulsivity in frontotemporal lobar degeneration syndromes. Brain. 2017;140(6):1792-1807. doi:10.1093/brain/awx101</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awx101</ArticleId><ArticleId IdType="pmc">PMC5868210</ArticleId><ArticleId IdType="pubmed">28486594</ArticleId></ArticleIdList></Reference><Reference><Citation>Snowden JS, Bathgate D, Varma A, Blackshaw A, Gibbons ZC, Neary D. Distinct behavioural profiles in frontotemporal dementia and semantic dementia. J Neurol Neurosurg Psychiatry. 2001;70(3):323-332. doi:10.1136/jnnp.70.3.323</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.70.3.323</ArticleId><ArticleId IdType="pmc">PMC1737271</ArticleId><ArticleId IdType="pubmed">11181853</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen HJ, Allison SC, Ogar JM, et al. . Behavioral features in semantic dementia vs other forms of progressive aphasias. Neurology. 2006;67(10):1752-1756. doi:10.1212/01.wnl.0000247630.29222.34</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000247630.29222.34</ArticleId><ArticleId IdType="pubmed">17130406</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozeat S, Gregory CA, Ralph MA, Hodges JR. Which neuropsychiatric and behavioural features distinguish frontal and temporal variants of frontotemporal dementia from Alzheimer&#x2019;s disease? J Neurol Neurosurg Psychiatry. 2000;69(2):178-186. doi:10.1136/jnnp.69.2.178</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.69.2.178</ArticleId><ArticleId IdType="pmc">PMC1737062</ArticleId><ArticleId IdType="pubmed">10896690</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Langenhove T, Leyton CE, Piguet O, Hodges JR. Comparing longitudinal behavior changes in the primary progressive aphasias. J Alzheimers Dis. 2016;53(3):1033-1042. doi:10.3233/JAD-160010</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-160010</ArticleId><ArticleId IdType="pubmed">27340847</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Connor CM, Clemson L, Hornberger M, et al. . Longitudinal change in everyday function and behavioral symptoms in frontotemporal dementia. Neurol Clin Pract. 2016;6(5):419-428. doi:10.1212/CPJ.0000000000000264</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/CPJ.0000000000000264</ArticleId><ArticleId IdType="pmc">PMC5100706</ArticleId><ArticleId IdType="pubmed">27847684</ArticleId></ArticleIdList></Reference><Reference><Citation>Marczinski CA, Davidson W, Kertesz A. A longitudinal study of behavior in frontotemporal dementia and primary progressive aphasia. Cogn Behav Neurol. 2004;17(4):185-190.</Citation><ArticleIdList><ArticleId IdType="pubmed">15622012</ArticleId></ArticleIdList></Reference><Reference><Citation>Diehl-Schmid J, Pohl C, Perneczky R, F&#xf6;rstl H, Kurz A. Behavioral disturbances in the course of frontotemporal dementia. Dement Geriatr Cogn Disord. 2006;22(4):352-357. doi:10.1159/000095625</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000095625</ArticleId><ArticleId IdType="pubmed">16954691</ArticleId></ArticleIdList></Reference><Reference><Citation>Chow TW, Fridhandler JD, Binns MA, et al. . Trajectories of behavioral disturbance in dementia. J Alzheimers Dis. 2012;31(1):143-149. doi:10.3233/JAD-2012-111916</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2012-111916</ArticleId><ArticleId IdType="pmc">PMC4309273</ArticleId><ArticleId IdType="pubmed">22531424</ArticleId></ArticleIdList></Reference><Reference><Citation>Boutoleau-Bretonni&#xe8;re C, Lebouvier T, Volteau C, et al. . Prospective evaluation of behavioral scales in the behavioral variant of frontotemporal dementia. Dement Geriatr Cogn Disord. 2012;34(2):75-82. doi:10.1159/000341784</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000341784</ArticleId><ArticleId IdType="pubmed">22922703</ArticleId></ArticleIdList></Reference><Reference><Citation>Mioshi E, Hsieh S, Savage S, Hornberger M, Hodges JR. Clinical staging and disease progression in frontotemporal dementia. Neurology. 2010;74(20):1591-1597. doi:10.1212/WNL.0b013e3181e04070</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181e04070</ArticleId><ArticleId IdType="pubmed">20479357</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon E, Rohrer JD, Kim LG, et al. . Measuring disease progression in frontotemporal lobar degeneration: a clinical and MRI study. Neurology. 2010;74(8):666-673. doi:10.1212/WNL.0b013e3181d1a879</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181d1a879</ArticleId><ArticleId IdType="pmc">PMC2830919</ArticleId><ArticleId IdType="pubmed">20177120</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal S, Ahmed RM, D&#x2019;Mello M, et al. . Predictors of survival and progression in behavioural variant frontotemporal dementia. Eur J Neurol. 2019;26(5):774-779. doi:10.1111/ene.13887</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.13887</ArticleId><ArticleId IdType="pubmed">30565360</ArticleId></ArticleIdList></Reference><Reference><Citation>Cosseddu M, Benussi A, Gazzina S, et al. . Progression of behavioural disturbances in frontotemporal dementia: a longitudinal observational study. Eur J Neurol. 2020;27(2):265-272. doi:10.1111/ene.14071</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14071</ArticleId><ArticleId IdType="pubmed">31448481</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrer JD, Nicholas JM, Cash DM, et al. . Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis. Lancet Neurol. 2015;14(3):253-262. doi:10.1016/S1474-4422(14)70324-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(14)70324-2</ArticleId><ArticleId IdType="pmc">PMC6742501</ArticleId><ArticleId IdType="pubmed">25662776</ArticleId></ArticleIdList></Reference><Reference><Citation>World Medical Association World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-2194. doi:10.1001/jama.2013.281053</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2013.281053</ArticleId><ArticleId IdType="pubmed">24141714</ArticleId></ArticleIdList></Reference><Reference><Citation>McCormick K, Salcedo J. SPSS Statistics for Data Analysis and Visualization. Wiley; 2017.</Citation></Reference><Reference><Citation>Schwarz G. Estimating the dimension of a model. Ann Statist. 1978;6(2):461-464.</Citation></Reference><Reference><Citation>Sullivan LM, Dukes KA, Losina E. Tutorial in biostatistics: an introduction to hierarchical linear modelling. Stat Med. 1999;18(7):855-888. doi:10.1002/(SICI)1097-0258(19990415)18:7&lt;855::AID-SIM117&gt;3.0.CO;2-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-0258(19990415)18:7&lt;855::AID-SIM117&gt;3.0.CO;2-7</ArticleId><ArticleId IdType="pubmed">10327531</ArticleId></ArticleIdList></Reference><Reference><Citation>Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics. 1982;38(4):963-974. doi:10.2307/2529876</Citation><ArticleIdList><ArticleId IdType="doi">10.2307/2529876</ArticleId><ArticleId IdType="pubmed">7168798</ArticleId></ArticleIdList></Reference><Reference><Citation>Krzywinski M, Schein J, Birol I, et al. . Circos: an information aesthetic for comparative genomics. Genome Res. 2009;19(9):1639-1645. doi:10.1101/gr.092759.109</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.092759.109</ArticleId><ArticleId IdType="pmc">PMC2752132</ArticleId><ArticleId IdType="pubmed">19541911</ArticleId></ArticleIdList></Reference><Reference><Citation>Heuer HW, Wang P, Rascovsky K, et al. ; ARTFL and LEFFTDS consortia . Comparison of sporadic and familial behavioral variant frontotemporal dementia (FTD) in a North American cohort. Alzheimers Dement. 2020;16(1):60-70. doi:10.1002/alz.12046</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12046</ArticleId><ArticleId IdType="pmc">PMC7192555</ArticleId><ArticleId IdType="pubmed">31914226</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheran G, Silverman H, Manoochehri M, et al. . Psychiatric symptoms in preclinical behavioural-variant frontotemporal dementia in MAPT mutation carriers. J Neurol Neurosurg Psychiatry. 2018;89(5):449-455. doi:10.1136/jnnp-2017-317263</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-317263</ArticleId><ArticleId IdType="pmc">PMC6317727</ArticleId><ArticleId IdType="pubmed">29353234</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiskoot LC, Panman JL, Meeter LH, et al. . Longitudinal multimodal MRI as prognostic and diagnostic biomarker in presymptomatic familial frontotemporal dementia. Brain. 2019;142(1):193-208. doi:10.1093/brain/awy288</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awy288</ArticleId><ArticleId IdType="pmc">PMC6308313</ArticleId><ArticleId IdType="pubmed">30508042</ArticleId></ArticleIdList></Reference><Reference><Citation>Tavares TP, Mitchell DGV, Coleman KK, et al. . Early symptoms in symptomatic and preclinical genetic frontotemporal lobar degeneration. J Neurol Neurosurg Psychiatry. 2020;91(9):975-984. doi:10.1136/jnnp-2020-322987</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-322987</ArticleId><ArticleId IdType="pmc">PMC7611534</ArticleId><ArticleId IdType="pubmed">32769115</ArticleId></ArticleIdList></Reference><Reference><Citation>Sellami L, Bocchetta M, Masellis M, et al. ; Genetic FTD Initiative, GENFI . Distinct neuroanatomical correlates of neuropsychiatric symptoms in the three main forms of genetic frontotemporal dementia in the GENFI Cohort. J Alzheimers Dis. 2018;65(1):147-163. doi:10.3233/JAD-180053</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-180053</ArticleId><ArticleId IdType="pmc">PMC6087430</ArticleId><ArticleId IdType="pubmed">30010122</ArticleId></ArticleIdList></Reference><Reference><Citation>Riedijk SR, De Vugt ME, Duivenvoorden HJ, et al. . Caregiver burden, health-related quality of life and coping in dementia caregivers: a comparison of frontotemporal dementia and Alzheimer&#x2019;s disease. Dement Geriatr Cogn Disord. 2006;22(5-6):405-412. doi:10.1159/000095750</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000095750</ArticleId><ArticleId IdType="pubmed">16966830</ArticleId></ArticleIdList></Reference><Reference><Citation>Arighi A, Fumagalli GG, Jacini F, et al. . Early onset behavioral variant frontotemporal dementia due to the C9ORF72 hexanucleotide repeat expansion: psychiatric clinical presentations. J Alzheimers Dis. 2012;31(2):447-452. doi:10.3233/JAD-2012-120523</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2012-120523</ArticleId><ArticleId IdType="pubmed">22571983</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarioni M, Gami-Patel P, Timar Y, et al. ; Netherlands Brain Bank . Frontotemporal dementia: correlations between psychiatric symptoms and pathology. Ann Neurol. 2020;87(6):950-961. doi:10.1002/ana.25739</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25739</ArticleId><ArticleId IdType="pmc">PMC7318614</ArticleId><ArticleId IdType="pubmed">32281118</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Ende EL, Meeter LH, Poos JM, et al. ; Genetic Frontotemporal dementia Initiative (GENFI) . Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. Lancet Neurol. 2019;18(12):1103-1111. doi:10.1016/S1474-4422(19)30354-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(19)30354-0</ArticleId><ArticleId IdType="pubmed">31701893</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore KM, Nicholas J, Grossman M, et al. ; FTD Prevention Initiative . Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. Lancet Neurol. 2020;19(2):145-156. doi:10.1016/S1474-4422(19)30394-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(19)30394-1</ArticleId><ArticleId IdType="pmc">PMC7007771</ArticleId><ArticleId IdType="pubmed">31810826</ArticleId></ArticleIdList></Reference><Reference><Citation>Kertesz A, Davidson W, Fox H. Frontal behavioral inventory: diagnostic criteria for frontal lobe dementia. Can J Neurol Sci. 1997;24(1):29-36. doi:10.1017/S0317167100021053</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0317167100021053</ArticleId><ArticleId IdType="pubmed">9043744</ArticleId></ArticleIdList></Reference><Reference><Citation>Alberici A, Geroldi C, Cotelli M, et al. . The Frontal Behavioural Inventory (Italian version) differentiates frontotemporal lobar degeneration variants from Alzheimer&#x2019;s disease. Neurol Sci. 2007;28(2):80-86. doi:10.1007/s10072-007-0791-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-007-0791-3</ArticleId><ArticleId IdType="pubmed">17464470</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33417012</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>25</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-0533</ISSN><JournalIssue CitedMedium="Internet"><Volume>141</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Acta neuropathologica</Title><ISOAbbreviation>Acta Neuropathol</ISOAbbreviation></Journal><ArticleTitle>Exosomes induce endolysosomal permeabilization as a gateway by which exosomal tau seeds escape into the cytosol.</ArticleTitle><Pagination><StartPage>235</StartPage><EndPage>256</EndPage><MedlinePgn>235-256</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00401-020-02254-3</ELocationID><Abstract><AbstractText>The microtubule-associated protein tau has a critical role in Alzheimer's disease and other tauopathies. A proposed pathomechanism in the progression of tauopathies is the trans-synaptic spreading of tau seeds, with a role for exosomes which are secretory nanovesicles generated by late endosomes. Our previous work demonstrated that brain-derived exosomes isolated from tau transgenic rTg4510 mice encapsulate tau seeds with the ability to induce tau aggregation in recipient cells. We had also shown that exosomes can hijack the endosomal pathway to spread through interconnected neurons. Here, we reveal how tau seeds contained within internalized exosomes exploit mechanisms of lysosomal degradation to escape the endosome and induce tau aggregation in the cytosol of HEK293T-derived 'tau biosensor cells'. We found that the majority of the exosome-containing endosomes fused with lysosomes to form endolysosomes. Exosomes induced their permeabilization, irrespective of the presence of tau seeds, or whether the exosomal preparations originated from mouse brains or HEK293T cells. We also found that permeabilization is a conserved mechanism, operating in both non-neuronal tau biosensor cells and primary neurons. However, permeabilization of endolysosomes only occurred in a small fraction of cells, which supports the notion that permeabilization occurs by a thresholded mechanism. Interestingly, tau aggregation was only induced in cells that exhibited permeabilization, presenting this as an escape route of exosomal tau seeds into the cytosol. Overexpression of RAB7, which is required for the formation of endolysosomes, strongly increased tau aggregation. Conversely, inhibition of lysosomal function with alkalinizing agents, or by knocking-down RAB7, decreased tau aggregation. Together, we conclude that the enzymatic activities of lysosomes permeabilize exosomal and endosomal membranes, thereby facilitating access of exosomal tau seeds to cytosolic tau to induce its aggregation. Our data underscore the importance of endosomal membrane integrity in mechanisms of cellular invasion by misfolded proteins that are resistant to lysosomal degradation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Polanco</LastName><ForeName>Juan Carlos</ForeName><Initials>JC</Initials><Identifier Source="ORCID">0000-0002-3335-6332</Identifier><AffiliationInfo><Affiliation>Clem Jones Centre for Ageing Dementia Research (CJCADR), Queensland Brain Institute (QBI), The University of Queensland, Brisbane, QLD, 4072, Australia. j.polanco@uq.edu.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hand</LastName><ForeName>Gabriel Rhys</ForeName><Initials>GR</Initials><AffiliationInfo><Affiliation>Clem Jones Centre for Ageing Dementia Research (CJCADR), Queensland Brain Institute (QBI), The University of Queensland, Brisbane, QLD, 4072, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Briner</LastName><ForeName>Adam</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Clem Jones Centre for Ageing Dementia Research (CJCADR), Queensland Brain Institute (QBI), The University of Queensland, Brisbane, QLD, 4072, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Chuanzhou</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medical Genetics, School of Basic Medicine and Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf6;tz</LastName><ForeName>J&#xfc;rgen</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-8501-7896</Identifier><AffiliationInfo><Affiliation>Clem Jones Centre for Ageing Dementia Research (CJCADR), Queensland Brain Institute (QBI), The University of Queensland, Brisbane, QLD, 4072, Australia. j.goetz@uq.edu.au.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>01</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Acta Neuropathol</MedlineTA><NlmUniqueID>0412041</NlmUniqueID><ISSNLinking>0001-6322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000090802">rab7 GTP-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000716463">rab7 GTP-binding proteins, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000716465">rab7 GTP-binding proteins, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.5.2</RegistryNumber><NameOfSubstance UI="D020691">rab GTP-Binding Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003600" MajorTopicYN="N">Cytosol</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011992" MajorTopicYN="N">Endosomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055354" MajorTopicYN="N">Exosomes</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016086" MajorTopicYN="N">Lentivirus</DescriptorName><QualifierName UI="Q000254" MajorTopicYN="N">growth &amp; development</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008247" MajorTopicYN="N">Lysosomes</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010539" MajorTopicYN="N">Permeability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057165" MajorTopicYN="N">Proteostasis Deficiencies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020691" MajorTopicYN="N">rab GTP-Binding Proteins</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000090802" MajorTopicYN="N">rab7 GTP-Binding Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Autophagy</Keyword><Keyword MajorTopicYN="N">Endosome</Keyword><Keyword MajorTopicYN="N">Exosome</Keyword><Keyword MajorTopicYN="N">Lysosome</Keyword><Keyword MajorTopicYN="N">Microtubule-associated protein tau</Keyword><Keyword MajorTopicYN="N">Protein aggregation</Keyword><Keyword MajorTopicYN="N">Spreading</Keyword><Keyword MajorTopicYN="N">seeding</Keyword></KeywordList><CoiStatement>The authors declare that they have no conflicts of interest with the contents of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>10</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>12</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>12</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>1</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>1</Month><Day>8</Day><Hour>12</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>1</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33417012</ArticleId><ArticleId IdType="pmc">PMC7847444</ArticleId><ArticleId IdType="doi">10.1007/s00401-020-02254-3</ArticleId><ArticleId IdType="pii">10.1007/s00401-020-02254-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abeliovich A, Gitler AD. Defects in trafficking bridge Parkinson&#x2019;s disease pathology and genetics. Nature. 2016;539:207&#x2013;216. doi: 10.1038/nature20414.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature20414</ArticleId><ArticleId IdType="pubmed">27830778</ArticleId></ArticleIdList></Reference><Reference><Citation>Aits S, Jaattela M. Lysosomal cell death at a glance. J Cell Sci. 2013;126:1905&#x2013;1912. doi: 10.1242/jcs.091181.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.091181</ArticleId><ArticleId IdType="pubmed">23720375</ArticleId></ArticleIdList></Reference><Reference><Citation>Aits S, Kricker J, Liu B, Ellegaard AM, Hamalisto S, Tvingsholm S, et al. Sensitive detection of lysosomal membrane permeabilization by lysosomal galectin puncta assay. Autophagy. 2015;11:1408&#x2013;1424. doi: 10.1080/15548627.2015.1063871.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15548627.2015.1063871</ArticleId><ArticleId IdType="pmc">PMC4590643</ArticleId><ArticleId IdType="pubmed">26114578</ArticleId></ArticleIdList></Reference><Reference><Citation>Asai H, Ikezu S, Tsunoda S, Medalla M, Luebke J, Haydar T, et al. Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nat Neurosci. 2015;18:1584&#x2013;1593. doi: 10.1038/nn.4132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4132</ArticleId><ArticleId IdType="pmc">PMC4694577</ArticleId><ArticleId IdType="pubmed">26436904</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker S, Polanco JC, G&#xf6;tz J. Extracellular vesicles containing P301L mutant Tau accelerate pathological Tau phosphorylation and oligomer formation but do not seed mature neurofibrillary tangles in ALZ17 Mice. J Alzheimers Dis. 2016;54:1207&#x2013;1217. doi: 10.3233/JAD-160371.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-160371</ArticleId><ArticleId IdType="pubmed">27567840</ArticleId></ArticleIdList></Reference><Reference><Citation>Baritaki S, Apostolakis S, Kanellou P, Dimanche-Boitrel MT, Spandidos DA, Bonavida B. Reversal of tumor resistance to apoptotic stimuli by alteration of membrane fluidity: therapeutic implications. Adv Cancer Res. 2007;98:149&#x2013;190. doi: 10.1016/S0065-230X(06)98005-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0065-230X(06)98005-1</ArticleId><ArticleId IdType="pubmed">17433910</ArticleId></ArticleIdList></Reference><Reference><Citation>Barth S, Glick D, Macleod KF. Autophagy: assays and artifacts. J Pathol. 2010;221:117&#x2013;124. doi: 10.1002/path.2694.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.2694</ArticleId><ArticleId IdType="pmc">PMC2989884</ArticleId><ArticleId IdType="pubmed">20225337</ArticleId></ArticleIdList></Reference><Reference><Citation>Benetatos J, Bennett RE, Evans HT, Ellis SA, Hyman BT, Bodea LG, et al. PTEN activation contributes to neuronal and synaptic engulfment by microglia in tauopathy. Acta Neuropathol. 2020;140:7&#x2013;24. doi: 10.1007/s00401-020-02151-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-020-02151-9</ArticleId><ArticleId IdType="pmc">PMC7300099</ArticleId><ArticleId IdType="pubmed">32236736</ArticleId></ArticleIdList></Reference><Reference><Citation>Boker KO, Lemus-Diaz N, Rinaldi Ferreira R, Schiller L, Schneider S, Gruber J. The impact of the CD9 tetraspanin on lentivirus infectivity and exosome secretion. Mol Ther. 2018;26:634&#x2013;647. doi: 10.1016/j.ymthe.2017.11.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2017.11.008</ArticleId><ArticleId IdType="pmc">PMC5835022</ArticleId><ArticleId IdType="pubmed">29221804</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyiadzis M, Whiteside TL. The emerging roles of tumor-derived exosomes in hematological malignancies. Leukemia. 2017;31:1259&#x2013;1268. doi: 10.1038/leu.2017.91.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/leu.2017.91</ArticleId><ArticleId IdType="pubmed">28321122</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Staging of Alzheimer&#x2019;s disease-related neurofibrillary changes. Neurobiol Aging. 1995;16:271&#x2013;278. doi: 10.1016/0197-4580(95)00021-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-4580(95)00021-6</ArticleId><ArticleId IdType="pubmed">7566337</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Del Tredici K. Alzheimer&#x2019;s pathogenesis: is there neuron-to-neuron propagation? Acta Neuropathol. 2011;121:589&#x2013;595. doi: 10.1007/s00401-011-0825-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0825-z</ArticleId><ArticleId IdType="pubmed">21516512</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol. 2011;70:960&#x2013;969. doi: 10.1097/NEN.0b013e318232a379.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e318232a379</ArticleId><ArticleId IdType="pubmed">22002422</ArticleId></ArticleIdList></Reference><Reference><Citation>Bright NA, Davis LJ, Luzio JP. Endolysosomes are the principal intracellular sites of acid hydrolase activity. Curr Biol. 2016;26:2233&#x2013;2245. doi: 10.1016/j.cub.2016.06.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cub.2016.06.046</ArticleId><ArticleId IdType="pmc">PMC5026700</ArticleId><ArticleId IdType="pubmed">27498570</ArticleId></ArticleIdList></Reference><Reference><Citation>Briner A, G&#xf6;tz J, Polanco JC. Fyn kinase controls Tau aggregation in vivo. Cell Rep. 2020;32:108045. doi: 10.1016/j.celrep.2020.108045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.108045</ArticleId><ArticleId IdType="pubmed">32814048</ArticleId></ArticleIdList></Reference><Reference><Citation>Calafate S, Buist A, Miskiewicz K, Vijayan V, Daneels G, de Strooper B, et al. Synaptic contacts enhance cell-to-cell Tau pathology propagation. Cell Rep. 2015;11:1176&#x2013;1183. doi: 10.1016/j.celrep.2015.04.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2015.04.043</ArticleId><ArticleId IdType="pubmed">25981034</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen JJ, Nathaniel DL, Raghavan P, Nelson M, Tian R, Tse E, et al. Compromised function of the ESCRT pathway promotes endolysosomal escape of tau seeds and propagation of tau aggregation. J Biol Chem. 2019;294:18952&#x2013;18966. doi: 10.1074/jbc.RA119.009432.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA119.009432</ArticleId><ArticleId IdType="pmc">PMC6916486</ArticleId><ArticleId IdType="pubmed">31578281</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciregia F, Urbani A, Palmisano G. Extracellular vesicles in brain tumors and neurodegenerative diseases. Front Mol Neurosci. 2017;10:276. doi: 10.3389/fnmol.2017.00276.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2017.00276</ArticleId><ArticleId IdType="pmc">PMC5583211</ArticleId><ArticleId IdType="pubmed">28912682</ArticleId></ArticleIdList></Reference><Reference><Citation>David DC. Aging and the aggregating proteome. Front Genet. 2012;3:247. doi: 10.3389/fgene.2012.00247.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2012.00247</ArticleId><ArticleId IdType="pmc">PMC3501694</ArticleId><ArticleId IdType="pubmed">23181070</ArticleId></ArticleIdList></Reference><Reference><Citation>David DC, Ollikainen N, Trinidad JC, Cary MP, Burlingame AL, Kenyon C. Widespread protein aggregation as an inherent part of aging in C. elegans. PLoS Biol. 2010;8:e1000450. doi: 10.1371/journal.pbio.1000450.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.1000450</ArticleId><ArticleId IdType="pmc">PMC2919420</ArticleId><ArticleId IdType="pubmed">20711477</ArticleId></ArticleIdList></Reference><Reference><Citation>Dujardin S, Begard S, Caillierez R, Lachaud C, Delattre L, Carrier S, et al. Ectosomes: a new mechanism for non-exosomal secretion of tau protein. PLoS ONE. 2014;9:e100760. doi: 10.1371/journal.pone.0100760.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0100760</ArticleId><ArticleId IdType="pmc">PMC4074092</ArticleId><ArticleId IdType="pubmed">24971751</ArticleId></ArticleIdList></Reference><Reference><Citation>Dujardin S, Lecolle K, Caillierez R, Begard S, Zommer N, Lachaud C, et al. Neuron-to-neuron wild-type Tau protein transfer through a trans-synaptic mechanism: relevance to sporadic tauopathies. Acta Neuropathol Commun. 2014;2:14. doi: 10.1186/2051-5960-2-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2051-5960-2-14</ArticleId><ArticleId IdType="pmc">PMC3922636</ArticleId><ArticleId IdType="pubmed">24479894</ArticleId></ArticleIdList></Reference><Reference><Citation>Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, et al. A third-generation lentivirus vector with a conditional packaging system. J Virol. 1998;72:8463&#x2013;8471. doi: 10.1128/JVI.72.11.8463-8471.1998.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.72.11.8463-8471.1998</ArticleId><ArticleId IdType="pmc">PMC110254</ArticleId><ArticleId IdType="pubmed">9765382</ArticleId></ArticleIdList></Reference><Reference><Citation>Eitan E, Suire C, Zhang S, Mattson MP. Impact of lysosome status on extracellular vesicle content and release. Ageing Res Rev. 2016;32:65&#x2013;74. doi: 10.1016/j.arr.2016.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arr.2016.05.001</ArticleId><ArticleId IdType="pmc">PMC5154730</ArticleId><ArticleId IdType="pubmed">27238186</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans HT, Benetatos J, van Roijen M, Bodea LG, G&#xf6;tz J. Decreased synthesis of ribosomal proteins in tauopathy revealed by non-canonical amino acid labelling. EMBO J. 2019;38:e101174. doi: 10.15252/embj.2018101174.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.2018101174</ArticleId><ArticleId IdType="pmc">PMC6600635</ArticleId><ArticleId IdType="pubmed">31268600</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon B, Cavallini A, Angers R, Glover S, Murray TK, Barnham L, et al. Conformation determines the seeding potencies of native and recombinant Tau aggregates. J Biol Chem. 2015;290:1049&#x2013;1065. doi: 10.1074/jbc.M114.589309.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M114.589309</ArticleId><ArticleId IdType="pmc">PMC4294473</ArticleId><ArticleId IdType="pubmed">25406315</ArticleId></ArticleIdList></Reference><Reference><Citation>Flavin WP, Bousset L, Green ZC, Chu Y, Skarpathiotis S, Chaney MJ, et al. Endocytic vesicle rupture is a conserved mechanism of cellular invasion by amyloid proteins. Acta Neuropathol. 2017;134:629&#x2013;653. doi: 10.1007/s00401-017-1722-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1722-x</ArticleId><ArticleId IdType="pubmed">28527044</ArticleId></ArticleIdList></Reference><Reference><Citation>Gan L, Cookson MR, Petrucelli L, La Spada AR. Converging pathways in neurodegeneration, from genetics to mechanisms. Nat Neurosci. 2018;21:1300&#x2013;1309. doi: 10.1038/s41593-018-0237-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0237-7</ArticleId><ArticleId IdType="pmc">PMC6278826</ArticleId><ArticleId IdType="pubmed">30258237</ArticleId></ArticleIdList></Reference><Reference><Citation>Gavet O, Pines J. Progressive activation of CyclinB1-Cdk1 coordinates entry to mitosis. Dev Cell. 2010;18:533&#x2013;543. doi: 10.1016/j.devcel.2010.02.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.devcel.2010.02.013</ArticleId><ArticleId IdType="pmc">PMC3325599</ArticleId><ArticleId IdType="pubmed">20412769</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginsberg SD, Mufson EJ, Alldred MJ, Counts SE, Wuu J, Nixon RA, et al. Upregulation of select rab GTPases in cholinergic basal forebrain neurons in mild cognitive impairment and Alzheimer&#x2019;s disease. J Chem Neuroanat. 2011;42:102&#x2013;110. doi: 10.1016/j.jchemneu.2011.05.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jchemneu.2011.05.012</ArticleId><ArticleId IdType="pmc">PMC3163754</ArticleId><ArticleId IdType="pubmed">21669283</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginsberg SD, Mufson EJ, Counts SE, Wuu J, Alldred MJ, Nixon RA, et al. Regional selectivity of rab5 and rab7 protein upregulation in mild cognitive impairment and Alzheimer&#x2019;s disease. J Alzheimers Dis. 2010;22:631&#x2013;639. doi: 10.3233/JAD-2010-101080.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2010-101080</ArticleId><ArticleId IdType="pmc">PMC3031860</ArticleId><ArticleId IdType="pubmed">20847427</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatch RJ, Wei Y, Xia D, G&#xf6;tz J. Hyperphosphorylated tau causes reduced hippocampal CA1 excitability by relocating the axon initial segment. Acta Neuropathol. 2017;133:717&#x2013;730. doi: 10.1007/s00401-017-1674-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1674-1</ArticleId><ArticleId IdType="pmc">PMC5389999</ArticleId><ArticleId IdType="pubmed">28091722</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes BB, Diamond MI. Prion-like properties of Tau protein: the importance of extracellular Tau as a therapeutic target. J Biol Chem. 2014;289:19855&#x2013;19861. doi: 10.1074/jbc.R114.549295.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.R114.549295</ArticleId><ArticleId IdType="pmc">PMC4106306</ArticleId><ArticleId IdType="pubmed">24860099</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes BB, Furman JL, Mahan TE, Yamasaki TR, Mirbaha H, Eades WC, et al. Proteopathic tau seeding predicts tauopathy in vivo. Proc Natl Acad Sci USA. 2014;111:E4376&#x2013;4385. doi: 10.1073/pnas.1411649111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1411649111</ArticleId><ArticleId IdType="pmc">PMC4205609</ArticleId><ArticleId IdType="pubmed">25261551</ArticleId></ArticleIdList></Reference><Reference><Citation>Howitt J, Hill AF. Exosomes in the pathology of neurodegenerative diseases. J Biol Chem. 2016;291:26589&#x2013;26597. doi: 10.1074/jbc.R116.757955.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.R116.757955</ArticleId><ArticleId IdType="pmc">PMC5207170</ArticleId><ArticleId IdType="pubmed">27852825</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu YB, Dammer EB, Ren RJ, Wang G. The endosomal-lysosomal system: from acidification and cargo sorting to neurodegeneration. Transl Neurodegener. 2015;4:18. doi: 10.1186/s40035-015-0041-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40035-015-0041-1</ArticleId><ArticleId IdType="pmc">PMC4596472</ArticleId><ArticleId IdType="pubmed">26448863</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung YH, Chen LM, Yang JY, Yang WY. Spatiotemporally controlled induction of autophagy-mediated lysosome turnover. Nat Commun. 2013;4:2111. doi: 10.1038/ncomms3111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms3111</ArticleId><ArticleId IdType="pubmed">23817530</ArticleId></ArticleIdList></Reference><Reference><Citation>Huotari J, Helenius A. Endosome maturation. EMBO J. 2011;30:3481&#x2013;3500. doi: 10.1038/emboj.2011.286.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emboj.2011.286</ArticleId><ArticleId IdType="pmc">PMC3181477</ArticleId><ArticleId IdType="pubmed">21878991</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyttinen JM, Niittykoski M, Salminen A, Kaarniranta K. Maturation of autophagosomes and endosomes: a key role for Rab7. Biochim Biophys Acta. 2013;1833:503&#x2013;510. doi: 10.1016/j.bbamcr.2012.11.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbamcr.2012.11.018</ArticleId><ArticleId IdType="pubmed">23220125</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia J, Claude-Taupin A, Gu Y, Choi SW, Peters R, Bissa B, et al. Galectin-3 coordinates a cellular system for lysosomal repair and removal. Dev Cell. 2020;52(69&#x2013;87):e68. doi: 10.1016/j.devcel.2019.10.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.devcel.2019.10.025</ArticleId><ArticleId IdType="pmc">PMC6997950</ArticleId><ArticleId IdType="pubmed">31813797</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson DE, Ostrowski P, Jaumouille V, Grinstein S. The position of lysosomes within the cell determines their luminal pH. J Cell Biol. 2016;212:677&#x2013;692. doi: 10.1083/jcb.201507112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.201507112</ArticleId><ArticleId IdType="pmc">PMC4792074</ArticleId><ArticleId IdType="pubmed">26975849</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang S, Son SM, Baik SH, Yang J, Mook-Jung I. Autophagy-mediated secretory pathway is responsible for both normal and pathological tau in neurons. J Alzheimers Dis. 2019;70:667&#x2013;680. doi: 10.3233/JAD-190180.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-190180</ArticleId><ArticleId IdType="pubmed">31256134</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy S, Shoham T. The tetraspanin web modulates immune-signalling complexes. Nat Rev Immunol. 2005;5:136&#x2013;148. doi: 10.1038/nri1548.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri1548</ArticleId><ArticleId IdType="pubmed">15688041</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C, G&#xf6;tz J. Somatodendritic accumulation of Tau in Alzheimer&#x2019;s disease is promoted by Fyn-mediated local protein translation. EMBO J. 2017;36:3120&#x2013;3138. doi: 10.15252/embj.201797724.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201797724</ArticleId><ArticleId IdType="pmc">PMC5666608</ArticleId><ArticleId IdType="pubmed">28864542</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim S, Haque MM, Kim D, Kim DJ, Kim YK. Cell-based models to investigate Tau aggregation. Comput Struct Biotechnol J. 2014;12:7&#x2013;13. doi: 10.1016/j.csbj.2014.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.csbj.2014.09.011</ArticleId><ArticleId IdType="pmc">PMC4262059</ArticleId><ArticleId IdType="pubmed">25505502</ArticleId></ArticleIdList></Reference><Reference><Citation>Luzio JP, Pryor PR, Bright NA. Lysosomes: fusion and function. Nat Rev Mol Cell Biol. 2007;8:622&#x2013;632. doi: 10.1038/nrm2217.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm2217</ArticleId><ArticleId IdType="pubmed">17637737</ArticleId></ArticleIdList></Reference><Reference><Citation>Maejima I, Takahashi A, Omori H, Kimura T, Takabatake Y, Saitoh T, et al. Autophagy sequesters damaged lysosomes to control lysosomal biogenesis and kidney injury. EMBO J. 2013;32:2336&#x2013;2347. doi: 10.1038/emboj.2013.171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emboj.2013.171</ArticleId><ArticleId IdType="pmc">PMC3770333</ArticleId><ArticleId IdType="pubmed">23921551</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik BR, Maddison DC, Smith GA, Peters OM. Autophagic and endo-lysosomal dysfunction in neurodegenerative disease. Mol Brain. 2019;12:100. doi: 10.1186/s13041-019-0504-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13041-019-0504-x</ArticleId><ArticleId IdType="pmc">PMC6884906</ArticleId><ArticleId IdType="pubmed">31783880</ArticleId></ArticleIdList></Reference><Reference><Citation>McGough IJ, Vincent JP. Exosomes in developmental signalling. Development. 2016;143:2482&#x2013;2493. doi: 10.1242/dev.126516.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dev.126516</ArticleId><ArticleId IdType="pubmed">27436038</ArticleId></ArticleIdList></Reference><Reference><Citation>Miranda AM, Lasiecka ZM, Xu Y, Neufeld J, Shahriar S, Simoes S, et al. Neuronal lysosomal dysfunction releases exosomes harboring APP C-terminal fragments and unique lipid signatures. Nat Commun. 2018;9:291. doi: 10.1038/s41467-017-02533-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-02533-w</ArticleId><ArticleId IdType="pmc">PMC5773483</ArticleId><ArticleId IdType="pubmed">29348617</ArticleId></ArticleIdList></Reference><Reference><Citation>Mudher A, Colin M, Dujardin S, Medina M, Dewachter I, Alavi Naini SM, et al. What is the evidence that tau pathology spreads through prion-like propagation? Acta Neuropathol Commun. 2017;5:99. doi: 10.1186/s40478-017-0488-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-017-0488-7</ArticleId><ArticleId IdType="pmc">PMC5735872</ArticleId><ArticleId IdType="pubmed">29258615</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA. Amyloid precursor protein and endosomal-lysosomal dysfunction in Alzheimer&#x2019;s disease: inseparable partners in a multifactorial disease. FASEB J. 2017;31:2729&#x2013;2743. doi: 10.1096/fj.201700359.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.201700359</ArticleId><ArticleId IdType="pmc">PMC6137496</ArticleId><ArticleId IdType="pubmed">28663518</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA. Endosome function and dysfunction in Alzheimer&#x2019;s disease and other neurodegenerative diseases. Neurobiol Aging. 2005;26:373&#x2013;382. doi: 10.1016/j.neurobiolaging.2004.09.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2004.09.018</ArticleId><ArticleId IdType="pubmed">15639316</ArticleId></ArticleIdList></Reference><Reference><Citation>Novak M, Kabat J, Wischik CM. Molecular characterization of the minimal protease resistant tau unit of the Alzheimer&#x2019;s disease paired helical filament. EMBO J. 1993;12:365&#x2013;370. doi: 10.1002/j.1460-2075.1993.tb05665.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/j.1460-2075.1993.tb05665.x</ArticleId><ArticleId IdType="pmc">PMC413214</ArticleId><ArticleId IdType="pubmed">7679073</ArticleId></ArticleIdList></Reference><Reference><Citation>Papadopoulos C, Kirchner P, Bug M, Grum D, Koerver L, Schulze N, et al. VCP/p97 cooperates with YOD1, UBXD1 and PLAA to drive clearance of ruptured lysosomes by autophagy. EMBO J. 2017;36:135&#x2013;150. doi: 10.15252/embj.201695148.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201695148</ArticleId><ArticleId IdType="pmc">PMC5242375</ArticleId><ArticleId IdType="pubmed">27753622</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Gonzalez R, Gauthier SA, Kumar A, Saito M, Saito M, Levy E. A method for isolation of extracellular vesicles and characterization of exosomes from brain extracellular space. Methods Mol Biol. 2017;1545:139&#x2013;151. doi: 10.1007/978-1-4939-6728-5_10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-6728-5_10</ArticleId><ArticleId IdType="pubmed">27943212</ArticleId></ArticleIdList></Reference><Reference><Citation>Piras A, Collin L, Gruninger F, Graff C, Ronnback A. Autophagic and lysosomal defects in human tauopathies: analysis of post-mortem brain from patients with familial Alzheimer disease, corticobasal degeneration and progressive supranuclear palsy. Acta Neuropathol Commun. 2016;4:22. doi: 10.1186/s40478-016-0292-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-016-0292-9</ArticleId><ArticleId IdType="pmc">PMC4774096</ArticleId><ArticleId IdType="pubmed">26936765</ArticleId></ArticleIdList></Reference><Reference><Citation>Polanco JC, Li C, Bodea LG, Martinez-Marmol R, Meunier FA, G&#xf6;tz J. Amyloid-beta and tau complexity&#x2014;towards improved biomarkers and targeted therapies. Nat Rev Neurol. 2018;14:22&#x2013;39. doi: 10.1038/nrneurol.2017.162.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2017.162</ArticleId><ArticleId IdType="pubmed">29242522</ArticleId></ArticleIdList></Reference><Reference><Citation>Polanco JC, Li C, Durisic N, Sullivan R, G&#xf6;tz J. Exosomes taken up by neurons hijack the endosomal pathway to spread to interconnected neurons. Acta Neuropathol Commun. 2018;6:10. doi: 10.1186/s40478-018-0514-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-018-0514-4</ArticleId><ArticleId IdType="pmc">PMC5815204</ArticleId><ArticleId IdType="pubmed">29448966</ArticleId></ArticleIdList></Reference><Reference><Citation>Polanco JC, Scicluna BJ, Hill AF, G&#xf6;tz J. Extracellular vesicles isolated from the brains of rTg4510 mice seed Tau protein aggregation in a threshold-dependent manner. J Biol Chem. 2016;291:12445&#x2013;12466. doi: 10.1074/jbc.M115.709485.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M115.709485</ArticleId><ArticleId IdType="pmc">PMC4933440</ArticleId><ArticleId IdType="pubmed">27030011</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez L, Mohamed NV, Desjardins A, Lippe R, Fon EA, Leclerc N. Rab7A regulates tau secretion. J Neurochem. 2017;141:592&#x2013;605. doi: 10.1111/jnc.13994.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13994</ArticleId><ArticleId IdType="pubmed">28222213</ArticleId></ArticleIdList></Reference><Reference><Citation>Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science. 2005;309:476&#x2013;481. doi: 10.1126/science.1113694.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1113694</ArticleId><ArticleId IdType="pmc">PMC1574647</ArticleId><ArticleId IdType="pubmed">16020737</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaeffer V, Lavenir I, Ozcelik S, Tolnay M, Winkler DT, Goedert M. Stimulation of autophagy reduces neurodegeneration in a mouse model of human tauopathy. Brain. 2012;135:2169&#x2013;2177. doi: 10.1093/brain/aws143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aws143</ArticleId><ArticleId IdType="pmc">PMC3381726</ArticleId><ArticleId IdType="pubmed">22689910</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva MC, Nandi GA, Tentarelli S, Gurrell IK, Jamier T, Lucente D, et al. Prolonged tau clearance and stress vulnerability rescue by pharmacological activation of autophagy in tauopathy neurons. Nat Commun. 2020;11:3258. doi: 10.1038/s41467-020-16984-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-16984-1</ArticleId><ArticleId IdType="pmc">PMC7320012</ArticleId><ArticleId IdType="pubmed">32591533</ArticleId></ArticleIdList></Reference><Reference><Citation>Skotland T, Sandvig K, Llorente A. Lipids in exosomes: current knowledge and the way forward. Prog Lipid Res. 2017;66:30&#x2013;41. doi: 10.1016/j.plipres.2017.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.plipres.2017.03.001</ArticleId><ArticleId IdType="pubmed">28342835</ArticleId></ArticleIdList></Reference><Reference><Citation>Skowyra ML, Schlesinger PH, Naismith TV, Hanson PI. Triggered recruitment of ESCRT machinery promotes endolysosomal repair. Science. 2018;360:eaar5078. doi: 10.1126/science.aar5078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aar5078</ArticleId><ArticleId IdType="pmc">PMC6195421</ArticleId><ArticleId IdType="pubmed">29622626</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi A, Okada R, Nagao K, Kawamata Y, Hanyu A, Yoshimoto S, et al. Exosomes maintain cellular homeostasis by excreting harmful DNA from cells. Nat Commun. 2017;8:15287. doi: 10.1038/ncomms15287.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms15287</ArticleId><ArticleId IdType="pmc">PMC5440838</ArticleId><ArticleId IdType="pubmed">28508895</ArticleId></ArticleIdList></Reference><Reference><Citation>Taniguchi-Watanabe S, Arai T, Kametani F, Nonaka T, Masuda-Suzukake M, Tarutani A, et al. Biochemical classification of tauopathies by immunoblot, protein sequence and mass spectrometric analyses of sarkosyl-insoluble and trypsin-resistant tau. Acta Neuropathol. 2016;131:267&#x2013;280. doi: 10.1007/s00401-015-1503-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1503-3</ArticleId><ArticleId IdType="pmc">PMC4713716</ArticleId><ArticleId IdType="pubmed">26538150</ArticleId></ArticleIdList></Reference><Reference><Citation>Tardivel M, Begard S, Bousset L, Dujardin S, Coens A, Melki R, et al. Tunneling nanotube (TNT)-mediated neuron-to neuron transfer of pathological Tau protein assemblies. Acta Neuropathol Commun. 2016;4:117. doi: 10.1186/s40478-016-0386-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-016-0386-4</ArticleId><ArticleId IdType="pmc">PMC5096005</ArticleId><ArticleId IdType="pubmed">27809932</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, Beach TG, Zanette M, Lilja J, Heurling K, Chakrabarty A, et al. Estimation of amyloid distribution by [18F]flutemetamol PET predicts the neuropathological phase of amyloid &#x3b2;-protein deposition. Acta Neuropathol. 2018;136:557&#x2013;567. doi: 10.1007/s00401-018-1897-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1897-9</ArticleId><ArticleId IdType="pmc">PMC6132944</ArticleId><ArticleId IdType="pubmed">30123935</ArticleId></ArticleIdList></Reference><Reference><Citation>Thurston TLM, Wandel MP, von Muhlinen N, Foeglein A, Randow F. Galectin 8 targets damaged vesicles for autophagy to defend cells against bacterial invasion. Nature. 2012;482:414&#x2013;U1515. doi: 10.1038/nature10744.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature10744</ArticleId><ArticleId IdType="pmc">PMC3343631</ArticleId><ArticleId IdType="pubmed">22246324</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian T, Zhu YL, Hu FH, Wang YY, Huang NP, Xiao ZD. Dynamics of exosome internalization and trafficking. J Cell Physiol. 2013;228:1487&#x2013;1495. doi: 10.1002/jcp.24304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.24304</ArticleId><ArticleId IdType="pubmed">23254476</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiscornia G, Singer O, Verma IM. Production and purification of lentiviral vectors. Nat Protoc. 2006;1:241&#x2013;245. doi: 10.1038/nprot.2006.37.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2006.37</ArticleId><ArticleId IdType="pubmed">17406239</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsujimura A, Taguchi K, Watanabe Y, Tatebe H, Tokuda T, Mizuno T, et al. Lysosomal enzyme cathepsin B enhances the aggregate forming activity of exogenous alpha-synuclein fibrils. Neurobiol Dis. 2015;73:244&#x2013;253. doi: 10.1016/j.nbd.2014.10.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2014.10.011</ArticleId><ArticleId IdType="pubmed">25466281</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang FJ, Gomez-Sintes R, Boya P. Lysosomal membrane permeabilization and cell death. Traffic. 2018;19:918&#x2013;931. doi: 10.1111/tra.12613.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/tra.12613</ArticleId><ArticleId IdType="pubmed">30125440</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang JKT, Langfelder P, Horvath S, Palazzolo MJ. Exosomes and homeostatic synaptic plasticity are linked to each other and to Huntington&#x2019;s, Parkinson&#x2019;s, and other neurodegenerative diseases by database-enabled analyses of comprehensively curated datasets. Front Neurosci. 2017;11:149. doi: 10.3389/fnins.2017.00149.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2017.00149</ArticleId><ArticleId IdType="pmc">PMC5374209</ArticleId><ArticleId IdType="pubmed">28611571</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Balaji V, Kaniyappan S, Kruger L, Irsen S, Tepper K, et al. The release and trans-synaptic transmission of Tau via exosomes. Mol Neurodegener. 2017;12:5. doi: 10.1186/s13024-016-0143-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-016-0143-y</ArticleId><ArticleId IdType="pmc">PMC5237256</ArticleId><ArticleId IdType="pubmed">28086931</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang YP, Garg S, Mandelkow EM, Mandelkow E. Proteolytic processing of tau. Biochem Soc Trans. 2010;38:955&#x2013;961. doi: 10.1042/Bst0380955.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/Bst0380955</ArticleId><ArticleId IdType="pubmed">20658984</ArticleId></ArticleIdList></Reference><Reference><Citation>Whyte LS, Lau AA, Hemsley KM, Hopwood JJ, Sargeant TJ. Endo-lysosomal and autophagic dysfunction: a driving factor in Alzheimer&#x2019;s disease? J Neurochem. 2017;140:703&#x2013;717. doi: 10.1111/jnc.13935.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13935</ArticleId><ArticleId IdType="pubmed">28027395</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia D, Li CZ, G&#xf6;tz J. Pseudophosphorylation of Tau at distinct epitopes or the presence of the P301L mutation targets the microtubule-associated protein Tau to dendritic spines. Biochim Biophys Acta. 2015;1852:913&#x2013;924. doi: 10.1016/j.bbadis.2014.12.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2014.12.017</ArticleId><ArticleId IdType="pubmed">25558816</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao ZL, Qiao YS, Li XF, Chen JL, Ding JH, Bai L, et al. Exosomes exploit the virus entry machinery and pathway to transmit alpha interferon-induced antiviral activity. J Virol. 2018;92:e01578&#x2013;e11518. doi: 10.1128/JVI.01578-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01578-18</ArticleId><ArticleId IdType="pmc">PMC6258946</ArticleId><ArticleId IdType="pubmed">30282711</ArticleId></ArticleIdList></Reference><Reference><Citation>You Y, Ikezu T. Emerging roles of extracellular vesicles in neurodegenerative disorders. Neurobiol Dis. 2019;130:104512. doi: 10.1016/j.nbd.2019.104512.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2019.104512</ArticleId><ArticleId IdType="pmc">PMC6689424</ArticleId><ArticleId IdType="pubmed">31229685</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuyama K, Igarashi Y. Physiological and pathological roles of exosomes in the nervous system. Biomol Concepts. 2016;7:53&#x2013;68. doi: 10.1515/bmc-2015-0033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/bmc-2015-0033</ArticleId><ArticleId IdType="pubmed">26812803</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaborowski MP, Balaj L, Breakefield XO, Lai CP. Extracellular vesicles: composition, biological relevance, and methods of study. Bioscience. 2015;65:783&#x2013;797. doi: 10.1093/biosci/biv084.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/biosci/biv084</ArticleId><ArticleId IdType="pmc">PMC4776721</ArticleId><ArticleId IdType="pubmed">26955082</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33429394</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>14</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1423-0003</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>3</Issue><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>Gerontology</Title><ISOAbbreviation>Gerontology</ISOAbbreviation></Journal><ArticleTitle>Residence, Clinical Features, and Genetic Risk Factors Associated with Symptoms of COVID-19 in a Cohort of Older People in Madrid.</ArticleTitle><Pagination><StartPage>281</StartPage><EndPage>289</EndPage><MedlinePgn>281-289</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1159/000513182</ELocationID><Abstract><AbstractText Label="BACKGROUND">The older population has been especially affected by the severe acute respiratory syndrome coronavirus 2 pandemic (COVID-19).</AbstractText><AbstractText Label="OBJECTIVE">The aim of the study was to explore the incidence, severity, mortality rate, clinical features, and risk factors of symptoms of COVID-19 in home-dwelling older people, and its association with type of residence, cognitive deterioration, and neurodegenerative diseases.</AbstractText><AbstractText Label="METHODS">Data about symptoms of COVID-19 were collected through a telephone survey in the cohort of 913 older volunteers of the Vallecas Project, aged 75-90 years, most of them (902) home-dwelling, in Madrid, Spain. The association of demographic and anthropometric measures, genetic polymorphisms, comorbidities, life habits, type of residence, and frailty surrogates were explored as potential risk factors for the incidence, severity, and mortality of COVID-19 in the older population.</AbstractText><AbstractText Label="FINDINGS">Sixty-two cases reported symptoms compatible with COVID-19; 6 of them had died, 4 in their home and 2 in the nursing home. Moderate/severe cases were significantly older and more frequently males. The APOE &#x3b5;4 allele was associated with the presence of symptoms of COVID-19. Higher systolic blood pressure, more intense smoking habit, more alcohol intake, lower consumption of coffee and tea, and cognitive impairment were associated with disease severity.</AbstractText><AbstractText Label="CONCLUSIONS">The estimated incidence of symptomatic COVID-19 in this older cohort of Madrid was 6.8%, with an overall mortality rate of 0.7% (18.2% in those living in a nursing home) and a fatality rate of 9.9%. Our exploratory study indicates that life habits, other clinical conditions and, the &#x3b5;4 variant of the APOE gene are associated with the presence and clinical severity of coronavirus infection.</AbstractText><CopyrightInformation>&#xa9; 2021 S. Karger AG, Basel.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Del Ser</LastName><ForeName>Teodoro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Investigation Research Unit, CIEN Foundation, Institute of Health Carlos III, Queen Sofia Foundation Alzheimer Research Center, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fern&#xe1;ndez-Bl&#xe1;zquez</LastName><ForeName>Miguel A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Investigation Research Unit, CIEN Foundation, Institute of Health Carlos III, Queen Sofia Foundation Alzheimer Research Center, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valent&#xed;</LastName><ForeName>Meritxell</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Investigation Research Unit, CIEN Foundation, Institute of Health Carlos III, Queen Sofia Foundation Alzheimer Research Center, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zea-Sevilla</LastName><ForeName>Mar&#xed;a Ascensi&#xf3;n</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Investigation Research Unit, CIEN Foundation, Institute of Health Carlos III, Queen Sofia Foundation Alzheimer Research Center, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frades</LastName><ForeName>Bel&#xe9;n</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Investigation Research Unit, CIEN Foundation, Institute of Health Carlos III, Queen Sofia Foundation Alzheimer Research Center, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alfayate</LastName><ForeName>Eva</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Investigation Research Unit, CIEN Foundation, Institute of Health Carlos III, Queen Sofia Foundation Alzheimer Research Center, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saiz</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Investigation Research Unit, CIEN Foundation, Institute of Health Carlos III, Queen Sofia Foundation Alzheimer Research Center, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calero</LastName><ForeName>Olga</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red sobre Enfermedades Degenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chronic Disease Program, Institute of Health Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a-L&#xf3;pez</LastName><ForeName>Fernando Jos&#xe9;</ForeName><Initials>FJ</Initials><AffiliationInfo><Affiliation>National Epidemiology Centre, Institute of Health Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>R&#xe1;bano</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Investigation Research Unit, CIEN Foundation, Institute of Health Carlos III, Queen Sofia Foundation Alzheimer Research Center, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Medina</LastName><ForeName>Miguel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Investigation Research Unit, CIEN Foundation, Institute of Health Carlos III, Queen Sofia Foundation Alzheimer Research Center, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red sobre Enfermedades Degenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calero</LastName><ForeName>Miguel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Investigation Research Unit, CIEN Foundation, Institute of Health Carlos III, Queen Sofia Foundation Alzheimer Research Center, Madrid, Spain, mcalero@fundacioncien.es.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red sobre Enfermedades Degenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain, mcalero@fundacioncien.es.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chronic Disease Program, Institute of Health Carlos III, Madrid, Spain, mcalero@fundacioncien.es.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>01</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Gerontology</MedlineTA><NlmUniqueID>7601655</NlmUniqueID><ISSNLinking>0304-324X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Gerontology. 2021;67(3):320-322. doi: 10.1159/000516200.</RefSource><PMID Version="1">33965962</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000428" MajorTopicYN="N">Alcohol Drinking</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057187" MajorTopicYN="Y">Independent Living</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009735" MajorTopicYN="Y">Nursing Homes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012907" MajorTopicYN="N">Smoking</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">APOE gene</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Clinical features</Keyword><Keyword MajorTopicYN="N">Cognitive impairment</Keyword><Keyword MajorTopicYN="N">Incidence</Keyword><Keyword MajorTopicYN="N">Madrid</Keyword><Keyword MajorTopicYN="N">Mortality</Keyword><Keyword MajorTopicYN="N">Nursing home</Keyword><Keyword MajorTopicYN="N">Older people</Keyword><Keyword MajorTopicYN="N">Risk factors</Keyword><Keyword MajorTopicYN="N">Vallecas Project</Keyword></KeywordList><CoiStatement>A.R. and M.C. are cofounders of Biocross SL and own stock options from the company, which is developing blood tests for the diagnosis of Alzheimer's disease, including the e4Risk&#xae; test, which is a method to detect the presence of the protein ApoE4 in human blood plasma, using high-throughput chemistry analyzers. O.C. and M.C. participate in the European patent application EP 16 794 966.8-1111, entitled &#x201c;Methods for Apolipoprotein Detection&#x201d; that was granted by the European patent Agency on January 09, 2019, which is licensed to Biocross SL and directly related to the e4Risk&#xae; test. The other authors do not report any financial or personal conflicts of interest. They do not have any employment, consultancies, stock ownership, honoraria, paid expert testimony, patents or patent applications, or travel grants related to the content of this research.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>7</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>1</Month><Day>11</Day><Hour>20</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>2</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33429394</ArticleId><ArticleId IdType="pmc">PMC7900450</ArticleId><ArticleId IdType="doi">10.1159/000513182</ArticleId><ArticleId IdType="pii">000513182</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rothan HA, Byrareddy SN, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020;109:102433.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7127067</ArticleId><ArticleId IdType="pubmed">32113704</ArticleId></ArticleIdList></Reference><Reference><Citation>Instituto de Salud Carlos III; RENAVE, Red Nacional de Vigilancia Epidemiol&#xf3;gica. Informe n&#xba; 26. Situaci&#xf3;n de COVID-19 en Espa&#xf1;a a 27 de abril de 2020. Equipo COVID-19.Centro Nacional de Epidemiolog&#xed;a. Centro Nacional de Microbiolog&#xed;a. Avalable from:  https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Documents/INFORMES/Informes%20COVID-19/Informe%20n%c2%ba%2026.%20Situaci%c3%b3n%20de%20COVID-19%20en%20Espa%c3%b1a%20a%2027%20de%20abril%20de%202020.pdf.</Citation></Reference><Reference><Citation>Wang L, He W, Yu X, Hu D, Bao M, Liu H, et al. Coronavirus disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up. J Infect. 2020 Jun;80((6)):639&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7118526</ArticleId><ArticleId IdType="pubmed">32240670</ArticleId></ArticleIdList></Reference><Reference><Citation>Korean Society of Infectious Diseases; Korean Society of Pediatric Infectious Diseases; Korean Society of Epidemiology; Korean Society for Antimicrobial Therapy; Korean Society for Healthcare-associated Infection Control and Prevention; Korea Centers for Disease Control and Prevention Report on the epidemiological features of coronavirus disease 2019 (COVID-19) outbreak in the Republic of Korea from January 19 to March 2, 2020. J Korean Med Sci. 2020 Mar 16;35((10)):e112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7073313</ArticleId><ArticleId IdType="pubmed">32174069</ArticleId></ArticleIdList></Reference><Reference><Citation>Olazar&#xe1;n J, Valent&#xed; M, Frades B, Zea-Sevilla MA, &#xc1;vila-Villanueva M, Fern&#xe1;ndez-Bl&#xe1;zquez M&#xc1;, et al. Identifying early markers and mechanisms In Alzheimer's disease: methods and inclusion results of the Vallecas Project. Frontiers in Aging Neuroscience. 2015;7:181.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4588692</ArticleId><ArticleId IdType="pubmed">26483681</ArticleId></ArticleIdList></Reference><Reference><Citation>Podsiadlo D, Richardson S. The timed &#x201c;Up &amp; Go&#x201d;: a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc. 1991;39:142&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">1991946</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeffer RI, Kurosaki TT, Harrah CH, Chance JM, Filos S. Measurement of functional activities in older adults in the community. J Gerontol. 1982;37((3)):323&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">7069156</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly patients: a comparison with young and middle-aged patients. J Infect. 2020 Jun;80((6)):e14&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102640</ArticleId><ArticleId IdType="pubmed">32171866</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung C. Risk factors for predicting mortality in elderly patients with COVID-19: a review of clinical data in China. Mech Ageing Dev. 2020 Apr 27;188:111255.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7184979</ArticleId><ArticleId IdType="pubmed">32353398</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 National Incident Room Surveillance Team COVID-19, Australia: epidemiology report 6 (reporting week ending 19:00 AEDT 7 March 2020) Commun Dis Intell. 20182020 Mar 11;:44.</Citation><ArticleIdList><ArticleId IdType="pubmed">32156224</ArticleId></ArticleIdList></Reference><Reference><Citation>Bendavid E, Mulaney B, Sood N, Shah S, Ling E, Bromley-Dulfano R, et al. COVID-19 antibody seroprevalence in Santa Clara county, California. medRxiv Preprint. 2020 Apr 4;:20062463.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7928865</ArticleId><ArticleId IdType="pubmed">33615345</ArticleId></ArticleIdList></Reference><Reference><Citation>Levesque J, Maybury DW. A note on COVID-19 seroprevalence studies: a meta-analysis using hierarchical modelling. medRxiv Preprint. 2020 May 03;:20089201.</Citation></Reference><Reference><Citation>Poll&#xe1;n M, P&#xe9;rez-G&#xf3;mez B, Pastor-Barriuso R, Oteo J, Hern&#xe1;n MA, P&#xe9;rez-Olmeda M, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet. 2020 Aug 22;396((10250)):535&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7336131</ArticleId><ArticleId IdType="pubmed">32645347</ArticleId></ArticleIdList></Reference><Reference><Citation>McMichael TM, Clark S, Pogosjans S, Kay M, Lewis J, Baer A, et al. COVID-19 in a long-term care facility: King County, Washington, February 27&#x2013;March 9, 2020. MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69((12)):339&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7725515</ArticleId><ArticleId IdType="pubmed">32214083</ArticleId></ArticleIdList></Reference><Reference><Citation>Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 16,749 hospitalised UK patients with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol. medRxiv Preprint. 2020 Apr 23;:20076042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7243036</ArticleId><ArticleId IdType="pubmed">32444460</ArticleId></ArticleIdList></Reference><Reference><Citation>Instituto de Salud Carlos III  Estudio ENE-COVID19: Primera ronda estudio nacional de sero-epidemiolog&#xed;a de la infecci&#xf3;n por SARS-CoV-2 en Espa&#xf1;a. Informe preliminar. 13. De Mayo De 2020.  Available from:  https://www.ciencia.gob.es/stfls/MICINN/Ministerio/FICHEROS/ENECOVID_Informe_preliminar_cierre_primera_ronda_13Mayo2020.pdf.</Citation></Reference><Reference><Citation>Lovato A, de Filippis C. Clinical presentation of COVID-19: a systematic review focusing on upper airway symptoms. Ear Nose Throat J. 2020 Apr 13;99((9)):569.</Citation><ArticleIdList><ArticleId IdType="pubmed">32283980</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong JY, Wong A, Zhu D, Fastenberg JH, Tham T. The prevalence of olfactory and gustatory dysfunction in COVID-19 patients: a systematic review and meta-analysis. Otolaryngol Head Neck Surg. 2020 Jul;163((1)):3&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">32369429</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease. J Clin Invest. 2020 May 1;130((5)):2620&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7190990</ArticleId><ArticleId IdType="pubmed">32217835</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo CL, Pilling LC, Atkins JL, Masoli JAH, Delgado J, Kuchel GA, et al. APOE E4 genotype predicts severe COVID-19 in the UK biobank community cohort. J Gerontol A Biol Sci Med Sci. 2020 Oct 15;75((11)):2231&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7314139</ArticleId><ArticleId IdType="pubmed">32451547</ArticleId></ArticleIdList></Reference><Reference><Citation>Emi M, Wu LL, Robertson MA, Myers RL, Hegele RA, Williams RR, et al. Genotyping and sequence analysis of apolipoprotein E isoforms. Genomics. 1988;3((4)):373&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">3243553</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahley RW, Rall SC., Jr Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet. 2000;1:507&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">11701639</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261((5123)):921&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997;278:1349&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>van Bockxmeer FM, Mamotte CD. Apolipoprotein epsilon 4 homozygosity in young men with coronary heart disease. Lancet. 1992;340((8824)):879&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">1357300</ArticleId></ArticleIdList></Reference><Reference><Citation>Tavazoie MF, Pollack I, Tanqueco R, Ostendorf BN, Reis BS, Gonsalves FC, et al. LXR/ApoE activation restricts innate immune suppression in cancer. Cell. 2018;172((4)):825&#x2013;e18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5846344</ArticleId><ArticleId IdType="pubmed">29336888</ArticleId></ArticleIdList></Reference><Reference><Citation>Price DA, Bassendine MF, Norris SM, Golding C, Toms GL, Schmid ML, et al. Apolipoprotein epsilon3 allele is associated with persistent hepatitis C virus infection. Gut. 2006;55((5)):715&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1856106</ArticleId><ArticleId IdType="pubmed">16299033</ArticleId></ArticleIdList></Reference><Reference><Citation>Burt TD, Agan BK, Marconi VC, He W, Kulkarni H, Mold JE, et al. Apolipoprotein (apo) E4 enhances HIV-1 cell entry in vitro, and the APOE epsilon-4/epsilon-4 genotype accelerates HIV disease progression. Proc Nat Acad Sci U S A. 2008;105:8718&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2438419</ArticleId><ArticleId IdType="pubmed">18562290</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgos JS, Ramirez C, Sastre I, Valdivieso F. Effect of apolipoprotein E on the cerebral load of latent herpes simplex virus type 1 DNA. J Virol. 2006;80((11)):5383&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1472141</ArticleId><ArticleId IdType="pubmed">16699018</ArticleId></ArticleIdList></Reference><Reference><Citation>Itzhaki RF, Wozniak MA. Herpes simplex virus type 1, apolipoprotein E, and cholesterol: a dangerous liaison in Alzheimer's disease and other disorders. Prog Lipid Res. 2006;45:73&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">16406033</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao X, Gordon EM, Figueroa DM, Barochia AV, Levine SJ. Emerging roles of apolipoprotein E and apolipoprotein A-I in the pathogenesis and treatment of lung disease. Am J Respir Cell Mol Biol. 2016;55((2)):159&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4979372</ArticleId><ArticleId IdType="pubmed">27073971</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulminski AM, Barochia AV, Loika Y, Raghavachari N, Arbeev KG, Wojczynski MK, et al. The APOE &#x3b5;4 allele is associated with a reduction in FEV1/FVC in women: a cross-sectional analysis of the Long Life Family Study. PLoS One. 2018;13:e0206873.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6226172</ArticleId><ArticleId IdType="pubmed">30412599</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Chopra P, Li X, Wolfert MA, Tompkins SM, Boons G-J. SARS-CoV-2 spike protein binds heparan sulfate in a length- and sequence-dependent manner. BioRxiv Preprint. 2020 May 10;:2020.05.10.087288.</Citation></Reference><Reference><Citation>Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8((4)):e21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7118626</ArticleId><ArticleId IdType="pubmed">32171062</ArticleId></ArticleIdList></Reference><Reference><Citation>Vardavas C, Nikitara K. COVID-19 and smoking: a systematic review of the evidence. Tob Induc Dis. 2020 Mar 20;18((March)):20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7083240</ArticleId><ArticleId IdType="pubmed">32206052</ArticleId></ArticleIdList></Reference><Reference><Citation>Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020;109((5)):531&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7087935</ArticleId><ArticleId IdType="pubmed">32161990</ArticleId></ArticleIdList></Reference><Reference><Citation>Alfaro TM, Monteiro RA, Cunha RA, Cordeiro CR. Chronic coffee consumption and respiratory disease: a systematic review. Clin Respir J. 2018;12((3)):1283&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">28671769</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33427873</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>10</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>78</Volume><Issue>4</Issue><PubDate><Year>2021</Year><Month>Apr</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease.</ArticleTitle><Pagination><StartPage>396</StartPage><EndPage>406</EndPage><MedlinePgn>396-406</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2020.4986</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Plasma phosphorylated tau at threonine 181 (p-tau181) has been proposed as an easily accessible biomarker for the detection of Alzheimer disease (AD) pathology, but its ability to monitor disease progression in AD remains unclear.</AbstractText><AbstractText Label="OBJECTIVE">To study the potential of longitudinal plasma p-tau181 measures for assessing neurodegeneration progression and cognitive decline in AD in comparison to plasma neurofilament light chain (NfL), a disease-nonspecific marker of neuronal injury.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This longitudinal cohort study included data from the Alzheimer's Disease Neuroimaging Initiative from February 1, 2007, to June 6, 2016. Follow-up blood sampling was performed for up to 8 years. Plasma p-tau181 measurements were performed in 2020. This was a multicentric observational study of 1113 participants, including cognitively unimpaired participants as well as patients with cognitive impairment (mild cognitive impairment and AD dementia). Participants were eligible for inclusion if they had available plasma p-tau181 and NfL measurements and at least 1 fluorine-18-labeled fluorodeoxyglucose (FDG) positron emission tomography (PET) or structural magnetic resonance imaging scan performed at the same study visit. Exclusion criteria included any significant neurologic disorder other than suspected AD; presence of infection, infarction, or multiple lacunes as detected by magnetic resonance imaging; and any significant systemic condition that could lead to difficulty complying with the protocol.</AbstractText><AbstractText Label="EXPOSURES">Plasma p-tau181 and NfL measured with single-molecule array technology.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Longitudinal imaging markers of neurodegeneration (FDG PET and structural magnetic resonance imaging) and cognitive test scores (Preclinical Alzheimer Cognitive Composite and Alzheimer Disease Assessment Scale-Cognitive Subscale with 13 tasks). Data were analyzed from June 20 to August 15, 2020.</AbstractText><AbstractText Label="RESULTS">Of the 1113 participants (mean [SD] age, 74.0 [7.6] years; 600 men [53.9%]; 992 non-Hispanic White participants [89.1%]), a total of 378 individuals (34.0%) were cognitively unimpaired (CU) and 735 participants (66.0%) were cognitively impaired (CImp). Of the CImp group, 537 (73.1%) had mild cognitive impairment, and 198 (26.9%) had AD dementia. Longitudinal changes of plasma p-tau181 were associated with cognitive decline (CU: r&#x2009;=&#x2009;-0.24, P&#x2009;&lt;&#x2009;.001; CImp: r&#x2009;=&#x2009;0.34, P&#x2009;&lt;&#x2009;.001) and a prospective decrease in glucose metabolism (CU: r&#x2009;=&#x2009;-0.05, P&#x2009;=&#x2009;.48; CImp: r&#x2009;=&#x2009;-0.27, P&#x2009;&lt;&#x2009;.001) and gray matter volume (CU: r&#x2009;=&#x2009;-0.19, P&#x2009;&lt;&#x2009;.001; CImp: r&#x2009;=&#x2009;-0.31, P&#x2009;&lt;&#x2009;.001) in highly AD-characteristic brain regions. These associations were restricted to amyloid-&#x3b2;-positive individuals. Both plasma p-tau181 and NfL were independently associated with cognition and neurodegeneration in brain regions typically affected in AD. However, NfL was also associated with neurodegeneration in brain regions exceeding this AD-typical spatial pattern in amyloid-&#x3b2;-negative participants. Mediation analyses found that approximately 25% to 45% of plasma p-tau181 outcomes on cognition measures were mediated by the neuroimaging-derived markers of neurodegeneration, suggesting links between plasma p-tau181 and cognition independent of these measures.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">Study findings suggest that plasma p-tau181 was an accessible and scalable marker for predicting and monitoring neurodegeneration and cognitive decline and was, unlike plasma NfL, AD specific. The study findings suggest implications for the use of plasma biomarkers as measures to monitor AD progression in clinical practice and treatment trials.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Moscoso</LastName><ForeName>Alexis</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grothe</LastName><ForeName>Michel J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unidad de Trastornos del Movimiento, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Roc&#xed;o/CSIC/Universidad de Sevilla, Seville, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ashton</LastName><ForeName>Nicholas J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>King's College London, Institute of Psychiatry, Psychology &amp; Neuroscience, Maurice Wohl Clinical Neuroscience Institute, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Biomedical Research Centre for Mental Health &amp; Biomedical Research Unit for Dementia at South London &amp; Maudsley NHS Foundation, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karikari</LastName><ForeName>Thomas K</ForeName><Initials>TK</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lantero Rodr&#xed;guez</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Snellman</LastName><ForeName>Anniina</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Turku PET Centre, University of Turku, Turku, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su&#xe1;rez-Calvet</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Barcelona&#xdf;eta Brain Research Center, Pasqual Maragall Foundation. Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hospital del Mar Medical Research Institute, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Servei de Neurologia, Hospital del Mar, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Fragilidad y Envejecimiento Saludable, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute at University College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sch&#xf6;ll</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Alzheimer&#x2019;s Disease Neuroimaging Initiative</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016900">Neurofilament Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C044882">neurofilament protein L</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016900" MajorTopicYN="N">Neurofilament Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Zetterberg reported receiving grants from the Wallenberg Foundation, Swedish Research Council, European Research Council, Swedish State Support for Clinical Research, Alzheimer Drug Discovery Foundation, and UK Dementia Research Institute at University College London; serving on the scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics, and CogRx; giving lectures in symposia sponsored by Fujirebio, Alzecure, and Biogen, and cofounding Brain Biomarker Solutions in Gothenburg AB, which is a part of the GU Ventures Incubator Program, outside the submitted work. Dr Blennow reported serving as a consultant, on advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu, Julius Clinical, Lilly, MagQu, Novartis, Roche Diagnostics, and Siemens Healthineers; and cofounding Brain Biomarker Solutions in Gothenburg AB, which is a part of the GU Ventures Incubator Program, outside the submitted work. Dr Su&#xe1;rez-Calvet reported giving lectures in symposia sponsored by Roche Diagnostics, S.L.U., outside the submitted work. Dr Sch&#xf6;ll reported serving on a scientific advisory board for Servier outside the submitted work. No other disclosures were reported.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael W</ForeName><Initials>MW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Jagust</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trojanowki</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toga</LastName><ForeName>Arthur W</ForeName><Initials>AW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beckett</LastName><ForeName>Laurel</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Green</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saykin</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shaw</LastName><ForeName>Leslie M</ForeName><Initials>LM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Khachaturian</LastName><ForeName>Zaven</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sorensen</LastName><ForeName>Greg</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carrillo</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kuller</LastName><ForeName>Lew</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raichle</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paul</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davies</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fillit</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hefti</LastName><ForeName>Franz</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mesulam</LastName><ForeName>M Marcel</ForeName><Initials>MM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Potter</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Snyder</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Logovinsky</LastName><ForeName>Veronika</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Montine</LastName><ForeName>Tom</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jimenez</LastName><ForeName>Gustavo</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Donohue</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gessert</LastName><ForeName>Devon</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harless</LastName><ForeName>Kelly</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salazar</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cabrera</LastName><ForeName>Yuliana</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Walter</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hergesheimer</LastName><ForeName>Lindsey</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harvey</LastName><ForeName>Danielle</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bernstein</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fox</LastName><ForeName>Nick</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thompson</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schuff</LastName><ForeName>Norbert</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeCarli</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Borowski</LastName><ForeName>Bret</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gunter</LastName><ForeName>Jeff</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Senjem</LastName><ForeName>Matt</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vemuri</LastName><ForeName>Prashanthi</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jones</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kantarci</LastName><ForeName>Kejal</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ward</LastName><ForeName>Chad</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koeppe</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foster</LastName><ForeName>Norm</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>Kewei</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mathis</LastName><ForeName>Chet</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Landau</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cairns</LastName><ForeName>Nigel J</ForeName><Initials>NJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Franklin</LastName><ForeName>Erin</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taylor-Reinwald</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Virginia</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Korecka</LastName><ForeName>Magdalena</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Figurski</LastName><ForeName>Michal</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crawford</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Neu</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foroud</LastName><ForeName>Tatiana M</ForeName><Initials>TM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Potkin</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shen</LastName><ForeName>Li</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Faber</LastName><ForeName>Kelley</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kim</LastName><ForeName>Sungeun</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nho</LastName><ForeName>Kwangsik</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thal</LastName><ForeName>Lean</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Buckholtz</LastName><ForeName>Neil</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Albert</LastName><ForeName>Marilyn</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frank</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hsiao</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>1</Month><Day>11</Day><Hour>12</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>1</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33427873</ArticleId><ArticleId IdType="pmc">PMC7802009</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2020.4986</ArticleId><ArticleId IdType="pii">2774467</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hyman BT, Phelps CH, Beach TG, et al. . National Institute on Aging-Alzheimer&#x2019;s Association guidelines for the neuropathologic assessment of Alzheimer&#x2019;s disease. Alzheimers Dement. 2012;8(1):1-13. doi:10.1016/j.jalz.2011.10.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.10.007</ArticleId><ArticleId IdType="pmc">PMC3266529</ArticleId><ArticleId IdType="pubmed">22265587</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Holtzman DM. Biomarker modeling of Alzheimer&#x2019;s disease. Neuron. 2013;80(6):1347-1358. doi:10.1016/j.neuron.2013.12.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.12.003</ArticleId><ArticleId IdType="pmc">PMC3928967</ArticleId><ArticleId IdType="pubmed">24360540</ArticleId></ArticleIdList></Reference><Reference><Citation>Joshi AD, Pontecorvo MJ, Clark CM, et al. ; Florbetapir F 18 Study Investigators . Performance characteristics of amyloid PET with florbetapir F 18 in patients with Alzheimer&#x2019;s disease and cognitively normal subjects. J Nucl Med. 2012;53(3):378-384. doi:10.2967/jnumed.111.090340</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.111.090340</ArticleId><ArticleId IdType="pubmed">22331215</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark CM, Schneider JA, Bedell BJ, et al. ; AV45-A07 Study Group . Use of florbetapir-PET for imaging &#x3b2;-amyloid pathology. JAMA. 2011;305(3):275-283. doi:10.1001/jama.2010.2008</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2010.2008</ArticleId><ArticleId IdType="pmc">PMC7041965</ArticleId><ArticleId IdType="pubmed">21245183</ArticleId></ArticleIdList></Reference><Reference><Citation>Pike KE, Savage G, Villemagne VL, et al. . Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer&#x2019;s disease. Brain. 2007;130(pt 11):2837-2844. doi:10.1093/brain/awm238</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awm238</ArticleId><ArticleId IdType="pubmed">17928318</ArticleId></ArticleIdList></Reference><Reference><Citation>de Leon MJ, Mosconi L, Blennow K, et al. . Imaging and CSF studies in the preclinical diagnosis of Alzheimer&#x2019;s disease. Ann N Y Acad Sci. 2007;1097:114-145. doi:10.1196/annals.1379.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1196/annals.1379.012</ArticleId><ArticleId IdType="pubmed">17413016</ArticleId></ArticleIdList></Reference><Reference><Citation>Thijssen EH, La Joie R, Wolf A, et al. ; Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) Investigators . Diagnostic value of plasma phosphorylated tau181 in Alzheimer&#x2019;s disease and frontotemporal lobar degeneration. Nat Med. 2020;26(3):387-397. doi:10.1038/s41591-020-0762-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0762-2</ArticleId><ArticleId IdType="pmc">PMC7101073</ArticleId><ArticleId IdType="pubmed">32123386</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Janelidze S, Quiroz YT, et al. . Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2020;324(8):772-781. doi:10.1001/jama.2020.12134</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12134</ArticleId><ArticleId IdType="pmc">PMC7388060</ArticleId><ArticleId IdType="pubmed">32722745</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Connor A, Karikari TK, Poole T, et al. . Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer&#x2019;s disease: a longitudinal cohort study. Mol Psychiatry. 2020. doi:10.1038/s41380-020-0838-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-020-0838-x</ArticleId><ArticleId IdType="pmc">PMC7612227</ArticleId><ArticleId IdType="pubmed">32665603</ArticleId></ArticleIdList></Reference><Reference><Citation>Lantero Rodriguez J, Karikari TK, Su&#xe1;rez-Calvet M, et al. . Plasma p-tau181 accurately predicts Alzheimer&#x2019;s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline. Acta Neuropathol. 2020;140(3):267-278. doi:10.1007/s00401-020-02195-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-020-02195-x</ArticleId><ArticleId IdType="pmc">PMC7423866</ArticleId><ArticleId IdType="pubmed">32720099</ArticleId></ArticleIdList></Reference><Reference><Citation>Karikari TK, Pascoal TA, Ashton NJ, et al. . Blood phosphorylated tau 181 as a biomarker for Alzheimer&#x2019;s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19(5):422-433. doi:10.1016/S1474-4422(20)30071-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(20)30071-5</ArticleId><ArticleId IdType="pubmed">32333900</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, Mattsson N, Palmqvist S, et al. . Plasma P-tau181 in Alzheimer&#x2019;s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer&#x2019;s dementia. Nat Med. 2020;26(3):379-386. doi:10.1038/s41591-020-0755-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0755-1</ArticleId><ArticleId IdType="pubmed">32123385</ArticleId></ArticleIdList></Reference><Reference><Citation>Vergallo A, M&#xe9;gret L, Lista S, et al. ; INSIGHT-preAD study group; Alzheimer Precision Medicine Initiative (APMI) . Plasma amyloid &#x3b2; 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer&#x2019;s disease. Alzheimers Dement. 2019;15(6):764-775. doi:10.1016/j.jalz.2019.03.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2019.03.009</ArticleId><ArticleId IdType="pubmed">31113759</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindler SE, Bollinger JG, Ovod V, et al. . High-precision plasma &#x3b2;-amyloid 42/40 predicts current and future brain amyloidosis. Neurology. 2019;93(17):e1647-e1659. doi:10.1212/WNL.0000000000008081</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000008081</ArticleId><ArticleId IdType="pmc">PMC6946467</ArticleId><ArticleId IdType="pubmed">31371569</ArticleId></ArticleIdList></Reference><Reference><Citation>Risacher SL, Fandos N, Romero J, et al. . Plasma amyloid beta levels are associated with cerebral amyloid and tau deposition. Alzheimers Dement (Amst). 2019;11:510-519. doi:10.1016/j.dadm.2019.05.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dadm.2019.05.007</ArticleId><ArticleId IdType="pmc">PMC6661419</ArticleId><ArticleId IdType="pubmed">31384662</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashton NJ, Nevado-Holgado AJ, Barber IS, et al. . A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer&#x2019;s disease. Sci Adv. 2019;5(2):eaau7220. doi:10.1126/sciadv.aau7220</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.aau7220</ArticleId><ArticleId IdType="pmc">PMC6365111</ArticleId><ArticleId IdType="pubmed">30775436</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura A, Kaneko N, Villemagne VL, et al. . High performance plasma amyloid-&#x3b2; biomarkers for Alzheimer&#x2019;s disease. Nature. 2018;554(7691):249-254. doi:10.1038/nature25456</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature25456</ArticleId><ArticleId IdType="pubmed">29420472</ArticleId></ArticleIdList></Reference><Reference><Citation>Barth&#xe9;lemy NR, Horie K, Sato C, Bateman RJ. Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer&#x2019;s disease. J Exp Med. 2020;217(11):e20200861. doi:10.1084/jem.20200861</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20200861</ArticleId><ArticleId IdType="pmc">PMC7596823</ArticleId><ArticleId IdType="pubmed">32725127</ArticleId></ArticleIdList></Reference><Reference><Citation>Karikari TK, Benedet AL, Ashton NJ, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer&#x2019;s Disease Neuroimaging Initiative. Mol Psychiatry. 2020. doi:10.1038/s41380-020-00923-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-020-00923-z</ArticleId><ArticleId IdType="pubmed">33106600</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Cullen NC, Andreasson U, Zetterberg H, Blennow K. Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 2019;76(7):791-799. doi:10.1001/jamaneurol.2019.0765</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.0765</ArticleId><ArticleId IdType="pmc">PMC6583067</ArticleId><ArticleId IdType="pubmed">31009028</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Andreasson U, Zetterberg H, Blennow K; Alzheimer&#x2019;s Disease Neuroimaging Initiative. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 2017;74(5):557-566. doi:10.1001/jamaneurol.2016.6117</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2016.6117</ArticleId><ArticleId IdType="pmc">PMC5822204</ArticleId><ArticleId IdType="pubmed">28346578</ArticleId></ArticleIdList></Reference><Reference><Citation>Forgrave LM, Ma M, Best JR, DeMarco ML. The diagnostic performance of neurofilament light chain in CSF and blood for Alzheimer&#x2019;s disease, frontotemporal dementia, and amyotrophic lateral sclerosis: a systematic review and meta-analysis. Alzheimers Dement (Amst). 2019;11:730-743. doi:10.1016/j.dadm.2019.08.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dadm.2019.08.009</ArticleId><ArticleId IdType="pmc">PMC6939029</ArticleId><ArticleId IdType="pubmed">31909174</ArticleId></ArticleIdList></Reference><Reference><Citation>ADNI . Alzheimer&#x2019;s Disease Neuroimaging Initiative. Accessed June 19, 2020. http://adni.loni.usc.edu</Citation></Reference><Reference><Citation>Petersen RC, Aisen PS, Beckett LA, et al. . Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology. 2010;74(3):201-209. doi:10.1212/WNL.0b013e3181cb3e25</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181cb3e25</ArticleId><ArticleId IdType="pmc">PMC2809036</ArticleId><ArticleId IdType="pubmed">20042704</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang JH, Korecka M, Figurski MJ, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . The Alzheimer&#x2019;s Disease Neuroimaging Initiative 2 Biomarker Core: a review of progress and plans. Alzheimers Dement. 2015;11(7):772-791. doi:10.1016/j.jalz.2015.05.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2015.05.003</ArticleId><ArticleId IdType="pmc">PMC5127404</ArticleId><ArticleId IdType="pubmed">26194312</ArticleId></ArticleIdList></Reference><Reference><Citation>Gissl&#xe9;n M, Price RW, Andreasson U, et al. . Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: a cross-sectional study. EBioMedicine. 2015;3:135-140. doi:10.1016/j.ebiom.2015.11.036</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2015.11.036</ArticleId><ArticleId IdType="pmc">PMC4739412</ArticleId><ArticleId IdType="pubmed">26870824</ArticleId></ArticleIdList></Reference><Reference><Citation>ADNI . Access and data samples. Accessed June 19, 2020. http://adni.loni.usc.edu/data-samples/access-data/</Citation></Reference><Reference><Citation>Jagust WJ, Landau SM, Koeppe RA, et al. . The Alzheimer&#x2019;s Disease Neuroimaging Initiative 2 PET core: 2015. Alzheimers Dement. 2015;11(7):757-771. doi:10.1016/j.jalz.2015.05.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2015.05.001</ArticleId><ArticleId IdType="pmc">PMC4510459</ArticleId><ArticleId IdType="pubmed">26194311</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Barnes J, Bernstein MA, et al. . Magnetic resonance imaging in Alzheimer&#x2019;s Disease Neuroimaging Initiative 2. Alzheimers Dement. 2015;11(7):740-756. doi:10.1016/j.jalz.2015.05.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2015.05.002</ArticleId><ArticleId IdType="pmc">PMC4523217</ArticleId><ArticleId IdType="pubmed">26194310</ArticleId></ArticleIdList></Reference><Reference><Citation>Lange C, Suppa P, Frings L, Brenner W, Spies L, Buchert R. Optimization of statistical single subject analysis of brain FDG PET for the prognosis of mild cognitive impairment-to-Alzheimer&#x2019;s disease conversion. J Alzheimers Dis. 2016;49(4):945-959. doi:10.3233/JAD-150814</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-150814</ArticleId><ArticleId IdType="pubmed">26577523</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Harvey D, Madison CM, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging. 2011;32(7):1207-1218. doi:10.1016/j.neurobiolaging.2009.07.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2009.07.002</ArticleId><ArticleId IdType="pmc">PMC2891865</ArticleId><ArticleId IdType="pubmed">19660834</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Wiste HJ, Weigand SD, et al. . Defining imaging biomarker cut points for brain aging and Alzheimer&#x2019;s disease. Alzheimers Dement. 2017;13(3):205-216. doi:10.1016/j.jalz.2016.08.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.08.005</ArticleId><ArticleId IdType="pmc">PMC5344738</ArticleId><ArticleId IdType="pubmed">27697430</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Bennett DA, Blennow K, et al. . NIA-AA research framework: toward a biological definition of Alzheimer&#x2019;s disease. Alzheimers Dement. 2018;14(4):535-562. doi:10.1016/j.jalz.2018.02.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.02.018</ArticleId><ArticleId IdType="pmc">PMC5958625</ArticleId><ArticleId IdType="pubmed">29653606</ArticleId></ArticleIdList></Reference><Reference><Citation>Donohue MC, Sperling RA, Salmon DP, et al. ; Australian Imaging, Biomarkers, and Lifestyle Flagship Study of Ageing; Alzheimer&#x2019;s Disease Neuroimaging Initiative; Alzheimer&#x2019;s Disease Cooperative Study . The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol. 2014;71(8):961-970. doi:10.1001/jamaneurol.2014.803</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.803</ArticleId><ArticleId IdType="pmc">PMC4439182</ArticleId><ArticleId IdType="pubmed">24886908</ArticleId></ArticleIdList></Reference><Reference><Citation>Donohue MC, Sperling RA, Petersen R, Sun CK, Weiner MW, Aisen PS; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons. JAMA. 2017;317(22):2305-2316. doi:10.1001/jama.2017.6669</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2017.6669</ArticleId><ArticleId IdType="pmc">PMC5736301</ArticleId><ArticleId IdType="pubmed">28609533</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohs RC, Knopman D, Petersen RC, et al. . Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer&#x2019;s Disease Assessment Scale that broaden its scope: the Alzheimer&#x2019;s Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11(suppl 2):S13-S21. doi:10.1097/00002093-199700112-00003</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00002093-199700112-00003</ArticleId><ArticleId IdType="pubmed">9236948</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Lu M, Joshi AD, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Comparing positron emission tomography imaging and cerebrospinal fluid measurements of &#x3b2;-amyloid. Ann Neurol. 2013;74(6):826-836. doi:10.1002/ana.23908</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.23908</ArticleId><ArticleId IdType="pmc">PMC3748164</ArticleId><ArticleId IdType="pubmed">23536396</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology. 1990;1(1):43-46. doi:10.1097/00001648-199001000-00010</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00001648-199001000-00010</ArticleId><ArticleId IdType="pubmed">2081237</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson-Carlgren N, Janelidze S, Palmqvist S, et al. . Longitudinal plasma p-tau217 is increased in early stages of Alzheimer&#x2019;s disease. Brain. 2020;awaa286. doi:10.1093/brain/awaa286</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa286</ArticleId><ArticleId IdType="pmc">PMC7719022</ArticleId><ArticleId IdType="pubmed">33068398</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitwell JL, Przybelski SA, Weigand SD, et al. . 3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer&#x2019;s disease. Brain. 2007;130(pt 7):1777-1786. doi:10.1093/brain/awm112</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awm112</ArticleId><ArticleId IdType="pmc">PMC2752411</ArticleId><ArticleId IdType="pubmed">17533169</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabinovici GD, Seeley WW, Kim EJ, et al. . Distinct MRI atrophy patterns in autopsy-proven Alzheimer&#x2019;s disease and frontotemporal lobar degeneration. Am J Alzheimers Dis Other Demen. 2007;22(6):474-488. doi:10.1177/1533317507308779</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1533317507308779</ArticleId><ArticleId IdType="pmc">PMC2443731</ArticleId><ArticleId IdType="pubmed">18166607</ArticleId></ArticleIdList></Reference><Reference><Citation>Edison P, Archer HA, Hinz R, et al. . Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology. 2007;68(7):501-508. doi:10.1212/01.wnl.0000244749.20056.d4</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000244749.20056.d4</ArticleId><ArticleId IdType="pubmed">17065593</ArticleId></ArticleIdList></Reference><Reference><Citation>Habes M, Erus G, Toledo JB, et al. . White matter hyperintensities and imaging patterns of brain ageing in the general population. Brain. 2016;139(pt 4):1164-1179. doi:10.1093/brain/aww008</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww008</ArticleId><ArticleId IdType="pmc">PMC5006227</ArticleId><ArticleId IdType="pubmed">26912649</ArticleId></ArticleIdList></Reference><Reference><Citation>Pascual B, Prieto E, Arbizu J, Marti-Climent J, Olier J, Masdeu JC. Brain glucose metabolism in vascular white matter disease with dementia: differentiation from Alzheimer disease. Stroke. 2010;41(12):2889-2893. doi:10.1161/STROKEAHA.110.591552</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.110.591552</ArticleId><ArticleId IdType="pubmed">21051671</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith EE, O&#x2019;Donnell M, Dagenais G, et al. ; PURE Investigators . Early cerebral small vessel disease and brain volume, cognition, and gait. Ann Neurol. 2015;77(2):251-261. doi:10.1002/ana.24320</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24320</ArticleId><ArticleId IdType="pmc">PMC4338762</ArticleId><ArticleId IdType="pubmed">25428654</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y, Tan L, Xu W, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Plasma neurofilament light and longitudinal progression of white matter hyperintensity in elderly persons without dementia. J Alzheimers Dis. 2020;75(3):729-737. doi:10.3233/JAD-200022</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-200022</ArticleId><ArticleId IdType="pubmed">32310173</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas JC, Karydas A, Bang J, et al. . Plasma neurofilament light chain predicts progression in progressive supranuclear palsy. Ann Clin Transl Neurol. 2016;3(3):216-225. doi:10.1002/acn3.290</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.290</ArticleId><ArticleId IdType="pmc">PMC4774256</ArticleId><ArticleId IdType="pubmed">27042681</ArticleId></ArticleIdList></Reference><Reference><Citation>Benussi A, Karikari TK, Ashton N, et al. . Diagnostic and prognostic value of serum NfL and p-Tau181 in frontotemporal lobar degeneration. J Neurol Neurosurg Psychiatry. 2020;91(9):960-967. doi:10.1136/jnnp-2020-323487</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-323487</ArticleId><ArticleId IdType="pubmed">32611664</ArticleId></ArticleIdList></Reference><Reference><Citation>Aschenbrenner AJ, Gordon BA, Benzinger TLS, Morris JC, Hassenstab JJ. Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease. Neurology. 2018;91(9):e859-e866. doi:10.1212/WNL.0000000000006075</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000006075</ArticleId><ArticleId IdType="pmc">PMC6133625</ArticleId><ArticleId IdType="pubmed">30068637</ArticleId></ArticleIdList></Reference><Reference><Citation>Bejanin A, Schonhaut DR, La Joie R, et al. . Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer&#x2019;s disease. Brain. 2017;140(12):3286-3300. doi:10.1093/brain/awx243</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awx243</ArticleId><ArticleId IdType="pmc">PMC5841139</ArticleId><ArticleId IdType="pubmed">29053874</ArticleId></ArticleIdList></Reference><Reference><Citation>Saint-Aubert L, Almkvist O, Chiotis K, Almeida R, Wall A, Nordberg A. Regional tau deposition measured by [18F]THK5317 positron emission tomography is associated to cognition via glucose metabolism in Alzheimer&#x2019;s disease. Alzheimers Res Ther. 2016;8(1):38. doi:10.1186/s13195-016-0204-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-016-0204-z</ArticleId><ArticleId IdType="pmc">PMC5041516</ArticleId><ArticleId IdType="pubmed">27683159</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabinovici GD, Gatsonis C, Apgar C, et al. . Association of amyloid positron emission tomography with subsequent change in clinical management among Medicare beneficiaries with mild cognitive impairment or dementia. JAMA. 2019;321(13):1286-1294. doi:10.1001/jama.2019.2000</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2019.2000</ArticleId><ArticleId IdType="pmc">PMC6450276</ArticleId><ArticleId IdType="pubmed">30938796</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceccaldi M, Jonveaux T, Verger A, et al. ; NEUUS in AD Study Group . Added value of 18F-florbetaben amyloid PET in the diagnostic workup of most complex patients with dementia in France: A naturalistic study. Alzheimers Dement. 2018;14(3):293-305. doi:10.1016/j.jalz.2017.09.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2017.09.009</ArticleId><ArticleId IdType="pubmed">29107051</ArticleId></ArticleIdList></Reference><Reference><Citation>Moscoso A, Rey-Bretal D, Silva-Rodr&#xed;guez J, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . White matter hyperintensities are associated with subthreshold amyloid accumulation. Neuroimage. 2020;218:116944. doi:10.1016/j.neuroimage.2020.116944</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2020.116944</ArticleId><ArticleId IdType="pubmed">32445880</ArticleId></ArticleIdList></Reference><Reference><Citation>Caballero MAA, Song Z, Rubinski A, et al. . Age-dependent amyloid deposition is associated with white matter alterations in cognitively normal adults during the adult life span. Alzheimers Dement. 2020;16(4):651-661. doi:10.1002/alz.12062</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12062</ArticleId><ArticleId IdType="pubmed">32147939</ArticleId></ArticleIdList></Reference><Reference><Citation>Graff-Radford J, Arenaza-Urquijo EM, Knopman DS, et al. . White matter hyperintensities: relationship to amyloid and tau burden. Brain. 2019;142(8):2483-2491. doi:10.1093/brain/awz162</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz162</ArticleId><ArticleId IdType="pmc">PMC6658846</ArticleId><ArticleId IdType="pubmed">31199475</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33432193</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>29</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Molecular characterization of selectively vulnerable neurons in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>276</StartPage><EndPage>287</EndPage><MedlinePgn>276-287</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41593-020-00764-7</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is characterized by the selective vulnerability of specific neuronal populations, the molecular signatures of which are largely unknown. To identify and characterize selectively vulnerable neuronal populations, we used single-nucleus RNA sequencing to profile the caudal entorhinal cortex and the superior frontal gyrus-brain regions where neurofibrillary inclusions and neuronal loss occur early and late in AD, respectively-from postmortem brains spanning the progression of AD-type tau neurofibrillary pathology. We identified RORB as a marker of selectively vulnerable excitatory neurons in the entorhinal cortex and subsequently validated their depletion and selective susceptibility to neurofibrillary inclusions during disease progression using quantitative neuropathological methods. We also discovered an astrocyte subpopulation, likely representing reactive astrocytes, characterized by decreased expression of genes involved in homeostatic functions. Our characterization of selectively vulnerable neurons in AD paves the way for future mechanistic studies of selective vulnerability and potential therapeutic strategies for enhancing neuronal resilience.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Leng</LastName><ForeName>Kun</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute for Neurodegenerative Disease, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chan Zuckerberg Biohub, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Sciences Graduate Program, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Scientist Training Program, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Li</LastName><ForeName>Emmy</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Institute for Neurodegenerative Disease, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chan Zuckerberg Biohub, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Sciences Graduate Program, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eser</LastName><ForeName>Rana</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-4078-1502</Identifier><AffiliationInfo><Affiliation>Memory and Aging Center, Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piergies</LastName><ForeName>Antonia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sit</LastName><ForeName>Rene</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Chan Zuckerberg Biohub, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Michelle</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Chan Zuckerberg Biohub, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neff</LastName><ForeName>Norma</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-7141-5420</Identifier><AffiliationInfo><Affiliation>Chan Zuckerberg Biohub, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Song Hua</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodriguez</LastName><ForeName>Roberta Diehl</ForeName><Initials>RD</Initials><AffiliationInfo><Affiliation>Department of Neurology, Universidade de S&#xe3;o Paulo, Faculdade de Medicina, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suemoto</LastName><ForeName>Claudia Kimie</ForeName><Initials>CK</Initials><AffiliationInfo><Affiliation>Department of Pathology, Universidade de S&#xe3;o Paulo, Faculdade de Medicina, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Geriatrics, Department of Clinical Medicine, Universidade de S&#xe3;o Paulo, Faculdade de Medicina, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leite</LastName><ForeName>Renata Elaine Paraizo</ForeName><Initials>REP</Initials><AffiliationInfo><Affiliation>Department of Pathology, Universidade de S&#xe3;o Paulo, Faculdade de Medicina, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ehrenberg</LastName><ForeName>Alexander J</ForeName><Initials>AJ</Initials><Identifier Source="ORCID">0000-0003-4334-9424</Identifier><AffiliationInfo><Affiliation>Memory and Aging Center, Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pasqualucci</LastName><ForeName>Carlos A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Department of Pathology, Universidade de S&#xe3;o Paulo, Faculdade de Medicina, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seeley</LastName><ForeName>William W</ForeName><Initials>WW</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spina</LastName><ForeName>Salvatore</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heinsen</LastName><ForeName>Helmut</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pathology, Universidade de S&#xe3;o Paulo, Faculdade de Medicina, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of W&#xfc;rzburg, W&#xfc;rzburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grinberg</LastName><ForeName>Lea T</ForeName><Initials>LT</Initials><Identifier Source="ORCID">0000-0002-6809-0618</Identifier><AffiliationInfo><Affiliation>Memory and Aging Center, Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA. lea.grinberg@ucsf.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Universidade de S&#xe3;o Paulo, Faculdade de Medicina, S&#xe3;o Paulo, Brazil. lea.grinberg@ucsf.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Global Brain Health Institute, University of California, San Francisco, San Francisco, CA, USA. lea.grinberg@ucsf.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kampmann</LastName><ForeName>Martin</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-3819-7019</Identifier><AffiliationInfo><Affiliation>Institute for Neurodegenerative Disease, University of California, San Francisco, San Francisco, CA, USA. martin.kampmann@ucsf.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chan Zuckerberg Biohub, San Francisco, CA, USA. martin.kampmann@ucsf.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA, USA. martin.kampmann@ucsf.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 NS100717</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AG057528</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 AG052648</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F30 AG066418</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007618</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AG053435</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>01</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2021 Mar;17(3):132. doi: 10.1038/s41582-021-00462-3.</RefSource><PMID Version="1">33504978</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018728" MajorTopicYN="N">Entorhinal Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>4</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>11</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>7</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33432193</ArticleId><ArticleId IdType="mid">NIHMS1648848</ArticleId><ArticleId IdType="pmc">PMC7854528</ArticleId><ArticleId IdType="doi">10.1038/s41593-020-00764-7</ArticleId><ArticleId IdType="pii">10.1038/s41593-020-00764-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Braak H &amp; Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82, 239&#x2013;259 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Scholl M, et al. PET Imaging of Tau Deposition in the Aging Human Brain. Neuron 89, 971&#x2013;982 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4779187</ArticleId><ArticleId IdType="pubmed">26938442</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeley WW, Crawford RK, Zhou J, Miller BL &amp; Greicius MD Neurodegenerative diseases target large-scale human brain networks. Neuron 62, 42&#x2013;52 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2691647</ArticleId><ArticleId IdType="pubmed">19376066</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H &amp; Braak E. Staging of Alzheimer&#x2019;s disease-related neurofibrillary changes. Neurobiol Aging 16, 271&#x2013;278; discussion 278&#x2013;284 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7566337</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, et al. Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch Neurol 58, 1395&#x2013;1402 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11559310</ArticleId></ArticleIdList></Reference><Reference><Citation>Stranahan AM &amp; Mattson MP Selective vulnerability of neurons in layer II of the entorhinal cortex during aging and Alzheimer&#x2019;s disease. Neural Plast 2010, 108190 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3039218</ArticleId><ArticleId IdType="pubmed">21331296</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Hoesen GW, Hyman BT &amp; Damasio AR Entorhinal cortex pathology in Alzheimer&#x2019;s disease. Hippocampus 1, 1&#x2013;8 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1669339</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Isla T, et al. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer&#x2019;s disease. J Neurosci 16, 4491&#x2013;4500 (1996).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578866</ArticleId><ArticleId IdType="pubmed">8699259</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H &amp; Braak E. The human entorhinal cortex: normal morphology and lamina-specific pathology in various diseases. Neurosci Res 15, 6&#x2013;31 (1992).</Citation><ArticleIdList><ArticleId IdType="pubmed">1336586</ArticleId></ArticleIdList></Reference><Reference><Citation>Kordower JH, et al. Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment. Ann Neurol 49, 202&#x2013;213 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11220740</ArticleId></ArticleIdList></Reference><Reference><Citation>Drummond E &amp; Wisniewski T. Alzheimer&#x2019;s disease: experimental models and reality. Acta Neuropathol 133, 155&#x2013;175 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5253109</ArticleId><ArticleId IdType="pubmed">28025715</ArticleId></ArticleIdList></Reference><Reference><Citation>Lake BB, et al. Neuronal subtypes and diversity revealed by single-nucleus RNA sequencing of the human brain. Science 352, 1586&#x2013;1590 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5038589</ArticleId><ArticleId IdType="pubmed">27339989</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodge RD, et al. Conserved cell types with divergent features in human versus mouse cortex. Nature 573, 61&#x2013;68 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6919571</ArticleId><ArticleId IdType="pubmed">31435019</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H, et al. Single-cell transcriptomic analysis of Alzheimer&#x2019;s disease. Nature 570, 332&#x2013;337 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6865822</ArticleId><ArticleId IdType="pubmed">31042697</ArticleId></ArticleIdList></Reference><Reference><Citation>Grubman A, et al. A single-cell atlas of entorhinal cortex from individuals with Alzheimer&#x2019;s disease reveals cell-type-specific gene expression regulation. Nature neuroscience 22, 2087&#x2013;2097 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31768052</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol 71, 362&#x2013;381 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3560290</ArticleId><ArticleId IdType="pubmed">22487856</ArticleId></ArticleIdList></Reference><Reference><Citation>Hof PR, et al. Parvalbumin-immunoreactive neurons in the neocortex are resistant to degeneration in Alzheimer&#x2019;s disease. J Neuropathol Exp Neurol 50, 451&#x2013;462 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">2061713</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu H, et al. A tau homeostasis signature is linked with the cellular and regional vulnerability of excitatory neurons to tau pathology. Nature neuroscience 22, 47&#x2013;56 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6330709</ArticleId><ArticleId IdType="pubmed">30559469</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinsen H, et al. Quantitative investigations on the human entorhinal area: left-right asymmetry and age-related changes. Anat Embryol (Berl) 190, 181&#x2013;194 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">7818090</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobro-Flatmoen A &amp; Witter MP Neuronal chemo-architecture of the entorhinal cortex: A comparative review. Eur J Neurosci 50, 3627&#x2013;3662 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31293027</ArticleId></ArticleIdList></Reference><Reference><Citation>Naumann RK, et al. Conserved size and periodicity of pyramidal patches in layer 2 of medial/caudal entorhinal cortex. J Comp Neurol 524, 783&#x2013;806 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5014138</ArticleId><ArticleId IdType="pubmed">26223342</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramsden HL, Surmeli G, McDonagh SG &amp; Nolan MF Laminar and dorsoventral molecular organization of the medial entorhinal cortex revealed by large-scale anatomical analysis of gene expression. PLoS Comput Biol 11, e1004032 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4304787</ArticleId><ArticleId IdType="pubmed">25615592</ArticleId></ArticleIdList></Reference><Reference><Citation>Jabaudon D, Shnider SJ, Tischfield DJ, Galazo MJ &amp; Macklis JD RORbeta induces barrel-like neuronal clusters in the developing neocortex. Cereb Cortex 22, 996&#x2013;1006 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3328343</ArticleId><ArticleId IdType="pubmed">21799210</ArticleId></ArticleIdList></Reference><Reference><Citation>Oishi K, Aramaki M &amp; Nakajima K. Mutually repressive interaction between Brn1/2 and Rorb contributes to the establishment of neocortical layer 2/3 and layer 4. Proceedings of the National Academy of Sciences of the United States of America 113, 3371&#x2013;3376 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4812710</ArticleId><ArticleId IdType="pubmed">26951672</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakagawa Y &amp; O&#x2019;Leary DD Dynamic patterned expression of orphan nuclear receptor genes RORalpha and RORbeta in developing mouse forebrain. Dev Neurosci 25, 234&#x2013;244 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12966220</ArticleId></ArticleIdList></Reference><Reference><Citation>Marinaro F, et al. Molecular and cellular pathology of monogenic Alzheimer&#x2019;s disease at single cell resolution. bioRxiv, 2020.2007.2014.202317 (2020).</Citation></Reference><Reference><Citation>Liang WS, et al. Altered neuronal gene expression in brain regions differentially affected by Alzheimer&#x2019;s disease: a reference data set. Physiol Genomics 33, 240&#x2013;256 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2826117</ArticleId><ArticleId IdType="pubmed">18270320</ArticleId></ArticleIdList></Reference><Reference><Citation>Franjic D, et al. Molecular Diversity Among Adult Human Hippocampal and Entorhinal Cells. bioRxiv doi: 10.1101/2019.12.31.889139 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2019.12.31.889139</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehrenberg AJ, et al. A manual multiplex immunofluorescence method for investigating neurodegenerative diseases. Journal of Neuroscience Methods In press, 10.1016/j.jneumeth.2020.108708. (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneumeth.2020.108708</ArticleId><ArticleId IdType="pmc">PMC7269157</ArticleId><ArticleId IdType="pubmed">32243897</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H, et al. A Unique Microglia Type Associated with Restricting Development of Alzheimer&#x2019;s Disease. Cell 169, 1276&#x2013;1290 e1217 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Srinivasan K, et al. Alzheimer&#x2019;s patient brain myeloid cells exhibit enhanced aging and unique transcriptional activation. bioRxiv doi: 10.1101/610345 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/610345</ArticleId><ArticleId IdType="pmc">PMC7422733</ArticleId><ArticleId IdType="pubmed">32610143</ArticleId></ArticleIdList></Reference><Reference><Citation>Thrupp N, et al. Single nucleus sequencing fails to detect microglial activation in human tissue. bioRxiv, 2020.2004.2013.035386 (2020).</Citation></Reference><Reference><Citation>Chen WT, et al. Spatial Transcriptomics and In Situ Sequencing to Study Alzheimer&#x2019;s Disease. Cell (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32702314</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Nievas BG &amp; Serrano-Pozo A. Deciphering the Astrocyte Reaction in Alzheimer&#x2019;s Disease. Front Aging Neurosci 10, 114 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5996928</ArticleId><ArticleId IdType="pubmed">29922147</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson JE, et al. Microarray analysis of the astrocyte transcriptome in the aging brain: relationship to Alzheimer&#x2019;s pathology and APOE genotype. Neurobiol Aging 32, 1795&#x2013;1807 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21705112</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekar S, et al. Alzheimer&#x2019;s disease is associated with altered expression of genes involved in immune response and mitochondrial processes in astrocytes. Neurobiol Aging 36, 583&#x2013;591 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4315763</ArticleId><ArticleId IdType="pubmed">25448601</ArticleId></ArticleIdList></Reference><Reference><Citation>Liddelow SA, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541, 481&#x2013;487 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5404890</ArticleId><ArticleId IdType="pubmed">28099414</ArticleId></ArticleIdList></Reference><Reference><Citation>Laywell ED, et al. Enhanced expression of the developmentally regulated extracellular matrix molecule tenascin following adult brain injury. Proceedings of the National Academy of Sciences of the United States of America 89, 2634&#x2013;2638 (1992).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC48716</ArticleId><ArticleId IdType="pubmed">1372985</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamanian JL, et al. Genomic analysis of reactive astrogliosis. J Neurosci 32, 6391&#x2013;6410 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3480225</ArticleId><ArticleId IdType="pubmed">22553043</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson MA, et al. Astrocyte scar formation aids central nervous system axon regeneration. Nature 532, 195&#x2013;200 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5243141</ArticleId><ArticleId IdType="pubmed">27027288</ArticleId></ArticleIdList></Reference><Reference><Citation>Kampmann M. A CRISPR Approach to Neurodegenerative Diseases. Trends in molecular medicine 23, 483&#x2013;485 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5604856</ArticleId><ArticleId IdType="pubmed">28478951</ArticleId></ArticleIdList></Reference><Reference><Citation>Kampmann M. CRISPR-based functional genomics for neurological disease. Nat Rev Neurol (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7484261</ArticleId><ArticleId IdType="pubmed">32641861</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian R, et al. CRISPR Interference-Based Platform for Multimodal Genetic Screens in Human iPSC-Derived Neurons. Neuron 104, 239&#x2013;255 e212 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6813890</ArticleId><ArticleId IdType="pubmed">31422865</ArticleId></ArticleIdList></Reference><Reference><Citation>Hof PR &amp; Morrison JH Neocortical neuronal subpopulations labeled by a monoclonal antibody to calbindin exhibit differential vulnerability in Alzheimer&#x2019;s disease. Exp Neurol 111, 293&#x2013;301 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1999232</ArticleId></ArticleIdList></Reference><Reference><Citation>Hof PR, Cox K &amp; Morrison JH Quantitative analysis of a vulnerable subset of pyramidal neurons in Alzheimer&#x2019;s disease: I. Superior frontal and inferior temporal cortex. J Comp Neurol 301, 44&#x2013;54 (1990).</Citation><ArticleIdList><ArticleId IdType="pubmed">2127598</ArticleId></ArticleIdList></Reference><Reference><Citation>Mikkonen M, Alafuzoff I, Tapiola T, Soininen H &amp; Miettinen R. Subfield- and layer-specific changes in parvalbumin, calretinin and calbindin-D28K immunoreactivity in the entorhinal cortex in Alzheimer&#x2019;s disease. Neuroscience 92, 515&#x2013;532 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10408601</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian R, et al. CRISPR Interference-Based Platform for Multimodal Genetic Screens in Human iPSC-Derived Neurons. Neuron 104, 239&#x2013;255 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6813890</ArticleId><ArticleId IdType="pubmed">31422865</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine TJ, et al. National Institute on Aging-Alzheimer&#x2019;s Association guidelines for the neuropathologic assessment of Alzheimer&#x2019;s disease: a practical approach. Acta Neuropathol 123, 1&#x2013;11 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3268003</ArticleId><ArticleId IdType="pubmed">22101365</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes CP, Berg L, Danziger WL, Coben LA &amp; Martin RL A new clinical scale for the staging of dementia. Br J Psychiatry 140, 566&#x2013;572 (1982).</Citation><ArticleIdList><ArticleId IdType="pubmed">7104545</ArticleId></ArticleIdList></Reference><Reference><Citation>Grinberg LT, et al. Brain bank of the Brazilian aging brain study group - a milestone reached and more than 1,600 collected brains. Cell Tissue Bank 8, 151&#x2013;162 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17075689</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, et al. National Institute on Aging-Alzheimer&#x2019;s Association guidelines for the neuropathologic assessment of Alzheimer&#x2019;s disease. Alzheimers Dement 8, 1&#x2013;13 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3266529</ArticleId><ArticleId IdType="pubmed">22265587</ArticleId></ArticleIdList></Reference><Reference><Citation>Suemoto CK, et al. Neuropathological diagnoses and clinical correlates in older adults in Brazil: A cross-sectional study. PLoS Med 14, e1002267 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5369698</ArticleId><ArticleId IdType="pubmed">28350821</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns NJ, et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol 114, 5&#x2013;22 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2827877</ArticleId><ArticleId IdType="pubmed">17579875</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrer I, Santpere G &amp; van Leeuwen FW Argyrophilic grain disease. Brain 131, 1416&#x2013;1432 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18234698</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez RD &amp; Grinberg LT Argyrophilic grain disease: An underestimated tauopathy. Dement Neuropsychol 9, 2&#x2013;8 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5618985</ArticleId><ArticleId IdType="pubmed">29213935</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez RD, et al. Argyrophilic Grain Disease: Demographics, Clinical, and Neuropathological Features From a Large Autopsy Study. J Neuropathol Exp Neurol 75, 628&#x2013;635 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4913431</ArticleId><ArticleId IdType="pubmed">27283329</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Thal DR, Ghebremedhin E &amp; Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol 70, 960&#x2013;969 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">22002422</ArticleId></ArticleIdList></Reference><Reference><Citation>Mo A, et al. Epigenomic Signatures of Neuronal Diversity in the Mammalian Brain. Neuron 86, 1369&#x2013;1384 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4499463</ArticleId><ArticleId IdType="pubmed">26087164</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabula Muris C, et al. Single-cell transcriptomics of 20 mouse organs creates a Tabula Muris. Nature 562, 367&#x2013;372 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6642641</ArticleId><ArticleId IdType="pubmed">30283141</ArticleId></ArticleIdList></Reference><Reference><Citation>Lun ATL, et al. EmptyDrops: distinguishing cells from empty droplets in droplet-based single-cell RNA sequencing data. Genome biology 20, 63 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6431044</ArticleId><ArticleId IdType="pubmed">30902100</ArticleId></ArticleIdList></Reference><Reference><Citation>Lun AT, Bach K &amp; Marioni JC Pooling across cells to normalize single-cell RNA sequencing data with many zero counts. Genome biology 17, 75 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4848819</ArticleId><ArticleId IdType="pubmed">27122128</ArticleId></ArticleIdList></Reference><Reference><Citation>Lun AT, McCarthy DJ &amp; Marioni JC A step-by-step workflow for low-level analysis of single-cell RNA-seq data with Bioconductor. F1000Res 5, 2122 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5112579</ArticleId><ArticleId IdType="pubmed">27909575</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy DJ, Campbell KR, Lun AT &amp; Wills QF Scater: pre-processing, quality control, normalization and visualization of single-cell RNA-seq data in R. Bioinformatics 33, 1179&#x2013;1186 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5408845</ArticleId><ArticleId IdType="pubmed">28088763</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuart T, et al. Comprehensive Integration of Single-Cell Data. Cell 177, 1888&#x2013;1902 e1821 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6687398</ArticleId><ArticleId IdType="pubmed">31178118</ArticleId></ArticleIdList></Reference><Reference><Citation>Johansen N &amp; Quon G. scAlign: a tool for alignment, integration, and rare cell identification from scRNA-seq data. Genome biology 20, 166 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6693154</ArticleId><ArticleId IdType="pubmed">31412909</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson MD, McCarthy DJ &amp; Smyth GK edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139&#x2013;140 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2796818</ArticleId><ArticleId IdType="pubmed">19910308</ArticleId></ArticleIdList></Reference><Reference><Citation>Amezquita RA, et al. Orchestrating single-cell analysis with Bioconductor. Nat Methods 17, 137&#x2013;145 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7358058</ArticleId><ArticleId IdType="pubmed">31792435</ArticleId></ArticleIdList></Reference><Reference><Citation>Szklarczyk D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic acids research 47, D607&#x2013;D613 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6323986</ArticleId><ArticleId IdType="pubmed">30476243</ArticleId></ArticleIdList></Reference><Reference><Citation>Shannon P, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13, 2498&#x2013;2504 (2003).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC403769</ArticleId><ArticleId IdType="pubmed">14597658</ArticleId></ArticleIdList></Reference><Reference><Citation>Stelzer G, et al. The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses. Curr Protoc Bioinformatics 54, 1 30 31&#x2013;31 30 33 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27322403</ArticleId></ArticleIdList></Reference><Reference><Citation>Arriza JL, et al. Functional comparisons of three glutamate transporter subtypes cloned from human motor cortex. J Neurosci 14, 5559&#x2013;5569 (1994).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6577102</ArticleId><ArticleId IdType="pubmed">7521911</ArticleId></ArticleIdList></Reference><Reference><Citation>Borden LA, et al. Cloning of the human homologue of the GABA transporter GAT-3 and identification of a novel inhibitor with selectivity for this site. Receptors Channels 2, 207&#x2013;213 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">7874447</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendreau S, et al. A trimeric quaternary structure is conserved in bacterial and human glutamate transporters. J Biol Chem 279, 39505&#x2013;39512 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15265858</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe4;berle J, et al. Congenital glutamine deficiency with glutamine synthetase mutations. N Engl J Med 353, 1926&#x2013;1933 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16267323</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawakami H, Tanaka K, Nakayama T, Inoue K &amp; Nakamura S. Cloning and expression of a human glutamate transporter. Biochem Biophys Res Commun 199, 171&#x2013;176 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">8123008</ArticleId></ArticleIdList></Reference><Reference><Citation>Melzer N, Biela A &amp; Fahlke C. Glutamate modifies ion conduction and voltage-dependent gating of excitatory amino acid transporter-associated anion channels. J Biol Chem 278, 50112&#x2013;50119 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">14506254</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xfc;dhof TC Synaptic Neurexin Complexes: A Molecular Code for the Logic of Neural Circuits. Cell 171, 745&#x2013;769 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5694349</ArticleId><ArticleId IdType="pubmed">29100073</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellissier F, Gerber A, Bauer C, Ballivet M &amp; Ossipow V. The adhesion molecule Necl-3/SynCAM-2 localizes to myelinated axons, binds to oligodendrocytes and promotes cell adhesion. BMC Neurosci 8, 90 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2176061</ArticleId><ArticleId IdType="pubmed">17967169</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonz&#xe1;lez-Castillo C, Ortu&#xf1;o-Sahag&#xfa;n D, Guzm&#xe1;n-Brambila C, Pall&#xe0;s M &amp; Rojas-Mayorqu&#xed;n AE Pleiotrophin as a central nervous system neuromodulator, evidences from the hippocampus. Front Cell Neurosci 8, 443 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4287103</ArticleId><ArticleId IdType="pubmed">25620911</ArticleId></ArticleIdList></Reference><Reference><Citation>Siddiqui TJ, et al. An LRRTM4-HSPG complex mediates excitatory synapse development on dentate gyrus granule cells. Neuron 79, 680&#x2013;695 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23911104</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinsen H, Arzberger T &amp; Schmitz C. Celloidin mounting (embedding without infiltration) - a new, simple and reliable method for producing serial sections of high thickness through complete human brains and its application to stereological and immunohistochemical investigations. J Chem Neuroanat 20, 49&#x2013;59 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">11074343</ArticleId></ArticleIdList></Reference><Reference><Citation>Insausti R &amp; Amaral DG Entorhinal cortex of the monkey: IV. Topographical and laminar organization of cortical afferents. J Comp Neurol 509, 608&#x2013;641 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3313676</ArticleId><ArticleId IdType="pubmed">18551518</ArticleId></ArticleIdList></Reference><Reference><Citation>Insausti R, Munoz-Lopez M, Insausti AM &amp; Artacho-Perula E. The Human Periallocortex: Layer Pattern in Presubiculum, Parasubiculum and Entorhinal Cortex. A Review. Front Neuroanat 11, 84 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5632821</ArticleId><ArticleId IdType="pubmed">29046628</ArticleId></ArticleIdList></Reference><Reference><Citation>Rose S. Vergleichende Messungen im Allocortex bei Tier und Mensch. J Psychol Neurol 34, 250&#x2013;255 (1927).</Citation></Reference><Reference><Citation>Fu H, et al. Tau Pathology Induces Excitatory Neuron Loss, Grid Cell Dysfunction, and Spatial Memory Deficits Reminiscent of Early Alzheimer&#x2019;s Disease. Neuron 93, 533&#x2013;541 e535 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5363269</ArticleId><ArticleId IdType="pubmed">28111080</ArticleId></ArticleIdList></Reference><Reference><Citation>Hevner RF, et al. Tbr1 regulates differentiation of the preplate and layer 6. Neuron 29, 353&#x2013;366 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11239428</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrari SLP &amp; Cribari-Neto F. Beta regression for modelling rates and proportions. J Appl Stat 31, 799&#x2013;815 (2004).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33433872</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0065-2598</ISSN><JournalIssue CitedMedium="Print"><Volume>1281</Volume><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>Advances in experimental medicine and biology</Title><ISOAbbreviation>Adv Exp Med Biol</ISOAbbreviation></Journal><ArticleTitle>The Frontotemporal Dementia Prevention Initiative: Linking Together Genetic Frontotemporal Dementia Cohort Studies.</ArticleTitle><Pagination><StartPage>113</StartPage><EndPage>121</EndPage><MedlinePgn>113-121</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/978-3-030-51140-1_8</ELocationID><Abstract><AbstractText>Around one-third of frontotemporal dementia (FTD) is autosomal dominant with the major genetic causes being mutations in MAPT, GRN and C9orf72. Studying familial forms of FTD can provide a window into the earliest stages of the illness, many years before symptoms start. Large cohort studies have been set up in recent years to better understand this presymptomatic phase, including the Genetic FTD Initiative (GENFI) and the Advancing Research and Treatment for Frontotemporal Lobar Degeneration and Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects (ARTFL/LEFFTDS) studies. Whilst these studies have focused on the investigation of a variety of aspects of genetic FTD, from understanding the molecular pathogenesis to developing biomarkers, they also have a common goal: finding a way to prevent FTD. Researchers from these cohort studies have therefore come together to form the FTD Prevention Initiative (FPI), which has the overarching aim of promoting clinical trials of new therapies to prevent FTD through creating an international database of participants eligible for trials and uniform standards for conducting such trials. This chapter outlines the work of the FPI so far and its future goals over the next few years.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rohrer</LastName><ForeName>Jonathan D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK. j.rohrer@ucl.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boxer</LastName><ForeName>Adam L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/J009482/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/M008525/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/M023664/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/T046015/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Adv Exp Med Biol</MedlineTA><NlmUniqueID>0121103</NlmUniqueID><ISSNLinking>0065-2598</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020774" MajorTopicYN="Y">Pick Disease of the Brain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">C9orf72</Keyword><Keyword MajorTopicYN="N">Clinical trials</Keyword><Keyword MajorTopicYN="N">Frontotemporal dementia</Keyword><Keyword MajorTopicYN="N">Genetics</Keyword><Keyword MajorTopicYN="N">Progranulin</Keyword><Keyword MajorTopicYN="N">Tau</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>1</Month><Day>12</Day><Hour>12</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33433872</ArticleId><ArticleId IdType="doi">10.1007/978-3-030-51140-1_8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bateman RJ, Benzinger TL, Berry S, Clifford DB, Duggan C, Fagan AM et al (2017) DIAN-TU pharma consortium for the dominantly inherited Alzheimer network. The DIAN-TU Next Generation Alzheimer&#x2019;s prevention trial: Adaptive design and disease progression model. Alzheimers Dement 13(1):8&#x2013;19</Citation></Reference><Reference><Citation>Boxer AL, Gold M, Feldman H, Boeve BF, Dickinson SL, Fillit H et al (2020) New directions in clinical trials for frontotemporal lobar degeneration: methods and outcome measures. Alzheimers Dement 16(1):131&#x2013;143</Citation></Reference><Reference><Citation>Chen Q, Boeve BF, Senjem M, Tosakulwong N, Lesnick T, Brushaber D et al (2020) Trajectory of lobar atrophy in asymptomatic and symptomatic GRN mutation carriers: a longitudinal MRI study Neurobiol Aging 88:42&#x2013;50</Citation></Reference><Reference><Citation>Chen Q, Boeve BF, Senjem M, Tosakulwong N, Lesnick TG, Brushaber D et al (2019) Rates of lobar atrophy in asymptomatic MAPT mutation carriers. Alzheimers Dement (N Y) 5:338&#x2013;346</Citation></Reference><Reference><Citation>Coyle-Gilchrist IT, Dick KM, Patterson K, V&#xe1;zquez Rodr&#xed;quez P, Wehmann E, Wilcox A et al (2016) Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes. Neurology 86(18):1736&#x2013;1743</Citation></Reference><Reference><Citation>Galimberti D, Fumagalli GG, Fenoglio C, Cioffi SMG, Arighi A, Serpente M et al (2018) Genetic FTD Initiative (GENFI) Progranulin plasma levels predict the presence of GRN mutations in asymptomatic subjects and do not correlate with brain atrophy: results from the GENFI study. Neurobiol Aging 62:245.e9&#x2013;245.e12</Citation></Reference><Reference><Citation>Greaves CV, Rohrer JD (2019) An update on genetic frontotemporal dementia. J Neurol 266(8):2075&#x2013;2086</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-019-09363-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Heller C, Foiani MS, Moore K, Convery R, Bocchetta M, Neason M et al (2020 Mar) Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia. J Neurol Neurosurg Psychiatry 91(3):263&#x2013;270</Citation></Reference><Reference><Citation>Jiskoot LC, Bocchetta M, Nicholas JM, Cash DM, Thomas D, Modat M et al (2018) Presymptomatic white matter integrity loss in familial frontotemporal dementia in the GENFI cohort: a cross-sectional diffusion tensor imaging study. Ann Clin Transl Neurol 5(9):1025&#x2013;1036</Citation></Reference><Reference><Citation>Meeter LH, Dopper EG, Jiskoot LC, Sanchez-Valle R, Graff C, Benussi L et al (2016) Neurofilament light chain: a biomarker for genetic frontotemporal dementia. Ann Clin Transl Neurol 3(8):623&#x2013;636</Citation></Reference><Reference><Citation>Meeter LHH, Gendron TF, Sias AC, Jiskoot LC, Russo SP, Donker Kaat L et al (2018) Poly(GP), neurofilament and grey matter deficits in C9orf72 expansion carriers. Ann Clin Transl Neurol 5(5):583&#x2013;597</Citation></Reference><Reference><Citation>Miyagawa T, Brushaber D, Syrjanen J, Kremers W, Fields J, Forsberg LK et al (2020) Use of the CDR&#xae; plus NACC FTLD in mild FTLD: data from the ARTFL/LEFFTDS consortium. Alzheimers Dement 16(1):79&#x2013;90</Citation></Reference><Reference><Citation>Moore KM, Nicholas J, Grossman M, McMillan CT, Irwin DJ, Massimo L et al (2020) Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. Lancet Neurol 19(2):145&#x2013;156</Citation></Reference><Reference><Citation>Olney NT, Ong E, Goh SM, Bajorek L, Dever R, Staffaroni AM et al (2020) Clinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degeneration. Alzheimers Dement 16(1):49&#x2013;59</Citation></Reference><Reference><Citation>Onyike CU, Diehl-Schmid J (2013) The epidemiology of frontotemporal dementia. Int Rev Psychiatry 25(2):130&#x2013;137</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/09540261.2013.776523</ArticleId></ArticleIdList></Reference><Reference><Citation>Quintana M, Shrader J, Slota C, Joe G, McKew JC, Fitzgerald M et al (2019) Bayesian model of disease progression in GNE myopathy. Stat Med 38(8):1459&#x2013;1474</Citation></Reference><Reference><Citation>Rohrer JD, Nicholas JM, Cash DM, van Swieten J, Dopper E, Jiskoot L et al (2015) Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis. Lancet Neurol 14(3):253&#x2013;262</Citation></Reference><Reference><Citation>Rohrer JD, Warren JD, Fox NC, Rossor MN (2013) Presymptomatic studies in genetic frontotemporal dementia. Rev Neurol (Paris) 169(10):820&#x2013;824</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurol.2013.07.010</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen HJ, Boeve BF, Boxer AL (2020) Tracking disease progression in familial and sporadic frontotemporal lobar degeneration: recent findings from ARTFL and LEFFTDS. Alzheimers Dement 16(1):71&#x2013;78</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12004</ArticleId></ArticleIdList></Reference><Reference><Citation>Staffaroni AM, Bajorek L, Casaletto KB, Cobigo Y, Goh SM, Wolf A et al (2020 Jan) Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIH-EXAMINER as a potential clinical trial endpoint. Alzheimers Dement 16(1):11&#x2013;21</Citation></Reference><Reference><Citation>Sudre CH, Bocchetta M, Heller C, Convery R, Neason M, Moore KM et al (2019) White matter hyperintensities in progranulin-associated frontotemporal dementia: a longitudinal GENFI study. Neuroimage Clin 24:102077</Citation></Reference><Reference><Citation>Tsai RM, Bejanin A, Lesman-Segev O, LaJoie R, Visani A, Bourakova V et al (2019) <sub>18</sub>F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes. Alzheimers Res Ther 11(1):13</Citation></Reference><Reference><Citation>van der Ende EL, Meeter LH, Poos JM, Panman JL, Jiskoot LC, Dopper EGP et al (2019 Dec) Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. Lancet Neurol 18(12):1103&#x2013;1111</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33433624</PMID><DateCompleted><Year>2021</Year><Month>01</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1540-9538</ISSN><JournalIssue CitedMedium="Internet"><Volume>218</Volume><Issue>3</Issue><PubDate><Year>2021</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>The Journal of experimental medicine</Title><ISOAbbreviation>J Exp Med</ISOAbbreviation></Journal><ArticleTitle>Neuroinvasion of SARS-CoV-2 in human and mouse brain.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e20202135</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1084/jem.20202135</ELocationID><Abstract><AbstractText>Although COVID-19 is considered to be primarily a respiratory disease, SARS-CoV-2 affects multiple organ systems including the central nervous system (CNS). Yet, there is no consensus on the consequences of CNS infections. Here, we used three independent approaches to probe the capacity of SARS-CoV-2 to infect the brain. First, using human brain organoids, we observed clear evidence of infection with accompanying metabolic changes in infected and neighboring neurons. However, no evidence for type I interferon responses was detected. We demonstrate that neuronal infection can be prevented by blocking ACE2 with antibodies or by administering cerebrospinal fluid from a COVID-19 patient. Second, using mice overexpressing human ACE2, we demonstrate SARS-CoV-2 neuroinvasion in vivo. Finally, in autopsies from patients who died of COVID-19, we detect SARS-CoV-2 in cortical neurons and note pathological features associated with infection with minimal immune cell infiltrates. These results provide evidence for the neuroinvasive capacity of SARS-CoV-2 and an unexpected consequence of direct infection of neurons by SARS-CoV-2.</AbstractText><CopyrightInformation>&#xa9; 2021 Song et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Song</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Immunobiology, Yale School of Medicine, New Haven, CT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhang</LastName><ForeName>Ce</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Genetics, Yale School of Medicine, New Haven, CT.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, Yale School of Medicine, New Haven, CT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Israelow</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Immunobiology, Yale School of Medicine, New Haven, CT.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Section of Infectious Diseases, Yale School of Medicine, New Haven, CT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu-Culligan</LastName><ForeName>Alice</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Immunobiology, Yale School of Medicine, New Haven, CT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prado</LastName><ForeName>Alba Vieites</ForeName><Initials>AV</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, INSERM U1127, French National Centre for Scientific Research, Joint Research Unit 7225, Paris Brain Institute, Institut du Cerveau et de la Moelle &#xc9;pini&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skriabine</LastName><ForeName>Sophie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, INSERM U1127, French National Centre for Scientific Research, Joint Research Unit 7225, Paris Brain Institute, Institut du Cerveau et de la Moelle &#xc9;pini&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Peiwen</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Immunobiology, Yale School of Medicine, New Haven, CT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weizman</LastName><ForeName>Orr-El</ForeName><Initials>OE</Initials><AffiliationInfo><Affiliation>Department of Immunobiology, Yale School of Medicine, New Haven, CT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Feimei</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Immunobiology, Yale School of Medicine, New Haven, CT.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Engineering, Yale University, New Haven, CT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dai</LastName><ForeName>Yile</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Immunobiology, Yale School of Medicine, New Haven, CT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Szigeti-Buck</LastName><ForeName>Klara</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Comparative Medicine, Yale School of Medicine, New Haven, CT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yasumoto</LastName><ForeName>Yuki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Comparative Medicine, Yale School of Medicine, New Haven, CT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Guilin</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Yale Center for Genome Analysis, West Haven, CT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castaldi</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Yale Center for Genome Analysis, West Haven, CT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heltke</LastName><ForeName>Jaime</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Yale Center for Genome Analysis, West Haven, CT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ng</LastName><ForeName>Evelyn</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Yale Center for Genome Analysis, West Haven, CT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wheeler</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Yale Center for Genome Analysis, West Haven, CT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alfajaro</LastName><ForeName>Mia Madel</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Immunobiology, Yale School of Medicine, New Haven, CT.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Yale School of Medicine, New Haven, CT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levavasseur</LastName><ForeName>Etienne</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, INSERM U1127, French National Centre for Scientific Research, Joint Research Unit 7225, Paris Brain Institute, Institut du Cerveau et de la Moelle &#xc9;pini&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fontes</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Yale Environmental Health and Safety, Yale University, New Haven, CT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ravindra</LastName><ForeName>Neal G</ForeName><Initials>NG</Initials><AffiliationInfo><Affiliation>Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Computer Science, Yale University, New Haven, CT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Dijk</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Computer Science, Yale University, New Haven, CT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mane</LastName><ForeName>Shrikant</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Genetics, Yale School of Medicine, New Haven, CT.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Yale Center for Genome Analysis, West Haven, CT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gunel</LastName><ForeName>Murat</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Genetics, Yale School of Medicine, New Haven, CT.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, Yale School of Medicine, New Haven, CT.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosurgery, Yale School of Medicine, New Haven, CT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ring</LastName><ForeName>Aaron</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Immunobiology, Yale School of Medicine, New Haven, CT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kazmi</LastName><ForeName>Syed A Jaffar</ForeName><Initials>SAJ</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Geisinger Medical Center, Danville, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Kai</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Geisinger Medical Center, Danville, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilen</LastName><ForeName>Craig B</ForeName><Initials>CB</Initials><AffiliationInfo><Affiliation>Department of Immunobiology, Yale School of Medicine, New Haven, CT.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Yale School of Medicine, New Haven, CT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horvath</LastName><ForeName>Tamas L</ForeName><Initials>TL</Initials><AffiliationInfo><Affiliation>Department of Comparative Medicine, Yale School of Medicine, New Haven, CT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Plu</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, INSERM U1127, French National Centre for Scientific Research, Joint Research Unit 7225, Paris Brain Institute, Institut du Cerveau et de la Moelle &#xc9;pini&#xe8;re, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Assistance Publique H&#xf4;pitaux de Paris, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, D&#xe9;partement de Neuropathologie, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haik</LastName><ForeName>Stephane</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, INSERM U1127, French National Centre for Scientific Research, Joint Research Unit 7225, Paris Brain Institute, Institut du Cerveau et de la Moelle &#xc9;pini&#xe8;re, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Yale Environmental Health and Safety, Yale University, New Haven, CT.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Assistance Publique H&#xf4;pitaux de Paris, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, D&#xe9;partement de Neuropathologie, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Assistance Publique H&#xf4;pitaux de Paris, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Cellule nationale de r&#xe9;f&#xe9;rence des maladies de Creutzfeldt-Jakob, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>Jean-Leon</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, INSERM U1127, French National Centre for Scientific Research, Joint Research Unit 7225, Paris Brain Institute, Institut du Cerveau et de la Moelle &#xc9;pini&#xe8;re, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Yale School of Medicine, New Haven, CT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Louvi</LastName><ForeName>Angeliki</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Yale School of Medicine, New Haven, CT.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosurgery, Yale School of Medicine, New Haven, CT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farhadian</LastName><ForeName>Shelli F</ForeName><Initials>SF</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Section of Infectious Diseases, Yale School of Medicine, New Haven, CT.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Yale School of Medicine, New Haven, CT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huttner</LastName><ForeName>Anita</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pathology, Yale School of Medicine, New Haven, CT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seilhean</LastName><ForeName>Danielle</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, INSERM U1127, French National Centre for Scientific Research, Joint Research Unit 7225, Paris Brain Institute, Institut du Cerveau et de la Moelle &#xc9;pini&#xe8;re, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Assistance Publique H&#xf4;pitaux de Paris, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, D&#xe9;partement de Neuropathologie, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Renier</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, INSERM U1127, French National Centre for Scientific Research, Joint Research Unit 7225, Paris Brain Institute, Institut du Cerveau et de la Moelle &#xc9;pini&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bilguvar</LastName><ForeName>Kaya</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Genetics, Yale School of Medicine, New Haven, CT.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Yale Center for Genome Analysis, West Haven, CT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iwasaki</LastName><ForeName>Akiko</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Immunobiology, Yale School of Medicine, New Haven, CT.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular, Cellular, and Developmental Biology, Yale School of Medicine, New Haven, CT.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, Chevy Chase, MD.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32 AI055403</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AI007517</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001863</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS111242</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 MH118999</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007205</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F30 CA239444</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI157488</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Exp Med</MedlineTA><NlmUniqueID>2985109R</NlmUniqueID><ISSNLinking>0022-1007</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019138">Antibodies, Blocking</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.17.23</RegistryNumber><NameOfSubstance UI="C000705307">ACE2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.17.23</RegistryNumber><NameOfSubstance UI="D000085962">Angiotensin-Converting Enzyme 2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>bioRxiv. 2020 Sep 08:2020.06.25.169946. doi: 10.1101/2020.06.25.169946.</RefSource><PMID Version="1">32935108</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000085962" MajorTopicYN="Y">Angiotensin-Converting Enzyme 2</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019138" MajorTopicYN="N">Antibodies, Blocking</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="Y">Cerebral Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="Y">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009940" MajorTopicYN="N">Organoids</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Disclosures: M. Gunel reported personal fees from AI Therapeutics outside the submitted work; and reported, "AI Therapeutics is currently sponsoring a clinical trial for a therapeutic, which has no relevance for this study, in COVID-19. I am the Chief Scientific Advisor to AI Therapeutics." C.B. Wilen reported personal fees from ZymoResearch outside the submitted work; in addition, C.B. Wilen had a patent for compounds and compositions for treating, ameliorating, and/or preventing SARS-CoV-2 infection and/or complications thereof pending. S. Haik reported a patent to Method for treating prion diseases (PCT/EP 2019/070457) pending. A. Iwasaki reported "other" from RIGImmune and grants from Spring Discovery during the conduct of the study; in addition, A. Iwasaki had a patent to 14/776,463 pending, a patent for a T cell-based immunotherapy for central nervous system viral infections and tumors pending, and a patent to manipulation of meningeal lymphatic vasculature for brain and CNS tumor therapy pending. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>10</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>11</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>12</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>1</Month><Day>12</Day><Hour>12</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>1</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>1</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33433624</ArticleId><ArticleId IdType="pmc">PMC7808299</ArticleId><ArticleId IdType="doi">10.1084/jem.20202135</ArticleId><ArticleId IdType="pii">211674</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Amin, N.D., and Pa&#x15f;ca S.P.. 2018. Building Models of Brain Disorders with Three-Dimensional Organoids. Neuron. 100:389&#x2013;405. 10.1016/j.neuron.2018.10.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.10.007</ArticleId><ArticleId IdType="pubmed">30359604</ArticleId></ArticleIdList></Reference><Reference><Citation>Baig, A.M., and Sanders E.C.. 2020. Potential neuroinvasive pathways of SARS-CoV-2: Deciphering the spectrum of neurological deficit seen in coronavirus disease-2019 (COVID-19). J. Med. Virol. 92:1845&#x2013;1857. 10.1002/jmv.26105</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26105</ArticleId><ArticleId IdType="pmc">PMC7300748</ArticleId><ArticleId IdType="pubmed">32492193</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco-Melo, D., Nilsson-Payant B.E., Liu W.C., Uhl S., Hoagland D., M&#xf8;ller R., Jordan T.X., Oishi K., Panis M., Sachs D., et al. . 2020. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell. 181:1036&#x2013;1045.e9. 10.1016/j.cell.2020.04.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.04.026</ArticleId><ArticleId IdType="pmc">PMC7227586</ArticleId><ArticleId IdType="pubmed">32416070</ArticleId></ArticleIdList></Reference><Reference><Citation>Bullen, C.K., Hogberg H.T., Bahadirli-Talbott A., Bishai W.R., Hartung T., Keuthan C., Looney M.M., Pekosz A., Romero J.C., Sill&#xe9; F.C.M., et al. . 2020. Infectability of human BrainSphere neurons suggests neurotropism of SARS-CoV-2. ALTEX. 37:665&#x2013;671. 10.14573/altex.2006111</Citation><ArticleIdList><ArticleId IdType="doi">10.14573/altex.2006111</ArticleId><ArticleId IdType="pubmed">32591839</ArticleId></ArticleIdList></Reference><Reference><Citation>Cakir, B., Xiang Y., Tanaka Y., Kural M.H., Parent M., Kang Y.J., Chapeton K., Patterson B., Yuan Y., He C.S., et al. . 2019. Engineering of human brain organoids with a functional vascular-like system. Nat. Methods. 16:1169&#x2013;1175. 10.1038/s41592-019-0586-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41592-019-0586-5</ArticleId><ArticleId IdType="pmc">PMC6918722</ArticleId><ArticleId IdType="pubmed">31591580</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantuti-Castelvetri, L., Ojha R., Pedro L.D., Djannatian M., Franz J., Kuivanen S., Kallio K., Kaya T., Anastasina M., Smura T., et al. . 2020. Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. Science. 370:856&#x2013;860. 10.1126/science.abd2985</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd2985</ArticleId><ArticleId IdType="pmc">PMC7857391</ArticleId><ArticleId IdType="pubmed">33082293</ArticleId></ArticleIdList></Reference><Reference><Citation>Coolen, T., Lolli V., Sadeghi N., Rovai A., Trotta N., Taccone F.S., Creteur J., Henrard S., Goffard J.C., Dewitte O., et al. . 2020. Early postmortem brain MRI findings in COVID-19 non-survivors. Neurology. 95:e2016&#x2013;e2027. 10.1212/WNL.0000000000010116</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000010116</ArticleId><ArticleId IdType="pubmed">32546654</ArticleId></ArticleIdList></Reference><Reference><Citation>Daly, J.L., Simonetti B., Klein K., Chen K.E., Williamson M.K., Ant&#xf3;n-Pl&#xe1;garo C., Shoemark D.K., Sim&#xf3;n-Gracia L., Bauer M., Hollandi R., et al. . 2020. Neuropilin-1 is a host factor for SARS-CoV-2 infection. Science. 370:861&#x2013;865. 10.1126/science.abd3072</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd3072</ArticleId><ArticleId IdType="pmc">PMC7612957</ArticleId><ArticleId IdType="pubmed">33082294</ArticleId></ArticleIdList></Reference><Reference><Citation>Daniels, B.P., Kofman S.B., Smith J.R., Norris G.T., Snyder A.G., Kolb J.P., Gao X., Locasale J.W., Martinez J., Gale M. Jr., et al. . 2019. The Nucleotide Sensor ZBP1 and Kinase RIPK3 Induce the Enzyme IRG1 to Promote an Antiviral Metabolic State in Neurons. Immunity. 50:64&#x2013;76.e4. 10.1016/j.immuni.2018.11.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2018.11.017</ArticleId><ArticleId IdType="pmc">PMC6342485</ArticleId><ArticleId IdType="pubmed">30635240</ArticleId></ArticleIdList></Reference><Reference><Citation>De Felice, F.G., Tovar-Moll F., Moll J., Munoz D.P., and Ferreira S.T.. 2020. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and the Central Nervous System. Trends Neurosci. 43:355&#x2013;357. 10.1016/j.tins.2020.04.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2020.04.004</ArticleId><ArticleId IdType="pmc">PMC7172664</ArticleId><ArticleId IdType="pubmed">32359765</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcez, P.P., Loiola E.C., Madeiro da Costa R., Higa L.M., Trindade P., Delvecchio R., Nascimento J.M., Brindeiro R., Tanuri A., and Rehen S.K.. 2016. Zika virus impairs growth in human neurospheres and brain organoids. Science. 352:816&#x2013;818. 10.1126/science.aaf6116</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaf6116</ArticleId><ArticleId IdType="pubmed">27064148</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka, M.T., Golenbock D., Latz E., Morgan D., and Brown R.. 2020. Immediate and long-term consequences of COVID-19 infections for the development of neurological disease. Alzheimers Res. Ther. 12:69. 10.1186/s13195-020-00640-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-020-00640-3</ArticleId><ArticleId IdType="pmc">PMC7271826</ArticleId><ArticleId IdType="pubmed">32498691</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann, M., Kleine-Weber H., Schroeder S., Kr&#xfc;ger N., Herrler T., Erichsen S., Schiergens T.S., Herrler G., Wu N.H., Nitsche A., et al. . 2020. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 181:271&#x2013;280.e8. 10.1016/j.cell.2020.02.052</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.052</ArticleId><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosier, H., Farhadian S.F., Morotti R.A., Deshmukh U., Lu-Culligan A., Campbell K.H., Yasumoto Y., Vogels C.B., Casanovas-Massana A., Vijayakumar P., et al. . 2020. SARS-CoV-2 infection of the placenta. J. Clin. Invest. 130:4947&#x2013;4953. 10.1172/JCI139569</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI139569</ArticleId><ArticleId IdType="pmc">PMC7456249</ArticleId><ArticleId IdType="pubmed">32573498</ArticleId></ArticleIdList></Reference><Reference><Citation>Israelow, B., Song E., Mao T., Lu P., Meir A., Liu F., Alfajaro M.M., Wei J., Dong H., Homer R.J., et al. . 2020. Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling. J. Exp. Med. 217:e20201241. 10.1084/jem.20201241</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20201241</ArticleId><ArticleId IdType="pmc">PMC7401025</ArticleId><ArticleId IdType="pubmed">32750141</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacob, F., Pather S.R., Huang W.-K., Zhang F., Wong S.Z.H., Zhou H., Cubitt B., Fan W., Chen C.Z., Xu M., et al. . 2020. Human Pluripotent Stem Cell-Derived Neural Cells and Brain Organoids Reveal SARS-CoV-2 Neurotropism Predominates in Choroid Plexus Epithelium. Cell Stem Cell. 27:937&#x2013;950.e9. 10.1016/j.stem.2020.09.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2020.09.016</ArticleId><ArticleId IdType="pmc">PMC7505550</ArticleId><ArticleId IdType="pubmed">33010822</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanton, S., Boyle M.J., He Z., Santel M., Weigert A., Sanch&#xed;s-Calleja F., Guijarro P., Sidow L., Fleck J.S., Han D., et al. . 2019. Organoid single-cell genomic atlas uncovers human-specific features of brain development. Nature. 574:418&#x2013;422. 10.1038/s41586-019-1654-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1654-9</ArticleId><ArticleId IdType="pubmed">31619793</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirst, C. 2020. Mapping whole brain structure and activity at cellular resolution: iDISCO+ and ClearMap. J. Biomol. Tech. In press. PMC.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancaster, M.A., and Knoblich J.A.. 2014. Generation of cerebral organoids from human pluripotent stem cells. Nat. Protoc. 9:2329&#x2013;2340. 10.1038/nprot.2014.158</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2014.158</ArticleId><ArticleId IdType="pmc">PMC4160653</ArticleId><ArticleId IdType="pubmed">25188634</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancaster, M.A., Renner M., Martin C.A., Wenzel D., Bicknell L.S., Hurles M.E., Homfray T., Penninger J.M., Jackson A.P., and Knoblich J.A.. 2013. Cerebral organoids model human brain development and microcephaly. Nature. 501:373&#x2013;379. 10.1038/nature12517</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature12517</ArticleId><ArticleId IdType="pmc">PMC3817409</ArticleId><ArticleId IdType="pubmed">23995685</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, M.Y., Li L., Zhang Y., and Wang X.S.. 2020. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. Infect. Dis. Poverty. 9:45. 10.1186/s40249-020-00662-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40249-020-00662-x</ArticleId><ArticleId IdType="pmc">PMC7186534</ArticleId><ArticleId IdType="pubmed">32345362</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao, L., Jin H., Wang M., Hu Y., Chen S., He Q., Chang J., Hong C., Zhou Y., Wang D., et al. . 2020. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol. 77:683&#x2013;690. 10.1001/jamaneurol.2020.1127</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.1127</ArticleId><ArticleId IdType="pmc">PMC7149362</ArticleId><ArticleId IdType="pubmed">32275288</ArticleId></ArticleIdList></Reference><Reference><Citation>McCray, P.B. Jr., Pewe L., Wohlford-Lenane C., Hickey M., Manzel L., Shi L., Netland J., Jia H.P., Halabi C., Sigmund C.D., et al. . 2007. Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. J. Virol. 81:813&#x2013;821. 10.1128/JVI.02012-06</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02012-06</ArticleId><ArticleId IdType="pmc">PMC1797474</ArticleId><ArticleId IdType="pubmed">17079315</ArticleId></ArticleIdList></Reference><Reference><Citation>Netland, J., Meyerholz D.K., Moore S., Cassell M., and Perlman S.. 2008. Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2. J. Virol. 82:7264&#x2013;7275. 10.1128/JVI.00737-08</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00737-08</ArticleId><ArticleId IdType="pmc">PMC2493326</ArticleId><ArticleId IdType="pubmed">18495771</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellegrini, L., Bonfio C., Chadwick J., Begum F., Skehel M., and Lancaster M.A.. 2020. Human CNS barrier-forming organoids with cerebrospinal fluid production. Science. 369:eaaz5626. 10.1126/science.aaz5626</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaz5626</ArticleId><ArticleId IdType="pmc">PMC7116154</ArticleId><ArticleId IdType="pubmed">32527923</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira, A. 2020. Long-Term Neurological Threats of COVID-19: A Call to Update the Thinking About the Outcomes of the Coronavirus Pandemic. Front. Neurol. 11:308. 10.3389/fneur.2020.00308</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.00308</ArticleId><ArticleId IdType="pmc">PMC7182030</ArticleId><ArticleId IdType="pubmed">32362868</ArticleId></ArticleIdList></Reference><Reference><Citation>Puelles, V.G., L&#xfc;tgehetmann M., Lindenmeyer M.T., Sperhake J.P., Wong M.N., Allweiss L., Chilla S., Heinemann A., Wanner N., Liu S., et al. . 2020. Multiorgan and Renal Tropism of SARS-CoV-2. N. Engl. J. Med. 383:590&#x2013;592. 10.1056/NEJMc2011400</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2011400</ArticleId><ArticleId IdType="pmc">PMC7240771</ArticleId><ArticleId IdType="pubmed">32402155</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi, F., Qian S., Zhang S., and Zhang Z.. 2020. Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses. Biochem. Biophys. Res. Commun. 526:135&#x2013;140. 10.1016/j.bbrc.2020.03.044</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2020.03.044</ArticleId><ArticleId IdType="pmc">PMC7156119</ArticleId><ArticleId IdType="pubmed">32199615</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian, X., Nguyen H.N., Song M.M., Hadiono C., Ogden S.C., Hammack C., Yao B., Hamersky G.R., Jacob F., Zhong C., et al. . 2016. Brain-Region-Specific Organoids Using Mini-bioreactors for Modeling ZIKV Exposure. Cell. 165:1238&#x2013;1254. 10.1016/j.cell.2016.04.032</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.04.032</ArticleId><ArticleId IdType="pmc">PMC4900885</ArticleId><ArticleId IdType="pubmed">27118425</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramani, A., M&#xfc;ller L., Ostermann P.N., Gabriel E., Abida-Islam P., M&#xfc;ller-Schiffmann A., Mariappan A., Goureau O., Gruell H., Walker A., et al. . 2020. SARS-CoV-2 targets neurons of 3D human brain organoids. EMBO J. 3:e106230. 10.15252/embj.2020106230</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.2020106230</ArticleId><ArticleId IdType="pmc">PMC7560208</ArticleId><ArticleId IdType="pubmed">32876341</ArticleId></ArticleIdList></Reference><Reference><Citation>Renier, N., Adams E.L., Kirst C., Wu Z., Azevedo R., Kohl J., Autry A.E., Kadiri L., Umadevi Venkataraju K., Zhou Y., et al. . 2016. Mapping of Brain Activity by Automated Volume Analysis of Immediate Early Genes. Cell. 165:1789&#x2013;1802. 10.1016/j.cell.2016.05.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.05.007</ArticleId><ArticleId IdType="pmc">PMC4912438</ArticleId><ArticleId IdType="pubmed">27238021</ArticleId></ArticleIdList></Reference><Reference><Citation>Renier, N., Wu Z., Simon D.J., Yang J., Ariel P., and Tessier-Lavigne M.. 2014. iDISCO: a simple, rapid method to immunolabel large tissue samples for volume imaging. Cell. 159:896&#x2013;910. 10.1016/j.cell.2014.10.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2014.10.010</ArticleId><ArticleId IdType="pubmed">25417164</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts, A., Deming D., Paddock C.D., Cheng A., Yount B., Vogel L., Herman B.D., Sheahan T., Heise M., Genrich G.L., et al. . 2007. A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice. PLoS Pathog. 3:e5. 10.1371/journal.ppat.0030005</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.0030005</ArticleId><ArticleId IdType="pmc">PMC1769406</ArticleId><ArticleId IdType="pubmed">17222058</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon, I.H., Normandin E., Bhattacharyya S., Mukerji S.S., Keller K., Ali A.S., Adams G., Hornick J.L., Padera R.F. Jr., and Sabeti P.. 2020. Neuropathological Features of Covid-19. N. Engl. J. Med. 383:989&#x2013;992. 10.1056/NEJMc2019373</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2019373</ArticleId><ArticleId IdType="pmc">PMC7304421</ArticleId><ArticleId IdType="pubmed">32530583</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun, S.H., Chen Q., Gu H.J., Yang G., Wang Y.X., Huang X.Y., Liu S.S., Zhang N.N., Li X.F., Xiong R., et al. . 2020. A Mouse Model of SARS-CoV-2 Infection and Pathogenesis. Cell Host Microbe. 28:124&#x2013;133.e4. 10.1016/j.chom.2020.05.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.05.020</ArticleId><ArticleId IdType="pmc">PMC7250783</ArticleId><ArticleId IdType="pubmed">32485164</ArticleId></ArticleIdList></Reference><Reference><Citation>Sungnak, W., Huang N., B&#xe9;cavin C., Berg M., Queen R., Litvinukova M., Talavera-L&#xf3;pez C., Maatz H., Reichart D., Sampaziotis F., et al. . HCA Lung Biological Network . 2020. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat. Med. 26:681&#x2013;687. 10.1038/s41591-020-0868-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0868-6</ArticleId><ArticleId IdType="pmc">PMC8637938</ArticleId><ArticleId IdType="pubmed">32327758</ArticleId></ArticleIdList></Reference><Reference><Citation>Velasco, S., Kedaigle A.J., Simmons S.K., Nash A., Rocha M., Quadrato G., Paulsen B., Nguyen L., Adiconis X., Regev A., et al. . 2019. Individual brain organoids reproducibly form cell diversity of the human cerebral cortex. Nature. 570:523&#x2013;527. 10.1038/s41586-019-1289-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1289-x</ArticleId><ArticleId IdType="pmc">PMC6906116</ArticleId><ArticleId IdType="pubmed">31168097</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe, M., Buth J.E., Vishlaghi N., de la Torre-Ubieta L., Taxidis J., Khakh B.S., Coppola G., Pearson C.A., Yamauchi K., Gong D., et al. . 2017. Self-Organized Cerebral Organoids with Human-Specific Features Predict Effective Drugs to Combat Zika Virus Infection. Cell Rep. 21:517&#x2013;532. 10.1016/j.celrep.2017.09.047</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2017.09.047</ArticleId><ArticleId IdType="pmc">PMC5637483</ArticleId><ArticleId IdType="pubmed">29020636</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia, H., and Lazartigues E.. 2008. Angiotensin-converting enzyme 2 in the brain: properties and future directions. J. Neurochem. 107:1482&#x2013;1494. 10.1111/j.1471-4159.2008.05723.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2008.05723.x</ArticleId><ArticleId IdType="pmc">PMC2667944</ArticleId><ArticleId IdType="pubmed">19014390</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu, Y.P., Qiu Y., Zhang B., Chen G., Chen Q., Wang M., Mo F., Xu J., Wu J., Zhang R.R., et al. . 2019. Zika virus infection induces RNAi-mediated antiviral immunity in human neural progenitors and brain organoids. Cell Res. 29:265&#x2013;273. 10.1038/s41422-019-0152-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-019-0152-9</ArticleId><ArticleId IdType="pmc">PMC6461993</ArticleId><ArticleId IdType="pubmed">30814679</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang, L., Han Y., Nilsson-Payant B.E., Gupta V., Wang P., Duan X., Tang X., Zhu J., Zhao Z., Jaffre F., et al. . 2020. A Human Pluripotent Stem Cell-based Platform to Study SARS-CoV-2 Tropism and Model Virus Infection in Human Cells and Organoids. Cell Stem Cell. 27:125&#x2013;136. 10.1016/j.stem.2020.06.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2020.06.015</ArticleId><ArticleId IdType="pmc">PMC7303620</ArticleId><ArticleId IdType="pubmed">32579880</ArticleId></ArticleIdList></Reference><Reference><Citation>Yordy, B., Iijima N., Huttner A., Leib D., and Iwasaki A.. 2012. A neuron-specific role for autophagy in antiviral defense against herpes simplex virus. Cell Host Microbe. 12:334&#x2013;345. 10.1016/j.chom.2012.07.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2012.07.013</ArticleId><ArticleId IdType="pmc">PMC3454454</ArticleId><ArticleId IdType="pubmed">22980330</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, P., Li J., Liu H., Han N., Ju J., Kou Y., Chen L., Jiang M., Pan F., Zheng Y., et al. . 2020. Long-term bone and lung consequences associated with hospital-acquired severe acute respiratory syndrome: a 15-year follow-up from a prospective cohort study. Bone Res. 8:8. 10.1038/s41413-020-0084-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41413-020-0084-5</ArticleId><ArticleId IdType="pmc">PMC7018717</ArticleId><ArticleId IdType="pubmed">32128276</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33523961</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>01</Month><Day>12</Day></DateRevised><Article PubModel="Electronic-Print"><Journal><ISSN IssnType="Electronic">2375-2548</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Science advances</Title><ISOAbbreviation>Sci Adv</ISOAbbreviation></Journal><ArticleTitle>Molecular subtyping of Alzheimer's disease using RNA sequencing data reveals novel mechanisms and targets.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">eabb5398</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/sciadv.abb5398</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD), the most common form of dementia, is recognized as a heterogeneous disease with diverse pathophysiologic mechanisms. In this study, we interrogate the molecular heterogeneity of AD by analyzing 1543 transcriptomes across five brain regions in two AD cohorts using an integrative network approach. We identify three major molecular subtypes of AD corresponding to different combinations of multiple dysregulated pathways, such as susceptibility to tau-mediated neurodegeneration, amyloid-&#x3b2; neuroinflammation, synaptic signaling, immune activity, mitochondria organization, and myelination. Multiscale network analysis reveals subtype-specific drivers such as <i>GABRB2</i>, <i>LRP10</i>, <i>MSN</i>, <i>PLP1</i>, and <i>ATP6V1A</i> We further demonstrate that variations between existing AD mouse models recapitulate a certain degree of subtype heterogeneity, which may partially explain why a vast majority of drugs that succeeded in specific mouse models do not align with generalized human trials across all AD subtypes. Therefore, subtyping patients with AD is a critical step toward precision medicine for this devastating disease.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Neff</LastName><ForeName>Ryan A</ForeName><Initials>RA</Initials><Identifier Source="ORCID">0000-0003-1870-7031</Identifier><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mount Sinai Center for Transformative Disease Modeling, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Scientist Training Program, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Minghui</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9171-4962</Identifier><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mount Sinai Center for Transformative Disease Modeling, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vatansever</LastName><ForeName>Sezen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mount Sinai Center for Transformative Disease Modeling, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Lei</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-6072-2377</Identifier><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mount Sinai Center for Transformative Disease Modeling, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ming</LastName><ForeName>Chen</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-3295-301X</Identifier><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mount Sinai Center for Transformative Disease Modeling, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mount Sinai Center for Transformative Disease Modeling, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Erming</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mount Sinai Center for Transformative Disease Modeling, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horgusluoglu-Moloch</LastName><ForeName>Emrin</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mount Sinai Center for Transformative Disease Modeling, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Won-Min</ForeName><Initials>WM</Initials><Identifier Source="ORCID">0000-0003-0948-119X</Identifier><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mount Sinai Center for Transformative Disease Modeling, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Aiqun</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1485-5352</Identifier><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nash Family Department of Neuroscience, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, New York, NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, New York, NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castranio</LastName><ForeName>Emilie L</ForeName><Initials>EL</Initials><Identifier Source="ORCID">0000-0001-6817-7388</Identifier><AffiliationInfo><Affiliation>Alzheimer's Disease Research Center, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tcw</LastName><ForeName>Julia</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-3054-9374</Identifier><AffiliationInfo><Affiliation>Nash Family Department of Neuroscience, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, New York, NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ronald M. Loeb Center for Alzheimer's Disease, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>Lap</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-1895-2398</Identifier><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mount Sinai Center for Transformative Disease Modeling, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-0576-2472</Identifier><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nash Family Department of Neuroscience, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, New York, NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, New York, NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ronald M. Loeb Center for Alzheimer's Disease, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Icahn School of Medicine at Mount Sinai, New York NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alzheimer's Disease Research Center, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fossati</LastName><ForeName>Valentina</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0003-1825-9371</Identifier><AffiliationInfo><Affiliation>New York Stem Cell Foundation Research Institute, New York, NY 10019, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Noggle</LastName><ForeName>Scott</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-0374-2240</Identifier><AffiliationInfo><Affiliation>New York Stem Cell Foundation Research Institute, New York, NY 10019, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gandy</LastName><ForeName>Sam</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, New York, NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Icahn School of Medicine at Mount Sinai, New York NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alzheimer's Disease Research Center, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ehrlich</LastName><ForeName>Michelle E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Department of Neurology, Icahn School of Medicine at Mount Sinai, New York NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katsel</LastName><ForeName>Pavel</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-8076-0162</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, New York, NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Psychiatry, JJ Peters VA Medical Center, 130 West Kingsbridge Road, Bronx, NY 10468, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schadt</LastName><ForeName>Eric</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-7892-8808</Identifier><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Dongming</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-0601-6826</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Icahn School of Medicine at Mount Sinai, New York NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology, JJ Peters VA Medical Center, 130 West Kingsbridge Road, Bronx, NY 10468, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brennand</LastName><ForeName>Kristen J</ForeName><Initials>KJ</Initials><Identifier Source="ORCID">0000-0003-0993-5956</Identifier><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nash Family Department of Neuroscience, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, New York, NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haroutunian</LastName><ForeName>Vahram</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0001-5860-2512</Identifier><AffiliationInfo><Affiliation>Nash Family Department of Neuroscience, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, New York, NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, New York, NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alzheimer's Disease Research Center, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mental Illness Research, Education and Clinical Centers, JJ Peters VA Medical Center, 130 West Kingsbridge Road, Bronx, NY 10468, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Psychiatry, JJ Peters VA Medical Center, 130 West Kingsbridge Road, Bronx, NY 10468, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Bin</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-9549-5653</Identifier><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA. bin.zhang@mssm.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mount Sinai Center for Transformative Disease Modeling, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 AG046152</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG072562</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG057440</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG054014</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG062683</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG059319</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG068030</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG044546</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007280</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG058635</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG048923</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066514</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG052411</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG032984</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG030146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG046170</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG057907</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>I01 BX003380</GrantID><Acronym>BX</Acronym><Agency>BLRD VA</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG058501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>I01 RX002290</GrantID><Acronym>RX</Acronym><Agency>RRD VA</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AG058655</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG062355</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG036836</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>01</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Adv</MedlineTA><NlmUniqueID>101653440</NlmUniqueID><ISSNLinking>2375-2548</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>63231-63-0</RegistryNumber><NameOfSubstance UI="D012313">RNA</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012313" MajorTopicYN="N">RNA</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017423" MajorTopicYN="N">Sequence Analysis, RNA</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>3</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>11</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>2</Month><Day>1</Day><Hour>17</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>1</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33523961</ArticleId><ArticleId IdType="pmc">PMC7787497</ArticleId><ArticleId IdType="doi">10.1126/sciadv.abb5398</ArticleId><ArticleId IdType="pii">7/2/eabb5398</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alzheimer&#x2019;s Association, 2019 Alzheimer&#x2019;s Disease Facts and Figures (2019); https://alz.org/media/Documents/alzheimers-facts-and-figures-2019-r.pdf.</Citation></Reference><Reference><Citation>Fiandaca M. S., Mapstone M. E., Cheema A. K., Federoff H. J., The critical need for defining preclinical biomarkers in Alzheimer&#x2019;s disease. Alzheimers Dement. 10, S196&#x2013;S212 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24924671</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B., Karran E., The cellular phase of Alzheimer&#x2019;s disease. Cell 164, 603&#x2013;615 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26871627</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekiya M., Wang M., Fujisaki N., Sakakibara Y., Quan X., Ehrlich M. E., De Jager P. L., Bennett D. A., Schadt E. E., Gandy S., Ando K., Zhang B., Iijima K. M., Integrated biology approach reveals molecular and pathological interactions among Alzheimer&#x2019;s A&#x3b2;42, Tau, TREM2, and TYROBP in Drosophila models. Genome Med. 10, 26 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5875009</ArticleId><ArticleId IdType="pubmed">29598827</ArticleId></ArticleIdList></Reference><Reference><Citation>Iacono D., Resnick S. M., O&#x2019;Brien R., Zonderman A. B., An Y., Pletnikova O., Rudow G., Crain B., Troncoso J. C., Mild cognitive impairment and asymptomatic alzheimer disease subjects: Equivalent &#x3b2;-amyloid and tau loads with divergent cognitive outcomes. J. Neuropathol. Exp. Neurol. 73, 295&#x2013;304 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4062187</ArticleId><ArticleId IdType="pubmed">24607960</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert J. C., Ibrahim-Verbaas C. A., Harold D., Naj A. C., Sims R., Bellenguez C., Jun G., DeStefano A. L., Bis J. C., Beecham G. W., Grenier-Boley B., Russo G., Thornton-Wells T. A., Jones N., Smith A. V., Chouraki V., Thomas C., Ikram M. A., Zelenika D., Vardarajan B. N., Kamatani Y., Lin C. F., Gerrish A., Schmidt H., Kunkle B., Fi&#xe9;vet N., Amouyel P., Pasquier F., Deramecourt V., De Bruijn R. F. A. G., Amin N., Hofman A., Van Duijn C. M., Dunstan M. L., Hollingworth P., Owen M. J., O&#x2019;Donovan M. C., Jones L., Holmans P. A., Moskvina V., Williams J., Baldwin C., Farrer L. A., Choi S. H., Lunetta K. L., Fitzpatrick A. L., Harris T. B., Psaty B. M., Gilbert J. R., Hamilton-Nelson K. L., Martin E. R., Pericak-Vance M. A., Haines J. L., Gudnason V., Jonsson P. V., Eiriksdottir G., Bihoreau M. T., Lathrop M., Valladares O., Cantwell L. B., Wang L. S., Schellenberg G. D., Ruiz A., Boada M., Reitz C., Mayeux R., Ramirez A., Maier W., Hanon O., Kukull W. A., Buxbaum J. D., Campion D., Wallon D., Hannequin D., Crane P. K., Larson E. B., Becker T., Cruchaga C., Goate A. M., Craig D., Johnston J. A., Mc-Guinness B., Todd S., Passmore P., Berr C., Ritchie K., Lopez O. L., De Jager P. L., Evans D., Lovestone S., Proitsi P., Powell J. F., Letenneur L., Barberger-Gateau P., Dufouil C., Dartigues J. F., Mor&#xf3;n F. J., Rubinsztein D. C., St. George-Hyslop P., Sleegers K., Bettens K., Van Broeckhoven C., Huentelman M. J., Gill M., Brown K., Morgan K., Kamboh M. I., Keller L., Fratiglioni L., Green R., Myers A. J., Love S., Rogaeva E., Gallacher J., Bayer A., Clarimon J., Lleo A., Tsuang D. W., Yu L., Bennett D. A., Tsolaki M., Boss&#xf9; P., Spalletta G., Collinge J., Mead S., Sorbi S., Nacmias B., Sanchez-Garcia F., Naranjo M. C. D., Fox N. C., Hardy J., Bosco P., Clarke R., Brayne C., Galimberti D., Mancuso M., Matthews F., Moebus S., Mecocci P., Del Zompo M., Hampel H., Pilotto A., Bullido M., Panza F., Caffarra P., Mayhaus M., Pichler S., Gu W., Riemenschneider M., Lannfelt L., Ingelsson M., Hakonarson H., Carrasquillo M. M., Zou F., Younkin S. G., Beekly D., Alvarez V., Coto E., Razquin C., Pastor P., Mateo I., Combarros O., Faber K. M., Foroud T. M., Soininen H., Hiltunen M., Blacker D., Mosley T. H., Graff C., Holmes C., Montine T. J., Rotter J. I., Brice A., Nalls M. A., Kauwe J. S. K., Boerwinkle E., Schmidt R., Rujescu D., Tzourio C., N&#xf6;then M. M., Launer L. J., Seshadri S., Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer&#x2019;s disease. Nat. Genet. 45, 1452&#x2013;1458 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Risacher S. L., Anderson W. H., Charil A., Castelluccio P. F., Shcherbinin S., Saykin A. J., Schwarz A. J.; Alzheimer&#x2019;s Disease Neuroimaging Initiative , Alzheimer disease brain atrophy subtypes are associated with cognition and rate of decline. Neurology 89, 2176&#x2013;2186 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5696639</ArticleId><ArticleId IdType="pubmed">29070667</ArticleId></ArticleIdList></Reference><Reference><Citation>Bredesen D. E., Metabolic profiling distinguishes three subtypes of Alzheimer&#x2019;s disease. Aging 7, 595&#x2013;600 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4586104</ArticleId><ArticleId IdType="pubmed">26343025</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips J. S., Da Re F., Dratch L., Xie S. X., Irwin D. J., McMillan C. T., Vaishnavi S. N., Ferrarese C., Lee E. B., Shaw L. M., Trojanowski J. Q., Wolk D. A., Grossman M., Neocortical origin and progression of gray matter atrophy in nonamnestic Alzheimer&#x2019;s disease. Neurobiol. Aging 63, 75&#x2013;87 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5801003</ArticleId><ArticleId IdType="pubmed">29223682</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian W., Fischer C. E., Schweizer T. A., Munoz D. G., Association between psychosis phenotype and APOE genotype on the clinical profiles of Alzheimer&#x2019;s disease. Curr. Alzheimer Res. 15, 187&#x2013;194 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6211852</ArticleId><ArticleId IdType="pubmed">28847281</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee Y.-M., Chung Y.-I., Park J.-M., Lee B.-D., Moon E., Jeong H.-J., Kim J.-H., Kim H.-J., Mun C.-W., Kim T.-H., Kim Y.-H., Kim E.-J., Decreased gray matter volume is associated with the subtypes of psychotic symptoms in patients with antipsychotic-na&#xef;ve mild or moderate Alzheimer&#x2019;s disease: A voxel-based morphometry study. Psychiatry Res. Neuroimaging 249, 45&#x2013;51 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27000306</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapp M. A., Schnaider-Beeri M., Purohit D. P., Perl D. P., Haroutunian V., Sano M., Increased neurofibrillary tangles in patients with Alzheimer disease with comorbid depression. Am. J. Geriatr. Psychiatry 16, 168&#x2013;174 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18239198</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y., Mucke L., Alzheimer mechanisms and therapeutic strategies. Cell 148, 1204&#x2013;1222 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3319071</ArticleId><ArticleId IdType="pubmed">22424230</ArticleId></ArticleIdList></Reference><Reference><Citation>Crary J. F., Trojanowski J. Q., Schneider J. A., Abisambra J. F., Abner E. L., Alafuzoff I., Arnold S. E., Attems J., Beach T. G., Bigio E. H., Cairns N. J., Dickson D. W., Gearing M., Grinberg L. T., Hof P. R., Hyman B. T., Jellinger K., Jicha G. A., Kovacs G. G., Knopman D. S., Kofler J., Kukull W. A., Mackenzie I. R., Masliah E., McKee A., Montine T. J., Murray M. E., Neltner J. H., Santa-Maria I., Seeley W. W., Serrano-Pozo A., Shelanski M. L., Stein T., Takao M., Thal D. R., Toledo J. B., Troncoso J. C., Vonsattel J. P., White C. L. III, Wisniewski T., Woltjer R. L., Yamada M., Nelson P. T., Primary age-related tauopathy (PART): A common pathology associated with human aging. Acta Neuropathol. 128, 755&#x2013;766 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4257842</ArticleId><ArticleId IdType="pubmed">25348064</ArticleId></ArticleIdList></Reference><Reference><Citation>Chornenkyy Y., Wang W.-X., Wei A., Nelson P. T., Alzheimer&#x2019;s disease and type 2 diabetes mellitus are distinct diseases with potential overlapping metabolic dysfunction upstream of observed cognitive decline. Brain Pathol. 29, 3&#x2013;17 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6427919</ArticleId><ArticleId IdType="pubmed">30106209</ArticleId></ArticleIdList></Reference><Reference><Citation>Bang J., Spina S., Miller B. L., Frontotemporal dementia. Lancet 386, 1672&#x2013;1682 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5970949</ArticleId><ArticleId IdType="pubmed">26595641</ArticleId></ArticleIdList></Reference><Reference><Citation>Blalock E. M., Geddes J. W., Chen K. C., Porter N. M., Markesbery W. R., Landfield P. W., Incipient Alzheimer&#x2019;s disease: Microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc. Natl. Acad. Sci. U.S.A. 101, 2173&#x2013;2178 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC357071</ArticleId><ArticleId IdType="pubmed">14769913</ArticleId></ArticleIdList></Reference><Reference><Citation>Courtney E., Kornfeld S., Janitz K., Janitz M., Transcriptome profiling in neurodegenerative disease. J. Neurosci. Methods 193, 189&#x2013;202 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20800617</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M., Li A., Sekiya M., Beckmann N. D., Quan X., Schrode N., Fernando M. B., Yu A., Zhu L., Cao J., Lyu L., Horgusluoglu E., Wang Q., Guo L., Wang Y., Neff R., Song W.-m., Wang E., Shen Q., Zhou X., Ming C., Ho S.-M., Vatansever S., Kaniskan H. U., Jin J., Zhou M.-M., Ando K., Ho L., Slesinger P. A., Yue Z., Zhu J., Gandy S., Ehrlich M. E., Cai D., Haroutunian V., Iijima K. M., Schadt E., Brennand K. J., Zhang B., Molecular networks and key regulators of the dysregulated neuronal system in Alzheimer&#x2019;s disease. bioRxiv 788323 (2019).</Citation></Reference><Reference><Citation>Twine N. A., Janitz K., Wilkins M. R., Janitz M., Whole transcriptome sequencing reveals gene expression and splicing differences in brain regions affected by Alzheimer&#x2019;s disease. PLOS ONE 6, e16266 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3025006</ArticleId><ArticleId IdType="pubmed">21283692</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M., Beckmann N. D., Roussos P., Wang E., Zhou X., Wang Q., Ming C., Neff R., Ma W., Fullard J. F., Hauberg M. E., Bendl J., Peters M. A., Logsdon B., Wang P., Mahajan M., Mangravite L. M., Dammer E. B., Duong D. M., Lah J. J., Seyfried N. T., Levey A. I., Buxbaum J. D., Ehrlich M., Gandy S., Katsel P., Haroutunian V., Schadt E., Zhang B., The Mount Sinai cohort of large-scale genomic, transcriptomic and proteomic data in Alzheimer&#x2019;s disease. Sci. Data 5, 180185 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6132187</ArticleId><ArticleId IdType="pubmed">30204156</ArticleId></ArticleIdList></Reference><Reference><Citation>De Jager P. L., Ma Y., McCabe C., Xu J., Vardarajan B. N., Felsky D., Klein H.-U., White C. C., Peters M. A., Lodgson B., Nejad P., Tang A., Mangravite L. M., Yu L., Gaiteri C., Mostafavi S., Schneider J. A., Bennett D. A., A multi-omic atlas of the human frontal cortex for aging and Alzheimer&#x2019;s disease research. Sci. Data 5, 180142 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6080491</ArticleId><ArticleId IdType="pubmed">30084846</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett D. A., Buchman A. S., Boyle P. A., Barnes L. L., Wilson R. S., Schneider J. A., Religious orders study and rush memory and aging project. J. Alzheimers Dis. 64, S161&#x2013;S189 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6380522</ArticleId><ArticleId IdType="pubmed">29865057</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M., Roussos P., McKenzie A., Zhou X., Kajiwara Y., Brennand K. J., De Luca G. C., Crary J. F., Casaccia P., Buxbaum J. D., Ehrlich M., Gandy S., Goate A., Katsel P., Schadt E., Haroutunian V., Zhang B., Integrative network analysis of nineteen brain regions identifies molecular signatures and networks underlying selective regional vulnerability to Alzheimer&#x2019;s disease. Genome Med. 8, 104 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5088659</ArticleId><ArticleId IdType="pubmed">27799057</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogata H., Goto S., Sato K., Fujibuchi W., Bono H., Kanehisa M., KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 27, 29&#x2013;34 (1999).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC148090</ArticleId><ArticleId IdType="pubmed">9847135</ArticleId></ArticleIdList></Reference><Reference><Citation>McKenzie A. T., Wang M., Hauberg M. E., Fullard J. F., Kozlenkov A., Keenan A., Hurd Y. L., Dracheva S., Casaccia P., Roussos P., Zhang B., Brain cell type specific gene expression and co-expression network architectures. Sci. Rep. 8, 8868 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5995803</ArticleId><ArticleId IdType="pubmed">29892006</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B., Gaiteri C., Bodea L.-G., Wang Z., McElwee J., Podtelezhnikov A. A., Zhang C., Xie T., Tran L., Dobrin R., Fluder E., Clurman B., Melquist S., Narayanan M., Suver C., Shah H., Mahajan M., Gillis T., Mysore J., MacDonald M. E., Lamb J. R., Bennett D. A., Molony C., Stone D. J., Gudnason V., Myers A. J., Schadt E. E., Neumann H., Zhu J., Emilsson V., Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer&#x2019;s disease. Cell 153, 707&#x2013;720 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677161</ArticleId><ArticleId IdType="pubmed">23622250</ArticleId></ArticleIdList></Reference><Reference><Citation>Blalock E. M., Buechel H. M., Popovic J., Geddes J. W., Landfield P. W., Microarray analyses of laser-captured hippocampus reveal distinct gray and white matter signatures associated with incipient Alzheimer&#x2019;s disease. J. Chem. Neuroanat. 42, 118&#x2013;126 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3163806</ArticleId><ArticleId IdType="pubmed">21756998</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweeney M. D., Sagare A. P., Zlokovic B. V., Blood&#x2013;brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat. Rev. Neurol. 14, 133&#x2013;150 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5829048</ArticleId><ArticleId IdType="pubmed">29377008</ArticleId></ArticleIdList></Reference><Reference><Citation>Song W. M., Zhang B., Multiscale embedded gene co-expression network analysis. PLOS Comput. Biol. 11, e1004574 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4664553</ArticleId><ArticleId IdType="pubmed">26618778</ArticleId></ArticleIdList></Reference><Reference><Citation>M. Scutari, Journal of Statistical Software Learning Bayesian Networks with the bnlearn R Package (1996); www.jstatsoft.org/.</Citation></Reference><Reference><Citation>Wang Q., Zhang Y., Wang M., Song W.-M., Shen Q., McKenzie A., Choi I., Zhou X., Pan P.-Y., Yue Z., Zhang B., The landscape of multiscale transcriptomic networks and key regulators in Parkinson&#x2019;s disease. Nat. Commun. 10, 5234 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6868244</ArticleId><ArticleId IdType="pubmed">31748532</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunkle B. W., Grenier-Boley B., Sims R., Bis J. C., Damotte V., Naj A. C., Boland A., Vronskaya M., van der Lee S. J., Amlie-Wolf A., Bellenguez C., Frizatti A., Chouraki V., Martin E. R., Sleegers K., Badarinarayan N., Jakobsdottir J., Hamilton-Nelson K. L., Moreno-Grau S., Olaso R., Raybould R., Chen Y., Kuzma A. B., Hiltunen M., Morgan T., Ahmad S., Vardarajan B. N., Epelbaum J., Hoffmann P., Boada M., Beecham G. W., Garnier J. G., Harold D., Fitzpatrick A. L., Valladares O., Moutet M.-L., Gerrish A., Smith A. V., Qu L., Bacq D., Denning N., Jian X., Zhao Y., Del Zompo M., Fox N. C., Choi S.-H., Mateo I., Hughes J. T., Adams H. H., Malamon J., Sanchez-Garcia F., Patel Y., Brody J. A., Dombroski B. A., Naranjo M. C. D., Daniilidou M., Eiriksdottir G., Mukherjee S., Wallon D., Uphill J., Aspelund T., Cantwell L. B., Garzia F., Galimberti D., Hofer E., Butkiewicz M., Fin B., Scarpini E., Sarnowski C., Bush W. S., Meslage S., Kornhuber J., White C. C., Song Y., Barber R. C., Engelborghs S., Sordon S., Voijnovic D., Adams P. M., Vandenberghe R., Mayhaus M., Cupples L. A., Albert M. S., De Deyn P. P., Gu W., Himali J. J., Beekly D., Squassina A., Hartmann A. M., Orellana A., Blacker D., Rodriguez-Rodriguez E., Lovestone S., Garcia M. E., Doody R. S., Munoz-Fernadez C., Sussams R., Lin H., Fairchild T. J., Benito Y. A., Holmes C., Karamuji&#x107;-&#x10c;omi&#x107; H., Frosch M. P., Thonberg H., Maier W., Roschupkin G., Ghetti B., Giedraitis V., Kawalia A., Li S., Huebinger R. M., Kilander L., Moebus S., Hern&#xe1;ndez I., Kamboh M. I., Brundin R. M., Turton J., Yang Q., Katz M. J., Concari L., Lord J., Beiser A. S., Keene C. D., Helisalmi S., Kloszewska I., Kukull W. A., Koivisto A. M., Lynch A., Tarraga L., Larson E. B., Haapasalo A., Lawlor B., Mosley T. H., Lipton R. B., Solfrizzi V., Gill M., Longstreth W. T., Montine T. J., Frisardi V., Diez-Fairen M., Rivadeneira F., Petersen R. C., Deramecourt V., Alvarez I., Salani F., Ciaramella A., Boerwinkle E., Reiman E. M., Fievet N., Rotter J. I., Reisch J. S., Hanon O., Cupidi C., Uitterlinden A. G. A., Royall D. R., Dufouil C., Maletta R. G., de Rojas I., Sano M., Brice A., Cecchetti R., George-Hyslop P. S., Ritchie K., Tsolaki M., Tsuang D. W., Dubois B., Craig D., Wu C. K., Soininen H., Avramidou D., Albin R. L., Fratiglioni L., Germanou A., Apostolova L. G., Keller L., Koutroumani M., Arnold S. E., Panza F., Gkatzima O., Asthana S., Hannequin D., Whitehead P., Atwood C. S., Caffarra P., Hampel H., Quintela I., Carracedo &#xc1;., Lannfelt L., Rubinsztein D. C., Barnes L. L., Pasquier F., Fr&#xf6;lich L., Barral S., McGuinness B., Beach T. G., Johnston J. A., Becker J. T., Passmore P., Bigio E. H., Schott J. M., Bird T. D., Warren J. D., Boeve B. F., Lupton M. K., Bowen J. D., Proitsi P., Boxer A., Powell J. F., Burke J. R., Kauwe J. S. K., Burns J. M., Mancuso M., Buxbaum J. D., Bonuccelli U., Cairns N. J., McQuillin A., Cao C., Livingston G., Carlson C. S., Bass N. J., Carlsson C. M., Hardy J., Carney R. M., Bras J., Carrasquillo M. M., Guerreiro R., Allen M., Chui H. C., Fisher E., Masullo C., Crocco E. A., DeCarli C., Bisceglio G., Dick M., Ma L., Duara R., Graff-Radford N. R., Evans D. A., Hodges A., Faber K. M., Scherer M., Fallon K. B., Riemenschneider M., Fardo D. W., Heun R., Farlow M. R., K&#xf6;lsch H., Ferris S., Leber M., Foroud T. M., Heuser I., Galasko D. R., Giegling I., Gearing M., H&#xfc;ll M., Geschwind D. H., Gilbert J. R., Morris J., Green R. C., Mayo K., Growdon J. H., Feulner T., Hamilton R. L., Harrell L. E., Drichel D., Honig L. S., Cushion T. D., Huentelman M. J., Hollingworth P., Hulette C. M., Hyman B. T., Marshall R., Jarvik G. P., Meggy A., Abner E., Menzies G. E., Jin L.-W., Leonenko G., Real L. M., Jun G. R., Baldwin C. T., Grozeva D., Karydas A., Russo G., Kaye J. A., Kim R., Jessen F., Kowall N. W., Vellas B., Kramer J. H., Vardy E., LaFerla F. M., J&#xf6;ckel K.-H., Lah J. J., Dichgans M., Leverenz J. B., Mann D., Levey A. I., Pickering-Brown S., Lieberman A. P., Klopp N., Lunetta K. L., Wichmann H. E., Lyketsos C. G., Morgan K., Marson D. C., Brown K., Martiniuk F., Medway C., Mash D. C., N&#xf6;then M. M., Masliah E., Hooper N. M., McCormick W. C., Daniele A., McCurry S. M., Bayer A., McDavid A. N., Gallacher J., McKee A. C., van den Bussche H., Mesulam M., Brayne C., Miller B. L., Riedel-Heller S., Miller C. A., Miller J. W., Al-Chalabi A., Morris J. C., Shaw C. E., Myers A. J., Wiltfang J., O&#x2019;Bryant S., Olichney J. M., Alvarez V., Parisi J. E., Singleton A. B., Paulson H. L., Collinge J., Perry W. R., Mead S., Peskind E., Cribbs D. H., Rossor M., Pierce A., Ryan N. S., Poon W. W., Nacmias B., Potter H., Sorbi S., Quinn J. F., Sacchinelli E., Raj A., Spalletta G., Raskind M., Caltagirone C., Boss&#xf9; P., Orfei M. D., Reisberg B., Clarke R., Reitz C., Smith A. D., Ringman J. M., Warden D., Roberson E. D., Wilcock G., Rogaeva E., Bruni A. C., Rosen H. J., Gallo M., Rosenberg R. N., Ben-Shlomo Y., Sager M. A., Mecocci P., Saykin A. J., Pastor P., Cuccaro M. L., Vance J. M., Schneider J. A., Schneider L. S., Slifer S., Seeley W. W., Smith A. G., Sonnen J. A., Spina S., Stern R. A., Swerdlow R. H., Tang M., Tanzi R. E., Trojanowski J. Q., Troncoso J. C., Van Deerlin V. M., Van Eldik L. J., Vinters H. V., Vonsattel J. P., Weintraub S., Welsh-Bohmer K. A., Wilhelmsen K. C., Williamson J., Wingo T. S., Woltjer R. L., Wright C. B., Yu C. E., Yu L., Saba Y., Pilotto A., Bullido M. J., Peters O., Crane P. K., Bennett D., Bosco P., Coto E., Boccardi V., De Jager P. L., Lleo A., Warner N., Lopez O. L., Ingelsson M., Deloukas P., Cruchaga C., Graff C., Gwilliam R., Fornage M., Goate A. M., Sanchez-Juan P., Kehoe P. G., Amin N., Ertekin-Taner N., Berr C., Debette S., Love S., Launer L. J., Younkin S. G., Dartigues J. F., Corcoran C., Ikram M. A., Dickson D. W., Nicolas G., Campion D., Tschanz J. A., Schmidt H., Hakonarson H., Clarimon J., Munger R., Schmidt R., Farrer L. A., Van Broeckhoven C., O&#x2019;Donovan M. C., DeStefano A. L., Jones L., Haines J. L., Deleuze J. F., Owen M. J., Gudnason V., Mayeux R., Escott-Price V., Psaty B. M., Ramirez A., Wang L. S., Ruiz A., van Duijn C. M., Holmans P. A., Seshadri S., Williams J., Amouyel P., Schellenberg G. D., Lambert J.-C., Pericak-Vance M. A.; Alzheimer Disease Genetics Consortium (ADGC); European Alzheimer&#x2019;s Disease Initiative (EADI); Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium (CHARGE); Genetic and Environmental Risk in AD/Defining Genetic, Polygenic and Environmental Risk for Alzheimer&#x2019;s Disease Consortium (GERAD/PERADES) , Genetic meta-analysis of diagnosed Alzheimer&#x2019;s disease identifies new risk loci and implicates A&#x3b2;, tau, immunity and lipid processing. Nat. Genet. 51, 414&#x2013;430 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6463297</ArticleId><ArticleId IdType="pubmed">30820047</ArticleId></ArticleIdList></Reference><Reference><Citation>Euesden J., Lewis C. M., O&#x2019;Reilly P. F., PRSice: Polygenic risk score software. Bioinformatics 31, 1466&#x2013;1468 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4410663</ArticleId><ArticleId IdType="pubmed">25550326</ArticleId></ArticleIdList></Reference><Reference><Citation>De Rossi P., Buggia-Pr&#xe9;vot V., Clayton B. L. L., Vasquez J. B., van Sanford C., Andrew R. J., Lesnick R., Bott&#xe9; A., Deyts C., Salem S., Rao E., Rice R. C., Parent A., Kar S., Popko B., Pytel P., Estus S., Thinakaran G., Predominant expression of Alzheimer&#x2019;s disease-associated BIN1 in mature oligodendrocytes and localization to white matter tracts. Mol. Neurodegener. 11, 59 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4973113</ArticleId><ArticleId IdType="pubmed">27488240</ArticleId></ArticleIdList></Reference><Reference><Citation>Calafate S., Flavin W., Verstreken P., Moechars D., Loss of Bin1 promotes the propagation of tau pathology. Cell Rep. 17, 931&#x2013;940 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27760323</ArticleId></ArticleIdList></Reference><Reference><Citation>Werner C., Pauli M., Doose S., Weishaupt A., Haselmann H., Gr&#xfc;newald B., Sauer M., Heckmann M., Toyka K. V., Asan E., Sommer C., Geis C., Human autoantibodies to amphiphysin induce defective presynaptic vesicle dynamics and composition. Brain 139, 365&#x2013;379 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26582558</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett D. A., Schneider J. A., Arvanitakis Z., Wilson R. S., Overview and findings from the religious orders study. Curr. Alzheimer Res. 9, 628&#x2013;645 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3409291</ArticleId><ArticleId IdType="pubmed">22471860</ArticleId></ArticleIdList></Reference><Reference><Citation>Perneczky R., Wagenpfeil S., Komossa K., Grimmer T., Diehl J., Kurz A., Mapping scores onto stages: Mini-mental state examination and clinical dementia rating. Am. J. Geriatr. Psychiatry 14, 139&#x2013;144 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16473978</ArticleId></ArticleIdList></Reference><Reference><Citation>Jax Mouse Model 005642 - B6.Cg-Clutm1Jakh/J (2020); www.jax.org/strain/005642.</Citation></Reference><Reference><Citation>Liu L., Caselli R. J., Age stratification corrects bias in estimated hazard of APOE genotype for Alzheimer&#x2019;s disease. Alzheimer&#x2019;s Dementia 4, 602&#x2013;608 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6226550</ArticleId><ArticleId IdType="pubmed">30450407</ArticleId></ArticleIdList></Reference><Reference><Citation>Norambuena A., Wallrabe H., Cao R., Wang D. B., Silva A., Svindrych Z., Periasamy A., Hu S., Tanzi R. E., Kim D. Y., Bloom G. S., A novel lysosome-to-mitochondria signaling pathway disrupted by amyloid-&#x3b2; oligomers. EMBO J. 37, e100241 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6236329</ArticleId><ArticleId IdType="pubmed">30348864</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan S. S., LaCroix M., Boyle G., Sherman M. A., Brown J. L., Amar F., Aldaco J., Lee M. K., Bloom G. S., Lesn&#xe9; S. E., Bidirectional modulation of Alzheimer phenotype by alpha-synuclein in mice and primary neurons. Acta Neuropathol. 136, 589&#x2013;605 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6329667</ArticleId><ArticleId IdType="pubmed">29995210</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz A., Heilmann S., Becker T., Hern&#xe1;ndez I., Wagner H., Thelen M., Maule&#xf3;n A., Rosende-Roca M., Bellenguez C., Bis J. C., Harold D., Gerrish A., Sims R., Sotolongo-Grau O., Espinosa A., Alegret M., Arrieta J. L., Lacour A., Leber M., Becker J., Lafuente A., Ruiz S., Vargas L., Rodr&#xed;guez O., Ortega G., Dominguez M. A., Mayeux R., Haines J. L., Pericak-Vance M. A., Farrer L. A., Schellenberg G. D., Chouraki V., Launer L. J., Van Duijn C., Seshadri S., Ant&#xfa;nez C., Breteler M. M., Serrano-R&#xed;os M., Jessen F., T&#xe1;rraga L., N&#xf6;then M. M., Maier W., Boada M., Ram&#xed;rez A. L., Follow-up of loci from the International Genomics of Alzheimer&#x2019;s Disease Project identifies TRIP4 as a novel susceptibility gene. Transl. Psychiatry 4, e358 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3944635</ArticleId><ArticleId IdType="pubmed">24495969</ArticleId></ArticleIdList></Reference><Reference><Citation>Karch C. M., Cruchaga C., Goate A. M., Alzheimer&#x2019;s disease genetics: From the bench to the clinic. Neuron 83, 11&#x2013;26 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4120741</ArticleId><ArticleId IdType="pubmed">24991952</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson O., Zetterberg H., Buchhave P., Londos E., Blennow K., Minthon L., Association between CSF biomarkers and incipient Alzheimer&#x2019;s disease in patients with mild cognitive impairment: A follow-up study. Lancet Neurol. 5, 228&#x2013;234 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16488378</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X., Wang M., Katsyv I., Irie H., Zhang B., EMUDRA: Ensemble of multiple drug repositioning approaches to improve prediction accuracy. Bioinformatics 34, 3151&#x2013;3159 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6138000</ArticleId><ArticleId IdType="pubmed">29688306</ArticleId></ArticleIdList></Reference><Reference><Citation>McKenzie A. T., Moyon S., Wang M., Katsyv I., Song W.-M., Zhou X., Dammer E. B., Duong D. M., Aaker J., Zhao Y., Beckmann N., Wang P., Zhu J., Lah J. J., Seyfried N. T., Levey A. I., Katsel P., Haroutunian V., Schadt E. E., Popko B., Casaccia P., Zhang B., Multiscale network modeling of oligodendrocytes reveals molecular components of myelin dysregulation in Alzheimer&#x2019;s disease. Mol. Neurodegener. 12, 82 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5674813</ArticleId><ArticleId IdType="pubmed">29110684</ArticleId></ArticleIdList></Reference><Reference><Citation>B. Zhang, J. Zhu, in Proceedings of the World Congress on Engineering 2013 (International Association of Engineers), vol. 2, pp. 1309&#x2013;1312.</Citation></Reference><Reference><Citation>Millstein J., Zhang B., Zhu J., Schadt E. E., Disentangling molecular relationships with a causal inference test. BMC Genet. 10, 23 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3224661</ArticleId><ArticleId IdType="pubmed">19473544</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu J., Wiener M. C., Zhang C., Fridman A., Minch E., Lum P. Y., Sachs J. R., Schadt E. E., Increasing the power to detect causal associations by combining genotypic and expression data in segregating populations. PLOS Comput. Biol. 3, 692&#x2013;703 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1851982</ArticleId><ArticleId IdType="pubmed">17432931</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Sloan S. A., Clarke L. E., Caneda C., Plaza C. A., Blumenthal P. D., Vogel H., Steinberg G. K., Edwards M. S. B., Li G., Duncan J. A., Cheshier S. H., Shuer L. M., Chang E. F., Grant G. A., Gephart M. G. H., Barres B. A., Purification and characterization of progenitor and mature human astrocytes reveals transcriptional and functional differences with mouse. Neuron 89, 37&#x2013;53 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4707064</ArticleId><ArticleId IdType="pubmed">26687838</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33450230</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>25</Day></DateCompleted><DateRevised><Year>2021</Year><Month>08</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1083-351X</ISSN><JournalIssue CitedMedium="Internet"><Volume>296</Volume><PubDate><Year>2021</Year><Season>Jan-Jun</Season></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Familial Alzheimer's disease mutations in amyloid protein precursor alter proteolysis by &#x3b3;-secretase to increase amyloid &#x3b2;-peptides of &#x2265;45 residues.</ArticleTitle><Pagination><StartPage>100281</StartPage><MedlinePgn>100281</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">100281</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jbc.2021.100281</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0021-9258(21)00049-1</ELocationID><Abstract><AbstractText>Production of amyloid &#x3b2;-protein (A&#x3b2;) is carried out by the membrane-embedded &#x3b3;-secretase complex. Mutations in the transmembrane domain of amyloid &#x3b2;-protein precursor (APP) associated with early-onset familial Alzheimer's disease (FAD) can alter the ratio of aggregation-prone 42-residue A&#x3b2; (A&#x3b2;42) to 40-residue A&#x3b2; (A&#x3b2;40). However, APP substrate is proteolyzed processively by &#x3b3;-secretase along two pathways: A&#x3b2;49&#x2192;A&#x3b2;46&#x2192;A&#x3b2;43&#x2192;A&#x3b2;40 and A&#x3b2;48&#x2192;A&#x3b2;45&#x2192;A&#x3b2;42&#x2192;A&#x3b2;38. Effects of FAD mutations on each proteolytic step are unknown, largely due to difficulties in detecting and quantifying longer A&#x3b2; peptides. To address this, we carried out systematic and quantitative analyses of all tri- and tetrapeptide coproducts from proteolysis of wild-type and 14 FAD-mutant APP substrates by purified &#x3b3;-secretase. These small peptides, including FAD-mutant forms, were detected by tandem mass spectrometry and quantified by establishing concentration curves for each of 32 standards. APP intracellular domain (AICD) coproducts were quantified by immunoblot, and the ratio of AICD products corresponding to A&#x3b2;48 and A&#x3b2;49 was determined by mass spectrometry. Levels of individual A&#x3b2; peptides were determined by subtracting levels of peptide coproducts associated with degradation from those associated with production. This method was validated for A&#x3b2;40 and A&#x3b2;42 by specific ELISAs and production of equimolar levels of A&#x3b2; and AICD. Not all mutant substrates led to increased A&#x3b2;42/40. However, all 14 disease-causing mutations led to inefficient processing of longer forms of A&#x3b2; &#x2265; 45 residues. In addition, the effects of certain mutations provided insight into the mechanism of processive proteolysis: intermediate A&#x3b2; peptides apparently remain bound for subsequent trimming and are not released and reassociated.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Devkota</LastName><ForeName>Sujan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicinal Chemistry, University of Kansas, Lawrence, Kansas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Todd D</ForeName><Initials>TD</Initials><AffiliationInfo><Affiliation>Mass Spectrometry Laboratory, University of Kansas, Lawrence, Kansas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolfe</LastName><ForeName>Michael S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Medicinal Chemistry, University of Kansas, Lawrence, Kansas, USA. Electronic address: mswolfe@ku.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG066986</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM122894</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>01</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016466" MajorTopicYN="N">CHO Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003412" MajorTopicYN="N">Cricetulus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072417" MajorTopicYN="N">Protein Domains</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059748" MajorTopicYN="N">Proteolysis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyloid &#x3b2;-protein (A&#x3b2;)</Keyword><Keyword MajorTopicYN="N">amyloid &#x3b2;-protein precursor (APP)</Keyword><Keyword MajorTopicYN="N">intramembrane proteolysis</Keyword><Keyword MajorTopicYN="N">mass spectrometry</Keyword><Keyword MajorTopicYN="N">pathogenesis</Keyword></KeywordList><CoiStatement>Conflict of interest The authors declare that they have no conflicts of interest with the contents of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>11</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>12</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>1</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>1</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>1</Month><Day>15</Day><Hour>20</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>1</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33450230</ArticleId><ArticleId IdType="pmc">PMC7948801</ArticleId><ArticleId IdType="doi">10.1016/j.jbc.2021.100281</ArticleId><ArticleId IdType="pii">S0021-9258(21)00049-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Querfurth H.W., LaFerla F.M. Alzheimer's disease. N.&#xa0;Engl. J. Med. 2010;362:329&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">20107219</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole S.L., Vassar R. The role of APP processing by BACE1, the &#x3b2;-secretase, in Alzheimer's disease pathophysiology. J.&#xa0;Biol. Chem. 2008;283:29621&#x2013;29625.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2662048</ArticleId><ArticleId IdType="pubmed">18650431</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe M.S. Structure and function of the &#x3b3;-secretase complex. Biochemistry. 2019;58:2953&#x2013;2966.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6618299</ArticleId><ArticleId IdType="pubmed">31198028</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwatsubo T., Odaka A., Suzuki N., Mizusawa H., Nukina N., Ihara Y. Visualization of A&#x3b2;42(43) and A&#x3b2;40 in senile plaques with end-specific A&#x3b2; monoclonals: Evidence that an initially deposited species is A&#x3b2;42(43) Neuron. 1994;13:45&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">8043280</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi R.E. The genetics of Alzheimer disease. Cold Spring Harb. Perspect. Med. 2012;2</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3475404</ArticleId><ArticleId IdType="pubmed">23028126</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun L., Zhou R., Yang G., Shi Y. Analysis of 138 pathogenic mutations in presenilin-1 on the in&#xa0;vitro production of A&#x3b2;42 and A&#x3b2;40 peptides by &#x3b3;-secretase. Proc. Natl. Acad. Sci. U. S. A. 2017;114:E476&#x2013;E485.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5278480</ArticleId><ArticleId IdType="pubmed">27930341</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu Y., Misonou H., Sato T., Dohmae N., Takio K., Ihara Y. Distinct intramembrane cleavage of the &#x3b2;-amyloid precursor protein family resembling &#x3b3;-secretase-like cleavage of Notch. J.&#xa0;Biol. Chem. 2001;276:35235&#x2013;35238.</Citation><ArticleIdList><ArticleId IdType="pubmed">11483588</ArticleId></ArticleIdList></Reference><Reference><Citation>Takami M., Nagashima Y., Sano Y., Ishihara S., Morishima-Kawashima M., Funamoto S., Ihara Y. &#x3b3;-Secretase: Successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment. J.&#xa0;Neurosci. 2009;29:13042&#x2013;13052.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6665297</ArticleId><ArticleId IdType="pubmed">19828817</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez M.A., Klutkowski J.A., Freret T., Wolfe M.S. Alzheimer presenilin-1 mutations dramatically reduce trimming of long amyloid &#x3b2;-peptides (A&#x3b2;) by &#x3b3;-secretase to increase 42-to-40-residue A&#x3b2;. J.&#xa0;Biol. Chem. 2014;289:31043&#x2013;31052.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4223309</ArticleId><ArticleId IdType="pubmed">25239621</ArticleId></ArticleIdList></Reference><Reference><Citation>Quintero-Monzon O., Martin M.M., Fernandez M.A., Cappello C.A., Krzysiak A.J., Osenkowski P., Wolfe M.S. Dissociation between the processivity and total activity of &#x3b3;-secretase: Implications for the mechanism of Alzheimer's disease-causing presenilin mutations. Biochemistry. 2011;50:9023&#x2013;9035.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3205908</ArticleId><ArticleId IdType="pubmed">21919498</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y.M., Lai M.T., Xu M., Huang Q., DiMuzio-Mower J., Sardana M.K., Shi X.P., Yin K.C., Shafer J.A., Gardell S.J. Presenilin 1 is linked with &#x3b3;-secretase activity in the detergent solubilized state. Proc. Natl. Acad. Sci. U. S. A. 2000;97:6138&#x2013;6143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18571</ArticleId><ArticleId IdType="pubmed">10801983</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolduc D.M., Montagna D.R., Seghers M.C., Wolfe M.S., Selkoe D.J. The amyloid-&#x3b2; forming tripeptide cleavage mechanism of &#x3b3;-secretase. eLife. 2016;5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5134833</ArticleId><ArticleId IdType="pubmed">27580372</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu P., Bai X.C., Ma D., Xie T., Yan C., Sun L., Yang G., Zhao Y., Zhou R., Scheres S.H.W., Shi Y. Three-dimensional structure of human &#x3b3;-secretase. Nature. 2014;512:166&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4134323</ArticleId><ArticleId IdType="pubmed">25043039</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin Y.I., Bassit B., Zhu L., Yang X., Wang C., Li Y.-M. &#x3b3;-Secretase substrate concentration modulates the A&#x3b2;42/A&#x3b2;40 ratio: Implications for Alzheimer's Disease. J.&#xa0;Biol. Chem. 2007;282:23639&#x2013;23644.</Citation><ArticleIdList><ArticleId IdType="pubmed">17556361</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato T., Dohmae N., Qi Y., Kakuda N., Misonou H., Mitsumori R., Maruyama H., Koo E.H., Haass C., Takio K., Morishima-Kawashima M., Ishiura S., Ihara Y. Potential link between amyloid &#x3b2;-protein 42 and C-terminal fragment &#x3b3;49-99 of &#x3b2;-amyloid precursor protein. J.&#xa0;Biol. Chem. 2003;278:24294&#x2013;24301.</Citation><ArticleIdList><ArticleId IdType="pubmed">12707272</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimitrov M., Alattia J.R., Lemmin T., Lehal R., Fligier A., Houacine J., Hussain I., Radtke F., Dal Peraro M., Beher D., Fraering P.C. Alzheimer's disease mutations in APP but not &#x3b3;-secretase modulators affect &#x3b5;-cleavage-dependent AICD production. Nat. Commun. 2013;4:2246.</Citation><ArticleIdList><ArticleId IdType="pubmed">23907250</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamp F., Winkler E., Trambauer J., Ebke A., Fluhrer R., Steiner H. Intramembrane proteolysis of &#x3b2;-amyloid precursor protein by &#x3b3;-secretase is an unusually slow process. Biophys. J. 2015;108:1229&#x2013;1237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4375682</ArticleId><ArticleId IdType="pubmed">25762334</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolduc D.M., Montagna D.R., Gu Y., Selkoe D.J., Wolfe M.S. Nicastrin functions to sterically hinder &#x3b3;-secretase-substrate interactions driven by substrate transmembrane domain. Proc. Natl. Acad. Sci. U. S. A. 2016;113:E509&#x2013;E518.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4747693</ArticleId><ArticleId IdType="pubmed">26699478</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickey S.W., Baker R.P., Cho S., Urban S. Proteolysis inside the membrane is a rate-governed reaction not driven by substrate affinity. Cell. 2013;155:1270&#x2013;1281.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3917317</ArticleId><ArticleId IdType="pubmed">24315097</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito T., Suemoto T., Brouwers N., Sleegers K., Funamoto S., Mihira N., Matsuba Y., Yamada K., Nilsson P., Takano J., Nishimura M., Iwata N., Van Broeckhoven C., Ihara Y., Saido T.C. Potent amyloidogenicity and pathogenicity of A&#x3b2;43. Nat. Neurosci. 2011;14:1023&#x2013;1032.</Citation><ArticleIdList><ArticleId IdType="pubmed">21725313</ArticleId></ArticleIdList></Reference><Reference><Citation>Kretner B., Trambauer J., Fukumori A., Mielke J., Kuhn P.H., Kremmer E., Giese A., Lichtenthaler S.F., Haass C., Arzberger T., Steiner H. Generation and deposition of A&#x3b2;43 by the virtually inactive presenilin-1 L435F mutant contradicts the presenilin loss-of-function hypothesis of Alzheimer's disease. EMBO Mol. Med. 2016;8:458&#x2013;465.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5119496</ArticleId><ArticleId IdType="pubmed">26988102</ArticleId></ArticleIdList></Reference><Reference><Citation>Veugelen S., Saito T., Saido T.C., Chavez-Gutierrez L., De Strooper B. Familial Alzheimer's disease mutations in presenilin generate amyloidogenic A&#x3b2; peptide seeds. Neuron. 2016;90:410&#x2013;416.</Citation><ArticleIdList><ArticleId IdType="pubmed">27100199</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez M.A., Biette K.M., Dolios G., Seth D., Wang R., Wolfe M.S. Transmembrane substrate determinants for &#x3b3;-secretase processing of APP CTF&#x3b2;. Biochemistry. 2016;55:5675&#x2013;5688.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5539764</ArticleId><ArticleId IdType="pubmed">27649271</ArticleId></ArticleIdList></Reference><Reference><Citation>Kakuda N., Funamoto S., Yagishita S., Takami M., Osawa S., Dohmae N., Ihara Y. Equimolar production of amyloid &#x3b2;-protein and amyloid precursor protein intracellular domain from &#x3b2;-carboxyl-terminal fragment by &#x3b3;-secretase. J.&#xa0;Biol. Chem. 2006;281:14776&#x2013;14786.</Citation><ArticleIdList><ArticleId IdType="pubmed">16595682</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi-Takahara Y., Morishima-Kawashima M., Tanimura Y., Dolios G., Hirotani N., Horikoshi Y., Kametani F., Maeda M., Saido T.C., Wang R., Ihara Y. Longer forms of amyloid &#x3b2; protein: Implications for the mechanism of intramembrane cleavage by &#x3b3;-secretase. J.&#xa0;Neurosci. 2005;25:436&#x2013;445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725472</ArticleId><ArticleId IdType="pubmed">15647487</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraering P.C., Ye W., Strub J.M., Dolios G., LaVoie M.J., Ostaszewski B.L., van Dorsselaer A., Wang R., Selkoe D.J., Wolfe M.S. Purification and characterization of the human &#x3b3;-secretase complex. Biochemistry. 2004;43:9774&#x2013;9789.</Citation><ArticleIdList><ArticleId IdType="pubmed">15274632</ArticleId></ArticleIdList></Reference><Reference><Citation>Osenkowski P., Li H., Ye W., Li D., Aeschbach L., Fraering P.C., Wolfe M.S., Selkoe D.J., Li H. Cryoelectron microscopy structure of purified &#x3b3;-secretase at 12 &#xc5; resolution. J.&#xa0;Mol. Biol. 2009;385:642&#x2013;652.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2830092</ArticleId><ArticleId IdType="pubmed">19013469</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolduc D.M., Selkoe D.J., Wolfe M.S. Enzymatic assays for studying intramembrane proteolysis. Methods Enzymol. 2017;584:295&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5539767</ArticleId><ArticleId IdType="pubmed">28065268</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33450186</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>16</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1875-9777</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>Feb</Month><Day>04</Day></PubDate></JournalIssue><Title>Cell stem cell</Title><ISOAbbreviation>Cell Stem Cell</ISOAbbreviation></Journal><ArticleTitle>ApoE-Isoform-Dependent SARS-CoV-2 Neurotropism and Cellular Response.</ArticleTitle><Pagination><StartPage>331</StartPage><EndPage>342.e5</EndPage><MedlinePgn>331-342.e5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.stem.2020.12.018</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1934-5909(20)30602-0</ELocationID><Abstract><AbstractText>ApoE4, a strong genetic risk factor for Alzheimer disease, has been associated with increased risk for severe COVID-19. However, it is unclear whether ApoE4 alters COVID-19 susceptibility or severity, and the role of direct viral infection in brain cells remains obscure. We tested the neurotropism of SARS-CoV2 in human-induced pluripotent stem cell (hiPSC) models and observed low-grade infection of neurons and astrocytes that is boosted in neuron-astrocyte co-cultures and organoids. We then generated isogenic ApoE3/3 and ApoE4/4 hiPSCs and found an increased rate of SARS-CoV-2 infection in ApoE4/4 neurons and astrocytes. ApoE4 astrocytes exhibited enlarged size and elevated nuclear fragmentation upon SARS-CoV-2 infection. Finally, we show that remdesivir treatment inhibits SARS-CoV2 infection of hiPSC neurons and astrocytes. These findings suggest that ApoE4 may play a causal role in COVID-19 severity. Understanding how risk factors impact COVID-19 susceptibility and severity will help us understand the potential long-term effects in different patient populations.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Cheng</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Stem Cell Biology Research, Department of Developmental and Stem Cell Biology, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Mingzi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Stem Cell Biology Research, Department of Developmental and Stem Cell Biology, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia</LastName><ForeName>Gustavo</ForeName><Initials>G</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tian</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Stem Cell Biology Research, Department of Developmental and Stem Cell Biology, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Qi</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Division of Stem Cell Biology Research, Department of Developmental and Stem Cell Biology, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xianwei</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Division of Stem Cell Biology Research, Department of Developmental and Stem Cell Biology, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Guihua</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Diabetes Complications &amp; Metabolism, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jinhui</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Integrative Genomics Core, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arumugaswami</LastName><ForeName>Vaithilingaraja</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA 90095, USA; Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, Los Angeles, CA 90095, USA. Electronic address: varumugaswami@mednet.ucla.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Yanhong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Stem Cell Biology Research, Department of Developmental and Stem Cell Biology, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA. Electronic address: yshi@coh.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R56 AG061171</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG056305</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA033572</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG061794</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AI129471</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>01</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Stem Cell</MedlineTA><NlmUniqueID>101311472</NlmUniqueID><ISSNLinking>1875-9777</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance></Chemical><Chemical><RegistryNumber>3QKI37EEHE</RegistryNumber><NameOfSubstance UI="C000606551">remdesivir</NameOfSubstance></Chemical><Chemical><RegistryNumber>415SHH325A</RegistryNumber><NameOfSubstance UI="D000249">Adenosine Monophosphate</NameOfSubstance></Chemical><Chemical><RegistryNumber>OF5P57N2ZX</RegistryNumber><NameOfSubstance UI="D000409">Alanine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000249" MajorTopicYN="N">Adenosine Monophosphate</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000409" MajorTopicYN="N">Alanine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="N">Induced Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016501" MajorTopicYN="N">Neurites</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009940" MajorTopicYN="N">Organoids</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020033" MajorTopicYN="N">Protein Isoforms</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018523" MajorTopicYN="N">Tropism</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">ApoE</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 neurotropism</Keyword><Keyword MajorTopicYN="N">astrocytes</Keyword><Keyword MajorTopicYN="N">brain organoids</Keyword><Keyword MajorTopicYN="N">iPSCs</Keyword><Keyword MajorTopicYN="N">induced pluripotent stem cells</Keyword><Keyword MajorTopicYN="N">neuron-astrocyte co-culture</Keyword><Keyword MajorTopicYN="N">neurons</Keyword><Keyword MajorTopicYN="N">remdesivir</Keyword></KeywordList><CoiStatement>Declaration of Interests The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>10</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>12</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>12</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>1</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>1</Month><Day>15</Day><Hour>20</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>1</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33450186</ArticleId><ArticleId IdType="pmc">PMC7832490</ArticleId><ArticleId IdType="doi">10.1016/j.stem.2020.12.018</ArticleId><ArticleId IdType="pii">S1934-5909(20)30602-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Azkur A.K., Akdis M., Azkur D., Sokolowska M., van de Veen W., Br&#xfc;ggen M.C., O&#x2019;Mahony L., Gao Y., Nadeau K., Akdis C.A. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy. 2020;75:1564&#x2013;1581.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7272948</ArticleId><ArticleId IdType="pubmed">32396996</ArticleId></ArticleIdList></Reference><Reference><Citation>Baas T., Roberts A., Teal T.H., Vogel L., Chen J., Tumpey T.M., Katze M.G., Subbarao K. Genomic analysis reveals age-dependent innate immune responses to severe acute respiratory syndrome coronavirus. J.&#xa0;Virol. 2008;82:9465&#x2013;9476.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2546950</ArticleId><ArticleId IdType="pubmed">18632870</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee S., Kane P.M. Regulation of V-ATPase Activity and Organelle pH by Phosphatidylinositol Phosphate Lipids. Front. Cell Dev. Biol. 2020;8:510.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7324685</ArticleId><ArticleId IdType="pubmed">32656214</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbar L., Jain T., Zimmer M., Kruglikov I., Sadick J.S., Wang M., Kalpana K., Rose I.V.L., Burstein S.R., Rusielewicz T., et al. CD49f Is a Novel Marker of Functional and Reactive Human iPSC-Derived Astrocytes. Neuron. 2020;107:436&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8274549</ArticleId><ArticleId IdType="pubmed">32485136</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram L., Tanzi R.E. Thirty years of Alzheimer&#x2019;s disease genetics: the implications of systematic meta-analyses. Nature Rev. 2008;9:768&#x2013;778.</Citation><ArticleIdList><ArticleId IdType="pubmed">18802446</ArticleId></ArticleIdList></Reference><Reference><Citation>Bullen C.K., Hogberg H.T., Bahadirli-Talbott A., Bishai W.R., Hartung T., Keuthan C., Looney M.M., Pekosz A., Romero J.C., Sille F.C.M., et al. Infectability of human BrainSphere neurons suggests neurotropism of SARS-CoV-2. ALTEX. 2020 doi: 10.14573/altex.2006111. Published online October 20, 2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.14573/altex.2006111</ArticleId><ArticleId IdType="pubmed">32591839</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgos J.S., Ramirez C., Sastre I., Valdivieso F. Effect of apolipoprotein E on the cerebral load of latent herpes simplex virus type 1 DNA. J.&#xa0;Virol. 2006;80:5383&#x2013;5387.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1472141</ArticleId><ArticleId IdType="pubmed">16699018</ArticleId></ArticleIdList></Reference><Reference><Citation>Burt T.D., Agan B.K., Marconi V.C., He W., Kulkarni H., Mold J.E., Cavrois M., Huang Y., Mahley R.W., Dolan M.J., et al. Apolipoprotein (apo) E4 enhances HIV-1 cell entry in&#xa0;vitro, and the APOE epsilon4/epsilon4 genotype accelerates HIV disease progression. Proc. Natl. Acad. Sci. USA. 2008;105:8718&#x2013;8723.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2438419</ArticleId><ArticleId IdType="pubmed">18562290</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantuti-Castelvetri L., Ojha R., Pedro L.D., Djannatian M., Franz J., Kuivanen S., van der Meer F., Kallio K., Kaya T., Anastasina M., et al. Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. Science. 2020;370:856&#x2013;860.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7857391</ArticleId><ArticleId IdType="pubmed">33082293</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataldo A.M., Peterhoff C.M., Troncoso J.C., Gomez-Isla T., Hyman B.T., Nixon R.A. Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer&#x2019;s disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. Am. J. Pathol. 2000;157:277&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850219</ArticleId><ArticleId IdType="pubmed">10880397</ArticleId></ArticleIdList></Reference><Reference><Citation>Coronaviridae Study Group of the International Committee on Taxonomy of Viruses The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol. 2020;5:536&#x2013;544.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095448</ArticleId><ArticleId IdType="pubmed">32123347</ArticleId></ArticleIdList></Reference><Reference><Citation>Daniloski Z., Jordan T.X., Wessels H.H., Hoagland D.A., Kasela S., Legut M., Maniatis S., Mimitou E.P., Lu L., Geller E., et al. Identification of Required Host Factors for SARS-CoV-2 Infection in Human Cells. Cell. 2020 doi: 10.1016/j.cell.2020.10.030. Published online October 24, 2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.10.030</ArticleId><ArticleId IdType="pmc">PMC7584921</ArticleId><ArticleId IdType="pubmed">33147445</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellul M.A., Benjamin L., Singh B., Lant S., Michael B.D., Easton A., Kneen R., Defres S., Sejvar J., Solomon T. Neurological associations of COVID-19. Lancet Neurol. 2020;19:767&#x2013;783.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7332267</ArticleId><ArticleId IdType="pubmed">32622375</ArticleId></ArticleIdList></Reference><Reference><Citation>Erickson M.A., Banks W.A. Neuroimmune Axes of the Blood-Brain Barriers and Blood-Brain Interfaces: Bases for Physiological Regulation, Disease States, and Pharmacological Interventions. Pharmacol. Rev. 2018;70:278&#x2013;314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5833009</ArticleId><ArticleId IdType="pubmed">29496890</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer L.A., Cupples L.A., Haines J.L., Hyman B., Kukull W.A., Mayeux R., Myers R.H., Pericak-Vance M.A., Risch N., van Duijn C.M., APOE and Alzheimer Disease Meta Analysis Consortium Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. JAMA. 1997;278:1349&#x2013;1356.</Citation><ArticleIdList><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng L., Chao J., Tian E., Li L., Ye P., Zhang M., Chen X., Cui Q., Sun G., Zhou T., et al. Cell-Based Therapy for Canavan Disease Using Human iPSC-Derived NPCs and OPCs. Adv. Sci. (Weinh.) 2020;7:2002155.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7709977</ArticleId><ArticleId IdType="pubmed">33304759</ArticleId></ArticleIdList></Reference><Reference><Citation>Giacomelli A., Pezzati L., Conti F., Bernacchia D., Siano M., Oreni L., Rusconi S., Gervasoni C., Ridolfo A.L., Rizzardini G., et al. Self-reported Olfactory and Taste Disorders in Patients With Severe Acute Respiratory Coronavirus 2 Infection: A Cross-sectional Study. Clin. Infect. Dis. 2020;71:889&#x2013;890.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7184514</ArticleId><ArticleId IdType="pubmed">32215618</ArticleId></ArticleIdList></Reference><Reference><Citation>Helms J., Kremer S., Merdji H., Clere-Jehl R., Schenck M., Kummerlen C., Collange O., Boulay C., Fafi-Kremer S., Ohana M., et al. Neurologic Features in Severe SARS-CoV-2 Infection. N.&#xa0;Engl. J. Med. 2020;382:2268&#x2013;2270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7179967</ArticleId><ArticleId IdType="pubmed">32294339</ArticleId></ArticleIdList></Reference><Reference><Citation>Hockemeyer D., Jaenisch R. Induced Pluripotent Stem Cells Meet Genome Editing. Cell Stem Cell. 2016;18:573&#x2013;586.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4871596</ArticleId><ArticleId IdType="pubmed">27152442</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M., Kleine-Weber H., Schroeder S., Kr&#xfc;ger N., Herrler T., Erichsen S., Schiergens T.S., Herrler G., Wu N.H., Nitsche A., et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181:271&#x2013;280.e8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacob F., Pather S.R., Huang W.K., Wong S.Z.H., Zhou H., Zhang F., Cubitt B., Chen C.Z., Xu M., Pradhan M., et al. Human Pluripotent Stem Cell-Derived Neural Cells and Brain Organoids Reveal SARS-CoV-2 Neurotropism. bioRxiv. 2020 doi: 10.1101/2020.07.28.225151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.07.28.225151</ArticleId><ArticleId IdType="pmc">PMC7505550</ArticleId><ArticleId IdType="pubmed">33010822</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanberg N., Ashton N.J., Andersson L.M., Yilmaz A., Lindh M., Nilsson S., Price R.W., Blennow K., Zetterberg H., Gissl&#xe9;n M. Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19. Neurology. 2020;95:e1754&#x2013;e1759.</Citation><ArticleIdList><ArticleId IdType="pubmed">32546655</ArticleId></ArticleIdList></Reference><Reference><Citation>Kujawski S.A.a. First 12 patients with coronavirus disease 2019 (COVID-19) in the United States. MedRxiv. 2020 doi: 10.1101/2020.03.09.20032896.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.03.09.20032896</ArticleId><ArticleId IdType="pubmed">32327757</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo C.L., Pilling L.C., Atkins J.L., Masoli J.A.H., Delgado J., Kuchel G.A., Melzer D. APOE e4 genotype predicts severe COVID-19 in the UK Biobank community cohort. J.&#xa0;Gerontol. A Biol. Sci. Med. Sci. 2020;75:2231&#x2013;2232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7314139</ArticleId><ArticleId IdType="pubmed">32451547</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancaster M.A., Renner M., Martin C.A., Wenzel D., Bicknell L.S., Hurles M.E., Homfray T., Penninger J.M., Jackson A.P., Knoblich J.A. Cerebral organoids model human brain development and microcephaly. Nature. 2013;501:373&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3817409</ArticleId><ArticleId IdType="pubmed">23995685</ArticleId></ArticleIdList></Reference><Reference><Citation>Lechien J.R., Chiesa-Estomba C.M., De Siati D.R., Horoi M., Le Bon S.D., Rodriguez A., Dequanter D., Blecic S., El Afia F., Distinguin L., et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur. Arch. Otorhinolaryngol. 2020;277:2251&#x2013;2261.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7134551</ArticleId><ArticleId IdType="pubmed">32253535</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L., Shi Y. When glia meet induced pluripotent stem cells (iPSCs) Mol. Cell. Neurosci. 2020;109:103565.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10506562</ArticleId><ArticleId IdType="pubmed">33068719</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L., Chao J., Shi Y. Modeling neurological diseases using iPSC-derived neural cells : iPSC modeling of neurological diseases. Cell Tissue Res. 2018;371:143&#x2013;151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6029980</ArticleId><ArticleId IdType="pubmed">29079884</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L., Tian E., Chen X., Chao J., Klein J., Qu Q., Sun G., Sun G., Huang Y., Warden C.D., et al. GFAP Mutations in Astrocytes Impair Oligodendrocyte Progenitor Proliferation and Myelination in an hiPSC Model of Alexander Disease. Cell Stem Cell. 2018;23:239&#x2013;251.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6230521</ArticleId><ArticleId IdType="pubmed">30075130</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y.T., Seo J., Gao F., Feldman H.M., Wen H.L., Penney J., Cam H.P., Gjoneska E., Raja W.K., Cheng J., et al. APOE4 Causes Widespread Molecular and Cellular Alterations Associated with Alzheimer&#x2019;s Disease Phenotypes in Human iPSC-Derived Brain Cell Types. Neuron. 2018;98:1294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6048952</ArticleId><ArticleId IdType="pubmed">29953873</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C.C., Liu C.C., Kanekiyo T., Xu H., Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat. Rev. Neurol. 2013;9:106&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3726719</ArticleId><ArticleId IdType="pubmed">23296339</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao X.Y., Jin W.L. iPSCs-Derived Platform: A Feasible Tool for Probing the Neurotropism of SARS-CoV-2. ACS Chem. Neurosci. 2020;11:2489&#x2013;2491.</Citation><ArticleIdList><ArticleId IdType="pubmed">32840109</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao L., Jin H., Wang M., Hu Y., Chen S., He Q., Chang J., Hong C., Zhou Y., Wang D., et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol. 2020;77:683&#x2013;690.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7149362</ArticleId><ArticleId IdType="pubmed">32275288</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchetto M.C., Brennand K.J., Boyer L.F., Gage F.H. Induced pluripotent stem cells (iPSCs) and neurological disease modeling: progress and promises. Hum. Mol. Genet. 2011;20(R2):R109&#x2013;R115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4447776</ArticleId><ArticleId IdType="pubmed">21828073</ArticleId></ArticleIdList></Reference><Reference><Citation>Mertens J., Paquola A.C.M., Ku M., Hatch E., B&#xf6;hnke L., Ladjevardi S., McGrath S., Campbell B., Lee H., Herdy J.R., et al. Directly Reprogrammed Human Neurons Retain Aging-Associated Transcriptomic Signatures and Reveal Age-Related Nucleocytoplasmic Defects. Cell Stem Cell. 2015;17:705&#x2013;718.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5929130</ArticleId><ArticleId IdType="pubmed">26456686</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesci P., Macia A., Salehi A., Martin-Sancho L., Yin X., Snethlage C., Chanda S.K., Moutri A. Sofosbuvir protects human brain organoids against SARS-CoV-2. bioRxiv. 2020</Citation></Reference><Reference><Citation>Moriguchi T., Harii N., Goto J., Harada D., Sugawara H., Takamino J., Ueno M., Sakata H., Kondo K., Myose N., et al. A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. Int. J. Infect. Dis. 2020;94:55&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7195378</ArticleId><ArticleId IdType="pubmed">32251791</ArticleId></ArticleIdList></Reference><Reference><Citation>Paniz-Mondolfi A., Bryce C., Grimes Z., Gordon R.E., Reidy J., Lednicky J., Sordillo E.M., Fowkes M. Central nervous system involvement by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) J.&#xa0;Med. Virol. 2020;92:699&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7264598</ArticleId><ArticleId IdType="pubmed">32314810</ArticleId></ArticleIdList></Reference><Reference><Citation>Parma V., Ohla K., Veldhuizen M.G., Niv M.Y., Kelly C.E., Bakke A.J., Cooper K.W., Bouysset C., Pirastu N., Dibattista M., et al. GCCR Group Author More than smell - COVID-19 is associated with severe impairment of smell, taste, and chemesthesis. Chem. Senses. 2020;45:609&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7337664</ArticleId><ArticleId IdType="pubmed">32564071</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellegrini L., Albecka A., Mallery D.L., Kellner M.J., Paul D., Carter A.P., James L.C., Lancaster M.A. SARS-CoV-2 Infects the Brain Choroid Plexus and Disrupts the Blood-CSF Barrier in Human Brain Organoids. Cell Stem Cell. 2020;27:951&#x2013;961.e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7553118</ArticleId><ArticleId IdType="pubmed">33113348</ArticleId></ArticleIdList></Reference><Reference><Citation>Potokar M., Jorga&#x10d;evski J., Zorec R. Astrocytes in Flavivirus Infections. Int. J. Mol. Sci. 2019;20:20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6386967</ArticleId><ArticleId IdType="pubmed">30736273</ArticleId></ArticleIdList></Reference><Reference><Citation>Puelles V.G., L&#xfc;tgehetmann M., Lindenmeyer M.T., Sperhake J.P., Wong M.N., Allweiss L., Chilla S., Heinemann A., Wanner N., Liu S., et al. Multiorgan and Renal Tropism of SARS-CoV-2. N.&#xa0;Engl. J. Med. 2020;383:590&#x2013;592.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7240771</ArticleId><ArticleId IdType="pubmed">32402155</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian X., Nguyen H.N., Song M.M., Hadiono C., Ogden S.C., Hammack C., Yao B., Hamersky G.R., Jacob F., Zhong C., et al. Brain-Region-Specific Organoids Using Mini-bioreactors for Modeling ZIKV Exposure. Cell. 2016;165:1238&#x2013;1254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4900885</ArticleId><ArticleId IdType="pubmed">27118425</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu Q., Sun G., Li W., Yang S., Ye P., Zhao C., Yu R.T., Gage F.H., Evans R.M., Shi Y. Orphan nuclear receptor TLX activates Wnt/beta-catenin signalling to stimulate neural stem cell proliferation and self-renewal. Nat. Cell Biol. 2010;12:31&#x2013;40. suppl. 31&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2880892</ArticleId><ArticleId IdType="pubmed">20010817</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramani A., M&#xfc;ller L., Ostermann P.N., Gabriel E., Abida-Islam P., M&#xfc;ller-Schiffmann A., Mariappan A., Goureau O., Gruell H., Walker A., et al. SARS-CoV-2 targets neurons of 3D human brain organoids. EMBO J. 2020;39:e106230.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7560208</ArticleId><ArticleId IdType="pubmed">32876341</ArticleId></ArticleIdList></Reference><Reference><Citation>Ran F.A., Hsu P.D., Lin C.Y., Gootenberg J.S., Konermann S., Trevino A.E., Scott D.A., Inoue A., Matoba S., Zhang Y., Zhang F. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell. 2013;154:1380&#x2013;1389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3856256</ArticleId><ArticleId IdType="pubmed">23992846</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma A., Garcia G., Jr., Wang Y., Plummer J.T., Morizono K., Arumugaswami V., Svendsen C.N. Human iPSC-Derived Cardiomyocytes Are Susceptible to SARS-CoV-2 Infection. Cell Rep Med. 2020;1:100052.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7323681</ArticleId><ArticleId IdType="pubmed">32835305</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y., Chichung Lie D., Taupin P., Nakashima K., Ray J., Yu R.T., Gage F.H., Evans R.M. Expression and function of orphan nuclear receptor TLX in adult neural stem cells. Nature. 2004;427:78&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">14702088</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y., Inoue H., Wu J.C., Yamanaka S. Induced pluripotent stem cell technology: a decade of progress. Nat. Rev. Drug Discov. 2017;16:115&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6416143</ArticleId><ArticleId IdType="pubmed">27980341</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y., Yamada K., Liddelow S.A., Smith S.T., Zhao L., Luo W., Tsai R.M., Spina S., Grinberg L.T., Rojas J.C., et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature. 2017;549:523&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5641217</ArticleId><ArticleId IdType="pubmed">28959956</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon I.H., Normandin E., Bhattacharyya S., Mukerji S.S., Keller K., Ali A.S., Adams G., Hornick J.L., Padera R.F., Jr., Sabeti P. Neuropathological Features of Covid-19. N.&#xa0;Engl. J. Med. 2020;383:989&#x2013;992.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7304421</ArticleId><ArticleId IdType="pubmed">32530583</ArticleId></ArticleIdList></Reference><Reference><Citation>Song E., Zhang C., Israelow B., Lu-Culligan A., Prado A.V., Skriabine S., Lu P., Weizman O.E., Liu F., Dai Y., et al. Neuroinvasion of SARS-CoV-2 in human and mouse brain. bioRxiv. 2020 doi: 10.1101/2020.06.25.169946.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.06.25.169946</ArticleId><ArticleId IdType="pmc">PMC7808299</ArticleId><ArticleId IdType="pubmed">33433624</ArticleId></ArticleIdList></Reference><Reference><Citation>Studer L., Vera E., Cornacchia D. Programming and Reprogramming Cellular Age in the Era of Induced Pluripotency. Cell Stem Cell. 2015;16:591&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4508309</ArticleId><ArticleId IdType="pubmed">26046759</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun G., Chiuppesi F., Chen X., Wang C., Tian E., Nguyen J., Kha M., Trinh D., Zhang H., Marchetto M.C., et al. Modeling Human Cytomegalovirus-Induced Microcephaly in Human iPSC-Derived Brain Organoids. Cell Rep Med. 2020;1:100002.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7659592</ArticleId><ArticleId IdType="pubmed">33205055</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pubmed">18035408</ArticleId></ArticleIdList></Reference><Reference><Citation>Warren T.K., Jordan R., Lo M.K., Ray A.S., Mackman R.L., Soloveva V., Siegel D., Perron M., Bannister R., Hui H.C., et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. 2016;531:381&#x2013;385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5551389</ArticleId><ArticleId IdType="pubmed">26934220</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C., Chen X., Cai Y., Xia J., Zhou X., Xu S., Huang H., Zhang L., Zhou X., Du C., et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern. Med. 2020;180:934&#x2013;943.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7070509</ArticleId><ArticleId IdType="pubmed">32167524</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu F., Zhao S., Yu B., Chen Y.M., Wang W., Song Z.G., Hu Y., Tao Z.W., Tian J.H., Pei Y.Y., et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579:265&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7094943</ArticleId><ArticleId IdType="pubmed">32015508</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L., Han Y., Nilsson-Payant B.E., Gupta V., Wang P., Duan X., Tang X., Zhu J., Zhao Z., Jaffr&#xe9; F., et al. A Human Pluripotent Stem Cell-based Platform to Study SARS-CoV-2 Tropism and Model Virus Infection in Human Cells and Organoids. Cell Stem Cell. 2020;27:125&#x2013;136.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7303620</ArticleId><ArticleId IdType="pubmed">32579880</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye Q., Wang B., Mao J. The pathogenesis and treatment of the &#x2018;Cytokine Storm&#x2019; in COVID-19. J.&#xa0;Infect. 2020;80:607&#x2013;613.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7194613</ArticleId><ArticleId IdType="pubmed">32283152</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu J., Vodyanik M.A., Smuga-Otto K., Antosiewicz-Bourget J., Frane J.L., Tian S., Nie J., Jonsdottir G.A., Ruotti V., Stewart R., et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318:1917&#x2013;1920.</Citation><ArticleIdList><ArticleId IdType="pubmed">18029452</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B.Z., Chu H., Han S., Shuai H., Deng J., Hu Y.F., Gong H.R., Lee A.C., Zou Z., Yau T., et al. SARS-CoV-2 infects human neural progenitor cells and brain organoids. Cell Res. 2020;30:928&#x2013;931.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7399356</ArticleId><ArticleId IdType="pubmed">32753756</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu N., Zhang D., Wang W., Li X., Yang B., Song J., Zhao X., Huang B., Shi W., Lu R., et al. China Novel Coronavirus Investigating and Research Team A Novel Coronavirus from Patients with Pneumonia in China, 2019. N.&#xa0;Engl. J. Med. 2020;382:727&#x2013;733.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7092803</ArticleId><ArticleId IdType="pubmed">31978945</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33449094</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>12</Day></DateCompleted><DateRevised><Year>2021</Year><Month>03</Month><Day>12</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2574-3805</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Jan</Month><Day>04</Day></PubDate></JournalIssue><Title>JAMA network open</Title><ISOAbbreviation>JAMA Netw Open</ISOAbbreviation></Journal><ArticleTitle>Association of Cognitive Function Trajectories in Centenarians With Postmortem Neuropathology, Physical Health, and Other Risk Factors for Cognitive Decline.</ArticleTitle><Pagination><StartPage>e2031654</StartPage><MedlinePgn>e2031654</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e2031654</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamanetworkopen.2020.31654</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Understanding mechanisms associated with prolonged cognitive health in combination with exceptional longevity might lead to approaches to enable successful aging.</AbstractText><AbstractText Label="OBJECTIVE">To investigate trajectories of cognitive functioning in centenarians across domains, and to examine the association of these trajectories with factors underlying cognitive reserve, physical health, and postmortem levels of Alzheimer disease (AD)-associated neuropathology.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This cohort study used neuropsychological test data and postmortem neuropathological reports from Dutch centenarians who were drawn from the 100-plus Study between January 2013 and April 2019. Eligible participants self-reported being cognitively healthy, which was confirmed by a proxy. Data analysis was performed between June 2019 and June 2020.</AbstractText><AbstractText Label="EXPOSURES">Age, sex, APOE &#x3b5; genotype, factors of cognitive reserve, physical health, and AD-associated neuropathology (ie, amyloid-&#x3b2;, neurofibrillary tangles, and neuritic plaques).</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">In annual visits (until death or until participation was no longer possible), centenarians underwent an extensive neuropsychological test battery, from which an mean z score of global cognition, memory, executive functions, verbal fluency, visuospatial functions, and attention/processing speed was calculated. Linear mixed models with a random intercept and time as independent variable were used to investigate cognitive trajectories, adjusted for sex, age, education, and vision and hearing capacities. In a second step, linear mixed models were used to associate cognitive trajectories with factors underlying cognitive reserve, physical health at baseline, and AD-associated neuropathology.</AbstractText><AbstractText Label="RESULTS">Of the 1023 centenarians approached, 340 were included in the study. We analyzed 330 centenarians for whom cognitive tests were available at baseline (239 [72.4%] women; median [interquartile range] age of 100.5 [100.2-101.7] years), with a mean (SD) follow-up duration of 1.6 (0.8) years. We observed no decline across investigated cognitive domains, with the exception of a slight decline in memory function (&#x3b2;, -0.10 SD per year; 95% CI, -0.14 to -0.05 SD; P&#x2009;&lt;&#x2009;.001). Cognitive performance was associated with factors of physical health (eg, higher Barthel index: &#x3b2;, 0.37 SD per year; 95% CI, 0.24-0.49; P&#x2009;&lt;&#x2009;.001) and cognitive reserve (eg, higher education: &#x3b2;, 0.41 SD per year; 95% CI, 0.29-0.53; P&#x2009;&lt;&#x2009;.001), but none of these factors were associated with the rate of decline. Neuropathological reports were available for 44 participants. While centenarian brains revealed varying loads of postmortem neuropathological hallmarks of AD, this was not associated with cognitive performance or rate of decline.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">While we observed a slight vulnerability for decline in memory function, centenarians maintained high levels of performance in all other investigated cognitive domains for up to 4 years despite the presence of risk factors of cognitive decline. These findings suggest that mechanisms of resilience may underlie the prolongation of cognitive health until exceptional ages.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Beker</LastName><ForeName>Nina</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ganz</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Neurogenomics and Cognitive Research, Department of Molecular and Cellular Neuroscience, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Amsterdam Neuroscience, Amsterdam UMC, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hulsman</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Clinical Genetics, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klausch</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Amsterdam Public Health Research Institute, Department of Epidemiology and Biostatistics, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmand</LastName><ForeName>Ben A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Brain &amp; Cognition, Department of Psychology, University of Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scheltens</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sikkes</LastName><ForeName>Sietske A M</ForeName><Initials>SAM</Initials><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Psychology, Neuropsychology and Developmental Psychology, Faculty of Behavioural and Movement Sciences, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holstege</LastName><ForeName>Henne</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Genetics, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>01</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Netw Open</MedlineTA><NlmUniqueID>101729235</NlmUniqueID><ISSNLinking>2574-3805</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Netw Open. 2021 Jan 4;4(1):e2032538. doi: 10.1001/jamanetworkopen.2020.32538.</RefSource><PMID Version="1">33449091</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001344" MajorTopicYN="N">Autopsy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="Y">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="Y">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009426" MajorTopicYN="N" Type="Geographic">Netherlands</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Scheltens reported receiving consultancy fees (paid to his institution) from AC Immune SA, Alkermes, Alnylam Pharmaceuticals, Alzheon, Anavex Life Sciences, Biogen, Brainstorm Cell, Cortexyme, Denali Therapeutics, EIP Pharma, ImmunoBrain Checkpoint, GemVax, Genentech, Green Valley, Novartis, Novo Noridisk, PeopleBio Co, Renew LLC, and Roche Holding AG; he is also primary investigator of studies with AC Immune SA, Cognition Therapeutics, Inc, FUJIFILM Toyama Chemical Co, Ltd, IONIS Pharmaceuticals Inc, UCB, Vivoryon Therapeutics AG, and he serves on the board of the Brain Research Center. Dr Sikkes reported receiving personal fees (paid to his institution) from Boehringer Ingelheim, FUJIFILM Toyama Chemical Co, Ltd, Lundbeck, and Janssen Pharmaceuticals. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>1</Month><Day>15</Day><Hour>12</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>1</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>1</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33449094</ArticleId><ArticleId IdType="pmc">PMC7811180</ArticleId><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.31654</ArticleId><ArticleId IdType="pii">2775218</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Poon LW, Woodard JL, Stephen Miller L, et al. . Understanding dementia prevalence among centenarians. J Gerontol A Biol Sci Med Sci. 2012;67(4):358-365. doi:10.1093/gerona/glr250</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gerona/glr250</ArticleId><ArticleId IdType="pmc">PMC3309877</ArticleId><ArticleId IdType="pubmed">22389466</ArticleId></ArticleIdList></Reference><Reference><Citation>Perls T. Dementia-free centenarians. Exp Gerontol. 2004;39(11-12):1587-1593. doi:10.1016/j.exger.2004.08.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exger.2004.08.015</ArticleId><ArticleId IdType="pubmed">15582273</ArticleId></ArticleIdList></Reference><Reference><Citation>Mossakowska M, Broczek K, Wieczorowska-Tobis K, et al. . Cognitive performance and functional status are the major factors predicting survival of centenarians in Poland. J Gerontol A Biol Sci Med Sci. 2014;69(10):1269-1275. doi:10.1093/gerona/glu003</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gerona/glu003</ArticleId><ArticleId IdType="pubmed">24509978</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen-Ranberg K, Vasegaard L, Jeune B. Dementia is not inevitable: a population-based study of Danish centenarians. J Gerontol B Psychol Sci Soc Sci. 2001;56(3):152-159. doi:10.1093/geronb/56.3.P152</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/geronb/56.3.P152</ArticleId><ArticleId IdType="pubmed">11316833</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagberg B, Bauer Alfredson B, Poon LW, Homma A. Cognitive functioning in centenarians: a coordinated analysis of results from three countries. J Gerontol B Psychol Sci Soc Sci. 2001;56(3):141-151. doi:10.1093/geronb/56.3.P141</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/geronb/56.3.P141</ArticleId><ArticleId IdType="pubmed">11316832</ArticleId></ArticleIdList></Reference><Reference><Citation>Small SA, Stern Y, Tang M, Mayeux R. Selective decline in memory function among healthy elderly. Neurology. 1999;52(7):1392-1396. doi:10.1212/WNL.52.7.1392</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.52.7.1392</ArticleId><ArticleId IdType="pubmed">10227623</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedden T, Gabrieli JD. Insights into the ageing mind: a view from cognitive neuroscience. Nat Rev Neurosci. 2004;5(2):87-96. doi:10.1038/nrn1323</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn1323</ArticleId><ArticleId IdType="pubmed">14735112</ArticleId></ArticleIdList></Reference><Reference><Citation>Park DC, Lautenschlager G, Hedden T, Davidson NS, Smith AD, Smith PK. Models of visuospatial and verbal memory across the adult life span. Psychol Aging. 2002;17(2):299-320. doi:10.1037/0882-7974.17.2.299</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/0882-7974.17.2.299</ArticleId><ArticleId IdType="pubmed">12061414</ArticleId></ArticleIdList></Reference><Reference><Citation>Christensen H. What cognitive changes can be expected with normal ageing? Aust N Z J Psychiatry. 2001;35(6):768-775. doi:10.1046/j.1440-1614.2001.00966.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1440-1614.2001.00966.x</ArticleId><ArticleId IdType="pubmed">11990887</ArticleId></ArticleIdList></Reference><Reference><Citation>Salthouse TA. Neuroanatomical substrates of age-related cognitive decline. Psychol Bull. 2011;137(5):753-784. doi:10.1037/a0023262</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/a0023262</ArticleId><ArticleId IdType="pmc">PMC3132227</ArticleId><ArticleId IdType="pubmed">21463028</ArticleId></ArticleIdList></Reference><Reference><Citation>Salthouse TA. Trajectories of normal cognitive aging. Psychol Aging. 2019;34(1):17-24. doi:10.1037/pag0000288</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/pag0000288</ArticleId><ArticleId IdType="pmc">PMC6367038</ArticleId><ArticleId IdType="pubmed">30211596</ArticleId></ArticleIdList></Reference><Reference><Citation>Corrada MM, Brookmeyer R, Paganini-Hill A, Berlau D, Kawas CH. Dementia incidence continues to increase with age in the oldest old: the 90+ study. Ann Neurol. 2010;67(1):114-121. doi:10.1002/ana.21915</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21915</ArticleId><ArticleId IdType="pmc">PMC3385995</ArticleId><ArticleId IdType="pubmed">20186856</ArticleId></ArticleIdList></Reference><Reference><Citation>Lobo A, Lopez-Anton R, Santab&#xe1;rbara J, et al. . Incidence and lifetime risk of dementia and Alzheimer&#x2019;s disease in a Southern European population. Acta Psychiatr Scand. 2011;124(5):372-383. doi:10.1111/j.1600-0447.2011.01754.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0447.2011.01754.x</ArticleId><ArticleId IdType="pubmed">21848704</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y. Cognitive reserve. Neuropsychologia. 2009;47(10):2015-2028. doi:10.1016/j.neuropsychologia.2009.03.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropsychologia.2009.03.004</ArticleId><ArticleId IdType="pmc">PMC2739591</ArticleId><ArticleId IdType="pubmed">19467352</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y, Arenaza-Urquijo EM, Bartr&#xe9;s-Faz D, et al. . Whitepaper: defining and investigating cognitive reserve, brain reserve, and brain maintenance. Alzheimer&#x2019;s &amp; Dementia. 2020;16(9):1305-1311. doi:10.1016/j.jalz.2018.07.219</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.07.219</ArticleId><ArticleId IdType="pmc">PMC6417987</ArticleId><ArticleId IdType="pubmed">30222945</ArticleId></ArticleIdList></Reference><Reference><Citation>World Medical Association World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-2194. doi:10.1001/jama.2013.281053</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2013.281053</ArticleId><ArticleId IdType="pubmed">24141714</ArticleId></ArticleIdList></Reference><Reference><Citation>Holstege H, Beker N, Dijkstra T, et al. . The 100-plus Study of cognitively healthy centenarians: rationale, design and cohort description. Eur J Epidemiol. 2018;33(12):1229-1249. doi:10.1007/s10654-018-0451-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10654-018-0451-3</ArticleId><ArticleId IdType="pmc">PMC6290855</ArticleId><ArticleId IdType="pubmed">30362018</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198. doi:10.1016/0022-3956(75)90026-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-3956(75)90026-6</ArticleId><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>van Buuren S, Groothuis-Oudshoorn K. mice: multivariate imputation by chained equations in R. J Stat Software. 2011;45(3):1-67. doi:10.18637/jss.v045.i03</Citation><ArticleIdList><ArticleId IdType="doi">10.18637/jss.v045.i03</ArticleId></ArticleIdList></Reference><Reference><Citation>Beker N, Sikkes SA, Hulsman M, Schmand B, Scheltens P, Holstege H. Neuropsychological test performance of cognitively healthy centenarians: normative data from the Dutch 100-plus Study. J Am Geriatr Soc. 2019;67(4):759-767. doi:10.1111/jgs.15729</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgs.15729</ArticleId><ArticleId IdType="pmc">PMC7379661</ArticleId><ArticleId IdType="pubmed">30592018</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson B, Cockburn J, Baddeley A.. The Rivermead Behavioural Memory Test. Nederlandstalige bewerking. Handleiding. Balen HGG, Groot Zwaaftink AJM , trans. Swets &amp; Zeitling; 1987.</Citation></Reference><Reference><Citation>Wilson B, Cockburn J, Baddeley A.. The Rivermead Behavioural Memory Test Reading. Thames Valley Test Co; 1985.</Citation></Reference><Reference><Citation>Reitan RM. Validity of the Trail Making Test as an indicator of organic brain damage. Perceptual and Motor Skills. 1958;8(3):271-276. doi:10.2466/pms.1958.8.3.271</Citation><ArticleIdList><ArticleId IdType="doi">10.2466/pms.1958.8.3.271</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson BA, Alderman N, Burgess PW, Emslie H, Evans JJ. BADS: Behavioural Assessment of the Dysexecutive Syndrome. Pearson ; 1996.</Citation></Reference><Reference><Citation>Wechsler D. WAIS-III: Wechsler Adult Intelligence Scale. Psychological Corporation; 1997.</Citation></Reference><Reference><Citation>Benton AL, Hamsher KD, Sivan A. Multilingual Aphasia Examination. Vol 59 AJA Associates; 1989.</Citation></Reference><Reference><Citation>Van der Elst W, Van Boxtel MP, Van Breukelen GJ, Jolles J. Normative data for the animal, profession and letter m naming verbal fluency tests for Dutch speaking participants and the effects of age, education, and sex. J Int Neuropsychol Soc. 2006;12(1):80-89. doi:10.1017/S1355617706060115</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1355617706060115</ArticleId><ArticleId IdType="pubmed">16433947</ArticleId></ArticleIdList></Reference><Reference><Citation>Warrington EK, James M. The Visual Object and Space Perception Battery: VOSP. Pearson London; 1991.</Citation></Reference><Reference><Citation>Munang L, Chan M, Lim W. Diagnostic performance of the clock drawing test using a pre-drawn circle in persons with early dementia. Asian J Gerontol Geriatr. 2010;5:54-61.</Citation></Reference><Reference><Citation>Shulman KI. Clock-drawing: is it the ideal cognitive screening test? Int J Geriatr Psychiatry. 2000;15(6):548-561. doi:10.1002/1099-1166(200006)15:6&lt;548::AID-GPS242&gt;3.0.CO;2-U</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1099-1166(200006)15:6&lt;548::AID-GPS242&gt;3.0.CO;2-U</ArticleId><ArticleId IdType="pubmed">10861923</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiepers OJ, Harris SE, Gow AJ, et al. . APOE E4 status predicts age-related cognitive decline in the ninth decade: longitudinal follow-up of the Lothian Birth Cohort 1921. Mol Psychiatry. 2012;17(3):315-324. doi:10.1038/mp.2010.137</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2010.137</ArticleId><ArticleId IdType="pubmed">21263443</ArticleId></ArticleIdList></Reference><Reference><Citation>Genin E, Hannequin D, Wallon D, et al. . APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol Psychiatry. 2011;16(9):903-907. doi:10.1038/mp.2011.52</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2011.52</ArticleId><ArticleId IdType="pmc">PMC3162068</ArticleId><ArticleId IdType="pubmed">21556001</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA, Cupples LA, Haines JL, et al. ; APOE and Alzheimer Disease Meta Analysis Consortium . Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease&#x2014;a meta-analysis. JAMA. 1997;278(16):1349-1356. doi:10.1001/jama.1997.03550160069041</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.1997.03550160069041</ArticleId><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Lee SJ, Wolters FJ, Ikram MK, et al. . The effect of APOE and other common genetic variants on the onset of Alzheimer&#x2019;s disease and dementia: a community-based cohort study. Lancet Neurol. 2018;17(5):434-444. doi:10.1016/S1474-4422(18)30053-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30053-X</ArticleId><ArticleId IdType="pubmed">29555425</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahoney FI, Barthel DW. Functional Evaluation: The Barthel Index. Mary State Matiland GD; 1965.</Citation><ArticleIdList><ArticleId IdType="pubmed">14258950</ArticleId></ArticleIdList></Reference><Reference><Citation>Reijnierse EM, de Jong N, Trappenburg MC, et al. . Assessment of maximal handgrip strength: how many attempts are needed? J Cachexia Sarcopenia Muscle. 2017;8(3):466-474. doi:10.1002/jcsm.12181</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcsm.12181</ArticleId><ArticleId IdType="pmc">PMC5476859</ArticleId><ArticleId IdType="pubmed">28150387</ArticleId></ArticleIdList></Reference><Reference><Citation>United Nations Educational, Scientific, and Cultural Organization  International standard classification of education or ISCED-1997. Published 1997.  Accessed November 19, 2020. https://en.unesco.org/themes/education</Citation></Reference><Reference><Citation>Wilson R, Barnes L, Bennett D. Assessment of lifetime participation in cognitively stimulating activities. J Clin Exp Neuropsychol. 2003;25(5):634-642. doi:10.1076/jcen.25.5.634.14572</Citation><ArticleIdList><ArticleId IdType="doi">10.1076/jcen.25.5.634.14572</ArticleId><ArticleId IdType="pubmed">12815501</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson HE, O&#x2019;Connell A. Dementia: the estimation of premorbid intelligence levels using the New Adult Reading Test. Cortex. 1978;14(2):234-244. doi:10.1016/S0010-9452(78)80049-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0010-9452(78)80049-5</ArticleId><ArticleId IdType="pubmed">679704</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmand B, Bakker D, Saan R, Louman J. The Dutch Reading Test for Adults: a measure of premorbid intelligence level. Tijdschr Gerontol Geriatr. 1991;22(1):15-19.</Citation><ArticleIdList><ArticleId IdType="pubmed">1877068</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmand B, Lindeboom J, van Harskamp F. Dutch Adult Reading Test. Swets &amp; Zeitlinger; 1992.</Citation></Reference><Reference><Citation>Ganz AB, Beker N, Hulsman M, et al. ; Netherlands Brain Bank . Neuropathology and cognitive performance in self-reported cognitively healthy centenarians. Acta Neuropathol Commun. 2018;6(1):64. doi:10.1186/s40478-018-0558-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-018-0558-5</ArticleId><ArticleId IdType="pmc">PMC6055341</ArticleId><ArticleId IdType="pubmed">30037350</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, R&#xfc;b U, Schultz C, et al. . Sequence of Abeta-protein deposition in the human medial temporal lobe. J Neuropathol Exp Neurol. 2000;59(8):733-748. doi:10.1093/jnen/59.8.733</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/59.8.733</ArticleId><ArticleId IdType="pubmed">10952063</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239-259. doi:10.1007/BF00308809</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00308809</ArticleId><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006;112(4):389-404. doi:10.1007/s00401-006-0127-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-006-0127-z</ArticleId><ArticleId IdType="pmc">PMC3906709</ArticleId><ArticleId IdType="pubmed">16906426</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Staging of Alzheimer&#x2019;s disease-related neurofibrillary changes. Neurobiol Aging. 1995;16(3):271-278. doi:10.1016/0197-4580(95)00021-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-4580(95)00021-6</ArticleId><ArticleId IdType="pubmed">7566337</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS, Heyman A, McKeel D, et al. . The Consortium to Establish a Registry for Alzheimer&#x2019;s Disease (CERAD)&#x2014;part II, standardization of the neuropathologic assessment of Alzheimer&#x2019;s disease. Neurology. 1991;41(4):479-486. doi:10.1212/WNL.41.4.479</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.41.4.479</ArticleId><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Nylund KL, Asparouhov T, Muth&#xe9;n BO. Deciding on the number of classes in latent class analysis and growth mixture modeling: a Monte Carlo simulation study. Structural equation modeling. 2007;14(4):535-569. doi:10.1080/10705511.2014.882690</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10705511.2014.882690</ArticleId></ArticleIdList></Reference><Reference><Citation>Proust-Lima C, Philipps V, Liquet B. 
Estimation of extended mixed models using latent classes and latent processes: the R package lcmm. Preprint. Posted online January 24, 2015.  Accessed December 4, 2020. arXiv 150300890. https://arxiv.org/pdf/1503.00890.pdf</Citation></Reference><Reference><Citation>Bates D. Computational methods for mixed models. Vignette for lme4. Created October 14, 2007.  Accessed November 19, 2020. http://btr0xq.rz.uni-bayreuth.de/math/statlib/R/CRAN/doc/vignettes/lme4/Theory.pdf</Citation></Reference><Reference><Citation>Wright DB. Some Limits Using Random Slope Models to Measure Academic Growth. Frontiers in Education. 2017;2(58). doi:10.3389/feduc.2017.00058</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/feduc.2017.00058</ArticleId></ArticleIdList></Reference><Reference><Citation>Beker N, Sikkes SAM, Hulsman M, et al. . Longitudinal maintenance of cognitive health in centenarians in the 100-plus Study. JAMA Netw Open. 2020;3(2):e200094. doi:10.1001/jamanetworkopen.2020.0094</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.0094</ArticleId><ArticleId IdType="pmc">PMC7137688</ArticleId><ArticleId IdType="pubmed">32101309</ArticleId></ArticleIdList></Reference><Reference><Citation>Smits LL, van Harten AC, Pijnenburg YA, et al. . Trajectories of cognitive decline in different types of dementia. Psychol Med. 2015;45(5):1051-1059.</Citation><ArticleIdList><ArticleId IdType="pubmed">25229325</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg S. Aging, Behavior, and Terminal Decline. Academic Press; 1996.</Citation></Reference><Reference><Citation>Arenaza-Urquijo EM, Vemuri P. Resistance vs resilience to Alzheimer disease: clarifying terminology for preclinical studies. Neurology. 2018;90(15):695-703. doi:10.1212/WNL.0000000000005303</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000005303</ArticleId><ArticleId IdType="pmc">PMC5894932</ArticleId><ArticleId IdType="pubmed">29592885</ArticleId></ArticleIdList></Reference><Reference><Citation>Arenaza-Urquijo EM, Vemuri P. Improving the resistance and resilience framework for aging and dementia studies. Alzheimers Res Ther. 2020;12(1):41. doi:10.1186/s13195-020-00609-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-020-00609-2</ArticleId><ArticleId IdType="pmc">PMC7158381</ArticleId><ArticleId IdType="pubmed">32290864</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine TJ, Cholerton BA, Corrada MM, et al. . Concepts for brain aging: resistance, resilience, reserve, and compensation. Alzheimers Res Ther. 2019;11(1):22. doi:10.1186/s13195-019-0479-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-019-0479-y</ArticleId><ArticleId IdType="pmc">PMC6410486</ArticleId><ArticleId IdType="pubmed">30857563</ArticleId></ArticleIdList></Reference><Reference><Citation>Khachaturian AS, Corcoran CD, Mayer LS, Zandi PP, Breitner JCS; Cache County Study Investigators . Apolipoprotein E &#x3f5;4 count affects age at onset of Alzheimer disease, but not lifetime susceptibility: the Cache County Study. Arch Gen Psychiatry. 2004;61(5):518-524. doi:10.1001/archpsyc.61.5.518</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archpsyc.61.5.518</ArticleId><ArticleId IdType="pubmed">15123497</ArticleId></ArticleIdList></Reference><Reference><Citation>Balasubramanian AB, Kawas CH, Peltz CB, Brookmeyer R, Corrada MM. Alzheimer disease pathology and longitudinal cognitive performance in the oldest-old with no dementia. Neurology. 2012;79(9):915-921.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3425842</ArticleId><ArticleId IdType="pubmed">22895581</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Yu L, Lamar M, Schneider JA, Boyle PA, Bennett DA. Education and cognitive reserve in old age. Neurology. 2019;92(10):e1041-e1050. doi:10.1212/WNL.0000000000007036</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000007036</ArticleId><ArticleId IdType="pmc">PMC6442015</ArticleId><ArticleId IdType="pubmed">30728309</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagberg B, Samuelsson G.. Survival after 100 years of age: a multivariate model of exceptional survival in Swedish Centenarians. J Gerontol. 2008;63(11):1219-1226. doi:10.1093/gerona/63.11.1219</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gerona/63.11.1219</ArticleId><ArticleId IdType="pubmed">19038837</ArticleId></ArticleIdList></Reference><Reference><Citation>Poon L, Johnson M, Davey A, Dawson D, Siegler I, Martin P. 
Psychosocial predictors of survival among centenarians. Facts, Res, and Intervent in Geriatr. 2000:77-89. Accessed December 4, 2020. http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=1449384</Citation></Reference><Reference><Citation>Samuelsson SM, Alfredson BB, Hagberg B, et al. . The Swedish Centenarian Study: a multidisciplinary study of five consecutive cohorts at the age of 100. Int J Aging Hum Dev. 1997;45(3):223-253. doi:10.2190/XKG9-YP7Y-QJTK-BGPG</Citation><ArticleIdList><ArticleId IdType="doi">10.2190/XKG9-YP7Y-QJTK-BGPG</ArticleId><ArticleId IdType="pubmed">9438877</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawas CH, Corrada MM Successful cognitive aging: what the oldest-old can teach us about resistance and resilience. Neurology. 2020;95(8):329-330. doi:10.1212/WNL.0000000000010251</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000010251</ArticleId><ArticleId IdType="pubmed">32699142</ArticleId></ArticleIdList></Reference><Reference><Citation>Calamia M, Markon K, Tranel D. Scoring higher the second time around: meta-analyses of practice effects in neuropsychological assessment. Clin Neuropsychol. 2012;26(4):543-570. doi:10.1080/13854046.2012.680913</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13854046.2012.680913</ArticleId><ArticleId IdType="pubmed">22540222</ArticleId></ArticleIdList></Reference><Reference><Citation>Christensen K, Thinggaard M, Oksuzyan A, et al. . Physical and cognitive functioning of people older than 90 years: a comparison of two Danish cohorts born 10 years apart. Lancet. 2013;382(9903):1507-1513. doi:10.1016/S0140-6736(13)60777-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(13)60777-1</ArticleId><ArticleId IdType="pmc">PMC3818336</ArticleId><ArticleId IdType="pubmed">23849796</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilsanz P, Corrada MM, Kawas CH, et al. . Incidence of dementia after age 90 in a multiracial cohort. Alzheimers Dement. 2019;15(4):497-505. doi:10.1016/j.jalz.2018.12.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.12.006</ArticleId><ArticleId IdType="pmc">PMC6497045</ArticleId><ArticleId IdType="pubmed">30797730</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33473210</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>08</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>590</Volume><Issue>7844</Issue><PubDate><Year>2021</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Restoring metabolism of myeloid cells reverses cognitive decline in ageing.</ArticleTitle><Pagination><StartPage>122</StartPage><EndPage>128</EndPage><MedlinePgn>122-128</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41586-020-03160-0</ELocationID><Abstract><AbstractText>Ageing is characterized by the development of persistent pro-inflammatory responses that contribute to atherosclerosis, metabolic syndrome, cancer and frailty<sup>1-3</sup>. The ageing brain is also vulnerable to inflammation, as demonstrated by the high prevalence of age-associated cognitive decline and Alzheimer's disease<sup>4-6</sup>. Systemically, circulating pro-inflammatory factors can promote cognitive decline<sup>7,8</sup>, and in the brain, microglia lose the ability to clear misfolded proteins that are associated with neurodegeneration<sup>9,10</sup>. However, the underlying mechanisms that initiate and sustain maladaptive inflammation with ageing are not well defined. Here we show that in ageing mice myeloid cell bioenergetics are suppressed in response to increased signalling by the lipid messenger prostaglandin E<sub>2</sub> (PGE<sub>2</sub>), a major modulator of inflammation<sup>11</sup>. In ageing macrophages and microglia, PGE<sub>2</sub> signalling through its EP2 receptor promotes the sequestration of glucose into glycogen, reducing glucose flux and mitochondrial respiration. This energy-deficient state, which drives maladaptive pro-inflammatory responses, is further augmented by a dependence of aged myeloid cells on glucose as a principal fuel source. In aged mice, inhibition of myeloid EP2 signalling rejuvenates cellular bioenergetics, systemic and brain inflammatory states, hippocampal synaptic plasticity and spatial memory. Moreover, blockade of peripheral myeloid EP2 signalling is sufficient to restore cognition in aged mice. Our study suggests that cognitive ageing is not a static or irrevocable condition but can be reversed by reprogramming myeloid glucose metabolism to restore youthful immune functions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Minhas</LastName><ForeName>Paras S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurosciences Graduate Program, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Scientist Training Program, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Latif-Hernandez</LastName><ForeName>Amira</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>McReynolds</LastName><ForeName>Melanie R</ForeName><Initials>MR</Initials><Identifier Source="ORCID">0000-0001-5427-2739</Identifier><AffiliationInfo><Affiliation>Department of Chemistry, Princeton University, Princeton, NJ, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Durairaj</LastName><ForeName>Aarooran S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rubin</LastName><ForeName>Amanda</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurosciences Graduate Program, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joshi</LastName><ForeName>Amit U</ForeName><Initials>AU</Initials><Identifier Source="ORCID">0000-0002-2472-7672</Identifier><AffiliationInfo><Affiliation>Department of Chemical and Systems Biology, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Joy Q</ForeName><Initials>JQ</Initials><AffiliationInfo><Affiliation>Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gauba</LastName><ForeName>Esha</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Ling</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Princeton University, Princeton, NJ, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Congcong</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-6471-3865</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Linde</LastName><ForeName>Miles</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2553-2890</Identifier><AffiliationInfo><Affiliation>Department of Hematology, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sugiura</LastName><ForeName>Yuki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Keio University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moon</LastName><ForeName>Peter K</ForeName><Initials>PK</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Majeti</LastName><ForeName>Ravi</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Hematology, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suematsu</LastName><ForeName>Makoto</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-7165-6336</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry, Keio University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mochly-Rosen</LastName><ForeName>Daria</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-6691-8733</Identifier><AffiliationInfo><Affiliation>Department of Chemical and Systems Biology, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weissman</LastName><ForeName>Irving L</ForeName><Initials>IL</Initials><Identifier Source="ORCID">0000-0002-9077-7467</Identifier><AffiliationInfo><Affiliation>Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Longo</LastName><ForeName>Frank M</ForeName><Initials>FM</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rabinowitz</LastName><ForeName>Joshua D</ForeName><Initials>JD</Initials><Identifier Source="ORCID">0000-0002-1247-4727</Identifier><AffiliationInfo><Affiliation>Department of Chemistry, Princeton University, Princeton, NJ, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andreasson</LastName><ForeName>Katrin I</ForeName><Initials>KI</Initials><Identifier Source="ORCID">0000-0001-8391-4155</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA. kandreas@stanford.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA, USA. kandreas@stanford.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stanford Immunology Program, Stanford University, Stanford, CA, USA. kandreas@stanford.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R35 CA220434</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>DP1 DK113643</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS087639</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066515</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG058047</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F30 CA228215</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1S10RR02678001</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG048232</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG047366</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>AHA</Acronym><Agency>American Heart Association-American Stroke Association</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>01</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058307">Receptors, Prostaglandin E, EP2 Subtype</NameOfSubstance></Chemical><Chemical><RegistryNumber>9005-79-2</RegistryNumber><NameOfSubstance UI="D006003">Glycogen</NameOfSubstance></Chemical><Chemical><RegistryNumber>IY9XDZ35W2</RegistryNumber><NameOfSubstance UI="D005947">Glucose</NameOfSubstance></Chemical><Chemical><RegistryNumber>K7Q1JQR04M</RegistryNumber><NameOfSubstance UI="D015232">Dinoprostone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2021 Feb;590(7844):44-45. doi: 10.1038/d41586-021-00063-6.</RefSource><PMID Version="1">33473186</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Drug Discov. 2021 Mar;20(3):176. doi: 10.1038/d41573-021-00020-y.</RefSource><PMID Version="1">33510472</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Immunol. 2021 Mar;21(3):133. doi: 10.1038/s41577-021-00515-0.</RefSource><PMID Version="1">33568783</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Cell Metab. 2021 Mar 2;33(3):468-470. doi: 10.1016/j.cmet.2021.02.004.</RefSource><PMID Version="1">33657391</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neuroscientist. 2021 Oct;27(5):453. doi: 10.1177/10738584211041575.</RefSource><PMID Version="1">34519550</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019069" MajorTopicYN="N">Cell Respiration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015232" MajorTopicYN="N">Dinoprostone</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004734" MajorTopicYN="N">Energy Metabolism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005947" MajorTopicYN="N">Glucose</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006003" MajorTopicYN="N">Glycogen</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D022423" MajorTopicYN="N">Myeloid Cells</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058307" MajorTopicYN="N">Receptors, Prostaglandin E, EP2 Subtype</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065852" MajorTopicYN="N">Spatial Memory</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing interests</b> The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>1</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>12</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>1</Month><Day>21</Day><Hour>5</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>8</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33473210</ArticleId><ArticleId IdType="mid">NIHMS1720880</ArticleId><ArticleId IdType="pmc">PMC8274816</ArticleId><ArticleId IdType="doi">10.1038/s41586-020-03160-0</ArticleId><ArticleId IdType="pii">10.1038/s41586-020-03160-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Franceschi C et al. Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech. Ageing Dev 128, 92&#x2013;105 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17116321</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikolich-&#x17d;ugich J The twilight of immunity: emerging concepts in aging of the immune system. Nat. Immunol 19, 10&#x2013;19 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29242543</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrucci L &amp; Fabbri E Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. Nat. Rev. Cardiol 15, 505&#x2013;522 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6146930</ArticleId><ArticleId IdType="pubmed">30065258</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindenberger U Human cognitive aging: corriger la fortune? Science 346, 572&#x2013;578 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25359964</ArticleId></ArticleIdList></Reference><Reference><Citation>Brayne C The elephant in the room&#x2014;healthy brains in later life, epidemiology and public health. Nat. Rev. Neurosci 8, 233&#x2013;239 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17299455</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunningham C &amp; Hennessy E Co-morbidity and systemic inflammation as drivers of cognitive decline: new experimental models adopting a broader paradigm in dementia research. Alzheimers Res. Ther 7, 33 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4369837</ArticleId><ArticleId IdType="pubmed">25802557</ArticleId></ArticleIdList></Reference><Reference><Citation>Villeda SA et al. The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature 477, 90&#x2013;94 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3170097</ArticleId><ArticleId IdType="pubmed">21886162</ArticleId></ArticleIdList></Reference><Reference><Citation>Villeda SA et al. Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice. Nat. Med 20, 659&#x2013;663 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4224436</ArticleId><ArticleId IdType="pubmed">24793238</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarlus H &amp; Heneka MT Microglia in Alzheimer&#x2019;s disease. J. Clin. Invest 127, 3240&#x2013;3249 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5669553</ArticleId><ArticleId IdType="pubmed">28862638</ArticleId></ArticleIdList></Reference><Reference><Citation>Mhatre SD, Tsai CA, Rubin AJ, James ML &amp; Andreasson KI Microglial malfunction: the third rail in the development of Alzheimer&#x2019;s disease. Trends Neurosci 38, 621&#x2013;636 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4670239</ArticleId><ArticleId IdType="pubmed">26442696</ArticleId></ArticleIdList></Reference><Reference><Citation>Ricciotti E &amp; FitzGerald GA Prostaglandins and inflammation. Arterioscler. Thromb. Vasc. Biol 31, 986&#x2013;1000 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3081099</ArticleId><ArticleId IdType="pubmed">21508345</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearce EL &amp; Pearce EJ Metabolic pathways in immune cell activation and quiescence. Immunity 38, 633&#x2013;643 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3654249</ArticleId><ArticleId IdType="pubmed">23601682</ArticleId></ArticleIdList></Reference><Reference><Citation>Biswas SK &amp; Mantovani A Orchestration of metabolism by macrophages. Cell Metab 15, 432&#x2013;437 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22482726</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganeshan K &amp; Chawla A Metabolic regulation of immune responses. Annu. Rev. Immunol 32, 609&#x2013;634 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5800786</ArticleId><ArticleId IdType="pubmed">24655299</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly B &amp; O&#x2019;Neill LA Metabolic reprogramming in macrophages and dendritic cells in innate immunity. Cell Res 25, 771&#x2013;784 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4493277</ArticleId><ArticleId IdType="pubmed">26045163</ArticleId></ArticleIdList></Reference><Reference><Citation>Mills EL, Kelly B &amp; O&#x2019;Neill LAJ Mitochondria are the powerhouses of immunity. Nat. Immunol 18, 488&#x2013;498 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28418387</ArticleId></ArticleIdList></Reference><Reference><Citation>Minhas PS et al. Macrophage de novo NAD+ synthesis specifies immune function in aging and inflammation. Nat. Immunol 20, 50&#x2013;63 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6768398</ArticleId><ArticleId IdType="pubmed">30478397</ArticleId></ArticleIdList></Reference><Reference><Citation>Casolini P, Catalani A, Zuena AR &amp; Angelucci L Inhibition of COX-2 reduces the age-dependent increase of hippocampal inflammatory markers, corticosterone secretion, and behavioral impairments in the rat. J. Neurosci. Res 68, 337&#x2013;343 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12111864</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine TJ et al. Elevated CSF prostaglandin E2 levels in patients with probable AD. Neurology 53, 1495&#x2013;1498 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10534257</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu D &amp; Meydani SN Mechanism of age-associated up-regulation in macrophage PGE2 synthesis. Brain Behav. Immun 18, 487&#x2013;494 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15331118</ArticleId></ArticleIdList></Reference><Reference><Citation>Breyer RM, Bagdassarian CK, Myers SA &amp; Breyer MD Prostanoid receptors: subtypes and signaling. Annu. Rev. Pharmacol. Toxicol 41, 661&#x2013;690 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11264472</ArticleId></ArticleIdList></Reference><Reference><Citation>Forselles KA et al. In vitro and in vivo characterisation of PF-04418948, a novel, potent and selective prostaglandin EP2 receptor antagonist. Br. J. Pharmacol 164, 1847&#x2013;1856 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3246710</ArticleId><ArticleId IdType="pubmed">21595651</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox BM et al. A selective prostaglandin E2 receptor subtype 2 (EP2) antagonist increases the macrophage-mediated clearance of amyloid-beta plaques. J. Med. Chem 58, 5256&#x2013;5273 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26061158</ArticleId></ArticleIdList></Reference><Reference><Citation>Johansson JU et al. Suppression of inflammation with conditional deletion of the prostaglandin E2 EP2 receptor in macrophages and brain microglia. J. Neurosci 33, 16016&#x2013;16032 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3787507</ArticleId><ArticleId IdType="pubmed">24089506</ArticleId></ArticleIdList></Reference><Reference><Citation>Sidhu VK, Huang BX, Desai A, Kevala K &amp; Kim HY Role of DHA in aging-related changes in mouse brain synaptic plasma membrane proteome. Neurobiol. Aging 41, 73&#x2013;85 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4841916</ArticleId><ArticleId IdType="pubmed">27103520</ArticleId></ArticleIdList></Reference><Reference><Citation>VanGuilder HD, Yan H, Farley JA, Sonntag WE &amp; Freeman WM Aging alters the expression of neurotransmission-regulating proteins in the hippocampal synaptoproteome. J. Neurochem 113, 1577&#x2013;1588 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3010414</ArticleId><ArticleId IdType="pubmed">20374424</ArticleId></ArticleIdList></Reference><Reference><Citation>Lynch MA Long-term potentiation and memory. Physiol. Rev 84, 87&#x2013;136 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">14715912</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellone MD, Teramoto H, Williams BO, Druey KM &amp; Gutkind JS Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-&#x3b2;-catenin signaling axis. Science 310, 1504&#x2013;1510 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16293724</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang J &amp; Dingledine R Prostaglandin receptor EP2 in the crosshairs of anti-inflammation, anti-cancer, and neuroprotection. Trends Pharmacol. Sci 34, 413&#x2013;423 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4031445</ArticleId><ArticleId IdType="pubmed">23796953</ArticleId></ArticleIdList></Reference><Reference><Citation>Jha AK et al. Network integration of parallel metabolic and transcriptional data reveals metabolic modules that regulate macrophage polarization. Immunity 42, 419&#x2013;430 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25786174</ArticleId></ArticleIdList></Reference><Reference><Citation>Lampropoulou V et al. Itaconate links inhibition of succinate dehydrogenase with macrophage metabolic remodeling and regulation of inflammation. Cell Metab 24, 158&#x2013;166 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5108454</ArticleId><ArticleId IdType="pubmed">27374498</ArticleId></ArticleIdList></Reference><Reference><Citation>Mills EL et al. Succinate dehydrogenase supports metabolic repurposing of mitochondria to drive inflammatory macrophages. Cell 167, 457&#x2013;470 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5863951</ArticleId><ArticleId IdType="pubmed">27667687</ArticleId></ArticleIdList></Reference><Reference><Citation>Tannahill GM et al. Succinate is an inflammatory signal that induces IL-1&#x3b2; through HIF-1&#x3b1;. Nature 496, 238&#x2013;242 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4031686</ArticleId><ArticleId IdType="pubmed">23535595</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanin DE et al. Mitochondrial membrane potential regulates nuclear gene expression in macrophages exposed to prostaglandin E2. Immunity 49, 1021&#x2013;1033 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7271981</ArticleId><ArticleId IdType="pubmed">30566880</ArticleId></ArticleIdList></Reference><Reference><Citation>Thwe PM et al. Cell-intrinsic glycogen metabolism supports early glycolytic reprogramming required for dendritic cell immune responses. Cell Metab 26, 558&#x2013;567 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5657596</ArticleId><ArticleId IdType="pubmed">28877459</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma J et al. Glycogen metabolism regulates macrophage-mediated acute inflammatory responses. Nat. Commun 11, 1769 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7156451</ArticleId><ArticleId IdType="pubmed">32286295</ArticleId></ArticleIdList></Reference><Reference><Citation>Gauba E, Chen H, Guo L &amp; Du H Cyclophilin D deficiency attenuates mitochondrial F1Fo ATP synthase dysfunction via OSCP in Alzheimer&#x2019;s disease. Neurobiol. Dis 121, 138&#x2013;147 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6250052</ArticleId><ArticleId IdType="pubmed">30266287</ArticleId></ArticleIdList></Reference><Reference><Citation>Johansson JU et al. Prostaglandin signaling suppresses beneficial microglial function in Alzheimer&#x2019;s disease models. J. Clin. Invest 125, 350&#x2013;364 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4382270</ArticleId><ArticleId IdType="pubmed">25485684</ArticleId></ArticleIdList></Reference><Reference><Citation>Aoki T et al. Prostaglandin E2&#x2013;EP2&#x2013;NF-&#x3ba;B signaling in macrophages as a potential therapeutic target for intracranial aneurysms. Sci. Signal 10, eaah6037 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28174280</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodling NS &amp; Andreasson KI Untangling the web: toxic and protective effects of neuroinflammation and PGE2 signaling in Alzheimer&#x2019;s disease. ACS Chem. Neurosci 7, 454&#x2013;463 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5239037</ArticleId><ArticleId IdType="pubmed">26979823</ArticleId></ArticleIdList></Reference><Reference><Citation>Monvoisin A et al. VE-cadherin-CreERT2 transgenic mouse: a model for inducible recombination in the endothelium. Dev. Dyn 235, 3413&#x2013;3422 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17072878</ArticleId></ArticleIdList></Reference><Reference><Citation>Wimmer ME, Hernandez PJ, Blackwell J &amp; Abel T Aging impairs hippocampus-dependent long-term memory for object location in mice. Neurobiol. Aging 33, 2220&#x2013;2224 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3227775</ArticleId><ArticleId IdType="pubmed">21872364</ArticleId></ArticleIdList></Reference><Reference><Citation>Attar A et al. A shortened Barnes maze protocol reveals memory deficits at 4-months of age in the triple-transgenic mouse model of Alzheimer&#x2019;s disease. PLoS ONE 8, e80355 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3827415</ArticleId><ArticleId IdType="pubmed">24236177</ArticleId></ArticleIdList></Reference><Reference><Citation>Latif-Hernandez A, Faldini E, Ahmed T &amp; Balschun D Separate ionotropic and metabotropic glutamate receptor functions in depotentiation vs. LTP: a distinct role for group1 mGluR subtypes and NMDARs. Front. Cell. Neurosci 10, 252 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5098392</ArticleId><ArticleId IdType="pubmed">27872582</ArticleId></ArticleIdList></Reference><Reference><Citation>Su X, Lu W &amp; Rabinowitz JD Metabolite spectral accuracy on Orbitraps. Anal. Chem 89, 5940&#x2013;5948 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5748891</ArticleId><ArticleId IdType="pubmed">28471646</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamashita A et al. Increased metabolite levels of glycolysis and pentose phosphate pathway in rabbit atherosclerotic arteries and hypoxic macrophage. PLoS ONE 9, e86426 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3900532</ArticleId><ArticleId IdType="pubmed">24466087</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada M et al. A comprehensive quantification method for eicosanoids and related compounds by using liquid chromatography/mass spectrometry with high speed continuous ionization polarity switching. J. Chromatogr. B 995&#x2013;996, 74&#x2013;84 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26046978</ArticleId></ArticleIdList></Reference><Reference><Citation>Kita Y, Takahashi T, Uozumi N &amp; Shimizu T A multiplex quantitation method for eicosanoids and platelet-activating factor using column-switching reversed-phase liquid chromatography-tandem mass spectrometry. Anal. Biochem 342, 134&#x2013;143 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15958190</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou L &amp; Li Q Isolation of region-specific microglia from one adult mouse brain hemisphere for deep single-cell RNA sequencing. J. Vis. Exp 154, e60347 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31868174</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33657269</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>12</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-1331</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>6</Issue><PubDate><Year>2021</Year><Month>Jun</Month></PubDate></JournalIssue><Title>European journal of neurology</Title><ISOAbbreviation>Eur J Neurol</ISOAbbreviation></Journal><ArticleTitle>Antiherpetic medication and incident dementia: Observational cohort studies in four countries.</ArticleTitle><Pagination><StartPage>1840</StartPage><EndPage>1848</EndPage><MedlinePgn>1840-1848</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/ene.14795</ELocationID><Abstract><AbstractText Label="BACKGROUND AND PURPOSE">Several epidemiological studies from Taiwan, all using the same data resource, found significant associations between herpes virus infection, antiherpetic medication, and subsequent dementia. We conducted a multicenter observational cohort study using health registry data from Wales, Germany, Scotland, and Denmark to investigate potential associations between antiherpetic medication and incident dementia, and also to comprehensively investigate such associations broken down according to medication type and dose, type of herpes virus, and dementia subtype.</AbstractText><AbstractText Label="METHODS">A total of 2.5 million individuals aged 65&#xa0;years or more were followed up using linked electronic health records in four national observational cohort studies. Exposure and outcome were classified using coded data from primary and secondary care. Data were analyzed using survival analysis with time-dependent covariates.</AbstractText><AbstractText Label="RESULTS">Results were heterogeneous, with a tendency toward decreased dementia risk in individuals exposed to antiherpetic medication. Associations were not affected by treatment number, herpes subtype, dementia subtype, or specific medication. In one cohort, individuals diagnosed with herpes but not exposed to antiherpetic medication were at higher dementia risk.</AbstractText><AbstractText Label="CONCLUSIONS">Short-term antiherpetic medication is not markedly associated with incident dementia. Because neither dementia subtype nor herpes subtype modified the association, the small but significant decrease in dementia incidence with antiherpetic administration may reflect confounding and misclassification.</AbstractText><CopyrightInformation>&#xa9; 2021 The Authors. European Journal of Neurology published by John Wiley &amp; Sons Ltd on behalf of European Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schnier</LastName><ForeName>Christian</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-7238-7871</Identifier><AffiliationInfo><Affiliation>Division of Infection Medicine, University of Edinburgh, Edinburgh, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Janbek</LastName><ForeName>Janet</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-1605-3396</Identifier><AffiliationInfo><Affiliation>Danish Dementia Research Center, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Linda</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Usher Institute, Edinburgh University, Bioquarter, Edinburgh, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilkinson</LastName><ForeName>Tim</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-8952-0982</Identifier><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, Edinburgh University, Edinburgh, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laursen</LastName><ForeName>Thomas M</ForeName><Initials>TM</Initials><Identifier Source="ORCID">0000-0001-6934-1784</Identifier><AffiliationInfo><Affiliation>National Center for Register-Based Research, Department of Economics and Business Economics, Aarhus BSS, Aarhus University, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waldemar</LastName><ForeName>Gunhild</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-0293-220X</Identifier><AffiliationInfo><Affiliation>National Center for Register-Based Research, Department of Economics and Business Economics, Aarhus BSS, Aarhus University, Aarhus, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richter</LastName><ForeName>Hartmut</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>IQVIA Epidemiology, Frankfurt am Main, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kostev</LastName><ForeName>Karel</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-2124-7227</Identifier><AffiliationInfo><Affiliation>IQVIA Epidemiology, Frankfurt am Main, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lathe</LastName><ForeName>Richard</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-9698-9834</Identifier><AffiliationInfo><Affiliation>Division of Infection Medicine, University of Edinburgh, Edinburgh, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G Haas</LastName><ForeName>J&#xfc;rgen</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-4658-4673</Identifier><AffiliationInfo><Affiliation>Division of Infection Medicine, University of Edinburgh, Edinburgh, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/P011349/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>03</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Neurol</MedlineTA><NlmUniqueID>9506311</NlmUniqueID><ISSNLinking>1351-5101</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="Y">Dementia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006566" MajorTopicYN="Y">Herpesviridae Infections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer disease</Keyword><Keyword MajorTopicYN="N">antiviral</Keyword><Keyword MajorTopicYN="N">cognitive decline</Keyword><Keyword MajorTopicYN="N">herpes</Keyword><Keyword MajorTopicYN="N">vascular dementia</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>2</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>1</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>2</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>3</Day><Hour>17</Hour><Minute>11</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33657269</ArticleId><ArticleId IdType="doi">10.1111/ene.14795</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Abbott A. Are infections seeding some cases of Alzheimer's disease? Nature. 2020;587(7832):22-25.</Citation></Reference><Reference><Citation>Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele &#x3f5;4 with late-onset familial and sporadic Alzheimer's disease. Neurology. 1993;43(8):1467-1472.</Citation></Reference><Reference><Citation>Itzhaki RF, Lin WR, Shang D, Wilcock GK, Faragher B, Jamieson GA. Herpes simplex virus type 1 in brain and risk of Alzheimer's disease. Lancet. 1997;349(9047):241-244.</Citation></Reference><Reference><Citation>Powell-Doherty RD, Abbott ARN, Nelson LA, Bertke AS. Amyloid-&#x3b2; and p-Tau anti-threat response to herpes simplex virus 1 infection in primary adult murine hippocampal neurons. J Virol. 2020;94(9):e01874-19.</Citation></Reference><Reference><Citation>Cairns DM, Rouleau N, Parker RN, Walsh KG, Gehrke L, Kaplan DL. A 3D human brain-like tissue model of herpes-induced Alzheimer&#x2019;s disease. Sci Adv. 2020;6(19):eaay8828.</Citation></Reference><Reference><Citation>Bubak AN, Beseler C, Como CN, et al. Amylin, A&#x3b2;42, and amyloid in varicella zoster virus vasculopathy cerebrospinal fluid and infected vascular cells. J Infect Dis. 2020. https://doi.org/10.1093/infdis/jiaa513.</Citation></Reference><Reference><Citation>Tsai MC, Cheng WL, Sheu JJ, et al. Increased risk of dementia following herpes zoster ophthalmicus. PLoS One. 2017;12(11):e0188490.</Citation></Reference><Reference><Citation>Chen VCH, Wu SI, Huang KY, et al. Herpes zoster and dementia: a nationwide population-based cohort study. J Clin Psychiatry. 2018;79(1):16m11312.</Citation></Reference><Reference><Citation>Tzeng N-S, Chung C-H, Lin F-H, et al. Anti-herpetic medications and reduced risk of dementia in patients with herpes simplex virus infections-a nationwide population-based cohort study in Taiwan. Neurotherapeutics. 2018;15(2):417-429.</Citation></Reference><Reference><Citation>Bae S, Yun S-C, Kim M-C, et al. Association of herpes zoster with dementia and effect of antiviral therapy on dementia: a population-based cohort study. European Archives of Psychiatry and Clinical Neuroscience. 2020;http://dx.doi.org/10.1007/s00406-020-01157-4.</Citation></Reference><Reference><Citation>Warren-Gash C, Forbes HJ, Williamson E, et al. Human herpesvirus infections and dementia or mild cognitive impairment: a systematic review and meta-analysis. Sci Rep. 2019;9(1):4743.</Citation></Reference><Reference><Citation>Lyons RA, Jones KH, John G, et al. The SAIL databank: linking multiple health and social care datasets. BMC Med Inform Decis Mak. 2009;9(1). https://doi.org/10.1186/1472-6947-9-3.</Citation></Reference><Reference><Citation>Rathmann W, Bongaerts B, Carius HJ, Kruppert S, Kostev K. Basic characteristics and representativeness of the German Disease Analyzer database. Int J Clin Pharmacol Ther. 2018;56(10):459-466.</Citation></Reference><Reference><Citation>Pedersen CB. The Danish civil registration system. Scand J Public Health. 2011;39(7):22-25.</Citation></Reference><Reference><Citation>Schmidt M, Schmidt SAJ, Sandegaard JL, Ehrenstein V, Pedersen L, S&#xf8;rensen HT. The Danish National patient registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449-490.</Citation></Reference><Reference><Citation>Wallach Kildemoes H, Toft S&#xf8;rensen H, Hallas J. The Danish national prescription registry. Scand J Public Health. 2011;39(7):38-41.</Citation></Reference><Reference><Citation>Hagger-Johnson G. Opportunities for longitudinal data linkage in Scotland. Scott Med J. 2016;61(3):136-145.</Citation></Reference><Reference><Citation>Wilkinson T, Schnier C, Bush K, et al. Identifying dementia outcomes in UK Biobank: a validation study of primary care, hospital admissions and mortality data. Eur J Epidemiol. 2019;34(6):557-565.</Citation></Reference><Reference><Citation>Phung TKT, Andersen BB, H&#xf8;gh P, Kessing LV, Mortensen PB, Waldemar G. Validity of dementia diagnoses in the Danish hospital registers. Dement Geriatr Cogn Disord. 2007;24(3):220-228.</Citation></Reference><Reference><Citation>Friedman M. Piecewise exponential models for survival data with covariates. Ann Stat. 1982;10(1):101-113.</Citation></Reference><Reference><Citation>Therneau TM. A Package for Survival Analysis in R. R package version 3.2-7. 2020. https://CRAN.R-project.org/package=survival.</Citation></Reference><Reference><Citation>Therneau T. coxme: mixed effects Cox models. R package version 2.2-3. Oikos. 2012. Retrieved from www.cran.R-project.org/package=coxme</Citation></Reference><Reference><Citation>Corbo RM, Scacchi R. Apolipoprotein E (APOE) allele distribution in the world. Is APOE * 4 a &#x2018;thrifty&#x2019; allele? Ann Hum Genet. 1999;63(4):301-310.</Citation></Reference><Reference><Citation>Pincus T, Callahan LF. What explains the association between socioeconomic status and health: primarily access to medical care or mind-body variables? Advances. 1995;11(1):4-36.</Citation></Reference><Reference><Citation>Wilkinson T, Schnier C, Bush K, Hutchison A, Rannikm&#xe4;e K, Sudlow C. P1-559: drug prescriptions and dementia incidence: a medication-wide association study. Alzheimer's Dement. 2019;15:P488-P489.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33495636</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>29</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>3</Issue><PubDate><Year>2021</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Phagocyte-mediated synapse removal in cortical neuroinflammation is promoted by local calcium accumulation.</ArticleTitle><Pagination><StartPage>355</StartPage><EndPage>367</EndPage><MedlinePgn>355-367</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41593-020-00780-7</ELocationID><Abstract><AbstractText>Cortical pathology contributes to chronic cognitive impairment of patients suffering from the neuroinflammatory disease multiple sclerosis (MS). How such gray matter inflammation affects neuronal structure and function is not well understood. In the present study, we use functional and structural in vivo imaging in a mouse model of cortical MS to demonstrate that bouts of cortical inflammation disrupt cortical circuit activity coincident with a widespread, but transient, loss of dendritic spines. Spines destined for removal show local calcium accumulations and are subsequently removed by invading macrophages or activated microglia. Targeting phagocyte activation with a new antagonist of the colony-stimulating factor 1 receptor prevents cortical synapse loss. Overall, our study identifies synapse loss as a key pathological feature of inflammatory gray matter lesions that is amenable to immunomodulatory therapy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Jafari</LastName><ForeName>Mehrnoosh</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Clinical Neuroimmunology, University Hospital, Ludwig-Maximilians University Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Center, Faculty of Medicine, Ludwig-Maximilians University Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Schumacher</LastName><ForeName>Adrian-Minh</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Institute of Clinical Neuroimmunology, University Hospital, Ludwig-Maximilians University Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Center, Faculty of Medicine, Ludwig-Maximilians University Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Snaidero</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Institute of Clinical Neuroimmunology, University Hospital, Ludwig-Maximilians University Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Neuronal Cell Biology, Technical University of Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ullrich Gavilanes</LastName><ForeName>Emily M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Institute of Clinical Neuroimmunology, University Hospital, Ludwig-Maximilians University Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Center, Faculty of Medicine, Ludwig-Maximilians University Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neziraj</LastName><ForeName>Tradite</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institute of Clinical Neuroimmunology, University Hospital, Ludwig-Maximilians University Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Center, Faculty of Medicine, Ludwig-Maximilians University Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kocsis-Jutka</LastName><ForeName>Vir&#xe1;g</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Institute of Clinical Neuroimmunology, University Hospital, Ludwig-Maximilians University Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Center, Faculty of Medicine, Ludwig-Maximilians University Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Engels</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute of Clinical Neuroimmunology, University Hospital, Ludwig-Maximilians University Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Center, Faculty of Medicine, Ludwig-Maximilians University Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>J&#xfc;rgens</LastName><ForeName>Tanja</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wagner</LastName><ForeName>Ingrid</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weidinger</LastName><ForeName>Juan Daniel Fl&#xf3;rez</ForeName><Initials>JDF</Initials><AffiliationInfo><Affiliation>Max Planck Institute for Dynamics and Self-Organization, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bernstein Center for Computational Neuroscience, University of G&#xf6;ttingen, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Max Planck Institute for Experimental Medicine, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Biostructural Imaging of Neurodegeneration, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Stephanie S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Institute of Clinical Neuroimmunology, University Hospital, Ludwig-Maximilians University Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beltr&#xe1;n</LastName><ForeName>Eduardo</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-7266-4098</Identifier><AffiliationInfo><Affiliation>Institute of Clinical Neuroimmunology, University Hospital, Ludwig-Maximilians University Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Center, Faculty of Medicine, Ludwig-Maximilians University Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hagan</LastName><ForeName>Nellwyn</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Rare and Neurological Disease Research, Sanofi, Framingham, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woodworth</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Rare and Neurological Disease Research, Sanofi, Framingham, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ofengeim</LastName><ForeName>Dimitry</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Rare and Neurological Disease Research, Sanofi, Framingham, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gans</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Translational Sciences Genomics, Sanofi, Framingham, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolf</LastName><ForeName>Fred</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Max Planck Institute for Dynamics and Self-Organization, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bernstein Center for Computational Neuroscience, University of G&#xf6;ttingen, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Max Planck Institute for Experimental Medicine, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Biostructural Imaging of Neurodegeneration, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Campus Institute for Dynamics of Biological Networks, University of G&#xf6;ttingen, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kreutzfeldt</LastName><ForeName>Mario</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-0335-2733</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Clinical Pathology, Geneva University Hospital, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Portugues</LastName><ForeName>Ruben</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-1495-9314</Identifier><AffiliationInfo><Affiliation>Sensorimotor Control, Max Planck Institute of Neurobiology, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merkler</LastName><ForeName>Doron</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-0247-2007</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland. doron.merkler@unige.ch.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Clinical Pathology, Geneva University Hospital, Geneva, Switzerland. doron.merkler@unige.ch.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Misgeld</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-9875-6794</Identifier><AffiliationInfo><Affiliation>Institute of Neuronal Cell Biology, Technical University of Munich, Munich, Germany. thomas.misgeld@tum.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, Munich, Germany. thomas.misgeld@tum.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany. thomas.misgeld@tum.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kerschensteiner</LastName><ForeName>Martin</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-4898-9383</Identifier><AffiliationInfo><Affiliation>Institute of Clinical Neuroimmunology, University Hospital, Ludwig-Maximilians University Munich, Munich, Germany. martin.kerschensteiner@med.uni-muenchen.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Center, Faculty of Medicine, Ludwig-Maximilians University Munich, Munich, Germany. martin.kerschensteiner@med.uni-muenchen.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany. martin.kerschensteiner@med.uni-muenchen.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>01</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Drug Discov. 2021 Mar;20(3):178. doi: 10.1038/d41573-021-00024-8.</RefSource><PMID Version="1">33564176</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049229" MajorTopicYN="N">Dendritic Spines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066128" MajorTopicYN="N">Gray Matter</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009103" MajorTopicYN="N">Multiple Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010586" MajorTopicYN="N">Phagocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>12</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>1</Month><Day>26</Day><Hour>5</Hour><Minute>47</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33495636</ArticleId><ArticleId IdType="doi">10.1038/s41593-020-00780-7</ArticleId><ArticleId IdType="pii">10.1038/s41593-020-00780-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Reich, D. S., Lucchinetti, C. F. &amp; Calabresi, P. A. Multiple sclerosis. N. Engl. J. Med. 378, 169&#x2013;180 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29320652</ArticleId><ArticleId IdType="pmc">6942519</ArticleId><ArticleId IdType="doi">10.1056/NEJMra1401483</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahad, D. H., Trapp, B. D. &amp; Lassmann, H. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol. 14, 183&#x2013;193 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25772897</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(14)70256-X</ArticleId></ArticleIdList></Reference><Reference><Citation>Damjanovic, D. et al. Hippocampal and deep gray matter nuclei atrophy is relevant for explaining cognitive impairment in MS: a multicenter study. Am. J. Neuroradiol. 38, 18&#x2013;24 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27686487</ArticleId><ArticleId IdType="pmc">7963669</ArticleId><ArticleId IdType="doi">10.3174/ajnr.A4952</ArticleId></ArticleIdList></Reference><Reference><Citation>Eshaghi, A. et al. Deep gray matter volume loss drives disability worsening in multiple sclerosis. Ann. Neurol. 83, 210&#x2013;222 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29331092</ArticleId><ArticleId IdType="pmc">5838522</ArticleId><ArticleId IdType="doi">10.1002/ana.25145</ArticleId></ArticleIdList></Reference><Reference><Citation>Scalfari, A. et al. The cortical damage, early relapses, and onset of the progressive phase in multiple sclerosis. Neurology 90, e2099&#x2013;e2106 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000005685</ArticleId></ArticleIdList></Reference><Reference><Citation>Peterson, J. W., B&#xf6;, L., M&#xf6;rk, S., Chang, A. &amp; Trapp, B. D. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann. Neurol. 50, 389&#x2013;400 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11558796</ArticleId><ArticleId IdType="doi">10.1002/ana.1123</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagumersindez-Denis, N. et al. Differential contribution of immune effector mechanisms to cortical demyelination in multiple sclerosis. Acta Neuropathol. 134, 15&#x2013;34 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28386765</ArticleId><ArticleId IdType="pmc">5486638</ArticleId><ArticleId IdType="doi">10.1007/s00401-017-1706-x</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#xfc;rgens, T. et al. Reconstruction of single cortical projection neurons reveals primary spine loss in multiple sclerosis. Brain 139, 39&#x2013;46 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26667278</ArticleId><ArticleId IdType="doi">10.1093/brain/awv353</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert, M. et al. Synaptic pathology in the cerebellar dentate nucleus in chronic multiple sclerosis. Brain Pathol. 27, 737&#x2013;747 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27706868</ArticleId><ArticleId IdType="pmc">8028945</ArticleId><ArticleId IdType="doi">10.1111/bpa.12450</ArticleId></ArticleIdList></Reference><Reference><Citation>Rose, T., Jaepel, J., H&#xfc;bener, M. &amp; Bonhoeffer, T. Cell-specific restoration of stimulus preference after monocular deprivation in the visual cortex. Science 352, 1319&#x2013;1322 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27284193</ArticleId><ArticleId IdType="doi">10.1126/science.aad3358</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu, T. et al. Rapid formation and selective stabilization of synapses for enduring motor memories. Nature 462, 915&#x2013;919 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19946267</ArticleId><ArticleId IdType="pmc">2844762</ArticleId><ArticleId IdType="doi">10.1038/nature08389</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuchibhotla, K. V. et al. A&#x3b2; plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks. Neuron 59, 214&#x2013;225 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18667150</ArticleId><ArticleId IdType="pmc">2578820</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2008.06.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Merlini, M. et al. Fibrinogen induces microglia-mediated spine elimination and cognitive impairment in an Alzheimer&#x2019;s disease model. Neuron 101, 1099&#x2013;1108.e6 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30737131</ArticleId><ArticleId IdType="pmc">6602536</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2019.01.014</ArticleId></ArticleIdList></Reference><Reference><Citation>Merkler, D., Ernsting, T., Kerschensteiner, M., Br&#xfc;ck, W. &amp; Stadelmann, C. A new focal EAE model of cortical demyelination: multiple sclerosis-like lesions with rapid resolution of inflammation and extensive remyelination. Brain 129, 1972&#x2013;1983 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16714315</ArticleId><ArticleId IdType="doi">10.1093/brain/awl135</ArticleId></ArticleIdList></Reference><Reference><Citation>Gardner, C. et al. Cortical grey matter demyelination can be induced by elevated pro-inflammatory cytokines in the subarachnoid space of MOG-immunized rats. Brain 136, 3596&#x2013;3608 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24176976</ArticleId><ArticleId IdType="doi">10.1093/brain/awt279</ArticleId></ArticleIdList></Reference><Reference><Citation>Lodygin, D. et al. &#x3b2;-Synuclein-reactive T cells induce autoimmune CNS grey matter degeneration. Nature 566, 503&#x2013;508 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30787438</ArticleId><ArticleId IdType="doi">10.1038/s41586-019-0964-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Magliozzi, R. et al. Inflammatory intrathecal profiles and cortical damage in multiple sclerosis. Ann. Neurol. 83, 739&#x2013;755 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29518260</ArticleId><ArticleId IdType="doi">10.1002/ana.25197</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucchinetti, C. F. et al. Inflammatory cortical demyelination in early multiple sclerosis. N. Engl. J. Med. 365, 2188&#x2013;2197 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">22150037</ArticleId><ArticleId IdType="pmc">3282172</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1100648</ArticleId></ArticleIdList></Reference><Reference><Citation>Dana, H. et al. Thy1-GCaMP6 transgenic mice for neuronal population imaging in vivo. PLoS ONE 9, e108697 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25250714</ArticleId><ArticleId IdType="pmc">4177405</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0108697</ArticleId></ArticleIdList></Reference><Reference><Citation>Schain, A. J., Hill, R. A. &amp; Grutzendler, J. Label-free in vivo imaging of myelinated axons in health and disease with spectral confocal reflectance microscopy. Nat. Med. 20, 443&#x2013;449 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24681598</ArticleId><ArticleId IdType="pmc">3981936</ArticleId><ArticleId IdType="doi">10.1038/nm.3495</ArticleId></ArticleIdList></Reference><Reference><Citation>Siffrin, V. et al. In vivo imaging of partially reversible Th17 cell-induced neuronal dysfunction in the course of encephalomyelitis. Immunity 33, 424&#x2013;436 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20870176</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2010.08.018</ArticleId></ArticleIdList></Reference><Reference><Citation>Witte, M. E. et al. Calcium influx through plasma-membrane nanoruptures drives axon degeneration in a model of multiple sclerosis. Neuron 101, 615&#x2013;624.e5 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30686733</ArticleId><ArticleId IdType="pmc">6389591</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2018.12.023</ArticleId></ArticleIdList></Reference><Reference><Citation>Thestrup, T. et al. Optimized ratiometric calcium sensors for functional in vivo imaging of neurons and T lymphocytes. Nat. Methods 11, 175&#x2013;182 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24390440</ArticleId><ArticleId IdType="doi">10.1038/nmeth.2773</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamasaki, R. et al. Differential roles of microglia and monocytes in the inflamed central nervous system. J. Exp. Med. 211, 1533&#x2013;1549 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25002752</ArticleId><ArticleId IdType="pmc">4113947</ArticleId><ArticleId IdType="doi">10.1084/jem.20132477</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagan, N. et al. CSF1R signaling is a regulator of pathogenesis in progressive MS. Cell Death Dis. 11, 904 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33097690</ArticleId><ArticleId IdType="pmc">7584629</ArticleId><ArticleId IdType="doi">10.1038/s41419-020-03084-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Nissen, J. C., Thompson, K. K., West, B. L. &amp; Tsirka, S. E. Csf1R inhibition attenuates experimental autoimmune encephalomyelitis and promotes recovery. Exp. Neurol. 307, 24&#x2013;36 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29803827</ArticleId><ArticleId IdType="pmc">6380683</ArticleId><ArticleId IdType="doi">10.1016/j.expneurol.2018.05.021</ArticleId></ArticleIdList></Reference><Reference><Citation>Olmos-Alonso, A. et al. Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer&#x2019;s-like pathology. Brain 139, 891&#x2013;907 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26747862</ArticleId><ArticleId IdType="pmc">4766375</ArticleId><ArticleId IdType="doi">10.1093/brain/awv379</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang, D., Wang, J., Kivisakk, P., Rollins, B. J. &amp; Ransohoff, R. M. Absence of monocyte chemoattractant protein 1 in mice leads to decreased local macrophage recruitment and antigen-specific T helper cell type 1 immune response in experimental autoimmune encephalomyelitis. J. Exp. Med. 193, 713&#x2013;725 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11257138</ArticleId><ArticleId IdType="pmc">2193420</ArticleId><ArticleId IdType="doi">10.1084/jem.193.6.713</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann, S. et al. The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity 47, 566&#x2013;581.e9 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28930663</ArticleId><ArticleId IdType="pmc">5719893</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2017.08.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Calabrese, M. et al. Cortical lesion load associates with progression of disability in multiple sclerosis. Brain 135, 2952&#x2013;2961 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">23065788</ArticleId><ArticleId IdType="doi">10.1093/brain/aws246</ArticleId></ArticleIdList></Reference><Reference><Citation>Dutta, R. et al. Demyelination causes synaptic alterations in hippocampi from multiple sclerosis patients. Ann. Neurol. 69, 445&#x2013;454 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21446020</ArticleId><ArticleId IdType="pmc">3073544</ArticleId><ArticleId IdType="doi">10.1002/ana.22337</ArticleId></ArticleIdList></Reference><Reference><Citation>Michailidou, I. et al. Complement C1q-C3-associated synaptic changes in multiple sclerosis hippocampus. Ann. Neurol. 77, 1007&#x2013;1026 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25727254</ArticleId><ArticleId IdType="doi">10.1002/ana.24398</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry, R. D. et al. Physical basis of cognitive alterations in alzheimer&#x2019;s disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 30, 572&#x2013;580 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId><ArticleId IdType="doi">10.1002/ana.410300410</ArticleId></ArticleIdList></Reference><Reference><Citation>Busche, M. A. et al. Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer&#x2019;s disease. Science 321, 1686&#x2013;1689 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18802001</ArticleId><ArticleId IdType="doi">10.1126/science.1162844</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x160;i&#x161;kov&#xe1;, Z. et al. Dendritic structural degeneration is functionally linked to cellular hyperexcitability in a mouse model of Alzheimer&#x2019;s disease. Neuron 84, 1023&#x2013;1033 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25456500</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2014.10.024</ArticleId></ArticleIdList></Reference><Reference><Citation>Marinkovi&#x107;, P. et al. In vivo imaging reveals reduced activity of neuronal circuits in a mouse tauopathy model. Brain 142, 1051&#x2013;1062 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30847469</ArticleId><ArticleId IdType="doi">10.1093/brain/awz035</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocca, M. A. et al. Default-mode network dysfunction and cognitive impairment in progressive MS. Neurology 74, 1252&#x2013;1259 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20404306</ArticleId><ArticleId IdType="doi">10.1212/WNL.0b013e3181d9ed91</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerschensteiner, M. et al. Remodeling of axonal connections contributes to recovery in an animal model of multiple sclerosis. J. Exp. Med. 200, 1027&#x2013;1038 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15492125</ArticleId><ArticleId IdType="pmc">2211840</ArticleId><ArticleId IdType="doi">10.1084/jem.20040452</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellwardt, E. et al. Maladaptive cortical hyperactivity upon recovery from experimental autoimmune encephalomyelitis. Nat. Neurosci. 21, 1392&#x2013;1403 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30258239</ArticleId><ArticleId IdType="doi">10.1038/s41593-018-0193-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Jawaid, S. et al. Alterations in CA1 hippocampal synapses in a mouse model of fragile X syndrome. Glia 66, 789&#x2013;800 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29274095</ArticleId><ArticleId IdType="doi">10.1002/glia.23284</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasek, M. J. et al. A complement-microglial axis drives synapse loss during virus-induced memory impairment. Nature 534, 538&#x2013;543 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27337340</ArticleId><ArticleId IdType="pmc">5452615</ArticleId><ArticleId IdType="doi">10.1038/nature18283</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Liberto, G. et al. Neurons under T cell attack coordinate phagocyte-mediated synaptic stripping. Cell 175, 458&#x2013;471.e19 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30173917</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2018.07.049</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy, K. L. et al. Synaptic alterations and immune response are sexually dimorphic in a non-pertussis toxin model of experimental autoimmune encephalomyelitis. Exp. Neurol. 323, 113061 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31499065</ArticleId><ArticleId IdType="doi">10.1016/j.expneurol.2019.113061</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong, S. &amp; Stevens, B. Microglia: phagocytosing to clear, sculpt, and eliminate. Dev. Cell 38, 126&#x2013;128 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27459063</ArticleId><ArticleId IdType="doi">10.1016/j.devcel.2016.07.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond, J. W. et al. Complement-dependent synapse loss and microgliosis in a mouse model of multiple sclerosis. Brain Behav. Immun. 87, 739&#x2013;750 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32151684</ArticleId><ArticleId IdType="pmc">8698220</ArticleId><ArticleId IdType="doi">10.1016/j.bbi.2020.03.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Werneburg, S. et al. Targeted complement inhibition at synapses prevents microglial synaptic engulfment and synapse loss in demyelinating disease. Immunity 52, 167&#x2013;182.e7 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31883839</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2019.12.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Tufail, Y. et al. Phosphatidylserine exposure controls viral innate immune responses by microglia. Neuron 93, 574&#x2013;586.e8 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28111081</ArticleId><ArticleId IdType="pmc">5600182</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2016.12.021</ArticleId></ArticleIdList></Reference><Reference><Citation>Andres, A. L. et al. NMDA receptor activation and calpain contribute to disruption of dendritic spines by the stress neuropeptide CRH. J. Neurosci. 33, 16945&#x2013;16960 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24155300</ArticleId><ArticleId IdType="pmc">3807024</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.1445-13.2013</ArticleId></ArticleIdList></Reference><Reference><Citation>Schirmer, L. et al. Neuronal vulnerability and multilineage diversity in multiple sclerosis. Nature 573, 75&#x2013;82 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31316211</ArticleId><ArticleId IdType="pmc">6731122</ArticleId><ArticleId IdType="doi">10.1038/s41586-019-1404-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanabe, S., Saitoh, S., Miyajima, H., Itokazu, T. &amp; Yamashita, T. Microglia suppress the secondary progression of autoimmune encephalomyelitis. Glia 67, 1694&#x2013;1704 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31106910</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtmaat, A. et al. Long-term, high-resolution imaging in the mouse neocortex through a chronic cranial window. Nat. Protoc. 4, 1128&#x2013;1144 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19617885</ArticleId><ArticleId IdType="pmc">3072839</ArticleId><ArticleId IdType="doi">10.1038/nprot.2009.89</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider, C. A., Rasband, W. S. &amp; Eliceiri, K. W. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 9, 671&#x2013;675 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22930834</ArticleId><ArticleId IdType="pmc">5554542</ArticleId><ArticleId IdType="doi">10.1038/nmeth.2089</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez, A. et al. Automated reconstruction of three-dimensional neuronal morphology from laser scanning microscopy images. Methods 30, 94&#x2013;105 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12695107</ArticleId><ArticleId IdType="doi">10.1016/S1046-2023(03)00011-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Wearne, S. L. et al. New techniques for imaging, digitization and analysis of three-dimensional neural morphology on multiple scales. Neuroscience 136, 661&#x2013;680 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16344143</ArticleId><ArticleId IdType="doi">10.1016/j.neuroscience.2005.05.053</ArticleId></ArticleIdList></Reference><Reference><Citation>R Core Team. R: A Language and Environment for Statistical Computing (R Foundation for Statistical Computing, 2014); https://www.R-project.org .</Citation></Reference><Reference><Citation>Vogelstein, J. T. et al. Fast nonnegative deconvolution for spike train inference from population calcium imaging. J. Neurophysiol. 104, 3691&#x2013;3704 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20554834</ArticleId><ArticleId IdType="pmc">3007657</ArticleId><ArticleId IdType="doi">10.1152/jn.01073.2009</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler, A., Hoffman, P., Smibert, P., Papalexi, E. &amp; Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36, 411&#x2013;420 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29608179</ArticleId><ArticleId IdType="pmc">6700744</ArticleId><ArticleId IdType="doi">10.1038/nbt.4096</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahmmoud, R. R. et al. Spatial and working memory is linked to spine density and mushroom spines. PLoS ONE 10, e0139739 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26469788</ArticleId><ArticleId IdType="pmc">4607435</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0139739</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, J. L. et al. Pathway-specific reorganization of projection neurons in somatosensory cortex during learning. Nat. Neurosci. 18, 1101&#x2013;1108 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26098757</ArticleId><ArticleId IdType="doi">10.1038/nn.4046</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacmeister, C. M. et al. Motor learning promotes remyelination via new and surviving oligodendrocytes. Nat. Neurosci. 23, 819&#x2013;831 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32424285</ArticleId><ArticleId IdType="pmc">7329620</ArticleId><ArticleId IdType="doi">10.1038/s41593-020-0637-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Snaidero, N. et al. Myelin membrane wrapping of CNS axons by PI(3,4,5)P3-dependent polarized growth at the inner tongue. Cell 156, 277&#x2013;290 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24439382</ArticleId><ArticleId IdType="pmc">4862569</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2013.11.044</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33496840</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>05</Day></DateCompleted><DateRevised><Year>2025</Year><Month>01</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-0533</ISSN><JournalIssue CitedMedium="Internet"><Volume>141</Volume><Issue>3</Issue><PubDate><Year>2021</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Acta neuropathologica</Title><ISOAbbreviation>Acta Neuropathol</ISOAbbreviation></Journal><ArticleTitle>Photodynamic studies reveal rapid formation and appreciable turnover of tau inclusions.</ArticleTitle><Pagination><StartPage>359</StartPage><EndPage>381</EndPage><MedlinePgn>359-381</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00401-021-02264-9</ELocationID><Abstract><AbstractText>Accumulation of the tau protein in fibrillar intracellular aggregates is a defining feature of multiple neurodegenerative diseases collectively referred to as tauopathies. Despite intensive study of tau, there is limited information on the formation and clearance dynamics of tau inclusions. Using rAAV vectors to mediate expression of Dendra2-tagged human wild-type, P301L and pro-aggregant P301L/S320F tau proteins, with and without the addition of exogenous tau fibrillar seeds, we evaluated tau inclusion dynamics in organotypic brain slice culture (BSC) models using long-term optical pulse labeling methodology. Our studies reveal that tau inclusions typically form in 12-96&#xa0;h in tauopathy BSC models. Unexpectedly, we demonstrate appreciable turnover of tau within inclusions with an average half-life of&#x2009;~&#x2009;1&#xa0;week when inclusions are newly formed. When BSCs with inclusions are aged in culture for extended periods, tau inclusions continue to turnover, but their half-lives increase to&#x2009;~&#x2009;2&#xa0;weeks and&#x2009;~&#x2009;3&#xa0;weeks after 1 and 2&#xa0;months in culture, respectively. Individual tau inclusions can be long-lived structures that can persist for months in these BSC models and for even longer in the human brain. However, our data indicate that tau inclusions, are not 'tombstones', but dynamic structures with appreciable turnover. Understanding the cellular processes mediating this inclusion turnover may lead to new therapeutic strategies that could reverse pathological tau inclusion formation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Croft</LastName><ForeName>Cara L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, College of Medicine, University of Florida, Gainesville, FL, 32610, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Translational Research in Neurodegenerative Disease, College of Medicine, University of Florida, Gainesville, FL, 32610, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>McKnight Brain Institute, College of Medicine, University of Florida, Gainesville, FL, 32610, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute at University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goodwin</LastName><ForeName>Marshall S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, College of Medicine, University of Florida, Gainesville, FL, 32610, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Translational Research in Neurodegenerative Disease, College of Medicine, University of Florida, Gainesville, FL, 32610, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>McKnight Brain Institute, College of Medicine, University of Florida, Gainesville, FL, 32610, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryu</LastName><ForeName>Daniel H</ForeName><Initials>DH</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, College of Medicine, University of Florida, Gainesville, FL, 32610, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Translational Research in Neurodegenerative Disease, College of Medicine, University of Florida, Gainesville, FL, 32610, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lessard</LastName><ForeName>Christian B</ForeName><Initials>CB</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, College of Medicine, University of Florida, Gainesville, FL, 32610, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Translational Research in Neurodegenerative Disease, College of Medicine, University of Florida, Gainesville, FL, 32610, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>McKnight Brain Institute, College of Medicine, University of Florida, Gainesville, FL, 32610, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tejeda</LastName><ForeName>Giancarlo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, College of Medicine, University of Florida, Gainesville, FL, 32610, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Translational Research in Neurodegenerative Disease, College of Medicine, University of Florida, Gainesville, FL, 32610, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marrero</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, College of Medicine, University of Florida, Gainesville, FL, 32610, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Translational Research in Neurodegenerative Disease, College of Medicine, University of Florida, Gainesville, FL, 32610, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vause</LastName><ForeName>Ava R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, College of Medicine, University of Florida, Gainesville, FL, 32610, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Translational Research in Neurodegenerative Disease, College of Medicine, University of Florida, Gainesville, FL, 32610, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paterno</LastName><ForeName>Giavanna</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, College of Medicine, University of Florida, Gainesville, FL, 32610, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Translational Research in Neurodegenerative Disease, College of Medicine, University of Florida, Gainesville, FL, 32610, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cruz</LastName><ForeName>Pedro E</ForeName><Initials>PE</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, College of Medicine, University of Florida, Gainesville, FL, 32610, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Translational Research in Neurodegenerative Disease, College of Medicine, University of Florida, Gainesville, FL, 32610, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>McKnight Brain Institute, College of Medicine, University of Florida, Gainesville, FL, 32610, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lewis</LastName><ForeName>Jada</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, College of Medicine, University of Florida, Gainesville, FL, 32610, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Translational Research in Neurodegenerative Disease, College of Medicine, University of Florida, Gainesville, FL, 32610, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>McKnight Brain Institute, College of Medicine, University of Florida, Gainesville, FL, 32610, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giasson</LastName><ForeName>Benoit I</ForeName><Initials>BI</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, College of Medicine, University of Florida, Gainesville, FL, 32610, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Translational Research in Neurodegenerative Disease, College of Medicine, University of Florida, Gainesville, FL, 32610, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>McKnight Brain Institute, College of Medicine, University of Florida, Gainesville, FL, 32610, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Golde</LastName><ForeName>Todd E</ForeName><Initials>TE</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, College of Medicine, University of Florida, Gainesville, FL, 32610, USA. tgolde@ufl.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Translational Research in Neurodegenerative Disease, College of Medicine, University of Florida, Gainesville, FL, 32610, USA. tgolde@ufl.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>McKnight Brain Institute, College of Medicine, University of Florida, Gainesville, FL, 32610, USA. tgolde@ufl.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, College of Medicine, University of Florida, Gainesville, FL, 32610, USA. tgolde@ufl.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>RF1AG064914</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01AG046139</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG064914</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50AG047266</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30AG066506</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066506</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>01</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Acta Neuropathol</MedlineTA><NlmUniqueID>0412041</NlmUniqueID><ISSNLinking>0001-6322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2021 Mar;17(3):132. doi: 10.1038/s41582-021-00469-w.</RefSource><PMID Version="1">33564185</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002479" MajorTopicYN="N">Inclusion Bodies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009924" MajorTopicYN="N">Organ Culture Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Brain slice culture</Keyword><Keyword MajorTopicYN="N">Microtubule-associated protein tau</Keyword><Keyword MajorTopicYN="N">Optical pulse labeling</Keyword><Keyword MajorTopicYN="N">Recombinant adeno-associated viruses</Keyword><Keyword MajorTopicYN="N">Tau inclusion turnover</Keyword></KeywordList><CoiStatement>TEG is a founder of Lacerta Therapeutics.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>1</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>1</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>1</Month><Day>26</Day><Hour>12</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>1</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33496840</ArticleId><ArticleId IdType="pmc">PMC7882582</ArticleId><ArticleId IdType="doi">10.1007/s00401-021-02264-9</ArticleId><ArticleId IdType="pii">10.1007/s00401-021-02264-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Barmada SJ, Serio A, Arjun A, Bilican B, Daub A, Ando DM, et al. Autophagy induction enhances TDP43 turnover and survival in neuronal ALS models. Nat Chem Biol. 2014;10:677&#x2013;685. doi: 10.1038/nchembio.1563.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nchembio.1563</ArticleId><ArticleId IdType="pmc">PMC4106236</ArticleId><ArticleId IdType="pubmed">24974230</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239&#x2013;259. doi: 10.1007/bf00308809.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/bf00308809</ArticleId><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Bu&#xe9;e L, Troquier L, Burnouf S, Belarbi K, Van der Jeugd A, Ahmed T, et al. From tau phosphorylation to tau aggregation: what about neuronal death? Biochem Soc Trans. 2010;38:967. doi: 10.1042/BST0380967.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BST0380967</ArticleId><ArticleId IdType="pubmed">20658986</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceballos-Diaz C, Rosario AM, Park H-J, Chakrabarty P, Sacino A, Cruz PE, et al. Viral expression of ALS-linked ubiquilin-2 mutants causes inclusion pathology and behavioral deficits in mice. Mol Neurodegener. 2015;10:25. doi: 10.1186/s13024-015-0026-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-015-0026-7</ArticleId><ArticleId IdType="pmc">PMC4495639</ArticleId><ArticleId IdType="pubmed">26152284</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakrabarty P, Ceballos-Diaz C, Beccard A, Janus C, Dickson D, Golde TE, et al. IFN-&#x3b3; promotes complement expression and attenuates amyloid plaque deposition in amyloid &#x3b2; precursor protein transgenic mice. J Immunol. 2010;184:5333&#x2013;5343. doi: 10.4049/jimmunol.0903382.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0903382</ArticleId><ArticleId IdType="pmc">PMC3798002</ArticleId><ArticleId IdType="pubmed">20368278</ArticleId></ArticleIdList></Reference><Reference><Citation>Chudakov DM, Lukyanov S, Lukyanov KA. Tracking intracellular protein movements using photoswitchable fluorescent proteins PS-CFP2 and Dendra2. Nat Protoc. 2007;2:2024. doi: 10.1038/nprot.2007.291.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2007.291</ArticleId><ArticleId IdType="pubmed">17703215</ArticleId></ArticleIdList></Reference><Reference><Citation>Chudakov DM, Lukyanov S, Lukyanov KA. Using photoactivatable fluorescent protein Dendra2 to track protein movement. Biotechniques. 2018 doi: 10.2144/000112470.</Citation><ArticleIdList><ArticleId IdType="doi">10.2144/000112470</ArticleId><ArticleId IdType="pubmed">17515192</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F, Akatsu H, Fraser G, Crowther RA, Frank S, Hench J, et al. Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc Natl Acad Sci USA. 2013;110:9535&#x2013;9540. doi: 10.1073/pnas.1301175110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1301175110</ArticleId><ArticleId IdType="pmc">PMC3677441</ArticleId><ArticleId IdType="pubmed">23690619</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S, Probst A, et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol. 2009;11:909&#x2013;913. doi: 10.1038/ncb1901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb1901</ArticleId><ArticleId IdType="pmc">PMC2726961</ArticleId><ArticleId IdType="pubmed">19503072</ArticleId></ArticleIdList></Reference><Reference><Citation>Croft CL, Cruz PE, Ryu DH, Ceballos-Diaz C, Strang KH, Woody BM, et al. rAAV-based brain slice culture models of Alzheimer&#x2019;s and Parkinson&#x2019;s disease inclusion pathologies. J Exp Med. 2019;216:539&#x2013;555. doi: 10.1084/jem.20182184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20182184</ArticleId><ArticleId IdType="pmc">PMC6400529</ArticleId><ArticleId IdType="pubmed">30770411</ArticleId></ArticleIdList></Reference><Reference><Citation>Croft CL, Futch HS, Moore BD, Golde TE. Organotypic brain slice cultures to model neurodegenerative proteinopathies. Mol Neurodegener. 2019;14:45. doi: 10.1186/s13024-019-0346-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-019-0346-0</ArticleId><ArticleId IdType="pmc">PMC6889333</ArticleId><ArticleId IdType="pubmed">31791377</ArticleId></ArticleIdList></Reference><Reference><Citation>Croft CL, Kurbatskaya K, Hanger DP, Noble W. Inhibition of glycogen synthase kinase-3 by BTA-EG(4) reduces tau abnormalities in an organotypic brain slice culture model of Alzheimer&#x2019;s disease. Sci Rep. 2017;7:7434. doi: 10.1038/s41598-017-07906-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-07906-1</ArticleId><ArticleId IdType="pmc">PMC5547074</ArticleId><ArticleId IdType="pubmed">28785087</ArticleId></ArticleIdList></Reference><Reference><Citation>Croft CL, Moore BD, Ran Y, Chakrabarty P, Levites Y, Golde TE, et al. Novel monoclonal antibodies targeting the microtubule-binding domain of human tau. PLoS ONE. 2018;13:e0195211&#x2013;e0195211. doi: 10.1371/journal.pone.0195211.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0195211</ArticleId><ArticleId IdType="pmc">PMC5880389</ArticleId><ArticleId IdType="pubmed">29608591</ArticleId></ArticleIdList></Reference><Reference><Citation>Croft CL, Noble W. Preparation of organotypic brain slice cultures for the study of Alzheimer&#x2019;s disease. F1000Res. 2018;7:592. doi: 10.12688/f1000research.14500.2.</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.14500.2</ArticleId><ArticleId IdType="pmc">PMC5964634</ArticleId><ArticleId IdType="pubmed">29904599</ArticleId></ArticleIdList></Reference><Reference><Citation>Crowther RA. Straight and paired helical filaments in Alzheimer disease have a common structural unit. Proc Natl Acad Sci USA. 1991 doi: 10.1073/pnas.88.6.2288.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.88.6.2288</ArticleId><ArticleId IdType="pmc">PMC51216</ArticleId><ArticleId IdType="pubmed">1706519</ArticleId></ArticleIdList></Reference><Reference><Citation>David DC, Layfield R, Serpell L, Narain Y, Goedert M, Spillantini MG. Proteasomal degradation of tau protein. J Neurochem. 2002;83:176&#x2013;185. doi: 10.1046/j.1471-4159.2002.01137.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.2002.01137.x</ArticleId><ArticleId IdType="pubmed">12358741</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawson TM, Golde TE, Lagier-Tourenne C. Animal models of neurodegenerative diseases. Nat Neurosci. 2018 doi: 10.1038/s41593-018-0236-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0236-8</ArticleId><ArticleId IdType="pmc">PMC6615039</ArticleId><ArticleId IdType="pubmed">30250265</ArticleId></ArticleIdList></Reference><Reference><Citation>de Calignon A, Fox LM, Pitstick R, Carlson GA, Bacskai BJ, Spires-Jones TL, et al. Caspase activation precedes and leads to tangles. Nature. 2010;464:1201&#x2013;1204. doi: 10.1038/nature08890.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature08890</ArticleId><ArticleId IdType="pmc">PMC3091360</ArticleId><ArticleId IdType="pubmed">20357768</ArticleId></ArticleIdList></Reference><Reference><Citation>de Calignon A, Polydoro M, Su&#xe1;rez-Calvet M, William C, Adamowicz DH, Kopeikina KJ, et al. Propagation of tau pathology in a model of early Alzheimer&#x2019;s disease. Neuron. 2012;73:685&#x2013;697. doi: 10.1016/j.neuron.2011.11.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.11.033</ArticleId><ArticleId IdType="pmc">PMC3292759</ArticleId><ArticleId IdType="pubmed">22365544</ArticleId></ArticleIdList></Reference><Reference><Citation>Forman MS, Trojanowski JQ, Lee VMY. Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat Med. 2004;10:1055. doi: 10.1038/nm1113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1113</ArticleId><ArticleId IdType="pubmed">15459709</ArticleId></ArticleIdList></Reference><Reference><Citation>Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron. 2002;34:521&#x2013;533. doi: 10.1016/s0896-6273(02)00682-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0896-6273(02)00682-7</ArticleId><ArticleId IdType="pubmed">12062037</ArticleId></ArticleIdList></Reference><Reference><Citation>Giasson BI, Forman MS, Higuchi M, Golbe LI, Graves CL, Kotzbauer PT, et al. Initiation and synergistic fibrillization of tau and alpha-synuclein. Science. 2003;300:636. doi: 10.1126/science.1082324.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1082324</ArticleId><ArticleId IdType="pubmed">12714745</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Spillantini MG. Propagation of Tau aggregates. Mol Brain. 2017;10:18. doi: 10.1186/s13041-017-0298-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13041-017-0298-7</ArticleId><ArticleId IdType="pmc">PMC5450399</ArticleId><ArticleId IdType="pubmed">28558799</ArticleId></ArticleIdList></Reference><Reference><Citation>Golde TE, Borchelt DR, Giasson BI, Lewis J. Thinking laterally about neurodegenerative proteinopathies. J Clin Investig. 2013;123:1847&#x2013;1855. doi: 10.1172/JCI66029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI66029</ArticleId><ArticleId IdType="pmc">PMC3635732</ArticleId><ArticleId IdType="pubmed">23635781</ArticleId></ArticleIdList></Reference><Reference><Citation>Golde TE, DeKosky ST, Galasko D. Alzheimer's disease: the right drug, the right time. Science. 2018;362:1250&#x2013;1251. doi: 10.1126/science.aau0437.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aau0437</ArticleId><ArticleId IdType="pubmed">30545877</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer&#x2019; disease. Ann Neurol. 1997;41:17&#x2013;24. doi: 10.1002/ana.410410106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410410106</ArticleId><ArticleId IdType="pubmed">9005861</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodwin MS, Croft CL, Futch HS, Ryu D, Ceballos-Diaz C, Liu X, et al. Utilizing minimally purified secreted rAAV for rapid and cost-effective manipulation of gene expression in the CNS. Mol Neurodegener. 2020;15:15. doi: 10.1186/s13024-020-00361-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-020-00361-z</ArticleId><ArticleId IdType="pmc">PMC7053119</ArticleId><ArticleId IdType="pubmed">32122372</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodwin MS, Sinyavskaya O, Burg F, O&#x2019;Neal V, Ceballos-Diaz C, Cruz PE, et al. Anti-tau scFvs targeted to the cytoplasm or secretory pathway variably modify pathology and neurodegenerative phenotypes. Mol Ther. 2020 doi: 10.1016/j.ymthe.2020.10.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2020.10.007</ArticleId><ArticleId IdType="pmc">PMC7854277</ArticleId><ArticleId IdType="pubmed">33128896</ArticleId></ArticleIdList></Reference><Reference><Citation>Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem. 1986;261:6084&#x2013;6089. doi: 10.1016/S0021-9258(17)38495-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9258(17)38495-8</ArticleId><ArticleId IdType="pubmed">3084478</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo JL, Narasimhan S, Changolkar L, He Z, Stieber A, Zhang B, et al. Unique pathological tau conformers from Alzheimer&#x2019;s brains transmit tau pathology in nontransgenic mice. J Exp Med. 2016;213:2635. doi: 10.1084/jem.20160833.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20160833</ArticleId><ArticleId IdType="pmc">PMC5110027</ArticleId><ArticleId IdType="pubmed">27810929</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo T, Noble W, Hanger DP. Roles of tau protein in health and disease. Acta Neuropathol. 2017;133:665&#x2013;704. doi: 10.1007/s00401-017-1707-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1707-9</ArticleId><ArticleId IdType="pmc">PMC5390006</ArticleId><ArticleId IdType="pubmed">28386764</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurskaya NG, Verkhusha VV, Shcheglov AS, Staroverov DB, Chepurnykh TV, Fradkov AF, et al. Engineering of a monomeric green-to-red photoactivatable fluorescent protein induced by blue light. Nat Biotechnol. 2006;24:461. doi: 10.1038/nbt1191.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt1191</ArticleId><ArticleId IdType="pubmed">16550175</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvie EA, Green JM, Neely MN, Huttenlocher A. Innate immune response to Streptococcus iniae infection in zebrafish larvae. Infect Immun. 2013;81:110&#x2013;121. doi: 10.1128/IAI.00642-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.00642-12</ArticleId><ArticleId IdType="pmc">PMC3536132</ArticleId><ArticleId IdType="pubmed">23090960</ArticleId></ArticleIdList></Reference><Reference><Citation>Jicha GA, Bowser R, Kazam IG, Davies P. Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau. J Neurosci Res. 1997;48:128&#x2013;132. doi: 10.1002/(sici)1097-4547(19970415)48:2&lt;128::aid-jnr5&gt;3.0.co;2-e.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(sici)1097-4547(19970415)48:2&lt;128::aid-jnr5&gt;3.0.co;2-e</ArticleId><ArticleId IdType="pubmed">9130141</ArticleId></ArticleIdList></Reference><Reference><Citation>Koller EJ, Gonzalez De La Cruz E, Machula T, Ibanez KR, Lin W-L, Williams T, et al. Combining P301L and S320F tau variants produces a novel accelerated model of tauopathy. Hum Mol Gen. 2020;28:3255&#x2013;3269. doi: 10.1093/hmg/ddz151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddz151</ArticleId><ArticleId IdType="pmc">PMC6859436</ArticleId><ArticleId IdType="pubmed">31261380</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuchibhotla KV, Wegmann S, Kopeikina KJ, Hawkes J, Rudinskiy N, Andermann ML, et al. Neurofibrillary tangle-bearing neurons are functionally integrated in cortical circuits in vivo. Proc Natl Acad Sci USA. 2014;111:510&#x2013;514. doi: 10.1073/pnas.1318807111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1318807111</ArticleId><ArticleId IdType="pmc">PMC3890777</ArticleId><ArticleId IdType="pubmed">24368848</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis J, Dickson DW. Propagation of tau pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies. Acta Neuropathol. 2016;131:27&#x2013;48. doi: 10.1007/s00401-015-1507-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1507-z</ArticleId><ArticleId IdType="pubmed">26576562</ArticleId></ArticleIdList></Reference><Reference><Citation>Li A, Ceballos-Diaz C, DiNunno N, Levites Y, Cruz PE, Lewis J, et al. IFN-&#x3b3; promotes &#x3c4; phosphorylation without affecting mature tangles. FASEB J. 2015;29:4384&#x2013;4398. doi: 10.1096/fj.15-275834.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.15-275834</ArticleId><ArticleId IdType="pmc">PMC6137542</ArticleId><ArticleId IdType="pubmed">26156074</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Kumar Y, Zempel H, Mandelkow E-M, Biernat J, Mandelkow E. Novel diffusion barrier for axonal retention of Tau in neurons and its failure in neurodegeneration. EMBO J. 2011;30:4825&#x2013;4837. doi: 10.1038/emboj.2011.376.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emboj.2011.376</ArticleId><ArticleId IdType="pmc">PMC3243615</ArticleId><ArticleId IdType="pubmed">22009197</ArticleId></ArticleIdList></Reference><Reference><Citation>Luna-Mu&#xf1;oz J, Peralta-Ramirez J, Ch&#xe1;vez-Mac&#xed;as L, Harrington CR, Wischik CM, Mena R. Thiazin red as a neuropathological tool for the rapid diagnosis of Alzheimer&#x2019;s disease in tissue imprints. Acta Neuropathol. 2008;116:507&#x2013;515. doi: 10.1007/s00401-008-0431-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-008-0431-x</ArticleId><ArticleId IdType="pubmed">18810470</ArticleId></ArticleIdList></Reference><Reference><Citation>Mena R, Edwards P, P&#xe9;rez-Olvera O, Wischik CM. Monitoring pathological assembly of tau and beta-amyloid proteins in Alzheimer&#x2019;s disease. Acta Neuropathol. 1995;89:50&#x2013;56. doi: 10.1007/bf00294259.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/bf00294259</ArticleId><ArticleId IdType="pubmed">7709731</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, de Calignon A, Rozkalne A, et al. Rapid appearance and local toxicity of amyloid-&#x3b2; plaques in a mouse model of Alzheimer&#x2019;s disease. Nature. 2008;451:720&#x2013;724. doi: 10.1038/nature06616.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature06616</ArticleId><ArticleId IdType="pmc">PMC3264491</ArticleId><ArticleId IdType="pubmed">18256671</ArticleId></ArticleIdList></Reference><Reference><Citation>Mudher A, Colin M, Dujardin S, Medina M, Dewachter ISM, et al. What is the evidence that tau pathology spreads through prion-like propagation? Acta Neuropathol Commun. 2017;5:99. doi: 10.1186/s40478-017-0488-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-017-0488-7</ArticleId><ArticleId IdType="pmc">PMC5735872</ArticleId><ArticleId IdType="pubmed">29258615</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocher AB, Crimins JL, Amatrudo JM, Kinson MS, Todd-Brown MA, Lewis J, et al. Structural and functional changes in tau mutant mice neurons are not linked to the presence of NFTs. Exp Neurol. 2010;223:385&#x2013;393. doi: 10.1016/j.expneurol.2009.07.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2009.07.029</ArticleId><ArticleId IdType="pmc">PMC2864360</ArticleId><ArticleId IdType="pubmed">19665462</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez EM, Yulis R, Peruzzo B, Alvial G, Andrade R. Standardization of various applications of methacrylate embedding and silver methenamine for light and electron microscopy immunocytochemistry. Histochem. 1984;81:253&#x2013;263. doi: 10.1007/bf00495636.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/bf00495636</ArticleId><ArticleId IdType="pubmed">6209248</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosario AM, Cruz PE, Ceballos-Diaz C, Strickland MR, Siemienski Z, Pardo M, et al. Microglia-specific targeting by novel capsid-modified AAV6 vectors. Mol Ther Methods Clin Dev. 2016;3:16026. doi: 10.1038/mtm.2016.26.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mtm.2016.26</ArticleId><ArticleId IdType="pmc">PMC4909093</ArticleId><ArticleId IdType="pubmed">27308302</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudinskiy N, Hawkes JM, Wegmann S, Kuchibhotla KV, Muzikansky A, Betensky RA, et al. Tau pathology does not affect experience-driven single-neuron and network-wide Arc/Arg3.1 responses. Acta Neuropathol Commun. 2014;2:63. doi: 10.1186/2051-5960-2-63.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2051-5960-2-63</ArticleId><ArticleId IdType="pmc">PMC4229905</ArticleId><ArticleId IdType="pubmed">24915991</ArticleId></ArticleIdList></Reference><Reference><Citation>Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science. 2005;309:476&#x2013;481. doi: 10.1126/science.1113694.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1113694</ArticleId><ArticleId IdType="pmc">PMC1574647</ArticleId><ArticleId IdType="pubmed">16020737</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato C, Barth&#xe9;lemy NR, Mawuenyega KG, Patterson BW, Gordon BA, Jockel-Balsarotti J, et al. Tau kinetics in neurons and the human central nervous system. Neuron. 2018;97:1284&#x2013;1298.e1287. doi: 10.1016/j.neuron.2018.02.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.02.015</ArticleId><ArticleId IdType="pmc">PMC6137722</ArticleId><ArticleId IdType="pubmed">29566794</ArticleId></ArticleIdList></Reference><Reference><Citation>Strang KH, Croft CL, Sorrentino ZA, Chakrabarty P, Golde TE, Giasson BI. Distinct differences in prion-like seeding and aggregation between tau protein variants provide mechanistic insights into tauopathies. J Biol Chem. 2017 doi: 10.1074/jbc.M117.815357.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M117.815357</ArticleId><ArticleId IdType="pmc">PMC5818185</ArticleId><ArticleId IdType="pubmed">29259137</ArticleId></ArticleIdList></Reference><Reference><Citation>Strang KH, Goodwin MS, Riffe C, Moore BD, Chakrabarty P, Levites Y, et al. Generation and characterization of new monoclonal antibodies targeting the PHF1 and AT8 epitopes on human tau. Acta Neuropathol Commun. 2017;5:58. doi: 10.1186/s40478-017-0458-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-017-0458-0</ArticleId><ArticleId IdType="pmc">PMC5537986</ArticleId><ArticleId IdType="pubmed">28760159</ArticleId></ArticleIdList></Reference><Reference><Citation>Tseng Q, Duchemin-Pelletier E, Deshiere A, Balland M, Guillou H, Filhol O, et al. Spatial organization of the extracellular matrix regulates cell-cell junction positioning. Proc Natl Acad Sci USA. 2012 doi: 10.1073/pnas.1106377109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1106377109</ArticleId><ArticleId IdType="pmc">PMC3277177</ArticleId><ArticleId IdType="pubmed">22307605</ArticleId></ArticleIdList></Reference><Reference><Citation>Waxman EA, Giasson BI. Induction of intracellular tau aggregation is promoted by &#x3b1;-synuclein seeds and provides novel insights into the hyperphosphorylation of tau. J Neurosci. 2011;31:7604&#x2013;7618. doi: 10.1523/JNEUROSCI.0297-11.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0297-11.2011</ArticleId><ArticleId IdType="pmc">PMC3122484</ArticleId><ArticleId IdType="pubmed">21613474</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada K, Cirrito JR, Stewart FR, Jiang H, Finn MB, Holmes BB, et al. In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. J Neurosci. 2011;31:13110&#x2013;13117. doi: 10.1523/jneurosci.2569-11.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/jneurosci.2569-11.2011</ArticleId><ArticleId IdType="pmc">PMC4299126</ArticleId><ArticleId IdType="pubmed">21917794</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada K, Patel TK, Hochgr&#xe4;fe K, Mahan TE, Jiang H, Stewart FR, et al. Analysis of in vivo turnover of tau in a mouse model of tauopathy. Mol Neurodegener. 2015;10:55&#x2013;55. doi: 10.1186/s13024-015-0052-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-015-0052-5</ArticleId><ArticleId IdType="pmc">PMC4621881</ArticleId><ArticleId IdType="pubmed">26502977</ArticleId></ArticleIdList></Reference><Reference><Citation>Yazawa I, Giasson BI, Sasaki R, Zhang B, Joyce S, Uryu K, et al. Mouse model of multiple system atrophy alpha-synuclein expression in oligodendrocytes causes glial and neuronal degeneration. Neuron. 2005;45:847&#x2013;859. doi: 10.1016/j.neuron.2005.01.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2005.01.032</ArticleId><ArticleId IdType="pubmed">15797547</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33480976</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>20</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>78</Volume><Issue>5</Issue><PubDate><Year>2021</Year><Month>May</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Absent Blood Oxygen Level-Dependent Functional Magnetic Resonance Imaging Activation of the Orbitofrontal Cortex in a Patient With Persistent Cacosmia and Cacogeusia After COVID-19 Infection.</ArticleTitle><Pagination><StartPage>609</StartPage><EndPage>610</EndPage><MedlinePgn>609-610</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2021.0009</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ismail</LastName><ForeName>Ismail Ibrahim</ForeName><Initials>II</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ibn Sina Hospital, Sabah Health Region, Kuwait.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gad</LastName><ForeName>Khaled A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Department of Radiology, Ibn Sina Hospital, Sabah Health Region, Kuwait.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Diagnostic Radiology Department, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>S88TT14065</RegistryNumber><NameOfSubstance UI="D010100">Oxygen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004569" MajorTopicYN="N">Electroencephalography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000857" MajorTopicYN="N">Olfaction Disorders</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010100" MajorTopicYN="N">Oxygen</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017397" MajorTopicYN="N">Prefrontal Cortex</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>1</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>1</Month><Day>22</Day><Hour>12</Hour><Minute>15</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33480976</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2021.0009</ArticleId><ArticleId IdType="pii">2775589</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">33469596</PMID><DateRevised><Year>2021</Year><Month>06</Month><Day>08</Day></DateRevised><Article PubModel="Electronic"><Journal><JournalIssue CitedMedium="Internet"><PubDate><Year>2021</Year><Month>Jan</Month><Day>12</Day></PubDate></JournalIssue><Title>medRxiv : the preprint server for health sciences</Title><ISOAbbreviation>medRxiv</ISOAbbreviation></Journal><ArticleTitle>Cerebrospinal fluid in COVID-19 neurological complications: no cytokine storm or neuroinflammation.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2021.01.10.20249014</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1101/2021.01.10.20249014</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Neurological complications occur in COVID-19. We aimed to examine cerebrospinal fluid (CSF) of COVID-19 subjects with neurological complications and determine presence of neuroinflammatory changes implicated in pathogenesis.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Cross-sectional study of CSF neuroinflammatory profiles from 18 COVID-19 subjects with neurological complications categorized by diagnosis (stroke, encephalopathy, headache) and illness severity (critical, severe, moderate, mild). COVID-19 CSF was compared with CSF from healthy, infectious and neuroinflammatory disorders and stroke controls (n=82). Cytokines (IL-6, TNF&#x3b1;, IFN&#x3b3;, IL-10, IL-12p70, IL-17A), inflammation and coagulation markers (high-sensitivity-C Reactive Protein [hsCRP], ferritin, fibrinogen, D-dimer, Factor VIII) and neurofilament light chain (NF-L), were quantified. SARS-CoV2 RNA and SARS-CoV2 IgG and IgA antibodies in CSF were tested with RT-PCR and ELISA.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">CSF from COVID-19 subjects showed a paucity of neuroinflammatory changes, absence of pleocytosis or specific increases in pro-inflammatory markers or cytokines (IL-6, ferritin, or D-dimer). Anti-SARS-CoV2 antibodies in CSF of COVID-19 subjects (77%) were observed despite no evidence of SARS-CoV2 viral RNA. A similar increase of pro-inflammatory cytokines (IL-6, TNF&#x3b1;, IL-12p70) and IL-10 in CSF of COVID-19 and non-COVID-19 stroke subjects was observed compared to controls. CSF-NF-L was elevated in subjects with stroke and critical COVID-19. CSF-hsCRP was present almost exclusively in COVID-19 cases.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The paucity of neuroinflammatory changes in CSF of COVID-19 subjects and lack of SARS-CoV2 RNA do not support the presumed neurovirulence of SARS-CoV2 or neuroinflammation in pathogenesis of neurological complications in COVID-19. Elevated CSF-NF-L indicates neuroaxonal injury in COVID-19 cases. The role of CSF SARS-CoV2 IgG antibodies is still undetermined.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">This work was supported by NIH R01-NS110122 and The Bart McLean Fund for Neuroimmunology Research.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Garcia</LastName><ForeName>Maria A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Barreras</LastName><ForeName>Paula V</ForeName><Initials>PV</Initials></Author><Author ValidYN="Y"><LastName>Lewis</LastName><ForeName>Allie</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Pinilla</LastName><ForeName>Gabriel</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Sokoll</LastName><ForeName>Lori J</ForeName><Initials>LJ</Initials></Author><Author ValidYN="Y"><LastName>Kickler</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Mostafa</LastName><ForeName>Heba</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Caturegli</LastName><ForeName>Mario</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Moghekar</LastName><ForeName>Abhay</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Fitzgerald</LastName><ForeName>Kathryn C</ForeName><Initials>KC</Initials></Author><Author ValidYN="Y"><LastName>Pardo</LastName><ForeName>Carlos A</ForeName><Initials>CA</Initials><Identifier Source="ORCID">0000-0002-4128-5335</Identifier></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS110122</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D000076942">Preprint</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>01</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>medRxiv</MedlineTA><NlmUniqueID>101767986</NlmUniqueID></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="UpdateIn"><RefSource>J Neurol Sci. 2021 Aug 15;427:117517. doi: 10.1016/j.jns.2021.117517.</RefSource><PMID Version="1">34090021</PMID></CommentsCorrections></CommentsCorrectionsList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>1</Month><Day>20</Day><Hour>5</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>1</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>1</Month><Day>21</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>1</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33469596</ArticleId><ArticleId IdType="pmc">PMC7814842</ArticleId><ArticleId IdType="doi">10.1101/2021.01.10.20249014</ArticleId><ArticleId IdType="pii">2021.01.10.20249014</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33477869</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>02</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Jan</Month><Day>19</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>Neuroinvasion and Encephalitis Following Intranasal Inoculation of SARS-CoV-2 in K18-hACE2 Mice.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">132</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v13010132</ELocationID><Abstract><AbstractText>Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection can cause neurological disease in humans, but little is known about the pathogenesis of SARS-CoV-2 infection in the central nervous system (CNS). Herein, using K18-hACE2 mice, we demonstrate that SARS-CoV-2 neuroinvasion and encephalitis is associated with mortality in these mice. Intranasal infection of K18-hACE2 mice with 10<sup>5</sup> plaque-forming units of SARS-CoV-2 resulted in 100% mortality by day 6 after infection. The highest virus titers in the lungs were observed on day 3 and declined on days 5 and 6 after infection. By contrast, very high levels of infectious virus were uniformly detected in the brains of all the animals on days 5 and 6. Onset of severe disease in infected mice correlated with peak viral levels in the brain. SARS-CoV-2-infected mice exhibited encephalitis hallmarks characterized by production of cytokines and chemokines, leukocyte infiltration, hemorrhage and neuronal cell death. SARS-CoV-2 was also found to productively infect cells within the nasal turbinate, eye and olfactory bulb, suggesting SARS-CoV-2 entry into the brain by this route after intranasal infection. Our data indicate that direct infection of CNS cells together with the induced inflammatory response in the brain resulted in the severe disease observed in SARS-CoV-2-infected K18-hACE2 mice.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kumari</LastName><ForeName>Pratima</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Biology, College of Arts and Sciences, Georgia State University, Atlanta, GA 30303, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rothan</LastName><ForeName>Hussin A</ForeName><Initials>HA</Initials><Identifier Source="ORCID">0000-0002-7300-6388</Identifier><AffiliationInfo><Affiliation>Department of Biology, College of Arts and Sciences, Georgia State University, Atlanta, GA 30303, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Natekar</LastName><ForeName>Janhavi P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Department of Biology, College of Arts and Sciences, Georgia State University, Atlanta, GA 30303, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stone</LastName><ForeName>Shannon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biology, College of Arts and Sciences, Georgia State University, Atlanta, GA 30303, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pathak</LastName><ForeName>Heather</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Biology, College of Arts and Sciences, Georgia State University, Atlanta, GA 30303, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strate</LastName><ForeName>Philip G</ForeName><Initials>PG</Initials><AffiliationInfo><Affiliation>Department of Biology, College of Arts and Sciences, Georgia State University, Atlanta, GA 30303, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arora</LastName><ForeName>Komal</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Biology, College of Arts and Sciences, Georgia State University, Atlanta, GA 30303, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brinton</LastName><ForeName>Margo A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Biology, College of Arts and Sciences, Georgia State University, Atlanta, GA 30303, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Mukesh</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-0970-4875</Identifier><AffiliationInfo><Affiliation>Department of Biology, College of Arts and Sciences, Georgia State University, Atlanta, GA 30303, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R21 OD024896</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21OD024896</GrantID><Agency>NIH Office of the Director</Agency><Country>International</Country></Grant><Grant><GrantID>R21 NS099838</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AI131130</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21NS099838</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>01</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.17.23</RegistryNumber><NameOfSubstance UI="C000705307">ACE2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.17.23</RegistryNumber><NameOfSubstance UI="D000085962">Angiotensin-Converting Enzyme 2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000085962" MajorTopicYN="N">Angiotensin-Converting Enzyme 2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018792" MajorTopicYN="N">Encephalitis, Viral</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">COVID-19</Keyword><Keyword MajorTopicYN="Y">K18-hACE2 mice</Keyword><Keyword MajorTopicYN="Y">SARS-CoV-2</Keyword><Keyword MajorTopicYN="Y">encephalitis</Keyword><Keyword MajorTopicYN="Y">neuroinflammation</Keyword><Keyword MajorTopicYN="Y">neuroinvasion</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>12</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>1</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>1</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>1</Month><Day>22</Day><Hour>1</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>1</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>1</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33477869</ArticleId><ArticleId IdType="pmc">PMC7832889</ArticleId><ArticleId IdType="doi">10.3390/v13010132</ArticleId><ArticleId IdType="pii">v13010132</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rothan H.A., Byrareddy S.N. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J. Autoimmun. 2020;109:102433. doi: 10.1016/j.jaut.2020.102433.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2020.102433</ArticleId><ArticleId IdType="pmc">PMC7127067</ArticleId><ArticleId IdType="pubmed">32113704</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothan H.A., Acharya A., Reid S.P., Kumar M., Byrareddy S.N. Molecular Aspects of COVID-19 Differential Pathogenesis. Pathogens. 2020;9:538. doi: 10.3390/pathogens9070538.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens9070538</ArticleId><ArticleId IdType="pmc">PMC7400297</ArticleId><ArticleId IdType="pubmed">32640525</ArticleId></ArticleIdList></Reference><Reference><Citation>Espinosa P.S., Rizvi Z., Sharma P., Hindi F., Filatov A. Neurological Complications of Coronavirus Disease (COVID-19): Encephalopathy, MRI Brain and Cerebrospinal Fluid Findings: Case 2. Cureus. 2020;12:e7930. doi: 10.7759/cureus.7930.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.7930</ArticleId><ArticleId IdType="pmc">PMC7266087</ArticleId><ArticleId IdType="pubmed">32499974</ArticleId></ArticleIdList></Reference><Reference><Citation>Filatov A., Sharma P., Hindi F., Espinosa P.S. Neurological Complications of Coronavirus Disease (COVID-19): Encephalopathy. Cureus. 2020;12:e7352. doi: 10.7759/cureus.7352.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.7352</ArticleId><ArticleId IdType="pmc">PMC7170017</ArticleId><ArticleId IdType="pubmed">32328364</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka M.T., Golenbock D., Latz E., Morgan D., Brown R. Immediate and long-term consequences of COVID-19 infections for the development of neurological disease. Alzheimer&#x2019;s Res. Ther. 2020;12:69. doi: 10.1186/s13195-020-00640-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-020-00640-3</ArticleId><ArticleId IdType="pmc">PMC7271826</ArticleId><ArticleId IdType="pubmed">32498691</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahammedi A., Saba L., Vagal A., Leali M., Rossi A., Gaskill M., Sengupta S., Zhang B., Carriero A., Bachir S., et al. Imaging in Neurological Disease of Hospitalized COVID-19 Patients: An Italian Multicenter Retrospective Observational Study. Radiology. 2020;297:E270&#x2013;E273. doi: 10.1148/radiol.2020201933.</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiol.2020201933</ArticleId><ArticleId IdType="pmc">PMC7587295</ArticleId><ArticleId IdType="pubmed">32437313</ArticleId></ArticleIdList></Reference><Reference><Citation>Parry A.H., Wani A.H., Yaseen M. Neurological Dysfunction in Coronavirus Disease-19 (COVID-19) Acad. Radiol. 2020;27:1329&#x2013;1330. doi: 10.1016/j.acra.2020.05.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.acra.2020.05.024</ArticleId><ArticleId IdType="pmc">PMC7284232</ArticleId><ArticleId IdType="pubmed">32546339</ArticleId></ArticleIdList></Reference><Reference><Citation>Baig A.M., Sanders E.C. Potential neuroinvasive pathways of SARS-CoV-2: Deciphering the spectrum of neurological deficit seen in coronavirus disease-2019 (COVID-19) J. Med. Virol. 2020;92:1845&#x2013;1857. doi: 10.1002/jmv.26105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26105</ArticleId><ArticleId IdType="pmc">PMC7300748</ArticleId><ArticleId IdType="pubmed">32492193</ArticleId></ArticleIdList></Reference><Reference><Citation>Adamczyk-Sowa M., Niedziela N., Kubicka-Baczyk K., Wierzbicki K., Jaroszewicz J., Sowa P. Neurological symptoms as a clinical manifestation of COVID-19: Implications for internists. Polish Arch. Intern. Med. 2020 doi: 10.20452/pamw.15575.</Citation><ArticleIdList><ArticleId IdType="doi">10.20452/pamw.15575</ArticleId><ArticleId IdType="pubmed">32820884</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H.Y., Li X.L., Yan Z.R., Sun X.P., Han J., Zhang B.W. Potential neurological symptoms of COVID-19. Ther. Adv. Neurol. Disord. 2020;13:1756286420917830. doi: 10.1177/1756286420917830.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1756286420917830</ArticleId><ArticleId IdType="pmc">PMC7119227</ArticleId><ArticleId IdType="pubmed">32284735</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaumburg C.S., Held K.S., Lane T.E. Mouse hepatitis virus infection of the CNS: A model for defense, disease, and repair. Front. Biosci. 2008;13:4393&#x2013;4406. doi: 10.2741/3012.</Citation><ArticleIdList><ArticleId IdType="doi">10.2741/3012</ArticleId><ArticleId IdType="pmc">PMC5025298</ArticleId><ArticleId IdType="pubmed">18508518</ArticleId></ArticleIdList></Reference><Reference><Citation>Verstrepen K., Baisier L., De Cauwer H. Neurological manifestations of COVID-19, SARS and MERS. Acta Neurol Belg. 2020;120:1051&#x2013;1060. doi: 10.1007/s13760-020-01412-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13760-020-01412-4</ArticleId><ArticleId IdType="pmc">PMC7303437</ArticleId><ArticleId IdType="pubmed">32562214</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavoie J.L., Cassell M.D., Gross K.W., Sigmund C.D. Adjacent expression of renin and angiotensinogen in the rostral ventrolateral medulla using a dual-reporter transgenic model. Hypertension. 2004;43:1116&#x2013;1119. doi: 10.1161/01.HYP.0000125143.73301.94.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.HYP.0000125143.73301.94</ArticleId><ArticleId IdType="pubmed">15037561</ArticleId></ArticleIdList></Reference><Reference><Citation>Gowrisankar Y.V., Clark M.A. Angiotensin II regulation of angiotensin-converting enzymes in spontaneously hypertensive rat primary astrocyte cultures. J. Neurochem. 2016;138:74&#x2013;85. doi: 10.1111/jnc.13641.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13641</ArticleId><ArticleId IdType="pubmed">27085714</ArticleId></ArticleIdList></Reference><Reference><Citation>Lukiw W.J., Pogue A., Hill J.M. SARS-CoV-2 Infectivity and Neurological Targets in the Brain. Cell. Mol. Neurobiol. 2020:1&#x2013;8. doi: 10.1007/s10571-020-00947-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10571-020-00947-7</ArticleId><ArticleId IdType="pmc">PMC7445393</ArticleId><ArticleId IdType="pubmed">32840758</ArticleId></ArticleIdList></Reference><Reference><Citation>Puelles V.G., Lutgehetmann M., Lindenmeyer M.T., Sperhake J.P., Wong M.N., Allweiss L., Chilla S., Heinemann A., Wanner N., Liu S., et al. Multiorgan and Renal Tropism of SARS-CoV-2. N. Engl. J. Med. 2020;383:590&#x2013;592. doi: 10.1056/NEJMc2011400.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2011400</ArticleId><ArticleId IdType="pmc">PMC7240771</ArticleId><ArticleId IdType="pubmed">32402155</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon I.H., Normandin E., Bhattacharyya S., Mukerji S.S., Keller K., Ali A.S., Adams G., Hornick J.L., Padera R.F., Jr., Sabeti P. Neuropathological Features of Covid-19. N. Engl. J. Med. 2020;383:989&#x2013;992. doi: 10.1056/NEJMc2019373.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2019373</ArticleId><ArticleId IdType="pmc">PMC7304421</ArticleId><ArticleId IdType="pubmed">32530583</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B.Z., Chu H., Han S., Shuai H., Deng J., Hu Y.F., Gong H.R., Lee A.C., Zou Z., Yau T., et al. SARS-CoV-2 infects human neural progenitor cells and brain organoids. Cell Res. 2020;30:928&#x2013;931. doi: 10.1038/s41422-020-0390-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-020-0390-x</ArticleId><ArticleId IdType="pmc">PMC7399356</ArticleId><ArticleId IdType="pubmed">32753756</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramani A., Muller L., Ostermann P.N., Gabriel E., Abida-Islam P., Muller-Schiffmann A., Mariappan A., Goureau O., Gruell H., Walker A., et al. SARS-CoV-2 targets neurons of 3D human brain organoids. EMBO J. 2020;39:e106230. doi: 10.15252/embj.2020106230.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.2020106230</ArticleId><ArticleId IdType="pmc">PMC7560208</ArticleId><ArticleId IdType="pubmed">32876341</ArticleId></ArticleIdList></Reference><Reference><Citation>von Weyhern C.H., Kaufmann I., Neff F., Kremer M. Early evidence of pronounced brain involvement in fatal COVID-19 outcomes. Lancet. 2020;395:e109. doi: 10.1016/S0140-6736(20)31282-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31282-4</ArticleId><ArticleId IdType="pmc">PMC7272176</ArticleId><ArticleId IdType="pubmed">32505222</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng Q., Yang Y., Gao J. Infectivity of human coronavirus in the brain. EBioMedicine. 2020;56:102799. doi: 10.1016/j.ebiom.2020.102799.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2020.102799</ArticleId><ArticleId IdType="pmc">PMC7255711</ArticleId><ArticleId IdType="pubmed">32474399</ArticleId></ArticleIdList></Reference><Reference><Citation>Golden J.W., Cline C.R., Zeng X., Garrison A.R., Carey B.D., Mucker E.M., White L.E., Shamblin J.D., Brocato R.L., Liu J., et al. Human angiotensin-converting enzyme 2 transgenic mice infected with SARS-CoV-2 develop severe and fatal respiratory disease. JCI Insight. 2020;5:e142032. doi: 10.1172/jci.insight.142032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.142032</ArticleId><ArticleId IdType="pmc">PMC7566707</ArticleId><ArticleId IdType="pubmed">32841215</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler E.S., Bailey A.L., Kafai N.M., Nair S., McCune B.T., Yu J., Fox J.M., Chen R.E., Earnest J.T., Keeler S.P., et al. SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Nat. Immunol. 2020;21:1327&#x2013;1335. doi: 10.1038/s41590-020-0778-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-020-0778-2</ArticleId><ArticleId IdType="pmc">PMC7578095</ArticleId><ArticleId IdType="pubmed">32839612</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreau G.B., Burgess S.L., Sturek J.M., Donlan A.N., Petri W.A., Mann B.J. Evaluation of K18-hACE2 Mice as a Model of SARS-CoV-2 Infection. Am. J. Trop. Med. Hyg. 2020;103:1215&#x2013;1219. doi: 10.4269/ajtmh.20-0762.</Citation><ArticleIdList><ArticleId IdType="doi">10.4269/ajtmh.20-0762</ArticleId><ArticleId IdType="pmc">PMC7470527</ArticleId><ArticleId IdType="pubmed">32723427</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng J., Wong L.R., Li K., Verma A.K., Ortiz M., Wohlford-Lenane C., Leidinger M.R., Knudson C.M., Meyerholz D.K., McCray P.B., Jr., et al. COVID-19 treatments and pathogenesis including anosmia in K18-hACE2 mice. Nature. 2020:1&#x2013;5. doi: 10.1038/s41586-020-2943-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2943-z</ArticleId><ArticleId IdType="pmc">PMC7855185</ArticleId><ArticleId IdType="pubmed">33166988</ArticleId></ArticleIdList></Reference><Reference><Citation>Perlman S., Evans G., Afifi A. Effect of olfactory bulb ablation on spread of a neurotropic coronavirus into the mouse brain. J Exp. Med. 1990;172:1127&#x2013;1132. doi: 10.1084/jem.172.4.1127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.172.4.1127</ArticleId><ArticleId IdType="pmc">PMC2188595</ArticleId><ArticleId IdType="pubmed">1698910</ArticleId></ArticleIdList></Reference><Reference><Citation>Netland J., Meyerholz D.K., Moore S., Cassell M., Perlman S. Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2. J. Virol. 2008;82:7264&#x2013;7275. doi: 10.1128/JVI.00737-08.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00737-08</ArticleId><ArticleId IdType="pmc">PMC2493326</ArticleId><ArticleId IdType="pubmed">18495771</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothan H.A., Stone S., Natekar J., Kumari P., Arora K., Kumar M. The FDA-approved gold drug auranofin inhibits novel coronavirus (SARS-COV-2) replication and attenuates inflammation in human cells. Virology. 2020;547:7&#x2013;11. doi: 10.1016/j.virol.2020.05.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2020.05.002</ArticleId><ArticleId IdType="pmc">PMC7236683</ArticleId><ArticleId IdType="pubmed">32442105</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothan H.A., Arora K., Natekar J.P., Strate P.G., Brinton M.A., Kumar M. Z-DNA-Binding Protein 1 Is Critical for Controlling Virus Replication and Survival in West Nile Virus Encephalitis. Front. Microbiol. 2019;10:2089. doi: 10.3389/fmicb.2019.02089.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2019.02089</ArticleId><ArticleId IdType="pmc">PMC6749019</ArticleId><ArticleId IdType="pubmed">31572318</ArticleId></ArticleIdList></Reference><Reference><Citation>Natekar J.P., Rothan H.A., Arora K., Strate P.G., Kumar M. Cellular microRNA-155 Regulates Virus-Induced Inflammatory Response and Protects against Lethal West Nile Virus Infection. Viruses. 2019;12:9. doi: 10.3390/v12010009.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v12010009</ArticleId><ArticleId IdType="pmc">PMC7019255</ArticleId><ArticleId IdType="pubmed">31861621</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar M., Roe K., Orillo B., Muruve D.A., Nerurkar V.R., Gale M., Jr., Verma S. Inflammasome adaptor protein Apoptosis-associated speck-like protein containing CARD (ASC) is critical for the immune response and survival in west Nile virus encephalitis. J. Virol. 2013;87:3655&#x2013;3667. doi: 10.1128/JVI.02667-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02667-12</ArticleId><ArticleId IdType="pmc">PMC3624239</ArticleId><ArticleId IdType="pubmed">23302887</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar M., Krause K.K., Azouz F., Nakano E., Nerurkar V.R. A guinea pig model of Zika virus infection. Virol. J. 2017;14:75. doi: 10.1186/s12985-017-0750-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-017-0750-4</ArticleId><ArticleId IdType="pmc">PMC5387205</ArticleId><ArticleId IdType="pubmed">28399888</ArticleId></ArticleIdList></Reference><Reference><Citation>Krause K., Azouz F., Nakano E., Nerurkar V.R., Kumar M. Deletion of Pregnancy Zone Protein and Murinoglobulin-1 Restricts the Pathogenesis of West Nile Virus Infection in Mice. Front. Microbiol. 2019;10:259. doi: 10.3389/fmicb.2019.00259.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2019.00259</ArticleId><ArticleId IdType="pmc">PMC6381297</ArticleId><ArticleId IdType="pubmed">30814992</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar M., Roe K., Nerurkar P.V., Orillo B., Thompson K.S., Verma S., Nerurkar V.R. Reduced immune cell infiltration and increased pro-inflammatory mediators in the brain of Type 2 diabetic mouse model infected with West Nile virus. J. Neuroinflamm. 2014;11:80. doi: 10.1186/1742-2094-11-80.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-11-80</ArticleId><ArticleId IdType="pmc">PMC4001407</ArticleId><ArticleId IdType="pubmed">24750819</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar M., Roe K., O&#x2019;Connell M., Nerurkar V.R. Induction of virus-specific effector immune cell response limits virus replication and severe disease in mice infected with non-lethal West Nile virus Eg101 strain. J. Neuroinflamm. 2015;12:178. doi: 10.1186/s12974-015-0400-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-015-0400-y</ArticleId><ArticleId IdType="pmc">PMC4578235</ArticleId><ArticleId IdType="pubmed">26392176</ArticleId></ArticleIdList></Reference><Reference><Citation>McCray P.B., Jr., Pewe L., Wohlford-Lenane C., Hickey M., Manzel L., Shi L., Netland J., Jia H.P., Halabi C., Sigmund C.D., et al. Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. J. Virol. 2007;81:813&#x2013;821. doi: 10.1128/JVI.02012-06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02012-06</ArticleId><ArticleId IdType="pmc">PMC1797474</ArticleId><ArticleId IdType="pubmed">17079315</ArticleId></ArticleIdList></Reference><Reference><Citation>tenOever B.R. The Evolution of Antiviral Defense Systems. Cell Host Microbe. 2016;19:142&#x2013;149. doi: 10.1016/j.chom.2016.01.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2016.01.006</ArticleId><ArticleId IdType="pubmed">26867173</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwasaki A., Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science. 2010;327:291&#x2013;295. doi: 10.1126/science.1183021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1183021</ArticleId><ArticleId IdType="pmc">PMC3645875</ArticleId><ArticleId IdType="pubmed">20075244</ArticleId></ArticleIdList></Reference><Reference><Citation>Roth-Cross J.K., Bender S.J., Weiss S.R. Murine coronavirus mouse hepatitis virus is recognized by MDA5 and induces type I interferon in brain macrophages/microglia. J. Virol. 2008;82:9829&#x2013;9838. doi: 10.1128/JVI.01199-08.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01199-08</ArticleId><ArticleId IdType="pmc">PMC2566260</ArticleId><ArticleId IdType="pubmed">18667505</ArticleId></ArticleIdList></Reference><Reference><Citation>Meinhardt J., Radke J., Dittmayer C., Franz J., Thomas C., Mothes R., Laue M., Schneider J., Brunink S., Greuel S., et al. Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. Nat. Neurosci. 2020:1&#x2013;8. doi: 10.1038/s41593-020-00758-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-020-00758-5</ArticleId><ArticleId IdType="pubmed">33257876</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanjanaumporn J., Aeumjaturapat S., Snidvongs K., Seresirikachorn K., Chusakul S. Smell and taste dysfunction in patients with SARS-CoV-2 infection: A review of epidemiology, pathogenesis, prognosis, and treatment options. Asian Pac. J. Allergy Immunol. 2020;38:69&#x2013;77. doi: 10.12932/AP-030520-0826.</Citation><ArticleIdList><ArticleId IdType="doi">10.12932/AP-030520-0826</ArticleId><ArticleId IdType="pubmed">32563234</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantuti-Castelvetri L., Ojha R., Pedro L.D., Djannatian M., Franz J., Kuivanen S., van der Meer F., Kallio K., Kaya T., Anastasina M., et al. Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. Science. 2020;370:856&#x2013;860. doi: 10.1126/science.abd2985.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd2985</ArticleId><ArticleId IdType="pmc">PMC7857391</ArticleId><ArticleId IdType="pubmed">33082293</ArticleId></ArticleIdList></Reference><Reference><Citation>Dube M., Le Coupanec A., Wong A.H.M., Rini J.M., Desforges M., Talbot P.J. Axonal Transport Enables Neuron-to-Neuron Propagation of Human Coronavirus OC43. J. Virol. 2018;92:e00404&#x2013;e00418. doi: 10.1128/JVI.00404-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00404-18</ArticleId><ArticleId IdType="pmc">PMC6096804</ArticleId><ArticleId IdType="pubmed">29925652</ArticleId></ArticleIdList></Reference><Reference><Citation>Swanson P.A., 2nd, McGavern D.B. Viral diseases of the central nervous system. Curr. Opin. Virol. 2015;11:44&#x2013;54. doi: 10.1016/j.coviro.2014.12.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coviro.2014.12.009</ArticleId><ArticleId IdType="pmc">PMC4456224</ArticleId><ArticleId IdType="pubmed">25681709</ArticleId></ArticleIdList></Reference><Reference><Citation>van Riel D., Verdijk R., Kuiken T. The olfactory nerve: A shortcut for influenza and other viral diseases into the central nervous system. J. Pathol. 2015;235:277&#x2013;287. doi: 10.1002/path.4461.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.4461</ArticleId><ArticleId IdType="pubmed">25294743</ArticleId></ArticleIdList></Reference><Reference><Citation>Blinzinger K., Anzil A.P. Neural route of infection in viral diseases of the central nervous system. Lancet. 1974;2:1374&#x2013;1375. doi: 10.1016/S0140-6736(74)92234-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(74)92234-X</ArticleId><ArticleId IdType="pubmed">4143329</ArticleId></ArticleIdList></Reference><Reference><Citation>Durrant D.M., Ghosh S., Klein R.S. The Olfactory Bulb: An Immunosensory Effector Organ during Neurotropic Viral Infections. ACS Chem. Neurosci. 2016;7:464&#x2013;469. doi: 10.1021/acschemneuro.6b00043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.6b00043</ArticleId><ArticleId IdType="pmc">PMC5775964</ArticleId><ArticleId IdType="pubmed">27058872</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34052228</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>26</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1083-351X</ISSN><JournalIssue CitedMedium="Internet"><Volume>297</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Jul</Month></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Alzheimer's disease-associated &#x3b2;-amyloid does not protect against herpes simplex virus 1 infection in the mouse brain.</ArticleTitle><Pagination><StartPage>100845</StartPage><MedlinePgn>100845</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">100845</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jbc.2021.100845</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0021-9258(21)00643-8</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is a devastating fatal neurodegenerative disease. An alternative to the amyloid cascade hypothesis is that a viral infection is key to the etiology of late-onset AD, with &#x3b2;-amyloid (A&#x3b2;) peptides playing a protective role. In the current study, young 5XFAD mice that overexpress mutant human amyloid precursor protein with the Swedish, Florida, and London familial AD mutations were infected with one of two strains of herpes simplex virus 1 (HSV-1), 17syn+ and McKrae, at three different doses. Contrary to previous work, 5XFAD genotype failed to protect mice against HSV-1 infection. The region- and cell-specific tropisms of HSV-1 were not affected by the 5XFAD genotype, indicating that host-pathogen interactions were not altered. Seven- to ten-month-old 5XFAD animals in which extracellular A&#x3b2; aggregates were abundant showed slightly better survival rate relative to their wild-type (WT) littermates, although the difference was not statistically significant. In these 5XFAD mice, HSV-1 replication centers were partially excluded from the brain areas with high densities of A&#x3b2; aggregates. A&#x3b2; aggregates were free of HSV-1 viral particles, and the limited viral invasion to areas with a high density of A&#x3b2; aggregates was attributed to phagocytic activity of reactive microglia. In the oldest mice (12-15 months old), the survival rate did not differ between 5XFAD and WT littermates. While the current study questions the antiviral role of A&#x3b2;, it neither supports nor refutes the viral etiology hypothesis of late-onset AD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bocharova</LastName><ForeName>Olga</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Center for Biomedical Engineering and Technology, University of Maryland School of Medicine, Baltimore, Maryland, USA; Department of Anatomy and Neurobiology, University of Maryland School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pandit</LastName><ForeName>Narayan P</ForeName><Initials>NP</Initials><AffiliationInfo><Affiliation>Center for Biomedical Engineering and Technology, University of Maryland School of Medicine, Baltimore, Maryland, USA; Department of Anatomy and Neurobiology, University of Maryland School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molesworth</LastName><ForeName>Kara</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Center for Biomedical Engineering and Technology, University of Maryland School of Medicine, Baltimore, Maryland, USA; Department of Anatomy and Neurobiology, University of Maryland School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fisher</LastName><ForeName>Aidan</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Biomedical Engineering and Technology, University of Maryland School of Medicine, Baltimore, Maryland, USA; Department of Anatomy and Neurobiology, University of Maryland School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mychko</LastName><ForeName>Olga</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Center for Biomedical Engineering and Technology, University of Maryland School of Medicine, Baltimore, Maryland, USA; Department of Anatomy and Neurobiology, University of Maryland School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Makarava</LastName><ForeName>Natallia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Center for Biomedical Engineering and Technology, University of Maryland School of Medicine, Baltimore, Maryland, USA; Department of Anatomy and Neurobiology, University of Maryland School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baskakov</LastName><ForeName>Ilia V</ForeName><Initials>IV</Initials><AffiliationInfo><Affiliation>Center for Biomedical Engineering and Technology, University of Maryland School of Medicine, Baltimore, Maryland, USA; Department of Anatomy and Neurobiology, University of Maryland School of Medicine, Baltimore, Maryland, USA. Electronic address: Baskakov@som.umaryland.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS045585</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>05</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Biol Chem. 2021 Aug;297(2):100936. doi: 10.1016/j.jbc.2021.100936.</RefSource><PMID Version="1">34217702</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006561" MajorTopicYN="N">Herpes Simplex</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018259" MajorTopicYN="N">Herpesvirus 1, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054884" MajorTopicYN="N">Host-Pathogen Interactions</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014777" MajorTopicYN="N">Virus Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">5XFAD mice</Keyword><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">A&#x3b2; aggregates</Keyword><Keyword MajorTopicYN="N">amyloid precursor protein</Keyword><Keyword MajorTopicYN="N">astrocytes</Keyword><Keyword MajorTopicYN="N">herpes simplex virus 1</Keyword><Keyword MajorTopicYN="N">microglia</Keyword></KeywordList><CoiStatement>Conflicts of interest The authors declare that they have no conflict of interests with the contents of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>1</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>5</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>30</Day><Hour>20</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>5</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34052228</ArticleId><ArticleId IdType="pmc">PMC8214219</ArticleId><ArticleId IdType="doi">10.1016/j.jbc.2021.100845</ArticleId><ArticleId IdType="pii">S0021-9258(21)00643-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lambert J.-C., Ibrahim-Verbaas C.A., Harold D., Naj A.C., Sims R., Bellenguez C., Jun G., DeStefano A.L., Bis J.C., Beecham G.W., Grenier-Boley B., Russo G., Thornton-Wells T.A., Jones N., Smith A.V. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat. Genet. 2013;45:1452.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Glenner G.G., Wong C.W. Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 1984;120:885&#x2013;890.</Citation><ArticleIdList><ArticleId IdType="pubmed">6375662</ArticleId></ArticleIdList></Reference><Reference><Citation>Goate A., Chartier-Harlin M.C., Mullan M., Brown J., Crawford F., Fidani L., Giuffra L., Haynes A., Irving N., James L., Mant R., Newton P., Rooke K., Roques P., Talbot C. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature. 1991;349:704&#x2013;706.</Citation><ArticleIdList><ArticleId IdType="pubmed">1671712</ArticleId></ArticleIdList></Reference><Reference><Citation>Piacentini R., De Chiara G., Li Puma D.D., Ripoli C., Marcocci M.E., Garaci E., Palamara A.T., Grassi C. HSV-1 and Alzheimer&#x2019;s disease: More than a hypothesis. Front. Pharmacol. 2014;5:97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4019841</ArticleId><ArticleId IdType="pubmed">24847267</ArticleId></ArticleIdList></Reference><Reference><Citation>Itzhaki R.F., Wozniak M.A., Appelt D.M., Balin B.J. Infiltration of the brain by pathogens causes Alzheimer&#x2019;s disease. Neurobiol. Aging. 2004;25:619&#x2013;627.</Citation><ArticleIdList><ArticleId IdType="pubmed">15172740</ArticleId></ArticleIdList></Reference><Reference><Citation>De Chiara G., Marcocci M.E., Sgarbanti R., Civitelli L., Ripoli C., Piacentini R., Garaci E., Grassi C., Palamara A.T. Infectious agents and neurodegeneration. Mol. Neurobiol. 2012;46:614&#x2013;638.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3496540</ArticleId><ArticleId IdType="pubmed">22899188</ArticleId></ArticleIdList></Reference><Reference><Citation>Eimer W.A., Vijaya Kumar D.K., Navalpur Shanmugam N.K., Rodriguez A.S., Mitchell T., Washicosky K.J., Gy&#xf6;rgy B., Breakefield X.O., Tanzi R.E., Moir R.D. Alzheimer&#x2019;s disease-associated &#x3b2;-amyloid is rapidly seeded by herpesviridae to protect against brain infection. Neuron. 2018;99:56&#x2013;63.e53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6075814</ArticleId><ArticleId IdType="pubmed">30001512</ArticleId></ArticleIdList></Reference><Reference><Citation>Ezzat K., Pernemalm M., P&#xe5;lsson S., Roberts T.C., J&#xe4;rver P., Dondalska A., Bestas B., Sobkowiak M.J., Lev&#xe4;nen B., Sk&#xf6;ld M., Thompson E.A., Saher O., Kari O.K., Lajunen T., Sverremark Ekstr&#xf6;m E. The viral protein corona directs viral pathogenesis and amyloid aggregation. Nat. Commun. 2019;10:2331.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6536551</ArticleId><ArticleId IdType="pubmed">31133680</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar D.K.V., Choi S.H., Washicosky K.J., Eimer W.A., Tucker S., Ghofrani J., Lefkowitz A., McColl G., Goldstein L.E., Tanzi R.E., Moir R.D. Amyloid-&#x3b2; peptide protects against microbial infection in mouse and worm models of Alzheimer&#x2019;s disease. Sci. Transl. Med. 2016;8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5505565</ArticleId><ArticleId IdType="pubmed">27225182</ArticleId></ArticleIdList></Reference><Reference><Citation>Moir R.D., Lathe R., Tanzi R.E. The antimicrobial protection hypothesis of Alzheimer's disease. Alzheimers Dement. 2018;14:1602&#x2013;1614.</Citation><ArticleIdList><ArticleId IdType="pubmed">30314800</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns D.M., Rouleau N., Parker R.N., Walsh K.G., Gehrke L., Kaplan D.L. A&#xa0;3D human brain&#x2013;like tissue model of herpes-induced Alzheimer&#x2019;s disease. Sci. Adv. 2020;6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7202879</ArticleId><ArticleId IdType="pubmed">32494701</ArticleId></ArticleIdList></Reference><Reference><Citation>Little C.S., Hammond C.J., MacIntyre A., Balin B.J., Appelt D.M. Chlamydia pneumoniae induces Alzheimer-like amyloid plaques in brains of BALB/c mice. Neurobiol. Aging. 2004;25:419&#x2013;429.</Citation><ArticleIdList><ArticleId IdType="pubmed">15013562</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond C.J., Hallock L.R., Howanski R.J., Appelt D.M., Little C.S., Balin B.J. Immunohistological detection of Chlamydia pneumoniae in the Alzheimer's disease brain. BMC Neurosci. 2010;11:121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2949767</ArticleId><ArticleId IdType="pubmed">20863379</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xe9;rard H.C., Wildt K.L., Whittum-Hudson J.A., Lai Z., Ager J., Hudson A.P. The load of Chlamydia pneumoniae in the Alzheimer's brain varies with APOE genotype. Microb. Pathog. 2005;39:19&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">15998578</ArticleId></ArticleIdList></Reference><Reference><Citation>Little C.S., Joyce T.A., Hammond C.J., Matta H., Cahn D., Appelt D.M., Balin B.J. Detection of bacterial antigens and Alzheimer&#x2019;s disease-like pathology in the central nervous system of BALB/c mice following intranasal infection with a laboratory isolate of Chlamydia pneumoniae. Front. Aging Neurosci. 2014;6:304.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4257355</ArticleId><ArticleId IdType="pubmed">25538615</ArticleId></ArticleIdList></Reference><Reference><Citation>Miklossy J., Kis A., Radenovic A., Miller L., Forro L., Martins R., Reiss K., Darbinian N., Darekar P., Mihaly L., Khalili K. Beta-amyloid deposition and Alzheimer's type changes induced by Borrelia spirochetes. Neurobiol. Aging. 2006;27:228&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pubmed">15894409</ArticleId></ArticleIdList></Reference><Reference><Citation>Miklossy J. Historic evidence to support a causal relationship between spirochetal infections and Alzheimer&#x2019;s disease. Front. Aging Neurosci. 2015;7:46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4399390</ArticleId><ArticleId IdType="pubmed">25932012</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai M.-C., Cheng W.-L., Sheu J.-J., Huang C.-C., Shia B.-C., Kao L.-T., Lin H.-C. Increased risk of dementia following herpes zoster ophthalmicus. PLoS One. 2017;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5699837</ArticleId><ArticleId IdType="pubmed">29166672</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogestyn J., Mock D., Mayer-Proschel M. Contributions of neurotropic human herpesviruses herpes simplex virus 1 and human herpesvirus 6 to neurodegenerative disease pathology. Neural Regen. Res. 2018;13:211&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5879884</ArticleId><ArticleId IdType="pubmed">29557362</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris S.A., Harris E.A. Molecular mechanisms for herpes simplex virus type 1 pathogenesis in Alzheimer&#x2019;s disease. Front. Aging Neurosci. 2018;10:48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5845560</ArticleId><ArticleId IdType="pubmed">29559905</ArticleId></ArticleIdList></Reference><Reference><Citation>De Chiara G., Piacentini R., Fabiani M., Mastrodonato A., Marcocci M.E., Limongi D., Napoletani G., Protto V., Coluccio P., Celestino I., Li Puma D.D., Grassi C., Palamara A.T. Recurrent herpes simplex virus-1 infection induces hallmarks of neurodegeneration and cognitive deficits in mice. PLoS Pathog. 2019;15</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6417650</ArticleId><ArticleId IdType="pubmed">30870531</ArticleId></ArticleIdList></Reference><Reference><Citation>Duarte L.F., Far&#xed;as M.A., &#xc1;lvarez D.M., Bueno S.M., Riedel C.A., Gonz&#xe1;lez P.A. Herpes simplex virus type 1 infection of the central nervous system: Insights into proposed interrelationships with neurodegenerative disorders. Front. Cell Neurosci. 2019;13:46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6399123</ArticleId><ArticleId IdType="pubmed">30863282</ArticleId></ArticleIdList></Reference><Reference><Citation>Itzhaki R.F. Corroboration of a major role for herpes simplex virus type 1 in Alzheimer&#x2019;s disease. Front. Aging Neurosci. 2018;10:324.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6202583</ArticleId><ArticleId IdType="pubmed">30405395</ArticleId></ArticleIdList></Reference><Reference><Citation>Readhead B., Haure-Mirande J.-V., Funk C.C., Richards M.A., Shannon P., Haroutunian V., Sano M., Liang W.S., Beckmann N.D., Price N.D., Reiman E.M., Schadt E.E., Ehrlich M.E., Gandy S., Dudley J.T. Multiscale analysis of independent Alzheimer&#x2019;s cohorts finds disruption of molecular, genetic, and clinical networks by human herpesvirus. Neuron. 2018;99:64&#x2013;82.e67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6551233</ArticleId><ArticleId IdType="pubmed">29937276</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeong H.-H., Liu Z. Are HHV-6A and HHV-7 really more abundant in Alzheimer&#x2019;s disease? Neuron. 2019;104:1034&#x2013;1035.</Citation><ArticleIdList><ArticleId IdType="pubmed">31855626</ArticleId></ArticleIdList></Reference><Reference><Citation>Allnutt M.A., Johnson K., Bennett D.A., Connor S.M., Troncoso J.C., Pletnikova O., Albert M.S., Resnick S.M., Scholz S.W., De Jager P.L., Jacobson S. Human herpesvirus 6 detection in Alzheimer&#x2019;s disease cases and controls across multiple cohorts. Neuron. 2020;105:1027&#x2013;1035.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7182308</ArticleId><ArticleId IdType="pubmed">31983538</ArticleId></ArticleIdList></Reference><Reference><Citation>Webre J.M., Hill J.M., Nolan N.M., Clement C., McFerrin H.E., Bhattacharjee P.S., Hsia V., Neumann D.M., Foster T.P., Lukiw W.J., Thompson H.W. Rabbit and mouse models of HSV-1 latency, reactivation, and recurrent eye diseases. J.&#xa0;Biomed. Biotechnol. 2012;2012:612316.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3467953</ArticleId><ArticleId IdType="pubmed">23091352</ArticleId></ArticleIdList></Reference><Reference><Citation>Szpara M.L., Gatherer D., Ochoa A., Greenbaum B., Dolan A., Bowden R.J., Enquist L.W., Legendre M., Davison A.J. Evolution and diversity in human herpes simplex virus genomes. J.&#xa0;Virol. 2014;88:1209&#x2013;1227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3911644</ArticleId><ArticleId IdType="pubmed">24227835</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawtell N.M., Poon D.K., Tansky C.S., Thompson R.L. The latent herpes simplex virus type 1 genome copy number in individual neurons is virus strain specific and correlates with reactivation. J.&#xa0;Virol. 1998;72:5343&#x2013;5350.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC110155</ArticleId><ArticleId IdType="pubmed">9620987</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawtell N.M., Thompson R.L. Rapid in&#xa0;vivo reactivation of herpes simplex virus in latently infected murine ganglionic neurons after transient hyperthermia. J.&#xa0;Virol. 1992;66:2150&#x2013;2156.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC289007</ArticleId><ArticleId IdType="pubmed">1312625</ArticleId></ArticleIdList></Reference><Reference><Citation>Kollias C.M., Huneke R.B., Wigdahl B., Jennings S.R. Animal models of herpes simplex virus immunity and pathogenesis. J.&#xa0;Neurovirol. 2015;21:8&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">25388226</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H., Cole S.L., Logan S., Maus E., Shao P., Craft J., Guillozet-Bongaarts A., Ohno M., Disterhoft J., Van Eldik L., Berry R., Vassar R. Intraneuronal &#x3b2;-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: Potential factors in amyloid plaque formation. J.&#xa0;Neurosci. 2006;26:10129&#x2013;10140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Davido D.J., Morrison L.A. HSV-1 strain McKrae is more neuroinvasive than HSV-1 KOS after corneal or vaginal inoculation in mice. Virus Res. 2014;173:436&#x2013;440.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3640688</ArticleId><ArticleId IdType="pubmed">23339898</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadleir K.R., Eimer W.A., Cole S.L., Vassar R. A&#x3b2; reduction in BACE1 heterozygous null 5XFAD mice is associated with transgenic APP level. Mol. Neurodegener. 2015;10:1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4297413</ArticleId><ArticleId IdType="pubmed">25567526</ArticleId></ArticleIdList></Reference><Reference><Citation>Drayman N., Patel P., Vistain L., Tay S. HSV-1 single-cell analysis reveals the activation of anti-viral and developmental programs in distinct sub-populations. Elife. 2019;8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6570482</ArticleId><ArticleId IdType="pubmed">31090537</ArticleId></ArticleIdList></Reference><Reference><Citation>Braun E., Zimmerman T., Hur T.B., Reinhartz E., Fellig Y., Panet A., Steiner I. Neurotropism of herpes simplex virus type 1 in brain organ cultures. J.&#xa0;Gen. Virol. 2006;87:2827&#x2013;2837.</Citation><ArticleIdList><ArticleId IdType="pubmed">16963740</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinert L.S., Lopu&#x161;n&#xe1; K., Winther H., Sun C., Thomsen M.K., Nandakumar R., Mogensen T.H., Meyer M., V&#xe6;gter C., Nyengaard J.R., Fitzgerald K.A., Paludan S.R. Sensing of HSV-1 by the cGAS&#x2013;STING pathway in microglia orchestrates antiviral defence in the CNS. Nat. Commun. 2016;7:13348.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5109551</ArticleId><ArticleId IdType="pubmed">27830700</ArticleId></ArticleIdList></Reference><Reference><Citation>Cymerys J., Kowalczyk A., Mikotajewicz K., ajewicz K., Stonska A., Krzyzowska M. Nitric oxide influences HSV-1-induced neuroinflammation. Oxid. Med. Cell Longev. 2019;2019:2302835.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6388346</ArticleId><ArticleId IdType="pubmed">30886672</ArticleId></ArticleIdList></Reference><Reference><Citation>Villalba M., Hott M., Martin C., Aguila B., Valdivia S., Quezada C., Zambrano &#xc1;., Concha M.I., Otth C. Herpes simplex virus type 1 induces simultaneous activation of Toll-like receptors 2 and 4 and expression of the endogenous ligand serum amyloid A in astrocytes. Med. Microbiol. Immunol. 2012;201:371&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pubmed">22622619</ArticleId></ArticleIdList></Reference><Reference><Citation>Bello-Morales R., Praena B., de la Nuez C., Rejas M.T., Guerra M., Gal&#xe1;n-Ganga M., Izquierdo M., Calvo V., Krummenacher C., L&#xf3;pez-Guerrero J.A. Role of microvesicles in the spread of herpes simplex virus 1 in oligodendrocytic cells. J.&#xa0;Virol. 2018;92</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5923088</ArticleId><ArticleId IdType="pubmed">29514899</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunn K.W., Kamocka M.M., McDonald J.H. A&#xa0;practical guide to evaluating colocalization in biological microscopy. Am. J. Physiol. Cell Physiol. 2011;300:C723&#x2013;C742.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3074624</ArticleId><ArticleId IdType="pubmed">21209361</ArticleId></ArticleIdList></Reference><Reference><Citation>Fekete R., Cser&#xe9;p C., L&#xe9;n&#xe1;rt N., T&#xf3;th K., Orsolits B., Martinecz B., M&#xe9;hes E., Szab&#xf3; B., N&#xe9;meth V., G&#xf6;nci B., Sperl&#xe1;gh B., Boldogk&#x151;i Z., Kittel &#xc1;., Baranyi M., Ferenczi S. Microglia control the spread of neurotropic virus infection via P2Y12 signalling and recruit monocytes through P2Y12-independent mechanisms. Acta Neuropathol. 2018;136:461&#x2013;482.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6096730</ArticleId><ArticleId IdType="pubmed">30027450</ArticleId></ArticleIdList></Reference><Reference><Citation>Spangenberg E., Severson P.L., Hohsfield L.A., Crapser J., Zhang J., Burton E.A., Zhang Y., Spevak W., Lin J., Phan N.Y., Habets G., Rymar A., Tsang G., Walters J., Nespi M. Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer's disease model. Nat. Commun. 2019;10:3758.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6704256</ArticleId><ArticleId IdType="pubmed">31434879</ArticleId></ArticleIdList></Reference><Reference><Citation>Spangenberg E.E., Lee R.J., Najafi A.R., Rice R.A., Elmore M.R., Blurton-Jones M., West B.L., Green K.N. Eliminating microglia in Alzheimer's mice prevents neuronal loss without modulating amyloid-&#x3b2; pathology. Brain. 2016;139:1265&#x2013;1281.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5006229</ArticleId><ArticleId IdType="pubmed">26921617</ArticleId></ArticleIdList></Reference><Reference><Citation>Janda E., Boi L., Carta A.R. Microglial phagocytosis and its regulation: A therapeutic target in Parkinson&#x2019;s disease? Front. Mol. Neurosci. 2018;11:144.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5934476</ArticleId><ArticleId IdType="pubmed">29755317</ArticleId></ArticleIdList></Reference><Reference><Citation>Haynes S.E., Hollopeter G., Yang G., Kurpius D., Dailey M.E., Gan W.-B., Julius D. The P2Y12 receptor regulates microglial activation by extracellular nucleotides. Nat. Neurosci. 2006;9:1512&#x2013;1519.</Citation><ArticleIdList><ArticleId IdType="pubmed">17115040</ArticleId></ArticleIdList></Reference><Reference><Citation>Hidetoshi T.-S., Makoto T., Inoue K. P2Y receptors in microglia and neuroinflammation. Wiley Interdiscip. Rev. Membr. Transp. Signal. 2012;1:493&#x2013;501.</Citation></Reference><Reference><Citation>Hatton C.F., Duncan C.J.A. Microglia are essential to protective antiviral immunity: Lessons from mouse models of viral encephalitis. Front. Immunol. 2019;10:2656.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6863772</ArticleId><ArticleId IdType="pubmed">31798586</ArticleId></ArticleIdList></Reference><Reference><Citation>Fricker M., Oliva-Mart&#xed;n M.J., Brown G.C. Primary phagocytosis of viable neurons by microglia activated with LPS or A&#x3b2; is dependent on calreticulin/LRP phagocytic signalling. J.&#xa0;Neuroinflammation. 2012;9:196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3481398</ArticleId><ArticleId IdType="pubmed">22889139</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanguas-Cas&#xe1;s N., Crespo-Castrillo A., Arevalo M.-A., Garcia-Segura L.M. Aging and sex: Impact on microglia phagocytosis. Aging Cell. 2020;19</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7431836</ArticleId><ArticleId IdType="pubmed">32725944</ArticleId></ArticleIdList></Reference><Reference><Citation>Th&#xe9;riault P., Rivest S. Microglia: Senescence impairs clearance of myelin debris. Curr. Biol. 2016;26:R772&#x2013;R775.</Citation><ArticleIdList><ArticleId IdType="pubmed">27554659</ArticleId></ArticleIdList></Reference><Reference><Citation>Baik S.H., Kang S., Son S.M., Mook-Jung I. Microglia contributes to plaque growth by cell death due to uptake of amyloid &#x3b2; in the brain of Alzheimer's disease mouse model. Glia. 2016;64:2274&#x2013;2290.</Citation><ArticleIdList><ArticleId IdType="pubmed">27658617</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y., Happonen K.E., Burrola P.G., O'Connor C., Hah N., Huang L., Nimmerjahn A., Lemke G. Microglia use TAM receptors to detect and engulf amyloid &#x3b2; plaques. Nat. Immunol. 2021;22:586&#x2013;594.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8102389</ArticleId><ArticleId IdType="pubmed">33859405</ArticleId></ArticleIdList></Reference><Reference><Citation>Makarava N., Chang J.C.-Y., Molesworth K., Baskakov I.V. Region-specific glial homeostatic signature in prion diseases is replaced by a uniform neuroinflammation signature, common for brain regions and prion strains with different cell tropism. Neurobiol. Dis. 2020;137</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7052953</ArticleId><ArticleId IdType="pubmed">32001329</ArticleId></ArticleIdList></Reference><Reference><Citation>Costes S.V., Daelemans D., Cho E.H., Dobbin Z., Pavlakis G., Lockett S. Automatic and quantitative measurement of protein-protein colocalization in live cells. Biophys. J. 2004;86:3993&#x2013;4003.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1304300</ArticleId><ArticleId IdType="pubmed">15189895</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33510477</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>04</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1718</ISSN><JournalIssue CitedMedium="Internet"><Volume>53</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Nature genetics</Title><ISOAbbreviation>Nat Genet</ISOAbbreviation></Journal><ArticleTitle>Integrating human brain proteomes with genome-wide association data implicates new proteins in Alzheimer's disease pathogenesis.</ArticleTitle><Pagination><StartPage>143</StartPage><EndPage>146</EndPage><MedlinePgn>143-146</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41588-020-00773-z</ELocationID><Abstract><AbstractText>Genome-wide association studies (GWAS) have identified many risk loci for Alzheimer's disease (AD)<sup>1,2</sup>, but how these loci confer AD risk is unclear. Here, we aimed to identify loci that confer AD risk through their effects on brain protein abundance to provide new insights into AD pathogenesis. To that end, we integrated AD GWAS results with human brain proteomes to perform a proteome-wide association study (PWAS) of AD, followed by Mendelian randomization and colocalization analysis. We identified 11 genes that are consistent with being causal in AD, acting via their cis-regulated brain protein abundance. Nine replicated in a confirmation PWAS and eight represent new AD risk genes not identified before by AD GWAS. Furthermore, we demonstrated that our results were independent of APOE e4. Together, our findings provide new insights into AD pathogenesis and promising targets for further mechanistic and therapeutic studies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wingo</LastName><ForeName>Aliza P</ForeName><Initials>AP</Initials><Identifier Source="ORCID">0000-0002-6360-6726</Identifier><AffiliationInfo><Affiliation>Division of Mental Health, Atlanta VA Medical Center, Decatur, GA, USA. aliza.wingo@emory.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Emory University School of Medicine, Atlanta, GA, USA. aliza.wingo@emory.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yue</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gerasimov</LastName><ForeName>Ekaterina S</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gockley</LastName><ForeName>Jake</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Sage Bionetworks, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Logsdon</LastName><ForeName>Benjamin A</ForeName><Initials>BA</Initials><Identifier Source="ORCID">0000-0002-0572-2569</Identifier><AffiliationInfo><Affiliation>Sage Bionetworks, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duong</LastName><ForeName>Duc M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dammer</LastName><ForeName>Eric B</ForeName><Initials>EB</Initials><Identifier Source="ORCID">0000-0003-2947-7606</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robins</LastName><ForeName>Chloe</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beach</LastName><ForeName>Thomas G</ForeName><Initials>TG</Initials><AffiliationInfo><Affiliation>Banner Sun Health Research Institute, Sun City, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials><Identifier Source="ORCID">0000-0002-0705-3696</Identifier><AffiliationInfo><Affiliation>Banner Alzheimer's Institute, Arizona State University and University of Arizona, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Epstein</LastName><ForeName>Michael P</ForeName><Initials>MP</Initials><Identifier Source="ORCID">0000-0001-9647-9738</Identifier><AffiliationInfo><Affiliation>Department of Human Genetics, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Jager</LastName><ForeName>Philip L</ForeName><Initials>PL</Initials><Identifier Source="ORCID">0000-0002-8057-2505</Identifier><AffiliationInfo><Affiliation>Center for Translational and Computational Neuroimmunology, Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lah</LastName><ForeName>James J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seyfried</LastName><ForeName>Nicholas T</ForeName><Initials>NT</Initials><Identifier Source="ORCID">0000-0002-4507-624X</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levey</LastName><ForeName>Allan I</ForeName><Initials>AI</Initials><Identifier Source="ORCID">0000-0002-3153-502X</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wingo</LastName><ForeName>Thomas S</ForeName><Initials>TS</Initials><Identifier Source="ORCID">0000-0002-7679-6282</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA. thomas.wingo@emory.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Human Genetics, Emory University School of Medicine, Atlanta, GA, USA. thomas.wingo@emory.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 AG046152</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>IK4 BX005219</GrantID><Acronym>BX</Acronym><Agency>BLRD VA</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG061800</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066511</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG061356</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG053960</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG061357</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC2 AG036547</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG057470</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 MH115484</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG056533</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>I01 BX003853</GrantID><Acronym>BX</Acronym><Agency>BLRD VA</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AG062256</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AG062633</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG057911</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AG060757</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG025688</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 NS072026</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG046161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS055077</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>01</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Genet</MedlineTA><NlmUniqueID>9216904</NlmUniqueID><ISSNLinking>1061-4036</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000612345">ApoE protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020543">Proteome</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011991">Receptors, Virus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C066100">poliovirus receptor</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.3.2.-</RegistryNumber><NameOfSubstance UI="D004851">Epoxide Hydrolases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.3.2.10</RegistryNumber><NameOfSubstance UI="C506428">EPHX2 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004851" MajorTopicYN="N">Epoxide Hydrolases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020543" MajorTopicYN="N">Proteome</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D040641" MajorTopicYN="N">Quantitative Trait Loci</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011991" MajorTopicYN="N">Receptors, Virus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017423" MajorTopicYN="N">Sequence Analysis, RNA</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059010" MajorTopicYN="N">Single-Cell Analysis</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>3</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>12</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>1</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>1</Month><Day>29</Day><Hour>5</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>7</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33510477</ArticleId><ArticleId IdType="mid">NIHMS1656683</ArticleId><ArticleId IdType="pmc">PMC8130821</ArticleId><ArticleId IdType="doi">10.1038/s41588-020-00773-z</ArticleId><ArticleId IdType="pii">10.1038/s41588-020-00773-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jansen IE, et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer&#x2019;s disease risk. Nature genetics 51, 404&#x2013;413 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6836675</ArticleId><ArticleId IdType="pubmed">30617256</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunkle BW, et al. Genetic meta-analysis of diagnosed Alzheimer&#x2019;s disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing. Nature genetics 51, 414&#x2013;430 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6463297</ArticleId><ArticleId IdType="pubmed">30820047</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballard C, et al. Alzheimer&#x2019;s disease. Lancet (London, England) 377, 1019&#x2013;1031 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21371747</ArticleId></ArticleIdList></Reference><Reference><Citation>Wingo AP, et al. Shared proteomic effects of cerebral atherosclerosis and Alzheimer&#x2019;s disease on the human brain. Nature neuroscience 23, 696&#x2013;700 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7269838</ArticleId><ArticleId IdType="pubmed">32424284</ArticleId></ArticleIdList></Reference><Reference><Citation>Gusev A, et al. Integrative approaches for large-scale transcriptome-wide association studies. Nature genetics 48, 245&#x2013;252 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4767558</ArticleId><ArticleId IdType="pubmed">26854917</ArticleId></ArticleIdList></Reference><Reference><Citation>Beach TG, et al. Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program. Neuropathology 35, 354&#x2013;389 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4593391</ArticleId><ArticleId IdType="pubmed">25619230</ArticleId></ArticleIdList></Reference><Reference><Citation>Giambartolomei C, et al. Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. PLoS genetics 10, e1004383 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4022491</ArticleId><ArticleId IdType="pubmed">24830394</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Z, et al. Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. Nature genetics 48, 481&#x2013;487 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27019110</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolas A, et al. Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron 97, 1268&#x2013;1283.e1266 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5867896</ArticleId><ArticleId IdType="pubmed">29566793</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalls MA, et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson&#x2019;s disease: a meta-analysis of genome-wide association studies. The Lancet. Neurology 18, 1091&#x2013;1102 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8422160</ArticleId><ArticleId IdType="pubmed">31701892</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagel M, et al. Meta-analysis of genome-wide association studies for neuroticism in 449,484 individuals identifies novel genetic loci and pathways. Nature genetics 50, 920&#x2013;927 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29942085</ArticleId></ArticleIdList></Reference><Reference><Citation>Yengo L, et al. Meta-analysis of genome-wide association studies for height and body mass index in &#x223c;700000 individuals of European ancestry. Human molecular genetics 27, 3641&#x2013;3649 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6488973</ArticleId><ArticleId IdType="pubmed">30124842</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulit SL, et al. Meta-analysis of genome-wide association studies for body fat distribution in 694 649 individuals of European ancestry. Human molecular genetics 28, 166&#x2013;174 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6298238</ArticleId><ArticleId IdType="pubmed">30239722</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y, et al. Integrative analysis of omics summary data reveals putative mechanisms underlying complex traits. Nat Commun 9, 918 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5834629</ArticleId><ArticleId IdType="pubmed">29500431</ArticleId></ArticleIdList></Reference><Reference><Citation>Langfelder P. &amp; Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC bioinformatics 9, 559 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2631488</ArticleId><ArticleId IdType="pubmed">19114008</ArticleId></ArticleIdList></Reference><Reference><Citation>Wainberg M, et al. Opportunities and challenges for transcriptome-wide association studies. Nature genetics 51, 592&#x2013;599 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6777347</ArticleId><ArticleId IdType="pubmed">30926968</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H, et al. Single-cell transcriptomic analysis of Alzheimer&#x2019;s disease. Nature 570, 332&#x2013;337 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6865822</ArticleId><ArticleId IdType="pubmed">31042697</ArticleId></ArticleIdList></Reference><Reference><Citation>Gusev A, et al. Transcriptome-wide association study of schizophrenia and chromatin activity yields mechanistic disease insights. Nature genetics 50, 538&#x2013;548 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5942893</ArticleId><ArticleId IdType="pubmed">29632383</ArticleId></ArticleIdList></Reference><Reference><Citation>Huckins LM, et al. Gene expression imputation across multiple brain regions provides insights into schizophrenia risk. Nature genetics 51, 659&#x2013;674 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7034316</ArticleId><ArticleId IdType="pubmed">30911161</ArticleId></ArticleIdList></Reference><Reference><Citation>Raj T, et al. Integrative transcriptome analyses of the aging brain implicate altered splicing in Alzheimer&#x2019;s disease susceptibility. Nature genetics 50, 1584&#x2013;1592 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6354244</ArticleId><ArticleId IdType="pubmed">30297968</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, et al. Religious Orders Study and Rush Memory and Aging Project. Journal of Alzheimer&#x2019;s disease : JAD 64, S161&#x2013;s189 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6380522</ArticleId><ArticleId IdType="pubmed">29865057</ArticleId></ArticleIdList></Reference><Reference><Citation>Mertins P, et al. Reproducible workflow for multiplexed deep-scale proteome and phosphoproteome analysis of tumor tissues by liquid chromatography-mass spectrometry. Nature protocols 13, 1632&#x2013;1661 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6211289</ArticleId><ArticleId IdType="pubmed">29988108</ArticleId></ArticleIdList></Reference><Reference><Citation>De Jager PL, et al. A multi-omic atlas of the human frontal cortex for aging and Alzheimer&#x2019;s disease research. Scientific data 5, 180142 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6080491</ArticleId><ArticleId IdType="pubmed">30084846</ArticleId></ArticleIdList></Reference><Reference><Citation>Purcell S, et al. PLINK: a toolset for whole-genome association and population-based linkage analysis. American journal of human genetics 81, 559&#x2013;575 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1950838</ArticleId><ArticleId IdType="pubmed">17701901</ArticleId></ArticleIdList></Reference><Reference><Citation>Manichaikul A, et al. Robust relationship inference in genome-wide association studies. Bioinformatics (Oxford, England) 26, 2867&#x2013;2873 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3025716</ArticleId><ArticleId IdType="pubmed">20926424</ArticleId></ArticleIdList></Reference><Reference><Citation>Abecasis GR, et al. An integrated map of genetic variation from 1,092 human genomes. Nature 491, 56&#x2013;65 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3498066</ArticleId><ArticleId IdType="pubmed">23128226</ArticleId></ArticleIdList></Reference><Reference><Citation>Das S, et al. Next-generation genotype imputation service and methods. Nature genetics 48, 1284&#x2013;1287 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5157836</ArticleId><ArticleId IdType="pubmed">27571263</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen M, et al. Human whole genome genotype and transcriptome data for Alzheimer&#x2019;s and other neurodegenerative diseases. Scientific data 3, 160089 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5058336</ArticleId><ArticleId IdType="pubmed">27727239</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M, et al. The Mount Sinai cohort of large-scale genomic, transcriptomic and proteomic data in Alzheimer&#x2019;s disease. Scientific data 5, 180185 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6132187</ArticleId><ArticleId IdType="pubmed">30204156</ArticleId></ArticleIdList></Reference><Reference><Citation>Logsdon BA, et al. Meta-analysis of the human brain transcriptome identifies heterogeneity across human AD coexpression modules robust to sample collection and methodological approach. bioRxiv, 510420 (2019).</Citation></Reference><Reference><Citation>Dobin A, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics (Oxford, England) 29, 15&#x2013;21 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3530905</ArticleId><ArticleId IdType="pubmed">23104886</ArticleId></ArticleIdList></Reference><Reference><Citation>Devlin B. &amp; Roeder K. Genomic control for association studies. Biometrics 55, 997&#x2013;1004 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">11315092</ArticleId></ArticleIdList></Reference><Reference><Citation>Freedman ML, et al. Assessing the impact of population stratification on genetic association studies. Nature genetics 36, 388&#x2013;393 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15052270</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu L, et al. A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. Nature genetics 50, 968&#x2013;978 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6314198</ArticleId><ArticleId IdType="pubmed">29915430</ArticleId></ArticleIdList></Reference><Reference><Citation>Sieberts SK, et al. Large eQTL meta-analysis reveals differing patterns between cerebral cortical and cerebellar brain regions. Scientific data 7, 340 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7550587</ArticleId><ArticleId IdType="pubmed">33046718</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler A, Hoffman P, Smibert P, Papalexi E. &amp; Satija R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nature biotechnology 36, 411&#x2013;420 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6700744</ArticleId><ArticleId IdType="pubmed">29608179</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33523105</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>10</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>78</Volume><Issue>4</Issue><PubDate><Year>2021</Year><Month>Apr</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Identification of Candidate Parkinson Disease Genes by Integrating Genome-Wide Association Study, Expression, and Epigenetic Data Sets.</ArticleTitle><Pagination><StartPage>464</StartPage><EndPage>472</EndPage><MedlinePgn>464-472</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2020.5257</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Substantial genome-wide association study (GWAS) work in Parkinson disease (PD) has led to the discovery of an increasing number of loci shown reliably to be associated with increased risk of disease. Improved understanding of the underlying genes and mechanisms at these loci will be key to understanding the pathogenesis of PD.</AbstractText><AbstractText Label="OBJECTIVE">To investigate what genes and genomic processes underlie the risk of sporadic PD.</AbstractText><AbstractText Label="DESIGN AND SETTING">This genetic association study used the bioinformatic tools Coloc and transcriptome-wide association study (TWAS) to integrate PD case-control GWAS data published in 2017 with expression data (from Braineac, the Genotype-Tissue Expression [GTEx], and CommonMind) and methylation data (derived from UK Parkinson brain samples) to uncover putative gene expression and splicing mechanisms associated with PD GWAS signals. Candidate genes were further characterized using cell-type specificity, weighted gene coexpression networks, and weighted protein-protein interaction networks.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">It was hypothesized a priori that some genes underlying PD loci would alter PD risk through changes to expression, splicing, or methylation. Candidate genes are presented whose change in expression, splicing, or methylation are associated with risk of PD as well as the functional pathways and cell types in which these genes have an important role.</AbstractText><AbstractText Label="RESULTS">Gene-level analysis of expression revealed 5 genes (WDR6 [OMIM 606031], CD38 [OMIM 107270], GPNMB [OMIM 604368], RAB29 [OMIM 603949], and TMEM163 [OMIM 618978]) that replicated using both Coloc and TWAS analyses in both the GTEx and Braineac expression data sets. A further 6 genes (ZRANB3 [OMIM 615655], PCGF3 [OMIM 617543], NEK1 [OMIM 604588], NUPL2 [NCBI 11097], GALC [OMIM 606890], and CTSB [OMIM 116810]) showed evidence of disease-associated splicing effects. Cell-type specificity analysis revealed that gene expression was overall more prevalent in glial cell types compared with neurons. The weighted gene coexpression performed on the GTEx data set showed that NUPL2 is a key gene in 3 modules implicated in catabolic processes associated with protein ubiquitination and in the ubiquitin-dependent protein catabolic process in the nucleus accumbens, caudate, and putamen. TMEM163 and ZRANB3 were both important in modules in the frontal cortex and caudate, respectively, indicating regulation of signaling and cell communication. Protein interactor analysis and simulations using random networks demonstrated that the candidate genes interact significantly more with known mendelian PD and parkinsonism proteins than would be expected by chance.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">Together, these results suggest that several candidate genes and pathways are associated with the findings observed in PD GWAS studies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kia</LastName><ForeName>Demis A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Molecular Neuroscience, University College London Institute of Neurology, Queen Square, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Molecular Neuroscience, University College London Institute of Neurology, Queen Square, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guelfi</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Molecular Neuroscience, University College London Institute of Neurology, Queen Square, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manzoni</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, School of Pharmacy, University College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hubbard</LastName><ForeName>Leon</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Psychological Medicine and Clinical Neurosciences, School of Medicine, University of Cardiff, Cardiff, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reynolds</LastName><ForeName>Regina H</ForeName><Initials>RH</Initials><AffiliationInfo><Affiliation>Department of Molecular Neuroscience, University College London Institute of Neurology, Queen Square, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bot&#xed;a</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Departamento de Ingenier&#xed;a de la Informaci&#xf3;n y las Comunicaciones, Universidad de Murcia, Murcia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryten</LastName><ForeName>Mina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Molecular Neuroscience, University College London Institute of Neurology, Queen Square, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferrari</LastName><ForeName>Raffaele</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Molecular Neuroscience, University College London Institute of Neurology, Queen Square, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lewis</LastName><ForeName>Patrick A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Department of Comparative Biomedical Sciences, The Royal Veterinary College, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Pharmacy, University of Reading, Reading, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Nigel</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of Psychological Medicine and Clinical Neurosciences, School of Medicine, University of Cardiff, Cardiff, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trabzuni</LastName><ForeName>Daniah</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Molecular Neuroscience, University College London Institute of Neurology, Queen Square, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hardy</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease and Reta Lila Weston Laboratories, University College London Dementia Research Institute, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wood</LastName><ForeName>Nicholas W</ForeName><Initials>NW</Initials><AffiliationInfo><Affiliation>Department of Molecular Neuroscience, University College London Institute of Neurology, Queen Square, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>United Kingdom Brain Expression Consortium (UKBEC) and the International Parkinson&#x2019;s Disease Genomics Consortium (IPDGC)</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K-1602</GrantID><Acronym>PUK_</Acronym><Agency>Parkinson's UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>J-0804</GrantID><Acronym>PUK_</Acronym><Agency>Parkinson's UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L501542/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0802462</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0701075</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G1100643</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L010933/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G-1502</GrantID><Acronym>PUK_</Acronym><Agency>Parkinson's UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/N026004/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/K01417X/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G-0907</GrantID><Acronym>PUK_</Acronym><Agency>Parkinson's UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/N008324/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0901254</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G-1309</GrantID><Acronym>PUK_</Acronym><Agency>Parkinson's UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0700943</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D030541" MajorTopicYN="Y">Databases, Genetic</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044127" MajorTopicYN="N">Epigenesis, Genetic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056726" MajorTopicYN="N">Genetic Association Studies</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Manzoni and Dr Lewis reported receiving grants from Medical Research Council (MRC) during the conduct of the study. Dr Williams reported receiving grants from Parkinson&#x2019;s UK during the conduct of the study. Dr Trabzuni reported receiving personal fees from King Faisal Specialist Hospital during the conduct of the study; and grants from University College London outside the submitted work. No other disclosures were reported.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Noyce</LastName><ForeName>Alastair J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaiyrzhanov</LastName><ForeName>Rauan</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Middlehurst</LastName><ForeName>Ben</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kia</LastName><ForeName>Demis A</ForeName><Initials>DA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tan</LastName><ForeName>Manuela</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Houlden</LastName><ForeName>Henry</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>Huw R</ForeName><Initials>HR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Plun-Favreau</LastName><ForeName>Helene</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Holmans</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hardy</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trabzuni</LastName><ForeName>Daniah</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bras</LastName><ForeName>Jose</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>PhD</LastName><ForeName>John Quinn</ForeName><Initials>JQ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mok</LastName><ForeName>Kin Y</ForeName><Initials>KY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kinghorn</LastName><ForeName>Kerri J</ForeName><Initials>KJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Billingsley</LastName><ForeName>Kimberley</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wood</LastName><ForeName>Nicholas W</ForeName><Initials>NW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lewis</LastName><ForeName>Patrick</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schreglmann</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guerreiro</LastName><ForeName>Rita</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lovering</LastName><ForeName>Ruth</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>R'Bibo</LastName><ForeName>Lea</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Manzoni</LastName><ForeName>Claudia</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rizig</LastName><ForeName>Mie</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ryten</LastName><ForeName>Mina</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guelfi</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Escott-Price</LastName><ForeName>Valentina</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chelban</LastName><ForeName>Viorica</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foltynie</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williams</LastName><ForeName>Nigel</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brice</LastName><ForeName>Alexis</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Danjou</LastName><ForeName>Fabrice</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lesage</LastName><ForeName>Suzanne</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Corvol</LastName><ForeName>Jean-Christophe</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martinez</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schulte</LastName><ForeName>Claudia</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brockmann</LastName><ForeName>Kathrin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sim&#xf3;n-S&#xe1;nchez</LastName><ForeName>Javier</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heutink</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rizzu</LastName><ForeName>Patrizia</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sharma</LastName><ForeName>Manu</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gasser</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nicolas</LastName><ForeName>Aude</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cookson</LastName><ForeName>Mark R</ForeName><Initials>MR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bandres-Ciga</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blauwendraat</LastName><ForeName>Cornelis</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Craig</LastName><ForeName>David W</ForeName><Initials>DW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Faghri</LastName><ForeName>Faraz</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gibbs</LastName><ForeName>J Raphael</ForeName><Initials>JR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hernandez</LastName><ForeName>Dena G</ForeName><Initials>DG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Van Keuren-Jensen</LastName><ForeName>Kendall</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shulman</LastName><ForeName>Joshua M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leonard</LastName><ForeName>Hampton L</ForeName><Initials>HL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nalls</LastName><ForeName>Mike A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Robak</LastName><ForeName>Laurie</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lubbe</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Finkbeiner</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mencacci</LastName><ForeName>Niccolo E</ForeName><Initials>NE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lungu</LastName><ForeName>Codrin</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Singleton</LastName><ForeName>Andrew B</ForeName><Initials>AB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scholz</LastName><ForeName>Sonja W</ForeName><Initials>SW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reed</LastName><ForeName>Xylena</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alcalay</LastName><ForeName>Roy N</ForeName><Initials>RN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gan-Or</LastName><ForeName>Ziv</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rouleau</LastName><ForeName>Guy A</ForeName><Initials>GA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Krohn</LastName><ForeName>Lynne</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Hilten</LastName><ForeName>Jacobus J</ForeName><Initials>JJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marinus</LastName><ForeName>Johan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Adarmes-G&#xf3;mez</LastName><ForeName>Astrid D</ForeName><Initials>AD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aguilar</LastName><ForeName>Miquel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alvarez</LastName><ForeName>Ignacio</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alvarez</LastName><ForeName>Victoria</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Javier Barrero</LastName><ForeName>Francisco</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bergareche Yarza</LastName><ForeName>Jes&#xfa;s A</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bernal-Bernal</LastName><ForeName>Inmaculada</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blazquez</LastName><ForeName>Marta</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bonilla-Toribio</LastName><ForeName>Marta</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bot&#xed;a</LastName><ForeName>Juan A</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boungiorno</LastName><ForeName>Mar&#xed;a T</ForeName><Initials>MT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Buiza-Rueda</LastName><ForeName>Dolores</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>C&#xe0;mara</LastName><ForeName>Ana</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carrillo</LastName><ForeName>F&#xe1;tima</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carri&#xf3;n-Claro</LastName><ForeName>Mario</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cerdan</LastName><ForeName>Debora</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clarim&#xf3;n</LastName><ForeName>Jordi</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Compta</LastName><ForeName>Yaroslau</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Diez-Fairen</LastName><ForeName>Monica</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dols-Icardo</LastName><ForeName>Oriol</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duarte</LastName><ForeName>Jacinto</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duran</LastName><ForeName>Raquel</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Escamilla-Sevilla</LastName><ForeName>Francisco</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ezquerra</LastName><ForeName>Mario</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Feliz</LastName><ForeName>Cici</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fern&#xe0;ndez</LastName><ForeName>Manel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fern&#xe0;ndez-Santiago</LastName><ForeName>Rub&#xe9;n</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garcia</LastName><ForeName>Ciara</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garc&#xed;a-Ruiz</LastName><ForeName>Pedro</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>G&#xf3;mez-Garre</LastName><ForeName>Pilar</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gomez Heredia</LastName><ForeName>Maria J</ForeName><Initials>MJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gonzalez-Aramburu</LastName><ForeName>Isabel</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pagola</LastName><ForeName>Ana G</ForeName><Initials>AG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hoenicka</LastName><ForeName>Janet</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Infante</LastName><ForeName>Jon</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jimenez-Escrig</LastName><ForeName>Adriano</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kulisevsky</LastName><ForeName>Jaime</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Labrador-Espinosa</LastName><ForeName>Miguel A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lopez-Sendon</LastName><ForeName>Jose Luis</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arregui</LastName><ForeName>Adolfo L&#xf3;pez de Munain</ForeName><Initials>ALM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Macias</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Torres</LastName><ForeName>Irene Mart&#xed;nez</ForeName><Initials>IM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mar&#xed;n</LastName><ForeName>Juan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marti</LastName><ForeName>Maria Jose</ForeName><Initials>MJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mart&#xed;nez-Castrillo</LastName><ForeName>Juan Carlos</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>M&#xe8;ndez-Del-Barrio</LastName><ForeName>Carlota</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gonz&#xe1;lez</LastName><ForeName>Manuel Men&#xe9;ndez</ForeName><Initials>MM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Adolfo M&#xed;nguez</LastName><ForeName>Marina Mata</ForeName><Initials>MM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mir</LastName><ForeName>Pablo</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rezola</LastName><ForeName>Elisabet Mondragon</ForeName><Initials>EM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mu&#xf1;oz</LastName><ForeName>Esteban</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pagonabarraga</LastName><ForeName>Javier</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pastor</LastName><ForeName>Pau</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Errazquin</LastName><ForeName>Francisco Perez</ForeName><Initials>FP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peri&#x144;&#xe1;n-Tocino</LastName><ForeName>Teresa</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ruiz-Mart&#xed;nez</LastName><ForeName>Javier</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ruz</LastName><ForeName>Clara</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rodriguez</LastName><ForeName>Antonio Sanchez</ForeName><Initials>AS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sierra</LastName><ForeName>Mar&#xed;a</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Suarez-Sanmartin</LastName><ForeName>Esther</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tabernero</LastName><ForeName>Cesar</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tartari</LastName><ForeName>Juan Pablo</ForeName><Initials>JP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tejera-Parrado</LastName><ForeName>Cristina</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tolosa</LastName><ForeName>Eduard</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Valldeoriola</LastName><ForeName>Francesc</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vargas-Gonz&#xe1;lez</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vela</LastName><ForeName>Lydia</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vives</LastName><ForeName>Francisco</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zimprich</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pihlstrom</LastName><ForeName>Lasse</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toft</LastName><ForeName>Mathias</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koks</LastName><ForeName>Sulev</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taba</LastName><ForeName>Pille</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hassin-Baer</LastName><ForeName>Sharon</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weale</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ramasamy</LastName><ForeName>Adaikalavan</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Colin</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guelfi</LastName><ForeName>Manuel Sebastian</ForeName><Initials>MS</Initials></Investigator><Investigator ValidYN="Y"><LastName>D'sa</LastName><ForeName>Karishma</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Forabosco</LastName><ForeName>Paola</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boti&#xe1;</LastName><ForeName>Juan A</ForeName><Initials>JA</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>2</Month><Day>1</Day><Hour>12</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>2</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33523105</ArticleId><ArticleId IdType="pmc">PMC7851759</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2020.5257</ArticleId><ArticleId IdType="pii">2775977</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lees AJ, Hardy J, Revesz T. Parkinson&#x2019;s disease. Lancet. 2009;373(9680):2055-2066. doi:10.1016/S0140-6736(09)60492-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(09)60492-X</ArticleId><ArticleId IdType="pubmed">19524782</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang D, Nalls MA, Hallgr&#xed;msd&#xf3;ttir IB, et al. ; International Parkinson&#x2019;s Disease Genomics Consortium; 23andMe Research Team . A meta-analysis of genome-wide association studies identifies 17 new Parkinson&#x2019;s disease risk loci. Nat Genet. 2017;49(10):1511-1516. doi:10.1038/ng.3955</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3955</ArticleId><ArticleId IdType="pmc">PMC5812477</ArticleId><ArticleId IdType="pubmed">28892059</ArticleId></ArticleIdList></Reference><Reference><Citation>Murthy MN, Blauwendraat C, Guelfi S, Hardy J, Lewis PA, Trabzuni D; UKBEC; IPDGC . Increased brain expression of GPNMB is associated with genome wide significant risk for Parkinson&#x2019;s disease on chromosome 7p15.3. Neurogenetics. 2017;18(3):121-133. doi:10.1007/s10048-017-0514-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10048-017-0514-8</ArticleId><ArticleId IdType="pmc">PMC5522530</ArticleId><ArticleId IdType="pubmed">28391543</ArticleId></ArticleIdList></Reference><Reference><Citation>Emilsson V, Thorleifsson G, Zhang B, et al. . Genetics of gene expression and its effect on disease. Nature. 2008;452(7186):423-428. doi:10.1038/nature06758</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature06758</ArticleId><ArticleId IdType="pubmed">18344981</ArticleId></ArticleIdList></Reference><Reference><Citation>Nica AC, Montgomery SB, Dimas AS, et al. . Candidate causal regulatory effects by integration of expression QTLs with complex trait genetic associations. PLoS Genet. 2010;6(4):e1000895. doi:10.1371/journal.pgen.1000895</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1000895</ArticleId><ArticleId IdType="pmc">PMC2848550</ArticleId><ArticleId IdType="pubmed">20369022</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramasamy A, Trabzuni D, Guelfi S, et al. ; UK Brain Expression Consortium; North American Brain Expression Consortium . Genetic variability in the regulation of gene expression in ten regions of the human brain. Nat Neurosci. 2014;17(10):1418-1428. doi:10.1038/nn.3801</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3801</ArticleId><ArticleId IdType="pmc">PMC4208299</ArticleId><ArticleId IdType="pubmed">25174004</ArticleId></ArticleIdList></Reference><Reference><Citation>GTEx Consortium . Human genomics: the Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science. 2015;348(6235):648-660. doi:10.1126/science.1262110</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1262110</ArticleId><ArticleId IdType="pmc">PMC4547484</ArticleId><ArticleId IdType="pubmed">25954001</ArticleId></ArticleIdList></Reference><Reference><Citation>Trabzuni D, Ryten M, Walker R, et al. . Quality control parameters on a large dataset of regionally dissected human control brains for whole genome expression studies. J Neurochem. 2011;119(2):275-282. doi:10.1111/j.1471-4159.2011.07432.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2011.07432.x</ArticleId><ArticleId IdType="pmc">PMC3664422</ArticleId><ArticleId IdType="pubmed">21848658</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobbyn A, Huckins LM, Boocock J, et al. ; CommonMind Consortium . Landscape of conditional eQTL in dorsolateral prefrontal cortex and co-localization with schizophrenia GWAS. Am J Hum Genet. 2018;102(6):1169-1184. doi:10.1016/j.ajhg.2018.04.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2018.04.011</ArticleId><ArticleId IdType="pmc">PMC5993513</ArticleId><ArticleId IdType="pubmed">29805045</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardi&#xf1;as AF, Holmans P, Pocklington AJ, et al. ; GERAD1 Consortium; CRESTAR Consortium . Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection. Nat Genet. 2018;50(3):381-389. doi:10.1038/s41588-018-0059-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-018-0059-2</ArticleId><ArticleId IdType="pmc">PMC5918692</ArticleId><ArticleId IdType="pubmed">29483656</ArticleId></ArticleIdList></Reference><Reference><Citation>Giambartolomei C, Vukcevic D, Schadt EE, et al. . Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. PLoS Genet. 2014;10(5):e1004383. doi:10.1371/journal.pgen.1004383</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1004383</ArticleId><ArticleId IdType="pmc">PMC4022491</ArticleId><ArticleId IdType="pubmed">24830394</ArticleId></ArticleIdList></Reference><Reference><Citation>Gusev A, Ko A, Shi H, et al. . Integrative approaches for large-scale transcriptome-wide association studies. Nat Genet. 2016;48(3):245-252. doi:10.1038/ng.3506</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3506</ArticleId><ArticleId IdType="pmc">PMC4767558</ArticleId><ArticleId IdType="pubmed">26854917</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbeira AN, Dickinson SP, Bonazzola R, et al. ; GTEx Consortium . Exploring the phenotypic consequences of tissue specific gene expression variation inferred from GWAS summary statistics. Nat Commun. 2018;9(1):1825. doi:10.1038/s41467-018-03621-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-03621-1</ArticleId><ArticleId IdType="pmc">PMC5940825</ArticleId><ArticleId IdType="pubmed">29739930</ArticleId></ArticleIdList></Reference><Reference><Citation>Trabzuni D, Ryten M, Emmett W, et al. ; International Parkinson Disease Genomics Consortium (IPDGC) . Fine-mapping, gene expression and splicing analysis of the disease associated LRRK2 locus. PLoS One. 2013;8(8):e70724. doi:10.1371/journal.pone.0070724</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0070724</ArticleId><ArticleId IdType="pmc">PMC3742662</ArticleId><ArticleId IdType="pubmed">23967090</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Sloan SA, Clarke LE, et al. . Purification and characterization of progenitor and mature human astrocytes reveals transcriptional and functional differences with mouse. Neuron. 2016;89(1):37-53. doi:10.1016/j.neuron.2015.11.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2015.11.013</ArticleId><ArticleId IdType="pmc">PMC4707064</ArticleId><ArticleId IdType="pubmed">26687838</ArticleId></ArticleIdList></Reference><Reference><Citation>Soreq L, Rose J, Soreq E, et al. ; UK Brain Expression Consortium; North American Brain Expression Consortium . Major shifts in glial regional identity are a transcriptional hallmark of human brain aging. Cell Rep. 2017;18(2):557-570. doi:10.1016/j.celrep.2016.12.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2016.12.011</ArticleId><ArticleId IdType="pmc">PMC5263238</ArticleId><ArticleId IdType="pubmed">28076797</ArticleId></ArticleIdList></Reference><Reference><Citation>Braineac. Braineac&#x2014;the brain eQTL almanac. Accessed December 14, 2020. http://www.braineac.org/</Citation></Reference><Reference><Citation>GTEx Portal . Explore GTEx. Accessed December 14, 2020. https://www.gtexportal.org/home/</Citation></Reference><Reference><Citation>Senthil G, Dutka T, Bingaman L, Lehner T. Genomic resources for the study of neuropsychiatric disorders. Mol Psychiatry. 2017;22(12):1659-1663. doi:10.1038/mp.2017.29</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2017.29</ArticleId><ArticleId IdType="pubmed">28322284</ArticleId></ArticleIdList></Reference><Reference><Citation>Bot&#xed;a JA, Vandrovcova J, Forabosco P, et al. ; United Kingdom Brain Expression Consortium . An additional k-means clustering step improves the biological features of WGCNA gene co-expression networks. BMC Syst Biol. 2017;11(1):47. doi:10.1186/s12918-017-0420-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12918-017-0420-6</ArticleId><ArticleId IdType="pmc">PMC5389000</ArticleId><ArticleId IdType="pubmed">28403906</ArticleId></ArticleIdList></Reference><Reference><Citation>Bettencourt C, Ryten M, Forabosco P, et al. ; United Kingdom Brain Expression Consortium . Insights from cerebellar transcriptomic analysis into the pathogenesis of ataxia. JAMA Neurol. 2014;71(7):831-839. doi:10.1001/jamaneurol.2014.756</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.756</ArticleId><ArticleId IdType="pmc">PMC4469030</ArticleId><ArticleId IdType="pubmed">24862029</ArticleId></ArticleIdList></Reference><Reference><Citation>Forabosco P, Ramasamy A, Trabzuni D, et al. . Insights into TREM2 biology by network analysis of human brain gene expression data. Neurobiol Aging. 2013;34(12):2699-2714. doi:10.1016/j.neurobiolaging.2013.05.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.05.001</ArticleId><ArticleId IdType="pmc">PMC3988951</ArticleId><ArticleId IdType="pubmed">23855984</ArticleId></ArticleIdList></Reference><Reference><Citation>GitHub . CoExpNets. Accessed December 14, 2020. https://github.com/juanbot/CoExpNets</Citation></Reference><Reference><Citation>Zhang Y, Chen K, Sloan SA, et al. . An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci. 2014;34(36):11929-11947. doi:10.1523/JNEUROSCI.1860-14.2014</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1860-14.2014</ArticleId><ArticleId IdType="pmc">PMC4152602</ArticleId><ArticleId IdType="pubmed">25186741</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrari R, Lovering RC, Hardy J, Lewis PA, Manzoni C. Weighted protein interaction network analysis of frontotemporal dementia. J Proteome Res. 2017;16(2):999-1013. doi:10.1021/acs.jproteome.6b00934</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jproteome.6b00934</ArticleId><ArticleId IdType="pmc">PMC6152613</ArticleId><ArticleId IdType="pubmed">28004582</ArticleId></ArticleIdList></Reference><Reference><Citation>GitHub. fusion_twas. Accessed December 14, 2020. https://github.com/gusevlab/fusion_twas</Citation></Reference><Reference><Citation>g:Profiler. Accessed December 14, 2020. https://biit.cs.ut.ee/gprofiler/gost</Citation></Reference><Reference><Citation>GitHub. pd_gwas_qtl_2020. Accessed December 22, 2020. https://github.com/demiskia/pd_gwas_qtl_2020</Citation></Reference><Reference><Citation>Okamoto H, Takasawa S, Nata K. The CD38-cyclic ADP-ribose signalling system in insulin secretion: molecular basis and clinical implications. Diabetologia. 1997;40(12):1485-1491. doi:10.1007/s001250050854</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s001250050854</ArticleId><ArticleId IdType="pubmed">9447959</ArticleId></ArticleIdList></Reference><Reference><Citation>Noyce AJ, Kia DA, Hemani G, et al. ; International Parkinson Disease Genomics Consortium . Estimating the causal influence of body mass index on risk of Parkinson disease: a mendelian randomisation study. PLoS Med. 2017;14(6):e1002314. doi:10.1371/journal.pmed.1002314</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1002314</ArticleId><ArticleId IdType="pmc">PMC5469450</ArticleId><ArticleId IdType="pubmed">28609445</ArticleId></ArticleIdList></Reference><Reference><Citation>Athauda D, Maclagan K, Skene SS, et al. . Exenatide once weekly versus placebo in Parkinson&#x2019;s disease: a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10103):1664-1675. doi:10.1016/S0140-6736(17)31585-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)31585-4</ArticleId><ArticleId IdType="pmc">PMC5831666</ArticleId><ArticleId IdType="pubmed">28781108</ArticleId></ArticleIdList></Reference><Reference><Citation>Kou W, Banerjee S, Eudy J, et al. . CD38 regulation in activated astrocytes: implications for neuroinflammation and HIV-1 brain infection. J Neurosci Res. 2009;87(10):2326-2339. doi:10.1002/jnr.22060</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.22060</ArticleId><ArticleId IdType="pubmed">19365854</ArticleId></ArticleIdList></Reference><Reference><Citation>Purlyte E, Dhekne HS, Sarhan AR, et al. . Rab29 activation of the Parkinson&#x2019;s disease-associated LRRK2 kinase. EMBO J. 2018;37(1):1-18. doi:10.15252/embj.201798099</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201798099</ArticleId><ArticleId IdType="pmc">PMC5753036</ArticleId><ArticleId IdType="pubmed">29212815</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujimoto T, Kuwahara T, Eguchi T, Sakurai M, Komori T, Iwatsubo T. Parkinson&#x2019;s disease-associated mutant LRRK2 phosphorylates Rab7L1 and modifies trans-Golgi morphology. Biochem Biophys Res Commun. 2018;495(2):1708-1715. doi:10.1016/j.bbrc.2017.12.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2017.12.024</ArticleId><ArticleId IdType="pubmed">29223392</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z, Bryant N, Kumaran R, et al. . LRRK2 phosphorylates membrane-bound Rabs and is activated by GTP-bound Rab7L1 to promote recruitment to the trans-Golgi network. Hum Mol Genet. 2018;27(2):385-395. doi:10.1093/hmg/ddx410</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddx410</ArticleId><ArticleId IdType="pmc">PMC5886198</ArticleId><ArticleId IdType="pubmed">29177506</ArticleId></ArticleIdList></Reference><Reference><Citation>Wenger DA, Rafi MA, Luzi P. Krabbe disease: one hundred years from the bedside to the bench to the bedside. J Neurosci Res. 2016;94(11):982-989. doi:10.1002/jnr.23743</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.23743</ArticleId><ArticleId IdType="pubmed">27638583</ArticleId></ArticleIdList></Reference><Reference><Citation>Dehay B, Martinez-Vicente M, Caldwell GA, et al. . Lysosomal impairment in Parkinson&#x2019;s disease. Mov Disord. 2013;28(6):725-732. doi:10.1002/mds.25462</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.25462</ArticleId><ArticleId IdType="pmc">PMC5131721</ArticleId><ArticleId IdType="pubmed">23580333</ArticleId></ArticleIdList></Reference><Reference><Citation>Robak LA, Jansen IE, van Rooij J, et al. ; International Parkinson&#x2019;s Disease Genomics Consortium (IPDGC) . Excessive burden of lysosomal storage disorder gene variants in Parkinson&#x2019;s disease. Brain. 2017;140(12)(suppl):3191-3203. doi:10.1093/brain/awx285</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awx285</ArticleId><ArticleId IdType="pmc">PMC5841393</ArticleId><ArticleId IdType="pubmed">29140481</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33516288</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>24</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2468-2667</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>Feb</Month></PubDate></JournalIssue><Title>The Lancet. Public health</Title><ISOAbbreviation>Lancet Public Health</ISOAbbreviation></Journal><ArticleTitle>Cognitive and social activities and long-term dementia risk: the prospective UK Million Women Study.</ArticleTitle><Pagination><StartPage>e116</StartPage><EndPage>e123</EndPage><MedlinePgn>e116-e123</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S2468-2667(20)30284-X</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2468-2667(20)30284-X</ELocationID><Abstract><AbstractText Label="BACKGROUND">Although dementia is associated with non-participation in cognitive and social activities, this association might merely reflect the consequences of dementia, rather than any direct effect of non-participation on the subsequent incidence of dementia. Because of the slowness with which dementia can develop, unbiased assessment of any such direct effects must relate non-participation in such activities to dementia detection rates many years later. Prospective studies with long-term follow-up can help achieve this by analysing separately the first and second decade of follow-up. We report such analyses of a large, 20-year study.</AbstractText><AbstractText Label="METHODS">The UK Million Women Study is a population-based prospective study of 1&#xb7;3 million women invited for National Health Service (NHS) breast cancer screening in median year 1998 (IQR 1997-1999). In median year 2001 (IQR 2001-2003), women were asked about participation in adult education, groups for art, craft, or music, and voluntary work, and in median year 2006 (IQR 2006-2006), they were asked about reading. All participants were followed up through electronic linkage to NHS records of hospital admission with mention of dementia, the first mention of which was the main outcome. Comparing non-participation with participation in a particular activity, we used Cox regression to assess fully adjusted dementia risk ratios (RRs) during 0-4, 5-9, and 10 or more years, after information on that activity was obtained.</AbstractText><AbstractText Label="FINDINGS">In 2001, 851&#x2008;307 women with a mean age of 60 years (SD 5) provided information on participation in adult education, groups for art, craft, or music, and voluntary work. After 10 years, only 9591 (1%) had been lost to follow-up and 789&#x2008;339 (93%) remained alive with no recorded dementia. Follow-up was for a mean of 16 years (SD 3), during which 31&#x2008;187 (4%) had at least one hospital admission with mention of dementia, including 25&#x2008;636 (3%) with a hospital admission with dementia mentioned for the first time 10 years or more after follow-up began. Non-participation in cognitive or social activities was associated with higher relative risks of dementia detection only during the first decade after participation was recorded. During the second decade, there was little association. This was true for non-participation in adult education (RR 1&#xb7;04, 99% CI 0&#xb7;98-1&#xb7;09), in groups for art, craft, or music (RR 1&#xb7;04, 0&#xb7;99-1&#xb7;09), in voluntary work (RR 0&#xb7;96, 0&#xb7;92-1&#xb7;00), or in any of these three (RR 0&#xb7;99, 0&#xb7;95-1&#xb7;03). In 2006, 655&#x2008;118 women provided information on reading. For non-reading versus any reading, there were similar associations with dementia, again with strong attenuation over time since reading was recorded, but longer follow-up is needed to assess this reliably.</AbstractText><AbstractText Label="INTERPRETATION">Life has to be lived forwards, but can be understood only backwards. Long before dementia is diagnosed, there is a progressive reduction in various mental and physical activities, but this is chiefly because its gradual onset causes inactivity and not because inactivity causes dementia.</AbstractText><AbstractText Label="FUNDING">UK Medical Research Council, Cancer Research UK.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Floud</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cancer Epidemiology Unit, University of Oxford, Oxford, UK. Electronic address: sarah.floud@ndph.ox.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Balkwill</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cancer Epidemiology Unit, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sweetland</LastName><ForeName>Si&#xe2;n</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cancer Epidemiology Unit, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cancer Epidemiology Unit, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reus</LastName><ForeName>Elsa Mauricio</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hofman</LastName><ForeName>Albert</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Harvard T H Chan School of Public Health, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blacker</LastName><ForeName>Deborah</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Harvard T H Chan School of Public Health, Boston, MA, USA; Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kivimaki</LastName><ForeName>Mika</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Public Health, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Green</LastName><ForeName>Jane</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Cancer Epidemiology Unit, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peto</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Nuffield Department of Population Health, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reeves</LastName><ForeName>Gillian K</ForeName><Initials>GK</Initials><AffiliationInfo><Affiliation>Cancer Epidemiology Unit, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beral</LastName><ForeName>Valerie</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Cancer Epidemiology Unit, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_PC_MR/S02249X/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>16491</GrantID><Acronym>CRUK_</Acronym><Agency>Cancer Research UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>29186</GrantID><Acronym>CRUK_</Acronym><Agency>Cancer Research UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>A29186</GrantID><Acronym>CRUK_</Acronym><Agency>Cancer Research UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>C570/A16491</GrantID><Acronym>CRUK_</Acronym><Agency>Cancer Research UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G9900923</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/K02700X/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0700474</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/S011676/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/S02249X/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Public Health</MedlineTA><NlmUniqueID>101699003</NlmUniqueID></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Public Health. 2021 Feb;6(2):e85-e86. doi: 10.1016/S2468-2667(21)00010-4.</RefSource><PMID Version="1">33516290</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Public Health. 2021 May;6(5):e269. doi: 10.1016/S2468-2667(21)00071-2.</RefSource><PMID Version="1">33915084</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Public Health. 2021 May;6(5):e270. doi: 10.1016/S2468-2667(21)00072-4.</RefSource><PMID Version="1">33915085</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>J Womens Health (Larchmt). 2022 Dec;31(12):1686-1689. doi: 10.1089/jwh.2021.0320.</RefSource><PMID Version="1">34448597</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="Y">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015438" MajorTopicYN="N">Health Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006304" MajorTopicYN="N">Health Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008603" MajorTopicYN="N">Mental Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011932" MajorTopicYN="N">Reading</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058992" MajorTopicYN="Y">Social Participation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013222" MajorTopicYN="N">State Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N" Type="Geographic">United Kingdom</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014838" MajorTopicYN="N">Volunteers</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>6</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>11</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>11</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>1</Month><Day>31</Day><Hour>20</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>1</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33516288</ArticleId><ArticleId IdType="pmc">PMC7848753</ArticleId><ArticleId IdType="doi">10.1016/S2468-2667(20)30284-X</ArticleId><ArticleId IdType="pii">S2468-2667(20)30284-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Public Health England  Guidance: health matters: midlife approaches to reduce dementia risk. 2016. https://www.gov.uk/government/publications/health-matters-midlife-approaches-to-reduce-dementia-risk</Citation></Reference><Reference><Citation>Livingston G, Huntley J, Sommerlad A. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396:413&#x2013;446.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7392084</ArticleId><ArticleId IdType="pubmed">32738937</ArticleId></ArticleIdList></Reference><Reference><Citation>National Academies of Sciences and Medicine . The National Academies Press; Washington, DC: 2017. Preventing cognitive decline and dementia: a way forward.</Citation><ArticleIdList><ArticleId IdType="pubmed">28650595</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO . World Health Organization; Geneva: 2019. Risk reduction of cognitive decline and dementia: WHO guidelines.</Citation><ArticleIdList><ArticleId IdType="pubmed">31219687</ArticleId></ArticleIdList></Reference><Reference><Citation>Sajeev G, Weuve J, Jackson JW. Late-life cognitive activity and dementia: a systematic review and bias analysis. Epidemiology. 2016;27:732&#x2013;742.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5460628</ArticleId><ArticleId IdType="pubmed">27227783</ArticleId></ArticleIdList></Reference><Reference><Citation>Deckers K, Kohler S, van Boxtel M, Verhey F, Brayne C, Fleming J. Lack of associations between modifiable risk factors and dementia in the very old: findings from the Cambridge City over-75s cohort study. Aging Ment Health. 2018;22:1272&#x2013;1278.</Citation><ArticleIdList><ArticleId IdType="pubmed">28151002</ArticleId></ArticleIdList></Reference><Reference><Citation>Fancourt D, Steptoe A, Cadar D. Community engagement and dementia risk: time-to-event analyses from a national cohort study. J Epidemiol Community Health. 2020;74:71&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6929705</ArticleId><ArticleId IdType="pubmed">31662344</ArticleId></ArticleIdList></Reference><Reference><Citation>Marioni RE, Proust-Lima C, Amieva H. Social activity, cognitive decline and dementia risk: a 20-year prospective cohort study. BMC Public Health. 2015;15</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4619410</ArticleId><ArticleId IdType="pubmed">26499254</ArticleId></ArticleIdList></Reference><Reference><Citation>Najar J, Ostling S, Gudmundsson P. Cognitive and physical activity and dementia: a 44-year longitudinal population study of women. Neurology. 2019;92:e1322&#x2013;e1330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6511097</ArticleId><ArticleId IdType="pubmed">30787164</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorman DE, Sundstrom A, Ronnlund M, Adolfsson R, Nilsson LG. Leisure activity in old age and risk of dementia: a 15-year prospective study. J Gerontol B Psychol Sci Soc Sci. 2014;69:493&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pubmed">23766435</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Burnham S, Bourgeat P. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 2013;12:357&#x2013;367.</Citation><ArticleIdList><ArticleId IdType="pubmed">23477989</ArticleId></ArticleIdList></Reference><Reference><Citation>Korczyn AD, Bornstein NM, Guekht A. Vascular dementia. J Neurol Sci. 2012;322:1.</Citation><ArticleIdList><ArticleId IdType="pubmed">22472726</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabia S, Dugravot A, Dartigues JF. Physical activity, cognitive decline, and risk of dementia: 28 year follow-up of Whitehall II cohort study. BMJ. 2017;357</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5480222</ArticleId><ArticleId IdType="pubmed">28642251</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart R, Masaki K, Xue QL. A 32-year prospective study of change in body weight and incident dementia: the Honolulu-Asia Aging Study. Arch Neurol. 2005;62:55&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">15642850</ArticleId></ArticleIdList></Reference><Reference><Citation>Green J, Reeves GK, Floud S. Cohort profile: the Million Women Study. Int J Epidemiol. 2018;48:28&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6380310</ArticleId><ArticleId IdType="pubmed">29873753</ArticleId></ArticleIdList></Reference><Reference><Citation>Floud S, Simpson RF, Balkwill A. Body mass index, diet, physical inactivity, and the incidence of dementia in 1 million UK women. Neurology. 2020;94:e123&#x2013;e132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6988985</ArticleId><ArticleId IdType="pubmed">31852815</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown A, Kirichek O, Balkwill A. Comparison of dementia recorded in routinely collected hospital admission data in England with dementia recorded in primary care. Emerg Themes Epidemiol. 2016;13:11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5084368</ArticleId><ArticleId IdType="pubmed">27800007</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrett E, Gallagher AM, Bhaskaran K. Data resource profile: Clinical Practice Research Datalink (CPRD) Int J Epidemiol. 2015;44:827&#x2013;836.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4521131</ArticleId><ArticleId IdType="pubmed">26050254</ArticleId></ArticleIdList></Reference><Reference><Citation>Floud S, Balkwill A, Moser K. The role of health-related behavioural factors in accounting for inequalities in coronary heart disease risk by education and area deprivation: prospective study of 1&#xb7;2 million UK women. BMC Med. 2016;14:145.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5062936</ArticleId><ArticleId IdType="pubmed">27733163</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend P, Beattie A, Phillimore P. Croom Helm; London: 1988. Health and deprivation: inequality and the north.</Citation></Reference><Reference><Citation>R Core Team . R Foundation for Statistical Computing; Vienna: 2013. R: a language and environment for statistical computing.</Citation></Reference><Reference><Citation>Heser K, Wagner M, Wiese B. Associations between dementia outcomes and depressive symptoms, leisure activities, and social support. Dement Geriatr Cogn Dis Extra. 2014;4:481&#x2013;493.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4296229</ArticleId><ArticleId IdType="pubmed">25685139</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee ATC, Richards M, Chan WC, Chiu HFK, Lee RSY, Lam LCW. Association of daily intellectual activities with lower risk of incident dementia among older Chinese adults. JAMA Psychiatry. 2018;75:697&#x2013;703.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6583858</ArticleId><ArticleId IdType="pubmed">29847678</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganini-Hill A, Kawas CH, Corrada MM. Lifestyle factors and dementia in the oldest-old: the 90+ study. Alzheimer Dis Assoc Disord. 2016;30:21&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4561216</ArticleId><ArticleId IdType="pubmed">25710250</ArticleId></ArticleIdList></Reference><Reference><Citation>Rafnsson SB, Orrell M, d'Orsi E, Hogervorst E, Steptoe A. Loneliness, social integration, and incident dementia over 6 years: prospective findings from the English Longitudinal Study of Ageing. J Gerontol B Psychol Sci Soc Sci. 2020;75:114&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6909434</ArticleId><ArticleId IdType="pubmed">28658937</ArticleId></ArticleIdList></Reference><Reference><Citation>Nemoto Y, Saito T, Kanamori S. An additive effect of leading role in the organization between social participation and dementia onset among Japanese older adults: the AGES cohort study. BMC Geriatr. 2017;17:297.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5747184</ArticleId><ArticleId IdType="pubmed">29284406</ArticleId></ArticleIdList></Reference><Reference><Citation>Akbaraly TN, Portet F, Fustinoni S. Leisure activities and the risk of dementia in the elderly: results from the Three-City Study. Neurology. 2009;73:854&#x2013;861.</Citation><ArticleIdList><ArticleId IdType="pubmed">19752452</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y. What is cognitive reserve? Theory and research application of the reserve concept. J Int Neuropsychol Soc. 2002;8:448&#x2013;460.</Citation><ArticleIdList><ArticleId IdType="pubmed">11939702</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuiper JS, Zuidersma M, Oude Voshaar RC. Social relationships and risk of dementia: a systematic review and meta-analysis of longitudinal cohort studies. Ageing Res Rev. 2015;22:39&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">25956016</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson T, Schnier C, Bush K. Identifying dementia outcomes in UK Biobank: a validation study of primary care, hospital admissions and mortality data. Eur J Epidemiol. 2019;34:557&#x2013;565.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6497624</ArticleId><ArticleId IdType="pubmed">30806901</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33531382</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>22</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1937-9145</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>668</Issue><PubDate><Year>2021</Year><Month>Feb</Month><Day>02</Day></PubDate></JournalIssue><Title>Science signaling</Title><ISOAbbreviation>Sci Signal</ISOAbbreviation></Journal><ArticleTitle>Correction of eIF2-dependent defects in brain protein synthesis, synaptic plasticity, and memory in mouse models of Alzheimer's disease.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">eabc5429</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/scisignal.abc5429</ELocationID><Abstract><AbstractText>Neuronal protein synthesis is essential for long-term memory consolidation, and its dysregulation is implicated in various neurodegenerative disorders, including Alzheimer's disease (AD). Cellular stress triggers the activation of protein kinases that converge on the phosphorylation of eukaryotic translation initiation factor 2&#x3b1; (eIF2&#x3b1;), which attenuates mRNA translation. This translational inhibition is one aspect of the integrated stress response (ISR). We found that postmortem brain tissue from AD patients showed increased phosphorylation of eIF2&#x3b1; and reduced abundance of eIF2B, another key component of the translation initiation complex. Systemic administration of the small-molecule compound ISRIB (which blocks the ISR downstream of phosphorylated eIF2&#x3b1;) rescued protein synthesis in the hippocampus, measures of synaptic plasticity, and performance on memory-associated behavior tests in wild-type mice cotreated with salubrinal (which inhibits translation by inducing eIF2&#x3b1; phosphorylation) and in both &#x3b2;-amyloid-treated and transgenic AD model mice. Thus, attenuating the ISR downstream of phosphorylated eIF2&#x3b1; may restore hippocampal protein synthesis and delay cognitive decline in AD patients.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Oliveira</LastName><ForeName>Mauricio M</ForeName><Initials>MM</Initials><Identifier Source="ORCID">0000-0001-5684-2512</Identifier><AffiliationInfo><Affiliation>Institute of Medical Biochemistry Leopoldo de Meis, Federal University of Rio de Janeiro, Rio de Janeiro, RJ 21941-902, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Neural Science, New York University, New York, NY 10003, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lourenco</LastName><ForeName>Mychael V</ForeName><Initials>MV</Initials><Identifier Source="ORCID">0000-0002-1078-0296</Identifier><AffiliationInfo><Affiliation>Institute of Medical Biochemistry Leopoldo de Meis, Federal University of Rio de Janeiro, Rio de Janeiro, RJ 21941-902, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Longo</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-1183-0101</Identifier><AffiliationInfo><Affiliation>Center for Neural Science, New York University, New York, NY 10003, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kasica</LastName><ForeName>Nicole P</ForeName><Initials>NP</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Gerontology and Geriatric Medicine, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Wenzhong</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Gerontology and Geriatric Medicine, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ureta</LastName><ForeName>Gonzalo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3;n Ciencia &amp; Vida, Santiago 7780272, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferreira</LastName><ForeName>Danielle D P</ForeName><Initials>DDP</Initials><AffiliationInfo><Affiliation>Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, RJ 21941-902, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mendon&#xe7;a</LastName><ForeName>Paulo H J</ForeName><Initials>PHJ</Initials><AffiliationInfo><Affiliation>Institute of Medical Biochemistry Leopoldo de Meis, Federal University of Rio de Janeiro, Rio de Janeiro, RJ 21941-902, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bernales</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3;n Ciencia &amp; Vida, Santiago 7780272, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Tao</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-0763-7261</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Gerontology and Geriatric Medicine, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Felice</LastName><ForeName>Fernanda G</ForeName><Initials>FG</Initials><AffiliationInfo><Affiliation>Institute of Medical Biochemistry Leopoldo de Meis, Federal University of Rio de Janeiro, Rio de Janeiro, RJ 21941-902, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Neuroscience Studies and Department of Psychiatry, Queen's University, Kingston, ON K7L 3N6, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klann</LastName><ForeName>Eric</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-7379-6802</Identifier><AffiliationInfo><Affiliation>Center for Neural Science, New York University, New York, NY 10003, USA. ferreira@bioqmed.ufrj.br eklann@cns.nyu.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NYU Neuroscience Institute, New York University School of Medicine, New York, NY 10016, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferreira</LastName><ForeName>Sergio T</ForeName><Initials>ST</Initials><Identifier Source="ORCID">0000-0001-7160-9866</Identifier><AffiliationInfo><Affiliation>Institute of Medical Biochemistry Leopoldo de Meis, Federal University of Rio de Janeiro, Rio de Janeiro, RJ 21941-902, Brazil. ferreira@bioqmed.ufrj.br eklann@cns.nyu.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Biophysics Carlos Chagas Filho, Federal University of Rio de Janeiro, Rio de Janeiro, RJ 21941-902, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG055581</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS034007</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS047384</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG056622</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 NS034007</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R29 NS034007</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>02</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Signal</MedlineTA><NlmUniqueID>101465400</NlmUniqueID><ISSNLinking>1945-0877</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C103652">Elf2 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004622" MajorTopicYN="N">Embryo, Mammalian</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061251" MajorTopicYN="N">Primary Cell Culture</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing interests:</b> The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>2</Month><Day>3</Day><Hour>5</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>8</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33531382</ArticleId><ArticleId IdType="mid">NIHMS1722744</ArticleId><ArticleId IdType="pmc">PMC8317334</ArticleId><ArticleId IdType="doi">10.1126/scisignal.abc5429</ArticleId><ArticleId IdType="pii">14/668/eabc5429</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Selkoe DJ, Hardy J, The amyloid hypothesis of Alzheimer&#x2019;s disease at 25 years. EMBO Mol Med 8, 595&#x2013;608 (2016); published online EpubJun (10.15252/emmm.201606210).</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201606210</ArticleId><ArticleId IdType="pmc">PMC4888851</ArticleId><ArticleId IdType="pubmed">27025652</ArticleId></ArticleIdList></Reference><Reference><Citation>Flexner LB, Flexner JB, Roberts RB, Delahaba G, Loss of Recent Memory in Mice as Related to Regional Inhibition of Cerebral Protein Synthesis. Proc Natl Acad Sci U S A 52, 1165&#x2013;1169 (1964); published online EpubNov (10.1073/pnas.52.5.1165).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.52.5.1165</ArticleId><ArticleId IdType="pmc">PMC300416</ArticleId><ArticleId IdType="pubmed">14231435</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa-Mattioli M, Gobert D, Harding H, Herdy B, Azzi M, Bruno M, Bidinosti M, Ben Mamou C, Marcinkiewicz E, Yoshida M, Imataka H, Cuello AC, Seidah N, Sossin W, Lacaille JC, Ron D, Nader K, Sonenberg N, Translational control of hippocampal synaptic plasticity and memory by the eIF2alpha kinase GCN2. Nature 436, 1166&#x2013;1173 (2005); published online EpubAug 25 (10.1038/nature03897).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature03897</ArticleId><ArticleId IdType="pmc">PMC1464117</ArticleId><ArticleId IdType="pubmed">16121183</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa-Mattioli M, Gobert D, Stern E, Gamache K, Colina R, Cuello C, Sossin W, Kaufman R, Pelletier J, Rosenblum K, Krnjevic K, Lacaille JC, Nader K, Sonenberg N, eIF2alpha phosphorylation bidirectionally regulates the switch from short- to long-term synaptic plasticity and memory. Cell 129, 195&#x2013;206 (2007); published online EpubApr 6 (10.1016/j.cell.2007.01.050).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2007.01.050</ArticleId><ArticleId IdType="pmc">PMC4149214</ArticleId><ArticleId IdType="pubmed">17418795</ArticleId></ArticleIdList></Reference><Reference><Citation>Trinh MA, Klann E, Translational control by eIF2alpha kinases in long-lasting synaptic plasticity and long-term memory. Neurobiol Learn Mem 105, 93&#x2013;99 (2013); published online EpubOct (10.1016/j.nlm.2013.04.013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nlm.2013.04.013</ArticleId><ArticleId IdType="pmc">PMC3769507</ArticleId><ArticleId IdType="pubmed">23707798</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Prisco GV, Huang W, Buffington SA, Hsu CC, Bonnen PE, Placzek AN, Sidrauski C, Krnjevic K, Kaufman RJ, Walter P, Costa-Mattioli M, Translational control of mGluR-dependent long-term depression and object-place learning by eIF2alpha. Nat Neurosci 17, 1073&#x2013;1082 (2014); published online EpubAug (10.1038/nn.3754).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3754</ArticleId><ArticleId IdType="pmc">PMC4340591</ArticleId><ArticleId IdType="pubmed">24974795</ArticleId></ArticleIdList></Reference><Reference><Citation>Placzek AN, Prisco GV, Khatiwada S, Sgritta M, Huang W, Krnjevic K, Kaufman RJ, Dani JA, Walter P, Costa-Mattioli M, eIF2alpha-mediated translational control regulates the persistence of cocaine-induced LTP in midbrain dopamine neurons. Elife 5, (2016); published online EpubDec 13 (10.7554/eLife.17517).</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.17517</ArticleId><ArticleId IdType="pmc">PMC5154759</ArticleId><ArticleId IdType="pubmed">27960077</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson RJ, Hellen CU, Pestova TV, The mechanism of eukaryotic translation initiation and principles of its regulation. Nat Rev Mol Cell Biol 11, 113&#x2013;127 (2010); published online EpubFeb (10.1038/nrm2838).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm2838</ArticleId><ArticleId IdType="pmc">PMC4461372</ArticleId><ArticleId IdType="pubmed">20094052</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavitt GD, Regulation of translation initiation factor eIF2B at the hub of the integrated stress response. Wiley Interdiscip Rev RNA 9, e1491 (2018); published online EpubNov (10.1002/wrna.1491).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/wrna.1491</ArticleId><ArticleId IdType="pubmed">29989343</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenner LR, Anand AA, Nguyen HC, Myasnikov AG, Klose CJ, McGeever LA, Tsai JC, Miller-Vedam LE, Walter P, Frost A, eIF2B-catalyzed nucleotide exchange and phosphoregulation by the integrated stress response. Science 364, 491&#x2013;495 (2019); published online EpubMay 3 (10.1126/science.aaw2922).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaw2922</ArticleId><ArticleId IdType="pmc">PMC6601628</ArticleId><ArticleId IdType="pubmed">31048491</ArticleId></ArticleIdList></Reference><Reference><Citation>Pakos-Zebrucka K, Koryga I, Mnich K, Ljujic M, Samali A, Gorman AM, The integrated stress response. EMBO Rep 17, 1374&#x2013;1395 (2016); published online EpubOct (10.15252/embr.201642195).</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embr.201642195</ArticleId><ArticleId IdType="pmc">PMC5048378</ArticleId><ArticleId IdType="pubmed">27629041</ArticleId></ArticleIdList></Reference><Reference><Citation>Freeman OJ, Mallucci GR, The UPR and synaptic dysfunction in neurodegeneration. Brain Res 1648, 530&#x2013;537 (2016); published online EpubOct 1 (10.1016/j.brainres.2016.03.029).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2016.03.029</ArticleId><ArticleId IdType="pubmed">27021956</ArticleId></ArticleIdList></Reference><Reference><Citation>Abisambra JF, Jinwal UK, Blair LJ, O&#x2019;Leary JC 3rd, Li Q, Brady S, Wang L, Guidi CE, Zhang B, Nordhues BA, Cockman M, Suntharalingham A, Li P, Jin Y, Atkins CA, Dickey CA, Tau accumulation activates the unfolded protein response by impairing endoplasmic reticulum-associated degradation. J Neurosci 33, 9498&#x2013;9507 (2013); published online EpubMay 29 (10.1523/JNEUROSCI.5397-12.2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5397-12.2013</ArticleId><ArticleId IdType="pmc">PMC3733249</ArticleId><ArticleId IdType="pubmed">23719816</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno JA, Radford H, Peretti D, Steinert JR, Verity N, Martin MG, Halliday M, Morgan J, Dinsdale D, Ortori CA, Barrett DA, Tsaytler P, Bertolotti A, Willis AE, Bushell M, Mallucci GR, Sustained translational repression by eIF2alpha-P mediates prion neurodegeneration. Nature 485, 507&#x2013;511 (2012); published online EpubMay 24 (10.1038/nature11058).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11058</ArticleId><ArticleId IdType="pmc">PMC3378208</ArticleId><ArticleId IdType="pubmed">22622579</ArticleId></ArticleIdList></Reference><Reference><Citation>Lourenco MV, Clarke JR, Frozza RL, Bomfim TR, Forny-Germano L, Batista AF, Sathler LB, Brito-Moreira J, Amaral OB, Silva CA, Freitas-Correa L, Espirito-Santo S, Campello-Costa P, Houzel JC, Klein WL, Holscher C, Carvalheira JB, Silva AM, Velloso LA, Munoz DP, Ferreira ST, De Felice FG, TNFalpha mediates PKR-dependent memory impairment and brain IRS-1 inhibition induced by Alzheimer&#x2019;s beta-amyloid oligomers in mice and monkeys. Cell Metab 18, 831&#x2013;843 (2013); published online EpubDec 3 (10.1016/j.cmet.2013.11.002).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2013.11.002</ArticleId><ArticleId IdType="pubmed">24315369</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma T, Trinh MA, Wexler AJ, Bourbon C, Gatti E, Pierre P, Cavener DR, Klann E, Suppression of eIF2alpha kinases alleviates Alzheimer&#x2019;s disease-related plasticity and memory deficits. Nat Neurosci 16, 1299&#x2013;1305 (2013); published online EpubSep (10.1038/nn.3486).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3486</ArticleId><ArticleId IdType="pmc">PMC3756900</ArticleId><ArticleId IdType="pubmed">23933749</ArticleId></ArticleIdList></Reference><Reference><Citation>Baleriola J, Walker CA, Jean YY, Crary JF, Troy CM, Nagy PL, Hengst U, Axonally synthesized ATF4 transmits a neurodegenerative signal across brain regions. Cell 158, 1159&#x2013;1172 (2014); published online EpubAug 28 (10.1016/j.cell.2014.07.001).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2014.07.001</ArticleId><ArticleId IdType="pmc">PMC4149755</ArticleId><ArticleId IdType="pubmed">25171414</ArticleId></ArticleIdList></Reference><Reference><Citation>Halliday M, Radford H, Sekine Y, Moreno J, Verity N, le Quesne J, Ortori CA, Barrett DA, Fromont C, Fischer PM, Harding HP, Ron D, Mallucci GR, Partial restoration of protein synthesis rates by the small molecule ISRIB prevents neurodegeneration without pancreatic toxicity. Cell Death Dis 6, e1672 (2015)10.1038/cddis.2015.49).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2015.49</ArticleId><ArticleId IdType="pmc">PMC4385927</ArticleId><ArticleId IdType="pubmed">25741597</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou A, Krukowski K, Jopson T, Zhu PJ, Costa-Mattioli M, Walter P, Rosi S, Inhibition of the integrated stress response reverses cognitive deficits after traumatic brain injury. Proc Natl Acad Sci U S A 114, E6420&#x2013;E6426 (2017); published online EpubAug 1 (10.1073/pnas.1707661114).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1707661114</ArticleId><ArticleId IdType="pmc">PMC5547647</ArticleId><ArticleId IdType="pubmed">28696288</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng W, Wang S, Mestre AA, Fu C, Makarem A, Xian F, Hayes LR, Lopez-Gonzalez R, Drenner K, Jiang J, Cleveland DW, Sun S, C9ORF72 GGGGCC repeat-associated non-AUG translation is upregulated by stress through eIF2alpha phosphorylation. Nat Commun 9, 51 (2018); published online EpubJan 4 (10.1038/s41467-017-02495-z).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-02495-z</ArticleId><ArticleId IdType="pmc">PMC5754368</ArticleId><ArticleId IdType="pubmed">29302060</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez G, Khatiwada S, Costa-Mattioli M, Hetz C, ER Proteostasis Control of Neuronal Physiology and Synaptic Function. Trends Neurosci 41, 610&#x2013;624 (2018); published online EpubSep (10.1016/j.tins.2018.05.009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2018.05.009</ArticleId><ArticleId IdType="pmc">PMC7268632</ArticleId><ArticleId IdType="pubmed">29945734</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong YL, LeBon L, Basso AM, Kohlhaas KL, Nikkel AL, Robb HM, Donnelly-Roberts DL, Prakash J, Swensen AM, Rubinstein ND, Krishnan S, McAllister FE, Haste NV, O&#x2019;Brien JJ, Roy M, Ireland A, Frost JM, Shi L, Riedmaier S, Martin K, Dart MJ, Sidrauski C, eIF2B activator prevents neurological defects caused by a chronic integrated stress response. Elife 8, (2019); published online EpubJan 9 (10.7554/eLife.42940).</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.42940</ArticleId><ArticleId IdType="pmc">PMC6326728</ArticleId><ArticleId IdType="pubmed">30624206</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu PJ, Khatiwada S, Cui Y, Reineke LC, Dooling SW, Kim JJ, Li W, Walter P, Costa-Mattioli M, Activation of the ISR mediates the behavioral and neurophysiological abnormalities in Down syndrome. Science 366, 843&#x2013;849 (2019); published online EpubNov 15 (10.1126/science.aaw5185).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaw5185</ArticleId><ArticleId IdType="pmc">PMC7299149</ArticleId><ArticleId IdType="pubmed">31727829</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang RC, Wong AK, Ng HK, Hugon J, Phosphorylation of eukaryotic initiation factor-2alpha (eIF2alpha) is associated with neuronal degeneration in Alzheimer&#x2019;s disease. Neuroreport 13, 2429&#x2013;2432 (2002); published online EpubDec 20 (10.1097/00001756-200212200-00011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00001756-200212200-00011</ArticleId><ArticleId IdType="pubmed">12499843</ArticleId></ArticleIdList></Reference><Reference><Citation>Page G, Rioux Bilan A, Ingrand S, Lafay-Chebassier C, Pain S, Perault Pochat MC, Bouras C, Bayer T, Hugon J, Activated double-stranded RNA-dependent protein kinase and neuronal death in models of Alzheimer&#x2019;s disease. Neuroscience 139, 1343&#x2013;1354 (2006)10.1016/j.neuroscience.2006.01.047).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2006.01.047</ArticleId><ArticleId IdType="pubmed">16581193</ArticleId></ArticleIdList></Reference><Reference><Citation>Segev Y, Barrera I, Ounallah-Saad H, Wibrand K, Sporild I, Livne A, Rosenberg T, David O, Mints M, Bramham CR, Rosenblum K, PKR Inhibition Rescues Memory Deficit and ATF4 Overexpression in ApoE epsilon4 Human Replacement Mice. J Neurosci 35, 12986&#x2013;12993 (2015); published online EpubSep 23 (10.1523/JNEUROSCI.5241-14.2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5241-14.2015</ArticleId><ArticleId IdType="pmc">PMC6605432</ArticleId><ArticleId IdType="pubmed">26400930</ArticleId></ArticleIdList></Reference><Reference><Citation>Sidrauski C, Acosta-Alvear D, Khoutorsky A, Vedantham P, Hearn BR, Li H, Gamache K, Gallagher CM, Ang KK, Wilson C, Okreglak V, Ashkenazi A, Hann B, Nader K, Arkin MR, Renslo AR, Sonenberg N, Walter P, Pharmacological brake-release of mRNA translation enhances cognitive memory. Elife 2, e00498 (2013)10.7554/eLife.00498).</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.00498</ArticleId><ArticleId IdType="pmc">PMC3667625</ArticleId><ArticleId IdType="pubmed">23741617</ArticleId></ArticleIdList></Reference><Reference><Citation>Sidrauski C, Tsai JC, Kampmann M, Hearn BR, Vedantham P, Jaishankar P, Sokabe M, Mendez AS, Newton BW, Tang EL, Verschueren E, Johnson JR, Krogan NJ, Fraser CS, Weissman JS, Renslo AR, Walter P, Pharmacological dimerization and activation of the exchange factor eIF2B antagonizes the integrated stress response. Elife 4, e07314 (2015)10.7554/eLife.07314).</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.07314</ArticleId><ArticleId IdType="pmc">PMC4426669</ArticleId><ArticleId IdType="pubmed">25875391</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekine Y, Zyryanova A, Crespillo-Casado A, Fischer PM, Harding HP, Ron D, Stress responses. Mutations in a translation initiation factor identify the target of a memory-enhancing compound. Science 348, 1027&#x2013;1030 (2015); published online EpubMay 29 (10.1126/science.aaa6986).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaa6986</ArticleId><ArticleId IdType="pmc">PMC4538794</ArticleId><ArticleId IdType="pubmed">25858979</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira ST, Lourenco MV, Oliveira MM, De Felice FG, Soluble amyloid-beta oligomers as synaptotoxins leading to cognitive impairment in Alzheimer&#x2019;s disease. Front Cell Neurosci 9, 191 (2015)10.3389/fncel.2015.00191).</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2015.00191</ArticleId><ArticleId IdType="pmc">PMC4443025</ArticleId><ArticleId IdType="pubmed">26074767</ArticleId></ArticleIdList></Reference><Reference><Citation>Figueiredo CP, Clarke JR, Ledo JH, Ribeiro FC, Costa CV, Melo HM, Mota-Sales AP, Saraiva LM, Klein WL, Sebollela A, De Felice FG, Ferreira ST, Memantine rescues transient cognitive impairment caused by high-molecular-weight abeta oligomers but not the persistent impairment induced by low-molecular-weight oligomers. J Neurosci 33, 9626&#x2013;9634 (2013); published online EpubJun 5 (10.1523/JNEUROSCI.0482-13.2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0482-13.2013</ArticleId><ArticleId IdType="pmc">PMC6619709</ArticleId><ArticleId IdType="pubmed">23739959</ArticleId></ArticleIdList></Reference><Reference><Citation>Lourenco MV, Frozza RL, de Freitas GB, Zhang H, Kincheski GC, Ribeiro FC, Goncalves RA, Clarke JR, Beckman D, Staniszewski A, Berman H, Guerra LA, Forny-Germano L, Meier S, Wilcock DM, de Souza JM, Alves-Leon S, Prado VF, Prado MAM, Abisambra JF, Tovar-Moll F, Mattos P, Arancio O, Ferreira ST, De Felice FG, Exercise-linked FNDC5/irisin rescues synaptic plasticity and memory defects in Alzheimer&#x2019;s models. Nat Med 25, 165&#x2013;175 (2019); published online EpubJan (10.1038/s41591-018-0275-4).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-018-0275-4</ArticleId><ArticleId IdType="pmc">PMC6327967</ArticleId><ArticleId IdType="pubmed">30617325</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt EK, Clavarino G, Ceppi M, Pierre P, SUnSET, a nonradioactive method to monitor protein synthesis. Nat Methods 6, 275&#x2013;277 (2009); published online EpubApr (10.1038/nmeth.1314).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.1314</ArticleId><ArticleId IdType="pubmed">19305406</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowling H, Bhattacharya A, Zhang G, Lebowitz JZ, Alam D, Smith PT, Kirshenbaum K, Neubert TA, Vogel C, Chao MV, Klann E, BONLAC: A combinatorial proteomic technique to measure stimulus-induced translational profiles in brain slices. Neuropharmacology 100, 76&#x2013;89 (2016); published online EpubJan (10.1016/j.neuropharm.2015.07.017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2015.07.017</ArticleId><ArticleId IdType="pmc">PMC4584208</ArticleId><ArticleId IdType="pubmed">26205778</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, Copeland NG, Lee MK, Younkin LH, Wagner SL, Younkin SG, Borchelt DR, Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet 13, 159&#x2013;170 (2004); published online EpubJan 15 (10.1093/hmg/ddh019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddh019</ArticleId><ArticleId IdType="pubmed">14645205</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoozemans JJ, Veerhuis R, Van Haastert ES, Rozemuller JM, Baas F, Eikelenboom P, Scheper W, The unfolded protein response is activated in Alzheimer&#x2019;s disease. Acta Neuropathol 110, 165&#x2013;172 (2005); published online EpubAug (10.1007/s00401-005-1038-0).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-005-1038-0</ArticleId><ArticleId IdType="pubmed">15973543</ArticleId></ArticleIdList></Reference><Reference><Citation>Tible M, Mouton Liger F, Schmitt J, Giralt A, Farid K, Thomasseau S, Gourmaud S, Paquet C, Rondi Reig L, Meurs E, Girault JA, Hugon J, PKR knockout in the 5xFAD model of Alzheimer&#x2019;s disease reveals beneficial effects on spatial memory and brain lesions. Aging Cell 18, e12887 (2019); published online EpubJun (10.1111/acel.12887).</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/acel.12887</ArticleId><ArticleId IdType="pmc">PMC6516179</ArticleId><ArticleId IdType="pubmed">30821420</ArticleId></ArticleIdList></Reference><Reference><Citation>Bugallo R, Marlin E, Baltanas A, Toledo E, Ferrero R, Vinueza-Gavilanes R, Larrea L, Arrasate M, Aragon T, Fine tuning of the unfolded protein response by ISRIB improves neuronal survival in a model of amyotrophic lateral sclerosis. Cell Death Dis 11, 397 (2020); published online EpubMay 26 (10.1038/s41419-020-2601-2).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-020-2601-2</ArticleId><ArticleId IdType="pmc">PMC7250913</ArticleId><ArticleId IdType="pubmed">32457286</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabir ZD, Che A, Fischer DK, Rice RC, Rizzo BK, Byrne M, Glass MJ, De Marco Garcia NV, Rajadhyaksha AM, Rescue of impaired sociability and anxiety-like behavior in adult cacna1c-deficient mice by pharmacologically targeting eIF2alpha. Mol Psychiatry 22, 1096&#x2013;1109 (2017); published online EpubAug (10.1038/mp.2017.124).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2017.124</ArticleId><ArticleId IdType="pmc">PMC5863913</ArticleId><ArticleId IdType="pubmed">28584287</ArticleId></ArticleIdList></Reference><Reference><Citation>Briggs DI, Defensor E, Memar Ardestani P, Yi B, Halpain M, Seabrook G, Shamloo M, Role of Endoplasmic Reticulum Stress in Learning and Memory Impairment and Alzheimer&#x2019;s Disease-Like Neuropathology in the PS19 and APP(Swe) Mouse Models of Tauopathy and Amyloidosis. eNeuro 4, (2017); published online EpubJul-Aug (10.1523/ENEURO.0025-17.2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/ENEURO.0025-17.2017</ArticleId><ArticleId IdType="pmc">PMC5510086</ArticleId><ArticleId IdType="pubmed">28721361</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrestha P, Ayata P, Herrero-Vidal P, Longo F, Gastone A, LeDoux JE, Heintz N, Klann E, Cell-type-specific drug-inducible protein synthesis inhibition demonstrates that memory consolidation requires rapid neuronal translation. Nat Neurosci 23, 281&#x2013;292 (2020); published online EpubFeb (10.1038/s41593-019-0568-z).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-019-0568-z</ArticleId><ArticleId IdType="pmc">PMC7147976</ArticleId><ArticleId IdType="pubmed">31959934</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabouw HH, Langereis MA, Anand AA, Visser LJ, de Groot RJ, Walter P, van Kuppeveld FJM, Small molecule ISRIB suppresses the integrated stress response within a defined window of activation. Proc Natl Acad Sci U S A 116, 2097&#x2013;2102 (2019); published online EpubFeb 5 (10.1073/pnas.1815767116).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1815767116</ArticleId><ArticleId IdType="pmc">PMC6369741</ArticleId><ArticleId IdType="pubmed">30674674</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa-Mattioli M, Walter P, The integrated stress response: From mechanism to disease. Science 368, (2020); published online EpubApr 24 (10.1126/science.aat5314).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aat5314</ArticleId><ArticleId IdType="pmc">PMC8997189</ArticleId><ArticleId IdType="pubmed">32327570</ArticleId></ArticleIdList></Reference><Reference><Citation>Dey S, Baird TD, Zhou D, Palam LR, Spandau DF, Wek RC, Both transcriptional regulation and translational control of ATF4 are central to the integrated stress response. J Biol Chem 285, 33165&#x2013;33174 (2010); published online EpubOct 22 (10.1074/jbc.M110.167213).</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.167213</ArticleId><ArticleId IdType="pmc">PMC2963398</ArticleId><ArticleId IdType="pubmed">20732869</ArticleId></ArticleIdList></Reference><Reference><Citation>Teske BF, Wek SA, Bunpo P, Cundiff JK, McClintick JN, Anthony TG, Wek RC, The eIF2 kinase PERK and the integrated stress response facilitate activation of ATF6 during endoplasmic reticulum stress. Mol Biol Cell 22, 4390&#x2013;4405 (2011); published online EpubNov (10.1091/mbc.E11-06-0510).</Citation><ArticleIdList><ArticleId IdType="doi">10.1091/mbc.E11-06-0510</ArticleId><ArticleId IdType="pmc">PMC3216664</ArticleId><ArticleId IdType="pubmed">21917591</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H, Davila-Velderrain J, Peng Z, Gao F, Mohammadi S, Young JZ, Menon M, He L, Abdurrob F, Jiang X, Martorell AJ, Ransohoff RM, Hafler BP, Bennett DA, Kellis M, Tsai LH, Single-cell transcriptomic analysis of Alzheimer&#x2019;s disease. Nature 570, 332&#x2013;337 (2019); published online EpubJun (10.1038/s41586-019-1195-2).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1195-2</ArticleId><ArticleId IdType="pmc">PMC6865822</ArticleId><ArticleId IdType="pubmed">31042697</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai JC, Miller-Vedam LE, Anand AA, Jaishankar P, Nguyen HC, Renslo AR, Frost A, Walter P, Structure of the nucleotide exchange factor eIF2B reveals mechanism of memory-enhancing molecule. Science 359, (2018); published online EpubMar 30 (10.1126/science.aaq0939).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaq0939</ArticleId><ArticleId IdType="pmc">PMC6120582</ArticleId><ArticleId IdType="pubmed">29599213</ArticleId></ArticleIdList></Reference><Reference><Citation>Halliday M, Radford H, Zents KAM, Molloy C, Moreno JA, Verity NC, Smith E, Ortori CA, Bushell DA, Mallucci GR, Repurposed drugs targeting eIF2&#x3b1;- P-mediated translational repression prevent neurodegeneration in mice. Brain 140, 1768&#x2013;1783 (2017); published online EpubJun 1 (10.1093/brain/awx074).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awx074</ArticleId><ArticleId IdType="pmc">PMC5445255</ArticleId><ArticleId IdType="pubmed">28430857</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL, Diffusible, nonfibrillar ligands derived from Abeta1&#x2013;42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A 95, 6448&#x2013;6453 (1998); published online EpubMay 26 (10.1073/pnas.95.11.6448).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.95.11.6448</ArticleId><ArticleId IdType="pmc">PMC27787</ArticleId><ArticleId IdType="pubmed">9600986</ArticleId></ArticleIdList></Reference><Reference><Citation>Sebollela A, Freitas-Correa L, Oliveira FF, Paula-Lima AC, Saraiva LM, Martins SM, Mota LD, Torres C, Alves-Leon S, de Souza JM, Carraro DM, Brentani H, De Felice FG, Ferreira ST, Amyloid-beta oligomers induce differential gene expression in adult human brain slices. J Biol Chem 287, 7436&#x2013;7445 (2012); published online EpubMar 2 (10.1074/jbc.M111.298471).</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.298471</ArticleId><ArticleId IdType="pmc">PMC3293600</ArticleId><ArticleId IdType="pubmed">22235132</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmittgen TD, Livak KJ, Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3, 1101&#x2013;1108 (2008)10.1038/nprot.2008.73).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2008.73</ArticleId><ArticleId IdType="pubmed">18546601</ArticleId></ArticleIdList></Reference><Reference><Citation>Dieterich DC, Link AJ, Graumann J, Tirrell DA, Schuman EM, Selective identification of newly synthesized proteins in mammalian cells using bioorthogonal noncanonical amino acid tagging (BONCAT). Proc Natl Acad Sci U S A 103, 9482&#x2013;9487 (2006); published online EpubJun 20 (10.1073/pnas.0601637103).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0601637103</ArticleId><ArticleId IdType="pmc">PMC1480433</ArticleId><ArticleId IdType="pubmed">16769897</ArticleId></ArticleIdList></Reference><Reference><Citation>Ledo JH, Azevedo EP, Clarke JR, Ribeiro FC, Figueiredo CP, Foguel D, De Felice FG, Ferreira ST, Amyloid-beta oligomers link depressive-like behavior and cognitive deficits in mice. Mol Psychiatry 18, 1053&#x2013;1054 (2013); published online EpubOct (10.1038/mp.2012.168).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2012.168</ArticleId><ArticleId IdType="pmc">PMC3781315</ArticleId><ArticleId IdType="pubmed">23183490</ArticleId></ArticleIdList></Reference><Reference><Citation>Trinchese F, Fa M, Liu S, Zhang H, Hidalgo A, Schmidt SD, Yamaguchi H, Yoshii N, Mathews PM, Nixon RA, Arancio O, Inhibition of calpains improves memory and synaptic transmission in a mouse model of Alzheimer disease. J Clin Invest 118, 2796&#x2013;2807 (2008); published online EpubAug (10.1172/JCI34254).</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI34254</ArticleId><ArticleId IdType="pmc">PMC2441853</ArticleId><ArticleId IdType="pubmed">18596919</ArticleId></ArticleIdList></Reference><Reference><Citation>Banko JL, Poulin F, Hou L, DeMaria CT, Sonenberg N, Klann E, The translation repressor 4E-BP2 is critical for eIF4F complex formation, synaptic plasticity, and memory in the hippocampus. J Neurosci 25, 9581&#x2013;9590 (2005); published online EpubOct 19 (10.1523/JNEUROSCI.2423-05.2005).</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2423-05.2005</ArticleId><ArticleId IdType="pmc">PMC6725736</ArticleId><ArticleId IdType="pubmed">16237163</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang W, Zhou X, Zimmermann HR, Cavener DR, Klann E, Ma T, Repression of the eIF2alpha kinase PERK alleviates mGluR-LTD impairments in a mouse model of Alzheimer&#x2019;s disease. Neurobiol Aging 41, 19&#x2013;24 (2016); published online EpubMay (10.1016/j.neurobiolaging.2016.02.005).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2016.02.005</ArticleId><ArticleId IdType="pmc">PMC4841914</ArticleId><ArticleId IdType="pubmed">27103515</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33536284</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>12</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>579</Issue><PubDate><Year>2021</Year><Month>Feb</Month><Day>03</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>Smartwatch inertial sensors continuously monitor real-world motor fluctuations in Parkinson's disease.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">eabd7865</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.abd7865</ELocationID><Abstract><AbstractText>Longitudinal, remote monitoring of motor symptoms in Parkinson's disease (PD) could enable more precise treatment decisions. We developed the Motor fluctuations Monitor for Parkinson's Disease (MM4PD), an ambulatory monitoring system that used smartwatch inertial sensors to continuously track fluctuations in resting tremor and dyskinesia. We designed and validated MM4PD in 343 participants with PD, including a longitudinal study of up to 6 months in a 225-subject cohort. MM4PD measurements correlated to clinical evaluations of tremor severity (&#x3c1; = 0.80) and mapped to expert ratings of dyskinesia presence (<i>P</i> &lt; 0.001) during in-clinic tasks. MM4PD captured symptom changes in response to treatment that matched the clinician's expectations in 94% of evaluated subjects. In the remaining 6% of cases, symptom data from MM4PD identified opportunities to make improvements in pharmacologic strategy. These results demonstrate the promise of MM4PD as a tool to support patient-clinician communication, medication titration, and clinical trial design.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Powers</LastName><ForeName>Rob</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-9161-0303</Identifier><AffiliationInfo><Affiliation>Apple Inc., Cupertino, CA 95014, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Etezadi-Amoli</LastName><ForeName>Maryam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Apple Inc., Cupertino, CA 95014, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arnold</LastName><ForeName>Edith M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Apple Inc., Cupertino, CA 95014, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kianian</LastName><ForeName>Sara</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-4060-133X</Identifier><AffiliationInfo><Affiliation>Apple Inc., Cupertino, CA 95014, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Renaissance School of Medicine, Stony Brook University, Stony Brook, NY 11794, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mance</LastName><ForeName>Irida</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Apple Inc., Cupertino, CA 95014, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gibiansky</LastName><ForeName>Maxsim</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0055-4762</Identifier><AffiliationInfo><Affiliation>Apple Inc., Cupertino, CA 95014, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trietsch</LastName><ForeName>Dan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Apple Inc., Cupertino, CA 95014, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alvarado</LastName><ForeName>Alexander Singh</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Apple Inc., Cupertino, CA 95014, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kretlow</LastName><ForeName>James D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Apple Inc., Cupertino, CA 95014, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herrington</LastName><ForeName>Todd M</ForeName><Initials>TM</Initials><Identifier Source="ORCID">0000-0001-9489-7418</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Boston, MA 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brillman</LastName><ForeName>Salima</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-0520-4611</Identifier><AffiliationInfo><Affiliation>Parkinson's Disease and Movement Center of Silicon Valley, Menlo Park, CA 94025, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Nengchun</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Silicon Valley Parkinson's Center, Los Gatos, CA 95032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Peter T</ForeName><Initials>PT</Initials><Identifier Source="ORCID">0000-0003-1198-7763</Identifier><AffiliationInfo><Affiliation>Silicon Valley Parkinson's Center, Los Gatos, CA 95032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pham</LastName><ForeName>Hung A</ForeName><Initials>HA</Initials><AffiliationInfo><Affiliation>Apple Inc., Cupertino, CA 95014, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ullal</LastName><ForeName>Adeeti V</ForeName><Initials>AV</Initials><Identifier Source="ORCID">0000-0002-1639-6754</Identifier><AffiliationInfo><Affiliation>Apple Inc., Cupertino, CA 95014, USA. adeeti@apple.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018670" MajorTopicYN="N">Monitoring, Ambulatory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="Y">Parkinson Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014202" MajorTopicYN="N">Tremor</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>8</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>1</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>2</Month><Day>4</Day><Hour>5</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33536284</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.abd7865</ArticleId><ArticleId IdType="pii">13/579/eabd7865</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33558694</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>29</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>3</Issue><PubDate><Year>2021</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Fully defined human pluripotent stem cell-derived microglia and tri-culture system model C3 production in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>343</StartPage><EndPage>354</EndPage><MedlinePgn>343-354</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41593-020-00796-z</ELocationID><Abstract><AbstractText>Aberrant inflammation in the CNS has been implicated as a major player in the pathogenesis of human neurodegenerative disease. We developed a new approach to derive microglia from human pluripotent stem cells (hPSCs) and built a defined hPSC-derived tri-culture system containing pure populations of hPSC-derived microglia, astrocytes, and neurons to dissect cellular cross-talk along the neuroinflammatory axis in vitro. We used the tri-culture system to model neuroinflammation in Alzheimer's disease with hPSCs harboring the APP<sup>SWE</sup>+/+ mutation and their isogenic control. We found that complement C3, a protein that is increased under inflammatory conditions and implicated in synaptic loss, is potentiated in tri-culture and further enhanced in APP<sup>SWE</sup>+/+ tri-cultures due to microglia initiating reciprocal signaling with astrocytes to produce excess C3. Our study defines the major cellular players contributing to increased C3 in Alzheimer's disease and presents a broadly applicable platform to study neuroinflammation in human disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Guttikonda</LastName><ForeName>Sudha R</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>The Center for Stem Cell Biology, Sloan Kettering Institute for Cancer Research, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Developmental Biology Program, Sloan Kettering Institute for Cancer Research, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Weill Cornell/Rockefeller/Sloan Kettering Tri-Institutional MD-PhD Program, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sikkema</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-9686-6295</Identifier><AffiliationInfo><Affiliation>Computational and Systems Biology Program, Sloan Kettering Institute for Cancer Research, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Metastasis &amp; Tumor Ecosystems Center, Sloan Kettering Institute for Cancer Research, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tchieu</LastName><ForeName>Jason</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-9793-9836</Identifier><AffiliationInfo><Affiliation>The Center for Stem Cell Biology, Sloan Kettering Institute for Cancer Research, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Developmental Biology Program, Sloan Kettering Institute for Cancer Research, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saurat</LastName><ForeName>Nathalie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>The Center for Stem Cell Biology, Sloan Kettering Institute for Cancer Research, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Developmental Biology Program, Sloan Kettering Institute for Cancer Research, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walsh</LastName><ForeName>Ryan M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>The Center for Stem Cell Biology, Sloan Kettering Institute for Cancer Research, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Developmental Biology Program, Sloan Kettering Institute for Cancer Research, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harschnitz</LastName><ForeName>Oliver</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0001-6496-881X</Identifier><AffiliationInfo><Affiliation>The Center for Stem Cell Biology, Sloan Kettering Institute for Cancer Research, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Developmental Biology Program, Sloan Kettering Institute for Cancer Research, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ciceri</LastName><ForeName>Gabriele</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>The Center for Stem Cell Biology, Sloan Kettering Institute for Cancer Research, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Developmental Biology Program, Sloan Kettering Institute for Cancer Research, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sneeboer</LastName><ForeName>Marjolein</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Computational Biomedicine, Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mazutis</LastName><ForeName>Linas</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Computational and Systems Biology Program, Sloan Kettering Institute for Cancer Research, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Metastasis &amp; Tumor Ecosystems Center, Sloan Kettering Institute for Cancer Research, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Setty</LastName><ForeName>Manu</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0344-2627</Identifier><AffiliationInfo><Affiliation>Computational and Systems Biology Program, Sloan Kettering Institute for Cancer Research, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Metastasis &amp; Tumor Ecosystems Center, Sloan Kettering Institute for Cancer Research, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zumbo</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Applied Bioinformatics Core &amp; Department of Physiology and Biophysics, Weill Cornell Medicine, Weill Cornell Medical College, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Betel</LastName><ForeName>Doron</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-8006-7752</Identifier><AffiliationInfo><Affiliation>Institute for Computational Biomedicine, Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Witte</LastName><ForeName>Lot D</ForeName><Initials>LD</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Icahn School of Medicine at Mount Sinai, NY Mount Sinai Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pe'er</LastName><ForeName>Dana</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-9259-8817</Identifier><AffiliationInfo><Affiliation>Computational and Systems Biology Program, Sloan Kettering Institute for Cancer Research, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Metastasis &amp; Tumor Ecosystems Center, Sloan Kettering Institute for Cancer Research, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Studer</LastName><ForeName>Lorenz</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-0741-7987</Identifier><AffiliationInfo><Affiliation>The Center for Stem Cell Biology, Sloan Kettering Institute for Cancer Research, New York, NY, USA. studerl@mskcc.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Developmental Biology Program, Sloan Kettering Institute for Cancer Research, New York, NY, USA. studerl@mskcc.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG056298</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG054720</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA008748</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F30 MH115616</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS084334</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 MH116590</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007739</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>02</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C038245">C3 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003176">Complement C3</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003176" MajorTopicYN="N">Complement C3</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006410" MajorTopicYN="N">Hematopoiesis</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039904" MajorTopicYN="N">Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>3</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>12</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>8</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33558694</ArticleId><ArticleId IdType="mid">NIHMS1658009</ArticleId><ArticleId IdType="pmc">PMC8382543</ArticleId><ArticleId IdType="doi">10.1038/s41593-020-00796-z</ArticleId><ArticleId IdType="pii">10.1038/s41593-020-00796-z</ArticleId></ArticleIdList><ReferenceList><Title>CITED REFERENCES</Title><Reference><Citation>Keren-Shaul H. et al.A Unique Microglia Type Associated with Restricting Development of Alzheimer&#x2019;s Disease. Cell 169, 1276&#x2013;1290.e1217, doi:10.1016/j.cell.2017.05.018 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.05.018</ArticleId><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Lecours C. et al.Microglial Implication in Parkinson&#x2019;s Disease: Loss of Beneficial Physiological Roles or Gain of Inflammatory Functions? Front Cell Neurosci 12, doi:10.3389/fncel.2018.00282 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2018.00282</ArticleId><ArticleId IdType="pmc">PMC6125334</ArticleId><ArticleId IdType="pubmed">30214398</ArticleId></ArticleIdList></Reference><Reference><Citation>Geloso MC et al.The Dual Role of Microglia in ALS: Mechanisms and Therapeutic Approaches. Front Aging Neurosci 9, doi:10.3389/fnagi.2017.00242 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2017.00242</ArticleId><ArticleId IdType="pmc">PMC5524666</ArticleId><ArticleId IdType="pubmed">28790913</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke LE et al.Normal aging induces A1-like astrocyte reactivity. Proc Natl Acad Sci U S A 115, E1896&#x2013;e1905, doi:10.1073/pnas.1800165115 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1800165115</ArticleId><ArticleId IdType="pmc">PMC5828643</ArticleId><ArticleId IdType="pubmed">29437957</ArticleId></ArticleIdList></Reference><Reference><Citation>Liddelow SA et al.Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541, 481&#x2013;487, doi:doi:10.1038/nature21029 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature21029</ArticleId><ArticleId IdType="pmc">PMC5404890</ArticleId><ArticleId IdType="pubmed">28099414</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith AM &amp; Dragunow M. The human side of microglia. Trends Neurosci 37, 125&#x2013;135, doi:10.1016/j.tins.2013.12.001 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2013.12.001</ArticleId><ArticleId IdType="pubmed">24388427</ArticleId></ArticleIdList></Reference><Reference><Citation>Chambers SM et al.Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat Biotechnol 27, 275&#x2013;280, doi:10.1038/nbt.1529 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.1529</ArticleId><ArticleId IdType="pmc">PMC2756723</ArticleId><ArticleId IdType="pubmed">19252484</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi Y. et al.Combined small-molecule inhibition accelerates the derivation of functional cortical neurons from human pluripotent stem cells. Nat Biotechnol 35, 154&#x2013;163, doi:10.1038/nbt.3777 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.3777</ArticleId><ArticleId IdType="pmc">PMC5516899</ArticleId><ArticleId IdType="pubmed">28112759</ArticleId></ArticleIdList></Reference><Reference><Citation>Tchieu J. et al.NFIA is a gliogenic switch enabling rapid derivation of functional human astrocytes from pluripotent stem cells. Nat Biotechnol 37, 267&#x2013;275, doi:10.1038/s41587-019-0035-0 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-019-0035-0</ArticleId><ArticleId IdType="pmc">PMC6591152</ArticleId><ArticleId IdType="pubmed">30804533</ArticleId></ArticleIdList></Reference><Reference><Citation>Muffat J. et al.Efficient derivation of microglia-like cells from human pluripotent stem cells. Nat Med 22, 1358&#x2013;1367, doi:10.1038/nm.4189 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.4189</ArticleId><ArticleId IdType="pmc">PMC5101156</ArticleId><ArticleId IdType="pubmed">27668937</ArticleId></ArticleIdList></Reference><Reference><Citation>Abud EM et al.iPSC-Derived Human Microglia-like Cells to Study Neurological Diseases. Neuron 94, 278&#x2013;293.e279, doi:10.1016/j.neuron.2017.03.042 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.03.042</ArticleId><ArticleId IdType="pmc">PMC5482419</ArticleId><ArticleId IdType="pubmed">28426964</ArticleId></ArticleIdList></Reference><Reference><Citation>Douvaras P. et al.Directed Differentiation of Human Pluripotent Stem Cells to Microglia. Stem Cell Reports 8, 1516&#x2013;1524, doi:10.1016/j.stemcr.2017.04.023 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2017.04.023</ArticleId><ArticleId IdType="pmc">PMC5470097</ArticleId><ArticleId IdType="pubmed">28528700</ArticleId></ArticleIdList></Reference><Reference><Citation>Haenseler W. et al.A Highly Efficient Human Pluripotent Stem Cell Microglia Model Displays a Neuronal-Co-culture-Specific Expression Profile and Inflammatory Response. Stem Cell Reports 8, 1727&#x2013;1742, doi:10.1016/j.stemcr.2017.05.017 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2017.05.017</ArticleId><ArticleId IdType="pmc">PMC5470330</ArticleId><ArticleId IdType="pubmed">28591653</ArticleId></ArticleIdList></Reference><Reference><Citation>Takata K. et al.Induced-Pluripotent-Stem-Cell-Derived Primitive Macrophages Provide a Platform for Modeling Tissue-Resident Macrophage Differentiation and Function. Immunity 47, 183&#x2013;198.e186, doi:10.1016/j.immuni.2017.06.017 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2017.06.017</ArticleId><ArticleId IdType="pubmed">28723550</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandya H. et al.Differentiation of human and murine induced pluripotent stem cells to microglia-like cells. Nat Neurosci 20, 753&#x2013;759, doi:10.1038/nn.4534 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4534</ArticleId><ArticleId IdType="pmc">PMC5404968</ArticleId><ArticleId IdType="pubmed">28253233</ArticleId></ArticleIdList></Reference><Reference><Citation>Brownjohn PW et al.Functional Studies of Missense TREM2 Mutations in Human Stem Cell-Derived Microglia. Stem Cell Reports 10, 1294&#x2013;1307, doi:10.1016/j.stemcr.2018.03.003 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2018.03.003</ArticleId><ArticleId IdType="pmc">PMC5998752</ArticleId><ArticleId IdType="pubmed">29606617</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturgeon CM, Ditadi A, Awong G, Kennedy M. &amp; Keller G. Wnt Signaling Controls the Specification of Definitive and Primitive Hematopoiesis From Human Pluripotent Stem Cells. Nat Biotechnol 32, 554&#x2013;561, doi:10.1038/nbt.2915 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.2915</ArticleId><ArticleId IdType="pmc">PMC4152856</ArticleId><ArticleId IdType="pubmed">24837661</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginhoux F. et al.Fate Mapping Analysis Reveals That Adult Microglia Derive from Primitive Macrophages. Science 330, 841&#x2013;845, doi:10.1126/science.1194637 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1194637</ArticleId><ArticleId IdType="pmc">PMC3719181</ArticleId><ArticleId IdType="pubmed">20966214</ArticleId></ArticleIdList></Reference><Reference><Citation>Ditadi A. &amp; Sturgeon CM Directed differentiation of definitive hemogenic endothelium and hematopoietic progenitors from human pluripotent stem cells. Methods, 4&#x2013;11, doi:10.1016/j.ymeth.2015.10.001 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymeth.2015.10.001</ArticleId><ArticleId IdType="pubmed">26439174</ArticleId></ArticleIdList></Reference><Reference><Citation>Palis J. Hematopoietic stem cell-independent hematopoiesis: emergence of erythroid, megakaryocyte, and myeloid potential in the mammalian embryo. FEBS Lett 590, 3965&#x2013;3974, doi:10.1002/1873-3468.12459 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1873-3468.12459</ArticleId><ArticleId IdType="pubmed">27790707</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine JH et al.Data-Driven Phenotypic Dissection of AML Reveals Progenitor-like Cells that Correlate with Prognosis. Cell 162, 184&#x2013;197, doi:10.1016/j.cell.2015.05.047 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.05.047</ArticleId><ArticleId IdType="pmc">PMC4508757</ArticleId><ArticleId IdType="pubmed">26095251</ArticleId></ArticleIdList></Reference><Reference><Citation>Setty M. et al.Characterization of cell fate probabilities in single-cell data with Palantir. Nat Biotechnol 37, 451&#x2013;460, doi:10.1038/s41587-019-0068-4 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-019-0068-4</ArticleId><ArticleId IdType="pmc">PMC7549125</ArticleId><ArticleId IdType="pubmed">30899105</ArticleId></ArticleIdList></Reference><Reference><Citation>Kierdorf K. et al.Microglia emerge from erythromyeloid precursors via Pu.1- and Irf8-dependent pathways. Nat Neurosci 16, 273&#x2013;280, doi:10.1038/nn.3318 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3318</ArticleId><ArticleId IdType="pubmed">23334579</ArticleId></ArticleIdList></Reference><Reference><Citation>ES N. et al.Differentiation of Human Embryonic Stem Cells to HOXA + Hemogenic Vasculature That Resembles the Aorta-Gonad-Mesonephros. Nature biotechnology 34, doi:10.1038/nbt.3702 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.3702</ArticleId><ArticleId IdType="pubmed">27748754</ArticleId></ArticleIdList></Reference><Reference><Citation>Mass E. et al.Specification of tissue-resident macrophages during organogenesis. Science 353, doi:10.1126/science.aaf4238 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaf4238</ArticleId><ArticleId IdType="pmc">PMC5066309</ArticleId><ArticleId IdType="pubmed">27492475</ArticleId></ArticleIdList></Reference><Reference><Citation>Pijuan-Sala B. et al.A single-cell molecular map of mouse gastrulation and early organogenesis. Nature 566, 490&#x2013;495, doi:10.1038/s41586-019-0933-9 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-0933-9</ArticleId><ArticleId IdType="pmc">PMC6522369</ArticleId><ArticleId IdType="pubmed">30787436</ArticleId></ArticleIdList></Reference><Reference><Citation>Haghverdi L, Lun ATL, Morgan MD &amp; Marioni JC Batch effects in single-cell RNA sequencing data are corrected by matching mutual nearest neighbours. Nat Biotechnol 36, 421&#x2013;427, doi:10.1038/nbt.4091 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.4091</ArticleId><ArticleId IdType="pmc">PMC6152897</ArticleId><ArticleId IdType="pubmed">29608177</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y. et al.IL-34 is a tissue-restricted ligand of CSF1R required for the development of Langerhans cells and microglia. Nat Immunol 13, 753&#x2013;760, doi:10.1038/ni.2360 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.2360</ArticleId><ArticleId IdType="pmc">PMC3941469</ArticleId><ArticleId IdType="pubmed">22729249</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohlen CJ et al.Diverse Requirements for Microglial Survival, Specification, and Function Revealed by Defined-Medium Cultures. Neuron 94, 759&#x2013;773.e758, doi:10.1016/j.neuron.2017.04.043 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.04.043</ArticleId><ArticleId IdType="pmc">PMC5523817</ArticleId><ArticleId IdType="pubmed">28521131</ArticleId></ArticleIdList></Reference><Reference><Citation>Greter M, Lelios I. &amp; Croxford AL Microglia Versus Myeloid Cell Nomenclature during Brain Inflammation. Front Immunol 6, doi:10.3389/fimmu.2015.00249 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2015.00249</ArticleId><ArticleId IdType="pmc">PMC4443742</ArticleId><ArticleId IdType="pubmed">26074918</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O. et al.Identification of a unique TGF-beta-dependent molecular and functional signature in microglia. Nat Neurosci 17, 131&#x2013;143, doi:10.1038/nn.3599 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3599</ArticleId><ArticleId IdType="pmc">PMC4066672</ArticleId><ArticleId IdType="pubmed">24316888</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett ML et al.New tools for studying microglia in the mouse and human CNS. Proc Natl Acad Sci U S A 113, E1738&#x2013;1746, doi:10.1073/pnas.1525528113 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1525528113</ArticleId><ArticleId IdType="pmc">PMC4812770</ArticleId><ArticleId IdType="pubmed">26884166</ArticleId></ArticleIdList></Reference><Reference><Citation>Matcovitch-Natan O. et al.Microglia development follows a stepwise program to regulate brain homeostasis. Science 353, aad8670, doi:10.1126/science.aad8670 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aad8670</ArticleId><ArticleId IdType="pubmed">27338705</ArticleId></ArticleIdList></Reference><Reference><Citation>Gosselin D. et al.An environment-dependent transcriptional network specifies human microglia identity. Science 356, doi:10.1126/science.aal3222 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aal3222</ArticleId><ArticleId IdType="pmc">PMC5858585</ArticleId><ArticleId IdType="pubmed">28546318</ArticleId></ArticleIdList></Reference><Reference><Citation>Ormel PR et al.Microglia innately develop within cerebral organoids. Nature Communications 9, 1&#x2013;14, doi:doi:10.1038/s41467-018-06684-2 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-06684-2</ArticleId><ArticleId IdType="pmc">PMC6177485</ArticleId><ArticleId IdType="pubmed">30301888</ArticleId></ArticleIdList></Reference><Reference><Citation>G A et al.A CX3CR1 Reporter hESC Line Facilitates Integrative Analysis of In-Vitro-Derived Microglia and Improved Microglia Identity upon Neuron-Glia Co-culture. Stem cell reports 14, doi:10.1016/j.stemcr.2020.04.007 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2020.04.007</ArticleId><ArticleId IdType="pmc">PMC7355140</ArticleId><ArticleId IdType="pubmed">32442534</ArticleId></ArticleIdList></Reference><Reference><Citation>TF G. et al.Transcriptomic analysis of purified human cortical microglia reveals age-associated changes. Nature neuroscience 20, doi:10.1038/nn.4597 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4597</ArticleId><ArticleId IdType="pubmed">28671693</ArticleId></ArticleIdList></Reference><Reference><Citation>Nimmerjahn A, Kirchhoff F. &amp; Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 308, 1314&#x2013;1318, doi:10.1126/science.1110647 (2005).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1110647</ArticleId><ArticleId IdType="pubmed">15831717</ArticleId></ArticleIdList></Reference><Reference><Citation>Wake H. &amp; Fields RD Physiological Function of Microglia. Neuron Glia Biol 7, 1&#x2013;3, doi:10.1017/s1740925&#xd7;12000166 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/s1740925&#xd7;12000166</ArticleId><ArticleId IdType="pmc">PMC4439926</ArticleId><ArticleId IdType="pubmed">22857736</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens B. et al.The classical complement cascade mediates CNS synapse elimination. Cell 131, 1164&#x2013;1178, doi:10.1016/j.cell.2007.10.036 (2007).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2007.10.036</ArticleId><ArticleId IdType="pubmed">18083105</ArticleId></ArticleIdList></Reference><Reference><Citation>Schafer DP et al.Microglia Sculpt Postnatal Neural Circuits in an Activity and Complement-Dependent Manner. Neuron 74, 691&#x2013;705, doi:10.1016/j.neuron.2012.03.026 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2012.03.026</ArticleId><ArticleId IdType="pmc">PMC3528177</ArticleId><ArticleId IdType="pubmed">22632727</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z. et al. in J Neurosci Vol. 32 11706&#x2013;11715 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4461442</ArticleId><ArticleId IdType="pubmed">22915113</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Q. et al.Complement C3-Deficient Mice Fail to Display Age-Related Hippocampal Decline. J Neurosci 35, 13029&#x2013;13042, doi:10.1523/jneurosci.1698-15.2015 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/jneurosci.1698-15.2015</ArticleId><ArticleId IdType="pmc">PMC6605437</ArticleId><ArticleId IdType="pubmed">26400934</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu T. et al.Complement C3 Is Activated in Human AD Brain and Is Required for Neurodegeneration in Mouse Models of Amyloidosis and Tauopathy. Cell Rep 28, 2111&#x2013;2123.e2116, doi:10.1016/j.celrep.2019.07.060 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2019.07.060</ArticleId><ArticleId IdType="pubmed">31433986</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Q. et al.Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice. Sci Transl Med 9, doi:10.1126/scitranslmed.aaf6295 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aaf6295</ArticleId><ArticleId IdType="pmc">PMC6936623</ArticleId><ArticleId IdType="pubmed">28566429</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S. et al.Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 352, 712&#x2013;716, doi:10.1126/science.aad8373 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aad8373</ArticleId><ArticleId IdType="pmc">PMC5094372</ArticleId><ArticleId IdType="pubmed">27033548</ArticleId></ArticleIdList></Reference><Reference><Citation>Paquet D. et al.Efficient introduction of specific homozygous and heterozygous mutations using CRISPR/Cas9. Nature 533, 125&#x2013;129, doi:10.1038/nature17664 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature17664</ArticleId><ArticleId IdType="pubmed">27120160</ArticleId></ArticleIdList></Reference><Reference><Citation>Afagh A, Cummings BJ, Cribbs DH, Cotman CW &amp; Tenner AJ Localization and cell association of C1q in Alzheimer&#x2019;s disease brain. Exp Neurol 138, 22&#x2013;32, doi:10.1006/exnr.1996.0043 (1996).</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/exnr.1996.0043</ArticleId><ArticleId IdType="pubmed">8593893</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonseca MI et al.Cell-specific deletion of C1qa identifies microglia as the dominant source of C1q in mouse brain. J Neuroinflammation 14, 48, doi:10.1186/s12974-017-0814-9 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-017-0814-9</ArticleId><ArticleId IdType="pmc">PMC5340039</ArticleId><ArticleId IdType="pubmed">28264694</ArticleId></ArticleIdList></Reference><Reference><Citation>Morizawa YM et al.Reactive astrocytes function as phagocytes after brain ischemia via ABCA1-mediated pathway. Nature Communications 8, 1&#x2013;15, doi:doi:10.1038/s41467-017-00037-1 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-00037-1</ArticleId><ArticleId IdType="pmc">PMC5481424</ArticleId><ArticleId IdType="pubmed">28642575</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>METHODS REFERENCES</Title><Reference><Citation>Azizi E. et al.Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment. Cell 174, 1293&#x2013;1308 e1236, doi:10.1016/j.cell.2018.05.060 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.05.060</ArticleId><ArticleId IdType="pmc">PMC6348010</ArticleId><ArticleId IdType="pubmed">29961579</ArticleId></ArticleIdList></Reference><Reference><Citation>Haghverdi L, Buettner F. &amp; Theis FJ Diffusion maps for high-dimensional single-cell analysis of differentiation data. Bioinformatics 31, 2989&#x2013;2998, doi:10.1093/bioinformatics/btv325 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btv325</ArticleId><ArticleId IdType="pubmed">26002886</ArticleId></ArticleIdList></Reference><Reference><Citation>Stegle O, Teichmann SA &amp; Marioni JC Computational and analytical challenges in single-cell transcriptomics. Nat Rev Genet 16, 133&#x2013;145, doi:10.1038/nrg3833 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrg3833</ArticleId><ArticleId IdType="pubmed">25628217</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacomy M, Venturini T, Heymann S. &amp; Bastian M. ForceAtlas2, a continuous graph layout algorithm for handy network visualization designed for the Gephi software. PLoS One 9, e98679, doi:10.1371/journal.pone.0098679 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0098679</ArticleId><ArticleId IdType="pmc">PMC4051631</ArticleId><ArticleId IdType="pubmed">24914678</ArticleId></ArticleIdList></Reference><Reference><Citation>Haghverdi L, Buttner M, Wolf FA, Buettner F. &amp; Theis FJ Diffusion pseudotime robustly reconstructs lineage branching. Nat Methods 13, 845&#x2013;848, doi:10.1038/nmeth.3971 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.3971</ArticleId><ArticleId IdType="pubmed">27571553</ArticleId></ArticleIdList></Reference><Reference><Citation>van Dijk D. et al.Recovering Gene Interactions from Single-Cell Data Using Data Diffusion. Cell 174, 716&#x2013;729 e727, doi:10.1016/j.cell.2018.05.061 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.05.061</ArticleId><ArticleId IdType="pmc">PMC6771278</ArticleId><ArticleId IdType="pubmed">29961576</ArticleId></ArticleIdList></Reference><Reference><Citation>Buenrostro JD et al.Integrated Single-Cell Analysis Maps the Continuous Regulatory Landscape of Human Hematopoietic Differentiation. Cell 173, 1535&#x2013;1548 e1516, doi:10.1016/j.cell.2018.03.074 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.03.074</ArticleId><ArticleId IdType="pmc">PMC5989727</ArticleId><ArticleId IdType="pubmed">29706549</ArticleId></ArticleIdList></Reference><Reference><Citation>Velten L. et al.Human haematopoietic stem cell lineage commitment is a continuous process. Nat Cell Biol 19, 271&#x2013;281, doi:10.1038/ncb3493 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb3493</ArticleId><ArticleId IdType="pmc">PMC5496982</ArticleId><ArticleId IdType="pubmed">28319093</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinsella RJ et al.Ensembl BioMarts: a hub for data retrieval across taxonomic space. Database (Oxford) 2011, bar030, doi:10.1093/database/bar030 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/database/bar030</ArticleId><ArticleId IdType="pmc">PMC3170168</ArticleId><ArticleId IdType="pubmed">21785142</ArticleId></ArticleIdList></Reference><Reference><Citation>Satija R, Farrell JA, Gennert D, Schier AF &amp; Regev A. Spatial reconstruction of single-cell gene expression data. Nat Biotechnol 33, 495&#x2013;502, doi:10.1038/nbt.3192 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.3192</ArticleId><ArticleId IdType="pmc">PMC4430369</ArticleId><ArticleId IdType="pubmed">25867923</ArticleId></ArticleIdList></Reference><Reference><Citation>Haghverdi L, Lun ATL, Morgan MD &amp; Marioni JC Batch effects in single-cell RNA-sequencing data are corrected by matching mutual nearest neighbors. Nat Biotechnol 36, 421&#x2013;427, doi:10.1038/nbt.4091 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.4091</ArticleId><ArticleId IdType="pmc">PMC6152897</ArticleId><ArticleId IdType="pubmed">29608177</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf FA et al.PAGA: graph abstraction reconciles clustering with trajectory inference through a topology preserving map of single cells. Genome Biol 20, 59, doi:10.1186/s13059-019-1663-x (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-019-1663-x</ArticleId><ArticleId IdType="pmc">PMC6425583</ArticleId><ArticleId IdType="pubmed">30890159</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf FA, Angerer P. &amp; Theis FJ SCANPY: large-scale single-cell gene expression data analysis. Genome Biol 19, 15, doi:10.1186/s13059-017-1382-0 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-017-1382-0</ArticleId><ArticleId IdType="pmc">PMC5802054</ArticleId><ArticleId IdType="pubmed">29409532</ArticleId></ArticleIdList></Reference><Reference><Citation>Sneeboer MAM et al.Microglia in post-mortem brain tissue of patients with bipolar disorder are not immune activated. Transl Psychiatry 9, 153, doi:10.1038/s41398-019-0490-x (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41398-019-0490-x</ArticleId><ArticleId IdType="pmc">PMC6534632</ArticleId><ArticleId IdType="pubmed">31127084</ArticleId></ArticleIdList></Reference><Reference><Citation>Ran FA et al.Genome engineering using the CRISPR-Cas9 system. Nat Protoc 8, 2281&#x2013;2308, doi:10.1038/nprot.2013.143 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2013.143</ArticleId><ArticleId IdType="pmc">PMC3969860</ArticleId><ArticleId IdType="pubmed">24157548</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33586680</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>20</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1558-8238</ISSN><JournalIssue CitedMedium="Internet"><Volume>131</Volume><Issue>4</Issue><PubDate><Year>2021</Year><Month>Feb</Month><Day>15</Day></PubDate></JournalIssue><Title>The Journal of clinical investigation</Title><ISOAbbreviation>J Clin Invest</ISOAbbreviation></Journal><ArticleTitle>Aberrant AZIN2 and polyamine metabolism precipitates tau neuropathology.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e126299</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1172/JCI126299</ELocationID><ELocationID EIdType="pii" ValidYN="Y">126299</ELocationID><Abstract><AbstractText>Tauopathies display a spectrum of phenotypes from cognitive to affective behavioral impairments; however, mechanisms promoting tau pathology and how tau elicits behavioral impairment remain unclear. We report a unique interaction between polyamine metabolism, behavioral impairment, and tau fate. Polyamines are ubiquitous aliphatic molecules that support neuronal function, axonal integrity, and cognitive processing. Transient increases in polyamine metabolism hallmark the cell's response to various insults, known as the polyamine stress response (PSR). Dysregulation of gene transcripts associated with polyamine metabolism in Alzheimer's disease (AD) brains were observed, and we found that ornithine decarboxylase antizyme inhibitor 2 (AZIN2) increased to the greatest extent. We showed that sustained AZIN2 overexpression elicited a maladaptive PSR in mice with underlying tauopathy (MAPT P301S; PS19). AZIN2 also increased acetylpolyamines, augmented tau deposition, and promoted cognitive and affective behavioral impairments. Higher-order polyamines displaced microtubule-associated tau to facilitate polymerization but also decreased tau seeding and oligomerization. Conversely, acetylpolyamines promoted tau seeding and oligomers. These data suggest that tauopathies launch an altered enzymatic signature that endorses a feed-forward cycle of disease progression. Taken together, the tau-induced PSR affects behavior and disease continuance, but may also position the polyamine pathway as a potential entry point for plausible targets and treatments of tauopathy, including AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sandusky-Beltran</LastName><ForeName>Leslie A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Byrd Alzheimer's Institute and.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmaceutical Sciences, University of South Florida, Tampa, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kovalenko</LastName><ForeName>Andrii</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Byrd Alzheimer's Institute and.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmaceutical Sciences, University of South Florida, Tampa, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Placides</LastName><ForeName>Devon S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Byrd Alzheimer's Institute and.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmaceutical Sciences, University of South Florida, Tampa, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ratnasamy</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Byrd Alzheimer's Institute and.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmaceutical Sciences, University of South Florida, Tampa, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Chao</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Byrd Alzheimer's Institute and.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Pharmacology and Physiology, University of South Florida, Tampa, Florida, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sanders-Brown Center on Aging.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hunt</LastName><ForeName>Jerry B</ForeName><Initials>JB</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Sanders-Brown Center on Aging.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Huimin</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Sanders-Brown Center on Aging.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calahatian</LastName><ForeName>John Ivan T</ForeName><Initials>JIT</Initials><AffiliationInfo><Affiliation>Byrd Alzheimer's Institute and.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmaceutical Sciences, University of South Florida, Tampa, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Michalski</LastName><ForeName>Camilla</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Psychiatry &amp; Behavioral Neurosciences, McMaster University, Hamilton, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fahnestock</LastName><ForeName>Margaret</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry &amp; Behavioral Neurosciences, McMaster University, Hamilton, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blair</LastName><ForeName>Laura J</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Byrd Alzheimer's Institute and.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Medicine and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Darling</LastName><ForeName>April L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Byrd Alzheimer's Institute and.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Medicine and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baker</LastName><ForeName>Jeremy D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Byrd Alzheimer's Institute and.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Medicine and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fontaine</LastName><ForeName>Sarah N</ForeName><Initials>SN</Initials><AffiliationInfo><Affiliation>Byrd Alzheimer's Institute and.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Medicine and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickey</LastName><ForeName>Chad A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Byrd Alzheimer's Institute and.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Medicine and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gamsby</LastName><ForeName>Joshua J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Byrd Alzheimer's Institute and.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Medicine and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nash</LastName><ForeName>Kevin R</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>Department of Molecular Pharmacology and Physiology, University of South Florida, Tampa, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abner</LastName><ForeName>Erin</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Sanders-Brown Center on Aging.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Selenica</LastName><ForeName>Maj-Linda B</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Sanders-Brown Center on Aging.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular &amp; Cellular Biochemistry, University of Kentucky, Lexington, Kentucky, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Daniel C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Sciences, University of South Florida, Tampa, Florida, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sanders-Brown Center on Aging.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG028383</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG072946</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG054559</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG055996</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Invest</MedlineTA><NlmUniqueID>7802877</NlmUniqueID><ISSNLinking>0021-9738</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015317">Biogenic Polyamines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C558298">Mapt protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C549629">antizyme inhibitor 2, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 4.1.1.-</RegistryNumber><NameOfSubstance UI="D002262">Carboxy-Lyases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 4.1.1.19</RegistryNumber><NameOfSubstance UI="C546395">AZIN2 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015317" MajorTopicYN="N">Biogenic Polyamines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002262" MajorTopicYN="N">Carboxy-Lyases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002352" MajorTopicYN="N">Carrier Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer disease</Keyword><Keyword MajorTopicYN="N">Metabolism</Keyword><Keyword MajorTopicYN="N">Neurological disorders</Keyword><Keyword MajorTopicYN="N">Neuroscience</Keyword><Keyword MajorTopicYN="N">Polyamines</Keyword></KeywordList><CoiStatement><b>Conflict of interest:</b> The authors have declared that no conflict of interest exists.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>11</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>12</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>2</Month><Day>15</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>5</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33586680</ArticleId><ArticleId IdType="pmc">PMC7880423</ArticleId><ArticleId IdType="doi">10.1172/JCI126299</ArticleId><ArticleId IdType="pii">126299</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Spillantini MG, Goedert M. Tau pathology and neurodegeneration. Lancet Neurol. 2013;12(6):609&#x2013;622. doi: 10.1016/S1474-4422(13)70090-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70090-5</ArticleId><ArticleId IdType="pubmed">23684085</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu P, et al. Altered arginine metabolism in Alzheimer&#x2019;s disease brains. Neurobiol Aging. 2014;35(9):1992&#x2013;2003. doi: 10.1016/j.neurobiolaging.2014.03.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2014.03.013</ArticleId><ArticleId IdType="pubmed">24746363</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoue K, et al. Metabolic profiling of Alzheimer&#x2019;s disease brains. Sci Rep. 2013;3:2364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3734482</ArticleId><ArticleId IdType="pubmed">23917584</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigrist SJ, et al. Spermidine-triggered autophagy ameliorates memory during aging. Autophagy. 2014;10(1):178&#x2013;179. doi: 10.4161/auto.26918.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/auto.26918</ArticleId><ArticleId IdType="pmc">PMC4389874</ArticleId><ArticleId IdType="pubmed">24262970</ArticleId></ArticleIdList></Reference><Reference><Citation>Signor C, et al. Spermidine improves fear memory persistence. Eur J Pharmacol. 2014;730:72&#x2013;76. doi: 10.1016/j.ejphar.2014.02.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2014.02.035</ArticleId><ArticleId IdType="pubmed">24630833</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta VK, et al. Restoring polyamines protects from age-induced memory impairment in an autophagy-dependent manner. Nat Neurosci. 2013;16(10):1453&#x2013;1460. doi: 10.1038/nn.3512.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3512</ArticleId><ArticleId IdType="pubmed">23995066</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerra GP, et al. Spermidine-induced improvement of memory involves a cross-talk between protein kinases C and A. J Neurochem. 2012;122(2):363&#x2013;373. doi: 10.1111/j.1471-4159.2012.07778.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2012.07778.x</ArticleId><ArticleId IdType="pubmed">22564082</ArticleId></ArticleIdList></Reference><Reference><Citation>Pegg AE. Regulation of ornithine decarboxylase. J Biol Chem. 2006;281(21):14529&#x2013;14532. doi: 10.1074/jbc.R500031200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.R500031200</ArticleId><ArticleId IdType="pubmed">16459331</ArticleId></ArticleIdList></Reference><Reference><Citation>Mangold U. The antizyme family: polyamines and beyond. IUBMB Life. 2005;57(10):671&#x2013;676. doi: 10.1080/15216540500307031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15216540500307031</ArticleId><ArticleId IdType="pubmed">16223706</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilad GM, Gilad VH. Overview of the brain polyamine-stress-response: regulation, development, and modulation by lithium and role in cell survival. Cell Mol Neurobiol. 2003;23(4&#x2013;5):637&#x2013;649.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11530194</ArticleId><ArticleId IdType="pubmed">14514021</ArticleId></ArticleIdList></Reference><Reference><Citation>Park MH, Igarashi K. Polyamines and their metabolites as diagnostic markers of human diseases. Biomol Ther (Seoul) 2013;21(1):1&#x2013;9. doi: 10.4062/biomolther.2012.097.</Citation><ArticleIdList><ArticleId IdType="doi">10.4062/biomolther.2012.097</ArticleId><ArticleId IdType="pmc">PMC3762300</ArticleId><ArticleId IdType="pubmed">24009852</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabor CW, Tabor H. Polyamines. Annu Rev Biochem. 1984;53:749&#x2013;790. doi: 10.1146/annurev.bi.53.070184.003533.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.bi.53.070184.003533</ArticleId><ArticleId IdType="pubmed">6206782</ArticleId></ArticleIdList></Reference><Reference><Citation>Zahedi K, et al. Polyamine catabolism is enhanced after traumatic brain injury. J Neurotrauma. 2010;27(3):515&#x2013;525. doi: 10.1089/neu.2009.1097.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/neu.2009.1097</ArticleId><ArticleId IdType="pmc">PMC2867553</ArticleId><ArticleId IdType="pubmed">19968558</ArticleId></ArticleIdList></Reference><Reference><Citation>Pegg AE, et al. Current status of the polyamine research field. Methods Mol Biol. 2011;720:3&#x2013;35. doi: 10.1007/978-1-61779-034-8_1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-61779-034-8_1</ArticleId><ArticleId IdType="pmc">PMC3652263</ArticleId><ArticleId IdType="pubmed">21318864</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan X, et al. Alzheimer&#x2019;s disease-like pathology has transient effects on the brain and blood metabolome. Neurobiol Aging. 2016;38:151&#x2013;163. doi: 10.1016/j.neurobiolaging.2015.11.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2015.11.014</ArticleId><ArticleId IdType="pubmed">26827653</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, et al. Characterization of the interaction between the transcription factors human polyamine modulated factor (PMF-1) and NF-E2-related factor 2 (Nrf-2) in the transcriptional regulation of the spermidine/spermine N1-acetyltransferase (SSAT) gene. Biochem J. 2001;355(pt 1):45&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1221710</ArticleId><ArticleId IdType="pubmed">11256947</ArticleId></ArticleIdList></Reference><Reference><Citation>Hiasa M, et al. Identification of a mammalian vesicular polyamine transporter. Sci Rep. 2014;4:6836.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4213795</ArticleId><ArticleId IdType="pubmed">25355561</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura K, et al. Decrease in polyamines with aging and their ingestion from food and drink. J Biochem. 2006;139(1):81&#x2013;90. doi: 10.1093/jb/mvj003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jb/mvj003</ArticleId><ArticleId IdType="pubmed">16428322</ArticleId></ArticleIdList></Reference><Reference><Citation>Jasper TW, et al. Polyamines in the developing mouse brain. Dev Neurosci. 1982;5(2&#x2013;3):233&#x2013;242.</Citation><ArticleIdList><ArticleId IdType="pubmed">6181956</ArticleId></ArticleIdList></Reference><Reference><Citation>Makitie LT, et al. Brain neurons express ornithine decarboxylase-activating antizyme inhibitor 2 with accumulation in Alzheimer&#x2019;s disease. Brain Pathol. 2010;20(3):571&#x2013;580. doi: 10.1111/j.1750-3639.2009.00334.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1750-3639.2009.00334.x</ArticleId><ArticleId IdType="pmc">PMC8094758</ArticleId><ArticleId IdType="pubmed">19832840</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham SF, et al. Untargeted metabolomic analysis of human plasma indicates differentially affected polyamine and L-arginine metabolism in mild cognitive impairment subjects converting to Alzheimer&#x2019;s disease. PLoS One. 2015;10(3):e0119452. doi: 10.1371/journal.pone.0119452.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0119452</ArticleId><ArticleId IdType="pmc">PMC4372431</ArticleId><ArticleId IdType="pubmed">25803028</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi J, et al. L-arginine and Alzheimer&#x2019;s disease. Int J Clin Exp Pathol. 2009;2(3):211&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2600464</ArticleId><ArticleId IdType="pubmed">19079617</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrison LD, et al. Ornithine decarboxylase in human brain: influence of aging, regional distribution, and Alzheimer&#x2019;s disease. J Neurochem. 1998;71(1):288&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pubmed">9648877</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandusky-Beltran LA, et al. Spermidine/spermine-N1-acetyltransferase ablation impacts tauopathy-induced polyamine stress response. Alzheimers Res Ther. 2019;11(1):58. doi: 10.1186/s13195-019-0507-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-019-0507-y</ArticleId><ArticleId IdType="pmc">PMC6599347</ArticleId><ArticleId IdType="pubmed">31253191</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerra GP, et al. Modulation of learning and memory by natural polyamines. Pharmacol Res. 2016;112:99&#x2013;118. doi: 10.1016/j.phrs.2016.03.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2016.03.023</ArticleId><ArticleId IdType="pubmed">27015893</ArticleId></ArticleIdList></Reference><Reference><Citation>Limon A, et al. Targets of polyamine dysregulation in major depression and suicide: activity-dependent feedback, excitability, and neurotransmission. Neurosci Biobehav Rev. 2016;66:80&#x2013;91. doi: 10.1016/j.neubiorev.2016.04.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neubiorev.2016.04.010</ArticleId><ArticleId IdType="pmc">PMC5096383</ArticleId><ArticleId IdType="pubmed">27108532</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen GG, et al. Evidence of altered polyamine concentrations in cerebral cortex of suicide completers. Neuropsychopharmacology. 2010;35(7):1477&#x2013;1484. doi: 10.1038/npp.2010.17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/npp.2010.17</ArticleId><ArticleId IdType="pmc">PMC2874419</ArticleId><ArticleId IdType="pubmed">20200507</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiori LM, Turecki G. Genetic and epigenetic influences on expression of spermine synthase and spermine oxidase in suicide completers. Int J Neuropsychopharmacol. 2010;13(6):725&#x2013;736. doi: 10.1017/S1461145709991167.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1461145709991167</ArticleId><ArticleId IdType="pubmed">20059804</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiori LM, et al. Association of polyaminergic loci with anxiety, mood disorders, and attempted suicide. PLoS One. 2010;5(11):e15146. doi: 10.1371/journal.pone.0015146.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0015146</ArticleId><ArticleId IdType="pmc">PMC2994870</ArticleId><ArticleId IdType="pubmed">21152090</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeuchi H, et al. P301S mutant human tau transgenic mice manifest early symptoms of human tauopathies with dementia and altered sensorimotor gating. PLoS One. 2011;6(6):e21050. doi: 10.1371/journal.pone.0021050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0021050</ArticleId><ArticleId IdType="pmc">PMC3115982</ArticleId><ArticleId IdType="pubmed">21698260</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasagna-Reeves CA, et al. Reduction of Nuak1 decreases tau and reverses phenotypes in a tauopathy mouse model. Neuron. 2016;92(2):407&#x2013;418. doi: 10.1016/j.neuron.2016.09.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.09.022</ArticleId><ArticleId IdType="pmc">PMC5745060</ArticleId><ArticleId IdType="pubmed">27720485</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba M, et al. Synthetic Tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer&#x2019;s-like tauopathy. J Neurosci. 2013;33(3):1024&#x2013;1037. doi: 10.1523/JNEUROSCI.2642-12.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2642-12.2013</ArticleId><ArticleId IdType="pmc">PMC3575082</ArticleId><ArticleId IdType="pubmed">23325240</ArticleId></ArticleIdList></Reference><Reference><Citation>Vemula P, et al. Altered brain arginine metabolism in a mouse model of tauopathy. Amino Acids. 2019;51(3):513&#x2013;528. doi: 10.1007/s00726-018-02687-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00726-018-02687-x</ArticleId><ArticleId IdType="pmc">PMC6431576</ArticleId><ArticleId IdType="pubmed">30604097</ArticleId></ArticleIdList></Reference><Reference><Citation>Lefevre J, et al. The C terminus of tubulin, a versatile partner for cationic molecules: binding of tau, polyamines, and calcium. J Biol Chem. 2011;286(4):3065&#x2013;3078. doi: 10.1074/jbc.M110.144089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.144089</ArticleId><ArticleId IdType="pmc">PMC3024800</ArticleId><ArticleId IdType="pubmed">21062741</ArticleId></ArticleIdList></Reference><Reference><Citation>LaFerla FM. Calcium dyshomeostasis and intracellular signalling in Alzheimer&#x2019;s disease. Nat Rev Neurosci. 2002;3(11):862&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pubmed">12415294</ArticleId></ArticleIdList></Reference><Reference><Citation>Michalski B, et al. Brain-derived neurotrophic factor and TrkB expression in the &#x201c;oldest-old,&#x201d; the 90+ Study: correlation with cognitive status and levels of soluble amyloid-beta. Neurobio Aging. 2015;36(12):3130&#x2013;3139. doi: 10.1016/j.neurobiolaging.2015.08.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2015.08.022</ArticleId><ArticleId IdType="pmc">PMC4756909</ArticleId><ArticleId IdType="pubmed">26410307</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama Y, et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 2007;53(3):337&#x2013;351. doi: 10.1016/j.neuron.2007.01.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2007.01.010</ArticleId><ArticleId IdType="pubmed">17270732</ArticleId></ArticleIdList></Reference><Reference><Citation>Carty N, et al. Convection-enhanced delivery and systemic mannitol increase gene product distribution of AAV vectors 5, 8, and 9 and increase gene product in the adult mouse brain. J Neurosci Methods. 2010;194(1):144&#x2013;153. doi: 10.1016/j.jneumeth.2010.10.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneumeth.2010.10.010</ArticleId><ArticleId IdType="pmc">PMC2995441</ArticleId><ArticleId IdType="pubmed">20951738</ArticleId></ArticleIdList></Reference><Reference><Citation>Carty N, et al. Intracranial injection of AAV expressing NEP but not IDE reduces amyloid pathology in APP+PS1 transgenic mice. PLoS One. 2013;8(3):e59626. doi: 10.1371/journal.pone.0059626.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0059626</ArticleId><ArticleId IdType="pmc">PMC3610740</ArticleId><ArticleId IdType="pubmed">23555730</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunt JB, Jr, et al. Sustained arginase 1 expression modulates pathological tau deposits in a mouse model of tauopathy. J Neurosci. 2015;35(44):14842&#x2013;14860. doi: 10.1523/JNEUROSCI.3959-14.2015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3959-14.2015</ArticleId><ArticleId IdType="pmc">PMC6605229</ArticleId><ArticleId IdType="pubmed">26538654</ArticleId></ArticleIdList></Reference><Reference><Citation>Fontaine SN, et al. The active Hsc70/tau complex can be exploited to enhance tau turnover without damaging microtubule dynamics. Hum Mol Genet. 2015;24(14):3971&#x2013;3981. doi: 10.1093/hmg/ddv135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddv135</ArticleId><ArticleId IdType="pmc">PMC4560066</ArticleId><ArticleId IdType="pubmed">25882706</ArticleId></ArticleIdList></Reference><Reference><Citation>Fontaine SN, et al. Isoform-selective genetic inhibition of constitutive cytosolic Hsp70 activity promotes client tau degradation using an altered co-chaperone complement. J Biol Chem. 2015;290(21):13115&#x2013;13127. doi: 10.1074/jbc.M115.637595.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M115.637595</ArticleId><ArticleId IdType="pmc">PMC4505567</ArticleId><ArticleId IdType="pubmed">25864199</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33585983</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-0533</ISSN><JournalIssue CitedMedium="Internet"><Volume>141</Volume><Issue>5</Issue><PubDate><Year>2021</Year><Month>May</Month></PubDate></JournalIssue><Title>Acta neuropathologica</Title><ISOAbbreviation>Acta Neuropathol</ISOAbbreviation></Journal><ArticleTitle>Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology.</ArticleTitle><Pagination><StartPage>709</StartPage><EndPage>724</EndPage><MedlinePgn>709-724</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00401-021-02275-6</ELocationID><Abstract><AbstractText>The quantification of phosphorylated tau in biofluids, either cerebrospinal fluid (CSF) or plasma, has shown great promise in detecting Alzheimer's disease (AD) pathophysiology. Tau phosphorylated at threonine 231 (p-tau231) is one such biomarker in CSF but its usefulness as a blood biomarker is currently unknown. Here, we developed an ultrasensitive Single molecule array (Simoa) for the quantification of plasma p-tau231 which was validated in four independent cohorts (n&#x2009;=&#x2009;588) in different settings, including the full AD continuum and non-AD neurodegenerative disorders. Plasma p-tau231 was able to identify patients with AD and differentiate them from amyloid-&#x3b2; negative cognitively unimpaired (CU) older adults with high accuracy (AUC&#x2009;=&#x2009;0.92-0.94). Plasma p-tau231 also distinguished AD patients from patients with non-AD neurodegenerative disorders (AUC&#x2009;=&#x2009;0.93), as well as from amyloid-&#x3b2; negative MCI patients (AUC&#x2009;=&#x2009;0.89). In a neuropathology cohort, plasma p-tau231 in samples taken on avergae 4.2&#xa0;years prior to post-mortem very accurately identified AD neuropathology in comparison to non-AD neurodegenerative disorders (AUC&#x2009;=&#x2009;0.99), this is despite all patients being given an AD dementia diagnosis during life. Plasma p-tau231 was highly correlated with CSF p-tau231, tau pathology as assessed by [<sup>18</sup>F]MK-6240 positron emission tomography (PET), and brain amyloidosis by [<sup>18</sup>F]AZD469 PET. Remarkably, the inflection point of plasma p-tau231, increasing as a function of continuous [<sup>18</sup>F]AZD469 amyloid-&#x3b2; PET standardized uptake value ratio, was shown to be earlier than standard thresholds of amyloid-&#x3b2; PET positivity and the increase of plasma p-tau181. Furthermore, plasma p-tau231 was significantly increased in amyloid-&#x3b2; PET quartiles 2-4, whereas CSF p-tau217 and plasma p-tau181 increased only at quartiles 3-4 and 4, respectively. Finally, plasma p-tau231 differentiated individuals across the entire Braak stage spectrum, including Braak staging from Braak 0 through Braak I-II, which was not observed for plasma p-tau181. To conclude, this novel plasma p-tau231 assay identifies the clinical&#xa0;stages of AD&#xa0;and neuropathology equally well as plasma p-tau181, but increases earlier, already with subtle amyloid-&#x3b2; deposition, prior to the threshold for amyloid-&#x3b2; PET positivity has been attained, and also in response to early brain tau deposition. Thus, plasma p-tau231 is a promising novel biomarker of emerging AD pathology with the potential to facilitate clinical trials to identify vulnerable populations below PET threshold of amyloid-&#x3b2; positivity or apparent entorhinal tau deposition.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Ashton</LastName><ForeName>Nicholas J</ForeName><Initials>NJ</Initials><Identifier Source="ORCID">0000-0002-6353-9316</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden. nicholas.ashton@gu.se.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden. nicholas.ashton@gu.se.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>King's College London, Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Institute Clinical Neuroscience Institute, London, UK. nicholas.ashton@gu.se.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation, London, UK. nicholas.ashton@gu.se.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Pascoal</LastName><ForeName>Tharick A</ForeName><Initials>TA</Initials><AffiliationInfo><Affiliation>Translational Neuroimaging Laboratory, McGill Centre for Studies in Aging, McGill University, Montreal, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Neurology, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karikari</LastName><ForeName>Thomas K</ForeName><Initials>TK</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benedet</LastName><ForeName>Andr&#xe9;a L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Translational Neuroimaging Laboratory, McGill Centre for Studies in Aging, McGill University, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lantero-Rodriguez</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brinkmalm</LastName><ForeName>Gunnar</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Snellman</LastName><ForeName>Anniina</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sch&#xf6;ll</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Troakes</LastName><ForeName>Claire</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hye</LastName><ForeName>Abdul</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>King's College London, Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Institute Clinical Neuroscience Institute, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gauthier</LastName><ForeName>Serge</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Research Unit, The McGill University Research Centre for Studies in Aging, Montreal, McGill University, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vanmechelen</LastName><ForeName>Eugeen</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>ADx NeuroSciences, Technologiepark 94, 9052, Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute at UCL, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Rosa-Neto</LastName><ForeName>Pedro</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Montreal Neurological Institute, Montreal, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Neurosurgery, McGill University, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden. kaj.blennow@neuro.gu.se.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden. kaj.blennow@neuro.gu.se.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/L016397/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MOP-11&#x2013;51-31</GrantID><Agency>CIHR</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>02</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Acta Neuropathol</MedlineTA><NlmUniqueID>0412041</NlmUniqueID><ISSNLinking>0001-6322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Biomarkers</Keyword><Keyword MajorTopicYN="N">Blood</Keyword><Keyword MajorTopicYN="N">Braak</Keyword><Keyword MajorTopicYN="N">Preclinical</Keyword><Keyword MajorTopicYN="N">Tau</Keyword><Keyword MajorTopicYN="N">p-tau181</Keyword><Keyword MajorTopicYN="N">p-tau217</Keyword><Keyword MajorTopicYN="N">p-tau231</Keyword></KeywordList><CoiStatement>HZ has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics and CogRx, and has given lectures in symposia sponsored by Fujirebio, Alzecure and Biogen. KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. EVM is a co-founder of ADx NeuroSciences. The other authors declare no competing interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>12</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>1</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>1</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>2</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33585983</ArticleId><ArticleId IdType="pmc">PMC8043944</ArticleId><ArticleId IdType="doi">10.1007/s00401-021-02275-6</ArticleId><ArticleId IdType="pii">10.1007/s00401-021-02275-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Amniai L, Barbier P, Sillen A, Wieruszeski JM, Peyrot V, Lippens G, Landrieu I. Alzheimer disease specific phosphoepitopes of Tau interfere with assembly of tubulin but not binding to microtubules. FASEB J. 2009;23:1146&#x2013;1152. doi: 10.1096/fj.08-121590.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.08-121590</ArticleId><ArticleId IdType="pubmed">19074508</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai H, Ishiguro K, Ohno H, Moriyama M, Itoh N, Okamura N, Matsui T, Morikawa Y, Horikawa E, Kohno H, et al. CSF phosphorylated tau protein and mild cognitive impairment: a prospective study. Exp Neurol. 2000;166:201&#x2013;203. doi: 10.1006/exnr.2000.7501.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/exnr.2000.7501</ArticleId><ArticleId IdType="pubmed">11031097</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashton NJ, Benedet AL, Pascoal TA, Karikari TK, Lantero-Rodriguez J, Mathotaarachchi S, Therriault J, Savard M, Chamoun M, Stoops E et al (2021) Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer&#x2019;s disease. Research Square.&#xa0;10.21203/rs.3.rs-155736/v1 (PREPRINT (Version 1))</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8850760</ArticleId><ArticleId IdType="pubmed">35158308</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashton NJ, Janelidze S, Al-Khleifat A, Leuzy A, Van der Ende EL, Karikari TK, Benedet AL, Pascoal TA, Lle&#xf3; A, Parnetti L&#xa0;et al (2020) Diagnostic value of plasma neurofilament light: a multicentre validation study. Research Square. 10.21203/rs.3.rs-63386/v1 (PREPRINT (Version 1))</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8185001</ArticleId><ArticleId IdType="pubmed">34099648</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashton NJ, Leuzy A, Lim YM, Troakes C, Hortobagyi T, Hoglund K, Aarsland D, Lovestone S, Scholl M, Blennow K, et al. Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration. Acta Neuropathol Commun. 2019;7:5. doi: 10.1186/s40478-018-0649-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-018-0649-3</ArticleId><ArticleId IdType="pmc">PMC6327431</ArticleId><ArticleId IdType="pubmed">30626432</ArticleId></ArticleIdList></Reference><Reference><Citation>Barthelemy NR, Bateman RJ, Hirtz C, Marin P, Becher F, Sato C, Gabelle A, Lehmann S. Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer's disease and PET amyloid-positive patient identification. Alzheimers Res Ther. 2020;12:26. doi: 10.1186/s13195-020-00596-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-020-00596-4</ArticleId><ArticleId IdType="pmc">PMC7079453</ArticleId><ArticleId IdType="pubmed">32183883</ArticleId></ArticleIdList></Reference><Reference><Citation>Barthelemy NR, Horie K, Sato C, Bateman RJ. Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer's disease. J Exp Med. 2020 doi: 10.1084/jem.20200861.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20200861</ArticleId><ArticleId IdType="pmc">PMC7596823</ArticleId><ArticleId IdType="pubmed">32725127</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012;367:795&#x2013;804. doi: 10.1056/NEJMoa1202753.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1202753</ArticleId><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Benedet AL, Leuzy A, Pascoal TA, Ashton NJ, Mathotaarachchi S, Savard M, Therriault J, Kang MS, Chamoun M, Scholl M, et al. Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease. Brain. 2020 doi: 10.1093/brain/awaa342.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa342</ArticleId><ArticleId IdType="pmc">PMC7805809</ArticleId><ArticleId IdType="pubmed">33210117</ArticleId></ArticleIdList></Reference><Reference><Citation>Benussi A, Karikari TK, Ashton N, Gazzina S, Premi E, Benussi L, Ghidoni R, Rodriguez JL, Emersic A, Simren J, et al. Diagnostic and prognostic value of serum NfL and p-Tau181 in frontotemporal lobar degeneration. J Neurol Neurosurg Psychiatry. 2020;91:960&#x2013;967. doi: 10.1136/jnnp-2020-323487.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-323487</ArticleId><ArticleId IdType="pubmed">32611664</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Vanmechelen E, Hampel H. CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease. Mol Neurobiol. 2001;24:87&#x2013;97. doi: 10.1385/MN:24:1-3:087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1385/MN:24:1-3:087</ArticleId><ArticleId IdType="pubmed">11831556</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Zetterberg H. Biomarkers for Alzheimer's disease: current status and prospects for the future. J Intern Med. 2018;284:643&#x2013;663. doi: 10.1111/joim.12816.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joim.12816</ArticleId><ArticleId IdType="pubmed">30051512</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006;112:389&#x2013;404. doi: 10.1007/s00401-006-0127-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-006-0127-z</ArticleId><ArticleId IdType="pmc">PMC3906709</ArticleId><ArticleId IdType="pubmed">16906426</ArticleId></ArticleIdList></Reference><Reference><Citation>Brys M, Pirraglia E, Rich K, Rolstad S, Mosconi L, Switalski R, Glodzik-Sobanska L, De Santi S, Zinkowski R, Mehta P, et al. Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Neurobiol Aging. 2009;30:682&#x2013;690. doi: 10.1016/j.neurobiolaging.2007.08.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2007.08.010</ArticleId><ArticleId IdType="pmc">PMC2774781</ArticleId><ArticleId IdType="pubmed">17889968</ArticleId></ArticleIdList></Reference><Reference><Citation>Buerger K, Teipel SJ, Zinkowski R, Blennow K, Arai H, Engel R, Hofmann-Kiefer K, McCulloch C, Ptok U, Heun R, et al. CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology. 2002;59:627&#x2013;629. doi: 10.1212/wnl.59.4.627.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.59.4.627</ArticleId><ArticleId IdType="pubmed">12196665</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellani RJ, Perry G. Tau biology, tauopathy, traumatic brain injury, and diagnostic challenges. J Alzheimers Dis. 2019;67:447&#x2013;467. doi: 10.3233/JAD-180721.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-180721</ArticleId><ArticleId IdType="pmc">PMC6398540</ArticleId><ArticleId IdType="pubmed">30584140</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleveland WS. Robust locally weighted regression and smoothing scatterplots. Journal of the American statistical association. 1979;74:829&#x2013;836. doi: 10.1080/01621459.1979.10481038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/01621459.1979.10481038</ArticleId></ArticleIdList></Reference><Reference><Citation>de Leon MJ, Segal S, Tarshish CY, DeSanti S, Zinkowski R, Mehta PD, Convit A, Caraos C, Rusinek H, Tsui W, et al. Longitudinal cerebrospinal fluid tau load increases in mild cognitive impairment. Neurosci Lett. 2002;333:183&#x2013;186. doi: 10.1016/s0304-3940(02)01038-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0304-3940(02)01038-8</ArticleId><ArticleId IdType="pubmed">12429378</ArticleId></ArticleIdList></Reference><Reference><Citation>Ercan-Herbst E, Ehrig J, Schondorf DC, Behrendt A, Klaus B, Gomez Ramos B, Prat Oriol N, Weber C, Ehrnhoefer DE. A post-translational modification signature defines changes in soluble tau correlating with oligomerization in early stage Alzheimer's disease brain. Acta Neuropathol Commun. 2019;7:192. doi: 10.1186/s40478-019-0823-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-019-0823-2</ArticleId><ArticleId IdType="pmc">PMC6892178</ArticleId><ArticleId IdType="pubmed">31796124</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampel H, Burger K, Pruessner JC, Zinkowski R, DeBernardis J, Kerkman D, Leinsinger G, Evans AC, Davies P, Moller HJ, et al. Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease. Arch Neurol. 2005;62:770&#x2013;773. doi: 10.1001/archneur.62.5.770.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.62.5.770</ArticleId><ArticleId IdType="pubmed">15883264</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanes J, Kovac A, Kvartsberg H, Kontsekova E, Fialova L, Katina S, Kovacech B, Stevens E, Hort J, Vyhnalek M, et al. Evaluation of a novel immunoassay to detect p-Tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias. Neurology. 2020 doi: 10.1212/WNL.0000000000010814.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000010814</ArticleId><ArticleId IdType="pmc">PMC7734919</ArticleId><ArticleId IdType="pubmed">32973122</ArticleId></ArticleIdList></Reference><Reference><Citation>Horie K, Barthelemy NR, Mallipeddi N, Li Y, Franklin EE, Perrin RJ, Bateman RJ, Sato C. Regional correlation of biochemical measures of amyloid and tau phosphorylation in the brain. Acta Neuropathol Commun. 2020;8:149. doi: 10.1186/s40478-020-01019-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-020-01019-z</ArticleId><ArticleId IdType="pmc">PMC7450927</ArticleId><ArticleId IdType="pubmed">32854776</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14:535&#x2013;562. doi: 10.1016/j.jalz.2018.02.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.02.018</ArticleId><ArticleId IdType="pmc">PMC5958625</ArticleId><ArticleId IdType="pubmed">29653606</ArticleId></ArticleIdList></Reference><Reference><Citation>Jadhav S, Avila J, Scholl M, Kovacs GG, Kovari E, Skrabana R, Evans LD, Kontsekova E, Malawska B, de Silva R, et al. A walk through tau therapeutic strategies. Acta Neuropathol Commun. 2019;7:22. doi: 10.1186/s40478-019-0664-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-019-0664-z</ArticleId><ArticleId IdType="pmc">PMC6376692</ArticleId><ArticleId IdType="pubmed">30767766</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach TG, Serrano GE, Chai X, Proctor NK, Eichenlaub U, Zetterberg H, et al. Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia. Nat Med. 2020;26:379&#x2013;386. doi: 10.1038/s41591-020-0755-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0755-1</ArticleId><ArticleId IdType="pubmed">32123385</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, Stomrud E, Smith R, Palmqvist S, Mattsson N, Airey DC, Proctor NK, Chai X, Shcherbinin S, Sims JR, et al. Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease. Nat Commun. 2020;11:1683. doi: 10.1038/s41467-020-15436-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-15436-0</ArticleId><ArticleId IdType="pmc">PMC7125218</ArticleId><ArticleId IdType="pubmed">32246036</ArticleId></ArticleIdList></Reference><Reference><Citation>Karikari TK, Benedet AL, Ashton NJ, Lantero Rodriguez J, Snellman A, Suarez-Calvet M, Saha-Chaudhuri P, Lussier F, Kvartsberg H, Rial AM, et al. Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative. Mol Psychiatry. 2020 doi: 10.1038/s41380-020-00923-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-020-00923-z</ArticleId><ArticleId IdType="pubmed">33106600</ArticleId></ArticleIdList></Reference><Reference><Citation>Karikari TK, Emersic A, Vrillon A, Lantero-Rodriguez J, Ashton NJ, Kramberger MG, Dumurgier J, Hourregue C, Cucnik S, Brinkmalm G, et al. Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer's disease diagnosis. Alzheimers Dement. 2020 doi: 10.1002/alz.12236.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12236</ArticleId><ArticleId IdType="pmc">PMC8246793</ArticleId><ArticleId IdType="pubmed">33252199</ArticleId></ArticleIdList></Reference><Reference><Citation>Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, Chamoun M, Savard M, Kang MS, Therriault J, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19:422&#x2013;433. doi: 10.1016/S1474-4422(20)30071-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(20)30071-5</ArticleId><ArticleId IdType="pubmed">32333900</ArticleId></ArticleIdList></Reference><Reference><Citation>Kidemet-Piskac S, Babic Leko M, Blazekovic A, Langer Horvat L, Klepac N, Sonicki Z, Kolenc D, Hof PR, Boban M, Mimica N, et al. Evaluation of cerebrospinal fluid phosphorylated tau231 as a biomarker in the differential diagnosis of Alzheimer's disease and vascular dementia. CNS Neurosci Ther. 2018;24:734&#x2013;740. doi: 10.1111/cns.12814.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cns.12814</ArticleId><ArticleId IdType="pmc">PMC6047904</ArticleId><ArticleId IdType="pubmed">29453935</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein A, Tourville J. 101 labeled brain images and a consistent human cortical labeling protocol. Front Neurosci. 2012;6:171. doi: 10.3389/fnins.2012.00171.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2012.00171</ArticleId><ArticleId IdType="pmc">PMC3514540</ArticleId><ArticleId IdType="pubmed">23227001</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD, Sr, Jagust WJ, Johnson KA, Mathis CA, Minhas D, Pontecorvo MJ, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11(1&#x2013;15):e11&#x2013;14. doi: 10.1016/j.jalz.2014.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2014.07.003</ArticleId><ArticleId IdType="pmc">PMC4300247</ArticleId><ArticleId IdType="pubmed">25443857</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohnken R, Buerger K, Zinkowski R, Miller C, Kerkman D, DeBernardis J, Shen J, Moller HJ, Davies P, Hampel H. Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients. Neurosci Lett. 2000;287:187&#x2013;190. doi: 10.1016/s0304-3940(00)01178-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0304-3940(00)01178-2</ArticleId><ArticleId IdType="pubmed">10863026</ArticleId></ArticleIdList></Reference><Reference><Citation>Lantero Rodriguez J, Karikari TK, Suarez-Calvet M, Troakes C, King A, Emersic A, Aarsland D, Hye A, Zetterberg H, Blennow K, et al. Plasma p-tau181 accurately predicts Alzheimer's disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline. Acta Neuropathol. 2020;140:267&#x2013;278. doi: 10.1007/s00401-020-02195-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-020-02195-x</ArticleId><ArticleId IdType="pmc">PMC7423866</ArticleId><ArticleId IdType="pubmed">32720099</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuzy A, Smith R, Ossenkoppele R, Santillo A, Borroni E, Klein G, Ohlsson T, Jogi J, Palmqvist S, Mattsson-Carlgren N, et al. Diagnostic Performance of RO948 F 18 Tau positron emission tomography in the differentiation of Alzheimer disease from other neurodegenerative disorders. JAMA Neurol. 2020;77:955&#x2013;965. doi: 10.1001/jamaneurol.2020.0989.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.0989</ArticleId><ArticleId IdType="pmc">PMC7215644</ArticleId><ArticleId IdType="pubmed">32391858</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathotaarachchi S, Wang S, Shin M, Pascoal TA, Benedet AL, Kang MS, Beaudry T, Fonov VS, Gauthier S, Labbe A, et al. VoxelStats: a matlab package for multi-modal voxel-wise brain image analysis. Front Neuroinform. 2016;10:20. doi: 10.3389/fninf.2016.00020.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fninf.2016.00020</ArticleId><ArticleId IdType="pmc">PMC4908129</ArticleId><ArticleId IdType="pubmed">27378902</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Andreasson U, Zetterberg H, Blennow K, Alzheimer's Disease Neuroimaging I. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 2017;74:557&#x2013;566. doi: 10.1001/jamaneurol.2016.6117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2016.6117</ArticleId><ArticleId IdType="pmc">PMC5822204</ArticleId><ArticleId IdType="pubmed">28346578</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson-Carlgren N, Janelidze S, Palmqvist S, Cullen N, Svenningsson AL, Strandberg O, Mengel D, Walsh DM, Stomrud E, Dage JL, et al. Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease. Brain. 2020 doi: 10.1093/brain/awaa286.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa286</ArticleId><ArticleId IdType="pmc">PMC7719022</ArticleId><ArticleId IdType="pubmed">33068398</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939&#x2013;944. doi: 10.1212/wnl.34.7.939.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.34.7.939</ArticleId><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:263&#x2013;269. doi: 10.1016/j.jalz.2011.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.03.005</ArticleId><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Mielke MM, Hagen CE, Xu J, Chai X, Vemuri P, Lowe VJ, Airey DC, Knopman DS, Roberts RO, Machulda MM, et al. Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimer's Dement. 2018;14:989&#x2013;997. doi: 10.1016/j.jalz.2018.02.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.02.013</ArticleId><ArticleId IdType="pmc">PMC6097897</ArticleId><ArticleId IdType="pubmed">29626426</ArticleId></ArticleIdList></Reference><Reference><Citation>Mila-Aloma M, Salvado G, Gispert JD, Vilor-Tejedor N, Grau-Rivera O, Sala-Vila A, Sanchez-Benavides G, Arenaza-Urquijo EM, Crous-Bou M, Gonzalez-de-Echavarri JM, et al. Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum. Alzheimer's Dement. 2020;16:1358&#x2013;1371. doi: 10.1002/alz.12131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12131</ArticleId><ArticleId IdType="pmc">PMC7586814</ArticleId><ArticleId IdType="pubmed">32573951</ArticleId></ArticleIdList></Reference><Reference><Citation>Molinuevo JL, Ayton S, Batrla R, Bednar MM, Bittner T, Cummings J, Fagan AM, Hampel H, Mielke MM, Mikulskis A, et al. Current state of Alzheimer's fluid biomarkers. Acta Neuropathol. 2018;136:821&#x2013;853. doi: 10.1007/s00401-018-1932-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1932-x</ArticleId><ArticleId IdType="pmc">PMC6280827</ArticleId><ArticleId IdType="pubmed">30488277</ArticleId></ArticleIdList></Reference><Reference><Citation>Moscoso A, Grothe MJ, Ashton NJ, Karikari TK, Rodriguez JL, Snellman A, Su&#xe1;rez-Calvet M, Zetterberg H, Blennow K, Sch&#xf6;ll M, Alzheimer&#x2019;s Disease Neuroimaging Initiative Time course of phosphorylated-tau181 in blood across the Alzheimer&#x2019;s disease spectrum. Brain. 2020 doi: 10.1093/brain/awaa399.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa399</ArticleId><ArticleId IdType="pmc">PMC7880671</ArticleId><ArticleId IdType="pubmed">33257949</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Dore V, Fowler C, Li QX, Martins R, Rowe C, et al. High performance plasma amyloid-beta biomarkers for Alzheimer's disease. Nature. 2018;554:249&#x2013;254. doi: 10.1038/nature25456.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature25456</ArticleId><ArticleId IdType="pubmed">29420472</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsson B, Lautner R, Andreasson U, Ohrfelt A, Portelius E, Bjerke M, Holtta M, Rosen C, Olsson C, Strobel G, et al. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15:673&#x2013;684. doi: 10.1016/S1474-4422(16)00070-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(16)00070-3</ArticleId><ArticleId IdType="pubmed">27068280</ArticleId></ArticleIdList></Reference><Reference><Citation>Orfanidis SJ. Introduction to signal processing. New York City: Prentice-Hall Inc; 1995.</Citation></Reference><Reference><Citation>Palmqvist S, Janelidze S, Quiroz YT, Zetterberg H, Lopera F, Stomrud E, Su Y, Chen Y, Serrano GE, Leuzy A, et al. Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA. 2020;324:772&#x2013;781. doi: 10.1001/jama.2020.12134.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12134</ArticleId><ArticleId IdType="pmc">PMC7388060</ArticleId><ArticleId IdType="pubmed">32722745</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Scholl M, Strandberg O, Mattsson N, Stomrud E, Zetterberg H, Blennow K, Landau S, Jagust W, Hansson O. Earliest accumulation of beta-amyloid occurs within the default-mode network and concurrently affects brain connectivity. Nat Commun. 2017;8:1214. doi: 10.1038/s41467-017-01150-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-01150-x</ArticleId><ArticleId IdType="pmc">PMC5663717</ArticleId><ArticleId IdType="pubmed">29089479</ArticleId></ArticleIdList></Reference><Reference><Citation>Pascoal TA, Shin M, Kang MS, Chamoun M, Chartrand D, Mathotaarachchi S, Bennacef I, Therriault J, Ng KP, Hopewell R, et al. In vivo quantification of neurofibrillary tangles with [(18)F]MK-6240. Alzheimers Res Ther. 2018;10:74. doi: 10.1186/s13195-018-0402-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-018-0402-y</ArticleId><ArticleId IdType="pmc">PMC6069775</ArticleId><ArticleId IdType="pubmed">30064520</ArticleId></ArticleIdList></Reference><Reference><Citation>Pascoal TA, Therriault J, Benedet AL, Savard M, Lussier FZ, Chamoun M, Tissot C, Qureshi MNI, Kang MS, Mathotaarachchi S, et al. 18F-MK-6240 PET for early and late detection of neurofibrillary tangles. Brain. 2020 doi: 10.1093/brain/awaa180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa180</ArticleId><ArticleId IdType="pubmed">32671408</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabinovici GD, Gatsonis C, Apgar C, Chaudhary K, Gareen I, Hanna L, Hendrix J, Hillner BE, Olson C, Lesman-Segev OH, et al. Association of amyloid positron emission tomography with subsequent change in clinical management among medicare beneficiaries with mild cognitive impairment or dementia. JAMA. 2019;321:1286&#x2013;1294. doi: 10.1001/jama.2019.2000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2019.2000</ArticleId><ArticleId IdType="pmc">PMC6450276</ArticleId><ArticleId IdType="pubmed">30938796</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos JRF, Bauer C, Schuchhardt J, Wedekind D, Waniek K, Lachmann I, Wiltfang J, Vogelgsang J. Validation of a prototype tau Thr231 phosphorylation CSF ELISA as a potential biomarker for Alzheimer's disease. J Neural Transm (Vienna) 2019;126:339&#x2013;348. doi: 10.1007/s00702-019-01982-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-019-01982-5</ArticleId><ArticleId IdType="pubmed">30767082</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato C, Barthelemy NR, Mawuenyega KG, Patterson BW, Gordon BA, Jockel-Balsarotti J, Sullivan M, Crisp MJ, Kasten T, Kirmess KM, et al. Tau kinetics in neurons and the human central nervous system. Neuron. 2018;97(1284&#x2013;1298):e1287. doi: 10.1016/j.neuron.2018.02.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.02.015</ArticleId><ArticleId IdType="pmc">PMC6137722</ArticleId><ArticleId IdType="pubmed">29566794</ArticleId></ArticleIdList></Reference><Reference><Citation>Savastano A, Flores D, Kadavath H, Biernat J, Mandelkow E, Zweckstetter M. Disease-associated tau phosphorylation hinders tubulin assembly within tau condensates. Angew Chem Int Ed Engl. 2020 doi: 10.1002/anie.202011157.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anie.202011157</ArticleId><ArticleId IdType="pmc">PMC7839466</ArticleId><ArticleId IdType="pubmed">33017094</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Li Y, Gordon BA, Holtzman DM, Morris JC, Benzinger TLS, Xiong C, et al. High-precision plasma beta-amyloid 42/40 predicts current and future brain amyloidosis. Neurology. 2019;93:e1647&#x2013;e1659. doi: 10.1212/WNL.0000000000008081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000008081</ArticleId><ArticleId IdType="pmc">PMC6946467</ArticleId><ArticleId IdType="pubmed">31371569</ArticleId></ArticleIdList></Reference><Reference><Citation>Simr&#xe9;n J, Leuzy A, Karikari TK, Hye A, Benedet AL, Lantero-Rodriguez J, Mattsson-Carlgren N, Sch&#xf6;ll M, Mecocci P, Vellas B et al (2021) The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease. Alzheimers Dement. 10.1002/alz.12283</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8359457</ArticleId><ArticleId IdType="pubmed">33491853</ArticleId></ArticleIdList></Reference><Reference><Citation>Suarez-Calvet M, Karikari TK, Ashton NJ, Lantero Rodriguez J, Mila-Aloma M, Gispert JD, Salvado G, Minguillon C, Fauria K, Shekari M et al (2020) Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer's continuum when only subtle changes in Abeta pathology are detected. EMBO Mol Med. 10.15252/emmm.202012921</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7721364</ArticleId><ArticleId IdType="pubmed">33169916</ArticleId></ArticleIdList></Reference><Reference><Citation>Therriault J, Benedet A, Pascoal TA, Savard M, Ashton N, Chamoun M, Tissot C, Lussier F, Kang MSP, Bezgin G, et al. Determining Amyloid-beta positivity using [(18)F]AZD4694 PET imaging. J Nucl Med. 2020 doi: 10.2967/jnumed.120.245209.</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.120.245209</ArticleId><ArticleId IdType="pubmed">32737243</ArticleId></ArticleIdList></Reference><Reference><Citation>Thijssen EH, La Joie R, Wolf A, Strom A, Wang P, Iaccarino L, Bourakova V, Cobigo Y, Heuer H, Spina S, et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration. Nat Med. 2020;26:387&#x2013;397. doi: 10.1038/s41591-020-0762-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0762-2</ArticleId><ArticleId IdType="pmc">PMC7101073</ArticleId><ArticleId IdType="pubmed">32123386</ArticleId></ArticleIdList></Reference><Reference><Citation>Tolar M, Abushakra S, Hey JA, Porsteinsson A, Sabbagh M. Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval. Alzheimers Res Ther. 2020;12:95. doi: 10.1186/s13195-020-00663-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-020-00663-w</ArticleId><ArticleId IdType="pmc">PMC7424995</ArticleId><ArticleId IdType="pubmed">32787971</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo JB, Xie SX, Trojanowski JQ, Shaw LM. Longitudinal change in CSF Tau and Abeta biomarkers for up to 48 months in ADNI. Acta Neuropathol. 2013;126:659&#x2013;670. doi: 10.1007/s00401-013-1151-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1151-4</ArticleId><ArticleId IdType="pmc">PMC3875373</ArticleId><ArticleId IdType="pubmed">23812320</ArticleId></ArticleIdList></Reference><Reference><Citation>Uhlmann RE, Rother C, Rasmussen J, Schelle J, Bergmann C, Ullrich Gavilanes EM, Fritschi SK, Buehler A, Baumann F, Skodras A, et al. Acute targeting of pre-amyloid seeds in transgenic mice reduces Alzheimer-like pathology later in life. Nat Neurosci: Doi; 2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7783656</ArticleId><ArticleId IdType="pubmed">33199898</ArticleId></ArticleIdList></Reference><Reference><Citation>Wihersaari L, Ashton NJ, Reinikainen M, Jakkula P, Pettila V, Hastbacka J, Tiainen M, Loisa P, Friberg H, Cronberg T, et al. Neurofilament light as an outcome predictor after cardiac arrest: a post hoc analysis of the COMACARE trial. Intensive Care Med. 2020 doi: 10.1007/s00134-020-06218-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-020-06218-9</ArticleId><ArticleId IdType="pmc">PMC7782453</ArticleId><ArticleId IdType="pubmed">32852582</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33589841</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>08</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1718</ISSN><JournalIssue CitedMedium="Internet"><Volume>53</Volume><Issue>3</Issue><PubDate><Year>2021</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Nature genetics</Title><ISOAbbreviation>Nat Genet</ISOAbbreviation></Journal><ArticleTitle>Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture.</ArticleTitle><Pagination><StartPage>294</StartPage><EndPage>303</EndPage><MedlinePgn>294-303</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41588-021-00785-3</ELocationID><Abstract><AbstractText>The genetic basis of Lewy body dementia (LBD) is not well understood. Here, we performed whole-genome sequencing in large cohorts of LBD cases and neurologically healthy controls to study the genetic architecture of this understudied form of dementia, and to generate a resource for the scientific community. Genome-wide association analysis identified five independent risk loci, whereas genome-wide gene-aggregation tests implicated mutations in the gene GBA. Genetic risk scores demonstrate that LBD shares risk profiles and pathways with Alzheimer's disease and Parkinson's disease, providing a deeper molecular understanding of the complex genetic architecture of this age-related neurodegenerative condition.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Chia</LastName><ForeName>Ruth</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Neuromuscular Diseases Research Section, Laboratory of Neurogenetics, National Institute on Aging, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Sabir</LastName><ForeName>Marya S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Neurodegenerative Diseases Research Unit, Laboratory of Neurogenetics, National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bandres-Ciga</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Molecular Genetics Section, Laboratory of Neurogenetics, National Institute on Aging, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saez-Atienzar</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Neuromuscular Diseases Research Section, Laboratory of Neurogenetics, National Institute on Aging, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reynolds</LastName><ForeName>Regina H</ForeName><Initials>RH</Initials><Identifier Source="ORCID">0000-0001-6470-7919</Identifier><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Great Ormond Street Hospital Biomedical Research Centre, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Great Ormond Street Institute of Child Health, Genetics and Genomic Medicine, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gustavsson</LastName><ForeName>Emil</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-0541-7537</Identifier><AffiliationInfo><Affiliation>NIHR Great Ormond Street Hospital Biomedical Research Centre, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Great Ormond Street Institute of Child Health, Genetics and Genomic Medicine, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walton</LastName><ForeName>Ronald L</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmed</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Neurodegenerative Diseases Research Unit, Laboratory of Neurogenetics, National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Viollet</LastName><ForeName>Coralie</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Collaborative Health Initiative Research Program, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Jinhui</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Computational Biology Group, Laboratory of Neurogenetics, National Institute on Aging, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Makarious</LastName><ForeName>Mary B</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Neurodegenerative Diseases Research Unit, Laboratory of Neurogenetics, National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diez-Fairen</LastName><ForeName>Monica</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-1882-0309</Identifier><AffiliationInfo><Affiliation>Memory and Movement Disorders Units, Department of Neurology, University Hospital Mutua de Terrassa, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Portley</LastName><ForeName>Makayla K</ForeName><Initials>MK</Initials><Identifier Source="ORCID">0000-0003-2866-9198</Identifier><AffiliationInfo><Affiliation>Neurodegenerative Diseases Research Unit, Laboratory of Neurogenetics, National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Zalak</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Neurodegenerative Diseases Research Unit, Laboratory of Neurogenetics, National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abramzon</LastName><ForeName>Yevgeniya</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Neuromuscular Diseases Research Section, Laboratory of Neurogenetics, National Institute on Aging, Bethesda, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Reta Lila Weston Institute, UCL Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hernandez</LastName><ForeName>Dena G</ForeName><Initials>DG</Initials><AffiliationInfo><Affiliation>Molecular Genetics Section, Laboratory of Neurogenetics, National Institute on Aging, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blauwendraat</LastName><ForeName>Cornelis</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-9358-8111</Identifier><AffiliationInfo><Affiliation>Molecular Genetics Section, Laboratory of Neurogenetics, National Institute on Aging, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stone</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Cerevel Therapeutics, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eicher</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Genetics and Pharmacogenomics, Merck &amp; Co., Inc., West Point, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parkkinen</LastName><ForeName>Laura</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-3392-8564</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, Oxford Parkinson's Disease Centre, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ansorge</LastName><ForeName>Olaf</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, Oxford Parkinson's Disease Centre, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clark</LastName><ForeName>Lorraine</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Taub Institute for Alzheimer Disease and the Aging Brain, and Department of Pathology and Cell Biology, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Honig</LastName><ForeName>Lawrence S</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>Taub Institute for Alzheimer Disease and the Aging Brain, G. H. Sergievsky Center and Department of Neurology, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marder</LastName><ForeName>Karen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Taub Institute for Alzheimer Disease and the Aging Brain, G. H. Sergievsky Center and Department of Neurology, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lemstra</LastName><ForeName>Afina</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology and Alzheimer Center, Neuroscience Campus Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>St George-Hyslop</LastName><ForeName>Peter</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-0796-7209</Identifier><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, Cambridge Institute of Medical Research, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Londos</LastName><ForeName>Elisabet</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Institution of Clinical Sciences Malmo, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morgan</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-8217-2396</Identifier><AffiliationInfo><Affiliation>Human Genetics, School of Life Sciences, Queens Medical Centre, University of Nottingham, Nottingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lashley</LastName><ForeName>Tammaryn</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Queen Square Brain Bank for Neurological Disorders, Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Warner</LastName><ForeName>Thomas T</ForeName><Initials>TT</Initials><AffiliationInfo><Affiliation>Reta Lila Weston Institute, UCL Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Queen Square Brain Bank for Neurological Disorders, Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jaunmuktane</LastName><ForeName>Zane</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Queen Square Brain Bank for Neurological Disorders, Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galasko</LastName><ForeName>Douglas</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Veterans Affairs San Diego Healthcare System, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santana</LastName><ForeName>Isabel</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Neurology Service, University of Coimbra Hospital, Coimbra, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro Hospitalar e Universit&#xe1;rio de Coimbra, Coimbra, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, University of Coimbra, Coimbra, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Innovative Biomedicine and Biotechnology, University of Coimbra, Coimbra, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tienari</LastName><ForeName>Pentti J</ForeName><Initials>PJ</Initials><Identifier Source="ORCID">0000-0001-5686-2900</Identifier><AffiliationInfo><Affiliation>Translational Immunology, Research Programs Unit, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Helsinki University Hospital, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Myllykangas</LastName><ForeName>Liisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pathology, Medicum, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>HUS Diagnostic Center, Helsinki University Hospital, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oinas</LastName><ForeName>Minna</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-6150-091X</Identifier><AffiliationInfo><Affiliation>Department of Clinical Medicine, Faculty of Health, UiT The Arctic University of Norway, Troms&#xf8;, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cairns</LastName><ForeName>Nigel J</ForeName><Initials>NJ</Initials><Identifier Source="ORCID">0000-0001-9858-3344</Identifier><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Department of Neurology, Washington University School of Medicine, Saint Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Department of Neurology, Washington University School of Medicine, Saint Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Halliday</LastName><ForeName>Glenda M</ForeName><Initials>GM</Initials><Identifier Source="ORCID">0000-0003-0422-8398</Identifier><AffiliationInfo><Affiliation>Neuroscience Research Australia, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medical Sciences, Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brain and Mind Centre, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Deerlin</LastName><ForeName>Vivianna M</ForeName><Initials>VM</Initials><Identifier Source="ORCID">0000-0002-7400-9097</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Center for Neurodegenerative Disease Research, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials><Identifier Source="ORCID">0000-0002-9239-8794</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Center for Neurodegenerative Disease Research, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grassano</LastName><ForeName>Maurizio</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Neuromuscular Diseases Research Section, Laboratory of Neurogenetics, National Institute on Aging, Bethesda, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rita Levi Montalcini Department of Neuroscience, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calvo</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-5122-7243</Identifier><AffiliationInfo><Affiliation>Rita Levi Montalcini Department of Neuroscience, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Azienda Ospedaliero Universitaria Citt&#xe0; della Salute e della Scienza, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mora</LastName><ForeName>Gabriele</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Istituti Clinici Scientifici Maugeri, IRCCS, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Canosa</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Rita Levi Montalcini Department of Neuroscience, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Azienda Ospedaliero Universitaria Citt&#xe0; della Salute e della Scienza, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Floris</LastName><ForeName>Gianluca</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospital of Cagliari, Cagliari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bohannan</LastName><ForeName>Ryan C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Department of Neurobiology and Behavior, University of California Irvine, Irvine, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brett</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Dublin Brain Bank, Neuropathology Department, Beaumont Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gan-Or</LastName><ForeName>Ziv</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0003-0332-234X</Identifier><AffiliationInfo><Affiliation>Montreal Neurological Institute and Hospital, Department of Neurology &amp; Neurosurgery, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geiger</LastName><ForeName>Joshua T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Neurodegenerative Diseases Research Unit, Laboratory of Neurogenetics, National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>Anni</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Computational Biology Group, Laboratory of Neurogenetics, National Institute on Aging, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>May</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-8698-3770</Identifier><AffiliationInfo><Affiliation>Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kr&#xfc;ger</LastName><ForeName>Rejko</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Transversal Translational Medicine, Luxembourg Institute of Health, Strassen, Luxembourg.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Parkinson Research Clinic, Centre Hospitalier de Luxembourg, Luxembourg City, Luxembourg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldstein</LastName><ForeName>David S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Clinical Neurocardiology Section, National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>Grisel</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Medical Genetics Branch, National Human Genome Research Institute, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tayebi</LastName><ForeName>Nahid</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-1007-4957</Identifier><AffiliationInfo><Affiliation>Medical Genetics Branch, National Human Genome Research Institute, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sidransky</LastName><ForeName>Ellen</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Medical Genetics Branch, National Human Genome Research Institute, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>American Genome Center</CollectiveName></Author><Author ValidYN="Y"><LastName>Norcliffe-Kaufmann</LastName><ForeName>Lucy</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, New York University School of Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palma</LastName><ForeName>Jose-Alberto</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Neurology, New York University School of Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaufmann</LastName><ForeName>Horacio</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-1851-9981</Identifier><AffiliationInfo><Affiliation>Department of Neurology, New York University School of Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shakkottai</LastName><ForeName>Vikram G</ForeName><Initials>VG</Initials><Identifier Source="ORCID">0000-0003-2742-6469</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan Medical School, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perkins</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-7715-0638</Identifier><AffiliationInfo><Affiliation>Michigan Brain Bank, University of Michigan Medical School, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Newell</LastName><ForeName>Kathy L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gasser</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Diseases, Center of Neurology and Hertie-Institute for Clinical Brain Research, University of T&#xfc;bingen and German Center for Neurodegenerative Diseases, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schulte</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Diseases, Center of Neurology and Hertie-Institute for Clinical Brain Research, University of T&#xfc;bingen and German Center for Neurodegenerative Diseases, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landi</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Fondazione Policlinico Universitario Agostino Gemelli IRCCS Universit&#xe0; Cattolica del Sacro Cuore, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salvi</LastName><ForeName>Erika</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Neuroalgology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cusi</LastName><ForeName>Daniele</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-1006-7597</Identifier><AffiliationInfo><Affiliation>Bio4Dreams-Business Nursery for Life, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masliah</LastName><ForeName>Eliezer</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Molecular Neuropathology Section, Laboratory of Neurogenetics, National Institute on Aging, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Ronald C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Department of Neuropathology, School of Medicine, University of California Irvine, Irvine, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caraway</LastName><ForeName>Chad A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Institute for Memory Impairments and Neurological Disorders, University of California Irvine, Irvine, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monuki</LastName><ForeName>Edwin S</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>Department of Pathology &amp; Laboratory Medicine, School of Medicine, University of California Irvine, Irvine, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brunetti</LastName><ForeName>Maura</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Rita Levi Montalcini Department of Neuroscience, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dawson</LastName><ForeName>Ted M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University Medical Center, Baltimore, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute of Cell Engineering, Johns Hopkins University Medical Center, Baltimore, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacology and Molecular Science, Johns Hopkins University Medical Center, Baltimore, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Solomon H. Snyder Department of Neuroscience, Johns Hopkins University Medical Center, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosenthal</LastName><ForeName>Liana S</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University Medical Center, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albert</LastName><ForeName>Marilyn S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University Medical Center, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pletnikova</LastName><ForeName>Olga</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Pathology (Neuropathology), Johns Hopkins University Medical Center, Baltimore, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Anatomical Sciences, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Troncoso</LastName><ForeName>Juan C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Pathology (Neuropathology), Johns Hopkins University Medical Center, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flanagan</LastName><ForeName>Margaret E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Mesulam Center for Cognitive Neurology and Alzheimer's Disease, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Qinwen</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0000-0001-7876-2046</Identifier><AffiliationInfo><Affiliation>Mesulam Center for Cognitive Neurology and Alzheimer's Disease, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bigio</LastName><ForeName>Eileen H</ForeName><Initials>EH</Initials><AffiliationInfo><Affiliation>Mesulam Center for Cognitive Neurology and Alzheimer's Disease, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodr&#xed;guez-Rodr&#xed;guez</LastName><ForeName>Eloy</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-7742-677X</Identifier><AffiliationInfo><Affiliation>Neurology Service, University Hospital Marqu&#xe9;s de Valdecilla-IDIVAL-UC-CIBERNED, Santander, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Infante</LastName><ForeName>Jon</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Neurology Service, University Hospital Marqu&#xe9;s de Valdecilla-IDIVAL-UC-CIBERNED, Santander, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lage</LastName><ForeName>Carmen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Neurology Service, University Hospital Marqu&#xe9;s de Valdecilla-IDIVAL-UC-CIBERNED, Santander, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonz&#xe1;lez-Aramburu</LastName><ForeName>Isabel</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Neurology Service, University Hospital Marqu&#xe9;s de Valdecilla-IDIVAL-UC-CIBERNED, Santander, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanchez-Juan</LastName><ForeName>Pascual</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-6081-8037</Identifier><AffiliationInfo><Affiliation>Neurology Service, University Hospital Marqu&#xe9;s de Valdecilla-IDIVAL-UC-CIBERNED, Santander, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghetti</LastName><ForeName>Bernardino</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keith</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Anatomical Pathology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Black</LastName><ForeName>Sandra E</ForeName><Initials>SE</Initials><Identifier Source="ORCID">0000-0001-7093-8289</Identifier><AffiliationInfo><Affiliation>Institute of Medical Science, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Heart and Stroke Foundation Canadian Partnership for Stroke Recovery, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>LC Campbell Cognitive Neurology Research Unit, Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masellis</LastName><ForeName>Mario</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>LC Campbell Cognitive Neurology Research Unit, Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cognitive &amp; Movement Disorders Clinic, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Division of Neurology, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rogaeva</LastName><ForeName>Ekaterina</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duyckaerts</LastName><ForeName>Charles</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neuropathology Escourolle, Paris Brain Institute, Sorbonne Universit&#xe9;s, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, DMU Neuroscience 6, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brice</LastName><ForeName>Alexis</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, DMU Neuroscience 6, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lesage</LastName><ForeName>Suzanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, DMU Neuroscience 6, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiromerisiou</LastName><ForeName>Georgia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospital of Larissa, University of Thessalia, Larissa, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barrett</LastName><ForeName>Matthew J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Virginia Commonwealth University, Richmond, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tilley</LastName><ForeName>Bension S</ForeName><Initials>BS</Initials><AffiliationInfo><Affiliation>Neuropathology Unit, Department of Brain Sciences, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gentleman</LastName><ForeName>Steve</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Neuropathology Unit, Department of Brain Sciences, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Logroscino</LastName><ForeName>Giancarlo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Basic Medicine Neurosciences and Sense Organs, University Aldo Moro, Bari, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Neurodegenerative Diseases and the Aging Brain - Department of Clinical Research in Neurology of the University of Bari at 'Pia Fondazione Card G. Panico' Hospital Tricase (Le), Bari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serrano</LastName><ForeName>Geidy E</ForeName><Initials>GE</Initials><AffiliationInfo><Affiliation>Civin Laboratory for Neuropathology, Banner Sun Health Research Institute, Sun City, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beach</LastName><ForeName>Thomas G</ForeName><Initials>TG</Initials><AffiliationInfo><Affiliation>Civin Laboratory for Neuropathology, Banner Sun Health Research Institute, Sun City, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McKeith</LastName><ForeName>Ian G</ForeName><Initials>IG</Initials><AffiliationInfo><Affiliation>Newcastle Brain Tissue Resource, Translational and Clinical Research Institute, Biomedical Research Building, Newcastle University, Newcastle upon Tyne, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>Alan J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Newcastle Brain Tissue Resource, Translational and Clinical Research Institute, Biomedical Research Building, Newcastle University, Newcastle upon Tyne, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Attems</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Newcastle Brain Tissue Resource, Translational and Clinical Research Institute, Biomedical Research Building, Newcastle University, Newcastle upon Tyne, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>Christopher M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Newcastle Brain Tissue Resource, Translational and Clinical Research Institute, Biomedical Research Building, Newcastle University, Newcastle upon Tyne, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palmer</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>South West Dementia Brain Bank, Bristol Medical School, University of Bristol, Bristol, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Love</LastName><ForeName>Seth</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Dementia Research Group, Bristol Medical School, University of Bristol, Bristol, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Troakes</LastName><ForeName>Claire</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-1790-7376</Identifier><AffiliationInfo><Affiliation>Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Sarraj</LastName><ForeName>Safa</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Clinical Neuropathology and London Neurodegenerative Diseases Brain Bank, Institute of Psychiatry, Psychology and Neuroscience, King's College Hospital and King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hodges</LastName><ForeName>Angela K</ForeName><Initials>AK</Initials><Identifier Source="ORCID">0000-0002-5565-6678</Identifier><AffiliationInfo><Affiliation>Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aarsland</LastName><ForeName>Dag</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klein</LastName><ForeName>Gregory</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaiser</LastName><ForeName>Scott M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Neuropathology, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woltjer</LastName><ForeName>Randy</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Oregon Health &amp; Sciences University, Portland, OR, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pastor</LastName><ForeName>Pau</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-7493-8777</Identifier><AffiliationInfo><Affiliation>Memory and Movement Disorders Units, Department of Neurology, University Hospital Mutua de Terrassa, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bekris</LastName><ForeName>Lynn M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Genomic Medicine Institute, Cleveland Clinic, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leverenz</LastName><ForeName>James B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Cleveland Lou Ruvo Center for Brain Health, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Besser</LastName><ForeName>Lilah M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Institute for Human Health and Disease Intervention, Florida Atlantic University, Boca Raton, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuzma</LastName><ForeName>Amanda</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Renton</LastName><ForeName>Alan E</ForeName><Initials>AE</Initials><Identifier Source="ORCID">0000-0001-6702-8268</Identifier><AffiliationInfo><Affiliation>Ronald M. Loeb Center for Alzheimer's Disease, Nash Family Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-0576-2472</Identifier><AffiliationInfo><Affiliation>Ronald M. Loeb Center for Alzheimer's Disease, Nash Family Department of Neuroscience, Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scherzer</LastName><ForeName>Clemens R</ForeName><Initials>CR</Initials><Identifier Source="ORCID">0000-0002-0567-9193</Identifier><AffiliationInfo><Affiliation>Precision Neurology Program, Brigham &amp; Women's Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>Huw R</ForeName><Initials>HR</Initials><Identifier Source="ORCID">0000-0002-5473-3774</Identifier><AffiliationInfo><Affiliation>Department of Clinical and Movement Neuroscience, UCL Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferrari</LastName><ForeName>Raffaele</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albani</LastName><ForeName>Diego</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-7050-6723</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pickering-Brown</LastName><ForeName>Stuart</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-1561-6054</Identifier><AffiliationInfo><Affiliation>Division of Neuroscience and Experimental Psychology, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Faber</LastName><ForeName>Kelley</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kukull</LastName><ForeName>Walter A</ForeName><Initials>WA</Initials><AffiliationInfo><Affiliation>National Alzheimer's Coordinating Center, Department of Epidemiology, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morenas-Rodriguez</LastName><ForeName>Estrella</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Biomedizinisches Centrum, Biochemie, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen &amp; Deutsches Zentrum f&#xfc;r Neurodegenerative Erkrankungen, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sant Pau Biomedical Research Institute, Hospital de la Santa Creu i Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Network Center for Biomedical Research in Neurodegenerative Diseases, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lle&#xf3;</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sant Pau Biomedical Research Institute, Hospital de la Santa Creu i Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Network Center for Biomedical Research in Neurodegenerative Diseases, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fortea</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Sant Pau Biomedical Research Institute, Hospital de la Santa Creu i Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Network Center for Biomedical Research in Neurodegenerative Diseases, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alcolea</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-3819-3245</Identifier><AffiliationInfo><Affiliation>Sant Pau Biomedical Research Institute, Hospital de la Santa Creu i Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Network Center for Biomedical Research in Neurodegenerative Diseases, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clarimon</LastName><ForeName>Jordi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Sant Pau Biomedical Research Institute, Hospital de la Santa Creu i Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Network Center for Biomedical Research in Neurodegenerative Diseases, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nalls</LastName><ForeName>Mike A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Laboratory of Neurogenetics, National Institute on Aging, Bethesda, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Data Tecnica International, Glen Echo, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Alzheimer's and Related Dementias, National Institute on Aging, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferrucci</LastName><ForeName>Luigi</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-6273-1613</Identifier><AffiliationInfo><Affiliation>Longitudinal Studies Section, National Institute on Aging, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Resnick</LastName><ForeName>Susan M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Laboratory of Behavioral Neuroscience, National Institute on Aging, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanaka</LastName><ForeName>Toshiko</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Longitudinal Studies Section, National Institute on Aging, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foroud</LastName><ForeName>Tatiana M</ForeName><Initials>TM</Initials><Identifier Source="ORCID">0000-0002-5549-2212</Identifier><AffiliationInfo><Affiliation>Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>Neill R</ForeName><Initials>NR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wszolek</LastName><ForeName>Zbigniew K</ForeName><Initials>ZK</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferman</LastName><ForeName>Tanis</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychology, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boeve</LastName><ForeName>Bradley F</ForeName><Initials>BF</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hardy</LastName><ForeName>John A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Reta Lila Weston Institute, UCL Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute of UCL, UCL Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UCL Movement Disorders Centre, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Advanced Study, The Hong Kong University of Science and Technology, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Topol</LastName><ForeName>Eric J</ForeName><Initials>EJ</Initials><Identifier Source="ORCID">0000-0002-1478-4729</Identifier><AffiliationInfo><Affiliation>Scripps Research Translational Institute, Scripps Research, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torkamani</LastName><ForeName>Ali</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Scripps Research Translational Institute, Scripps Research, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singleton</LastName><ForeName>Andrew B</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Molecular Genetics Section, Laboratory of Neurogenetics, National Institute on Aging, Bethesda, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Alzheimer's and Related Dementias, National Institute on Aging, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryten</LastName><ForeName>Mina</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9520-6957</Identifier><AffiliationInfo><Affiliation>NIHR Great Ormond Street Hospital Biomedical Research Centre, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Great Ormond Street Institute of Child Health, Genetics and Genomic Medicine, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis W</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chi&#xf2;</LastName><ForeName>Adriano</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-9579-5341</Identifier><AffiliationInfo><Affiliation>Rita Levi Montalcini Department of Neuroscience, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Azienda Ospedaliero Universitaria Citt&#xe0; della Salute e della Scienza, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Cognitive Sciences and Technologies, C.N.R., Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ross</LastName><ForeName>Owen A</ForeName><Initials>OA</Initials><Identifier Source="ORCID">0000-0003-4813-756X</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Genomics, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gibbs</LastName><ForeName>J Raphael</ForeName><Initials>JR</Initials><Identifier Source="ORCID">0000-0002-6985-0658</Identifier><AffiliationInfo><Affiliation>Computational Biology Group, Laboratory of Neurogenetics, National Institute on Aging, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dalgard</LastName><ForeName>Clifton L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Department of Anatomy, Physiology &amp; Genetics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The American Genome Center, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Traynor</LastName><ForeName>Bryan J</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Neuromuscular Diseases Research Section, Laboratory of Neurogenetics, National Institute on Aging, Bethesda, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Reta Lila Weston Institute, UCL Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University Medical Center, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scholz</LastName><ForeName>Sonja W</ForeName><Initials>SW</Initials><Identifier Source="ORCID">0000-0002-6623-0429</Identifier><AffiliationInfo><Affiliation>Neurodegenerative Diseases Research Unit, Laboratory of Neurogenetics, National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA. sonja.scholz@nih.gov.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University Medical Center, Baltimore, MD, USA. sonja.scholz@nih.gov.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG013854</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 AG065463</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066507</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G1100540</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>ZIA AG000935</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0900652</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0502157</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P50 NS062684</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 NS110435</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 NS095736</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS096740</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 NS095871</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>ZIA NS003034</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>ZIA NS003033</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0400074</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P50 NS072187</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG072977</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG062418</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/L016397/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>ZIA NS003154</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000040</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L023784/2</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>UL1 TR001873</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/N008324/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U01 NS100620</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS071674</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 NS100693</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS115144</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>02</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Genet</MedlineTA><NlmUniqueID>9216904</NlmUniqueID><ISSNLinking>1061-4036</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C101410">BIN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497604">SNCA protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D025521">Tumor Suppressor Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.1.45</RegistryNumber><NameOfSubstance UI="C000633564">GBA protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.1.45</RegistryNumber><NameOfSubstance UI="D005962">Glucosylceramidase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2021 Apr;17(4):193. doi: 10.1038/s41582-021-00478-9.</RefSource><PMID Version="1">33649530</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D048868" MajorTopicYN="N">Adaptor Proteins, Signal Transducing</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015894" MajorTopicYN="N">Genome, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="Y">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005962" MajorTopicYN="N">Glucosylceramidase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009687" MajorTopicYN="N">Nuclear Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D025521" MajorTopicYN="N">Tumor Suppressor Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Sotis</LastName><ForeName>Anthony R</ForeName><Initials>AR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sukumar</LastName><ForeName>Gauthaman</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alba</LastName><ForeName>Camille</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lott</LastName><ForeName>Nathaniel</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martinez</LastName><ForeName>Elisa McGrath</ForeName><Initials>EM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tuck</LastName><ForeName>Meila</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Singh</LastName><ForeName>Jatinder</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bacikova</LastName><ForeName>Dagmar</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xijun</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hupalo</LastName><ForeName>Daniel N</ForeName><Initials>DN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Adeleye</LastName><ForeName>Adelani</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wilkerson</LastName><ForeName>Matthew D</ForeName><Initials>MD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pollard</LastName><ForeName>Harvey B</ForeName><Initials>HB</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>7</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>1</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>2</Month><Day>16</Day><Hour>6</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>8</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33589841</ArticleId><ArticleId IdType="mid">NIHMS1662931</ArticleId><ArticleId IdType="pmc">PMC7946812</ArticleId><ArticleId IdType="doi">10.1038/s41588-021-00785-3</ArticleId><ArticleId IdType="pii">10.1038/s41588-021-00785-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Walker Z, Possin KL, Boeve BF &amp; Aarsland D Lewy body dementias. Lancet 386, 1683&#x2013;1697 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5792067</ArticleId><ArticleId IdType="pubmed">26595642</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith IG et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology 89, 88&#x2013;100 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5496518</ArticleId><ArticleId IdType="pubmed">28592453</ArticleId></ArticleIdList></Reference><Reference><Citation>Meeus B, Theuns J &amp; Van Broeckhoven C The genetics of dementia with Lewy bodies: what are we missing? Arch. Neurol. 69, 1113&#x2013;1118 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22635379</ArticleId></ArticleIdList></Reference><Reference><Citation>  https://www.lbda.org/page/what-lbd.</Citation></Reference><Reference><Citation>Guerreiro R et al. Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. Lancet Neurol. 17, 64&#x2013;74 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5805394</ArticleId><ArticleId IdType="pubmed">29263008</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabir MS et al. Assessment of APOE in atypical parkinsonism syndromes. Neurobiol. Dis 127, 142&#x2013;146 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6588472</ArticleId><ArticleId IdType="pubmed">30798004</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalls MA et al. A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol. 70, 727&#x2013;735 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3841974</ArticleId><ArticleId IdType="pubmed">23588557</ArticleId></ArticleIdList></Reference><Reference><Citation>Singleton AB et al. alpha-Synuclein locus triplication causes Parkinson&#x2019;s disease. Science 302, 841 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">14593171</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuang D et al. APOE epsilon4 increases risk for dementia in pure synucleinopathies. JAMA Neurol 70, 223&#x2013;228 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3580799</ArticleId><ArticleId IdType="pubmed">23407718</ArticleId></ArticleIdList></Reference><Reference><Citation>Pickering-Brown SM et al. Apolipoprotein E4 and Alzheimer&#x2019;s disease pathology in Lewy body disease and in other beta-amyloid-forming diseases. Lancet 343, 1155 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">7818636</ArticleId></ArticleIdList></Reference><Reference><Citation>Seshadri S et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA 303, 1832&#x2013;1840 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2989531</ArticleId><ArticleId IdType="pubmed">20460622</ArticleId></ArticleIdList></Reference><Reference><Citation>Pankratz N et al. Genomewide association study for susceptibility genes contributing to familial Parkinson disease. Hum. Genet 124, 593&#x2013;605 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2627511</ArticleId><ArticleId IdType="pubmed">18985386</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S et al. Optimal unified approach for rare-variant association testing with application to small-sample case-control whole-exome sequencing studies. Am. J. Hum. Genet 91, 224&#x2013;237 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3415556</ArticleId><ArticleId IdType="pubmed">22863193</ArticleId></ArticleIdList></Reference><Reference><Citation>Geiger JT et al. Next-generation sequencing reveals substantial genetic contribution to dementia with Lewy bodies. Neurobiol Dis. 94, 55&#x2013;62 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4983488</ArticleId><ArticleId IdType="pubmed">27312774</ArticleId></ArticleIdList></Reference><Reference><Citation>Singleton A &amp; Hardy J A generalizable hypothesis for the genetic architecture of disease: pleomorphic risk loci. Hum. Mol. Genet 20, R158&#x2013;R162 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3179380</ArticleId><ArticleId IdType="pubmed">21875901</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolae DL et al. Trait-associated SNPs are more likely to be eQTLs: annotation to enhance discovery from GWAS. PLoS Genet. 6, e1000888 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2848547</ArticleId><ArticleId IdType="pubmed">20369019</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YI et al. RNA splicing is a primary link between genetic variation and disease. Science 352, 600&#x2013;604 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5182069</ArticleId><ArticleId IdType="pubmed">27126046</ArticleId></ArticleIdList></Reference><Reference><Citation>V&#xf5;sa U
et al.
Unraveling the polygenic architecture of complex traits using blood eQTL metaanalysis. Preprint at https://www.biorxiv.org/content/10.1101/447367v1 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/447367v1</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D et al. Comprehensive functional genomic resource and integrative model for the human brain. Science 362, eaat8464 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6413328</ArticleId><ArticleId IdType="pubmed">30545857</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawrylycz MJ et al. An anatomically comprehensive atlas of the adult human brain transcriptome. Nature 489, 391&#x2013;399 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4243026</ArticleId><ArticleId IdType="pubmed">22996553</ArticleId></ArticleIdList></Reference><Reference><Citation>GTEx Consortium. Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science 348, 648&#x2013;660 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4547484</ArticleId><ArticleId IdType="pubmed">25954001</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunkle BW et al. Genetic meta-analysis of diagnosed Alzheimer&#x2019;s disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing. Nat. Genet 51, 414&#x2013;430 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6463297</ArticleId><ArticleId IdType="pubmed">30820047</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalls MA et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson&#x2019;s disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 18, 1091&#x2013;1102 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8422160</ArticleId><ArticleId IdType="pubmed">31701892</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramarz B et al. Improving the Gene Ontology resource to facilitate more informative analysis and interpretation of Alzheimer&#x2019;s disease data. Genes (Basel) 9, 593 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6315915</ArticleId><ArticleId IdType="pubmed">30501127</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandres-Ciga S et al. The endocytic membrane trafficking pathway plays a major role in the risk of Parkinson&#x2019;s disease. Mov. Disord 34, 460&#x2013;468 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6467788</ArticleId><ArticleId IdType="pubmed">30675927</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43, 2412&#x2013;2414 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyagawa T et al. BIN1 regulates BACE1 intracellular trafficking and amyloid-beta production. Hum. Mol. Genet 25, 2948&#x2013;2958 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27179792</ArticleId></ArticleIdList></Reference><Reference><Citation>Calafate S, Flavin W, Verstreken P &amp; Moechars D Loss of Bin1 promotes the propagation of Tau pathology. Cell Rep. 17, 931&#x2013;940 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27760323</ArticleId></ArticleIdList></Reference><Reference><Citation>Jinn S et al. TMEM175 deficiency impairs lysosomal and mitochondrial function and increases alpha-synuclein aggregation. Proc. Natl. Acad. Sci. USA 114, 2389&#x2013;2394 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5338534</ArticleId><ArticleId IdType="pubmed">28193887</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer&#x2019;s disease in late onset families. Science 261, 921&#x2013;923 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Sidransky E et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson&#x2019;s disease. N. Engl. J. Med 361, 1651&#x2013;1661 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2856322</ArticleId><ArticleId IdType="pubmed">19846850</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon-Sanchez J et al. Genome-wide association study reveals genetic risk underlying Parkinson&#x2019;s disease. Nat. Genet 41, 1308&#x2013;1312 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2787725</ArticleId><ArticleId IdType="pubmed">19915575</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen IE et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer&#x2019;s disease risk. Nat. Genet 51, 404&#x2013;413 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6836675</ArticleId><ArticleId IdType="pubmed">30617256</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross OA et al. Genomic investigation of alpha-synuclein multiplication and parkinsonism. Ann. Neurol 63, 743&#x2013;750 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3850281</ArticleId><ArticleId IdType="pubmed">18571778</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollard MO, Gurdasani D, Mentzer AJ, Porter T &amp; Sandhu MS Long reads: their purpose and place. Hum. Mol. Genet 27, R234&#x2013;R241 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6061690</ArticleId><ArticleId IdType="pubmed">29767702</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Methods-only References</Title><Reference><Citation>Erikson GA et al. Whole-genome sequencing of a healthy aging cohort. Cell 165, 1002&#x2013;1011 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4860090</ArticleId><ArticleId IdType="pubmed">27114037</ArticleId></ArticleIdList></Reference><Reference><Citation>Emre M et al. Clinical diagnostic criteria for dementia associated with Parkinson&#x2019;s disease. Mov. Disord 22, 1689&#x2013;1707 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17542011</ArticleId></ArticleIdList></Reference><Reference><Citation>Savica R et al. Incidence of dementia with Lewy bodies and Parkinson disease dementia. JAMA Neurol. 70, 1396&#x2013;1402 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4181848</ArticleId><ArticleId IdType="pubmed">24042491</ArticleId></ArticleIdList></Reference><Reference><Citation>Regier AA et al. Functional equivalence of genome sequencing analysis pipelines enables harmonized variant calling across human genetics projects. Nat. Commun 9, 4038 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6168605</ArticleId><ArticleId IdType="pubmed">30279509</ArticleId></ArticleIdList></Reference><Reference><Citation>Van der Auwera GA et al. From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. Curr. Protoc. Bioinformatics 43, 11 10 1&#x2013;11 10 33 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4243306</ArticleId><ArticleId IdType="pubmed">25431634</ArticleId></ArticleIdList></Reference><Reference><Citation>Jun G et al. Detecting and estimating contamination of human DNA samples in sequencing and array-based genotype data. Am. J. Hum. Genet. 91, 839&#x2013;848 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3487130</ArticleId><ArticleId IdType="pubmed">23103226</ArticleId></ArticleIdList></Reference><Reference><Citation>International HapMap Consortium et al. Integrating common and rare genetic variation in diverse human populations. Nature 467, 52&#x2013;58 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3173859</ArticleId><ArticleId IdType="pubmed">20811451</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider VA et al. Evaluation of GRCh38 and de novo haploid genome assemblies demonstrates the enduring quality of the reference assembly. Genome Res. 27, 849&#x2013;864 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5411779</ArticleId><ArticleId IdType="pubmed">28396521</ArticleId></ArticleIdList></Reference><Reference><Citation>Karczewski KJ et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 581, 434&#x2013;443 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7334197</ArticleId><ArticleId IdType="pubmed">32461654</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang CC et al. Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience 4, 7 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4342193</ArticleId><ArticleId IdType="pubmed">25722852</ArticleId></ArticleIdList></Reference><Reference><Citation>Venables WN &amp; Ripley BD Modern Applied Statistics with S, (Springer, New York, 2002).</Citation></Reference><Reference><Citation>Das S et al. Next-generation genotype imputation service and methods. Nat. Genet. 48, 1284&#x2013;1287 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5157836</ArticleId><ArticleId IdType="pubmed">27571263</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuchsberger C, Abecasis GR &amp; Hinds DA minimac2: faster genotype imputation. Bioinformatics 31, 782&#x2013;784 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4341061</ArticleId><ArticleId IdType="pubmed">25338720</ArticleId></ArticleIdList></Reference><Reference><Citation>Taliun D
et al.
Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program. Preprint at https://www.biorxiv.org/content/10.1101/563866v1 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/563866v1</ArticleId><ArticleId IdType="pmc">PMC7875770</ArticleId><ArticleId IdType="pubmed">33568819</ArticleId></ArticleIdList></Reference><Reference><Citation>Willer CJ, Li Y &amp; Abecasis GR METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics 26, 2190&#x2013;2191 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2922887</ArticleId><ArticleId IdType="pubmed">20616382</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS et al. The Consortium to Establish a Registry for Alzheimer&#x2019;s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer&#x2019;s disease. Neurology 41, 479&#x2013;486 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Alafuzoff I, Arzberger T, Kretzschmar H &amp; Del Tredici K Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 112, 389&#x2013;404 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3906709</ArticleId><ArticleId IdType="pubmed">16906426</ArticleId></ArticleIdList></Reference><Reference><Citation>Giambartolomei C et al. Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. PLoS Genet. 10, e1004383 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4022491</ArticleId><ArticleId IdType="pubmed">24830394</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace C Eliciting priors and relaxing the single causal variant assumption in colocalisation analyses. PLoS Genet. 16, e1008720 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7192519</ArticleId><ArticleId IdType="pubmed">32310995</ArticleId></ArticleIdList></Reference><Reference><Citation>Bryois J et al. Genetic identification of cell types underlying brain complex traits yields insights into the etiology of Parkinson&#x2019;s disease. Nat. Genet 52, 482&#x2013;493 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7930801</ArticleId><ArticleId IdType="pubmed">32341526</ArticleId></ArticleIdList></Reference><Reference><Citation>Skene NG &amp; Grant SG Identification of vulnerable cell types in major brain disorders using single cell transcriptomes and expression weighted cell type enrichment. Front. Neurosci 10, 16 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4730103</ArticleId><ArticleId IdType="pubmed">26858593</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J et al. Genetic variance estimation with imputed variants finds negligible missing heritability for human height and body mass index. Nat. Genet 47, 1114&#x2013;1120 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4589513</ArticleId><ArticleId IdType="pubmed">26323059</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang K, Li M &amp; Hakonarson H ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38, e164 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2938201</ArticleId><ArticleId IdType="pubmed">20601685</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhan X, Hu Y, Li B, Abecasis GR &amp; Liu DJ RVTESTS: an efficient and comprehensive tool for rare variant association analysis using sequence data. Bioinformatics 32, 1423&#x2013;1426 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4848408</ArticleId><ArticleId IdType="pubmed">27153000</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohler A et al. Reactome from a WikiPathways perspective. PLoS Comput. Biol 12, e1004941 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4874630</ArticleId><ArticleId IdType="pubmed">27203685</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanehisa M, Sato Y, Kawashima M, Furumichi M &amp; Tanabe M KEGG as a reference resource for gene and protein annotation. Nucleic Acids Res. 44, D457&#x2013;D462 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4702792</ArticleId><ArticleId IdType="pubmed">26476454</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33589840</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>08</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1718</ISSN><JournalIssue CitedMedium="Internet"><Volume>53</Volume><Issue>3</Issue><PubDate><Year>2021</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Nature genetics</Title><ISOAbbreviation>Nat Genet</ISOAbbreviation></Journal><ArticleTitle>Genome-wide meta-analysis, fine-mapping and integrative prioritization implicate new Alzheimer's disease risk genes.</ArticleTitle><Pagination><StartPage>392</StartPage><EndPage>402</EndPage><MedlinePgn>392-402</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41588-020-00776-w</ELocationID><Abstract><AbstractText>Genome-wide association studies have discovered numerous genomic loci associated with Alzheimer's disease (AD); yet the causal genes and variants are incompletely identified. We performed an updated genome-wide AD meta-analysis, which identified 37 risk loci, including new associations near CCDC6, TSPAN14, NCK2 and SPRED2. Using three SNP-level fine-mapping methods, we identified 21 SNPs with &gt;50% probability each of being causally involved in AD risk and others strongly suggested by functional annotation. We followed this with colocalization analyses across 109 gene expression quantitative trait loci datasets and prioritization of genes by using protein interaction networks and tissue-specific expression. Combining this information into a quantitative score, we found that evidence converged on likely causal genes, including the above four genes, and those at previously discovered AD loci, including BIN1, APH1B, PTK2B, PILRA and CASS4.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schwartzentruber</LastName><ForeName>Jeremy</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-6183-2092</Identifier><AffiliationInfo><Affiliation>European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Cambridge, UK. jeremys@ebi.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Open Targets, Wellcome Genome Campus, Cambridge, UK. jeremys@ebi.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK. jeremys@ebi.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cooper</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Open Targets, Wellcome Genome Campus, Cambridge, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jimmy Z</ForeName><Initials>JZ</Initials><AffiliationInfo><Affiliation>Biogen, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barrio-Hernandez</LastName><ForeName>Inigo</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-5686-0451</Identifier><AffiliationInfo><Affiliation>European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Cambridge, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Open Targets, Wellcome Genome Campus, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bello</LastName><ForeName>Erica</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Open Targets, Wellcome Genome Campus, Cambridge, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumasaka</LastName><ForeName>Natsuhiko</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-3557-0375</Identifier><AffiliationInfo><Affiliation>Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Young</LastName><ForeName>Adam M H</ForeName><Initials>AMH</Initials><AffiliationInfo><Affiliation>Wellcome-Medical Research Council Cambridge Stem Cell Institute, Cambridge Biomedical Campus, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Franklin</LastName><ForeName>Robin J M</ForeName><Initials>RJM</Initials><AffiliationInfo><Affiliation>Wellcome-Medical Research Council Cambridge Stem Cell Institute, Cambridge Biomedical Campus, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Toby</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Target Sciences-R&amp;D, GSK Medicines Research Centre, Stevenage, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Estrada</LastName><ForeName>Karol</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>BioMarin Pharmaceutical, San Rafael, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaffney</LastName><ForeName>Daniel J</ForeName><Initials>DJ</Initials><Identifier Source="ORCID">0000-0002-1529-1862</Identifier><AffiliationInfo><Affiliation>Open Targets, Wellcome Genome Campus, Cambridge, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Genomics Plc, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beltrao</LastName><ForeName>Pedro</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-2724-7703</Identifier><AffiliationInfo><Affiliation>European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Cambridge, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Open Targets, Wellcome Genome Campus, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bassett</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1632-9137</Identifier><AffiliationInfo><Affiliation>Open Targets, Wellcome Genome Campus, Cambridge, UK. ab42@sanger.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK. ab42@sanger.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_PC_17230</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>203151/Z/16/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>50</GrantID><Acronym>MSS_</Acronym><Agency>Multiple Sclerosis Society</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>206194</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>203151</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>02</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Genet</MedlineTA><NlmUniqueID>9216904</NlmUniqueID><ISSNLinking>1061-4036</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C088832">CCDC6 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003598">Cytoskeletal Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C485544">NCK2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015513">Oncogene Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C556849">TSPAN14 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D059470">Tetraspanins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Nat Genet. 2021 Apr;53(4):585-586. doi: 10.1038/s41588-021-00822-1.</RefSource><PMID Version="1">33637963</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2021 Apr;17(4):193. doi: 10.1038/s41582-021-00478-9.</RefSource><PMID Version="1">33649530</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D048868" MajorTopicYN="N">Adaptor Proteins, Signal Transducing</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002874" MajorTopicYN="N">Chromosome Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003598" MajorTopicYN="N">Cytoskeletal Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015810" MajorTopicYN="N">Linkage Disequilibrium</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015513" MajorTopicYN="N">Oncogene Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060066" MajorTopicYN="N">Protein Interaction Maps</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D040641" MajorTopicYN="N">Quantitative Trait Loci</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059470" MajorTopicYN="N">Tetraspanins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>
<b>Competing interests</b>
. J.Z.L. was an employee of Biogen at the time of the study, and is now an employee of GSK. D.J.G. is an employee of Genomics Plc. T.J. is an employee of GSK. K.E. is an employee of BioMarin Pharmaceutical.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>1</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>12</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>2</Month><Day>16</Day><Hour>6</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>8</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33589840</ArticleId><ArticleId IdType="mid">EMS118040</ArticleId><ArticleId IdType="pmc">PMC7610386</ArticleId><ArticleId IdType="doi">10.1038/s41588-020-00776-w</ArticleId><ArticleId IdType="pii">10.1038/s41588-020-00776-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Liu JZ, Erlich Y, Pickrell JK. Case-control association mapping by proxy using family history of disease. Nat Genet. 2017;49:325&#x2013;331.</Citation><ArticleIdList><ArticleId IdType="pubmed">28092683</ArticleId></ArticleIdList></Reference><Reference><Citation>Marioni RE, et al. GWAS on family history of Alzheimer&#x2019;s disease. Transl Psychiatry. 2018;8:99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5959890</ArticleId><ArticleId IdType="pubmed">29777097</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen IE, et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer&#x2019;s disease risk. Nat Genet. 2019;51:404&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6836675</ArticleId><ArticleId IdType="pubmed">30617256</ArticleId></ArticleIdList></Reference><Reference><Citation>Claussnitzer M, et al. FTO obesity variant circuitry and adipocyte browning in humans. N Engl J Med. 2015;373:895&#x2013;907.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4959911</ArticleId><ArticleId IdType="pubmed">26287746</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekar A, et al. Schizophrenia risk from complex variation of complement component 4. Nature. 2016;530:177&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4752392</ArticleId><ArticleId IdType="pubmed">26814963</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang H, et al. Fine-mapping inflammatory bowel disease loci to single-variant resolution. Nature. 2017;547:173&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5511510</ArticleId><ArticleId IdType="pubmed">28658209</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik M, et al. CD33 Alzheimer&#x2019;s risk-altering polymorphism, CD33 expression, and exon 2 splicing. J Neurosci. 2013;33:13320&#x2013;13325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3742922</ArticleId><ArticleId IdType="pubmed">23946390</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, et al. TREM2 variants in Alzheimer&#x2019;s disease. N Engl J Med. 2013;368:117&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Sims R, et al. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer&#x2019;s disease. Nat Genet. 2017;49:1373&#x2013;1384.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5669039</ArticleId><ArticleId IdType="pubmed">28714976</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerimov N, et al. eQTL Catalogue: a compendium of uniformly processed human gene expression and splicing QTLs. bioRxiv. 2020 doi: 10.1101/2020.01.29.924266.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.01.29.924266</ArticleId><ArticleId IdType="pmc">PMC8423625</ArticleId><ArticleId IdType="pubmed">34493866</ArticleId></ArticleIdList></Reference><Reference><Citation>GTEx Consortium. The GTEx Consortium atlas of genetic regulatory effects across human tissues. Science. 2020;369:1318&#x2013;1330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7737656</ArticleId><ArticleId IdType="pubmed">32913098</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunkle BW, et al. Genetic meta-analysis of diagnosed Alzheimer&#x2019;s disease identifies new risk loci and implicates A&#x3b2;, tau, immunity and lipid processing. Nat Genet. 2019;51:414&#x2013;430.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6463297</ArticleId><ArticleId IdType="pubmed">30820047</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer&#x2019;s disease. Nat Genet. 2013;45:1452&#x2013;1458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Young AMH, et al. A map of transcriptional heterogeneity and regulatory variation in human microglia. bioRxiv. 2019 doi: 10.1101/2019.12.20.874099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2019.12.20.874099</ArticleId><ArticleId IdType="pmc">PMC7610960</ArticleId><ArticleId IdType="pubmed">34083789</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung YY, et al. Identifying amyloid pathology&#x2013;related cerebrospinal fluid biomarkers for Alzheimer&#x2019;s disease in a multicohort study. Alzheimers Dement. 2015;1:339&#x2013;348.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4672388</ArticleId><ArticleId IdType="pubmed">26693175</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulik-Sullivan BK, et al. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. Nat Genet. 2015;47:291&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4495769</ArticleId><ArticleId IdType="pubmed">25642630</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-Grau S, et al. Genome-wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer&#x2019;s disease and three causality networks: The GR@ACE project. Alzheimers Dement. 2019;15:1333&#x2013;1347.</Citation><ArticleIdList><ArticleId IdType="pubmed">31473137</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J, et al. Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. Nat Genet. 2012;44:369&#x2013;75. S1-3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3593158</ArticleId><ArticleId IdType="pubmed">22426310</ArticleId></ArticleIdList></Reference><Reference><Citation>Giambartolomei C, et al. Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. PLoS Genet. 2014;10:e1004383.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4022491</ArticleId><ArticleId IdType="pubmed">24830394</ArticleId></ArticleIdList></Reference><Reference><Citation>Sieberts SK, et al. Large eQTL meta-analysis reveals differing patterns between cerebral cortical and cerebellar brain regions. Sci Data. 2020;7:340.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7550587</ArticleId><ArticleId IdType="pubmed">33046718</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng B, et al. An xQTL map integrates the genetic architecture of the human brain&#x2019;s transcriptome and epigenome. Nat Neurosci. 2017;20:1418&#x2013;1426.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5785926</ArticleId><ArticleId IdType="pubmed">28869584</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmiedel BJ, et al. Impact of genetic polymorphisms on human immune cell gene expression. Cell. 2018;175:1701&#x2013;1715.e16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6289654</ArticleId><ArticleId IdType="pubmed">30449622</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaffe AE, et al. Developmental and genetic regulation of the human cortex transcriptome illuminate schizophrenia pathogenesis. Nat Neurosci. 2018;21:1117&#x2013;1125.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6438700</ArticleId><ArticleId IdType="pubmed">30050107</ArticleId></ArticleIdList></Reference><Reference><Citation>Buil A, et al. Gene-gene and gene-environment interactions detected by transcriptome sequence analysis in twins. Nat Genet. 2015;47:88&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4643454</ArticleId><ArticleId IdType="pubmed">25436857</ArticleId></ArticleIdList></Reference><Reference><Citation>Fairfax BP, et al. Genetics of gene expression in primary immune cells identifies cell type&#x2013;specific master regulators and roles of HLA alleles. Nat Genet. 2012;44:502&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3437404</ArticleId><ArticleId IdType="pubmed">22446964</ArticleId></ArticleIdList></Reference><Reference><Citation>Fairfax BP, et al. Innate immune activity conditions the effect of regulatory variants upon monocyte gene expression. Science. 2014;343 1246949.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4064786</ArticleId><ArticleId IdType="pubmed">24604202</ArticleId></ArticleIdList></Reference><Reference><Citation>Naranbhai V, et al. Genomic modulators of gene expression in human neutrophils. Nat Commun. 2015;6:7545.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4507005</ArticleId><ArticleId IdType="pubmed">26151758</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, et al. Genetic drivers of epigenetic and transcriptional variation in human immune cells. Cell. 2016;167:1398&#x2013;141.e24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5119954</ArticleId><ArticleId IdType="pubmed">27863251</ArticleId></ArticleIdList></Reference><Reference><Citation>Alasoo K, et al. Shared genetic effects on chromatin and gene expression indicate a role for enhancer priming in immune response. Nat Genet. 2018;50:424&#x2013;431.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6548559</ArticleId><ArticleId IdType="pubmed">29379200</ArticleId></ArticleIdList></Reference><Reference><Citation>Gutierrez-Arcelus M, et al. Passive and active DNA methylation and the interplay with genetic variation in gene regulation. Elife. 2013;2:e00523.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3673336</ArticleId><ArticleId IdType="pubmed">23755361</ArticleId></ArticleIdList></Reference><Reference><Citation>Lappalainen T, et al. Transcriptome and genome sequencing uncovers functional variation in humans. Nature. 2013;501:506&#x2013;511.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3918453</ArticleId><ArticleId IdType="pubmed">24037378</ArticleId></ArticleIdList></Reference><Reference><Citation>Kilpinen H, et al. Common genetic variation drives molecular heterogeneity in human iPSCs. Nature. 2017;546:370&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5524171</ArticleId><ArticleId IdType="pubmed">28489815</ArticleId></ArticleIdList></Reference><Reference><Citation>N&#xe9;d&#xe9;lec Y, et al. Genetic ancestry and natural selection drive population differences in immune responses to pathogens. Cell. 2016;167:657&#x2013;669.e21.</Citation><ArticleIdList><ArticleId IdType="pubmed">27768889</ArticleId></ArticleIdList></Reference><Reference><Citation>Quach H, et al. Genetic adaptation and Neandertal admixture shaped the immune system of human populations. Cell. 2016;167:643&#x2013;656.e17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5075285</ArticleId><ArticleId IdType="pubmed">27768888</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartzentruber J, et al. Molecular and functional variation in iPSC-derived sensory neurons. Nat Genet. 2018;50:54&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5742539</ArticleId><ArticleId IdType="pubmed">29229984</ArticleId></ArticleIdList></Reference><Reference><Citation>van de Bunt M, et al. Transcript expression data from human islets links regulatory signals from genome-wide association studies for type 2 diabetes and glycemic traits to their downstream effectors. PLoS Genet. 2015;11:e1005694.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4666611</ArticleId><ArticleId IdType="pubmed">26624892</ArticleId></ArticleIdList></Reference><Reference><Citation>Momozawa Y, et al. IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genes. Nat Commun. 2018;9:2427.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6013502</ArticleId><ArticleId IdType="pubmed">29930244</ArticleId></ArticleIdList></Reference><Reference><Citation>Chun S, et al. Limited statistical evidence for shared genetic effects of eQTLs and autoimmune-disease-associated loci in three major immune-cell types. Nat Genet. 2017;49:600&#x2013;605.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5374036</ArticleId><ArticleId IdType="pubmed">28218759</ArticleId></ArticleIdList></Reference><Reference><Citation>Salazar SV, et al. Alzheimer&#x2019;s disease risk factor Pyk2 mediates amyloid-&#x3b2;-induced synaptic dysfunction and loss. J Neurosci. 2019;39:758&#x2013;772.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6343652</ArticleId><ArticleId IdType="pubmed">30518596</ArticleId></ArticleIdList></Reference><Reference><Citation>Raj T, et al. Integrative transcriptome analyses of the aging brain implicate altered splicing in Alzheimer&#x2019;s disease susceptibility. Nat Genet. 2018;50:1584&#x2013;1592.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6354244</ArticleId><ArticleId IdType="pubmed">30297968</ArticleId></ArticleIdList></Reference><Reference><Citation>Calafate S, Flavin W, Verstreken P, Moechars D. Loss of Bin1 promotes the propagation of Tau pathology. Cell Rep. 2016;17:931&#x2013;940.</Citation><ArticleIdList><ArticleId IdType="pubmed">27760323</ArticleId></ArticleIdList></Reference><Reference><Citation>Nott A, et al. Brain cell type&#x2013;specific enhancer&#x2013;promoter interactome maps and disease-risk association. Science. 2019;366:1134&#x2013;1139.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7028213</ArticleId><ArticleId IdType="pubmed">31727856</ArticleId></ArticleIdList></Reference><Reference><Citation>Rathore N, et al. Paired Immunoglobulin-like Type 2 Receptor Alpha G78R variant alters ligand binding and confers protection to Alzheimer&#x2019;s disease. PLoS Genet. 2018;14:e1007427.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6235402</ArticleId><ArticleId IdType="pubmed">30388101</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan G, et al. CD33 modulates TREM2: convergence of Alzheimer loci. Nat Neurosci. 2015;18:1556&#x2013;1558.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4682915</ArticleId><ArticleId IdType="pubmed">26414614</ArticleId></ArticleIdList></Reference><Reference><Citation>Raj T, et al. CD33: increased inclusion of exon 2 implicates the Ig V-set domain in Alzheimer&#x2019;s disease susceptibility. Hum Mol Genet. 2014;23:2729&#x2013;2736.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3990171</ArticleId><ArticleId IdType="pubmed">24381305</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, et al. Variant of TREM2 associated with the risk of Alzheimer&#x2019;s disease. N Engl J Med. 2013;368:107&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Claes C, et al. Human stem cell-derived monocytes and microglia-like cells reveal impaired amyloid plaque clearance upon heterozygous or homozygous loss of TREM2. Alzheimers Dement. 2019;15:453&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pubmed">30442540</ArticleId></ArticleIdList></Reference><Reference><Citation>Wellcome Trust Case Control Consortium et al. Bayesian refinement of association signals for 14 loci in 3 common diseases. Nat Genet. 2012;44:1294&#x2013;1301.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3791416</ArticleId><ArticleId IdType="pubmed">23104008</ArticleId></ArticleIdList></Reference><Reference><Citation>Benner C, et al. FINEMAP: efficient variable selection using summary data from genome-wide association studies. Bioinformatics. 2016;32:1493&#x2013;1501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4866522</ArticleId><ArticleId IdType="pubmed">26773131</ArticleId></ArticleIdList></Reference><Reference><Citation>Kichaev G, et al. Integrating functional data to prioritize causal variants in statistical fine-mapping studies. PLoS Genet. 2014;10:e1004722.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4214605</ArticleId><ArticleId IdType="pubmed">25357204</ArticleId></ArticleIdList></Reference><Reference><Citation>Benner C, et al. Prospects of fine-mapping trait-associated genomic regions by using summary statistics from genome-wide association studies. Am J Hum Genet. 2017;101:539&#x2013;551.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5630179</ArticleId><ArticleId IdType="pubmed">28942963</ArticleId></ArticleIdList></Reference><Reference><Citation>Gosselin D, et al. An environment-dependent transcriptional network specifies human microglia identity. Science. 2017;356 eaal3222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5858585</ArticleId><ArticleId IdType="pubmed">28546318</ArticleId></ArticleIdList></Reference><Reference><Citation>Alasoo K, et al. Shared genetic effects on chromatin and gene expression indicate a role for enhancer priming in immune response. Nat Genet. 2018;50:424&#x2013;431.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6548559</ArticleId><ArticleId IdType="pubmed">29379200</ArticleId></ArticleIdList></Reference><Reference><Citation>Roadmap Epigenomics Consortium et al. Integrative analysis of 111 reference human epigenomes. Nature. 2015;518:317&#x2013;330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4530010</ArticleId><ArticleId IdType="pubmed">25693563</ArticleId></ArticleIdList></Reference><Reference><Citation>McLaren W, et al. The Ensembl Variant Effect Predictor. Genome Biol. 2016;17:122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4893825</ArticleId><ArticleId IdType="pubmed">27268795</ArticleId></ArticleIdList></Reference><Reference><Citation>Davydov EV, et al. Identifying a high fraction of the human genome to be under selective constraint using GERP++ PLoS Comput Biol. 2010;6:e1001025.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2996323</ArticleId><ArticleId IdType="pubmed">21152010</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J, Troyanskaya OG. Predicting effects of noncoding variants with deep learning-based sequence model. Nat Methods. 2015;12:931&#x2013;934.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4768299</ArticleId><ArticleId IdType="pubmed">26301843</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaganathan K, et al. Predicting splicing from primary sequence with deep learning. Cell. 2019;176:535&#x2013;548.e24.</Citation><ArticleIdList><ArticleId IdType="pubmed">30661751</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinberg S, et al. Loss-of-function variants in ABCA7 confer risk of Alzheimer&#x2019;s disease. Nat Genet. 2015;47:445&#x2013;447.</Citation><ArticleIdList><ArticleId IdType="pubmed">25807283</ArticleId></ArticleIdList></Reference><Reference><Citation>De Roeck A, et al. An intronic VNTR affects splicing of ABCA7 and increases risk of Alzheimer&#x2019;s disease. Acta Neuropathol. 2018;135:827&#x2013;837.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5954066</ArticleId><ArticleId IdType="pubmed">29589097</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernstein AI, et al. 5-Hydroxymethylation-associated epigenetic modifiers of Alzheimer&#x2019;s disease modulate Tau-induced neurotoxicity. Hum Mol Genet. 2016;25:2437&#x2013;2450.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5181627</ArticleId><ArticleId IdType="pubmed">27060332</ArticleId></ArticleIdList></Reference><Reference><Citation>Witoelar A, et al. Meta-analysis of Alzheimer&#x2019;s disease on 9,751 samples from Norway and IGAP study identifies four risk loci. Sci Rep. 2018;8:18088.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6308232</ArticleId><ArticleId IdType="pubmed">30591712</ArticleId></ArticleIdList></Reference><Reference><Citation>Jun GR, et al. Transethnic genome-wide scan identifies novel Alzheimer&#x2019;s disease loci. Alzheimers Dement. 2017;13:727&#x2013;738.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5496797</ArticleId><ArticleId IdType="pubmed">28183528</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen OM, Rudolph I-M, Willnow TE. Risk factor SORL1: from genetic association to functional validation in Alzheimer&#x2019;s disease. Acta Neuropathol. 2016;132:653&#x2013;665.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5073117</ArticleId><ArticleId IdType="pubmed">27638701</ArticleId></ArticleIdList></Reference><Reference><Citation>Sassi C, et al. Influence of coding variability in APP-A&#x3b2; metabolism genes in sporadic Alzheimer&#x2019;s disease. PLoS One. 2016;11:e0150079.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4889076</ArticleId><ArticleId IdType="pubmed">27249223</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Q, et al. Systematic tissue-specific functional annotation of the human genome highlights immune-related DNA elements for late-onset Alzheimer&#x2019;s disease. PLoS Genet. 2017;13:e1006933.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5546707</ArticleId><ArticleId IdType="pubmed">28742084</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghanbari M, et al. A functional variant in the miR&#x2010;142 promoter modulating its expression and conferring risk of Alzheimer disease. Hum Mutat. 2019;40:2131&#x2013;2145.</Citation><ArticleIdList><ArticleId IdType="pubmed">31322790</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung C-M, et al. Fine-mapping angiotensin-converting enzyme gene: separate QTLs identified for hypertension and for ACE activity. PLoS One. 2013;8:e56119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3587614</ArticleId><ArticleId IdType="pubmed">23469169</ArticleId></ArticleIdList></Reference><Reference><Citation>Nylocks KM, et al. An angiotensin-converting enzyme (ACE) polymorphism may mitigate the effects of angiotensin-pathway medications on posttraumatic stress symptoms. Am J Med Genet B Neuropsychiatr Genet. 2015;168B:307&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pubmed">25921615</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamboh MI, et al. Genome-wide association study of Alzheimer&#x2019;s disease. Transl Psychiatry. 2012;2:e117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3365264</ArticleId><ArticleId IdType="pubmed">22832961</ArticleId></ArticleIdList></Reference><Reference><Citation>Canela-Xandri O, Rawlik K, Tenesa A. An atlas of genetic associations in UK Biobank. Nat Genet. 2018;50:1593&#x2013;1599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6707814</ArticleId><ArticleId IdType="pubmed">30349118</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu JZ, et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet. 2015;47:979&#x2013;986.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4881818</ArticleId><ArticleId IdType="pubmed">26192919</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanoisel&#xe9;e H-M, et al. APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases. PLoS Med. 2017;14:e1002270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5370101</ArticleId><ArticleId IdType="pubmed">28350801</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang H, et al. A genetics-led approach defines the drug target landscape of 30 immune-related traits. Nat Genet. 2019;51:1082&#x2013;1091.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7124888</ArticleId><ArticleId IdType="pubmed">31253980</ArticleId></ArticleIdList></Reference><Reference><Citation>Amin L, Harris DA. A&#x3b2; receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers. bioRxiv. 2019 doi: 10.1101/822361.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/822361</ArticleId><ArticleId IdType="pmc">PMC8187732</ArticleId><ArticleId IdType="pubmed">34103486</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordestgaard LT, Tybj&#xe6;rg-Hansen A, Nordestgaard BG, Frikke-Schmidt R. Loss-of-function mutation in ABCA1 and risk of Alzheimer&#x2019;s disease and cerebrovascular disease. Alzheimers Dement. 2015;11:1430&#x2013;1438.</Citation><ArticleIdList><ArticleId IdType="pubmed">26079414</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodge RD, et al. Conserved cell types with divergent features in human versus mouse cortex. Nature. 2019;573:61&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6919571</ArticleId><ArticleId IdType="pubmed">31435019</ArticleId></ArticleIdList></Reference><Reference><Citation>Pickrell JK. Joint analysis of functional genomic data and genome-wide association studies of 18 human traits. Am JHum Genet. 2014;94:559&#x2013;573.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3980523</ArticleId><ArticleId IdType="pubmed">24702953</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakken TE, et al. Evolution of cellular diversity in primary motor cortex of human, marmoset monkey, and mouse. bioRxiv. 2020 doi: 10.1101/2020.03.31.016972.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.03.31.016972</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang D, et al. A meta-analysis of genome-wide association studies identifies 17 new Parkinson&#x2019;s disease risk loci. Nat Genet. 2017;49:1511&#x2013;1516.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5812477</ArticleId><ArticleId IdType="pubmed">28892059</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukherjee S, Klaus C, Pricop-Jeckstadt M, Miller JA, Struebing FL. A microglial signature directing human aging and neurodegeneration-related gene networks. Front Neurosci. 2019;13:2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6353788</ArticleId><ArticleId IdType="pubmed">30733664</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, et al. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer&#x2019;s disease. Cell. 2013;153:707&#x2013;720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677161</ArticleId><ArticleId IdType="pubmed">23622250</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel KR, et al. Single cell-type integrative network modeling identified novel microglial-specific targets for the phagosome in Alzheimer&#x2019;s disease. bioRxiv. 2020 doi: 10.1101/2020.06.09.143529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.06.09.143529</ArticleId></ArticleIdList></Reference><Reference><Citation>Novikova G, et al. Integration of Alzheimer&#x2019;s disease genetics and myeloid genomics reveals novel disease risk mechanisms. bioRxiv. 2019 doi: 10.1101/694281.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/694281</ArticleId></ArticleIdList></Reference><Reference><Citation>Battle A, et al. Characterizing the genetic basis of transcriptome diversity through RNA-sequencing of 922 individuals. Genome Res. 2014;24:14&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3875855</ArticleId><ArticleId IdType="pubmed">24092820</ArticleId></ArticleIdList></Reference><Reference><Citation>Biundo F, Ishiwari K, Del Prete D, D&#x2019;Adamio L. Deletion of the &#x3b3;-secretase subunits Aph1B/C impairs memory and worsens the deficits of knock-in mice modeling the Alzheimer-like familial Danish dementia. Oncotarget. 2016;7:11923&#x2013;11944.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4914259</ArticleId><ArticleId IdType="pubmed">26942869</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolas G, et al. Somatic variants in autosomal dominant genes are a rare cause of sporadic Alzheimer&#x2019;s disease. Alzheimers Dement. 2018;14:1632&#x2013;1639.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6544509</ArticleId><ArticleId IdType="pubmed">30114415</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, et al. Negative evidence for a role of APH1B T27I variant in Alzheimer&#x2019;s disease. Hum Mol Genet. 2020;29:955&#x2013;966.</Citation><ArticleIdList><ArticleId IdType="pubmed">31995180</ArticleId></ArticleIdList></Reference><Reference><Citation>Acx H, et al. Inactivation of &#x3b3;-secretases leads to accumulation of substrates and non-Alzheimer neurodegeneration. EMBO Mol Med. 2017;9:1088&#x2013;1099.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5538297</ArticleId><ArticleId IdType="pubmed">28588032</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthews AL, et al. Regulation of leukocytes by TspanC8 tetraspanins and the &#x2018;molecular scissor&#x2019; ADAM10. Front Immunol. 2018;9:1451.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6036176</ArticleId><ArticleId IdType="pubmed">30013551</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlepckow K, et al. An Alzheimer&#x2010;associated TREM2 variant occurs at the ADAM cleavage site and affects shedding and phagocytic function. EMBO Mol Med. 2017;9:1356&#x2013;1365.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5623859</ArticleId><ArticleId IdType="pubmed">28855300</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohkura T, et al. Spred2 regulates high fat diet-induced adipose tissue inflammation, and metabolic abnormalities in mice. Front Immunol. 2019;10:17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6349710</ArticleId><ArticleId IdType="pubmed">30723473</ArticleId></ArticleIdList></Reference><Reference><Citation>Juul Rasmussen I, Tybj&#xe6;rg-Hansen A, Rasmussen KL, Nordestgaard BG, Frikke-Schmidt R. Blood-brain barrier transcytosis genes, risk of dementia and stroke: a prospective cohort study of 74,754 individuals. Eur J Epidemiol. 2019;34:579&#x2013;590.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6497814</ArticleId><ArticleId IdType="pubmed">30830563</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J, et al. Rare 3-O-sulfation of heparan sulfate enhances Tau interaction and cellular uptake. Angew Chem Int Ed Engl. 2020;59:1818&#x2013;1827.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6982596</ArticleId><ArticleId IdType="pubmed">31692167</ArticleId></ArticleIdList></Reference><Reference><Citation>Bycroft C, et al. The UK Biobank resource with deep phenotyping and genomic data. Nature. 2018;562:203&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6786975</ArticleId><ArticleId IdType="pubmed">30305743</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellenguez C, et al. A robust clustering algorithm for identifying problematic samples in genome-wide association studies. Bioinformatics. 2012;28:134&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3244763</ArticleId><ArticleId IdType="pubmed">22057162</ArticleId></ArticleIdList></Reference><Reference><Citation>Manichaikul A, et al. Robust relationship inference in genome-wide association studies. Bioinformatics. 2010;26:2867&#x2013;2873.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3025716</ArticleId><ArticleId IdType="pubmed">20926424</ArticleId></ArticleIdList></Reference><Reference><Citation>Loh P-R, et al. Efficient Bayesian mixed-model analysis increases association power in large cohorts. Nat Genet. 2015;47:284&#x2013;290.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4342297</ArticleId><ArticleId IdType="pubmed">25642633</ArticleId></ArticleIdList></Reference><Reference><Citation>Pirinen M, Donnelly P, Spencer CCA. Efficient computation with a linear mixed model on large-scale data sets with applications to genetic studies. Ann Applied Stat. 2013;7:369&#x2013;390.</Citation></Reference><Reference><Citation>Zhao H, et al. CrossMap: a versatile tool for coordinate conversion between genome assemblies. Bioinformatics. 2014;30:1006&#x2013;1007.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3967108</ArticleId><ArticleId IdType="pubmed">24351709</ArticleId></ArticleIdList></Reference><Reference><Citation>Wakefield J. Bayes factors for genome-wide association studies: comparison with P-values. Genet Epidemiol. 2009;33:79&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">18642345</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumasaka N, Knights AJ, Gaffney DJ. Fine-mapping cellular QTLs with RASQUAL and ATAC-seq. Nat Genet. 2016;48:206&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5098600</ArticleId><ArticleId IdType="pubmed">26656845</ArticleId></ArticleIdList></Reference><Reference><Citation>Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics. 2010;26:841&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2832824</ArticleId><ArticleId IdType="pubmed">20110278</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersson R, et al. An atlas of active enhancers across human cell types and tissues. Nature. 2014;507:455&#x2013;461.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5215096</ArticleId><ArticleId IdType="pubmed">24670763</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics. 2010;26:589&#x2013;595.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2828108</ArticleId><ArticleId IdType="pubmed">20080505</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, et al. Model-based analysis of ChIP-Seq (MACS) Genome Biol. 2008;9:R137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2592715</ArticleId><ArticleId IdType="pubmed">18798982</ArticleId></ArticleIdList></Reference><Reference><Citation>Alasoo K. wiggleplotr: Make read coverage plots from BigWig files. R package version 1101. 2019</Citation></Reference><Reference><Citation>Orchard S, et al. The MIntAct project&#x2014;IntAct as a common curation platform for 11 molecular interaction databases. Nucleic Acids Res. 2014;42:D358&#x2013;D363.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3965093</ArticleId><ArticleId IdType="pubmed">24234451</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatr-Aryamontri A, et al. The BioGRID interaction database: 2017 update. Nucleic Acids Res. 2017;45:D369&#x2013;D379.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5210573</ArticleId><ArticleId IdType="pubmed">27980099</ArticleId></ArticleIdList></Reference><Reference><Citation>Szklarczyk D, et al. The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res. 2017;45:D362&#x2013;D368.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5210637</ArticleId><ArticleId IdType="pubmed">27924014</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogaras D, R&#xe1;cz B, Csalog&#xe1;ny K, Sarl&#xf3;s T. Towards scaling fully personalized PageRank: algorithms, lower bounds, and experiments. Internet Mathematics. 2005;2:333&#x2013;358.</Citation></Reference><Reference><Citation>Csardi G, Nepusz T. The igraph software package for complex network research. Inter Journal, Complex Systems. 2006;1695:1&#x2013;9. Others.</Citation></Reference><Reference><Citation>Raudvere U, et al. g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update) Nucleic Acids Res. 2019;47:W191&#x2013;W198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6602461</ArticleId><ArticleId IdType="pubmed">31066453</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbeira AN, et al. Widespread dose-dependent effects of RNA expression and splicing on complex diseases and traits. bioRxiv. 2019 doi: 10.1101/814350.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/814350</ArticleId></ArticleIdList></Reference><Reference><Citation>Stacey D, et al. ProGeM: a framework for the prioritization of candidate causal genes at molecular quantitative trait loci. Nucleic Acids Res. 2019;47:e3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6326795</ArticleId><ArticleId IdType="pubmed">30239796</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw. 2010;33:1&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2929880</ArticleId><ArticleId IdType="pubmed">20808728</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33589835</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>29</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>3</Issue><PubDate><Year>2021</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Reactive astrocyte nomenclature, definitions, and future directions.</ArticleTitle><Pagination><StartPage>312</StartPage><EndPage>325</EndPage><MedlinePgn>312-325</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41593-020-00783-4</ELocationID><Abstract><AbstractText>Reactive astrocytes are astrocytes undergoing morphological, molecular, and functional remodeling in response to injury, disease, or infection of the CNS. Although this remodeling was first described over a century ago, uncertainties and controversies remain regarding the contribution of reactive astrocytes to CNS diseases, repair, and aging. It is also unclear whether fixed categories of reactive astrocytes exist and, if so, how to identify them. We point out the shortcomings of binary divisions of reactive astrocytes into good-vs-bad, neurotoxic-vs-neuroprotective or A1-vs-A2. We advocate, instead, that research on reactive astrocytes include assessment of multiple molecular and functional parameters-preferably in vivo-plus multivariate statistics and determination of impact on pathological hallmarks in relevant models. These guidelines may spur the discovery of astrocyte-based biomarkers as well as astrocyte-targeting therapies that abrogate detrimental actions of reactive astrocytes, potentiate their neuro- and glioprotective actions, and restore or augment their homeostatic, modulatory, and defensive functions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Escartin</LastName><ForeName>Carole</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-3613-4118</Identifier><AffiliationInfo><Affiliation>Universit&#xe9; Paris-Saclay, CEA, CNRS, MIRCen, Laboratoire des Maladies Neurod&#xe9;g&#xe9;n&#xe9;ratives, Fontenay-aux-Roses, France. carole.escartin@cea.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galea</LastName><ForeName>Elena</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-4537-9897</Identifier><AffiliationInfo><Affiliation>Institut de Neuroci&#xe8;ncies and Departament de Bioqu&#xed;mica i Biologia Molecular, Unitat de Bioqu&#xed;mica de Medicina, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain. Elena.Galea@uab.es.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>ICREA, Barcelona, Spain. Elena.Galea@uab.es.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Lakatos</LastName><ForeName>Andr&#xe1;s</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-1301-2292</Identifier><AffiliationInfo><Affiliation>John van Geest Centre for Brain Repair and Division of Stem Cell Neurobiology, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wellcome Trust-MRC Cambridge Stem Cell Institute, Cambridge Biomedical Campus, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>O'Callaghan</LastName><ForeName>James P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Health Effects Laboratory Division, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, Morgantown, West Virginia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Petzold</LastName><ForeName>Gabor C</ForeName><Initials>GC</Initials><Identifier Source="ORCID">0000-0002-0145-8641</Identifier><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Vascular Neurology, Department of Neurology, University Hospital Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Serrano-Pozo</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-0899-7530</Identifier><AffiliationInfo><Affiliation>Alzheimer Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Steinh&#xe4;user</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Cellular Neurosciences, Medical Faculty, University of Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Volterra</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1069-1602</Identifier><AffiliationInfo><Affiliation>Department of Fundamental Neuroscience, University of Lausanne, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Carmignoto</LastName><ForeName>Giorgio</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Neuroscience Institute, Italian National Research Council (CNR), Padua, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Sciences, University of Padua, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agarwal</LastName><ForeName>Amit</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>The Chica and Heinz Schaller Research Group, Institute for Anatomy and Cell Biology, Heidelberg University, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allen</LastName><ForeName>Nicola J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Salk Institute for Biological Studies, Molecular Neurobiology Laboratory, La Jolla, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Araque</LastName><ForeName>Alfonso</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-3840-1144</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barbeito</LastName><ForeName>Luis</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-3047-232X</Identifier><AffiliationInfo><Affiliation>Institut Pasteur de Montevideo, Montevideo, Uruguay.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barzilai</LastName><ForeName>Ari</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, George S. Wise, Faculty of Life Sciences and Sagol School of Neuroscience, Tel Aviv University, Ramat Aviv Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bergles</LastName><ForeName>Dwight E</ForeName><Initials>DE</Initials><AffiliationInfo><Affiliation>The Solomon H. Snyder Department of Neuroscience, Kavli Neuroscience Discovery Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonvento</LastName><ForeName>Gilles</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-2886-4228</Identifier><AffiliationInfo><Affiliation>Universit&#xe9; Paris-Saclay, CEA, CNRS, MIRCen, Laboratoire des Maladies Neurod&#xe9;g&#xe9;n&#xe9;ratives, Fontenay-aux-Roses, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Butt</LastName><ForeName>Arthur M</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0000-0001-7579-0746</Identifier><AffiliationInfo><Affiliation>School of Pharmacy and Biomedical Science, University of Portsmouth, Portsmouth, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Wei-Ting</ForeName><Initials>WT</Initials><AffiliationInfo><Affiliation>Center for Brain and Disease Research, VIB and University of Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohen-Salmon</LastName><ForeName>Martine</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>'Physiology and Physiopathology of the Gliovascular Unit' Research Group, Center for Interdisciplinary Research in Biology (CIRB), College de France, Unit&#xe9; Mixte de Recherche 7241 CNRS, Unit&#xe9;1050 INSERM, PSL Research University, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cunningham</LastName><ForeName>Colm</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Trinity Biomedical Sciences Institute &amp; Trinity College Institute of Neuroscience, School of Biochemistry &amp; Immunology, Trinity College Dublin, Dublin, Republic of Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deneen</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-6335-1081</Identifier><AffiliationInfo><Affiliation>Center for Cell and Gene Therapy, Department of Neurosurgery, Baylor College of Medicine, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Strooper</LastName><ForeName>Bart</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Center for Brain and Disease Research, VIB and University of Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute at the University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D&#xed;az-Castro</LastName><ForeName>Blanca</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>UK Dementia Research Institute at the University of Edinburgh, Centre for Discovery Brain Sciences, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farina</LastName><ForeName>Cinthia</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-4466-9676</Identifier><AffiliationInfo><Affiliation>Institute of Experimental Neurology (INSpe) and Division of Neuroscience, San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Freeman</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Vollum Institute, OHSU, Portland, Oregon, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gallo</LastName><ForeName>Vittorio</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-2429-0845</Identifier><AffiliationInfo><Affiliation>Center for Neuroscience Research, Children's National Research Institute, Children's National Hospital, Washington DC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldman</LastName><ForeName>James E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Department of Pathology &amp; Cell Biology, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldman</LastName><ForeName>Steven A</ForeName><Initials>SA</Initials><Identifier Source="ORCID">0000-0002-5498-4303</Identifier><AffiliationInfo><Affiliation>University of Rochester Medical Center, Rochester, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Translational Neuromedicine, University of Copenhagen Faculty of Health and Medical Science and Rigshospitalet, Kobenhavn N, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf6;tz</LastName><ForeName>Magdalena</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-1551-9203</Identifier><AffiliationInfo><Affiliation>Physiological Genomics, Biomedical Center, Ludwig-Maximilians-Universitaet &amp; Institute of Stem Cell Research, Helmholtz Center Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Synergy, Excellence Cluster of Systems Neurology, Biomedical Center, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guti&#xe9;rrez</LastName><ForeName>Antonia</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-6264-6152</Identifier><AffiliationInfo><Affiliation>Dpto. Biolog&#xed;a Celular, Gen&#xe9;tica y Fisiolog&#xed;a, Instituto de Investigaci&#xf3;n Biom&#xe9;dica de M&#xe1;laga-IBIMA, Facultad de Ciencias, Universidad de M&#xe1;laga, M&#xe1;laga, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haydon</LastName><ForeName>Philip G</ForeName><Initials>PG</Initials><Identifier Source="ORCID">0000-0001-5698-6698</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Tufts University School of Medicine, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heiland</LastName><ForeName>Dieter H</ForeName><Initials>DH</Initials><Identifier Source="ORCID">0000-0002-9258-3033</Identifier><AffiliationInfo><Affiliation>Microenvironment and Immunology Research Laboratory, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosurgery, Medical Center, University of Freiburg, Faculty of Medicine, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hol</LastName><ForeName>Elly M</ForeName><Initials>EM</Initials><Identifier Source="ORCID">0000-0001-5604-2603</Identifier><AffiliationInfo><Affiliation>Department of Translational Neuroscience, University Medical Center Utrecht Brain Center, Utrecht University, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holt</LastName><ForeName>Matthew G</ForeName><Initials>MG</Initials><Identifier Source="ORCID">0000-0002-8958-4027</Identifier><AffiliationInfo><Affiliation>Laboratory of Glia Biology, VIB-KU Leuven Center for Brain and Disease Research, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iino</LastName><ForeName>Masamitsu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Cellular and Molecular Pharmacology, Nihon University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kastanenka</LastName><ForeName>Ksenia V</ForeName><Initials>KV</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kettenmann</LastName><ForeName>Helmut</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Cellular Neurosciences, Max Delbr&#xfc;ck Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khakh</LastName><ForeName>Baljit S</ForeName><Initials>BS</Initials><AffiliationInfo><Affiliation>Department of Physiology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koizumi</LastName><ForeName>Schuichi</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-6184-3106</Identifier><AffiliationInfo><Affiliation>Department of Neuropharmacology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>C Justin</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Center for Cognition and Sociality, Institute for Basic Science 55, Expo-ro, Yuseong-gu, Daejeon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liddelow</LastName><ForeName>Shane A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Neuroscience Institute, Department of Neuroscience and Physiology, Department of Ophthalmology, NYU School of Medicine, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>MacVicar</LastName><ForeName>Brian A</ForeName><Initials>BA</Initials><Identifier Source="ORCID">0000-0003-4596-4623</Identifier><AffiliationInfo><Affiliation>Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Magistretti</LastName><ForeName>Pierre</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Division of Biological and Environmental Sciences and Engineering, King Abdullah University of Science and Technology (KAUST), Thuwal, Saudi Arabia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre de Neurosciences Psychiatriques, University of Lausanne and CHUV, Site de Cery, Prilly-Lausanne, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Messing</LastName><ForeName>Albee</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Waisman Center and School of Veterinary Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mishra</LastName><ForeName>Anusha</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-3642-5049</Identifier><AffiliationInfo><Affiliation>Department of Neurology Jungers Center for Neurosciences Research and Knight Cardiovascular Institute, Oregon Health &amp; Science University, Portland, Oregon, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molofsky</LastName><ForeName>Anna V</ForeName><Initials>AV</Initials><Identifier Source="ORCID">0000-0002-4709-2411</Identifier><AffiliationInfo><Affiliation>Departments of Psychiatry/Weill Institute for Neuroscience University of California, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murai</LastName><ForeName>Keith K</ForeName><Initials>KK</Initials><AffiliationInfo><Affiliation>Centre for Research in Neuroscience, Department of Neurology &amp; Neurosurgery, Brain Repair and Integrative Neuroscience Program, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Norris</LastName><ForeName>Christopher M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Sanders-Brown Center on Aging, University of Kentucky College of Medicine, Lexington, Kentucky, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okada</LastName><ForeName>Seiji</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-5107-8209</Identifier><AffiliationInfo><Affiliation>Department of Immunobiology and Neuroscience, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oliet</LastName><ForeName>St&#xe9;phane H R</ForeName><Initials>SHR</Initials><AffiliationInfo><Affiliation>Universit&#xe9; de Bordeaux, Inserm, Neurocentre Magendie, U1215, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oliveira</LastName><ForeName>Jo&#xe3;o F</ForeName><Initials>JF</Initials><Identifier Source="ORCID">0000-0002-1005-2328</Identifier><AffiliationInfo><Affiliation>Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>ICVS/3B's -PT Government Associate Laboratory, Braga/Guimar&#xe3;es, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IPCA-EST-2Ai, Polytechnic Institute of C&#xe1;vado and Ave, Applied Artificial Intelligence Laboratory, Campus of IPCA, Barcelos, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Panatier</LastName><ForeName>Aude</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-6107-4463</Identifier><AffiliationInfo><Affiliation>Universit&#xe9; de Bordeaux, Inserm, Neurocentre Magendie, U1215, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parpura</LastName><ForeName>Vladimir</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, The University of Alabama at Birmingham, Birmingham, Alabama, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pekna</LastName><ForeName>Marcela</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2734-8237</Identifier><AffiliationInfo><Affiliation>Laboratory of Regenerative Neuroimmunology, Center for Brain Repair, Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pekny</LastName><ForeName>Milos</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory of Astrocyte Biology and CNS Regeneration, Center for Brain Repair, Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pellerin</LastName><ForeName>Luc</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>INSERM U1082, Universit&#xe9; de Poitiers, Poitiers, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perea</LastName><ForeName>Gertrudis</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-5924-9175</Identifier><AffiliationInfo><Affiliation>Department of Functional and Systems Neurobiology, Cajal Institute, CSIC, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>P&#xe9;rez-Nievas</LastName><ForeName>Beatriz G</ForeName><Initials>BG</Initials><AffiliationInfo><Affiliation>Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pfrieger</LastName><ForeName>Frank W</ForeName><Initials>FW</Initials><Identifier Source="ORCID">0000-0001-7085-1431</Identifier><AffiliationInfo><Affiliation>Centre National de la Recherche Scientifique, Universit&#xe9; de Strasbourg, Institut des Neurosciences Cellulaires et Int&#xe9;gratives, Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poskanzer</LastName><ForeName>Kira E</ForeName><Initials>KE</Initials><Identifier Source="ORCID">0000-0003-4830-8891</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry &amp; Biophysics, Kavli Institute for Fundamental Neuroscience, University of California, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quintana</LastName><ForeName>Francisco J</ForeName><Initials>FJ</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School. Associate Member, The Broad Institute, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ransohoff</LastName><ForeName>Richard M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Third Rock Ventures, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riquelme-Perez</LastName><ForeName>Miriam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Paris-Saclay, CEA, CNRS, MIRCen, Laboratoire des Maladies Neurod&#xe9;g&#xe9;n&#xe9;ratives, Fontenay-aux-Roses, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robel</LastName><ForeName>Stefanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Fralin Biomedical Research Institute at Virginia Tech Carilion, School of Neuroscience Virginia Tech, Riverside Circle, Roanoke, Virginia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rose</LastName><ForeName>Christine R</ForeName><Initials>CR</Initials><Identifier Source="ORCID">0000-0002-9684-3592</Identifier><AffiliationInfo><Affiliation>Institute of Neurobiology, Heinrich Heine University, D&#xfc;sseldorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rothstein</LastName><ForeName>Jeffrey D</ForeName><Initials>JD</Initials><Identifier Source="ORCID">0000-0003-2001-8470</Identifier><AffiliationInfo><Affiliation>Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rouach</LastName><ForeName>Nathalie</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-5574-888X</Identifier><AffiliationInfo><Affiliation>Neuroglial Interactions in Cerebral Physiology and Pathologies, Center for Interdisciplinary Research in Biology, Coll&#xe8;ge de France, CNRS UMR 7241, INSERM U1050, Labex Memolife, PSL Research University Paris, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rowitch</LastName><ForeName>David H</ForeName><Initials>DH</Initials><Identifier Source="ORCID">0000-0002-0079-0060</Identifier><AffiliationInfo><Affiliation>Wellcome Trust-MRC Cambridge Stem Cell Institute, Cambridge Biomedical Campus, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Semyanov</LastName><ForeName>Alexey</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-6800-0942</Identifier><AffiliationInfo><Affiliation>Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Moscow, Russia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sechenov First Moscow State Medical University, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sirko</LastName><ForeName>Swetlana</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-5950-616X</Identifier><AffiliationInfo><Affiliation>Physiological Genomics, Biomedical Center, LMU Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Stem Cell Research, Helmholtz Zentrum Munich, Neuherberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sontheimer</LastName><ForeName>Harald</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-5843-9871</Identifier><AffiliationInfo><Affiliation>Virginia Tech School of Neuroscience and Center for Glial Biology in Health, Disease and Cancer, Virginia Tech at the Fralin Biomedical Research Institute, Roanoke, Virginia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swanson</LastName><ForeName>Raymond A</ForeName><Initials>RA</Initials><Identifier Source="ORCID">0000-0002-3664-5359</Identifier><AffiliationInfo><Affiliation>Dept. of Neurology, University of California San Francisco and San Francisco Veterans Affairs Health Care System, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vitorica</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dept. Bioqu&#xed;mica y Biolog&#xed;a Molecular, Instituto de Biomedicina de Sevilla, Universidad de Sevilla, Hospital Virgen del Roc&#xed;o/CSIC, Sevilla, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wanner</LastName><ForeName>Ina-Beate</ForeName><Initials>IB</Initials><AffiliationInfo><Affiliation>Semel Institute for Neuroscience &amp; Human Behavior, IDDRC, David Geffen School of Medicine, UCLA, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wood</LastName><ForeName>Levi B</ForeName><Initials>LB</Initials><AffiliationInfo><Affiliation>George W. Woodruff School of Mechanical Engineering, Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory, and Parker H. Petit Institute for Bioengineering &amp; Bioscience, Georgia Institute of Technology, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Jiaqian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The Vivian L. Smith Department of Neurosurgery, Center for Stem Cell and Regenerative Medicine, MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, McGovern Medical School, UTHealth, University of Texas Health Science Center at Houston, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Binhai</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, UC San Diego School of Medicine, La Jolla; VA San Diego Research Service, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zimmer</LastName><ForeName>Eduardo R</ForeName><Initials>ER</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zorec</LastName><ForeName>Robert</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-7478-3875</Identifier><AffiliationInfo><Affiliation>Laboratory of Neuroendocrinology, Molecular Cell Physiology, Institute of Pathophysiology, University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Celica Biomedical, 1000, Ljubljana, Slovenia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sofroniew</LastName><ForeName>Michael V</ForeName><Initials>MV</Initials><Identifier Source="ORCID">0000-0001-6075-0178</Identifier><AffiliationInfo><Affiliation>Department of Neurobiology, David Geffen School of Medicine, University of California, Los Angeles, California, USA. sofroniew@mednet.ucla.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verkhratsky</LastName><ForeName>Alexei</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-2592-9898</Identifier><AffiliationInfo><Affiliation>Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK. alexej.verkhratsky@manchester.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ach&#xfa;carro Basque Center for Neuroscience, IKERBASQUE, Basque Foundation for Science, Bilbao, Spain. alexej.verkhratsky@manchester.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS110690</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG027297</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG066171</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH104701</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AG060974</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/P008658/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>RF1 AG061774</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG056998</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>CC999999</GrantID><Acronym>ImCDC</Acronym><Agency>Intramural CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS084030</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 AG064039</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MC_PC_17230</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 NS102807</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG054598</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DA048822</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM123971</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS105807</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS036692</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>02</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001927" MajorTopicYN="N">Brain Diseases</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001930" MajorTopicYN="N">Brain Injuries</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013119" MajorTopicYN="N">Spinal Cord Injuries</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>8</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>12</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>2</Month><Day>16</Day><Hour>6</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>3</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33589835</ArticleId><ArticleId IdType="mid">NIHMS1675128</ArticleId><ArticleId IdType="pmc">PMC8007081</ArticleId><ArticleId IdType="doi">10.1038/s41593-020-00783-4</ArticleId><ArticleId IdType="pii">10.1038/s41593-020-00783-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Virchow R Cellular Pathology (De Witt Robert M., 1860).</Citation></Reference><Reference><Citation>Achucarro N Some pathological findings in the neuroglia and in the ganglion cells of the cortex in senile conditions. Bull. Gov. Hosp. Insane 2, 81&#x2013;90 (1910).</Citation></Reference><Reference><Citation>Weigert C Beitr&#xe4;ge zur Kenntnis der normalen menschlichen Neuroglia. in Zeitschrift f&#xfc;r Psychologie und Physiologie der Sinnesorgane (Moritz Diesterweg, 1895).</Citation></Reference><Reference><Citation>Del R&#xed;o-Hortega P &amp; Penfield WG Cerebral cicatrix: The reaction of neuroglia and microglia to brain wounds. Bull. Johns Hopkins Hosp. 41, 278&#x2013;303 (1927).</Citation></Reference><Reference><Citation>Escartin C, Guillemaud O &amp; Carrillo-de Sauvage MA Questions and (some) answers on reactive astrocytes. Glia 67, 2221&#x2013;2247 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31429127</ArticleId></ArticleIdList></Reference><Reference><Citation>Sofroniew MV Astrocyte barriers to neurotoxic inflammation. Nat. Rev. Neurosci. 16, 249&#x2013;263 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5253239</ArticleId><ArticleId IdType="pubmed">25891508</ArticleId></ArticleIdList></Reference><Reference><Citation>Verkhratsky A, Zorec R &amp; Parpura V Stratification of astrocytes in healthy and diseased brain. Brain Pathol 27, 629&#x2013;644 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5599174</ArticleId><ArticleId IdType="pubmed">28805002</ArticleId></ArticleIdList></Reference><Reference><Citation>Messing A, Brenner M, Feany MB, Nedergaard M &amp; Goldman JE Alexander disease. J. Neurosci 32, 5017&#x2013;5023 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3336214</ArticleId><ArticleId IdType="pubmed">22496548</ArticleId></ArticleIdList></Reference><Reference><Citation>Brusilow SW, Koehler RC, Traystman RJ &amp; Cooper AJ Astrocyte glutamine synthetase: importance in hyperammonemic syndromes and potential target for therapy. Neurotherapeutics 7, 452&#x2013;470 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2975543</ArticleId><ArticleId IdType="pubmed">20880508</ArticleId></ArticleIdList></Reference><Reference><Citation>Griemsmann S et al. Characterization of panglial gap junction networks in the thalamus, neocortex, and hippocampus reveals a unique population of glial cells. Cereb. Cortex 25, 3420&#x2013;3433 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4585496</ArticleId><ArticleId IdType="pubmed">25037920</ArticleId></ArticleIdList></Reference><Reference><Citation>Ben Haim L &amp; Rowitch DH Functional diversity of astrocytes in neural circuit regulation. Nat. Rev. Neurosci 18, 31&#x2013;41 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27904142</ArticleId></ArticleIdList></Reference><Reference><Citation>Kriegstein A &amp; Alvarez-Buylla A The glial nature of embryonic and adult neural stem cells. Annu. Rev. Neurosci. 32, 149&#x2013;184 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3086722</ArticleId><ArticleId IdType="pubmed">19555289</ArticleId></ArticleIdList></Reference><Reference><Citation>Roybon L et al. Human stem cell-derived spinal cord astrocytes with defined mature or reactive phenotypes. Cell Rep 4, 1035&#x2013;1048 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4229657</ArticleId><ArticleId IdType="pubmed">23994478</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi D et al. Focal degeneration of astrocytes in amyotrophic lateral sclerosis. Cell Death Differ. 15, 1691&#x2013;1700 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18617894</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez JJ, Terzieva S, Olabarria M, Lanza RG &amp; Verkhratsky A Enriched environment and physical activity reverse astrogliodegeneration in the hippocampus of AD transgenic mice. Cell Death Dis 4, e678 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3702309</ArticleId><ArticleId IdType="pubmed">23788035</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Callaghan JP, Brinton RE &amp; McEwen BS Glucocorticoids regulate the synthesis of glial fibrillary acidic protein in intact and adrenalectomized rats but do not affect its expression following brain injury. J. Neurochem. 57, 860&#x2013;869 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1677678</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano-Pozo A, G&#xf3;mez-Isla T, Growdon JH, Frosch MP &amp; Hyman BT A phenotypic change but not proliferation underlies glial responses in Alzheimer disease. Am. J. Pathol 182, 2332&#x2013;2344 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3668030</ArticleId><ArticleId IdType="pubmed">23602650</ArticleId></ArticleIdList></Reference><Reference><Citation>Sosunov AA et al. Phenotypic heterogeneity and plasticity of isocortical and hippocampal astrocytes in the human brain. J. Neurosci. 34, 2285&#x2013;2298 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3913872</ArticleId><ArticleId IdType="pubmed">24501367</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu X, Nagai J &amp; Khakh BS Improved tools to study astrocytes. Nat. Rev. Neurosci 21, 121&#x2013;138 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32042146</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiweck J, Eickholt BJ &amp; Murk K Important shapeshifter: mechanisms allowing astrocytes to respond to the changing nervous system during development, injury and disease. Front. Cell. Neurosci 12, 261 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6111612</ArticleId><ArticleId IdType="pubmed">30186118</ArticleId></ArticleIdList></Reference><Reference><Citation>Olabarria M, Noristani HN, Verkhratsky A &amp; Rodr&#xed;guez JJ Concomitant astroglial atrophy and astrogliosis in a triple transgenic animal model of Alzheimer&#x2019;s disease. Glia 58, 831&#x2013;838 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20140958</ArticleId></ArticleIdList></Reference><Reference><Citation>Black JA, Newcombe J &amp; Waxman SG Astrocytes within multiple sclerosis lesions upregulate sodium channel Nav1.5. Brain 133, 835&#x2013;846 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20147455</ArticleId></ArticleIdList></Reference><Reference><Citation>Tachibana M et al. Clasmatodendrosis is associated with dendritic spines and does not represent autophagic astrocyte death in influenza-associated encephalopathy. Brain Dev 41, 85&#x2013;95 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30057207</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine J et al. Traumatically injured astrocytes release a proteomic signa ture modulated by STAT3-dependent cell survival. Glia 64, 668&#x2013;694 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4805454</ArticleId><ArticleId IdType="pubmed">26683444</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramon y Cajal S Contribuci&#xf3;n al conocimiento de la neurogl&#xed;a del cerebro humano. Trabajos del Laboratorio de Investigaciones Biol&#xf3;gicas de la Universidad de Madrid 11, 255&#x2013;315 (1913).</Citation></Reference><Reference><Citation>Theis M et al. Accelerated hippocampal spreading depression and enhanced locomotory activity in mice with astrocyte-directed inactivation of connexin43. J. Neurosci 23, 766&#x2013;776 (2003).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741919</ArticleId><ArticleId IdType="pubmed">12574405</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraft AW et al. Attenuating astrocyte activation accelerates plaque pathogenesis in APP/PS1 mice. FASEB J. 27, 187&#x2013;198 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3528309</ArticleId><ArticleId IdType="pubmed">23038755</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L, Emery JF, Ouyang YB, Voloboueva LA &amp; Giffard RG Astrocyte targeted overexpression of Hsp72 or SOD2 reduces neuronal vulnerability to forebrain ischemia. Glia 58, 1042&#x2013;1049 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3108566</ArticleId><ArticleId IdType="pubmed">20235222</ArticleId></ArticleIdList></Reference><Reference><Citation>Furman JL et al. Targeting astrocytes ameliorates neurologic changes in a mouse model of Alzheimer&#x2019;s disease. J. Neurosci. 32, 16129&#x2013;16140 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3506017</ArticleId><ArticleId IdType="pubmed">23152597</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardo L et al. Targeted activation of CREB in reactive astrocytes is neuroprotective in focal acute cortical injury. Glia 64, 853&#x2013;874 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26880229</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceyz&#xe9;riat K et al. Modulation of astrocyte reactivity improves functional deficits in mouse models of Alzheimer&#x2019;s disease. Acta Neuropathol. Commun. 6, 104 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6190663</ArticleId><ArticleId IdType="pubmed">30322407</ArticleId></ArticleIdList></Reference><Reference><Citation>Reichenbach N et al. Inhibition of Stat3-mediated astrogliosis ameliorates pathology in an Alzheimer&#x2019;s disease model. EMBO Mol. Med. 11, e9665 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6365929</ArticleId><ArticleId IdType="pubmed">30617153</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamphuis W et al. GFAP and vimentin deficiency alters gene expression in astrocytes and microglia in wild-type mice and changes the transcriptional response of reactive glia in mouse model for Alzheimer&#x2019;s disease. Glia 63, 1036&#x2013;1056 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25731615</ArticleId></ArticleIdList></Reference><Reference><Citation>Wheeler MA &amp; Quintana FJ Regulation of astrocyte functions in multiple sclerosis. Cold Spring Harb. Perspect. Med 9, a029009 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6314073</ArticleId><ArticleId IdType="pubmed">29358321</ArticleId></ArticleIdList></Reference><Reference><Citation>Colombo E &amp; Farina C Astrocytes: key regulators of neuroinflammation. Trends Immunol 37, 608&#x2013;620 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27443914</ArticleId></ArticleIdList></Reference><Reference><Citation>Nobuta H et al. STAT3-mediated astrogliosis protects myelin development in neonatal brain injury. Ann. Neurol 72, 750&#x2013;765 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3514566</ArticleId><ArticleId IdType="pubmed">22941903</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson MA et al. Astrocyte scar formation aids central nervous system axon regeneration. Nature 532, 195&#x2013;200 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5243141</ArticleId><ArticleId IdType="pubmed">27027288</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrmann JE et al. STAT3 is a critical regulator of astrogliosis and scar formation after spinal cord injury. J. Neurosci 28, 7231&#x2013;7243 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2583788</ArticleId><ArticleId IdType="pubmed">18614693</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyzack GE et al. Astrocyte response to motor neuron injury promotes structural synaptic plasticity via STAT3-regulated TSP-1 expression. Nat. Commun 5, 4294 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4104454</ArticleId><ArticleId IdType="pubmed">25014177</ArticleId></ArticleIdList></Reference><Reference><Citation>Santello M, Toni N &amp; Volterra A Astrocyte function from information processing to cognition and cognitive impairment. Nat. Neurosci 22, 154&#x2013;166 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30664773</ArticleId></ArticleIdList></Reference><Reference><Citation>Semyanov A, Henneberger C &amp; Agarwal A Making sense of astrocytic calcium signals - from acquisition to interpretation. Nat. Rev. Neurosci 21, 551&#x2013;564 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32873937</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang R, Diaz-Castro B, Looger LL &amp; Khakh BS Dysfunctional calcium and glutamate signaling in striatal astrocytes from Huntington&#x2019;s disease model mice. J. Neurosci 36, 3453&#x2013;3470 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4804005</ArticleId><ArticleId IdType="pubmed">27013675</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuchibhotla KV, Lattarulo CR, Hyman BT &amp; Bacskai BJ Synchronous hyperactivity and intercellular calcium waves in astrocytes in Alzheimer mice. Science 323, 1211&#x2013;1215 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2884172</ArticleId><ArticleId IdType="pubmed">19251629</ArticleId></ArticleIdList></Reference><Reference><Citation>Reichenbach N et al. P2Y1 receptor blockade normalizes network dysfunction and cognition in an Alzheimer&#x2019;s disease model. J. Exp. Med 215, 1649&#x2013;1663 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5987918</ArticleId><ArticleId IdType="pubmed">29724785</ArticleId></ArticleIdList></Reference><Reference><Citation>Bedner P et al. Astrocyte uncoupling as a cause of human temporal lobe epilepsy. Brain 138, 1208&#x2013;1222 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5963418</ArticleId><ArticleId IdType="pubmed">25765328</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Arboledas A et al. Phagocytic clearance of presynaptic dystrophies by reactive astrocytes in Alzheimer&#x2019;s disease. Glia 66, 637&#x2013;653 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5814816</ArticleId><ArticleId IdType="pubmed">29178139</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Douce J et al. Impairment of glycolysis-derived L-serine production in astrocytes contributes to cognitive deficits in Alzheimer&#x2019;s disease. Cell Metab 31, 503&#x2013;517.e8 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32130882</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M et al. Lactate deficit in an Alzheimer disease mouse model: the relationship with neuronal damage. J. Neuropathol. Exp. Neurol 77, 1163&#x2013;1176 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30383244</ArticleId></ArticleIdList></Reference><Reference><Citation>Heo JY et al. Aberrant tonic inhibition of dopaminergic neuronal activity causes motor symptoms in animal models of Parkinson&#x2019;s disease. Curr. Biol 30, 276&#x2013;291.e9 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31928877</ArticleId></ArticleIdList></Reference><Reference><Citation>Chai H et al. Neural circuit-specialized astrocytes: transcriptomic, proteomic, morphological, and functional evidence. Neuron 95, 531&#x2013;549.e9 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5811312</ArticleId><ArticleId IdType="pubmed">28712653</ArticleId></ArticleIdList></Reference><Reference><Citation>Orre M et al. Isolation of glia from Alzheimer&#x2019;s mice reveals inflammation and dysfunction. Neurobiol. Aging 35, 2746&#x2013;2760 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25002035</ArticleId></ArticleIdList></Reference><Reference><Citation>Sirko S et al. Astrocyte reactivity after brain injury-: The role of galectins 1 and 3. Glia 63, 2340&#x2013;2361 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5042059</ArticleId><ArticleId IdType="pubmed">26250529</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz-Castro B, Gangwani MR, Yu X, Coppola G &amp; Khakh BS Astrocyte molecular signatures in Huntington&#x2019;s disease. Sci. Transl. Med 11, eaaw8546 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31619545</ArticleId></ArticleIdList></Reference><Reference><Citation>Itoh N et al. Cell-specific and region-specific transcriptomics in the multiple sclerosis model: Focus on astrocytes. Proc. Natl Acad. Sci. USA 115, E302&#x2013;E309 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5777065</ArticleId><ArticleId IdType="pubmed">29279367</ArticleId></ArticleIdList></Reference><Reference><Citation>John Lin CC et al. Identification of diverse astrocyte populations and their malignant analogs. Nat. Neurosci 20, 396&#x2013;405 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5824716</ArticleId><ArticleId IdType="pubmed">28166219</ArticleId></ArticleIdList></Reference><Reference><Citation>Liddelow SA et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541, 481&#x2013;487 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5404890</ArticleId><ArticleId IdType="pubmed">28099414</ArticleId></ArticleIdList></Reference><Reference><Citation>Ransohoff RM A polarizing question: do M1 and M2 microglia exist? Nat. Neurosci 19, 987&#x2013;991 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27459405</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Dalahmah O et al. Single-nucleus RNA-seq identifies Huntington disease astrocyte states. Acta Neuropathol. Commun. 8, 19 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7029580</ArticleId><ArticleId IdType="pubmed">32070434</ArticleId></ArticleIdList></Reference><Reference><Citation>Grubman A et al. A single-cell atlas of entorhinal cortex from individuals with Alzheimer&#x2019;s disease reveals cell-type-specific gene expression regulation. Nat. Neurosci 22, 2087&#x2013;2097 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31768052</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y et al. Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer&#x2019;s disease. Nat. Med 26, 131&#x2013;142 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6980793</ArticleId><ArticleId IdType="pubmed">31932797</ArticleId></ArticleIdList></Reference><Reference><Citation>Das S, Li Z, Noori A, Hyman BT &amp; Serrano-Pozo A Meta-analysis of mouse transcriptomic studies supports a context-dependent astrocyte reaction in acute CNS injury versus neurodegeneration. J. Neuroinflammation 17, 227 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7393869</ArticleId><ArticleId IdType="pubmed">32736565</ArticleId></ArticleIdList></Reference><Reference><Citation>Habib N et al. Disease-associated astrocytes in Alzheimer&#x2019;s disease and aging. Nat. Neurosci 23, 701&#x2013;706 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9262034</ArticleId><ArticleId IdType="pubmed">32341542</ArticleId></ArticleIdList></Reference><Reference><Citation>Henrik Heiland D et al. Tumor-associated reactive astrocytes aid the evolution of immunosuppressive environment in glioblastoma. Nat. Commun 10, 2541 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6559986</ArticleId><ArticleId IdType="pubmed">31186414</ArticleId></ArticleIdList></Reference><Reference><Citation>Varcianna A et al. Micro-RNAs secreted through astrocyte-derived extracellular vesicles cause neuronal network degeneration in C9orf72 ALS. EBioMedicine 40, 626&#x2013;635 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6413467</ArticleId><ArticleId IdType="pubmed">30711519</ArticleId></ArticleIdList></Reference><Reference><Citation>di Domenico A et al. Patient-specific iPSC-derived astrocytes contribute to non-cell-autonomous neurodegeneration in Parkinson&#x2019;s disease. Stem Cell Reports 12, 213&#x2013;229 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6372974</ArticleId><ArticleId IdType="pubmed">30639209</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyzack GE et al. A neuroprotective astrocyte state is induced by neuronal signal EphB1 but fails in ALS models. Nat. Commun 8, 1164 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5660125</ArticleId><ArticleId IdType="pubmed">29079839</ArticleId></ArticleIdList></Reference><Reference><Citation>Ledur PF et al. Zika virus infection leads to mitochondrial failure, oxidative stress and DNA damage in human iPSC-derived astrocytes. Sci. Rep 10, 1218 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6985105</ArticleId><ArticleId IdType="pubmed">31988337</ArticleId></ArticleIdList></Reference><Reference><Citation>Perriot S et al. Human induced pluripotent stem cell-derived astrocytes are differentially activated by multiple sclerosis-associated cytokines. Stem Cell Reports 11, 1199&#x2013;1210 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6234919</ArticleId><ArticleId IdType="pubmed">30409508</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez-Arellano JJ, Parpura V, Zorec R &amp; Verkhratsky A Astrocytes in physiological aging and Alzheimer&#x2019;s disease. Neuroscience 323, 170&#x2013;182 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">25595973</ArticleId></ArticleIdList></Reference><Reference><Citation>Jyothi HJ et al. Aging causes morphological alterations in astrocytes and microglia in human substantia nigra pars compacta. Neurobiol. Aging 36, 3321&#x2013;3333 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26433682</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez JJ et al. Complex and region-specific changes in astroglial markers in the aging brain. Neurobiol. Aging 35, 15&#x2013;23 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">23969179</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerbai F et al. The neuron-astrocyte-microglia triad in normal brain ageing and in a model of neuroinflammation in the rat hippocampus. PLoS One 7, e45250 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3445467</ArticleId><ArticleId IdType="pubmed">23028880</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Callaghan JP &amp; Miller DB The concentration of glial fibrillary acidic protein increases with age in the mouse and rat brain. Neurobiol. Aging 12, 171&#x2013;174 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1904995</ArticleId></ArticleIdList></Reference><Reference><Citation>Boisvert MM, Erikson GA, Shokhirev MN &amp; Allen NJ The aging astrocyte transcriptome from multiple regions of the mouse brain. Cell Rep 22, 269&#x2013;285 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5783200</ArticleId><ArticleId IdType="pubmed">29298427</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke LE et al. Normal aging induces A1-like astrocyte reactivity. Proc. Natl Acad. Sci. USA 115, E1896&#x2013;E1905 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5828643</ArticleId><ArticleId IdType="pubmed">29437957</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters O et al. Astrocyte function is modified by Alzheimer&#x2019;s disease-like pathology in aged mice. J. Alzheimers Dis. 18, 177&#x2013;189 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19584439</ArticleId></ArticleIdList></Reference><Reference><Citation>Childs BG et al. Senescent cells: an emerging target for diseases of ageing. Nat. Rev. Drug Discov. 16, 718&#x2013;735 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5942225</ArticleId><ArticleId IdType="pubmed">28729727</ArticleId></ArticleIdList></Reference><Reference><Citation>Batiuk MY et al. Identification of region-specific astrocyte subtypes at single cell resolution. Nat. Commun 11, 1220 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7058027</ArticleId><ArticleId IdType="pubmed">32139688</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen WT et al. Spatial transcriptomics and in situ sequencing to study Alzheimer&#x2019;s Disease. Cell 182, 976&#x2013;991.e19 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32702314</ArticleId></ArticleIdList></Reference><Reference><Citation>Hennessy E, Griffin EW &amp; Cunningham C Astrocytes are primed by chronic neurodegeneration to produce exaggerated chemokine and cell infiltration responses to acute stimulation with the cytokines IL-1&#x3b2; and TNF-&#x3b1;. J. Neurosci 35, 8411&#x2013;8422 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4452550</ArticleId><ArticleId IdType="pubmed">26041910</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JH et al. Newly developed reversible MAO-B inhibitor circumvents the shortcomings of irreversible inhibitors in Alzheimer&#x2019;s disease. Sci. Adv 5, v0316 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6426469</ArticleId><ArticleId IdType="pubmed">30906861</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuidema JM, Gilbert RJ &amp; Gottipati MK Biomaterial approaches to modulate reactive astroglial response. Cells Tissues Organs 205, 372&#x2013;395 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6397084</ArticleId><ArticleId IdType="pubmed">30517922</ArticleId></ArticleIdList></Reference><Reference><Citation>Bedner P, Jabs R &amp; Steinh&#xe4;user C Properties of human astrocytes and NG2 glia. Glia 68, 756&#x2013;767 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31596522</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberheim NA et al. Uniquely hominid features of adult human astrocytes. J. Neurosci 29, 3276&#x2013;3287 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2819812</ArticleId><ArticleId IdType="pubmed">19279265</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberheim NA, Wang X, Goldman S &amp; Nedergaard M Astrocytic complexity distinguishes the human brain. Trends Neurosci. 29, 547&#x2013;553 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16938356</ArticleId></ArticleIdList></Reference><Reference><Citation>Tchieu J et al. NFIA is a gliogenic switch enabling rapid derivation of functional human astrocytes from pluripotent stem cells. Nat. Biotechnol. 37, 267&#x2013;275 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6591152</ArticleId><ArticleId IdType="pubmed">30804533</ArticleId></ArticleIdList></Reference><Reference><Citation>Sloan SA et al. Human astrocyte maturation captured in 3D cerebral cortical spheroids derived from pluripotent stem cells. Neuron 95, 779&#x2013;790.e6 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5890820</ArticleId><ArticleId IdType="pubmed">28817799</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancaster MA et al. Cerebral organoids model human brain development and microcephaly. Nature 501, 373&#x2013;379 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3817409</ArticleId><ArticleId IdType="pubmed">23995685</ArticleId></ArticleIdList></Reference><Reference><Citation>Quadrato G et al. Cell diversity and network dynamics in photosensitive human brain organoids. Nature 545, 48&#x2013;53 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5659341</ArticleId><ArticleId IdType="pubmed">28445462</ArticleId></ArticleIdList></Reference><Reference><Citation>Giandomenico SL et al. Cerebral organoids at the air-liquid interface generate diverse nerve tracts with functional output. Nat. Neurosci. 22, 669&#x2013;679 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6436729</ArticleId><ArticleId IdType="pubmed">30886407</ArticleId></ArticleIdList></Reference><Reference><Citation>Colombo E et al. Siponimod (BAF312) activates Nrf2 while hampering NF&#x3ba;B in human astrocytes, and protects from astrocyte-induced neurodegeneration. Front. Immunol 11, 635 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7156595</ArticleId><ArticleId IdType="pubmed">32322257</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirbec H et al. Emerging technologies to study glial cells. Glia 68, 1692&#x2013;1728 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31958188</ArticleId></ArticleIdList></Reference><Reference><Citation>Guttenplan KA &amp; Liddelow SA Astrocytes and microglia: Models and tools. J. Exp. Med 216, 71&#x2013;83 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6314517</ArticleId><ArticleId IdType="pubmed">30541903</ArticleId></ArticleIdList></Reference><Reference><Citation>Almad A &amp; Maragakis NJ A stocked toolbox for understanding the role of astrocytes in disease. Nat. Rev. Neurol 14, 351&#x2013;362 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29769699</ArticleId></ArticleIdList></Reference><Reference><Citation>Han X et al. Forebrain engraftment by human glial progenitor cells enhances synaptic plasticity and learning in adult mice. Cell Stem Cell 12, 342&#x2013;353 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3700554</ArticleId><ArticleId IdType="pubmed">23472873</ArticleId></ArticleIdList></Reference><Reference><Citation>Osipovitch M et al. Human ESC-derived chimeric mouse models of Huntington&#x2019;s disease reveal cell-Intrinsic defects in glial progenitor cell differentiation. Cell Stem Cell 24, 107&#x2013;122.e7 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6700734</ArticleId><ArticleId IdType="pubmed">30554964</ArticleId></ArticleIdList></Reference><Reference><Citation>Craig-Schapiro R et al. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer&#x2019;s disease. Biol. Psychiatry 68, 903&#x2013;912 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3011944</ArticleId><ArticleId IdType="pubmed">21035623</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter SF et al. Astrocyte biomarkers in Alzheimer&#x2019;s disease. Trends Mol. Med. 25, 77&#x2013;95 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30611668</ArticleId></ArticleIdList></Reference><Reference><Citation>Romeo-Guitart D et al. Neuroprotective drug for nerve trauma revealed using artificial intelligence. Sci. Rep 8, 1879 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5790005</ArticleId><ArticleId IdType="pubmed">29382857</ArticleId></ArticleIdList></Reference><Reference><Citation>Bindocci E et al. Three-dimensional Ca2+ imaging advances understanding of astrocyte biology. Science 356, eaai8185 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28522470</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y et al. Accurate quantification of astrocyte and neurotransmitter fluorescence dynamics for single-cell and population-level physiology. Nat. Neurosci 22, 1936&#x2013;1944 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6858541</ArticleId><ArticleId IdType="pubmed">31570865</ArticleId></ArticleIdList></Reference><Reference><Citation>Ben Haim L et al. The JAK/STAT3 pathway is a common inducer of astrocyte reactivity in Alzheimer&#x2019;s and Huntington&#x2019;s diseases. J. Neurosci 35, 2817&#x2013;2829 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6605603</ArticleId><ArticleId IdType="pubmed">25673868</ArticleId></ArticleIdList></Reference><Reference><Citation>Hol EM &amp; Pekny M Glial fibrillary acidic protein (GFAP) and the astrocyte intermediate filament system in diseases of the central nervous system. Curr. Opin. Cell Biol 32, 121&#x2013;130 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25726916</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreels M, Vandenabeele F, Dumont D, Robben J &amp; Lambrichts I Alpha-smooth muscle actin (alpha-SMA) and nestin expression in reactive astrocytes in multiple sclerosis lesions: potential regulatory role of trans-forming growth factor-beta 1 (TGF-beta1). Neuropathol. Appl. Neurobiol 34, 532&#x2013;546 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18005096</ArticleId></ArticleIdList></Reference><Reference><Citation>Jing R et al. Synemin is expressed in reactive astrocytes in neurotrauma and interacts differentially with vimentin and GFAP intermediate filament networks. J. Cell Sci. 120, 1267&#x2013;1277 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17356066</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada T, Kawamata T, Walker DG &amp; McGeer PL Vimentin immuno reactivity in normal and pathological human brain tissue. Acta Neuropathol. 84, 157&#x2013;162 (1992).</Citation><ArticleIdList><ArticleId IdType="pubmed">1523971</ArticleId></ArticleIdList></Reference><Reference><Citation>Gui Y, Marks JD, Das S, Hyman BT &amp; Serrano-Pozo A Characterization of the 18 kDa translocator protein (TSPO) expression in post-mortem normal and Alzheimer&#x2019;s disease brains. Brain Pathol 30, 151&#x2013;164 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6904423</ArticleId><ArticleId IdType="pubmed">31276244</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilhelmus MM et al. Specific association of small heat shock proteins with the pathological hallmarks of Alzheimer&#x2019;s disease brains. Neuropathol. Appl. Neurobiol 32, 119&#x2013;130 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16599941</ArticleId></ArticleIdList></Reference><Reference><Citation>Furman JL et al. Blockade of astrocytic calcineurin/NFAT signaling helps to normalize hippocampal synaptic function and plasticity in a rat model of traumatic brain injury. J. Neurosci 36, 1502&#x2013;1515 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4737766</ArticleId><ArticleId IdType="pubmed">26843634</ArticleId></ArticleIdList></Reference><Reference><Citation>Michetti F et al. The S100B story: from biomarker to active factor in neural injury. J. Neurochem 148, 168&#x2013;187 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30144068</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun W et al. SOX9 is an astrocyte-specific nuclear marker in the adult brain outside the neurogenic regions. J. Neurosci 37, 4493&#x2013;4507 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5413187</ArticleId><ArticleId IdType="pubmed">28336567</ArticleId></ArticleIdList></Reference><Reference><Citation>Wanner IB et al. Glial scar borders are formed by newly proliferated, elongated astrocytes that interact to corral inflammatory and fibrotic cells via STAT3-dependent mechanisms after spinal cord injury. J. Neurosci 33, 12870&#x2013;12886 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3728693</ArticleId><ArticleId IdType="pubmed">23904622</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell SC et al. Potassium and glutamate transport is impaired in scar-forming tumor-associated astrocytes. Neurochem. Int 133, 104628 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6957761</ArticleId><ArticleId IdType="pubmed">31825815</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss CM et al. AMP-activated protein kinase (AMPK) regulates astrocyte oxidative metabolism by balancing TCA cycle dynamics. Glia 68, 1824&#x2013;1839 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32092215</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimbrough IF, Robel S, Roberson ED &amp; Sontheimer H Vascular amyloidosis impairs the gliovascular unit in a mouse model of Alzheimer&#x2019;s disease. Brain 138, 3716&#x2013;3733 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5006220</ArticleId><ArticleId IdType="pubmed">26598495</ArticleId></ArticleIdList></Reference><Reference><Citation>Deshpande T et al. Subcellular reorganization and altered phosphorylation of the astrocytic gap junction protein connexin43 in human and experimental temporal lobe epilepsy. Glia 65, 1809&#x2013;1820 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28795432</ArticleId></ArticleIdList></Reference><Reference><Citation>Frakes AE et al. Microglia induce motor neuron death via the classical NF-&#x3ba;B pathway in amyotrophic lateral sclerosis. Neuron 81, 1009&#x2013;1023 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3978641</ArticleId><ArticleId IdType="pubmed">24607225</ArticleId></ArticleIdList></Reference><Reference><Citation>Eraso-Pichot A et al. GSEA of mouse and human mitochondriomes reveals fatty acid oxidation in astrocytes. Glia 66, 1724&#x2013;1735 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29575211</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xe4;chler P et al. In vivo evidence for a lactate gradient from astrocytes to neurons. Cell Metab 23, 94&#x2013;102 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26698914</ArticleId></ArticleIdList></Reference><Reference><Citation>Lerchundi R, Huang N &amp; Rose CR Quantitative imaging of changes in astrocytic and neuronal adenosine triphosphate using two different variants of ATeam. Front. Cell. Neurosci 14, 80 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7186936</ArticleId><ArticleId IdType="pubmed">32372916</ArticleId></ArticleIdList></Reference><Reference><Citation>Ioannou MS et al. Neuron-astrocyte metabolic coupling protects against activity-induced fatty acid toxicity. Cell 177, 1522&#x2013;1535.e14 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31130380</ArticleId></ArticleIdList></Reference><Reference><Citation>Polyzos AA et al. Metabolic reprogramming in astrocytes distinguishes region-specific neuronal susceptibility in Huntington mice. Cell Metab 29, 1258&#x2013;1273.e11 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6583797</ArticleId><ArticleId IdType="pubmed">30930170</ArticleId></ArticleIdList></Reference><Reference><Citation>Oe Y, Akther S &amp; Hirase H Regional distribution of glycogen in the mouse brain visualized by immunohistochemistry. Adv. Neurobiol 23, 147&#x2013;168 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31667808</ArticleId></ArticleIdList></Reference><Reference><Citation>Vezzoli E et al. Ultrastructural evidence for a role of astrocytes and glycogen-derived lactate in learning-dependent synaptic stabilization. Cereb. Cortex 30, 2114&#x2013;2127 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7174989</ArticleId><ArticleId IdType="pubmed">31807747</ArticleId></ArticleIdList></Reference><Reference><Citation>Vicente-Gutierrez C et al. Astrocytic mitochondrial ROS modulate brain metabolism and mouse behaviour. Nat. Metab 1, 201&#x2013;211 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">32694785</ArticleId></ArticleIdList></Reference><Reference><Citation>Damisah EC et al. Astrocytes and microglia play orchestrated roles and respect phagocytic territories during neuronal corpse removal in vivo. Sci. Adv 6, a3239 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7319765</ArticleId><ArticleId IdType="pubmed">32637606</ArticleId></ArticleIdList></Reference><Reference><Citation>Simonovitch S et al. Impaired autophagy in APOE4 astrocytes. J. Alzheimers Dis. 51, 915&#x2013;927 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26923027</ArticleId></ArticleIdList></Reference><Reference><Citation>Goetzl EJ et al. Traumatic brain injury increases plasma astrocyte-derived exosome levels of neurotoxic complement proteins. FASEB J. 34, 3359&#x2013;3366 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7459190</ArticleId><ArticleId IdType="pubmed">31916313</ArticleId></ArticleIdList></Reference><Reference><Citation>Orre M et al. Reactive glia show increased immunoproteasome activity in Alzheimer&#x2019;s disease. Brain 136, 1415&#x2013;1431 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23604491</ArticleId></ArticleIdList></Reference><Reference><Citation>Sirko S et al. Reactive glia in the injured brain acquire stem cell properties in response to sonic hedgehog. Cell Stem Cell 12, 426&#x2013;439 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23561443</ArticleId></ArticleIdList></Reference><Reference><Citation>Buffo A et al. Origin and progeny of reactive gliosis: A source of multipotent cells in the injured brain. Proc. Natl Acad. Sci. USA 105, 3581&#x2013;3586 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2265175</ArticleId><ArticleId IdType="pubmed">18299565</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33606969</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>27</Day></DateCompleted><DateRevised><Year>2021</Year><Month>04</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>109</Volume><Issue>7</Issue><PubDate><Year>2021</Year><Month>Apr</Month><Day>07</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>White matter aging drives microglial diversity.</ArticleTitle><Pagination><StartPage>1100</StartPage><EndPage>1117.e10</EndPage><MedlinePgn>1100-1117.e10</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2021.01.027</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(21)00073-8</ELocationID><Abstract><AbstractText>Aging results in gray and white matter degeneration, but the specific microglial responses are unknown. Using single-cell RNA sequencing from white and gray matter separately, we identified white matter-associated microglia (WAMs), which share parts of the disease-associated microglia (DAM) gene signature and are characterized by activation of genes implicated in phagocytic activity and lipid metabolism. WAMs depend on triggering receptor expressed on myeloid cells 2 (TREM2) signaling and are aging dependent. In the aged brain, WAMs form independent of apolipoprotein E (APOE), in contrast to mouse models of Alzheimer's disease, in which microglia with the WAM gene signature are generated prematurely and in an APOE-dependent pathway similar to DAMs. Within the white matter, microglia frequently cluster in nodules, where they are engaged in clearing degenerated myelin. Thus, WAMs may represent a potentially protective response required to clear degenerated myelin accumulating during white matter aging and disease.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Safaiyan</LastName><ForeName>Shima</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Neuronal Cell Biology, Technical University Munich, 80802 Munich, Germany; German Center for Neurodegenerative Diseases (DZNE), 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Besson-Girard</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute for Stroke and Dementia Research, University Hospital of Munich, LMU Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaya</LastName><ForeName>Tu&#x11f;berk</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institute of Neuronal Cell Biology, Technical University Munich, 80802 Munich, Germany; German Center for Neurodegenerative Diseases (DZNE), 81377 Munich, Germany; Institute for Stroke and Dementia Research, University Hospital of Munich, LMU Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cantuti-Castelvetri</LastName><ForeName>Ludovico</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute of Neuronal Cell Biology, Technical University Munich, 80802 Munich, Germany; German Center for Neurodegenerative Diseases (DZNE), 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Lu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute for Stroke and Dementia Research, University Hospital of Munich, LMU Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ji</LastName><ForeName>Hao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institute for Stroke and Dementia Research, University Hospital of Munich, LMU Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schifferer</LastName><ForeName>Martina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gouna</LastName><ForeName>Garyfallia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Institute of Neuronal Cell Biology, Technical University Munich, 80802 Munich, Germany; German Center for Neurodegenerative Diseases (DZNE), 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Usifo</LastName><ForeName>Fumere</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Institute for Stroke and Dementia Research, University Hospital of Munich, LMU Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kannaiyan</LastName><ForeName>Nirmal</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Ludwig-Maximilians-Universit&#xe4;t, 80336 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fitzner</LastName><ForeName>Dirk</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of G&#xf6;ttingen, 37075 G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiang</LastName><ForeName>Xianyuan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universit&#xe4;t Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rossner</LastName><ForeName>Moritz J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Ludwig-Maximilians-Universit&#xe4;t, 80336 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brendel</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, 81377 Munich, Germany; Munich Cluster of Systems Neurology (SyNergy), 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gokce</LastName><ForeName>Ozgun</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Institute for Stroke and Dementia Research, University Hospital of Munich, LMU Munich, 81377 Munich, Germany; Munich Cluster of Systems Neurology (SyNergy), 81377 Munich, Germany. Electronic address: oezguen.goekce@med.uni-muenchen.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simons</LastName><ForeName>Mikael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Neuronal Cell Biology, Technical University Munich, 80802 Munich, Germany; German Center for Neurodegenerative Diseases (DZNE), 81377 Munich, Germany; Munich Cluster of Systems Neurology (SyNergy), 81377 Munich, Germany. Electronic address: msimons@gwdg.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>02</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498716">Trem2 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003711" MajorTopicYN="N">Demyelinating Diseases</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066128" MajorTopicYN="N">Gray Matter</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000254" MajorTopicYN="N">growth &amp; development</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009186" MajorTopicYN="N">Myelin Sheath</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017423" MajorTopicYN="N">Sequence Analysis, RNA</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059010" MajorTopicYN="N">Single-Cell Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066127" MajorTopicYN="N">White Matter</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000254" MajorTopicYN="Y">growth &amp; development</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ApoE</Keyword><Keyword MajorTopicYN="N">Trem2</Keyword><Keyword MajorTopicYN="N">microglia, aging</Keyword><Keyword MajorTopicYN="N">myelin</Keyword><Keyword MajorTopicYN="N">white matter</Keyword></KeywordList><CoiStatement>Declaration of interests The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>8</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>12</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>1</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>2</Month><Day>19</Day><Hour>20</Hour><Minute>10</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33606969</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2021.01.027</ArticleId><ArticleId IdType="pii">S0896-6273(21)00073-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33597265</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>12</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>581</Issue><PubDate><Year>2021</Year><Month>Feb</Month><Day>17</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>APOE immunotherapy reduces cerebral amyloid angiopathy and amyloid plaques while improving cerebrovascular function.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">eabd7522</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.abd7522</ELocationID><Abstract><AbstractText>The &#x3b5;4 allele of the apolipoprotein E (<i>APOE</i>) gene is the strongest genetic risk factor for late-onset Alzheimer's disease (AD) and greatly influences the development of amyloid-&#x3b2; (A&#x3b2;) pathology. Our current study investigated the potential therapeutic effects of the anti-human APOE antibody HAE-4, which selectively recognizes human APOE that is co-deposited with A&#x3b2; in cerebral amyloid angiopathy (CAA) and parenchymal amyloid pathology. In addition, we tested whether HAE-4 provoked brain hemorrhages, a component of amyloid-related imaging abnormalities (ARIA). ARIA is an adverse effect secondary to treatment with anti-A&#x3b2; antibodies that can occur in blood vessels with CAA. We used 5XFAD mice expressing human <i>APOE4</i> <sup>+/+</sup> (5XE4) that have prominent CAA and parenchymal plaque pathology to assess the efficacy of HAE-4 compared to an A&#x3b2; antibody that removes parenchymal A&#x3b2; but increases ARIA in humans. In chronically treated 5XE4 mice, HAE-4 reduced A&#x3b2; deposition including CAA compared to a control antibody, whereas the anti-A&#x3b2; antibody had no effect on CAA. Furthermore, the anti-A&#x3b2; antibody exacerbated microhemorrhage severity, which highly correlated with reactive astrocytes surrounding CAA. In contrast, HAE-4 did not stimulate microhemorrhages and instead rescued CAA-induced cerebrovascular dysfunction in leptomeningeal arteries in vivo. HAE-4 not only reduced amyloid but also dampened reactive microglial, astrocytic, and proinflammatory-associated genes in the cortex. These results suggest that targeting APOE in the core of both CAA and plaques could ameliorate amyloid pathology while protecting cerebrovascular integrity and function.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Monica</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-8398-1814</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Biology and Biomedical Sciences (DBBS), Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Hong</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-6480-7469</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serrano</LastName><ForeName>Javier Remolina</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonzales</LastName><ForeName>Ernesto R</ForeName><Initials>ER</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Chao</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gratuze</LastName><ForeName>Maud</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoyle</LastName><ForeName>Rosa</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-3383-424X</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bien-Ly</LastName><ForeName>Nga</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Denali Therapeutics, South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silverman</LastName><ForeName>Adam P</ForeName><Initials>AP</Initials><Identifier Source="ORCID">0000-0003-1749-6607</Identifier><AffiliationInfo><Affiliation>Codexis, Redwood City, CA 94063, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sullivan</LastName><ForeName>Patrick M</ForeName><Initials>PM</Initials><Identifier Source="ORCID">0000-0001-8402-2634</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watts</LastName><ForeName>Ryan J</ForeName><Initials>RJ</Initials><Identifier Source="ORCID">0000-0002-4973-5089</Identifier><AffiliationInfo><Affiliation>Denali Therapeutics, South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ulrich</LastName><ForeName>Jason D</ForeName><Initials>JD</Initials><Identifier Source="ORCID">0000-0002-4743-926X</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zipfel</LastName><ForeName>Gregory J</ForeName><Initials>GJ</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials><Identifier Source="ORCID">0000-0002-3400-0856</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA. holtzman@wustl.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32 GM008151</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 NS090934</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 NS103276</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG072980</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG047644</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG047644</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 OD021629</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F31 AG062027</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2021 Apr;17(4):194. doi: 10.1038/s41582-021-00479-8.</RefSource><PMID Version="1">33750931</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016657" MajorTopicYN="Y">Cerebral Amyloid Angiopathy</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Competing interests. D.M.H. and H.J. are listed as inventors on US patent application #20190270794 entitled &#x201c;Anti-APOE antibodies&#x201d; from Washington University on APOE antibodies. N.B.L and R.J.W. are employees at Denali. A.P.S. is an employee of Codexis but conducted this work at Denali. D.M.H. co-founded and is on the scientific advisory board of C2N Diagnostics. D.M.H. is on the scientific advisory board of Denali and consults for Genentech, Merck, and Idorsia. Washington University (D.M.H.) has a sponsored research agreement to work on APOE antibodies from NextCure. All other authors have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>7</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>10</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>2</Month><Day>18</Day><Hour>5</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>2</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33597265</ArticleId><ArticleId IdType="mid">NIHMS1699453</ArticleId><ArticleId IdType="pmc">PMC8128342</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.abd7522</ArticleId><ArticleId IdType="pii">13/581/eabd7522</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Long JM, Holtzman DM, Alzheimer Disease: An Update on Pathobiology and Treatment Strategies, Cell 179, 312&#x2013;339 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6778042</ArticleId><ArticleId IdType="pubmed">31564456</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling R, Salloway S, Brooks DJ, Tampieri D, Barakos J, Fox NC, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Lieberburg I, Arrighi HM, Morris KA, Lu Y, Liu E, Gregg KM, Brashear HR, Kinney GG, Black R, Grundman M, Amyloid-related imaging abnormalities in patients with Alzheimer&#x2019;s disease treated with bapineuzumab: A retrospective analysis, Lancet Neurol. 11, 241&#x2013;249 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4063417</ArticleId><ArticleId IdType="pubmed">22305802</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Jack CR, Black SE, Frosch MP, Greenberg SM, Hyman BT, Scheltens P, Carrillo MC, Thies W, Bednar MM, Black RS, Brashear HR, Grundman M, Siemers ER, Feldman HH, Schindler RJ, Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer&#x2019;s Association Research Roundtable Workgroup, Alzheimer&#x2019;s Dement. 7, 367&#x2013;385 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3693547</ArticleId><ArticleId IdType="pubmed">21784348</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN, Morgan D, Passive immunotherapy against A&#x3b2; in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage, J. Neuroinflammation 1, 1&#x2013;11 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC539292</ArticleId><ArticleId IdType="pubmed">15588287</ArticleId></ArticleIdList></Reference><Reference><Citation>Racke MM, Boone LI, Hepburn DL, Parsadainian M, Bryan MT, Ness DK, Piroozi KS, Jordan WH, Brown DD, Hoffman WP, Holtzman DM, Bales KR, Gitter BD, May PC, Paul SM, DeMattos RB, Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid &#x3b2;, J. Neurosci. 25, 629&#x2013;636 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725332</ArticleId><ArticleId IdType="pubmed">15659599</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, Staufenbiel M, Mathews PM, Jucker M, Cerebral hemorrhage after passive anti-a&#x3b2; immunotherapy, Science (80-. ). 298, 1379&#x2013;1380 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12434053</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostrowitzki S, Deptula D, Thurfjell L, Barkhof F, Bohrmann B, Brooks DJ, Klunk WE, Ashford E, Yoo K, Xu ZX, Loetscher H, Santarelli L, Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab, Arch. Neurol. 69, 198&#x2013;207 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">21987394</ArticleId></ArticleIdList></Reference><Reference><Citation>Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR, Two phase 3 trials of Bapineuzumab in mild-to-moderate Alzheimer&#x2019;s disease, N. Engl. J. Med. 370, 322&#x2013;333 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4159618</ArticleId><ArticleId IdType="pubmed">24450891</ArticleId></ArticleIdList></Reference><Reference><Citation>Sevigny J, Chiao P, Bussi&#xe8;re T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, O&#x2019;Gorman J, Qian F, Arastu M, Li M, Chollate S, Brennan MS, Quintero-Monzon O, Scannevin RH, Arnold HM, Engber T, Rhodes K, Ferrero J, Hang Y, Mikulskis A, Grimm J, Hock C, Nitsch RM, Sandrock A, The antibody aducanumab reduces A&#x3b2; plaques in Alzheimer&#x2019;s disease, Nature 537, 50&#x2013;56 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27582220</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostrowitzki S, Lasser RA, Dorflinger E, Scheltens P, Barkhof F, Nikolcheva T, Ashford E, Retout S, Hofmann C, Delmar P, Klein G, Andjelkovic M, Dubois B, Boada M, Blennow K, Santarelli L, Fontoura P, A phase III randomized trial of gantenerumab in prodromal Alzheimer&#x2019;s disease, Alzheimer&#x2019;s Res. Ther. 9, 95 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5723032</ArticleId><ArticleId IdType="pubmed">29221491</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg SM, Bacskai BJ, Hernandez-Guillamon M, Pruzin J, Sperling R, van Veluw SJ, Cerebral amyloid angiopathy and Alzheimer disease &#x2014; one peptide, two pathways, Nat. Rev. Neurol. 16, 30&#x2013;42 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7268202</ArticleId><ArticleId IdType="pubmed">31827267</ArticleId></ArticleIdList></Reference><Reference><Citation>Attems J, Jellinger KA, Lintner F, Alzheimer&#x2019;s disease pathology influences severity and topographical distribution of cerebral amyloid angiopathy, Acta Neuropathol. 110, 222&#x2013;231 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16133541</ArticleId></ArticleIdList></Reference><Reference><Citation>Namba K, Tomonaga Y, Kawasaki M, Otomo H, Ikeda E, Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer&#x2019;s disease and kuru plaque amyloid in Creutzfeldt-Jakob disease, Brain Res. 541, 163&#x2013;166 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">2029618</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong F, Ge W, Ma C, Quantitative proteomics reveals distinct composition of amyloid plaques in Alzheimer&#x2019;s disease, Alzheimer&#x2019;s Dement. 15, 429&#x2013;440 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30502339</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, Fagan AM, Morris JC, Mawuenyega KG, Cruchaga C, Goate AM, Bales KR, Paul SM, Bateman RJ, Holtzman DM, Human apoE Isoforms Differentially Regulate Brain Amyloid-beta Peptide Clearance, Sci. Transl. Med. 3, 89ra57 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3192364</ArticleId><ArticleId IdType="pubmed">21715678</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C-C, Kanekiyo T, Xu H, Bu G, Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy, Nat. Rev. Neurol. 9, 106&#x2013;118 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3726719</ArticleId><ArticleId IdType="pubmed">23296339</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Eltorai AEM, Jiang H, Liao F, Verghese PB, Kim J, Stewart FR, Basak JM, Holtzman DM, Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of A&#x3b2; amyloidosis, J. Exp. Med. 209, 2149&#x2013;2156 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3501350</ArticleId><ArticleId IdType="pubmed">23129750</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao F, Hori Y, Hudry E, Bauer AQ, Jiang H, Mahan TE, Lefton KB, Zhang TJ, Dearborn JT, Kim J, Culver JP, Betensky R, Wozniak DF, Hyman BT, Holtzman DM, Anti-ApoE antibody given after plaque onset decreases A&#x3b2; accumulation and improves brain function in a mouse model of A&#x3b2; amyloidosis, J. Neurosci. 34, 7281&#x2013;7292 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4028501</ArticleId><ArticleId IdType="pubmed">24849360</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao F, Li A, Xiong M, Bien-Ly N, Jiang H, Zhang Y, Finn MB, Hoyle R, Keyser J, Lefton KA, Robinson GO, Serrano JR, Silverman AP, Guo JL, Getz J, Henne K, Leyns CEG, Gallardo G, Ulrich JD, Sullivan PM, Lerner EP, Hudry E, Sweeney ZK, Dennis MS, Hyman BT, Watts RJ, Holtzman DM, Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation, J. Clin. Invest. 128, 2144&#x2013;2155 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5919821</ArticleId><ArticleId IdType="pubmed">29600961</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao F, Zhang TJ, Jiang H, Lefton KB, Robinson GO, Vassar R, Sullivan PM, Holtzman DM, Murine versus human apolipoprotein E4: differential facilitation of and co-localization in cerebral amyloid angiopathy and amyloid plaques in APP transgenic mouse models, Acta Neuropathol. Commun. 3, 70 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4641345</ArticleId><ArticleId IdType="pubmed">26556230</ArticleId></ArticleIdList></Reference><Reference><Citation>Golde TE, Open questions for Alzheimer&#x2019;s disease immunotherapy, Alzheimer&#x2019;s Res. Ther. 6, 3 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4056616</ArticleId><ArticleId IdType="pubmed">24393284</ArticleId></ArticleIdList></Reference><Reference><Citation>Han BH, Zhou ML, Abousaleh F, Brendza RP, Dietrich HH, Koenigsknecht-Talboo J, Cirrito JR, Milner E, Holtzman DM, Zipfel GJ, Cerebrovascular dysfunction in amyloid precursor protein transgenic mice: Contribution of soluble and insoluble amyloid-&#x3b2; peptide, partial restoration via &#x3b3;-secretase inhibition, J. Neurosci. 28, 13542&#x2013;13550 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2626633</ArticleId><ArticleId IdType="pubmed">19074028</ArticleId></ArticleIdList></Reference><Reference><Citation>Bales KR, O&#x2019;Neill SM, Pozdnyakov N, Pan F, Caouette D, Pi Y, Wood KM, Volfson D, Cirrito JR, Han BH, Johnson AW, Zipfel GJ, Samad TA, Passive immunotherapy targeting amyloid-&#x3b2; reduces cerebral amyloid angiopathy and improves vascular reactivity, Brain 139, 563&#x2013;577 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26493635</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweeney MD, Sagare AP, Zlokovic BV, Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders, Nat. Rev. Neurol. 14, 133&#x2013;150 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5829048</ArticleId><ArticleId IdType="pubmed">29377008</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C, The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia, Acta Neuropathol 120, 287&#x2013;296 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3001188</ArticleId><ArticleId IdType="pubmed">20623294</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK, David E, Baruch K, Lara-Astaiso D, Toth B, Itzkovitz S, Colonna M, Schwartz M, Amit I, A Unique Microglia Type Associated with Restricting Development of Alzheimer&#x2019;s Disease, Cell 169, 1276&#x2013;1290.e17 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann S, Madore C, Cialic R, Baufeld C, Calcagno N, El Fatimy R, Beckers L, O&#x2019;Loughlin E, Xu Y, Fanek Z, Greco DJ, Smith ST, Tweet G, Humulock Z, Zrzavy T, Conde-Sanroman P, Gacias M, Weng Z, Chen H, Tjon E, Mazaheri F, Hartmann K, Madi A, Ulrich JD, Glatzel M, Worthmann A, Heeren J, Budnik B, Lemere C, Ikezu T, Heppner FL, Litvak V, Holtzman DM, Lassmann H, Weiner HL, Ochando J, Haass C, Butovsky O, The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases, Immunity 47, 566&#x2013;581.e9 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5719893</ArticleId><ArticleId IdType="pubmed">28930663</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamazaki Y, Zhao N, Caulfield TR, Liu CC, Bu G, Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies, Nat. Rev. Neurol. 15, 501&#x2013;518 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7055192</ArticleId><ArticleId IdType="pubmed">31367008</ArticleId></ArticleIdList></Reference><Reference><Citation>Herzig MC, Winkler DT, Burgermeister P, Pfeifer M, Kohler E, Schmidt SD, Danner S, Abramowski D, St&#xfc;rchler-Pierrat C, B&#xfc;rki K, Van Duinen SG, Maat-Schieman MLC, Staufenbiel M, Mathews PM, Jucker M, A&#x3b2; is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis, Nat. Neurosci. 7, 954&#x2013;960 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15311281</ArticleId></ArticleIdList></Reference><Reference><Citation>Weller RO, Subash M, Preston SD, Mazanti I, Carare RO, Perivascular drainage of amyloid-&#x3b2; peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer&#x2019;s disease, Brain Pathol. 18, 253&#x2013;266 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8095597</ArticleId><ArticleId IdType="pubmed">18363936</ArticleId></ArticleIdList></Reference><Reference><Citation>Haeberlein SB, von Hehn C, Tian Y, Chalkias S, Muralidharan KK, Chen T, Wu S, Li J, Skordos L, Nisenbaum L, Rajagovindan R, Dent G, Harrison K, Nestorov I, Zhu Y, Mallinckrodt C, Sandrock A, in CTAD 2019, (San Diego, CA, 2019), pp. 1&#x2013;60.</Citation></Reference><Reference><Citation>Cummings JL, Cohen S, Van Dyck CH, Brody M, Curtis C, Cho W, Ward M, Friesenhahn M, Brunstein F, Quartino A, Honigberg LA, Fuji RN, Clayton D, Mortensen D, Ho A, Paul R, Rabe C, A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease, Neurology 90, E1889&#x2013;E1897 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5962917</ArticleId><ArticleId IdType="pubmed">29695589</ArticleId></ArticleIdList></Reference><Reference><Citation>Siemers ER, Sundell KL, Carlson C, Case M, Sethuraman G, Liu-Seifert H, Dowsett SA, Pontecorvo MJ, Dean RA, DeMattos R, Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer&#x2019;s disease patients, Alzheimer&#x2019;s Dement. 12, 110&#x2013;120 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26238576</ArticleId></ArticleIdList></Reference><Reference><Citation>Leurent C, Goodman JA, Zhang Y, He P, Polimeni JR, Gurol ME, Lindsay M, Frattura L, Sohur US, Viswanathan A, Bednar MM, Smith EE, Greenberg SM, Immunotherapy with ponezumab for probable cerebral amyloid angiopathy, Ann. Clin. Transl. Neurol. 6, 795&#x2013;806 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6469253</ArticleId><ArticleId IdType="pubmed">31020004</ArticleId></ArticleIdList></Reference><Reference><Citation>Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, Bennett ML, M&#xfc;nch AE, Chung WS, Peterson TC, Wilton DK, Frouin A, Napier BA, Panicker N, Kumar M, Buckwalter MS, Rowitch DH, Dawson VL, Dawson TM, Stevens B, Barres BA, Neurotoxic reactive astrocytes are induced by activated microglia, Nature 541, 481&#x2014;487 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5404890</ArticleId><ArticleId IdType="pubmed">28099414</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Manis M, Long J, Wang K, Sullivan PM, Serrano JR, Hoyle R, Holtzman DM, Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model, J. Exp. Med.216, 2546&#x2013;2561 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6829593</ArticleId><ArticleId IdType="pubmed">31601677</ArticleId></ArticleIdList></Reference><Reference><Citation>Fryer JD, Simmons K, Parsadanian M, Bales KR, Paul SM, Sullivan PM, Holtzman DM, Human apolipoprotein E4 alters the amyloid-&#x3b2; 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model, J. Neurosci. 25, 2803&#x2013;2810 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725147</ArticleId><ArticleId IdType="pubmed">15772340</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor X, Cisternas P, You Y, You Y, Xiang S, Marambio Y, Zhang J, Vidal R, Lasagna-Reeves CA, A1 reactive astrocytes and a loss of TREM2 are associated with an early stage of pathology in a mouse model of cerebral amyloid angiopathy, J. Neuroinflammation 17, 223 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7382050</ArticleId><ArticleId IdType="pubmed">32711525</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao F, Yoon H, Kim J, Apolipoprotein E metabolism and functions in brain and its role in Alzheimer&#x2019;s disease, Curr. Opin. Lipidol. , 1 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5213812</ArticleId><ArticleId IdType="pubmed">27922847</ArticleId></ArticleIdList></Reference><Reference><Citation>Koldamova R, Fitz NF, Lefterov I, ATP-binding cassette transporter A1: From metabolism to neurodegeneration, Neurobiol. Dis. 72, 13&#x2013;21 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4302328</ArticleId><ArticleId IdType="pubmed">24844148</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahrle SE, Jiang H, Parsadanian M, Hartman RE, Bales KR, Paul SM, Holtzman DM, Deletion of Abca1 increases A&#x3b2; deposition in the PDAPP transgenic mouse model of Alzheimer disease, J. Biol. Chem. 280, 43236&#x2013;43242 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16207708</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitz NF, Cronican AA, Saleem M, Fauq AH, Chapman R, Lefterov I, Koldamova R, Abca1 deficiency affects Alzheimer&#x2019;s disease-like phenotype in human ApoE4 but not in ApoE3-targeted replacement mice, J. Neurosci. 32, 13125&#x2013;13136 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3646580</ArticleId><ArticleId IdType="pubmed">22993429</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahrle SE, Jiang H, Parsadanian M, Kim J, Li A, Knoten A, Jain S, Hirsch-Reinshagen V, Wellington CL, Bales KR, Paul SM, Holtzman DM, Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease, J. Clin. Invest. 118, 671&#x2013;682 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2200302</ArticleId><ArticleId IdType="pubmed">18202749</ArticleId></ArticleIdList></Reference><Reference><Citation>Cramer PE, Cirrito JR, Wesson DW, Lee CYD, Karlo JC, Zinn AE, Casali BT, Restivo JL, Goebel WD, James MJ, Brunden KR, Wilson DA, Landreth GE, ApoE-directed therapeutics rapidly clear &#x3b2;-amyloid and reverse deficits in AD mouse models, Science (80-. ). 335, 1503&#x2013;1506 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3651582</ArticleId><ArticleId IdType="pubmed">22323736</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanson AJ, Bayer-Carter JL, Green PS, Montine TJ, Wilkinson CW, Baker LD, Watson GS, Bonner LM, Callaghan M, Leverenz JB, Tsai E, Postupna N, Zhang J, Lampe J, Craft S, Effect of apolipoprotein e genotype and diet on apolipoprotein e lipidation and amyloid peptides randomized clinical trial, JAMA Neurol. 70, 972&#x2013;980 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3859238</ArticleId><ArticleId IdType="pubmed">23779114</ArticleId></ArticleIdList></Reference><Reference><Citation>Huynh TPV, Wang C, Tran AC, Tabor GT, Mahan TE, Francis CM, Finn MB, Spellman R, Manis M, Tanzi RE, Ulrich JD, Holtzman DM, Lack of hepatic apoE does not influence early A&#x3b2; deposition: Observations from a new APOE knock-in model, Mol. Neurodegener. 14(2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6796484</ArticleId><ArticleId IdType="pubmed">31623648</ArticleId></ArticleIdList></Reference><Reference><Citation>Han GJ, Zhou BH, Johnson ML, Singh AW, Liao I, Vellimana F, Nelson AK, Milner JW, Cirrito E, Basak JR, Yoo J, Han M, Zhou BH, Johnson ML, Singh AW, Liao I, Vellimana F, Nelson AK, Milner JW, Cirrito E, J.R., Contribution of reactive oxygen species to cerebral amyloid angiopathy, vasomotor dysfunction, and microhemorrhage in aged Tg2576 mice, Proc. Natl. Acad. Sci. 112, E881&#x2013;E890 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4345564</ArticleId><ArticleId IdType="pubmed">25675483</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, Berry R, Vassar R, Intraneuronal &#x3b2;-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer&#x2019;s disease mutations: Potential factors in amyloid plaque formation, J. Neurosci. 26, 10129&#x2013;10140 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan PM, Mezdour H, Aratani Y, Knouff C, Najib J, Reddick RL, Quarfordt SH, Maeda N, Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis, J. Biol. Chem. 272, 17972&#x2013;17980 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9218423</ArticleId></ArticleIdList></Reference><Reference><Citation>Wojtas AM, Kang SS, Olley BM, Gatherer M, Shinohara M, Lozano PA, Liu CC, Kurti A, Baker KE, Dickson DW, Yue M, Petrucelli L, Bu G, Carare RO, Fryer JD, Loss of clusterin shifts amyloid deposition to the cerebrovasculature via disruption of perivascular drainage pathways, Proc. Natl. Acad. Sci. U. S. A 114, E6962&#x2013;E6971 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5565413</ArticleId><ArticleId IdType="pubmed">28701379</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Yamada K, Liddelow SA, Smith ST, Zhao L, Luo W, Tsai RM, Spina S, Grinberg LT, Rojas JC, Gallardo G, Wang K, Roh J, Robinson G, Finn MB, Jiang H, Sullivan PM, Baufeld C, Wood MW, Sutphen C, McCue L, Xiong C, Del-Aguila JL, Morris JC, Cruchaga C, Fagan AM, Miller BL, Boxer AL, Seeley WW, Butovsky O, Barres BA, Paul SM, Holtzman DM, ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy, Nature 549, 523&#x2013;527 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5641217</ArticleId><ArticleId IdType="pubmed">28959956</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">33614892</PMID><DateRevised><Year>2024</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2352-8737</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>1</Issue><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>Alzheimer's &amp; dementia (New York, N. Y.)</Title><ISOAbbreviation>Alzheimers Dement (N Y)</ISOAbbreviation></Journal><ArticleTitle>Herpesvirus infections, antiviral treatment, and the risk of dementia-a registry-based cohort study in Sweden.</ArticleTitle><Pagination><StartPage>e12119</StartPage><MedlinePgn>e12119</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e12119</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/trc2.12119</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Herpesviruses, including Herpes simplex virus type 1 (HSV1) and varicella zoster-virus (VZV), have been implicated in Alzheimer's disease (AD) development. Likewise, antiviral treatment has been suggested to protect against dementia development in herpes-infected individuals.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The study enrolled 265,172 subjects aged &#x2265; 50 years, with diagnoses of VZV or HSV, or prescribed antiviral drugs between 31 December 2005 and 31 December 2017. Controls were matched in a 1:1 ratio by sex and birth year.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Antiviral treatment was associated with decreased risk of dementia (adjusted hazard ratio [HR] 0.89, 95% confidence interval [CI] 0.86 to 0.92), while herpes infection without antiviral drugs increased the risk of dementia (adjusted HR 1.50, 95% CI 1.29 to 1.74).</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Antiviral treatment was associated with a reduced long-term risk of dementia among individuals with overt signs of herpes infection. This is consistent with earlier findings indicating that herpesviruses are involved in the pathogenesis of AD.</AbstractText><CopyrightInformation>&#xa9; 2020 The Authors. Alzheimer's &amp; Dementia: Translational Research &amp; Clinical Interventions published by Wiley Periodicals, Inc. on behalf of Alzheimer's Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lopatko Lindman</LastName><ForeName>Karin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Community Medicine and Rehabilitation, Geriatric Medicine Ume&#xe5; University Ume&#xe5; Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hemmingsson</LastName><ForeName>Eva-Stina</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>Department of Community Medicine and Rehabilitation, Geriatric Medicine Ume&#xe5; University Ume&#xe5; Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weidung</LastName><ForeName>Bodil</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Community Medicine and Rehabilitation, Geriatric Medicine Ume&#xe5; University Ume&#xe5; Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Public Health and Caring Sciences, Geriatric Medicine Uppsala University Uppsala Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Br&#xe4;nnstr&#xf6;m</LastName><ForeName>Jon</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Community Medicine and Rehabilitation, Geriatric Medicine Ume&#xe5; University Ume&#xe5; Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Josefsson</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centre for Demographic and Ageing Research Ume&#xe5; University Ume&#xe5; Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olsson</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Clinical Microbiology, Virology Ume&#xe5; University Ume&#xe5; Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elgh</LastName><ForeName>Fredrik</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Clinical Microbiology, Virology Ume&#xe5; University Ume&#xe5; Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nordstr&#xf6;m</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Community Medicine and Rehabilitation, Geriatric Medicine Ume&#xe5; University Ume&#xe5; Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf6;vheim</LastName><ForeName>Hugo</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Community Medicine and Rehabilitation, Geriatric Medicine Ume&#xe5; University Ume&#xe5; Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wallenberg Centre for Molecular Medicine (WCMM) Ume&#xe5; University Ume&#xe5; Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>02</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Alzheimers Dement (N Y)</MedlineTA><NlmUniqueID>101650118</NlmUniqueID><ISSNLinking>2352-8737</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">antiviral agents</Keyword><Keyword MajorTopicYN="N">dementia</Keyword><Keyword MajorTopicYN="N">herpes simplex</Keyword><Keyword MajorTopicYN="N">herpes zoster</Keyword><Keyword MajorTopicYN="N">retrospective cohort study</Keyword><Keyword MajorTopicYN="N">varicella zoster</Keyword></KeywordList><CoiStatement>The authors have no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>10</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>11</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>2</Month><Day>22</Day><Hour>5</Hour><Minute>58</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>2</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33614892</ArticleId><ArticleId IdType="pmc">PMC7882534</ArticleId><ArticleId IdType="doi">10.1002/trc2.12119</ArticleId><ArticleId IdType="pii">TRC212119</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Itzhaki RF, Lathe R, Balin BJ, et&#xa0;al. Microbes and Alzheimer's Disease. J Alzheimers Dis. 2016;51:979&#x2010;984.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5457904</ArticleId><ArticleId IdType="pubmed">26967229</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris SA, Harris EA. Herpes simplex virus Type 1 and other pathogens are key causative factors in sporadic Alzheimer's disease. J Alzheimers Dis. 2015;48:319&#x2010;353.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4923765</ArticleId><ArticleId IdType="pubmed">26401998</ArticleId></ArticleIdList></Reference><Reference><Citation>Steel AJ, Eslick GD. Herpes viruses increase the risk of Alzheimer's disease: a meta&#x2010;analysis. J Alzheimers Dis. 2015;47:351&#x2010;364.</Citation><ArticleIdList><ArticleId IdType="pubmed">26401558</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovheim H, Gilthorpe J, Adolfsson R, Nilsson LG, Elgh F. Reactivated herpes simplex infection increases the risk of Alzheimer's disease. Alzheimer's Dement. 2015;11:593&#x2010;599.</Citation><ArticleIdList><ArticleId IdType="pubmed">25043910</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovheim H, Gilthorpe J, Johansson A, Eriksson S, Hallmans G, Elgh F. Herpes simplex infection and the risk of Alzheimer's disease: a nested case&#x2010;control study. Alzheimer's Dement. 2015;11:587&#x2010;592.</Citation><ArticleIdList><ArticleId IdType="pubmed">25304990</ArticleId></ArticleIdList></Reference><Reference><Citation>Letenneur L, Peres K, Fleury H, et&#xa0;al. Seropositivity to herpes simplex virus antibodies and risk of Alzheimer's disease: a population&#x2010;based cohort study. PloS One. 2008;3:e3637.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2572852</ArticleId><ArticleId IdType="pubmed">18982063</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovheim H, Norman T, Weidung B, et&#xa0;al. Herpes simplex virus, APOEvarepsilon4, and cognitive decline in old age: results from the betula cohort study. J Alzheimers Dis. 2019;67:211&#x2010;220.</Citation><ArticleIdList><ArticleId IdType="pubmed">30636735</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopatko Lindman K, Weidung B, Olsson J, et&#xa0;al. A genetic signature including apolipoprotein E&#x3b5;4 potentiates the risk of herpes simplex&#x2013;associated Alzheimer's disease. Alzheimer's Dement. 2019;5:697&#x2010;704.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6944738</ArticleId><ArticleId IdType="pubmed">31921962</ArticleId></ArticleIdList></Reference><Reference><Citation>Linard M, Letenneur L, Garrigue I, Doize A, Dartigues JF, Helmer C. Interaction between APOE4 and herpes simplex virus type 1 in Alzheimer's disease. Alzheimer's Dement. 2020;16:200&#x2010;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">31914220</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns DM, Rouleau N, Parker RN, Walsh KG, Gehrke L, Kaplan DL. A 3D human brain&#x2010;like tissue model of herpes&#x2010;induced Alzheimer's disease. Sci Adv. 2020;6:eaay8828.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7202879</ArticleId><ArticleId IdType="pubmed">32494701</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar DK, Choi SH, Washicosky KJ, et&#xa0;al. Amyloid&#x2010;beta peptide protects against microbial infection in mouse and worm models of Alzheimer's disease. Sci Transl Med. 2016;8:340ra72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5505565</ArticleId><ArticleId IdType="pubmed">27225182</ArticleId></ArticleIdList></Reference><Reference><Citation>Eimer W, Vijaya Kumar D, Washicosky KJ, et&#xa0;al. Antiviral activities of amyloid&#x2010;&#x3b2; (A&#x3b2;) against the AD&#x2010;linked virus HSV1. Unpublished abstract. Soc Neurosci. 2016;2016.</Citation></Reference><Reference><Citation>De Chiara G, Piacentini R, Fabiani M, et&#xa0;al. Recurrent herpes simplex virus&#x2010;1 infection induces hallmarks of neurodegeneration and cognitive deficits in mice. PLoS Pathog. 2019;15:e1007617.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6417650</ArticleId><ArticleId IdType="pubmed">30870531</ArticleId></ArticleIdList></Reference><Reference><Citation>Bearer EL. HSV, axonal transport and Alzheimer's disease: in vitro and in vivo evidence for causal relationships. Future Virol. 2012;7:885&#x2010;899.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3546524</ArticleId><ArticleId IdType="pubmed">23335944</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen VC, Wu SI, Huang KY, et&#xa0;al. Herpes Zoster and dementia: a nationwide population&#x2010;based cohort study. J Clin Psychiatry. 2018;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">29244265</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai MC, Cheng WL, Sheu JJ, et&#xa0;al. Increased risk of dementia following herpes zoster ophthalmicus. PloS One. 2017;12:e0188490.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5699837</ArticleId><ArticleId IdType="pubmed">29166672</ArticleId></ArticleIdList></Reference><Reference><Citation>Bubak AN, Como CN, Coughlan CM, et&#xa0;al. Varicella zoster virus infection of primary human spinal astrocytes produces intracellular amylin, amyloid&#x2010;beta, and an amyloidogenic extracellular environment. J Infect Dis. 2019;221(7):1088&#x2010;1097.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7075411</ArticleId><ArticleId IdType="pubmed">31665341</ArticleId></ArticleIdList></Reference><Reference><Citation>Bae S, Yun SC, Kim MC, et&#xa0;al. Association of herpes zoster with dementia and effect of antiviral therapy on dementia: a population&#x2010;based cohort study. Eur Arch Psychiatry Clin Neurosci. 2020. Epub ahead of print.</Citation><ArticleIdList><ArticleId IdType="pubmed">32613564</ArticleId></ArticleIdList></Reference><Reference><Citation>Grahn A, Nilsson S, Nordlund A, Linden T, Studahl M. Cognitive impairment 3 years after neurological Varicella&#x2010;zoster virus infection: a long&#x2010;term case control study. J Neurol. 2013;260:2761&#x2010;2769.</Citation><ArticleIdList><ArticleId IdType="pubmed">23900759</ArticleId></ArticleIdList></Reference><Reference><Citation>Persson A, Bergstrom T, Lindh M, Namvar L, Studahl M. Varicella&#x2010;zoster virus CNS disease&#x2014;viral load, clinical manifestations and sequels. J Clin Virol. 2009;46:249&#x2010;253.</Citation><ArticleIdList><ArticleId IdType="pubmed">19709927</ArticleId></ArticleIdList></Reference><Reference><Citation>Itzhaki RF, Lathe R. Herpes viruses and senile dementia: first population evidence for a causal link. J Alzheimers Dis. 2018;64:363&#x2010;366.</Citation><ArticleIdList><ArticleId IdType="pubmed">29889070</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzeng NS, Chung CH, Lin FH, et&#xa0;al. Anti&#x2010;herpetic medications and reduced risk of dementia in patients with herpes simplex virus infections&#x2010;a nationwide, population&#x2010;based cohort study in Taiwan. Neurotherapeutics. 2018;15:417&#x2010;429.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5935641</ArticleId><ArticleId IdType="pubmed">29488144</ArticleId></ArticleIdList></Reference><Reference><Citation>
https://www.socialstyrelsen.se/en/statistics-and-data/registers/register-information/the-national-patient-register/. Accsessed 15 July 2020. Stockholm, Sweden. Published 25 April 2019. Last updated 20 May 2019.</Citation></Reference><Reference><Citation>
https://www.socialstyrelsen.se/statistik-och-data/register/alla-register/lakemedelsregistret/. Accsessed 15 July 2020. Stockholm, Sweden. Published 7 November 2018. Last updated 9 July 2020.</Citation></Reference><Reference><Citation>
https://www.socialstyrelsen.se/statistik-och-data/register/alla-register/. Accsessed 15 July 2020. Stockholm, Sweden. Published 14 May 2019. Last updated 27 May 2019.</Citation></Reference><Reference><Citation>Wettermark B, Hammar N, Fored CM, et&#xa0;al. The new Swedish prescribed drug register&#x2013;opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf. 2007;16:726&#x2010;735.</Citation><ArticleIdList><ArticleId IdType="pubmed">16897791</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludvigsson JF, Andersson E, Ekbom A, et&#xa0;al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3142234</ArticleId><ArticleId IdType="pubmed">21658213</ArticleId></ArticleIdList></Reference><Reference><Citation>Measures to assess the prognostic ability of the stratified Cox proportional hazards model. Stat Med. 2009;28:389&#x2010;411.</Citation><ArticleIdList><ArticleId IdType="pubmed">18833567</ArticleId></ArticleIdList></Reference><Reference><Citation>Lian Y, Zhu Y, Tang F, Yang B, Duan R. Herpes zoster and the risk of ischemic and hemorrhagic stroke: a systematic review and meta&#x2010;analysis. PloS One. 2017;12:e0171182.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5298244</ArticleId><ArticleId IdType="pubmed">28178287</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsson J, Kok E, Adolfsson R, Lovheim H, Elgh F. Herpes virus seroepidemiology in the adult Swedish population. Immunity Ageing. 2017;14:10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5424393</ArticleId><ArticleId IdType="pubmed">28491117</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin WR, Casas I, Wilcock GK, Itzhaki RF. Neurotropic viruses and Alzheimer's disease: a search for varicella zoster virus DNA by the polymerase chain reaction. J Neurol Neurosurg Psychiatry. 1997;62:586&#x2010;589.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1074141</ArticleId><ArticleId IdType="pubmed">9219743</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemling N, Roytta M, Rinne J, et&#xa0;al. Herpesviruses in brains in Alzheimer's and Parkinson's diseases. Ann Neurol. 2003;54:267&#x2010;271.</Citation><ArticleIdList><ArticleId IdType="pubmed">12891684</ArticleId></ArticleIdList></Reference><Reference><Citation>Readhead B, Haure&#x2010;Mirande JV, Funk CC, et&#xa0;al. Multiscale analysis of independent Alzheimer's cohorts finds disruption of molecular, genetic, and clinical networks by human herpesvirus. Neuron. 2018;99:64&#x2010;82.e7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6551233</ArticleId><ArticleId IdType="pubmed">29937276</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovheim H, Olsson J, Weidung B, et&#xa0;al. Interaction between cytomegalovirus and herpes simplex virus type 1 associated with the risk of Alzheimer's disease development. J Alzheimers Dis. 2017;61(3):939&#x2010;945.</Citation><ArticleIdList><ArticleId IdType="pubmed">29254081</ArticleId></ArticleIdList></Reference><Reference><Citation>Itzhaki RF, Lin WR, Shang D, Wilcock GK, Faragher B, Jamieson GA. Herpes simplex virus type 1 in brain and risk of Alzheimer's disease. Lancet. 1997;349:241&#x2010;244.</Citation><ArticleIdList><ArticleId IdType="pubmed">9014911</ArticleId></ArticleIdList></Reference><Reference><Citation>Koelle DM, Magaret A, Warren T, Schellenberg GD, Wald A. APOE genotype is associated with oral herpetic lesions but not genital or oral herpes simplex virus shedding. Sex Transm Infect. 2010;86:202&#x2010;206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2881187</ArticleId><ArticleId IdType="pubmed">20410080</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhlmann I, Minihane AM, Huebbe P, Nebel A, Rimbach G. Apolipoprotein E genotype and hepatitis C, HIV and herpes simplex disease risk: a literature review. Lipids Health Dis. 2010;9:8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2830997</ArticleId><ArticleId IdType="pubmed">20109174</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizzuto D, Feldman AL, Karlsson IK, Dahl Aslan AK, Gatz M, Pedersen NL. Detection of Dementia cases in two swedish health registers: a validation study. J Alzheimers Dis. 2018;61:1301&#x2010;1310.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6218116</ArticleId><ArticleId IdType="pubmed">29376854</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonnen JA, Santa Cruz K, Hemmy LS, et&#xa0;al. Ecology of the aging human brain. Arch Neurol. 2011;68:1049&#x2010;1056.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3218566</ArticleId><ArticleId IdType="pubmed">21825242</ArticleId></ArticleIdList></Reference><Reference><Citation>Religa D, Fereshtehnejad SM, Cermakova P, et&#xa0;al. SveDem, the Swedish Dementia Registry&#x2013;a tool for improving the quality of diagnostics, treatment and care of dementia patients in clinical practice. PloS One. 2015;10:e0116538.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4335024</ArticleId><ArticleId IdType="pubmed">25695768</ArticleId></ArticleIdList></Reference><Reference><Citation>Jedenius E, Johnell K, Fastbom J, Stromqvist J, Winblad B, Andreasen N. Dementia management programme in a community setting and the use of psychotropic drugs in the elderly population. Scand J Prim Health Care. 2011;29:181&#x2010;186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3347957</ArticleId><ArticleId IdType="pubmed">21740344</ArticleId></ArticleIdList></Reference><Reference><Citation>Zahirovic I, Torisson G, Wattmo C, Londos E. Psychotropic and anti&#x2010;dementia treatment in elderly persons with clinical signs of dementia with Lewy bodies: a cross&#x2010;sectional study in 40 nursing homes in Sweden. BMC Geriatr. 2018;18:50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5816356</ArticleId><ArticleId IdType="pubmed">29454305</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33630089</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>12</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2574-3805</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA network open</Title><ISOAbbreviation>JAMA Netw Open</ISOAbbreviation></Journal><ArticleTitle>Sex Differences in Cognitive Decline Among US Adults.</ArticleTitle><Pagination><StartPage>e210169</StartPage><MedlinePgn>e210169</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e210169</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamanetworkopen.2021.0169</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Sex differences in dementia risk are unclear, but some studies have found greater risk for women.</AbstractText><AbstractText Label="OBJECTIVE">To determine associations between sex and cognitive decline in order to better understand sex differences in dementia risk.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This cohort study used pooled analysis of individual participant data from 5 cohort studies for years 1971 to 2017: Atherosclerosis Risk in Communities Study, Coronary Artery Risk Development in Young Adults Study, Cardiovascular Health Study, Framingham Offspring Study, and Northern Manhattan Study. Linear mixed-effects models were used to estimate changes in each continuous cognitive outcome over time by sex. Data analysis was completed from March 2019 to October 2020.</AbstractText><AbstractText Label="EXPOSURE">Sex.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">The primary outcome was change in global cognition. Secondary outcomes were change in memory and executive function. Outcomes were standardized as t scores (mean [SD], 50 [10]); a 1-point difference represents a 0.1-SD difference in cognition.</AbstractText><AbstractText Label="RESULTS">Among 34&#x202f;349 participants, 26&#x202f;088 who self-reported Black or White race, were free of stroke and dementia, and had covariate data at or before the first cognitive assessment were included for analysis. Median (interquartile range) follow-up was 7.9 (5.3-20.5) years. There were 11&#x202f;775 (44.7%) men (median [interquartile range] age, 58 [51-66] years at first cognitive assessment; 2229 [18.9%] Black) and 14&#x202f;313 women (median [interquartile range] age, 58 [51-67] years at first cognitive assessment; 3636 [25.4%] Black). Women had significantly higher baseline performance than men in global cognition (2.20 points higher; 95% CI, 2.04 to 2.35 points; P&#x2009;&lt;&#x2009;.001), executive function (2.13 points higher; 95% CI, 1.98 to 2.29 points; P&#x2009;&lt;&#x2009;.001), and memory (1.89 points higher; 95% CI, 1.72 to 2.06 points; P&#x2009;&lt;&#x2009;.001). Compared with men, women had significantly faster declines in global cognition (-0.07 points/y faster; 95% CI, -0.08 to -0.05 points/y; P&#x2009;&lt;&#x2009;.001) and executive function (-0.06 points/y faster; 95% CI, -0.07 to -0.05 points/y; P&#x2009;&lt;&#x2009;.001). Men and women had similar declines in memory (-0.004 points/y faster; 95% CI, -0.023 to 0.014; P&#x2009;=&#x2009;.61).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">The results of this cohort study suggest that women may have greater cognitive reserve but faster cognitive decline than men, which could contribute to sex differences in late-life dementia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Levine</LastName><ForeName>Deborah A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Cognitive Health Services Research Program, Department of Internal Medicine, University of Michigan, Ann Arbor.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Stroke Program, University of Michigan, Ann Arbor.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gross</LastName><ForeName>Alden L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brice&#xf1;o</LastName><ForeName>Emily M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Cognitive Health Services Research Program, Department of Internal Medicine, University of Michigan, Ann Arbor.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physical Medicine and Rehabilitation, University of Michigan, Ann Arbor.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tilton</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Cognitive Health Services Research Program, Department of Internal Medicine, University of Michigan, Ann Arbor.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giordani</LastName><ForeName>Bruno J</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Michigan, Ann Arbor.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Michigan Alzheimer's Disease Center, University of Michigan, Ann Arbor.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sussman</LastName><ForeName>Jeremy B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Cognitive Health Services Research Program, Department of Internal Medicine, University of Michigan, Ann Arbor.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VA Ann Arbor Healthcare System, Ann Arbor, Michigan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hayward</LastName><ForeName>Rodney A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Cognitive Health Services Research Program, Department of Internal Medicine, University of Michigan, Ann Arbor.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VA Ann Arbor Healthcare System, Ann Arbor, Michigan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burke</LastName><ForeName>James F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Department of Neurology and Stroke Program, University of Michigan, Ann Arbor.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VA Ann Arbor Healthcare System, Ann Arbor, Michigan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hingtgen</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cognitive Health Services Research Program, Department of Internal Medicine, University of Michigan, Ann Arbor.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elkind</LastName><ForeName>Mitchell S V</ForeName><Initials>MSV</Initials><AffiliationInfo><Affiliation>Vagelos College of Physicians and Surgeons, Department of Neurology, Columbia University, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mailman School of Public Health, Department of Epidemiology, Columbia University, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manly</LastName><ForeName>Jennifer J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Vagelos College of Physicians and Surgeons, Department of Neurology, Columbia University, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gottesman</LastName><ForeName>Rebecca F</ForeName><Initials>RF</Initials><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaskin</LastName><ForeName>Darrell J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sidney</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Kaiser Permanente Northern California Division of Research, Oakland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sacco</LastName><ForeName>Ralph L</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Miami, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tom</LastName><ForeName>Sarah E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Vagelos College of Physicians and Surgeons, Department of Neurology, Columbia University, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mailman School of Public Health, Department of Epidemiology, Columbia University, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wright</LastName><ForeName>Clinton B</ForeName><Initials>CB</Initials><AffiliationInfo><Affiliation>Division of Clinical Research, National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yaffe</LastName><ForeName>Kristine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of California, San Francisco.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galecki</LastName><ForeName>Andrzej T</ForeName><Initials>AT</Initials><AffiliationInfo><Affiliation>Cognitive Health Services Research Program, Department of Internal Medicine, University of Michigan, Ann Arbor.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, University of Michigan, Ann Arbor.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG066507</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG050699</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG024824</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS102715</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG050723</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 NS029993</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG054443</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS029993</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG063887</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG053760</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG051827</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>02</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Netw Open</MedlineTA><NlmUniqueID>101729235</NlmUniqueID><ISSNLinking>2574-3805</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>JAMA Netw Open. 2023 Mar 1;6(3):e234786. doi: 10.1001/jamanetworkopen.2023.4786.</RefSource><PMID Version="1">36877526</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058245" MajorTopicYN="Y">Cognitive Reserve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056344" MajorTopicYN="Y">Executive Function</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="Y">Memory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Levine reported receiving consulting fees and grants from the National Institutes of Health (NIH)/ National Institute on Aging (NIA) outside the submitted work. Dr Tilton reported receiving consulting fees and grants from NIH/NIA outside the submitted work. Dr Hayward reported receiving grants from the US Veterans Affairs Department during the conduct of the study. Dr Burke reported grants from the NIH outside the submitted work. Dr Gottesman reported receiving grants from American Academy of Neurology and previous editorial work at the journal <i>Neurology</i> outside the submitted work. Dr Gaskin reported receiving grants from the US Centers for Disease Control and Prevention during the conduct of the study and personal fees from Altarum and the Robert Wood Johnson Foundation outside the submitted work. Dr Sidney reported receiving grants from the National Heart, Lung, and Blood Institute during the conduct of the study. Dr Sacco reported receiving grants from the NIH Northern Manhattan Study during the conduct of the study and grants from Florida Department of Health Florida Stroke Registry, grants from the NIH Miami Clinical Translational Science Institute, and compensation as editor-in-chief of the American Heart Association&#x2019;s <i>Stroke</i> outside the submitted work. Dr Wright reported receiving grants from the NIH during the conduct of the study and royalty fees from UpToDate.com outside the submitted work. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>2</Month><Day>25</Day><Hour>12</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>2</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33630089</ArticleId><ArticleId IdType="pmc">PMC7907956</ArticleId><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.0169</ArticleId><ArticleId IdType="pii">2776902</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alzheimer's Association . 2020 Alzheimer's Disease facts and figures. Alzheimers Dement. 2020;16(3):391-460. doi:10.1002/alz.12068</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12068</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Ch&#xea;ne G, Beiser A, Au R, et al. . Gender and incidence of dementia in the Framingham Heart Study from mid-adult life. Alzheimers Dement. 2015;11(3):310-320. doi:10.1016/j.jalz.2013.10.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2013.10.005</ArticleId><ArticleId IdType="pmc">PMC4092061</ArticleId><ArticleId IdType="pubmed">24418058</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebert LE, Scherr PA, McCann JJ, Beckett LA, Evans DA. Is the risk of developing Alzheimer&#x2019;s disease greater for women than for men? Am J Epidemiol. 2001;153(2):132-136. doi:10.1093/aje/153.2.132</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/153.2.132</ArticleId><ArticleId IdType="pubmed">11159157</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen K, Launer LJ, Dewey ME, et al. ; EURODEM Incidence Research Group . Gender differences in the incidence of AD and vascular dementia: the EURODEM Studies. Neurology. 1999;53(9):1992-1997. doi:10.1212/WNL.53.9.1992</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.53.9.1992</ArticleId><ArticleId IdType="pubmed">10599770</ArticleId></ArticleIdList></Reference><Reference><Citation>Edland SD, Rocca WA, Petersen RC, Cha RH, Kokmen E. Dementia and Alzheimer disease incidence rates do not vary by sex in Rochester, Minn. Arch Neurol. 2002;59(10):1589-1593. doi:10.1001/archneur.59.10.1589</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.59.10.1589</ArticleId><ArticleId IdType="pubmed">12374497</ArticleId></ArticleIdList></Reference><Reference><Citation>Seshadri S, Wolf PA, Beiser A, et al. . Lifetime risk of dementia and Alzheimer&#x2019;s disease: the impact of mortality on risk estimates in the Framingham Study. Neurology. 1997;49(6):1498-1504. doi:10.1212/WNL.49.6.1498</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.49.6.1498</ArticleId><ArticleId IdType="pubmed">9409336</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter CL, Resnick EM, Mallampalli M, Kalbarczyk A. Sex and gender differences in Alzheimer&#x2019;s disease: recommendations for future research. J Womens Health (Larchmt). 2012;21(10):1018-1023. doi:10.1089/jwh.2012.3789</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jwh.2012.3789</ArticleId><ArticleId IdType="pubmed">22917473</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocca WA, Mielke MM, Vemuri P, Miller VM. Sex and gender differences in the causes of dementia: a narrative review. Maturitas. 2014;79(2):196-201. doi:10.1016/j.maturitas.2014.05.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.maturitas.2014.05.008</ArticleId><ArticleId IdType="pmc">PMC4169309</ArticleId><ArticleId IdType="pubmed">24954700</ArticleId></ArticleIdList></Reference><Reference><Citation>Glymour MM, Manly JJ. Lifecourse social conditions and racial and ethnic patterns of cognitive aging. Neuropsychol Rev. 2008;18(3):223-254. doi:10.1007/s11065-008-9064-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11065-008-9064-z</ArticleId><ArticleId IdType="pubmed">18815889</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaffe K, Falvey C, Harris TB, et al. ; Health ABC Study . Effect of socioeconomic disparities on incidence of dementia among biracial older adults: prospective study. BMJ. 2013;347:f7051. doi:10.1136/bmj.f7051</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.f7051</ArticleId><ArticleId IdType="pmc">PMC3898154</ArticleId><ArticleId IdType="pubmed">24355614</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine DA, Gross AL, Brice&#xf1;o EM, et al. . Association between blood pressure and later-life cognition among Black and White individuals. JAMA Neurol. 2020;77(7):810-819. doi:10.1001/jamaneurol.2020.0568</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.0568</ArticleId><ArticleId IdType="pmc">PMC7154952</ArticleId><ArticleId IdType="pubmed">32282019</ArticleId></ArticleIdList></Reference><Reference><Citation>The ARIC investigators . The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. Am J Epidemiol. 1989;129(4):687-702. doi:10.1093/oxfordjournals.aje.a115184</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/oxfordjournals.aje.a115184</ArticleId><ArticleId IdType="pubmed">2646917</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman GD, Cutter GR, Donahue RP, et al. . CARDIA: study design, recruitment, and some characteristics of the examined subjects. J Clin Epidemiol. 1988;41(11):1105-1116. doi:10.1016/0895-4356(88)90080-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0895-4356(88)90080-7</ArticleId><ArticleId IdType="pubmed">3204420</ArticleId></ArticleIdList></Reference><Reference><Citation>Fried LP, Borhani NO, Enright P, et al. . The Cardiovascular Health Study: design and rationale. Ann Epidemiol. 1991;1(3):263-276. doi:10.1016/1047-2797(91)90005-W</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/1047-2797(91)90005-W</ArticleId><ArticleId IdType="pubmed">1669507</ArticleId></ArticleIdList></Reference><Reference><Citation>Feinleib M, Kannel WB, Garrison RJ, McNamara PM, Castelli WP. The Framingham Offspring Study. Design and preliminary data. Prev Med. 1975;4(4):518-525. doi:10.1016/0091-7435(75)90037-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0091-7435(75)90037-7</ArticleId><ArticleId IdType="pubmed">1208363</ArticleId></ArticleIdList></Reference><Reference><Citation>Gardener H, Wright CB, Dong C, et al. . Ideal cardiovascular health and cognitive aging in the Northern Manhattan Study. J Am Heart Assoc. 2016;5(3):e002731. doi:10.1161/JAHA.115.002731</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.115.002731</ArticleId><ArticleId IdType="pmc">PMC4943249</ArticleId><ArticleId IdType="pubmed">26984255</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine DA, Galecki AT, Langa KM, et al. . Trajectory of cognitive decline after incident stroke. JAMA. 2015;314(1):41-51. doi:10.1001/jama.2015.6968</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2015.6968</ArticleId><ArticleId IdType="pmc">PMC4655087</ArticleId><ArticleId IdType="pubmed">26151265</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine DA, Galecki AT, Langa KM, et al. . Blood pressure and cognitive decline over 8 years in middle-aged and older Black and White Americans. Hypertension. 2019;73(2):310-318. doi:10.1161/HYPERTENSIONAHA.118.12062</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.118.12062</ArticleId><ArticleId IdType="pmc">PMC6450556</ArticleId><ArticleId IdType="pubmed">30624986</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji H, Kim A, Ebinger JE, et al. . Sex differences in blood pressure trajectories over the life course. JAMA Cardiol. 2020;5(3):19-26. doi:10.1001/jamacardio.2019.5306</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2019.5306</ArticleId><ArticleId IdType="pmc">PMC6990675</ArticleId><ArticleId IdType="pubmed">31940010</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferraro F. Minority and Cross-Cultural Aspects of Neuropsychological Assessment (Studies on Neuropsychology, Neurology and Cognition). Swets &amp; Zeitlinger; 2002.</Citation></Reference><Reference><Citation>Lucas JA, Ivnik RJ, Smith GE, et al. . Mayo&#x2019;s older African Americans normative studies: norms for Boston Naming Test, controlled oral word association, category fluency, animal naming, token test, WRAT-3 reading, trail making test, stroop test, and judgment of line orientation. Clin Neuropsychol. 2005;19(2):243-269. doi:10.1080/13854040590945337</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13854040590945337</ArticleId><ArticleId IdType="pubmed">16019707</ArticleId></ArticleIdList></Reference><Reference><Citation>Hachinski V, Iadecola C, Petersen RC, et al. . National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke. 2006;37(9):2220-2241. doi:10.1161/01.STR.0000237236.88823.47</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.STR.0000237236.88823.47</ArticleId><ArticleId IdType="pubmed">16917086</ArticleId></ArticleIdList></Reference><Reference><Citation>Samejima F. Estimation of latent ability using a response pattern of graded scores. Psychometrika. 1969;34(1):1-17. doi:10.1007/BF03372160</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF03372160</ArticleId></ArticleIdList></Reference><Reference><Citation>Gross AL, Mungas DM, Crane PK, et al. . Effects of education and race on cognitive decline: an integrative study of generalizability versus study-specific results. Psychol Aging. 2015;30(4):863-880. doi:10.1037/pag0000032</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/pag0000032</ArticleId><ArticleId IdType="pmc">PMC4679562</ArticleId><ArticleId IdType="pubmed">26523693</ArticleId></ArticleIdList></Reference><Reference><Citation>Asparouhov T, Muthen B. Plausible values for latent variables using Mplus. Published August 21, 2010. Accessed January 15, 2021. http://www.statmodel.com/download/Plausible.pdf</Citation></Reference><Reference><Citation>Muthen L, Muthen B.. Mplus User&#x2019;s Guide. 8th ed. Muthen &amp; Muthen; 2017.</Citation></Reference><Reference><Citation>Franklin SS, Jacobs MJ, Wong ND, L&#x2019;Italien GJ, Lapuerta P. Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension. 2001;37(3):869-874. doi:10.1161/01.HYP.37.3.869</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.HYP.37.3.869</ArticleId><ArticleId IdType="pubmed">11244010</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau KK, Li L, Simoni M, Mehta Z, K&#xfc;ker W, Rothwell PM; Oxford Vascular Study . Long-term premorbid blood pressure and cerebral small vessel disease burden on imaging in transient ischemic attack and ischemic stroke. Stroke. 2018;49(9):2053-2060. doi:10.1161/STROKEAHA.118.021578</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.118.021578</ArticleId><ArticleId IdType="pmc">PMC6116796</ArticleId><ArticleId IdType="pubmed">30354991</ArticleId></ArticleIdList></Reference><Reference><Citation>Pool LR, Ning H, Wilkins J, Lloyd-Jones DM, Allen NB. Use of long-term cumulative blood pressure in cardiovascular risk prediction models. JAMA Cardiol. 2018;3(11):1096-1100. doi:10.1001/jamacardio.2018.2763</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2018.2763</ArticleId><ArticleId IdType="pmc">PMC6583053</ArticleId><ArticleId IdType="pubmed">30193291</ArticleId></ArticleIdList></Reference><Reference><Citation>Levey AS, Stevens LA, Schmid CH, et al. ; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) . A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-612. doi:10.7326/0003-4819-150-9-200905050-00006</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-150-9-200905050-00006</ArticleId><ArticleId IdType="pmc">PMC2763564</ArticleId><ArticleId IdType="pubmed">19414839</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarrey AC, An Y, Kitner-Triolo MH, Ferrucci L, Resnick SM. Sex differences in cognitive trajectories in clinically normal older adults. Psychol Aging. 2016;31(2):166-175. doi:10.1037/pag0000070</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/pag0000070</ArticleId><ArticleId IdType="pmc">PMC4783196</ArticleId><ArticleId IdType="pubmed">26796792</ArticleId></ArticleIdList></Reference><Reference><Citation>Tschanz JT, Corcoran CD, Schwartz S, et al. . Progression of cognitive, functional, and neuropsychiatric symptom domains in a population cohort with Alzheimer dementia: the Cache County Dementia Progression study. Am J Geriatr Psychiatry. 2011;19(6):532-542. doi:10.1097/JGP.0b013e3181faec23</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/JGP.0b013e3181faec23</ArticleId><ArticleId IdType="pmc">PMC3101372</ArticleId><ArticleId IdType="pubmed">21606896</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin KA, Choudhury KR, Rathakrishnan BG, Marks DM, Petrella JR, Doraiswamy PM; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Marked gender differences in progression of mild cognitive impairment over 8 years. Alzheimers Dement (N Y). 2015;1(2):103-110. doi:10.1016/j.trci.2015.07.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trci.2015.07.001</ArticleId><ArticleId IdType="pmc">PMC4593067</ArticleId><ArticleId IdType="pubmed">26451386</ArticleId></ArticleIdList></Reference><Reference><Citation>Sundermann EE, Maki PM, Rubin LH, Lipton RB, Landau S, Biegon A; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Female advantage in verbal memory: evidence of sex-specific cognitive reserve. Neurology. 2016;87(18):1916-1924. doi:10.1212/WNL.0000000000003288</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003288</ArticleId><ArticleId IdType="pmc">PMC5100712</ArticleId><ArticleId IdType="pubmed">27708128</ArticleId></ArticleIdList></Reference><Reference><Citation>Sundermann EE, Biegon A, Rubin LH, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Better verbal memory in women than men in MCI despite similar levels of hippocampal atrophy. Neurology. 2016;86(15):1368-1376. doi:10.1212/WNL.0000000000002570</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002570</ArticleId><ArticleId IdType="pmc">PMC4831033</ArticleId><ArticleId IdType="pubmed">26984945</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolinsky FD, Unverzagt FW, Smith DM, Jones R, Stoddard A, Tennstedt SL. The ACTIVE cognitive training trial and health-related quality of life: protection that lasts for 5 years. J Gerontol A Biol Sci Med Sci. 2006;61(12):1324-1329. doi:10.1093/gerona/61.12.1324</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gerona/61.12.1324</ArticleId><ArticleId IdType="pubmed">17234829</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossetti HC, Munro Cullum C, Hynan LS, Lacritz LH. The CERAD neuropsychologic battery total score and the progression of Alzheimer&#x2019;s disease. Alzheimer Dis Assoc Disord. 2010;24(2):138-142. doi:10.1097/WAD.0b013e3181b76415</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WAD.0b013e3181b76415</ArticleId><ArticleId IdType="pmc">PMC2920638</ArticleId><ArticleId IdType="pubmed">20505431</ArticleId></ArticleIdList></Reference><Reference><Citation>Unger JM, van Belle G, Heyman A; Consortium to Establish a Registry for Alzheimer&#x2019;s Disease . Cross-sectional versus longitudinal estimates of cognitive change in nondemented older people: a CERAD study. J Am Geriatr Soc. 1999;47(5):559-563. doi:10.1111/j.1532-5415.1999.tb02570.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1532-5415.1999.tb02570.x</ArticleId><ArticleId IdType="pubmed">10323649</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett HP, Corbett AJ, Gaden S, Grayson DA, Kril JJ, Broe GA. Subcortical vascular disease and functional decline: a 6-year predictor study. J Am Geriatr Soc. 2002;50(12):1969-1977. doi:10.1046/j.1532-5415.2002.50608.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1532-5415.2002.50608.x</ArticleId><ArticleId IdType="pubmed">12473008</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark LJ, Gatz M, Zheng L, Chen Y-L, McCleary C, Mack WJ. Longitudinal verbal fluency in normal aging, preclinical, and prevalent Alzheimer&#x2019;s disease. Am J Alzheimers Dis Other Demen. 2009;24(6):461-468. doi:10.1177/1533317509345154</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1533317509345154</ArticleId><ArticleId IdType="pmc">PMC2824246</ArticleId><ArticleId IdType="pubmed">19759254</ArticleId></ArticleIdList></Reference><Reference><Citation>Cosentino S, Scarmeas N, Albert SM, Stern Y. Verbal fluency predicts mortality in Alzheimer disease. Cogn Behav Neurol. 2006;19(3):123-129. doi:10.1097/01.wnn.0000213912.87642.3d</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.wnn.0000213912.87642.3d</ArticleId><ArticleId IdType="pmc">PMC2441850</ArticleId><ArticleId IdType="pubmed">16957489</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Barrio V. Diagnostic and statistical manual of mental disorders. 5th ed. 2016. doi:10.1016/B978-0-12-809324-5.05530-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-12-809324-5.05530-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller DI, Halpern DF. The new science of cognitive sex differences. Trends Cogn Sci. 2014;18(1):37-45. doi:10.1016/j.tics.2013.10.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tics.2013.10.011</ArticleId><ArticleId IdType="pubmed">24246136</ArticleId></ArticleIdList></Reference><Reference><Citation>DeCarli C, Massaro J, Harvey D, et al. . Measures of brain morphology and infarction in the Framingham Heart Study: establishing what is normal. Neurobiol Aging. 2005;26(4):491-510. doi:10.1016/j.neurobiolaging.2004.05.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2004.05.004</ArticleId><ArticleId IdType="pubmed">15653178</ArticleId></ArticleIdList></Reference><Reference><Citation>Mielke MM, Vemuri P, Rocca WA. Clinical epidemiology of Alzheimer&#x2019;s disease: assessing sex and gender differences. Clin Epidemiol. 2014;6:37-48. doi:10.2147/CLEP.S37929</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CLEP.S37929</ArticleId><ArticleId IdType="pmc">PMC3891487</ArticleId><ArticleId IdType="pubmed">24470773</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CRJ Jr, Wiste HJ, Weigand SD, et al. . Age, sex, and APOE epsilon4 effects on memory, brain structure, and beta-amyloid across the adult life span. JAMA Neurol. 2015;72(5):511-519. doi:10.1001/jamaneurol.2014.4821</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.4821</ArticleId><ArticleId IdType="pmc">PMC4428984</ArticleId><ArticleId IdType="pubmed">25775353</ArticleId></ArticleIdList></Reference><Reference><Citation>Shokouhi S, Taylor WD, Albert K, Kang H, Newhouse PA; Alzheimer&#x2019;s Disease Neuroimaging Initiative . In vivo network models identify sex differences in the spread of tau pathology across the brain. Alzheimers Dement (Amst). 2020;12(1):e12016. doi:10.1002/dad2.12016</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dad2.12016</ArticleId><ArticleId IdType="pmc">PMC7144772</ArticleId><ArticleId IdType="pubmed">32280740</ArticleId></ArticleIdList></Reference><Reference><Citation>Prins ND, van Dijk EJ, den Heijer T, et al. . Cerebral small-vessel disease and decline in information processing speed, executive function and memory. Brain. 2005;128(Pt 9):2034-2041. doi:10.1093/brain/awh553</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awh553</ArticleId><ArticleId IdType="pubmed">15947059</ArticleId></ArticleIdList></Reference><Reference><Citation>Grieve SM, Williams LM, Paul RH, Clark CR, Gordon E. Cognitive aging, executive function, and fractional anisotropy: a diffusion tensor MR imaging study. AJNR Am J Neuroradiol. 2007;28(2):226-235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7977408</ArticleId><ArticleId IdType="pubmed">17296985</ArticleId></ArticleIdList></Reference><Reference><Citation>Gennatas ED, Avants BB, Wolf DH, et al. . Age-related effects and sex differences in gray matter density, volume, mass, and cortical thickness from childhood to young adulthood. J Neurosci. 2017;37(20):5065-5073. doi:10.1523/JNEUROSCI.3550-16.2017</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3550-16.2017</ArticleId><ArticleId IdType="pmc">PMC5444192</ArticleId><ArticleId IdType="pubmed">28432144</ArticleId></ArticleIdList></Reference><Reference><Citation>Driscoll I, Davatzikos C, An Y, et al. . Longitudinal pattern of regional brain volume change differentiates normal aging from MCI. Neurology. 2009;72(22):1906-1913. doi:10.1212/WNL.0b013e3181a82634</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181a82634</ArticleId><ArticleId IdType="pmc">PMC2690968</ArticleId><ArticleId IdType="pubmed">19487648</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes LL, Wilson RS, Bienias JL, Schneider JA, Evans DA, Bennett DA. Sex differences in the clinical manifestations of Alzheimer disease pathology. Arch Gen Psychiatry. 2005;62(6):685-691. doi:10.1001/archpsyc.62.6.685</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archpsyc.62.6.685</ArticleId><ArticleId IdType="pubmed">15939846</ArticleId></ArticleIdList></Reference><Reference><Citation>Filon JR, Intorcia AJ, Sue LI, et al. . Gender differences in Alzheimer Disease: brain atrophy, histopathology burden, and cognition. J Neuropathol Exp Neurol. 2016;75(8):748-754. doi:10.1093/jnen/nlw047</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/nlw047</ArticleId><ArticleId IdType="pmc">PMC7299435</ArticleId><ArticleId IdType="pubmed">27297671</ArticleId></ArticleIdList></Reference><Reference><Citation>Liesinger AM, Graff-Radford NR, Duara R, et al. . Sex and age interact to determine clinicopathologic differences in Alzheimer&#x2019;s disease. Acta Neuropathol. 2018;136(6):873-885. doi:10.1007/s00401-018-1908-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1908-x</ArticleId><ArticleId IdType="pmc">PMC6280837</ArticleId><ArticleId IdType="pubmed">30219939</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorm AF, Rodgers B, Henderson AS, et al. . Occupation type as a predictor of cognitive decline and dementia in old age. Age Ageing. 1998;27(4):477-483. doi:10.1093/ageing/27.4.477</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ageing/27.4.477</ArticleId><ArticleId IdType="pubmed">9884005</ArticleId></ArticleIdList></Reference><Reference><Citation>Zahodne LB, Glymour MM, Sparks C, et al. . Education does not slow cognitive decline with aging: 12-year evidence from the Victoria longitudinal study. J Int Neuropsychol Soc. 2011;17(6):1039-1046. doi:10.1017/S1355617711001044</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1355617711001044</ArticleId><ArticleId IdType="pmc">PMC3285821</ArticleId><ArticleId IdType="pubmed">21923980</ArticleId></ArticleIdList></Reference><Reference><Citation>Euser SM, Schram MT, Hofman A, Westendorp RGJ, Breteler MMB. Measuring cognitive function with age: the influence of selection by health and survival. Epidemiology. 2008;19(3):440-447. doi:10.1097/EDE.0b013e31816a1d31</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EDE.0b013e31816a1d31</ArticleId><ArticleId IdType="pubmed">18414086</ArticleId></ArticleIdList></Reference><Reference><Citation>Salthouse TA. Selectivity of attrition in longitudinal studies of cognitive functioning. J Gerontol B Psychol Sci Soc Sci. 2014;69(4):567-574. doi:10.1093/geronb/gbt046</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/geronb/gbt046</ArticleId><ArticleId IdType="pmc">PMC4049149</ArticleId><ArticleId IdType="pubmed">23733858</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein J, Luppa M, Luck T, et al. . The assessment of changes in cognitive functioning: age-, education-, and gender-specific reliable change indices for older adults tested on the CERAD-NP battery: results of the German Study on Ageing, Cognition, and Dementia in Primary Care Patients (AgeCoDe). Am J Geriatr Psychiatry. 2012;20(1):84-97. doi:10.1097/JGP.0b013e318209dd08</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/JGP.0b013e318209dd08</ArticleId><ArticleId IdType="pubmed">22183013</ArticleId></ArticleIdList></Reference><Reference><Citation>Avila JF, Vonk JMJ, Verney SP, et al. . Sex/gender differences in cognitive trajectories vary as a function of race/ethnicity. Alzheimers Dement. 2019;15(12):1516-1523. doi:10.1016/j.jalz.2019.04.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2019.04.006</ArticleId><ArticleId IdType="pmc">PMC6925640</ArticleId><ArticleId IdType="pubmed">31606366</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolters FJ, Chibnik LB, Waziry R, et al. . Twenty-seven-year time trends in dementia incidence in Europe and the United States. Neurology. 2020;95(5):e519-e531. doi:10.1212/WNL.0000000000010022</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000010022</ArticleId><ArticleId IdType="pmc">PMC7455342</ArticleId><ArticleId IdType="pubmed">32611641</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">33658354</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>12</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>583</Issue><PubDate><Year>2021</Year><Month>Mar</Month><Day>03</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle><i>APOE4</i> disrupts intracellular lipid homeostasis in human iPSC-derived glia.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">eaaz4564</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.aaz4564</ELocationID><Abstract><AbstractText>The <i>E4</i> allele of the apolipoprotein E gene (<i>APOE</i>) has been established as a genetic risk factor for many diseases including cardiovascular diseases and Alzheimer's disease (AD), yet its mechanism of action remains poorly understood. APOE is a lipid transport protein, and the dysregulation of lipids has recently emerged as a key feature of several neurodegenerative diseases including AD. However, it is unclear how APOE4 perturbs the intracellular lipid state. Here, we report that <i>APOE4</i>, but not <i>APOE3</i>, disrupted the cellular lipidomes of human induced pluripotent stem cell (iPSC)-derived astrocytes generated from fibroblasts of <i>APOE4</i> or <i>APOE3</i> carriers, and of yeast expressing human <i>APOE</i> isoforms. We combined lipidomics and unbiased genome-wide screens in yeast with functional and genetic characterization to demonstrate that human APOE4 induced altered lipid homeostasis. These changes resulted in increased unsaturation of fatty acids and accumulation of intracellular lipid droplets both in yeast and in <i>APOE4</i>-expressing human iPSC-derived astrocytes. We then identified genetic and chemical modulators of this lipid disruption. We showed that supplementation of the culture medium with choline (a soluble phospholipid precursor) restored the cellular lipidome to its basal state in <i>APOE4</i>-expressing human iPSC-derived astrocytes and in yeast expressing human <i>APOE4</i> Our study illuminates key molecular disruptions in lipid metabolism that may contribute to the disease risk linked to the <i>APOE4</i> genotype. Our study suggests that manipulating lipid metabolism could be a therapeutic approach to help alleviate the consequences of carrying the <i>APOE4</i> allele.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sienski</LastName><ForeName>Grzegorz</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-2730-7710</Identifier><AffiliationInfo><Affiliation>Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Narayan</LastName><ForeName>Priyanka</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-9328-4959</Identifier><AffiliationInfo><Affiliation>Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Department of Brain and Cognitive Sciences, MIT, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Genetics and Biochemistry Branch, NIDDK, National Institutes of Health, Bethesda, MD 20814, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonner</LastName><ForeName>Julia Maeve</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0003-3551-9972</Identifier><AffiliationInfo><Affiliation>Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Department of Brain and Cognitive Sciences, MIT, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kory</LastName><ForeName>Nora</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-5307-9021</Identifier><AffiliationInfo><Affiliation>Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boland</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-6694-2039</Identifier><AffiliationInfo><Affiliation>Department of Molecular Metabolism, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arczewska</LastName><ForeName>Aleksandra A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ralvenius</LastName><ForeName>William T</ForeName><Initials>WT</Initials><Identifier Source="ORCID">0000-0002-0408-3443</Identifier><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Department of Brain and Cognitive Sciences, MIT, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akay</LastName><ForeName>Leyla</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-5944-2466</Identifier><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Department of Brain and Cognitive Sciences, MIT, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lockshin</LastName><ForeName>Elana</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-5808-7995</Identifier><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Department of Brain and Cognitive Sciences, MIT, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Liang</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Duke University, Durham, NC 27708, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Milo</LastName><ForeName>Blerta</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Department of Brain and Cognitive Sciences, MIT, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graziosi</LastName><ForeName>Agnese</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-4992-7902</Identifier><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Department of Brain and Cognitive Sciences, MIT, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baru</LastName><ForeName>Valeriya</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0001-8518-9313</Identifier><AffiliationInfo><Affiliation>Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lewis</LastName><ForeName>Caroline A</ForeName><Initials>CA</Initials><Identifier Source="ORCID">0000-0003-1787-5084</Identifier><AffiliationInfo><Affiliation>Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kellis</LastName><ForeName>Manolis</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-7113-9630</Identifier><AffiliationInfo><Affiliation>Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sabatini</LastName><ForeName>David M</ForeName><Initials>DM</Initials><Identifier Source="ORCID">0000-0002-1446-7256</Identifier><AffiliationInfo><Affiliation>Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Massachusetts Institute of Technology, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Koch Institute for Integrative Cancer Research and Massachusetts Institute of Technology, Department of Biology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Li-Huei</ForeName><Initials>LH</Initials><Identifier Source="ORCID">0000-0003-1262-0592</Identifier><AffiliationInfo><Affiliation>Picower Institute for Learning and Memory, Department of Brain and Cognitive Sciences, MIT, Cambridge, MA 02139, USA. lhtsai@mit.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lindquist</LastName><ForeName>Susan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Massachusetts Institute of Technology, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 CA103866</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG058002</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062421</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K99 AG055697</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG062377</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG048029</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 NS110453</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG062335</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053318">Apolipoprotein E3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053318" MajorTopicYN="N">Apolipoprotein E3</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006706" MajorTopicYN="N">Homeostasis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="Y">Induced Pluripotent Stem Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009457" MajorTopicYN="N">Neuroglia</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing interests</b>: SL was a co-founder of Yumanity Therapeutics. LHT is a member of the Scientific Advisory Board of Yumanity Therapeutics. PN and SL are co-inventors on US Patent PCT/US2015/049674 (Cells expressing Apolipoprotein E and uses thereof). GS, PN, JMB, LHT are co-inventors on patent application 63/023,698 (Use of choline supplementation as therapy for APOE4-related disorders). GS and AAA are currently employees and shareholders of AstraZeneca. CAL is a paid consultant for ReviveMed Inc.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>9</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>5</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>11</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>4</Day><Hour>5</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>9</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33658354</ArticleId><ArticleId IdType="mid">NIHMS1706136</ArticleId><ArticleId IdType="pmc">PMC8218593</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.aaz4564</ArticleId><ArticleId IdType="pii">13/583/eaaz4564</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fanning S, Haque A, Imberdis T, Baru V, Barrasa MI, Nuber S, Termine D, Ramalingam N, Ho GPH, Noble T, Sandoe J, Lou Y, Landgraf D, Freyzon Y, Newby G, Soldner F, Terry-Kantor E, Kim TE, Hofbauer HF, Becuwe M, Jaenisch R, Pincus D, Clish CB, Walther TC, Farese RV, Srinivasan S, Welte MA, Kohlwein SD, Dettmer U, Lindquist S, Selkoe D, Lipidomic Analysis of &#x3b1;-Synuclein Neurotoxicity Identifies Stearoyl CoA Desaturase as a Target for Parkinson Treatment, Mol. Cell 73, 1001&#x2013;1014.e8 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6408259</ArticleId><ArticleId IdType="pubmed">30527540</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimabukuro MK, Langhi LGP, Cordeiro I, Brito JM, Batista CMDC, Mattson MP, De Mello Coelho V, Lipid-laden cells differentially distributed in the aging brain are functionally active and correspond to distinct phenotypes, Sci. Rep 6, 1&#x2013;12 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4814830</ArticleId><ArticleId IdType="pubmed">27029648</ArticleId></ArticleIdList></Reference><Reference><Citation>Tcw J, Liang SA, Qian L, Pipalia NH, Chao MJ, Shi Y, Bertelsen SE, Kapoor M, Marcora E, Sikora E, Holtzman DM, Maxfield FR, Zhang B, Wang M, Poon WW, Goate AM, Goate AM, Cholesterol and matrisome pathways dysregulated in human APOE E4 glia, bioRxiv 4, 713362 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9340815</ArticleId><ArticleId IdType="pubmed">35750033</ArticleId></ArticleIdList></Reference><Reference><Citation>Marschallinger J, Iram T, Zardeneta M, Lee SE, Lehallier B, Haney MS, V Pluvinage J, Mathur V, Hahn O, Morgens DW, Kim J, Tevini J, Felder TK, Wolinski H, Bertozzi CR, Bassik MC, Aigner L, Wyss-Coray T, Lipid-droplet-accumulating microglia represent a dysfunctional and proinflammatory state in the aging brain, Nat. Neurosci 23, 194&#x2013;208 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7595134</ArticleId><ArticleId IdType="pubmed">31959936</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton LK, Dufresne M, Jopp&#xe9; SE, Petryszyn S, Aumont A, Calon F, Barnab&#xe9;-Heider F, Furtos A, Parent M, Chaurand P, Fernandes KJL, Aberrant Lipid Metabolism in the Forebrain Niche Suppresses Adult Neural Stem Cell Proliferation in an Animal Model of Alzheimer&#x2019;s Disease, Cell Stem Cell 17, 397&#x2013;411 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26321199</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer A, Stelzmann RA, Schnitzlein HN, Murtagh FR, An English translation of Alzheimer&#x2019;s 1907 paper, &#x201c;Uber eine eigenartige Erkankung der Hirnrinde&#x201d;., Clin. Anat 8, 429&#x2013;31 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">8713166</ArticleId></ArticleIdList></Reference><Reference><Citation>Innerarity TL, Mahley RW, Enhanced binding by cultured human fibroblasts of apo-E-containing lipoproteins as compared with low density lipoproteins., Biochemistry 17, 1440&#x2013;7 (1978).</Citation><ArticleIdList><ArticleId IdType="pubmed">206278</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahley RW, Bersot TP, Lequire VS, Levy RI, Windmueller HG, Brown WV, Identity of Very Low Density Lipoprotein Apoproteins of Plasma and Liver Golgi Apparatus, Science (80-.). 168, 380&#x2013;382 (1970).</Citation><ArticleIdList><ArticleId IdType="pubmed">4985196</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahley RW, Apolipoprotein E : Cholesterol Transport, Science (80-.). 240, 622&#x2013;630 (1988).</Citation><ArticleIdList><ArticleId IdType="pubmed">3283935</ArticleId></ArticleIdList></Reference><Reference><Citation>McIntosh AM, Bennett C, Dickson D, Anestis SF, Watts DP, Webster TH, Fontenot MB, Bradley BJ, The apolipoprotein E (APOE) gene appears functionally monomorphic in chimpanzees (Pan troglodytes)., PLoS One 7, e47760 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3480407</ArticleId><ArticleId IdType="pubmed">23112842</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, Combarros O, Zelenika D, Bullido MJ, Tavernier B, Letenneur L, Bettens K, Berr C, Pasquier F, Fi&#xe9;vet N, Barberger-Gateau P, Engelborghs S, De Deyn P, Mateo I, Franck A, Helisalmi S, Porcellini E, Hanon O, De Pancorbo MM, Lendon C, Dufouil C, Jaillard C, Leveillard T, Alvarez V, Bosco P, Mancuso M, Panza F, Nacmias B, Boss P, Piccardi P, Annoni G, Seripa D, Galimberti D, Hannequin D, Licastro F, Soininen H, Ritchie K, Blanch&#xe9; H, Dartigues JF, Tzourio C, Gut I, Van Broeckhoven C, Alp&#xe9;rovitch A, Lathrop M, Amouyel P, Arosio B, Coto E, Del Zompo M, Deramecourt V, Epelbaum J, Forti P, Brice A, Ferri R, Scarpini E, Siciliano G, Solfrizzi V, Sorbi S, Spalletta G, Ravaglia G, Sahel J, Valdivieso F, Veps&#xe4;l&#xe4;inen S, Pilotto A, Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer&#x2019;s disease, Nat. Genet 41, 1094&#x2013;1099 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19734903</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA, Cupples LA, Haines JL, Hyman B, a Kukull W, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van Duijn CM, Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium., JAMA 278, 1349&#x2013;1356 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Roses AD, M.D, Apolipoprotein E Alleles As Risk Factors in Alzheimer&#x2019;S Disease, Annu. Rev. Med 47, 387&#x2013;400 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8712790</ArticleId></ArticleIdList></Reference><Reference><Citation>Davignon J, Gregg RE, Sing CF, Apolipoprotein E polymorphism and atherosclerosis, Arterioscler. Thromb. Vasc. Biol 8, 1&#x2013;21 (1988).</Citation><ArticleIdList><ArticleId IdType="pubmed">3277611</ArticleId></ArticleIdList></Reference><Reference><Citation>Sing CF, Moll PP, Genetics of Variability of CHD Risk, Int. J. Epidemiol 18, S183&#x2013;S195 (1989).</Citation><ArticleIdList><ArticleId IdType="pubmed">2807701</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres-Perez E, Ledesma M, Garcia-Sobreviela MP, Leon-Latre M, Arbones-Mainar JM, Apolipoprotein E4 association with metabolic syndrome depends on body fatness, Atherosclerosis 245, 35&#x2013;42 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26691908</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright KM, Rand KA, Kermany A, Noto K, Curtis D, Garrigan D, Slinkov D, Dorfman I, Granka JM, Byrnes J, Myres N, Ball CA, Ruby JG, A Prospective Analysis of Genetic Variants Associated with Human Lifespan., G3 (Bethesda). 9, 2863&#x2013;2878 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6723124</ArticleId><ArticleId IdType="pubmed">31484785</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA, Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer&#x2019;s disease in late onset families., Science 261, 921&#x2013;3 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao N, Liu CC, Qiao W, Bu G, Apolipoprotein E, Receptors, and Modulation of Alzheimer&#x2019;s Disease, Biol. Psychiatry 83, 347&#x2013;357 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5599322</ArticleId><ArticleId IdType="pubmed">28434655</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Sloan SA, Clarke LE, Caneda C, Plaza CA, Blumenthal PD, Vogel H, Steinberg GK, Edwards MSB, Li G, Duncan JA, Cheshier SH, Shuer LM, Chang EF, Grant GA, Gephart MGH, Barres BA, Purification and Characterization of Progenitor and Mature Human Astrocytes Reveals Transcriptional and Functional Differences with Mouse., Neuron 89, 37&#x2013;53 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4707064</ArticleId><ArticleId IdType="pubmed">26687838</ArticleId></ArticleIdList></Reference><Reference><Citation>Petranovic D, Tyo K, Vemuri GN, Nielsen J, Prospects of yeast systems biology for human health: Integrating lipid, protein and energy metabolism, FEMS Yeast Res. 10, 1046&#x2013;1059 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20977625</ArticleId></ArticleIdList></Reference><Reference><Citation>Khurana V, Lindquist S, Modelling neurodegeneration in Saccharomyces cerevisiae: Why cook with baker&#x2019;s yeast?, Nat. Rev. Neurosci 11, 436&#x2013;449 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20424620</ArticleId></ArticleIdList></Reference><Reference><Citation>Kachroo AH, Laurent JM, Yellman CM, Meyer AG, Wilke CO, Marcotte EM, Systematic humanization of yeast genes reveals conserved functions and genetic modularity, Science (80-.). 348, 921&#x2013;925 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4718922</ArticleId><ArticleId IdType="pubmed">25999509</ArticleId></ArticleIdList></Reference><Reference><Citation>Natter K, Kohlwein SD, Yeast and cancer cells - Common principles in lipid metabolismBiochim. Biophys. Acta - Mol. Cell Biol. Lipids (2013), doi:10.1016/j.bbalip.2012.09.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbalip.2012.09.003</ArticleId><ArticleId IdType="pmc">PMC3549488</ArticleId><ArticleId IdType="pubmed">22989772</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyles JK, Pitas RE, Wilson E, Mahley RW, Taylor JM, Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system., J. Clin. Invest 76, 1501&#x2013;13 (1985).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC424114</ArticleId><ArticleId IdType="pubmed">3932467</ArticleId></ArticleIdList></Reference><Reference><Citation>Farmer B, Kluemper J, Johnson L, Apolipoprotein E4 Alters Astrocyte Fatty Acid Metabolism and Lipid Droplet Formation, Cells 8, 182 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6406677</ArticleId><ArticleId IdType="pubmed">30791549</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YT, Seo J, Gao F, Feldman HM, Wen HL, Penney J, Cam HP, Gjoneska E, Raja WK, Cheng J, Rueda R, Kritskiy O, Abdurrob F, Peng Z, Milo B, Yu CJ, Elmsaouri S, Dey D, Ko T, Yankner BA, Tsai LH, APOE4 Causes Widespread Molecular and Cellular Alterations Associated with Alzheimer&#x2019;s Disease Phenotypes in Human iPSC-Derived Brain Cell Types, Neuron 98, 1141&#x2013;1154.e7 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6023751</ArticleId><ArticleId IdType="pubmed">29861287</ArticleId></ArticleIdList></Reference><Reference><Citation>Knittelfelder OL, Kohlwein SD, Lipid extraction from yeast cells, Cold Spring Harb. Protoc 2017, 408&#x2013;411 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28461651</ArticleId></ArticleIdList></Reference><Reference><Citation>Ejsing CS, Sampaio JL, Surendranath V, Duchoslav E, Ekroos K, Klemm RW, Simons K, Shevchenko A, Global analysis of the yeast lipidome by quantitative shotgun mass spectrometry., Proc. Natl. Acad. Sci. {U.S.A.} 106, 2136&#x2013;2141 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2650121</ArticleId><ArticleId IdType="pubmed">19174513</ArticleId></ArticleIdList></Reference><Reference><Citation>Walther TC, Chung J, V Farese R, Lipid Droplet Biogenesis., Annu. Rev. Cell Dev. Biol 33, 491&#x2013;510 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6986389</ArticleId><ArticleId IdType="pubmed">28793795</ArticleId></ArticleIdList></Reference><Reference><Citation>Fam TK, Klymchenko AS, Collot M, Recent Advances in Fluorescent Probes for Lipid Droplets., Mater. (Basel, Switzerland) 11 (2018), doi:10.3390/ma11091768.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ma11091768</ArticleId><ArticleId IdType="pmc">PMC6163203</ArticleId><ArticleId IdType="pubmed">30231571</ArticleId></ArticleIdList></Reference><Reference><Citation>Straub BK, Gyoengyoesi B, Koenig M, Hashani M, Pawella LM, Herpel E, Mueller W, Macher-Goeppinger S, Heid H, Schirmacher P, Adipophilin/perilipin-2 as a lipid droplet-specific marker for metabolically active cells and diseases associated with metabolic dysregulation, Histopathology 62, 617&#x2013;631 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23347084</ArticleId></ArticleIdList></Reference><Reference><Citation>V Hansen D, Hanson JE, Sheng M, Microglia in Alzheimer&#x2019;s disease., J. Cell Biol 217, 459&#x2013;472 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5800817</ArticleId><ArticleId IdType="pubmed">29196460</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh P, Budding Yeast: An Ideal Backdrop for In vivo Lipid Biochemistry, Front. Cell Dev. Biol 4, 1&#x2013;8 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5222803</ArticleId><ArticleId IdType="pubmed">28119915</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahley RW, Rall SC, Apolipoprotein E: far more than a lipid transport protein., Annu. Rev. Genomics Hum. Genet 1, 507&#x2013;37 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">11701639</ArticleId></ArticleIdList></Reference><Reference><Citation>Treusch S, Hamamichi S, Goodman JL, Matlack KES, Chung CY, Baru V, Shulman JM, Parrado A, Bevis BJ, Valastyan JS, Han H, Lindhagen-Persson M, Reiman EM, Evans DA, Bennett DA, Olofsson A, DeJager PL, Tanzi RE, Caldwell KA, Caldwell GA, Lindquist S, Functional links between A&#x3b2; toxicity, endocytic trafficking, and Alzheimer&#x2019;s disease risk factors in yeast, Science (80-.). 334, 1241&#x2013;1245 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3281757</ArticleId><ArticleId IdType="pubmed">22033521</ArticleId></ArticleIdList></Reference><Reference><Citation>Aranda-D&#xed;az A, Mace K, Zuleta I, Harrigan P, El-Samad H, Robust Synthetic Circuits for Two-Dimensional Control of Gene Expression in Yeast., ACS Synth. Biol 6, 545&#x2013;554 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5507677</ArticleId><ArticleId IdType="pubmed">27930885</ArticleId></ArticleIdList></Reference><Reference><Citation>Athenstaedt K, Zweytick D, Jandrositz A, Kohlwein SD, Daum G, Identification and characterization of major lipid particle proteins of the yeast Saccharomyces cerevisiae., J. Bacteriol 181, 6441&#x2013;8 (1999).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC103780</ArticleId><ArticleId IdType="pubmed">10515935</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong AHY, Evangelista M, Parsons AB, Xu H, Bader GD, Pag&#xe9; N, Robinson M, Raghibizadeh S, V Hogue CW, Bussey H, Andrews B, Tyers M, Boone C, Systematic genetic analysis with ordered arrays of yeast deletion mutants, Science (80-.). 294, 2364&#x2013;2368 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11743205</ArticleId></ArticleIdList></Reference><Reference><Citation>Giaever G, Chu AM, Ni L, Connelly C, Riles L, V&#xe9;ronneau S, Dow S, Lucau-Danila A, Anderson K, Andr&#xe9; B, Arkin AP, Astromoff A, El Bakkoury M, Bangham R, Benito R, Brachat S, Campanaro S, Curtiss M, Davis K, Deutschbauer A, Entian KD, Flaherty P, Foury F, Garfinkel DJ, Gerstein M, Gotte D, G&#xfc;ldener U, Hegemann JH, Hempel S, Herman Z, Jaramillo DF, Kelly DE, Kelly SL, K&#xf6;tter P, LaBonte D, Lamb DC, Lan N, Liang H, Liao H, Liu L, Luo C, Lussier M, Mao R, Menard P, Ooi SL, Revuelta JL, Roberts CJ, Rose M, Ross-Macdonald P, Scherens B, Schimmack G, Shafer B, Shoemaker DD, Sookhai-Mahadeo S, Storms RK, Strathern JN, Valle G, Voet M, Volckaert G, yun Wang C, Ward TR, Wilhelmy J, Winzeler EA, Yang Y, Yen G, Youngman E, Yu K, Bussey H, Boeke JD, Snyder M, Philippsen P, Davis RW, Johnston M, Functional profiling of the Saccharomyces cerevisiae genome, Nature 418, 387&#x2013;391 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12140549</ArticleId></ArticleIdList></Reference><Reference><Citation>Costanzo M, VanderSluis B, Koch EN, Baryshnikova A, Pons C, Tan G, Wang W, Usaj M, Hanchard J, Lee SD, Pelechano V, Styles EB, Billmann M, Van Leeuwen J, Van Dyk N, Lin ZY, Kuzmin E, Nelson J, Piotrowski JS, Srikumar T, Bahr S, Chen Y, Deshpande R, Kurat CF, Li SC, Li Z, Usaj MM, Okada H, Pascoe N, Luis BJS, Sharifpoor S, Shuteriqi E, Simpkins SW, Snider J, Suresh HG, Tan Y, Zhu H, Malod-Dognin N, Janjic V, Przulj N, Troyanskaya OG, Stagljar I, Xia T, Ohya Y, Gingras AC, Raught B, Boutros M, Steinmetz LM, Moore CL, Rosebrock AP, Caudy AA, Myers CL, Andrews B, Boone C, A global genetic interaction network maps a wiring diagram of cellular function, Science (80-.). 353 (2016), doi:10.1126/science.aaf1420.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaf1420</ArticleId><ArticleId IdType="pmc">PMC5661885</ArticleId><ArticleId IdType="pubmed">27708008</ArticleId></ArticleIdList></Reference><Reference><Citation>Surma MA, Klose C, Peng D, Shales M, Mrejen C, Stefanko A, Braberg H, Gordon DE, Vorkel D, Ejsing CS, Farese R, Simons K, Krogan NJ, Ernst R, A lipid E-MAP identifies Ubx2 as a critical regulator of lipid saturation and lipid bilayer stress, Mol. Cell 51, 519&#x2013;530 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3791312</ArticleId><ArticleId IdType="pubmed">23891562</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuldiner M, Collins SR, Thompson NJ, Denic V, Bhamidipati A, Punna T, Ihmels J, Andrews B, Boone C, Greenblatt JF, Weissman JS, Krogan NJ, Exploration of the function and organization of the yeast early secretory pathway through an epistatic miniarray profile, Cell 123, 507&#x2013;519 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16269340</ArticleId></ArticleIdList></Reference><Reference><Citation>Covino R, Ballweg S, Stordeur C, Michaelis JB, Puth K, Wernig F, Bahrami A, Ernst AM, Hummer G, Ernst R, A Eukaryotic Sensor for Membrane Lipid Saturation, Mol. Cell (2016), doi:10.1016/j.molcel.2016.05.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2016.05.015</ArticleId><ArticleId IdType="pubmed">27320200</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C-W, Lee S-C, The ubiquitin-like (UBX)-domain-containing protein Ubx2/Ubxd8 regulates lipid droplet homeostasis, J. Cell Sci 125, 2930&#x2013;2939 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22454508</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolawa N, Sweredoski MJ, Graham RLJ, Oania R, Hess S, Deshaies RJ, Perturbations to the Ubiquitin Conjugate Proteome in Yeast &#x394; ubx Mutants Identify Ubx2 as a Regulator of Membrane Lipid Composition, Mol. Cell. Proteomics 12, 2791&#x2013;2803 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3790291</ArticleId><ArticleId IdType="pubmed">23793018</ArticleId></ArticleIdList></Reference><Reference><Citation>Hofbauer HF, Schopf FH, Schleifer H, Knittelfelder OL, Pieber B, Rechberger GN, Wolinski H, Gaspar ML, Kappe CO, Stadlmann J, Mechtler K, Zenz A, Lohner K, Tehlivets O, Henry SA, Kohlwein SD, Regulation of gene expression through a transcriptional repressor that senses acyl-chain length in membrane phospholipids., Dev. Cell 29, 729&#x2013;39 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4070385</ArticleId><ArticleId IdType="pubmed">24960695</ArticleId></ArticleIdList></Reference><Reference><Citation>Klig LS, Homann MJ, Carman GM, Henry SA, Coordinate regulation of phospholipid biosynthesis in Saccharomyces cerevisiae: Pleiotropically constitutive opil mutant, J. Bacteriol 162, 1135&#x2013;1141 (1985).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC215894</ArticleId><ArticleId IdType="pubmed">3888957</ArticleId></ArticleIdList></Reference><Reference><Citation>Young BP, Shin JJH, Orij R, Chao JT, Li SC, Guan XL, Khong A, Jan E, Wenk MR, Prinz WA, Smits GJ, Loewen CJR, Phosphatidic Acid Is a pH Biosensor That Links Membrane Biogenesis to Metabolism, Science (80-.). 329, 1085&#x2013;1088 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20798321</ArticleId></ArticleIdList></Reference><Reference><Citation>Burr R, Stewart EV, Shao W, Zhao S, Hannibal-Bach HK, Ejsing CS, Espenshade PJ, Mga2 transcription factor regulates an oxygen-responsive lipid homeostasis pathway in fission yeast, J. Biol. Chem 291, 12171&#x2013;12183 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4933267</ArticleId><ArticleId IdType="pubmed">27053105</ArticleId></ArticleIdList></Reference><Reference><Citation>Chellappa R, Kandasamy P, Oh CS, Jiang Y, Vemula M, Martin CE, The membrane proteins, Spt23p and Mga2p, play distinct roles in the activation of Saccharomyces cerevisiae OLE1 gene expression. Fatty acid-mediated regulation of Mga2p activity is independent of its proteolytic processing into a soluble transcription act, J. Biol. Chem 276, 43548&#x2013;56 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11557770</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S, Skalsky Y, Garfinkel DJ, MGA2 or SPT23 is required for transcription of the delta9 fatty acid desaturase gene, OLE1, and nuclear membrane integrity in Saccharomyces cerevisiae., Genetics 151, 473&#x2013;483 (1999).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1460504</ArticleId><ArticleId IdType="pubmed">9927444</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu D, Sillaots S, Davison J, Hu W, Jiang B, Kauffman S, Martel N, Ocampo P, Oh C, Trosok S, Veillette K, Wang H, Yang M, Zhang L, Becker J, Martin CE, Roemer T, Chemical genetic profiling and characterization of small-molecule compounds that affect the biosynthesis of unsaturated fatty acids in Candida albicans., J. Biol. Chem 284, 19754&#x2013;64 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2740599</ArticleId><ArticleId IdType="pubmed">19487691</ArticleId></ArticleIdList></Reference><Reference><Citation>Olzmann JA, Carvalho P, Dynamics and functions of lipid droplets., Nat. Rev. Mol. Cell Biol 20, 137&#x2013;155 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6746329</ArticleId><ArticleId IdType="pubmed">30523332</ArticleId></ArticleIdList></Reference><Reference><Citation>Fei W, Shui G, Zhang Y, Krahmer N, Ferguson C, Kapterian TS, Lin RC, Dawes IW, Brown AJ, Li P, Huang X, Parton RG, Wenk MR, Walther TC, Yang H, A role for phosphatidic acid in the formation of &#x201c;supersized&#x201d; Lipid droplets, PLoS Genet 7 (2011), doi:10.1371/journal.pgen.1002201.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1002201</ArticleId><ArticleId IdType="pmc">PMC3145623</ArticleId><ArticleId IdType="pubmed">21829381</ArticleId></ArticleIdList></Reference><Reference><Citation>Loewen CJR, Gaspar ML, a Jesch S, Delon C, Ktistakis NT, a Henry S, Levine TP, Phospholipid metabolism regulated by a transcription factor sensing phosphatidic acid., Science (80-.). 304, 1644&#x2013;1647 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15192221</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry SA, Kohlwein SD, Carman GM, Metabolism and regulation of glycerolipids in the yeast Saccharomyces cerevisiae, Genetics 190, 317&#x2013;349 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3276621</ArticleId><ArticleId IdType="pubmed">22345606</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramirez-Gaona M, Marcu A, Pon A, Guo AC, Sajed T, Wishart NA, Karu N, Feunang YD, Arndt D, Wishart DS, YMDB 2.0: A significantly expanded version of the yeast metabolome database, Nucleic Acids Res. 45, D440&#x2013;D445 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5210545</ArticleId><ArticleId IdType="pubmed">27899612</ArticleId></ArticleIdList></Reference><Reference><Citation>Wurtman RJ, Cansev M, Sakamoto T, Ulus IH, Use of Phosphatide Precursors to Promote Synaptogenesis, Annu. Rev. Nutr 29, 59&#x2013;87 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19400698</ArticleId></ArticleIdList></Reference><Reference><Citation>Ridgway ND, The role of phosphatidylcholine and choline metabolites to cell proliferation and survival, Crit. Rev. Biochem. Mol. Biol 48, 20&#x2013;38 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23350810</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-Murray JP, Ngo MH, McMaster CR, Choline transport activity regulates phosphatidylcholine synthesis through choline transporter Hnm1 stability., J. Biol. Chem 288, 36106&#x2013;15 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3861658</ArticleId><ArticleId IdType="pubmed">24187140</ArticleId></ArticleIdList></Reference><Reference><Citation>Xin Z, Zhao H, Serby MD, Liu B, Liu M, Szczepankiewicz BG, Nelson LTJ, Smith HT, Suhar TS, Janis RS, Cao N, Camp HS, Collins CA, Sham HL, Surowy TK, Liu G, Discovery of piperidine-aryl urea-based stearoyl-CoA desaturase 1 inhibitors., Bioorg. Med. Chem. Lett 18, 4298&#x2013;302 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18632269</ArticleId></ArticleIdList></Reference><Reference><Citation>Futatsugi K, Kung DW, Orr STM, Cabral S, Hepworth D, Aspnes G, Bader S, Bian J, Boehm M, Carpino PA, Coffey SB, Dowling MS, Herr M, Jiao W, Lavergne SY, Li Q, Clark RW, Erion DM, Kou K, Lee K, Pabst BA, Perez SM, Purkal J, Jorgensen CC, Goosen TC, Gosset JR, Niosi M, Pettersen JC, Pfefferkorn JA, Ahn K, Goodwin B, Discovery and Optimization of Imidazopyridine-Based Inhibitors of Diacylglycerol Acyltransferase 2 (DGAT2)., J. Med. Chem 58, 7173&#x2013;85 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26349027</ArticleId></ArticleIdList></Reference><Reference><Citation>Dow RL, Li J-C, Pence MP, Gibbs EM, LaPerle JL, Litchfield J, Piotrowski DW, Munchhof MJ, Manion TB, Zavadoski WJ, Walker GS, McPherson RK, Tapley S, Sugarman E, Guzman-Perez A, DaSilva-Jardine P, Discovery of PF-04620110, a Potent, Selective, and Orally Bioavailable Inhibitor of DGAT-1., ACS Med. Chem. Lett 2, 407&#x2013;12 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4018057</ArticleId><ArticleId IdType="pubmed">24900321</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeisel SH, da Costa K-A, Choline: an essential nutrient for public health., Nutr. Rev 67, 615&#x2013;23 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2782876</ArticleId><ArticleId IdType="pubmed">19906248</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR, Bangdiwala S, Tyroler HA, High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies., Circulation 79, 8&#x2013;15 (1989).</Citation><ArticleIdList><ArticleId IdType="pubmed">2642759</ArticleId></ArticleIdList></Reference><Reference><Citation>Maxfield FR, W&#xfc;stner D, Analysis of cholesterol trafficking with fluorescent probes., Methods Cell Biol. 108, 367&#x2013;93 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3626500</ArticleId><ArticleId IdType="pubmed">22325611</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagace TA, Phosphatidylcholine: Greasing the Cholesterol Transport Machinery., Lipid Insights 8, 65&#x2013;73 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4821435</ArticleId><ArticleId IdType="pubmed">27081313</ArticleId></ArticleIdList></Reference><Reference><Citation>Payne F, Lim K, Girousse A, Brown RJ, Kory N, Robbins A, Xue Y, Sleigh A, Cochran E, Adams C, Dev Borman A, Russel-Jones D, Gorden P, Semple RK, Saudek V, O&#x2019;Rahilly S, Walther TC, Barroso I, Savage DB, Mutations disrupting the Kennedy phosphatidylcholine pathway in humans with congenital lipodystrophy and fatty liver disease., Proc. Natl. Acad. Sci. U. S. A 111, 8901&#x2013;6 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4066527</ArticleId><ArticleId IdType="pubmed">24889630</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance DE, Vance JE, Physiological consequences of disruption of mammalian phospholipid biosynthetic genes, J. Lipid Res 50, S132&#x2013;S137 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2674686</ArticleId><ArticleId IdType="pubmed">18955728</ArticleId></ArticleIdList></Reference><Reference><Citation>Bi XH, Zhao HL, Zhang ZX, Zhang JW, PEMT G523A (V175M) is associated with sporadic Alzheimer&#x2019;s disease in a Chinese population, J. Mol. Neurosci (2012), doi:10.1007/s12031-011-9630-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-011-9630-3</ArticleId><ArticleId IdType="pubmed">21881829</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson LA, Torres ERS, Impey S, Stevens JF, Raber J, Apolipoprotein E4 and Insulin Resistance Interact to Impair Cognition and Alter the Epigenome and Metabolome, Sci. Rep (2017), doi:10.1038/srep43701.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep43701</ArticleId><ArticleId IdType="pmc">PMC5341123</ArticleId><ArticleId IdType="pubmed">28272510</ArticleId></ArticleIdList></Reference><Reference><Citation>Nuriel T, Angulo SL, Khan U, Ashok A, Chen Q, Figueroa HY, Emrani S, Liu L, Herman M, Barrett G, Savage V, Buitrago L, Cepeda-Prado E, Fung C, Goldberg E, Gross SS, Hussaini SA, Moreno H, Small SA, Duff KE, Neuronal hyperactivity due to loss of inhibitory tone in APOE4 mice lacking Alzheimer&#x2019;s disease-like pathology, Nat. Commun (2017), doi:10.1038/s41467-017-01444-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-01444-0</ArticleId><ArticleId IdType="pmc">PMC5684208</ArticleId><ArticleId IdType="pubmed">29133888</ArticleId></ArticleIdList></Reference><Reference><Citation>Tambini MD, Pera M, Kanter E, Yang H, Guardia-Laguarta C, Holtzman D, Sulzer D, Area-Gomez E, Schon EA, ApoE4 upregulates the activity of mitochondria-associated ER membranes, EMBO Rep. 17, 27&#x2013;36 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4718413</ArticleId><ArticleId IdType="pubmed">26564908</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, MacKenzie KR, Putluri N, Maleti&#x107;-Savati&#x107; M, Bellen HJ, The Glia-Neuron Lactate Shuttle and Elevated ROS Promote Lipid Synthesis in Neurons and Lipid Droplet Accumulation in Glia via APOE/D, Cell Metab. 26, 719&#x2013;737.e6 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5677551</ArticleId><ArticleId IdType="pubmed">28965825</ArticleId></ArticleIdList></Reference><Reference><Citation>Mapstone M, Cheema AK, Fiandaca MS, Zhong X, Mhyre TR, Macarthur LH, Hall WJ, Fisher SG, Peterson DR, Haley JM, Nazar MD, Rich SA, Berlau DJ, Peltz CB, Tan MT, Kawas CH, Federoff HJ, Plasma phospholipids identify antecedent memory impairment in older adults, Nat. Med 20, 415&#x2013;418 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5360460</ArticleId><ArticleId IdType="pubmed">24608097</ArticleId></ArticleIdList></Reference><Reference><Citation>Blusztajn JK, Gonzalez-Coviella IL, Logue M, Growdon JH, Wurtman RJ, Levels of phospholipid catabolic intermediates, glycerophosphocholine and glycerophosphoethanolamine, are elevated in brains of Alzheimer&#x2019;s disease but not of Down&#x2019;s syndrome patients, Brain Res. (1990), doi:10.1016/0006-8993(90)90030-F.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-8993(90)90030-F</ArticleId><ArticleId IdType="pubmed">2150771</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie CW, Bajwa J, Coleman G, Hope K, Jones RW, Lawton M, Marven M, Passmore P, Souvenaid (R): a New Approach To Management of Early Alzheimer&#x2019;S Disease, J. Nutr. Heal. Aging 18, 291&#x2013;299 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24626757</ArticleId></ArticleIdList></Reference><Reference><Citation>Caccamo A, Huentelman MJ, Naymik M, Dave N, Velazquez R, Winslow W, Tran A, Ferreira E, Oddo S, Piras IS, Maternal choline supplementation ameliorates Alzheimer&#x2019;s disease pathology by reducing brain homocysteine levels across multiple generations, Mol. Psychiatry (2019), doi:10.1038/s41380-018-0322-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-018-0322-z</ArticleId><ArticleId IdType="pmc">PMC6697226</ArticleId><ArticleId IdType="pubmed">30622336</ArticleId></ArticleIdList></Reference><Reference><Citation>Grieb P, Neuroprotective properties of citicoline: Facts, doubts and unresolved issues, CNS Drugs 28, 185&#x2013;193 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3933742</ArticleId><ArticleId IdType="pubmed">24504829</ArticleId></ArticleIdList></Reference><Reference><Citation>Conant R, Schauss AG, Therapeutic applications of citicoline for stroke and cognitive dysfunction in the elderly: a review of the literature., Altern. Med. Rev 9, 17&#x2013;31 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15005642</ArticleId></ArticleIdList></Reference><Reference><Citation>Da Costa KA, Corbin KD, Niculescu MD, Galanko JA, Zeisel SH, Identification of new genetic polymorphisms that alter the dietary requirement for choline and vary in their distribution across ethnic and racial groups, FASEB J. 28, 2970&#x2013;2978 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4062831</ArticleId><ArticleId IdType="pubmed">24671709</ArticleId></ArticleIdList></Reference><Reference><Citation>Neu SC, Pa J, Kukull W, Beekly D, Kuzma A, Gangadharan P, Wang LS, Romero K, Arneric SP, Redolfi A, Orlandi D, Frisoni GB, Au R, Devine S, Auerbach S, Espinosa A, Boada M, Ruiz A, Johnson SC, Koscik R, Wang JJ, Hsu WC, Chen YL, Toga AW, Apolipoprotein E genotype and sex risk factors for Alzheimer disease: A meta-analysis, JAMA Neurol. 74, 1178&#x2013;1189 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5759346</ArticleId><ArticleId IdType="pubmed">28846757</ArticleId></ArticleIdList></Reference><Reference><Citation>Damoiseaux JS, Seeley WW, Zhou J, Shirer WR, Coppola G, Karydas A, Rosen HJ, Miller BL, Kramer JH, Greicius MD, Gender Modulates the APOE 4 Effect in Healthy Older Adults: Convergent Evidence from Functional Brain Connectivity and Spinal Fluid Tau Levels, J. Neurosci 32, 8254&#x2013;8262 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3394933</ArticleId><ArticleId IdType="pubmed">22699906</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarez XA, Mouzo R, Pichel V, P&#xe9;rez P, Laredo M, Fern&#xe1;ndez-Novoa L, Corzo L, Zas R, Alcaraz M, Secades JJ, Lozano R, Cacabelos R, Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer&#x2019;s disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion., Methods Find. Exp. Clin. Pharmacol 21, 633&#x2013;44 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10669911</ArticleId></ArticleIdList></Reference><Reference><Citation>Harayama T, Riezman H, Understanding the diversity of membrane lipid composition., Nat. Rev. Mol. Cell Biol 19, 281&#x2013;296 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29410529</ArticleId></ArticleIdList></Reference><Reference><Citation>McQuade A, Coburn M, Tu CH, Hasselmann J, Davtyan H, Blurton-Jones M, Development and validation of a simplified method to generate human microglia from pluripotent stem cells., Mol. Neurodegener 13, 67 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6303871</ArticleId><ArticleId IdType="pubmed">30577865</ArticleId></ArticleIdList></Reference><Reference><Citation>Love MI, Huber W, Anders S, Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2., Genome Biol. 15, 550 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4302049</ArticleId><ArticleId IdType="pubmed">25516281</ArticleId></ArticleIdList></Reference><Reference><Citation>Janke C, Magiera MM, Rathfelder N, Taxis C, Reber S, Maekawa H, Moreno-Borchart A, Doenges G, Schwob E, Schiebel E, Knop M, A versatile toolbox for PCR-based tagging of yeast genes: new fluorescent proteins, more markers and promoter substitution cassettes., Yeast 21, 947&#x2013;62 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15334558</ArticleId></ArticleIdList></Reference><Reference><Citation>McIsaac RS, Oakes BL, Wang X, Dummit KA, Botstein D, Noyes MB, Synthetic gene expression perturbation systems with rapid, tunable, single-gene specificity in yeast., Nucleic Acids Res. 41, e57 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3575806</ArticleId><ArticleId IdType="pubmed">23275543</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuzmin E, Costanzo M, Andrews B, Boone C, Synthetic genetic array analysis, Cold Spring Harb. Protoc 2016, 359&#x2013;372 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27037072</ArticleId></ArticleIdList></Reference><Reference><Citation>FOLCH J, LEES M, SLOANE STANLEY GH, A simple method for the isolation and purification of total lipides from animal tissues., J. Biol. Chem 226, 497&#x2013;509 (1957).</Citation><ArticleIdList><ArticleId IdType="pubmed">13428781</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, Tinevez J-Y, White DJ, Hartenstein V, Eliceiri K, Tomancak P, Cardona A, Fiji: an open-source platform for biological-image analysis., Nat. Methods 9, 676&#x2013;82 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3855844</ArticleId><ArticleId IdType="pubmed">22743772</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33619379</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>15</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2522-5812</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Nature metabolism</Title><ISOAbbreviation>Nat Metab</ISOAbbreviation></Journal><ArticleTitle>Gut microbiome pattern reflects healthy ageing and predicts survival in humans.</ArticleTitle><Pagination><StartPage>274</StartPage><EndPage>286</EndPage><MedlinePgn>274-286</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s42255-021-00348-0</ELocationID><Abstract><AbstractText>The gut microbiome has important effects on human health, yet its importance in human ageing remains unclear. In the present study, we demonstrate that, starting in mid-to-late adulthood, gut microbiomes become increasingly unique to individuals with age. We leverage three independent cohorts comprising over 9,000 individuals and find that compositional uniqueness is strongly associated with microbially produced amino acid derivatives circulating in the bloodstream. In older age (over ~80&#x2009;years), healthy individuals show continued microbial drift towards a unique compositional state, whereas this drift is absent in less healthy individuals. The identified microbiome pattern of healthy ageing is characterized by a depletion of core genera found across most humans, primarily Bacteroides. Retaining a high Bacteroides dominance into older age, or having a low gut microbiome uniqueness measure, predicts decreased survival in a 4-year follow-up. Our analysis identifies increasing compositional uniqueness of the gut microbiome as a component of healthy ageing, which is characterized by distinct microbial metabolic outputs in the blood.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wilmanski</LastName><ForeName>Tomasz</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-1059-073X</Identifier><AffiliationInfo><Affiliation>Institute for Systems Biology, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diener</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute for Systems Biology, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rappaport</LastName><ForeName>Noa</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-8643-2055</Identifier><AffiliationInfo><Affiliation>Institute for Systems Biology, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patwardhan</LastName><ForeName>Sushmita</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute for Systems Biology, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiedrick</LastName><ForeName>Jack</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Oregon Health and Science University, Portland, OR, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lapidus</LastName><ForeName>Jodi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Oregon Health and Science University, Portland, OR, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Earls</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Institute for Systems Biology, Seattle, WA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Onegevity Health, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zimmer</LastName><ForeName>Anat</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute for Systems Biology, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glusman</LastName><ForeName>Gustavo</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-8060-5955</Identifier><AffiliationInfo><Affiliation>Institute for Systems Biology, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robinson</LastName><ForeName>Max</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-0878-114X</Identifier><AffiliationInfo><Affiliation>Institute for Systems Biology, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yurkovich</LastName><ForeName>James T</ForeName><Initials>JT</Initials><Identifier Source="ORCID">0000-0002-9403-509X</Identifier><AffiliationInfo><Affiliation>Institute for Systems Biology, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kado</LastName><ForeName>Deborah M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Herbert Wertheim School of Public Health and Human Longevity Science at UCSD and Department of Medicine, University of California, San Diego School of Medicine, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cauley</LastName><ForeName>Jane A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zmuda</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lane</LastName><ForeName>Nancy E</ForeName><Initials>NE</Initials><AffiliationInfo><Affiliation>Center for Musculoskeletal Health, Department of Internal Medicine, University of California Davis Medical Center, Sacramento, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Magis</LastName><ForeName>Andrew T</ForeName><Initials>AT</Initials><Identifier Source="ORCID">0000-0003-0576-677X</Identifier><AffiliationInfo><Affiliation>Institute for Systems Biology, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lovejoy</LastName><ForeName>Jennifer C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Institute for Systems Biology, Seattle, WA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lifestyle Medicine Institute, Redlands, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hood</LastName><ForeName>Leroy</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute for Systems Biology, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gibbons</LastName><ForeName>Sean M</ForeName><Initials>SM</Initials><Identifier Source="ORCID">0000-0002-8724-7916</Identifier><AffiliationInfo><Affiliation>Institute for Systems Biology, Seattle, WA, USA. sgibbons@isbscience.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>eScience Institute, University of Washington, Seattle, WA, USA. sgibbons@isbscience.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Bioengineering, University of Washington, Seattle, WA, USA. sgibbons@isbscience.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orwoll</LastName><ForeName>Eric S</ForeName><Initials>ES</Initials><Identifier Source="ORCID">0000-0002-8520-7355</Identifier><AffiliationInfo><Affiliation>Oregon Health and Science University, Portland, OR, USA. orwoll@ohsu.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Price</LastName><ForeName>Nathan D</ForeName><Initials>ND</Initials><Identifier Source="ORCID">0000-0002-4157-0267</Identifier><AffiliationInfo><Affiliation>Institute for Systems Biology, Seattle, WA, USA. nprice@isbscience.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Onegevity Health, New York, NY, USA. nprice@isbscience.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U19 AG023122</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000128</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002369</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG042124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG042145</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AR061445</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG042168</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG042140</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG027810</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG042143</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG042139</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AR066160</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>02</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Nat Metab</MedlineTA><NlmUniqueID>101736592</NlmUniqueID><ISSNLinking>2522-5812</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000596">Amino Acids</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Nat Metab. 2021 Apr;3(4):586. doi: 10.1038/s42255-021-00377-9.</RefSource><PMID Version="1">33731896</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000596" MajorTopicYN="N">Amino Acids</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001439" MajorTopicYN="N">Bacteroides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069196" MajorTopicYN="N">Gastrointestinal Microbiome</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073656" MajorTopicYN="N">Healthy Aging</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008019" MajorTopicYN="N">Life Style</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055432" MajorTopicYN="N">Metabolomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>7</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>1</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>8</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33619379</ArticleId><ArticleId IdType="mid">NIHMS1664974</ArticleId><ArticleId IdType="pmc">PMC8169080</ArticleId><ArticleId IdType="doi">10.1038/s42255-021-00348-0</ArticleId><ArticleId IdType="pii">10.1038/s42255-021-00348-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Yatsunenko T. et al. Human gut microbiome viewed across age and geography. Nature 486, 222&#x2013;227 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3376388</ArticleId><ArticleId IdType="pubmed">22699611</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Toole PW &amp; Jeffery IB Gut microbiota and aging. Science (80-. ). 350, 1214&#x2013;1215 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26785481</ArticleId></ArticleIdList></Reference><Reference><Citation>Castro-Mej&#xed;a JL et al. Physical fitness in community-dwelling older adults is linked to dietary intake, gut microbiota, and metabolomic signatures. Aging Cell (2020). doi:10.1111/acel.13105</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/acel.13105</ArticleId><ArticleId IdType="pmc">PMC7059135</ArticleId><ArticleId IdType="pubmed">31967716</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson M. et al. Signatures of early frailty in the gut microbiota. Genome Med. (2016). doi:10.1186/s13073-016-0262-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13073-016-0262-7</ArticleId><ArticleId IdType="pmc">PMC4731918</ArticleId><ArticleId IdType="pubmed">26822992</ArticleId></ArticleIdList></Reference><Reference><Citation>Claesson MJ et al. Gut microbiota composition correlates with diet and health in the elderly. Nature 488, 178&#x2013;184 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22797518</ArticleId></ArticleIdList></Reference><Reference><Citation>Biagi E. et al. Gut Microbiota and Extreme Longevity. Curr Biol 26, 1480&#x2013;1485 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27185560</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim BS et al. Comparison of the Gut Microbiota of Centenarians in Longevity Villages of South Korea with Those of Other Age Groups. J. Microbiol. Biotechnol (2019). doi:10.4014/jmb.1811.11023</Citation><ArticleIdList><ArticleId IdType="doi">10.4014/jmb.1811.11023</ArticleId><ArticleId IdType="pubmed">30661321</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu L. et al. A Cross-Sectional Study of Compositional and Functional Profiles of Gut Microbiota in Sardinian Centenarians. mSystems 4, (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6616150</ArticleId><ArticleId IdType="pubmed">31289141</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong F. et al. Gut microbiota signatures of longevity. Current Biology (2016). doi:10.1016/j.cub.2016.08.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cub.2016.08.015</ArticleId><ArticleId IdType="pubmed">27676296</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong F, Deng F, Li Y. &amp; Zhao J. Identification of gut microbiome signatures associated with longevity provides a promising modulation target for healthy aging. Gut Microbes (2019). doi:10.1080/19490976.2018.1494102</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19490976.2018.1494102</ArticleId><ArticleId IdType="pmc">PMC6546316</ArticleId><ArticleId IdType="pubmed">30142010</ArticleId></ArticleIdList></Reference><Reference><Citation>Vangay P. et al. US Immigration Westernizes the Human Gut Microbiome. Cell (2018). doi:10.1016/j.cell.2018.10.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.10.029</ArticleId><ArticleId IdType="pmc">PMC6498444</ArticleId><ArticleId IdType="pubmed">30388453</ArticleId></ArticleIdList></Reference><Reference><Citation>Claesson MJ et al. Composition, variability, and temporal stability of the intestinal microbiota of the elderly. Proc Natl Acad Sci U S A 108 Suppl, 4586&#x2013;4591 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3063589</ArticleId><ArticleId IdType="pubmed">20571116</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeffery IB, Lynch DB &amp; O&#x2019;Toole PW Composition and temporal stability of the gut microbiota in older persons. ISME J. (2016). doi:10.1038/ismej.2015.88</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ismej.2015.88</ArticleId><ArticleId IdType="pmc">PMC4681863</ArticleId><ArticleId IdType="pubmed">26090993</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh TS, Das M, Jeffery IB &amp; O&#x2019;Toole PW Adjusting for age improves identification of gut microbiome alterations in multiple diseases. Elife (2020). doi:10.7554/eLife.50240</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.50240</ArticleId><ArticleId IdType="pmc">PMC7065848</ArticleId><ArticleId IdType="pubmed">32159510</ArticleId></ArticleIdList></Reference><Reference><Citation>Tierney BT et al. The predictive power of the microbiome exceeds that of genome-wide association studies in the discrimination of complex human disease. bioRxiv 2019.12.31.891978 (2020). doi:10.1101/2019.12.31.891978</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2019.12.31.891978</ArticleId></ArticleIdList></Reference><Reference><Citation>Salosensaari A. et al. Taxonomic Signatures of Long-Term Mortality Risk in Human Gut Microbiota. medRxiv 2019.12.30.19015842 (2020). doi:10.1101/2019.12.30.19015842</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2019.12.30.19015842</ArticleId></ArticleIdList></Reference><Reference><Citation>Zubair N. et al. Genetic Predisposition Impacts Clinical Changes in a Lifestyle Coaching Program. Sci. Rep (2019). doi:10.1038/s41598-019-43058-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-43058-0</ArticleId><ArticleId IdType="pmc">PMC6497671</ArticleId><ArticleId IdType="pubmed">31048771</ArticleId></ArticleIdList></Reference><Reference><Citation>Blank JB et al. Overview of recruitment for the osteoporotic fractures in men study (MrOS). Contemp. Clin. Trials (2005). doi:10.1016/j.cct.2005.05.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cct.2005.05.005</ArticleId><ArticleId IdType="pubmed">16085466</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrahamson M, Hooker E, Ajami NJ, Petrosino JF &amp; Orwoll ES Successful collection of stool samples for microbiome analyses from a large community-based population of elderly men. Contemp. Clin. Trials Commun (2017). doi:10.1016/j.conctc.2017.07.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.conctc.2017.07.002</ArticleId><ArticleId IdType="pmc">PMC5726580</ArticleId><ArticleId IdType="pubmed">29250605</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald D. et al. American Gut: an Open Platform for Citizen Science Microbiome Research. mSystems (2018). doi:10.1128/msystems.00031-18</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/msystems.00031-18</ArticleId><ArticleId IdType="pmc">PMC5954204</ArticleId><ArticleId IdType="pubmed">29795809</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbons SM, Duvallet C. &amp; Alm EJ Correcting for batch effects in case-control microbiome studies. PLoS Comput. Biol (2018). doi:10.1371/journal.pcbi.1006102</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1006102</ArticleId><ArticleId IdType="pmc">PMC5940237</ArticleId><ArticleId IdType="pubmed">29684016</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilmanski T. et al. Blood metabolome predicts gut microbiome &#x3b1;-diversity in humans. Nat. Biotechnol (2019). doi:10.1038/s41587-019-0233-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-019-0233-9</ArticleId><ArticleId IdType="pubmed">31477923</ArticleId></ArticleIdList></Reference><Reference><Citation>Rampelli S. et al. Functional metagenomic profiling of intestinal microbiome in extreme ageing. Aging (Albany. NY) (2013). doi:10.18632/aging.100623</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.100623</ArticleId><ArticleId IdType="pmc">PMC3883706</ArticleId><ArticleId IdType="pubmed">24334635</ArticleId></ArticleIdList></Reference><Reference><Citation>Collino S. et al. Metabolic Signatures of Extreme Longevity in Northern Italian Centenarians Reveal a Complex Remodeling of Lipids, Amino Acids, and Gut Microbiota Metabolism. PLoS One (2013). doi:10.1371/journal.pone.0056564</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0056564</ArticleId><ArticleId IdType="pmc">PMC3590212</ArticleId><ArticleId IdType="pubmed">23483888</ArticleId></ArticleIdList></Reference><Reference><Citation>Vich Vila A. et al. Impact of commonly used drugs on the composition and metabolic function of the gut microbiota. Nat. Commun (2020). doi:10.1038/s41467-019-14177-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-14177-z</ArticleId><ArticleId IdType="pmc">PMC6969170</ArticleId><ArticleId IdType="pubmed">31953381</ArticleId></ArticleIdList></Reference><Reference><Citation>Nemet I. et al. A Cardiovascular Disease-Linked Gut Microbial Metabolite Acts via Adrenergic Receptors. Cell (2020). doi:10.1016/j.cell.2020.02.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.016</ArticleId><ArticleId IdType="pmc">PMC7402401</ArticleId><ArticleId IdType="pubmed">32142679</ArticleId></ArticleIdList></Reference><Reference><Citation>Han H. et al. p-Cresyl sulfate aggravates cardiac dysfunction associated with chronic kidney disease by enhancing apoptosis of cardiomyocytes. J. Am. Heart Assoc (2015). doi:10.1161/JAHA.115.001852</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.115.001852</ArticleId><ArticleId IdType="pmc">PMC4599533</ArticleId><ArticleId IdType="pubmed">26066032</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis KN, Rubinstein ND &amp; Buffenstein R. A window into extreme longevity; the circulating metabolomic signature of the naked mole-rat, a mammal that shows negligible senescence. GeroScience (2018). doi:10.1007/s11357-018-0014-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11357-018-0014-2</ArticleId><ArticleId IdType="pmc">PMC5964061</ArticleId><ArticleId IdType="pubmed">29679203</ArticleId></ArticleIdList></Reference><Reference><Citation>Roager HM &amp; Licht TR Microbial tryptophan catabolites in health and disease. Nature Communications (2018). doi:10.1038/s41467-018-05470-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-05470-4</ArticleId><ArticleId IdType="pmc">PMC6098093</ArticleId><ArticleId IdType="pubmed">30120222</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonowal R. et al. Indoles from commensal bacteria extend healthspan. Proc. Natl. Acad. Sci. U. S. A (2017). doi:10.1073/pnas.1706464114</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1706464114</ArticleId><ArticleId IdType="pmc">PMC5594673</ArticleId><ArticleId IdType="pubmed">28827345</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnan S. et al. Gut Microbiota-Derived Tryptophan Metabolites Modulate Inflammatory Response in Hepatocytes and Macrophages. Cell Rep. (2018). doi:10.1016/j.celrep.2018.03.109</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2018.03.109</ArticleId><ArticleId IdType="pmc">PMC6392449</ArticleId><ArticleId IdType="pubmed">29694888</ArticleId></ArticleIdList></Reference><Reference><Citation>Beaumont M. et al. The gut microbiota metabolite indole alleviates liver inflammation in mice. FASEB J. (2018). doi:10.1096/fj.201800544</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.201800544</ArticleId><ArticleId IdType="pmc">PMC6219839</ArticleId><ArticleId IdType="pubmed">29906245</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexeev EE et al. Microbiota-Derived Indole Metabolites Promote Human and Murine Intestinal Homeostasis through Regulation of Interleukin-10 Receptor. Am. J. Pathol (2018). doi:10.1016/j.ajpath.2018.01.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2018.01.011</ArticleId><ArticleId IdType="pmc">PMC5906738</ArticleId><ArticleId IdType="pubmed">29454749</ArticleId></ArticleIdList></Reference><Reference><Citation>Lustgarten MS, Price LL, Chal&#xe9; A. &amp; Fielding RA Metabolites related to gut bacterial metabolism, peroxisome proliferator-activated receptor-alpha activation, and insulin sensitivity are associated with physical function in functionally-limited older adults. Aging Cell (2014). doi:10.1111/acel.12251</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/acel.12251</ArticleId><ArticleId IdType="pmc">PMC4331755</ArticleId><ArticleId IdType="pubmed">25041144</ArticleId></ArticleIdList></Reference><Reference><Citation>Cussotto S. et al. Tryptophan Metabolic Pathways Are Altered in Obesity and Are Associated With Systemic Inflammation. Front. Immunol (2020). doi:10.3389/fimmu.2020.00557</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.00557</ArticleId><ArticleId IdType="pmc">PMC7174689</ArticleId><ArticleId IdType="pubmed">32351500</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xe1;rquez EJ et al. Sexual-dimorphism in human immune system aging. Nat. Commun (2020). doi:10.1038/s41467-020-14396-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-14396-9</ArticleId><ArticleId IdType="pmc">PMC7005316</ArticleId><ArticleId IdType="pubmed">32029736</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xe1;rcena C. et al. Healthspan and lifespan extension by fecal microbiota transplantation into progeroid mice. Nature Medicine (2019). doi:10.1038/s41591-019-0504-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-019-0504-5</ArticleId><ArticleId IdType="pubmed">31332389</ArticleId></ArticleIdList></Reference><Reference><Citation>Kundu P. et al. Neurogenesis and prolongevity signaling in young germ-free mice transplanted with the gut microbiota of old mice. Sci. Transl. Med (2019). doi:10.1126/scitranslmed.aau4760</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aau4760</ArticleId><ArticleId IdType="pubmed">31723038</ArticleId></ArticleIdList></Reference><Reference><Citation>Zwielehner J. et al. Combined PCR-DGGE fingerprinting and quantitative-PCR indicates shifts in fecal population sizes and diversity of Bacteroides, bifidobacteria and Clostridium cluster IV in institutionalized elderly. Exp. Gerontol (2009). doi:10.1016/j.exger.2009.04.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exger.2009.04.002</ArticleId><ArticleId IdType="pubmed">19376217</ArticleId></ArticleIdList></Reference><Reference><Citation>Earls JC et al. Multi-Omic Biological Age Estimation and Its Correlation With Wellness and Disease Phenotypes: A Longitudinal Study of 3,558 Individuals. J. Gerontol. A. Biol. Sci. Med. Sci 74, S52&#x2013;S60 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6853785</ArticleId><ArticleId IdType="pubmed">31724055</ArticleId></ArticleIdList></Reference><Reference><Citation>Cawthon PM, Shahnazari M, Orwoll ES &amp; Lane NE Osteoporosis in men: Findings from the Osteoporotic Fractures in Men Study (MrOS). Therapeutic Advances in Musculoskeletal Disease (2016). doi:10.1177/1759720X15621227</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1759720X15621227</ArticleId><ArticleId IdType="pmc">PMC4707416</ArticleId><ArticleId IdType="pubmed">26834847</ArticleId></ArticleIdList></Reference><Reference><Citation>Callahan BJ et al. DADA2: High-resolution sample inference from Illumina amplicon data. Nat Methods 13, 581&#x2013;583 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4927377</ArticleId><ArticleId IdType="pubmed">27214047</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright ES DECIPHER: Harnessing local sequence context to improve protein multiple sequence alignment. BMC Bioinformatics (2015). doi:10.1186/s12859-015-0749-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12859-015-0749-z</ArticleId><ArticleId IdType="pmc">PMC4595117</ArticleId><ArticleId IdType="pubmed">26445311</ArticleId></ArticleIdList></Reference><Reference><Citation>Price MN, Dehal PS &amp; Arkin AP FastTree 2 - Approximately maximum-likelihood trees for large alignments. PLoS One (2010). doi:10.1371/journal.pone.0009490</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0009490</ArticleId><ArticleId IdType="pmc">PMC2835736</ArticleId><ArticleId IdType="pubmed">20224823</ArticleId></ArticleIdList></Reference><Reference><Citation>McMurdie PJ &amp; Holmes S. Phyloseq: An R Package for Reproducible Interactive Analysis and Graphics of Microbiome Census Data. PLoS One (2013). doi:10.1371/journal.pone.0061217</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0061217</ArticleId><ArticleId IdType="pmc">PMC3632530</ArticleId><ArticleId IdType="pubmed">23630581</ArticleId></ArticleIdList></Reference><Reference><Citation>Bray JR &amp; Curtis JT An Ordination of the Upland Forest Communities of Southern Wisconsin. Ecol. Monogr (1957). doi:10.2307/1942268</Citation><ArticleIdList><ArticleId IdType="doi">10.2307/1942268</ArticleId></ArticleIdList></Reference><Reference><Citation>Lozupone C. &amp; Knight R. UniFrac: A new phylogenetic method for comparing microbial communities. Appl. Environ. Microbiol (2005). doi:10.1128/AEM.71.12.8228-8235.2005</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AEM.71.12.8228-8235.2005</ArticleId><ArticleId IdType="pmc">PMC1317376</ArticleId><ArticleId IdType="pubmed">16332807</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin BD, Witten D. &amp; Willis AD Modeling microbial abundances and dysbiosis with beta-binomial regression. Ann. Appl. Stat (2020). doi:10.1214/19-AOAS1283</Citation><ArticleIdList><ArticleId IdType="doi">10.1214/19-AOAS1283</ArticleId><ArticleId IdType="pmc">PMC7514055</ArticleId><ArticleId IdType="pubmed">32983313</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald D. et al. American Gut Project fecal sOTU counts table. (2018). doi:10.6084/m9.figshare.6137192.v1</Citation><ArticleIdList><ArticleId IdType="doi">10.6084/m9.figshare.6137192.v1</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald D. et al. Full American Gut Project mapping file. (2018). doi:10.6084/m9.figshare.6137315.v1</Citation><ArticleIdList><ArticleId IdType="doi">10.6084/m9.figshare.6137315.v1</ArticleId></ArticleIdList></Reference><Reference><Citation>Manor O. et al. A Multi-omic Association Study of Trimethylamine N-Oxide. Cell Rep. (2018). doi:10.1016/j.celrep.2018.06.096</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2018.06.096</ArticleId><ArticleId IdType="pubmed">30044989</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackey DC et al. Life-space mobility and mortality in older men: A prospective cohort study. J. Am. Geriatr. Soc (2014). doi:10.1111/jgs.12892</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgs.12892</ArticleId><ArticleId IdType="pmc">PMC4251711</ArticleId><ArticleId IdType="pubmed">24934163</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier L. et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature (2018). doi:10.1038/nature25979</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature25979</ArticleId><ArticleId IdType="pmc">PMC6108420</ArticleId><ArticleId IdType="pubmed">29555994</ArticleId></ArticleIdList></Reference><Reference><Citation>Charlesworth CJ, Smit E, Lee DSH, Alramadhan F. &amp; Odden MC Polypharmacy among adults aged 65 years and older in the United States: 1988&#xe2;&#x20ac;&#x201d;2010. Journals of Gerontology - Series A Biological Sciences and Medical Sciences (2015). doi:10.1093/gerona/glv013</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gerona/glv013</ArticleId><ArticleId IdType="pmc">PMC4573668</ArticleId><ArticleId IdType="pubmed">25733718</ArticleId></ArticleIdList></Reference><Reference><Citation>Mach&#xf3;n M, Vergara I, Dorronsoro M, Vrotsou K. &amp; Larra&#xf1;aga I. Self-perceived health in functionally independent older people: Associated factors. BMC Geriatr. (2016). doi:10.1186/s12877-016-0239-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12877-016-0239-9</ArticleId><ArticleId IdType="pmc">PMC4784324</ArticleId><ArticleId IdType="pubmed">26961707</ArticleId></ArticleIdList></Reference><Reference><Citation>Idler EL &amp; Benyamini Y. Self-Rated Health and Mortality: A Review of Twenty-Seven Community Studies. Journal of Health and Social Behavior (1997). doi:10.2307/2955359</Citation><ArticleIdList><ArticleId IdType="doi">10.2307/2955359</ArticleId><ArticleId IdType="pubmed">9097506</ArticleId></ArticleIdList></Reference><Reference><Citation>Mossey JM &amp; Shapiro E. Self-rated health: a predictor of mortality among the elderly. Am. J. Public Health (1982). doi:10.2105/AJPH.72.8.800</Citation><ArticleIdList><ArticleId IdType="doi">10.2105/AJPH.72.8.800</ArticleId><ArticleId IdType="pmc">PMC1650365</ArticleId><ArticleId IdType="pubmed">7091475</ArticleId></ArticleIdList></Reference><Reference><Citation>Peel C. et al. Assessing Mobility in Older Adults: The UAB Study of Aging Life-Space Assessment. Phys. Ther (2005). doi:10.1093/ptj/85.10.1008</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ptj/85.10.1008</ArticleId><ArticleId IdType="pubmed">16180950</ArticleId></ArticleIdList></Reference><Reference><Citation>Middleton A, Fritz SL &amp; Lusardi M. Walking speed: The functional vital sign. Journal of Aging and Physical Activity (2015). doi:10.1123/japa.2013-0236</Citation><ArticleIdList><ArticleId IdType="doi">10.1123/japa.2013-0236</ArticleId><ArticleId IdType="pmc">PMC4254896</ArticleId><ArticleId IdType="pubmed">24812254</ArticleId></ArticleIdList></Reference><Reference><Citation>Mielke MM et al. Assessing the temporal relationship between cognition and gait: Slow gait predicts cognitive decline in the mayo clinic study of aging. Journals Gerontol. - Ser. A Biol. Sci. Med. Sci (2013). doi:10.1093/gerona/gls256</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gerona/gls256</ArticleId><ArticleId IdType="pmc">PMC3712358</ArticleId><ArticleId IdType="pubmed">23250002</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33686287</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>03</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1718</ISSN><JournalIssue CitedMedium="Internet"><Volume>53</Volume><Issue>4</Issue><PubDate><Year>2021</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Nature genetics</Title><ISOAbbreviation>Nat Genet</ISOAbbreviation></Journal><ArticleTitle>Genome-wide CRISPR screening identifies TMEM106B as a proviral host factor for SARS-CoV-2.</ArticleTitle><Pagination><StartPage>435</StartPage><EndPage>444</EndPage><MedlinePgn>435-444</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41588-021-00805-2</ELocationID><Abstract><AbstractText>The ongoing COVID-19 pandemic has caused a global economic and health crisis. To identify host factors essential for coronavirus infection, we performed genome-wide functional genetic screens with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and human coronavirus 229E. These screens uncovered virus-specific as well as shared host factors, including TMEM41B and PI3K type 3. We discovered that SARS-CoV-2 requires the lysosomal protein TMEM106B to infect human cell lines and primary lung cells. TMEM106B overexpression enhanced SARS-CoV-2 infection as well as pseudovirus infection, suggesting a role in viral entry. Furthermore, single-cell RNA-sequencing of airway cells from patients with COVID-19 demonstrated that TMEM106B expression correlates with SARS-CoV-2 infection. The present study uncovered a collection of coronavirus host factors that may be exploited to develop drugs against SARS-CoV-2 infection or future zoonotic coronavirus outbreaks.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Baggen</LastName><ForeName>Jim</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-1628-6766</Identifier><AffiliationInfo><Affiliation>KU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, Rega Institute, Leuven, Belgium. jim.baggen@kuleuven.be.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Persoons</LastName><ForeName>Leentje</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-7898-0868</Identifier><AffiliationInfo><Affiliation>KU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, Rega Institute, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Vanstreels</LastName><ForeName>Els</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-7814-8035</Identifier><AffiliationInfo><Affiliation>KU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, Rega Institute, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Jansen</LastName><ForeName>Sander</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-9344-131X</Identifier><AffiliationInfo><Affiliation>KU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, Rega Institute, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Looveren</LastName><ForeName>Dominique</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-6439-3753</Identifier><AffiliationInfo><Affiliation>KU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, Rega Institute, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>KU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, Translational Platform Virology and Chemotherapy, Rega Institute, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boeckx</LastName><ForeName>Bram</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>KU Leuven Department of Human Genetics, Laboratory for Translational Genetics, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VIB Center for Cancer Biology, VIB, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geudens</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-4386-1746</Identifier><AffiliationInfo><Affiliation>KU Leuven Department of Chronic Diseases and Metabolism, Laboratory of Respiratory Diseases and Thoracic Surgery (BREATHE), Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Man</LastName><ForeName>Julie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>KU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, Rega Institute, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jochmans</LastName><ForeName>Dirk</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-9265-6028</Identifier><AffiliationInfo><Affiliation>KU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, Rega Institute, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wauters</LastName><ForeName>Joost</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>KU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Clinical Infectious and Inflammatory Disorders, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wauters</LastName><ForeName>Els</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-0115-0030</Identifier><AffiliationInfo><Affiliation>KU Leuven Department of Chronic Diseases and Metabolism, Laboratory of Respiratory Diseases and Thoracic Surgery (BREATHE), Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vanaudenaerde</LastName><ForeName>Bart M</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>KU Leuven Department of Chronic Diseases and Metabolism, Laboratory of Respiratory Diseases and Thoracic Surgery (BREATHE), Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lambrechts</LastName><ForeName>Diether</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>KU Leuven Department of Human Genetics, Laboratory for Translational Genetics, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VIB Center for Cancer Biology, VIB, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neyts</LastName><ForeName>Johan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>KU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, Rega Institute, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dallmeier</LastName><ForeName>Kai</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-8117-9166</Identifier><AffiliationInfo><Affiliation>KU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, Rega Institute, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thibaut</LastName><ForeName>Hendrik Jan</ForeName><Initials>HJ</Initials><Identifier Source="ORCID">0000-0001-5785-8276</Identifier><AffiliationInfo><Affiliation>KU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, Rega Institute, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>KU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, Translational Platform Virology and Chemotherapy, Rega Institute, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jacquemyn</LastName><ForeName>Maarten</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2626-4189</Identifier><AffiliationInfo><Affiliation>KU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, Rega Institute, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maes</LastName><ForeName>Piet</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>KU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Clinical and Epidemiological Virology, Rega Institute, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daelemans</LastName><ForeName>Dirk</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-7092-1153</Identifier><AffiliationInfo><Affiliation>KU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, Rega Institute, Leuven, Belgium. dirk.daelemans@kuleuven.be.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>03</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Genet</MedlineTA><NlmUniqueID>9216904</NlmUniqueID><ISSNLinking>1061-4036</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C556915">TMEM106B protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001992" MajorTopicYN="N">Bronchoalveolar Lavage Fluid</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064113" MajorTopicYN="Y">CRISPR-Cas Systems</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D028941" MajorTopicYN="N">Coronavirus 229E, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058872" MajorTopicYN="N">Epidemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004847" MajorTopicYN="N">Epithelial Cells</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015894" MajorTopicYN="N">Genome, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054884" MajorTopicYN="N">Host-Pathogen Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011533" MajorTopicYN="N">Proviruses</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053586" MajorTopicYN="N">Virus Internalization</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>10</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>1</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>9</Day><Hour>6</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33686287</ArticleId><ArticleId IdType="doi">10.1038/s41588-021-00805-2</ArticleId><ArticleId IdType="pii">10.1038/s41588-021-00805-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dong, E., Du, H. &amp; Gardner, L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect. Dis. 20, 533&#x2013;534 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30120-1</ArticleId><ArticleId IdType="pubmed">32087114</ArticleId><ArticleId IdType="pmc">7159018</ArticleId></ArticleIdList></Reference><Reference><Citation>Beigel, J. H. et al. Remdesivir for the treatment of Covid-19&#x2014;preliminary report. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2007764 (2020).</Citation></Reference><Reference><Citation>WHO Solidarity Trial Consortium et al. Repurposed antiviral drugs for Covid-19&#x2014;interim WHO solidarity trial results. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2023184 (2020).</Citation></Reference><Reference><Citation>Horby, P. et al. Effect of dexamethasone in hospitalized patients with COVID-19: preliminary report. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2021436 (2020).</Citation></Reference><Reference><Citation>Ye, Z. W. et al. Zoonotic origins of human coronaviruses. Int. J. Biol. Sci. 16, 1686&#x2013;1697 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijbs.45472</ArticleId><ArticleId IdType="pubmed">32226286</ArticleId><ArticleId IdType="pmc">7098031</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, D. X., Liang, J. Q. &amp; Fung, T. S. Human Coronavirus-229E, -OC43, -NL63, and -HKU1. Ref. Modul. Life Sci. https://doi.org/10.1016/b978-0-12-809633-8.21501-x (2020).</Citation></Reference><Reference><Citation>Chan, J. F., To, K. K., Tse, H., Jin, D. Y. &amp; Yuen, K. Y. Interspecies transmission and emergence of novel viruses: lessons from bats and birds. Trends Microbiol. 21, 544&#x2013;555 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tim.2013.05.005</ArticleId><ArticleId IdType="pubmed">23770275</ArticleId><ArticleId IdType="pmc">7126491</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui, J., Li, F. &amp; Shi, Z. L. Origin and evolution of pathogenic coronaviruses. Nat. Rev. Microbiol. 17, 181&#x2013;192 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-018-0118-9</ArticleId><ArticleId IdType="pubmed">30531947</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei, J. et al. Genome-wide CRISPR screens reveal host factors critical for SARS-CoV-2 infection. Cell https://doi.org/10.1016/j.cell.2020.10.028 (2020).</Citation></Reference><Reference><Citation>Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell https://doi.org/10.1016/j.cell.2020.02.052 (2020).</Citation></Reference><Reference><Citation>Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270&#x2013;273 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2012-7</ArticleId><ArticleId IdType="pubmed">32015507</ArticleId><ArticleId IdType="pmc">7095418</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu, Y. et al. The S1/S2 boundary of SARS-CoV-2 spike protein modulates cell entry pathways and transmission. Preprint at bioRxiv https://doi.org/10.1101/2020.08.25.266775 (2020).</Citation></Reference><Reference><Citation>Shang, J. et al. Cell entry mechanisms of SARS-CoV-2. Proc. Natl Acad. Sci. USA 117, 11727&#x2013;11734 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2003138117</ArticleId><ArticleId IdType="pubmed">32376634</ArticleId><ArticleId IdType="pmc">7260975</ArticleId></ArticleIdList></Reference><Reference><Citation>Flint, M. et al. A genome-wide CRISPR screen identifies N-acetylglucosamine-1-phosphate transferase as a potential antiviral target for Ebola virus. Nat. Commun. 10, 1&#x2013;13 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-08135-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, B. et al. Genome-wide CRISPR screen identifies host dependency factors for influenza A virus infection. Nat. Commun. 11, 164 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-13965-x</ArticleId><ArticleId IdType="pubmed">31919360</ArticleId><ArticleId IdType="pmc">6952391</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, R. et al. Genetic screens identify host factors for SARS-CoV-2 and common cold coronaviruses. Cell https://doi.org/10.1016/j.cell.2020.12.004 (2020).</Citation></Reference><Reference><Citation>Schneider, W. M. et al. Genome-scale identification of SARS-CoV-2 and pan-coronavirus host factor networks. Cell https://doi.org/10.1016/j.cell.2020.12.006 (2020).</Citation></Reference><Reference><Citation>Daniloski, Z. et al. Identification of required host factors for SARS-CoV-2 infection in human cells. Cell https://doi.org/10.1016/j.cell.2020.10.030 (2020).</Citation></Reference><Reference><Citation>Heaton, B. E. et al. SRSF protein kinases 1 and 2 are essential host factors for human coronaviruses including SARS-CoV-2. Preprint at bioRxiv https://doi.org/10.1101/2020.08.14.251207 (2020).</Citation></Reference><Reference><Citation>Doench, J. G. et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR&#x2013;Cas9. Nat. Biotechnol. 34, 184&#x2013;191 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.3437</ArticleId><ArticleId IdType="pubmed">26780180</ArticleId><ArticleId IdType="pmc">4744125</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeager, C. L. et al. Human aminopeptidase N is a receptor for human coronavirus 229E. Nature 357, 420&#x2013;422 (1992).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/357420a0</ArticleId><ArticleId IdType="pubmed">1350662</ArticleId><ArticleId IdType="pmc">7095410</ArticleId></ArticleIdList></Reference><Reference><Citation>Clausen, T. M. et al. SARS-CoV-2 infection depends on cellular heparan sulfate and ACE2. Cell 183, P1043&#x2013;P1057 (2020).</Citation></Reference><Reference><Citation>Nicholson, A. M. &amp; Rademakers, R. What we know about TMEM106B in neurodegeneration. Acta Neuropathol. 132, 639&#x2013;651 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1610-9</ArticleId><ArticleId IdType="pubmed">27543298</ArticleId><ArticleId IdType="pmc">5074873</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngo, M. &amp; Ridgway, N. D. Oxysterol binding protein-related protein 9 (ORP9) is a cholesterol transfer protein that regulates Golgi structure and function. Mol. Biol. Cell 20, 1388&#x2013;1399 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1091/mbc.e08-09-0905</ArticleId><ArticleId IdType="pubmed">19129476</ArticleId><ArticleId IdType="pmc">2649274</ArticleId></ArticleIdList></Reference><Reference><Citation>Coleman, J. A. &amp; Molday, R. S. Critical role of the beta-subunit CDC50A in the stable expression, assembly, subcellular localization, and lipid transport activity of the P4-ATPase ATP8A2. J. Biol. Chem. 286, 17205&#x2013;17216 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.229419</ArticleId><ArticleId IdType="pubmed">21454556</ArticleId><ArticleId IdType="pmc">3089563</ArticleId></ArticleIdList></Reference><Reference><Citation>Backer, J. M. The intricate regulation and complex functions of the class III phosphoinositide 3-kinase Vps34. Biochem. J. 473, 2251&#x2013;2271 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BCJ20160170</ArticleId><ArticleId IdType="pubmed">27470591</ArticleId></ArticleIdList></Reference><Reference><Citation>Ronan, B. et al. A highly potent and selective Vps34 inhibitor alters vesicle trafficking and autophagy. Nat. Chem. Biol. 10, 1013&#x2013;1019 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nchembio.1681</ArticleId><ArticleId IdType="pubmed">25326666</ArticleId></ArticleIdList></Reference><Reference><Citation>Dikic, I. &amp; Elazar, Z. Mechanism and medical implications of mammalian autophagy. Nat. Rev. Mol. Cell Biol. 19, 349&#x2013;364 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41580-018-0003-4</ArticleId><ArticleId IdType="pubmed">29618831</ArticleId></ArticleIdList></Reference><Reference><Citation>Morita, K. et al. Genome-wide CRISPR screen identifies TMEM41B as a gene required for autophagosome formation. J. Cell Biol. 217, 3817&#x2013;3828 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.201804132</ArticleId><ArticleId IdType="pubmed">30093494</ArticleId><ArticleId IdType="pmc">6219718</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann, H. et al. TMEM41B is a pan-flavivirus host factor. Cell https://doi.org/10.1016/j.cell.2020.12.005 (2020).</Citation></Reference><Reference><Citation>W&#xf6;lfel, R. et al. Virological assessment of hospitalized patients with COVID-2019. Nature 581, 465&#x2013;469 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2196-x</ArticleId><ArticleId IdType="pubmed">32235945</ArticleId></ArticleIdList></Reference><Reference><Citation>Wauters, E. et al. Discriminating mild from critical COVID-19 by innate and adaptive immune single-cell profiling of bronchoalveolar lavages. Cell Res. https://doi.org/10.1101/2020.07.09.196519 (2021).</Citation></Reference><Reference><Citation>Bost, P. et al. Host-viral infection maps reveal signatures of severe COVID-19 patients. Cell 181, 1475&#x2013;1488.e12 (2020).</Citation></Reference><Reference><Citation>Gu, Y. et al. Interaction network of SARS-CoV-2 with host receptome through spike protein. Preprint at bioRxiv https://doi.org/10.1101/2020.09.09.287508 (2020).</Citation></Reference><Reference><Citation>Silvas, J. A., Jureka, A. S., Nicolini, A. M., Chvatal, S. A. &amp; Basler, C. F. Inhibitors of VPS34 and lipid metabolism suppress SARS-CoV-2 replication. Preprint at bioRxiv https://doi.org/10.1101/2020.07.18.210211 (2020).</Citation></Reference><Reference><Citation>Klein, Z. A. et al. Loss of TMEM106B ameliorates lysosomal and frontotemporal dementia-related phenotypes in article loss of TMEM106B ameliorates lysosomal and frontotemporal dementia-related phenotypes in progranulin-deficient mice. Neuron 95, 281&#x2013;296.e6 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.06.026</ArticleId><ArticleId IdType="pubmed">28728022</ArticleId><ArticleId IdType="pmc">5558861</ArticleId></ArticleIdList></Reference><Reference><Citation>Ou, X. et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat. Commun. 11, 1620 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-15562-9</ArticleId><ArticleId IdType="pubmed">32221306</ArticleId><ArticleId IdType="pmc">7100515</ArticleId></ArticleIdList></Reference><Reference><Citation>Blau, D. M. &amp; Holmes, K. V. Human coronavirus HCoV-229E enters susceptible cells via the endocytic pathway. Adv. Exp. Med. Biol. 494, 193&#x2013;198 (2001).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4615-1325-4_31</ArticleId><ArticleId IdType="pubmed">11774468</ArticleId></ArticleIdList></Reference><Reference><Citation>Carette, J. E. et al. Ebola virus entry requires the cholesterol transporter Niemann&#x2013;Pick C1. Nature 477, 340&#x2013;343 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature10348</ArticleId><ArticleId IdType="pubmed">21866103</ArticleId><ArticleId IdType="pmc">3175325</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung, K. et al. Early empirical assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to November 2020. Euro. Surveill. 26, 2002106 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">7791602</ArticleId><ArticleId IdType="doi">10.2807/1560-7917.ES.2020.26.1.2002106</ArticleId></ArticleIdList></Reference><Reference><Citation>Uhl&#xe9;n, M. et al. Tissue-based map of the human proteome. Science 347, 1260419 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1260419</ArticleId><ArticleId IdType="pubmed">25613900</ArticleId></ArticleIdList></Reference><Reference><Citation>Varatharaj, A. et al. Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. Lancet Psychiatry 7, 875&#x2013;882 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2215-0366(20)30287-X</ArticleId><ArticleId IdType="pubmed">32593341</ArticleId><ArticleId IdType="pmc">7316461</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, H. et al. Impaired spermatogenesis in COVID-19 patients. EClinicalMedicine 28, 100604 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2020.100604</ArticleId><ArticleId IdType="pubmed">33134901</ArticleId><ArticleId IdType="pmc">7584442</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeong, H. H., Kim, S. Y., Rousseaux, M. W. C., Zoghbi, H. Y. &amp; Liu, Z. Beta-binomial modeling of CRISPR pooled screen data identifies target genes with greater sensitivity and fewer false negatives. Genome Res. 29, 999&#x2013;1008 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.245571.118</ArticleId><ArticleId IdType="pubmed">31015259</ArticleId><ArticleId IdType="pmc">6581060</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathyssen, C. et al. Vitamin D modulates the response of bronchial epithelial cells exposed to cigarette smoke extract. Nutrients 11, 2138 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu11092138</ArticleId><ArticleId IdType="pmc">6770037</ArticleId></ArticleIdList></Reference><Reference><Citation>Boudewijns, R. et al. STAT2 signaling restricts viral dissemination but drives severe pneumonia in SARS-CoV-2 infected hamsters. Nat. Commun. 11, 5838 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-19684-y</ArticleId><ArticleId IdType="pubmed">33203860</ArticleId><ArticleId IdType="pmc">7672082</ArticleId></ArticleIdList></Reference><Reference><Citation>Vijgen, L. et al. Development of one-step, real-time, quantitative reverse transcriptase PCR assays for absolute quantitation of human coronaviruses OC43 and 229E. J. Clin. Microbiol. 43, 5452&#x2013;5456 (2005).</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.43.11.5452-5456.2005</ArticleId><ArticleId IdType="pubmed">16272469</ArticleId><ArticleId IdType="pmc">1287813</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao, M. et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat. Med. 26, 842&#x2013;844 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0901-9</ArticleId><ArticleId IdType="pubmed">32398875</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuart, T. et al. Comprehensive integration of single-cell data. Cell 177, 1888&#x2013;1902.e21 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31178118</ArticleId><ArticleId IdType="pmc">6687398</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2019.05.031</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33382968</PMID><DateCompleted><Year>2021</Year><Month>01</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4172</ISSN><JournalIssue CitedMedium="Internet"><Volume>184</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Jan</Month><Day>07</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>Genome-Scale Identification of SARS-CoV-2 and Pan-coronavirus Host Factor Networks.</ArticleTitle><Pagination><StartPage>120</StartPage><EndPage>132.e14</EndPage><MedlinePgn>120-132.e14</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2020.12.006</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0092-8674(20)31676-7</ELocationID><Abstract><AbstractText>The coronavirus disease 2019 (COVID-19) pandemic has claimed the lives of over one million people worldwide. The causative agent, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a member of the Coronaviridae family of viruses that can cause respiratory infections of varying severity. The cellular host factors and pathways co-opted during SARS-CoV-2 and related coronavirus life cycles remain ill defined. To address this gap, we performed genome-scale CRISPR knockout screens during infection by SARS-CoV-2 and three seasonal coronaviruses (HCoV-OC43, HCoV-NL63, and HCoV-229E). These screens uncovered host factors and pathways with pan-coronavirus and virus-specific functional roles, including major dependency on glycosaminoglycan biosynthesis, sterol regulatory element-binding protein (SREBP) signaling, bone morphogenetic protein (BMP) signaling, and glycosylphosphatidylinositol biosynthesis, as well as a requirement for several poorly characterized proteins. We identified an absolute requirement for the VMP1, TMEM41, and TMEM64 (VTT) domain-containing protein transmembrane protein 41B (TMEM41B) for infection by SARS-CoV-2 and three seasonal coronaviruses. This human coronavirus host factor compendium represents a rich resource to develop new therapeutic strategies for acute COVID-19 and potential future coronavirus pandemics.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>William M</ForeName><Initials>WM</Initials><AffiliationInfo><Affiliation>Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luna</LastName><ForeName>Joseph M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoffmann</LastName><ForeName>H-Heinrich</ForeName><Initials>HH</Initials><AffiliationInfo><Affiliation>Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xe1;nchez-Rivera</LastName><ForeName>Francisco J</ForeName><Initials>FJ</Initials><AffiliationInfo><Affiliation>Cancer Biology and Genetics, MSKCC, New York, NY 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leal</LastName><ForeName>Andrew A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Laura and Isaac Perlmutter Cancer Center, New York University Grossman School of Medicine, NYU Langone Health, New York, NY 10016, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ashbrook</LastName><ForeName>Alison W</ForeName><Initials>AW</Initials><AffiliationInfo><Affiliation>Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le Pen</LastName><ForeName>J&#xe9;r&#xe9;mie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ricardo-Lax</LastName><ForeName>Inna</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Michailidis</LastName><ForeName>Eleftherios</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peace</LastName><ForeName>Avery</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stenzel</LastName><ForeName>Ansgar F</ForeName><Initials>AF</Initials><AffiliationInfo><Affiliation>Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY 10065, USA; Department of Infectious Diseases, Molecular Virology, Heidelberg University, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lowe</LastName><ForeName>Scott W</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>Cancer Biology and Genetics, MSKCC, New York, NY 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>MacDonald</LastName><ForeName>Margaret R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rice</LastName><ForeName>Charles M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY 10065, USA. Electronic address: ricec@rockefeller.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poirier</LastName><ForeName>John T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Laura and Isaac Perlmutter Cancer Center, New York University Grossman School of Medicine, NYU Langone Health, New York, NY 10016, USA. Electronic address: john.poirier@nyulangone.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AI150275</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI116943</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA016087</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI091707</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 CA213359</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 CA190261</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI124690</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 AI133910</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AI138938</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA008748</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 CA213448</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AI111825</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R03 AI141855</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 CA160001</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AI161212</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI143295</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AI142010</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>12</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000631469">TMEM41B protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>bioRxiv. 2020 Oct 08:2020.10.07.326462. doi: 10.1101/2020.10.07.326462.</RefSource><PMID Version="1">33052332</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000072283" MajorTopicYN="N">A549 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064112" MajorTopicYN="N">Clustered Regularly Interspaced Short Palindromic Repeats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D028941" MajorTopicYN="N">Coronavirus 229E, Human</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058957" MajorTopicYN="N">Coronavirus NL63, Human</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D028962" MajorTopicYN="N">Coronavirus OC43, Human</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055786" MajorTopicYN="N">Gene Knockout Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="Y">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054884" MajorTopicYN="N">Host-Pathogen Interactions</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053858" MajorTopicYN="N">Metabolic Networks and Pathways</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D025941" MajorTopicYN="N">Protein Interaction Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">CRISPR</Keyword><Keyword MajorTopicYN="N">HCoV-229E</Keyword><Keyword MajorTopicYN="N">HCoV-NL63</Keyword><Keyword MajorTopicYN="N">HCoV-OC43</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">TMEM41B</Keyword><Keyword MajorTopicYN="N">coronavirus</Keyword><Keyword MajorTopicYN="N">genetic screens</Keyword><Keyword MajorTopicYN="N">host factors</Keyword></KeywordList><CoiStatement>Declaration of Interests S.W.L. is an advisor for and has equity in the following biotechnology companies: ORIC Pharmaceuticals, Faeth Therapeutics, Blueprint Medicines, Geras Bio, Mirimus Inc., PMV Pharmaceuticals, and Constellation Pharmaceuticals. C.M.R. is a founder of Apath LLC; a Scientific Advisory Board member of Imvaq Therapeutics; Vir Biotechnology, and Arbutus Biopharma; and an advisor for Regulus Therapeutics and Pfizer.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>10</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>11</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>12</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>1</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>1</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>12</Month><Day>31</Day><Hour>20</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>12</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33382968</ArticleId><ArticleId IdType="mid">NIHMS1653502</ArticleId><ArticleId IdType="pmc">PMC7796900</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2020.12.006</ArticleId><ArticleId IdType="pii">S0092-8674(20)31676-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aikawa J., Grobe K., Tsujimoto M., Esko J.D. Multiple isozymes of heparan sulfate/heparin GlcNAc N-deacetylase/GlcN N-sulfotransferase. Structure and activity of the fourth member, NDST4. J.&#xa0;Biol. Chem. 2001;276:5876&#x2013;5882.</Citation><ArticleIdList><ArticleId IdType="pubmed">11087757</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen B.L., Taatjes D.J. The Mediator complex: a central integrator of transcription. Nat. Rev. Mol. Cell Biol. 2015;16:155&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4963239</ArticleId><ArticleId IdType="pubmed">25693131</ArticleId></ArticleIdList></Reference><Reference><Citation>Babbey C.M., Bacallao R.L., Dunn K.W. Rab10 associates with primary cilia and the exocyst complex in renal epithelial cells. Am. J. Physiol. Renal Physiol. 2010;299:F495&#x2013;F506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2944301</ArticleId><ArticleId IdType="pubmed">20576682</ArticleId></ArticleIdList></Reference><Reference><Citation>Baggen J., Persoons L., Jansen S., Vanstreels E., Jacquemyn M., Jochmans D., Neyts J., Dallmeier K., Maes P., Daelemans D. Identification of TMEM106B as proviral host factor for SARS-CoV-2. bioRxiv. 2020 doi: 10.1101/2020.09.28.316281.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.09.28.316281</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai X., Zhou D., Brown J.R., Crawford B.E., Hennet T., Esko J.D. Biosynthesis of the linkage region of glycosaminoglycans: cloning and activity of galactosyltransferase II, the sixth member of the beta 1,3-galactosyltransferase family (beta 3GalT6) J.&#xa0;Biol. Chem. 2001;276:48189&#x2013;48195.</Citation><ArticleIdList><ArticleId IdType="pubmed">11551958</ArticleId></ArticleIdList></Reference><Reference><Citation>Blackburn J.B., D&#x2019;Souza Z., Lupashin V.V. Maintaining order: COG complex controls Golgi trafficking, processing, and sorting. FEBS Lett. 2019;593:2466&#x2013;2487.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6771879</ArticleId><ArticleId IdType="pubmed">31381138</ArticleId></ArticleIdList></Reference><Reference><Citation>Blight K.J., McKeating J.A., Rice C.M. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J.&#xa0;Virol. 2002;76:13001&#x2013;13014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC136668</ArticleId><ArticleId IdType="pubmed">12438626</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourgeois C., Bour J.B., Lidholt K., Gauthray C., Pothier P. Heparin-like structures on respiratory syncytial virus are involved in its infectivity in&#xa0;vitro. J.&#xa0;Virol. 1998;72:7221&#x2013;7227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC109944</ArticleId><ArticleId IdType="pubmed">9696816</ArticleId></ArticleIdList></Reference><Reference><Citation>Buhaescu I., Izzedine H. Mevalonate pathway: a review of clinical and therapeutical implications. Clin. Biochem. 2007;40:575&#x2013;584.</Citation><ArticleIdList><ArticleId IdType="pubmed">17467679</ArticleId></ArticleIdList></Reference><Reference><Citation>Carette J.E., Raaben M., Wong A.C., Herbert A.S., Obernosterer G., Mulherkar N., Kuehne A.I., Kranzusch P.J., Griffin A.M., Ruthel G., et al. Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature. 2011;477:340&#x2013;343.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3175325</ArticleId><ArticleId IdType="pubmed">21866103</ArticleId></ArticleIdList></Reference><Reference><Citation>Casanova J.C., Kuhn J., Kleesiek K., G&#xf6;tting C. Heterologous expression and biochemical characterization of soluble human xylosyltransferase II. Biochem. Biophys. Res. Commun. 2008;365:678&#x2013;684.</Citation><ArticleIdList><ArticleId IdType="pubmed">18023272</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen B., Gilbert L.A., Cimini B.A., Schnitzbauer J., Zhang W., Li G.-W., Park J., Blackburn E.H., Weissman J.S., Qi L.S., Huang B. Dynamic imaging of genomic loci in living human cells by an optimized CRISPR/Cas system. Cell. 2013;155:1479&#x2013;1491.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3918502</ArticleId><ArticleId IdType="pubmed">24360272</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu D.K.W., Pan Y., Cheng S.M.S., Hui K.P.Y., Krishnan P., Liu Y., Ng D.Y.M., Wan C.K.C., Yang P., Wang Q., et al. Molecular Diagnosis of a Novel Coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia. Clin. Chem. 2020;66:549&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7108203</ArticleId><ArticleId IdType="pubmed">32031583</ArticleId></ArticleIdList></Reference><Reference><Citation>Chua R.L., Lukassen S., Trump S., Hennig B.P., Wendisch D., Pott F., Debnath O., Th&#xfc;rmann L., Kurth F., V&#xf6;lker M.T., et al. COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis. Nat. Biotechnol. 2020;38:970&#x2013;979.</Citation><ArticleIdList><ArticleId IdType="pubmed">32591762</ArticleId></ArticleIdList></Reference><Reference><Citation>Clausen T.M., Sandoval D.R., Spliid C.B., Pihl J., Perrett H.R., Painter C.D., Narayanan A., Majowicz S.A., Kwong E.M., McVicar R.N., et al. SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2. Cell. 2020;183:P1043&#x2013;P1057.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7489987</ArticleId><ArticleId IdType="pubmed">32970989</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz-Oliveira C., Freire J.M., Concei&#xe7;&#xe3;o T.M., Higa L.M., Castanho M.A., Da Poian A.T. Receptors and routes of dengue virus entry into the host cells. FEMS Microbiol. Rev. 2015;39:155&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">25725010</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuellar K., Chuong H., Hubbell S.M., Hinsdale M.E. Biosynthesis of chondroitin and heparan sulfate in chinese hamster ovary cells depends on xylosyltransferase II. J.&#xa0;Biol. Chem. 2007;282:5195&#x2013;5200.</Citation><ArticleIdList><ArticleId IdType="pubmed">17189266</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui J., Li F., Shi Z.L. Origin and evolution of pathogenic coronaviruses. Nat. Rev. Microbiol. 2019;17:181&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7097006</ArticleId><ArticleId IdType="pubmed">30531947</ArticleId></ArticleIdList></Reference><Reference><Citation>Daniloski Z., Jordan T.X., Wessels H.H., Hoagland D.A., Kasela S., Legut M., Maniatis S., Mimitou E.P., Lu L., Geller E., et al. Identification of Required Host Factors for SARS-CoV-2 Infection in Human Cells. Cell. 2020 doi: 10.1016/j.cell.2020.10.030. Published online October 24, 2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.10.030</ArticleId><ArticleId IdType="pmc">PMC7584921</ArticleId><ArticleId IdType="pubmed">33147445</ArticleId></ArticleIdList></Reference><Reference><Citation>Dechecchi M.C., Tamanini A., Bonizzato A., Cabrini G. Heparan sulfate glycosaminoglycans are involved in adenovirus type 5 and 2-host cell interactions. Virology. 2000;268:382&#x2013;390.</Citation><ArticleIdList><ArticleId IdType="pubmed">10704346</ArticleId></ArticleIdList></Reference><Reference><Citation>Dechecchi M.C., Melotti P., Bonizzato A., Santacatterina M., Chilosi M., Cabrini G. Heparan sulfate glycosaminoglycans are receptors sufficient to mediate the initial binding of adenovirus types 2 and 5. J.&#xa0;Virol. 2001;75:8772&#x2013;8780.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC115122</ArticleId><ArticleId IdType="pubmed">11507222</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimitrov D.S. Virus entry: molecular mechanisms and biomedical applications. Nat. Rev. Microbiol. 2004;2:109&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7097642</ArticleId><ArticleId IdType="pubmed">15043007</ArticleId></ArticleIdList></Reference><Reference><Citation>Doench J.G., Fusi N., Sullender M., Hegde M., Vaimberg E.W., Donovan K.F., Smith I., Tothova Z., Wilen C., Orchard R., et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat. Biotechnol. 2016;34:184&#x2013;191.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4744125</ArticleId><ArticleId IdType="pubmed">26780180</ArticleId></ArticleIdList></Reference><Reference><Citation>Earnest J.T., Hantak M.P., Li K., McCray P.B., Jr., Perlman S., Gallagher T. The tetraspanin CD9 facilitates MERS-coronavirus entry by scaffolding host cell receptors and proteases. PLoS Pathog. 2017;13:e1006546.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5552337</ArticleId><ArticleId IdType="pubmed">28759649</ArticleId></ArticleIdList></Reference><Reference><Citation>Escribano-Romero E., Rawling J., Garc&#xed;a-Barreno B., Melero J.A. The soluble form of human respiratory syncytial virus attachment protein differs from the membrane-bound form in its oligomeric state but is still capable of binding to cell surface proteoglycans. J.&#xa0;Virol. 2004;78:3524&#x2013;3532.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC371076</ArticleId><ArticleId IdType="pubmed">15016875</ArticleId></ArticleIdList></Reference><Reference><Citation>Ewen-Campen B., Mohr S.E., Hu Y., Perrimon N. Accessing the Phenotype Gap: Enabling Systematic Investigation of Paralog Functional Complexity with CRISPR. Dev. Cell. 2017;43:6&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">29017030</ArticleId></ArticleIdList></Reference><Reference><Citation>Fajgenbaum D.C., Rader D.J. Teaching Old Drugs New Tricks: Statins for COVID-19? Cell Metab. 2020;32:145&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7402379</ArticleId><ArticleId IdType="pubmed">32755604</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman S.A., Audet S., Beeler J.A. The fusion glycoprotein of human respiratory syncytial virus facilitates virus attachment and infectivity via an interaction with cellular heparan sulfate. J.&#xa0;Virol. 2000;74:6442&#x2013;6447.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC112152</ArticleId><ArticleId IdType="pubmed">10864656</ArticleId></ArticleIdList></Reference><Reference><Citation>Forni D., Cagliani R., Clerici M., Sironi M. Molecular Evolution of Human Coronavirus Genomes. Trends Microbiol. 2017;25:35&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7111218</ArticleId><ArticleId IdType="pubmed">27743750</ArticleId></ArticleIdList></Reference><Reference><Citation>Gardner C.L., Ebel G.D., Ryman K.D., Klimstra W.B. Heparan sulfate binding by natural eastern equine encephalitis viruses promotes neurovirulence. Proc. Natl. Acad. Sci. USA. 2011;108:16026&#x2013;16031.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3179095</ArticleId><ArticleId IdType="pubmed">21896745</ArticleId></ArticleIdList></Reference><Reference><Citation>Giroglou T., Florin L., Sch&#xe4;fer F., Streeck R.E., Sapp M. Human papillomavirus infection requires cell surface heparan sulfate. J.&#xa0;Virol. 2001;75:1565&#x2013;1570.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC114064</ArticleId><ArticleId IdType="pubmed">11152531</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein J.L., Brown M.S. Regulation of the mevalonate pathway. Nature. 1990;343:425&#x2013;430.</Citation><ArticleIdList><ArticleId IdType="pubmed">1967820</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon D.E., Jang G.M., Bouhaddou M., Xu J., Obernier K., White K.M., O&#x2019;Meara M.J., Rezelj V.V., Guo J.Z., Swaney D.L., et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020;583:459&#x2013;468.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7431030</ArticleId><ArticleId IdType="pubmed">32353859</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu Y., Cao J., Zhang X., Gao H., Wang Y., Wang J., Zhang J., Shen G., Jiang X., Yang J., et al. Interaction network of SARS-CoV-2 with host receptome through spike protein. bioRxiv. 2020 doi: 10.1101/2020.09.09.287508.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.09.09.287508</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall M.P., Unch J., Binkowski B.F., Valley M.P., Butler B.L., Wood M.G., Otto P., Zimmerman K., Vidugiris G., Machleidt T., et al. Engineered luciferase reporter from a deep sea shrimp utilizing a novel imidazopyrazinone substrate. ACS Chem. Biol. 2012;7:1848&#x2013;1857.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3501149</ArticleId><ArticleId IdType="pubmed">22894855</ArticleId></ArticleIdList></Reference><Reference><Citation>Hallak L.K., Collins P.L., Knudson W., Peeples M.E. Iduronic acid-containing glycosaminoglycans on target cells are required for efficient respiratory syncytial virus infection. Virology. 2000;271:264&#x2013;275.</Citation><ArticleIdList><ArticleId IdType="pubmed">10860881</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris J., Werling D. Binding and entry of respiratory syncytial virus into host cells and initiation of the innate immune response. Cell. Microbiol. 2003;5:671&#x2013;680.</Citation><ArticleIdList><ArticleId IdType="pubmed">12969373</ArticleId></ArticleIdList></Reference><Reference><Citation>Heaton B.E., Trimarco J.D., Hamele C.E., Harding A.T., Tata A., Zhu X., Tata P.R., Smith C.M., Heaton N.S. SRSF protein kinases 1 and 2 are essential host factors for human coronaviruses including SARS-CoV-2. bioRxiv. 2020 doi: 10.1101/2020.08.14.251207.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.08.14.251207</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M., Kleine-Weber H., Schroeder S., Kr&#xfc;ger N., Herrler T., Erichsen S., Schiergens T.S., Herrler G., Wu N.-H., Nitsche A., et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181:271&#x2013;280.e8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann H.-H., Schneider W.M., Rozen-Gagnon K., Miles L.A., Schuster F., Razooky B., Jacobson E., Wu X., Yi S., Rudin C.M., et al. TMEM41B is a pan-flavivirus host factor. Cell. 2020;184 doi: 10.1016/j.cell.2020.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.12.005</ArticleId><ArticleId IdType="pmc">PMC7954666</ArticleId><ArticleId IdType="pubmed">33338421</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann H.-H., S&#xe1;nchez-Rivera F.J., Schneider W.M., Luna J.M., Soto-Feliciano Y.M., Ashbrook A.W., Le Pen J., Leal A.A., Ricardo-Lax I., Michailidis E., et al. Functional interrogation of a SARS-CoV-2 host protein interactome identifies unique and shared coronavirus host factors. Cell Host Microbe. 2020 doi: 10.1016/j.chom.2020.12.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.12.009</ArticleId><ArticleId IdType="pmc">PMC7833927</ArticleId><ArticleId IdType="pubmed">33357464</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang R., Grishagin I., Wang Y., Zhao T., Greene J., Obenauer J.C., Ngan D., Nguyen D.T., Guha R., Jadhav A., et al. The NCATS BioPlanet - An Integrated Platform for Exploring the Universe of Cellular Signaling Pathways for Toxicology, Systems Biology, and Chemical Genomics. Front. Pharmacol. 2019;10:445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6524730</ArticleId><ArticleId IdType="pubmed">31133849</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibrahim J., Griffin P., Coombe D.R., Rider C.C., James W. Cell-surface heparan sulfate facilitates human immunodeficiency virus Type 1 entry into some cell lines but not primary lymphocytes. Virus Res. 1999;60:159&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pubmed">10392724</ArticleId></ArticleIdList></Reference><Reference><Citation>Imlach W.L., Beck E.S., Choi B.J., Lotti F., Pellizzoni L., McCabe B.D. SMN is required for sensory-motor circuit function in Drosophila. Cell. 2012;151:427&#x2013;439. doi: 10.1016/j.cell.2012.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2012.09.011</ArticleId><ArticleId IdType="pmc">PMC3475188</ArticleId><ArticleId IdType="pubmed">23063130</ArticleId></ArticleIdList></Reference><Reference><Citation>Joyce J.G., Tung J.S., Przysiecki C.T., Cook J.C., Lehman E.D., Sands J.A., Jansen K.U., Keller P.M. The L1 major capsid protein of human papillomavirus type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes. J.&#xa0;Biol. Chem. 1999;274:5810&#x2013;5822.</Citation><ArticleIdList><ArticleId IdType="pubmed">10026203</ArticleId></ArticleIdList></Reference><Reference><Citation>Karger A., Schmidt U., Buchholz U.J. Recombinant bovine respiratory syncytial virus with deletions of the G or SH genes: G and F proteins bind heparin. J.&#xa0;Gen. Virol. 2001;82:631&#x2013;640.</Citation><ArticleIdList><ArticleId IdType="pubmed">11172105</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitagawa H., Tone Y., Tamura J., Neumann K.W., Ogawa T., Oka S., Kawasaki T., Sugahara K. Molecular cloning and expression of glucuronyltransferase I involved in the biosynthesis of the glycosaminoglycan-protein linkage region of proteoglycans. J.&#xa0;Biol. Chem. 1998;273:6615&#x2013;6618.</Citation><ArticleIdList><ArticleId IdType="pubmed">9506957</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleinfelter L.M., Jangra R.K., Jae L.T., Herbert A.S., Mittler E., Stiles K.M., Wirchnianski A.S., Kielian M., Brummelkamp T.R., Dye J.M., Chandran K. Haploid Genetic Screen Reveals a Profound and Direct Dependence on Cholesterol for Hantavirus Membrane Fusion. MBio. 2015;6:e00801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4488941</ArticleId><ArticleId IdType="pubmed">26126854</ArticleId></ArticleIdList></Reference><Reference><Citation>Knoops K., Kikkert M., Worm S.H., Zevenhoven-Dobbe J.C., van der Meer Y., Koster A.J., Mommaas A.M., Snijder E.J. SARS-coronavirus replication is supported by a reticulovesicular network of modified endoplasmic reticulum. PLoS Biol. 2008;6:e226.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2535663</ArticleId><ArticleId IdType="pubmed">18798692</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreuger J., Kjell&#xe9;n L. Heparan sulfate biosynthesis: regulation and variability. J.&#xa0;Histochem. Cytochem. 2012;60:898&#x2013;907.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3527889</ArticleId><ArticleId IdType="pubmed">23042481</ArticleId></ArticleIdList></Reference><Reference><Citation>Krusat T., Streckert H.J. Heparin-dependent attachment of respiratory syncytial virus (RSV) to host cells. Arch. Virol. 1997;142:1247&#x2013;1254.</Citation><ArticleIdList><ArticleId IdType="pubmed">9229012</ArticleId></ArticleIdList></Reference><Reference><Citation>Letko M., Marzi A., Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat. Microbiol. 2020;5:562&#x2013;569.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095430</ArticleId><ArticleId IdType="pubmed">32094589</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W., Xu H., Xiao T., Cong L., Love M.I., Zhang F., Irizarry R.A., Liu J.S., Brown M., Liu X.S. MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens. Genome Biol. 2014;15:554.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4290824</ArticleId><ArticleId IdType="pubmed">25476604</ArticleId></ArticleIdList></Reference><Reference><Citation>Lind T., Tufaro F., McCormick C., Lindahl U., Lidholt K. The putative tumor suppressors EXT1 and EXT2 are glycosyltransferases required for the biosynthesis of heparan sulfate. J.&#xa0;Biol. Chem. 1998;273:26265&#x2013;26268.</Citation><ArticleIdList><ArticleId IdType="pubmed">9756849</ArticleId></ArticleIdList></Reference><Reference><Citation>Lotti F., Imlach W.L., Saieva L., Beck E.S., Hao L.T., Li D.K., Jiao W., Mentis G.Z., Beattie C.E., McCabe B.D., Pellizzoni L. An SMN-dependent U12 splicing event essential for motor circuit function. Cell. 2012;151:440&#x2013;454. doi: 10.1016/j.cell.2012.09.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2012.09.012</ArticleId><ArticleId IdType="pmc">PMC3474596</ArticleId><ArticleId IdType="pubmed">23063131</ArticleId></ArticleIdList></Reference><Reference><Citation>Marceau C.D., Puschnik A.S., Majzoub K., Ooi Y.S., Brewer S.M., Fuchs G., Swaminathan K., Mata M.A., Elias J.E., Sarnow P., Carette J.E. Genetic dissection of Flaviviridae host factors through genome-scale CRISPR screens. Nature. 2016;535:159&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4964798</ArticleId><ArticleId IdType="pubmed">27383987</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin-Urdiroz M., Deeks M.J., Horton C.G., Dawe H.R., Jourdain I. The Exocyst Complex in Health and Disease. Front. Cell Dev. Biol. 2016;4:24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4828438</ArticleId><ArticleId IdType="pubmed">27148529</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez I., Melero J.A. Binding of human respiratory syncytial virus to cells: implication of sulfated cell surface proteoglycans. J.&#xa0;Gen. Virol. 2000;81:2715&#x2013;2722.</Citation><ArticleIdList><ArticleId IdType="pubmed">11038384</ArticleId></ArticleIdList></Reference><Reference><Citation>Mei K., Guo W. The exocyst complex. Curr. Biol. 2018;28:R922&#x2013;R925.</Citation><ArticleIdList><ArticleId IdType="pubmed">30205058</ArticleId></ArticleIdList></Reference><Reference><Citation>Moretti F., Bergman P., Dodgson S., Marcellin D., Claerr I., Goodwin J.M., DeJesus R., Kang Z., Antczak C., Begue D., et al. TMEM41B is a novel regulator of autophagy and lipid mobilization. EMBO Rep. 2018;19:e45889.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6123663</ArticleId><ArticleId IdType="pubmed">30126924</ArticleId></ArticleIdList></Reference><Reference><Citation>Morita K., Hama Y., Izume T., Tamura N., Ueno T., Yamashita Y., Sakamaki Y., Mimura K., Morishita H., Shihoya W., et al. Genome-wide CRISPR screen identifies TMEM41B as a gene required for autophagosome formation. J.&#xa0;Cell Biol. 2018;217:3817&#x2013;3828.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6219718</ArticleId><ArticleId IdType="pubmed">30093494</ArticleId></ArticleIdList></Reference><Reference><Citation>Morita K., Hama Y., Mizushima N. TMEM41B functions with VMP1 in autophagosome formation. Autophagy. 2019;15:922&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6526808</ArticleId><ArticleId IdType="pubmed">30773971</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Donnell C.D., Shukla D. The Importance of Heparan Sulfate in Herpesvirus Infection. Virol. Sin. 2008;23:383&#x2013;393.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2778322</ArticleId><ArticleId IdType="pubmed">19956628</ArticleId></ArticleIdList></Reference><Reference><Citation>Okajima T., Yoshida K., Kondo T., Furukawa K. Human homolog of Caenorhabditis elegans sqv-3 gene is galactosyltransferase I involved in the biosynthesis of the glycosaminoglycan-protein linkage region of proteoglycans. J.&#xa0;Biol. Chem. 1999;274:22915&#x2013;22918.</Citation><ArticleIdList><ArticleId IdType="pubmed">10438455</ArticleId></ArticleIdList></Reference><Reference><Citation>Perera-Lecoin M., Meertens L., Carnec X., Amara A. Flavivirus entry receptors: an update. Viruses. 2013;6:69&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3917432</ArticleId><ArticleId IdType="pubmed">24381034</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xf6;nighaus C., Ambrosius M., Casanova J.C., Prante C., Kuhn J., Esko J.D., Kleesiek K., G&#xf6;tting C. Human xylosyltransferase II is involved in the biosynthesis of the uniform tetrasaccharide linkage region in chondroitin sulfate and heparan sulfate proteoglycans. J.&#xa0;Biol. Chem. 2007;282:5201&#x2013;5206.</Citation><ArticleIdList><ArticleId IdType="pubmed">17189265</ArticleId></ArticleIdList></Reference><Reference><Citation>Puschnik A.S., Majzoub K., Ooi Y.S., Carette J.E. A CRISPR toolbox to study virus-host interactions. Nat. Rev. Microbiol. 2017;15:351&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5800792</ArticleId><ArticleId IdType="pubmed">28420884</ArticleId></ArticleIdList></Reference><Reference><Citation>Riblett A.M., Blomen V.A., Jae L.T., Altamura L.A., Doms R.W., Brummelkamp T.R., Wojcechowskyj J.A. A Haploid Genetic Screen Identifies Heparan Sulfate Proteoglycans Supporting Rift Valley Fever Virus Infection. J.&#xa0;Virol. 2015;90:1414&#x2013;1423.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4719632</ArticleId><ArticleId IdType="pubmed">26581979</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz A., Pauls E., Badia R., Riveira-Mu&#xf1;oz E., Clotet B., Ballana E., Est&#xe9; J.A. Characterization of the influence of mediator complex in HIV-1 transcription. J.&#xa0;Biol. Chem. 2014;289:27665&#x2013;27676.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4183804</ArticleId><ArticleId IdType="pubmed">25100719</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanjana N.E., Shalem O., Zhang F. Improved vectors and genome-wide libraries for CRISPR screening. Nat. Methods. 2014;11:783&#x2013;784.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4486245</ArticleId><ArticleId IdType="pubmed">25075903</ArticleId></ArticleIdList></Reference><Reference><Citation>Savidis G., McDougall W.M., Meraner P., Perreira J.M., Portmann J.M., Trincucci G., John S.P., Aker A.M., Renzette N., Robbins D.R., et al. Identification of Zika Virus and Dengue Virus Dependency Factors using Functional Genomics. Cell Rep. 2016;16:232&#x2013;246.</Citation><ArticleIdList><ArticleId IdType="pubmed">27342126</ArticleId></ArticleIdList></Reference><Reference><Citation>Shannon P., Markiel A., Ozier O., Baliga N.S., Wang J.T., Ramage D., Amin N., Schwikowski B., Ideker T. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13:2498&#x2013;2504.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC403769</ArticleId><ArticleId IdType="pubmed">14597658</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoemaker C.J., Huang T.Q., Weir N.R., Polyakov N.J., Schultz S.W., Denic V. CRISPR screening using an expanded toolkit of autophagy reporters identifies TMEM41B as a novel autophagy factor. PLoS Biol. 2019;17:e2007044.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6459555</ArticleId><ArticleId IdType="pubmed">30933966</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith R.D., Lupashin V.V. Role of the conserved oligomeric Golgi (COG) complex in protein glycosylation. Carbohydr. Res. 2008;343:2024&#x2013;2031.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2773262</ArticleId><ArticleId IdType="pubmed">18353293</ArticleId></ArticleIdList></Reference><Reference><Citation>Snijder E.J., Limpens R.W.A.L., de Wilde A.H., de Jong A.W.M., Zevenhoven-Dobbe J.C., Maier H.J., Faas F.F.G.A., Koster A.J., B&#xe1;rcena M. A unifying structural and functional model of the coronavirus replication organelle: Tracking down RNA synthesis. PLoS Biol. 2020;18:e3000715.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7302735</ArticleId><ArticleId IdType="pubmed">32511245</ArticleId></ArticleIdList></Reference><Reference><Citation>Soffientini U., Caridis A.M., Dolan S., Graham A. Intracellular cholesterol transporters and modulation of hepatic lipid metabolism: Implications for diabetic dyslipidaemia and steatosis. Biochim. Biophys. Acta. 2014;1842:1372&#x2013;1382.</Citation><ArticleIdList><ArticleId IdType="pubmed">25014273</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuart T., Butler A., Hoffman P., Hafemeister C., Papalexi E., Mauck W.M., 3rd, Hao Y., Stoeckius M., Smibert P., Satija R. Comprehensive Integration of Single-Cell Data. Cell. 2019;177:1888&#x2013;1902.e21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6687398</ArticleId><ArticleId IdType="pubmed">31178118</ArticleId></ArticleIdList></Reference><Reference><Citation>Szklarczyk D., Gable A.L., Lyon D., Junge A., Wyder S., Huerta-Cepas J., Simonovic M., Doncheva N.T., Morris J.H., Bork P., et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607&#x2013;D613.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6323986</ArticleId><ArticleId IdType="pubmed">30476243</ArticleId></ArticleIdList></Reference><Reference><Citation>Techaarpornkul S., Collins P.L., Peeples M.E. Respiratory syncytial virus with the fusion protein as its only viral glycoprotein is less dependent on cellular glycosaminoglycans for attachment than complete virus. Virology. 2002;294:296&#x2013;304.</Citation><ArticleIdList><ArticleId IdType="pubmed">12009871</ArticleId></ArticleIdList></Reference><Reference><Citation>Thao T.T.N., Labroussaa F., Ebert N., Jores J., Thiel V. In-Yeast Assembly of Coronavirus Infectious cDNA Clones Using a Synthetic Genomics Pipeline. Methods Mol. Biol. 2020;2203:167&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pubmed">32833212</ArticleId></ArticleIdList></Reference><Reference><Citation>V&#x2019;kovski P., Gultom M., Steiner S., Kelly J., Russeil J., Mangeat B., Cora E., Pezoldt J., Holwerda M., Kratzel A., et al. Disparate temperature-dependent virus &#x2013; host dynamics for SARS-CoV-2 and SARS-CoV in the human respiratory epithelium. bioRxiv. 2020 doi: 10.1101/2020.04.27.062315.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.04.27.062315</ArticleId><ArticleId IdType="pmc">PMC8032198</ArticleId><ArticleId IdType="pubmed">33780434</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang N., Shi X., Jiang L., Zhang S., Wang D., Tong P., Guo D., Fu L., Cui Y., Liu X., et al. Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell Res. 2013;23:986&#x2013;993.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3731569</ArticleId><ArticleId IdType="pubmed">23835475</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S.P., Tang Z., Chen C.W., Shimada M., Koche R.P., Wang L.H., Nakadai T., Chramiec A., Krivtsov A.V., Armstrong S.A., et al. A UTX-MLL4-p300 Transcriptional Regulatory Network Coordinately Shapes Active Enhancer Landscapes for Eliciting Transcription. Mol. Cell. 2017;67:308&#x2013;321.e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5574165</ArticleId><ArticleId IdType="pubmed">28732206</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R., Simoneau C.R., Kulsuptrakul J., Bouhaddou M., Travisano K., Hayashi J.M., Carlson-Stevermer J., Oki J., Holden K., Krogan N.J., et al. Functional genomic screens identify human host factors for SARS-CoV-2 and common cold coronaviruses. bioRxiv. 2020 doi: 10.1101/2020.09.24.312298.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.09.24.312298</ArticleId><ArticleId IdType="pmc">PMC7723770</ArticleId><ArticleId IdType="pubmed">33333024</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei J., Alfajaro M.M., DeWeirdt P.C., Hanna R.E., Lu-Culligan W.J., Cai W.L., Strine M.S., Zhang S.M., Graziano V.R., Schmitz C.O., et al. Genome-wide CRISPR Screens Reveal Host Factors Critical for SARS-CoV-2 Infection. Cell. 2020 doi: 10.1016/j.cell.2020.10.028. Published online October 20, 2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.10.028</ArticleId><ArticleId IdType="pmc">PMC7574718</ArticleId><ArticleId IdType="pubmed">33147444</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu B., Guo W. The Exocyst at a Glance. J.&#xa0;Cell Sci. 2015;128:2957&#x2013;2964.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4541039</ArticleId><ArticleId IdType="pubmed">26240175</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu D., Smyth G.K. Camera: a competitive gene set test accounting for inter-gene correlation. Nucleic Acids Res. 2012;40:e133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3458527</ArticleId><ArticleId IdType="pubmed">22638577</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y., Martinez P., S&#xe9;ron K., Luo G., Allain F., Dubuisson J., Belouzard S. Characterization of hepatitis C virus interaction with heparan sulfate proteoglycans. J.&#xa0;Virol. 2015;89:3846&#x2013;3858.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4403428</ArticleId><ArticleId IdType="pubmed">25609801</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeager C.L., Ashmun R.A., Williams R.K., Cardellichio C.B., Shapiro L.H., Look A.T., Holmes K.V. Human aminopeptidase N is a receptor for human coronavirus 229E. Nature. 1992;357:420&#x2013;422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095410</ArticleId><ArticleId IdType="pubmed">1350662</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X.-J., Qin J.-J., Cheng X., Shen L., Zhao Y.-C., Yuan Y., Lei F., Chen M.-M., Yang H., Bai L., et al. In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19. Cell Metab. 2020;32:176&#x2013;187.e4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7311917</ArticleId><ArticleId IdType="pubmed">32592657</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou P., Yang X.L., Wang X.G., Hu B., Zhang L., Zhang W., Si H.R., Zhu Y., Li B., Huang C.L., et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270&#x2013;273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095418</ArticleId><ArticleId IdType="pubmed">32015507</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu N., Zhang D., Wang W., Li X., Yang B., Song J., Zhao X., Huang B., Shi W., Lu R., et al. China Novel Coronavirus Investigating and Research Team A Novel Coronavirus from Patients with Pneumonia in China, 2019. N.&#xa0;Engl. J. Med. 2020;382:727&#x2013;733.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7092803</ArticleId><ArticleId IdType="pubmed">31978945</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y., Feng F., Hu G., Wang Y., Yu Y., Zhu Y., Xu W., Cai X., Sun Z., Han W., et al. The S1/S2 boundary of SARS-CoV-2 spike protein modulates cell entry pathways and transmission. bioRxiv. 2020 doi: 10.1101/2020.08.25.266775.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.08.25.266775</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33333024</PMID><DateCompleted><Year>2021</Year><Month>01</Month><Day>15</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4172</ISSN><JournalIssue CitedMedium="Internet"><Volume>184</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Jan</Month><Day>07</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>Genetic Screens Identify Host Factors for SARS-CoV-2 and Common Cold Coronaviruses.</ArticleTitle><Pagination><StartPage>106</StartPage><EndPage>119.e14</EndPage><MedlinePgn>106-119.e14</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2020.12.004</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0092-8674(20)31626-3</ELocationID><Abstract><AbstractText>The Coronaviridae are a family of viruses that cause disease in humans ranging from mild respiratory infection to potentially lethal acute respiratory distress syndrome. Finding host factors common to multiple coronaviruses could facilitate the development of therapies to combat current and future coronavirus pandemics. Here, we conducted genome-wide CRISPR screens in cells infected by SARS-CoV-2 as well as two seasonally circulating common cold coronaviruses, OC43 and 229E. This approach correctly identified the distinct viral entry factors ACE2 (for SARS-CoV-2), aminopeptidase N (for 229E), and glycosaminoglycans (for OC43). Additionally, we identified phosphatidylinositol phosphate biosynthesis and cholesterol homeostasis as critical host pathways supporting infection by all three coronaviruses. By contrast, the lysosomal protein TMEM106B appeared unique to SARS-CoV-2 infection. Pharmacological inhibition of phosphatidylinositol kinases and cholesterol homeostasis reduced replication of all three coronaviruses. These findings offer important insights for the understanding of the coronavirus life cycle and the development of host-directed therapies.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Ruofan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Chan Zuckerberg Biohub, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simoneau</LastName><ForeName>Camille R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Gladstone Institutes, San Francisco, CA 94158, USA; Department of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA; Quantitative Biosciences Institute COVID-19 Research Group (QCRG), University of California, San Francisco, San Francisco, CA 94158, USA; Biomedical Sciences Graduate Program, University of California, San Francisco, San Francisco, CA 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kulsuptrakul</LastName><ForeName>Jessie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Chan Zuckerberg Biohub, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bouhaddou</LastName><ForeName>Mehdi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Gladstone Institutes, San Francisco, CA 94158, USA; Quantitative Biosciences Institute COVID-19 Research Group (QCRG), University of California, San Francisco, San Francisco, CA 94158, USA; Quantitative Biosciences Institute (QBI), University of California, San Francisco, San Francisco, CA 94158, USA; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Travisano</LastName><ForeName>Katherine A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Chan Zuckerberg Biohub, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hayashi</LastName><ForeName>Jennifer M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Gladstone Institutes, San Francisco, CA 94158, USA; Department of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA; Quantitative Biosciences Institute COVID-19 Research Group (QCRG), University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carlson-Stevermer</LastName><ForeName>Jared</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Synthego Corporation, Menlo Park, CA 94025, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zengel</LastName><ForeName>James R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Stanford University, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richards</LastName><ForeName>Christopher M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Stanford University, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fozouni</LastName><ForeName>Parinaz</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Gladstone Institutes, San Francisco, CA 94158, USA; Department of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA; Quantitative Biosciences Institute COVID-19 Research Group (QCRG), University of California, San Francisco, San Francisco, CA 94158, USA; Biomedical Sciences Graduate Program, University of California, San Francisco, San Francisco, CA 94143, USA; Medical Scientist Training Program, University of California, San Francisco, San Francisco, CA 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oki</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Synthego Corporation, Menlo Park, CA 94025, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodriguez</LastName><ForeName>Lauren</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>UCSF CoLabs, Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joehnk</LastName><ForeName>Bastian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walcott</LastName><ForeName>Keith</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holden</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Synthego Corporation, Menlo Park, CA 94025, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sil</LastName><ForeName>Anita</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carette</LastName><ForeName>Jan E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Stanford University, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krogan</LastName><ForeName>Nevan J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Gladstone Institutes, San Francisco, CA 94158, USA; Quantitative Biosciences Institute COVID-19 Research Group (QCRG), University of California, San Francisco, San Francisco, CA 94158, USA; Quantitative Biosciences Institute (QBI), University of California, San Francisco, San Francisco, CA 94158, USA; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ott</LastName><ForeName>Melanie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Gladstone Institutes, San Francisco, CA 94158, USA; Department of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA; Quantitative Biosciences Institute COVID-19 Research Group (QCRG), University of California, San Francisco, San Francisco, CA 94158, USA. Electronic address: melanie.ott@gladstone.ucsf.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Puschnik</LastName><ForeName>Andreas S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Chan Zuckerberg Biohub, San Francisco, CA 94158, USA. Electronic address: andreas.puschnik@czbiohub.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32 AI060537</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI120694</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007618</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AI135990</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI122747</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 CA239333</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI141970</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI130123</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DP1 DA038043</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AI135972</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI143292</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AI063302</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI140186</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AI150476</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM136534</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>12</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010716">Phosphatidylinositols</NameOfSubstance></Chemical><Chemical><RegistryNumber>97C5T2UQ7J</RegistryNumber><NameOfSubstance UI="D002784">Cholesterol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>bioRxiv. 2020 Sep 24:2020.09.24.312298. doi: 10.1101/2020.09.24.312298.</RefSource><PMID Version="1">32995787</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Cell. 2021 Jan 7;184(1):15-17. doi: 10.1016/j.cell.2020.12.003.</RefSource><PMID Version="1">33338422</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000072283" MajorTopicYN="N">A549 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053898" MajorTopicYN="N">Biosynthetic Pathways</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002784" MajorTopicYN="N">Cholesterol</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016000" MajorTopicYN="N">Cluster Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064112" MajorTopicYN="N">Clustered Regularly Interspaced Short Palindromic Repeats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003139" MajorTopicYN="N">Common Cold</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017934" MajorTopicYN="N">Coronavirus</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055786" MajorTopicYN="N">Gene Knockout Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="Y">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054884" MajorTopicYN="Y">Host-Pathogen Interactions</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010716" MajorTopicYN="N">Phosphatidylinositols</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053586" MajorTopicYN="N">Virus Internalization</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">229E</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">CRISPR</Keyword><Keyword MajorTopicYN="N">OC43</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">coronavirus</Keyword><Keyword MajorTopicYN="N">genetic screen</Keyword><Keyword MajorTopicYN="N">host factors</Keyword><Keyword MajorTopicYN="N">host-targeted antivirals</Keyword><Keyword MajorTopicYN="N">virus-host interactions</Keyword></KeywordList><CoiStatement>Declaration of Interests J.C.-S., J.O., and K.H. are employees of Synthego Corporation. All authors declare no other competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>9</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>11</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>1</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>12</Month><Day>17</Day><Hour>20</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>12</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33333024</ArticleId><ArticleId IdType="pmc">PMC7723770</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2020.12.004</ArticleId><ArticleId IdType="pii">S0092-8674(20)31626-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aoki T., Ichimura S., Itoh A., Kuramoto M., Shinkawa T., Isobe T., Tagaya M. Identification of the neuroblastoma-amplified gene product as a component of the syntaxin 18 complex implicated in Golgi-to-endoplasmic reticulum retrograde transport. Mol. Biol. Cell. 2009;20:2639&#x2013;2649.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2688544</ArticleId><ArticleId IdType="pubmed">19369418</ArticleId></ArticleIdList></Reference><Reference><Citation>Baggen J., Persoons L., Jansen S., Vanstreels E., Jacquemyn M., Jochmans D., Neyts J., Dallmeier K., Maes P., Daelemans D. Identification of TMEM106B as proviral host factor for SARS-CoV-2. BioRxiv. 2020 doi: 10.1101/2020.09.28.316281.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.09.28.316281</ArticleId></ArticleIdList></Reference><Reference><Citation>Balderhaar H.J., Ungermann C. CORVET and HOPS tethering complexes - coordinators of endosome and lysosome fusion. J.&#xa0;Cell Sci. 2013;126:1307&#x2013;1316.</Citation><ArticleIdList><ArticleId IdType="pubmed">23645161</ArticleId></ArticleIdList></Reference><Reference><Citation>Beier K.T., Saunders A., Oldenburg I.A., Miyamichi K., Akhtar N., Luo L., Whelan S.P.J., Sabatini B., Cepko C.L. Anterograde or retrograde transsynaptic labeling of CNS neurons with vesicular stomatitis virus vectors. Proc. Natl. Acad. Sci. USA. 2011;108:15414&#x2013;15419.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3174680</ArticleId><ArticleId IdType="pubmed">21825165</ArticleId></ArticleIdList></Reference><Reference><Citation>Bekerman E., Einav S. Infectious disease. Combating emerging viral threats. Science. 2015;348:282&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4419706</ArticleId><ArticleId IdType="pubmed">25883340</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram S., Dijkman R., Habjan M., Heurich A., Gierer S., Glowacka I., Welsch K., Winkler M., Schneider H., Hofmann-Winkler H., et al. TMPRSS2 activates the human coronavirus 229E for cathepsin-independent host cell entry and is expressed in viral target cells in the respiratory epithelium. J.&#xa0;Virol. 2013;87:6150&#x2013;6160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3648130</ArticleId><ArticleId IdType="pubmed">23536651</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilanges B., Posor Y., Vanhaesebroeck B. PI3K isoforms in cell signalling and vesicle trafficking. Nat. Rev. Mol. Cell Biol. 2019;20:515&#x2013;534.</Citation><ArticleIdList><ArticleId IdType="pubmed">31110302</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouhaddou M., Memon D., Meyer B., White K.M., Rezelj V.V., Correa Marrero M., Polacco B.J., Melnyk J.E., Ulferts S., Kaake R.M., et al. The Global Phosphorylation Landscape of SARS-CoV-2 Infection. Cell. 2020;182:685&#x2013;712.e19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7321036</ArticleId><ArticleId IdType="pubmed">32645325</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown M.S., Radhakrishnan A., Goldstein J.L. Retrospective on Cholesterol Homeostasis: The Central Role of Scap. Annu. Rev. Biochem. 2018;87:783&#x2013;807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5828883</ArticleId><ArticleId IdType="pubmed">28841344</ArticleId></ArticleIdList></Reference><Reference><Citation>Campeau E., Ruhl V.E., Rodier F., Smith C.L., Rahmberg B.L., Fuss J.O., Campisi J., Yaswen P., Cooper P.K., Kaufman P.D. A versatile viral system for expression and depletion of proteins in mammalian cells. PLoS ONE. 2009;4:e6529.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2717805</ArticleId><ArticleId IdType="pubmed">19657394</ArticleId></ArticleIdList></Reference><Reference><Citation>Carette J.E., Raaben M., Wong A.C., Herbert A.S., Obernosterer G., Mulherkar N., Kuehne A.I., Kranzusch P.J., Griffin A.M., Ruthel G., et al. Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature. 2011;477:340&#x2013;343.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3175325</ArticleId><ArticleId IdType="pubmed">21866103</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerami E.G., Gross B.E., Demir E., Rodchenkov I., Babur O., Anwar N., Schultz N., Bader G.D., Sander C. Pathway Commons, a web resource for biological pathway data. Nucleic Acids Res. 2011;39:D685&#x2013;D690.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3013659</ArticleId><ArticleId IdType="pubmed">21071392</ArticleId></ArticleIdList></Reference><Reference><Citation>Charlton F.W., Hover S., Fuller J., Hewson R., Fontana J., Barr J.N., Mankouri J. Cellular cholesterol abundance regulates potassium accumulation within endosomes and is an important determinant in bunyavirus entry. J.&#xa0;Biol. Chem. 2019;294:7335&#x2013;7347.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6509484</ArticleId><ArticleId IdType="pubmed">30804209</ArticleId></ArticleIdList></Reference><Reference><Citation>Clausen T.M., Sandoval D.R., Spliid C.B., Pihl J., Perrett H.R., Painter C.D., Narayanan A., Majowicz S.A., Kwong E.M., McVicar R.N., et al. SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2. Cell. 2020;183:1043&#x2013;1057.e15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7489987</ArticleId><ArticleId IdType="pubmed">32970989</ArticleId></ArticleIdList></Reference><Reference><Citation>Cowen L., Ideker T., Raphael B.J., Sharan R. Network propagation: a universal amplifier of genetic associations. Nat. Rev. Genet. 2017;18:551&#x2013;562.</Citation><ArticleIdList><ArticleId IdType="pubmed">28607512</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuadrado A., Rojo A.I., Wells G., Hayes J.D., Cousin S.P., Rumsey W.L., Attucks O.C., Franklin S., Levonen A.-L., Kensler T.W., Dinkova-Kostova A.T. Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases. Nat. Rev. Drug Discov. 2019;18:295&#x2013;317.</Citation><ArticleIdList><ArticleId IdType="pubmed">30610225</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuadrado A., Pajares M., Benito C., Jim&#xe9;nez-Villegas J., Escoll M., Fern&#xe1;ndez-Gin&#xe9;s R., Garcia Yag&#xfc;e A.J., Lastra D., Manda G., Rojo A.I., Dinkova-Kostova A.T. Can Activation of NRF2 Be a Strategy against COVID-19? Trends Pharmacol. Sci. 2020;41:598&#x2013;610.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7359808</ArticleId><ArticleId IdType="pubmed">32711925</ArticleId></ArticleIdList></Reference><Reference><Citation>Daniels L.B., Sitapati A.M., Zhang J., Zou J., Bui Q.M., Ren J., Longhurst C.A., Criqui M.H., Messer K. Relation of Statin Use Prior to Admission to Severity and Recovery Among COVID-19 Inpatients. Am. J. Cardiol. 2020;136:149&#x2013;155.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7492151</ArticleId><ArticleId IdType="pubmed">32946859</ArticleId></ArticleIdList></Reference><Reference><Citation>Daniloski Z., Jordan T.X., Wessels H.-H., Hoagland D.A., Kasela S., Legut M., Maniatis S., Mimitou E.P., Lu L., Geller E., et al. Identification of Required Host Factors for SARS-CoV-2 Infection in Human Cells. Cell. 2020 doi: 10.1016/j.cell.2020.10.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.10.030</ArticleId><ArticleId IdType="pmc">PMC7584921</ArticleId><ArticleId IdType="pubmed">33147445</ArticleId></ArticleIdList></Reference><Reference><Citation>Dieterle M.E., Haslwanter D., Bortz R.H., 3rd, Wirchnianski A.S., Lasso G., Vergnolle O., Abbasi S.A., Fels J.M., Laudermilch E., Florez C., et al. A Replication-Competent Vesicular Stomatitis Virus for Studies of SARS-CoV-2 Spike-Mediated Cell Entry and Its Inhibition. Cell Host Microbe. 2020;28:486&#x2013;496.e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7332447</ArticleId><ArticleId IdType="pubmed">32738193</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong E., Du H., Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect. Dis. 2020;20:533&#x2013;534.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159018</ArticleId><ArticleId IdType="pubmed">32087114</ArticleId></ArticleIdList></Reference><Reference><Citation>Drosten C., G&#xfc;nther S., Preiser W., van der Werf S., Brodt H.-R., Becker S., Rabenau H., Panning M., Kolesnikova L., Fouchier R.A.M., et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N.&#xa0;Engl. J. Med. 2003;348:1967&#x2013;1976.</Citation><ArticleIdList><ArticleId IdType="pubmed">12690091</ArticleId></ArticleIdList></Reference><Reference><Citation>Edie S., Zaghloul N.A., Leitch C.C., Klinedinst D.K., Lebron J., Thole J.F., McCallion A.S., Katsanis N., Reeves R.H. Survey of Human Chromosome 21 Gene Expression Effects on Early Development in Danio rerio. G3 (Bethesda) 2018;8:2215&#x2013;2223.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6027891</ArticleId><ArticleId IdType="pubmed">29760202</ArticleId></ArticleIdList></Reference><Reference><Citation>Fimia G.M., Stoykova A., Romagnoli A., Giunta L., Di Bartolomeo S., Nardacci R., Corazzari M., Fuoco C., Ucar A., Schwartz P., et al. Ambra1 regulates autophagy and development of the nervous system. Nature. 2007;447:1121&#x2013;1125.</Citation><ArticleIdList><ArticleId IdType="pubmed">17589504</ArticleId></ArticleIdList></Reference><Reference><Citation>Flint M., Chatterjee P., Lin D.L., McMullan L.K., Shrivastava-Ranjan P., Bergeron &#xc9;., Lo M.K., Welch S.R., Nichol S.T., Tai A.W., Spiropoulou C.F. A genome-wide CRISPR screen identifies N-acetylglucosamine-1-phosphate transferase as a potential antiviral target for Ebola virus. Nat. Commun. 2019;10:285.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6336797</ArticleId><ArticleId IdType="pubmed">30655525</ArticleId></ArticleIdList></Reference><Reference><Citation>Fung T.S., Liu D.X. Human Coronavirus: Host-Pathogen Interaction. Annu. Rev. Microbiol. 2019;73:529&#x2013;557.</Citation><ArticleIdList><ArticleId IdType="pubmed">31226023</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon D.E., Jang G.M., Bouhaddou M., Xu J., Obernier K., White K.M., O&#x2019;Meara M.J., Rezelj V.V., Guo J.Z., Swaney D.L., et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020;583:459&#x2013;468.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7431030</ArticleId><ArticleId IdType="pubmed">32353859</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H., Jureka A.S., Obernier K., Guo J.Z., Batra J., et al. QCRG Structural Biology Consortium. Zoonomia Consortium Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms. Science. 2020;370:eabe9403.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7808408</ArticleId><ArticleId IdType="pubmed">33060197</ArticleId></ArticleIdList></Reference><Reference><Citation>Hart T., Chandrashekhar M., Aregger M., Steinhart Z., Brown K.R., MacLeod G., Mis M., Zimmermann M., Fradet-Turcotte A., Sun S., et al. High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities. Cell. 2015;163:1515&#x2013;1526.</Citation><ArticleIdList><ArticleId IdType="pubmed">26627737</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawkins J.L., Robbins M.D., Warren L.C., Xia D., Petras S.F., Valentine J.J., Varghese A.H., Wang I.-K., Subashi T.A., Shelly L.D., et al. Pharmacologic inhibition of site 1 protease activity inhibits sterol regulatory element-binding protein processing and reduces lipogenic enzyme gene expression and lipid synthesis in cultured cells and experimental animals. J.&#xa0;Pharmacol. Exp. Ther. 2008;326:801&#x2013;808.</Citation><ArticleIdList><ArticleId IdType="pubmed">18577702</ArticleId></ArticleIdList></Reference><Reference><Citation>Heged&#x171;s K., Tak&#xe1;ts S., Boda A., Jipa A., Nagy P., Varga K., Kov&#xe1;cs A.L., Juh&#xe1;sz G. The Ccz1-Mon1-Rab7 module and Rab5 control distinct steps of autophagy. Mol. Biol. Cell. 2016;27:3132&#x2013;3142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5063620</ArticleId><ArticleId IdType="pubmed">27559127</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann H.-H., Schneider W.M., Rozen-Gagnon K., Miles L.A., Schuster F., Razooky B., Jacobson E., Wu X., Yi S., Rudin C.M., et al. TMEM41B is a pan-flavivirus host factor. bioRxiv. 2020 doi: 10.1101/2020.10.09.334128.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.10.09.334128</ArticleId><ArticleId IdType="pmc">PMC7954666</ArticleId><ArticleId IdType="pubmed">33338421</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M., Kleine-Weber H., P&#xf6;hlmann S. A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells. Mol. Cell. 2020;78:779&#x2013;784.e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7194065</ArticleId><ArticleId IdType="pubmed">32362314</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M., Kleine-Weber H., Schroeder S., Kr&#xfc;ger N., Herrler T., Erichsen S., Schiergens T.S., Herrler G., Wu N.-H., Nitsche A., et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181:271&#x2013;280.e8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Hofmann H., Pyrc K., van der Hoek L., Geier M., Berkhout B., P&#xf6;hlmann S. Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry. Proc. Natl. Acad. Sci. USA. 2005;102:7988&#x2013;7993.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1142358</ArticleId><ArticleId IdType="pubmed">15897467</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xf6;glinger D., Burgoyne T., Sanchez-Heras E., Hartwig P., Colaco A., Newton J., Futter C.E., Spiegel S., Platt F.M., Eden E.R. NPC1 regulates ER contacts with endocytic organelles to mediate cholesterol egress. Nat. Commun. 2019;10:4276.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6753064</ArticleId><ArticleId IdType="pubmed">31537798</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiau T., Conant D., Rossi N., Maures T., Waite K., Yang J., Joshi S., Kelso R., Holden K., Enzmann B.L., et al. Inference of CRISPR Edits from Sanger Trace Data. bioRxiv. 2019 doi: 10.1101/251082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/251082</ArticleId><ArticleId IdType="pubmed">35119294</ArticleId></ArticleIdList></Reference><Reference><Citation>Hulswit R.J.G., Lang Y., Bakkers M.J.G., Li W., Li Z., Schouten A., Ophorst B., van Kuppeveld F.J.M., Boons G.-J., Bosch B.-J., et al. Human coronaviruses OC43 and HKU1 bind to 9-O-acetylated sialic acids via a conserved receptor-binding site in spike protein domain A. Proc. Natl. Acad. Sci. USA. 2019;116:2681&#x2013;2690.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6377473</ArticleId><ArticleId IdType="pubmed">30679277</ArticleId></ArticleIdList></Reference><Reference><Citation>Jefferies H.B.J., Cooke F.T., Jat P., Boucheron C., Koizumi T., Hayakawa M., Kaizawa H., Ohishi T., Workman P., Waterfield M.D., Parker P.J. A selective PIKfyve inhibitor blocks PtdIns(3,5)P(2) production and disrupts endomembrane transport and retroviral budding. EMBO Rep. 2008;9:164&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2246419</ArticleId><ArticleId IdType="pubmed">18188180</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang P., Nishimura T., Sakamaki Y., Itakura E., Hatta T., Natsume T., Mizushima N. The HOPS complex mediates autophagosome-lysosome fusion through interaction with syntaxin 17. Mol. Biol. Cell. 2014;25:1327&#x2013;1337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3982997</ArticleId><ArticleId IdType="pubmed">24554770</ArticleId></ArticleIdList></Reference><Reference><Citation>Johannessen C.M., Boehm J.S., Kim S.Y., Thomas S.R., Wardwell L., Johnson L.A., Emery C.M., Stransky N., Cogdill A.P., Barretina J., et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 2010;468:968&#x2013;972.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3058384</ArticleId><ArticleId IdType="pubmed">21107320</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamisuki S., Mao Q., Abu-Elheiga L., Gu Z., Kugimiya A., Kwon Y., Shinohara T., Kawazoe Y., Sato S., Asakura K., et al. A small molecule that blocks fat synthesis by inhibiting the activation of SREBP. Chem. Biol. 2009;16:882&#x2013;892.</Citation><ArticleIdList><ArticleId IdType="pubmed">19716478</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang Y.-L., Chou Y., Rothlauf P.W., Liu Z., Soh T.K., Cureton D., Case J.B., Chen R.E., Diamond M.S., Whelan S.P.J., et al. Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2. Proc. Natl. Acad. Sci. 2020;117:20803&#x2013;20813.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7456157</ArticleId><ArticleId IdType="pubmed">32764148</ArticleId></ArticleIdList></Reference><Reference><Citation>Katoh Y., Shiba Y., Mitsuhashi H., Yanagida Y., Takatsu H., Nakayama K. Tollip and Tom1 form a complex and recruit ubiquitin-conjugated proteins onto early endosomes. J.&#xa0;Biol. Chem. 2004;279:24435&#x2013;24443.</Citation><ArticleIdList><ArticleId IdType="pubmed">15047686</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein Z.A., Takahashi H., Ma M., Stagi M., Zhou M., Lam T.T., Strittmatter S.M. Loss of TMEM106B Ameliorates Lysosomal and Frontotemporal Dementia-Related Phenotypes in Progranulin-Deficient Mice. Neuron. 2017;95:281&#x2013;296.e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5558861</ArticleId><ArticleId IdType="pubmed">28728022</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleinfelter L.M., Jangra R.K., Jae L.T., Herbert A.S., Mittler E., Stiles K.M., Wirchnianski A.S., Kielian M., Brummelkamp T.R., Dye J.M., Chandran K. Haploid Genetic Screen Reveals a Profound and Direct Dependence on Cholesterol for Hantavirus Membrane Fusion. MBio. 2015;6:e00801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4488941</ArticleId><ArticleId IdType="pubmed">26126854</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemaire J.-F., McPherson P.S. Binding of Vac14 to neuronal nitric oxide synthase: Characterisation of a new internal PDZ-recognition motif. FEBS Lett. 2006;580:6948&#x2013;6954.</Citation><ArticleIdList><ArticleId IdType="pubmed">17161399</ArticleId></ArticleIdList></Reference><Reference><Citation>Letko M., Marzi A., Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat. Microbiol. 2020;5:562&#x2013;569.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095430</ArticleId><ArticleId IdType="pubmed">32094589</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W., Moore M.J., Vasilieva N., Sui J., Wong S.K., Berne M.A., Somasundaran M., Sullivan J.L., Luzuriaga K., Greenough T.C., et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450&#x2013;454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095016</ArticleId><ArticleId IdType="pubmed">14647384</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W., Xu H., Xiao T., Cong L., Love M.I., Zhang F., Irizarry R.A., Liu J.S., Brown M., Liu X.S. MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens. Genome Biol. 2014;15:554.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4290824</ArticleId><ArticleId IdType="pubmed">25476604</ArticleId></ArticleIdList></Reference><Reference><Citation>Liby K.T., Sporn M.B. Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease. Pharmacol. Rev. 2012;64:972&#x2013;1003.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3462991</ArticleId><ArticleId IdType="pubmed">22966038</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xfc;ningschr&#xf6;r P., Werner G., Stroobants S., Kakuta S., Dombert B., Sinske D., Wanner R., L&#xfc;llmann-Rauch R., Wefers B., Wurst W., et al. The FTLD Risk Factor TMEM106B Regulates the Transport of Lysosomes at the Axon Initial Segment of Motoneurons. Cell Rep. 2020;30:3506&#x2013;3519.e6.</Citation><ArticleIdList><ArticleId IdType="pubmed">32160553</ArticleId></ArticleIdList></Reference><Reference><Citation>Maeda Y., Ide T., Koike M., Uchiyama Y., Kinoshita T. GPHR is a novel anion channel critical for acidification and functions of the Golgi apparatus. Nat. Cell Biol. 2008;10:1135&#x2013;1145.</Citation><ArticleIdList><ArticleId IdType="pubmed">18794847</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuda T., Cepko C.L. Electroporation and RNA interference in the rodent retina in&#xa0;vivo and in&#xa0;vitro. Proc. Natl. Acad. Sci. USA. 2004;101:16&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC314130</ArticleId><ArticleId IdType="pubmed">14603031</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuyama S., Nao N., Shirato K., Kawase M., Saito S., Takayama I., Nagata N., Sekizuka T., Katoh H., Kato F., et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc. Natl. Acad. Sci. USA. 2020;117:7001&#x2013;7003.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7132130</ArticleId><ArticleId IdType="pubmed">32165541</ArticleId></ArticleIdList></Reference><Reference><Citation>McBride C.E., Li J., Machamer C.E. The cytoplasmic tail of the severe acute respiratory syndrome coronavirus spike protein contains a novel endoplasmic reticulum retrieval signal that binds COPI and promotes interaction with membrane protein. J.&#xa0;Virol. 2007;81:2418&#x2013;2428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1865919</ArticleId><ArticleId IdType="pubmed">17166901</ArticleId></ArticleIdList></Reference><Reference><Citation>Mei K., Guo W. The exocyst complex. Curr. Biol. 2018;28:R922&#x2013;R925.</Citation><ArticleIdList><ArticleId IdType="pubmed">30205058</ArticleId></ArticleIdList></Reference><Reference><Citation>Moretti F., Bergman P., Dodgson S., Marcellin D., Claerr I., Goodwin J.M., DeJesus R., Kang Z., Antczak C., Begue D., et al. TMEM41B is a novel regulator of autophagy and lipid mobilization. EMBO Rep. 2018;19:e45889.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6123663</ArticleId><ArticleId IdType="pubmed">30126924</ArticleId></ArticleIdList></Reference><Reference><Citation>Olagnier D., Farahani E., Thyrsted J., Blay-Cadanet J., Herengt A., Idorn M., Hait A., Hernaez B., Knudsen A., Iversen M.B., et al. SARS-CoV2-mediated suppression of NRF2-signaling reveals potent antiviral and anti-inflammatory activity of 4-octyl-itaconate and dimethyl fumarate. Nat Commun. 2020;11:4938.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7532469</ArticleId><ArticleId IdType="pubmed">33009401</ArticleId></ArticleIdList></Reference><Reference><Citation>Ou X., Liu Y., Lei X., Li P., Mi D., Ren L., Guo L., Guo R., Chen T., Hu J., et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat. Commun. 2020;11:1620.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7100515</ArticleId><ArticleId IdType="pubmed">32221306</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen J., Drake M.J., Bruce E.A., Riblett A.M., Didigu C.A., Wilen C.B., Malani N., Male F., Lee F.-H., Bushman F.D., et al. The major cellular sterol regulatory pathway is required for Andes virus infection. PLoS Pathog. 2014;10:e1003911.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3916400</ArticleId><ArticleId IdType="pubmed">24516383</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen E., Koopmans M., Go U., Hamer D.H., Petrosillo N., Castelli F., Storgaard M., Khalili S.A., Simonsen L. Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics. Lancet Infect. Dis. 2020;20:E238&#x2013;E244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7333991</ArticleId><ArticleId IdType="pubmed">32628905</ArticleId></ArticleIdList></Reference><Reference><Citation>Puschnik A.S., Majzoub K., Ooi Y.S., Carette J.E. A CRISPR toolbox to study virus-host interactions. Nat. Rev. Microbiol. 2017;15:351&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5800792</ArticleId><ArticleId IdType="pubmed">28420884</ArticleId></ArticleIdList></Reference><Reference><Citation>Ran F.A., Hsu P.D., Wright J., Agarwala V., Scott D.A., Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 2013;8:2281&#x2013;2308.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3969860</ArticleId><ArticleId IdType="pubmed">24157548</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapiteanu R., Davis L.J., Williamson J.C., Timms R.T., Paul Luzio J., Lehner P.J. A Genetic Screen Identifies a Critical Role for the WDR81-WDR91 Complex in the Trafficking and Degradation of Tetherin. Traffic. 2016;17:940&#x2013;958.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5025723</ArticleId><ArticleId IdType="pubmed">27126989</ArticleId></ArticleIdList></Reference><Reference><Citation>Riva L., Yuan S., Yin X., Martin-Sancho L., Matsunaga N., Pache L., Burgstaller-Muehlbacher S., De Jesus P.D., Teriete P., Hull M.V., et al. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature. 2020;586:113&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7603405</ArticleId><ArticleId IdType="pubmed">32707573</ArticleId></ArticleIdList></Reference><Reference><Citation>Ronan B., Flamand O., Vescovi L., Dureuil C., Durand L., Fassy F., Bachelot M.-F., Lamberton A., Mathieu M., Bertrand T., et al. A highly potent and selective Vps34 inhibitor alters vesicle trafficking and autophagy. Nat. Chem. Biol. 2014;10:1013&#x2013;1019.</Citation><ArticleIdList><ArticleId IdType="pubmed">25326666</ArticleId></ArticleIdList></Reference><Reference><Citation>Rong Y., McPhee C.K., Deng S., Huang L., Chen L., Liu M., Tracy K., Baehrecke E.H., Yu L., Lenardo M.J. Spinster is required for autophagic lysosome reformation and mTOR reactivation following starvation. Proc. Natl. Acad. Sci. U S A. 2011;108:7826&#x2013;7831.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3093520</ArticleId><ArticleId IdType="pubmed">21518918</ArticleId></ArticleIdList></Reference><Reference><Citation>Rousseaux M.W., de Haro M., Lasagna-Reeves C.A., De Maio A., Park J., Jafar-Nejad P., Al-Ramahi I., Sharma A., See L., Lu N., et al. TRIM28 regulates the nuclear accumulation and toxicity of both alpha-synuclein and tau. eLife. 2016;5:e19809.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5104516</ArticleId><ArticleId IdType="pubmed">27779468</ArticleId></ArticleIdList></Reference><Reference><Citation>Saftig P., Klumperman J. Lysosome biogenesis and lysosomal membrane proteins: trafficking meets function. Nat. Rev. Mol. Cell Biol. 2009;10:623&#x2013;635.</Citation><ArticleIdList><ArticleId IdType="pubmed">19672277</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanjana N.E., Shalem O., Zhang F. Improved vectors and genome-wide libraries for CRISPR screening. Nat. Methods. 2014;11:783&#x2013;784.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4486245</ArticleId><ArticleId IdType="pubmed">25075903</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider W.M., Luna J.M., Hoffmann H.-H., S&#xe1;nchez-Rivera F.J., Leal A.A., Ashbrook A.W., Pen J.L., Michailidis E., Ricardo-Lax I., Peace A., et al. Genome-scale identification of SARS-CoV-2 and pan-coronavirus host factor networks. bioRxiv. 2020 doi: 10.1101/2020.10.07.326462.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.10.07.326462</ArticleId><ArticleId IdType="pmc">PMC7796900</ArticleId><ArticleId IdType="pubmed">33382968</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirato K., Kawase M., Matsuyama S. Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2. J.&#xa0;Virol. 2013;87:12552&#x2013;12561.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3838146</ArticleId><ArticleId IdType="pubmed">24027332</ArticleId></ArticleIdList></Reference><Reference><Citation>Shisheva A. In: Phosphoinositides and Disease. Falasca M., editor. Springer Netherlands; Dordrecht: 2012. PIKfyve and its Lipid Products in Health and in Sickness; pp. 127&#x2013;162.</Citation></Reference><Reference><Citation>Simmons G., Gosalia D.N., Rennekamp A.J., Reeves J.D., Diamond S.L., Bates P. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc. Natl. Acad. Sci. USA. 2005;102:11876&#x2013;11881.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1188015</ArticleId><ArticleId IdType="pubmed">16081529</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart S.A., Dykxhoorn D.M., Palliser D., Mizuno H., Yu E.Y., An D.S., Sabatini D.M., Chen I.S.Y., Hahn W.C., Sharp P.A., et al. Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA. 2003;9:493&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1370415</ArticleId><ArticleId IdType="pubmed">12649500</ArticleId></ArticleIdList></Reference><Reference><Citation>Str&#xf6;h L.J., Stehle T. Glycan Engagement by Viruses: Receptor Switches and Specificity. Annu. Rev. Virol. 2014;1:285&#x2013;306.</Citation><ArticleIdList><ArticleId IdType="pubmed">26958723</ArticleId></ArticleIdList></Reference><Reference><Citation>Stukalov A., Girault V., Grass V., Bergant V., Karayel O., Urban C., Haas D.A., Huang Y., Oubraham L., Wang A., et al. Multi-level proteomics reveals host-perturbation strategies of SARS-CoV-2 and SARS-CoV. bioRxiv. 2020 doi: 10.1101/2020.06.17.156455.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.06.17.156455</ArticleId><ArticleId IdType="pubmed">33845483</ArticleId></ArticleIdList></Reference><Reference><Citation>Su G., Kuchinsky A., Morris J.H., States D.J., Meng F. GLay: community structure analysis of biological networks. Bioinformatics. 2010;26:3135&#x2013;3137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2995124</ArticleId><ArticleId IdType="pubmed">21123224</ArticleId></ArticleIdList></Reference><Reference><Citation>Sungnak W., Huang N., B&#xe9;cavin C., Berg M., Queen R., Litvinukova M., Talavera-L&#xf3;pez C., Maatz H., Reichart D., Sampaziotis F., et al. HCA Lung Biological Network SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat. Med. 2020;26:681&#x2013;687.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8637938</ArticleId><ArticleId IdType="pubmed">32327758</ArticleId></ArticleIdList></Reference><Reference><Citation>V&#x2019;kovski P., Gerber M., Kelly J., Pfaender S., Ebert N., Braga Lagache S., Simillion C., Portmann J., Stalder H., Gaschen V., et al. Determination of host proteins composing the microenvironment of coronavirus replicase complexes by proximity-labeling. eLife. 2019;8:e42037.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6372286</ArticleId><ArticleId IdType="pubmed">30632963</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Hoek L. Human coronaviruses: what do they cause? Antivir. Ther. 2007;12(4 Pt B):651&#x2013;658.</Citation><ArticleIdList><ArticleId IdType="pubmed">17944272</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei J., Alfajaro M.M., DeWeirdt P.C., Hanna R.E., Lu-Culligan W.J., Cai W.L., Strine M.S., Zhang S.-M., Graziano V.R., Schmitz C.O., et al. Genome-wide CRISPR Screens Reveal Host Factors Critical for SARS-CoV-2 Infection. Cell. 2020 doi: 10.1016/j.cell.2020.10.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.10.028</ArticleId><ArticleId IdType="pmc">PMC7574718</ArticleId><ArticleId IdType="pubmed">33147444</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W., Tian J.-H., Pei Y.-Y., et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579:265&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7094943</ArticleId><ArticleId IdType="pubmed">32015508</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeager C.L., Ashmun R.A., Williams R.K., Cardellichio C.B., Shapiro L.H., Look A.T., Holmes K.V. Human aminopeptidase N is a receptor for human coronavirus 229E. Nature. 1992;357:420&#x2013;422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095410</ArticleId><ArticleId IdType="pubmed">1350662</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaki A.M., van Boheemen S., Bestebroer T.M., Osterhaus A.D.M.E., Fouchier R.A.M. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N.&#xa0;Engl. J. Med. 2012;367:1814&#x2013;1820.</Citation><ArticleIdList><ArticleId IdType="pubmed">23075143</ArticleId></ArticleIdList></Reference><Reference><Citation>Zang R., Case J.B., Castro M.F.G., Liu Z., Zeng Q., Zhao H., Son J., Rothlauf P.W., Hou G., Bose S., et al. Cholesterol 25-hydroxylase suppresses SARS-CoV-2 replication by blocking membrane fusion. Proc Nat Acad Sci U S A. 2020 doi: 10.1073/pnas.2012197117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2012197117</ArticleId><ArticleId IdType="pmc">PMC7749331</ArticleId><ArticleId IdType="pubmed">33239446</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X.-J., Qin J.-J., Cheng X., Shen L., Zhao Y.-C., Yuan Y., Lei F., Chen M.-M., Yang H., Bai L., et al. In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19. Cell Metab. 2020;32:176&#x2013;187.e4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7311917</ArticleId><ArticleId IdType="pubmed">32592657</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong J., Gastaminza P., Cheng G., Kapadia S., Kato T., Burton D.R., Wieland S.F., Uprichard S.L., Wakita T., Chisari F.V. Robust hepatitis C virus infection in&#xa0;vitro. Proc. Natl. Acad. Sci. USA. 2005;102:9294&#x2013;9299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1166622</ArticleId><ArticleId IdType="pubmed">15939869</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y., Feng F., Hu G., Wang Y., Yu Y., Zhu Y., Xu W., Cai X., Sun Z., Han W., et al. The S1/S2 boundary of SARS-CoV-2 spike protein modulates cell entry pathways and transmission. bioRxiv. 2020 doi: 10.1101/2020.08.25.266775.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.08.25.266775</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">33688581</PMID><DateRevised><Year>2024</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2376-7839</ISSN><JournalIssue CitedMedium="Print"><Volume>7</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Neurology. Genetics</Title><ISOAbbreviation>Neurol Genet</ISOAbbreviation></Journal><ArticleTitle>Race and Alzheimer Disease Biomarkers: A Neglected Race.</ArticleTitle><Pagination><StartPage>e574</StartPage><MedlinePgn>e574</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e574</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1212/NXG.0000000000000574</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lle&#xf3;</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Memory Unit (A.L.), Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau-Universitat Aut&#xf2;noma de Barcelona; Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red Enfermedades Neurodegenerativas (CIBERNED) (A.L.), Madrid; Barcelona&#x3b2;eta Brain Research Center (BBRC) (M.S.-C.), Pasqual Maragall Foundation, Barcelona; Servei de Neurologia (M.S.-C.), Hospital del Mar, Barcelona; IMIM (Hospital del Mar Medical Research Institute) (M.S.-C.), Barcelona; and Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES) (M.S.-C.), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su&#xe1;rez-Calvet</LastName><ForeName>Marc</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-2993-569X</Identifier><AffiliationInfo><Affiliation>Memory Unit (A.L.), Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau-Universitat Aut&#xf2;noma de Barcelona; Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red Enfermedades Neurodegenerativas (CIBERNED) (A.L.), Madrid; Barcelona&#x3b2;eta Brain Research Center (BBRC) (M.S.-C.), Pasqual Maragall Foundation, Barcelona; Servei de Neurologia (M.S.-C.), Hospital del Mar, Barcelona; IMIM (Hospital del Mar Medical Research Institute) (M.S.-C.), Barcelona; and Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES) (M.S.-C.), Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>03</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurol Genet</MedlineTA><NlmUniqueID>101671068</NlmUniqueID><ISSNLinking>2376-7839</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Neurol Genet. 00:e571.</RefSource></CommentsCorrections></CommentsCorrectionsList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>10</Day><Hour>8</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>3</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33688581</ArticleId><ArticleId IdType="pmc">PMC7938472</ArticleId><ArticleId IdType="doi">10.1212/NXG.0000000000000574</ArticleId><ArticleId IdType="pii">NG2021016927</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mayeda ER, Glymour MM, Quesenberry CP, Whitmer RA. Inequalities in dementia incidence between six racial and ethnic groups over 14 years. Alzheimers Dement 2016;12:216&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4969071</ArticleId><ArticleId IdType="pubmed">26874595</ArticleId></ArticleIdList></Reference><Reference><Citation>Howard G, Safford MM, Moy CS, et al. . Racial differences in the incidence of cardiovascular risk factors in older black and white adults. J Am Geriatr Soc 2017;65:83&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5258649</ArticleId><ArticleId IdType="pubmed">27666895</ArticleId></ArticleIdList></Reference><Reference><Citation>Howell JC, Watts KD, Parker MW, et al. . Race modifies the relationship between cognition and Alzheimer's disease cerebrospinal fluid biomarkers. Alzheimers Res Ther 2017;9:88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5668981</ArticleId><ArticleId IdType="pubmed">29096697</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindler SE, Cruchaga C, Joseph A, et al. . African Americans have differences in CSF soluble TREM2 and associated genetic variants. Neurol Genet
2021;7:e571. doi: 10.1212/NXG.0000000000000571.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXG.0000000000000571</ArticleId><ArticleId IdType="pmc">PMC8054965</ArticleId><ArticleId IdType="pubmed">33884297</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulland TK, Colonna M. TREM2: a key player in microglial biology and Alzheimer disease. Nat Rev Neurol 2018;14:667&#x2013;675.</Citation><ArticleIdList><ArticleId IdType="pubmed">30266932</ArticleId></ArticleIdList></Reference><Reference><Citation>Suarez-Calvet M, Kleinberger G, Araque Caballero MA, et al. . sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers. EMBO Mol Med 2016;8:466&#x2013;476.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5120370</ArticleId><ArticleId IdType="pubmed">26941262</ArticleId></ArticleIdList></Reference><Reference><Citation>Su&#xe1;rez-Calvet M, Araque Caballero M&#xc1;, Kleinberger G, et al. . Early changes in CSF sTREM2 in dominantly inherited Alzheimer's disease occur after amyloid deposition and neuronal injury. Sci Transl Med 2016;8:369ra178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5385711</ArticleId><ArticleId IdType="pubmed">27974666</ArticleId></ArticleIdList></Reference><Reference><Citation>Ewers M, Franzmeier N, Suarez-Calvet M, et al. . Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimer's disease. Sci Transl Med 2019;11:eaav6221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7050285</ArticleId><ArticleId IdType="pubmed">31462511</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes C, Cunningham C, Zotpleaseova E, et al. . Systemic inflammation and disease progression in Alzheimer disease. Neurology 2009;73:768&#x2013;774.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2848584</ArticleId><ArticleId IdType="pubmed">19738171</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Mustafa M, Yuede CM, et al. . Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer's disease model. J Exp Med 2020;217:e20200785.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7478730</ArticleId><ArticleId IdType="pubmed">32579671</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33720637</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2021</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1533-4406</ISSN><JournalIssue CitedMedium="Internet"><Volume>384</Volume><Issue>18</Issue><PubDate><Year>2021</Year><Month>May</Month><Day>06</Day></PubDate></JournalIssue><Title>The New England journal of medicine</Title><ISOAbbreviation>N Engl J Med</ISOAbbreviation></Journal><ArticleTitle>Donanemab in Early Alzheimer's Disease.</ArticleTitle><Pagination><StartPage>1691</StartPage><EndPage>1704</EndPage><MedlinePgn>1691-1704</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1056/NEJMoa2100708</ELocationID><Abstract><AbstractText Label="BACKGROUND">A hallmark of Alzheimer's disease is the accumulation of amyloid-&#x3b2; (A&#x3b2;) peptide. Donanemab, an antibody that targets a modified form of deposited A&#x3b2;, is being investigated for the treatment of early Alzheimer's disease.</AbstractText><AbstractText Label="METHODS">We conducted a phase 2 trial of donanemab in patients with early symptomatic Alzheimer's disease who had tau and amyloid deposition on positron-emission tomography (PET). Patients were randomly assigned in a 1:1 ratio to receive donanemab (700 mg for the first three doses and 1400 mg thereafter) or placebo intravenously every 4 weeks for up to 72 weeks. The primary outcome was the change from baseline in the score on the Integrated Alzheimer's Disease Rating Scale (iADRS; range, 0 to 144, with lower scores indicating greater cognitive and functional impairment) at 76 weeks. Secondary outcomes included the change in scores on the Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB), the 13-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-Cog<sub>13</sub>), the Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living Inventory (ADCS-iADL), and the Mini-Mental State Examination (MMSE), as well as the change in the amyloid and tau burden on PET.</AbstractText><AbstractText Label="RESULTS">A total of 257 patients were enrolled; 131 were assigned to receive donanemab and 126 to receive placebo. The baseline iADRS score was 106 in both groups. The change from baseline in the iADRS score at 76 weeks was -6.86 with donanemab and -10.06 with placebo (difference, 3.20; 95% confidence interval, 0.12 to 6.27; P&#x2009;=&#x2009;0.04). The results for most secondary outcomes showed no substantial difference. At 76 weeks, the reductions in the amyloid plaque level and the global tau load were 85.06 centiloids and 0.01 greater, respectively, with donanemab than with placebo. Amyloid-related cerebral edema or effusions (mostly asymptomatic) occurred with donanemab.</AbstractText><AbstractText Label="CONCLUSIONS">In patients with early Alzheimer's disease, donanemab resulted in a better composite score for cognition and for the ability to perform activities of daily living than placebo at 76 weeks, although results for secondary outcomes were mixed. Longer and larger trials are necessary to study the efficacy and safety of donanemab in Alzheimer's disease. (Funded by Eli Lilly; TRAILBLAZER-ALZ ClinicalTrials.gov number, NCT03367403.).</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Massachusetts Medical Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mintun</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>From Eli Lilly (M.A.M., A.C.L., C.D.E., A.M.W., P.A.A., S.W.A., S.S., J.S., J.R.S., M.B., D.M.S.) and the Departments of Neurology, of Radiology and Imaging Sciences, and of Medical and Molecular Genetics and the Indiana Alzheimer Disease Center, Indiana University School of Medicine (L.G.A.) - both in Indianapolis; and the Departments of Psychiatry and Human Behavior and of Neurology, Butler Hospital, Warren Alpert Medical School of Brown University, Providence, RI (S.P.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lo</LastName><ForeName>Albert C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>From Eli Lilly (M.A.M., A.C.L., C.D.E., A.M.W., P.A.A., S.W.A., S.S., J.S., J.R.S., M.B., D.M.S.) and the Departments of Neurology, of Radiology and Imaging Sciences, and of Medical and Molecular Genetics and the Indiana Alzheimer Disease Center, Indiana University School of Medicine (L.G.A.) - both in Indianapolis; and the Departments of Psychiatry and Human Behavior and of Neurology, Butler Hospital, Warren Alpert Medical School of Brown University, Providence, RI (S.P.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duggan Evans</LastName><ForeName>Cynthia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>From Eli Lilly (M.A.M., A.C.L., C.D.E., A.M.W., P.A.A., S.W.A., S.S., J.S., J.R.S., M.B., D.M.S.) and the Departments of Neurology, of Radiology and Imaging Sciences, and of Medical and Molecular Genetics and the Indiana Alzheimer Disease Center, Indiana University School of Medicine (L.G.A.) - both in Indianapolis; and the Departments of Psychiatry and Human Behavior and of Neurology, Butler Hospital, Warren Alpert Medical School of Brown University, Providence, RI (S.P.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wessels</LastName><ForeName>Alette M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>From Eli Lilly (M.A.M., A.C.L., C.D.E., A.M.W., P.A.A., S.W.A., S.S., J.S., J.R.S., M.B., D.M.S.) and the Departments of Neurology, of Radiology and Imaging Sciences, and of Medical and Molecular Genetics and the Indiana Alzheimer Disease Center, Indiana University School of Medicine (L.G.A.) - both in Indianapolis; and the Departments of Psychiatry and Human Behavior and of Neurology, Butler Hospital, Warren Alpert Medical School of Brown University, Providence, RI (S.P.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ardayfio</LastName><ForeName>Paul A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>From Eli Lilly (M.A.M., A.C.L., C.D.E., A.M.W., P.A.A., S.W.A., S.S., J.S., J.R.S., M.B., D.M.S.) and the Departments of Neurology, of Radiology and Imaging Sciences, and of Medical and Molecular Genetics and the Indiana Alzheimer Disease Center, Indiana University School of Medicine (L.G.A.) - both in Indianapolis; and the Departments of Psychiatry and Human Behavior and of Neurology, Butler Hospital, Warren Alpert Medical School of Brown University, Providence, RI (S.P.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andersen</LastName><ForeName>Scott W</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>From Eli Lilly (M.A.M., A.C.L., C.D.E., A.M.W., P.A.A., S.W.A., S.S., J.S., J.R.S., M.B., D.M.S.) and the Departments of Neurology, of Radiology and Imaging Sciences, and of Medical and Molecular Genetics and the Indiana Alzheimer Disease Center, Indiana University School of Medicine (L.G.A.) - both in Indianapolis; and the Departments of Psychiatry and Human Behavior and of Neurology, Butler Hospital, Warren Alpert Medical School of Brown University, Providence, RI (S.P.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shcherbinin</LastName><ForeName>Sergey</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From Eli Lilly (M.A.M., A.C.L., C.D.E., A.M.W., P.A.A., S.W.A., S.S., J.S., J.R.S., M.B., D.M.S.) and the Departments of Neurology, of Radiology and Imaging Sciences, and of Medical and Molecular Genetics and the Indiana Alzheimer Disease Center, Indiana University School of Medicine (L.G.A.) - both in Indianapolis; and the Departments of Psychiatry and Human Behavior and of Neurology, Butler Hospital, Warren Alpert Medical School of Brown University, Providence, RI (S.P.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sparks</LastName><ForeName>JonDavid</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>From Eli Lilly (M.A.M., A.C.L., C.D.E., A.M.W., P.A.A., S.W.A., S.S., J.S., J.R.S., M.B., D.M.S.) and the Departments of Neurology, of Radiology and Imaging Sciences, and of Medical and Molecular Genetics and the Indiana Alzheimer Disease Center, Indiana University School of Medicine (L.G.A.) - both in Indianapolis; and the Departments of Psychiatry and Human Behavior and of Neurology, Butler Hospital, Warren Alpert Medical School of Brown University, Providence, RI (S.P.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sims</LastName><ForeName>John R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>From Eli Lilly (M.A.M., A.C.L., C.D.E., A.M.W., P.A.A., S.W.A., S.S., J.S., J.R.S., M.B., D.M.S.) and the Departments of Neurology, of Radiology and Imaging Sciences, and of Medical and Molecular Genetics and the Indiana Alzheimer Disease Center, Indiana University School of Medicine (L.G.A.) - both in Indianapolis; and the Departments of Psychiatry and Human Behavior and of Neurology, Butler Hospital, Warren Alpert Medical School of Brown University, Providence, RI (S.P.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brys</LastName><ForeName>Miroslaw</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From Eli Lilly (M.A.M., A.C.L., C.D.E., A.M.W., P.A.A., S.W.A., S.S., J.S., J.R.S., M.B., D.M.S.) and the Departments of Neurology, of Radiology and Imaging Sciences, and of Medical and Molecular Genetics and the Indiana Alzheimer Disease Center, Indiana University School of Medicine (L.G.A.) - both in Indianapolis; and the Departments of Psychiatry and Human Behavior and of Neurology, Butler Hospital, Warren Alpert Medical School of Brown University, Providence, RI (S.P.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Apostolova</LastName><ForeName>Liana G</ForeName><Initials>LG</Initials><AffiliationInfo><Affiliation>From Eli Lilly (M.A.M., A.C.L., C.D.E., A.M.W., P.A.A., S.W.A., S.S., J.S., J.R.S., M.B., D.M.S.) and the Departments of Neurology, of Radiology and Imaging Sciences, and of Medical and Molecular Genetics and the Indiana Alzheimer Disease Center, Indiana University School of Medicine (L.G.A.) - both in Indianapolis; and the Departments of Psychiatry and Human Behavior and of Neurology, Butler Hospital, Warren Alpert Medical School of Brown University, Providence, RI (S.P.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salloway</LastName><ForeName>Stephen P</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>From Eli Lilly (M.A.M., A.C.L., C.D.E., A.M.W., P.A.A., S.W.A., S.S., J.S., J.R.S., M.B., D.M.S.) and the Departments of Neurology, of Radiology and Imaging Sciences, and of Medical and Molecular Genetics and the Indiana Alzheimer Disease Center, Indiana University School of Medicine (L.G.A.) - both in Indianapolis; and the Departments of Psychiatry and Human Behavior and of Neurology, Butler Hospital, Warren Alpert Medical School of Brown University, Providence, RI (S.P.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skovronsky</LastName><ForeName>Daniel M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>From Eli Lilly (M.A.M., A.C.L., C.D.E., A.M.W., P.A.A., S.W.A., S.S., J.S., J.R.S., M.B., D.M.S.) and the Departments of Neurology, of Radiology and Imaging Sciences, and of Medical and Molecular Genetics and the Indiana Alzheimer Disease Center, Indiana University School of Medicine (L.G.A.) - both in Indianapolis; and the Departments of Psychiatry and Human Behavior and of Neurology, Butler Hospital, Warren Alpert Medical School of Brown University, Providence, RI (S.P.S.).</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT03367403</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>03</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>N Engl J Med</MedlineTA><NlmUniqueID>0255562</NlmUniqueID><ISSNLinking>0028-4793</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000939">Epitopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>SZB83O1W42</RegistryNumber><NameOfSubstance UI="D011761">Pyrrolidonecarboxylic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2021 May 6;384(18):1762-1763. doi: 10.1056/NEJMe2103722.</RefSource><PMID Version="1">33951366</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neuroscientist. 2021 Aug;27(4):319. doi: 10.1177/10738584211026887.</RefSource><PMID Version="1">34229515</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2021 Aug 12;385(7):666-667. doi: 10.1056/NEJMc2109455.</RefSource><PMID Version="1">34379933</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061605" MajorTopicYN="N">Administration, Intravenous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001929" MajorTopicYN="N">Brain Edema</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000939" MajorTopicYN="N">Epitopes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073216" MajorTopicYN="N">Mental Status and Dementia Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011761" MajorTopicYN="N">Pyrrolidonecarboxylic Acid</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>15</Day><Hour>13</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33720637</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2100708</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33737393</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>06</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>118</Volume><Issue>12</Issue><PubDate><Year>2021</Year><Month>Mar</Month><Day>23</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Rapid initiation of cell cycle reentry processes protects neurons from amyloid-&#x3b2; toxicity.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e2011876118</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.2011876118</ELocationID><Abstract><AbstractText>Neurons are postmitotic cells. Reactivation of the cell cycle by neurons has been reported in Alzheimer's disease (AD) brains and models. This gave rise to the hypothesis that reentering the cell cycle renders neurons vulnerable and thus contributes to AD pathogenesis. Here, we use the fluorescent ubiquitination-based cell cycle indicator (FUCCI) technology to monitor the cell cycle in live neurons. We found transient, self-limited cell cycle reentry activity in naive neurons, suggesting that their postmitotic state is a dynamic process. Furthermore, we observed a diverse response to oligomeric amyloid-&#x3b2; (oA&#x3b2;) challenge; neurons without cell cycle reentry activity would undergo cell death without activating the FUCCI reporter, while neurons undergoing cell cycle reentry activity at the time of the oA&#x3b2; challenge could maintain and increase FUCCI reporter signal and evade cell death. Accordingly, we observed marked neuronal FUCCI positivity in the brains of human mutant A&#x3b2; precursor protein transgenic (APP23) mice together with increased neuronal expression of the endogenous cell cycle control protein geminin in the brains of 3-mo-old APP23 mice and human AD brains. Taken together, our data challenge the current view on cell cycle in neurons and AD, suggesting that pathways active during early cell cycle reentry in neurons protect from A&#x3b2; toxicity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ippati</LastName><ForeName>Stefania</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-8408-6216</Identifier><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Biomedical Sciences, Faculty of Medicine Health and Human Sciences, Macquarie University, Sydney, NSW 2109, Australia; stefania.ippati@hsr.it lars.ittner@mq.edu.au.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>San Raffaele Scientific Institute, San Raffaele Hospital, 20132 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Yuanyuan</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-3366-165X</Identifier><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Biomedical Sciences, Faculty of Medicine Health and Human Sciences, Macquarie University, Sydney, NSW 2109, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Hoven</LastName><ForeName>Julia</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-9862-3016</Identifier><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Biomedical Sciences, Faculty of Medicine Health and Human Sciences, Macquarie University, Sydney, NSW 2109, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heu</LastName><ForeName>Celine</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-6976-9924</Identifier><AffiliationInfo><Affiliation>Biomedical Imaging Facility, Mark Wainwright Analytical Centre, University of New South Wales, Sydney NSW 2052, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Hummel</LastName><ForeName>Annika</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-5192-6434</Identifier><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Biomedical Sciences, Faculty of Medicine Health and Human Sciences, Macquarie University, Sydney, NSW 2109, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chua</LastName><ForeName>Sook Wern</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Biomedical Sciences, Faculty of Medicine Health and Human Sciences, Macquarie University, Sydney, NSW 2109, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paric</LastName><ForeName>Esmeralda</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Biomedical Sciences, Faculty of Medicine Health and Human Sciences, Macquarie University, Sydney, NSW 2109, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Gabriella</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Biomedical Sciences, Faculty of Medicine Health and Human Sciences, Macquarie University, Sydney, NSW 2109, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feiten</LastName><ForeName>Astrid</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-9134-2852</Identifier><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Biomedical Sciences, Faculty of Medicine Health and Human Sciences, Macquarie University, Sydney, NSW 2109, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fath</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-6877-7567</Identifier><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Biomedical Sciences, Faculty of Medicine Health and Human Sciences, Macquarie University, Sydney, NSW 2109, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ke</LastName><ForeName>Yazi D</ForeName><Initials>YD</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Biomedical Sciences, Faculty of Medicine Health and Human Sciences, Macquarie University, Sydney, NSW 2109, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haass</LastName><ForeName>Nikolas K</ForeName><Initials>NK</Initials><Identifier Source="ORCID">0000-0002-3928-5360</Identifier><AffiliationInfo><Affiliation>The University of Queensland Diamantina Institute, The University of Queensland, Brisbane, QLD 4102, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ittner</LastName><ForeName>Lars M</ForeName><Initials>LM</Initials><Identifier Source="ORCID">0000-0001-6738-3825</Identifier><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Biomedical Sciences, Faculty of Medicine Health and Human Sciences, Macquarie University, Sydney, NSW 2109, Australia; stefania.ippati@hsr.it lars.ittner@mq.edu.au.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002453" MajorTopicYN="N">Cell Cycle</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004198" MajorTopicYN="N">Disease Susceptibility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer</Keyword><Keyword MajorTopicYN="N">FUCCI</Keyword><Keyword MajorTopicYN="N">cell cycle</Keyword><Keyword MajorTopicYN="N">postmitotic neurons</Keyword></KeywordList><CoiStatement>The authors declare no competing interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>9</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33737393</ArticleId><ArticleId IdType="pmc">PMC8000021</ArticleId><ArticleId IdType="doi">10.1073/pnas.2011876118</ArticleId><ArticleId IdType="pii">2011876118</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Querfurth H. W., LaFerla F. M., Alzheimer&#x2019;s disease. N. Engl. J. Med. 362, 329&#x2013;344 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20107219</ArticleId></ArticleIdList></Reference><Reference><Citation>Busser J., Geldmacher D. S., Herrup K., Ectopic cell cycle proteins predict the sites of neuronal cell death in Alzheimer&#x2019;s disease brain. J. Neurosci. 18, 2801&#x2013;2807 (1998).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6792587</ArticleId><ArticleId IdType="pubmed">9525997</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoozemans J. J., et al. ., Cyclin D1 and cyclin E are co-localized with cyclo-oxygenase 2 (COX-2) in pyramidal neurons in Alzheimer disease temporal cortex. J. Neuropathol. Exp. Neurol. 61, 678&#x2013;688 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12152783</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y., Mufson E. J., Herrup K., Neuronal cell death is preceded by cell cycle events at all stages of Alzheimer&#x2019;s disease. J. Neurosci. 23, 2557&#x2013;2563 (2003).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742098</ArticleId><ArticleId IdType="pubmed">12684440</ArticleId></ArticleIdList></Reference><Reference><Citation>Arendt T., Cell cycle activation and aneuploid neurons in Alzheimer&#x2019;s disease. Mol. Neurobiol. 46, 125&#x2013;135 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22528601</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosch B., et al. ., Aneuploidy and DNA replication in the normal human brain and Alzheimer&#x2019;s disease. J. Neurosci. 27, 6859&#x2013;6867 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672221</ArticleId><ArticleId IdType="pubmed">17596434</ArticleId></ArticleIdList></Reference><Reference><Citation>Arendt T., Mosch B., Morawski M., Neuronal aneuploidy in health and disease: A cytomic approach to understand the molecular individuality of neurons. Int. J. Mol. Sci. 10, 1609&#x2013;1627 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2680637</ArticleId><ArticleId IdType="pubmed">19468329</ArticleId></ArticleIdList></Reference><Reference><Citation>Arendt T., Holzer M., G&#xe4;rtner U., Br&#xfc;ckner M. K., Aberrancies in signal transduction and cell cycle related events in Alzheimer&#x2019;s disease. J. Neural. Transm. Suppl. 54, 147&#x2013;158 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9850923</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W. K., Williams R. T., Hall F. L., Dickson D. W., Yen S. H., Detection of a Cdc2-related kinase associated with Alzheimer paired helical filaments. Am. J. Pathol. 146, 228&#x2013;238 (1995).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1870752</ArticleId><ArticleId IdType="pubmed">7856730</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith T. W., Lippa C. F., Ki-67 immunoreactivity in Alzheimer&#x2019;s disease and other neurodegenerative disorders. J. Neuropathol. Exp. Neurol. 54, 297&#x2013;303 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7745428</ArticleId></ArticleIdList></Reference><Reference><Citation>McShea A., Harris P. L., Webster K. R., Wahl A. F., Smith M. A., Abnormal expression of the cell cycle regulators P16 and CDK4 in Alzheimer&#x2019;s disease. Am. J. Pathol. 150, 1933&#x2013;1939 (1997).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1858317</ArticleId><ArticleId IdType="pubmed">9176387</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward B. E., Cook R. H., Robinson A., Austin J. H., Increased aneuploidy in Alzheimer disease. Am. J. Med. Genet. 3, 137&#x2013;144 (1979).</Citation><ArticleIdList><ArticleId IdType="pubmed">474626</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepherd C. E., Yang Y., Halliday G. M., Region- and cell-specific aneuploidy in brain aging and neurodegeneration. Neuroscience 374, 326&#x2013;334 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29432756</ArticleId></ArticleIdList></Reference><Reference><Citation>van Leeuwen L. A., Hoozemans J. J., Physiological and pathophysiological functions of cell cycle proteins in post-mitotic neurons: Implications for Alzheimer&#x2019;s disease. Acta Neuropathol. 129, 511&#x2013;525 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4366542</ArticleId><ArticleId IdType="pubmed">25618528</ArticleId></ArticleIdList></Reference><Reference><Citation>Hengstschl&#xe4;ger M., Braun K., Soucek T., Miloloza A., Hengstschl&#xe4;ger-Ottnad E., Cyclin-dependent kinases at the G1-S transition of the mammalian cell cycle. Mutat. Res. 436, 1&#x2013;9 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">9878675</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher R. P., The CDK network: Linking cycles of cell division and gene expression. Genes Cancer 3, 731&#x2013;738 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3636752</ArticleId><ArticleId IdType="pubmed">23634260</ArticleId></ArticleIdList></Reference><Reference><Citation>McShea A., Wahl A. F., Smith M. A., Re-entry into the cell cycle: A mechanism for neurodegeneration in Alzheimer disease. Med. Hypotheses 52, 525&#x2013;527 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10459833</ArticleId></ArticleIdList></Reference><Reference><Citation>Newman R. H., Zhang J., Fucci: Street lights on the road to mitosis. Chem. Biol. 15, 97&#x2013;98 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18291313</ArticleId></ArticleIdList></Reference><Reference><Citation>Beaumont K. A., et al. ., Cell cycle phase-specific drug resistance as an escape mechanism of melanoma cells. J. Invest. Dermatol. 136, 1479&#x2013;1489 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26970356</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass N. K., et al. ., Real-time cell cycle imaging during melanoma growth, invasion, and drug response. Pigment Cell Melanoma Res. 27, 764&#x2013;776 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24902993</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith M. P., et al. ., Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure. EMBO Mol. Med. 9, 1011&#x2013;1029 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5538298</ArticleId><ArticleId IdType="pubmed">28606996</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakaue-Sawano A., et al. ., Visualizing spatiotemporal dynamics of multicellular cell-cycle progression. Cell 132, 487&#x2013;498 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18267078</ArticleId></ArticleIdList></Reference><Reference><Citation>Beaumont K. A., Anfosso A., Ahmed F., Weninger W., Haass N. K., Imaging- and flow cytometry-based analysis of cell position and the cell cycle in 3D melanoma spheroids. J. Vis. Exp., e53486 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4780858</ArticleId><ArticleId IdType="pubmed">26779761</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh A. M., Trost R., Boward B., Dalton S., Utilizing FUCCI reporters to understand pluripotent stem cell biology. Methods 101, 4&#x2013;10 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4801677</ArticleId><ArticleId IdType="pubmed">26404921</ArticleId></ArticleIdList></Reference><Reference><Citation>Spoerri L., Beaumont K. A., Anfosso A., Haass N. K., Real-time cell cycle imaging in a 3D cell culture model of melanoma. Methods Mol. Biol. 1612, 401&#x2013;416 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28634959</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh D. M., et al. ., Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535&#x2013;539 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J., Selkoe D. J., The amyloid hypothesis of Alzheimer&#x2019;s disease: Progress and problems on the road to therapeutics. Science 297, 353&#x2013;356 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Oda T., et al. ., Clusterin (apoJ) alters the aggregation of amyloid beta-peptide (A beta 1-42) and forms slowly sedimenting A beta complexes that cause oxidative stress. Exp. Neurol. 136, 22&#x2013;31 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7589331</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturchler-Pierrat C., et al. ., Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl. Acad. Sci. U.S.A. 94, 13287&#x2013;13292 (1997).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24301</ArticleId><ArticleId IdType="pubmed">9371838</ArticleId></ArticleIdList></Reference><Reference><Citation>Spella M., et al. ., Licensing regulators Geminin and Cdt1 identify progenitor cells of the mouse CNS in a specific phase of the cell cycle. Neuroscience 147, 373&#x2013;387 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17533120</ArticleId></ArticleIdList></Reference><Reference><Citation>Zielke N., Edgar B. A., FUCCI sensors: Powerful new tools for analysis of cell proliferation. Wiley Interdiscip. Rev. Dev. Biol. 4, 469&#x2013;487 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6681141</ArticleId><ArticleId IdType="pubmed">25827130</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang X., et al. ., AAV2 production with optimized N/P ratio and PEI-mediated transfection results in low toxicity and high titer for in vitro and in vivo applications. J. Virol. Methods 193, 270&#x2013;277 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3775943</ArticleId><ArticleId IdType="pubmed">23791963</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner A., et al. ., Site-specific phosphorylation of tau inhibits amyloid-&#x3b2; toxicity in Alzheimer&#x2019;s mice. Science 354, 904&#x2013;908 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27856911</ArticleId></ArticleIdList></Reference><Reference><Citation>Seward M. E., et al. ., Amyloid-&#x3b2; signals through tau to drive ectopic neuronal cell cycle re-entry in Alzheimer&#x2019;s disease. J. Cell Sci. 126, 1278&#x2013;1286 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3635465</ArticleId><ArticleId IdType="pubmed">23345405</ArticleId></ArticleIdList></Reference><Reference><Citation>Kienzle A., et al. ., Dendritic mesoporous silica nanoparticles for pH-stimuli-responsive drug delivery of TNF-Alpha. Adv. Healthc. Mater. 6, 1700012 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28557249</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee E. F., et al. ., BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival. Cell Death Dis. 10, 342 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6482196</ArticleId><ArticleId IdType="pubmed">31019203</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuperstein I., et al. ., Neurotoxicity of Alzheimer&#x2019;s disease A&#x3b2; peptides is induced by small changes in the A&#x3b2;42 to A&#x3b2;40 ratio. EMBO J. 29, 3408&#x2013;3420 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2957213</ArticleId><ArticleId IdType="pubmed">20818335</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R., Lasagna-Reeves C. A., Molecular mechanisms of amyloid oligomers toxicity. J. Alzheimers Dis. 33 (suppl. 1), S67&#x2013;S78 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">22531422</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner L. M., et al. ., Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer&#x2019;s disease mouse models. Cell 142, 387&#x2013;397 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20655099</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner A. A., Gladbach A., Bertz J., Suh L. S., Ittner L. M., p38 MAP kinase-mediated NMDA receptor-dependent suppression of hippocampal hypersynchronicity in a mouse model of Alzheimer inverted question marks disease. Acta Neuropathol. Commun. 2, 149 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4212118</ArticleId><ArticleId IdType="pubmed">25331068</ArticleId></ArticleIdList></Reference><Reference><Citation>Ippati S., Stevens C. H., Ittner L. M., Ke Y. D., Early transient neuronal CyclinD1 expression precedes atrophy in the frontal cortex of APP23 mice. SM J. Neurol. Disord Stroke 3, 1015s4 (2017).</Citation></Reference><Reference><Citation>Folch J., et al. ., Role of cell cycle re-entry in neurons: A common apoptotic mechanism of neuronal cell death. Neurotox. Res. 22, 195&#x2013;207 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">21965004</ArticleId></ArticleIdList></Reference><Reference><Citation>Varvel N. H., et al. ., Abeta oligomers induce neuronal cell cycle events in Alzheimer&#x2019;s disease. J. Neurosci. 28, 10786&#x2013;10793 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2680286</ArticleId><ArticleId IdType="pubmed">18945886</ArticleId></ArticleIdList></Reference><Reference><Citation>Arendt T., R&#xf6;del L., G&#xe4;rtner U., Holzer M., Expression of the cyclin-dependent kinase inhibitor p16 in Alzheimer&#x2019;s disease. Neuroreport 7, 3047&#x2013;3049 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">9116237</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent I., Jicha G., Rosado M., Dickson D. W., Aberrant expression of mitotic cdc2/cyclin B1 kinase in degenerating neurons of Alzheimer&#x2019;s disease brain. J. Neurosci. 17, 3588&#x2013;3598 (1997).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573674</ArticleId><ArticleId IdType="pubmed">9133382</ArticleId></ArticleIdList></Reference><Reference><Citation>Maestre C., Delgado-Esteban M., Gomez-Sanchez J. C., Bola&#xf1;os J. P., Almeida A., Cdk5 phosphorylates Cdh1 and modulates cyclin B1 stability in excitotoxicity. EMBO J. 27, 2736&#x2013;2745 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2572178</ArticleId><ArticleId IdType="pubmed">18818692</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrio-Alonso E., Hern&#xe1;ndez-Vivanco A., Walton C. C., Perea G., Frade J. M., Cell cycle reentry triggers hyperploidization and synaptic dysfunction followed by delayed cell death in differentiated cortical neurons. Sci. Rep. 8, 14316 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6156334</ArticleId><ArticleId IdType="pubmed">30254284</ArticleId></ArticleIdList></Reference><Reference><Citation>Negis Y., Karabay A., Expression of cell cycle proteins in cortical neurons-Correlation with glutamate-induced neurotoxicity. Biofactors 42, 358&#x2013;367 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27040651</ArticleId></ArticleIdList></Reference><Reference><Citation>Negis Y., Unal A. Y., Korulu S., Karabay A., Cell cycle markers have different expression and localization patterns in neuron-like PC12 cells and primary hippocampal neurons. Neurosci. Lett. 496, 135&#x2013;140 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21511003</ArticleId></ArticleIdList></Reference><Reference><Citation>Copani A., et al. ., Activation of cell-cycle-associated proteins in neuronal death: A mandatory or dispensable path? Trends Neurosci. 24, 25&#x2013;31 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11163884</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray A. W., Recycling the cell cycle: Cyclins revisited. Cell 116, 221&#x2013;234 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">14744433</ArticleId></ArticleIdList></Reference><Reference><Citation>Hershko A., Ciechanover A., The ubiquitin system. Annu. Rev. Biochem. 67, 425&#x2013;479 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9759494</ArticleId></ArticleIdList></Reference><Reference><Citation>Lukas J., Bartek J., Cell division: The heart of the cycle. Nature 432, 564&#x2013;567 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15577895</ArticleId></ArticleIdList></Reference><Reference><Citation>W&#xe4;sch R., Cross F. R., APC-dependent proteolysis of the mitotic cyclin Clb2 is essential for mitotic exit. Nature 418, 556&#x2013;562 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12152084</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei W., et al. ., Degradation of the SCF component Skp2 in cell-cycle phase G1 by the anaphase-promoting complex. Nature 428, 194&#x2013;198 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15014503</ArticleId></ArticleIdList></Reference><Reference><Citation>Penas C., Ramachandran V., Ayad N. G., The APC/C ubiquitin ligase: From cell biology to tumorigenesis. Front. Oncol. 1, 60 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3356048</ArticleId><ArticleId IdType="pubmed">22655255</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao W., et al. ., Cdh1-APC is involved in the differentiation of neural stem cells into neurons. Neuroreport 21, 39&#x2013;44 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">19918205</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida A., Bola&#xf1;os J. P., Moreno S., Cdh1/Hct1-APC is essential for the survival of postmitotic neurons. J. Neurosci. 25, 8115&#x2013;8121 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725543</ArticleId><ArticleId IdType="pubmed">16148219</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida A., Regulation of APC/C-Cdh1 and its function in neuronal survival. Mol. Neurobiol. 46, 547&#x2013;554 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3496556</ArticleId><ArticleId IdType="pubmed">22836916</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam Y. A., et al. ., Inhibition of the ubiquitin-proteasome system in Alzheimer&#x2019;s disease. Proc. Natl. Acad. Sci. U.S.A. 97, 9902&#x2013;9906 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27620</ArticleId><ArticleId IdType="pubmed">10944193</ArticleId></ArticleIdList></Reference><Reference><Citation>Sulistio Y. A., Heese K., The ubiquitin-proteasome system and molecular chaperone deregulation in Alzheimer&#x2019;s disease. Mol. Neurobiol. 53, 905&#x2013;931 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">25561438</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson P. K., Developmental neurobiology: A destructive switch for neurons. Nature 442, 365&#x2013;366 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16871201</ArticleId></ArticleIdList></Reference><Reference><Citation>Krenning L., Feringa F. M., Shaltiel I. A., van den Berg J., Medema R. H., Transient activation of p53 in G2 phase is sufficient to induce senescence. Mol. Cell 55, 59&#x2013;72 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24910099</ArticleId></ArticleIdList></Reference><Reference><Citation>Pucci B., Kasten M., Giordano A., Cell cycle and apoptosis. Neoplasia 2, 291&#x2013;299 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1550296</ArticleId><ArticleId IdType="pubmed">11005563</ArticleId></ArticleIdList></Reference><Reference><Citation>Deshpande A., Sicinski P., Hinds P. W., Cyclins and cdks in development and cancer: A perspective. Oncogene 24, 2909&#x2013;2915 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15838524</ArticleId></ArticleIdList></Reference><Reference><Citation>Rou&#xe9; G., Pichereau V., Lincet H., Colomer D., Sola B., Cyclin D1 mediates resistance to apoptosis through upregulation of molecular chaperones and consequent redistribution of cell death regulators. Oncogene 27, 4909&#x2013;4920 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18438428</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi Y. J., et al. ., D-cyclins repress apoptosis in hematopoietic cells by controlling death receptor Fas and its ligand FasL. Dev. Cell 30, 255&#x2013;267 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4134362</ArticleId><ArticleId IdType="pubmed">25087893</ArticleId></ArticleIdList></Reference><Reference><Citation>Vousden K. H., p53: Death star. Cell 103, 691&#x2013;694 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">11114324</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohtsuka T., Ryu H., Minamishima Y. A., Ryo A., Lee S. W., Modulation of p53 and p73 levels by cyclin G: Implication of a negative feedback regulation. Oncogene 22, 1678&#x2013;1687 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12642871</ArticleId></ArticleIdList></Reference><Reference><Citation>Grant G. D., Kedziora K. M., Limas J. C., Cook J. G., Purvis J. E., Accurate delineation of cell cycle phase transitions in living cells with PIP-FUCCI. Cell Cycle 17, 2496&#x2013;2516 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6342071</ArticleId><ArticleId IdType="pubmed">30421640</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakaue-Sawano A., et al. ., Genetically encoded tools for optical dissection of the mammalian cell cycle. Mol. Cell 68, 626&#x2013;640.e5 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29107535</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajar B. T., et al. ., Fluorescent indicators for simultaneous reporting of all four cell cycle phases. Nat. Methods 13, 993&#x2013;996 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5548384</ArticleId><ArticleId IdType="pubmed">27798610</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xfc;gler S., Kilic E., B&#xe4;hr M., Human synapsin 1 gene promoter confers highly neuron-specific long-term transgene expression from an adenoviral vector in the adult rat brain depending on the transduced area. Gene Ther. 10, 337&#x2013;347 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12595892</ArticleId></ArticleIdList></Reference><Reference><Citation>Harasta A. E., et al. ., Septal glucagon-like peptide 1 receptor expression determines suppression of cocaine-induced behavior. Neuropsychopharmacology 40, 1969&#x2013;1978 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4839521</ArticleId><ArticleId IdType="pubmed">25669605</ArticleId></ArticleIdList></Reference><Reference><Citation>Fath T., Ke Y. D., Gunning P., G&#xf6;tz J., Ittner L. M., Primary support cultures of hippocampal and substantia nigra neurons. Nat. Protoc. 4, 78&#x2013;85 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19131959</ArticleId></ArticleIdList></Reference><Reference><Citation>Stine W. B. Jr, Dahlgren K. N., Krafft G. A., LaDu M. J., In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. J. Biol. Chem. 278, 11612&#x2013;11622 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12499373</ArticleId></ArticleIdList></Reference><Reference><Citation>Ke Y. D., et al. ., Short-term suppression of A315T mutant human TDP-43 expression improves functional deficits in a novel inducible transgenic mouse model of FTLD-TDP and ALS. Acta Neuropathol. 130, 661&#x2013;678 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26437864</ArticleId></ArticleIdList></Reference><Reference><Citation>Barca A., et al. ., Responsiveness of carnosine homeostasis genes in the pancreas and brain of streptozotocin-treated mice exposed to dietary carnosine. Int. J. Mol. Sci. 19, 1713 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6032234</ArticleId><ArticleId IdType="pubmed">29890740</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner L. M., Koller D., Muff R., Fischer J. A., Born W., The N-terminal extracellular domain 23-60 of the calcitonin receptor-like receptor in chimeras with the parathyroid hormone receptor mediates association with receptor activity-modifying protein 1. Biochemistry 44, 5749&#x2013;5754 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15823033</ArticleId></ArticleIdList></Reference><Reference><Citation>Barca A., et al. ., Carnosine modulates the Sp1-Slc31a1/Ctr1 copper-sensing system and influences copper homeostasis in murine CNS-derived cells. Am. J. Physiol. Cell Physiol. 316, C235&#x2013;C245 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30485136</ArticleId></ArticleIdList></Reference><Reference><Citation>Bi M., et al. ., Tau exacerbates excitotoxic brain damage in an animal model of stroke. Nat. Commun. 8, 473 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5589746</ArticleId><ArticleId IdType="pubmed">28883427</ArticleId></ArticleIdList></Reference><Reference><Citation>von Jonquieres G., et al. ., Glial promoter selectivity following AAV-delivery to the immature brain. PLoS One 8, e65646 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3683058</ArticleId><ArticleId IdType="pubmed">23799030</ArticleId></ArticleIdList></Reference><Reference><Citation>van Hummel A., et al. ., Selective spatiotemporal vulnerability of central nervous system neurons to pathologic TAR DNA-binding protein 43 in aged transgenic mice. Am. J. Pathol. 188, 1447&#x2013;1456 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29577934</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33762220</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>24</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1876-4754</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>3</Issue><PubDate><Year>2021</Year><Season>May-Jun</Season></PubDate></JournalIssue><Title>Brain stimulation</Title><ISOAbbreviation>Brain Stimul</ISOAbbreviation></Journal><ArticleTitle>Exposure to gamma tACS in Alzheimer's disease: A randomized, double-blind, sham-controlled, crossover, pilot study.</ArticleTitle><Pagination><StartPage>531</StartPage><EndPage>540</EndPage><MedlinePgn>531-540</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.brs.2021.03.007</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1935-861X(21)00058-9</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To assess whether exposure to non-invasive brain stimulation with transcranial alternating current stimulation at &#x3b3; frequency (&#x3b3;-tACS) applied over Pz (an area overlying the medial parietal cortex and the precuneus) can improve memory and modulate cholinergic transmission in mild cognitive impairment due to Alzheimer's disease (MCI-AD).</AbstractText><AbstractText Label="METHODS">In this randomized, double-blind, sham controlled, crossover pilot study, participants were assigned to a single 60&#xa0;min treatment with exposure to &#x3b3;-tACS over Pz or sham tACS. Each subject underwent a clinical evaluation including assessment of episodic memory pre- and post-&#x3b3;-tACS or sham stimulation. Indirect measures of cholinergic transmission evaluated using transcranial magnetic stimulation (TMS) pre- and post-&#x3b3;-tACS or sham tACS were evaluated.</AbstractText><AbstractText Label="RESULTS">Twenty MCI-AD participants completed the study. No tACS-related side effects were observed, and the intervention was well tolerated in all participants. We observed a significant improvement at the Rey auditory verbal learning (RAVL) test total recall (5.7 [95% CI, 4.0 to 7.4], p&#xa0;&lt;&#xa0;0.001) and long delayed recall scores (1.3 [95% CI, 0.4 to 2.1], p&#xa0;=&#xa0;0.007) after &#x3b3;-tACS but not after sham tACS. Face-name associations scores improved during &#x3b3;-tACS (4.3 [95% CI, 2.8 to 5.8], p&#xa0;&lt;&#xa0;0.001) but not after sham tACS. Short latency afferent inhibition, an indirect measure of cholinergic transmission evaluated with TMS, increased only after &#x3b3;-tACS (0.31 [95% CI, 0.24 to 0.38], p&#xa0;&lt;&#xa0;0.001) but not after sham tACS.</AbstractText><AbstractText Label="CONCLUSIONS">exposure to &#x3b3;-tACS over Pz showed a significant improvement of memory performances, along with restoration of intracortical connectivity measures of cholinergic neurotransmission, compared to sham tACS.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Benussi</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy; Neurology Unit, Department of Neurological and Vision Sciences, ASST Spedali Civili, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cantoni</LastName><ForeName>Valentina</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cotelli</LastName><ForeName>Maria Sofia</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Neurology Unit, Valle Camonica Hospital, Esine, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cotelli</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Neuropsychology Unit, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brattini</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Neurology Unit, Department of Neurological and Vision Sciences, ASST Spedali Civili, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Datta</LastName><ForeName>Abhishek</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Research &amp; Development, Soterix Medical, Inc., New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>Chris</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Research &amp; Development, Soterix Medical, Inc., New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santarnecchi</LastName><ForeName>Emiliano</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Berenson-Allen Center for Non-Invasive Brain Stimulation, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA; Department of Neurology, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pascual-Leone</LastName><ForeName>Alvaro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Harvard Medical School, Boston, MA, USA; Hinda and Arthur Marcus Institute for Aging Research and Center for Memory Health, Hebrew SeniorLife, Boston, MA, USA; Guttmann Brain Health Institut, Institut Guttmann, Universitat Autonoma Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borroni</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy; Neurology Unit, Department of Neurological and Vision Sciences, ASST Spedali Civili, Brescia, Italy. Electronic address: bborroni@inwind.it.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>03</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Brain Stimul</MedlineTA><NlmUniqueID>101465726</NlmUniqueID><ISSNLinking>1876-4754</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061212" MajorTopicYN="Y">Memory, Episodic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065908" MajorTopicYN="Y">Transcranial Direct Current Stimulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050781" MajorTopicYN="N">Transcranial Magnetic Stimulation</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer disease</Keyword><Keyword MajorTopicYN="N">Mild cognitive impairment</Keyword><Keyword MajorTopicYN="N">Transcranial alternate current stimulation</Keyword><Keyword MajorTopicYN="N">Transcranial magnetic stimulation</Keyword></KeywordList><CoiStatement>Declaration of competing interest Alberto Benussi, MD was partially supported by the Airalzh-AGYR2020; and is listed as an inventor on issued and pending patents on the use of non-invasive brain stimulation for the differential diagnosis of dementia and to increase cognitive functions in patients with neurodegenerative disorders. Maria Sofia Cotelli, MD received financial support by the Italian Ministry of Health (Ricerca Corrente). Emiliano Santarnecchi, PsyD, PhD: is consultant for Neuroelectrics and Neurocare Group Italy. Alvaro Pascual-Leone, MD, PhD is a co-founder of Linus Health and TI Solutions AG; serves on the scientific advisory boards for Starlab Neuroscience, Neuroelectrics, Magstim Inc., Nexstim, Cognito, and MedRhythms; and is listed as an inventor on several issued and pending patents on the real-time integration of noninvasive brain stimulation with electroencephalography and magnetic resonance imaging. Dr. Pascual-Leone was partly supported by the National Institutes of Health (R01MH100186, R21AG051846, R01MH111875, R01MH115949, R01 MH117063, R24AG06142, and P01 AG031720), the National Science Foundation, DARPA, and the Barcelona Brain Health Initiative (La Caixa and Institute Guttmann). Barbara Borroni, MD, is listed as an inventor on issued and pending patents on the use of non-invasive brain stimulation for the differential diagnosis of dementia and to increase cognitive functions in patients with neurodegenerative disorders. Valentina Cantoni, MS, Maria Cotelli, PhD, Chiara Brattini, MS, Abhishek Datta, PhD, Chris Thomas, BS, report no disclosures.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>11</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>3</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>3</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>25</Day><Hour>5</Hour><Minute>49</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33762220</ArticleId><ArticleId IdType="doi">10.1016/j.brs.2021.03.007</ArticleId><ArticleId IdType="pii">S1935-861X(21)00058-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33783469</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>20</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3598</ISSN><JournalIssue CitedMedium="Internet"><Volume>325</Volume><Issue>17</Issue><PubDate><Year>2021</Year><Month>May</Month><Day>04</Day></PubDate></JournalIssue><Title>JAMA</Title><ISOAbbreviation>JAMA</ISOAbbreviation></Journal><ArticleTitle>Evaluation of Aducanumab for Alzheimer Disease: Scientific Evidence and Regulatory Review Involving Efficacy, Safety, and Futility.</ArticleTitle><Pagination><StartPage>1717</StartPage><EndPage>1718</EndPage><MedlinePgn>1717-1718</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jama.2021.3854</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alexander</LastName><ForeName>G Caleb</ForeName><Initials>GC</Initials><AffiliationInfo><Affiliation>Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Emerson</LastName><ForeName>Scott</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, University of Washington, Seattle.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kesselheim</LastName><ForeName>Aaron S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA</MedlineTA><NlmUniqueID>7501160</NlmUniqueID><ISSNLinking>0098-7484</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>105J35OE21</RegistryNumber><NameOfSubstance UI="C000600266">aducanumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017277" MajorTopicYN="Y">Drug Approval</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018447" MajorTopicYN="N">Medical Futility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017211" MajorTopicYN="N">Treatment Failure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014486" MajorTopicYN="N">United States Food and Drug Administration</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>30</Day><Hour>12</Hour><Minute>26</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33783469</ArticleId><ArticleId IdType="doi">10.1001/jama.2021.3854</ArticleId><ArticleId IdType="pii">2778191</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">33842885</PMID><DateRevised><Year>2024</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2632-1297</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><Issue>2</Issue><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>Brain communications</Title><ISOAbbreviation>Brain Commun</ISOAbbreviation></Journal><ArticleTitle>Detection of &#x3b2;-amyloid positivity in Alzheimer's Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers.</ArticleTitle><Pagination><StartPage>fcab008</StartPage><MedlinePgn>fcab008</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">fcab008</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/braincomms/fcab008</ELocationID><Abstract><AbstractText><i>In vivo</i> gold standard for the ante-mortem assessment of brain &#x3b2;-amyloid pathology is currently &#x3b2;-amyloid positron emission tomography or cerebrospinal fluid measures of &#x3b2;-amyloid<sub>42</sub> or the &#x3b2;-amyloid<sub>42</sub>/&#x3b2;-amyloid<sub>40</sub> ratio. The widespread acceptance of a biomarker classification scheme for the Alzheimer's disease continuum has ignited interest in more affordable and accessible approaches to detect Alzheimer's disease &#x3b2;-amyloid pathology, a process that often slows down the recruitment into, and adds to the cost of, clinical trials. Recently, there has been considerable excitement concerning the value of blood biomarkers. Leveraging multidisciplinary data from cognitively unimpaired participants and participants with mild cognitive impairment recruited by the multisite biomarker study of Alzheimer's Disease Neuroimaging Initiative, here we assessed to what extent plasma &#x3b2;-amyloid<sub>42</sub>/&#x3b2;-amyloid<sub>40</sub>, neurofilament light and phosphorylated-tau at threonine-181 biomarkers detect the presence of &#x3b2;-amyloid pathology, and to what extent the addition of clinical information such as demographic data, <i>APOE</i> genotype, cognitive assessments and MRI can assist plasma biomarkers in detecting &#x3b2;-amyloid-positivity. Our results confirm plasma &#x3b2;-amyloid<sub>42</sub>/&#x3b2;-amyloid<sub>40</sub> as a robust biomarker of brain &#x3b2;-amyloid-positivity (area under curve, 0.80-0.87). Plasma phosphorylated-tau at threonine-181 detected &#x3b2;-amyloid-positivity only in the cognitively impaired with a moderate area under curve of 0.67, whereas plasma neurofilament light did not detect &#x3b2;-amyloid-positivity in either group of participants. Clinical information as well as MRI-score independently detected positron emission tomography &#x3b2;-amyloid-positivity in both cognitively unimpaired and impaired (area under curve, 0.69-0.81). Clinical information, particularly <i>APOE</i> &#x3b5;4 status, enhanced the performance of plasma biomarkers in the detection of positron emission tomography &#x3b2;-amyloid-positivity by 0.06-0.14 units of area under curve for cognitively unimpaired, and by 0.21-0.25 units for cognitively impaired; and further enhancement of these models with an MRI-score of &#x3b2;-amyloid-positivity yielded an additional improvement of 0.04-0.11 units of area under curve for cognitively unimpaired and 0.05-0.09 units for cognitively impaired. Taken together, these multi-disciplinary results suggest that when combined with clinical information, plasma phosphorylated-tau at threonine-181 and neurofilament light biomarkers, and an MRI-score could effectively identify &#x3b2;-amyloid+ cognitively unimpaired and impaired (area under curve, 0.80-0.90). Yet, when the MRI-score is considered in combination with clinical information, plasma phosphorylated-tau at threonine-181 and plasma neurofilament light have minimal added value for detecting &#x3b2;-amyloid-positivity. Our systematic comparison of &#x3b2;-amyloid-positivity detection models identified effective combinations of demographics, <i>APOE</i>, global cognition, MRI and plasma biomarkers. Promising minimally invasive and low-cost predictors such as plasma biomarkers of &#x3b2;-amyloid<sub>42</sub>/&#x3b2;-amyloid<sub>40</sub> may be improved by age and <i>APOE</i> genotype.</AbstractText><CopyrightInformation>&#xa9; The Author(s) (2021). Published by Oxford University Press on behalf of the Guarantors of Brain.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tosun</LastName><ForeName>Duygu</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>San Francisco Veterans Affairs Medical Center, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Veitch</LastName><ForeName>Dallas</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Alzheimer's Therapeutic Research Institute (ATRI), Keck School of Medicine, University of Southern California, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix><Identifier Source="ORCID">0000-0001-7916-622X</Identifier><AffiliationInfo><Affiliation>Department of Radiology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jagust</LastName><ForeName>William J</ForeName><Initials>WJ</Initials><Identifier Source="ORCID">0000-0002-4458-113X</Identifier><AffiliationInfo><Affiliation>School of Public Health and Helen Wills Neuroscience Institute, University of California, Berkeley, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saykin</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Radiology and Imaging Sciences, Center for Neuroimaging, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Indiana Alzheimer Disease Center, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bollinger</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ovod</LastName><ForeName>Vitaliy</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mawuenyega</LastName><ForeName>Kwasi G</ForeName><Initials>KG</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bateman</LastName><ForeName>Randall J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Leslie M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-3930-4354</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute at UCL, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>San Francisco Veterans Affairs Medical Center, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R56 AG061900</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG061900</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>02</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain Commun</MedlineTA><NlmUniqueID>101755125</NlmUniqueID><ISSNLinking>2632-1297</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s</Keyword><Keyword MajorTopicYN="N">MRI</Keyword><Keyword MajorTopicYN="N">PET</Keyword><Keyword MajorTopicYN="N">plasma</Keyword><Keyword MajorTopicYN="N">&#x3b2;-amyloid</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>10</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>12</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>12</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>12</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>13</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>2</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33842885</ArticleId><ArticleId IdType="pmc">PMC8023542</ArticleId><ArticleId IdType="doi">10.1093/braincomms/fcab008</ArticleId><ArticleId IdType="pii">fcab008</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aisen PS. &#xa0;Editorial: failure after failure. What next in AD drug development? &#xa0;J Prev Alzheimers Dis &#xa0;2019; 6: 150.</Citation><ArticleIdList><ArticleId IdType="pubmed">31062821</ArticleId></ArticleIdList></Reference><Reference><Citation>Altomare D &#xa0;de Wilde A &#xa0;Ossenkoppele R &#xa0;Pelkmans W &#xa0;Bouwman F &#xa0;Groot C, et al. &#xa0;Applying the ATN scheme in a memory clinic population. The ABIDE Project &#xa0;2019; 93: e1635&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">31597710</ArticleId></ArticleIdList></Reference><Reference><Citation>2020 Alzheimer&#x2019;s disease facts and figures. Alzheimer&#x2019;s &amp; Dementia 2020; 16: 391&#x2013;460.</Citation><ArticleIdList><ArticleId IdType="pubmed">32157811</ArticleId></ArticleIdList></Reference><Reference><Citation>Ansart M &#xa0;Epelbaum S &#xa0;Gagliardi G &#xa0;Colliot O &#xa0;Dormont D &#xa0;Dubois B, for the Alzheimer&#x2019;s Disease Neuroimaging Initiative and the INSIGHT-preAD study, et al. &#xa0;Reduction of recruitment costs in preclinical AD trials: validation of automatic pre-screening algorithm for brain amyloidosis. Stat Methods Med Res &#xa0;2020; 29: 151&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">30698081</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashford MT &#xa0;Veitch DP, Neuhaus J, Nosheny RL, Tosun D &#xa0;Weiner MW. The search for a convenient procedure to detect one of the earliest signs of Alzheimer&#x2019;s disease: a systematic review of the prediction of brain amyloid status. Alzheimers Dement 2021; 1&#x2013;22. doi: 10.1002/alz.12253.</Citation><ArticleIdList><ArticleId IdType="pubmed">33583100</ArticleId></ArticleIdList></Reference><Reference><Citation>Ba M &#xa0;Ng KP &#xa0;Gao X &#xa0;Kong M &#xa0;Guan L &#xa0;Yu L, The Alzheimer&#x2019;s Disease Neuroimaging Initiative. The combination of apolipoprotein E4, age and Alzheimer&#x2019;s Disease Assessment Scale&#x2014;Cognitive Subscale improves the prediction of amyloid positron emission tomography status in clinically diagnosed mild cognitive impairment. Eur J Neurol &#xa0;2019; 26: 733&#x2013;e53.</Citation><ArticleIdList><ArticleId IdType="pubmed">30561868</ArticleId></ArticleIdList></Reference><Reference><Citation>Barth&#xe9;lemy NR &#xa0;Horie K &#xa0;Sato C &#xa0;Bateman RJ. &#xa0;Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer&#x2019;s disease. J Exp Med &#xa0;2020; 217: e20200861.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7596823</ArticleId><ArticleId IdType="pubmed">32725127</ArticleId></ArticleIdList></Reference><Reference><Citation>Benussi A &#xa0;Karikari TK &#xa0;Ashton N &#xa0;Gazzina S &#xa0;Premi E &#xa0;Benussi L, et al. &#xa0;Diagnostic and prognostic value of serum NfL and p-Tau181 in frontotemporal lobar degeneration. J Neurol Neurosurg Psychiatry &#xa0;2020; 91: 960&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">32611664</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K. &#xa0;Cerebrospinal fluid protein biomarkers for Alzheimer&#x2019;s disease. Neurotherapeutics &#xa0;2004; 1: 213&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC534929</ArticleId><ArticleId IdType="pubmed">15717022</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourgeat P &#xa0;Ch&#xe9;telat G &#xa0;Villemagne VL &#xa0;Fripp J &#xa0;Raniga P &#xa0;Pike K, On behalf of the AIBL Research Group, et al. &#xa0;&#x3b2;-Amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia. Neurology &#xa0;2010; 74: 121&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">20065247</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunet HE &#xa0;Miller JB &#xa0;Shi J &#xa0;Chung B &#xa0;Munter BT &#xa0;Sabbagh MN. &#xa0;Does informant-based reporting of cognitive symptoms predict amyloid positivity on positron emission tomography? &#xa0;Alzheimers Dement &#xa0;2019; 11: 424&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6558087</ArticleId><ArticleId IdType="pubmed">31206008</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckley RF &#xa0;Sikkes S &#xa0;Villemagne VL &#xa0;Mormino EC &#xa0;Rabin JS &#xa0;Burnham S, et al. &#xa0;Using subjective cognitive decline to identify high global amyloid in community-based samples: a cross-cohort study. Alzheimer Dement 2019; 11: 670&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6816447</ArticleId><ArticleId IdType="pubmed">31673597</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnham SC &#xa0;Bourgeat P &#xa0;Dore V &#xa0;Savage G &#xa0;Brown B &#xa0;Laws S, et al. &#xa0;Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer&#x2019;s disease pathophysiology (SNAP) or Alzheimer&#x2019;s disease pathology: a longitudinal study. Lancet Neurol &#xa0;2016; 15: 1044&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">27450471</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnham SC &#xa0;Faux NG &#xa0;Wilson W &#xa0;Laws SM &#xa0;Ames D &#xa0;Bedo J, Alzheimer&#x2019;s Disease Neuroimaging Initiative, et al. &#xa0;A blood-based predictor for neocortical Abeta burden in Alzheimer&#x2019;s disease: results from the AIBL study. Mol Psychiatry &#xa0;2014; 19: 519&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">23628985</ArticleId></ArticleIdList></Reference><Reference><Citation>Cash DM &#xa0;Rohrer JD &#xa0;Ryan NS &#xa0;Ourselin S &#xa0;Fox NC. &#xa0;Imaging endpoints for clinical trials in Alzheimer&#x2019;s disease. Alz Res Therapy &#xa0;2014; 6: 87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4304258</ArticleId><ArticleId IdType="pubmed">25621018</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatterjee P &#xa0;Elmi M &#xa0;Goozee K &#xa0;Shah T &#xa0;Sohrabi HR &#xa0;Dias CB, et al. &#xa0;Ultrasensitive detection of plasma amyloid-beta as a biomarker for cognitively normal elderly individuals at risk of Alzheimer&#x2019;s disease. J Alzheimer Dis &#xa0;2019; 71: 775&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">31424403</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L &#xa0;Xu S &#xa0;Wu T &#xa0;Shao Y &#xa0;Luo L &#xa0;Zhou L, et al. &#xa0;Abnormal platelet amyloid&#x2010;&#x3b2; precursor protein metabolism in SAMP8 mice: evidence for peripheral marker in Alzheimer&#x2019;s disease. J Cell Physiol &#xa0;2019; 234: 23528&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">31183859</ArticleId></ArticleIdList></Reference><Reference><Citation>Ch&#xe9;telat G &#xa0;Villemagne VL &#xa0;Pike KE &#xa0;Baron J-C &#xa0;Bourgeat P &#xa0;Jones G, et al. &#xa0;Larger temporal volume in elderly with high versus low beta-amyloid deposition. Brain &#xa0;2010; 133: 3349&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">20739349</ArticleId></ArticleIdList></Reference><Reference><Citation>DeLong ER &#xa0;DeLong DM &#xa0;Clarke-Pearson DL. &#xa0;Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics &#xa0;1988; 44: 837&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">3203132</ArticleId></ArticleIdList></Reference><Reference><Citation>de Rojas I &#xa0;Romero J &#xa0;Rodriguez-Gomez O &#xa0;Pesini P &#xa0;Sanabria A &#xa0;Perez-Cordon A, on behalf of the FACEHBI study, et al. &#xa0;Correlations between plasma and PET beta-amyloid levels in individuals with subjective cognitive decline: the Fundacio ACE Healthy Brain Initiative (FACEHBI). Alz Res Therapy &#xa0;2018; 10: 119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6267075</ArticleId><ArticleId IdType="pubmed">30497535</ArticleId></ArticleIdList></Reference><Reference><Citation>DeTure MA &#xa0;Dickson DW. &#xa0;The neuropathological diagnosis of Alzheimer&#x2019;s disease. Mol Neurodegeneration &#xa0;2019; 14: 32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6679484</ArticleId><ArticleId IdType="pubmed">31375134</ArticleId></ArticleIdList></Reference><Reference><Citation>Donohue MC &#xa0;Sperling RA &#xa0;Petersen R &#xa0;Sun CK &#xa0;Weiner MW &#xa0;Aisen PS, for the Alzheimer&#x2019;s Disease Neuroimaging Initiative. Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons. J Am Med Assoc &#xa0;2017; 317: 2305&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5736301</ArticleId><ArticleId IdType="pubmed">28609533</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebenau JL &#xa0;Timmers T &#xa0;Wesselman LMP &#xa0;Verberk IMW &#xa0;Verfaillie SCJ &#xa0;Slot RER, et al. &#xa0;ATN classification and clinical progression in subjective cognitive decline: The SCIENCe project. Neurology &#xa0;2020; 95: e46&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7371376</ArticleId><ArticleId IdType="pubmed">32522798</ArticleId></ArticleIdList></Reference><Reference><Citation>Ezzati A &#xa0;Harvey DJ &#xa0;Habeck C &#xa0;Golzar A &#xa0;Qureshi IA &#xa0;Zammit AR, for the Alzheimer&#x2019;s Disease Neuroimaging Initiative, et al. &#xa0;Predicting amyloid-&#x3b2; levels in amnestic mild cognitive impairment using machine learning techniques. J Alzheimers Dis &#xa0;2020; 73: 1211&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7376527</ArticleId><ArticleId IdType="pubmed">31884486</ArticleId></ArticleIdList></Reference><Reference><Citation>Fandos N &#xa0;P&#xe9;rez-Grijalba V &#xa0;Pesini P &#xa0;Olmos S &#xa0;Bossa M &#xa0;Villemagne VL, AIBL Research Group, et al. &#xa0;Plasma amyloid &#x3b2; 42/40 ratios as biomarkers for amyloid &#x3b2; cerebral deposition in cognitively normal individuals. Alzheimers Dement &#xa0;2017; 8: 179&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5602863</ArticleId><ArticleId IdType="pubmed">28948206</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng Q &#xa0;Song Q &#xa0;Wang M &#xa0;Pang P &#xa0;Liao Z &#xa0;Jiang H, et al. &#xa0;Hippocampus radiomic biomarkers for the diagnosis of amnestic mild cognitive impairment: a machine learning method. Front Aging Neurosci &#xa0;2019; 11: 323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6881244</ArticleId><ArticleId IdType="pubmed">31824302</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-Delgado M &#xa0;Cernadas E &#xa0;Barro S &#xa0;Amorim DG. &#xa0;Do we need hundreds of classifiers to solve real world classification problems? &#xa0;J Mach Learn Res &#xa0;2014; 15: 3133&#x2013;81.</Citation></Reference><Reference><Citation>Frisoni GB &#xa0;Fox NC &#xa0;Jack CR Jr &#xa0;Scheltens P &#xa0;Thompson PM. &#xa0;The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol &#xa0;2010; 6: 67&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2938772</ArticleId><ArticleId IdType="pubmed">20139996</ArticleId></ArticleIdList></Reference><Reference><Citation>Goudey B &#xa0;Fung BJ &#xa0;Schieber C &#xa0;Faux NG, Alzheimer&#x2019;s Disease Metabolomics Consortium. Alzheimer&#x2019;s Disease Metabolomics C, Alzheimer's Disease Neuroimaging I. A blood-based signature of cerebrospinal fluid Abeta1-42 status. Sci Rep &#xa0;2019; 9: 4163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6409361</ArticleId><ArticleId IdType="pubmed">30853713</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanczar B &#xa0;Hua J &#xa0;Sima C &#xa0;Weinstein J &#xa0;Bittner M &#xa0;Dougherty ER. &#xa0;Small-sample precision of ROC-related estimates. Bioinformatics &#xa0;2010; 26: 822&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">20130029</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM. &#xa0;CSF biomarkers for Alzheimer&#x2019;s disease: current utility and potential future use. Neurobiol Aging &#xa0;2011; 32: S4&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3233690</ArticleId><ArticleId IdType="pubmed">22078172</ArticleId></ArticleIdList></Reference><Reference><Citation>Honig LS &#xa0;Vellas B &#xa0;Woodward M &#xa0;Boada M &#xa0;Bullock R &#xa0;Borrie M, et al. &#xa0;Trial of Solanezumab for mild dementia due to Alzheimer&#x2019;s disease. N Engl J Med &#xa0;2018; 378: 321&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">29365294</ArticleId></ArticleIdList></Reference><Reference><Citation>Insel PS &#xa0;Palmqvist S &#xa0;Mackin RS &#xa0;Nosheny RL &#xa0;Hansson O &#xa0;Weiner MW, Alzheimer&#x2019;s Disease Neuroimaging Initiative, et al. &#xa0;Assessing risk for preclinical &#x3b2;-amyloid pathology with APOE, cognitive, and demographic information. Alzheimer Dement &#xa0;2016; 4: 76&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5045949</ArticleId><ArticleId IdType="pubmed">27722193</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr &#xa0;Bennett DA &#xa0;Blennow K &#xa0;Carrillo MC &#xa0;Dunn B &#xa0;Haeberlein SB, et al. &#xa0;NIA-AA Research Framework: toward a biological definition of Alzheimer&#x2019;s disease. Alzheimers Dementia &#xa0;2018; 14: 535&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5958625</ArticleId><ArticleId IdType="pubmed">29653606</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr &#xa0;Shiung MM &#xa0;Gunter JL &#xa0;O'Brien PC &#xa0;Weigand SD &#xa0;Knopman DS, et al. &#xa0;Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology &#xa0;2004; 62: 591&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730165</ArticleId><ArticleId IdType="pubmed">14981176</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr &#xa0;Wiste HJ &#xa0;Therneau TM &#xa0;Weigand SD &#xa0;Knopman DS &#xa0;Mielke MM, et al. &#xa0;Associations of amyloid, tau, and neurodegeneration biomarker profiles with rates of memory decline among individuals without dementia. J Am Med Assoc &#xa0;2019; 321: 2316&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6582267</ArticleId><ArticleId IdType="pubmed">31211344</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagust WJ &#xa0;Landau SM &#xa0;Koeppe RA &#xa0;Reiman EM &#xa0;Chen K &#xa0;Mathis CA, et al. &#xa0;The Alzheimer&#x2019;s Disease Neuroimaging Initiative 2 PET Core: 2015. Alzheimers Dement &#xa0;2015; 11: 757&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4510459</ArticleId><ArticleId IdType="pubmed">26194311</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S &#xa0;Mattsson N &#xa0;Palmqvist S &#xa0;Smith R &#xa0;Beach TG &#xa0;Serrano GE, et al. &#xa0;Plasma P-tau181 in Alzheimer&#x2019;s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer&#x2019;s dementia. Nat Med &#xa0;2020a; 26: 379&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">32123385</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S &#xa0;Stomrud E &#xa0;Palmqvist S &#xa0;Zetterberg H &#xa0;van Westen D &#xa0;Jeromin A, et al. &#xa0;Plasma &#x3b2;-amyloid in Alzheimer&#x2019;s disease and vascular disease. Sci Rep &#xa0;2016; 6: 26801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4886210</ArticleId><ArticleId IdType="pubmed">27241045</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S &#xa0;Stomrud E &#xa0;Smith R &#xa0;Palmqvist S &#xa0;Mattsson N &#xa0;Airey DC, et al. &#xa0;Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer&#x2019;s disease. Nat Commun &#xa0;2020b; 11: 1683.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7125218</ArticleId><ArticleId IdType="pubmed">32246036</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen WJ &#xa0;Ossenkoppele R &#xa0;Tijms BM &#xa0;Fagan AM &#xa0;Hansson O &#xa0;Klunk WE, Amyloid Biomarker Study Group, et al. &#xa0;Association of cerebral amyloid-&#x3b2; aggregation with cognitive functioning in persons without dementia. JAMA Psychiatry &#xa0;2018; 75: 84&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5786156</ArticleId><ArticleId IdType="pubmed">29188296</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandel BM &#xa0;Avants BB &#xa0;Gee JC &#xa0;Arnold SE &#xa0;Wolk DA, for the Alzheimer&#x2019;s Disease Neuroimaging Initiative. Alzheimer&#x2019;s Disease Neuroimaging I. neuropsychological testing predicts cerebrospinal fluid amyloid-beta in mild cognitive impairment. J Alzheimers Dis &#xa0;2015; 46: 901&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4699841</ArticleId><ArticleId IdType="pubmed">25881908</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaneko N &#xa0;Nakamura A &#xa0;Washimi Y &#xa0;Kato T &#xa0;Sakurai T &#xa0;Arahata Y, et al. &#xa0;Novel plasma biomarker surrogating cerebral amyloid deposition. Proc Jpn Acad Ser B &#xa0;2014; 90: 353&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4324927</ArticleId><ArticleId IdType="pubmed">25391320</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang JH &#xa0;Korecka M &#xa0;Figurski MJ &#xa0;Toledo JB &#xa0;Blennow K &#xa0;Zetterberg H, Alzheimer's Disease Neuroimaging Initiative, et al. &#xa0;The Alzheimer&#x2019;s Disease Neuroimaging Initiative 2 Biomarker Core: a review of progress and plans. Alzheimer Dement 2015; 11: 772&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5127404</ArticleId><ArticleId IdType="pubmed">26194312</ArticleId></ArticleIdList></Reference><Reference><Citation>Karikari TK &#xa0;Pascoal TA &#xa0;Ashton NJ &#xa0;Janelidze S &#xa0;Benedet AL &#xa0;Rodriguez JL, et al. &#xa0;Blood phosphorylated tau 181 as a biomarker for Alzheimer&#x2019;s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol &#xa0;2020; 19: 422&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">32333900</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SE &#xa0;Woo S &#xa0;Kim SW &#xa0;Chin J &#xa0;Kim HJ &#xa0;Lee BI, et al. &#xa0;A nomogram for predicting amyloid PET positivity in amnestic mild cognitive impairment. J Alzheimers Dis &#xa0;2018; 66: 681&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">30320571</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE &#xa0;Engler H &#xa0;Nordberg A &#xa0;Wang Y &#xa0;Blomqvist G &#xa0;Holt DP, et al. &#xa0;Imaging brain amyloid in Alzheimers disease with Pittsburgh Compound-B. Ann Neurol &#xa0;2004; 55: 306&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Ko H &#xa0;Ihm JJ &#xa0;Kim HG, for the Alzheimer&#x2019;s Disease Neuroimaging Initiative. Alzheimer&#x2019;s Disease Neuroimaging I. Cognitive profiling related to cerebral amyloid beta burden using machine learning approaches. Front Aging Neurosci &#xa0;2019; 11: 95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6499028</ArticleId><ArticleId IdType="pubmed">31105554</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM &#xa0;Breault C &#xa0;Joshi AD &#xa0;Pontecorvo M &#xa0;Mathis CA &#xa0;Jagust WJ, et al. &#xa0;Amyloid-&#x3b2; imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. J Nucl Med &#xa0;2013; 54: 70&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3747730</ArticleId><ArticleId IdType="pubmed">23166389</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang A &#xa0;Weiner MW &#xa0;Tosun D. &#xa0;What can structural MRI tell about A/T/N staging? &#xa0;Alzheimers Dement &#xa0;2019; 15: 1237&#x2013;8.</Citation></Reference><Reference><Citation>Lantero Rodriguez J &#xa0;Karikari TK &#xa0;Su&#xe1;rez-Calvet M &#xa0;Troakes C &#xa0;King A &#xa0;Emersic A, et al. &#xa0;Plasma p-tau181 accurately predicts Alzheimer&#x2019;s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline. Acta Neuropathol &#xa0;2020; 140: 267&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7423866</ArticleId><ArticleId IdType="pubmed">32720099</ArticleId></ArticleIdList></Reference><Reference><Citation>LeCun Y &#xa0;Bengio Y &#xa0;Hinton G. &#xa0;Deep learning. Nature &#xa0;2015; 521: 436&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">26017442</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JH &#xa0;Byun MS &#xa0;Yi D &#xa0;Sohn BK &#xa0;Jeon SY &#xa0;Lee Y, et al. &#xa0;Prediction of cerebral amyloid with common information obtained from memory clinic practice. Front Aging Neurosci &#xa0;2018; 10: 309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6178978</ArticleId><ArticleId IdType="pubmed">30337868</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuzy A &#xa0;Chiotis K &#xa0;Lemoine L &#xa0;Gillberg P-G &#xa0;Almkvist O &#xa0;Rodriguez-Vieitez E, et al. &#xa0;Tau PET imaging in neurodegenerative tauopathies&#x2014;still a challenge. Mol Psychiatry &#xa0;2019; 24: 1112&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6756230</ArticleId><ArticleId IdType="pubmed">30635637</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin S-Y &#xa0;Lin K-J &#xa0;Lin P-C &#xa0;Huang C-C &#xa0;Chang C-C &#xa0;Lee Y-C, et al. &#xa0;Plasma amyloid assay as a pre-screening tool for amyloid positron emission tomography imaging in early stage Alzheimer&#x2019;s disease. Alz Res Therapy &#xa0;2019; 11: 111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6933740</ArticleId><ArticleId IdType="pubmed">31881963</ArticleId></ArticleIdList></Reference><Reference><Citation>Marquie M &#xa0;Normandin MD &#xa0;Vanderburg CR &#xa0;Costantino IM &#xa0;Bien EA &#xa0;Rycyna LG, et al. &#xa0;Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol &#xa0;2015; 78: 787&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4900162</ArticleId><ArticleId IdType="pubmed">26344059</ArticleId></ArticleIdList></Reference><Reference><Citation>Maserejian N &#xa0;Bian S &#xa0;Wang W &#xa0;Jaeger J &#xa0;Syrjanen JA &#xa0;Aakre J, et al. &#xa0;Practical algorithms for amyloid beta probability in subjective or mild cognitive impairmen. Alzheimers Dement &#xa0;2019; 11: 180.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6827360</ArticleId><ArticleId IdType="pubmed">31700988</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N &#xa0;Cullen NC &#xa0;Andreasson U &#xa0;Zetterberg H &#xa0;Blennow K. &#xa0;Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease. JAMA Neurol &#xa0;2019; 76: 791&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6583067</ArticleId><ArticleId IdType="pubmed">31009028</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM &#xa0;Knopman DS &#xa0;Chertkow H &#xa0;Hyman BT &#xa0;Jack CR Jr &#xa0;Kawas CH, et al. &#xa0;The diagnosis of dementia due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement &#xa0;2011; 7: 263&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Mielke MM &#xa0;Hagen CE &#xa0;Xu J &#xa0;Chai X &#xa0;Vemuri P &#xa0;Lowe VJ, et al. &#xa0;Plasma phospho-tau181 increases with Alzheimer&#x2019;s disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimers Dement &#xa0;2018; 14: 989&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6097897</ArticleId><ArticleId IdType="pubmed">29626426</ArticleId></ArticleIdList></Reference><Reference><Citation>Mielke MM &#xa0;Syrjanen JA &#xa0;Blennow K &#xa0;Zetterberg H &#xa0;Vemuri P &#xa0;Skoog I, et al. &#xa0;Plasma and CSF neurofilament light: relation to longitudinal neuroimaging and cognitive measures. Neurology &#xa0;2019; 93: e252&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6656645</ArticleId><ArticleId IdType="pubmed">31182505</ArticleId></ArticleIdList></Reference><Reference><Citation>Mielke MM &#xa0;Wiste HJ &#xa0;Weigand SD &#xa0;Knopman DS &#xa0;Lowe VJ &#xa0;Roberts RO, et al. &#xa0;Indicators of amyloid burden in a population-based study of cognitively normal elderly. Neurology &#xa0;2012; 79: 1570&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3475629</ArticleId><ArticleId IdType="pubmed">22972644</ArticleId></ArticleIdList></Reference><Reference><Citation>Moulder KL &#xa0;Besser LM &#xa0;Beekly D &#xa0;Blennow K &#xa0;Kukull W &#xa0;Morris JC. &#xa0;Factors influencing successful lumbar puncture in Alzheimer research. Alzheimer Dis Assoc Disord &#xa0;2017; 31: 287&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5699954</ArticleId><ArticleId IdType="pubmed">28891819</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura A &#xa0;Kaneko N &#xa0;Villemagne VL &#xa0;Kato T &#xa0;Doecke J &#xa0;Dor&#xe9; V, et al. &#xa0;High performance plasma amyloid-&#x3b2; biomarkers for Alzheimer&#x2019;s disease. Nature &#xa0;2018; 554: 249&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">29420472</ArticleId></ArticleIdList></Reference><Reference><Citation>Ovod V &#xa0;Ramsey KN &#xa0;Mawuenyega KG &#xa0;Bollinger JG &#xa0;Hicks T &#xa0;Schneider T, et al. &#xa0;Amyloid beta concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement &#xa0;2017; 13: 841&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5567785</ArticleId><ArticleId IdType="pubmed">28734653</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S &#xa0;Insel PS &#xa0;Zetterberg H &#xa0;Blennow K &#xa0;Brix B &#xa0;Stomrud E, the Alzheimer&#x2019;s Disease Neuroimaging Initiative, et al. &#xa0;Accurate risk estimation of beta-amyloid positivity to identify prodromal Alzheimer&#x2019;s disease: cross-validation study of practical algorithms. Alzheimers Dement. 2019a; 15: 194&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6374284</ArticleId><ArticleId IdType="pubmed">30365928</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S &#xa0;Janelidze S &#xa0;Quiroz YT &#xa0;Zetterberg H &#xa0;Lopera F &#xa0;Stomrud E, et al. &#xa0;Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. J Am Med Assoc &#xa0;2020; 324: 772&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7388060</ArticleId><ArticleId IdType="pubmed">32722745</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S &#xa0;Janelidze S &#xa0;Stomrud E &#xa0;Zetterberg H &#xa0;Karl J &#xa0;Zink K, et al. &#xa0;Performance of fully automated plasma assays as screening tests for Alzheimer disease-related beta-amyloid status. JAMA Neurol &#xa0;2019b; 76: 1060.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6593637</ArticleId><ArticleId IdType="pubmed">31233127</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S &#xa0;Mattsson N &#xa0;Hansson O, for the Alzheimer&#x2019;s Disease Neuroimaging Initiative. Cerebrospinal fluid analysis detects cerebral amyloid-&#x3b2; accumulation earlier than positron emission tomography. Brain &#xa0;2016; 139: 1226&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4806222</ArticleId><ArticleId IdType="pubmed">26936941</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JC &#xa0;Han SH &#xa0;Cho HJ &#xa0;Byun MS &#xa0;Yi D &#xa0;Choe YM, et al. &#xa0;Chemically treated plasma A&#x3b2; is a potential blood-based biomarker for screening cerebral amyloid deposition. Alzheimers Res Therapy &#xa0;2017; 9: 20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5361707</ArticleId><ArticleId IdType="pubmed">28330509</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JC &#xa0;Han SH &#xa0;Lee H &#xa0;Jeong H &#xa0;Byun MS &#xa0;Bae J, et al. &#xa0;Prognostic plasma protein panel for Abeta deposition in the brain in Alzheimer&#x2019;s disease. Prog Neurobiol &#xa0;2019; 183: 101690.</Citation><ArticleIdList><ArticleId IdType="pubmed">31605717</ArticleId></ArticleIdList></Reference><Reference><Citation>Payami H &#xa0;Grimslid H &#xa0;Oken B &#xa0;Camicioli R &#xa0;Sexton G &#xa0;Dame A, et al. &#xa0;A prospective study of cognitive health in the elderly (Oregon Brain Aging Study): effects of family history and apolipoprotein E genotype. Am J Hum Genet &#xa0;1997; 60: 948&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1712458</ArticleId><ArticleId IdType="pubmed">9106542</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Grijalba V &#xa0;Arbizu J &#xa0;Romero J &#xa0;Prieto E &#xa0;Pesini P &#xa0;Sarasa L, The AB255 Study Group, et al. &#xa0;Plasma Abeta42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study. Alz Res Therapy &#xa0;2019; 11: 96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6886187</ArticleId><ArticleId IdType="pubmed">31787105</ArticleId></ArticleIdList></Reference><Reference><Citation>Peskind E &#xa0;Nordberg A &#xa0;Darreh-Shori T &#xa0;Soininen H. &#xa0;Safety of lumbar puncture procedures in patients with Alzheimer&#x2019;s disease. Curr Alzheimers Res &#xa0;2009; 6: 290&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4035477</ArticleId><ArticleId IdType="pubmed">19519311</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC &#xa0;Aisen PS &#xa0;Beckett LA &#xa0;Donohue MC &#xa0;Gamst AC &#xa0;Harvey DJ, et al. &#xa0;Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology &#xa0;2010; 74: 201&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2809036</ArticleId><ArticleId IdType="pubmed">20042704</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrone PM &#xa0;Casamitjana A &#xa0;Falcon C &#xa0;Artigues M &#xa0;Operto G &#xa0;Cacciaglia R, for the Alzheimer&#x2019;s Disease Neuroimaging Initiative, et al. &#xa0;Prediction of amyloid pathology in cognitively unimpaired individuals using voxel-wise analysis of longitudinal structural brain MRI. Alzheimer Res Therapy &#xa0;2019; 11: 72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6698344</ArticleId><ArticleId IdType="pubmed">31421683</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranjbar S &#xa0;Velgos SN &#xa0;Dueck AC &#xa0;Geda YE &#xa0;Mitchell JR, The Alzheimer&#x2019;s Disease Neuroimaging Initiative. Brain MR radiomics to differentiate cognitive disorders. J Neuropsychiatry Clin Neurosci &#xa0;2019; 31: 210&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6626704</ArticleId><ArticleId IdType="pubmed">30636564</ArticleId></ArticleIdList></Reference><Reference><Citation>Roe CM &#xa0;Fagan AM &#xa0;Grant EA &#xa0;Hassenstab J &#xa0;Moulder KL &#xa0;Maue Dreyfus D, et al. &#xa0;Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology &#xa0;2013; 80: 1784&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3719431</ArticleId><ArticleId IdType="pubmed">23576620</ArticleId></ArticleIdList></Reference><Reference><Citation>Roher AE &#xa0;Esh CL &#xa0;Kokjohn TA &#xa0;Casta&#xf1;o EM &#xa0;Van Vickle GD &#xa0;Kalback WM, et al. &#xa0;Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer&#x2019;s disease. Alzheimers Dement &#xa0;2009; 5: 18&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2663406</ArticleId><ArticleId IdType="pubmed">19118806</ArticleId></ArticleIdList></Reference><Reference><Citation>Rozga M &#xa0;Bittner T &#xa0;Batrla R &#xa0;Karl J. &#xa0;Preanalytical sample handling recommendations for Alzheimer&#x2019;s disease plasma biomarkers. Alzheimers Dement &#xa0;2019; 11: 291&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6446057</ArticleId><ArticleId IdType="pubmed">30984815</ArticleId></ArticleIdList></Reference><Reference><Citation>Schilling LP &#xa0;Zimmer ER &#xa0;Shin M &#xa0;Leuzy A &#xa0;Pascoal TA &#xa0;Benedet AL, et al. &#xa0;Imaging Alzheimer&#x2019;s disease pathophysiology with PET. Dement Neuropsychol &#xa0;2016; 10: 79&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5642398</ArticleId><ArticleId IdType="pubmed">29213438</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindler SE &#xa0;Bollinger JG &#xa0;Ovod V &#xa0;Mawuenyega KG &#xa0;Li Y &#xa0;Gordon BA, et al. &#xa0;High-precision plasma beta-amyloid 42/40 predicts current and future brain amyloidosis. Neurology &#xa0;2019; 93: e1647&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6946467</ArticleId><ArticleId IdType="pubmed">31371569</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;ll M &#xa0;Ossenkoppele R &#xa0;Strandberg O &#xa0;Palmqvist S &#xa0;J&#xf6;gi J &#xa0;Ohlsson T, The Swedish BioFINDER study, et al. &#xa0;Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer&#x2019;s disease. Brain &#xa0;2017; 140: 2286&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">29050382</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xf8;rensen L &#xa0;Igel C &#xa0;Liv Hansen N &#xa0;Osler M &#xa0;Lauritzen M &#xa0;Rostrup E, for the Alzheimer&#x2019;s Disease Neuroimaging Initiative and the Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing, et al. &#xa0;Early detection of Alzheimer&#x2019;s disease using MRI hippocampal texture. Hum Brain Mapp &#xa0;2016; 37: 1148&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6867374</ArticleId><ArticleId IdType="pubmed">26686837</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA &#xa0;Rentz DM &#xa0;Johnson KA &#xa0;Karlawish J &#xa0;Donohue M &#xa0;Salmon DP, et al. &#xa0;The A4 study: stopping AD before symptoms begin? &#xa0;Sci Transl Med &#xa0;2014; 6: 228fs13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049292</ArticleId><ArticleId IdType="pubmed">24648338</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapiola T &#xa0;Alafuzoff I &#xa0;Herukka SK &#xa0;Parkkinen L &#xa0;Hartikainen P &#xa0;Soininen H, et al. &#xa0;Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol &#xa0;2009; 66: 382&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">19273758</ArticleId></ArticleIdList></Reference><Reference><Citation>Ten Kate M &#xa0;Redolfi A &#xa0;Peira E &#xa0;Bos I &#xa0;Vos SJ &#xa0;Vandenberghe R, et al. &#xa0;MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study. Alz Res Therapy &#xa0;2018; 10: 100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6161396</ArticleId><ArticleId IdType="pubmed">30261928</ArticleId></ArticleIdList></Reference><Reference><Citation>Thijssen EH &#xa0;La Joie R &#xa0;Wolf A &#xa0;Strom A &#xa0;Wang P &#xa0;Iaccarino L, Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) investigators, et al. &#xa0;Diagnostic value of plasma phosphorylated tau181 in Alzheimer&#x2019;s disease and frontotemporal lobar degeneration. Nat Med &#xa0;2020; 26: 387&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7101073</ArticleId><ArticleId IdType="pubmed">32123386</ArticleId></ArticleIdList></Reference><Reference><Citation>Tosun D &#xa0;Chen YF &#xa0;Yu P &#xa0;Sundell KL &#xa0;Suhy J &#xa0;Siemers E, Alzheimer&#x2019;s Disease Neuroimaging Initiative, et al. &#xa0;Amyloid status imputed from a multimodal classifier including structural MRI distinguishes progressors from nonprogressors in a mild Alzheimer&#x2019;s disease clinical trial cohort. Alzheimers Dement &#xa0;2016; 12: 977&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">27109039</ArticleId></ArticleIdList></Reference><Reference><Citation>Tosun D &#xa0;Joshi S &#xa0;Weiner MW, for the Alzheimer&#x2019;s Disease Neuroimaging Initiative. Neuroimaging predictors of brain amyloidosis in mild cognitive impairment. Ann Neurol &#xa0;2013; 74: 188&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4603555</ArticleId><ArticleId IdType="pubmed">23686534</ArticleId></ArticleIdList></Reference><Reference><Citation>Tosun D &#xa0;Joshi S &#xa0;Weiner MW, for the Alzheimer&#x2019;s Disease Neuroimaging Initiative. The Alzheimer&#x2019;s Disease Neuroimaging I. Multimodal MRI-based imputation of the Abeta+ in early mild cognitive impairment. Ann Clin Transl Neurol &#xa0;2014; 1: 160&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3981105</ArticleId><ArticleId IdType="pubmed">24729983</ArticleId></ArticleIdList></Reference><Reference><Citation>Tosun D &#xa0;Schuff N &#xa0;Mathis CA &#xa0;Jagust W &#xa0;Weiner MW, Alzheimer&#x2019;s Disease NeuroImaging Initiative. Initiative AsDN. Spatial patterns of brain amyloid-&#x3b2; burden and atrophy rate associations in mild cognitive impairment. Brain &#xa0;2011; 134: 1077&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3069703</ArticleId><ArticleId IdType="pubmed">21429865</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanschoren J &#xa0;Blockeel H &#xa0;Pfahringer B &#xa0;Holmes G. &#xa0;Experiment databases. Mach Learn &#xa0;2012; 87: 127&#x2013;58.</Citation></Reference><Reference><Citation>Verberk IMW &#xa0;Slot RE &#xa0;Verfaillie SCJ &#xa0;Heijst H &#xa0;Prins ND &#xa0;van Berckel BNM, et al. &#xa0;Plasma amyloid as prescreener for the earliest Alzheimer pathological changes. Ann Neurol &#xa0;2018; 84: 648&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6282982</ArticleId><ArticleId IdType="pubmed">30196548</ArticleId></ArticleIdList></Reference><Reference><Citation>Vergallo A &#xa0;Megret L &#xa0;Lista S &#xa0;Cavedo E &#xa0;Zetterberg H &#xa0;Blennow K, and the INSIGHT-preAD study group, et al. &#xa0;Plasma amyloid beta 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer&#x2019;s disease. Alzheimers Dement &#xa0;2019; 15: 764&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">31113759</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner MW &#xa0;Veitch DP &#xa0;Aisen PS &#xa0;Beckett LA &#xa0;Cairns NJ &#xa0;Green RC, Alzheimer&#x2019;s Disease Neuroimaging Initiative, et al. &#xa0;The Alzheimer&#x2019;s Disease Neuroimaging Initiative 3: continued innovation for clinical trial improvement. Alzheimers Dement &#xa0;2017; 13: 561&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5536850</ArticleId><ArticleId IdType="pubmed">27931796</ArticleId></ArticleIdList></Reference><Reference><Citation>Westwood S &#xa0;Baird AL &#xa0;Hye A &#xa0;Ashton NJ &#xa0;Nevado-Holgado AJ &#xa0;Anand SN, et al. &#xa0;Plasma protein biomarkers for the prediction of CSF amyloid and tau and [(18)F]-flutemetamol PET scan result. Front Aging Neurosci &#xa0;2018; 10: 409.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6297196</ArticleId><ArticleId IdType="pubmed">30618716</ArticleId></ArticleIdList></Reference><Reference><Citation>Zetterberg H. &#xa0;Blood-based biomarkers for Alzheimer&#x2019;s disease-An update. J Neurosci Methods &#xa0;2019; 319: 2&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">30352211</ArticleId></ArticleIdList></Reference><Reference><Citation>Zetterberg H &#xa0;Blennow K. &#xa0;Blood biomarkers: democratizing Alzheimer&#x2019;s diagnostics. Neuron &#xa0;2020; 106: 881&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">32553204</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">6824945</PMID><DateCompleted><Year>1983</Year><Month>04</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0006-8993</ISSN><JournalIssue CitedMedium="Print"><Volume>259</Volume><Issue>2</Issue><PubDate><Year>1983</Year><Month>Jan</Month><Day>24</Day></PubDate></JournalIssue><Title>Brain research</Title><ISOAbbreviation>Brain Res</ISOAbbreviation></Journal><ArticleTitle>The isolation and amino acid composition of senile plaque core protein.</ArticleTitle><Pagination><StartPage>348</StartPage><EndPage>352</EndPage><MedlinePgn>348-52</MedlinePgn></Pagination><Abstract><AbstractText>A new method has been developed for the isolation of intact senile (neuritic) plaque cores from post-mortem brains of patients with Alzheimer's disease. The plaque cores were found to be insoluble in various protein denaturants. The amino acid composition of the plaque core protein does not resemble that of any known form of amyloid.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Allsop</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Landon</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Kidd</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Brain Res</MedlineTA><NlmUniqueID>0045503</NlmUniqueID><ISSNLinking>0006-8993</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000596">Amino Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000596" MajorTopicYN="N">Amino Acids</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009454" MajorTopicYN="N">Neurofibrils</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1983</Year><Month>1</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1983</Year><Month>1</Month><Day>24</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1983</Year><Month>1</Month><Day>24</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">6824945</ArticleId><ArticleId IdType="doi">10.1016/0006-8993(83)91273-8</ArticleId><ArticleId IdType="pii">0006-8993(83)91273-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">33884297</PMID><DateRevised><Year>2025</Year><Month>01</Month><Day>07</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2376-7839</ISSN><JournalIssue CitedMedium="Print"><Volume>7</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Neurology. Genetics</Title><ISOAbbreviation>Neurol Genet</ISOAbbreviation></Journal><ArticleTitle>African Americans Have Differences in CSF Soluble TREM2 and Associated Genetic Variants.</ArticleTitle><Pagination><StartPage>e571</StartPage><MedlinePgn>e571</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e571</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1212/NXG.0000000000000571</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate for racial differences in triggering receptor expressed on myeloid cells 2 (TREM2), a key immune mediator in Alzheimer disease, the levels of CSF soluble TREM2 (sTREM2), and the frequency of associated genetic variants were compared in groups of individuals who self-reported their race as African American (AA) or non-Hispanic White (NHW).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Community-dwelling older research participants underwent measurement of CSF sTREM2 concentrations and genetic analyses.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The primary cohort included 91 AAs and 868 NHWs. CSF sTREM2 levels were lower in the AA compared with the NHW group (1,336 &#xb1; 470 vs 1,856 &#xb1; 624 pg/mL, <i>p</i> &lt; 0.0001). AAs were more likely to carry <i>TREM2</i> coding variants (15% vs 3%, <i>p</i> &lt; 0.0001), which were associated with lower CSF sTREM2. AAs were less likely to carry the rs1582763 minor allele (8% vs 37%, <i>p</i> &lt; 0.0001), located near <i>MS4A4A</i>, which was associated with higher CSF sTREM2. These findings were replicated in an independent cohort of 23 AAs and 917 NHWs: CSF sTREM2 levels were lower in the AA group (<i>p</i> = 0.03), AAs were more likely to carry coding <i>TREM2</i> variants (22% vs 4%, <i>p</i> = 0.002), and AAs were less likely to carry the rs1582763 minor allele (16% vs 37%, <i>p</i> = 0.003).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">On average, AAs had lower CSF sTREM2 levels compared with NHWs, potentially because AAs are more likely to carry genetic variants associated with lower CSF sTREM2 levels. Importantly, CSF sTREM2 reflects TREM2-mediated microglial activity, a critical step in the immune response to amyloid plaques. These findings suggest that race may be associated with risk for genetic variants that influence Alzheimer disease-related inflammation.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schindler</LastName><ForeName>Suzanne E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Department of Neurology (S.E.S., A.J., R.L.H., R.J.M., L.P., J.J.L.-G., K.L.M., A.M.F., D.M.H., J.C.M.), Department of Psychiatry (C.C., F.H.G.F.), and Division of Biostatistics (L.M., C.X.), Washington University School of Medicine, St. Louis, MO; Office of Health Equity and Department of Medicine (C.H.W.), Division of Geriatrics, Vanderbilt University Medical Center, Nashville, TN; Department of Internal Medicine (C.H.W.), Meharry Medical College, Nashville, TN; Alzheimers Disease Research Center (Y.D.), University of Wisconsin School of Medicine and Public Health, Madison; Brain and Mind Centre (L.P.), University of Sydney, NSW, Australia; and Mallinckrodt Institute of Radiology (B.M.A., T.L.S.B.), Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cruchaga</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology (S.E.S., A.J., R.L.H., R.J.M., L.P., J.J.L.-G., K.L.M., A.M.F., D.M.H., J.C.M.), Department of Psychiatry (C.C., F.H.G.F.), and Division of Biostatistics (L.M., C.X.), Washington University School of Medicine, St. Louis, MO; Office of Health Equity and Department of Medicine (C.H.W.), Division of Geriatrics, Vanderbilt University Medical Center, Nashville, TN; Department of Internal Medicine (C.H.W.), Meharry Medical College, Nashville, TN; Alzheimers Disease Research Center (Y.D.), University of Wisconsin School of Medicine and Public Health, Madison; Brain and Mind Centre (L.P.), University of Sydney, NSW, Australia; and Mallinckrodt Institute of Radiology (B.M.A., T.L.S.B.), Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joseph</LastName><ForeName>Amulya</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology (S.E.S., A.J., R.L.H., R.J.M., L.P., J.J.L.-G., K.L.M., A.M.F., D.M.H., J.C.M.), Department of Psychiatry (C.C., F.H.G.F.), and Division of Biostatistics (L.M., C.X.), Washington University School of Medicine, St. Louis, MO; Office of Health Equity and Department of Medicine (C.H.W.), Division of Geriatrics, Vanderbilt University Medical Center, Nashville, TN; Department of Internal Medicine (C.H.W.), Meharry Medical College, Nashville, TN; Alzheimers Disease Research Center (Y.D.), University of Wisconsin School of Medicine and Public Health, Madison; Brain and Mind Centre (L.P.), University of Sydney, NSW, Australia; and Mallinckrodt Institute of Radiology (B.M.A., T.L.S.B.), Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCue</LastName><ForeName>Lena</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology (S.E.S., A.J., R.L.H., R.J.M., L.P., J.J.L.-G., K.L.M., A.M.F., D.M.H., J.C.M.), Department of Psychiatry (C.C., F.H.G.F.), and Division of Biostatistics (L.M., C.X.), Washington University School of Medicine, St. Louis, MO; Office of Health Equity and Department of Medicine (C.H.W.), Division of Geriatrics, Vanderbilt University Medical Center, Nashville, TN; Department of Internal Medicine (C.H.W.), Meharry Medical College, Nashville, TN; Alzheimers Disease Research Center (Y.D.), University of Wisconsin School of Medicine and Public Health, Madison; Brain and Mind Centre (L.P.), University of Sydney, NSW, Australia; and Mallinckrodt Institute of Radiology (B.M.A., T.L.S.B.), Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farias</LastName><ForeName>Fabiana H G</ForeName><Initials>FHG</Initials><AffiliationInfo><Affiliation>Department of Neurology (S.E.S., A.J., R.L.H., R.J.M., L.P., J.J.L.-G., K.L.M., A.M.F., D.M.H., J.C.M.), Department of Psychiatry (C.C., F.H.G.F.), and Division of Biostatistics (L.M., C.X.), Washington University School of Medicine, St. Louis, MO; Office of Health Equity and Department of Medicine (C.H.W.), Division of Geriatrics, Vanderbilt University Medical Center, Nashville, TN; Department of Internal Medicine (C.H.W.), Meharry Medical College, Nashville, TN; Alzheimers Disease Research Center (Y.D.), University of Wisconsin School of Medicine and Public Health, Madison; Brain and Mind Centre (L.P.), University of Sydney, NSW, Australia; and Mallinckrodt Institute of Radiology (B.M.A., T.L.S.B.), Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilkins</LastName><ForeName>Consuelo H</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Department of Neurology (S.E.S., A.J., R.L.H., R.J.M., L.P., J.J.L.-G., K.L.M., A.M.F., D.M.H., J.C.M.), Department of Psychiatry (C.C., F.H.G.F.), and Division of Biostatistics (L.M., C.X.), Washington University School of Medicine, St. Louis, MO; Office of Health Equity and Department of Medicine (C.H.W.), Division of Geriatrics, Vanderbilt University Medical Center, Nashville, TN; Department of Internal Medicine (C.H.W.), Meharry Medical College, Nashville, TN; Alzheimers Disease Research Center (Y.D.), University of Wisconsin School of Medicine and Public Health, Madison; Brain and Mind Centre (L.P.), University of Sydney, NSW, Australia; and Mallinckrodt Institute of Radiology (B.M.A., T.L.S.B.), Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deming</LastName><ForeName>Yuetiva</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-7512-5703</Identifier><AffiliationInfo><Affiliation>Department of Neurology (S.E.S., A.J., R.L.H., R.J.M., L.P., J.J.L.-G., K.L.M., A.M.F., D.M.H., J.C.M.), Department of Psychiatry (C.C., F.H.G.F.), and Division of Biostatistics (L.M., C.X.), Washington University School of Medicine, St. Louis, MO; Office of Health Equity and Department of Medicine (C.H.W.), Division of Geriatrics, Vanderbilt University Medical Center, Nashville, TN; Department of Internal Medicine (C.H.W.), Meharry Medical College, Nashville, TN; Alzheimers Disease Research Center (Y.D.), University of Wisconsin School of Medicine and Public Health, Madison; Brain and Mind Centre (L.P.), University of Sydney, NSW, Australia; and Mallinckrodt Institute of Radiology (B.M.A., T.L.S.B.), Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henson</LastName><ForeName>Rachel L</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>Department of Neurology (S.E.S., A.J., R.L.H., R.J.M., L.P., J.J.L.-G., K.L.M., A.M.F., D.M.H., J.C.M.), Department of Psychiatry (C.C., F.H.G.F.), and Division of Biostatistics (L.M., C.X.), Washington University School of Medicine, St. Louis, MO; Office of Health Equity and Department of Medicine (C.H.W.), Division of Geriatrics, Vanderbilt University Medical Center, Nashville, TN; Department of Internal Medicine (C.H.W.), Meharry Medical College, Nashville, TN; Alzheimers Disease Research Center (Y.D.), University of Wisconsin School of Medicine and Public Health, Madison; Brain and Mind Centre (L.P.), University of Sydney, NSW, Australia; and Mallinckrodt Institute of Radiology (B.M.A., T.L.S.B.), Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mikesell</LastName><ForeName>Robert J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Neurology (S.E.S., A.J., R.L.H., R.J.M., L.P., J.J.L.-G., K.L.M., A.M.F., D.M.H., J.C.M.), Department of Psychiatry (C.C., F.H.G.F.), and Division of Biostatistics (L.M., C.X.), Washington University School of Medicine, St. Louis, MO; Office of Health Equity and Department of Medicine (C.H.W.), Division of Geriatrics, Vanderbilt University Medical Center, Nashville, TN; Department of Internal Medicine (C.H.W.), Meharry Medical College, Nashville, TN; Alzheimers Disease Research Center (Y.D.), University of Wisconsin School of Medicine and Public Health, Madison; Brain and Mind Centre (L.P.), University of Sydney, NSW, Australia; and Mallinckrodt Institute of Radiology (B.M.A., T.L.S.B.), Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piccio</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology (S.E.S., A.J., R.L.H., R.J.M., L.P., J.J.L.-G., K.L.M., A.M.F., D.M.H., J.C.M.), Department of Psychiatry (C.C., F.H.G.F.), and Division of Biostatistics (L.M., C.X.), Washington University School of Medicine, St. Louis, MO; Office of Health Equity and Department of Medicine (C.H.W.), Division of Geriatrics, Vanderbilt University Medical Center, Nashville, TN; Department of Internal Medicine (C.H.W.), Meharry Medical College, Nashville, TN; Alzheimers Disease Research Center (Y.D.), University of Wisconsin School of Medicine and Public Health, Madison; Brain and Mind Centre (L.P.), University of Sydney, NSW, Australia; and Mallinckrodt Institute of Radiology (B.M.A., T.L.S.B.), Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Llibre-Guerra</LastName><ForeName>Jorge J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Neurology (S.E.S., A.J., R.L.H., R.J.M., L.P., J.J.L.-G., K.L.M., A.M.F., D.M.H., J.C.M.), Department of Psychiatry (C.C., F.H.G.F.), and Division of Biostatistics (L.M., C.X.), Washington University School of Medicine, St. Louis, MO; Office of Health Equity and Department of Medicine (C.H.W.), Division of Geriatrics, Vanderbilt University Medical Center, Nashville, TN; Department of Internal Medicine (C.H.W.), Meharry Medical College, Nashville, TN; Alzheimers Disease Research Center (Y.D.), University of Wisconsin School of Medicine and Public Health, Madison; Brain and Mind Centre (L.P.), University of Sydney, NSW, Australia; and Mallinckrodt Institute of Radiology (B.M.A., T.L.S.B.), Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moulder</LastName><ForeName>Krista L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Department of Neurology (S.E.S., A.J., R.L.H., R.J.M., L.P., J.J.L.-G., K.L.M., A.M.F., D.M.H., J.C.M.), Department of Psychiatry (C.C., F.H.G.F.), and Division of Biostatistics (L.M., C.X.), Washington University School of Medicine, St. Louis, MO; Office of Health Equity and Department of Medicine (C.H.W.), Division of Geriatrics, Vanderbilt University Medical Center, Nashville, TN; Department of Internal Medicine (C.H.W.), Meharry Medical College, Nashville, TN; Alzheimers Disease Research Center (Y.D.), University of Wisconsin School of Medicine and Public Health, Madison; Brain and Mind Centre (L.P.), University of Sydney, NSW, Australia; and Mallinckrodt Institute of Radiology (B.M.A., T.L.S.B.), Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Neurology (S.E.S., A.J., R.L.H., R.J.M., L.P., J.J.L.-G., K.L.M., A.M.F., D.M.H., J.C.M.), Department of Psychiatry (C.C., F.H.G.F.), and Division of Biostatistics (L.M., C.X.), Washington University School of Medicine, St. Louis, MO; Office of Health Equity and Department of Medicine (C.H.W.), Division of Geriatrics, Vanderbilt University Medical Center, Nashville, TN; Department of Internal Medicine (C.H.W.), Meharry Medical College, Nashville, TN; Alzheimers Disease Research Center (Y.D.), University of Wisconsin School of Medicine and Public Health, Madison; Brain and Mind Centre (L.P.), University of Sydney, NSW, Australia; and Mallinckrodt Institute of Radiology (B.M.A., T.L.S.B.), Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ances</LastName><ForeName>Beau M</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>Department of Neurology (S.E.S., A.J., R.L.H., R.J.M., L.P., J.J.L.-G., K.L.M., A.M.F., D.M.H., J.C.M.), Department of Psychiatry (C.C., F.H.G.F.), and Division of Biostatistics (L.M., C.X.), Washington University School of Medicine, St. Louis, MO; Office of Health Equity and Department of Medicine (C.H.W.), Division of Geriatrics, Vanderbilt University Medical Center, Nashville, TN; Department of Internal Medicine (C.H.W.), Meharry Medical College, Nashville, TN; Alzheimers Disease Research Center (Y.D.), University of Wisconsin School of Medicine and Public Health, Madison; Brain and Mind Centre (L.P.), University of Sydney, NSW, Australia; and Mallinckrodt Institute of Radiology (B.M.A., T.L.S.B.), Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benzinger</LastName><ForeName>Tammie L S</ForeName><Initials>TLS</Initials><AffiliationInfo><Affiliation>Department of Neurology (S.E.S., A.J., R.L.H., R.J.M., L.P., J.J.L.-G., K.L.M., A.M.F., D.M.H., J.C.M.), Department of Psychiatry (C.C., F.H.G.F.), and Division of Biostatistics (L.M., C.X.), Washington University School of Medicine, St. Louis, MO; Office of Health Equity and Department of Medicine (C.H.W.), Division of Geriatrics, Vanderbilt University Medical Center, Nashville, TN; Department of Internal Medicine (C.H.W.), Meharry Medical College, Nashville, TN; Alzheimers Disease Research Center (Y.D.), University of Wisconsin School of Medicine and Public Health, Madison; Brain and Mind Centre (L.P.), University of Sydney, NSW, Australia; and Mallinckrodt Institute of Radiology (B.M.A., T.L.S.B.), Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Chengjie</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology (S.E.S., A.J., R.L.H., R.J.M., L.P., J.J.L.-G., K.L.M., A.M.F., D.M.H., J.C.M.), Department of Psychiatry (C.C., F.H.G.F.), and Division of Biostatistics (L.M., C.X.), Washington University School of Medicine, St. Louis, MO; Office of Health Equity and Department of Medicine (C.H.W.), Division of Geriatrics, Vanderbilt University Medical Center, Nashville, TN; Department of Internal Medicine (C.H.W.), Meharry Medical College, Nashville, TN; Alzheimers Disease Research Center (Y.D.), University of Wisconsin School of Medicine and Public Health, Madison; Brain and Mind Centre (L.P.), University of Sydney, NSW, Australia; and Mallinckrodt Institute of Radiology (B.M.A., T.L.S.B.), Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Neurology (S.E.S., A.J., R.L.H., R.J.M., L.P., J.J.L.-G., K.L.M., A.M.F., D.M.H., J.C.M.), Department of Psychiatry (C.C., F.H.G.F.), and Division of Biostatistics (L.M., C.X.), Washington University School of Medicine, St. Louis, MO; Office of Health Equity and Department of Medicine (C.H.W.), Division of Geriatrics, Vanderbilt University Medical Center, Nashville, TN; Department of Internal Medicine (C.H.W.), Meharry Medical College, Nashville, TN; Alzheimers Disease Research Center (Y.D.), University of Wisconsin School of Medicine and Public Health, Madison; Brain and Mind Centre (L.P.), University of Sydney, NSW, Australia; and Mallinckrodt Institute of Radiology (B.M.A., T.L.S.B.), Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Neurology (S.E.S., A.J., R.L.H., R.J.M., L.P., J.J.L.-G., K.L.M., A.M.F., D.M.H., J.C.M.), Department of Psychiatry (C.C., F.H.G.F.), and Division of Biostatistics (L.M., C.X.), Washington University School of Medicine, St. Louis, MO; Office of Health Equity and Department of Medicine (C.H.W.), Division of Geriatrics, Vanderbilt University Medical Center, Nashville, TN; Department of Internal Medicine (C.H.W.), Meharry Medical College, Nashville, TN; Alzheimers Disease Research Center (Y.D.), University of Wisconsin School of Medicine and Public Health, Madison; Brain and Mind Centre (L.P.), University of Sydney, NSW, Australia; and Mallinckrodt Institute of Radiology (B.M.A., T.L.S.B.), Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG066444</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG053426</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG044546</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG058501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG000213</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R03 AG050921</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>03</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurol Genet</MedlineTA><NlmUniqueID>101671068</NlmUniqueID><ISSNLinking>2376-7839</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Neurol Genet. 2021 May 3;7(3):e594. doi: 10.1212/NXG.0000000000000594.</RefSource><PMID Version="1">33959678</PMID></CommentsCorrections></CommentsCorrectionsList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>10</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>1</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>22</Day><Hour>6</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>3</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33884297</ArticleId><ArticleId IdType="pmc">PMC8054965</ArticleId><ArticleId IdType="doi">10.1212/NXG.0000000000000571</ArticleId><ArticleId IdType="pii">NG2020016352</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Babulal GM, Quiroz YT, Albensi BC, et al. . Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: update and areas of immediate need. Alzheimers Dement 2019;15:292&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6368893</ArticleId><ArticleId IdType="pubmed">30555031</ArticleId></ArticleIdList></Reference><Reference><Citation>Howell JC, Watts KD, Parker MW, et al. . Race modifies the relationship between cognition and Alzheimer's disease cerebrospinal fluid biomarkers. Alzheimers Res Ther 2017;9:88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5668981</ArticleId><ArticleId IdType="pubmed">29096697</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottesman RF, Schneider AL, Zhou Y, et al. . The ARIC-PET amyloid imaging study: brain amyloid differences by age, race, sex, and APOE. Neurology 2016;87:473&#x2013;480.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4970663</ArticleId><ArticleId IdType="pubmed">27371485</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Schindler SE, McCue LM, et al. . Assessment of racial disparities in biomarkers for Alzheimer disease. JAMA Neurol 2019;76:264&#x2013;273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6439726</ArticleId><ArticleId IdType="pubmed">30615028</ArticleId></ArticleIdList></Reference><Reference><Citation>Garrett SL, McDaniel D, Obideen M, et al. . Racial disparity in cerebrospinal fluid amyloid and tau biomarkers and associated cutoffs for mild cognitive impairment. JAMA Netw Open 2019;2:e1917363.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6991300</ArticleId><ArticleId IdType="pubmed">31834392</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonham VL, Green ED, Perez-Stable EJ. Examining how race, ethnicity, and ancestry data are used in biomedical research. JAMA 2018;320:1533&#x2013;1534.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6640836</ArticleId><ArticleId IdType="pubmed">30264136</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaffe K, Falvey C, Harris TB, et al. . Effect of socioeconomic disparities on incidence of dementia among biracial older adults: prospective study. BMJ 2013;347:f7051.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3898154</ArticleId><ArticleId IdType="pubmed">24355614</ArticleId></ArticleIdList></Reference><Reference><Citation>Gross AL, Mungas DM, Crane PK, et al. . Effects of education and race on cognitive decline: an integrative study of generalizability versus study-specific results. Psychol Aging 2015;30:863&#x2013;880.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4679562</ArticleId><ArticleId IdType="pubmed">26523693</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilsanz P, Quesenberry CP Jr, Mayeda ER, Glymour MM, Farias ST, Whitmer RA. Stressors in midlife and risk of dementia: the role of race and education. Alzheimer Dis Assoc Disord 2019;33:200&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6710152</ArticleId><ArticleId IdType="pubmed">31058684</ArticleId></ArticleIdList></Reference><Reference><Citation>Reitz C, Jun G, Naj A, et al. . Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein E 4,and the risk of late-onset Alzheimer disease in African Americans. JAMA 2013;309:1483&#x2013;1492.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3667653</ArticleId><ArticleId IdType="pubmed">23571587</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Cella M, Mallinson K, et al. . TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. Cell 2015;160:1061&#x2013;1071.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, Wu X, Li X, et al. . TREM2 is a receptor for beta-amyloid that mediates microglial function. Neuron 2018;97:1023&#x2013;1031.e7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5889092</ArticleId><ArticleId IdType="pubmed">29518356</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, Wojtas A, Bras J, et al. . TREM2 variants in Alzheimer's disease. N Engl J Med 2013;368:117&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, Stefansson H, Steinberg S, et al. . Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med 2013;368:107&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin SC, Benitez BA, Karch CM, et al. . Coding variants in TREM2 increase risk for Alzheimer's disease. Hum Mol Genet 2014;23:5838&#x2013;5846.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4189899</ArticleId><ArticleId IdType="pubmed">24899047</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich JD, Holtzman DM. TREM2 function in Alzheimer's disease and neurodegeneration. ACS Chem Neurosci 2016;7:420&#x2013;427.</Citation><ArticleIdList><ArticleId IdType="pubmed">26854967</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin SC, Carrasquillo MM, Benitez BA, et al. . TREM2 is associated with increased risk for Alzheimer's disease in African Americans. Mol Neurodegener 2015;10:19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4426167</ArticleId><ArticleId IdType="pubmed">25886450</ArticleId></ArticleIdList></Reference><Reference><Citation>Del-Aguila JL, Benitez BA, Li Z, et al. . TREM2 brain transcript-specific studies in AD and TREM2 mutation carriers. Mol Neurodegener 2019;14:18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6505298</ArticleId><ArticleId IdType="pubmed">31068200</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleinberger G, Yamanishi Y, Suarez-Calvet M, et al. . TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci Transl Med 2014;6:243ra286.</Citation><ArticleIdList><ArticleId IdType="pubmed">24990881</ArticleId></ArticleIdList></Reference><Reference><Citation>Ewers M, Franzmeier N, Suarez-Calvet M, et al. . Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimer's disease. Sci Transl Med 2019;11:eaav6221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7050285</ArticleId><ArticleId IdType="pubmed">31462511</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccio L, Deming Y, Del-Aguila JL, et al. . Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status. Acta Neuropathol 2016;131:925&#x2013;933.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4867123</ArticleId><ArticleId IdType="pubmed">26754641</ArticleId></ArticleIdList></Reference><Reference><Citation>Deming Y, Filipello F, Cignarella F, et al. . The MS4A gene cluster is a key modulator of soluble TREM2 and Alzheimer's disease risk. Sci Transl Med 2019;11:eaau2291.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6697053</ArticleId><ArticleId IdType="pubmed">31413141</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Ibrahim-Verbaas CA, Harold D, et al. . Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet 2013;45:1452&#x2013;1458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Weintraub S, Chui HC, et al. . The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord 2006;20:210&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">17132964</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruchaga C, Kauwe JS, Mayo K, et al. . SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease. PLoS Genet 2010;6:e1001101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2940763</ArticleId><ArticleId IdType="pubmed">20862329</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience 2015;4:7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4342193</ArticleId><ArticleId IdType="pubmed">25722852</ArticleId></ArticleIdList></Reference><Reference><Citation>Pemberton TJ, Wang C, Li JZ, Rosenberg NA. Inference of unexpected genetic relatedness among individuals in HapMap Phase III. Am J Hum Genet 2010;87:457&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2948801</ArticleId><ArticleId IdType="pubmed">20869033</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindler SE, Gray JD, Gordon BA, et al. . Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging. Alzheimers Dement 2018;14:1460&#x2013;1469.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6119652</ArticleId><ArticleId IdType="pubmed">29501462</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkins CH, Schindler SE, Morris JC. Addressing health disparities among minority populations: why clinical trial recruitment is not enough. JAMA Neurol 2020;77:1063&#x2013;1064.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7983552</ArticleId><ArticleId IdType="pubmed">32539100</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CYD, Daggett A, Gu X, et al. . Elevated TREM2 gene dosage reprograms microglia responsivity and ameliorates pathological phenotypes in Alzheimer's disease models. Neuron 2018;97:1032&#x2013;1048.e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5927822</ArticleId><ArticleId IdType="pubmed">29518357</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Ulland TK, Ulrich JD, et al. . TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. J Exp Med 2016;213:667&#x2013;675.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4854736</ArticleId><ArticleId IdType="pubmed">27091843</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan P, Condello C, Keene CD, et al. . TREM2 haplodeficiency in mice and humans impairs the microglia barrier function leading to decreased amyloid compaction and severe axonal dystrophy. Neuron 2016;92:252&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">27710785</ArticleId></ArticleIdList></Reference><Reference><Citation>Leyns CEG, Gratuze M, Narasimhan S, et al. . TREM2 function impedes tau seeding in neuritic plaques. Nat Neurosci 2019;22:1217&#x2013;1222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6660358</ArticleId><ArticleId IdType="pubmed">31235932</ArticleId></ArticleIdList></Reference><Reference><Citation>Suarez-Calvet M, Kleinberger G, Araque Caballero MA, et al. . sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers. EMBO Mol Med 2016;8:466&#x2013;476.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5120370</ArticleId><ArticleId IdType="pubmed">26941262</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K. Alzheimer's disease drug development pipeline: 2019. Alzheimers Dement 2019;5:272&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6617248</ArticleId><ArticleId IdType="pubmed">31334330</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang X, Werner G, Bohrmann B, et al. . TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearance. EMBO Mol Med 2016;8:992&#x2013;1004.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5009806</ArticleId><ArticleId IdType="pubmed">27402340</ArticleId></ArticleIdList></Reference><Reference><Citation>Honig LS, Vellas B, Woodward M, et al. . Trial of solanezumab for mild dementia due to Alzheimer's disease. N Engl J Med 2018;378:321&#x2013;330.</Citation><ArticleIdList><ArticleId IdType="pubmed">29365294</ArticleId></ArticleIdList></Reference><Reference><Citation>Egan MF, Kost J, Tariot PN, et al. . Randomized trial of verubecestat for mild-to-moderate Alzheimer's disease. N Engl J Med 2018;378:1691&#x2013;1703.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6776074</ArticleId><ArticleId IdType="pubmed">29719179</ArticleId></ArticleIdList></Reference><Reference><Citation>Kober DL, Brett TJ. TREM2-ligand interactions in health and disease. J Mol Biol 2017;429:1607&#x2013;1629.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5485854</ArticleId><ArticleId IdType="pubmed">28432014</ArticleId></ArticleIdList></Reference><Reference><Citation>Steenland K, Goldstein FC, Levey A, Wharton W. A meta-analysis of Alzheimer's disease incidence and prevalence comparing African-Americans and Caucasians. J Alzheimers Dis 2016;50:71&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4739787</ArticleId><ArticleId IdType="pubmed">26639973</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayeda ER, Glymour MM, Quesenberry CP, Whitmer RA. Inequalities in dementia incidence between six racial and ethnic groups over 14 years. Alzheimers Dement 2016;12:216&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4969071</ArticleId><ArticleId IdType="pubmed">26874595</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong C, Luo J, Coble D, Agboola F, Kukull W, Morris JC. Complex interactions underlie racial disparity in the risk of developing Alzheimer's disease dementia. Alzheimers Dement 2020;16:589&#x2013;597.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7259475</ArticleId><ArticleId IdType="pubmed">32067357</ArticleId></ArticleIdList></Reference><Reference><Citation>Bridel C, van Wieringen WN, Zetterberg H, et al. . Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis. JAMA Neurol 2019;76:1035&#x2013;1048.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6580449</ArticleId><ArticleId IdType="pubmed">31206160</ArticleId></ArticleIdList></Reference><Reference><Citation>George S, Duran N, Norris K. A systematic review of barriers and facilitators to minority research participation among African Americans, Latinos, Asian Americans, and Pacific Islanders. Am J Public Health 2014;104:e16&#x2013;e31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3935672</ArticleId><ArticleId IdType="pubmed">24328648</ArticleId></ArticleIdList></Reference><Reference><Citation>Pernick MS. Eugenics and public health in American history. Am J Public Health 1997;87:1767&#x2013;1772.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1381159</ArticleId><ArticleId IdType="pubmed">9366633</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J, Kraja AT, Oberman A, et al. . A summary of the effects of antihypertensive medications on measured blood pressure. Am J Hypertens 2005;18:935&#x2013;942.</Citation><ArticleIdList><ArticleId IdType="pubmed">16053990</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34031600</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>7</Issue><PubDate><Year>2021</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Genome-wide CRISPRi/a screens in human neurons link lysosomal failure to ferroptosis.</ArticleTitle><Pagination><StartPage>1020</StartPage><EndPage>1034</EndPage><MedlinePgn>1020-1034</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41593-021-00862-0</ELocationID><Abstract><AbstractText>Single-cell transcriptomics provide a systematic map of gene expression in different human cell types. The next challenge is to systematically understand cell-type-specific gene function. The integration of CRISPR-based functional genomics and stem cell technology enables the scalable interrogation of gene function in differentiated human cells. Here we present the first genome-wide CRISPR interference and CRISPR activation screens in human neurons. We uncover pathways controlling neuronal response to chronic oxidative stress, which is implicated in neurodegenerative diseases. Unexpectedly, knockdown of the lysosomal protein prosaposin strongly sensitizes neurons, but not other cell types, to oxidative stress by triggering the formation of lipofuscin, a hallmark of aging, which traps iron, generating reactive oxygen species and triggering ferroptosis. We also determine transcriptomic changes in neurons after perturbation of genes linked to neurodegenerative diseases. To enable the systematic comparison of gene function across different human cell types, we establish a data commons named CRISPRbrain.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tian</LastName><ForeName>Ruilin</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-7680-6682</Identifier><AffiliationInfo><Affiliation>Institute for Neurodegenerative Diseases, Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA, USA. tianrl@sustech.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biophysics Graduate Program, University of California, San Francisco, San Francisco, CA, USA. tianrl@sustech.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Southern University of Science and Technology, Shenzhen, China. tianrl@sustech.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abarientos</LastName><ForeName>Anthony</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute for Neurodegenerative Diseases, Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Jason</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute for Neurodegenerative Diseases, Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hashemi</LastName><ForeName>Sayed Hadi</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Department of Computer Science, University of Illinois at Urbana-Champaign, Urbana, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Rui</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-3391-133X</Identifier><AffiliationInfo><Affiliation>Department of Chemistry, University of California, Berkeley, Berkeley, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dr&#xe4;ger</LastName><ForeName>Nina</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Institute for Neurodegenerative Diseases, Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leng</LastName><ForeName>Kun</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-9931-1375</Identifier><AffiliationInfo><Affiliation>Institute for Neurodegenerative Diseases, Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nalls</LastName><ForeName>Mike A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Data Tecnica International, LLC, Glen Echo, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singleton</LastName><ForeName>Andrew B</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Ke</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-2788-194X</Identifier><AffiliationInfo><Affiliation>Department of Chemistry, University of California, Berkeley, Berkeley, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Faghri</LastName><ForeName>Faraz</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-5744-8728</Identifier><AffiliationInfo><Affiliation>Department of Computer Science, University of Illinois at Urbana-Champaign, Urbana, IL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Data Tecnica International, LLC, Glen Echo, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kampmann</LastName><ForeName>Martin</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-3819-7019</Identifier><AffiliationInfo><Affiliation>Institute for Neurodegenerative Diseases, Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA, USA. martin.kampmann@ucsf.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chan Zuckerberg Biohub, San Francisco, CA, USA. martin.kampmann@ucsf.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>ZIA AG000957</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>Z01 AG000957</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DP2 GM132681</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007618</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AG057528</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DP2 GM119139</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F30 AG066418</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 NS100717</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG062359</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>05</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C483345">PSAP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D049231">Saposins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Mov Disord. 2021 Oct;36(10):2224. doi: 10.1002/mds.28781.</RefSource><PMID Version="1">34480373</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D064112" MajorTopicYN="N">Clustered Regularly Interspaced Short Palindromic Repeats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008247" MajorTopicYN="N">Lysosomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049231" MajorTopicYN="N">Saposins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Declaration of interests. M.K. has filed a patent application related to CRISPRi and CRISPRa screening (PCT/US15/40449) and serves on the Scientific Advisory Board of Engine Biosciences, Casma Therapeutics, and Cajal Neuroscience.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>4</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>25</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>7</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34031600</ArticleId><ArticleId IdType="mid">NIHMS1710973</ArticleId><ArticleId IdType="pmc">PMC8254803</ArticleId><ArticleId IdType="doi">10.1038/s41593-021-00862-0</ArticleId><ArticleId IdType="pii">10.1038/s41593-021-00862-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Regev A et al. The human cell atlas. elife 6, (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5762154</ArticleId><ArticleId IdType="pubmed">29206104</ArticleId></ArticleIdList></Reference><Reference><Citation>Tazir M, Hamadouche T, Nouioua S, Mathis S &amp; Vallat J-M Hereditary motor and sensory neuropathies or Charcot-Marie-Tooth diseases: an update. J. Neurol. Sci 347, 14&#x2013;22 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25454638</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian R et al. CRISPR Interference-Based Platform for Multimodal Genetic Screens in Human iPSC-Derived Neurons. Neuron 104, 239&#x2013;255.e12 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6813890</ArticleId><ArticleId IdType="pubmed">31422865</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert LA et al. Genome-scale CRISPR-mediated control of gene repression and activation. Cell 159, 647&#x2013;661 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4253859</ArticleId><ArticleId IdType="pubmed">25307932</ArticleId></ArticleIdList></Reference><Reference><Citation>Kampmann M CRISPR-based functional genomics for neurological disease. Nat. Rev. Neurol 16, 465&#x2013;480 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7484261</ArticleId><ArticleId IdType="pubmed">32641861</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkel T &amp; Holbrook NJ Oxidants, oxidative stress and the biology of ageing. Nature 408, 239&#x2013;247 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">11089981</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnham KJ, Masters CL &amp; Bush AI Neurodegenerative diseases and oxidative stress. Nat. Rev. Drug Discov 3, 205&#x2013;214 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15031734</ArticleId></ArticleIdList></Reference><Reference><Citation>Weltner J et al. Human pluripotent reprogramming with CRISPR activators. Nat. Commun 9, 2643 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6035213</ArticleId><ArticleId IdType="pubmed">29980666</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C et al. Scalable Production of iPSC-Derived Human Neurons to Identify Tau-Lowering Compounds by High-Content Screening. Stem Cell Reports 9, 1221&#x2013;1233 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5639430</ArticleId><ArticleId IdType="pubmed">28966121</ArticleId></ArticleIdList></Reference><Reference><Citation>Horlbeck MA et al. Compact and highly active next-generation libraries for CRISPR-mediated gene repression and activation. elife 5, (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5094855</ArticleId><ArticleId IdType="pubmed">27661255</ArticleId></ArticleIdList></Reference><Reference><Citation>Yilmaz A, Peretz M, Aharony A, Sagi I &amp; Benvenisty N Defining essential genes for human pluripotent stem cells by CRISPR-Cas9 screening in haploid cells. Nat. Cell Biol 20, 610&#x2013;619 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29662178</ArticleId></ArticleIdList></Reference><Reference><Citation>Ihry RJ et al. Genome-Scale CRISPR Screens Identify Human Pluripotency-Specific Genes. Cell Rep 27, 616&#x2013;630.e6 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30970262</ArticleId></ArticleIdList></Reference><Reference><Citation>Mair B et al. Essential gene profiles for human pluripotent stem cells identify uncharacterized genes and substrate dependencies. Cell Rep 27, 599&#x2013;615.e12 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30970261</ArticleId></ArticleIdList></Reference><Reference><Citation>Hart T et al. Evaluation and Design of Genome-Wide CRISPR/SpCas9 Knockout Screens. G3 (Bethesda) 7, 2719&#x2013;2727 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5555476</ArticleId><ArticleId IdType="pubmed">28655737</ArticleId></ArticleIdList></Reference><Reference><Citation>Colacurcio DJ &amp; Nixon RA Disorders of lysosomal acidification-The emerging role of v-ATPase in aging and neurodegenerative disease. Ageing Res. Rev 32, 75&#x2013;88 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5112157</ArticleId><ArticleId IdType="pubmed">27197071</ArticleId></ArticleIdList></Reference><Reference><Citation>Dandage R &amp; Landry CR Paralog dependency indirectly affects the robustness of human cells. Mol. Syst. Biol 15, e8871 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757259</ArticleId><ArticleId IdType="pubmed">31556487</ArticleId></ArticleIdList></Reference><Reference><Citation>Unsain N, Higgins JM, Parker KN, Johnstone AD &amp; Barker PA XIAP regulates caspase activity in degenerating axons. Cell Rep 4, 751&#x2013;763 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23954782</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsang AHK et al. S-nitrosylation of XIAP compromises neuronal survival in Parkinson&#x2019;s disease. Proc Natl Acad Sci USA 106, 4900&#x2013;4905 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2660786</ArticleId><ArticleId IdType="pubmed">19273858</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xfc;gler S et al. The X-linked inhibitor of apoptosis (XIAP) prevents cell death in axotomized CNS neurons in vivo. Cell Death Differ 7, 815&#x2013;824 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">11042676</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu D et al. Attenuation of ischemia-induced cellular and behavioral deficits by X chromosome-linked inhibitor of apoptosis protein overexpression in the rat hippocampus. J. Neurosci 19, 5026&#x2013;5033 (1999).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782658</ArticleId><ArticleId IdType="pubmed">10366635</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz A et al. The stress-responsive gene GDPGP1/mcp-1 regulates neuronal glycogen metabolism and survival. J. Cell Biol 219, (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7041677</ArticleId><ArticleId IdType="pubmed">31968056</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Pichon CE et al. Loss of dual leucine zipper kinase signaling is protective in animal models of neurodegenerative disease. Sci. Transl. Med 9, (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28814543</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X et al. Antiapoptotic and trophic effects of dominant-negative forms of dual leucine zipper kinase in dopamine neurons of the substantia nigra in vivo. J. Neurosci 28, 672&#x2013;680 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2896687</ArticleId><ArticleId IdType="pubmed">18199767</ArticleId></ArticleIdList></Reference><Reference><Citation>Welsbie DS et al. Functional genomic screening identifies dual leucine zipper kinase as a key mediator of retinal ganglion cell death. Proc Natl Acad Sci USA 110, 4045&#x2013;4050 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3593842</ArticleId><ArticleId IdType="pubmed">23431148</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith CD et al. Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. Proc Natl Acad Sci USA 88, 10540&#x2013;10543 (1991).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC52964</ArticleId><ArticleId IdType="pubmed">1683703</ArticleId></ArticleIdList></Reference><Reference><Citation>Hensley K et al. Brain regional correspondence between Alzheimer&#x2019;s disease histopathology and biomarkers of protein oxidation. J. Neurochem 65, 2146&#x2013;2156 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7595501</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao Y et al. Enhanced brain levels of 8,12-iso-iPF2alpha-VI differentiate AD from frontotemporal dementia. Neurology 61, 475&#x2013;478 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12939420</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalf&#xf3; E et al. Evidence of oxidative stress in the neocortex in incidental Lewy body disease. J. Neuropathol. Exp. Neurol 64, 816&#x2013;830 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16141792</ArticleId></ArticleIdList></Reference><Reference><Citation>Subbarao KV, Richardson JS &amp; Ang LC Autopsy samples of Alzheimer&#x2019;s cortex show increased peroxidation in vitro. J. Neurochem 55, 342&#x2013;345 (1990).</Citation><ArticleIdList><ArticleId IdType="pubmed">2355227</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang WS et al. Regulation of ferroptotic cancer cell death by GPX4. Cell 156, 317&#x2013;331 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4076414</ArticleId><ArticleId IdType="pubmed">24439385</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C et al. Elevated p62/SQSTM1 determines the fate of autophagy-deficient neural stem cells by increasing superoxide. J. Cell Biol 212, 545&#x2013;560 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4772497</ArticleId><ArticleId IdType="pubmed">26929451</ArticleId></ArticleIdList></Reference><Reference><Citation>Taguchi K et al. Keap1 degradation by autophagy for the maintenance of redox homeostasis. Proc Natl Acad Sci USA 109, 13561&#x2013;13566 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3427110</ArticleId><ArticleId IdType="pubmed">22872865</ArticleId></ArticleIdList></Reference><Reference><Citation>Bensaad K, Cheung EC &amp; Vousden KH Modulation of intracellular ROS levels by TIGAR controls autophagy. EMBO J 28, 3015&#x2013;3026 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2736014</ArticleId><ArticleId IdType="pubmed">19713938</ArticleId></ArticleIdList></Reference><Reference><Citation>Reho JJ, Guo D-F &amp; Rahmouni K Mechanistic target of rapamycin complex 1 signaling modulates vascular endothelial function through reactive oxygen species. J. Am. Heart Assoc 8, e010662 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6512105</ArticleId><ArticleId IdType="pubmed">31020916</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin YJ et al. Rapamycin reduces reactive oxygen species in cultured human corneal endothelial cells. Curr. Eye Res 36, 1116&#x2013;1122 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21999191</ArticleId></ArticleIdList></Reference><Reference><Citation>Nacarelli T, Azar A &amp; Sell C Inhibition of mTOR Prevents ROS Production Initiated by Ethidium Bromide-Induced Mitochondrial DNA Depletion. Front Endocrinol (Lausanne) 5, 122 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4109433</ArticleId><ArticleId IdType="pubmed">25104948</ArticleId></ArticleIdList></Reference><Reference><Citation>Delgado-Camprubi M, Esteras N, Soutar MP, Plun-Favreau H &amp; Abramov AY Deficiency of Parkinson&#x2019;s disease-related gene Fbxo7 is associated with impaired mitochondrial metabolism by PARP activation. Cell Death Differ 24, 120&#x2013;131 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5260490</ArticleId><ArticleId IdType="pubmed">27689878</ArticleId></ArticleIdList></Reference><Reference><Citation>Hocsak E et al. PARP inhibition protects mitochondria and reduces ROS production via PARP-1-ATF4-MKP-1-MAPK retrograde pathway. Free Radic. Biol. Med 108, 770&#x2013;784 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28457938</ArticleId></ArticleIdList></Reference><Reference><Citation>Ou Y, Wang S-J, Li D, Chu B &amp; Gu W Activation of SAT1 engages polyamine metabolism with p53-mediated ferroptotic responses. Proc Natl Acad Sci USA 113, E6806&#x2013;E6812 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5098629</ArticleId><ArticleId IdType="pubmed">27698118</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xe1;nfi B et al. A Ca(2+)-activated NADPH oxidase in testis, spleen, and lymph nodes. J. Biol. Chem 276, 37594&#x2013;37601 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11483596</ArticleId></ArticleIdList></Reference><Reference><Citation>Bankoglu EE et al. Role of PTEN in Oxidative Stress and DNA Damage in the Liver of Whole-Body Pten Haplodeficient Mice. PLoS ONE 11, e0166956 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5125655</ArticleId><ArticleId IdType="pubmed">27893783</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudarshan S et al. Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor 1alpha stabilization by glucose-dependent generation of reactive oxygen species. Mol. Cell. Biol 29, 4080&#x2013;4090 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2715796</ArticleId><ArticleId IdType="pubmed">19470762</ArticleId></ArticleIdList></Reference><Reference><Citation>Bardella C et al. Cells lacking the fumarase tumor suppressor are protected from apoptosis through a hypoxia-inducible factor-independent, AMPK-dependent mechanism. Mol. Cell. Biol 32, 3081&#x2013;3094 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3434507</ArticleId><ArticleId IdType="pubmed">22645311</ArticleId></ArticleIdList></Reference><Reference><Citation>Doll S et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat. Chem. Biol 13, 91&#x2013;98 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5610546</ArticleId><ArticleId IdType="pubmed">27842070</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan H, Li X, Zhang X, Kang R &amp; Tang D Identification of ACSL4 as a biomarker and contributor of ferroptosis. Biochem. Biophys. Res. Commun 478, 1338&#x2013;1343 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27565726</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa M et al. Functional interactions of the cystine/glutamate antiporter, CD44v and MUC1-C oncoprotein in triple-negative breast cancer cells. Oncotarget 7, 11756&#x2013;11769 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4914246</ArticleId><ArticleId IdType="pubmed">26930718</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishimoto T et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(&#x2212;) and thereby promotes tumor growth. Cancer Cell 19, 387&#x2013;400 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21397861</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhitomirsky B &amp; Assaraf YG Lysosomal sequestration of hydrophobic weak base chemotherapeutics triggers lysosomal biogenesis and lysosome-dependent cancer multidrug resistance. Oncotarget 6, 1143&#x2013;1156 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4359223</ArticleId><ArticleId IdType="pubmed">25544758</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu M et al. A phenotypic compound screening assay for lysosomal storage diseases. J. Biomol. Screen 19, 168&#x2013;175 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4818652</ArticleId><ArticleId IdType="pubmed">23983233</ArticleId></ArticleIdList></Reference><Reference><Citation>Chikte S, Panchal N &amp; Warnes G Use of LysoTracker dyes: a flow cytometric study of autophagy. Cytometry A 85, 169&#x2013;178 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">23847175</ArticleId></ArticleIdList></Reference><Reference><Citation>DeVorkin L &amp; Gorski SM LysoTracker staining to aid in monitoring autophagy in Drosophila. Cold Spring Harb. Protoc 2014, 951&#x2013;958 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25183815</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixon SJ &amp; Stockwell BR The role of iron and reactive oxygen species in cell death. Nat. Chem. Biol 10, 9&#x2013;17 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24346035</ArticleId></ArticleIdList></Reference><Reference><Citation>Weber RA et al. Maintaining iron homeostasis is the key role of lysosomal acidity for cell proliferation. Mol. Cell 77, 645&#x2013;655.e7 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7176020</ArticleId><ArticleId IdType="pubmed">31983508</ArticleId></ArticleIdList></Reference><Reference><Citation>Bogdan AR, Miyazawa M, Hashimoto K &amp; Tsuji Y Regulators of iron homeostasis: new players in metabolism, cell death, and disease. Trends Biochem. Sci 41, 274&#x2013;286 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4783254</ArticleId><ArticleId IdType="pubmed">26725301</ArticleId></ArticleIdList></Reference><Reference><Citation>Seibler P et al. Iron overload is accompanied by mitochondrial and lysosomal dysfunction in WDR45 mutant cells. Brain 141, 3052&#x2013;3064 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7190033</ArticleId><ArticleId IdType="pubmed">30169597</ArticleId></ArticleIdList></Reference><Reference><Citation>Haack TB et al. Exome sequencing reveals de novo WDR45 mutations causing a phenotypically distinct, X-linked dominant form of NBIA. Am. J. Hum. Genet 91, 1144&#x2013;1149 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3516593</ArticleId><ArticleId IdType="pubmed">23176820</ArticleId></ArticleIdList></Reference><Reference><Citation>Muto Y, Nishiyama M, Nita A, Moroishi T &amp; Nakayama KI Essential role of FBXL5-mediated cellular iron homeostasis in maintenance of hematopoietic stem cells. Nat. Commun 8, 16114 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5520054</ArticleId><ArticleId IdType="pubmed">28714470</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong X-P et al. The type IV mucolipidosis-associated protein TRPML1 is an endolysosomal iron release channel. Nature 455, 992&#x2013;996 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4301259</ArticleId><ArticleId IdType="pubmed">18794901</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward DM &amp; Cloonan SM Mitochondrial iron in human health and disease. Annu. Rev. Physiol 81, 453&#x2013;482 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6641538</ArticleId><ArticleId IdType="pubmed">30485761</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz-Font A et al. A mutation within the saposin D domain in a Gaucher disease patient with normal glucocerebrosidase activity. Hum. Genet 117, 275&#x2013;277 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15856305</ArticleId></ArticleIdList></Reference><Reference><Citation>Radha Rama Devi A et al. Acute Gaucher Disease-Like Condition in an Indian Infant with a Novel Biallelic Mutation in the Prosaposin Gene. J. Pediatr. Genet 8, 81&#x2013;85 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6499618</ArticleId><ArticleId IdType="pubmed">31061751</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiegel R et al. A mutation in the saposin A coding region of the prosaposin gene in an infant presenting as Krabbe disease: first report of saposin A deficiency in humans. Mol. Genet. Metab 84, 160&#x2013;166 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15773042</ArticleId></ArticleIdList></Reference><Reference><Citation>Oji Y et al. Variants in saposin D domain of prosaposin gene linked to Parkinson&#x2019;s disease. Brain 143, 1190&#x2013;1205 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32201884</ArticleId></ArticleIdList></Reference><Reference><Citation>Hiraiwa M et al. Lysosomal proteolysis of prosaposin, the precursor of saposins (sphingolipid activator proteins): its mechanism and inhibition by ganglioside. Arch. Biochem. Biophys 341, 17&#x2013;24 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9143348</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandhoff K &amp; Harzer K Gangliosides and gangliosidoses: principles of molecular and metabolic pathogenesis. J. Neurosci 33, 10195&#x2013;10208 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6618597</ArticleId><ArticleId IdType="pubmed">23785136</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain IH et al. Genetic screen for cell fitness in high or low oxygen highlights mitochondrial and lipid metabolism. Cell 181, 716&#x2013;727.e11 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7293541</ArticleId><ArticleId IdType="pubmed">32259488</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartz F et al. Identification of cholesterol-regulating genes by targeted RNAi screening. Cell Metab 10, 63&#x2013;75 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19583955</ArticleId></ArticleIdList></Reference><Reference><Citation>Puri V et al. Sphingolipid storage induces accumulation of intracellular cholesterol by stimulating SREBP-1 cleavage. J. Biol. Chem 278, 20961&#x2013;20970 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12657626</ArticleId></ArticleIdList></Reference><Reference><Citation>Glaros EN et al. Glycosphingolipid accumulation inhibits cholesterol efflux via the ABCA1/apolipoprotein A-I pathway: 1-phenyl-2-decanoylamino-3-morpholino-1-propanol is a novel cholesterol efflux accelerator. J. Biol. Chem 280, 24515&#x2013;24523 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15890646</ArticleId></ArticleIdList></Reference><Reference><Citation>Rust MJ, Bates M &amp; Zhuang X Sub-diffraction-limit imaging by stochastic optical reconstruction microscopy (STORM). Nat. Methods 3, 793&#x2013;795 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2700296</ArticleId><ArticleId IdType="pubmed">16896339</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-Garc&#xed;a A, Kun A, Calero O, Medina M &amp; Calero M An Overview of the Role of Lipofuscin in Age-Related Neurodegeneration. Front. Neurosci 12, 464 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6041410</ArticleId><ArticleId IdType="pubmed">30026686</ArticleId></ArticleIdList></Reference><Reference><Citation>Mochizuki Y, Park MK, Mori T &amp; Kawashima S The difference in autofluorescence features of lipofuscin between brain and adrenal. Zool. Sci 12, 283&#x2013;288 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7580812</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xf6;hn A, Jung T, Grimm S &amp; Grune T Lipofuscin-bound iron is a major intracellular source of oxidants: role in senescent cells. Free Radic. Biol. Med 48, 1100&#x2013;1108 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20116426</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunk UT, Jones CB &amp; Sohal RS A novel hypothesis of lipofuscinogenesis and cellular aging based on interactions between oxidative stress and autophagocytosis. Mutat. Res 275, 395&#x2013;403 (1992).</Citation><ArticleIdList><ArticleId IdType="pubmed">1383780</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunkle BW et al. Genetic meta-analysis of diagnosed Alzheimer&#x2019;s disease identifies new risk loci and implicates A&#x3b2;, tau, immunity and lipid processing. Nat. Genet 51, 414&#x2013;430 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6463297</ArticleId><ArticleId IdType="pubmed">30820047</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang D et al. A meta-analysis of genome-wide association studies identifies 17 new Parkinson&#x2019;s disease risk loci. Nat. Genet 49, 1511&#x2013;1516 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5812477</ArticleId><ArticleId IdType="pubmed">28892059</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallagher MD &amp; Chen-Plotkin AS The Post-GWAS Era: From Association to Function. Am. J. Hum. Genet 102, 717&#x2013;730 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5986732</ArticleId><ArticleId IdType="pubmed">29727686</ArticleId></ArticleIdList></Reference><Reference><Citation>Datlinger P et al. Pooled CRISPR screening with single-cell transcriptome readout. Nat. Methods 14, 297&#x2013;301 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5334791</ArticleId><ArticleId IdType="pubmed">28099430</ArticleId></ArticleIdList></Reference><Reference><Citation>Adamson B et al. A Multiplexed Single-Cell CRISPR Screening Platform Enables Systematic Dissection of the Unfolded Protein Response. Cell 167, 1867&#x2013;1882.e21 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5315571</ArticleId><ArticleId IdType="pubmed">27984733</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixit A et al. Perturb-Seq: Dissecting Molecular Circuits with Scalable Single-Cell RNA Profiling of Pooled Genetic Screens. Cell 167, 1853&#x2013;1866.e17 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5181115</ArticleId><ArticleId IdType="pubmed">27984732</ArticleId></ArticleIdList></Reference><Reference><Citation>Pi&#xf1;ero J et al. DisGeNET: a discovery platform for the dynamical exploration of human diseases and their genes. Database (Oxford) 2015, bav028 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4397996</ArticleId><ArticleId IdType="pubmed">25877637</ArticleId></ArticleIdList></Reference><Reference><Citation>Slowik A et al. Paraoxonase gene polymorphisms and sporadic ALS. Neurology 67, 766&#x2013;770 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16822965</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitt-John T et al. Mutation of Vps54 causes motor neuron disease and defective spermiogenesis in the wobbler mouse. Nat. Genet 37, 1213&#x2013;1215 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16244655</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen JA et al. A multiancestral genome-wide exome array study of Alzheimer disease, frontotemporal dementia, and progressive supranuclear palsy. JAMA Neurol 72, 414&#x2013;422 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4397175</ArticleId><ArticleId IdType="pubmed">25706306</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao LY et al. An EBF3-mediated transcriptional program that induces cell cycle arrest and apoptosis. Cancer Res 66, 9445&#x2013;9452 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17018599</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu C et al. Long Noncoding RNA EBF3-AS Promotes Neuron Apoptosis in Alzheimer&#x2019;s Disease. DNA Cell Biol 37, 220&#x2013;226 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29298096</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H et al. Single-cell transcriptomic analysis of Alzheimer&#x2019;s disease. Nature 570, 332&#x2013;337 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6865822</ArticleId><ArticleId IdType="pubmed">31042697</ArticleId></ArticleIdList></Reference><Reference><Citation>Langfelder P &amp; Horvath S WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics 9, 559 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2631488</ArticleId><ArticleId IdType="pubmed">19114008</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Morales PL, Quiroga AC, Barbas JA &amp; Morales AV SOX5 controls cell cycle progression in neural progenitors by interfering with the WNT-beta-catenin pathway. EMBO Rep 11, 466&#x2013;472 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2892326</ArticleId><ArticleId IdType="pubmed">20448664</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xe9;ndez-G&#xf3;mez HR &amp; Vicario-Abej&#xf3;n C The homeobox gene Gsx2 regulates the self-renewal and differentiation of neural stem cells and the cell fate of postnatal progenitors. PLoS ONE 7, e29799 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3252334</ArticleId><ArticleId IdType="pubmed">22242181</ArticleId></ArticleIdList></Reference><Reference><Citation>Luu B, Ellisor D &amp; Zervas M The lineage contribution and role of Gbx2 in spinal cord development. PLoS ONE 6, e20940 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3116860</ArticleId><ArticleId IdType="pubmed">21698205</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross D &amp; Siegel D Functions of NQO1 in cellular protection and coq10 metabolism and its potential role as a redox sensitive molecular switch. Front. Physiol 8, 595 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5573868</ArticleId><ArticleId IdType="pubmed">28883796</ArticleId></ArticleIdList></Reference><Reference><Citation>SantaCruz KS, Yazlovitskaya E, Collins J, Johnson J &amp; DeCarli C Regional NAD(P)H:quinone oxidoreductase activity in Alzheimer&#x2019;s disease. Neurobiol. Aging 25, 63&#x2013;69 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">14675732</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Santa-Cruz K, DeCarli C &amp; Johnson JA NAD(P)H:quinone oxidoreductase activity is increased in hippocampal pyramidal neurons of patients with Aalzheimer&#x2019;s disease. Neurobiol. Aging 21, 525&#x2013;531 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10924765</ArticleId></ArticleIdList></Reference><Reference><Citation>Bian J-T, Zhao H-L, Zhang Z-X, Bi X-H &amp; Zhang J-W Association of NAD(P)H:quinone oxidoreductase 1 polymorphism and Alzheimer&#x2019;s disease in Chinese. J. Mol. Neurosci 34, 235&#x2013;240 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18253865</ArticleId></ArticleIdList></Reference><Reference><Citation>van Muiswinkel FL et al. Expression of NAD(P)H:quinone oxidoreductase in the normal and Parkinsonian substantia nigra. Neurobiol. Aging 25, 1253&#x2013;1262 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15312971</ArticleId></ArticleIdList></Reference><Reference><Citation>Raina AK, Templeton DJ, Deak JC, Perry G &amp; Smith MA Quinone reductase (NQO1), a sensitive redox indicator, is increased in Alzheimer&#x2019;s disease. Redox Rep 4, 23&#x2013;27 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10714272</ArticleId></ArticleIdList></Reference><Reference><Citation>Imaizumi Y et al. Mitochondrial dysfunction associated with increased oxidative stress and &#x3b1;-synuclein accumulation in PARK2 iPSC-derived neurons and postmortem brain tissue. Mol. Brain 5, 35 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3546866</ArticleId><ArticleId IdType="pubmed">23039195</ArticleId></ArticleIdList></Reference><Reference><Citation>Asher G, Lotem J, Kama R, Sachs L &amp; Shaul Y NQO1 stabilizes p53 through a distinct pathway. Proc Natl Acad Sci USA 99, 3099&#x2013;3104 (2002).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC122479</ArticleId><ArticleId IdType="pubmed">11867746</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Q Role of nrf2 in oxidative stress and toxicity. Annu. Rev. Pharmacol. Toxicol 53, 401&#x2013;426 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4680839</ArticleId><ArticleId IdType="pubmed">23294312</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramsey CP et al. Expression of Nrf2 in neurodegenerative diseases. J. Neuropathol. Exp. Neurol 66, 75&#x2013;85 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2253896</ArticleId><ArticleId IdType="pubmed">17204939</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel M Targeting oxidative stress in central nervous system disorders. Trends Pharmacol. Sci 37, 768&#x2013;778 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5333771</ArticleId><ArticleId IdType="pubmed">27491897</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin MT &amp; Beal MF Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443, 787&#x2013;795 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17051205</ArticleId></ArticleIdList></Reference><Reference><Citation>Rouault TA Iron metabolism in the CNS: implications for neurodegenerative diseases. Nat. Rev. Neurosci 14, 551&#x2013;564 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23820773</ArticleId></ArticleIdList></Reference><Reference><Citation>Stockwell BR et al. Ferroptosis: A regulated cell death nexus linking metabolism, redox biology, and disease. Cell 171, 273&#x2013;285 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5685180</ArticleId><ArticleId IdType="pubmed">28985560</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubreuil MM et al. Systematic Identification of Regulators of Oxidative Stress Reveals Non-canonical Roles for Peroxisomal Import and the Pentose Phosphate Pathway. Cell Rep 30, 1417&#x2013;1433.e7 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7184925</ArticleId><ArticleId IdType="pubmed">32023459</ArticleId></ArticleIdList></Reference><Reference><Citation>Reczek CR et al. A CRISPR screen identifies a pathway required for paraquat-induced cell death. Nat. Chem. Biol 13, 1274&#x2013;1279 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5698099</ArticleId><ArticleId IdType="pubmed">29058724</ArticleId></ArticleIdList></Reference><Reference><Citation>Ndayisaba A, Kaindlstorfer C &amp; Wenning GK Iron in Neurodegeneration - Cause or Consequence? Front. Neurosci 13, 180 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6405645</ArticleId><ArticleId IdType="pubmed">30881284</ArticleId></ArticleIdList></Reference><Reference><Citation>Han C et al. Ferroptosis and its potential role in human diseases. Front. Pharmacol 11, 239 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7090218</ArticleId><ArticleId IdType="pubmed">32256352</ArticleId></ArticleIdList></Reference><Reference><Citation>Kupershmidt L, Amit T, Bar-Am O, Weinreb O &amp; Youdim MBH Multi-target, neuroprotective and neurorestorative M30 improves cognitive impairment and reduces Alzheimer&#x2019;s-like neuropathology and age-related alterations in mice. Mol. Neurobiol 46, 217&#x2013;220 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22847630</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaur D et al. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson&#x2019;s disease. Neuron 37, 899&#x2013;909 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12670420</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J et al. Iron accumulates in Huntington&#x2019;s disease neurons: protection by deferoxamine. PLoS ONE 8, e77023 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3795666</ArticleId><ArticleId IdType="pubmed">24146952</ArticleId></ArticleIdList></Reference><Reference><Citation>Skouta R et al. Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models. J. Am. Chem. Soc 136, 4551&#x2013;4556 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3985476</ArticleId><ArticleId IdType="pubmed">24592866</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson GW, Goebel HH &amp; Simonati A Human pathology in NCL. Biochim. Biophys. Acta 1832, 1807&#x2013;1826 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23200925</ArticleId></ArticleIdList></Reference><Reference><Citation>Delori FC et al. In vivo measurement of lipofuscin in Stargardt&#x2019;s disease--Fundus flavimaculatus. Invest. Ophthalmol. Vis. Sci 36, 2327&#x2013;2331 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7558729</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorey CK, Wu G, Ebenstein D, Garsd A &amp; Weiter JJ Cell loss in the aging retina. Relationship to lipofuscin accumulation and macular degeneration. Invest. Ophthalmol. Vis. Sci 30, 1691&#x2013;1699 (1989).</Citation><ArticleIdList><ArticleId IdType="pubmed">2759786</ArticleId></ArticleIdList></Reference><Reference><Citation>Dowson JH, Mountjoy CQ, Cairns MR &amp; Wilton-Cox H Changes in intraneuronal lipopigment in Alzheimer&#x2019;s disease. Neurobiol. Aging 13, 493&#x2013;500 (1992).</Citation><ArticleIdList><ArticleId IdType="pubmed">1508300</ArticleId></ArticleIdList></Reference><Reference><Citation>Dowson JH, Mountjoy CQ, Cairns MR &amp; Wilton-Cox H Alzheimer&#x2019;s disease: distribution of changes in intraneuronal lipopigment in the frontal cortex. Dementia 6, 334&#x2013;342 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">8563787</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak E et al. alpha-synuclein immunopositive Parkinson&#x2019;s disease-related inclusion bodies in lower brain stem nuclei. Acta Neuropathol 101, 195&#x2013;201 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11307617</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H &amp; Braak E Allocortical involvement in Huntington&#x2019;s disease. Neuropathol. Appl. Neurobiol 18, 539&#x2013;547 (1992).</Citation><ArticleIdList><ArticleId IdType="pubmed">1488086</ArticleId></ArticleIdList></Reference><Reference><Citation>Goebel HH, Heipertz R, Scholz W, Iqbal K &amp; Tellez-Nagel I Juvenile Huntington chorea: clinical, ultrastructural, and biochemical studies. Neurology 28, 23&#x2013;31 (1978).</Citation><ArticleIdList><ArticleId IdType="pubmed">145549</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward ME et al. Individuals with progranulin haploinsufficiency exhibit features of neuronal ceroid lipofuscinosis. Sci. Transl. Med 9, (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5526610</ArticleId><ArticleId IdType="pubmed">28404863</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazan NG Lipid signaling in neural plasticity, brain repair, and neuroprotection. Mol. Neurobiol 32, 89&#x2013;103 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16077186</ArticleId></ArticleIdList></Reference><Reference><Citation>Isacson O, Brekk OR &amp; Hallett PJ Novel results and concepts emerging from lipid cell biology relevant to degenerative brain aging and disease. Front. Neurol 10, 1053 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6794469</ArticleId><ArticleId IdType="pubmed">31649605</ArticleId></ArticleIdList></Reference><Reference><Citation>Hallett PJ, Engelender S &amp; Isacson O Lipid and immune abnormalities causing age-dependent neurodegeneration and Parkinson&#x2019;s disease. J. Neuroinflammation 16, 153 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6647317</ArticleId><ArticleId IdType="pubmed">31331333</ArticleId></ArticleIdList></Reference><Reference><Citation>Yadav RS &amp; Tiwari NK Lipid integration in neurodegeneration: an overview of Alzheimer&#x2019;s disease. Mol. Neurobiol 50, 168&#x2013;176 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24590317</ArticleId></ArticleIdList></Reference><Reference><Citation>Boutry M et al. Inhibition of Lysosome Membrane Recycling Causes Accumulation of Gangliosides that Contribute to Neurodegeneration. Cell Rep 23, 3813&#x2013;3826 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6045775</ArticleId><ArticleId IdType="pubmed">29949766</ArticleId></ArticleIdList></Reference><Reference><Citation>Edens BM et al. FMRP Modulates Neural Differentiation through m6A-Dependent mRNA Nuclear Export. Cell Rep 28, 845&#x2013;854.e5 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6687293</ArticleId><ArticleId IdType="pubmed">31340148</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M et al. Ythdf2-mediated m6A mRNA clearance modulates neural development in mice. Genome Biol 19, 69 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5984442</ArticleId><ArticleId IdType="pubmed">29855337</ArticleId></ArticleIdList></Reference><Reference><Citation>Anzalone AV et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature 576, 149&#x2013;157 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6907074</ArticleId><ArticleId IdType="pubmed">31634902</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanna RE et al. Massively parallel assessment of human variants with base editor screens. BioRxiv (2020). doi:10.1101/2020.05.17.100818</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.05.17.100818</ArticleId><ArticleId IdType="pubmed">33606977</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsherniak A et al. Defining a cancer dependency map. Cell 170, 564&#x2013;576.e16 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5667678</ArticleId><ArticleId IdType="pubmed">28753430</ArticleId></ArticleIdList></Reference><Reference><Citation>Oughtred R et al. The BioGRID database: A comprehensive biomedical resource of curated protein, genetic, and chemical interactions. Protein Sci 30, 187&#x2013;200</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7737760</ArticleId><ArticleId IdType="pubmed">33070389</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui Y et al. CRISP-view: a database of functional genetic screens spanning multiple phenotypes. Nucleic Acids Res 49, D848&#x2013;D854 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7778972</ArticleId><ArticleId IdType="pubmed">33010154</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo X et al. Mitochondrial stress is relayed to the cytosol by an OMA1-DELE1-HRI pathway. Nature 579, 427&#x2013;432 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7147832</ArticleId><ArticleId IdType="pubmed">32132707</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyaoka Y et al. Isolation of single-base genome-edited human iPS cells without antibiotic selection. Nat. Methods 11, 291&#x2013;293 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4063274</ArticleId><ArticleId IdType="pubmed">24509632</ArticleId></ArticleIdList></Reference><Reference><Citation>Topol A, Tran NN &amp; Brennand KJ A guide to generating and using hiPSC derived NPCs for the study of neurological diseases. J. Vis. Exp e52495 (2015). doi:10.3791/52495</Citation><ArticleIdList><ArticleId IdType="doi">10.3791/52495</ArticleId><ArticleId IdType="pmc">PMC4354663</ArticleId><ArticleId IdType="pubmed">25742222</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng C, Fass DM, Folz-Donahue K, MacDonald ME &amp; Haggarty SJ Highly Expandable Human iPS Cell-Derived Neural Progenitor Cells (NPC) and Neurons for Central Nervous System Disease Modeling and High-Throughput Screening. Curr. Protoc. Hum. Genet 92, 21.8.1&#x2013;21.8.21 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5293008</ArticleId><ArticleId IdType="pubmed">28075486</ArticleId></ArticleIdList></Reference><Reference><Citation>Tcw J et al. An Efficient Platform for Astrocyte Differentiation from Human Induced Pluripotent Stem Cells. Stem Cell Reports 9, 600&#x2013;614 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5550034</ArticleId><ArticleId IdType="pubmed">28757165</ArticleId></ArticleIdList></Reference><Reference><Citation>Brownjohn PW et al. Functional Studies of Missense TREM2 Mutations in Human Stem Cell-Derived Microglia. Stem Cell Reports 10, 1294&#x2013;1307 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5998752</ArticleId><ArticleId IdType="pubmed">29606617</ArticleId></ArticleIdList></Reference><Reference><Citation>Bersuker K et al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature 575, 688&#x2013;692 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6883167</ArticleId><ArticleId IdType="pubmed">31634900</ArticleId></ArticleIdList></Reference><Reference><Citation>Komarov PG et al. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 285, 1733&#x2013;1737 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10481009</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao C et al. Dual regulatory switch through interactions of Tcf7l2/Tcf4 with stage-specific partners propels oligodendroglial maturation. Nat. Commun 7, 10883 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4786870</ArticleId><ArticleId IdType="pubmed">26955760</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauser M et al. The Spectrin-Actin-Based Periodic Cytoskeleton as a Conserved Nanoscale Scaffold and Ruler of the Neural Stem Cell Lineage. Cell Rep 24, 1512&#x2013;1522 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6119594</ArticleId><ArticleId IdType="pubmed">30089262</ArticleId></ArticleIdList></Reference><Reference><Citation>Wojcik M, Hauser M, Li W, Moon S &amp; Xu K Graphene-enabled electron microscopy and correlated super-resolution microscopy of wet cells. Nat. Commun 6, 7384 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4490578</ArticleId><ArticleId IdType="pubmed">26066680</ArticleId></ArticleIdList></Reference><Reference><Citation>Langmead B, Trapnell C, Pop M &amp; Salzberg SL Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol 10, R25 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2690996</ArticleId><ArticleId IdType="pubmed">19261174</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill AJ et al. On the design of CRISPR-based single-cell molecular screens. Nat. Methods 15, 271&#x2013;274 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5882576</ArticleId><ArticleId IdType="pubmed">29457792</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf FA, Angerer P &amp; Theis FJ SCANPY: large-scale single-cell gene expression data analysis. Genome Biol 19, 15 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5802054</ArticleId><ArticleId IdType="pubmed">29409532</ArticleId></ArticleIdList></Reference><Reference><Citation>Patro R, Duggal G, Love MI, Irizarry RA &amp; Kingsford C Salmon provides fast and bias-aware quantification of transcript expression. Nat. Methods 14, 417&#x2013;419 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5600148</ArticleId><ArticleId IdType="pubmed">28263959</ArticleId></ArticleIdList></Reference><Reference><Citation>Soneson C, Love MI &amp; Robinson MD Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences. [version 2; peer review: 2 approved]. F1000Res 4, 1521 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4712774</ArticleId><ArticleId IdType="pubmed">26925227</ArticleId></ArticleIdList></Reference><Reference><Citation>Pang XP, Hershman JM, Chung M &amp; Pekary AE Characterization of tumor necrosis factor-alpha receptors in human and rat thyroid cells and regulation of the receptors by thyrotropin. Endocrinology 125, 1783&#x2013;1788 (1989).</Citation><ArticleIdList><ArticleId IdType="pubmed">2551628</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao Y, Wang J, Jaehnig EJ, Shi Z &amp; Zhang B WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs. Nucleic Acids Res 47, W199&#x2013;W205 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6602449</ArticleId><ArticleId IdType="pubmed">31114916</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>